<SEC-DOCUMENT>0001193125-26-178716.txt : 20260427
<SEC-HEADER>0001193125-26-178716.hdr.sgml : 20260427
<ACCEPTANCE-DATETIME>20260427060603
ACCESSION NUMBER:		0001193125-26-178716
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		40
FILED AS OF DATE:		20260427
DATE AS OF CHANGE:		20260427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Seaport Therapeutics, Inc.
		CENTRAL INDEX KEY:			0002042347
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				992235719
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-294976
		FILM NUMBER:		26896383

	BUSINESS ADDRESS:	
		STREET 1:		6 TIDE STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		617-807-4062

	MAIL ADDRESS:	
		STREET 1:		6 TIDE STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d73463ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on April 27, 2026. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-294976</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Amendment No. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>to
</B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">99-2235719</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>101 Seaport Blvd., Floor 12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts 02210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">807-4062</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)
</B></P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Daphne Zohar </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>101 Seaport Blvd., Floor 12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts 02210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">807-4062</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service)
</B></P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Mitchell S. Bloom</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Benjamin K. Marsh</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Kristen
M. McCarthy</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Goodwin Procter LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>100 Northern Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Boston,
Massachusetts 02210</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">570-1000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Nathan Ajiashvili</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Salvatore Vanchieri</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Sandy
Kugbei</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>1271 Avenue of the Americas</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10020</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">906-1200</FONT></B></P></TD></TR>
</TABLE> <center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after this registration statement becomes
effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, as amended, check the following box:&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration
Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV STYLE="position:relative; overflow:visible; width:651pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt);">
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:10.0pt; font-size:9.5pt; font-family:ARIAL"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until
the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state or other
jurisdiction where the offer or sale is not permitted.<SUP STYLE="font-size:75%; line-height:7.0pt ; vertical-align:top">1</SUP>
</B></FONT></P></DIV><DIV STYLE="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt);"> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#de1a1e"><B>Subject to Completion, Dated April 27, 2026 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>11,800,000&nbsp;Shares </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g00a03.jpg" ALT="LOGO" STYLE="width:2.98667in;height:1.12833in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is an initial public offering of shares of common stock of Seaport Therapeutics, Inc. We are offering 11,800,000&nbsp;shares of our common
stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. It is currently estimated that the initial public
offering price per share will be between $16.00 and $18.00. We have applied to list our common stock on the Nasdaq Global Market under the symbol &#8220;SPTX.&#8221; We believe that upon the completion of this offering, we will meet the standards
for listing on the Nasdaq Global Market, and the completion of this offering is contingent upon such listing. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#8220;emerging growth company&#8221; and &#8220;smaller reporting company&#8221; as defined under the U.S. federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements in this
prospectus. For additional information, see the section titled &#8220;Prospectus Summary&#8212;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#8221; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See the section titled &#8220;<A HREF="#toc73463_4">Risk Factors</A>&#8221;
beginning on page 17 to read about factors you should consider before deciding to invest in shares of our common stock. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions
<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to Seaport Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For additional information regarding compensation payable to the underwriters, see the section titled
&#8220;Underwriting.&#8221; </P></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted the underwriters the option to purchase up to an additional 1,770,000
shares of common stock from us, at the initial public offering price, less the underwriting discounts and commissions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received
indications of interest from entities affiliated with General Atlantic to purchase up to $50&nbsp;million in shares of our common stock in this offering at the initial public offering price per share, on the same terms as the other purchasers in
this offering. However, because indications of interest are not binding agreements or commitments to purchase shares, nor a commitment of the Company or the underwriters to allocate or sell shares, more, fewer or no shares may be sold to General
Atlantic in this offering. The underwriters will receive the same underwriting discount and commissions on these shares as they will on any other shares sold to the public in this offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the underwriters have reserved up to 5% of the shares offered by this prospectus for sale, at the initial public offering
price, to our directors, officers, certain employees and certain other persons associated with us. See the section &#8220;<I>Underwriting&#8212;Directed Share Program</I>.&#8221;<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares against payment on or about &#8195;&#8195;&#8195;&#8195;, 2026. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13pt">
<TD VALIGN="top"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>J.P.&nbsp;Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Leerink&nbsp;Partners</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Stifel</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus dated &#8195;&#8195;&#8195;&#8195;, 2026 </B></P></DIV> <p STYLE="clear:both; font-size:1pt; height:0">&nbsp;</p>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_8">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_9">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_10">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_11">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_12">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_13">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_14">DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_15">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_16">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_17">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_18">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_19">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_20">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_21">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_22">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_23">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc73463_24">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all references in this prospectus to &#8220;Seaport,&#8221; the
&#8220;company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; or similar terms refer to Seaport Therapeutics, Inc. and its wholly owned subsidiaries, or either or all of them as the context may require. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide you any information or make any representations other than those contained
in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information
that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in any applicable
free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations, and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about,
and observe any restrictions relating to, the offering of the shares of our common stock, and the distribution of this prospectus outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own, have applied for, or have rights to use one or more registered and common law trademarks, service marks, and/or trade names in
connection with our business in the United States, which may be used throughout this prospectus. This prospectus also includes trademarks, tradenames, and service marks of third parties which are the property of their respective owners. Our use or
display of third-parties&#8217; trademarks, service marks, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tradenames, or products in this prospectus and our other public filings is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience,
the trademarks, service marks, logos and trade names referred to in this prospectus and our other public filings may appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, TM or SM symbols, but the omission of such references
is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the rights of the applicable owner of or licensor to these trademarks, service marks, and trade names. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARKET, INDUSTRY, AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market data and certain other statistical information used throughout this prospectus are based on independent industry publications,
governmental publications, reports by market research firms, or other independent sources that we believe to be reliable sources. Industry publications and third-party research, surveys, and studies generally indicate that their information has been
obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe that these sources are
reliable; however, we have not independently verified the information contained in such publications. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as
they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this
prospectus. Some data are also based on our good faith estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BASIS OF PRESENTATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware as SP Therapeutics, Inc. on April&nbsp;1, 2024 and changed our name to Seaport
Therapeutics, Inc. on April&nbsp;2, 2024. Our wholly owned subsidiary, SPTX, Inc., was a result of the incorporation of a predecessor company under the laws of the State of Delaware in February 2024 under the name Seaport Therapeutics, Inc., which
subsequently changed its name to Seaport Therapeutics Holdings, Inc. in March 2024 and to SPTX, Inc. in April 2024. In April 2024, we entered into a share exchange agreement, or the Share Exchange Agreement, with SPTX, Inc., which resulted in SPTX,
Inc. becoming our wholly owned subsidiary. On April&nbsp;8, 2024, or the Asset Transfer Date, we entered into an Asset Transfer Agreement as amended in December 2025, or the Asset Transfer Agreement, with PureTech Health LLC, or PureTech Health, and
PureTech LYT Inc., or PureTech LYT, pursuant to which PureTech Health and PureTech LYT agreed to contribute, convey, assign, transfer, and deliver to us all of their right, title, and interest in, to and under the assets related to its Glyph<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP><SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> technology or products, subject to the terms set forth in the Asset Transfer Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements presented in this prospectus for periods prior to the Asset Transfer Date, which are included in the consolidated
financial statements for the year ended December&nbsp;31, 2024, have been prepared on a <FONT STYLE="white-space:nowrap">&#8220;carve-out&#8221;</FONT> basis from the financial statements of PureTech Health plc, or PureTech, to represent our
financial position and performance as if we had existed on a standalone basis. The financial statements presented in this prospectus for periods from and after the Asset Transfer Date reflect our financial position and performance as a standalone
entity. All of our assets, liabilities and expenses as of and for the periods prior to the Asset Transfer Date were identified based on the assets and liabilities contributed to us from PureTech, as well as indirect costs that were not specifically
identifiable to us or our related programs but were considered necessary to operate as a standalone company. Management believes the assumptions underlying our <FONT STYLE="white-space:nowrap">carve-out</FONT> financial statements are reasonable.
Nevertheless, the <FONT STYLE="white-space:nowrap">carve-out</FONT> financial statements may not include all of the actual expenses that would have been incurred had we operated as a standalone company during the periods presented, and may not
reflect our results of operations, financial position, and cash flows had we operated as a standalone company during the periods presented. Actual costs that would have been incurred if we had operated as a standalone company would depend on
multiple factors, including organizational structure and strategic decisions made in various areas. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information
you should consider before investing in our common stock. You should read this entire prospectus carefully, including the sections of this prospectus titled &#8220;Risk Factors,&#8221; &#8220;Special Note Regarding Forward-Looking Statements,&#8221;
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an investment decision.
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated
mechanisms with established efficacy and safety profiles which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary
Glyph<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> platform to overcome those limitations and invent innovative oral therapies. Glyph is a lymphatic-targeting prodrug technology which is designed to bypass first-pass metabolism and thereby
enhance a drug&#8217;s oral bioavailability and reduce side effects. This process, which we call &#8220;Glyphing,&#8221; also creates new composition of matter intellectual property. Our experienced team of industry leaders has a proven track record
in neuropsychiatry drug discovery and development and delivering successful business outcomes. We aim to develop novel, leading treatment options that will make a significant impact for patients and their families. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, GlyphAllo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-300</FONT>
or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression, or PPD, a form of major depressive
disorder, or MDD, that shares symptomatology with MDD, as a rapidly acting antidepressant with anxiolytic and sleep-promoting effects. Additionally, an oral synthetic analog of allopregnanolone, zuranolone, demonstrated a rapid antidepressant effect
that deepened while patients were on drug and met the primary endpoint in five of the six trials in MDD. GlyphAllo is designed to overcome bioavailability limitations of allopregnanolone and deliver rapid and durable efficacy in MDD. We have
demonstrated in a Phase 1 clinical trial that GlyphAllo reaches therapeutically relevant exposures with oral dosing, and in a Phase 2a clinical trial, GlyphAllo demonstrated initial
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> with an objective biomarker of stress in healthy volunteers and a favorable tolerability profile. We have initiated the Phase 2b <FONT
STYLE="white-space:nowrap">BUOY-1</FONT> trial in patients with MDD with or without anxious distress and anticipate topline data in the first half of 2027. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second product candidate, GlyphAgo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-320</FONT>
or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder, or GAD, in Australia and MDD in Australia and the
European Union, or EU. In April 2026, we reported topline data from the single-ascending dose, or SAD, and crossover portions of our Phase&nbsp;1 proof-of-concept clinical trial for GlyphAgo. In the head-to-head crossover portion of the trial,
GlyphAgo demonstrated a 6.8-fold increase in bioavailability of agomelatine compared to unmodified orally administered agomelatine, and showed significantly lower (10-fold) pharmacokinetic variability compared to unmodified agomelatine. In the SAD
portion of the trial, GlyphAgo demonstrated a 9.6 to 14.5-fold increase in dose-normalized exposure compared to agomelatine. GlyphAgo was well-tolerated and no liver-related adverse events, or AEs, were observed. We plan to initiate a Phase 2a
proof-of-pharmacology trial designed to evaluate the potential sleep benefit of GlyphAgo in patients with GAD and sleep disturbance, with topline data expected in early 2028 and, in parallel, a Phase 2b trial designed to evaluate efficacy and safety
of GlyphAgo in patients with GAD, with topline data expected by the end of 2028. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also advancing Glyph2BLSD<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT
STYLE="white-space:nowrap">(SPT-348</FONT> or Glyph <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD),</FONT></FONT> a novel, Glyphed oral prodrug of the <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> LSD
analog <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> in preclinical studies for depressive disorders, including treatment-resistant depression, or TRD, post-traumatic stress disorder, or PTSD, and
headache disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Globally, over one billion people are living with mental illness as of 2021, comparable in prevalence to obesity or
hypertension. According to the World Health Organization, as of 2021, depression affects approximately 332&nbsp;million people worldwide and anxiety affects approximately 359 million people worldwide, and there is a significant need for novel
treatment options. Currently approved drugs for MDD and GAD have significant limitations, including modest efficacy, slow onset of action, and unfavorable side effects. Advancement of novel therapies has been limited by a lack of understanding of
disease pathophysiology, poor drug-like properties, and challenges in clinical trial design and execution leading to high clinical development failure rates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Differentiated Approach </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
uniquely positioned to overcome the challenges of developing medicines for depression, anxiety, and other neuropsychiatric disorders by leveraging our differentiated, three-pillar approach: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Identify clinically validated mechanisms held back by issues that can be addressed by our proprietary </I></B><B><I>Glyph</I></B><B><I>
platform. </I></B>We select our product candidates based on well-established clinical data, defined as demonstrated meaningful benefits compared to placebo in multiple randomized, placebo-controlled clinical trials in a large number of patients. We
identify drugs matching this profile where clinical and commercial potential have been limited by high first-pass metabolism, low bioavailability, and/or side effects. We advance candidates that have the potential to be novel medicines and to
impact<I> </I>a large number of patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Create novel medicines with strong intellectual property using
</I></B><B><I>Glyph</I></B><B>.</B> Glyph is our proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. Typically, <FONT STYLE="white-space:nowrap">non-Glyphed</FONT> oral small
molecules undergo first-pass metabolism, where the concentration of drug is significantly reduced by metabolic enzymes in the liver prior to systemic circulation. First-pass metabolism can lead to low bioavailability (i.e., reduced concentration of
active drug available to target organs) and/or side effects, including liver enzyme elevations or hepatotoxicity. Glyph leverages a separate absorption path taken by dietary fats. A Glyphed molecule uses this alternative route via the intestinal
lymphatic system to bypass first-pass metabolism and transit directly into systemic circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism. For each program, we use
Glyph to create unique sets of prodrugs with differentiated profiles, and evaluate these prodrugs as potential candidates to advance into preclinical and clinical studies. Glyph has been applied to create novel product candidates for our pipeline
resulting in new intellectual property, including composition of matter patents. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Benefits of Our Proprietary Glyph Platform </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01f03.jpg" ALT="LOGO" STYLE="width:6.33333in;height:3.25957in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Apply our team</I></B><B><I>&#8217;</I></B><B><I>s expertise to optimize the design and execution of
clinical trials and drive successful business outcomes</I></B><B>.</B> Our team is comprised of industry leaders with a proven track record of building successful companies that have developed and commercialized innovative neuropsychiatric
medicines. This includes Zyprexa<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Cymbalta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Latuda<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Zurzuvae<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and Cobenfy<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> (xanomeline-trospium or KarXT), which was approved by the FDA in September 2024 and is the first new class of medicines in over
30 years for patients living with schizophrenia. Leveraging our team&#8217;s track record of success in neuropsychiatry discovery and clinical development is important as we select new product candidates and as we implement key design elements in
our clinical trials to<B><I> </I></B>optimize treatment effect and duration and reduce placebo response. In parallel, we apply our deep experience in building successful companies to establish clear goals, drive strategic decision-making, and
maintain financial discipline. Drawing on our track record of success in neuropsychiatry, we aim to drive successful outcomes for patients and shareholders. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a pipeline of novel potential treatments for neuropsychiatric disorders with significant unmet need. We retain exclusive,
worldwide development and commercialization rights to all of our product candidates and discovery programs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01f04.jpg" ALT="LOGO" STYLE="width:6.31667in;height:2.09563in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph aims to unlock the therapeutic potential of drugs in CNS and beyond. In addition to our three lead
candidates, we have robust discovery programs and multiple pipeline programs underway. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>GlyphAllo: Potential Differentiated Therapy
for MDD </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAllo is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous neurosteroid and gamma-aminobutyric acid A,
or GABA<SUB STYLE="font-size:75%; vertical-align:bottom">A</SUB>, positive allosteric modulator, or PAM. Allopregnanolone is a naturally occurring molecule that reduces stress, with levels that peak during the third trimester of pregnancy. An
intravenous infusion formulation of allopregnanolone was approved for the treatment of PPD, a form of MDD. Allopregnanolone has been clinically validated in two third-party trials, which were sponsored by Sage Therapeutics in the United States for
the treatment of PPD and powered for statistical significance, as a rapidly acting antidepressant with anxiolytic and sleep-promoting effects. Due to the shared symptomatology between MDD and PPD, we believe data for MDD are relevant from such
third-party trials. In each trial, allopregnanolone demonstrated statistically significant results on the primary endpoint of change in baseline at 60 hours in the Hamilton Depression Rating Scale-17, or HAMD-17, a regulatory-standard depression
severity rating scale. However, its scope of clinical use has been constrained by oral bioavailability limitations that the Glyph platform is uniquely designed to solve. For example, a previous third-party clinical trial showed that oral
administration of allopregnanolone resulted in plasma exposure levels with an AUC<SUB STYLE="font-size:75%; vertical-align:bottom">inf</SUB> of 0.7 ng*hr/mL per 1 mg of allopregnanolone dosed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAllo: Preclinical Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our preclinical studies conducted in non-human primates, or NHPs, oral dosing of GlyphAllo resulted in a greater than nine-fold increase in
bioavailability compared to oral unmodified allopregnanolone over 24 hours. In these preclinical studies, evaluations of GlyphAllo and unmodified allopregnanolone were conducted simultaneously or sequentially using the same species. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAllo: Clinical Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our Phase 1 clinical trial conducted in Australia in 99 participants, GlyphAllo demonstrated therapeutically relevant exposures with a
favorable tolerability profile that supports chronic dosing. No treatment-related severe or serious adverse events were reported. Oral administration of GlyphAllo in our Phase 1 trial of GlyphAllo resulted in plasma exposure levels with an AUC<SUB
STYLE="font-size:75%; vertical-align:bottom">inf</SUB> of 6.6 ng*hr/mL per 1 mg of allopregnanolone dosed. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAllo has also demonstrated initial <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in a Phase 2a randomized, placebo-controlled trial conducted in Australia in 80&nbsp;participants, using the Trier Social Stress Test, or TSST, a validated clinical model of anxiety in
healthy volunteers. No severe or serious adverse events were reported. Based on these Phase 1 and Phase 2a data, we believe GlyphAllo has the potential to become a leading treatment for MDD. We advanced GlyphAllo into what we believe is a
registration-enabling Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial conducted in the US and EU in July 2025. <FONT STYLE="white-space:nowrap">BUOY-1</FONT> is a global, randomized, double-blind, placebo-controlled trial evaluating
the efficacy, safety, and tolerability of GlyphAllo in adults with MDD, with or without anxious distress. MDD with anxious distress is a form of MDD characterized by significant anxiety. Approximately 60% of patients with MDD meet the criteria for
anxious distress. This trial is expected to enroll up to approximately 360 patients, randomized 1:1 to receive either GlyphAllo or placebo once-daily over a <FONT STYLE="white-space:nowrap">six-week</FONT> treatment period. This randomized, <FONT
STYLE="white-space:nowrap">double-blind,</FONT> multiregional, <FONT STYLE="white-space:nowrap">placebo-controlled</FONT> trial is designed to be registration-enabling, subject to review by the FDA and other comparable regulatory authorities, as an
adequate and well-controlled investigation that seeks to help provide substantial evidence of effectiveness by assessing GlyphAllo&#8217;s efficacy and safety in several hundred patients. Additional clinical trials may be required prior to the
submission of a new drug application even if this trial is successful or positive. The primary endpoint of the trial is the change from baseline at six weeks in <FONT STYLE="white-space:nowrap">HAMD-17.</FONT> Following the initial treatment period,
eligible patients may enter an open-label extension trial, in which all participants will receive GlyphAllo for up to six additional weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Previous clinical development of allopregnanolone and its synthetic analog, which has been evaluated by Sage Therapeutics in multiple
late-stage clinical trials for the treatment of MDD, has been generally hindered by poor oral bioavailability, safety concerns, and clinical trial design limitations. GlyphAllo is designed to enhance the oral bioavailability of allopregnanolone and
achieve systemic exposures comparable to an intravenous infusion of allopregnanolone, with once-daily oral dosing. We believe our ongoing Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial improves upon the design of previous third-party
clinical trials that evaluated a synthetic analog of allopregnanolone in several important ways. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are improving durable efficacy by
treating patients for the full <FONT STYLE="white-space:nowrap">six-week</FONT> duration of the primary endpoint time frame, as opposed to previous trials that treated patients for only the first two weeks and assessed efficacy after six weeks. As
allopregnanolone also has an anxiolytic effect, we are also enrolling patients that have MDD with or without anxious distress. To reduce placebo response, we are optimizing the frequency of clinician-administered assessments, as our comprehensive
meta-analysis of recent antidepressant trials demonstrated that the frequency of these assessments is positively correlated with the magnitude of the placebo response in MDD trials. We are also including a single treatment arm and will flex dose to
a target dose, similar to the strategy implemented at Karuna Therapeutics, since the number of active arms is positively associated with increased placebo response. Additionally, we are scrutinizing site selection and patient enrollment to ensure
appropriate diagnosis and exclude inappropriate patients, including those with inflated baseline ratings and those who are concurrently participating in other studies. We expect topline data from the Phase 2b
<FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in the first half of 2027. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>GlyphAgo: Potential Differentiated Therapy for GAD
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAgo is a novel, Glyphed oral prodrug of agomelatine that we are advancing in a key Phase&nbsp;1 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial for the treatment of GAD in Australia, in which we plan to enroll up to approximately 190&nbsp;participants. Agomelatine, a clinically validated MT1/MT2
melatonin receptor agonist and serotonin 2C <FONT STYLE="white-space:nowrap">(5-HT2C)</FONT> receptor antagonist, is an effective anxiolytic and antidepressant approved for the treatment of GAD in Australia and MDD in Australia and the EU. In GAD,
agomelatine has demonstrated statistically significant </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
separation from placebo in four third-party <FONT STYLE="white-space:nowrap">placebo-controlled</FONT> studies<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>. Based on two of the largest
non-head-to- head literature meta-analyses of clinical trials of pharmacological agents for the treatment of GAD, agomelatine has been shown to have favorable efficacy and tolerability relative to other therapeutic agents. Specifically, in the first
of these meta-analyses, which included two of the placebo-controlled studies of agomelatine, agomelatine was observed to have better efficacy and tolerability than certain
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> drugs, such as selective serotonin-reuptake inhibitors, or SSRIs, which can result in sexual dysfunction and weight gain, and benzodiazepines, which can
result in dependence and abuse. In the second of these meta-analyses, which included three of the placebo-controlled studies of agomelatine, agomelatine was found to be the most favorable drug in terms of both efficacy and tolerability among the
analyzed competitors (venlafaxine, escitalopram, paroxetine, duloxetine, and pregabalin). However, despite this positive profile, over 90% of unmodified agomelatine is lost to first-pass liver metabolism and its use has been limited by
dose-dependent liver enzyme elevations. Its label in both Australia and the EU requires liver function testing before initiating treatment, during treatment, and upon increasing the dose. Agomelatine is not approved in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using our proprietary Glyph platform, GlyphAgo is designed to avoid first-pass liver metabolism and increase systemic exposure of agomelatine,
enabling exposure levels of agomelatine that are effective in GAD but at a lower dose that reduces liver exposure and reduces or eliminates the need for liver function testing. Based on internal analyses, we believe a
<FONT STYLE="white-space:nowrap">two-fold</FONT> increase in the bioavailability of agomelatine with GlyphAgo dosing will reduce or eliminate liver enzyme elevations. In preclinical studies in NHPs we showed that oral dosing of GlyphAgo increased
plasma exposure of agomelatine versus agomelatine alone above this <FONT STYLE="white-space:nowrap">two-fold</FONT> target. Therefore, based on the data we have generated to date, we believe GlyphAgo has the potential to become a leading treatment
for GAD. The ongoing Phase 1 trial will be conducted in multiple parts to evaluate the safety, tolerability, and pharmacokinetics of GlyphAgo and compare the pharmacokinetics of GlyphAgo to agomelatine alone. It will include single- and
multiple-ascending dose cohorts, as well as a food-effect crossover portion, using both open-label and placebo-controlled designs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
April 2026, we reported topline data from the SAD and crossover portions of our Phase&nbsp;1 proof-of-concept clinical trial of GlyphAgo. In the head-to-head crossover portion of the trial, GlyphAgo demonstrated a 6.8-fold increase in
bioavailability of agomelatine compared to unmodified orally administered agomelatine. GlyphAgo also showed significantly lower (10-fold) PK variability compared to unmodified agomelatine.&nbsp;The crossover portion included participants who were
taking estrogen-containing oral contraceptives that are known to increase agomelatine exposure due to liver drug-drug interaction. In contrast, GlyphAgo exposure was unaffected by oral contraceptives, further supporting the ability of GlyphAgo to
bypass first-pass liver metabolism. GlyphAgo demonstrated a 9.6 to 14.5-fold increase in dose-normalized exposure compared to agomelatine in a separate SAD portion of the trial in which no participants were on oral contraceptives. GlyphAgo was well
tolerated and no liver-related AEs were observed. We plan to initiate a Phase 2a proof-of-pharmacology trial designed to evaluate the potential sleep benefit of GlyphAgo in patients with GAD and sleep disturbance, with topline data expected in early
2028. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also plan to initiate, in parallel, a randomized, double-blind, placebo-controlled Phase 2b trial evaluating the efficacy and
safety of GlyphAgo in patients with GAD, with topline data expected by the end of 2028. This multiregional trial is designed to be registration-enabling, subject to review by the FDA and other comparable regulatory authorities, as an adequate and
well-controlled investigation that seeks to provide substantial evidence </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The statements above relating to the placebo-controlled studies of agomelatine in GAD are based on the
following, which represents a complete list of all placebo-controlled studies of agomelatine in GAD: Dan J. Stein, et al., Efficacy and safety of agomelatine (10 or 25&nbsp;mg/day) in non-depressed out-patients with generalized anxiety disorder: A
12-week, double-blind, placebo-controlled study, European Neuropsychopharmacology, Volume 27, Issue 5, 2017 (Also included in meta-analyses); Dan J. Stein, et al., Agomelatine in Generalized Anxiety Disorder: An Active Comparator and
Placebo-Controlled Study, J Clin Psychiatry 2014;75(4):362-368 (Also included in meta-analyses); Dan J. Stein, et al., Agomelatine Prevents Relapse in Generalized Anxiety Disorder: A 6-Month Randomized, Double-Blind, Placebo-Controlled
Discontinuation Study, J Clin Psychiatry <FONT STYLE="white-space:nowrap">2012;73(7):1002-1008;</FONT> Dan J. Stein, et al., Journal of Clinical Psychopharmacology 28(5):p 561-566, October 2008 (Also included in meta-analyses).
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of effectiveness by assessing GlyphAgo&#8217;s efficacy and safety in several hundred patients. Although this trial is designed to be registration-enabling, additional clinical trials may be
required prior to the submission of a new drug application even if this trial is successful or positive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the development and
commercialization of GlyphAgo for the treatment of GAD is our primary focus, as part of our longer-term growth strategy, we may evaluate GlyphAgo in other indications as well, including MDD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Glyph2BLSD and Additional Applications of the Glyph Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph2BLSD is our novel, Glyphed oral prodrug of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> a
differentiated <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> neuroplastogen. Glyph2BLSD is designed to harness the differentiated and <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> profile of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> which has rapidly acting clinical activity and is not expected to exhibit the fibrosis, cardiovascular effects, or hallucinations characteristic of some
other neuroplastogens. Glyph2BLSD is designed to improve the pharmacokinetic and tolerability profile of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD</FONT></FONT> while maintaining therapeutic exposure levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph2BLSD&#8217;s <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> profile unlocks the potential to enable convenient outpatient
and repeat dosing to improve efficacy. We are advancing Glyph2BLSD through preclinical studies and are developing Glyph2BLSD for the treatment of depressive disorders, including TRD, PTSD, and headache disorders with significant unmet need. We are
currently conducting first-in-human-enabling studies of Glyph2BLSD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also leveraging the power of the Glyph platform to explore
additional applications in central nervous system, or CNS, and <FONT STYLE="white-space:nowrap">non-CNS</FONT> diseases and advance programs that address significant unmet needs in these areas.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport was founded by pioneers
in the neuropsychiatry field and is led by a team of seasoned industry veterans with a shared mission to transform the treatment of neuropsychiatric disorders and improve patients&#8217; lives. We have assembled an experienced group of individuals
with a proven track record of building successful companies that have developed and commercialized innovative neuropsychiatric medicines. Members of our leadership team have collaborated successfully over several decades on the discovery,
development, and commercialization of neuropsychiatric medicines including Cobenfy, Latuda, Zyprexa, Cymbalta, and Zurzuvae. Our <FONT STYLE="white-space:nowrap">co-founders,</FONT> Daphne Zohar and Dr.&nbsp;Steven Paul, were central to the success
of Karuna Therapeutics, which invented and advanced the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicine Cobenfy, and was acquired by Bristol Myers Squibb in March 2024 for $14&nbsp;billion.
Cobenfy was approved by the FDA in September 2024 and is the first drug to provide a new mechanism of action for schizophrenia in over 30 years. Cobenfy is estimated to achieve annual peak sales of over $5&nbsp;billion. Despite the prior experience
of our team, our limited operating history as a standalone company makes any reliance on past performance uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception,
we have raised $325&nbsp;million in net proceeds from leading life science investors, including shareholders with holdings greater than 5%: ARCH Venture Partners, General Atlantic, Sofinnova Investments, Third Rock Ventures, and our founder,
PureTech. Prospective investors should not rely on the investment decisions of our existing investors, as these investors may have different risk tolerances and in certain cases received their shares in prior offerings at prices lower than the price
offered to the public in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We founded our company with a mission to develop life-changing treatments for patients with depression, anxiety, and other neuropsychiatric
disorders. The key elements of our business strategy are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Successfully advance GlyphAllo through clinical development for the treatment of patients with MDD with or
without anxious distress. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Successfully advance GlyphAgo through clinical development for the treatment of patients with GAD.<B> </B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Develop a robust pipeline of differentiated programs for neuropsychiatric and other CNS disorders by leveraging
our Glyph platform. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Opportunistically pursue strategic partnerships to maximize the value of our Glyph platform.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Differentiated Approach</B><B><I> </I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are uniquely positioned to develop novel medicines that will make a significant impact for patients and their families through our
differentiated, three-pillar approach: 1) identify clinically validated mechanisms held back by issues that can be addressed by our proprietary Glyph platform, 2) create novel medicines with strong intellectual property using Glyph, and 3) apply our
team&#8217;s expertise to optimize the design and execution of clinical trials and drive successful business outcomes. We believe our approach will enable us to develop transformative treatments for patients and build a leading neuropsychiatry
company.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated With Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks include, but are
not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a clinical-stage therapeutics company with a limited operating history, which may make it difficult to
evaluate our current business and predict our future success and viability. We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will require additional funding in order to finance operations. If we are
unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business is highly dependent on the success of our product candidates, particularly GlyphAllo for the
treatment of MDD with or without anxious distress and GlyphAgo for the treatment of generalized anxiety disorder, or GAD, and MDD. If we are unable to successfully complete clinical development, obtain regulatory approval for or commercialize one or
more of our product candidates, or if we experience delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical and preclinical development involves a lengthy and expensive process and is highly uncertain. Any
difficulties or delays in the commencement or completion, or the termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue or adversely affect our
commercial prospects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory approval processes of the FDA and other comparable regulatory authorities are lengthy,
time-consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The determination of whether the BUOY-1 clinical trial will be registration-enabling lies solely within the
discretion of the FDA and/or other comparable regulatory authorities, based on whether such body views this trial as an adequate and well-controlled clinical investigation that can support regulatory decision making, and whether the resulting data
from the trial provide substantial evidence of effectiveness. There can be no assurance that our clinical trials will ultimately be successful or support further clinical development of our product candidates, and we may have to complete multiple
additional clinical trials, which may be differently designed than prior clinical trials, to support a submission for marketing authorization for this product candidate. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our proprietary Glyph platform is based on a novel approach that may not result in approvable or marketable
products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials
conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the
development and commercialization of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our product candidates may be associated with adverse events, or AEs, or other undesirable properties or safety
risks, which could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials or abandon a product candidate, limit the commercial profile of an approved label, or result in significant negative consequences
following regulatory approval, if obtained, or result in other significant negative consequences that could severely harm our business, financial condition, results of operations, and prospects.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have concentrated our research and development efforts on the treatment of disorders of the brain and central
nervous system, a field that faces certain challenges in drug development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Existing and potential future competitive products may reduce or eliminate the commercial opportunity for our
product candidates, if approved. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer than ours, our ability to develop and successfully
commercialize our product candidates may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to develop product candidates, leverage our Glyph platform and our future growth depends on
attracting, hiring, and retaining our key personnel and recruiting additional qualified personnel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to assist in conducting our clinical trials and preclinical studies. If they do not
successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or
commercialization may be delayed, and our business could be substantially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our commercial success depends on our ability to obtain, maintain, enforce, and otherwise protect our
intellectual property and proprietary technology, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products and product candidates
similar to ours and our ability to successfully develop and commercialize our product candidates may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are heavily reliant upon the Amended and Restated License Agreement with Monash University, or the Monash
License Agreement, pursuant to which we have been granted an exclusive, royalty-bearing license to certain patent rights that are important or necessary to the development of our proprietary technology and product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">While we may in the future seek designations for our product candidates with the FDA and other comparable
regulatory authorities that are intended to confer benefits such as a faster development process, an accelerated regulatory pathway or regulatory exclusivity, there can be no assurance that we will successfully obtain such designations. In addition,
even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our results of operations for the period from January&nbsp;1, 2024 to April&nbsp;7, 2024, which are included in
the consolidated financial statements for the year ended December&nbsp;31, 2024, have been prepared on a <FONT STYLE="white-space:nowrap">&#8220;carve-out&#8221;</FONT> basis based on management estimates, assumptions, and judgments about
appropriate </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
allocation and may not be indicative of what they would have been had we actually been an independent standalone entity throughout such period. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There has been no prior public market for our common stock, and an active trading market may not develop or be
sustained. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary risk factors described above should be read together with the text of the full risk factors in
the section titled &#8220;Risk Factors&#8221; and the other information set forth in this prospectus, including our consolidated financial statements and the related notes, as well as in other documents that we file with the Securities and Exchange
Commission, or the SEC. The risks summarized above or described in full elsewhere in this prospectus are not the only risks that we face. Additional risks and uncertainties not presently known to us, or that we currently deem to be immaterial may
also materially adversely affect our business, financial condition, results of operations, and future growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware as SP Therapeutics, Inc. on April&nbsp;1, 2024 and changed our name to Seaport
Therapeutics, Inc. on April&nbsp;2, 2024. Our wholly owned subsidiary, SPTX, Inc., was a result of the incorporation of a predecessor company under the laws of the State of Delaware in February 2024 under the name Seaport Therapeutics, Inc., which
subsequently changed its name to Seaport Therapeutics Holdings, Inc. in March 2024 and to SPTX, Inc. in April 2024. In April 2024, we entered into a share exchange agreement, or the Share Exchange Agreement, with SPTX, Inc., which resulted in SPTX,
Inc. becoming our wholly owned subsidiary. At the time of the Share Exchange Agreement, we were a wholly-owned subsidiary of PureTech. Our principal executive offices are located at 101 Seaport Blvd., Floor 12, Boston, Massachusetts 02210, and our
telephone number is (617) <FONT STYLE="white-space:nowrap">807-4062.</FONT> We have three subsidiaries, Seaport Therapeutics Securities Corporation, formed in December 2024 under the laws of the Commonwealth of Massachusetts, SPTX, Inc., formed in
February 2024 under the laws of the State of Delaware, and Seaport Therapeutics Australia Pty Ltd, formed in February 2025 under the laws of Australia. Our website address is <I>www.seaporttx.com</I>. The information contained in or accessible from
our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS
Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to present only two years of audited financial statements, in addition to any required unaudited
interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any
golden parachute arrangements not previously approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#8217;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may remain an
emerging growth company for up to five years from the date of the first sale in this offering. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the fiscal year in which we have total annual gross revenues of $1.235&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the
completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules
of the SEC. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the information
you receive from other public companies in which you hold stock. Additionally, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This
allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging
growth company we may not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this election, our financial statements may not
be comparable to those of other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We have in the past chosen and may in the future choose to early adopt any new or revised accounting
standards whenever such early adoption is permitted for private companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#8220;smaller reporting company,&#8221; meaning
that the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue was less
than $100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our shares held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million measured on the last business day of our second fiscal quarter or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed
fiscal year and the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million measured on the last business day of our second fiscal quarter. If we are a smaller reporting company at the
time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only
the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations
regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>11,800,000 shares </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares of common <BR>stock offered by us </P></TD>
<TD>We have granted the underwriters an option for a period of 30 days to purchase up to 1,770,000 additional shares of common stock from us at the public offering price, less underwriting discounts and commissions on the same terms as set forth in
this prospectus. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately <BR>after this offering </P></TD>
<TD>50,667,817 shares (or 52,437,817 shares if the underwriters exercise their option to purchase additional shares of common stock in full) </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We
are offering voting stock in this offering and unless otherwise noted, all references in this prospectus to our &#8220;common stock&#8221; refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities
exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from the sale of our common stock in this offering will be approximately $183.5&nbsp;million (or approximately $211.4&nbsp;million if the underwriters exercise their option to purchase an&nbsp;additional
1,770,000 shares of common stock in full), based on an assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. In addition, if we consummate the concurrent private placement (as described below), we may receive up to an additional $18.6&nbsp;million in net proceeds if certain of our
existing stockholders purchase shares of our common stock in such concurrent private placement, after deducting placement agent fees and estimated private placement expenses payable by us. We intend to use the net proceeds we receive from this
offering, together with our existing cash, cash equivalents, and investments, to advance development of GlyphAllo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-300),</FONT> GlyphAgo<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-320),</FONT> and Glyph2BLSD<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP><SUP STYLE="font-size:75%; vertical-align:top"> </SUP><FONT
STYLE="white-space:nowrap">(SPT-348),</FONT> as well as to fund research and development activities for additional programs, and the remainder for working capital and general corporate purposes. For additional information, see the section titled
&#8220;Use of Proceeds.&#8221; </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Directed share program </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At our request, the underwriters have reserved up to 5% of the shares of common stock being offered by this prospectus for sale at the initial public
offering price to our directors, officers, certain employees, and certain other persons associated with us. The sales will be made by Goldman Sachs &amp; Co. LLC, an underwriter of this offering, through a directed share program. We do not know if
these persons will choose to </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
purchase all or any portion of these reserved shares, but any purchases they do make will reduce the number of shares of common stock available to the general public. Any reserved shares not so
purchased will be offered by the underwriters to the general public on the same terms as the other shares of common stock. Except for reserved shares purchased by our executive officers and directors, these reserved shares will not be subject to the
<FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described elsewhere in this prospectus. For additional information, see the section titled &#8220;Underwriting&#8212;Directed Share Program.&#8221; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Indications of interest </P></TD>
<TD>We have received indications of interest from entities affiliated with General Atlantic to purchase up to $50 million in shares of our common stock in this offering at the initial public offering price per share, on the same terms as the other
purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, nor a commitment of the Company or the underwriters to allocate or sell, more, fewer or no shares may be sold to General
Atlantic in this offering. The underwriters will receive the same underwriting discount and commissions on these shares as they will on any other shares sold to the public in this offering. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Concurrent private placement </P></TD>
<TD>Certain of our existing stockholders, including affiliates of the underwriters, may purchase up to an aggregate of $20&nbsp;million in shares of our common stock in a concurrent private placement exempt from the registration requirements of the
Securities Act of 1933, as amended, on the same pricing, terms and conditions of this offering. The private placement, if consummated, would close concurrently with, and be contingent and conditioned upon the consummation of, this offering, as well
as other customary closing conditions. However, this offering is not contingent on the consummation of the concurrent private placement. Because we have not entered into a binding agreement with such existing stockholders, we could determine to sell
fewer or no shares to these existing stockholders, and any of such existing stockholders could determine to purchase fewer or no shares in this offering. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>For a discussion of factors you should carefully consider before deciding whether to invest in our common stock, see the section titled &#8220;Risk Factors.&#8221; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market trading symbol </P></TD>
<TD>&#8220;SPTX&#8221; </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise noted, the number of shares of our common stock that will be outstanding after
this offering is based on 38,867,817 shares of common stock (which includes 154,778 shares of unvested restricted common stock) outstanding as of December&nbsp;31, 2025, after giving effect to the conversion of all outstanding
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of our convertible preferred stock into an aggregate of 36,272,475 shares of common stock immediately prior to the completion of this offering, or the Preferred Stock Conversion, and
excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">8,798,389 shares of common stock issuable upon exercise of outstanding stock options as of December&nbsp;31,
2025, which includes 228,770 performance-based awards that have not yet been deemed granted for accounting purposes, under our 2024 Equity Incentive Plan, as amended, or the 2024 Plan, with a weighted-average exercise price of $4.68 per share;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">962,655 shares of common stock issuable upon exercise of outstanding stock options granted after
December&nbsp;31, 2025 pursuant to our 2024 Plan, with a weighted-average exercise price of $10.31 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,503,698 shares of common stock reserved for future issuance as of December&nbsp;31, 2025 under the 2024 Plan,
which will cease to be available for issuance at the time that our 2026 Stock Option and Incentive Plan, or the 2026 Plan, becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,182,978&nbsp;shares of our common stock to be granted to an executive officer and a director under the 2026
Plan, issuable upon the exercise of stock options to be granted in connection with this offering, with an exercise price that is equal to the initial public offering price in this offering, or a number of shares of restricted common stock, as
applicable, or the IPO Grants, to maintain an aggregate of approximately 12.5% of the number of shares of our common stock to be outstanding upon the closing of this offering calculated on a fully diluted basis, based on an assumed initial public
offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus (See the sections titled &#8220;Executive Compensation&#8212;Narrative disclosure to the 2025 Summary Compensation
Table&#8212;Equity Incentive Compensation&#8221; and &#8220;Director Compensation&#8221; for more information on such grants, including a description of how the number of shares issuable pursuant to such grants will be determined);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,020,000 shares of our common stock that will become available for future issuance under our 2026 Plan,
including shares reserved for the IPO Grants, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of
shares of common stock reserved for future issuance under the 2026 Plan and any shares underlying outstanding stock awards granted under the 2024 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">510,000 shares of common stock reserved for future issuance under our 2026 Employee Stock Purchase Plan, or the
ESPP, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future
issuance under the ESPP. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the information in this prospectus reflects or assumes the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">1-for-3.1407</FONT> reverse stock split of our common stock and a
proportionate adjustment in the ratio at which our preferred stock is convertible into our common stock, which became effective on April&nbsp;24,&nbsp;2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of all outstanding shares of convertible preferred stock as of December&nbsp;31, 2025 into an
aggregate of 36,272,475 shares of common stock immediately prior to the completion of this offering; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding stock options described above after December&nbsp;31, 2025; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the underwriters&#8217; option to purchase up to an additional 1,770,000 shares of common stock in
this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no issuance by us of shares of our common stock in a concurrent private placement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no purchases by existing stockholders or their affiliates pursuant to the directed share program; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the
completion of this offering and the adoption of our amended and restated bylaws to be in effect upon the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth our summary consolidated statements of operations data for the years ended December&nbsp;31, 2025 and 2024 and
our summary consolidated balance sheet data as of December&nbsp;31, 2025. We have derived the summary consolidated statements of operations data for years ended December&nbsp;31, 2025 and 2024, and the summary consolidated balance sheet data as of
December&nbsp;31, 2025, from our audited consolidated financial statements included elsewhere in this prospectus. The historical results for the period from January&nbsp;1, 2024 to April&nbsp;7, 2024, which are included in the consolidated financial
statements for the year ended December&nbsp;31, 2024, have been prepared on a <FONT STYLE="white-space:nowrap">&#8220;carve-out&#8221;</FONT> basis and are not necessarily indicative of results that may be expected in the future, nor are our other
historical results necessarily indicative of the results that may be expected for any period in the future. You should read the following summary financial data together with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations&#8221; and our consolidated financial statements and the related notes included elsewhere in this prospectus. The summary consolidated financial data included in this section are not intended to replace the consolidated
financial statements and are qualified in their entirety by our consolidated financial statements and the related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development (including stock-based compensation expense of $2.3&nbsp;million and
$0.7&nbsp;million for 2025 and 2024, respectively) <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 25,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative (including stock-based compensation expense of $4.6&nbsp;million and
$15.2&nbsp;million for 2025 and 2024, respectively)<SUP STYLE="font-size:75%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other income (expense), net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted
<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted <SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,373,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">942,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited) <SUP
STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares outstanding, basic and diluted (unaudited) <SUP
STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,646,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Includes related-party amounts of $0.3 million and $14.2 million for research and development expenses for the
years ended December 31, 2025 and 2024, respectively. See Note 17 to our consolidated financial statements included elsewhere in this prospectus. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Includes related-party amounts of $0.1 million and $5.8 million for general administrative expenses for the
years ended December 31, 2025 and 2024, respectively. See Note 17 to our consolidated financial statements included elsewhere in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">See Notes 2 and 16 to our consolidated financial statements included elsewhere in this prospectus for details on
the calculation of basic and diluted net loss per share attributable to common stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Pro forma basic and diluted net loss per share attributable to common stockholders has been prepared to give
effect to adjustments to our capital structure arising in connection with the completion of this offering and is calculated by dividing the pro forma net loss attributable to common stockholders by the pro forma weighted-average common shares
outstanding for the period. Pro forma weighted-average common shares outstanding is computed by adjusting the weighted-average common shares outstanding to give pro forma effect to the Preferred Stock Conversion as if such conversion had occurred on
January&nbsp;1, 2025. Pro forma basic and diluted net loss per share attributable to common stockholders does not include the effect of the shares expected to be sold in this offering. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro</B><br><B>Forma&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>As</B><br><B>Adjusted&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">233,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">233,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">417,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">395,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">432,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(114,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">416,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The pro forma balance sheet data give effect to (i)&nbsp;the Preferred Stock Conversion and (ii)&nbsp;the filing
and effectiveness of our amended and restated certificate of incorporation in Delaware immediately prior to the completion of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The pro forma as adjusted balance sheet data give effect to (i)&nbsp;the pro forma adjustments set forth in
footnote (1)&nbsp;above and (ii)&nbsp;the issuance and sale of shares of our common stock in this offering at an assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Pro forma as adjusted balance sheet data is illustrative only and will change based on the actual initial public offering
price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus,
would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents, and investments, working capital, total assets, and total stockholders&#8217; equity by approximately $11.0&nbsp;million, assuming that the number of
shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each 1,000,000 increase (decrease) in
the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents, and investments, working capital, total assets and total
stockholders&#8217; equity by approximately $15.8 million, assuming no change in the assumed initial offering price per share, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. See our consolidated financial statements
appearing elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties
described below, as well as the other information in this prospectus, including our consolidated financial statements and the related notes included elsewhere in this prospectus and &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations&#8221; before deciding whether to invest in our common stock. The risks described below are not the only ones facing us. The following risks or additional risks and uncertainties not presently known to us or that
we currently believe to be immaterial could materially and adversely affect our business, financial condition, results of operations, and growth prospects. In such an event, the trading price of our common stock could decline, and you may lose all
or part of your investment. This prospectus also contains forward-looking statements and estimates that involve risks and uncertainties not presently known to us or that we currently deem immaterial that also may impair our business operations. Our
actual results could differ materially from those anticipated in our forward-looking statements as a result of specific factors, including the risks and uncertainties described below. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Limited Operating History, Financial Condition, and Need for Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage therapeutics company with a limited operating history, which may make it difficult to evaluate our current
business and predict our future success and viability. We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage therapeutics company with a limited operating history. We were formed by PureTech Health plc, or PureTech, in April
2024 and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, advancing our Glyph<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> platform and technology, identifying
potential product candidates, securing intellectual property rights, and planning and undertaking preclinical studies and clinical trials. Our Glyph platform was being developed by members of our current team during their tenure at PureTech up to
the date of our entry into an Asset Transfer Agreement , or the Asset Transfer Agreement, with PureTech Health LLC, or PureTech Health, and PureTech LYT, Inc., or PureTech LYT, at which time we became a standalone company. As such, our results of
operations for the period from January&nbsp;1, 2024 to April&nbsp;7, 2024, which are included in the consolidated financial statements for the year ended December&nbsp;31, 2024, have been carved out from the results of operations of PureTech that
were attributable to operations related to our Glyph platform and our product candidates, based on management estimates, assumptions, and judgments about appropriate allocation and may not be indicative of what they would have been had we actually
been an independent standalone entity throughout such period, nor are they necessarily indicative of our future results of operations, financial position, and cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At Seaport, we have not yet demonstrated an ability to generate product or collaboration revenues, obtain regulatory approvals, manufacture
any product on a commercial scale or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. All preclinical and early clinical development of GlyphAllo<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-300),</FONT> certain preclinical development of GlyphAgo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>
<FONT STYLE="white-space:nowrap">(SPT-320)</FONT> and our other candidates prior to our formation was conducted when we were part of PureTech. Despite our affiliation with PureTech, and members of our current team&#8217;s involvement in the
development of the Glyph platform while at PureTech, our limited operating history as a standalone company makes any reliance on past performance uncertain. We will encounter risks and difficulties frequently experienced by early-stage therapeutics
companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily upon our ability to identify, develop, and commercialize product candidates based on our Glyph
platform. We do not know whether we will be able to develop any product candidates that succeed through clinical development or to develop products of commercial value. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have no products approved for commercial sale and have not generated any revenue from product sales or collaboration arrangements to date. We will continue to incur significant research and
development and other expenses related to our preclinical and clinical development and ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. Net losses and negative cash flows have had,
and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. Our net losses totaled $74.9&nbsp;million and $46.9&nbsp;million for the years ended December&nbsp;31, 2025 and 2024, respectively. As of
December&nbsp;31, 2025, we have not yet generated product or collaboration revenue and had an accumulated deficit of $114.1&nbsp;million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to
increase as we continue our research and development of, and seek regulatory approvals for, our product candidates. The success of our product candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful initiation and completion of preclinical studies with favorable results, including toxicology and
other studies designed to be compliant with good laboratory practice, or GLP, requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allowance to proceed with clinical trials under Investigational New Drug applications, or INDs, by the United
States Food and Drug Administration, or the FDA, or of similar regulatory submissions by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful initiation, enrollment, and completion of clinical studies in accordance with good clinical practice,
or GCPs, requirements and other applicable rules and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the frequency and severity of adverse events, or AEs, observed in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining and establishing relationships with contract research organizations, or CROs, and clinical sites for
the clinical development of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrating the safety and efficacy of our product candidates to the satisfaction of the FDA and other
applicable regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of regulatory approvals from applicable regulatory authorities, including approvals of New Drug
applications, or NDAs, from the FDA, and maintaining any such approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making arrangements with third-party manufacturers for, or establishing, clinical or commercial manufacturing
capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales, marketing, and distribution capabilities and launching commercial sales of our product
candidates, if and when approved, either alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining, establishing, and maintaining patent and trade secret protection or regulatory exclusivity for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining an acceptable safety profile of our product candidates following regulatory approval, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining and growing an organization of people who can develop and, if approved, commercialize, market and
sell our product candidates, if approved; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of our product candidates, if approved, by patients, the medical community and third-party payors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our expenses will increase substantially if, and as, we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance our product candidates through preclinical and clinical development, including advancing GlyphAllo<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>and GlyphAgo through later-stage clinical trials, and other candidates through discovery and early clinical and preclinical stages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for our product candidates that successfully complete clinical trials from the U.S.
Food and Drug Administration, or the FDA, and/or other foreign comparable regulatory authorities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical, quality control, medical, scientific, and other technical personnel to support the
clinical development of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our internal capabilities to support clinical-stage development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increase our headcount as we expand our research and development organization, and
<FONT STYLE="white-space:nowrap">pre-commercial</FONT> planning activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">undertake any activities to establish sales, marketing, and distribution capabilities in preparation for
commercialization, as applicable, including hiring additional personnel to support such operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify, acquire, and develop additional product candidates where we can leverage our Glyph platform,
including through business development efforts to invest in or <FONT STYLE="white-space:nowrap">in-license</FONT> other technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience heightened regulatory scrutiny; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty, or other payments due under the Asset Transfer Agreement and/or the License Agreement
with Monash University, or the Monash License Agreement, and any future <FONT STYLE="white-space:nowrap">in-license</FONT> or collaboration agreements with third parties; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional legal, accounting, and other expenses associated with operating as a public company.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therapeutic product development entails substantial upfront capital expenditures and significant risk that any
potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, secure market access, and reimbursement and become commercially viable, and therefore any investment in us is highly
speculative. Accordingly, before making an investment in us, you should consider our prospects, factoring in the costs, uncertainties, delays, and difficulties frequently encountered by companies in clinical development, especially clinical-stage
therapeutics companies such as ours. Any predictions you make about our future success or viability may not be as accurate as they would otherwise be if we had a longer operating history or a history of successfully developing and commercializing
pharmaceutical products. We may encounter unforeseen expenses, difficulties, complications, delays, and other known or unknown factors in achieving our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our expenses could increase beyond our expectations if we are required by the FDA or other comparable regulatory authorities to
perform clinical trials in addition to those that we currently expect, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful, we will require additional funding in order to finance operations. If we are unable to raise
capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing therapeutic products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive, and
uncertain process that takes years to complete. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek regulatory approval for, our product candidates. Even
if our current or future product candidates are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. To date, we have funded our operations principally through
private financings. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the clinical and preclinical development of our product candidates, continue to identify additional targets using our Glyph
platform, commence additional preclinical studies and clinical trials, and continue to identify and develop additional product candidates either through internal development or through acquisitions or
<FONT STYLE="white-space:nowrap">in-licensing</FONT> product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, we had $233.7&nbsp;million of cash, cash equivalents and
investments. Based upon our current operating plan, we believe that our existing cash, cash equivalents, and investments, together with the net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure
requirements into 2029. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We may also raise additional financing on an opportunistic basis in the
future. For example, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may
divert our management from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop our product candidates. Our future capital requirements will
depend on many factors, including but not limited to: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, timing, progress, costs, and results of discovery, preclinical development and clinical trials for our
current or future product candidates and effectiveness of our Glyph platform; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of clinical trials required for regulatory approval of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with acquiring or licensing additional product candidates, technologies or assets, including
the timing and amount of any milestones, royalties or other payments due in connection with our acquisitions and licenses, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing clinical and commercial supplies of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and
distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses to attract, hire, and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of macroeconomic trends including inflation, tariffs, and fluctuating interest rates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any potential supply chain interruptions or delays; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological, and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with research and development of product candidates, we are unable to predict the
timing or amount of our working capital requirements. In addition, if we obtain regulatory approval for our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales, and
distribution which make it difficult to predict when or if we will be able to achieve or maintain profitability. Furthermore, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company.
Accordingly, we will need to obtain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantial additional funding in order to support our continuing operations. Our ability to raise additional funds will depend on financial, economic, political and market conditions and other
factors, over which we may have no or limited control. Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it
could force us to delay, limit, reduce, or terminate our product development programs, future commercialization efforts or other operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our
product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations
with our existing cash, cash equivalents, and investments, the net proceeds from this offering, any future equity, debt, royalty, other financings, or any future proceeds received under any licenses or collaborations, if any. If we raise additional
capital through the sale of equity or convertible debt securities, or issue any equity or convertible debt securities in connection with a collaboration agreement or other contractual arrangement, your ownership interest will be diluted, and the
terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. In addition, the possibility of such issuance may cause the market price of our common stock to decline. Debt
financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures,
declaring dividends, or acquiring, selling, or licensing intellectual property rights or assets, which could adversely impact our ability to conduct our business. If we raise additional funds through collaborations, strategic alliances, or
marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams, or product candidates, or grant licenses on terms that may not be
favorable to us. We could also be required to seek funds through arrangements with collaborators, or others at an earlier stage than otherwise would be desirable. Attempting to secure additional financing may also divert management from our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities. Any of these occurrences may have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our
business is highly dependent on the success of our product candidates, particularly GlyphAllo for the treatment of major depressive disorder, or MDD, with or without anxious distress and GlyphAgo for the treatment of generalized anxiety disorder, or
GAD, and MDD. If we are unable to successfully complete clinical development, obtain regulatory approval for or commercialize one or more of our product candidates, or if we experience delays in doing so, our business will be materially harmed.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, as an organization, we have not completed the development of any product candidates and nearly all of our candidates
remain in early-stage clinical or preclinical development. Our future success and ability to generate revenue from our product candidates is dependent on our ability to successfully develop, obtain regulatory approval for, and commercialize one or
more of our product candidates. All of our product candidates that we pursue will require substantial additional investment for clinical development, regulatory review, and approval in one or more jurisdictions. If any of our product candidates,
particularly GlyphAllo for MDD with or without anxious distress, and GlyphAgo for GAD and MDD, encounters safety or efficacy problems, development delays or regulatory issues, or other problems, our development plans and business would be materially
harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not have the financial resources to continue development of our product candidates if we experience any issues that delay
or prevent regulatory approval of, or our ability to commercialize, our product candidates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to demonstrate to the satisfaction of the FDA or other comparable regulatory authorities that our
product candidates are safe and effective; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insufficiency of our financial and other resources to complete the necessary clinical trials and preclinical
studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or inconclusive results from our clinical trials, preclinical studies, or the clinical trials of others
for product candidates similar to ours, leading to a decision or requirement to conduct additional clinical trials or preclinical studies, or abandon a program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product-related AEs experienced by subjects in our clinical trials, including unexpected toxicity results, or by
individuals using drugs or therapeutic biologics similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in submitting an IND application, a New Drug Application, or an NDA, or other regulatory submission to the
FDA or other comparable regulatory authorities, delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension, termination, or hold, of a clinical trial once commenced; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions imposed by the FDA or other comparable regulatory authorities regarding the scope or design of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">poor effectiveness of our product candidates during clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in enrolling subjects in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">high <FONT STYLE="white-space:nowrap">drop-out</FONT> rates of subjects from our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inadequate supply or quality of product candidates or other materials necessary for the conduct of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher than anticipated clinical trial or manufacturing costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable FDA or other comparable regulatory authority inspection and review of our clinical trial sites,
manufacturing sites, or those of our partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our third-party contractors or investigators to comply with regulatory requirements or the clinical
trial protocol or otherwise meet their contractual obligations in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition with existing platforms, product candidates, or therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays and changes in regulatory requirements, policies, and guidelines, including the imposition of additional
regulatory oversight around clinical testing generally or with respect to our therapies in particular; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insufficiency of our financial and other resources to complete the necessary activities to prepare for launch,
commercialization and/or resources to address coverage and reimbursement matters to the extent any of our products receive approval; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">varying interpretations of data by the FDA or other comparable regulatory authorities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical and preclinical development involves a lengthy and expensive process and is highly uncertain. Any difficulties or delays in the
commencement or completion, or the termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue or adversely affect our commercial prospects. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining approval from regulatory authorities for the commercialization of any of our product candidates, we must conduct extensive
clinical trials to demonstrate the safety and efficacy of the product candidate in humans. Before we can initiate clinical trials for any product candidates, we must submit the results of preclinical studies to the FDA or other comparable regulatory
authorities along with other information, including information about product candidate chemistry, manufacturing and controls, and our proposed clinical trial protocol, as part of an IND or similar regulatory submission. The FDA or other comparable
regulatory authorities may require us to conduct additional preclinical studies for any product candidate before it allows us </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to initiate clinical trials under any IND or similar regulatory submission, which may lead to delays and increase the costs of our preclinical development programs. Moreover, even if we commence
clinical trials, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Any such delays in the commencement or completion of our ongoing and planned clinical trials for our product candidates could
significantly affect our product development timelines and product development costs and harm our financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know
whether our planned clinical trials will begin on time or be completed on schedule, if at all. The timing for commencement, data readouts, and completion of clinical trials can be delayed for a number of reasons, including delays related to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology, or other <I>in vivo</I> or <I>in vitro</I> data to
support the initiation or continuation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining allowance or approval from regulatory authorities to commence a trial or reaching a consensus with
regulatory authorities on trial design; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities disagreeing as to the design or implementation of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be
subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying, recruiting, and training suitable clinical investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining approval from one or more institutional review boards, or IRBs, or ethics committees at clinical trial
sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IRBs refusing to approve, suspending, or terminating the trial at an investigational site, precluding enrollment
of additional subjects, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes or amendments to the clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from the trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by our CROs to perform in accordance with GCP requirements or applicable regulatory rules and guidelines
in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of our product candidates for use in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects failing to enroll or remain in our trials at the rate we expect, or failing to return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up,</FONT> including subjects failing to remain in our trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients choosing an alternative product for the indications for which we are developing our product candidates,
or participating in competing clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue a clinical trial or costs being greater than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects experiencing severe or serious unexpected drug-related AEs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious AEs in trials of the same class of agents conducted by other companies that could be
considered similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or extended analysis of
the resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfer of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization,
or CMO, delays or failure by our CMOs or us to make any necessary changes to such manufacturing process, or failure of our CMOs to produce clinical trial materials in accordance with current Good Manufacturing Practice, or cGMP, regulations or other
applicable requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties being unwilling or unable to satisfy their contractual obligations to us in a timely manner.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials must be conducted in accordance with the FDA and other comparable regulatory
authorities&#8217; legal requirements, regulations, and guidelines, and remain subject to oversight by these governmental agencies and ethics committees or IRBs at the medical institutions where such clinical trials are conducted. We could also
encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial, or by the FDA or other comparable regulatory
authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or applicable clinical trial protocols, adverse findings
from inspections of clinical trial sites by the FDA or other comparable regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or
administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may
require us to resubmit our clinical trial protocols to regulators or to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, conducting clinical trials in foreign countries, as we are currently doing and may do for our current or future product candidates,
presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled subjects in foreign countries to adhere to clinical protocols as a result of differences in healthcare services or cultural
customs, managing additional administrative burdens associated with foreign regulatory schemes, and political and economic risks, including war, relevant to such foreign countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many of the factors that cause or lead to the termination, suspension of, or a delay in the commencement or completion of
clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any resulting delays to our clinical trials could shorten any period during which we may have the exclusive right to commercialize our product
candidates. In such cases, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial
condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Due to the significant resources required for the development of our pipeline and
uncertainty regarding our ability to access capital, we must prioritize the development of certain product candidates over others. Moreover, we may fail to expend our limited resources on product candidates or indications that may have been more
profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to invent and develop new medicines for patients with
depression, anxiety, and other debilitating neuropsychiatric disorders. Our lead product candidate, GlyphAllo for the treatment of MDD, with or without anxious distress, has been evaluated in Phase 1 and Phase 2a studies in healthy volunteers and is
currently in Phase 2b clinical development in our <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial. Our second product candidate, GlyphAgo, is being evaluated in an ongoing Phase 1 trial and we intend to advance GlyphAgo into parallel Phase 2a
and Phase 2b clinical trials. Our third product candidate, Glyph2BLSD, is in preclinical studies and our other programs are at various stages of discovery and preclinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the significant resources required for the development of our product candidates, we must decide which product candidates and
indications to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management, and financial resources toward particular product candidates, therapeutic
areas, or indications may not lead to the development of viable commercial products and may divert resources away from better opportunities. If we make incorrect determinations regarding the viability or market potential of any of our product
candidates or misread trends in the pharmaceutical industry, in particular for disorders of the brain and nervous system, our business, financial condition, and results of operations could be materially and adversely affected. As a result, we may
fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or
relinquish valuable rights to such product candidates through collaboration, licensing, or royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We, third parties on which we rely, and our service providers are, or may become, subject to a variety of stringent and
evolving privacy and data security laws, regulations, and rules, contractual obligations, industry standards, policies, and other obligations related to privacy and data security. Any actual or perceived failure to comply with such obligations could
expose us to significant fines or other penalties and otherwise harm our business and operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our
business, we and the third parties upon which we rely (such as our third-party CROs, and other contractors and consultants) collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit,
and share, or, collectively, process, personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, financial
information, and data we collect about trial participants in connection with clinical trials, or, collectively, sensitive data. Our data processing activities subject us to numerous evolving privacy and data security obligations, such as various
laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to privacy and data security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The legislative and regulatory framework for the processing of personal data worldwide is rapidly evolving and is likely to remain uncertain
for the foreseeable future. Numerous federal, state, and local laws and regulations, including federal and state information security and data breach notification laws and regulations, federal and state consumer protection laws (e.g., Section&nbsp;5
of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws) govern the processing of health-related and other personal data. Many of these laws and regulations differ from each other and from the Health Insurance
Portability and Accountability Act of 1996, or HIPAA, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties, private litigation, and
injunctive relief. In the event that we are subject to or affected by HIPAA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses,
including providing specific disclosures in privacy notices and affording individuals certain rights concerning their personal data. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect
more states to pass similar laws in the future. While the comprehensive privacy laws that are in effect at the state level generally exempt certain data processed in the context of clinical trials, the continued development of new privacy laws at
the state level may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely. Further proposed privacy legislation, if enacted, may add additional complexity, variation in
requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of data and information that could be of potential use to the growth and development of
our business, and could result in increased compliance costs and/or the necessity of making changes in our business practices and policies. The continued further development of privacy laws in different states in the country would make our
compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may be subject to new laws governing the privacy of certain specific types of data, including, most notably, consumer health
data. For example, Washington State&#8217;s My Health My Data Act broadly defines consumer health data, creates a private right of action to allow individuals to sue for violations of the law, imposes stringent consent requirements, and grants
consumers certain rights with respect to their health </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data, including to request deletion of their information. Connecticut and Nevada have also passed similar laws regulating consumer health data. State laws are changing rapidly and there is
ongoing discussion in the U.S. Congress of a new comprehensive federal data privacy law to which we would likely become subject, if enacted. These various privacy and data security laws may impact our business activities, including our
identification of research subjects, relationships with business partners, and ultimately the marketing and distribution of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, an increasing number of laws, regulations, and industry standards may govern privacy and data security. For
example, the European Union&#8217;s General Data Protection Regulation, or EU GDPR, and the United Kingdom&#8217;s, or UK&#8217;s, GDPR, or UK GDPR, impose strict requirements for processing personal data. The EU GDPR and the UK GDPR, or together,
GDPR, establish stringent requirements regarding the processing of personal data, including strict requirements relating to processing of sensitive data (such as health data), ensuring there is a legal basis or condition to justify the processing of
personal data, where required strict requirements relating to obtaining consent of individuals, expanded disclosures about how personal data is to be used, limitations on retention of information, implementing safeguards to protect the security and
confidentiality of personal data, where required providing notification of data breaches, maintaining records of processing activities, and documenting data protection impact assessments where there is high risk processing and taking certain
measures when engaging third-party processors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under GDPR, companies may face temporary or definitive bans on data processing and other
corrective activities, fines of up to &#128;20&nbsp;million (&pound;17.5&nbsp;million GBP) or 4% of annual global revenues, whichever is greater, and private litigation related to processing of personal data brought by classes of data subjects or
consumer protection organizations authorized at law to represent their interests. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> could also result in a material adverse effect on our business, financial condition, and results of operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due
to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European
Economic Area, or EEA, and the UK have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent
interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the
EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework, and the UK extension thereto (which allows for transfers to
relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal
data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally compliant transfer are too onerous, we could face
significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense,
increased exposure to regulatory actions, substantial fines, and penalties, the inability to transfer data and work with partners, vendors, and other third parties, and injunctions against our processing or transferring of personal data necessary to
operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities
activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to privacy and data security laws, we are contractually subject to industry standards adopted by industry groups and may become
subject to such obligations in the future. We are also bound by other contractual obligations related to privacy and data security, and our efforts to comply with such obligations may not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successful. We may publish privacy policies and marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding privacy and data
security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other
adverse consequences. Obligations related to privacy and data security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject
to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services,
information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may at
times fail (or be perceived to have failed) in our efforts to comply with our privacy and data security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could
negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable privacy and data security obligations, we could face significant consequences,
including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements
and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass
arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any
of these events could have a material adverse effect on our reputation, business, financial condition, or results of operations, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as
relevant, clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or
substantial changes to our business model or operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Discovery and Development of Our Current or Future Product Candidates
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA and other comparable regulatory authorities are lengthy, time-consuming and
inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not permitted to commercialize, market, promote, or sell any product candidate in the United States without obtaining regulatory
approval from the FDA. Other comparable regulatory authorities impose similar requirements. The time required to obtain approval by the FDA or other comparable regulatory authorities is inherently unpredictable, but typically takes many years
following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain
approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. For instance, jurisdictions outside of the United States, such as the EU, may have different requirements for regulatory
approval, which may require us to conduct additional clinical, nonclinical, or chemistry, manufacturing, and control studies. To date, we have not submitted an NDA to the FDA or similar drug approval submissions to other comparable regulatory
authorities for any product candidate. We must complete additional preclinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is inherently uncertain as to outcome.
We cannot guarantee that our clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our initial and potential additional product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates is susceptible to the risk of failure inherent at any stage of development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the
occurrence of AEs that are severe or medically or commercially unacceptable, failure to comply with protocols or applicable regulatory requirements and determination by the FDA or other comparable regulatory authorities that a product candidate may
not continue development or is not approvable. It is possible that even if any of our product candidates have a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors,
including the size, duration, design, measurements, conduct, or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of such product candidate that is greater than
the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of, or intolerability caused by, such product candidate, or mistakenly believe that our product candidates are toxic or not well tolerated when that
is not in fact the case. Serious AEs or other AEs, as well as tolerability issues, could hinder or prevent market acceptance of the product candidate at issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future product candidates could fail to receive regulatory approval for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may disagree as to the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or other comparable regulatory authorities that a
product candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or other
comparable regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety
risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may disagree with our interpretation of data from clinical
trials or preclinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission
of an NDA to the FDA or other submission or to obtain regulatory approval in the United States, the European Union or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may find deficiencies with or fail to approve the
manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or other comparable regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This lengthy approval process as well as the
unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would substantially harm our business, results of operations and prospects. The FDA and other
comparable regulatory authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be granted for any product candidate that we develop. Even if we believe the data collected from future
clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or other comparable regulatory authorities. Furthermore, the U.S. Supreme Court&#8217;s July 2024 decision to overturn prior
established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which FDA&#8217;s regulations, policies, and decisions may become subject to
increasing legal challenges, delays, and/or changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we were to obtain approval, regulatory authorities may approve any of our
product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials or may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing
scenarios could materially harm the commercial prospects for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, FDA and foreign regulatory authorities
may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched
by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the
eligibility for expedited pathways, etc.) was published on April&nbsp;26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and Council of the EU and the proposals may therefore be substantially revised before
adoption, which is not anticipated before early 2026. The revisions may, however, have a significant impact on the pharmaceutical industry and our business in the long term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The FDA or other comparable regulatory authorities may disagree with our regulatory plan for our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general approach for FDA approval of a new drug is dispositive data from two or more adequate and well-controlled clinical trials of the
product candidate in the relevant patient population. Adequate and well-controlled clinical trials typically involve a large number of patients, have significant costs and take years to complete. The FDA or other comparable regulatory authorities
may disagree with us about whether a clinical trial is adequate and well-controlled or may request that we conduct additional clinical trials prior to regulatory approval. In addition, there is no assurance that the doses, endpoints, and trial
designs that we intend to use for our planned clinical trials, including those that we have developed based on feedback from regulatory agencies or those that have been used for the approval of similar drugs, will be acceptable for future approvals.
For instance, if we elect to pursue an indication of MDD with anxious distress, we will need to be able to reliably and consistently identify this <FONT STYLE="white-space:nowrap">sub-population</FONT> of MDD patients, and we will need to
demonstrate that GlyphAllo has a differentiated effect in these patients. However, the FDA may not agree with our proposed development plans, and our clinical trial results may not support approval of our product candidates for our target
indications. In addition, our product candidates could fail to receive regulatory approval, or regulatory approval could be delayed, for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may not file or accept our NDA or marketing application for
substantive review; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may disagree with the dosing regimen, design, or
implementation of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may determine there is not substantial evidence of
effectiveness to support approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or other comparable regulatory authorities that
our product candidates are safe and effective for any of their proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our clinical trials may not meet the level of statistical significance required by the FDA or
other comparable regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their
safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may disagree with our interpretation of data from preclinical
studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of
the FDA or other comparable regulatory authorities to support the submission of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may find deficiencies with or fail to approve the
manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or other comparable regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our proprietary Glyph platform is based
on a novel approach that may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is utilizing our proprietary Glyph platform, which is designed to leverage the lymphatic system to enable and
enhance the oral administration of drugs, avoid first-pass liver metabolism and reduce side effects that have previously impeded the development of certain active drugs. Despite favorable results in third-party clinical trials of the active moiety
that is chemically identical to the active moiety within our product candidates and the favorable results in clinical trials of our molecules and mechanisms to date, the scientific research that forms the basis of our approach is still ongoing. Each
of our current product candidates utilizes our Glyph platform. As a result, we are exposed to a number of unforeseen risks related to our Glyph platform, and these risks could impact each of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although our research and development efforts to date have resulted in a development portfolio of programs and product candidates, we may not
be able to discover or identify additional candidates that could appropriately utilize our Glyph platform and thus not be able to develop product candidates to expand our development portfolio. Even if we are successful in continuing to build and
expand our development portfolio, the potential product candidates that we identify may not be successful in clinical development. For example, even though our Glyph platform is intended to reduce certain side effects, our product candidates may
nonetheless be shown to have harmful side effects or other characteristics that indicate that they are unlikely to offer an improvement over standard of care or receive marketing approval and achieve market acceptance. If we do not successfully
develop and commercialize product candidates, we will not be able to obtain drug revenues in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third
parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
results observed from preclinical studies or early-stage clinical trials of our product candidates may not necessarily be predictive of the results of later-stage clinical trials that we conduct. Similarly, positive results from such preclinical
studies or early-stage clinical trials may not be replicated in our subsequent preclinical studies or clinical trials. For instance, results seen in preclinical animal models may not translate to similar results in patients, and results from our
initial studies in healthy volunteers may not translate to clinical trials in patients with MDD or GAD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that
any of our clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs proceeding through clinical trials. Many companies in the pharmaceutical and
biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused
by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported AEs. Additionally, GlyphAllo is a novel,
Glyphed oral prodrug of allopregnanolone, an endogenous neurosteroid with a well-established, clinically validated antidepressant, anxiolytic, and sleep-promoting effect, and GlyphAgo is a novel, Glyphed oral prodrug of agomelatine, a clinically
validated antidepressant and anxiolytic. We may be unable to replicate the previous clinical efficacy observed with such molecules in clinical trials utilizing our Glyph platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may in the future utilize an &#8220;open-label&#8221; clinical trial design
for certain of our future clinical trials. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or
placebo. Most open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as
patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of
receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have
received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results of a product candidate when studied in a
controlled environment with a placebo or active control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, preclinical and clinical data are often susceptible to varying
interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other comparable regulatory authority approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and
commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain the requisite regulatory approvals to commercialize any of our product
candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans. We have and may in the future experience delays in our clinical trials or preclinical studies and
initiating or completing additional clinical trials or preclinical studies, including as a result of regulators not allowing or delay in allowing clinical trials to proceed under an IND or similar foreign authorization (e.g. regulatory hold), or not
approving or delaying approval for any clinical trial grant or similar approval we need to initiate a clinical trial or a hold on an ongoing clinical trial. We may also experience numerous unforeseen events during our clinical trials that could
delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, IRBs, or other reviewing bodies may not authorize us or our investigators to commence a clinical
trial, to conduct, or continue a clinical trial at a prospective or specific trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which
can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience challenges or delays in recruiting principal investigators or study sites to lead our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subjects or patients required for clinical trials of our product candidates may be larger than we
anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any given clinical trial, or
patients may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors, including those manufacturing our product candidates or conducting clinical trials
on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may have to amend clinical trial protocols submitted to regulatory authorities or conduct additional studies
to reflect changes in regulatory requirements or guidance, which may be required to resubmit to an IRB and regulatory authorities for <FONT STYLE="white-space:nowrap">re-examination;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators or other reviewing bodies may find deficiencies with, fail to approve, or subsequently find fault with
the manufacturing processes or facilities of third-party manufacturers with which we enter </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
into agreements for clinical and commercial supplies, or the supply or quality of any product candidate or other materials necessary to conduct clinical trials of our product candidates may be
insufficient, inadequate, or not available at an acceptable cost, or we may experience interruptions in supply; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for approval policies or regulations of the FDA, or other comparable regulatory authorities to
significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulators or IRBs of the
institutions in which clinical trials are being conducted may suspend, limit, or terminate a clinical trial, or data monitoring committees may recommend that we suspend or terminate a clinical trial, due to a number of factors, including failure to
conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other comparable regulatory authorities resulting in the imposition of a
clinical hold, safety issues, or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations, or administrative actions or lack of adequate funding to continue the clinical trial. Negative or
inconclusive results from our clinical trials or preclinical studies could mandate repeated or additional clinical trials and, to the extent we choose to conduct clinical trials in other indications, could result in changes to or delays in clinical
trials of our product candidates in such other indications. We do not know whether any clinical trials that we conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market our product candidates for the
indications that we are pursuing. If later-stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates will be adversely impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our failure to successfully initiate and complete clinical trials and to demonstrate the efficacy and safety necessary to obtain regulatory
approval to market our product candidates would significantly harm our business. Our product candidate development costs will also increase if we experience delays in testing or regulatory approvals and we may be required to obtain additional funds
to complete clinical trials. We cannot assure you that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need to restructure or otherwise modify our trials after they have begun. Significant
clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully
commercialize our product candidates, which may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may be associated with adverse side effects, AEs, or other undesirable properties or safety
risks, which could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials or abandon a product candidate, limit the commercial profile of an approved label, or result in significant negative consequences
following regulatory approval, if obtained, or result in other significant negative consequences that could severely harm our business, financial condition, results of operations, and prospects.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by any of our product candidates could cause us or regulatory authorities to interrupt, delay, or
halt clinical trials and could result in a more restrictive label, the inclusion of a Risk Evaluation and Mitigation Strategy, or REMS, or the delay or denial of regulatory approval by the FDA or other comparable regulatory authorities. Any
treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial, or could result in potential product liability claims. Any of these occurrences may harm our business, financial
condition, and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may observe safety or tolerability issues beyond those we anticipate with our product
candidates in ongoing or future clinical trials. For example, to date, we have only completed clinical studies evaluating GlyphAllo in healthy volunteers, and it is possible that serious AEs related to GlyphAllo may occur in this clinical program or
in our clinical programs for other product candidates. Additionally, it is possible that human subjects with MDD may experience greater side effects in our clinical program for GlyphAllo than observed in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
healthy volunteers. We continue to learn more about our product candidates, and unfavorable profiles could lead to adverse outcomes or concerns by the FDA or other comparable regulatory
authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many compounds that initially showed promise in clinical or earlier-stage testing are later found to cause undesirable or
unexpected side effects that prevented further development of the compound. Results of future clinical trials of our product candidates could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics,
despite a favorable tolerability profile observed in earlier-stage testing. At any time, we may decide to terminate or greatly narrow the target population for a clinical development program due to unacceptable side effects or safety concerns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If unacceptable side effects arise in the development of our product candidates, we, the FDA or other comparable regulatory authorities, the
IRBs, or independent ethics committees at the institutions in which our trials are conducted, could suspend, limit, or terminate our clinical trials, or the independent safety monitoring committee could recommend that we suspend, limit, or terminate
our trials, or the FDA or other comparable regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. We may be unable to overcome any such suspensions or holds that
are placed on our clinical trials. Treatment-emergent side effects that are deemed to be drug-related could delay recruitment of clinical trial subjects or may cause subjects that enroll in our clinical trials to discontinue participation in our
clinical trials. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may need to train medical personnel using our product candidates to understand the side effect profiles for our
clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in harm to patients that are administered our product
candidates. Any of these occurrences may materially adversely affect our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical
trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, some of our product candidates utilize prodrugs of drugs that have been approved by regulatory authorities, such as the FDA and
other comparable regulatory authorities, which if such approval is revoked, could negatively impact the success of our own products. For example, GlyphAllo is an oral prodrug of allopregnanolone, and brexanolone, a synthetic formulation of
allopregnanolone, is currently approved by FDA for the treatment of postpartum depression. GlyphAgo is an oral prodrug of agomelatine, which has been approved for the treatment of GAD in Australia and MDD in Australia and Europe. It is possible that
one or more of the active moieties of our product candidates has also been approved by FDA or other comparable regulatory authorities. In addition, even if our product candidates were to receive marketing approval or be commercialized, we would
continue to be subject to the risks that the FDA or other comparable regulatory authorities could revoke approval of an active moiety that is chemically identical to the active moiety within our product candidates or any active moiety as our product
candidates, if applicable, or that efficacy or safety issues could arise with any active moiety that is chemically identical to the active moiety within our product candidates or active moiety as our product candidates, if applicable, which could
negatively impact the commercial opportunity for our own products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if any of our product candidates receives regulatory
approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a REMS, to ensure that the benefits of
treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems
and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. We or our collaborators may also be required to adopt a REMS or engage in similar actions, such as patient
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop alone. Other
potentially significant negative consequences associated with AEs include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to suspend marketing of a product, or we may decide to remove such product from the
marketplace; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw or change their approvals of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label or limit access of a product to selective
specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to create a medication guide outlining the risks of a product for patients, or to conduct
post-marketing studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a product is administered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or be sued and held
liable for harm caused to subjects or patients; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product may become less competitive, and our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving
or maintaining market acceptance of our product candidates, if approved by the FDA or other regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we
complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain, and may prevent us from obtaining approvals for the commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidate we develop and the activities associated with its development and commercialization, including its design, testing,
manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other comparable regulatory authorities in the United States, and by
other comparable foreign regulatory authorities. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product
candidates from regulatory authorities in any jurisdiction and it is possible that none of the product candidates we are developing or may seek to develop in the future will ever obtain regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team expects to rely, in addition to <FONT STYLE="white-space:nowrap">in-house</FONT> regulatory personnel, on third-party CROs and
regulatory consultants to assist us in submitting and supporting the applications necessary to gain marketing approvals. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to
the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to,
and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or
other characteristics that may preclude its obtaining marketing approval or prevent or limit commercial use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of obtaining
marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type,
complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted
product application, may cause delays </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the approval or rejection of an application. The FDA and other comparable regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or
may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent
marketing approval of a product candidate. Any marketing approval that we may ultimately obtain could be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial
prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interim,
topline, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the
final data. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim, topline, or preliminary data from our clinical trials and preclinical
studies. Such announcements or publications are typically based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to
the particular study or trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the
interim, topline, or preliminary results that we report may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated.
Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously published. As a result, topline, and preliminary
data should be viewed with caution until the final data are available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interim data from clinical trials that we may complete are further
subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim, topline, or preliminary data, and final data could
significantly harm our business prospects. Further, disclosure of such data by us or by our competitors could result in volatility in the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or
analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In
addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate
information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities, or otherwise regarding a particular product candidate
or our business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize,
our product candidates may be harmed, which could harm our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If
we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the development and commercialization of our product candidates may be delayed, and our business, financial condition, and results of
operations may be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For planning purposes, we sometimes estimate the timing of the accomplishment of various scientific,
clinical, regulatory and other product development objectives. These milestones may include our expectations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regarding the commencement or completion of scientific studies and clinical trials, the submission of regulatory filings, or commercialization objectives. From time to time, we may publicly
announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of marketing approval, or a commercial launch of a product. The achievement of many of
these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which, if not realized as expected, may cause the timing of achievement of the milestones to vary considerably from our estimates,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our available capital resources or capital constraints we experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate of progress, costs and results of our clinical trials and research and development activities, including
the extent of scheduling conflicts with participating clinicians and collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our receipt of approvals by the FDA and other comparable regulatory authorities and the timing thereof;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other actions, decisions, or rules issued by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to access sufficient, reliable and affordable supplies of materials used to manufacture our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts of our collaborators with respect to the commercialization of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and
marketing activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to achieve announced milestones in the timeframes we expect, the development and
commercialization of our product candidates may be delayed, and our business, financial condition, and results of operations may be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have concentrated our research and development efforts on the treatment of disorders of the brain and central nervous system, a field
that faces certain challenges in drug development. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have focused our research and development efforts on addressing disorders
of the brain and central nervous system. Developing a product candidate for treatment of these diseases is difficult and subjects us to a number of challenges specific to central nervous system, or CNS, companies. In particular, many
neuropsychiatric disorders, such as MDD and GAD, rely on subjective patient-reported outcomes as key clinical endpoints. This makes them more vulnerable to the placebo effect as compared to evaluating outcomes with more objective endpoints. For
example, our Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial of GlyphAllo is using endpoints based on subjective assessment scales such as the <FONT STYLE="white-space:nowrap">HAMD-17</FONT> and the Clinical Global Impressions-Severity
scale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, given the history of clinical failures in this field, future clinical or regulatory failures by us or others may result
in further negative perception of the likelihood of success in this field, which may significantly and adversely affect the market price of our common stock. We intend to work closely with the FDA and other comparable regulatory authorities to
perform the requisite scientific analyses and evaluation in an effort to obtain regulatory approval for our product candidates; however, the process of developing our product candidates may be complex and time-consuming for the reasons described
herein. We cannot be certain that our approach will lead to the development of product candidates that effectively and safely address the underlying diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or
otherwise adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is a significant factor impacting the duration of our clinical trials, along
with treatment duration and completion of required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. We may experience difficulties in patient enrollment in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with our protocols depends, among other things, on our ability to enroll a sufficient number
of patients who remain in the study until its conclusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is affected by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient eligibility criteria defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to study sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient misrepresentation of their eligibility or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the
clinical trial protocol, resulting in the need to drop such patients from the clinical trial, increase the needed enrollment size for the clinical trial, or extend the clinical trial&#8217;s duration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of new indications for existing therapies or approval of new therapies in general;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages
and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications that we are investigating; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued enrollment of prospective patients by clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patient consents; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in our clinical trials will drop out of the trials before completion.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience challenges in recruiting principal investigators and patients to participate in ongoing and future
clinical trials for such product candidates if we are unable to sufficiently demonstrate the potential of such product candidates to them. Furthermore, we may experience difficulties in reliably and consistently identifying the subpopulation of MDD
patients with anxious distress, which may delay our recruitment efforts for our Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial. We also plan to take additional screening steps for patients beyond what certain other sponsors have done
in similar trials, which may further narrow the eligible population of patients for our trials and cause delays in our recruitment efforts. In addition, our clinical trials may compete with other clinical trials for product candidates that are in
the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being
conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of
patients who are available for our clinical trials in such clinical trial site. Furthermore, if significant AEs or other side effects are observed in any of our clinical trials, we may have difficulty recruiting patients to our trials and patients
may drop out of our trials. Additionally, patients, including patients in any control groups, may withdraw from the clinical trial for various reasons, including but not limited to if they are not experiencing improvement in their underlying disease
or condition, or if they experience other difficulties or issues relating to their underlying disease or condition. Participants with neuropsychiatric disorders such as MDD and GAD constitute a vulnerable patient population and may withdraw from the
clinical trial if they are not experiencing improvement in their underlying disease or condition or if they experience other difficulties or issues relating to their underlying disease or condition or otherwise, which may or may not be related to
our product candidate in clinical trial. Withdrawal of patients from our clinical trials may compromise the quality of our data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on, and will continue to rely on, CROs and clinical trial sites to ensure
proper and timely conduct of our clinical trials and preclinical studies. Though we have entered into agreements governing their services, we will have limited influence over their actual performance. Our inability to enroll a sufficient number of
patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials or our development efforts altogether. Delays in patient enrollment may result in increased costs, affect the timing or
outcome of the planned clinical trials, product candidate development and approval process, and jeopardize our ability to seek and obtain the regulatory approval required to commence product sales and generate revenue, which could prevent completion
of these trials, adversely affect our ability to advance the development of our product candidates, cause our value to decline, and limit our ability to obtain additional financing if needed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may conduct clinical trials for our product candidates outside of the United States and the FDA may not accept data from such trials,
in which case our development plans may be delayed, which could materially harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted and are
conducting clinical trials for our product candidates outside the United States. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or other comparable regulatory authorities may be
subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for regulatory approval in the United States, the FDA will generally not approve the application on
the basis of foreign data alone unless (i)&nbsp;the data are applicable to the U.S. population and U.S. medical practice; (ii)&nbsp;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and
(iii)&nbsp;the data may be considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an <FONT
STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, if the study was not otherwise subject to an IND, the FDA will
not accept the data as support for an application for regulatory approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection
if deemed necessary. Many foreign regulatory authorities have similar requirements for clinical data gathered outside of their respective jurisdictions. In addition, such foreign trials would be subject to the applicable local laws of the foreign
jurisdictions where the trials are conducted. There can be no assurance that the FDA or any other comparable regulatory authorities will accept data from trials conducted outside of the United States or the relevant jurisdiction. If the FDA or any
other comparable regulatory authority does not accept such data, it may result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not
receiving approval for commercialization in the applicable jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if any of our product candidates receives regulatory
approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become
profitable. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never commercialized a product, and even if any of our product candidates are approved by the appropriate
regulatory authorities for marketing and sale, it may nonetheless fail to achieve sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. The commercial success of any of our product candidates
will depend significantly on the broad adoption and use of the resulting product by these individuals and organizations for approved indications. For example, Glyph2BLSD<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT
STYLE="white-space:nowrap">(SPT-348),</FONT> in development for the treatment of depressive disorders, including treatment-resistant depression, or TRD, post-traumatic stress disorder, or PTSD, and headache disorders, is a Glyphed oral prodrug of
the <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> neuroplastogen, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD.</FONT></FONT> There has been recent interest in psychedelics in part because of their
potential to demonstrate therapeutic effects in neuropsychiatric disorders. Although Glyph2BLSD is not a psychedelic, there is a risk that it will be viewed as such by investors and the public, or could be classified as such by regulatory
authorities based on its final structure. Treatments containing controlled substances or drugs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that have similar effects or characteristics of controlled substances may generate public controversy or unfavorable views, which could lead to delays in, and increased expenses for, and limit or
restrict the introduction and marketing of such types of therapeutic candidates. For more information on controlled substances, see subsection titled &#8220;&#8212;Certain of our product candidates may be regulated as controlled substances, the
making, use, sale, importation, exportation, and distribution of which are subject to significant regulation by the U.S. Drug Enforcement Administration and other regulatory agencies.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the indications for our product candidates have well-established standards of care that physicians, patients and payors are familiar
with and, in some cases, are available generically. Even if our product candidates are successful in registrational clinical trials, they may not be successful in displacing these current standards of care if we are unable to demonstrate superior
efficacy, safety, ease of administration, and/or cost-effectiveness. For example, physicians may be reluctant to take their patients off their current medications and switch their treatment regimen to our product candidates. Further, patients often
acclimate to the treatment regimen that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch due to inadequate coverage or reimbursement by third-party payors. Even
if we are able to demonstrate our product candidates&#8217; safety and efficacy to the FDA and other comparable regulatory authorities, safety or efficacy concerns in the medical community may hinder market acceptance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources,
including management time, and financial resources, and may not be successful. If any product candidate is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become
profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety of the product, including as compared to any more-established products or other
alternative products that may later be approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential advantages of the product compared to competitive therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the indications for which the product is approved, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the product is designated under physician treatment guidelines as a first-, second- or third-line
therapy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product&#8217;s convenience and ease of administration compared to alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try, and of physicians to prescribe, the product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay all, or a portion of, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated with the product in the absence of sufficient third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product&#8217;s acceptance into standard of care treatment algorithms by medical societies that could limit
payor and physician uptake; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings, including distribution or use restrictions contained in the product&#8217;s approved
labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of sales, marketing, and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care for the targeted indications for the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability and adequacy of coverage and reimbursement from government payors, managed care plans, and other
third-party payors, including any price concessions required by third-party payors to obtain coverage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product liability claims; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable publicity relating to the product, or favorable publicity about competitive products.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any failure by one or more of our product candidates that obtains regulatory approval to achieve market acceptance or
commercial success would adversely affect our business prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to discover, develop, and commercialize other product
candidates, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although
the development and commercialization of our current product candidates are our initial focus, as part of our longer-term growth strategy, we may seek to develop other product candidates leveraging our Glyph platform. We intend to evaluate internal
opportunities from our existing product candidates or other potential product candidates, and also may choose to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other product candidates to treat patients suffering from other disorders
with significant unmet medical needs and limited treatment options. Any other potential product candidates will require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials, and
approval by the FDA or other comparable regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development, including the possibility that the product candidate will not be shown
to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such products that are approved will be manufactured or produced economically, successfully commercialized or widely accepted in
the marketplace or be more effective than other commercially available alternatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we intend to devote capital and
resources for basic research to discover and identify additional product candidates. These research programs require substantial technical, financial, and human resources, whether or not any product candidates are ultimately identified. Our research
programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research methodology used may not be successful in identifying potential product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitors may develop alternatives that render our product candidates obsolete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates that we develop may nevertheless be covered by third parties&#8217; patents or other exclusive
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that
indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at
all; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party
payors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may also seek to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire product
candidates or the underlying technology. The process of proposing, negotiating, and implementing a license or acquisition is lengthy and complex. Other companies, including some with substantially greater financial, marketing, and sales resources,
may compete with us for the license or acquisition of product candidates. We have limited resources to identify and execute the acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of third-party products, businesses, and technologies
and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities that are never completed, or we may fail to realize the anticipated
benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, future acquisitions may entail numerous operational and financial risks, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exposure to unknown liabilities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruption of our business and diversion of management&#8217;s time and attention to develop acquired products or
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incurrence of substantial debt, dilutive issuances of securities or depletion of cash to pay for acquisitions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher than expected acquisition and integration costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty in combining the operations and personnel of any acquired businesses with our operations and
personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased amortization expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in
management and ownership; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with entering new markets in which we have limited or no experience; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to motivate key employees of any acquired businesses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To finance any acquisitions, we may choose to issue shares of our common stock as consideration, which could dilute the ownership of our
stockholders. If the price of our common stock is low or volatile, we may be unable to consummate any acquisitions using our common stock as consideration. Additional funds may not be available on terms that are favorable to us, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unsuccessful in identifying and developing additional product candidates, either through internal development or licensing or
acquisition from third parties, our potential for growth and achieving our strategic objectives may be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The number of
patients with the diseases and disorders for which we are developing our product candidates has not been established with precision. If the actual number of patients with the diseases or disorders we elect to pursue with our product candidates is
smaller than we anticipate, we may have difficulties in enrolling patients in our clinical trials, which may delay or prevent development of our product candidates. Even if such product candidates are successfully developed and approved, the markets
for our product candidates may be smaller than we expect and our revenue potential and ability to achieve profitability may be materially adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pipeline includes product candidates for a variety of neuropsychiatric disorders, including MDD and GAD. There is no precise method of
establishing the actual number of patients with any of these disorders in any geography over any time period. With respect to many of the indications in which we have developed, are developing, or plan to develop our product candidates, we have
estimates of the prevalence of the disease or disorder. Our estimates as to prevalence may not be accurate, and the actual prevalence or addressable patient population for some or all of those indications, or any other indication that we elect to
pursue, may be significantly smaller than our estimates. In estimating the potential prevalence of indications we are pursuing, or may in the future pursue, including our estimates as to the prevalence of MDD and GAD, we apply assumptions to
available information that may not prove to be accurate. In each case, there is a range of estimates in the published literature and in marketing studies, which include estimates within the range that are lower than our estimates. The actual number
of patients with these disease indications may, however, be significantly lower than we believe. Even if our prevalence estimates are correct, our product candidates may be developed for only a subset of patients with the relevant disease or
disorder or our product candidates, if approved, may be indicated for or used by only a subset. In the event the number of patients with the diseases and disorders we are studying is significantly lower than we expect, we may have difficulties in
enrolling patients in our clinical trials, which may delay or prevent development of our product candidates. If any of our product candidates are approved and our prevalence estimates with respect to any indication or our other market assumptions
are not accurate, the markets for our product candidates for these indications may be smaller than we anticipate, which could limit our ability to generate revenues and achieve profitability or to meet our expectations with respect to the foregoing.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Competitive products may reduce or eliminate the commercial opportunity for our
product candidates, if approved. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer than ours, our ability to develop and successfully
commercialize our product candidates may be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical and commercial landscapes for the treatment of
neuropsychiatric disorders are highly competitive and subject to rapid and significant technological change. We face competition with respect to our indications for our product candidates and will face competition with respect to any other drug
candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology
companies that currently market and sell drugs or are pursuing the development of drug candidates for the treatment of the CNS indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other
public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are aware that a significant number of product candidates are currently under development for MDD, GAD, and other indications that we are
currently pursuing and may pursue, and some or all may become commercially available in the future for the treatment of conditions for which we are trying or may try to develop product candidates. Additionally, if our product candidates were to be
approved, they would likely compete with historical standard of care therapies. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions,
government agencies, and research institutions. For examples of the competition that our product candidates face, see the section titled &#8220;Business&#8212;Competition&#8221; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In most cases, we do not currently plan to run <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT>
clinical trials evaluating our product candidates against the current standards of care, which may make it more challenging for our product candidates to compete against the current standards of care due to the lack of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> clinical trial data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may
have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals, and reimbursement, and marketing approved
products than we do. Accordingly, our competitors may be more successful than we may be in obtaining regulatory approval for therapies and achieving widespread market acceptance. Our competitors&#8217; products may be more effective, or more
effectively marketed and sold, than any product candidate we may commercialize and may render our therapies obsolete or <FONT STYLE="white-space:nowrap">non-competitive</FONT> before we can recover development and commercialization expenses. If any
of our product candidates are approved, it could compete with a range of therapeutic treatments that are in development. In addition, our competitors may succeed in developing, acquiring, or licensing technologies and drug products that are more
effective or less costly than our product candidates, which could render our product candidates obsolete and noncompetitive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we obtain
approval for any of our product candidates, we may face competition based on many different factors, including the efficacy, safety, and tolerability of our products, the ease with which our products can be administered, the timing and scope of
regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage, and patent position. Existing and future competing products could present superior treatment
alternatives, including being more effective, safer, less expensive, or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the
expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our competitors may obtain patent protection, regulatory exclusivities, or FDA approval and commercialize products more rapidly
than we do, which may impact future approvals or sales of any of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates that receive regulatory approval. If the FDA approves the commercial sale of any product candidate, we will also be competing with respect to marketing capabilities and
manufacturing efficiency. We expect competition among products will be based on product efficacy and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capabilities, product price, reimbursement
coverage by government and private third-party payors, regulatory exclusivities, and patent position. Our profitability and financial position will suffer if our product candidates receive regulatory approval but cannot compete effectively in the
marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being
concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties
compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to develop our sales, marketing, and distribution capability on our own or through collaborations with marketing
partners, we will not be successful in commercializing our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no marketing, sales, or
distribution capabilities. We intend to establish a sales and marketing organization, either on our own or in collaboration with third parties, with technical expertise and supporting distribution capabilities to commercialize one or more of our
product candidates that may receive regulatory approval in key territories. These efforts will require substantial additional resources, some or all of which may be incurred in advance of any approval of the product candidate. Any failure or delay
in the development of our or third parties&#8217; internal sales, marketing, and distribution capabilities would adversely impact the commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize our product candidates on our own include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to or our failure to educate an adequate number of physicians
on the benefits of any future products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our existing and future product candidates, we may choose to collaborate with third parties that have
direct sales forces and established distribution systems to serve as an alternative to our own sales force and distribution systems. Our future product revenue may be lower than if we directly marketed or sold our product candidates, if approved. In
addition, any revenue we receive will depend in whole or in part upon the efforts of these third parties, which may not be successful and are generally not within our control. If we are not successful in commercializing any approved products, our
future product revenue will suffer and we may incur significant additional losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be able to
develop <FONT STYLE="white-space:nowrap">in-house</FONT> sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas. If we do not establish
sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our
operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April 1, 2026, we had 58 full-time employees. We expect to experience significant growth in the number of our
employees and the scope of our operations over time. To manage these growth activities, we must continue to implement and improve our managerial, operational, quality, and financial systems, expand our facilities and continue to recruit and train
additional qualified personnel. Our management may need to devote a significant amount of its attention to managing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a
company with such anticipated growth, we may not be able to effectively manage the expansion or relocation of our operations, retain key employees, or identify, recruit, and train additional qualified personnel. Our inability to manage the expansion
or relocation of our operations effectively may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth
could also require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If we are unable to effectively manage our expected growth, our expenses may
increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy, including the successful commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to develop product candidates, leverage our Glyph platform and our future growth depends on attracting, hiring, and
retaining our key personnel and recruiting additional qualified personnel. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends upon the continued contributions
of our key management and scientific personnel, many of whom have been instrumental for us and have substantial experience with developing therapies, identifying potential product candidates and building the technologies related to the clinical
development of our product candidates. Given the specialized nature of neuropsychiatric disorders and our approach, there is an inherent scarcity of experienced personnel in these fields. As we continue developing our product candidates in our
pipeline, we will require personnel with medical, scientific, or technical qualifications specific to each program. The loss of key personnel, in particular our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer, <FONT
STYLE="white-space:nowrap">Co-Founder,</FONT> and Chair of the Board, Chief Financial Officer, Chief Medical Officer, <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Scientific Officer, General Counsel, and clinical development
personnel, would delay our research and development activities. The competition for qualified personnel in the therapeutics, biotechnology and biopharmaceutical industries is intense, and our future success depends upon our ability to attract,
retain, and motivate highly skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions, and other organizations. If our recruitment and
retention efforts are unsuccessful in the future, it may be difficult for us to implement our business strategy, which would have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical operations and research and development programs depend on our ability to attract and retain highly skilled
employees across multiple functions, particularly in Massachusetts. There is powerful competition for skilled personnel in this geographical market, and we have from time to time experienced, and we expect to continue to experience, difficulty in
hiring and retaining employees with appropriate qualifications on acceptable terms, or at all. Many of the companies with which we compete for experienced personnel have greater resources than we do, and any of our employees may terminate their
employment with us at any time. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources
and, potentially, damages. Furthermore, job candidates and existing employees often consider the value of the stock awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, either because we are
a public company or for other reasons, it may harm our ability to recruit and retain highly skilled employees. Our employees may be more likely to leave us if the shares they own have significantly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
appreciated in value relative to the original purchase prices of the shares, or if the exercise prices of the options they hold are significantly below the market price of our common stock,
particularly after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described herein. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects
would be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to assist in conducting our clinical trials and preclinical studies. If they do not successfully carry out their
contractual duties, comply with applicable regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may be delayed, and our
business could be substantially harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied upon and plan to continue to rely on third parties, such as CROs, clinical
data management organizations, medical institutions and clinical investigators, to conduct our clinical trials and preclinical studies and expect to rely on these third parties to conduct clinical trials and preclinical studies of any other product
candidate that we develop. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These factors include protocol design, regulatory, and IRB approval, patient enrollment rates, and compliance with GCPs. In
most cases, we use the services of third parties, including CROs, to carry out our clinical trial-related activities and rely on such parties to accurately report their results. Our reliance on third parties for clinical development activities may
impact or limit our control over the timing, conduct, expense, and quality of our clinical trials. Moreover, the FDA requires us to comply with GCPs for conducting, recording, and reporting the results of clinical trials to assure that data and
reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. The FDA enforces these GCPs through periodic inspections of clinical trial sponsors, principal investigators,
clinical trial sites, and IRBs. For certain commercial prescription drug products, manufacturers and other parties involved in the supply chain must also meet chain of distribution requirements and build electronic, interoperable systems for product
tracking and tracing and for notifying the FDA of counterfeit, diverted, stolen, and intentionally adulterated products or other products that are otherwise unfit for distribution in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory
requirements and scientific standards. Our failure or the failure of third parties to comply with the applicable protocol, legal and regulatory requirements and scientific standards can result in rejection of our clinical trial data or other
sanctions. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials, or the potential regulatory approval of a product candidate may be delayed or be
unsuccessful. Additionally, if we or our third-party contractors fail to comply with applicable GCPs for any reason, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional
clinical trials before approving our product candidates, which would delay the regulatory approval process. We cannot be certain that, upon inspection, the FDA will determine that any of our clinical trials comply with GCPs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under
our agreements with such contractors, we cannot control whether or not they devote sufficient time, skill, and resources to our ongoing development programs. Moreover, many CROs, including some of those that we have engaged to conduct our clinical
trials, are experiencing enrollment challenges as a result of, among other things, high employee turnover driven by macroeconomic environment and the inexperience of new employees. Additionally, at clinical trial sites, the availability of staff and
trial participants has been limited due to a decrease in the number of clinical investigative sites across the globe. These contractors may also have relationships with other commercial entities, including our competitors, for whom they may also be
conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If these third parties, including clinical investigators, do not successfully carry out their
contractual duties, meet expected deadlines, or conduct our clinical trials in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, regulatory approvals for our product candidates. If that occurs, we
will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. In such an event, our financial results and the commercial prospects for any product candidates that we seek to develop could be harmed, our
costs could increase and our ability to generate revenues could be delayed, impaired, or foreclosed. In addition, principal investigators for our clinical trials may be asked to serve as scientific advisors or consultants to us from time to time and
may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or foreign regulatory authorities conclude that the
financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result
in the delay or rejection by the FDA or foreign regulatory authorities of any NDA or foreign application we submit. Any such delay or rejection could prevent us from commercializing our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our
distributors could delay clinical development or regulatory approval of our product candidates or commercialization of any resulting products, producing additional losses, and depriving us of potential product revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the third-party organizations we utilize may terminate their engagements with us under certain circumstances. The replacement of an
existing CRO or other third party may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates. We may not be able to enter into alternative
arrangements or do so on commercially reasonable terms. In addition, even if there are suitable replacements for one or more of these service providers, there is a natural transition period when a new service provider begins work. As a result,
delays may occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we currently and may in the future rely on foreign CROs and CMOs. Such foreign CROs and CMOs may be subject to U.S. legislation,
sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to
secure significant commitments from governments to purchase our potential therapies. For example, in January 2024, there was congressional activity, including the introduction of the BIOSECURE Act (H.R. 7085) in the House of Representatives and a
substantially similar Senate bill (S.3558). In September 2024, the U.S. House of Representatives passed a version of the BIOSECURE Act (H.R. 8333), however, the Senate did not approve that legislation. In October 2025, both the U.S. House of
Representatives and Senate passed their respective versions of the National Defense Authorization Act of 2026 (NDAA), each including an amendment often referred to as &#8220;BIOSECURE 2.0.&#8221; While BIOSECURE 2.0 has not yet been enacted and must
still be reconciled in conference, the current text would establish federal government contracting, grant, and loan restrictions similar in effect to prior BIOSECURE proposals. However, unlike earlier versions of BIOSECURE that named specific
Chinese companies, BIOSECURE 2.0 would implement a process-based designation system through which biotechnology companies &#8220;of concern&#8221; would be identified based on whether companies fall within statutorily define categories, including
entities identified on the Department of Defense&#8217;s Section&nbsp;1260H list of &#8220;Chinese military companies&#8221; and other entities that are subject to the direction, control, or jurisdiction of a foreign adversary&#8217;s government
which pose national security risks based on specified criteria. If BIOSECURE 2.0 becomes law or similar laws are passed, they would have the potential to severely restrict the ability of therapeutics companies like us to purchase services or
products from, or otherwise collaborate with, certain Chinese biotechnology companies &#8220;of concern&#8221; without losing the ability to contract with, or otherwise receive funding from, the U.S. government. We do business with companies in
China, and it is possible some of our contractual counterparties could be impacted by this legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our use of third parties to manufacture our product candidates, including those
located outside of the United States, may increase the risk that we will not have sufficient quantities of our product candidates, raw materials, active pharmaceutical ingredients, or APIs, or drug products when needed or at an acceptable cost.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product
candidates, and we lack the resources and the capabilities to do so. Our current strategy is to outsource all manufacturing of our product candidates to third parties, including in jurisdictions outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on and engage third-party manufacturers to provide all of the API and the final drug product formulation of all of our
product candidates that are being used in our clinical trials and preclinical studies. If we were to need an alternate manufacturer, we would incur added costs and delays in identifying and qualifying any such replacement. In addition, we typically
order raw materials, API, and drug product and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements with any commercial manufacturer. We may not be able to timely secure needed supply
arrangements on satisfactory terms, or at all. Our failure to secure these arrangements as needed could have a material adverse effect on our ability to complete the development of our product candidates or, to commercialize them, if approved. We
may be unable to conclude agreements for commercial supply with third-party manufacturers or may be unable to do so on acceptable terms. There may be difficulties in scaling up to commercial quantities and formulation of our product candidates, and
the costs of manufacturing could be prohibitive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the third-party manufacturers we rely on have only recently begun working with
us and have limited experience manufacturing our API and final drug products. If our manufacturers have difficulty or suffer delays in successfully manufacturing material that meets our specifications, it may limit supply of our product candidates
and could delay our clinical trials.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are able to establish and maintain
arrangements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of the third-party manufacturer to comply with applicable regulatory requirements and reliance on
third parties for manufacturing process development, regulatory compliance, and quality assurance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over
our product candidates or otherwise do not satisfactorily perform according to the terms of the agreement between us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on supply availability resulting from capacity and scheduling constraints of third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of the third-party manufacturer to produce materials with acceptable quality on a larger scale;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach of manufacturing agreements by third parties because of factors beyond our control;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the manufacturing agreements
by the third party, at a time that is costly or inconvenient to us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not maintain our key manufacturing relationships, we may fail to
find replacement manufacturers or develop our own manufacturing capabilities, which could delay or impair our ability to obtain regulatory approval for our product candidates. If we do find replacement manufacturers, we may not be able to enter into
agreements with them on terms and conditions favorable to us and there could be a substantial delay before new facilities could be qualified and registered with the FDA and other comparable regulatory authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if any third-party manufacturer with whom we contract fails to perform its
obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different manufacturer. In either scenario, our clinical trials supply could be delayed
significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our product candidates may be proprietary to the original manufacturer and we may have difficulty, or there may be contractual
restrictions prohibiting us from transferring such skills to a <FONT STYLE="white-space:nowrap">back-up</FONT> or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change third-party
manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a
manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or other comparable regulatory authorities. We may be unsuccessful in
demonstrating the comparability of clinical supplies, which could require the conduct of additional clinical trials. The delays associated with the verification of a new third-party manufacturer could negatively affect our ability to develop product
candidates or commercialize our products in a timely manner or within budget. Furthermore, a third-party manufacturer may possess technology related to the manufacture of our product candidate that such third party owns independently. This would
increase our reliance on such third-party manufacturer or require us to obtain a license from such third-party manufacturer in order to have another third party manufacture our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates is approved by any regulatory agency, we intend to utilize arrangements with third-party contract
manufacturers for the commercial production of those products. This process is difficult and time-consuming and we may face competition for access to manufacturing facilities as there are a limited number of contract manufacturers operating under
cGMPs that are capable of manufacturing our product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our manufacturers are located outside of the United States. There is currently significant uncertainty about the future relationship
between the United States and various other countries with respect to trade policies, treaties, government regulations, and tariffs. Increased tariffs or pending legislation that would impose federal contracting or federal funding limitations on
parties directly using or connected to those using the services or equipment of certain foreign entities with known or alleged associations with foreign adversaries could potentially disrupt our existing supply chains and impose additional costs on
our business. Additionally, it is possible further tariffs may be imposed that could affect imports of any APIs used in our product candidates in the future, or our business may be adversely impacted by retaliatory trade measures taken by China or
other countries, including restricted access to such raw materials used in our product candidates. Given the uncertainty regarding how the U.S. or foreign governments will act with respect to tariffs, international trade agreements, and policies,
further governmental action related to tariffs, additional taxes, contracting matters, regulatory changes, or other retaliatory trade measures in the future could occur with a corresponding detrimental impact on our business and financial condition.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our failure, or the failure of our third-party manufacturers, to comply with applicable
regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or voluntary recalls of product candidates, operating restrictions, and
criminal prosecutions, any of which could significantly affect supplies of our product candidates. The facilities used by our contract manufacturers to manufacture our product candidates must be evaluated by the FDA and are required to register
their facilities with the FDA, subjecting them to inspections to assess whether these facilities are in compliance with cGMPs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not
control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMPs and comparable foreign requirements. If our contract manufacturers cannot successfully manufacture material that
conforms to our specifications and the strict regulatory requirements of the FDA or other comparable regulatory authorities, we may not be able to secure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and/or maintain regulatory approval for our product candidates manufactured at these facilities. In addition, we have no control over the ability of our contract manufacturers to maintain
adequate quality control, quality assurance, and qualified personnel. If the FDA finds deficiencies or the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it
withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for, or market our product candidates, if approved. Contract
manufacturers may face manufacturing or quality control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP and comparable foreign
requirements. Any failure to comply with cGMP requirements or other FDA and comparable foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop our product candidates and market our products,
if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contract manufacturers may face manufacturing or quality control problems causing drug substance production and shipment
delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA and other comparable regulatory requirements could adversely affect
our clinical research activities and our ability to develop our product candidates and market our products following approval, if obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, should we decide to use any APIs in any of our product candidates that are proprietary to one or more third parties, we would
need to maintain licenses to those APIs from those third parties. If we are unable to gain or continue to access rights to such APIs prior to conducting preclinical toxicology studies intended to support clinical trials, we may need to develop
alternate product candidates from these programs by either accessing or developing alternate APIs, resulting in increased development costs and delays in commercialization of these product candidates. If we are unable to gain or maintain continued
access rights to the desired APIs on commercially reasonable terms or develop suitable alternate APIs, we may not be able to commercialize product candidates from these programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter
our development and commercialization plans. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future opportunistically pursue strategic partnerships or
collaborations, as the advancement of our product candidates and development programs and the potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. If we believe that
partnerships or collaborations can accelerate the development or maximize the market potential of our product candidates, we will consider entering into product, target and/or geographic specific strategic partnerships or collaborations on an
opportunistic basis. Likely collaborators may include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies, and biotechnology companies. In addition, if we are able to
obtain regulatory approval for product candidates from foreign regulatory authorities, we may enter into partnerships or collaborations with international biotechnology or pharmaceutical companies for the commercialization of such product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a
partnership or collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed partnerships or collaboration, and the proposed collaborator&#8217;s
evaluation of a number of factors. Those factors may include the potential differentiation of our product candidate from competing product candidates, design, or results of clinical trials, the likelihood of approval by the FDA or other comparable
regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients, and the potential of competing products. The
collaborator may also consider alternative product candidates or technologies for similar indications that may be available for partnership or collaboration and whether such a partnership or collaboration could be more attractive than the one with
us for our product candidate. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or
bring them to market and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Partnerships and collaborations are each complex and time-consuming to negotiate and
document. Further, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any partnership or collaboration agreements that
we enter into in the future may contain restrictions on our ability to enter into potential partnerships or collaborations or to otherwise develop specified product candidates. We may not be able to negotiate partnerships or collaborations on a
timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce, or delay its development program or one or more of our other
development programs, delay its potential commercialization, reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if conflicts arise between our collaborators and us, the other party may act in a manner adverse to us and could limit our
ability to implement our strategies. Our collaborators could conduct multiple product development efforts and could develop, either alone or with others, products in related fields that are competitive with the product candidates we may develop that
are the subject of these partnerships or collaborations with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competing products may preclude us from entering into partnerships or
collaborations with their competitors, fail to obtain timely regulatory approvals, prevent us from obtaining timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the partnership or
collaboration efforts, including development, delivery, manufacturing, and commercialization of products. Any of these developments could harm our company and product development efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we enter into collaborations with third parties for the development and/or commercialization of our product candidates, our prospects
with respect to those product candidates will depend in significant part on the success of those collaborations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter
into collaborations with third parties for the development and/or commercialization of certain of our product candidates. If we enter into such collaborations, we will have limited control over the amount and timing of resources that our
collaborators will dedicate to the development or commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaborations involving our product
candidates pose a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and/or commercialization of our product candidates or may elect not to
continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, which divert resources or create
competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources
to the marketing and distribution of such product or products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreements with collaborators, including disagreements over proprietary rights, including trade secrets and
intellectual property rights, contract interpretation, or the preferred course of development might cause delays or termination of the research, development, or commercialization of product candidates, might lead to additional responsibilities for
us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary
information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation
and potential liability; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue
further development or commercialization of the applicable product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration agreements may not lead to
development or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours is involved in a business combination, it could decide to delay, diminish, or terminate the development or
commercialization of any product candidate licensed to it by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If any third-party manufacturer of our product candidates is
unable to increase the scale of its production of our product candidates or increase the product yield of its manufacturing, then our manufacturing costs may increase and commercialization may be delayed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our product
candidates, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of our product candidates. The transition to larger scale production could prove
difficult. In addition, if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates
while maintaining the same quality then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business, financial condition, and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or
delay. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and
commercialization, it is common that various aspects of the development program, such as the vendors used to manufacture drug product or manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results.
Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials
conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval and similar foreign notifications and approvals. This could delay or prevent completion of clinical
trials, require conducting bridging clinical trials, or the repetition of one or more clinical trials, increase clinical trial costs, delay or prevent approval of our product candidates, and jeopardize our ability to commence sales and generate
revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in
obtaining regulatory approval of our product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory approval of
our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a
product candidate, the European Commission or comparable foreign regulatory authorities must also approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve
requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by
regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend
to charge for our products is also subject to approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also submit marketing authorization applications in other countries.
Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with
foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in
international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued
regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging,
storage, distribution, AE reporting, advertising, promotion, sampling, import, export, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state
requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP (and comparable foreign requirements) and GCP requirements for any clinical trials
that we conduct post-approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the
approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and
efficacy of the product candidate. Certain endpoint data we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or secondary endpoint data such as patient-reported outcome measures. The FDA
may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient <FONT STYLE="white-space:nowrap">follow-up,</FONT> a medication guide, physician communication plans or
additional elements to ensure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. In addition, if the FDA or other comparable regulatory authority approves our product candidates, we will have to
comply with requirements including submissions of safety and other post-marketing information and reports and registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may
impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product
candidates, including AEs of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety
information, imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market, or
voluntary product recalls; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or
suspension or withdrawal of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention or refusal to permit the import or export of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue
and could require us to expend significant time and resources in response and could generate negative publicity. The policies of the FDA and other comparable regulatory authorities may change and additional government regulations may be enacted that
could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or
abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and
we may not achieve or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>While we may in the future seek designations for our product candidates with the FDA
and other comparable regulatory authorities that are intended to confer benefits such as a faster development process, an accelerated regulatory pathway, or regulatory exclusivity, there can be no assurance that we will successfully obtain such
designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other comparable regulatory authorities offer certain designations for product candidates that are designed to encourage the
research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated
regulatory pathway and priority review. However, there can be no assurance that we will successfully obtain such designations for our product candidates. In addition, while such designations could expedite the development or approval process, they
generally do not change the standards for approval. Even if we obtain such designations for our product candidates, there can be no assurance that we will realize their intended benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, we may seek a Fast Track Designation for future product candidates we develop. If a product is intended for the treatment of a
serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or
not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a
faster development process, review, or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek Breakthrough Therapy Designation for any product candidate that we develop. A breakthrough therapy is defined as a drug that is
intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and
the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible
for accelerated approval and priority review. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even
if we believe a product candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of Breakthrough Therapy Designation for a
product candidate may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if any product
candidate we develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even in the absence of obtaining Fast Track and/or Breakthrough Therapy Designations, a sponsor can seek priority review at the time of
submitting a marketing application. The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared with other
available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination, or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient
compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications,
and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months. Priority review designation may be rescinded if a product no longer meets the qualifying criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Where appropriate, we may secure approval from the FDA or other comparable regulatory authorities through the use of the accelerated
approval pathway. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of,
necessary marketing approvals. Even if we receive accelerated approval from the FDA or other comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing
requirements, the FDA or such other comparable regulatory authorities may seek to withdraw any accelerated approval we have obtained. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek an accelerated approval pathway for our one or more of our therapeutic candidates from the FDA or other comparable regulatory
authorities. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA&#8217;s implementing regulations, the FDA may grant accelerated approval to a therapeutic candidate designed to treat a serious or
life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the therapeutic candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to
predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated
approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical
endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct
therapeutic advantage but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional
post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. Under FDORA, the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a
specified time period after the date of approval for a product granted accelerated approval. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor
fails to conduct such studies in a timely manner, send status updates on such studies to the FDA every 180 days to be publicly posted by the agency, or if such post-approval studies fail to verify the drug&#8217;s predicted clinical benefit. The FDA
is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to seeking accelerated approval, we would seek feedback from the FDA or other
comparable regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no
assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review, or approval. Similarly, there can be no assurance that after
subsequent feedback from the FDA or other comparable regulatory authorities, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review, or approval, even if we initially decide to do so.
Furthermore, if we decide to submit an application for accelerated approval, there can be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA or other comparable regulatory
authorities could also require us to conduct further studies prior to considering our application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently converted by FDA
to full approval. A failure to obtain accelerated approval or any other form of expedited development, review, or approval for our therapeutic candidate would result in a longer time period to commercialization of such therapeutic candidate, could
increase the cost of development of such therapeutic candidate, and could harm our competitive position in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Certain
of our product candidates may be regulated as controlled substances, the making, use, sale, importation, exportation, and distribution of which are subject to significant regulation by the U.S. Drug Enforcement Administration and other regulatory
agencies. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not yet fully understand the potential for GlyphAllo or Glyph2BLSD to be classified as controlled substances, but
brexanolone is currently classified as a Schedule IV controlled substance under the Controlled Substances Act, or CSA and although <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">2-bromo-LSD</FONT></FONT> is not a controlled substance, it is an analogue of LSD, which is a Schedule I controlled substance under the CSA. Accordingly, we may need to conduct studies to assess the abuse potential of
GlyphAllo and/or Glyph2BLSD, and pending the outcome of such evaluations, we may be required to provide a proposal for scheduling by the Drug Enforcement Administration, or the DEA, when submitting an NDA, which could cause delays in our development
process or commercialization timing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DEA regulates controlled substances as Schedule I, II, III, IV, or V substances. Schedule I
substances by definition have no established medicinal use and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV, or V, with Schedule II substances considered to present the highest risk
of abuse and Schedule V substances the lowest relative risk of abuse among such substances. If any of our product candidates were to become subject to DEA oversight, such product candidates would be subject to additional restrictions regarding their
manufacture, shipment, storage, sale, and use, depending on the scheduling of the active ingredients, and may limit the commercial potential of any of our product candidates, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various states also independently regulate controlled substances. Though state controlled substances laws often mirror federal law, because
the states are separate jurisdictions, they may separately schedule drugs as well. While some states automatically schedule a drug when the DEA does so, in other states there must be rulemaking or a legislative action. State scheduling may delay
commercial sale of any controlled substance drug product for which we obtain federal regulatory approval and adverse scheduling could impair the commercial attractiveness of such product. If any of our product candidates is classified as a
controlled substance, we or our collaborators would also be required to obtain separate state registrations in order to be able to obtain, handle, and distribute controlled substances for clinical trials or for commercial sale, and failure to meet
applicable regulatory requirements could lead to enforcement and sanctions from the states in addition to those from the DEA or otherwise arising under federal law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For any of our product candidates that may be classified as controlled substances, we and our suppliers, manufacturers, contractors,
customers, and distributors are required to obtain and maintain applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registrations from state, federal, and foreign law enforcement and regulatory agencies and comply with state, federal, and foreign laws and regulations regarding the manufacture, use, sale,
importation, exportation and distribution of controlled substances. There is a risk that DEA regulations may limit the supply of the compounds used in clinical trials for our product candidates, and, in the future, the ability to produce and
distribute our products in the volume needed to meet commercial demand. Regulations associated with controlled substances govern manufacturing, labeling, packaging, testing, dispensing, production, and procurement quotas, recordkeeping, reporting,
handling, storage, shipment and disposal. These regulations increase the personnel needs and the expense associated with development and commercialization of product candidates including controlled substances. The DEA, and some states, conduct
periodic inspections of registered establishments that handle controlled substances. Failure to obtain and maintain required registrations or comply with any applicable regulations could delay or preclude us from developing and commercializing our
product candidates containing controlled substances and subject us to enforcement action. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In some circumstances,
violations could lead to criminal proceedings. Because of their restrictive nature, these regulations could limit commercialization of any of our products or product candidates that are classified as controlled substances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with healthcare providers and physicians and third-party payors subject us to anti-kickback, fraud and abuse and other
healthcare laws and regulations, which could increase our compliance costs, and expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits, and future earnings. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business operations and current and future arrangements with investigators, healthcare professionals, pharmacies, consultants, marketing
personnel, third-party payors, patient organizations, and customers expose us to broadly applicable foreign, federal and state fraud and abuse, and other healthcare laws and regulations. These laws include foreign, federal, and state anti-kickback
laws, false claims statutes, civil monetary penalties laws, healthcare data privacy, and security laws, and consumer protection and unfair competition laws, as well as transparency laws regarding payments or other items of value provided to
healthcare providers, and laws related to price reporting. Healthcare providers, physicians, and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. These laws
may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute any product for which we obtain regulatory approval. For more information on
healthcare laws and regulations that may impact our company, see the section titled &#8220;Business&#8212;Government Regulation&#8212;Other Healthcare Laws&#8221; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our current and future business arrangements both internally and with third parties will comply with applicable
healthcare and privacy laws and regulations will involve ongoing substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations,
or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which
they are subject, it is possible that some of our current or future practices or arrangements might be challenged under one or more of these laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,
especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of
investigations, prosecutions, convictions, and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be
time-consuming, resource-intensive, and can divert a company&#8217;s attention from the business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our business practices or operations
are found to be in violation of any of fraud and abuse, or other healthcare laws or governmental laws, regulations, agency guidance, or case law that may apply to us, we may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to significant penalties, including administrative, civil, and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs,
such as Medicare and Medicaid, integrity oversight, and reporting obligations, contractual damages, individual imprisonment, reputational harm, diminished profits, and future earnings, and the curtailment or restructuring of our operations, as well
as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws. Further, defending against
any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be
impaired. If any of the physicians, or other providers, or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusions
from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of any of our product candidates, if approved, will depend in part on the extent to which governmental
authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it
difficult for us to sell any approved product candidates profitably. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our product candidates, if approved, depends
on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors. Patients who are provided medical
treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Our ability to achieve coverage and acceptable levels of reimbursement for our product candidates by
third-party payors will have an effect on our ability to successfully commercialize those products. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, any product that we may
develop. For more information on the laws and regulations that may impact coverage and reimbursement of our product candidates, see the section titled &#8220;Business&#8212;Government Regulation&#8212;Coverage and Reimbursement&#8221; included
elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities and other third-party payors, such as private health insurers and health maintenance
organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use
of a product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective, and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining
coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the
use of our products, if approved, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement will be obtained. Furthermore, rules and
regulations regarding reimbursement change frequently, and, in some cases, at short notice, and we believe that additional changes in these rules and regulations are likely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain coverage for a given product, if approved, the resulting reimbursement payment rates might not be adequate for us to achieve
or sustain profitability or may require cost-sharing (e.g., <FONT STYLE="white-space:nowrap">co-payments</FONT> or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coinsurance) that patients find unacceptably high. There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. In the United States, the principal
decisions about reimbursement for new medicines are typically made by U.S. Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare, and private
payors tend to follow CMS coverage determinations to a substantial degree. Additionally, third-party payors may not cover or provide adequate reimbursement for a given product or, long-term <FONT STYLE="white-space:nowrap">follow-up</FONT>
evaluations, or other ancillary services required following the use of product candidates, once approved. Some third-party payors may require <FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage or implement prior authorization or step
therapy programs for new or innovative drug therapies before they will reimburse patients who use such therapies which may be time-consuming or costly for patients and lead to a reduction in revenue. Patients are unlikely to use our product
candidates, once approved, unless coverage is provided and reimbursement is adequate to cover a significant portion of their cost. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and
reimbursement for our product candidates. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented
in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors increasingly are challenging prices charged for therapeutics products and services, and many
third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as
substitutable and offer to reimburse patients only for a less expensive competitor product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs
may limit the amount we will be able to charge for our products, if approved. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable
us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products, if approved, and may not be able
to obtain a satisfactory financial return on products that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net prices for drugs may be reduced by mandatory discounts or
rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly,
third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product
candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price
and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Payment
methodologies may be subject to changes in healthcare legislation and regulatory initiatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by
governmental and other third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not
cover or provide adequate payment for our product candidates. If, for example, we participate in the Medicaid Drug Rebate Program or other governmental pricing programs, in certain circumstances, our products, if approved, would be subject to
ceiling prices set by such programs, which could reduce the revenue we may generate from any such products. Participation in such programs would also expose us to the risk of significant civil monetary penalties, sanctions, and fines should we be
found to be in violation of any applicable obligations thereunder. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent
U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform
government program reimbursement methodologies for drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that healthcare reform measures that may be adopted in the future may
result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to
generate revenue, attain profitability, or commercialize our products, if approved. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.
We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals or clearances of our product
candidates, if any, may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in some foreign countries, the proposed pricing for a product must be approved before it may be
lawfully marketed. The requirements governing product pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance
systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a
particular product candidate to currently available therapies. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the
medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product
candidates. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing healthcare legislative and regulatory reform measures and cost containment initiatives may have a material adverse effect on our
business and results of operations and increase the difficulty and cost for us to obtain coverage for and commercialize any of our current or future product candidates and may adversely affect the prices we may set. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes, or the interpretation of existing regulations could impact our business in the future by requiring, for
example, (1)&nbsp;changes to our manufacturing arrangements, (2)&nbsp;additions or modifications to product labeling, (3)&nbsp;the recall or discontinuation of our products, or (4)&nbsp;additional record-keeping requirements. Current and future
legislation and regulations may increase the difficulty and cost for us to commercialize our drugs, if approved, and affect the prices we may obtain, including changes in coverage and reimbursement policies in certain market segments for our product
candidates, which could make it difficult for us to sell our product candidates, if approved, profitably. If any such changes were to be imposed, they could adversely affect the operation of our business. See the section titled
&#8220;Business&#8212;Current and Future U.S. Healthcare Reform&#8221; included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among policy makers and
payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality, and/or expanding access. For example, in March 2010, the
ACA, was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and continues to significantly impact the U.S. pharmaceutical industry. Since its enactment, certain provisions of the ACA have
been subject to judicial, executive, and legislative challenges and may be subject to additional challenges in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers, effective April&nbsp;1, 2013, which, due to subsequent
legislative amendments, will stay in effect through 2032 unless additional congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several
providers, and increased the statute of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations period for the government to recover overpayments to providers from three to five years. The One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions
in the funding of the Medicaid program. Such reductions are expected to apply significant funding pressure on state Medicaid budgets, decrease the number of persons enrolled in Medicaid, and reduce the services covered by Medicaid, which could
adversely affect our sales of any of our product candidates that we commercialize. These laws and regulatory changes may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on
prescribers of our product candidates, if approved, and accordingly, our financial operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has
become a priority of federal, state, and foreign governments, and the prices of products have been a focus in this effort. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical
products, limiting coverage, and the amount of reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States. Governments have shown significant interest in implementing
cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. For example, the American Rescue Plan Act of 2021 eliminated the Medicaid statutory rebate cap of 100% of
average manufacturer price as of January&nbsp;1, 2024. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of prescription pharmaceuticals in the United States has also been the subject of considerable discussion in the United States. There
have been several Congressional inquiries, as well as legislative and regulatory initiatives and executive orders designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer
patient programs, and reform government program reimbursement methodologies for drug products. Most significantly, in August 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law. This statute marks the most
significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be
negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Part D
coverage gap discount program with a new manufacturer discount program (beginning in 2025). CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and has published the list of the subsequent 15
drugs that will be subject to negotiation. The IRA permits the Secretary of the Department of Health and Human Services, or the HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and
will continue to issue and update guidance as these programs are implemented, although the Medicare drug price negotiation program is currently subject to legal challenges. The impact of the IRA on us and the pharmaceutical industry cannot yet be
fully determined, but is likely to be significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trump administration is pursuing a
<FONT STYLE="white-space:nowrap">two-fold</FONT> strategy to reduce drug costs in the U.S. While it is unclear whether and how the Trump proposals will be implemented, the Trump policies are likely to have a negative impact on the pharmaceutical
industry and on our ability to receive adequate revenues for product candidates, if approved. On the one hand, the Trump administration has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies
such as most favored nation pricing, which would tie the price for drugs in the U.S. to the lowest price in a group of other countries. In response, multiple manufacturers have reportedly entered into confidential pricing agreements with the federal
government. On the other hand, the Trump administration is pursuing traditional regulatory pathways to impose drug pricing policies, although proposed regulations have not yet been published. Even regulatory proposals or executive actions that are
ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and our business. In addition, pharmaceutical pricing and marketing has long been the subject of considerable discussion in Congress and among policymakers. Additional
drug pricing proposals could appear in future legislation and it is possible that Congress could enact additional laws that negatively affect the pharmaceutical industry. Adoption of price controls and cost-containment measures, and adoption of more
restrictive policies in jurisdictions with existing controls and measures, could further limit our revenue generated from the sale of any approved products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and
regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their
commercial products, which has resulted in several Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing
and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Congress has indicated that it will continue to seek new legislative measures to control drug costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, state governments have become increasingly active in developing proposals, passing legislation, and implementing
regulations designed to control pharmaceutical and biological product pricing, including price or reimbursement constraints, discounts, formulary flexibility, restrictions on certain product access and marketing cost disclosure, drug price increase
reporting, and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating <FONT STYLE="white-space:nowrap">so-called</FONT> prescription drug
affordability boards with the goal of imposing price limits on certain drugs in these states, while some states are also seeking to implement general, across the board price caps for pharmaceuticals, or are seeking to regulate drug distribution.
These types of initiatives may result in additional reductions in Medicare, Medicaid, and other healthcare funding. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial
condition, results of operations, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their
prescription drug and other healthcare programs. These measures could reduce the ultimate demand for any of our current and future product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that these and other state and federal healthcare reform measures may
be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies, impose price controls, and additional downward pressure on the price
that we receive for any approved product candidate for which we may obtain regulatory approval, and the frequency with which any such product candidate is prescribed or used. Any reduction in reimbursement from Medicare or other government programs
may result in a similar reduction in payments from private payors. The implementation of cost containment measures, changes in healthcare spending and policy, or other healthcare reforms may prevent us from being able to generate revenue, attain
profitability, or commercialize our product candidates, and materially affect our business. If additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state
governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. We cannot predict with certainty what impact any federal or state health reforms will have on
us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new
interpretations of existing laws, regulations, or decisions, related to healthcare availability, the method of delivery, or payment for healthcare products and services could negatively impact our business, operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pricing of prescription pharmaceuticals is also subject to governmental control outside the United States. In these countries, pricing
negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares
the cost effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become
profitable could be impaired. For more details concerning the risks related to pricing and reimbursement in the EU, please refer to the discussion in the risk factor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar political, economic, and regulatory developments are occurring in the EU and may affect the ability of pharmaceutical companies to
profitably commercialize their products. In addition to continuing pressure on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating
costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National
governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU
member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this
could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and EU,
reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted. The
Regulation entered into force in January 2022 and has been applicable since January 2025, with phased implementation based on the type of product, i.e. oncology and advanced therapy medicinal products as of 2025, orphan medicinal products as of
2028, and all other medicinal products by 2030. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for cooperation at the EU level for joint
clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies
with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary
cooperation in other areas. Individual EU member states will continue to be responsible for assessing <FONT STYLE="white-space:nowrap">non-clinical</FONT> (e.g., economic, social, ethical) aspects of health technology, and making decisions on
pricing and reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business could be affected by litigation, government investigations and enforcement actions.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently operate in a number of jurisdictions in a highly regulated industry and we could be subject to litigation,
government investigation and enforcement actions on a variety of matters in the United States or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability, environmental, whistleblower, false claims,
privacy, anti-kickback, anti-bribery, securities, commercial, employment and other claims and legal proceedings that may arise from conducting our business. Any determination that our operations or activities are not in compliance with existing laws
or regulations could result in the imposition of fines, civil and criminal penalties, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, equitable remedies, including disgorgement, injunctive relief
and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legal
proceedings, government investigations and enforcement actions can be expensive and time-consuming. An adverse outcome resulting from any such proceedings, investigations, or enforcement actions could result in significant damages awards, fines,
penalties, exclusion from the federal healthcare programs, healthcare debarment, injunctive relief, product recalls, integrity oversight and reporting obligations, reputational damage and modifications of our business practices, which could have a
material adverse effect on our business, financial condition, results of operations and prospects. Even if such a proceeding, investigation, or enforcement action is ultimately decided in our favor, the investigation and defense thereof could
require substantial financial and management resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, and vendors may engage in
misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to
the risk of employee fraud or other illegal activity by our current and any future employees, independent contractors, consultants, CMOs, and vendors. Misconduct by these parties could include intentional, reckless, and/or negligent conduct that
fails to comply with the regulations set forth by the FDA or other comparable regulatory authorities, provide true, complete, and accurate information to the FDA and other comparable regulatory authorities, comply with manufacturing standards we may
establish, comply with healthcare fraud and abuse laws and regulations, report financial information or data accurately, or disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing
those products in the United States, our potential exposure under these laws will increase significantly, and our costs associated with compliance with these laws are likely to increase. Employee misconduct could also involve the improper use of
information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none
occurred. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a material and adverse effect on our business, financial condition, results of operations, and prospects, including, without limitation, the imposition of significant civil, criminal, and administrative penalties, damages,
monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, imprisonment, contractual damages, reputational harm, diminished profits, and future earnings, additional reporting
requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and curtailment of our operations, any of which
could adversely affect our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The FDA and other comparable
regulatory authorities actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising, and promotion of prescription drugs. These regulations include standards and
restrictions for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion. Any regulatory approval that the FDA grants is limited to those specific diseases and indications for which a product is deemed to be safe and effective by FDA. While physicians in the United
States may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, we may only
promote or market our products in a manner that is consistent with their <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling. Similar requirements may apply in foreign jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to have promoted such <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability.
The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> use and has enjoined several companies from engaging in <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage
the promotion any product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. In addition, any such
<FONT STYLE="white-space:nowrap">off-label</FONT> use of our product candidates could harm our reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use our
product candidates for these uses for which they are not approved, which could lead to product liability suits that might require significant financial and management resources and that could harm our reputation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Inadequate funding for the FDA or other comparable regulatory authorities or
government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing
normal business functions on which the operation of our business may rely, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, and accept the payment of user fees, and statutory, regulatory,
and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development
activities, is subject to the political process, which is inherently fluid and unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA or other comparable
regulatory authorities or government agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S.
government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. In addition, the current U.S. Presidential administration has issued certain policies and
Executive Orders directed towards reducing the employee headcount and costs associated with U.S. administrative agencies, including the FDA, and it remains unclear the degree to which these efforts may limit or otherwise adversely affect the
FDA&#8217;s ability to conduct routine activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a prolonged government shutdown occurs, including as a result of reaching the debt
ceiling, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to
access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>EU drug
marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the EU Member States. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to seek approval to market our product candidates in both the United States and potentially in selected foreign jurisdictions. If we
obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the European Union, the pricing of products is
subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after
obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product
candidates and may be affected by existing and future healthcare reform measures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Much like the federal Anti-Kickback Statute prohibition
in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The
provision of benefits or advantages to reward improper performance generally is typically governed by the national anti-bribery laws of EU Member States and the Bribery Act 2010 in the United Kingdom. Infringement of these laws could result in
substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them,
no gifts, pecuniary advantages or benefits in kind may be supplied, offered, or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines
Regulations 2012 and so remains applicable in the United Kingdom despite its departure from the European Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made to
physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employer, his or her competent professional organization, and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry
codes, or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in some foreign countries, including some countries in the European Union, the proposed pricing for a product must be approved
before it may be lawfully marketed. The requirements governing product pricing and reimbursement vary widely from country to country. For example, some EU Member States have the option to restrict the range of medicinal products for which their
national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between
<FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. An EU Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls
on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of any of our product candidates to other
available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for therapeutics products will allow favorable reimbursement and
pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party
payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited
in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to export and import controls, economic sanctions, and anti-corruption laws and regulations of the United States and
other jurisdictions. We can face criminal liability and other serious consequences for violations of these laws and regulations, which can harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs
regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control. Export controls and trade sanctions laws and regulations may restrict or prohibit altogether the
provision, sale, or supply of our products to certain governments, persons, entities, countries, and territories, including those that are the target of comprehensive sanctions or an embargo. We are also subject to anti-corruption and anti-bribery
laws, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, and other state and national anti-bribery laws in the countries in which we conduct
activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything
else of value to recipients in the public or private sector. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate
system of internal accounting controls. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities.
Any violation of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation,
reputational harm, and other consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we or any third-party manufacturer we engage now or in the future fail to comply with
environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and third-party manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous
environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally
contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could
be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain general liability insurance as well as workers&#8217; compensation insurance to cover us for costs and expenses we may
incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that
may be asserted against us in connection with our storage or disposal of biological, hazardous, or radioactive materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we
may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development, or commercialization efforts. Failure to
comply with these laws and regulations also may result in substantial fines, penalties, or other sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, with respect to the
operations of our current and any future third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations, or properly dispose of wastes associated
with our products, we could be held liable for any resulting damages, suffer reputational harm, or experience a disruption in the manufacture and supply of our product candidates or products. In addition, our supply chain may be adversely impacted
if any of our third-party contract manufacturers become subject to injunctions or other sanctions as a result of their <FONT STYLE="white-space:nowrap">non-compliance</FONT> with environmental, health, and safety laws and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our commercial success depends on our ability to obtain, maintain, enforce, and otherwise protect our intellectual property and
proprietary technology, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products and product candidates similar to ours and our
ability to successfully develop and commercialize our product candidates may be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success
depends, in large part, on our ability to obtain and maintain intellectual property rights protection through patents, trademarks, and trade secrets in the United States and other countries with respect to our technology and product candidates. If
we do not adequately protect our intellectual property rights, competitors or other third parties may be able to erode, negate or preempt any competitive advantage we may have, which could harm our business and ability to achieve profitability. To
protect our proprietary position, we and our licensors have filed patent applications and may file other patent applications in the United States or abroad related to our product candidates that are important to our business. In particular, we are
heavily reliant on patent rights we have exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> from Monash University pursuant to the Monash License Agreement. The patent application process is expensive, time-consuming and complex. We may
not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our licensors may not be able to obtain patents on certain inventions if those inventions are publicly disclosed prior to our filing a
patent application covering them. We enter into nondisclosure and confidentiality agreements with parties who have access to confidential information, including confidential information regarding inventions not yet disclosed in patent applications.
We cannot guarantee that any of these parties will not breach these confidentiality agreements and publicly disclose any of our inventions before a patent application is filed covering such inventions. If such confidential information is publicly
disclosed, we may not be able to successfully patent the inventions and consequently, we may not be able to prevent third parties from using such inventions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the scope of the patent protection we obtain is not sufficiently broad, we may not be
able to prevent others from developing and commercializing technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some
cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents have, or that any of our
owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> pending patent applications that mature into issued patents will include claims with a scope sufficient to protect our product candidates or otherwise provide any competitive advantage.
Other parties have developed or may develop technologies that may be related to or competitive with our approach, and may have filed or may file patent applications and may have been issued or may be issued patents with claims that overlap or
conflict with our patent portfolio, either by claiming the same compounds, formulations, or methods or by claiming subject matter that could dominate our patent position. In addition, the laws of foreign countries may not protect our rights to the
same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty years after the first <FONT STYLE="white-space:nowrap">non-provisional</FONT>
patent application has been filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing, and regulatory review of product
candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our patent portfolio may not provide us with adequate and continuing patent protection sufficient to
exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if they are unchallenged, our owned and <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our patent portfolio by
developing similar or alternative product candidates in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. For example, a third party may develop a product candidate that provides benefits similar to one of our product candidates but
falls outside the scope of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights. If the patent protection provided by the patent and patent applications we hold or pursue with respect to such product candidate is not
sufficiently broad to impede such competition, our ability to successfully commercialize our product candidate could be negatively affected, which would harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of
development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of our patent portfolio may exist, or may arise in the future, for example
with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our partners, collaborators, or licensees, whether now or in the future, fail to establish, maintain or protect such patents and
other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, or licensees are not fully cooperative or disagree with us as to the prosecution, maintenance, or enforcement of any patent rights, such
patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patent portfolio, such patents may be held to be invalid and/or unenforceable, and such applications may never result in
valid, enforceable patents. Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and/or applications will be due to be paid to the U.S. Patent and Trademark Office, or the USPTO, and various government
patent agencies outside of the United States over the lifetime of our owned or licensed patents and patent applications. We rely on our outside counsel or our licensing partners to pay these fees due to U.S. and
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government patent agencies require compliance with several procedural, documentary, fee payment and other
similar provisions during the patent application process. While an inadvertent lapse can, and in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which <FONT
STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
<FONT STYLE="white-space:nowrap">Non-compliant</FONT> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT
STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government agencies
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
require compliance with certain foreign filing requirements during the patent application process. For example, in some countries, including the U.S., China, India and some European countries, a
foreign filing license is required before certain patent applications are filed. The foreign filing license requirements vary by country and depend on various factors, including where the inventive activity occurred, citizenship status of the
inventors, the residency of the inventors and the invention owner, the place of business for the invention owner and the nature of the subject matter to be disclosed (e.g., items related to national security or national defense). In some, but not
all cases, for example in China and India, a foreign filing license cannot be obtained retroactively in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result
in abandonment of a pending patent application or can be grounds for revoking or invalidating an issued patent, resulting in the loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the
relevant markets with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations and prospects. We may also be dependent on our licensors to take the necessary
actions to comply with these requirements with respect to our licensed intellectual property. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of pharmaceutical and biotechnology companies carries uncertainty. As a result, the issuance, scope, validity,
enforceability and commercial value of our patent rights are characterized by uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending patent applications cannot be enforced
against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file a patent application is
generally entitled to the patent. However, prior to March&nbsp;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and
patent applications in the United States and other jurisdictions are not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patent
portfolio, or that we were the first to file for patent protection of such inventions. If third parties have filed prior patent applications on inventions claimed in our patent portfolio that were filed on or before March&nbsp;15, 2013, an
interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by our patent portfolio. If third parties have filed such prior applications after
March&nbsp;15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, any patents we may own
or license may be challenged in the courts or patent offices in the United States and abroad. There is no assurance that all the potentially relevant prior art relating to our patent portfolio has been published or found. Therefore, we cannot know
with certainty whether we were the first to make the inventions claimed in our patent portfolio, or that we were the first to file for patent protection of such inventions. If such prior art exists, it may be used to invalidate a patent, or may
prevent a patent from issuing from a pending patent application. For example, such patent filings may be subject to a third-party submission of prior art to the USPTO, or to other patent offices around the world. Alternatively or additionally, we
may become involved in post-grant review procedures, oppositions, derivation proceedings, ex parte reexaminations, inter partes review, supplemental examinations, or interference proceedings or challenges before the USPTO or in district court in the
United States, or similar proceedings in various foreign jurisdictions, including both national and regional, challenging patents or patent applications in which we have rights, including patents on which we rely to protect our business. An adverse
determination in any such challenge may result in loss of the patent or claims in the patent portfolio being narrowed, invalidated or held unenforceable, in whole or in part, or in denial of the patent application or loss or reduction in the scope
of one or more claims of the patent portfolio, any of which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and
products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our or our licensors&#8217; pending and future patent applications may not result in patents
being issued that protect our business, in whole or in part, or which effectively prevent others from commercializing competitive products. For example, our or our licensors&#8217; provisional applications may never result in issued patents. A
provisional patent application is not eligible to become an issued patent until, among other things, we or our licensors file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application within 12 months of filing the provisional
patent application. If we or our licensors do not timely file <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, we or our licensors may lose the priority dates with respect to such provisional patent applications and any
patent protection on the inventions disclosed in such provisional patent applications. While we intend to timely file <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications relating to our current and future provisional patent
applications, we cannot predict whether any of our or our licensors&#8217; <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications directed to our technology and product candidates will result in the issuance of patents that
effectively protect our technology and product candidates. Further, competitors may be able to design around our patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries also may
diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, patent laws
in various jurisdictions, including jurisdictions that coincide with significant commercial markets, such as the European Patent Office, China, and Japan, restrict the patentability of methods of treatment of the human body more than United States
law does, and India does not permit the patenting of methods of treatment at all. These differences in patent protection may have a material adverse effect on our ability to adequately protect our inventions against unauthorized use by third
parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of
our future development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance, whether intentional or not, can result in abandonment or lapse of a patent or patent application, resulting in partial or complete
loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications may not result in any patents being issued, or even if issued may not provide adequate patent
coverage to prevent a competitor from developing a competing product or otherwise provide us with any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">company-owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents that have been issued or may be
issued in the future may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors, some of which may have substantially greater resources, may seek or may have already obtained
patents that will limit, interfere with or eliminate our ability to make, use, and sell our product candidates, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope
of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S.
courts, allowing foreign competitors a better opportunity to create, develop and market competing products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the U.S. may, under certain circumstances, force us to grant a license under our patents to
a competitor, thus allowing the competitor to compete with us in that jurisdiction or forcing us to lower the price of our drug in that jurisdiction; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there could also be delays at the USPTO caused by staffing cuts and other U.S. government actions as a result of
the U.S. Department of Government Efficiency or other executive actions to reduce the size of the U.S. government. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
competitors may also seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent
infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors do not infringe our patents. Thus, even if we have valid and enforceable patents,
these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
maintain certain information as company trade secrets. This information may relate to inventions that are not patentable or not optimally protected with patents. We use commercially acceptable practices to protect this information, including, for
example, limiting access to the information and requiring passwords for our computers. Additionally, we execute confidentiality agreements with any third parties to whom we may provide access to the information and with our employees, consultants,
scientific advisors, collaborators, vendors, contractors, and advisors. We cannot provide any assurances that all such agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar
information independently. It is possible that technology relevant to our business will be independently developed by a person who is not a party to such a confidentiality or invention assignment agreement. If any of our trade secrets were to be
independently developed by a competitor or other third party, we would have no right to prevent such competitor or third party, or those to whom they communicate such independently developed information, from using that information to compete with
us. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by contract manufacturers, consultants, collaborators, vendors, advisors, former employees and current employees. Monitoring
unauthorized uses and disclosures is difficult and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Furthermore, if the parties to our confidentiality agreements breach or violate the terms of
these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a consequence of such breaches or violations. Our trade secrets could otherwise become known or be independently discovered
by our competitors. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we
otherwise lose protection for our trade secrets, our business, financial condition, results of operation and prospects may be materially and adversely harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are heavily reliant on <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property, and if we fail to comply with our
obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our current and future licensors, we could lose license rights that are
important to our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are heavily reliant upon the rights granted to us under the Asset Transfer Agreement and the Monash
License Agreement pursuant to which, for the latter, we have been granted an exclusive, royalty-bearing license to certain patent rights that are important or necessary to the development of our proprietary technology and product candidates.
Termination of the Asset Transfer Agreement or the Monash License Agreement or reduction or elimination of our licensed rights could lead to the loss of our ability to develop and commercialize our proprietary technology and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may need to obtain licenses to intellectual property rights necessary to develop and commercialize our product candidates or
may need to amend existing or future licenses. If we are unable to obtain or amend such licenses at a reasonable cost or on reasonable terms, we may be unable to develop or commercialize our product candidates, which could harm our business
significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, the Monash License Agreement imposes, and we expect that future license agreements will impose, diligence
obligations, milestone and royalty payments, indemnification and other obligations on us. If we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fail to comply with our obligations under one or more of these licenses, our licensors, including Monash University, may have the right to terminate the license agreement at issue. If one or more
of these licenses is terminated, we may be unable to develop or commercialize our product candidates. Termination of any of our current or future license agreements or reduction or elimination of our licensed rights may require us to negotiate new
or reinstated licenses with less favorable terms, even if available at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our license agreements are, and future license
agreements are likely to be, complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of
the licensed rights, or increase what we believe to be our diligence, development, regulatory, commercialization, financial or other obligations under the relevant agreement. In addition, if disputes over the license agreements or the <FONT
STYLE="white-space:nowrap">in-licensed</FONT> intellectual property prevent or impair our ability to maintain our current license agreements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected
product candidate. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">License agreements we may enter into in the future may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> or may not include all
territories or fields of use of interest to us. Accordingly, third parties may also obtain licenses from such licensors to the same intellectual property rights they have licensed to us. As a result, the licenses granted to us may not provide us
with exclusive rights to use such patent and other intellectual property rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our product candidates, which may permit competitors to develop and
commercialize a competitive product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, in some cases, we may not have the right to control the preparation, filing and
prosecution of patent applications, or to maintain the patents, covering technology that we <FONT STYLE="white-space:nowrap">in-license</FONT> from third parties. Therefore, we cannot be certain that any
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If our future licensors or collaboration partners fail to obtain, maintain
or protect any patents or patent applications licensed to us, decide not to pursue litigation against third-party infringers, fail to prosecute infringement, or fail to defend against counterclaims of patent invalidity and unenforceability, our
rights to such patents and patent applications may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may arise between us and our current or future licensors regarding intellectual property subject to a license agreement, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate
intellectual property of the licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patents and other rights to third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to transfer or assign the license; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our current or future licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed, or license in the future, prevent or impair our ability to maintain our current
licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite our best efforts, our current or future licensors might conclude that we materially
breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products, if approved, and technology covered by these license agreements. As a result, we may be
required to cease our development and commercialization of our product candidates and use of our proprietary technologies covered by the patent rights owned by the licensors. Furthermore, if the <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patent rights fail to provide the intended exclusivity, competitors will have the freedom to seek regulatory approval of, and to market, products identical to ours. These events could have a material adverse effect on our competitive position,
business, financial condition, results of operations, and prospects. For a more complete description of our license agreements, see the section titled &#8220;Business&#8212;License Agreement.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may need to acquire or license additional intellectual property from third parties, and such licenses may not be available or may not
be available on commercially reasonable terms. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A third party may hold intellectual property, including patent rights that are
important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of one or more third parties to commercialize our current and future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies
may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical
development. If we are unable to acquire such intellectual property outright, or obtain licenses to such intellectual property from such third parties when needed or on commercially reasonable terms, our ability to commercialize our product
candidates, if approved, would likely be delayed or we may have to abandon development of that product candidate and our business and financial condition could suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates in the future, we might become dependent on proprietary rights
from third parties with respect to those product candidates. Any termination of such licenses could result in the loss of significant rights and would cause material adverse harm to our ability to develop and commercialize any product candidates
subject to such licenses. Even if we are able to <FONT STYLE="white-space:nowrap">in-license</FONT> any such necessary intellectual property, it could be on nonexclusive terms, including with respect to the use, field or territory of the licensed
intellectual property, thereby giving our competitors and other third parties access to the same intellectual property licensed to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us
to make an appropriate return on our investment or at all. If we are unable to license such intellectual property, or if we are forced to license such intellectual property on unfavorable terms, our business could be materially harmed. <FONT
STYLE="white-space:nowrap">In-licensing</FONT> IP rights could require us to make substantial licensing and royalty payments. Patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against
our licensors or another licensee or in administrative proceedings. If any <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents are invalidated or held unenforceable, we may not be able to prevent competitors or other third parties from
developing and commercializing competitive products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, intellectual property rights that we may
<FONT STYLE="white-space:nowrap">in-license</FONT> in the future may be sublicensed under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our
sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to
which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not have the right to control the prosecution, maintenance, enforcement or defense of patents and patent applications that we license
from third parties, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents. In such cases, we would be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reliant on the licensor to take any necessary actions. We cannot be certain that such licensor would act with our best interests in mind, or in compliance with applicable laws and regulations, or
that their actions would result in valid and enforceable patents. For example, it is possible that a licensor&#8217;s actions in enforcing and/or defending a patent licensed by us may be less vigorous than had we conducted them ourselves. We cannot
be certain that such activities by our licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. We cannot be certain that our
licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome
could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. In addition, even when we have the right to control patent prosecution of licensed patents and patent
applications, enforcement of licensed patents or defense of claims asserting the invalidity of those patents, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to or
after our assuming control. This could cause us to lose rights in any applicable intellectual property that we <FONT STYLE="white-space:nowrap">in-license,</FONT> and as a result our ability to develop and commercialize product candidates may be
adversely affected and we may be unable to prevent competitors from making, using and selling competing products. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our present or future licensors may have relied upon or may rely upon third-party consultants or collaborators or on funds from third
parties such that our present or future licensors may not be the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-license.</FONT> If other third parties have ownership rights to our present or future <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive
position, business, financial conditions, results of operations, and prospects. Furthermore, government agencies may provide, funding or other assistance in connection with the development of the intellectual property rights owned by or licensed to
us. In addition, the U.S. federal government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive,
nontransferable, irrevocable, <FONT STYLE="white-space:nowrap">paid-up</FONT> license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with <FONT STYLE="white-space:nowrap">&#8220;march-in</FONT> rights.&#8221; <FONT
STYLE="white-space:nowrap">March-in</FONT> rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a
&#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. If we choose to collaborate with academic institutions to accelerate our preclinical research or development, we
cannot be sure that any <FONT STYLE="white-space:nowrap">co-developed</FONT> intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we <FONT STYLE="white-space:nowrap">co-own</FONT> or license in
technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we may own or
<FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future, and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could have an adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their
protection. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection
for our product candidates, as well as on successfully defending these patents against potential third-party challenges. Our ability to protect our product candidates from unauthorized making, using, selling, offering to sell or importing by third
parties is dependent on the extent to which we have rights under valid and enforceable patents that cover these activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent
positions of pharmaceutical, biotechnology and other life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unresolved and have in recent years been the subject of much litigation. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may
diminish the value of our intellectual property. Over the past decade, U.S. federal courts have increasingly invalidated pharmaceutical and biotechnology patents during litigation often based on changing interpretations of patent law. Further, the
determination that a patent application or patent claim meets all the requirements for patentability is a subjective determination based on the application of law and jurisprudence. The ultimate determination by the USPTO or by a court or other
trier of fact in the United States, or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot be assured. Although we have conducted searches for third-party publications, patents
and other information that may affect the patentability of claims in our patent portfolio, we cannot be certain that all relevant information has been identified. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced
in our own patent portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot provide assurances that any of our or our licensors&#8217; pending patent applications will be
found to be patentable, including over our own prior art publications or patent literature, or will issue as patents. Neither can we make assurances as to the scope of any claims of the issued patents that we own or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> or any claims that may issue from our or our licensors&#8217; pending and future patent applications nor to the outcome of any proceedings by any potential third parties that could challenge the
patentability, validity or enforceability of our patent portfolio in the United States or foreign jurisdictions. Any such challenge, if successful, could limit patent protection for our product candidates and/or materially harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not
adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to generate sufficient data to support full patent applications that protect the entire
breadth of developments in one or more of our programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that one or more of our pending patent applications will not become an issued patent or, if
issued, that the patent claims will not have sufficient scope to protect our technology, provide us with commercially viable patent protection or provide us with any competitive advantages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if our pending applications issue as patents, they may be challenged by third parties as invalid or unenforceable
under United States or foreign laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not successfully commercialize our product candidates, if approved, before our relevant patents expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be the first to file patent applications for the inventions covered by our patent portfolio; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are separately patentable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, to the extent that we are unable to obtain and maintain patent protection for our product candidates, or in the event that such
patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development of any of our product candidates for <FONT STYLE="white-space:nowrap">follow-on</FONT> indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited term. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
twenty years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. The patent term of a U.S. patent may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the
USPTO in granting a patent, or may be shortened if a patent is terminally disclaimed over another patent having an earlier expiration date. Even if patents covering our drug candidates are obtained, once the patent life has expired for a drug
candidate, we may be open to competition from competitive medications, including generic versions. Given the amount of time required for the development, testing and regulatory review </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of new drug candidates, patents directed towards such drug candidates might expire before or shortly after such drug candidates are commercialized. As a result, our owned and licensed patent
portfolio may not provide us with sufficient rights to exclude others from commercializing drug candidates similar or identical to ours for a meaningful amount of time, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Given the amount of time required
for the development, testing and regulatory review of product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a Patent Term Extension, or PTE, of up to
five years beyond the normal expiration of the patent to compensate patent owners for loss of enforceable patent term due to the lengthy regulatory approval process. A PTE grant cannot extend the remaining term of a patent beyond a total of 14 years
from the date of the product approval. Further, PTE may only be applied once per product, and only with respect to an approved indication&#8212;in other words, only one patent (for example, covering the product itself, an approved use of said
product, or a method of manufacturing said product) can be extended by PTE. Moreover, the scope of protection during the period of the PTE does not extend to the full scope of the claim, but instead only to the scope of the product as approved. We
anticipate applying for PTE in the United States. Similar extensions may be available in other countries where we are prosecuting patents and we likewise anticipate applying for such extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The granting of such patent term extensions is not guaranteed and is subject to numerous requirements. We might not be granted an extension
because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents, failure to exercise due diligence during the testing phase or regulatory review process or any other failure to
satisfy any of the numerous applicable requirements. In addition, to the extent we wish to pursue patent term extension based on a patent that we <FONT STYLE="white-space:nowrap">in-license</FONT> from a third party, we would need the cooperation of
that third party. Moreover, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and
may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and
preclinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse effect on our ability to generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug
Products with Therapeutic Equivalence Evaluations, or the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our
product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA
to obtain permission to sell a generic version of such drug candidate. Where patents are listed, an ANDA or 505(b)(2) applicant seeking approval before patent expiry must submit a Paragraph IV certification; if we sue within 45 days of notice,
approval of the ANDA or 505(b)(2) application may be stayed for up to 30 months, though the patent can still be invalidated or found not infringed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes in the interpretation of patent law in the United States and other jurisdictions could diminish the value of patents in general,
thereby impairing our ability to protect our products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology companies, our success is heavily
dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Changes in
either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
costs, and may diminish our ability to protect our inventions, obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of our intellectual
property or narrow the scope of our owned and licensed patents. The U.S. Congress is responsible for passing laws establishing patentability standards. As with any laws, implementation is left to federal agencies and the federal courts based on
their interpretations of the laws. Interpretation of patent standards can vary significantly within the USPTO, and across the various federal courts, including the U.S. Supreme Court. Recently, the Supreme Court has ruled on several patent cases,
generally limiting the types of inventions as well as the scope of inventions that can be patented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to increasing uncertainty
with regard to our ability to obtain patents in the future, the legal landscape in the U.S. has created uncertainty with respect to the value of patents. Depending on any proposed or already implemented actions by U.S. Congress, and future decisions
by the lower federal courts and the U.S. Supreme Court, along with interpretations by the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our
existing patents and patents that we might obtain in the future as well as the cost associated with the filing, prosecution and maintenance of our or our licensors patent rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patent reform legislation in the United States and other countries could increase those uncertainties and costs. For example, the Leahy-Smith
America Invents Act of 2011, or the Leahy-Smith Act, included a number of significant changes to United States patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and
cost-effective avenues for competitors to challenge the validity of patents, for example, via post grant review and inter partes review proceedings at the USPTO. Because of a lower evidentiary standard in USPTO proceedings compared to the
evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be
insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or any
patents we may license in the future that would not have been invalidated if first challenged by the third party as a defendant in a district court action. In addition, the Leahy-Smith Act transformed the United States patent system into a
&#8220;first to file&#8221; system. However, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant
<FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and
patents that we might obtain in the future. The U.S. Supreme Court has ruled on several patent cases in recent years; these cases often narrow the scope of patent protection available to inventions in the pharmaceutical and biotechnology industries.
We cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. For example, in 2023, the Federal Circuit issued a decision in <I>In re Cellect, LLC</I> involving the interaction of patent
term adjustment, or PTA, terminal disclaimers, and obviousness-type double patenting which may affect the patent term of any issued patents that rely on any PTA. In 2022, the U.S. Congress passed the Inflation Reduction Act, or IRA, which authorizes
the Secretary of the Department of Health and Human Services, or HHS, to negotiate prices directly with participating manufacturers for selected medicines covered by Medicare even if these medicines are protected by an existing patent. For small
molecule medicines, the process begins seven years after initial approval by the FDA. While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain that it will not affect our
patent strategy in the long run. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a new court system recently became operational in the European Union. The Unified Patent Court,
or UPC, began accepting patent cases on June&nbsp;1, 2023. The UPC is a common patent court with jurisdiction over patent infringement and revocation proceedings effective for multiple member states of the European Union. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
broad geographic reach of the UPC could enable third parties to seek revocation of any of our European patents in a single proceeding at the UPC rather than through multiple proceedings in each
of the individual European Union member states in which the European patent is validated. Under the UPC, a successful revocation proceeding for a European Patent under the UPC would result in loss of patent protection in those European Union
countries. Accordingly, a single proceeding under the UPC could result in the partial or complete loss of patent protection in numerous European Union countries. Such a loss of patent protection could have a material adverse impact on our business
and our ability to commercialize our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations. Moreover, the controlling laws and regulations of the UPC will develop over time and
we cannot predict what the outcomes of cases tried before the UPC will be. The case law of the UPC may adversely affect our ability to enforce or defend the validity of our European patents. Patent owners have the option to <FONT
STYLE="white-space:nowrap">opt-out</FONT> their European Patents from the jurisdiction of the UPC, defaulting to <FONT STYLE="white-space:nowrap">pre-UPC</FONT> enforcement mechanisms. We have not opted out our existing European patents and patent
applications but we may in the future decide to opt out certain European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, our European patents could be subject to the jurisdiction of the
UPC. We cannot be certain that our European patents will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to seek or obtain patent protection throughout the world or enforce such patent protection once obtained.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, enforcing, and defending patents protecting our product candidates in all countries throughout the world
would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries,
particularly in developing countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our products. Further, the standards applied by the USPTO and foreign
patent offices in granting patents are not always applied uniformly or predictably. As such, we do not know the degree of future protection that we will have on our technologies, products and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign
intellectual property laws. Additionally, laws of some countries outside of the United States and Europe do not afford intellectual property protection to the same extent as the laws of the United States and Europe. Geopolitical actions in the
United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our
issued patents or those of any current or future licensors. Many companies have encountered significant problems in protecting, enforcing and defending intellectual property rights in certain foreign jurisdictions, such as China and Russia. For
example, further to the United States and foreign government actions related to Russia&#8217;s invasion of Ukraine, the Kremlin issued Decree 299 stating that Russian companies and individuals can use patented inventions without the owner&#8217;s
permission or compensation, if the patent is held by owners from &#8220;unfriendly countries,&#8221; which include the United States. As a result, we would not be able to enforce our otherwise valid patent rights against an infringer in Russia.
These and other restrictions could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights in such countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties.
Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the United States and Europe or from selling or importing products made from our inventions in and into the United States or other
jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop and market their own products and, further, may export otherwise infringing products to territories where we have patent
protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them
from competing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proceedings to enforce our patent rights, whether successful or not, could result in
substantial costs and divert our efforts and resources from other aspects of our business. Further, such proceedings could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly; put our pending patent applications
at risk of not issuing; and provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, while we intend to protect our intellectual property rights in major markets for our products, we cannot ensure that we will be
able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products, if approved. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, we may
decide to abandon national and regional patent applications before they are granted. The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as
patents in some jurisdictions, such as in the U.S., but may issue as patents with claims of different scope or may even be refused in other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>In order to protect our competitive position around our product candidates, we may become involved in lawsuits to protect or enforce our
patents or other intellectual property, which could be expensive, time consuming and unsuccessful and which may result in our patents being found invalid or unenforceable. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we
may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to
assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide
that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court
will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation
or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products.
Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid
or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. We may find it impractical or
undesirable to enforce our intellectual property against some third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not
to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue
such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel
could outweigh any benefit we receive as a result of the proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our competitors are larger than we are and have
substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed
intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise violating our intellectual property. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims could result in substantial costs and
diversion of management resources, which could harm our business. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research
programs, or <FONT STYLE="white-space:nowrap">in-license</FONT> needed technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are sued for infringing intellectual
property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing current and future product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, on our ability to develop, manufacture, and market our current as well as any future product
candidates, without infringing the intellectual property and other proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual
property rights. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. If any third-party patents
or patent applications are found to cover our current or any future product candidates or their methods of use, or other aspects of our current or future product candidates, we may not be free to manufacture or market such product candidates as
planned without obtaining a license, which may not be available on commercially reasonable terms, or at all, or we may incur significant legal fees or damages. We may in the future become party to, or be threatened with, adversarial proceedings or
litigation regarding intellectual property rights with respect to our current and any future product candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO. Third parties may assert
infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. Moreover, in recent years, individuals and groups that are <FONT STYLE="white-space:nowrap">non-practicing</FONT>
entities, commonly referred to as &#8220;patent trolls,&#8221; have acquired patents and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive
threatening letters, notices or &#8220;invitations to license,&#8221; or may be the subject of claims that our products and business operations infringe or violate the intellectual property rights of others. If a patent infringement suit were
threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the actual or threatened suit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In spite of our efforts to avoid obstacles and disruptions arising from third-party intellectual property, it is impossible to establish with
certainty that our programs directed to our current and any future product candidates will be free of claims by third-party intellectual property holders. We cannot guarantee that any of our patent searches or analyses, including the identification
of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad
that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. Even with modern databases and <FONT STYLE="white-space:nowrap">on-line</FONT> search engines, literature searches are imperfect and may fail
to identify relevant patents and published applications. Even when a third-party patent is identified, we may conclude upon a thorough analysis, that we do not infringe the patent or that the patent is invalid. The scope of a patent claim is
determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively
impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope.
Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. If the third-party patent owner disagrees with our conclusion and we continue with the business activity in
question, patent litigation may be initiated against us. Alternatively, we might decide to initiate litigation in an attempt to have a court declare the third-party patent invalid or <FONT STYLE="white-space:nowrap">non-infringed</FONT> by our
activity. In either scenario, patent litigation typically is costly and time-consuming, and the outcome is uncertain. The outcome of patent litigation is subject to uncertainties that cannot be quantified in advance, for example, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
credibility of expert witnesses who may disagree on technical interpretation of scientific data. Ultimately, in the case of an adverse outcome in litigation, we could be prevented from
commercializing a product or using certain aspects of our technology platform as a result of patent infringement claims asserted against us. This could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of intellectual property litigation in the pharmaceutical and biotechnology industries, and we may become party
to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our current or future product candidates, including interference proceedings before the USPTO. Third parties may assert
infringement claims against us based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and
biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to
interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that any current or future product candidates, products, methods, processes, modeling or similar work
either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity
requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to
infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product or
cease some of our business operations, which could harm our business. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the
infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby
giving our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found
liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. We may be required to indemnify collaborators or contractors against such claims. A finding of infringement could
prevent us from commercializing any future product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third
parties could have a similar negative impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our involvement in litigation, and in, e.g., any interference, derivation,
reexamination, inter partes review, opposition or post-grant proceedings or other intellectual property proceedings in the United States, or other jurisdictions, may divert management time from focusing on business operations, could cause us to
spend significant amounts of money and may have no guarantee of success. Any current and potential intellectual property litigation also could force us to do one or more of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stop selling, manufacturing or using our products in the United States or other jurisdictions that use the
intellectual property at issue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain from a third party asserting its intellectual property rights, a license to sell or use the relevant
technology, which license may not be available on reasonable terms, or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive</FONT> thereby giving our competitors access to the same technologies licensed to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redesign those products or processes that use any allegedly infringing or misappropriated technology, which may
result in significant cost or delay to us, or which redesign could be technically infeasible; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay damages, including the possibility of treble damages in a patent case if a court finds us to have willfully
infringed certain intellectual property rights. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Others may challenge inventorship or claim an ownership interest in our intellectual
property which could expose it to litigation and have a significant adverse effect on its prospects. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims
that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper inventors on a patent
application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors or the effects of foreign laws where foreign
nationals are involved in the development of the subject matter of the patent. Furthermore, ownership disputes may arise from alleged contributions of third parties involved in developing our product candidates and may result in joint ownership of
our inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Any disagreement over inventorship could result in our being forced to defend our determination of inventorship in a legal
action which could result in substantial costs and be a distraction to our senior management and scientific personnel. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material
adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we typically require employees, consultants and contractors who may develop intellectual property on our behalf to execute agreements
assigning such intellectual property to us, we may be unsuccessful in obtaining execution of assignment agreements with each party who in fact develops intellectual property that we regard as our own. Moreover, even when we obtain agreements
assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached. In either case, we may be forced to bring claims against third parties, or defend claims
that they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have preexisting or competing obligations to a third party, such as an academic
institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. If we are unsuccessful in obtaining assignment agreements from an employee, consultant or contractor who develops
intellectual property on our behalf, the employee, consultant or contractor may later claim ownership of the invention. Any disagreement over ownership of intellectual property could result in our losing ownership, or exclusive ownership, of the
contested intellectual property, paying monetary damages and/or being enjoined from clinical testing, manufacturing and marketing of the affected product candidate(s). Even if we are successful in prosecuting or defending against such claims,
litigation could result in substantial costs and be a distraction to our senior management and scientific personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Any
intellectual property litigation could lead to unfavorable publicity that could harm our reputation and cause the market price of our common stock to decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of any patent litigation, there could be public announcements of the results of hearings, rulings on motions, and other
interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our products, programs, or intellectual property could be diminished. In such event, the market price of our
common stock may decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees or we have misappropriated intellectual property from a
competitor or third parties or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our current and
former employees and our licensors&#8217; current and former employees, including our senior management, were previously employed at other pharmaceutical or biotechnology companies, including some which may be competitors or potential competitors.
Although we take commercially reasonable steps to ensure that our employees do not use the proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, including incorporating such
intellectual property into our product candidates, we may be subject to claims that we or these employees have misappropriated the intellectual property of a third party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or any of our employees are accused of misappropriating the proprietary information, <FONT
STYLE="white-space:nowrap">know-how</FONT> or trade secrets of a third party, we may be forced to defend such claims in litigation. If we are found to have misappropriated the intellectual property rights of a third party, we may be forced to pay
monetary damages, sustain reputational damage, lose key personnel, or lose valuable intellectual property rights. Further, it may become necessary for us to obtain a license from such third party to commercialize any of our product candidates. Such
a license may not be available on commercially reasonable terms or at all. Any of the aforementioned could materially affect the commercialization of any of our product candidates. Even if we are successful in defending against such claims,
litigation could result in substantial costs and be a distraction to management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of
our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Along
with patent protection, we also rely on trade secret protection for our proprietary information that is not amenable to, or that we do not consider appropriate for, patent protection, including, for example, certain aspects of our manufacturing
processes. We seek to protect these trade secrets, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, consultants, independent
contractors, CROs, advisors, contract manufacturers, suppliers and other third parties. We also enter into confidentiality and invention or patent assignment agreements with employees and certain consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trade secrets and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> are difficult to maintain as confidential. Although we use
reasonable efforts to protect our trade secrets, any party with whom we have executed a confidentiality agreement may breach that agreement and disclose our proprietary information, including our trade secrets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the
outcome is unpredictable. Accordingly, we may not be able to obtain adequate remedies for such breaches, despite any legal action that we might take against persons making such unauthorized disclosures. In addition, courts outside the United States
sometimes are less willing than United States courts to protect trade secrets. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such
third party, or those to whom they communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our business
and competitive position could be harmed. For example, we may choose not to file a patent application for certain inventions, instead choosing to rely on trade secret protection, and a third party may subsequently file a patent application covering
such intellectual property. Although certain defenses maybe available to us, those defenses may not be available to a commercial partner or acquiror. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Those with whom we collaborate on research and development related to current and future product candidates may have rights to publish data
and other information to which we have rights. In addition, we sometimes engage individuals or entities to conduct research relevant to our business. The ability of these individuals or entities to publish or otherwise publicly disclose data and
other information generated during the course of their research is subject to certain contractual limitations. These contractual provisions may be insufficient or inadequate to protect our confidential information. If we do not apply for patent
protection prior to such publication, or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information
may be jeopardized. We may also need to share our trade secrets and proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> with current or future partners, collaborators, contractors and others located in countries at heightened risk of theft
of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be
able to build name recognition in our trademarks of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current or future
trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims
against third parties or initiate trademark opposition proceedings. This can be expensive and time-consuming, particularly for a company of our size. We may not be able to protect our rights to our trademarks and trade names or may be forced to stop
using these names, which we need for name recognition by potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and
possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered
trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. During trademark
registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign
jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not
survive such proceedings. Moreover, any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in
Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our
proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be
acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. If we are unable to
establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to
develop and commercialize our products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future collaborations that we enter into may not be successful. The success of our
collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to
continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business
combination that diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between us and a collaborator that causes the delay or termination of the research,
development or commercialization of our current or future products or that results in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to
collaborations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit
sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may use our intellectual property or proprietary information in a way that gives rise to actual or
threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability or business risk; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue
further development or commercialization of the applicable current or future product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our
product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and a collaborator&#8217;s sales and marketing activities or other
operations may not be in compliance with applicable laws resulting in civil or criminal proceedings. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering
and Ownership of Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>There has been no prior public market for our common stock, and an active trading market may
not develop or be sustained. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been no public market for our common stock prior to this offering. Although we have
applied to list our common stock on The Nasdaq Global Select Market, an active or liquid market in our common stock may not develop upon closing of this offering or, if it does develop, it may not be sustainable. The initial public offering price
for our common stock was determined through negotiations among the underwriters and us and may vary from the market price of our common stock following this offering. This price will not necessarily reflect the price at which investors in the market
will be willing to buy and sell our shares following this offering. The lack of an active market may impair the value of your shares, your ability to sell your shares at the time you wish to sell them and the prices that you may obtain for your
shares. An inactive market may also impair our ability to raise capital by selling our common stock and our ability to acquire other companies, products, or technologies by using our common stock as consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of our common stock may be volatile, and you could lose all or part of your investment. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in
response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this section and elsewhere in this prospectus, these factors include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement, enrollment, completion, or results of our current or future preclinical and clinical trials for
our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay in identifying and advancing a clinical candidate for our other programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse
development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results or delays, suspensions, or terminations in future preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical
trial; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates, or the
failure of a regulatory authority to accept data from preclinical studies or clinical trials conducted in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws or regulations applicable to our product candidates, including but not limited to clinical trial
requirements for approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse developments concerning our manufacturers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of the healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable
prices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to establish strategic partnerships or collaborations, if needed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to commercialize our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to any of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">introduction of new products or services offered by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us
or our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to effectively manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our cash position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to
the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about us or our industry, or product candidates in particular, or positive or
negative recommendations or withdrawal of research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock by us or our stockholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our
ability to obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general, and the market for therapeutics companies in particular, have experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating
performance. If the market price of our common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock after this offering does not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. In the past,
securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a
diversion of management&#8217;s attention and resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our operating results may fluctuate significantly, which makes our future
operating results difficult to predict and could cause our operating results to fall below expectations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our quarterly and annual
operating results may fluctuate significantly, due to a variety of factors, many of which are outside of our control and may be difficult to predict, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of, and level of investment in, research, development and, if approved, commercialization
activities relating to our current and future product candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and status of enrollment for clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our product candidates, as well as building out our supply chain, which may vary
depending on the quantity of production and the terms of our agreements with manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we may incur to acquire, develop, or commercialize additional product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing and amount of any milestone, royalty, or other payments due under any collaboration or license agreement,
including the Asset Transfer Agreement and/or the Monash License Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of preclinical studies and clinical trials for our product candidates or
competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of receipt of approvals for our product candidates from regulatory authorities in the United States
and internationally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exchange rate fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future
drugs that compete with our products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for our product candidates, if approved, which may vary significantly over time.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and
annual operating results. As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our past results
as an indication of our future performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This variability and unpredictability could also result in our failing to meet the
expectations of industry or financial analysts or investors for any period. If our future revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we
provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings
guidance we may provide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or
unfavorable research about our business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common
stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or
industry analysts commence coverage of our company, the trading price for our common stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades
our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could
decrease, which might cause our stock price and trading volume to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our executive officers, directors, principal
stockholders, and their respective affiliates own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the beneficial ownership of our common stock as of April 1, 2026, prior to this offering, our executive officers, directors, holders
of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 92.8% of our voting stock and, upon the completion of this offering, that same group will hold approximately 71.6% of our outstanding voting stock
(assuming no exercise of the underwriters&#8217; option to purchase additional shares, no exercise of outstanding options and no purchases of shares in this offering by any of this group), in each case assuming the conversion of all outstanding
shares of our convertible preferred stock into shares of our common stock. In particular, PureTech will own approximately 32.9% of our common stock following this offering and will be our largest stockholder following this offering. As a result,
PureTech along with stockholders who own more than 5% or more of our capital stock, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of
directors, amendment of our organizational documents, any merger, consolidation, or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may
even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an
opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the
trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Future
sales of our common stock in the public market could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stock price could decline as a result of
sales of a large number of shares of common stock after this offering or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in
the future at a time and price that we deem appropriate. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, 50,667,817 shares of common stock will
be outstanding (or 52,437,817 shares if the underwriters exercise their option to purchase additional shares from us in full), based on the number of shares outstanding as of December 31, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the
Securities Act of 1933, as amended, or the Securities Act, unless held by our &#8220;affiliates&#8221; as defined in Rule 144 under the Securities Act. The resale of the remaining 38,029,523&nbsp;shares, or 98% of our outstanding shares of common
stock following this offering, is currently prohibited or otherwise restricted, subject to certain limited exceptions, as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders with the underwriters in connection with this offering. However, subject to applicable securities law restrictions, these shares will be able to be sold in the public market
beginning on the 181<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> day after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted
under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements and/or <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see the section titled &#8220;Shares Eligible for Future Sale&#8221; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, the holders of 36,272,475 shares, or 71.6% of 50,667,817 our outstanding shares following this offering,
of our common stock will have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or our other
stockholders. We also intend to register the offer and sale of all shares of common stock that we may issue under our equity compensation plans. Once we register the offer and sale of shares for the holders of registration rights and shares that may
be issued under our equity incentive plans, these shares will be able to be sold in the public market upon issuance, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described under the section titled
&#8220;Underwriting&#8221; included elsewhere in this prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the future, we may issue additional shares of
common stock, or other equity or debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement, or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and
could cause the price of our common stock to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion in how we use the proceeds of this offering and
may not use these proceeds effectively, which could affect our results of operations and cause our stock price to decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
will have considerable discretion in the application of the net proceeds of this offering and, including for any of the purposes described in the section titled &#8220;Use of Proceeds,&#8221; and you will not have the opportunity as part of your
investment decision to assess whether the net proceeds are being used appropriately. As a result, investors will be relying upon management&#8217;s judgment with only limited information about our specific intentions for the use of the net proceeds
of this offering. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not
produce income or that loses value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of our common stock in our initial public offering, you will experience
substantial and immediate dilution. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumed initial public offering price of $17.00 per share, which is the midpoint of
the price range set forth on the cover page of this prospectus, is substantially higher than the pro forma as adjusted net tangible book value per share of our outstanding common stock immediately following the completion of this offering. If you
purchase shares of common stock in this offering, you will experience substantial and immediate dilution in the pro forma as adjusted net tangible book value per share of $8.78&nbsp;per share as of December&nbsp;31, 2025. That is because the price
that you pay will be substantially greater than the pro forma as adjusted net tangible book value per share of the common stock that you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than
the initial public offering price when they purchased their shares of our capital stock. You will experience additional dilution if the underwriters exercise their option to purchase additional shares in this offering, when those holding stock
options exercise their right to purchase common stock under our equity incentive plans, upon the vesting of outstanding restricted stock awards or when we otherwise issue additional shares of common stock, including if we issue additional shares of
common stock in connection with a concurrent private placement. For more information, see the section titled &#8220;Dilution&#8221; included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Participation in this offering by our existing stockholders and/or their affiliated
entities will reduce the public float for our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent our existing stockholders who are our affiliates or
their affiliated entities participate in this offering, such purchases would reduce the <FONT STYLE="white-space:nowrap">non-affiliate</FONT> public float of our common stock after this offering, which is the number of shares of common stock that
are not held by our officers, directors, and affiliated stockholders. As a result, the number of freely tradeable shares of our common stock following this offering will be reduced relative to what it would have been had these shares been sold to
investors that were not existing stockholders, affiliates, or purchasers. This could adversely impact the liquidity of our common stock and depress the price at which you may be able to sell shares of common stock purchased in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or
otherwise will dilute all other stockholders. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to issue additional capital stock in the future and to grant equity
awards to employees, directors, and consultants under our stock incentive plans. We may also raise capital through equity financings in the future. Additionally, as part of our business strategy, we may acquire or make investments in complementary
companies, products, or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and
the per share value of our common stock to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently intend to pay dividends on our common stock and,
consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation of the value of our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings
to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in the foreseeable future. In addition, any future debt agreements may preclude us from
paying dividends. As a result, any investment return on our common stock will depend upon increases in the value for our common stock, which is not certain. For more information on our dividend policy, see the section titled &#8220;Dividend
Policy&#8221; included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our corporate charter documents and under Delaware law could
make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and
our amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, will contain provisions that may discourage, delay, or prevent a merger, acquisition or other
change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be
willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may
frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a classified board of directors such that only one of three classes of directors is elected each year;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the manner in which stockholders can remove directors from our board of directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
nominations to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by
our stockholders by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit who may call stockholder meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to
institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the approval of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes that all
our stockholders would be entitled to cast to amend or repeal specified provisions of our amended and restated certificate of incorporation or amended and restated bylaws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation
Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our
outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated bylaws that
will become effective upon the effectiveness of this registration statement designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our
stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws that will become effective upon effectiveness of the registration statement of which this prospectus forms a
part provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i)&nbsp;any derivative action or proceeding brought on our
behalf, (ii)&nbsp;any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees to us or our stockholders, (iii)&nbsp;any action asserting a claim arising
pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws (including the interpretation, validity or enforceability thereof) or (iv)&nbsp;any action asserting a claim that is
governed by the internal affairs doctrine, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.
Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting
a cause or causes of action arising under the Securities Act, or the Federal Forum Provision. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock
is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on
stockholders in pursuing any such claims. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or
our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, Section&nbsp;22 of the Securities Act
creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. While the Delaware Supreme Court and other state courts have
upheld the validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
court, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs
associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the
federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such
judgments may be more or less favorable to us than our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to satisfy listing requirements of The
Nasdaq Stock Market, or Nasdaq, or obtain or maintain a listing of our common stock on Nasdaq. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our common stock is listed on
Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate Nasdaq&#8217;s listing requirements, our common stock may be delisted. If we fail to meet any of Nasdaq&#8217;s listing standards, our common stock
may be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock from Nasdaq may materially impair
our stockholders&#8217; ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair
our ability to raise capital and the value of your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The structure of our common stock may limit your ability to
influence corporate matters and may limit your visibility with respect to certain transactions. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The structure of our common stock
may also limit your ability to influence corporate matters. Holders of our common stock are entitled to one vote per share, while holders of our non-voting common stock are not entitled to any votes. We do not currently have any shares of non-voting
common stock outstanding. Nonetheless, we may issue non-voting common stock in the future and each outstanding share of our non-voting common stock may be converted at any time into one share of our common stock at the option of its holder by
providing written notice to us, subject to the limitations provided for in our amended and restated certificate of incorporation to become effective upon the completion of this offering. See &#8220;Description of Capital Stock&#8212;Voting Common
Stock and Non-Voting Common Stock.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other General Risks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition, stock price, and results of operations.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The global credit and financial markets have experienced extreme volatility and disruptions (including as a result of actual or
perceived changes in interest rates, inflation, and macroeconomic uncertainties), which has included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty
about economic stability, global supply chain disruptions, and increases in unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the
recent military action in Iran and effects thereof, the ongoing conflicts in the Middle East and between Russia and Ukraine, terrorism, political unrest, or other geopolitical events. Sanctions imposed by the United States and other countries in
response to such conflicts may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no
assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decrease in the demand
for our drug candidates and in our ability to raise additional capital when needed on acceptable terms, if at all. For example, there has been proposed U.S. legislation that may have the effect of restricting the ability of U.S. biopharmaceutical
companies to purchase services or products from, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise collaborate with, certain Chinese biotechnology companies that the government name as &#8220;companies of concern&#8221; without losing the ability to contract with, or otherwise
receive funding from, the U.S. government. We continue to assess the legislation as it develops to determine whether it could have an effect on our contractual relationships. Furthermore, any disruptions to our supply chain as a result of
unfavorable global economic conditions, including due to geopolitical conflicts, political unrest, tariff, and other trade-related cost pressures or public health crises, could negatively impact the timely execution of our ongoing and future
clinical trials. In addition, inflationary trends in the global economy may impact salaries and wages, costs of goods and transportation expenses, among other things, and recent events of political unrest and/or potential future disruptions in
access to bank deposits or lending commitments due to bank failures may create market and economic instability. We cannot anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally,
could adversely impact our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We, or the third parties upon whom we depend, may be adversely affected by natural disasters,
public health crises, or other business interruptions and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Natural disasters or public health crises could severely disrupt our operations and the operations of our suppliers, CROs, and clinical sites,
which would have a material adverse impact on our business, financial condition, results of operations, and prospects. If a natural disaster, power outage, public health crisis, or other event occurred that prevented us from conducting our clinical
trials, releasing clinical trial results, or delaying our ability to obtain regulatory approval for our product candidates, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are eligible to be treated as an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and our election
of reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we
may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements in addition to any required unaudited
interim financial statements and a correspondingly reduced &#8220;<I>Management</I><I>&#8217;</I><I>s Discussion and Analysis of Financial Condition and Results of Operations</I>&#8221; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting pursuant to of Section&nbsp;404 of the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#8217;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus,
we have not included all of the executive compensation-related information that would be required if we were not an emerging growth company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could be an emerging growth company for up to five years following the completion of this offering, although circumstances could cause us
to lose that status earlier, including if we are deemed to be a &#8220;large accelerated filer,&#8221; which occurs when the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds
$700&nbsp;million as of the last business day of our most recently completed second fiscal quarter, or if we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have total annual gross revenue of $1.235&nbsp;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the last day of our
fiscal year, or if we issue more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately. For so
long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can also take advantage of an extended transition period for complying with
new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we may not be subject to the same
requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a
&#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to
smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business
day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$700.0&nbsp;million measured on the last business day of our second fiscal quarter. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less
attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We
will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. We will be
subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley
Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of
effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant
corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Recent legislation permits
emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of this offering. Stockholder activism, the current political environment and the current high level of government
intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to
make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our business. The increased costs will decrease our
net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more
expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to
respond to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or
as executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to establish and maintain an effective system of internal control over financial reporting, we
may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate
financial statements on a timely basis is a costly and time-consuming effort that needs to be reevaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In connection with this offering, we began the process of documenting, reviewing, and improving our internal controls and
procedures for compliance with Section&nbsp;404 of the Sarbanes-Oxley Act, which will require annual management assessment of the effectiveness of our internal control over financial reporting. Under current rules, we will be subject to these
requirements beginning with our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ending 2026. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause
us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&nbsp;404 of the Sarbanes-Oxley Act, or any subsequent testing by our independent registered public accounting firm, may reveal
deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement.
Internal control deficiencies could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required
to assess the effectiveness of these controls annually. However, for as long as we are an emerging growth company or a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, our independent registered public accounting firm will not be
required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act. We could be an emerging growth company for up to five years following completion of this initial
public offering. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls over
financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our
disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering,
we will become subject to the periodic reporting requirements of the Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is
accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived
and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur
because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally,
controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to
error or fraud may occur and not be detected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Adverse developments affecting the financial services industry could adversely affect
our current and projected business operations and our financial condition and results of operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain the majority of
our cash, cash equivalents, and investments in accounts with major U.S. and multi-national financial institutions, and our cash equivalents are invested in U.S. government money market funds and our investments are invested in U.S. Treasury
obligations. Our deposits at certain of these institutions exceed insured limits, unless subject to a &#8220;sweep.&#8221; Market conditions and changes in financial regulations and policies can impact the viability of these institutions. Adverse
developments that affect financial institutions, such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to market-wide liquidity problems. For example, on March&nbsp;10, 2023, Silicon Valley Bank
was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. Although we assess our banking relationships as we believe necessary or appropriate, our access to
funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that us, the financial institutions with which we may have
future credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under
various types of financial, credit, or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial
services industry. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. In addition, changes in regulations governing financial institutions are beyond our control and difficult to
predict; consequently, the impact of such changes on our business and results of operations is difficult to predict and may have an adverse effect on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, we had approximately $53.4&nbsp;million of federal net operating losses, or NOLs. Federal NOLs generated in
taxable years beginning after December&nbsp;31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOL carryforwards in a taxable year is limited to 80% of our taxable income in such year. As of December&nbsp;31, 2025,
we had approximately $53.7&nbsp;million of state NOLs. As of December&nbsp;31, 2025, we had approximately $2.9&nbsp;million of federal research and development tax credit carryforwards. Federal tax credit carryforwards expire at various dates
beginning in 2044. As of December&nbsp;31, 2025, we had approximately $1.0&nbsp;million of state research and development tax credit carryforwards. The state tax credits carryforwards expire at various dates beginning in 2039. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership
change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by &#8220;5&nbsp;percent shareholders&#8221; over a three-year period, the corporation&#8217;s ability to use its <FONT
STYLE="white-space:nowrap">pre-change</FONT> NOLs and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. A corporation that
experiences an ownership change will generally be subject to an annual limitation on the use of its <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change NOLs equal to the value of the corporation immediately before the ownership change,
multiplied by the long-term <FONT STYLE="white-space:nowrap">tax-exempt</FONT> rate (subject to certain adjustments). We may have experienced ownership changes in the past and may experience ownership changes as a result of this offering and/or
subsequent shifts in our stock ownership (some of which are outside our control). There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs by federal or state taxing authorities or other unforeseen reasons,
portions of our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities. As a result, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and tax credits to offset future taxable
income, if any, or taxes could be subject to limitations. Similar provisions of state tax law may also apply. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and tax credits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes in tax law could adversely affect our business and financial condition.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. federal, state, local, and foreign tax laws, regulations and administrative guidance are subject to change as a result of
the legislative process and review and interpretation by the U.S. Internal Revenue Service, the U.S. Treasury Department and other taxing authorities. Changes to tax laws (which changes may have retroactive application), including with respect to
net operating losses and research and development tax credits, could adversely affect us or holders of our common stock. For example, on July&nbsp;4, 2025, President Donald Trump signed the One Big Beautiful Bill Act into law. Key tax provisions
included the restoration of 100% bonus depreciation for certain qualified property, immediate expensing for domestic research and experimental expenditures and the ability to make elective adjustments for prior years, changes to the
Section&nbsp;163(j) interest limitations and updates to net CFC tested income (formerly GILTI) and FDII rules. In recent years, many other such changes have been made and changes are likely to continue to occur in the future. Future changes in tax
laws could have a material adverse effect on our business, financial condition, results of operations, or cash flow. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an
investment in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our information technology systems and infrastructure, or those of our collaborators and service
providers, or our data, may be subject to cyberattacks, security breaches, compromises or other incidents, which could impact the confidentiality, integrity, and availability of our operational system and result in additional costs, loss of revenue,
significant liabilities, harm to our brand, material disruption of our development programs and operations, or other adverse consequences.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we and the third parties upon which we rely, process sensitive data, and, as a result, we and the
third parties upon which we rely face a variety of evolving threats that could cause cyber-attacks, security breaches, compromises, or other incidents that impact the confidentiality, integrity, and availability of our operational systems. Although
we, and the third parties upon which we rely, take steps to develop and maintain systems and controls designed to protect our sensitive data, systems, and infrastructure, there can be no assurance that our internal technology systems, and
infrastructure, or those of third parties upon which we rely, will be sufficient to protect against a cyber-attack, security breach, compromise, or other incident such as an industrial espionage attack, ransomware, or insider threat attack, which
may compromise the confidentiality, integrity, and availability of our system infrastructure, or those of third parties upon which we rely, or lead to the loss, destruction, alteration, or dissemination of, or damage to, our sensitive data. Such
threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors,
personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk of a cyber-attack,
security breach, compromise, or other adverse impact to our and our third-party service provider&#8217;s information technology systems and sensitive data has generally increased as the number, intensity, and sophistication of attempted attacks and
intrusions from around the world have increased. Such risks come from a variety of evolving threats, including but not limited to, social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as
fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT>
attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware errors (including vulnerabilities in commercial software that is
integrated into our information technology systems and those of third parties upon which we rely), failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by AI, telecommunications failures,
earthquakes, fires, floods, and other similar threats. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individuals engage in and are expected to continue to engage in cyber-attacks,
including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely, may be
vulnerable to a heightened risk of cyber-attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell, and distribute our products and services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also face increased risks of a cyber-attack, security breach, compromise, or adverse
impact to our and our third-party service provider&#8217;s information technology systems and sensitive data incident due to our reliance on internet technology and the number of our employees who work on a hybrid basis at home, in the office, or
other public spaces. This may create additional opportunities for cybercriminals to exploit vulnerabilities. Additionally, business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and
vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies that were not found during due diligence of such acquired or integrated entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain
attacks. We rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts and our ability to monitor these third parties&#8217; information security practices is
limited. These third parties may not have adequate information security measures in place and if our third-party service providers experience a cyber-attack, security breach, compromise or incident, or other interruption, we could experience adverse
consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such
award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be unable to detect vulnerabilities in our information technology systems and infrastructure on a timely basis or until
after a cyber-attack, security breach, compromise, or other incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to adequately address any such identified vulnerabilities. In addition, we
may be unable to comprehensively apply patches or confirm that measures are in place to mitigate all such vulnerabilities, or that patches will be applied before vulnerabilities are exploited by a threat actor. If attackers are able to exploit
critical vulnerabilities before patches are installed or mitigating measures are implemented, significant compromises could impact our and our customers&#8217; systems and data. Any integration of artificial intelligence in our or any third
party&#8217;s operations, products, or services is expected to pose new or unknown cybersecurity risks and challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can also be
no assurance that our cybersecurity risk management program and processes, including our policies, controls, or procedures, will be fully implemented, complied with, or effective in protecting our information technology systems (and those of third
parties upon which we rely) and sensitive data. We and certain of our third-party service providers regularly experience cyberattacks and other incidents, and we expect such attacks and incidents to continue in varying degrees. While to date no
incidents have had a material impact on our operations or financial results, we cannot guarantee that material incidents will not occur in the future. We may in the future experience additional threats, compromises, breaches, or incidents. If we, or
a third party upon whom we rely, experience a cyber-attack, security breach, compromise, or other adverse impact to the confidentiality, integrity and availability of our system infrastructure, or those of third parties upon which we rely, or
sensitive data, or are perceived to have experienced a cyber-attack, security breach, compromise, or other adverse impact to our and our third-party service provider&#8217;s information technology systems and sensitive data, we may experience
adverse consequences, such as government enforcement actions (e.g., investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data);
litigation (including individual and class action claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); significant incident response,
system restoration, or remediation and future compliance costs; financial loss; and other potentially significant harms. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of
liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations. Additionally, we cannot guarantee that any costs and liabilities incurred in relation to an attack or
incident will be covered by our existing insurance policies or that applicable insurance will be available to us in the future on economically reasonable terms or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, applicable privacy and data security obligations may require us to notify relevant stakeholders of a cyber-attack, security breach,
compromise, or other adverse impact to our and our third-party service provider&#8217;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information technology systems and sensitive data. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. In addition,
cyber-attacks, security breaches, compromises, or other incidents may cause stakeholders (including investors and potential customers) to stop supporting our business, deter new customers from using our products, and negatively impact our ability to
grow and operate our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were to experience a cyber-attack, security breach, compromise, or other adverse impact to our and
our third-party service provider&#8217;s information technology systems and sensitive data that causes interruptions in our operations, it could result in a material disruption of our product development programs, business, financial condition, and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may use artificial intelligence in our business, and challenges with properly managing its use, as well
as uncertainty regarding the legal landscape surrounding the use of AI could result in reputational harm, competitive harm, legal liability, and adversely affect our results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may use artificial intelligence, or AI, machine learning, and automated decision-making technologies, or, collectively, AI Technologies,
throughout our business, and are making investments in this area. We expect that increased investment will be required in the future to continuously improve our use of AI Technologies. As with many technological innovations, there are significant
risks involved in developing, maintaining and deploying these technologies, including that <FONT STYLE="white-space:nowrap">AI-generated</FONT> content, analyses, or recommendations we utilize could be deficient, that our competitors may more
quickly or effectively adopt AI capabilities, or that our use of AI or other emerging technologies increases regulatory, cybersecurity and other significant risks. There can be no assurance that the usage of, or our investments in such technologies
will always enhance our products or services or be beneficial to our business, including our efficiency or profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular,
if the models underlying our AI Technologies are: incorrectly designed or implemented; trained or reliant on incomplete, inadequate, inaccurate, biased or otherwise poor quality data, or on data to which we do not have sufficient rights or in
relation to which we and/or the providers of such data have not implemented sufficient legal compliance measures; used without sufficient oversight and governance to ensure their responsible use; and/or adversely impacted by unforeseen defects,
technical challenges, cybersecurity threats or material performance issues, the performance of our products, services and business, as well as our reputation, could suffer or we could incur liability resulting from the violation of laws or contracts
to which we are a party or civil claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be successful in our development and maintenance of these technologies in the face of
novel and evolving technical, reputational and market factors. Our efforts to develop proprietary AI models in the future could increase our operating costs. Our future ability to develop proprietary AI models may be limited by our access to
processing infrastructure or training data, and we may be dependent on third party providers for such resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to keep pace
with rapidly evolving AI Technologies, especially in the medical device industry, our competitive position and business results may suffer. The introduction and use of AI Technologies, particularly generative AI, into new or existing offerings may
result in new or expanded risks and liabilities, including due to enhanced governmental or regulatory scrutiny, litigation, compliance issues, ethical concerns, confidentiality or security risks, as the well as other factors that could adversely
affect our reputation, as the well as our business, operating results, and financial condition. For example, AI Technologies can lead to unintended consequences, including generating content that appears correct but is factually inaccurate,
misleading, or otherwise flawed, which could negatively impact our customers, harm our reputation and business, and expose us to liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use AI Technologies from third parties. If we are unable to obtain or maintain rights to use these AI Technologies on commercially
reasonable terms, or if any such third-party AI tools become incompatible with our products, we may be forced to acquire or develop alternate AI Technologies, which may limit or delay our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ability to provide competitive offerings and may increase our costs. These AI Technologies also may incorporate data from third party sources, which may expose us to risks associated with data
rights and protection. The legal and regulatory landscape surrounding AI Technologies is rapidly evolving and uncertain, including with respect to intellectual property ownership and license rights, cybersecurity, and data protection laws, among
others, and has not yet been fully addressed by courts or regulators. The evolving legal, regulatory, and compliance framework for AI Technologies may also impact our ability to protect our own data and intellectual property against infringing use.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory framework for AI Technologies is rapidly evolving as many federal, state, and foreign government bodies and agencies have
introduced or are currently considering additional laws and regulations and we expect to see increasing government and supranational regulation related to AI use and ethics, which may also significantly increase the burden and cost of research,
development and compliance in this area. In the U.S., a number of states have proposed and passed laws regulating various uses of AI, and federal regulators have issued guidance affecting the use of AI in regulated sectors. The FDA, for example,
also issued guidance on the use of AI in medical devices, requiring detailed risk management and review processes to obtain approvals. If we develop or use AI systems governed by these laws or regulations, we will need to apply significant resources
to design, develop, test and maintain such systems in accordance with applicable laws and regulations, with the potential for significant enforcement or litigation in the event of any perceived <FONT STYLE="white-space:nowrap">non-compliance.</FONT>
It is possible that new laws and regulations will be adopted in the U.S. and in other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, or that existing laws and regulations, including competition and antitrust laws, may be interpreted
in ways that would limit our ability to use AI Technologies for our business, or require us to change the way we use AI Technologies in a manner that negatively affects the performance of our products, services, and business and the way in which we
use AI Technologies. We may need to expend resources to adjust our products or services in certain jurisdictions if the laws, regulations, or decisions are not consistent across jurisdictions. Further, the cost to comply with such laws, regulations,
or decisions and/or guidance interpreting existing laws, could be significant and would increase our operating expenses (such as by imposing additional reporting obligations regarding our use of AI Technologies). Such an increase in operating
expenses, as well as any actual or perceived failure to comply with such laws and regulations, could adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even in the absence of dedicated AI laws and regulations, we may be subject to novel legal and business risks relating to our adoption of
these new technologies. Vendors may in turn incorporate AI tools into their own offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data
security. Bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information, and intellectual property. Our
use of AI Technologies may also, in the future, result in cybersecurity incidents that implicate the personal information of customers or patients. Any such cybersecurity incidents related to our use of AI applications could adversely affect our
reputation and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trial and product liability lawsuits against us could divert our resources and could
cause us to incur substantial liabilities and to limit commercialization of any products that we may develop. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent
risk of clinical trial and product liability exposure related to the testing of our product candidates in clinical trials, and we will face an even greater risk if we commercially sell any products that we develop. While we currently have no
products that have been approved for commercial sale, the ongoing, planned, and future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be
made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur
substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidates or products that we may develop; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant costs to defend any related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced resources of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any products that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we currently hold clinical trial liability insurance, we will need to maintain such insurance coverage as we expand our clinical
trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to obtain and maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability
that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business
operations could be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in litigation that could divert management&#8217;s attention and harm our
business, and insurance coverage may not be sufficient to cover all costs and damages. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we may be subject to
litigation claims through the ordinary course of our business operations regarding, but not limited to, securities litigation, employment matters, security of patient and employee personal data, contractual relations with collaborators and
licensors, and intellectual property rights. In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, the
announcement of negative events, such as negative results from clinical trials, or periods of volatility in the market price of a company&#8217;s securities. These events may also result in or be concurrent with investigations by the SEC. We may be
exposed to such litigation or investigation even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management&#8217;s attention and resources, which could adversely affect our business and cash resources and
our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements
other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials,
results of preclinical studies, clinical trials, research and development costs, regulatory approvals, commercial strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking
statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any
future results, performance, or achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify
forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221;
&#8220;target,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. Forward-looking
statements contained in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our current and future clinical trials, preclinical studies, and
research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of announcement of results from clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully complete our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance other product candidates that we may identify and successfully complete any clinical
studies, including the manufacture of any such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to quickly leverage programs within our initial target indications and to progress additional
programs to further develop our pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence of certain disorders we intend to treat and the size of the market opportunity for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of the number of patients with certain disorders we intend to treat and the number of patients that we
will enroll in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of our investigational new drug applications, or INDs, submissions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our strategic plans for our business, platform, and our programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments related to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to leverage the clinical, regulatory, and manufacturing advancements to accelerate our clinical
trials and approval of product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to meet future regulatory standards with respect to our product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our existing license agreements and identify and enter into future license agreements and
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct clinical trials of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties for the manufacture of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments related to our platform; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing, and manufacturing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS
Act or a smaller reporting company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and management personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated cash runway, use of proceeds from this offering, our financial performance, estimates of our
expenses, capital requirements, and needs for additional financing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based these forward-looking statements
largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these
forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in
&#8220;<I>Risk Factors</I>&#8221; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking
statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.
Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information, future events, or otherwise. Our
forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments that we may make or enter into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not
be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the
registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the sale of our common stock in this offering will be approximately $183.5&nbsp;million (or
approximately $211.4&nbsp;million if the underwriters exercise their option to purchase additional shares of our common stock in full) based on an assumed initial public offering price of $17.00 per share, which is the midpoint of the price range
set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. In addition, if we consummate the concurrent private placement, we may receive net
proceeds of up to approximately $18.6&nbsp;million from the sale of shares of our common stock to certain existing stockholders in such concurrent private placement, after deducting placement agent fees and estimated private placement expenses
payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase or decrease in the assumed initial public offering price of $17.00&nbsp;per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the net proceeds to us from this offering by $11.0&nbsp;million, assuming the number of shares offered by us, as set forth on the
cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&nbsp;million shares in the number of
shares of common stock offered by us, as set forth on the cover page of this prospectus, would increase or decrease, as applicable, the net proceeds to us from this offering by $15.8&nbsp;million, assuming the assumed initial public offering price
of $17.00&nbsp;per share remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purposes of this offering are to create a public market for our common stock and thereby facilitate future access to the public
equity markets, increase our visibility in the marketplace, and obtain additional capital to support our operations. We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents, and investments, as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $121.0&nbsp;million to advance development of GlyphAllo<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-300)</FONT> through Phase&nbsp;2b topline data and into Phase&nbsp;3 clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $97.0&nbsp;million to advance development of
GlyphAgo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-320)</FONT> through Phase&nbsp;2a and Phase&nbsp;2b topline data; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder to fund development of Glyph2BLSD<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP><FONT STYLE="white-space:nowrap">(SPT-348),</FONT> as well as research and development activities for additional programs, and working capital and general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may use a portion of the remaining net proceeds and our existing cash, cash equivalents, and investments to
<FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products, or assets. However, we have no current commitments, agreements, understandings, or obligations to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe, based on our current operating plan, that the net proceeds from this offering, together with our existing cash, cash equivalents
and investments, will be sufficient to fund our operations into 2029. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We do not have any
committed external source of funds. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our expected use of proceeds from this offering along with our existing cash, cash equivalents,
and investments described above represents our current intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received
upon the completion of this offering or the actual amounts that we will spend on the uses set forth above. We expect that we will require additional funds in order to fully accomplish the specified uses of the proceeds of this offering. The amounts
and timing of our actual expenditures will depend on numerous factors, including progress of our research and development, the status of and results from preclinical studies and clinical trials that we are conducting or may conduct in the future,
and other factors described in the section titled &#8220;Risk Factors,&#8221; as well as the amount of cash used in our operations and any unforeseen cash needs. Therefore, our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
actual expenditures may differ materially from the estimates described above. Moreover, our estimates of the costs to fund our trials are based on the current designs of the trials. If we were to
modify the design of any of these trials, for instance, to increase the number of patients in the trials, our costs to fund the trials could increase. We may find it necessary or advisable to use the net proceeds for other purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have broad discretion over how to use the net proceeds to us from this offering and investors will be relying on the judgment of our
management regarding the application of the net proceeds. Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation instruments, including short-term and long-term
interest-bearing instruments, investment-grade securities, and direct or guaranteed obligations of the U.S. government. We cannot predict whether the proceeds invested will yield a favorable return. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We do not anticipate declaring or paying, in the foreseeable future, any
cash dividends on our capital stock. We intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business. Any future determination regarding the declaration and payment of dividends, if any,
will be at the discretion of our board of directors, subject to applicable laws, and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects,
and other factors our board of directors may deem relevant. Investors should not purchase our common stock with the expectation of receiving cash dividends. In addition, our ability to pay cash dividends on our capital stock in the future may be
limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our existing cash, cash equivalents, and investments and our capitalization as of December&nbsp;31, 2025: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis, giving effect to (i)&nbsp;the Preferred Stock Conversion and (ii)&nbsp;the filing and
effectiveness of our amended and restated certificate of incorporation, which will occur immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis, giving effect to (i)&nbsp;the pro forma adjustments set forth above and
(ii)&nbsp;the issuance and sale of 11,800,000 shares of common stock in this offering at an assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
pro forma as adjusted information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing.
Cash, cash equivalents, and investments are not components of our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this information together with our
consolidated financial statements and the related notes included elsewhere in this prospectus, and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations<I>.</I>&#8221; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro<BR>Forma<BR>As<BR>Adjusted&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share and per share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">233,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">233,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">417,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock (Series A and B), $0.0001 par value; 113,921,040 shares authorized and
113,921,036 shares issued and outstanding, actual; no shares authorized, issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">325,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#8217; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; no shares authorized, issued, or outstanding, actual;
10,000,000 shares authorized, and no shares issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 159,070,000 shares authorized and 2,595,342 shares issued and
outstanding, actual; 700,000,000 shares authorized, 38,867,817 shares issued and outstanding, pro forma; 700,000,000 shares authorized, 50,667,817 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">530,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">416,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
pro forma as adjusted amount of each of cash, cash equivalents, and investments, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#8217; equity and total
capitalization by $11.0&nbsp;million, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares of common stock offered by us would increase (decrease) the pro forma as adjusted amount of each of cash, cash
equivalents, and investments, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#8217; equity and total capitalization by $15.8&nbsp;million, assuming no change in the assumed initial public offering price per
share, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock that will be outstanding after this offering on a pro forma and pro forma as adjusted basis is based
on 38,867,817 shares of common stock (which includes 154,778&nbsp;shares of unvested restricted common stock) outstanding as of December&nbsp;31, 2025, after giving effect to the Preferred Stock Conversion, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">8,798,389 shares of common stock issuable upon exercise of outstanding stock options as of December&nbsp;31,
2025, which includes 228,770 performance-based awards that have not yet been deemed granted for accounting purposes, under our 2024 Plan, with a weighted-average exercise price of $4.68&nbsp;per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">962,655&nbsp;shares of common stock issuable upon exercise of outstanding stock options granted after
December&nbsp;31, 2025 pursuant to our 2024 Plan, with a weighted-average exercise price of $10.31&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,503,698&nbsp;shares of common stock reserved for future issuance as of December&nbsp;31, 2025 under the 2024
Plan, which will cease to be available for issuance at the time that our 2026 Plan becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,182,978&nbsp;shares of our common stock issuable upon the exercise or grant of the IPO Grants, to maintain an
aggregate of approximately 12.5% of the number of shares of our common stock to be outstanding upon the closing of this offering calculated on a fully diluted basis (after giving effect to the number of shares of our common stock to be sold in this
offering, not including the exercise in full of the underwriters&#8217; option to purchase additional shares, based on an assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page
of this prospectus), to be granted to an executive officer and a director under the 2026 Plan. (See the sections titled &#8220;Executive Compensation&#8212;Narrative Disclosure to the 2025 Summary Compensation Table&#8212;Equity Incentive
Compensation&#8221; and &#8220;Director Compensation&#8221; for more information on such grants, including a description of how the number of shares issuable pursuant to such grants will be determined); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,020,000&nbsp;shares of our common stock that will become available for future issuance under our 2026 Plan,
including shares reserved for the IPO Grants, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of
shares of common stock reserved for future issuance under the 2026 Plan and any shares underlying outstanding stock awards granted under the 2024 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">510,000&nbsp;shares of common stock reserved for future issuance under the ESPP, which will become effective on
the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value (deficit) as of December&nbsp;31, 2025 was $(93.8)&nbsp;million, or $(38.43) per share of our common
stock. Our historical net tangible book value (deficit) represents the amount of our total tangible assets less our total liabilities and the carrying value of our convertible preferred stock, which is not included within stockholders&#8217;
deficit. Historical net tangible book value (deficit) per share represents historical net tangible book value (deficit) divided by 2,440,564 shares of our common stock outstanding (which excludes 154,778&nbsp;shares of unvested restricted common
stock) as of December&nbsp;31, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of December&nbsp;31, 2025 was $231.5&nbsp;million, or
$5.98&nbsp;per share. Pro forma net tangible book value per share represents the amount of our total tangible assets less our total liabilities, divided by the number of shares of our common stock outstanding as of December&nbsp;31, 2025, after
giving effect to (i)&nbsp;the Preferred Stock Conversion and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation, which will occur immediately prior to the completion of this offering. Pro forma net
tangible book value per share represents pro forma net tangible book value divided by 38,713,039, which represents the total number of shares outstanding (which excludes 154,778 shares of unvested restricted common stock) as of December&nbsp;31,
2025, after giving effect to the pro forma adjustments described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving further effect to the issuance and sale of
11,800,000 shares of common stock that we are offering at an assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of December&nbsp;31, 2025 would have been $416.2&nbsp;million, or $8.22 per share. This amount represents an
immediate increase in pro forma net tangible book value of $2.24 per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of $8.78 per share to new investors purchasing shares of common stock in this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value (deficit) per
share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution (without giving effect to any exercise by the underwriters of their option to purchase additional shares
or the concurrent private placement): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38.43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share as of December&nbsp;31, 2025 attributable to the pro forma adjustment described
above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information discussed above is illustrative only and may change based on the actual
initial public offering price and other terms of this offering. Each $1.00 increase or decrease, as applicable, in the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of
this prospectus, would increase or decrease, as applicable, the pro forma as adjusted net </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tangible book value per share after this offering by $0.22, and dilution per share to new investors purchasing common stock in this offering by $0.78, assuming that the number of shares of common
stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease, as
applicable, of 1.0&nbsp;million shares in the number of shares of common stock offered by us would increase or decrease, as applicable, our pro forma as adjusted net tangible book value per share after this offering by $0.15&nbsp;per share, in each
case, and increase or decrease, as applicable, the dilution to investors participating in this offering by $0.15 per share, assuming no change in the assumed initial public offering price, and after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares of our
common stock in full, our pro forma as adjusted net tangible book value after the offering would be $8.47 per share, representing an immediate increase in pro forma as adjusted net tangible book value of $0.25 per share to existing stockholders and
immediate dilution in pro forma as adjusted net tangible book value of $8.53&nbsp;per share to new investors, in each case assuming an initial public offering price of $17.00&nbsp;per share, which is the midpoint of the price range set forth on the
cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we sell to certain of our existing stockholders shares of our common stock in a concurrent private placement, our pro forma as adjusted net
tangible book value after the offering would be $8.39&nbsp;per share, representing an immediate increase in pro forma as adjusted net tangible book value of $0.17&nbsp;per share to existing stockholders and immediate dilution in pro forma as
adjusted net tangible book value of $8.61&nbsp;per share to new investors, in each case assuming an initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus and after
deducting placement agent fees and estimated private placement expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes on the pro forma as
adjusted basis described above, as of December&nbsp;31, 2025, the total number of shares of common stock purchased from us on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, the total consideration paid or to be paid to us, and the
average price per share paid by existing stockholders or to be paid by new investors in this offering, based on an assumed initial public offering price of $17.00&nbsp;per share, which is the midpoint of the price range set forth on the cover page
of this prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. New investors purchasing shares of our common stock in this offering will pay an average price per share
substantially higher than our existing stockholders paid. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:14pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total Consideration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,867,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">326,101,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,667,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">526,701,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br><br>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><br><br>&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom"><br><br>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above assumes no exercise of the underwriters&#8217; option to purchase additional shares
in this offering or a concurrent private placement. If the underwriters exercise their option to purchase additional shares of common stock from us in full, our existing stockholders would own 74.1%, and new investors purchasing shares of our common
stock in this offering would own 25.9%, of the total number of shares of our common stock outstanding immediately after the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we sell to certain of our existing stockholders shares of our common stock in a concurrent private placement, our existing stockholders
would own 77.2%, and new investors purchasing shares of our common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock in this offering would own 22.8%, of the total number of shares of our common stock outstanding immediately after the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock that will be outstanding after this offering is based on 38,867,817&nbsp;shares of common stock
(which includes 154,778 shares of unvested restricted common stock) outstanding as of December&nbsp;31, 2025, after giving effect to the Preferred Stock Conversion, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">8,798,389 shares of common stock issuable upon exercise of outstanding stock options as of December&nbsp;31,
2025, which includes 228,770 performance-based awards that have not yet been deemed granted for accounting purposes, under our 2024 Plan, with a weighted-average exercise price of $4.68 per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">962,655 shares of common stock issuable upon exercise of outstanding stock options granted after
December&nbsp;31, 2025 pursuant to our 2024 Plan, with a weighted-average exercise price of $10.31&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,503,698 shares of common stock reserved for future issuance as of December&nbsp;31, 2025 under the 2024 Plan,
which will cease to be available for issuance at the time that our 2026 Plan becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,182,978 shares of our common stock issuable upon the exercise or grant of the IPO Grants, to maintain an
aggregate of approximately 12.5% of the number of shares of our common stock to be outstanding upon the closing of this offering calculated on a fully diluted basis (after giving effect to the number of shares of our common stock to be sold in this
offering, not including the exercise in full of the underwriters&#8217; option to purchase additional shares, based on an assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page
of this prospectus), to be granted to an executive officer and a director under the 2026 Plan; (See the sections titled &#8220;Executive Compensation&#8212;Narrative Disclosure to the 2025 Summary Compensation Table&#8212;Equity Incentive
Compensation&#8221; and &#8220;Director Compensation&#8221; for more information on such grants, including a description of how the number of shares issuable pursuant to such grants will be determined): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,020,000 shares of our common stock that will become available for future issuance under our 2026 Plan,
including shares reserved for the IPO Grants, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of
shares of common stock reserved for future issuance under the 2026 Plan and any shares underlying outstanding stock awards granted under the 2024 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">510,000&nbsp;shares of common stock reserved for future issuance under our ESPP, which will become effective on
the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent any outstanding options are exercised, new options or other equity awards are issued under our
equity incentive plans, or we issue additional shares of common stock in the future, there will be further dilution to new investors. In addition, we may choose to raise additional capital because of market conditions or strategic considerations,
even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution
to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_10"></A>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results
of operations in conjunction with our audited consolidated financial statements and related notes and other financial information included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain
forward-looking statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, strategies, objectives, expectations, intentions, and beliefs. Financial results
through April&nbsp;8, 2024, which are included in the consolidated financial statements for the year ended December&nbsp;31, 2024, have been prepared on a <FONT STYLE="white-space:nowrap">&#8220;carve-out&#8221;</FONT> basis and our full year
results for the year ended December&nbsp;31, 2024 are not necessarily indicative of results that may be expected in the future, nor are our other historical results necessarily indicative of the results that may be expected for any period in the
future. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this
prospectus. You should carefully read the &#8220;Risk Factors&#8221; section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also
see the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; Unless otherwise indicated, all references in this section to &#8220;Seaport,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221;
&#8220;us,&#8221; or similar terms refer to Seaport Therapeutics, Inc. and its wholly owned subsidiaries, or either or all of them, before the Asset Transfer (as defined below) and after the Asset Transfer, as applicable and as the context may
require. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated
mechanisms with established efficacy and safety profiles which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary Glyph platform to overcome those limitations and invent
innovative oral therapies. Our lead product candidate, GlyphAllo <FONT STYLE="white-space:nowrap">(SPT-300</FONT> or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically
validated in two third-party trials in the United States for the treatment of postpartum depression, or PPD, a form of major depressive disorder, or MDD, as a rapidly acting antidepressant with anxiolytic and sleep-promoting effects. We have
initiated the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in patients with MDD with or without anxious distress and anticipate topline data in the first half of 2027. Our second product candidate, GlyphAgo <FONT
STYLE="white-space:nowrap">(SPT-320</FONT> or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder, or GAD, in
Australia and MDD in Australia and the European Union, or EU. In April 2026, we reported topline data from the single-ascending dose, or SAD, and crossover portions of our Phase 1 proof-of concept clinical trial for GlyphAgo. In the head-to-head
crossover portion of the trial, GlyphAgo demonstrated a 6.8-fold increase in bioavailability of agomelatine compared to unmodified orally administered agomelatine, and showed significantly lower (10- fold) pharmacokinetic variability compared to
unmodified agomelatine. In the SAD portion of the trial, GlyphAgo demonstrated a 9.6 to 14.5-fold increase in dose-normalized exposure compared to agomelatine. GlyphAgo was well-tolerated and no liver-related adverse events were observed. We plan to
initiate a Phase 2a proof-of-pharmacology trial designed to evaluate the potential sleep benefit of GlyphAgo in patients with GAD and sleep disturbance, with topline data expected in early 2028 and, in parallel, a Phase 2b trial designed to evaluate
the efficacy and safety of GlyphAgo in patients with GAD, with topline data expected by the end of 2028. We are also advancing Glyph2BLSD <FONT STYLE="white-space:nowrap">(SPT-348</FONT> or Glyph <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">2-bromo-LSD),</FONT></FONT> a novel, Glyphed oral prodrug of the <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> LSD analog
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> in preclinical studies for depressive disorders, including treatment-resistant depression, or TRD, post-traumatic stress disorder, or PTSD, and headache
disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in April 2024 by PureTech LYT Inc., or PureTech LYT, as our sole stockholder, and upon formation we
entered into an asset transfer agreement, as amended in December 2025, or the Asset Transfer Agreement, with PureTech LYT and PureTech Health LLC, or PureTech Health, pursuant to which PureTech </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Health and PureTech LYT agreed to contribute, convey, assign, transfer, and deliver to us all of its right, title, and interest in, to, and under the assets related to its Glyph technology or
products, including the Monash License Agreement (as defined below), subject to the terms set forth in the Asset Transfer Agreement or the Asset Transfer. See subsection titled &#8220;Asset Transfer Agreement and Financings&#8221; below. Our
historical consolidated financial statements up to April&nbsp;8, 2024, or the Asset Transfer Date, have been prepared on a <FONT STYLE="white-space:nowrap">&#8220;carve-out&#8221;</FONT> basis and are derived from the financial statements of
PureTech Health plc and its consolidated subsidiaries, or PureTech, to represent our financial position and performance as if we had existed on a standalone basis. Prior to the Asset Transfer, our combined financial statements included the assets,
liabilities, and expenses of PureTech that management determined were specifically identifiable to us and our related programs, as well as indirect costs that were not specifically identifiable to us or our related programs but were considered
necessary to operate as a standalone company. Management believes the assumptions underlying our <FONT STYLE="white-space:nowrap">carve-out</FONT> financial statements are reasonable. Nevertheless, the
<FONT STYLE="white-space:nowrap">carve-out</FONT> financial statements may not include all of the actual expenses that would have been incurred, and may not reflect our results of operations, financial position, and cash flows, had we operated as a
standalone company for the period prior to the Asset Transfer. Effective April&nbsp;8, 2024, our financial statements are presented on a consolidated basis, as PureTech Health LLC and PureTech LYT completed the transfer of the Glyph platform
business, or the Seaport Business, on such date. The audited financial statements presented, including our historical results prior to April&nbsp;8, 2024, are referred to as the consolidated financial statements. Our consolidated financial
statements are presented in conformity with accounting principles generally accepted in the U.S., or GAAP. For additional information on the preparation and basis of presentation of the consolidated financial statements, see Note 1&#8212;Nature of
Business and Basis of Presentation, in the notes to the consolidated financial statements appearing elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
devoted substantially all of our efforts to organizing and staffing our company, business planning, research and development activities, building and strengthening our intellectual property portfolio, and providing general and administrative support
for these operations. Subsequent to the Asset Transfer Date and to date, we have funded our operations with proceeds from the issuance and sale of convertible preferred stock, including the $100.1&nbsp;million gross proceeds we received in April
2024 from our Series <FONT STYLE="white-space:nowrap">A-2</FONT> Financing (as defined below) and the $226.0&nbsp;million gross proceeds we received in October 2024 from our Series B Financing (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses since the inception of our business and expect to continue to generate operating losses for the
foreseeable future. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of any product candidates we may develop. During the years ended
December&nbsp;31, 2025 and 2024, we had a net loss of $74.9&nbsp;million and $46.9&nbsp;million, respectively. As of December&nbsp;31, 2025, we had an accumulated deficit of $114.1&nbsp;million. We expect our expenses and operating losses will
increase substantially as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance our product candidates through preclinical and clinical development, including advancing GlyphAllo and
GlyphAgo through later-stage clinical trials, and other candidates through discovery and clinical and preclinical stages; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for our product candidates that successfully complete clinical trials from the U.S.
Food and Drug Administration, or the FDA, and/or other foreign comparable regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical, quality control, medical, scientific, and other technical personnel to support the
clinical development of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our internal capabilities to support clinical-stage development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increase our headcount as we expand our research and development organization, and
<FONT STYLE="white-space:nowrap">pre-commercial</FONT> planning activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">undertake any activities to establish sales, marketing, and distribution capabilities in preparation for
commercialization, as applicable, including hiring additional personnel to support such operations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify, acquire, and develop additional product candidates where we can leverage our Glyph platform,
including through business development efforts to invest in or <FONT STYLE="white-space:nowrap">in-license</FONT> other technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience heightened regulatory scrutiny; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty, or other payments due under the Asset Transfer Agreement and/or the Monash License
Agreement (as defined below), and any future <FONT STYLE="white-space:nowrap">in-license</FONT> or collaboration agreements with third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional legal, accounting, and other expenses associated with operating as a public company.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net losses may fluctuate significantly from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our preclinical studies
and planned clinical trials and our expenditures on other research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to generate any revenue
from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our potential future product candidates, which may not be for at least the next several years, if ever. If we obtain
regulatory approval for any of our existing or future product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. Accordingly, until such time as we can generate
significant revenue from our existing or future product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses, and other similar
arrangements. See the section titled &#8220;Liquidity and Capital Resources.&#8221; However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our inability to raise capital or
enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop
and market potential future product candidates that we would otherwise prefer to develop and market ourselves. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe, based on
our current operating plan, that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements into 2029. See sections titled &#8220;Use
of Proceeds&#8221;, &#8220;Liquidity and Capital Resources&#8221;, and &#8220;Risk Factors&#8212;Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Asset Transfer Agreement and Financings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in April 2024 by PureTech LYT, as our sole stockholder, and upon formation issued 318 shares of our common stock to
PureTech LYT. In April 2024, we entered into an Asset Transfer Agreement, or the Asset Transfer Agreement, with PureTech Health LLC, or PureTech Health and PureTech LYT Inc., or PureTech LYT, pursuant to which PureTech Health and PureTech LYT agreed
to contribute, convey, assign, transfer, and deliver to us all of PureTech Health&#8217;s and PureTech LYT&#8217;s right, title, and interest in, to, and under the assets related to its Glyph technology or products, including the Monash License
Agreement, subject to the terms set forth in the Asset Transfer Agreement. In exchange, we issued 40,000,000 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 302,161 shares of our common stock to
PureTech LYT. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Transfer Agreement, we have agreed to make milestone payments of up to an aggregate of
$10.0&nbsp;million for the first product covered by assets transferred through the Asset Transfer Agreement, or the Seaport Glyph Product, of $2.0&nbsp;million for the first patient dosed in the first phase 3 clinical trial, $4.0&nbsp;million for
the first commercial sale in the United States, $2.0&nbsp;million for the first commercial sale in a major European market, and $2.0&nbsp;million for the first commercial sale in Japan, and for each subsequent Seaport
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Glyph Product, we have agreed to make milestone payments of $1.0&nbsp;million for the first patient dosed in the first phase 3 clinical trial, $2.0&nbsp;million for the first commercial sale in
the United States, $1.0&nbsp;million for the first commercial sale in a major European market, and $1.0&nbsp;million for the first commercial sale in Japan. In addition, we are obligated to pay royalties between 3% and 5% on the annual net sales of
each Seaport Glyph Product and a percentage of net income generated by us from third parties on any products licensed under the Glyph intellectual property which was transferred to us as part of the Asset Transfer Agreement. The royalty term will
expire on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis as to each Seaport Glyph Product on the later of the ten year anniversary of the first commercial sale of such Seaport Glyph Product
in such country or the date on which the last valid claim of patent rights of such Seaport Glyph Product expires in such country. For additional information, see &#8220;Business&#8212;Agreements&#8212;Asset Transfer Agreement with PureTech.&#8221;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently, upon entry into the Asset Transfer Agreement, we entered into a stock purchase agreement with PureTech LYT and other
third-party investors, pursuant to which we issued 26,342,102 shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> convertible preferred stock, or the Series A Financing, of which 8,421,052 shares were issued and sold to PureTech
LYT, at a purchase price of $3.80 per share for gross aggregate proceeds of $100.1&nbsp;million. PureTech LYT remained a majority investor of Seaport, until the completion of our Series B convertible preferred stock financing, or the Series B
Financing, in October 2024, upon which we issued and sold an aggregate amount of 47,578,934 shares of its Series B convertible preferred stock, of which 3,031,578 shares were issued to PureTech LYT, and an aggregate of 494,734 shares issued to
certain of our management and Board of Directors, or the Board, at a purchase price of $4.75 per share, for gross aggregate proceeds of $226.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License and Collaboration Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Monash License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, PureTech Health exclusively assigned to us, and we assumed, all rights and obligations under a license agreement entered into in
August 2017 between PureTech Health and Monash University, or the Original License Agreement. In March 2025, we entered into the Monash License Agreement and amended and restated license agreement with Monash University, which amended and restated
the Original License Agreement, or the Monash License Agreement. Pursuant to the Monash License Agreement, Monash University has granted us (i)&nbsp;a worldwide, exclusive, sublicensable license under certain Monash University intellectual property
rights, including patent rights related to the Glyph platform, or the Licensed Patents, <FONT STYLE="white-space:nowrap">know-how,</FONT> and intellectual property stemming from joint research and development activities, for the purpose of
developing and commercializing products in all fields with one exception, (ii)&nbsp;a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable license under certain background technology and certain other intellectual property
strictly to the extent necessary to exercise the license described in subclause (i)&nbsp;above, and (iii)&nbsp;a first right and an exclusive option to obtain an exclusive license to any invention generated by Monash University outside of the
Licensed Patents and pertaining to certain prodrug technology. Additionally, we and Monash University agreed to collaborate in conducting research and development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Monash License Agreement, we have agreed to use reasonable commercial endeavors to (i)&nbsp;develop at least one Licensed Product
(as defined therein), (ii) seek regulatory approval for at least one Licensed Product, and (iii)&nbsp;after receipt of such regulatory approval in the United States or Europe, promote and develop the sale of at least one Licensed Product in such
territory. Monash University has agreed to provide reasonable technical assistance and advice based on Monash University&#8217;s <FONT STYLE="white-space:nowrap">know-how</FONT> relating to the technology licensed under the Monash License Agreement.
We have granted Monash University a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, royalty-free license under the Licensed Patents, related <FONT STYLE="white-space:nowrap">know-how,</FONT> and intellectual property stemming from
joint research and development activities solely for academic, teaching, and <FONT STYLE="white-space:nowrap">non-commercial</FONT> collaborative research uses, which includes the right to sublicense for
<FONT STYLE="white-space:nowrap">non-commercial</FONT> collaborative research to other academic institutions or <FONT STYLE="white-space:nowrap">non-commercial</FONT> research entities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional discussion around the obligations under the Monash License Agreement, see the
subsection titled &#8220;&#8212;Contractual Obligations and Commitments&#8221; and &#8220;Business&#8212;Agreements&#8212;Monash University Exclusive License Agreement&#8221; included elsewhere in this prospectus </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, our operations were managed as part of PureTech prior to the Asset Transfer Date. Accordingly, certain shared costs have been
allocated to us and reflected as expenses in our standalone consolidated financial statements, as described in greater detail in the notes to our consolidated financial statements appearing elsewhere in this prospectus. We considered the allocation
methodologies used to be a reasonable and appropriate reflection of the historical PureTech expenses attributable to us for purposes of our standalone consolidated financial statements. The expenses reflected in our consolidated financial statements
may not be indicative of expenses that will be incurred by us in the future. The following discussion summarizes the key factors we believe are necessary for an understanding of our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not
recognized any revenue and do not expect to generate any revenue from the sale of products in the near term, if at all. If our development efforts for our current or potential future product candidates are successful and result in regulatory
approval or if we enter into additional license or collaboration agreements with third parties, we may generate revenue in the future from product sales, payments from such license or collaboration agreements, or any combination thereof. However,
there can be no assurance as to when we will generate such revenue, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development, or R&amp;D, expenses consist primarily of costs incurred in connection with the discovery, <FONT
STYLE="white-space:nowrap">non-clinical</FONT> development, and clinical development of our lead product candidates and potential future product candidates. R&amp;D expenses include direct costs specifically attributable to our programs including
external fees to conduct certain clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> research and development activities, preclinical and early discovery assets, such as costs paid to contract research and manufacturing organizations,
consulting fees, laboratory services and supplies, and costs incurred in connection with the Monash License Agreement, as well as indirect costs that are not directly attributable to a specific program such as personnel related expenses, including
stock-based compensation, facility expenses, depreciation, and information technology costs. Prior to the Asset Transfer Date, R&amp;D expenses also included allocated indirect R&amp;D costs from PureTech, including personnel related expenses,
stock-based compensation, facility expenses, depreciation, and information technology costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development costs as
incurred. We recognize direct development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors or our estimate of the level of service that has been performed at each reporting
date. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as prepaid or accrued research and development
expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the inherently unpredictable nature of preclinical and clinical development, we do not allocate all of our internal
research and development expenses on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis as these expenses primarily relate to personnel and other overhead costs that are deployed across
multiple programs under development. Our research and development expenses also include external costs, which we do track on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis following the
program&#8217;s nomination as a product candidate. We began tracking such external costs upon the nomination for GlyphAllo in 2020, GlyphAgo at the end of our fiscal year ended December&nbsp;31, 2023 and Glyph2BLSD at the end of our fiscal year
ended December&nbsp;31, 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. We expect that our
research and development expenses will continue to increase for the foreseeable future as we advance our current and any future product candidates into and through clinical development and as we continue to develop additional product candidates.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist of salaries and personnel-related costs, including stock-based compensation expense, for our
personnel in executive, business development, legal, finance and accounting, human resources and other administrative functions, consulting fees, facility costs not otherwise included in R&amp;D expenses, fees paid for accounting and tax services,
insurance expenses, legal costs consisting of general corporate legal fees and patent legal fees, and allocated expenses from PureTech prior to our formation in April 2024. Allocated PureTech expenses included employee-related costs, including
salaries, bonuses, benefits, and stock-based compensation expenses for PureTech personnel and our personnel in executive, finance, accounting, human resources, and other administrative functions. Allocated expenses from PureTech also included
corporate overhead expenses and shared costs, such as general management and executive oversight, facilities, compliance, human resources, legal, including intellectual property costs, finance, risk management, and information technology all of
which supported the operations of PureTech as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will increase in the
future as we increase our headcount to support the expansion of our business, particularly in support of development of product candidates and our continued research and clinical development activities. We will also incur significant costs
associated with being a public company, including increased accounting, audit, legal, regulatory, compliance, and director and officer insurance costs, as well as expenses related to services associated with maintaining compliance with the
requirements of the Nasdaq Stock Market, the Securities and Exchange Commission, and investor relations costs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through the completion
of this offering, we continued to grant additional equity awards to certain individuals to maintain in total an aggregate of 12.5% ownership on a fully diluted basis as specified by underlying agreements. Assuming the issuance of 11,800,000 shares
of our common stock upon the completion of the offering, we will grant 2,182,978 equity awards to certain individuals to maintain an aggregate of 12.5% ownership, based on an assumed initial public offering of $17.00 per share and we will
immediately recognize total stock-based compensation expense of approximately $26.6&nbsp;million. In addition, certain individuals have accelerated vesting associated with the completion of an IPO which will result in 687,816 equity awards vesting
and recognition of stock-based compensation expense of $2.1&nbsp;million. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Income (expense), Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income (expense), net consists primarily of interest income earned on our investments and cash and cash equivalents, research and
development tax credits from the Australian government&#8217;s tax incentive program, and realized and unrealized foreign currency gains and losses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Provision for Income Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provision for income taxes consists of United States federal and state income taxes in jurisdictions in which we conduct business and foreign
income taxes related to our Australian subsidiary. The provision for income taxes is based on our taxable income. Our loss before income taxes is adjusted for permanent and temporary tax differences, primarily related to capitalized <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> research and development expenses, resulting in taxable income or loss. We recorded a full valuation allowance of our U.S. deferred tax asset position as of December&nbsp;31, 2025 and 2024 as we believe it
was more likely than not that we would not be able to utilize our deferred tax assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the years ended December&nbsp;31, 2025 and 2024 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development (including stock-based compensation expense of $2.3&nbsp;million and
$0.7&nbsp;million for 2025 and 2024, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative (including stock-based compensation expense of $4.6&nbsp;million and
$15.2&nbsp;million for 2025 and 2024, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,878</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Direct costs:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GlyphAllo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GlyphAgo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Glyph2BLSD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical and early discovery assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Indirect costs:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee compensation (excluding stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased by $41.2&nbsp;million from $25.1&nbsp;million for the year ended
December&nbsp;31, 2024 to $66.3&nbsp;million for the year ended December&nbsp;31, 2025. The increase in research and development expenses was primarily attributable to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$18.5&nbsp;million of increased costs associated with our lead program GlyphAllo, which was primarily due to
commencing our Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in July 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$8.3&nbsp;million of increased costs associated with our GlyphAgo program, which was primarily due to commencing
our Phase 1 trial in July 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$6.4&nbsp;million of increased costs associated with our Glyph2BLSD program, which was nominated as a development
candidate in late 2024; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$7.5&nbsp;million of increased costs associated with employee compensation primarily due to increased headcount
to support our operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$1.6&nbsp;million of increased costs associated with stock-based compensation costs primarily due to additional
equity grants under our Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.9&nbsp;million of increased costs associated with other research and development expenses primarily due to
increased facility costs associated with our lab space lease, which commenced in January 2025; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These increases were
partially offset by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$2.0&nbsp;million of decreased costs associated with preclinical and other early discovery assets as Glyph2BLSD
was nominated as a development candidate in late 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our general and administrative expenses (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee compensation (excluding stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities, depreciation, IT, and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses decreased by $6.4&nbsp;million from $27.3&nbsp;million for the year ended
December&nbsp;31, 2024 to $21.0&nbsp;million for the year ended December&nbsp;31, 2025. The decrease in general and administrative expenses was primarily attributable to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$10.6&nbsp;million of decreased stock-based compensation expense primarily due to a <FONT
STYLE="white-space:nowrap">one-time</FONT> charge recorded during the year ended December&nbsp;31, 2024 due to accelerated vesting of equity awards related to the closing of our Series B Financing; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These decreases were partially offset by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$2.7&nbsp;million of increased employee compensation, excluding stock-based compensation due to increased
headcount to support our operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$1.6&nbsp;million of increased facilities, depreciation, IT, and other costs primarily due to increased facility
costs associated with our corporate office lease which commenced in December 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Income, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income, net increased by $7.6&nbsp;million from $5.5&nbsp;million for the year ended December&nbsp;31, 2024 to $13.2&nbsp;million for the
year ended December&nbsp;31, 2025. The increase in other income, net was primarily attributed to a $5.8&nbsp;million increase in interest income on our investments and cash equivalents due to the amount of funds invested in interest bearing accounts
and a $1.9&nbsp;million increase in our research and development tax credit as a result of qualifying research and development spend in Australia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of
Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary source of liquidity for our business prior to our formation was funding by PureTech of the expenses
allocated to the Seaport Business. Prior to the Asset Transfer Date, transfers of cash to and from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PureTech have been reflected in net transfers from PureTech in the statement of cash flows and net parent investment in the statement of convertible preferred stock and stockholders&#8217;
deficit. Since the Asset Transfer Date, we have funded our operations with the aggregate gross proceeds of $326.1&nbsp;million from the Series A and Series B Financings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table
provides information regarding our cash flows for the period presented (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(77,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(184,245</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(263,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The balance sheet is affected by spot exchange rates used to translate local currency amounts into
U.S.&nbsp;dollars. In accordance with U.S. GAAP, we have eliminated the effect of foreign currency throughout our cash flow statement, except for its effect on our cash and cash equivalents. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2025 net cash used in operating activities was $77.9&nbsp;million, compared to $29.6&nbsp;million for
the year ended December&nbsp;31, 2024. Cash used in operating activities increased by $48.3&nbsp;million primarily due to increased operating expenses as we continue to advance our product candidates through preclinical and clinical developments.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the year ended December&nbsp;31, 2025 was $184.2 million, compared to net cash used in investing
activities of $0.1&nbsp;million for the year ended December&nbsp;31, 2024. Cash used in investing activities increased by $184.1&nbsp;million due to the purchases and maturities of U.S. treasuries during fiscal year 2025. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash (Used In) Provided by Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in financing activities for the year ended December&nbsp;31, 2025 was $0.9&nbsp;million, primarily due to payment of deferred
offering costs, as compared to cash provided of $339.3&nbsp;million for the year ended December&nbsp;31, 2024. Cash provided by financing activities decreased by $340.2 million&nbsp;due to the absence of financing transactions in fiscal year 2025.
Financing activities during the year ended December&nbsp;31, 2024 included $100.1&nbsp;million of gross proceeds received in April 2024 from our Series A financing and $226.0&nbsp;million of gross proceeds received in October 2024 from our Series B
financing, partially offset by $0.8&nbsp;million of issuance cost payments. In addition, PureTech managed our cash and financing arrangements through April&nbsp;8, 2024, and financing activities for the year ended December&nbsp;31, 2024 included
$14.0&nbsp;million of net transfers from PureTech. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, we had cash and cash equivalents, and investments of $233.7&nbsp;million. We expect that our cash and cash
equivalents as of December&nbsp;31, 2025, will be sufficient to fund our operating expenses and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital expenditure requirements through at least 12 months from the date our consolidated financial statements were available to be issued. We believe, based on our current operating plan, that
the net proceeds from this offering, together with our existing cash, cash equivalents, and investments will enable us to fund our operations and capital expenditure requirements into 2029. We have based this estimate on assumptions that may prove
to be wrong, and we could exhaust our available capital resources sooner than we expect. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the inherently unpredictable nature
of preclinical and clinical development and given the early stage of our programs and product candidates, we cannot reasonably estimate the costs we will incur and the timelines that will be required to complete development, obtain any marketing
approval, and commercialize our products, if and when approved. For the same reasons, we are also unable to predict when, if ever, we will generate revenue from product sales or whether, or when, if ever, we may achieve profitability. Clinical and
preclinical development timelines, the probability of success, and development costs can differ materially from expectations. In addition, we cannot forecast which products, if approved, may be subject to future collaborations, when such
arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We will need to raise substantial additional capital in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of capital are to fund research and development activities, compensation and related expenses, and general overhead costs. We
expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance our current and future product candidates through discovery, preclinical studies, and clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our funding requirements and timing and amount of our operating expenditures will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, timing, progress, costs, and results of discovery, preclinical development and clinical trials for our
current or future product candidates and effectiveness of our Glyph platform; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of clinical trials required for regulatory approval of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with acquiring or licensing additional product candidates, technologies or assets, including
the timing and amount of any milestones, royalties, or other payments due in connection with our acquisitions and licenses, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing clinical and commercial supplies of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and
distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses to attract, hire, and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of macroeconomic trends including inflation, tariffs, and fluctuating interest rates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any potential supply chain interruptions or delays; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, that we can generate substantial product revenue, we expect to finance our operations through a combination of
public and private equity offerings, debt and royalty financings, or other sources of capital, which may include additional collaborations with other companies, or licensing arrangements with third parties, or other similar arrangements. However, we
may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest
of our stockholders will or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt or royalty financing and preferred equity financing, if
available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures, or declaring dividends. If we raise additional
funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, product candidates, or grant
licenses on terms that may not be favorable to us. If we are unable to raise additional capital or obtain adequate funding when needed or on acceptable terms, we may be required to delay, scale back, or discontinue our research, product development,
or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations and Commitments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Asset Transfer Agreement with PureTech </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Asset Transfer Agreement, we have agreed to contingent payments to PureTech Health upon successful development and
commercialization of products developed using the Glyph platform. For more information, refer to the subsection titled &#8220;Asset Transfer Agreement and Financings&#8221; above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Monash License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Monash License Agreement, we have agreed to use reasonable commercial endeavors to (i)&nbsp;develop at least one Licensed Product,
(ii)&nbsp;seek regulatory approval for at least one Licensed Product, and (iii)&nbsp;after receipt of such regulatory approval in the United States or Europe, promote and develop the sale of at least one Licensed Product in such territory. Monash
University agrees to provide reasonable technical assistance and advice based on Monash University&#8217;s <FONT STYLE="white-space:nowrap">know-how</FONT> relating to the technology licensed under the Monash License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the licenses granted by Monash University, we are required to pay Monash University:
<FONT STYLE="white-space:nowrap">(i)&nbsp;low-single</FONT> digit royalties with a rate based on net sales per calendar year (subject to certain reductions); (ii) a <FONT STYLE="white-space:nowrap">low-double</FONT> digit percentage (within the
range of <FONT STYLE="white-space:nowrap">5-15%)</FONT> of any net income received under a sublicense (subject to a license payment stacking reduction) with the percentage varying based on the development stage of the licensed products at the time
the sublicense is granted during the term of the Monash License Agreement; (iii)&nbsp;an agreed upon research funding amount to progress mutually agreed research and development or commercialization activities; (iv)&nbsp;a <FONT
STYLE="white-space:nowrap">mid-five-figure</FONT> annual maintenance fee during the term of the agreement commencing on the third anniversary of the execution date of the Original License Agreement until the first commercial sale of a Licensed
Product creditable against net income sharing, royalties, and milestone payments; (v)&nbsp;milestone payments in the event of successful development milestones of up to $1.075&nbsp;million per Licensed Product for the first three Licensed Products;
and (vi)&nbsp;milestone payments in the event of successful commercial milestones of up to $7.25&nbsp;million per Licensed Product for the first three Licensed Products. We are also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligated to (a)&nbsp;pay all costs incurred for the prosecution and maintenance of the Licensed Patents and patent filings stemming from collaboration activities and (b)&nbsp;reimburse Monash
University for all patent prosecution costs of the Licensed Patents prior to the execution date of the Original License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Monash License Agreement commenced on the execution date of the Original License Agreement and will expire seven years after the last of the Licensed Patents expires, unless terminated earlier. Either party may terminate for due cause, including for
material breach and bankruptcy. Monash University may terminate if we fail to meet our diligence requirements. Either party may terminate the Monash License Agreement if we determine that the activities are no longer commercially viable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, the first two development milestones for a total of $0.2&nbsp;million were achieved and paid by PureTech as they
occurred prior to our formation, and we have paid the third development milestone of $0.1&nbsp;million as well as annual maintenance fees. No other milestones have occurred or have been paid under the Monash License Agreement as of December&nbsp;31,
2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information see the section titled &#8220;Business&#8212;Agreements&#8212;Monash License Agreement&#8221;, included
elsewhere in this prospectus.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Purchase and Other Obligations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with contract research organizations, or CROs, and other third-party vendors for
preclinical and commercial supply manufacturing, support for <FONT STYLE="white-space:nowrap">pre-commercial</FONT> activities, research, and development activities, and other services and products for our operations. These contracts are generally
cancelable upon written notice. Payments due upon cancellation consist generally of payments for services provided and expenses incurred up to the date of cancellation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Lease Obligations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
November 2024, we entered into a lease agreement with a third party for our corporate office space located in Boston, Massachusetts. The lease commenced in December 2024 and has an initial term of approximately six years, expiring in October 2030.
The aggregate payments under the full lease total approximately $6.1&nbsp;million, which will be recognized over the term of the lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2024, we entered into a laboratory license with a third party for lab space located in Boston, Massachusetts. The license
commenced in January 2025 and is for an initial term of 24 months from the commencement date. The aggregate payments under the full license total approximately $1.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information on our contractual obligation and commitments please see Note 8&#8212;Monash License Agreement and Note
14&#8212;Commitments and Contingencies, to our consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Estimates
and Significant Judgments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based
on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and
expenses and the related disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and judgments on an ongoing basis. Our actual
results may differ from these estimates under different assumptions or conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in Note 2 to our
consolidated financial statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses as of each balance sheet date. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. This process involves reviewing open contracts and purchase
orders, communicating with internal personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise
notified of the actual cost. We periodically confirm the accuracy of our estimates with our service providers and make adjustments if necessary. The majority of our service providers invoice us monthly in arrears for services performed or when
contractual milestones are met. The financial terms of agreements with these service providers are subject to negotiation, vary from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">contract-to-contract</FONT></FONT> and may result
in uneven payment flows. In circumstances where amounts have been paid in excess of costs incurred, we record a prepaid expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although
we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting
amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized that are expected to vest over
the requisite service period of the awards, which is usually the vesting period of the respective award. For stock-based awards with service-based vesting conditions, we recognize compensation expense on a straight-line basis. For stock-based awards
with performance-based vesting conditions, we recognize compensation expense over the requisite service period using the accelerated attribution method, commencing when achievement of the performance condition becomes probable. Subsequent to our
formation and the Asset Transfer, we estimated the fair value of stock option awards using the Black-Scholes option pricing model. Estimating the fair value of equity awards as of the grant date using valuation models, such as the Black-Scholes
option pricing model, is affected by assumptions regarding a number of variables, including the risk-free interest rate, the expected stock price volatility, the expected term of stock options, the expected dividend yield and the fair value of the
underlying common stock on the date of grant. These inputs are subjective and generally require significant analysis and judgment to develop. Forfeitures are accounted for as they occur. Changes in the assumptions can materially affect the fair
value and ultimately how much stock-based compensation expense is recognized. The fair value of time-vesting restricted stock unit awards is equal to the common stock price on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stock-based compensation expense we recognized in our financial statements prior to our formation and the Asset Transfer Date, and
separate from our 2024 Plan, has been determined based on the fair value of the underlying award as determined by PureTech, the total expense calculated for the period under GAAP, and the relative amount allocated to Seaport associated with each
employee. The assumptions used in the Black-Scholes option pricing model for these awards were those of PureTech, including the fair value of PureTech&#8217;s common stock, expected volatility, expected term, expected dividend yield, and risk-free
interest rates as of the grant date. Seaport employees continued to vest in their PureTech equity awards up until the completion of our Series B Financing in October 2024 at which time PureTech no longer maintained a controlling interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Determination of the Fair Value of Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As there has been no public market for our common stock subsequent to the Asset Transfer and to date, the estimated fair value of our common
stock has been determined by our Board , as of the date of each option grant with input from management, considering our most recently available third-party valuations of common stock, and our Boards&#8217; assessment of additional objective and
subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the
American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,<I> Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. Our common stock valuation was prepared using a market approach to
estimate our enterprise value and either an option pricing method, OPM, or a hybrid method to allocate value to the common stock. The OPM treats common stock and convertible preferred stock as call options on the total equity value of a company,
with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders
exceeded the value of the convertible preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighed expected return method, or PWERM, where the equity
value in one or more of the scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of the future value of our common stock, assuming various outcomes. The
value of a share of common stock is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the
common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. In each case, a discount for lack of
marketability of the common stock is then applied to arrive at an indication of value for the common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These third-party
valuations were performed at various dates, which resulted in valuations of our common stock of $7.39 per share as of October&nbsp;18, 2024, $7.95 per share as of July&nbsp;16, 2025 and $10.31 per share as of January&nbsp;14, 2026. Given the absence
of a public trading market, our Board, with input from management, considered the results of these third-party valuations in addition to numerous objective and subjective factors to determine the fair value of common stock. The factors included, but
were not limited to: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which we sold convertible preferred stock to new and existing investors and the rights and
preferences of the convertible preferred stock relative to our common stock at the time of each grant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise future financings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development efforts, including the status of clinical development for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of liquidity of our equity as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of enterprise milestones, including entering into license agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently
completed mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any external market conditions affecting the biotechnology industry and trends within the biotechnology industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our convertible preferred stock and holders of
our common stock, such as an initial public offering, or a sale of our company, given prevailing market conditions; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the analysis of initial public offerings and the market performance of similar companies in the biopharmaceutical
industry. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations were highly complex and subjective and represented
management&#8217;s best estimates, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our
stock-based compensation expense could have been materially different. Once a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary for our Board to
estimate the fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our common stock will be determined based on the quoted market price of our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes by grant date the number of shares subject to awards granted under our equity incentive plan from
January&nbsp;1, 2025 through the date of this prospectus, the per share exercise price of the awards and weighted average grant date fair value on each grant date: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Type of Award</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Subject to<BR>Award</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share<BR>Exercise<BR>Price of<BR>Award </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average&nbsp;Grant<BR>Date&nbsp;Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January 26, 2025 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock&nbsp;Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 25, 2025 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 3, 2025 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 25, 2025 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May 15, 2025 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 11, 2025 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 7, 2025 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January 27, 2026 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 24, 2026 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Stock Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">673,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we plan to grant equity awards to executive officers and
directors. For additional information, see the section titled &#8220;Executive Compensation&#8212;Narrative Disclosure to the 2025 Summary Compensation Table&#8212;Equity Incentive Compensation&#8221;, &#8220;Executive Compensation&#8212;Employee
Benefit and Equity Compensation Plans&#8221; and &#8220;Director Compensation&#8221;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transition From PureTech and Costs to Operate as an Independent
Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to our formation and the Asset Transfer, the financial statements reflect our operating results and financial position
as our business was operated by PureTech, rather than as an independent company. We may incur additional ongoing operating expenses to operate as an independent company. These costs will include the cost of various corporate functions, incremental
information technology-related costs and incremental costs to operate standalone accounting, legal and other administrative functions. We may also incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> expenses and <FONT
STYLE="white-space:nowrap">non-recurring</FONT> capital expenditures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transactions with Related Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Asset Transfer Date, we began incurring additional operating expenses necessary to operate as an independent company, including
various corporate functions and incremental costs to operate standalone accounting, legal, and other administrative functions. These functions were provided to us from PureTech prior to the Asset Transfer Date and continued under the Transition
Services Agreement, or the TSA, that we entered into with PureTech. Substantially all of these activities will be performed using our own resources at this time. The terms of the TSA are discussed in the section captioned &#8220;Certain
Relationships and Related Person Transactions.&#8221; On April 2, 2026, we and PureTech mutually agreed to terminate the TSA in accordance with its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company and Smaller Reporting Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company,&#8221; as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended, or the Securities
Act, as modified by the Jumpstart Our Business Startups Act, or the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging
growth companies including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements in addition to any required unaudited
interim financial statements and a correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#8217;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further,
Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration
statement declared effective or do not have a class of securities registered under the Exchange Act of 1934, as amended, or the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that
an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such election to opt out is irrevocable.
We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, will adopt the new or
revised standard whenever such adoption is required for private companies. We may also choose to early adopt any new or revised accounting standards whenever such early adoption is permitted. This may make comparison of our financial statements with
another public company, which is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest of (i)&nbsp;the last day of the fiscal year following the fifth anniversary
of the completion of this initial public offering, (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.235&nbsp;billion, (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a
&#8220;large accelerated filer&#8221; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, which would occur if the market value of the common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such year, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities
during the prior three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue
to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled
disclosures for so long as (i)&nbsp;the market value of our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the
last business day of our second fiscal quarter, or (ii)(a) our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year, and (b)&nbsp;the market value of our voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated mechanisms with
established efficacy and safety profiles which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary Glyph<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> platform to
overcome those limitations and invent innovative oral therapies. Glyph is a lymphatic-targeting prodrug technology which is designed to bypass first-pass metabolism and thereby enhance a drug&#8217;s oral bioavailability and reduce side effects.
This process, which we call &#8220;Glyphing,&#8221; also creates new composition of matter intellectual property. Our experienced team of industry leaders has a proven track record in neuropsychiatry drug discovery and development and delivering
successful business outcomes. We aim to develop novel, leading treatment options that will make a significant impact for patients and their families. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are leveraging our proprietary Glyph platform to advance a pipeline of novel therapies to address the significant unmet needs in depression
and anxiety. Our lead product candidate, GlyphAllo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-300</FONT> or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an
endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression, or PPD, a form of major depressive disorder, or MDD, that shares symptomatology with MDD, as a rapidly acting antidepressant
with anxiolytic and sleep-promoting effects. Additionally, an oral synthetic analog of allopregnanolone, zuranolone, demonstrated a rapid antidepressant effect that deepened while patients were on drug and met the primary endpoint in five of the six
trials in MDD. GlyphAllo is designed to overcome bioavailability limitations of allopregnanolone and deliver rapid and durable efficacy in MDD. We have demonstrated in a Phase 1 clinical trial that GlyphAllo reaches therapeutically relevant
exposures with oral dosing, and in a Phase 2a clinical trial, GlyphAllo demonstrated initial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> with an objective biomarker of stress in healthy volunteers
and a favorable tolerability profile. We have initiated the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in patients with MDD with or without anxious distress and anticipate topline data in the first half of 2027. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second product candidate, GlyphAgo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-320</FONT>
or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder, or GAD, in Australia and MDD in Australia and the
European Union, or EU. Due to extensive liver first-pass metabolism, agomelatine can cause dose-dependent liver enzyme elevations, and its use has been limited by the need for frequent liver function testing. GlyphAgo is designed to overcome this
limitation by avoiding first-pass metabolism and achieving therapeutic exposures of agomelatine while reducing or eliminating the need for liver monitoring. In April 2026, we reported topline data from the single-ascending dose, or SAD, and
crossover portions of our Phase 1 proof-of-concept clinical trial for GlyphAgo. In the head-to-head crossover portion of the trial, GlyphAgo demonstrated a 6.8-fold increase in bioavailability of agomelatine compared to unmodified orally
administered agomelatine, and showed significantly lower (10-fold) pharmacokinetic variability compared to unmodified agomelatine. In the SAD portion of the trial, GlyphAgo demonstrated a 9.6 to 14.5-fold increase in dose-normalized exposure
compared to agomelatine. GlyphAgo was well-tolerated and no liver-related adverse events, or AEs, were observed. We plan to initiate a Phase 2a proof-of-pharmacology trial designed to evaluate the potential sleep benefit of GlyphAgo in patients with
GAD and sleep disturbance, with topline data expected in early 2028 and, in parallel, a Phase 2b trial designed to evaluate the efficacy and safety of GlyphAgo in patients with GAD, with topline data expected by the end of 2028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also advancing Glyph2BLSD<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> <FONT STYLE="white-space:nowrap">(SPT-348</FONT> or
Glyph <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD),</FONT></FONT> a novel, Glyphed oral prodrug of the <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> LSD analog <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> in preclinical studies for depressive disorders, including treatment-resistant depression, or TRD, post-traumatic stress disorder, or PTSD, and headache disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Globally, over one billion people are living with mental illness as of 2021, comparable in prevalence to obesity or hypertension. According to
the World Health Organization, as of 2021, depression affects approximately </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
332&nbsp;million people worldwide and anxiety affects approximately 359 million people worldwide, and there is a significant need for novel treatment options. Currently approved drugs for MDD and
GAD have significant limitations, including modest efficacy, slow onset of action, and unfavorable side effects. Advancement of novel therapies has been limited by a lack of understanding of disease pathophysiology, poor drug-like properties, and
challenges in clinical trial design and execution leading to high clinical development failure rates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Differentiated Approach </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are uniquely positioned to overcome the challenges of developing medicines for depression, anxiety, and other neuropsychiatric disorders by
leveraging our differentiated, three-pillar approach: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Identify clinically validated mechanisms held back by issues that can be
addressed by our proprietary </I></B><B><I>Glyph</I></B><B><I> platform. </I></B>We select our product candidates based on well-established clinical data, defined as demonstrated meaningful benefits compared to placebo in multiple randomized,
placebo-controlled clinical trials in a large number of patients. We identify drugs matching this profile where clinical and commercial potential have been limited by high first-pass metabolism, low bioavailability, and/or side effects. We advance
candidates that have the potential to be novel medicines and to impact<I> </I>a large number of patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Create novel medicines
with strong intellectual property using </I></B><B><I>Glyph</I></B><B>.</B> Glyph is our proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. Typically, <FONT
STYLE="white-space:nowrap">non-Glyphed</FONT> oral small molecules undergo first-pass metabolism, where the concentration of drug is significantly reduced by metabolic enzymes in the liver prior to systemic circulation. First-pass metabolism can
lead to low bioavailability (i.e., reduced concentration of active drug available to target organs) and/or side effects, including liver enzyme elevations or hepatotoxicity. Glyph leverages a separate absorption path taken by dietary fats. A Glyphed
molecule uses this alternative route via the intestinal lymphatic system to bypass first-pass metabolism and transit directly into systemic circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that
have high first-pass metabolism. For each program, we use Glyph to create unique sets of prodrugs with differentiated profiles, and evaluate these prodrugs as potential candidates to advance into preclinical and clinical studies. Glyph has been
applied to create novel product candidates for our pipeline resulting in new intellectual property, including composition of matter patents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Benefits of Our Proprietary Glyph Platform </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01f03.jpg" ALT="LOGO" STYLE="width:6.33333in;height:3.25957in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Apply our team</I></B><B><I>&#8217;</I></B><B><I>s expertise to optimize the design
and execution of clinical trials and drive successful business outcomes</I></B><B>.</B> Our team is comprised of industry leaders with a proven track record of building successful companies that have developed and commercialized innovative
neuropsychiatric medicines. This includes Zyprexa<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Cymbalta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Latuda<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,
Zurzuvae<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and Cobenfy<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> (xanomeline-trospium or KarXT), which was approved by the FDA in September 2024 and is the first new class of
medicines in over 30 years for patients living with schizophrenia. Leveraging our team&#8217;s track record of success in neuropsychiatry discovery and clinical development is important as we select new product candidates and as we implement key
design elements in our clinical trials to<B><I> </I></B>optimize treatment effect and duration and reduce placebo response. In parallel, we apply our deep experience in building successful companies to establish clear goals, drive strategic
decision-making, and maintain financial discipline. Drawing on our track record of success in neuropsychiatry, we aim to drive successful outcomes for patients and shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a
pipeline of novel potential treatments for neuropsychiatric disorders with significant unmet need. We retain exclusive, worldwide development and commercialization rights to all of our product candidates and discovery programs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01f04.jpg" ALT="LOGO" STYLE="width:6.31667in;height:2.09563in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph aims to unlock the therapeutic potential of drugs in CNS and beyond. In addition to our three lead
candidates, we have robust discovery programs and multiple pipeline programs underway. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GlyphAllo: Potential Differentiated Therapy for MDD
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAllo is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous neurosteroid and gamma-aminobutyric acid A, or GABA<SUB
STYLE="font-size:75%; vertical-align:bottom">A</SUB>, positive allosteric modulator, or PAM. Allopregnanolone is a naturally occurring molecule that reduces stress, with levels that peak during the third trimester of pregnancy. An intravenous
infusion formulation of allopregnanolone was approved for the treatment of PPD, a form of MDD. Allopregnanolone has been clinically validated in two third-party trials, which were sponsored by Sage Therapeutics in the United States for the treatment
of PPD and powered for statistical significance, as a rapidly acting antidepressant with anxiolytic and sleep-promoting effects. Due to the shared symptomatology between MDD and PPD, we believe data for MDD are relevant from such third-party trials.
In each trial, allopregnanolone demonstrated statistically significant results on the primary endpoint of change in baseline at 60 hours in the Hamilton Depression Rating Scale-17, or HAMD-17, a regulatory-standard depression severity rating scale.
However, its scope of clinical use has been constrained by oral bioavailability limitations that the Glyph platform is uniquely designed to solve. For example, a previous third-party clinical trial showed that oral administration of allopregnanolone
resulted in plasma exposure levels with an AUC<SUB STYLE="font-size:75%; vertical-align:bottom">inf</SUB> of 0.7 ng*hr/mL per 1 mg of allopregnanolone dosed, as shown in the figure below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unmodified Allopregnanolone Oral Systemic Exposure &#8211; Third-Party Literature Data
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01f05.jpg" ALT="LOGO" STYLE="width:2.23in;height:2.9575in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B><I>GlyphAllo: Preclinical Results</I><B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our preclinical studies conducted in non-human primates, or NHPs, oral dosing of GlyphAllo resulted in a greater than nine-fold increase in
bioavailability compared to oral unmodified allopregnanolone over 24&nbsp;hours. In these preclinical studies, evaluations of GlyphAllo and unmodified allopregnanolone were conducted simultaneously or sequentially using the same species. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GlyphAllo: Clinical Results</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our Phase
1 clinical trial conducted in Australia in 99 participants, GlyphAllo demonstrated therapeutically relevant exposures with a favorable tolerability profile that supports chronic dosing. No treatment-related severe or serious AEs were reported. Oral
administration of GlyphAllo in our Phase&nbsp;1 trial of GlyphAllo resulted in plasma exposure levels with an AUC<SUB STYLE="font-size:75%; vertical-align:bottom">inf</SUB> of 6.6 ng*hr/mL per 1 mg of allopregnanolone dosed, as shown in the figure
below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GlyphAllo Oral Systemic Exposure: Phase 1 Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01f06.jpg" ALT="LOGO" STYLE="width:2.1975in;height:2.8675in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAllo has also demonstrated initial
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in a Phase 2a randomized, placebo-controlled trial conducted in Australia in 80 participants, using the Trier Social Stress Test, or TSST, a validated
clinical model of anxiety in healthy volunteers. No severe or serious adverse events were reported. Based on these Phase 1 and Phase 2a data, we believe GlyphAllo has the potential to become a leading treatment for MDD. We advanced GlyphAllo into
what we believe is a registration-enabling Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial conducted in the US and EU in July 2025. <FONT STYLE="white-space:nowrap">BUOY-1</FONT> is a global, randomized, double-blind,
placebo-controlled trial evaluating the efficacy, safety, and tolerability of GlyphAllo in adults with MDD, with or without anxious distress. MDD with anxious distress is a form of MDD characterized by significant anxiety. Approximately 60% of
patients with MDD meet the criteria for anxious distress. This trial is expected to enroll up to approximately 360 patients, randomized 1:1 to receive either GlyphAllo or placebo once-daily over a <FONT STYLE="white-space:nowrap">six-week</FONT>
treatment period. This randomized, double-blind, multiregional, placebo-controlled trial is designed to be registration-enabling, subject to review by the FDA and other comparable regulatory authorities, as an adequate and well-controlled
investigation that seeks to help provide substantial evidence of effectiveness by assessing GlyphAllo&#8217;s efficacy and safety in several hundred patients. Additional clinical trials may be required prior to the submission of a new drug
application even if this trial is successful or positive. The primary endpoint of the trial is the change from baseline at six weeks in <FONT STYLE="white-space:nowrap">HAMD-17.</FONT> Following the initial treatment period, eligible patients may
enter an open-label extension trial, in which all participants will receive GlyphAllo for up to six additional weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Previous clinical
development of allopregnanolone and its synthetic analog, which has been evaluated by Sage Therapeutics in multiple late-stage clinical trials for the treatment of MDD, has been generally hindered by poor oral bioavailability, safety concerns, and
clinical trial design limitations. GlyphAllo is designed to enhance the oral bioavailability of allopregnanolone and achieve systemic exposures comparable to an intravenous infusion of allopregnanolone, with once-daily oral dosing. We believe our
ongoing Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial improves upon the design of previous third-party clinical trials that evaluated a synthetic analog of allopregnanolone in several important ways. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are improving durable efficacy by treating patients for the full <FONT STYLE="white-space:nowrap">six-week</FONT> duration of the primary
endpoint time frame, as opposed to previous trials that treated patients for only the first two weeks and assessed efficacy after six weeks. As allopregnanolone also has an anxiolytic effect, we are also enrolling patients that have MDD with or
without anxious distress. To reduce placebo response, we are optimizing the frequency of clinician-administered assessments, as our comprehensive meta-analysis of recent antidepressant trials </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
demonstrated that the frequency of these assessments is positively correlated with the magnitude of the placebo response in MDD trials. We are also including a single treatment arm and will flex
dose to a target dose, similar to the strategy implemented at Karuna Therapeutics, since the number of active arms is positively associated with increased placebo response. Additionally, we are scrutinizing site selection and patient enrollment to
ensure appropriate diagnosis and exclude inappropriate patients, including those with inflated baseline ratings and those who are concurrently participating in other studies. We expect topline data from the Phase 2b
<FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in the first half of 2027. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GlyphAgo: Potential Differentiated Therapy for GAD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAgo is a novel, Glyphed oral prodrug of agomelatine that we are advancing in a key Phase 1 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial for the treatment of GAD in Australia, in which we plan to enroll up to approximately 190&nbsp;participants. Agomelatine, a clinically validated MT1/MT2 melatonin receptor agonist and
serotonin <FONT STYLE="white-space:nowrap">2C&nbsp;(5-HT2C)</FONT> receptor antagonist, is an effective anxiolytic and antidepressant approved for the treatment of GAD in Australia and MDD in Australia and the EU. In GAD, agomelatine has
demonstrated statistically significant separation from placebo in four third-party placebo-controlled studies<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>. Based on two of the largest non-head-to-head literature meta-analyses of clinical
trials of pharmacological agents for the treatment of GAD, agomelatine has been shown to have favorable efficacy and tolerability relative to other therapeutic agents. Specifically, in the first of these meta-analyses, which included two of the
placebo-controlled studies of agomelatine, agomelatine was observed to have better efficacy and tolerability than certain <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> drugs, such as selective
serotonin-reuptake inhibitors, or SSRIs, which can result in sexual dysfunction and weight gain, and benzodiazepines, which can result in dependence and abuse. In the second of these meta-analyses, which included three of the placebo-controlled
studies of agomelatine, agomelatine was found to be the most favorable drug in terms of both efficacy and tolerability among the analyzed competitors (venlafaxine, escitalopram, paroxetine, duloxetine, and pregabalin). However, despite this positive
profile, over 90% of unmodified agomelatine is lost to first-pass liver metabolism and its use has been limited by dose-dependent liver enzyme elevations. Its label in both Australia and the EU requires liver function testing before initiating
treatment, during treatment, and upon increasing the dose. Agomelatine is not approved in the United States. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The statements above relating to the placebo-controlled studies of agomelatine in GAD are based on the
following, which represents a complete list of all placebo-controlled studies of agomelatine in GAD: Dan&nbsp;J.&nbsp;Stein, et al., Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety
disorder: A 12-week, double-blind, placebo-controlled study, European Neuropsychopharmacology, Volume 27, Issue 5, 2017 (also included in the <FONT STYLE="white-space:nowrap">meta-analyses);</FONT> Dan&nbsp;J.&nbsp;Stein, et al., Agomelatine in
Generalized Anxiety Disorder: An Active Comparator and Placebo-Controlled Study, J Clin Psychiatry 2014;75(4):362-368 (also included in the meta-analyses); Dan J. Stein, et al., Agomelatine Prevents Relapse in Generalized Anxiety Disorder: A 6-Month
Randomized, Double-Blind, Placebo-Controlled Discontinuation Study, J Clin Psychiatry 2012;73(7):1002-1008; Dan J. Stein, et al., Journal of Clinical Psychopharmacology 28(5):p 561-566, October 2008 (also included in the meta-analyses).
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Agomelatine Significantly Reduces Anxiety in Patients with GAD </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g32a32.jpg" ALT="LOGO" STYLE="width:6.33333in;height:3.9029in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using our proprietary Glyph platform, GlyphAgo is designed to avoid first-pass liver metabolism and
increase systemic exposure of agomelatine, enabling exposure levels of agomelatine that are effective in GAD but at a lower dose that reduces liver exposure and reduces or eliminates the need for liver function testing. Based on internal analyses,
we believe a <FONT STYLE="white-space:nowrap">two-fold</FONT> increase in the bioavailability of agomelatine with GlyphAgo dosing will reduce or eliminate liver enzyme elevations. In preclinical studies in NHPs we showed that oral dosing of GlyphAgo
increased plasma exposure of agomelatine versus agomelatine alone above this <FONT STYLE="white-space:nowrap">two-fold</FONT> target. Therefore, based on the data we have generated to date, we believe GlyphAgo has the potential to become a leading
treatment for GAD. The ongoing Phase 1 trial will be conducted in multiple parts to evaluate the safety, tolerability, and pharmacokinetics of GlyphAgo and compare the pharmacokinetics of GlyphAgo to agomelatine alone. It will include single- and
multiple-ascending dose cohorts, as well as a food-effect crossover portion, using both open-label and placebo-controlled designs. In April 2026, we reported topline data from the SAD and crossover portions of our Phase 1 proof-of-concept clinical
trial of GlyphAgo. In the head-to-head crossover portion of the trial, GlyphAgo demonstrated a 6.8-fold increase in bioavailability of agomelatine compared to unmodified orally administered agomelatine. GlyphAgo also showed significantly lower
(10-fold) PK variability compared to unmodified agomelatine. The crossover portion included participants who were taking estrogen-containing oral contraceptives that are known to increase agomelatine exposure due to liver drug-drug interaction. In
contrast, GlyphAgo exposure was unaffected by oral contraceptives, further supporting the ability of GlyphAgo to bypass first-pass liver metabolism. GlyphAgo demonstrated a 9.6 to 14.5-fold increase in dose-normalized exposure compared to
agomelatine in a separate SAD portion of the trial in which no participants were on oral contraceptives. GlyphAgo was well tolerated and no liver-related AEs were observed. We plan to initiate a Phase 2a
<FONT STYLE="white-space:nowrap">proof-of-pharmacology</FONT> trial designed to evaluate the potential sleep benefit of GlyphAgo in patients with GAD and sleep disturbance, with topline data expected in early 2028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also plan to initiate in parallel, a randomized, double-blind, placebo-controlled Phase 2b trial evaluating the efficacy and safety of
GlyphAgo in patients with GAD, with topline data expected by the end of 2028. This multiregional trial is designed to be registration-enabling, subject to review by the FDA and other comparable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory authorities, as an adequate and well-controlled investigation that seeks to provide substantial evidence of effectiveness by assessing GlyphAgo&#8217;s efficacy and safety in several
hundred patients. Although this trial is designed to be registration-enabling, additional clinical trials may be required prior to the submission of a new drug application even if this trial is successful or positive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the development and commercialization of GlyphAgo for the treatment of GAD is our primary focus, as part of our longer-term growth
strategy, we may evaluate GlyphAgo in other indications as well, including MDD. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Glyph2BLSD and Additional Applications of the Glyph Platform
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph2BLSD is our novel, Glyphed oral prodrug of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> a differentiated <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> neuroplastogen. Glyph2BLSD is designed to harness the differentiated and <FONT
STYLE="white-space:nowrap">non-hallucinogenic</FONT> profile of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> which has rapidly acting clinical activity and is not expected to exhibit the fibrosis,
cardiovascular effects, or hallucinations characteristic of some other neuroplastogens. Glyph2BLSD is designed to improve the pharmacokinetic and tolerability profile of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD</FONT></FONT> while maintaining therapeutic exposure levels. Glyph2BLSD&#8217;s <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> profile unlocks the potential to
enable convenient outpatient and repeat dosing to improve efficacy. We are advancing Glyph2BLSD through preclinical studies and are developing Glyph2BLSD for the treatment of depressive disorders, including TRD, PTSD, and headache disorders with
significant unmet need. We are currently conducting first-in-human-enabling studies of Glyph2BLSD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also leveraging the power of
the Glyph platform to explore additional applications in CNS and <FONT STYLE="white-space:nowrap">non-CNS</FONT> diseases and advance programs that address significant unmet needs in these areas. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport was
founded by pioneers in the neuropsychiatry field and is led by a team of seasoned industry veterans with a shared mission to transform the treatment of neuropsychiatric disorders and improve patients&#8217; lives. We have assembled an experienced
group of individuals with a proven track record of building successful companies that have developed and commercialized innovative neuropsychiatric medicines. Members of our leadership team have collaborated successfully over several decades on the
discovery, development, and commercialization of neuropsychiatric medicines including Cobenfy, Latuda, Zyprexa, Cymbalta, and Zurzuvae. Our <FONT STYLE="white-space:nowrap">co-founders,</FONT> Daphne Zohar, and Dr.&nbsp;Steven Paul, were central to
the success of Karuna Therapeutics, which invented and advanced the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicine Cobenfy, and was acquired by Bristol Myers Squibb in March 2024 for
$14&nbsp;billion. Cobenfy was approved by the FDA in September 2024 and is the first drug to provide a new mechanism of action for schizophrenia in over 30 years. Cobenfy is estimated to achieve annual peak sales of over $5&nbsp;billion. The core
members of our leadership team include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Daphne Zohar</I></B>, Founder, Chief Executive Officer and Board Member, previously founded and led
PureTech Health for 20 years as CEO. She also <FONT STYLE="white-space:nowrap">co-founded</FONT> PureTech&#8217;s entities, including Karuna Therapeutics, which was acquired by Bristol Myers Squibb for $14 billion. Ms.&nbsp;Zohar was a key driver in
PureTech&#8217;s productive R&amp;D engine, which led to 28 new medicines and a clinical success rate at PureTech and founded entities that was around six times better than the industry average during her tenure. PureTech programs, including Cobenfy
(invented at PureTech) and deupirfenidone, met with clinical success pursuing the same three pillar strategy of identifying clinically validated medicines with previous issues that held back their development, applying new technology to address
previous limitations, and leveraging the team&#8217;s expertise to optimize the design and execution of clinical trials and drive successful business outcomes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Steven Paul, M.D., </I></B><FONT STYLE="white-space:nowrap">Co-founder</FONT> and the Chair of the board of
directors, brings over 40 years of experience as a physician-scientist specializing in CNS drug discovery and development and was previously the President, Chief Executive Officer, and Chair of the Board and Chief Scientific Officer and President of
Research and Development at Karuna Therapeutics. He was also formerly the Executive Vice President for Science and Technology and President of the Lilly Research Laboratories </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
at Eli Lilly. Prior to his tenure at Eli Lilly, Dr.&nbsp;Paul spent 18 years at the National Institute of Health and served as the Scientific Director of the National Institute of Mental Health.
Dr.&nbsp;Paul played a key role in the development of several important neuropsychiatric drugs, including Zyprexa, Cymbalta, Cobenfy, and Zurzuvae. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Antony Loebel, M.D.</I></B>, Chief Medical Officer and President of Clinical Development, brings over
20&nbsp;years of leadership experience in the biopharmaceutical industry and is a board-certified psychiatrist. He was formerly the President and Chief Executive Officer and Chief Medical Officer of Sunovion Pharmaceuticals. Dr.&nbsp;Loebel was
instrumental in the growth of Sunovion to a company with over $3.5&nbsp;billion in total revenue and played a key role in the development and commercialization of Latuda for the treatment of patients with bipolar depression and schizophrenia.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Michael Chen, Ph.D.</I></B>, <FONT STYLE="white-space:nowrap">Co-founder</FONT> and Chief Scientific
Officer, has over 20 years of experience in various research and leadership roles in the neuropsychiatry field. He was formerly the Head of Innovation at PureTech Health where he oversaw the rapid advancement of neuropsychiatric medicines and Glyph
platform translation and validation that led to the founding of Seaport Therapeutics. At PureTech, Dr.&nbsp;Chen played a key role in the clinical advancement of deupirfenidone, which recently demonstrated strong and durable efficacy with favorable
tolerability as a monotherapy in a Phase&nbsp;2b trial in idiopathic pulmonary fibrosis. Dr.&nbsp;Chen was previously <FONT STYLE="white-space:nowrap">Co-founder</FONT> and Head of Research and Strategy at Sonde Health, a leader in voice-based
health monitoring developing artificial intelligence powered-vocal biomarkers for depression and other neuropsychiatric disorders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Lauren White</I></B>, Chief Financial Officer, has over 22 years of corporate finance, accounting,
strategic partnering and investor relations experience. Most recently, she served as the Chief Financial Officer at ImmunoGen prior to and through its acquisition by AbbVie for $10.1&nbsp;billion in 2024. Before that she was the Chief Financial
Officer, Treasurer, and Principal Accounting Officer at C4 Therapeutics, responsible for developing and leading the company&#8217;s financial and capital strategies. Prior to that, Ms.&nbsp;White spent ten years at Novartis in various finance roles.
Ms.&nbsp;White started her career at General Electric and Boston Consulting Group in strategy and marketing roles. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Lana Gladstein, J.D.</I></B>, General Counsel, has over 25 years of legal expertise including corporate
governance and M&amp;A transactions, licensing and partnerships, and intellectual property matters. Most recently, Ms.&nbsp;Gladstein was the Group General Counsel at APRINOIA Therapeutics, a clinical-stage company developing therapeutics and
diagnostics for neurodegenerative diseases. Prior to APRINOIA, she was Chief Legal Officer at Arranta Bio and Executive Vice President and General Counsel at Brammer Bio until their acquisitions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors brings together seasoned leaders in the biopharmaceutical industry, with expertise spanning neuropsychiatry research
and development, regulatory affairs, financial operations, and commercialization. Our team is united by a shared commitment to develop transformative treatments for patients to address the significant unmet need in neuropsychiatry. Despite the prior
experience of our team, our limited operating history as a standalone company makes any reliance on past performance uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our
inception, we have raised $325&nbsp;million in net proceeds from leading life science investors, including shareholders with holdings greater than 5%: ARCH Venture Partners, General Atlantic, Sofinnova Investments, Third Rock Ventures, and our
founder, PureTech. Prospective investors should not rely on the investment decisions of our existing investors, as these investors may have different risk tolerances and in certain cases received their shares in prior offerings at prices lower than
the price offered to the public in this offering. See the sections titled &#8220;Certain Relationships and Related Person Transactions&#8221; and &#8220;Principal Stockholders&#8221; for more information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We founded our company with a mission to develop life-changing treatments for patients with depression, anxiety, and other neuropsychiatric
disorders. The key elements of our business strategy are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Successfully advance </B><B>GlyphAllo</B><B> through clinical development for the treatment of patients with
MDD with or without anxious distress</B>. GlyphAllo is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in two third-party trials as a rapidly acting antidepressant with anxiolytic and
sleep-promoting effects. GlyphAllo is designed to overcome bioavailability limitations of allopregnanolone and deliver rapid and durable efficacy in MDD. We have demonstrated in a Phase 1 clinical trial that GlyphAllo reaches therapeutically
relevant exposures with oral dosing, and in a Phase 2a clinical trial, GlyphAllo demonstrated initial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> with an objective biomarker of stress in healthy
volunteers and a favorable tolerability profile that supports chronic dosing. We have initiated the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in patients with MDD with or without anxious distress and anticipate topline data in
the first half of 2027. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Successfully advance </B><B>GlyphAgo</B><B> through clinical development for the treatment of patients with
GAD</B>.<B> </B>GlyphAgo is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of GAD in Australia and MDD in Australia and the EU. Due to extensive first-pass
metabolism, agomelatine can cause dose-dependent liver enzyme elevations, and its use has been limited by the need for frequent liver function testing. GlyphAgo is designed to overcome this limitation by avoiding first-pass metabolism and achieving
therapeutic exposures of agomelatine while reducing or eliminating the need for liver monitoring. In April 2026, we reported topline data from the SAD and crossover portions of our Phase 1 proof-of-concept clinical trial for GlyphAgo. In the
head-to-head crossover portion of the trial, GlyphAgo demonstrated a 6.8-fold increase in bioavailability of agomelatine compared to unmodified orally administered agomelatine, and showed significantly lower (10-fold) pharmacokinetic variability
compared to unmodified agomelatine. In the SAD portion of the trial, GlyphAgo demonstrated a 9.6 to 14.5-fold increase in dose-normalized exposure compared to agomelatine. GlyphAgo was well-tolerated and no liver-related AEs were observed. We plan
to initiate a Phase 2a proof-of-pharmacology trial designed to evaluate the potential sleep benefit of GlyphAgo in patients with GAD and sleep disturbance, with topline data expected in early 2028 and, in parallel, a Phase 2b trial designed to
evaluate the efficacy and safety of GlyphAgo in patients with GAD, with topline data expected by the end of 2028. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Develop a robust pipeline of differentiated programs for neuropsychiatric and other CNS disorders by
leveraging our </B><B>Glyph</B><B> platform</B>. We have used Glyph to create over 24 different small molecules based on the broad compatibility of our platform with a range of small molecule physicochemical properties. Given the novel prodrug
modifications to these drugs and resulting improvements in drug properties, we create new composition of matter intellectual property for these therapies. In addition to GlyphAllo and GlyphAgo, we have multiple preclinical programs, including
Glyph2BLSD, and are also evaluating the application of our Glyph platform in therapeutic areas beyond neuropsychiatry. Our team has a track record of building revolutionary biopharmaceutical companies that have developed successful medicines for
neuropsychiatric disorders, and we believe that our scientific expertise and world-class technical capabilities will enable us to identify and develop high value targets in the future. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Opportunistically pursue strategic partnerships to maximize the value of our </B><B>Glyph</B><B> platform.</B>
We have exclusive global rights to develop and commercialize our product candidates and pursue various discovery programs using our Glyph platform. We may seek strategic collaborations where we believe the resources and expertise of third-party
biopharmaceutical companies could accelerate the clinical development or maximize the commercial potential of our product candidates and/or discovery programs, or where such collaborations could expand the capabilities of our Glyph platform. We may
also opportunistically evaluate partnerships in therapeutic areas outside neuropsychiatry where our Glyph platform has demonstrated potential applicability, such as oncology, immunology and inflammation, metabolic disease, and obesity.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unmet Patient Need in Neuropsychiatry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the World Health Organization, as of 2021, depression affects approximately 332&nbsp;million people worldwide and anxiety affects
approximately 359 million people worldwide. Quality of life can be severely impacted and the societal economic burden of MDD totals over $300&nbsp;billion in the United States alone as of 2023. According to the National Institute of Mental Health,
MDD affects approximately 21&nbsp;million adults in the United States, as of 2021. According to the National Institute of Mental Health, approximately 4 in 10 people with MDD do not receive treatment, and for those that do, currently approved drugs
often have significant limitations, including modest efficacy, slow onset of action, and unfavorable side effects. Anxiety disorders are even more prevalent than MDD and affect approximately 350&nbsp;million people worldwide. Of these, approximately
100&nbsp;million adults suffer from GAD, including more than seven million adults in the United States, according to JAMA Psychiatry, as of 2017. There have been no new therapies approved for GAD in almost two decades, and the medicines currently
used for GAD have modest efficacy, slow onset, and/or unfavorable side effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the shortcomings of existing therapies, there has
been limited innovation in neuropsychiatric treatment options over the last 30 years and there remains a significant need for novel mechanisms and additional treatment options. The unmet need for improved therapies to treat depression and anxiety is
so great that even approved drugs with limited efficacy and significant tolerability issues have become widely prescribed drugs. For instance, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT>
therapies, such as Zoloft<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Zyprexa, and Cymbalta, have each generated $3&nbsp;billion to $5&nbsp;billion in peak annual sales between 2005 and 2012, despite significant limitations, such as
modest efficacy, slow onset, and undesirable side effects. SSRIs and serotonin-norepinephrine reuptake inhibitors, or SNRIs,&nbsp;both first-line treatments for MDD and GAD, can take weeks to improve symptoms, and often do not lead to complete
remission of symptoms. In addition, patients with MDD with anxious distress, a subtype of MDD representing approximately 60% of patients with MDD, have even lower rates of treatment response and remission, and there are no approved therapies
indicated for MDD with anxious distress. Patients with MDD have an increased likelihood of both suicidal ideation and suicide attempts, which is further increased in patients with MDD with anxious distress. Even for patients who benefit from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> drugs, many experience challenging side effects, such as unintended weight gain, sexual dysfunction, and sleep disturbances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GAD is characterized by excessive anxiety and worry that is difficult to control, and presents with associated symptoms such as restlessness,
sleep disturbance, and irritability. More than half of GAD patients are untreated, and of those that are treated, only half respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> treatments like
SSRIs and SNRIs. Current therapies provide limited efficacy and can cause significant adverse effects, including weight gain, sexual dysfunction, and sleep disturbances. There is a clear unmet need for novel therapies that provide improved efficacy
and reduce unfavorable side effects for patients suffering from GAD. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Challenges in Neuropsychiatric Drug Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the significant unmet need in neuropsychiatry, over 90% of neuropsychiatry product candidates fail in clinical trials, according to the
Biotechnology Innovation Organization. The challenges that have held back the development of novel treatments for neuropsychiatric disorders include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Fundamental pathophysiology is unknown:</B> High failure rates in clinical trials evaluating investigational
therapies without prior clinical validation can reflect an incomplete understanding of the underlying pathophysiology of depression and anxiety. Translation of data from animal models to humans is difficult due to the complexity of the CNS.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Poor drug-like properties:</B> Drugs for neuropsychiatric disorders have had low oral bioavailability and/or
significant side effects due in part to poor drug-like properties, often due to high first-pass metabolism in the liver. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Challenges with clinical trial design and execution:</B> Suboptimal trial design and execution of
neuropsychiatry clinical trials can lead to failed studies and prevent drug approvals. A key challenge in neuropsychiatry clinical development is the placebo effect, which can be impacted by the frequency of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
clinician-administered assessments, the number of treatment arms, the number of sites, and the inclusion of inappropriate patients, including those with inflated baseline ratings and those who
are concurrently participating in other studies. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Differentiated Approach</B><B><I> </I></B><B></B><I></I><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are uniquely positioned to develop novel medicines that will make a significant impact for patients and their families through our
differentiated, three-pillar approach: 1) identify clinically validated mechanisms held back by issues that can be addressed by our proprietary Glyph platform, 2) create novel medicines with strong intellectual property using Glyph, and 3) apply our
team&#8217;s expertise to optimize the design and execution of clinical trials and drive successful business outcomes. We believe our approach will enable us to develop transformative treatments for patients and build a leading neuropsychiatry
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1) Identify clinically validated mechanisms held back by issues that can be addressed by our proprietary Glyph platform.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our team&#8217;s deep expertise in neuropsychiatry drug discovery and development to analyze data generated from prior
clinical trials of investigational therapies for depression, anxiety, and other neuropsychiatric disorders. Of the investigational therapies that have demonstrated clinical efficacy, we analyze the factors that have held these molecules back from
achieving regulatory or commercial success and identify those that we can address with our Glyph platform, including poor oral bioavailability and/or liver-related adverse events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We select product candidates that have the potential to become high-impact, leading therapies and design and conduct early <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies that address key development questions and validate the fundamental hypotheses underlying each program. Molecules that meet all the above criteria
become candidates for our Glyph platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2) Create novel medicines with strong intellectual property using Glyph. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph is a lymphatic-targeting prodrug platform that has shown clinical proof of concept in our Phase 1 and Phase 2a clinical trials of
GlyphAllo. We can apply Glyph to molecules to overcome limitations such as low oral bioavailability, liver related adverse events, and other side effects. Importantly, every time we Glyph a molecule, it results in the creation of a novel molecule
and, therefore, new composition of matter intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of the Glyph platform has been a culmination of over 50
years of work since researchers began exploring the potential of lymphatic transport to improve drug delivery. Since the 1970s, research has been conducted on highly lipophilic molecules, or molecules that can be dissolved in lipids or fats, that
could take advantage of the lymphatic route to bypass first-pass metabolism and target lymphatic tissues. However, this approach was limited by the need for chemical properties like lipophilicity, which can negatively affect drug absorption and
metabolism. To overcome these limitations, Dr.&nbsp;Christopher Porter, the <FONT STYLE="white-space:nowrap">co-inventor</FONT> of Glyph and Director of the Monash Institute of Pharmaceutical Sciences, advanced cleavable prodrugs with lipophilic
moieties to promote lymphatic transport and the release of parent drug. Simple triglyceride-based prodrugs with direct conjugation of a desired drug with a lipophilic moiety were explored but did not fully capture the potential of lymphatic
targeting prodrugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Porter, in collaboration with our Head of Chemistry, Dr.&nbsp;Jamie Simpson, then invented our Glyph
platform, which advanced the creation of a new type of prodrug that significantly improved lymphatic transport. This proprietary prodrug chemistry is designed to promote enhanced lymphatic uptake while maintaining gut stability and the release of
the parent drug. Our Glyph platform enables the design of various linkers, glyceride </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
moieties, and self-immolative groups tailored for each active pharmaceutical ingredient, or API, candidate, to allow for the release of the API. An illustration of an exemplary lymphatic
targeting lipid prodrug is below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g13a34.jpg" ALT="LOGO" STYLE="width:6.30571in;height:2.77429in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When taken orally, conventional small molecule drugs are absorbed in the gut, enter the portal vein, and
travel to the liver, where they can undergo high first-pass metabolism before entering systemic circulation. This can result in low bioavailability, or very little of the drug actually circulating in the body or brain and can also increase the risk
of liver-related adverse events. In contrast, dietary fats enter systemic circulation through a completely different pathway: they enter the mesenteric lymphatic system of the gut and traffic into the thoracic duct, bypassing the liver on their way
into systemic circulation. With Glyph, we cloak drugs so that the body recognizes them as if they were dietary fats, and traffics them through the lymphatic system, avoiding the liver and transporting them directly into the bloodstream. This
improves a molecule&#8217;s bioavailability and thereby enables drugs that otherwise need to be given intravenously, to be dosed orally. Glyph also helps to overcome other issues&#8212;such as liver toxicity&#8212;by avoiding the liver on the first
pass and reducing dose while maintaining therapeutic exposure levels. Glyph is, to our knowledge, the only clinically validated lymphatic-targeting platform. Previous examples of oral lymphatic-targeting therapies have yet to result in efficient
lymphatic transport, generalized across molecules, or translated to humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have pioneered the use of preclinical models to test and
validate our lymphatic transport approach. We are able to use a streamlined series of <I>in vitro</I> and <I>in vivo</I> assays, which are efficient, repeatable, and highly translatable, and customize prodrug chemistry to each unique active drug.
The translatability of these models is illustrated by our GlyphAllo program, which was predicted to have enhanced bioavailability based on our preclinical data. This was confirmed in a Phase 1 trial of GlyphAllo in healthy volunteers, which
demonstrated therapeutically relevant exposures following dosing of GlyphAllo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have used Glyph to create over 24 different small
molecules based on our Glyph platform&#8217;s compatibility with a range of physiochemical properties of small molecules. Our Glyph platform can be used with a range of small molecules, including for indications beyond neuropsychiatry, including
oncology, immunology and inflammation, metabolic disease, and obesity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3) Apply our team&#8217;s expertise to optimize the design and
execution of clinical trials and drive successful business outcomes. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our experienced team has a proven track record of building
successful companies that have developed and commercialized innovative neuropsychiatric medicines. We are led by the team that discovered and advanced </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Cobenfy, which was first approved by the FDA in September 2024 and is the first new mechanism in over 30&nbsp;years for patients living with schizophrenia. Within each of our programs, we are
implementing key learnings from our collective experience to improve the probability of success. For instance, to optimize the design and execution of the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial of GlyphAllo in MDD, we aim to
implement learnings from the prior trials of allopregnanolone and its synthetic analogs such as zuranolone. These include key design elements to improve durable efficacy and reduce the placebo effect, namely treating patients for the full duration
of the primary endpoint, limiting the frequency of clinical assessments, randomizing patients 1:1 to either a single active treatment arm or placebo, and using rigorous patient inclusion criteria. Our strategy to optimize the frequency of clinical
assessments is supported by a recent meta-analysis we conducted of major MDD trials over the last 10 years to identify clinical design factors associated with the magnitude of the placebo response. A key finding from this analysis was that the
number and frequency of clinician-administered assessments were significantly associated with greater placebo response. Thus, reducing the number and frequency of clinician-administered assessments may decrease the placebo response in MDD trials.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes the key design elements we are incorporating into our clinical trials to improve durable efficacy and minimize
the placebo effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g04c52.jpg" ALT="LOGO" STYLE="width:5.59667in;height:3.09499in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are leveraging our Glyph platform to advance a pipeline of novel candidates to address the significant unmet need for patients with
depression and anxiety. Our lead product candidates include GlyphAllo for the treatment of MDD and GlyphAgo for the treatment of GAD. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GlyphAllo:
Potential Differentiated Therapy for MDD </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAllo, is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous
neurosteroid and GABA<SUB STYLE="font-size:75%; vertical-align:bottom">A</SUB> PAM that has been clinically validated in two third-party trials, which were sponsored by Sage Therapeutics in the United States for the treatment of PPD and powered for
statistical significance, as a rapidly acting antidepressant with anxiolytic and sleep-promoting effects. In each trial, allopregnanolone demonstrated statistically significant results on the primary endpoint of change in baseline at 60 hours in the
HAMD-17. However, its scope of clinical use has been constrained by oral bioavailability limitations that the Glyph platform is uniquely designed to solve. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently advancing GlyphAllo in the Phase 2b
<FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial in MDD with or without anxious distress, that we believe will be registration-enabling, subject to review by the FDA and/or other comparable regulatory authorities, as the trial is an adequate and
well-controlled investigation that seeks to help provide substantial evidence of effectiveness by definitively assessing GlyphAllo&#8217;s efficacy and safety in several hundred patients. We believe that GlyphAllo has the potential to be a leading
treatment for MDD. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Background on MDD and Market Opportunity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MDD is one of the most disabling neuropsychiatric disorders and ranks among the leading causes of disease burden worldwide. As of 2023, 29% of
adults in the United States reported having been diagnosed with depression at some point in their life, more than diabetes (16%) or chronic kidney disease (14%).<I> </I>Depression is often characterized by persistent low mood or anhedonia&#8212;loss
of interest in normally enjoyable activities&#8212;as well as changes in sleep, appetite, cognition, psychomotor function, fatigue, feelings of worthlessness, inappropriate guilt, or suicidal ideation. Depression can be debilitating to daily
functioning, including school, work, and interpersonal relationships, and it significantly reduces quality of life. Individuals with depression are 20&nbsp;times more likely to commit suicide than those without depression. In 2022, suicide was the
second leading cause of death for people ages 10-14 and 20-34, and the third leading cause of death for people ages 15-19. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MDD is a
highly heterogeneous disease that manifests in myriad ways, with variations in symptoms, severity, and duration. Furthermore, the underlying causes are multifaceted, encompassing genetic, biological, environmental, and psychological factors. For
example, according to The American Journal of Psychiatry, more than half of adults diagnosed with MDD also experience notable concurrent anxiety. Individuals with MDD with anxious distress have worse depressive symptoms, higher likelihood of
suicidal ideation, and attempted suicide, increased functional and physical impairment, reduced quality of life, and lower response to treatments for MDD. In recognition of the clinical impact of anxious distress, the
<FONT STYLE="white-space:nowrap">DSM-5</FONT> added in 2013 a specifier for anxious distress in the context of MDD. There are no drugs specifically approved for MDD patients with anxious distress. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations of the Current Standard of Care in MDD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although there are multiple approved antidepressant therapies, only 61% of adults with MDD in the United States received treatment in 2021,
according to the National Institute of Mental Health. Of MDD patients who do receive treatment, approximately <FONT STYLE="white-space:nowrap">one-half</FONT> fail to achieve remission with first-line therapies. Current standard of care for those
who respond poorly to initial antidepressant monotherapy treatment relies on polypharmacy and treatment-switching strategies between current options including SSRIs, SNRIs, dopaminergic/noradrenergic drugs, and atypical antipsychotics. Current
treatments are also in many cases associated with significant negative side effects such as sexual dysfunction, weight gain, gastrointestinal issues, insomnia, fatigue, nausea, emotional blunting, and others, which limit medication adherence and can
negatively impact treatment outcomes. Even when patients achieve symptom remission, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> therapies may take weeks to yield effect and can even make symptoms
like insomnia worse. Therefore, there is a significant unmet need for novel therapies that are more effective and better tolerated for the treatment of people with MDD. <B></B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Validation of Allopregnanolone and GABA Modulation in MDD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allopregnanolone is an endogenous neurosteroid that is synthesized in the periphery and brain and binds selectively with high affinity to GABA<SUB
STYLE="font-size:75%; vertical-align:bottom">A</SUB> receptors. Allopregnanolone has a rapid onset of action and a well-established, clinically validated antidepressant, anxiolytic, and sleep-promoting effect. GlyphAllo retains the activity and
potency of endogenous allopregnanolone in oral form. Levels of allopregnanolone peak during the third trimester of pregnancy, and an intravenous infusion formulation of allopregnanolone was approved for the treatment of PPD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GABA is the primary inhibitory neurotransmitter in the brain and is a pivotal component of the etiology of depression and anxiety disorders.
Reduced GABA levels in the brain are associated with MDD, and cerebrospinal fluid, or CSF, GABA levels are highly correlated with anxiety in patients with MDD and tend to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
normalize with successful treatment. Other drugs that target GABA, such as benzodiazepines, have been investigated for MDD; however, these have been largely ineffective as they lack
antidepressant effects driven by specific GABA receptor subtypes and can lead to dependence and abuse. Importantly, allopregnanolone binds to GABA<SUB STYLE="font-size:75%; vertical-align:bottom">A</SUB> receptors at distinct sites compared to
benzodiazepines and thereby modulates GABA<SUB STYLE="font-size:75%; vertical-align:bottom">A</SUB> signaling in a manner distinct from benzodiazepines. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Prior Clinical Studies of Allopregnanolone and its Synthetic Analogs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allopregnanolone and its synthetic analogs, including zuranolone, have been tested in multiple studies in MDD and PPD and have demonstrated
rapidly acting antidepressant and anxiolytic effects. An IV formulation of allopregnanolone, brexanolone, was developed and approved by the FDA in 2019 for the treatment of PPD and marketed under the trade name Zulresso. In two positive Phase 3
trials, brexanolone demonstrated statistically significant and clinically meaningful and rapid reductions in <FONT STYLE="white-space:nowrap">HAMD-17</FONT> as compared to placebo in patients with PPD. In addition, brexanolone demonstrated rapid and
statistically significant anxiolytic effects and improvement in insomnia symptoms from baseline, according to pooled <FONT STYLE="white-space:nowrap">post-hoc</FONT> analyses of three placebo-controlled trials of brexanolone in PPD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After oral administration, unmodified allopregnanolone is rapidly and nearly completely metabolized via liver first-pass metabolism, resulting
in only a small percentage reaching the systemic circulation and CNS. As a result, oral administration of allopregnanolone does not produce adequate exposure levels for efficacy and is poorly suited for chronic treatment of depression and anxiety
disorders. Due to the poor oral bioavailability of allopregnanolone, brexanolone was only available via a <FONT STYLE="white-space:nowrap">60-hour</FONT> IV infusion, requiring the presence of a health care provider to continuously monitor the
patient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To overcome the poor bioavailability of brexanolone and the challenges associated with IV administration, an oral synthetic
analog of allopregnanolone, zuranolone, was developed. In two Phase 3 studies in PPD conducted by Sage Therapeutics, zuranolone met the primary endpoint and also demonstrated a statistically significant improvement in symptoms of anxiety. Zuranolone
was approved by the FDA for the treatment of PPD in 2023 and is marketed under the trade name Zurzuvae. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to its development in
PPD, zuranolone was tested in six placebo-controlled clinical trials in patients with MDD. In these trials, patients received either zuranolone or placebo once daily for two weeks. The primary endpoint in these trials was change from baseline in <FONT
STYLE="white-space:nowrap">HAMD-17</FONT> score at Day 15 or Day 3. Change from baseline in <FONT STYLE="white-space:nowrap">HAMD-17</FONT> score was also assessed at Day 42, when patients had not received treatment for four weeks. Zuranolone
demonstrated a rapid antidepressant effect that deepened while patients were on drug and met the primary endpoint in five of the six trials. In the trial that did not meet its primary endpoint, zuranolone showed statistically significant reductions
in <FONT STYLE="white-space:nowrap">HAMD-17</FONT> total score at Days 3, 8 and 12, but not at Day 15. Zuranolone also demonstrated a statistically significant anxiolytic effect in the WATERFALL trial. We believe the negative results of these trials
at Day 42 was primarily due to two key factors related to clinical trial design and execution. First, as patients received treatment for only the first two weeks of the study, patients had not received treatment for approximately four weeks when <FONT
STYLE="white-space:nowrap">HAMD-17</FONT> score was assessed at Day 42. Second, these studies showed a high placebo response, likely driven by the elevated frequency of clinician-administered assessments. Indeed, according to our meta-analysis of
recent antidepressant trials, zuranolone&#8217;s WATERFALL trial had approximately double the placebo response and double the frequency of clinician-administered assessments compared to typical antidepressant trials. Zuranolone was generally safe
and well tolerated in 2,005 treated patients across seven randomized control<B> </B>trials, with the most common treatment-emergent adverse event being somnolence, an <FONT STYLE="white-space:nowrap">on-target</FONT> effect of GABA<SUB
STYLE="font-size:75%; vertical-align:bottom">A</SUB>. Despite its demonstrated antidepressant and anxiolytic activity, zuranolone was not approved in MDD by the FDA during its review of the product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAllo Overcomes Limitations of Allopregnanolone and its Synthetic Analogs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAllo is a novel, Glyphed oral prodrug of allopregnanolone designed to increase the oral bioavailability of allopregnanolone. After oral
dosing, GlyphAllo is metabolized to the parent API, allopregnanolone, chemically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
identical to the endogenous neurosteroid, which we believe can overcome safety limitations of synthetic analogs of allopregnanolone. Additionally, we believe GlyphAllo may have additional
benefits compared to other MDD drugs, including a rapid onset of action, anxiolytic activity, and sleep-promoting effects. Paired with our expertise in designing and executing neuropsychiatry clinical trials, we believe we can overcome the
historical limitations seen in the development of allopregnanolone and its synthetic analogs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAllo Phase 1 and Phase 2a Trial in
Healthy Volunteers </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As initial proof of concept for GlyphAllo, we conducted a trial in 179 healthy volunteers to evaluate the safety,
tolerability and pharmacokinetics of GlyphAllo, which included both Phase 1 and Phase 2a portions. Phase 1 was a multi-part trial with single ascending, multiple ascending, and food effect parts with doses ranging from 70 mg to 1,000 mg daily for up
to 7 days. The primary endpoints of the Phase 1 portion of the trial were safety and tolerability. The goal of this trial was to demonstrate that orally dosed GlyphAllo can safely achieve therapeutically relevant exposures and demonstrate
pharmacodynamic effects consistent with allopregnanolone activity in the brain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Phase 1 trial, we observed that GlyphAllo resulted
in dose-dependent levels of allopregnanolone in plasma with no accumulation and minimal evidence of a clinically meaningful food effect. Across dose groups, the estimated time to peak exposure was between three to four hours, and the terminal
half-life after single or multiple doses was approximately 24 hours. Unlike synthetic analogs of allopregnanolone that can exhibit delayed elimination rates compared to endogenous allopregnanolone, levels of allopregnanolone dropped to 15% of Cmax
by eight hours post-dose following administration of GlyphAllo, which we believe will reduce or eliminate <FONT STYLE="white-space:nowrap">next-day</FONT> somnolence or drowsiness. Oral administration of GlyphAllo in the Phase 1 trial of GlyphAllo
achieved therapeutic exposure levels comparable to those that occur naturally during the third trimester of pregnancy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At these
therapeutically relevant levels, GlyphAllo also demonstrated pharmacodynamic effects consistent with allopregnanolone activity in the brain. These additional measures include increased beta electroencephalogram, or beta EEG, power versus placebo and
reduced saccadic eye velocity, or SEV, at four hours post dose, consistent with the pharmacology of IV allopregnanolone. Both allopregnanolone blood concentrations and brain activity signals peaked at <FONT STYLE="white-space:nowrap">3-5</FONT>
hours post-dose and declined by <FONT STYLE="white-space:nowrap">6-8</FONT> hours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GlyphAllo Provided Therapeutically Relevant
Allopregnanolone Exposures and Demonstrated Pharmacodynamic Effects </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01n38.jpg" ALT="LOGO" STYLE="width:6.25in;height:2.65275in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the primary endpoints of safety and tolerability, GlyphAllo was generally well-tolerated with no serious
or severe adverse events, or AEs, including no events of excessive sedation, altered state of consciousness, loss of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consciousness, <FONT STYLE="white-space:nowrap">pre-syncope,</FONT> syncope, falls, or suicidal ideation or behavior. These data were consistent with the safety profile seen in our extensive <FONT
STYLE="white-space:nowrap">non-clinical</FONT> dog toxicity studies. All treatment-related AEs were transient, mild or moderate, and were consistent with the known pharmacology profile of allopregnanolone. These events were generally dose- and
time-dependent, occurring more frequently at high doses and early in dosing. The most common AE was mild and transient somnolence, an <FONT STYLE="white-space:nowrap">on-target</FONT> effect of
GABA<SUB STYLE="font-size:75%; vertical-align:bottom">A</SUB>. Furthermore, Stanford Sleepiness Score, or SSS, scores returned to baseline by six hours post-dosing, and this effect decreased after Day 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the demonstration of therapeutically relevant plasma exposures of allopregnanolone and pharmacodynamic markers of allopregnanolone
activity in the brain observed in Phase 1, we evaluated an active, well-tolerated dose of GlyphAllo in an initial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in healthy volunteers. As
allopregnanolone is an anti-stress hormone and has demonstrated clinical efficacy in PPD, a form of major depression that is also characterized by high anxiety, we conducted a Phase 2a initial <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in Australia using a validated clinical model of anxiety in healthy volunteers called the Trier Social Stress Test, or TSST. This randomized, double-blind, placebo-controlled trial
evaluated a single dose of GlyphAllo (375 mg) or placebo given in the morning to 80 healthy volunteers. The TSST involves preparing a speech and delivering it in front of a panel of judges, followed by a mental math test judged by the panel.
Typically, participants will have a robust increase in salivary cortisol, the body&#8217;s primary stress hormone, in response to the TSST. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Design of Phase 2a Trial of GlyphAllo Using the TSST in Healthy Volunteers </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01n39.jpg" ALT="LOGO" STYLE="width:6.33333in;height:2.61556in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this trial, individuals receiving placebo exhibited a robust increase in salivary
cortisol in response to the TSST. In contrast, this increase in the physiological stress response was potently blunted by a single dose of GlyphAllo, with a <FONT STYLE="white-space:nowrap">p-value</FONT> of 0.0001, meeting the primary endpoint. To
date, the only approved or investigational psychiatric medication to demonstrate reduced salivary cortisol levels in response to the TSST is alprazolam, a benzodiazepine that has been marketed as Xanax. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GlyphAllo Potently Blunted Salivary Cortisol Response to the TSST </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g02n39.jpg" ALT="LOGO" STYLE="width:4.50667in;height:3.45in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Self-reported assessments of anxiety were also collected using the State-Trait Anxiety Inventory which
confirmed that the TSST transiently and modestly increased self-reported anxiety in both the placebo and GlyphAllo groups. These results are consistent with previous data showing that healthy volunteers are less likely to self-report anxiety
symptoms following the TSST compared to patients with an anxiety disorder, who may experience a heightened negative psychological response to social stress. These results are also consistent with previously published self-reported assessments during
the TSST using known anxiolytic drugs such as alprazolam in healthy volunteers, in which self-reported anxiety increased in both drug and placebo groups in response to the TSST. Treatment-emergent related adverse events occurring at &gt;5% were
somnolence (29% GlyphAllo vs. 13% placebo) dizziness (20% GlyphAllo vs. 3% placebo), and headache (7.3% GlyphAllo vs. 7.7% placebo), all of which were transient and mild or moderate in severity. No treatment-related severe or serious AEs were
reported. The results of these Phase 1 and Phase 2a trials support the continued development of GlyphAllo as a potential medicine for MDD with or without anxious distress.<B> </B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAllo Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> Trial in MDD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2025, we initiated the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT> trial of GlyphAllo in the United States and the EU in
adults with MDD with or without anxious distress. <FONT STYLE="white-space:nowrap">BUOY-1</FONT> is a global, randomized, double-blind, placebo-controlled trial with an open-label extension to evaluate the efficacy, safety, and tolerability of
GlyphAllo. Patients will be randomized to GlyphAllo or placebo during the double-blind period. In the active treatment arm, GlyphAllo will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be administered once daily at bedtime at flexible fixed doses ranging from 125 mg to 375 mg. On Day 42, patients completing the double-blind period will be eligible to enter a <FONT
STYLE="white-space:nowrap">six-week</FONT> open label extension, or OLE, trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Design of Phase 2b
<FONT STYLE="white-space:nowrap">BUOY-1</FONT> Trial of GlyphAllo in MDD </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01f07.jpg" ALT="LOGO" STYLE="width:6.33333in;height:2.02269in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have included a prespecified sample size re-estimation, or SSRE, in BUOY-1 with the aim of optimizing
the sample size in the trial. We expect to receive topline data from BUOY-1 in the first half of 2027, and this anticipated timing is based on the full sample size of up to approximately 360 patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To further evaluate the safety profile of GlyphAllo in the BUOY-1 trial, we conducted intensive safety monitoring on approximately 40 patients
enrolled in the United States with oversight by a data monitoring committee, or DMC, as per protocol. In these patients, no events of loss of consciousness, syncope, excessive sedation, falls, or hypoxia were reported, and intensive safety
monitoring in BUOY-1 has been discontinued. There has been no intensive safety monitoring of patients enrolled in the EU. There is a full driving restriction for patients enrolled in the BOUY-1 trial in the United States, and a shorter, six-hour
driving restriction for patients enrolled in the EU. As part of the broader GlyphAllo development program, we plan to conduct additional studies, including a driving study, which we plan to initiate by the end of 2026, with data from that study
expected ahead of the topline readout of BUOY-1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect topline data from the Phase 2b <FONT STYLE="white-space:nowrap">BUOY-1</FONT>
trial in the first half of 2027. Based on the results of our Phase 2b clinical trial, we intend to consult with the FDA about the potential to use this trial to support our registrational filing for MDD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Opportunities to Expand the Potential for GlyphAllo in MDD and Other Indications </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the development and commercialization of GlyphAllo for the treatment of MDD with or without anxious distress is our primary focus, we
plan to evaluate GlyphAllo in additional indications as part of our longer-term growth strategy. For instance, since allopregnanolone is a rapidly acting antidepressant with anxiolytic and sleep-promoting effects, we may also evaluate GlyphAllo as a
treatment for other stress-related mood and anxiety disorders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GlyphAgo: Potential Differentiated Therapy for GAD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GlyphAgo is a novel, Glyphed oral prodrug of agomelatine that we are developing for the treatment of GAD. We are currently progressing a key
Phase 1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial of GlyphAgo in Australia in healthy volunteers in which we plan to enroll up to approximately 190 participants. Agomelatine, a clinically
validated melatonin receptor agonist and serotonin 2C receptor antagonist, is an effective anxiolytic and antidepressant approved for the treatment of GAD in Australia and MDD in Australia and the EU. With GlyphAgo, we aim to achieve the exposure
levels of agomelatine that are effective in GAD, but at a lower dose that reduces or eliminates the need for liver function testing, while creating new composition of matter IP.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g14k41.jpg" ALT="LOGO" STYLE="width:6.30571in;height:2.71143in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Background on GAD and Market Opportunity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the World Health Organization, anxiety disorders affect 359&nbsp;million people worldwide, as of 2021. Of these, 100&nbsp;million
adults suffer from GAD, including more than seven million adults in the United States, according to JAMA Psychiatry as of 2017. As there have been no new approved therapies for GAD in almost two decades, and the current standards of care for GAD are
characterized by modest efficacy, slow onset, and/or unfavorable side effects, there is a significant unmet need for novel treatments. GAD results in excessive, obsessive, and continuous stress to the point where patients are incapable of living
normal lives or carrying out standard daily routines. GAD patients typically have uncontrollable symptoms of restlessness, fatigue, inability to focus, irritability, muscle tension, and sleep disturbance. GAD places substantial strain on the broader
healthcare system, with patients with GAD having more than twice as many health care visits and almost nine times more mental health care visits than those without GAD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Current Standard of Care and Limitations in GAD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Anxiety &amp; Depression Association of America, as of 2025, more than approximately half of GAD patients do not receive
treatment, and those that do typically are prescribed SSRI or SNRI agents, which can have significant AEs including weight gain, sexual dysfunction, emotional blunting, and insomnia. These AEs, coupled with the observation that only half of patients
respond to these medications, lead many patients to pursue augmentation therapies including benzodiazepines, buspirone, gabapentin, mirtazapine, or antipsychotics&#8212;each with its own risks. For example, benzodiazepines are widely used and can
result in dependence and abuse in just a few weeks. Despite this, approximately 1 in 8 adults in the United States use benzodiazepines each year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Validation of Agomelatine in GAD</I><B><I> </I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Agomelatine is a clinically validated anxiolytic and antidepressant and is approved in Australia for the treatment of GAD. Agomelatine has
demonstrated clinical efficacy compared to placebo in four out of four third-party, randomized, placebo-controlled studies in GAD, and its efficacy in GAD is better than
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> drugs like benzodiazepines or SSRIs. These studies demonstrate a favorable efficacy and tolerability profile, with the only key exception being
dose-dependent elevations in liver enzymes in a small but notable percentage of patients. As a result, frequent liver function testing is required prior to and during use of agomelatine. Agomelatine is also approved in the EU and Australia for the
treatment of MDD, but it has never been approved in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The favorable efficacy and safety profile of agomelatine in GAD is
supported by a recent meta-analysis of 22 pharmacological treatments evaluated in randomized trials of adult outpatients with GAD. This non-head-to-head, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
literature meta-analysis, which was based on data collected from 25,441 patients across 89 trials, including two placebo-controlled trials of agomelatine, found that agomelatine demonstrated
superior efficacy compared to SSRIs and benzodiazepines. In addition, agomelatine demonstrated a superior tolerability profile compared to both benzodiazepines, which have abuse potential, and SSRIs, which can have significant AEs, including
insomnia, sexual dysfunction, emotional blunting, weight gain, and even withdrawal symptoms in the event of discontinuation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
favorable efficacy and safety profile of agomelatine in GAD is also supported by a recent systematic review and network meta-analysis that aimed to assess the efficacy and tolerability of agomelatine versus approved medications for the treatment of
GAD. This non-head-to-head analysis was based on a total of 25 trials, including three placebo-controlled trials of agomelatine. Using the treatment rankings based on the network meta-analysis results, agomelatine was found to be the most favorable
drug in terms of both efficacy (measured by remission rate) and tolerability (measured by discontinuation due to AEs) among the analyzed competitors (venlafaxine, escitalopram, paroxetine, duloxetine, and pregabalin). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, agomelatine&#8217;s favorable tolerability profile consists of no statistically significant difference in overall adverse events or
dropout rate and no association with clinically significant somnolence compared to placebo. Agomelatine does not cause sexual dysfunction. Specifically, no deleterious effect on sexual function was observed during agomelatine treatment over 12 or <FONT
STYLE="white-space:nowrap">24-week</FONT> treatment periods in a specific sexual dysfunction comparative trial in remitted depressed patients. Agomelatine also does not exhibit the &#8220;hangover&#8221; effects (e.g., lethargy, fatigue, decreased
motivation, anxiety, etc.) caused by various antidepressants and antipsychotics. Agomelatine, in a head-to-head study conducted by a third-party, also improves sleep latency, sleep architecture, and daytime sleepiness compared to escitalopram
(SSRI), which can worsen sleep and cause insomnia. This makes agomelatine well-suited for GAD, where sleep disturbance is a core symptom. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Agomelatine Improves Sleep Compared to Escitalopram (SSRI) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01k38.jpg" ALT="LOGO" STYLE="width:6.305in;height:4.13108in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Quera-Salva, Maria-Antonia, et al. (2011) Comparison of agomelatine and escitalopram on nighttime sleep and
daytime condition and efficacy in major depressive disorder patients. International clinical psychopharmacology, 26(5), 252-262 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite
the superior tolerability profile of agomelatine, clinical uptake has been limited by the requirement for frequent liver function monitoring. Due to extensive first-pass liver metabolism, the oral bioavailability of agomelatine is very low (~1%),
and the frequency of liver transaminase elevations with agomelatine treatment is two to five-fold greater than placebo. As a result, patients in Australia and the EU&#8212;where agomelatine is approved&#8212;are required to undergo frequent liver
function tests. Specifically, liver function tests must be performed before starting treatment, after 3, 6, 12, and 24 weeks, and when increasing dose. This burdensome liver testing, combined with a lack of patent protection, has limited clinical
and commercial adoption of agomelatine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph enables bypass of liver first-pass metabolism, improving oral bioavailability and enabling
the potential to achieve therapeutic exposures at a lower dose. As the increases in liver transaminase levels observed with agomelatine are dose-dependent, our goal is to achieve the exposure levels of agomelatine that are effective in GAD, but at a
higher bioavailability and thus lower dose that reduces or eliminates the need for liver function testing. Based on internal analyses, we believe a <FONT STYLE="white-space:nowrap">two-fold</FONT> increase in the bioavailability of agomelatine will
reduce or eliminate liver enzyme elevations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Agomelatine Can Cause Dose-Dependent Liver Enzyme Elevations </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g48a48.jpg" ALT="LOGO" STYLE="width:6.11111in;height:3.83437in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAgo in Preclinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As validation for GlyphAgo and further validation for our Glyph platform, we conducted in vivo studies in NHPs to evaluate the potential for
GlyphAgo to achieve therapeutic exposure levels at a lower dose that may reduce or eliminate the need for liver function testing. In these studies, we dosed NHPs with either GlyphAgo or an equivalent (i.e., equimolar) amount of agomelatine alone
(Dose A), or a greater dose of GlyphAgo (Dose B). GlyphAgo was shown to enhance lymphatic absorption and provide significantly higher systemic exposures of agomelatine compared to agomelatine alone. Oral dosing of GlyphAgo in a rat model resulted in
over 50% of agomelatine being transported through the mesenteric lymphatics versus less than 1% for orally dosed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agomelatine alone. Following administration of agomelatine alone, levels of agomelatine in plasma were below the limit of quantification, consistent with the low oral bioavailability of
agomelatine in humans and NHPs (Valdoxan EPAR). In contrast, administration of GlyphAgo substantially increased plasma exposures of agomelatine compared with agomelatine alone, demonstrating the potential of GlyphAgo to achieve therapeutic exposures
of agomelatine while minimizing the dose impacting the liver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GlyphAgo Substantially Increased Plasma Agomelatine Levels in <FONT
STYLE="white-space:nowrap">Non-Human</FONT> Primates </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g14k43.jpg" ALT="LOGO" STYLE="width:4.54333in;height:3.92253in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the therapeutic exposures achieved with GlyphAgo in our NHP studies, we modelled the clinical
implications of these data with respect to potential liver enzyme elevations using DILIsym, an analytical, computational model-based software capable of predicting and explaining Drug-Induced Liver Injury, or DILI. The FDA uses and cites DILIsym in
drug approvals as the standard software for the quantitative prediction and investigation of DILI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One useful output of DILIsym is an
eDISH (Evaluation of Drug-Induced Serious Hepatotoxicity) plot. eDISH plots are a standard way that the FDA evaluates liver safety of new drug candidates in clinical trials. eDISH graphs the peak serum alanine aminotransferase (ALT; a liver enzyme)
value and peak serum bilirubin value observed in each patient (or simulated patient) in a clinical trial along the <FONT STYLE="white-space:nowrap">x-axis</FONT> and <FONT STYLE="white-space:nowrap">y-axis,</FONT> respectively. Each patient (or
simulated patient) is represented by a single point on the graph, and liver enzyme elevations (&gt;3x upper limit of normal) are indicated by the presence of points on the right half of the graph. We first simulated the relationship between
agomelatine dose and liver enzyme elevations using available clinical data for two approved doses of agomelatine (25 and 50 mg). Next, we simulated potential liver enzyme elevations following administration of GlyphAgo at doses designed to generate
comparable systemic exposures of agomelatine, using assumptions derived from our in vivo study in NHPs described above. The results are shown in the four eDISH plots below. The eDISH plots in the upper row represent approved doses of agomelatine (25
mg and 50 mg) and recapitulate the liver enzyme elevations observed in previous clinic trials of agomelatine. The eDISH plots in the lower row represent doses of GlyphAgo with enhanced bioavailability and thus lower doses of agomelatine, which in
contrast show no liver enzyme elevations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DILIsym Simulations Demonstrate that GlyphAgo is Not Projected to Cause Liver Enzyme
Elevations </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g00n44.jpg" ALT="LOGO" STYLE="width:6.334in;height:3.914in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, our DILIsym simulations demonstrated that, with conservative estimates, clinically relevant
doses of GlyphAgo are not projected to cause liver enzyme elevations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan of GlyphAgo in GAD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are advancing a Phase 1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial of GlyphAgo
in healthy adult volunteers in which we plan to enroll up to approximately 190 participants, that we believe has the potential to be proof of concept, in addition to addressing key development questions for the GlyphAgo program. In this trial, we
aim to demonstrate that GlyphAgo can achieve exposure levels that have demonstrated efficacy in GAD at a lower dose that does not cause an increase in liver enzymes and reduces or eliminates the need for liver function testing. This Phase 1 trial
will be conducted in multiple parts to evaluate the safety, tolerability, and pharmacokinetics of GlyphAgo compared to agomelatine. The primary endpoints will be safety, tolerability, and pharmacokinetics. It will include single- and
multiple-ascending dose phases, as well as a food-effect crossover portion, using both open-label and placebo-controlled designs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
April 2026, we reported topline data from the SAD and crossover portions of our Phase&nbsp;1 proof-of-concept clinical trial of GlyphAgo. In the head-to-head crossover portion of the trial, GlyphAgo demonstrated a 6.8-fold increase in
bioavailability of agomelatine compared to unmodified orally administered agomelatine. GlyphAgo also showed significantly lower (10-fold) PK variability compared to unmodified agomelatine. The crossover portion included participants who were taking
estrogen-containing oral contraceptives that are known to increase agomelatine exposure due to liver drug-drug interaction. In contrast, GlyphAgo exposure was unaffected by oral contraceptives, further supporting the ability of GlyphAgo to bypass
first -pass liver metabolism. GlyphAgo demonstrated a 9.6 to 14.5-fold increase in dose-normalized exposure compared to agomelatine in a separate SAD portion of the trial in which no participants were on oral contraceptives. GlyphAgo was well
tolerated and no liver-related AEs were observed. We plan to initiate a Phase&nbsp;2a proof-of-pharmacology trial designed to evaluate the potential sleep benefit of GlyphAgo in patients with GAD and sleep disturbance, with topline data expected in
early 2028. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GlyphAgo<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Exceeded Target of
Two-Fold Increase in Bioavailability Compared to Unmodified Agomelatine </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g01f08.jpg" ALT="LOGO" STYLE="width:5.66667in;height:2.96667in;">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">Figure 1. Exposure (AUC<SUB STYLE="font-size:75%; vertical-align:bottom">0-24</SUB>) of agomelatine produced by agomelatine 25 mg (ago 25 mg) or three dose levels of GlypgAgo (containing 2.5 mg, 5mg, and 10 mg of Agomelatine
respectively) from the single ascending dose (SAD) portion of study (SPT-320-2024-101). GlyphAgo demonstrated a 9.6-14.5-fold increase in dose-normalized AUC compared to agomelatine. Horizontal line represents geometric mean.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Figure 2. Exposure (AUC<SUB STYLE="font-size:75%; vertical-align:bottom">0-24</SUB>) of agomelatine produced by a single dose of Agomelatine 25 mg (Ago 25 mg) or single dose of GlyphAgo (containing 10mg of Agomelatine) from the
crossover portion of study SPT-320-2024-101. In this portion of the trial, exposure provided by GlyphAgo and&nbsp;unmodified agomelatine were compared head-to-head within the same participants. GlyphAgo demonstrated a 6.8-fold increase in
does-normalized AUC compared to agomelatine (90% confidence interval, 4.7 to 10.0x; geometric means). Horizontal line represents geometric mean.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2a and Phase 2b trials of GlyphAgo </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to initiate a Phase 2a proof-of-pharmacology trial designed to evaluate the potential sleep benefit of GlyphAgo in patients with GAD
and sleep disturbance, with topline data expected in early 2028. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also plan to initiate in parallel, a randomized, double-blind,
placebo-controlled Phase 2b trial evaluating the efficacy and safety of GlyphAgo in patients with GAD, with topline data expected by the end of 2028. This multiregional trial is designed to be registration-enabling, subject to review by the FDA and
other comparable regulatory authorities, as an adequate and well-controlled investigation that seeks to provide substantial evidence of effectiveness by assessing GlyphAgo&#8217;s efficacy and safety in several hundred patients. Although this trial
is designed to be registration-enabling, additional clinical trials may be required prior to the submission of a new drug application even if this trial is successful or positive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Opportunities to Expand the Potential for GlyphAgo in GAD and Other Indications </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the development and commercialization of GlyphAgo for the treatment of GAD is our primary focus, as part of our longer-term growth
strategy, we may evaluate GlyphAgo in other indications as well, including MDD. Indeed, agomelatine is approved for MDD in Australia and the EU, but it is constrained by similar liver function testing requirements in MDD as well. As agomelatine also
improves sleep latency, sleep quality, and daytime sleepiness compared to SSRIs, which can worsen sleep and cause insomnia, we may also evaluate GlyphAgo for the treatment of insomnia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Glyph2BLSD: <FONT STYLE="white-space:nowrap">Non-Hallucinogenic</FONT> Neuroplastogen </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glyph2BLSD is our novel, Glyphed oral prodrug of the <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> neuroplastogen <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD,</FONT></FONT> which we are developing for the treatment of depressive disorders, including TRD, PTSD, and headache disorders with significant unmet need. Neuroplastogens are
compounds that enhance neuroplasticity, the brain&#8217;s ability to form, reorganize, and strengthen neural connections, and include psychedelics and ketamine. They offer the potential to repair disrupted brain circuits and have demonstrated
efficacy for treating neuropsychiatric disorders. However, significant challenges remain, including functional unblinding of clinical trials due to the production of hallucinations and sensory disturbances, the accompanying need for supervised
administration, and concerns over long-term safety, such as the risk of fibrosis. Leveraging our Glyph platform, we have designed Glyph2BLSD to harness the differentiated and non-hallucinogenic profile of 2-bromo-LSD, which has rapidly acting
clinical activity and is not expected to exhibit the risks of fibrosis, cardiovascular effects, or hallucinations characteristic of some other neuroplastogens. With Glyph2BLSD, we aim to improve the pharmacokinetic and tolerability profile of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD</FONT></FONT> while maintaining therapeutic exposure levels, and enable the execution of placebo-controlled trials, outpatient dosing, and an enhanced dosing regimen to optimize
efficacy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Development Plan of Glyph2BLSD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This candidate is in the early stages of development. We are currently conducting first-in-human-enabling studies of Glyph2BLSD, including
single- and repeat-dose toxicology studies, in addition to in vitro and in vivo assays to further characterize Glyph2BLSD. We expect to complete first-in-human-enabling studies by the end of 2027. We then expect to initiate a Phase&nbsp;1 trial to
evaluate the safety, tolerability and pharmacokinetics of Glyph2BLSD in healthy volunteers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Potential Indications for Glyph2BLSD
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approximately 3&nbsp;million adults in the United States have TRD, according to The Journal of Clinical Psychiatry, as of 2021. Unlike
MDD, which, according to the National Institute of Mental Health, as of 2021, impacts an estimated 21&nbsp;million adults annually, TRD is characterized by the failure to achieve an adequate response after two or more antidepressant treatments.
Patients with TRD face severe challenges, including a significantly lower likelihood of responding to subsequent therapies, a reduced quality of life, and an increased risk of attempting suicide, more than double the rate seen in <FONT
STYLE="white-space:nowrap">non-resistant</FONT> depression. Many of these individuals experience chronic disability, relying heavily on social support systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PTSD affects approximately 12&nbsp;million individuals in the United States and is also characterized by significant unmet need. There are
currently only two approved therapies for PTSD, both of which are SSRIs. We believe Glyph2BLSD has the potential to restore function and improve outcomes to address the significant unmet medical need in TRD and PTSD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trigeminal autonomic cephalalgias, notably cluster headaches, are severe neurological conditions linked to the trigeminal nerve. Cluster
headaches affect approximately 150,000 patients in the United States and cause the most severe pain known to humans, greater than labor pain or gunshot wounds. Individuals with cluster headache experience intense pain and autonomic symptoms
including eye watering, swelling, and redness, as well as nose congestion. Headache attacks may last for up to 3 hours per episode and occur up to 8 times a day, disrupting patients&#8217; lives. Cluster headache has also been called &#8220;suicide
headache&#8221; due to the increased risk of suicide during headache periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A small trial by Karst et al. showed that three doses of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD</FONT></FONT> over a <FONT STYLE="white-space:nowrap">10-day</FONT> period significantly reduced the frequency and intensity of chronic cluster headaches, with effects lasting
weeks to months. Importantly, the treatment did not induce hallucinations, making it a safer alternative to traditional psychedelics. While the trial was not placebo-controlled, and thus requires additional clinical investigation, we believe that
Glyph2BLSD has the potential to optimize the pharmacokinetics of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-bromo-LSD</FONT></FONT> to ensure precise and sustained dosing, while preserving its
<FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> profile. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage therapeutics company focused on inventing and developing novel medicines for patients with depression, anxiety, and
other debilitating neuropsychiatric disorders. While we believe our Glyph platform can produce small molecules that offer an attractive alternative to branded and generic therapeutics treating neuropsychiatric diseases if they are approved, today we
face competition from major pharmaceutical and biopharmaceutical companies, academic institutions, governmental agencies, consortiums, and public and private research institutions, among others. Many of our potential competitors, either alone or
with collaboration partners, have significantly greater financial resources than we do, as well as equal or greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of products, and the
commercialization of those products. Accordingly, our potential competitors may be more successful than we are in achieving regulatory approvals and commercializing their neuropsychiatric products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the key competitive factors affecting the success of our lead product candidates GlyphAllo and GlyphAgo, that we are developing to
address MDD and GAD, respectively, if approved, are likely to be efficacy, safety, and frequency of dosing, convenience, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing GlyphAllo for the treatment of MDD. We believe, if approved, that GlyphAllo would compete with several currently
approved therapeutics, including: Caplyta and Spravato (marketed by Janssen Pharmaceuticals), Vraylar (AbbVie and Gideon Richert Plc.), Trintellix (Takeda Pharmaceuticals and Lundbeck), Auvelity (Axsome Therapeutics), and Rexulti and Abilify (Ostuka
Pharmaceuticals). We are also aware of multiple potentially competitive late-clinical-stage assets, including azetukalner (Xenon Pharmaceuticals), <FONT STYLE="white-space:nowrap">ALTO-300</FONT> and <FONT STYLE="white-space:nowrap">ALTO-203</FONT>
(Alto Neuroscience) and CYB003 (Cybin). We also face competition from branded and generic atypical antipsychotics and SSRI/SNRIs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
developing GlyphAgo for the treatment of GAD. We believe, if approved, that GlyphAgo would compete with several currently marketed therapeutics, including: Lyrica and Buspirone (marketed by Viatris) and marketed generic SSRI/SNRIs and
benzodiazepines. In relation to both GlyphAgo and Glyph2BLSD, we are also aware of multiple potentially competitive late-clinical-stage assets, including an LSD program (Mind Medicine, MindMed), <FONT STYLE="white-space:nowrap">ENX-102</FONT>
(Engrail Therapeutics), CYB004 (Cybin), and <FONT STYLE="white-space:nowrap">non-hallucinogenic</FONT> neuroplastogens (Gilgamesh Pharma and AbbVie). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to
protect the proprietary technology, inventions and improvements that are commercially important to the development of our business, by seeking, maintaining and standing ready to defend patent rights, whether developed internally or licensed from
third parties. We also rely on trademarks, trade secrets and other intellectual property rights relating to our proprietary Glyph platform and product candidates, and on continuing technological innovation and
<FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen and maintain our proprietary and intellectual property position. We may also rely on regulatory and other protections afforded through data and marketing
exclusivities, where available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to protect the intellectual property and proprietary technology that we consider important to our
business by pursuing patent applications that cover our technologies (including the Glyph platform) and product candidates and methods of using the same, as well as any other relevant inventions and improvements that are considered commercially
important to the development of our business. We likewise seek to protect the intellectual property to which we obtain rights through licenses and sublicenses and work collaboratively with our licensors to ensure patent prosecution and protection.
Our commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for our product candidates, commercially important technologies (including the Glyph platform), inventions and trade secrets
related to our business, defend and enforce our intellectual property rights, particularly our patent rights and any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future, preserve the confidentiality of our trade
secrets and operate without infringing valid and enforceable intellectual property rights of others. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions for therapeutics companies like us are generally uncertain and can
involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a
result, we cannot guarantee that any of our product candidates will be protectable or remain protected by enforceable patents that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future. We cannot predict whether the
patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be
challenged, circumvented or invalidated by third parties. Notwithstanding the scope of the patent protection available to us, a competitor could develop competitive technologies and products that are not covered by our patents, and we may be unable
to stop such competitor from commercializing such technologies and products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio includes a combination of patents and
pending patent applications solely owned by us or <FONT STYLE="white-space:nowrap">co-owned</FONT> with Monash University where Monash University&#8217;s rights are exclusively licensed to us, and patents and pending patent applications owned by
Monash University that are exclusively licensed to us. As of April 1, 2026, our owned and exclusively licensed patent estate contains eight patent families comprising five issued U.S. patents, fourteen issued patents in Australia, Canada, China,
Europe (validated in Great Britain and through a Unitary Patent in Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Romania, Slovenia, and Sweden), Japan and
New Zealand, eight pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, two allowed European applications, 40 pending patent applications in various jurisdictions outside of the U.S., as further described below,
and three pending PCT international applications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAllo Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the Glyph platform patents and applications discussed below, as of April 1, 2026, with regard to the GlyphAllo program, we <FONT
STYLE="white-space:nowrap">co-own</FONT> with and exclusively license from Monash University one issued U.S. patent relating to composition of matter coverage of GlyphAllo, which is expected to expire in 2041. We also
<FONT STYLE="white-space:nowrap">co-own</FONT> with and exclusively license from Monash University two pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, one allowed European application, one issued Japanese
patent and 21 pending patent applications in Australia, Canada, China, Europe, Hong Kong, India, Israel, Japan, Korea, New Zealand, and Singapore, relating to the composition of matter and methods of treatment which, if issued, will be expected to
expire between 2039 and 2041. The foregoing expiration dates may not account for potentially available patent term adjustments or extensions and terminal disclaimers, and assume payment of all appropriate maintenance, renewal, and annuity fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also solely own one international patent application filed under the Patent Cooperation Treaty (PCT) directed to methods of treating MDD
with and without anxious distress using our GlyphAllo product candidate. We expect that any issued patents claiming priority to this application will expire in 2044, without taking into account any possible patent term adjustments or extensions and
if all maintenance and annuity fees are paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any other Company has composition of matter patent protection on the parent
molecule or the unmodified, non-glyphed form of allopregnanolone. Allopregnanolone, a naturally occurring neuroactive steroid, has no composition-of-matter patent protection in the United States or globally. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GlyphAgo Program </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to the Glyph platform patents and applications discussed below, we also solely own one international patent application filed under the PCT, directed to the composition of matter of our GlyphAgo product candidate and its use. We expect that
any issued patents claiming priority to the international patent application will expire in 2044, without taking into account any possible patent term adjustments or extensions and if all maintenance and annuity fees are paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any other Company has composition of matter patent protection on the parent
molecule or the unmodified, non-glyphed form of agomelatine. The composition-of-matter patents for agomelatine have expired in the United States and worldwide between 2010 and 2012. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Glyph2BLSD Program </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to the Glyph platform patents and applications discussed below, we also solely own one international patent application filed under the PCT, directed to the composition of matter of our Glyph2BLSD product candidate and its use. We expect
that any issued patents claiming priority to this international patent application will expire in 2044, without taking into account any possible patent term adjustments or extensions and if all maintenance and annuity fees are paid. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Glyph Platform </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With
regard to the Glyph platform, we exclusively license from Monash University two issued U.S. patents, twelve issued patents in Australia, Canada, China, Europe (validated in Great Britain and through a Unitary Patent in Austria, Belgium, Bulgaria,
Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Romania, Slovenia and Sweden), Japan, and New Zealand, and one allowed European patent application, relating to platform coverage of
GlyphAllo, GlyphAgo and Glyph2BLSD, as well as design-around coverage, which are expected to expire between 2035 and 2037. We also exclusively license from Monash University four pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT>
patent applications and 15 pending patent applications in Australia, Canada, China, Europe, Hong Kong, Japan, and New Zealand, relating to platform coverage of GlyphAllo, GlyphAgo and Glyph2BLSD, as well as design-around coverage, which are expected
to expire between 2035 and 2036 We also <FONT STYLE="white-space:nowrap">co-own</FONT> and exclusively license from Monash University two issued U.S. patents, two pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent
applications and four pending patent applications in Australia, Canada, Europe, and Hong Kong, relating to platform coverage of Glyph2BLSD, as well as design-around coverage, which are expected to expire in 2039. The foregoing expiration dates may
not account for potentially available patent term adjustments or extensions and terminal disclaimers, and assume payment of all appropriate maintenance, renewal, and annuity fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in
which we file, the patent term is 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which
compensates a patentee for administrative delays by the United States Patent and Trademark Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier expiring patent. Our patent applications
may not issue as patents, and even if issued, the scope or term of any issued patent may not afford sufficient protection or competitive advantage to our existing or future products. See the section titled &#8220;Risk Factors&#8212;Risks related to
our intellectual property&#8221; for a more comprehensive description of risks related to our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United
States, the term of a patent covering an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review
process. The period of extension may be up to five years beyond the expiration of the patent, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an
extension may be extended, and a given patent may only be extended once. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. If our product candidates receive FDA
approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We also intend to seek patent term extensions in any jurisdictions where they are available, however,
there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January 15, 2026, we have no outstanding litigation related to our intellectual
property nor any threat to initiate claims against us. In the future, we may need to engage in litigation to enforce patents issued or licensed to us, to protect our trade secrets or <FONT STYLE="white-space:nowrap">know-how</FONT> or to defend
against claims of infringement of the rights of others. Such litigation could be costly and could divert our attention from other functions and responsibilities. We may not receive adequate remedies even if we prevail in such litigation and adverse
determinations could subject us to significant liabilities to third parties, which could severely harm our business. See the section titled &#8220;Risk Factors&#8212;Risks related to our intellectual property&#8221; for a more comprehensive
description of risks related to our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we rely on intellectual property rights, including patents,
trademarks and trade secrets, as well as contractual protections to establish and protect our proprietary rights, we believe that factors such as the technological and creative skills of our personnel, creation of new solutions, features and
functionality, and frequent enhancements to our platform are also essential to establishing and maintaining our technology leadership position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secret protection for our
proprietary information to develop and maintain our proprietary position. However, trade secrets can be difficult to protect. Although we take steps to protect our proprietary information, including restricting and monitoring access to our premises
and our confidential information, as well as entering into agreements with our employees, consultants, advisors and potential collaborators, third parties may independently develop the same or similar proprietary information or may otherwise gain
access to our proprietary information. As a result, we may be unable to meaningfully protect our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secret information. See the section titled &#8220;Risk Factors&#8212;Risks related to our
intellectual property&#8221; for a more comprehensive description of risks related to our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we plan to
rely on regulatory protection based on orphan drug exclusivities, data exclusivities, and market exclusivities. See the section titled &#8220;&#8212;Government Regulation&#8221; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we have and will continue to pursue trademark protection for our company name and brand. As of April 6, 2026, we own seventeen
pending trademark applications in the United States and foreign jurisdictions, including eight allowed trademarks in the United States, and one registered trademark in Australia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Asset Transfer Agreement with PureTech
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, we entered into an Asset Transfer Agreement, as amended in December 2025, or the Asset Transfer Agreement, with
PureTech Health LLC, or PureTech Health, and PureTech LYT, Inc., or PureTech LYT, pursuant to which PureTech Health and PureTech LYT agreed to contribute, convey, assign, transfer, and deliver to us all of PureTech Health&#8217;s and PureTech
LYT&#8217;s right, title, and interest in, to, and under the assets related to its Glyph technology or products, including the Monash License Agreement and the exclusive patents thereunder, subject to the terms set forth in the Asset Transfer
Agreement. In exchange, we issued 40,000,000 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 302,161 shares of our common stock to PureTech LYT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Transfer Agreement, we have agreed to make milestone payments for the first product covered by assets transferred
through the Asset Transfer Agreement, or the first Seaport Glyph Product, of $2.0 million for the first patient dosed in the first phase 3 clinical trial, $4.0 million for the first commercial sale in the United States, $2.0 million for the first
commercial sale in a major European market, and $2.0 million for the first commercial sale in Japan, and for each subsequent Seaport Glyph Product, we have agreed to make milestone payments of $1.0 million for the first patient dosed in the first
phase 3 clinical trial, $2.0 million for the first commercial sale in the United States, $1.0 million for the first commercial sale in a major European market, and $1.0 million for the first commercial sale in Japan. In addition, we are obligated to
pay royalties between 3% and 5% on the annual net sales of each Seaport Glyph Product as follows: less than $500 million: 3%; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$500&nbsp;million to $1 billion: 3.5%; $1&nbsp;billion to $2.5 billion: 4%; $2.5&nbsp;billion to $3.5 billion: 4.5%; $3.5&nbsp;billion or greater: 5%. The royalty term will expire on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis as to each Seaport Glyph Product on the later of the ten year anniversary of the first commercial sale of such Seaport Glyph Product in such country
or the date on which the last valid claim of patent rights of such Seaport Glyph Product expires in such country. As of the date of this filing, the last-to-expire patents under the Asset Transfer Agreement expire in 2044, not including any patent
term extension or patent term adjustment. We may update or revise the year of the last-to-expire patents as the transferred assets under the Asset Transfer Agreement include patents exclusively licensed under the Monash License Agreement which
covers, in addition to a prespecified list, any patent or patent application that claims new intellectual property created under any research agreement entered into with Monash University. Please refer to the Monash License Agreement summary below
for further information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we license or sublicense to a third-party a product directed to an indication that is primarily
affecting or manifesting in the brain, spinal cord, or peripheral nervous system (with the exception of and not including the enteric nervous system), including neurological, psychiatric, neuropsychiatric, pain, mental, and behavioral indications
made using our Glyph platform under the Glyph intellectual property, transferred to us through the Asset Transfer Agreement, we have also agreed to pay a&nbsp;percentage of net income we receive from such third party under such a license within the
range of 5%<B></B>-7.5% and adjusted depending on the date such a license is granted, with the amount to be paid subject to certain reductions. Any such amount of net income are creditable against royalty payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Asset Transfer Agreement, PureTech may from time to time request that we grant it a license under the Glyph technology to utilize
certain products directed to an indication that is not primarily affecting or manifesting in the brain, spinal cord, or peripheral nervous system (such as, for example, neurological, psychiatric, neuropsychiatric, pain, mental, and behavioral
indications) under license terms that have already been agreed to by PureTech and us in the Asset Transfer Agreement; provided that such products (i) are not subject to an agreement, or we are not actively engaged in negotiations, with a third party
that would prevent us from granting such license, (ii) are not the subject of an internal research and development program, and (iii)&nbsp;have not been demonstrated or under experimental investigation by us to be potentially useful as a therapeutic
for any disease, disorder, or condition primarily affecting or manifesting in the brain, spinal cord, or peripheral nervous system. PureTech&#8217;s right to request such a license terminates upon a change of control of either PureTech or us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the upfront equity grant, we have not made any payments to date pursuant to the Asset Transfer Agreement. Should we sell our first
controlled affiliate that has exclusive rights to utilize any Seaport Glyph Product, we will be obligated to pay a low double-digit percentage, within the range of 5% to 15%, of the value of the aggregate amount of all change of control
consideration paid to us.<B><I> </I></B>We will not be obligated to pay any fee under the Asset Transfer Agreement in the event of a sale of the Company or any other subsequent controlled affiliate. The Asset Transfer Agreement closed on
April&nbsp;8, 2024, and it is not contractually permissible to terminate the Asset Transfer Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Monash University Exclusive License
Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, PureTech Health exclusively assigned to us, and we assumed, all rights and obligations under the Original
License Agreement. In March 2025, we entered Monash License Agreement. Pursuant to the Monash License Agreement, Monash University grants us (i)&nbsp;a worldwide, exclusive, sublicensable license under certain Monash University intellectual property
rights, including patent rights related to the Glyph platform, or the Licensed Patents, <FONT STYLE="white-space:nowrap">know-how,</FONT> and intellectual property stemming from joint research and development activities, for the purpose of
developing and commercializing products in all fields with one exception, (ii)&nbsp;a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable license under certain background technology and certain other intellectual property
strictly to the extent necessary to exercise the license described in subclause (i)&nbsp;above, and (iii)&nbsp;a first right and an exclusive option to obtain an exclusive license to any invention generated by Monash University outside of the
Licensed Patents and pertaining to certain prodrug technology. Additionally, we and Monash University agreed to collaborate in conducting research and development activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Monash License Agreement, we have agreed to use reasonable commercial endeavors to
(i)&nbsp;develop at least one Licensed Product, (ii)&nbsp;seek regulatory approval for at least one Licensed Product, and (iii)&nbsp;after receipt of such regulatory approval in the United States or Europe, promote and develop the sale of at least
one Licensed Product in such territory. Monash University agrees to provide reasonable technical assistance and advice based on Monash University&#8217;s <FONT STYLE="white-space:nowrap">know-how</FONT> relating to the technology licensed under the
Monash License Agreement. We grant Monash University a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, royalty-free license under the Licensed Patents, related <FONT STYLE="white-space:nowrap">know-how,</FONT> and intellectual
property stemming from joint research and development activities solely for academic, teaching, and <FONT STYLE="white-space:nowrap">non-commercial</FONT> collaborative research uses, which includes the right to sublicense for <FONT
STYLE="white-space:nowrap">non-commercial</FONT> collaborative research to other academic institutions or <FONT STYLE="white-space:nowrap">non-commercial</FONT> research entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the licenses granted by Monash University, we are required to pay Monash University:
<FONT STYLE="white-space:nowrap">(i)&nbsp;low-single</FONT> digit royalties with a rate based on net sales per calendar year (subject to certain reductions); (ii) a <FONT STYLE="white-space:nowrap">low-double</FONT> digit percentage (within the
range of 5-15%)<B></B> of any net income received under a sublicense (subject to a license payment stacking reduction) with the percentage varying based on the development stage of the Licensed Products at the time the sublicense is granted during
the term of the Monash License Agreement; (iii)&nbsp;an agreed upon research funding amount to progress mutually agreed research and development or commercialization activities; (iv)&nbsp;a <FONT STYLE="white-space:nowrap">mid-five-figure</FONT>
annual maintenance fee during the term of the agreement commencing on the third anniversary of the execution date of the Original License Agreement until the first commercial sale of a Licensed Product creditable against net income sharing,
royalties, and milestone payments; (v)&nbsp;milestone payments in the event of successful development milestones of up to $1.075&nbsp;million per Licensed Product for the first three Licensed Products; and (vi)&nbsp;milestone payments in the event
of successful commercial milestones of up to $7.25&nbsp;million per Licensed Product for the first three Licensed Products. We are also obligated to (a)&nbsp;pay all costs incurred for the prosecution and maintenance of the Licensed Patents and
patent filings stemming from collaboration activities and (b)&nbsp;reimburse Monash University for all patent prosecution costs of the Licensed Patents prior to the execution date of the Original License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Monash License Agreement commenced on the execution date of the Original License Agreement and will expire seven years after the last of
the Licensed Patents expires, unless terminated earlier. Although the last-to-expire patent licensed under the Monash License Agreement currently expires in 2041, the year of the last-to-expire patent may change as the Monash License Agreement
covers, in addition to a prespecified list, any patent or patent application that claims new intellectual property created under any research agreement entered into with Monash University. Either party may terminate for due cause, including for
material breach and bankruptcy. Monash University may terminate if we fail to meet our diligence requirements. Either party may terminate the Monash License Agreement if we determine that the activities are no longer commercially viable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2025, the first two development milestones for a total of $0.2 million were achieved and paid by PureTech as they occurred
prior to our formation, and we have paid the third development milestone of $0.1 million as well as annual maintenance fees. No other milestones have occurred or have been paid under the Monash License Agreement as of December 31, 2025. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government
authorities in the United States, at the federal, state, and local level, and in other countries and jurisdictions, including the European Union, or EU, extensively regulate, among other things, the research, development, testing, manufacturing,
quality control, safety, effectiveness, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes
for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Review and Approval of Drugs in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the U.S. Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations.
The failure to comply with applicable U.S. requirements at any time during the product development process, approval process, or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including
refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, and other types of letters, product seizures, total or partial suspension of production or distribution,
injunctions, fines, product recalls, and other post-market actions, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations, and penalties brought by the FDA and the U.S. Department of Justice or
other governmental entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An applicant seeking approval to market and distribute a new drug product in the United States must
typically undertake the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of nonclinical, or preclinical, laboratory tests, animal studies, and formulation studies in
compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an investigational new drug application, or IND, which must take effect before human
clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an institutional review board, or IRB, representing each clinical site before each clinical trial may
be initiated at that site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or
GCPs, to establish the safety and efficacy of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission to the FDA of a New Drug Application, or NDA, and payment of user fees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review of the product by an FDA advisory committee, where appropriate or if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the
product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity,
strength, quality, and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of
the clinical data; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before an
applicant begins testing a compound in humans, the drug candidate enters the preclinical testing stage. Preclinical studies include, among other things, laboratory evaluation of the purity and stability of the manufactured drug substance or active
pharmaceutical ingredient, or API, and the formulated drug or drug product, as well as <I>in vitro</I> and animal studies to assess the potential safety and activity of the drug for initial testing in humans and to establish a rationale for
therapeutic use. The conduct of certain preclinical studies is subject to federal regulations and requirements, including GLP regulations. Some long-term preclinical testing, such as animal tests of reproductive adverse effects, or AEs, and
carcinogenicity, may continue after the IND is submitted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The IND and IRB Processes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IND is an exemption from the FDCA that allows an investigational drug to be shipped in interstate commerce for use in a clinical trial and a
request for FDA authorization to administer such investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of the investigational </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
drug. In an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments. In addition, the results of the preclinical tests, manufacturing information,
analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that
time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. The FDA also may impose a clinical hold or partial clinical hold after commencement of a clinical trial under an IND. A
clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND.
No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation (or
full investigation in the case of a partial clinical hold) may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the
deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor may choose, but is not
required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical trial is not conducted under an IND, the sponsor must
ensure that the study is conducted in accordance with GCP, among other things, including review and approval by an independent ethics committee and obtaining informed consent from subjects. The GCP requirements are intended to help ensure the
protection of human subjects enrolled in <FONT STYLE="white-space:nowrap">non-IND</FONT> foreign clinical trials, as well as the quality and integrity of the resulting data. FDA must also be able to validate the data from the study through an <FONT
STYLE="white-space:nowrap">on-site</FONT> inspection if necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing IND requirements, an IRB representing
each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review of the study at least annually. The IRB must review and
approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its
institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety
monitoring board or committee. This group provides advice to the sponsor as to whether or not a trial may move forward at designated check points based on <FONT STYLE="white-space:nowrap">pre-specified</FONT> criteria and access that only the group
maintains to available data from the study. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public
dissemination on its ClinicalTrials.gov website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Human Clinical Trials in Support of an NDA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCP requirements, which include, among other things, the requirement that all research subjects, or their legal representative, provide their informed consent in writing before their participation in any clinical trial. Clinical
trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 1</I>. The product candidate is initially introduced into healthy human subjects or, in certain
indications such as cancer, patients with the target disease or condition and tested for safety, dosage </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness, and to determine maximal dosage. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 2</I>. The product candidate is administered to a limited patient population with the specified disease
or condition to identify possible AEs and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases or conditions and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 3</I>. The product candidate is administered to an expanded patient population, generally at
geographically dispersed clinical trial sites, in well-controlled clinical trials with the intent to generate enough data to evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product
candidate and to provide adequate information for the labeling of the product. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval studies, sometimes
referred to as Phase 4 studies, may be conducted after initial regulatory approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate
the performance of Phase 4 clinical trials as a condition of approval of an NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the IND is active, progress reports detailing the
results of the clinical trials, among other information, must be submitted at least annually to the FDA. In addition, within 15 calendar days after the sponsor determines that the information qualifies for reporting, IND safety reports must be
submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or <I>in vitro</I> testing that suggest a significant risk in humans exposed to the drug; and any clinically
important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within
seven calendar days after the sponsor&#8217;s initial receipt of the information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies often
complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP
requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the applicant must develop methods for testing the identity, strength, quality, purity, and potency of
the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Review of an NDA by the FDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials,
together with detailed information relating to the product&#8217;s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more
indications. Under federal law, the submission of most NDAs is additionally subject to a significant application user fee as well as annual prescription drug product program fees. These fees are typically increased annually. Certain exceptions and
waivers are available for some of these fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct
pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, NDAs, and certain supplements must contain a pediatric assessment unless the
sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each
pediatric subpopulation for which the product is deemed safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons,
including a finding that the product candidate is ready for approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before any pediatric clinical trials begin. The FDA must send
a <FONT STYLE="white-space:nowrap">non-compliance</FONT> letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA conducts a preliminary review of an NDA within 60 days of its receipt, before accepting the NDA for filing, to determine whether the
application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted
application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review. The FDA reviews an NDA to determine, among
other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP compliant to assure and preserve the product&#8217;s identity, strength, quality, and purity. Under the performance goals and policies
implemented by the FDA under the Prescription Drug User Fee Act, or PDUFA, FDA has agreed to specified performance goals in the review process of NDAs. Applications for drugs containing new molecular entities are meant to be reviewed within 10
months from the date of filing, and applications for &#8220;priority review&#8221; products containing new molecular entities are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional
months if FDA requests or the applicant otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date or is otherwise deemed a &#8220;major
amendment&#8221; to the application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During its review of an NDA, the FDA typically will inspect the facility or facilities where the
product is or will be manufactured. These <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections may cover all facilities associated with an NDA, including drug component manufacturing (such as APIs), finished drug product manufacturing,
and control testing laboratories. The FDA will not approve an NDA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within
required specifications. In addition, the FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a condition of approval, the FDA may require an applicant to develop a risk evaluation and mitigation strategy, or REMS. REMS
use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the
product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential AEs, and whether the product is a new molecular entity. REMS can include medication guides, physician
communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances,
special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an
advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is
not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fast
Track, Breakthrough Therapy, and Priority Review </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has a number of programs intended to facilitate and expedite development and
review of investigational drugs if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. Three of these programs are referred to as Fast Track Designation, Breakthrough Therapy
Designation, and priority review designation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">First, the FDA may designate a product candidate for Fast Track review if it is intended,
whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such disease or condition. For Fast Track
product candidates, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product candidate&#8217;s application before the application is complete. This rolling review may be available if the
FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product candidate may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining
information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track
Designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Second, a product candidate may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more
other drugs products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically
significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy Designation includes all of the benefits associated with Fast Track Designation, including the potential for rolling review of
an NDA submission. In addition, the FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding
development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third, the FDA may designate an NDA review for a priority review if it is for a product candidate that treats a serious or life-threatening
disease or condition and, if approved, would provide a significant improvement in safety or effectiveness compared to available therapies. The FDA determines, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, whether the product candidate may represent a significant improvement when compared with other available therapies. Significant improvement may be
illustrated, among other things, by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to
improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s
goal for taking action on a marketing application from 10 months to six months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Accelerated Approval Pathway </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may grant accelerated approval to a product candidate intended to treat a serious or life-threatening condition that provides
meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on an intermediate clinical
endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the
condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical
sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is
a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints,
but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the
therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accelerated approval pathway is often used in settings in which the course of a disease
is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accelerated approval pathway is typically contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional
post-approval confirmatory studies to verify and describe the product&#8217;s anticipated clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the
completion of Phase 4 or other post-approval clinical trials to verify and describe the anticipated the effect on the clinical endpoint. Under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is permitted to require, as appropriate,
that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Sponsors are also required to send updates to the FDA every 180 days on the status of such
studies, including progress toward enrollment targets, and the FDA must post this information publicly. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated
approval if, for example, the sponsor fails to conduct such studies in a timely manner and send the necessary updates to the FDA, or if a confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA
generally requires, unless otherwise informed by the agency, <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials for product candidates approved under accelerated regulations, which could adversely impact the timing of the
commercial launch of the product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA&#8217;s Decision on an NDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of any inspections of the
manufacturing facilities and select clinical trial sites, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific
indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If a complete response letter is issued,
the applicant may resubmit the NDA to address all of the deficiencies identified in the letter, withdraw the application, or request a hearing. If the applicant resubmits the NDA, the FDA will issue an approval letter only when the deficiencies have
been addressed to the FDA&#8217;s satisfaction. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may
decide that the application does not satisfy the regulatory criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA approves a product, it may limit the
approved indications for use for the product, require that contraindications, warnings, or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the
drug&#8217;s safety or effectiveness after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms,
including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution,
advertising, and promotion, reporting of adverse experiences with the product and applicable product tracking and tracing requirements. After approval, many changes to the approved product, such as adding new indications or other labeling claims,
are subject to prior FDA review and approval. There also are annual prescription drug product program fee requirements for certain marketed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs, and those supplying
products, ingredients, and components of them are required to register </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the
manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements
upon the NDA holder and any third-party manufacturers that the NDA holder may decide to use. Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing
requirements and notify the FDA of counterfeit, diverted, stolen, and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Accordingly, manufacturers must continue to expend time, money, and
effort in the area of production and quality control to maintain cGMP compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the
approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or
frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety
risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market, or voluntary product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning, or untitled letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted
only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA
and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted
<FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the distribution of
prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug
distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hatch-Waxman Amendments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing
authorization for a new drug. A Section&nbsp;505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy
but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the
investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. The FDA may also
require companies to perform additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies or measurements, including clinical trials, to support the change from the approved branded reference drug. The FDA may then approve the new product candidate for all, or some, of the
labeled indications for which the branded reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant. Section&nbsp;505(j) establishes an abbreviated approval process for a generic version of approved drug
products through the submission of an Abbreviated New Drug Application, or ANDA. An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance
characteristics and intended use, among other things, to a previously approved product, known as a reference listed drug, or RLD. ANDAs are termed &#8220;abbreviated&#8221; because they are generally not required to include preclinical (animal) and
clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through <I>in vitro</I>, <I>in
vivo</I>, or other testing. In certain situations, an applicant may obtain ANDA approval of a generic product with a strength or dosage form that differs from a referenced innovator drug pursuant to the filing and approval of an ANDA Suitability
Petition. The FDA will approve the generic product as suitable for an ANDA application if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the innovator product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Patent</FONT> Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Hatch-Waxman Amendments, the FDA may not approve (or in some cases accept) an ANDA or 505(b)(2) application until any applicable
period of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity for the RLD has expired. The FDCA provides a period of five years of <FONT STYLE="white-space:nowrap">non-patent</FONT> data exclusivity for a new drug containing a new
chemical entity, or NCE. For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or
pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, which
states the proposed generic drug will not infringe one or more of the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable, in which case the applicant may submit its application four years following the
original product approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDCA also provides for a period of three years of exclusivity for
<FONT STYLE="white-space:nowrap">non-NCE</FONT> drugs if the NDA or a supplement to the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the
applicant and are essential to the approval of the application or supplement. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination, or
indication, but it generally would not protect the original, unmodified product from generic competition. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic
versions of the drug as of the date of approval of the original drug product; it only prevents FDA from approving such ANDAs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A drug
product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the active moiety and to patent terms.
This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection and patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an <FONT
STYLE="white-space:nowrap">FDA-issued</FONT> &#8220;Written Request&#8221; for such a study, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hatch-Waxman Patent Certification and the <FONT STYLE="white-space:nowrap">30-Month</FONT> Stay </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In seeking approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the
applicant&#8217;s product or an approved method of using the product. Upon approval of an NDA, each of the patents listed in the application for the drug is published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence
Evaluations, commonly known as the Orange Book. Upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submission of an ANDA or 505(b)(2) NDA, an applicant is required to certify to the FDA concerning any patents listed for the RLD in the Orange Book that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no patent information on the drug product that is the subject of the application has been submitted to the FDA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such patent has expired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which such patent expires; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such patent is invalid, unenforceable, or will not be infringed upon by the manufacture, use, or sale of the drug
product for which the application is submitted. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, the ANDA or 505(b)(2) NDA cannot be approved until all
listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the listed patents or
indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant
has provided a paragraph IV certification, the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a
patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA
may not approve that application until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the
applicant&#8217;s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the <FONT STYLE="white-space:nowrap">30-month</FONT> stay. In instances where an ANDA or 505(b)(2) NDA
applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the <FONT STYLE="white-space:nowrap">30-month</FONT> stay, recognizing that the related patent litigation may take many months or years
to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s decision to initiate patent litigation. If the
drug has NCE exclusivity and the ANDA is submitted four years after approval, the <FONT STYLE="white-space:nowrap">30-month</FONT> stay is extended so that it expires seven and a half years after approval of the innovator drug, unless the patent
expires or there is a decision in the infringement case that is favorable to the ANDA applicant before then. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term Restoration and Extension
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which
permits a patent term restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the
effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date, provided the sponsor acted with diligence. Patent term restoration cannot be used to extend the remaining
term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration
of the patent in question and within 60 days of drug approval. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office, or USPTO, reviews and
approves the application for any patent term extension or restoration in consultation with the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Drug Enforcement Administration Regulation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our product candidates have the potential to be regulated as controlled substances by the U.S. Drug Enforcement
Administration, or DEA. The Controlled Substances Act of 1970, or CSA, establishes registration, security, recordkeeping, reporting, storage, distribution, and other requirements administered by the DEA. The DEA
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is concerned with the control of handlers of controlled substances, and with the equipment and raw materials used in their manufacture and packaging, in order to prevent loss and diversion into
illicit channels of commerce. The DEA regulates controlled substances as Schedule I, II, III, IV, or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the United States. A
pharmaceutical product may be listed as Schedule II, III, IV, or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual registration is required for any facility that manufactures, distributes, dispenses, imports, or exports any controlled substance. The
registration is specific to the particular location, activity, and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled
substances are authorized. The DEA typically inspects a facility to review its security measures prior to issuing a registration. Security requirements vary by controlled substance schedule, with the most stringent requirements applying to Schedule
I and Schedule II substances. Required security measures include background checks on employees and physical control of inventory through measures such as cages, surveillance cameras and inventory reconciliations. Records must be maintained for the
handling of all controlled substances, and periodic reports made to the DEA. Reports must also be made for thefts or losses of any controlled substance, and authorization must be obtained to destroy any controlled substance. In addition, special
authorization and notification requirements apply to imports and exports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To meet its responsibilities, the DEA conducts periodic
inspections of registered establishments that handle controlled substances. Failure to maintain compliance with applicable requirements, particularly as manifested in loss or diversion, can result in enforcement action. The DEA may seek civil
penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations can lead to criminal prosecution. Individual states also regulate controlled substances, and
manufacturers are also subject to state regulation on distribution of these products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rest of the World Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the United States, such as those in Europe, Latin America, or Asia, the requirements governing product
development, the conduct of clinical trials, product marketing, product licensing, pricing and reimbursement can vary from country to country. Failure to comply with applicable foreign regulatory requirements may subject sponsors, manufacturers, or
marketers of pharmaceutical products to, among other things, fines, suspension, or withdrawal of regulatory authorizations and approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Review and Approval of Medicinal Products in the European Union </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of
other countries and jurisdictions regarding quality, safety and efficacy, and governing, among other things, clinical trials, obtaining marketing authorization, or MA, commercial sales and distribution of products. Whether or not it obtains FDA
approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically,
the process governing approval of medicinal products in the EU generally follows similar lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the
safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of an MA application, or MAA, and granting of an MA by these authorities before the product can be marketed and
sold in the EU. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-clinical</FONT> Studies and Clinical Trials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly to the United States, the various phases of <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical research in the EU are
subject to significant regulatory controls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-clinical</FONT> studies are performed to demonstrate
the health or environmental safety of new chemical or biological substances. <FONT STYLE="white-space:nowrap">Non-clinical</FONT> (pharmaco-toxicological) studies must be conducted in compliance with the principles of good laboratory practice, or
GLP, as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products, e.g., radio-pharmaceutical precursors for radio-labeling purposes). These GLP standards reflect the Organization for Economic <FONT
STYLE="white-space:nowrap">Co-operation</FONT> and Development requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials of medicinal products in the EU must be
conducted in accordance with EU and national regulations and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines on Good Clinical Practices, or GCP, as well as the applicable
regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The
sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation, or CTR,
which was adopted in April 2014 and repealed the EU Clinical Trials Directive, became applicable on January&nbsp;31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further
implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the EU Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state in which
the clinical trial takes place, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single
application for multi-center trials. The CTR allowed sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other
things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as
well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is
communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicines
used in clinical trials must be manufactured in accordance with Good Manufacturing Practice, or GMP. Other national and <FONT STYLE="white-space:nowrap">EU-wide</FONT> regulatory requirements may also apply. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Marketing Authorization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market our product candidates in the EU and many other foreign jurisdictions, we must obtain separate regulatory approvals. More
concretely, in the EU, medicinal product candidates can only be commercialized after obtaining an MA. To obtain an MA, an applicant must submit an MAA either under a centralized procedure administered by the European Medicines Agency, or EMA, or one
of the procedures administered by competent authorities in the EU member states (decentralized procedure or mutual recognition procedure) for obtaining an MA in multiple EU Member States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Centralized MAs&#8221; are issued by the European Commission through the centralized procedure based on the opinion of the Committee
for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and are valid throughout the EU. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines
produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy and tissue-engineered products) and products with a new active substance
indicated for the treatment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of certain diseases, including products for the treatment of HIV, AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions and viral diseases. The centralized
procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific, or technical innovation or which are in the interest of public health in the
EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the centralized procedure, the maximum timeframe for the evaluation of an MAA by the EMA is 210&nbsp;days, excluding clock
stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Accelerated
evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from a public health perspective and in particular from the point of view of therapeutic innovation. If the CHMP accepts such request, the
time limit of 210 days will be reduced to 150 days, excluding clock stops, but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an
accelerated assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 67 days from the date of the CHMP opinion, the
European Commission will adopt its final decision on the MAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;National MAs&#8221; are issued by the competent authorities of the
EU member states, only cover their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state,
this national MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member
states through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the
reference member state. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Periods of Authorization and Renewals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A MA has an initial validity of five years. The MA may be renewed after five years on the basis of a
<FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the relevant EU member state for a nationally authorized product. To this end, the MA holder must provide the EMA or the
competent authority with a consolidated version of the file in respect of quality, safety, and efficacy, including all variations introduced since the MA was granted, at least nine months before the MA ceases to be valid. Once renewed, the MA is
valid for an unlimited period, unless the European Commission or the competent authorities of the relevant member states decide, on justified grounds relating to pharmacovigilance, to proceed with one further five year renewal period. Any
authorization which is not followed by the actual placing of the medicinal product on the EU market (for centrally-authorized products) or on the market of the authorizing EU member state (for nationally-authorized products) within three years after
authorization ceases to be valid (the <FONT STYLE="white-space:nowrap">so-called</FONT> &#8220;sunset clause&#8221;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Data and Market
Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, innovative medicinal products approved on the basis of a complete and independent data package generally
receive eight years of data exclusivity and an additional two years of market exclusivity upon grant of an MA. The data exclusivity period prevents applicants for authorization of generics or biosimilars of these innovative products from referencing
the innovator&#8217;s preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar (abbreviated) MA, for a period of eight years from the date on which the reference product was
first authorized in the EU. During an additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced, but no generic or
biosimilar medicinal product can be placed on the EU market until the expiration of the market exclusivity. The overall <FONT STYLE="white-space:nowrap">10-year</FONT> period will be extended to a maximum of 11 years if, during the first eight years
of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in comparison with existing therapies. There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity.
Even if a product is considered to be an innovative medicinal product so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained an MA
based on an MAA with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Orphan
Medicinal Products </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those
in the United States. A medicinal product can be designated as an orphan if its sponsor can establish that: (1)&nbsp;the product is intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition, (2)
either (i)&nbsp;such condition affects no more than five in ten thousand persons in the EU when the application is made, or (ii)&nbsp;without the benefits derived from orphan status, it is unlikely that the marketing of the product in the EU would
generate sufficient return to justify the necessary investment in its development; (3)&nbsp;there exists no satisfactory method of diagnosis, prevention, or treatment of the condition in question that has been authorized in the EU or, if such method
exists, the product would be of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An orphan designation provides a number of
benefits, including fee reductions, regulatory assistance, and the possibility to apply for a centralized EU MA. Upon grant of an MA, orphan medicinal products are entitled to a <FONT STYLE="white-space:nowrap">ten-year</FONT> period of market
exclusivity, which means that the EMA and the competent authorities of the EU member states cannot accept another MAA, or grant an MA, or accept an application to extend an MA for a similar medicinal product for the same indication for a period of
ten years. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic
indication. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed pediatric investigation plan, or PIP. No extension to any supplementary protection certificate, or SPC, can be
granted on the basis of pediatric studies for orphan indications. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The orphan exclusivity period may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets
the criteria for which it received orphan destination, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the
threshold. Additionally, an MA may be granted to a similar product for the same indication as an authorized orphan product at any time if (i)&nbsp;a second applicant can establish that its product, although similar to the authorized orphan product,
is safer, more effective or otherwise clinically superior; (ii)&nbsp;the MA holder for the authorized orphan product consents to a second medicinal product application; or (iii)&nbsp;the MA holder for the authorized product cannot supply enough
orphan medicinal product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Pediatric Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation (EC) No 1901/2006 provides that prior to obtaining an MA in the EU, applicants have to demonstrate compliance with all measures
included in a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee, or PDCO, and covering all subsets of the pediatric population, unless the PDCO has granted (1)&nbsp;a product-specific waiver, (2)&nbsp;a class
waiver, or (3)&nbsp;a deferral for one or more of the measures included in the PIP. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product for which an MA is being sought. Products that
are granted an MA with the results of the pediatric clinical trials conducted in accordance with the PIP are eligible for a <FONT STYLE="white-space:nowrap">six-month</FONT> extension of the protection under a SPC provided an application for such
extension is made at the same time as filing the SPC application for the product, or at any point up to two years before the SPC expires, even where the trial results are negative. In the case of orphan medicinal products, a <FONT
STYLE="white-space:nowrap">two-year</FONT> extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and
submitted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the
EMA, the European Commission and/or the competent regulatory authorities of the member states. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, or QPPV, who
is responsible for the establishment and maintenance of that system, and oversees the safety profiles of medicinal products and any emerging safety concerns. Key obligations include expedited reporting of suspected serious adverse reactions and
submission of periodic safety update reports, or PSURs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All new MAA must include a risk management plan, or RMP, describing the risk
management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or
post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with
physicians, misleading and comparative advertising, and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited in the EU. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is also prohibited in the EU.
Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each member state and can differ from one country to another. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the EU member states plus
Norway, Liechtenstein, and Iceland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with EU and member state laws that apply to the conduct of clinical trials,
manufacturing approval, authorization of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption, or with other
applicable regulatory requirements may result in administrative, civil, or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant an MA, product withdrawals and recalls, product
seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing, or clinical trials, operating restrictions, injunctions, suspension of licenses, fines, and criminal penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Reform of the Regulatory Framework in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe
initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data
protection, revising the eligibility for expedited pathways, etc.) was published on April&nbsp;26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and Council of the EU and the proposals may therefore be
substantially revised before adoption, which is not anticipated before early 2026. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Brexit and the Regulatory Framework in the United
Kingdom </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the end of the Brexit transition period on January&nbsp;1, 2021 and the implementation of the Windsor Framework on
January&nbsp;1, 2025, the United Kingdom, or UK, is not generally subject to EU laws in respect of medicines. The EU laws that have been transposed into UK law through secondary legislation remain applicable in the UK however, new legislation such
as the (EU) CTR is not applicable in the UK. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Medicines and Medical Devices Act 2021, the Secretary of State or an
&#8216;appropriate authority&#8217; have delegated powers to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which
aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials, and medical devices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, is the UK&#8217;s standalone medicines and
medical devices regulator. As a result of the Ireland/Northern Ireland protocol, different rules applied in Northern Ireland than in England, Wales, and Scotland (together, &#8220;Great Britain&#8221;, or GB), which continued to follow the EU
regulatory regime. However, on January&nbsp;1, 2025 a new arrangement called the &#8220;Windsor Framework&#8221; came into effect and reintegrated Northern Ireland under the regulatory authority of the MHRA with respect to medicinal products. The
Windsor Framework removes EU licensing processes and EU labeling and serialization requirements in relation to Northern Ireland and introduces a <FONT STYLE="white-space:nowrap">UK-wide</FONT> licensing process for medicines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The UK regulatory framework in relation to clinical trials is governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as
amended, which is derived from the CTD, as implemented into UK national law through secondary legislation. In April 2025, the UK introduced the Medicines for Human Use (Clinical Trials) (Amendment) Regulations. These changes, which will take full
effect from April 2026, aim to create a streamlined, risk-proportionate system that accelerates approvals while maintaining robust safety standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in October 2023, the MHRA announced a new Notification Scheme for clinical trials which enables a more streamlined and
risk-proportionate approach to initial clinical trial applications for Phase 4 and <FONT STYLE="white-space:nowrap">low-risk</FONT> Phase 3 clinical trial applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAs in the UK are governed by the Human Medicines Regulations (SI 2012/1916), as amended. All existing EU MAs for centrally authorized
products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January&nbsp;1, 2021, unless the MA holder chose to <FONT STYLE="white-space:nowrap">opt-out.</FONT> Under the terms of the Windsor
Framework, these licenses became valid for the whole of the UK from January&nbsp;1, 2025. In order to use the centralized procedure to obtain an MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore, after
Brexit, companies established in the UK can no longer use the EU centralized procedure and instead an EEA entity must hold any centralized MAs. In order to obtain a UK MA to commercialize products in the UK, an applicant must be established in the
UK and must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures. The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access
to new medicines that will benefit patients, a <FONT STYLE="white-space:nowrap">150-day</FONT> assessment (subject to clock-stops) and a rolling review procedure. The rolling-review procedure permits the separate or joint submission of quality, <FONT
STYLE="white-space:nowrap">non-clinical,</FONT> and clinical data to the MHRA which can be reviewed on a rolling basis. After an application under the rolling-review procedure has been validated, the final decision should be received within 100 days
(subject to clock-stops). In addition, since January&nbsp;1, 2024, the MHRA may rely on the International Recognition Procedure, or IRP, when reviewing certain types of MAAs. Pursuant to the IRP, the MHRA will take into account the expertise and
decision-making of trusted regulatory partners (e.g. the medicines regulatory authorities in Australia, Canada, Switzerland, Singapore, Japan, the U.S.A. and the EMA in the EU). The MHRA will conduct a targeted assessment of IRP applications but
retain the authority to reject applications if the evidence provided is considered insufficiently robust. Applications should be decided within a maximum of 60 days if there are no major objections identified that cannot be resolved within such 60
day period and the approval from the trusted regulatory partner selected has been granted within the previous 2 years. If there are such major objections identified or such approval hasn&#8217;t been granted within the previous 2 years, then the
relevant timeframe for the MHRA decision is within 110 days. Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions,
variations, and renewals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the UK, the initial duration of an MA is five years and following renewal will be valid
for an unlimited period unless the MHRA decides on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Any authorization which is not followed by the actual placing of the medicine on the market in
the UK (or GB, if the MA is only valid in GB) within three (3)&nbsp;years shall cease to be in force. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no <FONT
STYLE="white-space:nowrap">pre-MA</FONT> orphan designation in the UK. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for
the market, i.e., the prevalence of the condition in the UK, rather than the EU, must not be more than five in 10,000. Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the
product in the UK. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors,
patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws that may affect our ability to operate, and our proposed sales, marketing, and distribution strategies,
include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the
purchase, lease, order, or recommendation of any good, facility, item, or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to
have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved,
imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim
for purposes of the federal False Claims Act, or FCA (discussed below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws, including the FCA and civil monetary penalty laws, which impose
criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal healthcare programs that are false or
fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation.
Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting
as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or
making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty
of violating these statutes without actual knowledge of the statutes or specific intent to violate them; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failing to take appropriate steps to keep consumers&#8217; personal information secure could constitute an unfair
act or practice in or affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Commission Act, 15 U.S.C. &#167; 45(a) or similar state laws. The Federal Trade Commission, or FTC, and state regulators expect a company&#8217;s data security measures to be reasonable and
appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information
is considered sensitive data that merits stronger safeguards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, and its implementing regulations requires manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare,
Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Department of Health and Human Services, or HHS, information related to payments or other transfers of value made to physicians (defined to
include doctors, dentists, optometrists, podiatrists, and chiropractors), certain other licensed healthcare professionals (i.e., physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered
nurse anesthetists, and certified nurse midwives), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal government price reporting laws, which require manufacturers to calculate and report complex pricing
metrics in an accurate and timely manner to government programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer
protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales, and marketing arrangements as well as submitting claims involving healthcare items or services
reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing
information, such as the tracking and reporting of gifts, compensations, and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales
representatives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal, state, and foreign enforcement bodies are continuing to increase their scrutiny of
interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry. If our operations are found to be in violation of any of such
laws or any other governmental regulations that apply, we may be subject to significant penalties, including, without limitation, administrative, civil, and criminal penalties, damages, fines, disgorgement, contractual damages, the curtailment or
restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs, reputational harm, diminished profits and future earnings, and individual imprisonment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Privacy and Data Security </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
ordinary course of business, we and the third parties upon which we rely collect, receive, store, or otherwise process personal data, including information we may collect about participants in our clinical trials. This personal data can also include
data that is considered &#8220;sensitive&#8221; personal data under privacy laws, policies, or agreements to which we are subject. Accordingly, we are, or may be become, subject to numerous, evolving privacy and data security obligations, including
global, federal, state, and local laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations related to privacy and data security. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These privacy and data security laws are evolving and may impose potentially conflicting
obligations. Such obligations may include, without limitation, federal health information privacy laws, state information security and data breach notification laws, state health information privacy laws, and federal and state consumer protection
laws (e.g., the Federal Trade Commission Act). At the state level, numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and
affording individuals certain rights concerning their personal data. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. Additionally, a
smaller number of states have passed or are considering laws governing the privacy of consumer health data. While existing state consumer privacy laws provide exemptions for data processed in the context of clinical trials, the continued development
of complex requirements at the state level may further complicate compliance efforts and may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and
distribution of our products, and are examples of the increasingly stringent and evolving regulatory frameworks related to personal data processing, as more fully discussed in the section titled &#8220;Risk Factors.&#8221;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, to the extent we collect personal data outside of the United States, through clinical trials or otherwise, we are, or may
become, subject to foreign data and data security laws, such as the European Union&#8217;s General Data Protection Regulation 2016/679, or EU GDPR, and other national data protection legislation in force in relevant EEA Member States, and the EU
GDPR as it forms part UK law by virtue of section 3 of the European Union (Withdrawal) Act 2018, or UK GDPR. Foreign privacy and data security laws impose significant and complex compliance obligations on entities that are subject to those laws and
may impose significant sanctions for <FONT STYLE="white-space:nowrap">non-compliance</FONT> (including fines of up to the greater of 20&nbsp;million Euros (17.5&nbsp;million GBP for the UK) or 4% of worldwide annual revenue), as more fully discussed
in the section titled &#8220;Risk Factors.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the
prescribed services generally rely on third-party payors to reimburse all or part of the costs associated with their prescription. Therefore, adequate coverage and reimbursement from such third-party payors are critical to new and ongoing product
acceptance. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial
health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels, for the product. Factors payors consider in determining coverage and reimbursement are based on whether the product is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective, and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage
and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement
rate that the payor will pay for the product once coverage is approved. A third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Therefore, even if coverage is
provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our investment. Further, one payor&#8217;s determination to provide coverage for a product does not
assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly challenging the prices charged, examining the medical
necessity, and reviewing the cost- effectiveness of medical products and services and imposing controls to manage costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be
significant delays in obtaining coverage and reimbursement, as the process of determining coverage and reimbursement is often time consuming and costly. In order to secure coverage and reimbursement for any product that might be approved for sale, a
company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Moreover,
coverage may be more limited than the purposes for which the product is approved by FDA or regulatory authorities in other countries. Additionally, companies may also need to provide discounts to purchasers, private health plans, or government
healthcare programs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. Third-party payors could determine that
our product candidates are not medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of
operations and our financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal, state, and foreign
governments, and the prices of products have been a focus in this effort. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage and the amount of
reimbursement for drugs and other medical products, government control, and other changes to the healthcare system in the United States including the relaxation of laws that presently restrict imports of drugs from countries where they may be sold
at lower prices than in the United States. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. Net
prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at
lower prices than in the United&nbsp;States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, third-party payors are increasingly reducing reimbursements for drugs and services
and implementing measures to control utilization of drugs (such as requiring prior authorization or step therapy for coverage, among other things). Increasingly, third-party payors are requiring that drug companies provide them with predetermined
discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of
reimbursement. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Moreover,
payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, the U.S. Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, may develop new payment and delivery models, such as bundled
payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several U.S. Congressional inquiries and proposed and
enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies
for pharmaceutical products. Congress has indicated that it will continue to seek new legislative measures to control drug costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted
accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies
in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription
pharmaceuticals is subject to government control in many countries. Pricing negotiations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other
available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU,
pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that
compare the cost-effectiveness of a particular product candidate to currently available therapies or <FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example,
the EU Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific
price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and
control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to
manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a
result, increasingly high barriers are being erected to the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been
obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. There can be no assurance that
any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current and Future Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there have been, and continue to be, a number of legislative and regulatory changes to the healthcare system that could
impact our ability to sell our products profitably. For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical
industry. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments, and changes to fraud and abuse laws. For example, the ACA, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%
of the average manufacturer price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required collection of rebates for drugs paid by Medicaid managed care organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer
50% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D (later increased to 70%); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposed a <FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or
importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its
enactment, there have been judicial, administrative, executive, and legislative challenges to certain aspects of the ACA as well as executive orders related to the ACA&#8217;s implementation. It is unclear how healthcare reform measures of the
current presidential administration or other efforts, if any, to challenge repeal or replace the ACA, will impact our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers and health plans (including Part D prescription drug
plans) of up to 2% per fiscal year, effective April&nbsp;1, 2013, and which will stay </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in effect through 2032, unless Congress takes additional action. Additionally, American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Moreover, the One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions in the funding of
the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid. These new laws and regulatory changes may result in additional reductions in Medicare and other
healthcare funding, which could have a material adverse effect on prescribers of our drugs, if approved, and accordingly, our financial operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically,
there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the
relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, as of January&nbsp;1, 2024, the American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug
rebate cap of 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs. More recently, the Inflation Reduction Act of 2022, or IRA, among other things, directed HHS to negotiate the price of certain
high-expenditure, single-source drugs and biologics covered under Medicare, and created civil monetary penalties and an excise tax for manufacturers that fail to comply with the drug price negotiation requirements. The IRA also imposed rebates for
certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation, and, beginning in 2025, replaced the Part D coverage gap discount program with a new discounting program. The IRA
permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August&nbsp;15, 2024, HHS announced the negotiated prices for the first ten drugs that will be subject to price negotiations, and
on January&nbsp;17, 2025, HHS announced 15 additional drugs subject to negotiations. The Medicare drug price negotiation program is currently subject to multiple legal challenges. The impact of these challenges, as well as any other future
challenges, is uncertain, and it is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Trump administration is pursuing a <FONT STYLE="white-space:nowrap">two-fold</FONT> strategy to reduce drug costs in the U.S.
While it is unclear whether and how the Trump proposals will be implemented, the Trump policies are likely to have a negative impact on the pharmaceutical industry and on our ability to receive adequate revenues for product candidates, if approved.
On the one hand, President Trump has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most favored nation pricing, which would tie the price for drugs in the U.S. to the lowest price
in a group of other countries. In response, multiple manufacturers have reportedly entered into confidential pricing agreements with the federal government. On the other hand, the Trump administration is pursuing traditional regulatory pathways to
impose drug pricing policies, although proposed regulations have not yet been published. Even regulatory proposals or executive actions that are ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and our business. In
addition, pharmaceutical pricing and marketing has long been the subject of considerable discussion in Congress and among policymakers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, FDA released its implementing regulations regarding section 804 Importation Programs under the Medicare Prescription Drug Improvement
and Modernization Act of 2003, which create a pathway for states to submit proposals to import certain drugs from Canada. On January&nbsp;5, 2024, the FDA authorized a Florida program to import prescription drugs from Canada for a period of two
years to help reduce drug costs, provided that Florida&#8217;s Agency for Health Care Administration meets the requirements set forth by the FDA. If broadly implemented, importation of drugs under this program from Canada may materially and
adversely affect the price we receive for any of our product candidates. Additionally, it is unclear what steps the current presidential administration will take with respect to increasing importation of drugs at the state or federal level. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states have also been increasingly active in passing legislation and implementing regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries
and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other
healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could limit the amounts that federal and state
governments will pay for healthcare products and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although a number of these and other proposed measures may require
authorization through additional legislation to become effective, and the current presidential administration may reverse or otherwise change these measures, both the current presidential administration and Congress have indicated that they will
continue to seek new legislative measures to control drug costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar political, economic, and regulatory developments are occurring
in the EU and may affect the ability of pharmaceutical companies to profitably commercialize their products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may
result in significant additional requirements or obstacles. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for
national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however,
the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those
wishing to develop and market products, this could restrict or regulate post-approval activities and affect the ability of pharmaceutical companies to commercialize their products. In international markets, reimbursement and healthcare payment
systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU,
potential reductions in prices and changes in reimbursement levels could be the result of different factors, including reference pricing systems, parallel distribution, and parallel trade. It could also result from the application of external
reference pricing mechanisms, which consist of arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced countries. Reductions in the pricing of our medicinal products in one EU member state could affect the price in other
EU member states and, thus, have a negative impact on our financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health Technology Assessment, or HTA, of medicinal products
in the EU is an essential element of the pricing and reimbursement decision-making process in a number of EU member states. The outcome of HTA has a direct impact on the pricing and reimbursement status granted to the medicinal product. A negative
HTA by a leading and recognized HTA body concerning a medicinal product could undermine the prospects to obtain reimbursement for such product not only in the EU member state in which the negative assessment was issued, but also in other EU member
states. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2011, Directive 2011/24/EU was adopted at the EU level. This Directive establishes a voluntary network of national authorities
or bodies responsible for HTA in the individual EU member states. The network facilitates and supports the exchange of scientific information concerning HTAs. Further to this, on December&nbsp;13, 2021, Regulation No 2021/2282 on HTA, amending
Directive 2011/24/EU, was adopted. The Regulation entered into force in January 2022 and has been applicable since January 2025, with phased implementation based on the type of product, i.e. oncology and advanced therapy medicinal products as of
2025, orphan medicinal products as of 2028, and all other medicinal products by 2030. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for
cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment
of the innovative health technologies with the highest potential impact for patients, joint scientific </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary
cooperation in other areas. Individual EU member states will continue to be responsible for assessing <FONT STYLE="white-space:nowrap">non-clinical</FONT> (e.g., economic, social, ethical) aspects of health technology, and making decisions on
pricing and reimbursement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a physical corporate office for administrative purposes and a small non-GxP lab space, which we do not view as material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our existing facilities arrangements are sufficient for our needs for the foreseeable future. To meet the future needs of our
business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of April 1, 2026, we had 58 full-time employees. Within our workforce, 39 employees are engaged in research and development and 19 are engaged in business development, finance, legal, and general management and administration. Our human capital
resources objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel
through the granting of equity-based compensation awards in order to increase shareholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. None of our employees
is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal
Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any
litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of
operations and prospects because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth information regarding our executive officers and directors as of the date of this prospectus: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Officers:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daphne Zohar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael C. Chen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lana Gladstein, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General Counsel</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antony Loebel, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lauren A. White</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven M. Paul, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director and Board Chair</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Elenko, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy, M.D., Ph.D. <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Hombach <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sharon Mates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandra E. Peterson <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP><SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Pitts, Ph.D. <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denice Torres, J.D. <SUP STYLE="font-size:75%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wheadon, M.D. <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lyne LLB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Daphne
Zohar</B><B>.</B> Ms.&nbsp;Zohar was our founder and has served as our President and Chief Executive Officer and as a member of our board of directors since April 2024. Prior to joining us, Ms.&nbsp;Zohar served as Founder, Chief Executive Officer
and as a member of the board of directors of PureTech (Nasdaq/LSE: PRTC), since its formation in June 2015 to April 2024, and since 2005 at PureTech&#8217;s predecessor entity. A successful entrepreneur, Ms.&nbsp;Zohar created PureTech, assembling a
leading team and scientific network to help implement her vision for the company, and was a key participant in fundraising, business development and establishing the underlying programs and platforms that have resulted in PureTech&#8217;s
substantial pipeline of products and product candidates. She also <FONT STYLE="white-space:nowrap">co-founded</FONT> PureTech&#8217;s entities, including Karuna Therapeutics, Inc. (formerly Nasdaq: KRTX), which developed the groundbreaking
antipsychotic drug, Cobenfy (KarXT). The FDA approval of Cobenfy in September 2024 marked the first new schizophrenia mechanism in 70 years. Following FDA approval of Cobenfy (invented by PureTech), Karuna was acquired by Bristol Myers Squibb for
$14 billion. Ms.&nbsp;Zohar was a key driver in PureTech&#8217;s productive R&amp;D engine, which led to 28 new medicines and a clinical success rate at PureTech and founded entities that was around six times better than the industry average during
her tenure. Ms.&nbsp;Zohar is a founder&nbsp;&amp; <FONT STYLE="white-space:nowrap">co-host</FONT> of the weekly podcast &#8220;Biotech Hangout.&#8221; Ms.&nbsp;Zohar received a B.S. from Northeastern University. Our board of directors believes that
Ms.&nbsp;Zohar is qualified to serve as a member of our board of directors because of her extensive experience and leadership in the biopharmaceutical industry and her role as our company&#8217;s founder and chief executive officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Michael C. Chen, Ph.D.</B><I></I>&nbsp;Dr. Chen has served as our Chief Scientific Officer since May 2024. Prior to joining us, Dr. Chen
served various roles at PureTech from 2016 to May 2024, most recently as Head of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Innovation from 2016 to May 2024, where he oversaw the rapid advancement of the neuropsychiatric medicines that led to our launch. From 2016 to 2019, Dr. Chen was also <FONT
STYLE="white-space:nowrap">co-founder</FONT> and Head of Research and Strategy at Sonde Health, Inc., a company developing vocal biomarkers for depression and other neuropsychiatric disorders. He was a postdoctoral fellow at Beth Israel Deaconess
Medical Center and Harvard Medical School, Department of Neurology. Dr. Chen completed his Ph.D. at Stanford University, focusing on the neurobiological mechanisms of depression and sleep disorders. He received a B.A. from Yale University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Lana Gladstein, J.D.</B> Ms.&nbsp;Gladstein has served as our General Counsel since June 2024. Prior to joining us, she served as the Group
General Counsel at APRINOIA Therapeutics, Inc. (Nasdaq: APRI) from May 2023 to June 2024. From June 2022 to May 2023, she also served as Chief Legal Officer of Recipharm AB North America from June 2022 to May 2023, Chief Legal Officer and General
Counsel of Arranta Bio (acquired by Recipharm) from November 2019 to May 2023 and Executive Vice President and General Counsel of Brammer Bio (acquired by Thermo Fisher Scientific) from March 2017 to October 2019. Prior to that, Ms.&nbsp;Gladstein
was a partner at the law firm of Nutter McClennen&nbsp;&amp; Fish LLP and Pepper Hamilton LLP. Ms.&nbsp;Gladstein holds a J.D. from Northeastern University School of Law and a B.A. in Biology from Brandeis University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Antony Loebel, M.D. </B>Dr.&nbsp;Loebel has served as our Chief Medical Officer and President of Clinical Development since June 2024. He
was previously the President and Chief Executive Officer of Sunovion Pharmaceuticals Inc. from April 2019 to June 2023, and served as Chief Medical Officer from 2011 to March 2019. During his tenure at Sunovion, Dr.&nbsp;Loebel played a key role in
the company&#8217;s growth to over $3.5&nbsp;billion in total revenue and was instrumental in the development and commercialization of Latuda for the treatment of bipolar depression and schizophrenia. Prior to his time at Sunovion, he held senior
roles in research and development and medical affairs at Dainippon Sumitomo Pharma America and Pfizer Inc. (NYSE: PFE). Dr.&nbsp;Loebel earned his M.D. from the University of Washington in Seattle, completed his psychiatry residency at the Zucker
Hillside Hospital in New York, and is board certified in psychiatry. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Lauren A. White.</B><I></I>&nbsp;Ms.&nbsp;White has served as
our Chief Financial Officer since November 2024. Prior to joining us, Ms.&nbsp;White served as the Chief Financial Officer and Treasurer of ImmunoGen, Inc. (formerly Nasdaq: IMGN), or ImmunoGen, from September 2023 to June 2024 prior to its
acquisition by AbbVie. Prior to that, she served as Chief Financial Officer, Treasurer, and Principal Accounting Officer at C4 Therapeutics, Inc. (Nasdaq: CCCC) from June 2021 to September 2023, and held roles of increasing responsibility at
Novartis AG (NYSE: NVS), most recently as Vice President, Finance, and Global Head of Business Planning and Analysis at Novartis Institutes for BioMedical Research from July 2017 to June 2021. Ms.&nbsp;White earned an M.B.A. from Harvard Business
School and a B.S. from the Carroll School of Management at Boston College. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Steven M. Paul, M.D.</B> Dr. Paul has been a member and chair of our board of directors since April 2024. Dr.&nbsp;Paul was one
of our founders and has also served as our senior advisor since February 2024. From August 2018 to January 2024, Dr. Paul served in senior leadership roles at Karuna Therapeutics, Inc. (Nasdaq: KRTX, prior to its recent acquisition by Bristol Myers
Squibb Company), including as Chief Scientific Officer and President of Research and Development from January 2023 to January 2024, and President, Chief Executive Officer, and Chairman of the board of directors from August 2018 to January 2023. Dr.
Paul has also served as a Venture Partner at Third Rock Ventures since 2010. Dr. Paul is also board certified by the American Board of Psychiatry and Neurology. Dr. Paul has served on the board of directors of Rapport Therapeutics, Inc. (Nasdaq:
RAPP) since December 2022 and Sage Therapeutics, Inc. (Nasdaq: SAGE) from September 2011 until June 2024 and is also the chairman of the board of directors of the Foundation for the National Institutes of Health (FNIH). Previously, Dr. Paul served
on the boards of directors of Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) from September 2010 to April 2022, Voyager Therapeutics, Inc. (Nasdaq: VYGR) from September 2014 to June 2022 and Karuna Therapeutics, Inc. from March 2018 to March 2024. Dr.
Paul also previously spent 17 years at Eli Lilly and Company (NYSE: LLY), during which time he held several leadership roles, including Executive Vice President for Science and Technology, and President of the Lilly Research Laboratories. Prior to
Lilly, Dr. Paul </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
spent 18 years at the National Institute of Mental Health (NIMH) where he served as Scientific Director. Dr. Paul received a Bachelor of Arts degree in biology and psychology from Tulane
University and Master of Science and Doctor of Medicine degrees from the Tulane University School of Medicine. Our board of directors believes that Dr. Paul is qualified to serve on our board of directors due to his numerous leadership roles and
experience in the pharmaceutical industry and his expertise in neuroscience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>James I. Healy, M.D., Ph.D.</B> Dr. Healy has been a
member of our board of directors since April 2024. Dr.&nbsp;Healy has served as Managing Partner of Sofinnova Investments, Inc. since June 2000. Dr. Healy has served on the boards of directors of Rapport Therapeutics, Inc. (Nasdaq: RAPP) since
August 2023, ArriVent Biopharma, Inc. (Nasdaq: AVBP) since March 2023 and BioAge Labs, Inc. (Nasdaq: BIOA) since February of 2024. Previously, Dr. Healy served on numerous public company boards of directors including Bolt Biotherapeutics, Inc.
(Nasdaq: BOLT) from January 2021 until September 2024, Natera, Inc. (Nasdaq: NTRA) from November 2014 until June 2025, Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) from November 2017 until September 2025, Ascendis Pharma A/S (Nasdaq: ASND) from November
2014 to May 2022, Amarin Corporation PLC (Nasdaq: AMRN) from May 2008 to December 2016, CinCor Pharma, Inc. (Nasdaq: CINC, prior to its recent acquisition by AstraZeneca PLC) from May 2019 to February 2023, Coherus BioSciences, Inc. (Nasdaq: CHRS)
from February 2014 to February 2022, Karuna Therapeutics, Inc. (Nasdaq: KRTX, prior to its recent acquisition by Bristol Myers Squibb Company) from June 2019 to March 2024, Iterum Therapeutics plc (Nasdaq: ITRM) from November 2015 to February 2020,
ObsEva SA (Nasdaq: OBSEF) from August 2013 to May 2021, and NuCana PLC (Nasdaq: NCNA) from March 2014 to April 2022. He also previously served as a director on the Board of the National Venture Capital Association (NVCA) and the Board of the
Biotechnology Industry Organization (BIO). Dr. Healy holds Bachelor of Arts degrees in molecular biology and Scandinavian studies from the University of California, Berkeley, and Doctor of Medicine and Doctor of Philosophy degrees in immunology from
Stanford University School of Medicine. Our board of directors believes that Dr. Healy is qualified to serve on our board of directors due to his extensive experience and leadership roles in the biopharmaceutical industry and expertise in healthcare
investing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Robert J. Hombach.</B> Mr.&nbsp;Hombach has been a member of our board of directors since March 2025. Mr.&nbsp;Hombach
served as the Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta (NYSE: BXLT), a global biopharmaceutical company, until it was acquired by Shire plc. in 2016. Mr.&nbsp;Homach has served on the board of
directors of Henry Schein Inc (Nasdaq: HSIC) since February, 2025, BioMarin Pharmaceutical Inc (Nasdaq: BMRN) since September 2017, Embecta Corp. (Nasdaq: EMBC) since April, 2022, Aptinyx Inc. from April, 2018 to December, 2023, CarMax Inc, (NYSE:
KMX) from March, 2018 to June, 2022. He was instrumental in Baxalta&#8217;s successful spin off from its parent company, Baxter (NYSE: BAX), where he previously served as Corporate Vice President and Chief Financial Officer. In addition to his board
positions at BioMarin and Henry Schein, Mr.&nbsp;Hombach is the Chair of the Audit Committee at Embecta, a global diabetes care company spun out of Becton Dickinson, and has held previous board positions at several other companies including Naurex,
Inc., which was acquired by Allergan in 2015. Mr.&nbsp;Hombach received an MBA from Northwestern University&#8217;s J.L. Kellogg Graduate School of Management, and a BS in Finance cum laude from the University of Colorado. Our board of directors
believes that Mr.&nbsp;Hombach is qualified to serve on our board of directors due to his significant leadership experience in the biopharmaceutical industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Sharon Mates. </B>Sharon Mates, Ph.D., will join our Board upon the effectiveness of the registration statement of which this prospectus
forms a part. She served as Chairman of the Board, President and Chief Executive Officer of Intra-Cellular Therapies, Inc., which she co-founded in 2002, until its acquisition by Johnson &amp; Johnson in 2025. During her tenure, Intra-Cellular
Therapies developed and commercialized CAPLYTA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, an FDA-approved treatment for schizophrenia, bipolar depression, and was under FDA review for adjunctive treatment for major depressive
disorder. Earlier in her career, Dr. Mates served as President and a board member of North American Vaccine, Inc., where she oversaw the development of pediatric vaccines, and also helped to found other biotechnology companies. Dr. Mates has served
on several not-for-profit and industry organizations, including as Chair of the New York Biotechnology Association and a board member of the Biotechnology Industry Organization. Dr.&nbsp;Mates brings extensive leadership experience in building and
scaling </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
biotechnology companies and advancing innovative therapies from discovery through commercialization. She currently serves as a director of Medincell S.A. (EPA: MEDCL) and Benitec Biopharma
(Nasdaq: BNTC). She has also served on advisory councils affiliated with Harvard School of Public Health and the University of Maryland Biotechnology Institute. Dr.&nbsp;Mates received a B.S. from the Ohio State University, a Ph.D. from the
University of Washington, and completed postdoctoral fellowships at Massachusetts General Hospital and Harvard Medical School. Our board of directors believes that Ms. Mates is qualified to serve on our board of directors due to her extensive
knowledge of strategy and business development in the life sciences industry and her wide-ranging experience in leadership positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Robert Nelsen.</B> Mr.&nbsp;Nelsen has been a member of our board of directors since April 2024 and is expected to resign as a director
immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. Mr.&nbsp;Nelsen <FONT STYLE="white-space:nowrap">co-founded</FONT> ARCH Venture Partners, L.P., a venture capital firm focused on early-stage
technology companies, in 1986 and has served as a Managing Director of ARCH Venture Partners or its affiliated entities since 1994. Mr.&nbsp;Nelsen has served on the board of directors of Prime Medicine, Inc. (Nasdaq: PRME) since September 2020, and
Sana Biotechnology, Inc. (Nasdaq: SANA) since October 2018, each a U.S. publicly traded biotechnology company. Mr.&nbsp;Nelsen has served as the Chairman and as a member of the board of directors of Hua Medicine, Inc., a Hong Kong publicly listed
drug development company, since April 2010 and currently serves on the board of directors of a number of private companies. Mr.&nbsp;Nelsen previously served on the board of directors of a number of public biotechnology companies, including Vir
Biotechnology, Inc. from 2016 to 2025, Lyell Immunopharma, Inc. from 2018 to 2025, Brii Biosciences, Inc., from 2018 to 2024, Revolution Healthcare Acquisition Corp. from 2021 to 2022, Denali Therapeutics Inc. from 2015 to 2022, Unity Biotechnology,
Inc. from 2015 to December 2020, Agios Pharmaceuticals, Inc. from 2007 to June 2017, Syros Pharmaceuticals, Inc. from 2012 to June 2018, Juno Therapeutics, Inc. (acquired by Celgene Corporation in January 2018) from 2013 to March 2018, Sienna
Biopharmaceuticals, Inc. from 2015 to September 2018 and Gossamer Bio, Inc. from 2017 to December 2018 (prior to its initial public offering). Mr.&nbsp;Nelsen received his M.B.A. from the University of Chicago and his B.S. from the University of
Puget Sound in Economics and Biology. Our board of directors believes that Mr.&nbsp;Nelsen is qualified to serve on the Board due to his significant venture capital experience as a director and investor in the biotechnology industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Sandra E. Peterson.</B> Ms.&nbsp;Peterson has been a member of our board of directors since November 2024. She has served as an Operating
Partner at Clayton Dubilier&nbsp;&amp; Rice, or CD&amp;R, a private investment firm, since April 2019 where she invests in life sciences and consumer companies and oversees technology initiatives to enhance performance of the firm&#8217;s portfolio
companies. Prior to joining CD&amp;R, Ms.&nbsp;Peterson was the Group Worldwide Chair for Johnson&nbsp;&amp; Johnson, or J&amp;J, where she led J&amp;J&#8217;s consumer and medical devices businesses and was responsible for global operating
infrastructure, technology, supply chain, quality, and key strategic initiatives from 2012 to 2018. Ms.&nbsp;Peterson currently serves as Lead Independent Director of Microsoft Corp. (Nasdaq: MSFT) since March 2023 and a member of its board of
directors since December 2015. She also serves as Executive Chairwoman of the board of directors of Volastra Therapeutics since October 2019. Ms.&nbsp;Peterson received her M.P.A. from Princeton University and a B.A. from Cornell University. Our
board of directors believes that Ms.&nbsp;Peterson is qualified to serve on our board of directors due to her extensive knowledge of strategy and business development in the life sciences industry and her wide-ranging experience in leadership
positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Denice Torres, J.D.</B> Ms. Torres has been a member of our board of directors since May 2024. Ms. Torres is the founder
and Chief Executive Officer of The Ignited Company, a consulting firm she founded in November 2017, and is also the founder of The Mentoring Place, a nonprofit organization established in 2017. From December&nbsp;2004 to December&nbsp;2017, Ms.
Torres served in senior leadership roles at Johnson &amp; Johnson, including President of J&amp;J Neuroscience, President of J&amp;J Consumer Health, and Chief Strategy and Transformation Officer of the J&amp;J Medical Device Sector. Prior to that,
from 1990 to 2004, Ms. Torres held various leadership positions at Eli Lilly and Company, including Executive Director of Global Neuroscience and Director of U.S.&nbsp;Women&#8217;s Health. Ms. Torres currently serves on the board of directors of
Celldex Therapeutics Inc. (Nasdaq: CLDX), Glaukos&nbsp;Corp. (Nasdaq: GKOS), National Resilience Inc., and ByHeart Inc. Ms. Torres </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
previously served on the boards of Karuna Therapeutics, Inc., 2seventy bio, Inc., Thirty Madison, bluebird bio, Inc., and Surface Oncology, Inc. Ms.&nbsp;Torres holds an M.B.A. from the
University of Michigan, a J.D. from Indiana University School of Law, a B.S. in Psychology from Ball State University, and an M.A. in the Study of Happiness from Centenary University. She is currently pursuing a Ph.D. in Happiness Studies at
Centenary University. Our board of directors believes that Ms. Torres is qualified to serve on our board of directors due to her extensive leadership experience in the pharmaceutical, biotechnology, and consumer health industries and her expertise
in neuroscience, strategy, and business operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>David Wheadon, M.D.</B> Dr.&nbsp;Wheadon has been a member of our board of
directors since July 2024. He served as Senior Vice President, Global Regulatory Affairs, Patient Safety, and Quality Assurance for AstraZeneca Pharmaceuticals from 2014 to 2019 and as Executive Vice President, Research and Advocacy at the Juvenile
Diabetes Research Foundation from 2013 to 2014. From 2009 to 2013, Dr.&nbsp;Wheadon served as Senior Vice President, Scientific and Regulatory Affairs and as a member of the Management Committee of the Pharmaceutical Research and Manufacturers of
America, or PhRMA. Prior to his joining PhRMA, Dr.&nbsp;Wheadon held senior regulatory and clinical development leader roles at Abbott Laboratories and GlaxoSmithKline plc. Dr.&nbsp;Wheadon began his career as a clinical research physician in
neuroscience at Eli Lilly&nbsp;&amp; Company. Dr.&nbsp;Wheadon has served on the board of directors of Indivior, PLC (Nasdaq: INDV) since June 2024, Vaxart, Inc. (Nasdaq: VXRT) since April 2021, and&nbsp;Sotera Health, Inc. (Nasdaq:&nbsp;SHC) since
May 2021. He formerly served on the board of directors of Assertio Holdings, Inc. (formerly Assertio Therapeutics, Inc.), Karuna Therapeutics, Inc., and Chemocentryx, Inc. Dr.&nbsp;Wheadon holds an A.B. from Harvard College and an M.D. from Johns
Hopkins University School of Medicine. He completed his fellowship training in Psychiatry at the Tufts, New England Medical Center. Our board of directors believes that Dr.&nbsp;Wheadon is qualified to serve as a member of the board of directors due
to his leadership roles in the pharmaceutical industry and his extensive experience in regulatory affairs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Eric Elenko, Ph.D.</B>
Dr.&nbsp;Elenko has been a member of our board of directors since April 2024 and is expected to resign as a director immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. Dr.&nbsp;Elenko is the <FONT
STYLE="white-space:nowrap">co-founder</FONT> of PureTech Health (Nasdaq: PRTC) where he has served as the President since April 2024. Prior to his current role, Dr.&nbsp;Elenko previously served as PureTech Health&#8217;s Chief Innovation Officer
from June 2015 through April 2024. Prior to serving as Chief Innovation Officer, Dr. Elenko held multiple other leadership roles within PureTech. Prior to joining PureTech Health, Dr.&nbsp;Elenko was a consultant with McKinsey and Company.
Dr.&nbsp;Elenko has served on the Board of Directors of multiple PureTech portfolio companies during his tenure with PureTech. Dr.&nbsp;Elenko received his Ph.D. in biomedical sciences from the University of California, San Diego and his B.A. in
biology from Swarthmore College. Our board of directors believes that Dr.&nbsp;Elenko is qualified to serve on our board of directors because of his extensive understanding of the biotechnology and pharmaceutical industries and his senior management
experience. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Jason Pitts, Ph.D.</B> Dr.&nbsp;Pitts has been a member of our board of directors since October 2024. Dr.&nbsp;Pitts
has served as Principal at General Atlantic since December 2024, and prior to such role served in various roles, including Vice President, since March 2021 at General Atlantic, and focuses on investments in the life sciences sector. Prior to joining
General Atlantic, he was a Principal at Sofinnova Investments focused on therapeutics investments from June 2019 to January 2021. Dr.&nbsp;Pitts has also served as a board member of Solve Therapeutics since December 2024, CinCor Pharma, Inc. from
October 2021 to February 2023 and Bolt Biotherapeutics, Inc. from July 2020 to January 2021. He received his Ph.D. in neuroscience from The Rockefeller University and a B.S. in neuroscience from Cornell University. Our board of directors believes
that Dr.&nbsp;Pitts is qualified to serve on our board of directors due to his extensive expertise in healthcare investing and experience as a board member of other biotechnology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Robert Lyne, LLB.</B> Mr.&nbsp;Lyne is the chief executive officer and board member at PureTech and is expected to resign as a director
immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. Mr.&nbsp;Lyne is a seasoned executive with deep experience in life sciences, including his prior role as Chief Executive Officer at Arix
Bioscience plc, a transatlantic venture capital company focused on investing in innovative biotechnology companies from April 2021 to December 2023. Mr.&nbsp;Lyne brings more than a decade of experience leading London-listed life science companies
and portfolio management, with a strong track record in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
governance and executive team leadership. Mr.&nbsp;Lyne began his career as a lawyer at international law firm Bird&nbsp;&amp; Bird LLP in London before moving to Touchstone Innovations, a London
listed biotech and technology investor, which was acquired in 2017. Mr.&nbsp;Lyne has a BA from the University of Oxford and an LLB from Oxford Brookes University. Our board of directors believes that Mr.&nbsp;Lyne is qualified to serve as a member
of the board of directors due to his extensive experience and leadership roles in the pharmaceutical industry. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our executive officers or directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Composition of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our board of directors, which currently consists of eleven members, and will
consist of nine members upon effectiveness of the registration statement of which this prospectus forms a part, upon appointment of Sharon Mates, effective as of such time, and the resignations of Robert Lyne, Eric Elenko and Robert Nelsen,
effective as of such time. The primary responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis and additionally as required.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain members of our board of directors were elected under the provisions of our amended and restated certificate of incorporation
and agreements with our stockholders. These board composition provisions will terminate upon the completion of this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our
directors. Our nominating and corporate governance committee and our board of directors may therefore consider a broad range of factors relating to the qualifications and background of nominees. Our nominating and corporate governance
committee&#8217;s and our board of directors&#8217; priority in selecting board members is the identification of persons who will further the interests of our stockholders through their established record of professional accomplishment, the ability
to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape, professional and personal experiences, and expertise relevant to our growth strategy. Our directors
hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this
offering, and our amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, will also provide that our directors may be removed only for cause by the
affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors,
including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Staggered Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation, which will become effective immediately prior to the completion of this offering, and our amended and restated bylaws, which will be effective upon the effectiveness of the registration statement of which this
prospectus forms a part, will permit our board of directors to establish the authorized number of directors from time to time by resolution. Each director serves until the expiration of the term for which such director was elected or appointed, or
until such director&#8217;s earlier death, resignation or removal. In accordance with our amended and restated certificate of incorporation, our board of directors will be divided into three classes with staggered three-year terms. At each annual
meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will be divided among the three
classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors will be Daphne Zohar, James Healy and Jason Pitts, and their terms will expire at our
first annual meeting of stockholders following this offering, to be held in 2027; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors will be Denice Torres, Sandra Peterson and David Wheadon, and their terms will expire
at our second annual meeting of stockholders following this offering, to be held in 2028; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors will be Steven Paul, Sharon Mates and Robert Hombach, and their terms will expire at
our third annual meeting of stockholders following this offering, to be held in 2029. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that any
additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one third of the directors. The division of our board of directors
into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the listing standards, requirements and rules of The Nasdaq Stock Market LLC, or the Nasdaq Listing Rules, independent directors
must comprise a majority of our board of directors as a listed company within one year of the listing date. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit,
compensation, and nominating and governance committees be independent within twelve months from the date of listing. Audit committee members must also satisfy additional independence criteria, including those set forth in Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under the Nasdaq
Listing Rules, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, a member of an audit committee of a listed company may not,
other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (i)&nbsp;accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any
of its subsidiaries, other than compensation for board service; or (ii)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of
<FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1</FONT> under of the Exchange Act, the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a
director has a relationship to such company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of
compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning
her or his background, employment, and affiliations, including family relationships, our board of directors has determined that each of James Healy, Robert Hombach, Sharon Mates, Jason Pitts, Sandra Peterson, Denice Torres and David Wheadon does not
have relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term is defined under the Nasdaq Listing
Rules. Our board of directors has determined that Daphne Zohar and Steven Paul are not independent under applicable rules and regulations of the SEC and the Nasdaq Listing Rules. In making these determinations, our board of directors considered the
current and prior relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including
the beneficial ownership of our shares by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director and the transactions described in the section titled &#8220;Certain Relationships and Related Person Transactions.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this
offering, we have adopted policies and procedures for director candidates for our nominating and corporate governance committee, which will provide that factors, such as a candidate&#8217;s character, judgment, skills, education, expertise, and
absence of conflicts of interest should be considered in determining director candidates. Our priority in selection of board members will be identification of members who will further the interests of our stockholders through their established
records of professional accomplishment, their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ability to contribute positively to the collaborative culture among board members, and their knowledge of our business and understanding of the competitive landscape in which we operate and
adherence to high ethical standards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure and Board&#8217;s Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, the role of chair of our board of directors is separated from the role of chief executive officer. We believe that separating these
positions allows our chief executive officer to focus on our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business, while allowing the chairman of our board to lead the board of directors in its
fundamental role of providing advice to and independent oversight of management. Our board of directors recognizes the time, effort and energy that the chief executive officer is required to devote to her position in the current business
environment, as well as the commitment required to serve as our chair of our board of directors, particularly as the board of directors&#8217; oversight responsibilities continue to grow. While our amended and restated bylaws and corporate
governance guidelines will not require that our board chair and chief executive officer positions be separate, our board of directors believes that having separate positions is the appropriate leadership structure for us at this time and
demonstrates our commitment to good corporate governance. Our board of directors has adopted, effective prior to the completion of this offering, corporate governance guidelines that will provide that the board of directors may appoint a lead
independent director. The lead independent director will be responsible for calling and presiding over separate meetings of the independent directors. The lead independent director will preside over periodic meetings of independent directors, serve
as a liaison between the chair and the independent directors and perform such additional duties as the board of directors may otherwise determine and delegate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a number of risks,
including risks relating to our financial condition, development, and commercialization activities, operations, strategic direction, and intellectual property as more fully discussed in the section titled &#8220;Risk Factors.&#8221; Management is
responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of risks we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of
risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The role of the board of directors in overseeing the management of our risks is conducted primarily through committees of the board of
directors, as disclosed in the descriptions of each of the committees below and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview of a
particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or
risks, the chairperson of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the risk
oversight role, particularly with respect to risk interrelationships. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors will establish upon the completion of this offering an audit committee, a compensation committee, and a nominating and
corporate governance committee. The composition and responsibilities of each of the committees of our board of directors are described below. Members serve on these committees until their resignation or until otherwise determined by our board of
directors. Each committee will operate under a written charter that satisfies the application rules and regulation of the SEC and the Nasdaq Listing Rules, which we will post to our website at <I>www.seaporttx.com</I> upon the completion of this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has also established a science and technology committee of the board of directors which operates under a
charter duly adopted by the board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information contained on, or accessible through, our website is not a part of this
prospectus, and the inclusion of our website address in this prospectus is only an inactive textual reference. Our board of directors may establish other committees as it deems necessary or appropriate from time to time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the
completion of this offering, our audit committee will consist of Robert Hombach, Denice Torres and James Healy, and the chair of our audit committee will be Robert Hombach. Our board of directors has determined that each member of the audit
committee is independent under Nasdaq Listing Rules and <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3(b)(1)</FONT> of the Exchange Act and can read and understand fundamental financial statements in accordance with applicable requirements. Our
board of directors has also determined that Robert Hombach is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. In arriving at these determinations, our board of directors has examined each audit committee
member&#8217;s scope of experience and the nature of their employment in the corporate finance sector. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of the audit
committee will be to discharge the responsibilities of our board of directors with respect to our corporate accounting and financial reporting processes, systems of internal control and financial-statement audits, and to oversee our independent
registered public accounting firm. Specific responsibilities of our audit committee will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our board of directors oversee our corporate accounting and financial reporting processes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing the selection, engagement, qualifications, independence, and performance of a qualified firm to serve as
the independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing insurance coverage for our officers and directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the preparation of our annual proxy statement, reviewing with management our financial statements to
be included in our quarterly reports to be filed with the SEC, and reviewing with management the &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosures in
our periodic reports filed with the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving, or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our major risk exposures, including financial, operational, cybersecurity, competition, legal, and
regulatory exposures. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee will operate under a written charter, which will be effective upon the
completion of this offering, that satisfies the applicable Nasdaq Listing Rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our compensation committee will consist of Denice Torres, Sandra Peterson and Jason Pitts, and the chair
of our compensation committee will be Denice Torres. Our board of directors has determined that each member of the compensation committee is independent under the Nasdaq Listing Rules and is a
<FONT STYLE="white-space:nowrap">&#8220;non-employee</FONT> director&#8221; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of our compensation committee will be to discharge the responsibilities
of our board of directors in overseeing our compensation policies, plans, and programs and to review and determine the compensation to be paid to our executive officers, directors, and other senior management, as appropriate. Specific
responsibilities of our compensation committee will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation of our chief executive officer, other executive officers, and senior
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the compensation paid to our directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation arrangements with our executive officers and other senior management;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity incentive plans and other benefit programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, adopting, amending, and terminating incentive compensation and equity plans, severance agreements,
profit sharing plans, bonus plans, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections, and any other compensatory arrangements for our executive officers and other senior management;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, evaluating, and recommending to our board of directors succession plans for our executive officers;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and establishing general policies relating to compensation and benefits of our employees, including our
overall compensation philosophy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee will operate under a written charter, which will be
effective upon the completion of this offering, that satisfies the applicable Nasdaq Listing Rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our nominating and corporate governance committee will consist of Sandra Peterson, Denice
Torres and David Wheadon, and the chair of our nominating and corporate governance committee will be Sandra Peterson. Our board of directors has determined that each member of the nominating and corporate governance committee is independent under
the Nasdaq Listing Rules, a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, and free from any relationship that would interfere with the exercise of his or her independent judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of the nominating and corporate governance committee will be to discharge the responsibilities of our board of directors
with respect to our corporate governance functions and to identify, communicate with, evaluate and recommend candidates for our board of directors. Specific responsibilities of our nominating and corporate governance committee will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and
nominees recommended by stockholders, to serve on our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and making recommendations to our board of directors regarding the composition and chairmanship of
the committees of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">instituting plans or programs for the continuing education of our board of directors and orientation of new
directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and making recommendations to our board of directors regarding corporate governance guidelines and
matters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing periodic evaluations of the board of directors&#8217; performance, including committees of the board
of directors and management. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee will operate under a written charter,
which will be effective upon the completion of this offering, that satisfies the applicable Nasdaq Listing Rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Science and Technology Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The science and technology committee, which is chaired by Steven Paul, supports board oversight of our research and development, manufacturing
and supply activities, by providing a forum for review of strategic considerations and issues in such areas, as well as to evaluate relevant emerging technology and advances in the field. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with this offering, we have adopted a written code of business conduct and ethics that applies to all our employees, officers, and directors. This includes our principal executive officer, principal financial officer, and principal
accounting officer or controller, or persons performing similar functions. The full text of our code of business conduct and ethics will be posted on our website at <I>www.seaporttx.com</I>. We intend to disclose on our website any future amendments
of our code of business conduct and ethics or waivers that exempt any principal executive officer, principal financial officer, principal accounting officer or controller, persons performing similar functions, or our directors from provisions in the
code of business conduct and ethics. Information contained on, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only an inactive textual reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of the compensation committee is currently, or has been at any time, one of our officers or employees. None of our officers
currently serves, or has served during the last calendar year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation
committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Recovery </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with this offering, we have adopted a compensation recovery policy that is compliant with the Nasdaq Listing Rules, as required by the Dodd-Frank Act, to be effective in connection with the effectiveness of the registration statement of
which this prospectus forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by Delaware law, provisions in our amended and restated certificate of incorporation and amended and restated bylaws, which will
become effective immediately prior to the completion of this offering and upon the effectiveness of the registration statement of which this prospectus forms a part, respectively, limit or eliminate the personal liability of directors and officers
for a breach of their fiduciary duty of care as a director or officer. The duty of care generally requires that, when acting on behalf of the corporation, a director and, or officer exercise an informed business judgment based on all material
information reasonably available to him or her. Consequently, a director or officer will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director or officer, except for liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director or officer&#8217;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our directors, unlawful payments of dividends or unlawful stock repurchases, or redemptions as provided in
Section&nbsp;174 of the Delaware General Corporation Law, or DGCL; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our officers, any derivative action by or in the right of the corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations of liability do not limit or eliminate our rights or any
stockholder&#8217;s rights to seek <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, such as injunctive relief or rescission. These provisions will not alter a director or officer&#8217;s liability under other laws, such as the federal
securities laws or other state or federal laws. Our amended and restated certificate of incorporation that will become effective upon the closing of this offering also will authorize us to indemnify our officers, directors, and other agents to the
fullest extent permitted under Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by Delaware law, our amended and restated bylaws to be effective immediately
upon effectiveness of the registration statement will provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors, officers, employees, and other agents to the fullest extent permitted by law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we must advance expenses to our directors and officers, and may advance expenses to our employees and other
agents, in connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director or officer, then
the liability of our directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws will also permit us to secure insurance on behalf of any officer, director,
employee, or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our amended and restated bylaws permit such indemnification. We intend to obtain such insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the indemnification that will be provided for in our amended and restated certificate of incorporation and amended and restated
bylaws, we plan to enter into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the DGCL. These indemnification agreements may
require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys&#8217; fees, expenses, judgments, fines, and settlement amounts incurred by a director or executive officer in any action or
proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these provisions and agreements are necessary to attract and
retain qualified individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This description of the indemnification provisions of our
amended and restated certificate of incorporation, our amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as an exhibit to the registration statement
of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
our directors, officers, and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is,
therefore, unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no pending litigation or proceeding naming any of our directors or officers as to which
indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion contains forward-looking statements that are based on our current plans, considerations, expectations, and
determinations regarding future compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from the programs as summarized in this discussion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an emerging growth company and a smaller reporting company, we have opted to comply with the executive compensation disclosure rules
applicable to &#8220;smaller reporting companies,&#8221; as such terms are defined in the rules promulgated under the Securities Act. The compensation provided to our named executive officers for the fiscal year ended December&nbsp;31, 2025, or
Fiscal Year 2025, is detailed in the 2025 Summary Compensation Table and accompanying footnotes and narrative that follow. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named
executive officers for Fiscal Year 2025 are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Daphne Zohar, our Founder, Chief Executive Officer, President&nbsp;and Board Member; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Michael Chen, Ph.D., our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Scientific Officer; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Antony Loebel, M.D., our Chief Medical Officer and President of Clinical Development. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, the compensation of our named executive officers has consisted of a combination of base salary, cash incentive compensation, and
long-term incentive compensation, as more fully described below. Our executive officers, like all full-time employees, are eligible to participate in our health, welfare, and retirement benefit plans. As we transition from a private company to a
publicly traded company, we intend to evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances require. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2025 Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table shows the total compensation earned by, or paid to, our named executive officers for services rendered to us in all capacities during Fiscal Year 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(1)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive
Plan<BR>Compensation<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(2)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(3)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daphne Zohar</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Founder, Chief Executive Officer, President&nbsp;and Board Member</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">768,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">481,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,260,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Chen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">414,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">490,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,094,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antony Loebel, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer and President of Clinical Development</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">670,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount reported represents the aggregate grant date fair value of a stock option award granted to
Dr.&nbsp;Chen in Fiscal Year 2025, computed in accordance with FASB ASC Topic 718. Such grant date fair values do not take into account any estimated forfeitures related to service-based vesting. The assumptions used in calculating the grant date
fair values of the option awards reported in this column are set forth in Note 10 of our consolidated financial statements for Fiscal Year 2025, included elsewhere in this prospectus. The amounts reported in this column reflect the accounting cost
for these option awards and do not correspond to the actual economic value that may be received by Dr.&nbsp;Chen upon the exercise of the option awards or any sale of the underlying securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Annual cash incentive bonuses for performance during Fiscal Year 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent 401(k) employer matching contributions made by us. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to the 2025 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2025 Base Salaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named
executive officers each receive a base salary to compensate them for services rendered to us. Base salaries are intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role, and responsibilities.
Base salaries are expected to be reviewed annually, typically in connection with our annual performance review process, approved by our board of directors or the compensation committee of the board of directors, and may be adjusted from time to time
to realign salaries with market levels after taking into account individual responsibilities, performance, and experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Fiscal
Year 2025, the base salaries for Ms.&nbsp;Zohar, Dr.&nbsp;Chen, and Dr.&nbsp;Loebel were $768,922, $414,000 and $465,750, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2025 Cash
Bonuses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers are eligible to receive annual performance-based cash bonuses, which are designed to provide
appropriate incentives to our executives to achieve corporate performance goals and to reward our executives for individual achievement towards these goals. For Fiscal Year 2025, each of the named executive officers was eligible to earn an annual
performance bonus based on the achievement of certain corporate performance and individual performance goals, with any such bonus expected to be paid in February 2026. For Fiscal Year 2025, the target annual bonus for Ms.&nbsp;Zohar, Dr.&nbsp;Chen,
and Dr.&nbsp;Loebel was 50%, 35% and 35% of base salary, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Incentive Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we do not yet have a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe equity
grants provide our executives with a strong link to our long-term performance, create an ownership culture, and help to align the interests of our executives and our stockholders. In addition, we believe equity grants promote executive retention
because they incentivize our executive officers to remain in our service during the vesting period. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During Fiscal Year 2024, we
granted each of our named executive officers options to purchase common stock of the Company under our 2024 Equity Incentive Plan, as amended from time to time, or the 2024 Plan. In addition, Ms.&nbsp;Zohar received a grant of 1,194,001 shares of
restricted stock, which vested in full in conjunction with our Series B Convertible Preferred Stock Financing in October 2024, and she paid $1.8&nbsp;million to cover the tax liability associated with such grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During Fiscal Year 2025, we granted Dr.&nbsp;Chen an option to purchase common stock of the Company under the 2024 Plan, but none of our other
named executive officers received any equity awards in Fiscal Year 2025. For additional information regarding outstanding equity awards held by our named executive officers as of December&nbsp;31, 2025, see the &#8220;<I>Outstanding Equity Awards at
2025 Fiscal Year End</I>&#8221; table below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan and Health and Welfare Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently maintain a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) retirement savings plan, or the 401(k) Plan, for our
employees, including our named executive officers, who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the 401(k) Plan on the same terms as other full-time employees. Our 401(k) Plan is intended
to qualify for favorable tax treatment under Section&nbsp;401(a) of the Code and contains a cash or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. We provide nondiscretionary contributions under the
401(k) Plan of 3% of the employee&#8217;s annual eligible compensation, subject to the safe harbor limit. We believe that providing a vehicle for <FONT STYLE="white-space:nowrap">tax-deferred</FONT> retirement savings though our 401(k) Plan adds to
the overall desirability of our executive compensation package and further incentivizes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our employees, including our named executive officers, in accordance with our compensation policies. Other than the 401(k) plan, we do not provide any qualified or
<FONT STYLE="white-space:nowrap">non-qualified</FONT> retirement or deferred compensation benefits to our employees, including our named executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our full-time employees, including our named executive officers, are eligible to participate in our health and welfare plans, including
medical dental, and vision benefits, short-term and long-term disability insurance, and basic life and AD&amp;D insurance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements for
Named Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into offer letters with each of our named executive officers in connection with their commencement
of employment, which set forth the terms and conditions of their employment, including base salary, target annual bonus opportunity, initial equity awards and eligibility to participate in our employee benefit plans generally offered to our
employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Daphne Zohar </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;8, 2024, we entered into an offer letter with Ms.&nbsp;Zohar for the position of Chief Executive Officer, which provides for
Ms.&nbsp;Zohar&#8217;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment. Ms.&nbsp;Zohar&#8217;s offer letter was amended on September&nbsp;13, 2024. We refer to the offer letter with Ms.&nbsp;Zohar, as amended, as the Zohar Offer Letter.
Pursuant to the Zohar Offer Letter, Ms.&nbsp;Zohar is eligible to receive an annual base salary, subject to annual review for merit increases at the sole discretion of our board of directors, and an annual performance bonus, as determined by our
board of directors based on her individual performance and the performance of the Company. Ms.&nbsp;Zohar is also eligible to participate in the employee benefit plans generally available to our employees, subject to the terms of those plans. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Ms.&nbsp;Zohar received an initial equity award in the form of an option to purchase a number of shares of our common stock
equal to 7.5% of then fully diluted capitalization of the Company. 1/18th of the shares subject to this option vested on April&nbsp;16, 2024, with the remaining shares vesting in 34 equal monthly installments thereafter. 50% of the then-unvested
shares subject to this option accelerated and became fully vested upon the first closing of the Series B preferred stock financing, which occurred on October&nbsp;18, 2024. The remaining 50% of the unvested shares subject to this option will further
accelerate and become fully vested upon the closing of this offering, subject to Ms.&nbsp;Zohar&#8217;s continued service relationship as our Chief Executive Officer through such closing. In addition, for so long as Ms.&nbsp;Zohar remains our Chief
Executive Officer up to and including our initial public offering (but excluding any shares issued pursuant to any over-allotment option), Ms.&nbsp;Zohar shall receive additional equity grants (either in the form of stock options or restricted
stock) so that her share ownership shall remain at 7.5% of the fully diluted capitalization of the Company, excluding any annual awards or IPO grants that were not issued in connection with her initial award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Zohar Offer Letter, in the event that Ms.&nbsp;Zohar&#8217;s employment is terminated by us without &#8220;cause&#8221; or by
Ms.&nbsp;Zohar for &#8220;good reason&#8221; (each as defined in the Zohar Offer Letter), subject to Ms.&nbsp;Zohar&#8217;s execution of a general release of claims in favor of us and our affiliates, Ms.&nbsp;Zohar is entitled to receive
(i)&nbsp;continuation of her then-current base salary for a period of 12 months, (ii)&nbsp;up to 12 months of COBRA premium payments at the same rate we pay for active and similarly-situated employees, (iii)&nbsp;a prorated portion of her annual
performance bonus based on actual performance, or the Prorated Bonus; and (iv)&nbsp;an extension of the exercise period for Ms.&nbsp;Zohar&#8217;s outstanding stock options granted pursuant to the Zohar Offer Letter to the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the termination date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event that Ms.&nbsp;Zohar&#8217;s
employment is terminated by us without cause or by Ms.&nbsp;Zohar for good reason, in each case, within 12 months following a &#8220;sale event&#8221; (as defined in the Zohar Offer Letter), Ms.&nbsp;Zohar shall be entitled to the same payments and
benefits set forth above, except that in lieu of the Prorated Bonus, Ms.&nbsp;Zohar shall be entitled to receive a lump sum payment of 100% of her annual performance bonus for the year in which the termination occurs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Zohar Offer Letter provides that if any executive officer enters into an
employment agreement that provides for any termination or severance benefits that are more favorable, the Company shall seek to amend the Zohar Offer Letter to provide the more favorable benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Michael Chen </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
April&nbsp;29, 2024, we entered into an offer letter with Dr.&nbsp;Chen for the position of Chief Scientific Officer, which provides for Dr.&nbsp;Chen&#8217;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment. We refer to the offer letter
with Dr.&nbsp;Chen, as the Chen Offer Letter. Pursuant to the Chen Offer Letter, Dr.&nbsp;Chen is eligible to receive an annual base salary, subject to annual review for merit increases at the sole discretion of our board of directors, and an annual
performance bonus, as determined by our board of directors based on his individual performance and the performance of the Company. Dr.&nbsp;Chen is also eligible to participate in the employee benefit plans generally available to our employees,
subject to the terms of those plans. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Dr.&nbsp;Chen received an initial equity award in the form of an option to
purchase 400,618 shares of our common stock. 25% of Dr.&nbsp;Chen&#8217;s initial equity award vested on April&nbsp;9, 2025, with the remaining shares vesting in 36 equal monthly installments thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Chen Offer Letter, in the event that Dr.&nbsp;Chen&#8217;s employment is terminated by us without &#8220;cause&#8221; or by
Dr.&nbsp;Chen for &#8220;good reason&#8221; (each as defined in the Chen Offer Letter), subject to Dr.&nbsp;Chen&#8217;s execution of a general release of claims in favor of us and our affiliates, Dr.&nbsp;Chen is entitled to receive
(i)&nbsp;continuation of his then-current base salary for a period of 6 months, and (ii)&nbsp;up to six months of COBRA premium payments at the same rate we pay for active and similarly-situated employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event that Dr. Chen&#8217;s employment is terminated by us without cause or by Dr. Chen for good reason, in each case,
within 12 months following a &#8220;change in control&#8221; (as defined in the Chen Offer Letter), in lieu of the above benefits, Dr. Chen is entitled to receive (i) continuation of his then-current base salary for a period of 12 months, (ii) up to
12 months of COBRA premium payments at the same rate we pay for active and similarly-situated employees, and (iii) accelerated vesting of the initial equity award. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Antony Loebel, M.D. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;11, 2024, we entered into an offer letter with Dr.&nbsp;Loebel, or the Loebel Offer Letter, for the position of Chief Medical Officer and President of Clinical Development, which provides for Dr.&nbsp;Loebel&#8217;s <FONT
STYLE="white-space:nowrap">at-will</FONT> employment. Pursuant to the Loebel Offer Letter, Dr.&nbsp;Loebel is eligible to receive an annual base salary, subject to annual review for merit increases at the sole discretion of our board of directors,
and an annual performance bonus, as determined by our board of directors based on his individual performance and the performance of our Company. Dr.&nbsp;Loebel is also eligible to participate in the employee benefit plans generally available to our
employees, subject to the terms of those plans. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Dr.&nbsp;Loebel received an initial equity award in the form of an
option to purchase 539,293 shares of our common stock. 25% of Dr.&nbsp;Loebel&#8217;s initial equity award vested on July&nbsp;18, 2025, with the remaining shares vesting in 36 equal monthly installments thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Loebel Offer Letter, in the event that Dr.&nbsp;Loebel&#8217;s employment is terminated by us without &#8220;cause&#8221; or
by Dr.&nbsp;Loebel for &#8220;good reason&#8221; (each as defined in the Loebel Offer Letter), subject to Dr.&nbsp;Loebel&#8217;s execution of a general release of claims in favor of us and our affiliates, Dr.&nbsp;Loebel is entitled to receive
(i)&nbsp;continuation of his then-current base salary for a period of 12 months, (ii)&nbsp;up to 12 months of COBRA premium payments at the same rate we pay for active and similarly-situated employees, (iii)&nbsp;a prorated portion of his annual
performance bonus, and (iv)&nbsp;if the termination occurs after the first anniversary of his start date and on or prior to the second anniversary of his start date (or 12 months if such termination occurs after the first anniversary of his start
date), accelerated vesting of his initial equity award such that he will vest in the portion of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the award that would have vested during the six months following his termination date, or, if the termination occurs after the second anniversary of his start date, accelerated vesting of his
initial equity award such that he will vest in the portion of the award that would have vested during the nine months following the termination date, in each case as if he had remained employed through such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event that Dr.&nbsp;Loebel&#8217;s employment is terminated by us without cause or by Dr.&nbsp;Loebel for good reason
occurs on or within 12 months following a &#8220;change in control&#8221; (as defined in the Loebel Offer Letter), subject to Dr.&nbsp;Loebel&#8217;s execution of a general release of claims in favor of us and our affiliates, in lieu of the above
benefits, Dr.&nbsp;Loebel is entitled to receive (i) 12 months of his then-current base salary, (ii) 12 months of COBRA premium payments at the same rate we pay for active and similarly-situated employees, (iii)&nbsp;a lump sum payment of 100% of
his annual performance bonus, and (iv)&nbsp;accelerated vesting of Dr.&nbsp;Loebel&#8217;s initial equity grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2025
Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning outstanding equity
awards held by each of our named executive officers as of December&nbsp;31, 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>(#)</B><br><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>(#)</B><br><B>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daphne Zohar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/4/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,861,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/3/2034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/29/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/28/2034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Chen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/4/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/3/2034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/24/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/23/2034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/26/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/25/2035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antony Loebel, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/12/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/11/2034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/24/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/23/2034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All option awards were granted under our 2024 Plan, described below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying this stock option vest as follows: 1/18th of the shares vested on April&nbsp;16, 2024,
and the remaining shares vest in 34 equal monthly installments thereafter. Additionally, 50% of the then-unvested shares would accelerate and become fully vested upon the first closing of the Series B preferred stock financing, which occurred on
October&nbsp;18, 2024. The remaining 50% of the unvested shares will further accelerate and become fully vested upon the closing of this offering, subject to Ms.&nbsp;Zohar&#8217;s continued service relationship as our Chief Executive Officer
through such closing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying this stock option award vest as follows: 25% of the shares vested on April&nbsp;9, 2025,
and the remaining 75% of the shares vest in 36 equal monthly installments thereafter, subject to Dr.&nbsp;Chen&#8217;s continued service relationship through the applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying this stock option award vest as follows: 1/3rd of the shares will vest and become
exercisable in 2026 based on annual performance metrics (starting with the 2025 annual Company goals) as determined by our Chief Executive Officer in consultation with the Compensation Committee and the remaining shares will vest and become
exercisable in 1/3rd increments upon each of the two subsequent annual performance metrics (based on the annual Company goals) as determined by our Chief Executive Officer in consultation with the Compensation Committee. For accounting purposes,
this stock option award is not considered granted under FASB ASC Topic 718 as of the date hereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying this stock option award vest as follows: 25% of the shares vest on the first anniversary
of January&nbsp;26, 2025, and the remaining 75% of the shares vest in 36 equal monthly installments thereafter, subject to Dr.&nbsp;Chen&#8217;s continued service relationship through the applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying this stock option award vest as follows: 25% of the shares vested on the first
anniversary of July&nbsp;18, 2024, and the remaining 75% of the shares vest in 36 equal monthly installments thereafter, subject to the executive&#8217;s continued service relationship through the applicable vesting date. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefit and Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Severance Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
April&nbsp;7, 2026, our board of directors adopted the Executive Severance Plan (the &#8220;Severance Plan&#8221;), subject to the effectiveness of the registration statement of which this prospectus forms a part, in which our currently employed
named executive officers and certain other executives are expected to participate. The benefits provided in the Severance Plan will replace any severance for which such named executive officer may be eligible under their existing agreements (unless
otherwise specified). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Severance Plan provides that upon a termination by us for any reason other than for Cause, death or Disability,
or resignation for Good Reason, each as defined in the Severance Plan (a &#8220;Qualifying Termination&#8221;), in each case outside of the period commencing three months prior to and ending on the first month anniversary following a Change in
Control, as defined in the Severance Plan (the &#8220;Change in Control Period&#8221;), eligible participants will be entitled to receive, subject to the execution and delivery of a release of claims in favor of the company and continued compliance
with all applicable restrictive covenants, (a) 12 months of continued base salary (or the annual base salary in effect for the year immediately prior to the year in which the date of termination occurs) (&#8220;Base Salary&#8221;) for the Chief
Executive Officer and the Chief Medical Officer, and nine months for each other chief executive other than the Chief Executive Officer and the Chief Medical Officer, (b)&nbsp;an amount equal to the monthly employer contribution that we would have
made to provide health insurance for the applicable participant if he or she had remained employed by us while receiving payments of Base Salary, (c)&nbsp;a pro-rated annual bonus and (d) for all outstanding and unvested equity awards of the company
that are subject to time based vesting held by&nbsp;(i) the Chief Executive Officer, full accelerated vesting of such awards with an additional 12 months for the exercise period and (ii) the Chief Medical Officer, nine months acceleration on vesting
of such awards. The Severance Plan also provides that upon a Qualifying Termination within the Change in Control Period, an eligible participant will be entitled to receive, in lieu of the payments and benefits above and subject to the execution and
delivery of a release of claims in favor of the company and continued compliance with all applicable restrictive covenants, (a) a lump sum payment equal to the sum of (i)&nbsp;18 months&#8217; Base Salary for the Chief Executive Officer,
12&nbsp;months&#8217; Base Salary and bonus for each chief executive other than the Chief Executive Officer (such periods, the &#8220;CIC Periods&#8221;) and&nbsp;(ii) 1.5&nbsp;times the target annual bonus in effect immediately prior to the date of
termination (or immediately prior to the change in control if higher) for the Chief Executive Officer, 1.0&nbsp;times for each chief executive other than the Chief Executive Officer, (b)&nbsp;an amount equal to the monthly employer contribution,
based on the premiums as of the date of termination, that we would have made to provide health insurance for the applicable participant if he or she had remained employed by us for the duration of the applicable CIC Period and (c) for all
outstanding and unvested equity awards of the company that are subject to time-based vesting held by the participant, full accelerated vesting of such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The payments and benefits provided under the Severance Plan in connection with a Change in Control may not be eligible for a federal income
tax deduction by us pursuant to Section 280G of the Code. These payments and benefits may also subject an eligible participant, including named executive officers, to an excise tax under Section 4999 of the Code. If the payments or benefits payable
in connection with a Change in Control would be subject to the excise tax imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to the participant.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Senior Executive Cash Incentive Bonus Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;7, 2026, our board of directors adopted the Senior Executive Cash Incentive Bonus Plan (the Bonus Plan). The Bonus Plan provides
for cash bonus payments based upon company and individual performance targets established by our compensation committee. The payment targets will be related to financial and operational measures or objectives with respect to our company, or the
corporate performance goals, as well as individual performance objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee may select corporate performance
goals from among the following: developmental, publication, clinical or regulatory milestones; cash flow (including, but not limited to, operating cash flow and free cash flow); revenue; corporate revenue; earnings before interest, taxes,
depreciation and amortization; net income (loss) (either before or after interest, taxes, depreciation and/or amortization); changes in the market price of the Company&#8217;s common stock; economic value-added; acquisitions, licenses,
collaborations or strategic transactions; financing or other capital raising transactions; operating income (loss); return on capital, assets, equity, or investment; stockholder returns; return on sales; total shareholder return; gross or net profit
levels; productivity; expense efficiency; margins; operating efficiency; customer satisfaction; working capital; earnings (loss) per share of the Company&#8217;s common stock; bookings, new bookings or renewals; sales or market shares; number of
prescriptions or prescribing physicians; coverage decisions; leadership development, employee retention and recruiting and other human resources matters; operating income and/or net annual recurring revenue, or any other performance goal selected by
the Compensation Committee, any of which may be (A) measured in absolute terms, as compared to any incremental increase, (B) measured in terms of growth, as compared to results of a peer group, (C) measured against the market as a whole, compared to
applicable market indices and/or measured on a pre-tax or post-tax basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each executive officer who is selected to participate in the
Bonus Plan will have a target bonus opportunity set for each performance period. The bonus formulas will be adopted in each performance period by the compensation committee and communicated to each executive. The corporate performance goals will be
measured at the end of each performance period after our financial reports have been published or such other appropriate time as the compensation committee determines. If the corporate performance goals and individual performance objectives are met,
payments will be made as soon as practicable following the end of each performance period. Subject to the rights contained in any agreement between the executive officer and us, an executive officer shall be required to be employed by us on the
bonus payment date to be eligible to receive a bonus payment under the Bonus Plan. The Bonus Plan also permits the compensation committee to approve additional bonuses to executive officers in its sole discretion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2024 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2024 Plan, was approved by the Company&#8217;s subsidiary&#8217;s Board and Stockholders and became effective for the Company in April 2024
and was subsequently amended in April 2024 and October 2024 to increase the number of shares reserved for issuance thereunder. Under the 2024 Plan, as amended, we have reserved for issuance an aggregate of 12,292,486 shares of our common stock.
These numbers are subject to adjustment in the event of a stock dividend, stock split, <FONT STYLE="white-space:nowrap">spin-off,</FONT> recapitalization, or other similar equity restructuring. Our board of directors has determined not to issue any
further awards under the 2024 Plan following the closing of this offering, but all outstanding awards under the 2024 Plan will continue to be governed by their existing terms. In connection with this offering, we intend to adopt a new incentive
equity plan under which we will grant equity-based awards following this offering, as described below under &#8220;<I>2026 Equity Incentive Plan</I>.&#8221; The following summary describes the material terms of the 2024 Plan. This summary is not a
complete description of all provisions of the 2024 Plan and is qualified in its entirety by reference to the 2024 Plan, which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock underlying any awards that are expired, lapsed, terminated, surrendered, cancelled without having been fully
exercised, or is forfeited in whole or in part (including repurchased by us at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or below the original issuance price), and shares that are withheld upon exercise of an option or settlement of an award to cover the exercise price or tax withholding under our 2024 Plan are
currently added back to the shares of common stock available for issuance under our 2024 Plan (and, following the completion of this offering, will be added back to the shares of common stock available for issuance under the 2026 Equity Incentive
Plan, or the 2026 Plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has acted as administrator of the 2024 Plan. The administrator has full power to, among
other things, select, from among the individuals eligible for awards, determine the specific terms and conditions of each award, and accelerate at any time the exercisability or vesting of any award, subject to the provisions of the 2024 Plan.
Persons eligible to participate in our 2024 Plan are our employees, consultants and directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2024 Plan permits the granting of
(1)&nbsp;options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and (2)&nbsp;options that do not so qualify. The option exercise price of each option is determined by the administrator but
may not be less than 100% of the fair market value of the common stock on the date of grant or, in the case of an incentive stock option granted to a 10% owner, the exercise price shall not be less than 110% of the fair market value of our common
stock on the date of grant. The term of each option is fixed by the administrator and may not exceed ten years from the date of grant (or five years in the case of certain incentive stock option grants). The administrator determines at what time or
times each option may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The administrator of the 2024 Plan may award restricted shares of common stock and restricted stock
units subject to such conditions and restrictions as it determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The administrator of the 2024 Plan may also grant other stock-based
awards to be delivered in the future. The awards may be paid in shares of common stock, cash, or other forms of property, as determined by the administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of certain equity restructuring, including stock dividend, stock split, <FONT STYLE="white-space:nowrap">spin-off,</FONT>
recapitalization or other similar change to the Company&#8217;s capital structure, the administrator of the 2024 Plan shall make appropriate adjustments to the maximum number of shares reserved for issuance under the 2024 Plan, the number and type
of securities subject to outstanding awards under the 2024 Plan, and the exercise price of any outstanding awards under the 2024 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2024 Plan provides that in the event of a &#8220;change in control&#8221; (as defined in the 2024 Plan), the administrator is authorized
to take various actions, including, but not limited to: (i)&nbsp;canceling any award in exchange for cash or property, (ii)&nbsp;accelerating the vesting of any award, (iii)&nbsp;providing for the assumption or substitution of awards by the
successor entity, (iv)&nbsp;adjusting the number and type of shares subject to outstanding awards, (v)&nbsp;replacing the award with other rights or property selected by the administrator, and (vi)&nbsp;terminating the award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may amend, suspend or terminate the 2024 Plan at any time, subject to stockholder approval where required by applicable
law. The administrator of the 2024 Plan may also amend, modify or terminate any outstanding award. The participant&#8217;s consent to such action will be required unless (i)&nbsp;the administrator determines that the action would not materially and
adversely affect the participant, or (ii)&nbsp;the change is permitted under the 2024 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No awards may be granted under our 2024 Plan
after the date that is ten years from the date our 2024 Plan was adopted by our board of directors. As described above, our board of directors has determined not to issue any further awards under our 2024 Plan following the completion of this
offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, options to purchase up to 8,798,389 shares of common stock at a weighted average exercise
price of $4.68 per share and 1,990,001 shares of restricted stock were outstanding under the 2024 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2026 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2026 Plan was adopted by our board of directors on April 7, 2026, approved by our stockholders on April&nbsp;23, 2026 and will become
effective on the date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC. The 2026 Plan will allow us to make equity-based and cash-based incentive awards to our
officers, employees, directors, and consultants. The following summary describes the material terms of the 2026 Plan. This summary is not a complete description of all provisions of the 2026 Plan and is qualified in its entirety by reference to the
2026 Plan, which will be filed as an exhibit to the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>.
We have initially reserved 6,020,000 shares of our common stock for the issuance of awards under the 2026 Plan, or the Initial Limit. The 2026 Plan provides that the number of shares reserved and available for issuance under the 2026 Plan will
automatically increase on January&nbsp;1, 2027 and each January thereafter during the term of the 2026 Plan, by 5% of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31 or such lesser number of shares
as determined by our compensation committee, or the Annual Increase. The number of shares reserved for issuance under the 2026 Plan will be subject to adjustment in the event of a stock split, stock dividend, or other change in our capitalization.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares we issue under the 2026 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common stock
underlying any awards under the 2026 Plan and the 2024 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the
issuance of stock, expire, or are otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2026 Plan. The maximum number of shares of common stock that may be issued pursuant to
incentive stock options shall not exceed the Initial Limit, cumulatively increased on January&nbsp;1, 2027 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or 6,020,000 shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Limit</I>. The grant date fair value of all awards under the 2026 Plan and
all other cash compensation paid by us to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any one calendar year for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director may not exceed $1,000,000;
provided, however, that such amount shall be $750,000 for the calendar year in which the applicable <FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. The 2026 Plan will be administered by our compensation committee. Our compensation committee will have full power
to select, from among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination of awards to participants, to accelerate at any time the
exercisability or vesting of any award, and to determine the specific terms and conditions of each award, subject to the provisions of the 2026 Plan. The compensation committee is specifically authorized to exercise its discretion to reduce the
exercise price of outstanding stock options and stock appreciation rights or effect the repricing of such awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. Persons eligible to participate in the 2026 Plan will be those employees,
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, and consultants selected from time to time by our compensation committee in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options</I>. The 2026 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock
options under Section&nbsp;422 of the Code and options that do not so qualify. The option exercise price of each option will be determined by our compensation committee but may not be less than 100% of the fair market value of our common stock on
the date of grant unless the option (i)&nbsp;is granted pursuant to a transaction described in and in a manner consistent with, Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to United States income tax, or
(iii)&nbsp;complies with or is exempt from Section&nbsp;409A of the Code. The term of each option will be fixed by our compensation committee and may not exceed ten years from the date of grant (or five years in the case of certain incentive stock
options). Our compensation committee will determine at what time or times each option may be exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>. Our compensation committee may award stock appreciation
rights under the 2026 Plan subject to such conditions and restrictions as it determines. Stock appreciation rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise
price. The exercise price of each stock appreciation right may not be less than 100% of the fair market value of our common stock on the date of grant unless the stock appreciation right (i)&nbsp;is granted pursuant to a transaction described in,
and in a manner consistent with, Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to United States income tax, or (iii)&nbsp;complies with or is exempt from Section&nbsp;409A of the Code. The term of each
stock appreciation right will be fixed by our compensation committee and may not exceed ten years from the date of grant. Our compensation committee will determine at what time or times each stock appreciation right may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock and Restricted Stock Units</I>. Our compensation committee may award restricted shares of common stock and restricted
stock units to participants subject to such conditions and restrictions as it determines. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment or other service relationship with us
through a specified vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unrestricted Stock Awards</I>. Our compensation committee may grant shares of common stock that
are free from any restrictions under the 2026 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Equivalent Rights</I>. Our compensation committee may grant dividend equivalent rights to participants that entitle the recipient
to receive credits for dividends that would be paid if the recipient had held a specified number of shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cash-Based
Awards</I>. Our compensation committee may grant cash bonuses under the 2026 Plan to participants, subject to the achievement of certain performance goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sale Event</I>. The 2026 Plan provides that, upon the effectiveness of a &#8220;sale event&#8221; (as defined in the 2026 Plan), an
acquirer or successor entity may assume, continue, or substitute outstanding awards under the 2026 Plan. To the extent that awards granted under the 2026 Plan are not assumed, continued, or substituted by the successor entity, the 2026 Plan and all
awards granted under the 2026 Plan will terminate. In such case, except as may be otherwise provided in the relevant award agreement, all awards with time-based vesting, conditions, or restrictions will become fully vested and exercisable or
nonforfeitable as of the effective time of the sale event and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and exercisable or nonforfeitable in connection with the sale event in the
plan administrator&#8217;s discretion or to the extent specified in the relevant award agreement. In the event of such termination, (i)&nbsp;individuals holding options and stock appreciation rights will be permitted to exercise any options and
stock appreciation rights (to the extent exercisable) within a specified time period, as determined by the compensation committee, prior to the sale event or (ii)&nbsp;we may make or provide for a payment, in cash or in kind, to participants holding
vested and exercisable options and stock appreciation rights equal to the difference between the per share consideration payable to stockholders in the sale event and the exercise price of the options or stock appreciation rights; provided, that any
options or stock appreciation rights with exercise prices equal to or greater than such per share consideration will be cancelled for no consideration. In addition, we may make or provide for a payment, in cash or in kind, to the participants
holding other awards in an amount equal to the per share consideration payable to stockholders in the sale event multiplied by the number of vested shares of common stock under such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment</I>. Our board of directors may amend or discontinue the 2026 Plan and our compensation committee may amend or cancel outstanding
awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may materially and adversely affect rights under an award without the holder&#8217;s consent. Certain amendments to the 2026 Plan require the approval
of our stockholders. The compensation committee is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options and stock appreciation rights or effect the repricing of such awards through cancellation
and <FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No awards may be granted under the 2026 Plan after the date that is ten years from the
effective date of the 2026 Plan. No awards have been made under the 2026 Plan prior to the date hereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2026 Employee Stock Purchase Plan
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP was adopted by our board of directors on April 7, 2026, approved by our stockholders on April&nbsp;23, 2026, and will
become effective on the date immediately preceding the date on which the registration statement of which this prospectus is part is declared effective by the SEC. The ESPP has two components: a component intended to qualify as an &#8220;employee
stock purchase plan&#8221; within the meaning of Section&nbsp;423 of the Code, or the 423 Component, and a component that is not intended to so qualify, or the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. Except as otherwise provided,
the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component will be operated and administered in the same manner as the 423 Component, except where prohibited by law. The following summary describes the material terms of the ESPP. This summary is
not a complete description of all provisions of the ESPP and is qualified in its entirety by reference to the ESPP, which will be filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. The ESPP initially reserves and authorizes the issuance of up to a total of 510,000&nbsp;shares of our common stock
to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January&nbsp;1, 2027 and each January&nbsp;1 thereafter through January&nbsp;1, 2036, by the least of (i) 1%
of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31, (ii) 1,500,000&nbsp;shares of common stock, or (iii)&nbsp;such number of shares of common stock as determined by the administrator of the ESPP.
The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend, or other change in our capitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. All individuals classified as employees on the payroll records of the Company or a &#8220;designated company&#8221; (as
defined in the ESPP) as of the first day of the applicable offering period are eligible to participate in the ESPP, provided that the ESPP administrator may determine in advance of an offering that employees are eligible only if, as of the first day
of the offering, they (a)&nbsp;are customarily employed by us or a designated company for more than 20 hours a week (or such lesser amount determined by the ESPP administrator), (b) are customarily employed by us or a designated company for more
than five months per calendar year, (c)&nbsp;have completed a minimum period of employment as determined by the ESPP administrator, provided such service requirement does not exceed two years of employment, and/or (d)&nbsp;they are not highly
compensated employees. However, any employee who owns, or as a result of participation in the ESPP would own or hold, 5% or more of the total combined voting power or value of all classes of our stock will not be eligible to purchase shares of
common stock under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Offerings</I>. We may make one or more offerings each year to our employees to purchase shares of our
common stock under the ESPP, each of which may consist of one or more purchase periods. Offerings will begin and end on the dates determined by the ESPP administrator, except that no offering will exceed 27 months in duration. Each eligible employee
may elect to participate in any offering by submitting an enrollment form by the deadline established by the ESPP administrator. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
employee who is a participant in the ESPP may purchase shares by authorizing payroll deductions at a minimum of 1% and up to a maximum of 15% of such participant&#8217;s eligible compensation during an offering period (or such other minimum and
maximum as determined by the administrator in advance of an offering). Unless the participating employee has previously withdrawn from the offering, such participant&#8217;s accumulated payroll deductions will be used to purchase shares of our
common stock on the last day of each purchase period at a price equal to 85% of the fair market value of the shares on the first day or the last day of the purchase period, whichever is lower, provided that no more than the number of shares of
common stock determined by dividing $25,000 by the fair market value of our common stock on the first day of such offering period (or such other maximum number of shares as may be established by the administrator) may be purchased by any one
employee during any purchase period. Under applicable tax rules, an employee may purchase no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
more than $25,000 worth of shares of our common stock, valued at the start of the offering period, under the ESPP for each calendar year during which any option granted to the employee is
outstanding at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accumulated payroll deductions of any employee who is not a participant on the last day of an offering
period will be refunded. An employee&#8217;s rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sale Event.</I> In the case of and subject to the consummation of a &#8220;sale event&#8221; (as defined in the ESPP), the administrator of
the ESPP, in its discretion, and on such terms and conditions as it deems appropriate, is authorized to take any one or more of the following actions under the ESPP or with respect to any right under the ESPP to facilitate such transactions or
events: (i)&nbsp;provide for either (A)&nbsp;termination of any outstanding option in exchange for an amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such option had such option been currently
exercisable or (B)&nbsp;the replacement of such outstanding option with other options or property selected by the administrator of the ESPP in its sole discretion; (ii)&nbsp;provide that the outstanding options under the ESPP shall be assumed by the
successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for similar options covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the
number and kind of shares and prices; (iii)&nbsp;make adjustments in the number and type of shares of common stock (or other securities or property) subject to outstanding options under the ESPP and/or in terms and conditions of outstanding options
and options that may be granted in the future; (iv)&nbsp;provide that the offering with respect to which an option relates will be shortened by setting a new exercise date on which such offering period will end; and (v)&nbsp;provide that all
outstanding options shall terminate without being exercised and all amounts in the accounts of participants shall be promptly refunded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment</I>. The ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of
shares of our common stock authorized under the ESPP and certain other amendments require the approval of our stockholders. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive and
Director IPO Grants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the effective date of the registration statement of which this prospectus forms a part, assuming we issue
11,800,000&nbsp;shares in connection with this offering at an assumed public offering price of $17.00&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, we will grant certain executive officers
and directors an aggregate of 2,877,781 options to purchase shares under the 2026 Plan, subject to continued service through such grant date. Based on an assumed fair value of $17.00&nbsp;per share, which is the midpoint of the price range set forth
on the cover page of this prospectus, we estimate that the aggregate grant-date fair value of the shares to be granted in connection with this offering is approximately $35.6&nbsp;million, which is expected to be recognized as stock-based
compensation expense over a period of immediate vesting to four&nbsp;years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_14"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2025 Director Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table presents the compensation awarded to, earned by, or paid to each person who served as a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of our board of directors for their services to us during Fiscal Year 2025. During
Fiscal Year 2025, Ms.&nbsp;Zohar served as a member of our board of directors and received no additional compensation for her service as a member of our board of directors. The compensation for Fiscal Year 2025 received by Ms.&nbsp;Zohar as our
Founder, Chief Executive Officer, President&nbsp;&amp; Board Member is presented in the &#8220;<I>2025 Summary Compensation Table</I>&#8221; above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name
<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid&nbsp;in&nbsp;Cash&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(3)(4)</SUP><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(5)</SUP><SUP STYLE="font-size:75%; vertical-align:top">
</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Elenko, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandra E. Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Pitts, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denice Torres, J.D.<B><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wheadon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven M. Paul, M.D. <SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Hombach <SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">462,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lyne, LLB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bharatt Chowrira, Ph.D., J.D. <SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of Ms.&nbsp;Peterson, Ms.&nbsp;Torres, Dr.&nbsp;Wheadon, and Mr.&nbsp;Hombach has entered into a letter
agreement with our board pursuant to which he or she is entitled to receive an initial option grant and an annual cash retainer of $35,000. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent the cash fees each director earned for their services to our board of directors
during Fiscal Year 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent the aggregate grant date fair value of stock option awards granted to our
directors in Fiscal Year 2025, computed in accordance with FASB ASC Topic 718. Such grant date fair values do not take into account any estimated forfeitures related to service-based vesting. The assumptions used in calculating the grant date fair
values of the option awards reported in this column are set forth in Note 10 of our consolidated financial statements for Fiscal Year 2025, included elsewhere in this prospectus. The amounts reported in this column reflect the accounting cost for
these option awards and do not correspond to the actual economic value that may be received by our directors upon the exercise of the option awards or any sale of the underlying securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The aggregate number of unvested restricted stock and the aggregate number of stock option awards for each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director that were outstanding as of December&nbsp;31, 2025 are, as follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unvested<BR>Restricted<BR>Stock(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unexercised<BR>Stock<BR>Options (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Elenko, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandra E. Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Pitts, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denice Torres, J.D.<B><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wheadon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven M. Paul, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,662,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Hombach</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lyne, LLB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bharatt Chowrira, Ph.D., J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Paul has entered into a Senior Advisor Agreement with us, pursuant to which Dr.&nbsp;Paul spends
approximately 2.5 days per week at the company and shall be entitled to an annual fee of $500,000 and received an initial equity grant intended to represent 5.0% of the Company&#8217;s fully-diluted capitalization as of the effective date. In
addition, Dr.&nbsp;Paul shall receive additional equity grants (either in the form of stock options or restricted stock) so that his share ownership shall remain at 5.0% of the fully diluted capitalization of the Company through our initial public
offering but excluding any shares issued pursuant to any over-allotment option and excluding any annual awards or IPO grants that were not issued in connection with his initial award. 100% of the unvested restricted stock will accelerate and become
fully vested upon the closing of this offering, subject to Dr.&nbsp;Paul&#8217;s continued service relationship through such closing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Hombach was appointed as a director on March&nbsp;3, 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Chowrira resigned from the Board on July 16, 2025 in connection with his departure from PureTech.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we have adopted a new <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy that
will become effective upon the completion of this offering and is designed to enable us to attract and retain, on a long-term basis, highly qualified <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Under the policy, each director who
is not an employee will be paid cash compensation from and after the completion of this offering, as set forth below, which amounts will be payable quarterly in arrears and prorated for partial years of service: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Board of Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual<BR>Retainer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for <FONT STYLE="white-space:nowrap">non-executive</FONT> chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audit Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Nominating and Corporate Governance Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will
provide that, upon initial election to our board of directors, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be granted an equity award with a fair market value of $647,750 or an option to purchase 49,033 shares of our
common stock, or the Initial Grant. The Initial Grant will vest in equal monthly installments over three years from the date of grant, subject to continued service as a director through the applicable vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, on the date of each annual meeting of stockholders following the completion of this offering, each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director who continues as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director following such meeting will be granted an annual equity award with fair market value of $324,000 or option
to purchase 24,516 shares of our common stock, or the Annual Grant. The Annual Grant will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting. These awards are subject to full
accelerated vesting upon the sale of the company. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate amount of compensation, including both equity compensation and cash
compensation, paid to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director in a calendar year period will not exceed $750,000 (or $1,000,000 for the calendar
year in which the applicable <FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to our board of directors). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will reimburse all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses
incurred by <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in attending meetings of the board of directors and committees thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_15"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, and
indemnification arrangements discussed, when required, in the sections titled &#8220;Management,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; and the registration rights described in the section titled
&#8220;Description of Capital Stock&#8212;Registration Rights,&#8221; the following is a description of all transactions since our date of incorporation in April 2024 and each currently proposed transaction in which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have been or are to be a participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at <FONT
STYLE="white-space:nowrap">year-end</FONT> for the last two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of our directors, executive officers or holders of more than 5% or more of our outstanding capital stock, or
any immediate family member of, or person sharing the household with, any of these individuals or entities or affiliated entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Asset Transfer Agreement with PureTech and Convertible Preferred Stock Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, we entered into an Asset Transfer Agreement, as amended in December 2025, or the Asset Transfer Agreement, with PureTech Health
LLC, or PureTech Health, and PureTech LYT, Inc., or PureTech LYT, pursuant to which PureTech Health and PureTech LYT agreed to contribute, convey, assign, transfer, and deliver to us all of PureTech Health and PureTech LYT&#8217;s right, title and
interest in, to, and under the assets related to its Glyph technology or products, including the Monash License Agreement, subject to the terms set forth in the Asset Transfer Agreement. In exchange, we issued 40,000,000 shares of our Series <FONT
STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 302,161 shares of our common stock to PureTech LYT. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with the Asset Transfer Agreement, we have agreed to make milestone payments of up to an aggregate of $10.0&nbsp;million for the first product covered by assets transferred through the Asset Transfer Agreement, or the Seaport Glyph
Product, and up to an aggregate of $5.0&nbsp;million for each subsequent Seaport Glyph Product that achieves certain developmental and commercial milestones. In addition, we are obligated to pay royalties between 3% and 5% on the annual net sales of
each Seaport Glyph Product as follows: less than $500 million: 3%; $500&nbsp;million to $1 billion: 3.5%; $1&nbsp;billion to $2.5 billion: 4%; $2.5&nbsp;billion to $3.5 billion: 4.5%; $3.5&nbsp;billion or greater: 5%. The royalty term will expire on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis as to each Seaport Glyph Product on the later of the ten year anniversary of the first commercial sale of such Seaport Glyph Product in such
country or the date on which the last valid claim of patent rights of such Seaport Glyph Product expires in such country. For additional information, see &#8220;<I>Business-Agreements&#8212;Asset Transfer Agreement with PureTech.</I>&#8221;<I></I>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently, upon entry into the Asset Transfer Agreement, we entered into a stock purchase agreement with PureTech LYT and other
third-party investors, in which we issued 26,342,102 shares of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, or the Series A Financing, of which 8,421,052 shares were issued and sold to PureTech LYT. PureTech
LYT remained a majority investor of Seaport, until the completion of our Series B convertible preferred stock financing, or the Series B Financing, in October 2024, upon which we issued and sold an aggregate amount of 47,578,934 shares of its Series
B convertible preferred stock, of which 3,031,578 shares were issued to PureTech LYT, and an aggregate of 494,734 shares issued to certain of our management and board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transition Services Agreement with PureTech </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with entry into the Asset Transfer Agreement, we also entered into a Transition Services Agreement, or the TSA, with PureTech
pursuant to which PureTech agreed to provide us certain services relating to the orderly transition and continued operation on a transitional basis for one year following the entry into the TSA (unless extended by mutual agreement of the parties or
the earlier termination of all services provided under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the TSA) in consideration of our payment of all fees associated with the transitioned services. Pursuant to the TSA, we made an upfront payment of $0.5&nbsp;million to reimburse PureTech for work
performed by certain third-parties prior to the closing and have paid an aggregate of $14.2 million of expenses since entering into the Asset Transfer Agreement to advance our programs and activities. In 2025, the TSA was amended to extend through
July 2026 to provide ad hoc support as needed; however, the services to be provided under the amended TSA are expected to be de minimis. On April 2, 2026, we and PureTech mutually agreed to terminate the TSA in accordance with its terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Convertible Preferred Stock Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, we issued and sold to certain investors an aggregate of 26,342,102 of Series <FONT STYLE="white-space:nowrap">A-2</FONT>
convertible preferred stock at a price per share of $3.80, for an aggregate purchase price of approximately $100.1&nbsp;million. Each outstanding share of Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock will convert
into one share of common stock immediately prior to the completion of this offering. The following table summarizes the shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> convertible preferred stock issued to our related parties:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Purchasers&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;A&nbsp;Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech LYT, Inc. <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,421,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARCH Venture Fund XII, L.P. <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,894,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,999,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Venture Partners XI, L.P.
<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,052,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Rock Ventures VI, L.P. <SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,947,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional details regarding these stockholders and their equity holdings are included in the section titled
&#8220;Principal Stockholders.&#8221; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">PureTech LYT beneficially owns more than 5% of our outstanding capital stock. Dr.&nbsp;Elenko and
Mr.&nbsp;Lyne, members of our board of directors, were designated to our board of directors by PureTech LYT and are executive officers at PureTech. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ARCH Venture Fund XII, L.P. beneficially owns more than 5% of our outstanding capital stock. Mr.&nbsp;Nelsen, a
member of our board of directors, was designated to our board of directors by ARCH Venture Fund XII, L.P. and is a Managing Director of ARCH Venture Partners. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sofinnova beneficially owns more than 5% of our outstanding capital stock. Dr.&nbsp;Healy, a member of our
board of directors, was designated to our board of directors by Sofinnova and is a Managing Director of Sofinnova. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Third Rock Ventures beneficially own more than 5% of our outstanding capital stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series B Convertible Preferred Stock Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024 and November 2024, we issued and sold to certain investors an aggregate of 47,578,934 shares of Series B convertible preferred
stock at a price per share of $4.75, for an aggregate purchase price of approximately $226.0&nbsp;million. Each outstanding share of Series B convertible preferred stock will convert into one share of common stock immediately prior to the completion
of this offering. The following table summarizes the shares of our Series B convertible preferred stock issued to our related parties: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Purchasers&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B&nbsp;Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Atlantic (SP), L.P. <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,526,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARCH Venture Fund XII, L.P. <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,421,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,999,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech LYT, Inc. <SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,399,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Venture Partners XI, L.P.
<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,526,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Rock Ventures VI, L.P. <SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,526,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven M. Paul <SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lana Gladstein <SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antony Loebel <SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">299,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric D. Green and Jessica Santiago-Green, Trustees, or their Successors in interest, of the Eric
D. Green Living Trust dated November&nbsp;12, 2010&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denice M. Torres Revocable Trust
<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional details regarding these stockholders and their equity holdings are included in the section titled
&#8220;Principal Stockholders.&#8221; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General Atlantic beneficially owns more than 5% of our outstanding capital stock. Dr.&nbsp;Pitts, a member of
our board of directors, was designated to our board of directors by General Atlantic and is a Principal of General Atlantic. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ARCH Venture Fund XII, L.P. beneficially owns more than 5% of our outstanding capital stock. Mr.&nbsp;Nelsen, a
member of our board of directors, was designated to our board of directors by ARCH Venture Fund XII, L.P. and is a Managing Director of ARCH Venture Partners. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">PureTech LYT beneficially owns more than 5% of our outstanding capital stock. Dr.&nbsp;Elenko and
Mr.&nbsp;Lyne, members of our board of directors, were designated to our board of directors by PureTech LYT and are executive officers at PureTech. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sofinnova beneficially owns more than 5% of our outstanding capital stock. Dr.&nbsp;Healy, a member of our
board of directors, was designated to our board of directors by Sofinnova and is a Managing Director of Sofinnova. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Third Rock Ventures beneficially own more than 5% of our outstanding capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Steven M. Paul is Chairman and a member of our board of directors and a senior advisor to the Company.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lana Gladstein is our General Counsel. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Antony Loebel is our Chief Medical Officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Eric Green is our former Chief Operating Officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Denice Torres is a member of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with our Series <FONT STYLE="white-space:nowrap">A-2</FONT> and Series B convertible preferred stock financings, we entered into investors&#8217; rights, voting, and right of first refusal and
<FONT STYLE="white-space:nowrap">co-sale</FONT> agreements containing registration rights and information rights, among other things, with certain holders of our preferred stock and certain holders of our common stock, including holders of more than
5% of our capital stock and entities with which certain of our directors or officers are affiliated. These agreements will terminate upon the closing of this offering, except for the registration rights granted under our amended and restated
investors&#8217; rights agreement, as more fully described in &#8220;Description of Capital Stock&#8212;Registration Rights.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year-ended December&nbsp;31, 2024, we made payments of $0.2 million to Third Rock
Ventures for professional fees. During the year ended December 31, 2025, amounts paid to Third Rock Ventures were not material. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&nbsp;Rights&nbsp;and Side Letters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the initial issuance and sale of our convertible preferred stock, we entered into management rights and side letters with
certain purchasers of our convertible preferred stock, including holders of more than 5% of our capital stock and entities with which certain of our directors or officers are affiliated, pursuant to which such entities were granted
certain&nbsp;management&nbsp;rights, among other things, including the right to consult with and advise our management on significant business issues, review our operating plans, examine our books, and records and inspect our facilities. These
management rights letters will terminate upon completion of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steven M. Paul Advisor Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2024, we entered into a senior advisor agreement with Steven M. Paul, the chair of our board of directors, whereby we pay
Dr.&nbsp;Paul an annual fee of $500,000 and agreed that if at any time while Dr.&nbsp;Paul is providing services to us up to and including the closing of an initial public offering, Dr.&nbsp;Paul&#8217;s ownership reduces to below 5% of our total
outstanding capital on a fully diluted basis including all outstanding options and restricted common stock, we will grant him an additional equity award to maintain his ownership at the 5% threshold. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment and Benefit Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have entered into offer letter or employment agreements with certain of our executive officers, and granted restricted stock and stock options to our executive officers, including an agreement with our Chief Executive Officer pursuant to which we
have agreed to maintain our Chief Executive Officer&#8217;s ownership at a certain percentage of our shares on a fully diluted basis and an agreement pursuant to which we&#8217;ve extended additional benefits to our Chief Executive Officer, as more
fully described in the section titled &#8220;Executive Compensation.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Grants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted restricted stock and options to purchase shares of our common stock to certain of our executive officers and directors. For
more information regarding the options granted to our executive officers and directors, see the sections titled &#8220;Executive Compensation&#8221; and &#8220;Director Compensation.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended
and restated certificate of incorporation will contain provisions limiting the liability of directors and officers, and our amended and restated bylaws will provide that we will indemnify each of our directors and officers to the fullest extent
permitted under Delaware law. Our amended and restated certificate of incorporation and amended and restated bylaws will also provide our board of directors with discretion to indemnify our employees and other agents when determined appropriate by
our board of directors. In addition, we have entered into or intend to enter into an indemnification agreement with each of our directors and executive officers, which will require us to indemnify them. For more information regarding these
agreements, see the section titled &#8220;Management&#8212;Limitations on Liability and Indemnification Agreements.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directed Share Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the underwriters have reserved for sale, at the initial public offering price, up to approximately 590,000&nbsp;shares of our
common stock being offered hereby (approximately 5%) for directors, executive officers, employees and business associates. The directed share program will not limit the ability of our directors, officers, and their family members, or holders of more
than 5% of our capital stock, to purchase more than $120,000 in value of our common stock. We do not currently know the extent to which these related persons will participate in our directed share program, if at all, or the extent to which they will
purchase more than $120,000 in value of our common stock. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Transactions with Related Persons </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a written policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5%
of any series of our common stock, and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the approval or ratification of our board of directors or our
audit committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any series of our common stock, or any member of the immediate family of any
of the foregoing persons, in which the amount involved exceeds $120,000 (or, if less, 1% of the average of our total assets in a fiscal year) and such person would have a direct or indirect interest, must be presented to our board of directors or
our audit committee for review, consideration, and approval. In approving or rejecting any such proposal, our board of directors or our audit committee is to consider the material facts of the transaction, including whether the transaction is on
terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#8217;s interest in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding beneficial ownership of our capital stock as of April&nbsp;1, 2026 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC. Under these rules, beneficial ownership includes any shares
of common stock as to which the individual or entity has sole or shared voting power or investment power. Unless otherwise indicated below, to our knowledge the persons and entities named in the table have sole voting and sole investment power with
respect to all shares that they beneficially owned, subject to community property laws where applicable. We have deemed shares of common stock subject to options that are currently exercisable or exercisable within 60 days of April&nbsp;1, 2026 to
be outstanding and to be beneficially owned by the person holding the option for the purpose of computing the percentage ownership of that person but have not treated them as outstanding for the purpose of computing the percentage ownership of any
other person. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentage ownership before the offering is based on an aggregate of 38,867,817 shares of common stock
(which includes 121,612 shares of restricted common stock) deemed to be outstanding as of April&nbsp;1, 2026 after giving effect to the Preferred Stock Conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentage ownership after the offering is based on 50,667,817 shares of common stock assumed to be outstanding immediately after
the completion of this offering (assuming the sale of 11,800,000 shares of common stock in this offering based on an initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, and no exercise of the underwriters&#8217; option to purchase additional shares). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table does not reflect
any shares of common stock that may be purchased pursuant to our directed share program described under &#8220;Underwriting&#8212;Directed Share Program.&#8221; If any shares are purchased by our existing principal stockholders, directors or their
affiliated entities, the number and percentage of shares of our common stock beneficially owned by them after this offering will differ from those set forth in the following table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o Seaport Therapeutics, Inc., 101 Seaport
Blvd., Floor 12, Boston, Massachusetts 02210. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of Shares<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Greater than 5% Holders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech LYT, Inc. <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,685,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARCH Venture Fund XII, L.P. <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,194,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Atlantic (SP), L.P. <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,351,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Venture Partners XI, L.P.
<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,731,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Rock Ventures VI, L.P. <SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,061,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daphne Zohar,<I> Chief Executive Officer and Director</I><SUP
STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,393,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael C. Chen<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">% &nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of Shares<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antony Loebel, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">% &nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven M. Paul, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,317,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Elenko, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">% &nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy, M.D., Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,731,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Hombach<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">% &nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">% &nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandra E. Peterson<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">% &nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Pitts, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">% &nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denice Torres, J.D.<SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">% &nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wheadon, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">% &nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lyne, LLB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">% &nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (15 persons)<SUP
STYLE="font-size:75%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,824,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 302,479 shares of common stock, (ii) 12,736,014 shares of common stock issuable upon conversion
of Series A-1 preferred stock, (iii) 2,681,265 shares of common stock issuable upon conversion of Series A-2 preferred stock and (iv) 965,255 of common stock issuable upon conversion of Series B preferred stock held by PureTech LYT, Inc. Voting and
investment power over the shares held by PureTech LYT, Inc. is exercised by its parent entity, PureTech Health plc. The board of directors of PureTech Health plc consists of Ms. Sharon Barber-Lui, Dr. Michele Holcomb, Dr. John LaMattina, Dr. Robert
Langer, Ms. Kiran Mazumdar-Shaw and Robert Lyne. None of the members of the board of directors of PureTech Health plc or PureTech Health LLC has individual voting or investment power with respect to such shares. The address for PureTech Health LLC
and the individuals listed above is c/o PureTech Health LLC, 6 Tide Street, Boston, MA 02210. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 2,513,686 shares of common stock issuable upon conversion of Series A-2 preferred stock and
(ii) 2,681,265 shares of common stock issuable upon conversion of Series B preferred stock held by ARCH Venture Fund XII, L.P (&#8220;ARCH XII&#8221;). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture
Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP
XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC
and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. The address for ARCH Ventures Partners, L.P. and the individuals listed above is c/o ARCH Ventures Partners L.P.,
8755 W.&nbsp;Higgins Rd., Suite 1025, Chicago, IL 60631. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 3,351,582 shares of common stock issuable upon conversion of Series B preferred stock held by
General Atlantic (SP), L.P., or General Atlantic SP. The limited partners that share beneficial ownership of the shares held by General Atlantic SP, or the GA Funds, are General Atlantic Partners 100, L.P., or GAP 100, General Atlantic Partners
(Lux), SCSp, or GAP Lux, GAP Coinvestments III, LLC, or GAPCO III, GAP Coinvestments IV, LLC, or GAPCO IV, GAP Coinvestments V, LLC, or GAPCO V, and GAP Coinvestments CDA, L.P., or GAPCO CDA. The general partner of GAP 100 is General Atlantic
GenPar, L.P., or GA GenPar. General Atlantic, L.P., or GA LP, which is controlled by the Partnership Committee of GASC MGP, LLC (the &#8220;Partnership Committee&#8221;), is the managing member of GAPCO III, GAPCO IV and GAPCO V, the general partner
of GAPCO CDA and GA GenPar, and the sole member of General Atlantic (SPV) GP, LLC, or GA SPV. The general partner of GAP Lux is General Atlantic GenPar, (Lux) SCSp, or GA GenPar Lux, and the general partner of GA GenPar Lux is General Atlantic (Lux)
S.&agrave; r.l., or GA Lux. The sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P., or GenPar Bermuda. GAP (Bermuda) L.P., or GAP Bermuda, which is ultimately controlled by the Partnership Committee, is the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
general partner of GenPar Bermuda. There are six members of the Partnership Committee. The Partnership Committee is comprised of senior Managing Directors of General Atlantic: Mr. William E. Ford
(CEO and Chairman), Martin Escobari, Gabriel Caillaux, David Hodgson, Torbjorn Caesar, and Christopher G. Lanning. By virtue of the foregoing, such persons may be deemed to share voting power and the power to direct the disposition of the shares
that each owns of record. Each of the members of the Partnership Committee disclaims ownership of the shares of common stock reported herein except to the extent he or she has a pecuniary interest therein. GA LP, GAP Bermuda, GA Lux, GA GenPar Lux,
GA SPV, and the GA Funds are a &#8220;group&#8221; within the meaning of Rule 13d-5 of the Securities Exchange Act of 1934, as amended. The mailing address of each of the foregoing entities (other than GAP Lux, GA Lux, GA GenPar Lux, GAP Bermuda and
GenPar Bermuda) is c/o&nbsp;General Atlantic Service Company, L.P., 55 East 52nd Street, 33rd Floor, New York, NY 10055. The mailing address of GenPar Bermuda and GAP Bermuda is Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. The mailing
address of GAP Lux, GA GenPar Lux, and GA Lux is 412F, Route d&#8217;Esch, <FONT STYLE="white-space:nowrap">L-1471</FONT> Luxembourg. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,927,159 shares of common stock issuable upon conversion of Series A-2 preferred stock and
(ii) 804,379 shares of common stock issuable upon conversion of Series B preferred stock held by Sofinnova Venture Partners XI, L.P. (&#8220;SVP XI&#8221;), except that Sofinnova Management XI, L.P. (&#8220;SM XI LP&#8221;), the general partner of
SVP XI, may be deemed to have sole voting power, Sofinnova Management XI, L.L.C. (&#8220;SM XI LLC&#8221;), the general partner of SM XI LP, may be deemed to have sole voting power, and James I. Healy, M.D., Ph.D. and Maha Katabi, Ph.D., the
managing members of SM XI LLC, may be deemed to have shared power to vote these shares. Each of SM XI LP, SM XI LLC, Dr. Healy and Dr. Katabi disclaim beneficial ownership of the shares held by SVP XI, except to the extent of their respective
pecuniary interest therein. The principal address for the entities and individuals named in this paragraph is 3000 Sand Hill Road, Building 3-Suite 150, Menlo Park, CA 94025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,256,843 shares of common stock issuable upon conversion of Series A-2 preferred stock and
(ii) 804,379 shares of common stock issuable upon conversion of Series B preferred stock held by Third Rock Ventures VI, L.P., or TRV VI. The sole general partner of TRV VI is Third Rock Ventures GP VI, L.P., or TRV GP VI. The sole general partner
of TRV GP VI is TRV GP VI, LLC, or TRV GP VI LLC. Abbie Celniker, Ph.D.; Robert Tepper, M.D.; Reid Huber, Ph.D.; Jeffrey Tong, Ph.D.; Kevin Gillis; and David Kaufman, M.D., Ph.D. are the managing members of TRV GP VI LLC and collectively make voting
and investment decisions with respect to shares held by TRV VI. The principal address for the entities and individuals named in this paragraph is 201 Brookline Avenue, Suite&nbsp;1401, Boston, MA 02215. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,194,001 shares of common stock and (ii) 2,199,012 shares of common stock underlying
outstanding stock options that are immediately exercisable within 60 days of April 1, 2026. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 3,351 shares of common stock issuable upon conversion of Series B preferred stock and
(ii)&nbsp;259,432 shares of common stock underlying outstanding stock options that are immediately exercisable within 60 days of April 1, 2026. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 20,109 shares of common stock issuable upon conversion of Series B preferred stock and
(ii)&nbsp;256,462 shares of common stock underlying outstanding stock options that are immediately exercisable within 60 days of April 1, 2026. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 796,000 shares of common stock, (ii) 67,031 shares of common stock issuable upon conversion of
Series B preferred stock and (iii) 1,454,680 shares of common stock underlying outstanding stock options that are immediately exercisable within 60 days of April 1, 2026. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of the shares described in footnote (4) above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 29,960 shares of common stock underlying outstanding stock options that are immediately exercisable
within 60 days of April 1, 2026. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 36,380 shares of common stock underlying outstanding stock options that are immediately exercisable
within 60 days of April 1, 2026. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 13,406 shares of common stock issuable upon conversion of Series B preferred stock held by the
Denice M. Torres Revocable Trust and (ii) 53,501 shares of common stock underlying outstanding stock options that are immediately exercisable within 60 days of April 1, 2026. Ms. Torres exercises voting and dispositive power over the shares held by
the Denice M. Torres Revocable Trust. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 44,940 shares of common stock underlying outstanding stock options that are immediately exercisable
within 60 days of April 1, 2026. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 2,292,481 shares of common stock, (ii) 1,927,159 shares of common stock issuable upon
conversion of Series A-2 preferred stock, (iii) 948,493 shares of common stock issuable upon conversion of Series B preferred stock and (iii) 4,656,620 shares of common stock underlying outstanding stock options that are immediately exercisable
within 60 days of April 1, 2026 held by all of our directors and executive officers as a group. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our
capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation, which will become
effective immediately prior to the completion of this offering, and the amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part. Copies of these documents
have been filed with the SEC as exhibits to our registration statement of which this prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will be in effect on the completion
of this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon filing of our amended and restated certificate of incorporation and the completion of this offering, our
authorized capital stock will consist of 700,000,000 shares of common stock, par value $0.0001 per share, including (i) 500,000,000 shares of voting common stock and (ii) 200,000,000 shares of non-voting common stock, and 10,000,000 shares of
preferred stock, par value $0.0001 per share, all of which shares of preferred stock will be undesignated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025,
there were 2,595,342 shares of common stock outstanding (which includes 154,778 shares of unvested restricted common stock), held of record by 5 stockholders, 40,000,000 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock,
26,342,102 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred stock and 47,578,934 shares of Series B preferred stock outstanding and held of record by 34 stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Common Stock and Non-Voting Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are
offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our &#8220;common stock&#8221; refer to our voting common stock. The non-voting common stock will not be listed for trading on any
securities exchange. Immediately after consummation of this offering, no shares of non-voting common stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our common stock and non-voting common stock have identical rights, provided that, (i)&nbsp;except as otherwise expressly
provided in our amended and restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our voting common stock are entitled to one vote per share of common stock,
and holders of our non-voting common stock are not entitled to any votes per share of non-voting common stock, including for the election of directors, and (ii)&nbsp;holders of our voting common stock have no conversion rights, while holders of our
non-voting common stock shall have the right to convert each share of our non-voting common stock into one share of voting common stock at such holder&#8217;s election, provided that as a result of such conversion, such holder, together with its
affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 9.99% of our common stock immediately prior to and following such conversion, unless otherwise as expressly provided for in our amended
and restated certificate of incorporation. However, this ownership limitation may be increased or decreased to any other percentage (not to exceed 19.99%) designated by such holder of non-voting common stock upon 61 days&#8217; notice to us. Unless
otherwise expressly stated, all references to &#8220;common stock&#8221; in this prospectus refer to our voting common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of
our voting common stock and non-voting common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding
preferred stock and the terms of our certificate of incorporation. Our voting common stock and non-voting common stock have no preemptive rights or other subscription rights or redemption or sinking fund provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, holders of our common stock and
non-voting common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock subject to the terms of our certificate of
incorporation. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to
the completion of this offering, all outstanding shares of our convertible preferred stock will be converted into shares of our common stock. Upon the consummation of this offering, our board of directors will have the authority, without further
action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights,
conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms, and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The
issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock
could have the effect of delaying, deferring or preventing a change in control of our Company or other corporate action. Immediately after consummation of this offering, no shares of preferred stock will be outstanding, and we have no present plan
to issue any shares of preferred stock.</P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, 8,798,389 shares of common stock were issuable upon the exercise of outstanding stock options under the 2024
Plan, at a weighted-average exercise price of $4.68 per share; no shares of common stock were issuable upon exercise of outstanding stock options outside of our 2024 Plan; and 6,020,000 shares of our common stock that will become available for
future issuance under our 2026 Plan, including shares reserved for the IPO Grants, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any
automatic increases in the number of shares of common stock reserved for future issuance under the 2026 Plan and any shares underlying outstanding stock awards granted under the 2024 Plan that expire or are repurchased, forfeited, cancelled, or
withheld; and For additional information regarding terms of our equity incentive plans, see the section titled &#8220;Executive Compensation&#8212;Employee Benefit and Equity Compensation Plans.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion
of this offering and subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into in connection with this offering and federal securities laws, certain holders of shares of our common stock, including those shares of our
common stock that will be issued upon the Preferred Stock Conversion in connection with this offering, will initially be entitled to certain rights with respect to registration of such shares under the Securities Act. These shares are referred to as
registrable securities. The holders of these registrable securities will possess these registration rights pursuant to the terms of our second amended and restated investors&#8217; rights agreement and are described in additional detail below. The
registration of shares of our common stock pursuant to the exercise of the registration rights described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is
declared effective. We will pay all registration expenses, other than underwriting discounts, selling commissions, and stock transfer taxes, of the shares registered pursuant to the demand, piggyback and Form
<FONT STYLE="white-space:nowrap">S-3</FONT> registrations described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, in an underwritten offering, the managing
underwriter, if any, has the right, subject to specified conditions and limitations, to limit the number of shares the holders may include. The demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described
below will expire no later than four years after the completion of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, holders of 36,272,475 shares of our common stock, including those issuable upon the Preferred Stock
Conversion, will be entitled to certain demand registration rights pursuant to that certain Investors&#8217; Rights Agreement, by and between us and the investors party thereto, dated as of October&nbsp;18, 2024, or the investors&#8217; rights
agreement. At any time beginning 180 days after the completion of this offering, the holders of at least 9% of these registrable securities may request that we register all or a portion of their shares. We are not required to effect more than two
registration statements which are declared or ordered effective pursuant to these demand registration rights. Such request for registration must cover shares with an anticipated aggregate offering price of at least $15&nbsp;million, net of any
underwriting discounts, selling commissions, and other related expenses. With certain exceptions, we are not required to effect the filing of a registration statement during the period starting with the date of the filing of, and ending on a date 60
days following the effective date of the registration statement for this offering. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, holders of 36,272,475 shares of our common stock, including those issuable upon the Preferred Stock
Conversion, were entitled to, and the necessary percentage of holders waived, their rights to notice of this offering and to include their shares of registrable securities in this offering pursuant to the investors&#8217; rights agreement. After
this offering, in the event that we propose to register any of our securities under the Securities Act, either for our own account or for the account of other security holders, the holders of these registrable securities will be entitled to certain
piggyback registration rights allowing such holders to include their shares in such registration, subject to certain marketing and other limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, holders of 36,272,475 shares of our common stock, including those issuable upon the Preferred Stock
Conversion, will be entitled to certain Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights pursuant to the investors&#8217; rights agreement. Holders of at least 9% of these registrable securities can make a request that we
register their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are qualified to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (which qualification may occur no sooner than twelve calendar months
after the date of this offering) and if the reasonably anticipated aggregate net proceeds of the shares offered would equal or exceed $5&nbsp;million, net of any underwriting discounts, selling commissions and other related expenses. We will not be
required to effect more than two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> within any twelve-month period. The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is further subject to
other specified conditions and limitations. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The demand registration rights and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights granted under our Investor Rights
Agreement will terminate upon the earliest of (i)&nbsp;the closing of a &#8220;Deemed Liquidation Event,&#8221; as such term is defined in our amended and restated certificate of incorporation (as currently in effect), (ii) such date after the
completion of this offering when each holder (A)&nbsp;together with its affiliates (as determined under Rule 144 of the Securities Act) holds less than 1% of our outstanding capital stock and (B)&nbsp;may immediately sell all registrable securities
held by such holder pursuant to Rule 144 of the Securities Act without any volume limitations, or another similar exemption, during any three month period without registration, and (iii)&nbsp;the third anniversary of the completion of this offering.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Our Certificate of Incorporation and Bylaws and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws will include a number of provisions that may have the
effect of delaying, deferring, or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue <FONT
STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Composition and Filling Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will provide for the division of our board of directors into three classes serving
staggered three-year terms, with one class being elected each year. Our amended and restated certificate of incorporation also will provide that directors may be removed only for cause and then only by the affirmative vote of the holders of <FONT
STYLE="white-space:nowrap">two-thirds</FONT> or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size
of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has
the effect of making it more difficult for stockholders to change the composition of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Written Consent of Stockholders
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will provide that all stockholder actions are required to be taken by a vote
of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the
amendment of our amended and restated bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meetings of
Stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws will provide that only a
majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders.
Our amended and restated bylaws will limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advance Notice Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
amended and restated bylaws will establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These
procedures will provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal
executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our amended and restated bylaws will specify the requirements as to form and content of all
stockholders&#8217; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment to our amended and restated certificate of incorporation must first be approved by a majority of our board of directors and, if
required by law or our amended and restated certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote
thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding
shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our amended and restated bylaws may be amended by the
affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the amended and restated bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the
amendment, voting together as a single class, except that the amendment of the provisions relating to notice of stockholder business and nominations and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
special meetings must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and not less than <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority
of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will provide for 10,000,000 authorized shares of preferred stock. The
existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest, or otherwise. For example, if in the due exercise of
its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in
one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of incorporation will grant
our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to
holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring, or preventing a change in control of us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;203 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the DGCL. In general, Section&nbsp;203 prohibits
a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the
business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge, or other disposition involving the interested stockholder of 10% or more of
the assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested
stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated
bylaws will provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on
our behalf, (ii)&nbsp;any action asserting a claim of, or a claim based on, a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees or stockholders to us or our stockholders, (iii)&nbsp;any action
asserting a claim arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or amended and restated bylaws (including the interpretation, validity, or enforceability thereof) or as to which the DGCL
confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability
created by the Exchange Act or the rules and regulations thereunder. Consequently, this choice of forum provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Exchange Act or any other claim for
which the federal courts have exclusive jurisdiction or the Securities Act. Moreover, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created
by the Securities Act or the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our amended and restated bylaws will provide that, unless we
consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause or
causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and
directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents
underlying the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder
may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. We note that investors
cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our amended and restated
bylaws will provide that any person or entity holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section titled &#8220;Management&#8212;Limitations on Liability and Indemnification Agreements.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is currently not listed on any securities exchange. We have applied to have our common stock approved for listing on the
Nasdaq Global Market under the symbol &#8220;SPTX.&#8221; The non-voting common stock will not be listed for trading on any securities exchange. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Transfer Agent and Registrar for our common stock will be Computershare Trust Company, N.A. The transfer agent&#8217;s address is 150 Royall Street, Suite 101, Canton, MA 02021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of our common stock,
including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility of these sales or issuances occurring, could adversely affect the prevailing market price for our common stock or impair our
ability to raise equity capital. Although we have applied to list our common stock on the Nasdaq Global Market, we cannot assure you that there will be an active public market for our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, based on our shares outstanding as of December&nbsp;31, 2025, a total of 50,667,817&nbsp;shares of
common stock will be outstanding, assuming no exercise of the underwriters&#8217; option to purchase additional shares and no exercise of outstanding options. Of the outstanding shares, all of the shares sold in this offering will be freely
tradable, except that any shares held by our affiliates, as that term is defined in Rule 144 under the Securities Act, may only be sold in compliance with the limitations described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144 as
currently in effect, once we have been subject to public company reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, an eligible stockholder is entitled to sell such shares without complying with
the manner of sale, volume limitation, or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. To be an eligible stockholder under Rule 144, such stockholder must not be deemed to have been one
of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and must have beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than
our affiliates. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares without
complying with any of the requirements of Rule 144, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell
shares on expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. Beginning 90 days after the date of this prospectus, within any three-month period, such stockholders may sell a number of shares that does not
exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of common stock then outstanding, which will equal approximately 506,678&nbsp;shares
immediately after this offering, assuming no exercise of the underwriters&#8217; option to purchase additional shares of common stock from us; or </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on the Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form&nbsp;144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales under Rule 144 by our affiliates or
persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 under the Securities
Act, or Rule 701, generally allows a stockholder who was issued shares under a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days, to sell these shares in
reliance on Rule 144, but without being required to comply with the public information, holding period, volume limitation, or notice provisions of Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144
without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares under Rule 701, subject to the
expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act with the SEC
to register the offer and sale of shares of our common stock that are issuable under the 2024 Plan, the 2026 Plan, and the ESPP. These registration statements will become effective immediately upon filing. Shares covered by these registration
statements will then be eligible for sale in the public markets, subject to vesting restrictions, any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below, and Rule 144 limitations applicable to affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, all of our directors and executive officers, and the holders of substantially all of our capital stock and securities convertible into or
exchangeable for our capital stock have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters and/or are subject to market standoff agreements or other agreements with us, which prevents them from selling any
of our common stock or any securities convertible into or exercisable or exchangeable for common stock for a period of not less than 180 days from the date of this prospectus without the prior written consent of Goldman Sachs &amp; Co. LLC and J.P.
Morgan Securities LLC and the Company, subject to certain exceptions. For more information, see the section titled &#8220;Underwriting.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of
this offering, certain holders of our securities will be entitled to various rights with respect to registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming
fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. For more information, see the section titled &#8220;Description of Capital Stock&#8212;Registration Rights.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_19"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of material U.S. federal income tax
consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) of the purchase, ownership, and disposition of our common stock issued pursuant to this offering. This discussion is based on the Internal Revenue Code of
1986, as amended, or the Code, Treasury Regulations promulgated thereunder, published rulings, and administrative pronouncements of the U.S. Internal Revenue Service, or IRS, and judicial decisions, all as in effect on the date hereof. These
authorities are subject to differing interpretations and may change, possibly with retroactive effect, resulting in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the IRS with respect
to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders who purchase our common stock pursuant to this offering
and who hold our common stock as a &#8220;capital asset&#8221; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion is not a complete analysis of all potential U.S. federal income tax
consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules under Section&nbsp;451(b) of the Code, and also
does not address any U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax consequences, such as estate or gift tax consequences, or any tax consequences arising under any state, local, or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of such <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s particular circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject
to special rules under the U.S. federal income tax laws, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens, or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements treated as pass-through or disregarded entities for U.S. federal
income tax purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;controlled foreign corporations&#8221;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;passive foreign investment companies&#8221;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, mutual funds, financial institutions, investment funds, insurance companies, brokers, dealers, or traders
in stock, securities, commodities or currencies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations and governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquire our common stock through the exercise of an option or otherwise as compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">qualified foreign pension funds as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who have elected to mark securities to market; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedging or conversion transaction or straddle, or synthetic
security or a constructive sale, or other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity or arrangement
that is classified as a partnership for U.S. federal income tax purposes holds our common stock, the U.S. federal income tax treatment of a partner in the partnership generally will depend on the status of the partner, the activities of the
partnership and certain determinations made at the partner level. Partnerships holding our common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them
of owning and disposing of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE
INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS OR UNDER ANY APPLICABLE INCOME TAX TREATY. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder is any beneficial owner of our common stock that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or any organization taxable as a corporation for U.S. federal income taxes that is not created or
organized under the laws of the United States, any state thereof, or the District of Columbia; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign trust or estate, the income of which is not subject to U.S. federal income tax on a net income basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described under &#8220;<I>Dividend Policy</I>,&#8221; we do not currently anticipate declaring or paying, for the foreseeable future, any
distributions on our capital stock. However, if we were to distribute cash or other property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated
earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will then constitute a return of capital and will first be applied against and reduce a
holder&#8217;s tax basis in our common stock, but not below zero. Any excess will be treated as gain realized on the sale or other disposition of our common stock and will be treated as described under &#8220;&#8212;Gain on sale or other taxable
disposition of our common stock&#8221; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding effectively connected income, backup withholding
and FATCA (as defined below), dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such
lower rate specified by an applicable income tax treaty. To receive the benefit of a reduced treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must furnish to us or our withholding agent with a timely and valid IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of individuals) or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities), or other appropriate form, certifying such
holder&#8217;s qualification for the reduced rate. This certification must be provided to us or our withholding agent before the payment of the dividends and must be updated periodically. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder holds our common stock through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s behalf, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to
provide appropriate documentation to the agent, which then will be required to provide certification to us or our withholding agent, either directly or through other intermediaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock in connection with the conduct of a trade or business in
the United States, and dividends paid on our common stock are effectively connected with such holder&#8217;s U.S. trade or business (and, if required by an applicable tax treaty, are attributable to such holder&#8217;s permanent establishment or
fixed base in the United States), such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be exempt from U.S. federal withholding tax. To claim the exemption, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally
must furnish a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form), certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#8217;s conduct of
a trade or business within the United States to the applicable withholding agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, any such effectively connected dividends paid
on our common stock generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation also may be subject to an additional branch profits tax equal
to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected dividends, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not provide the required certification on a timely basis, but that qualify
for a reduced treaty rate, may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any
applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding backup withholding and FATCA (as defined below), a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder generally will not be subject to U.S. federal income tax on any gain realized on the sale or other taxable disposition of our common stock, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s
conduct of a trade or business in the United States and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the
United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in
the United States for a period or periods aggregating 183 days or more during the taxable year of the disposition, and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a &#8220;United States real property interest&#8221; by reason of our status as a
United States real property holding corporation, or USRPHC, for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s
holding period for our common stock, and our common stock is not &#8220;regularly traded&#8221; on an &#8220;established securities market&#8221; within the meaning of applicable Treasury Regulations, during the calendar year in which the sale or
other disposition occurs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above generally will be subject to U.S. federal
income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation also may be
subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the second bullet point above will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate specified by
an applicable income tax treaty), but may be offset by certain U.S.- source capital losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (even though the individual is not considered a resident of the United States), provided that
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Determining whether we are a USRPHC depends on the fair market value of our United States real property interests relative to the fair market
value of our worldwide real property interests and our other trade or business assets. We believe that we are not currently and we do not anticipate becoming a USRPHC for U.S. federal income tax purposes, although there can be no assurance we have
not been, are not currently or will not in the future become a USRPHC. Even if we are treated as a USRPHC, gain realized by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder on a disposition of our common stock will not be subject to U.S.
federal income tax so long as (1)&nbsp;the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder owned, directly, indirectly and constructively, no more than 5% of our common stock at all times within the shorter of (a)&nbsp;the five-year period
preceding the disposition or (b)&nbsp;the holder&#8217;s holding period and (2)&nbsp;our common stock is &#8220;regularly traded&#8221; on an &#8220;established securities market,&#8221; within the meaning of applicable Treasury Regulations. There
can be no assurance that our common stock qualifies as regularly traded on an established securities market for purposes of the rules described above. Prospective investors are encouraged to consult their own tax advisors regarding the possible
consequences to them if we have been, are or were to become a USRPHC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors
regarding any applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual reports are required to be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder indicating
the amount of distributions on our common stock paid to such holder and the amount of any tax withheld with respect to those distributions. These information reporting requirements apply even if no withholding was required because the distributions
were effectively connected with the holder&#8217;s conduct of a U.S. trade or business, or withholding was reduced or eliminated by an applicable income tax treaty. This information also may be made available under a specific treaty or agreement
with the tax authorities in the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is established. Backup withholding, currently at a 24% rate, generally will not apply to payments to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder of distributions on or the gross proceeds of a disposition of our common stock provided the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder furnishes the required certification for its <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> or IRS Form <FONT
STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption, and if the payor does not have actual knowledge, or reason to know, that the holder is a U.S. person who is not an exempt recipient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. If any amount is withheld under the backup withholding rules, the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder should consult with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a credit against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s
U.S. federal income tax liability, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withholding on Foreign Entities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sections 1471 through 1474 of the Code, which are commonly referred to as FATCA, impose a U.S. federal withholding tax of 30% on certain
payments made to a &#8220;foreign financial institution&#8221; (as specially defined under these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S.
tax authorities substantial information regarding certain U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or
an exemption applies. FATCA also generally imposes a U.S. federal withholding tax of 30% on certain payments made to a <FONT STYLE="white-space:nowrap">&#8220;non-financial</FONT> foreign entity&#8221; (as specially defined under these rules) unless
such entity provides the withholding agent a certification that it does not have any &#8220;substantial United States owners&#8221; or provides information identifying certain direct and indirect U.S. owners of the entity or an exemption applies. An
intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of
such taxes. FATCA currently applies to dividends paid on our common stock and would have applied also to payments of gross proceeds from the sale or other disposition of our common stock. However, proposed regulations under FATCA provide for the
elimination of the federal withholding tax of 30% applicable to gross proceeds of a sale or other disposition of from property of a type that can produce U.S.-source dividends or interest. Under these proposed Treasury Regulations (which may be
relied upon by taxpayers prior to finalization), FATCA withholding does not apply to gross proceeds from sales or other dispositions of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective investors are encouraged to consult with their tax advisors regarding the possible implications of FATCA on their investment in
our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF ACQUIRING, OWNING, AND DISPOSING OF OUR
COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT AND PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, <FONT STYLE="white-space:nowrap">NON-U.S.,</FONT> OR U.S. FEDERAL <FONT
STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain
conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC, J.P. Morgan Securities LLC, and Leerink Partners LLC are the representatives of the underwriters.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are committed to take and pay for all of the shares being offered, if any are taken,
other than the shares covered by the option described below unless and until this option is exercised. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have an
option to buy up to an additional 1,770,000&nbsp;shares of our common stock from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise that option for 30 days. If
any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received indications of interest from entities affiliated with General Atlantic to purchase up to $50&nbsp;million in shares of our
common stock in this offering at the initial public offering price per share, on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, nor a
commitment of the Company or the underwriters to allocate or sell, more, fewer or no shares may be sold to General Atlantic in this offering. The underwriters will receive the same underwriting discount and commissions on these shares as they will
on any other shares sold to the public in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per share and total estimated underwriting
discounts and commissions to be paid to the underwriters by us. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase 1,770,000 additional shares of our common stock from us. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares sold by the underwriters to the public will initially be offered at the initial public offering
price set forth on the cover page of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&#8195;&#8195;&#8195;&#8195; per share from the initial public offering price. After the initial
offering of the shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#8217; right to reject any
order in whole or in part. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our officers, directors, and holders of substantially all of our common stock and securities
convertible into or exchangeable for our common stock have agreed or will agree with the underwriters, subject to certain exceptions, not to dispose of or hedge any of our or their common stock or securities convertible into or exchangeable for
shares of common stock, or collectively, the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior written consent of Goldman Sachs &amp; Co. LLC and J.P. Morgan Securities LLC and the Company. This agreement does not apply to any existing employee benefit plans. See the section titled
&#8220;Shares Available for Future Sale&#8221; for a discussion of certain transfer restrictions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described in the
immediately preceding paragraph do not apply to our officers, directors and holders of substantially all of our capital stock and securities convertible into or exchangeable for our common stock with respect to: Transfers of <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities (i)&nbsp;as one or more bona fide gifts or charitable contributions, or for bona fide estate planning purposes, (ii)&nbsp;upon death by will, testamentary document or intestate succession,
(iii)&nbsp;if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a natural person, to any member of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s immediate family or to any trust for the direct or indirect benefit of
such <FONT STYLE="white-space:nowrap">lock-up</FONT> party or the immediate family of such <FONT STYLE="white-space:nowrap">lock-up</FONT> party or, if such <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a trust, to a trust or beneficiary
of the trust or the estate of a beneficiary of such trust, (iv)&nbsp;to a corporation, partnership, limited liability company or other entity of which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and the immediate family of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party are the legal and beneficial owner of all of the outstanding equity securities or similar interests, (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer would be
permissible under clauses (i)&nbsp;through (iv) above, (vi)&nbsp;if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation,
partnership, limited liability company, trust or other business entity that is a subsidiary or an affiliate (as defined in Rule 405 under the Securities Act) of such <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or
other entity which fund or entity is controlled or managed by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or affiliates of such <FONT STYLE="white-space:nowrap">lock-up</FONT> party (including, for the avoidance of doubt, where the
undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B)&nbsp;as part of a disposition, transfer or distribution by the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party to its stockholders, partners, members or other equityholders or to the estate of any such stockholders, partners, members or other equityholders, (vii)&nbsp;by operation of law, such as pursuant
to a qualified domestic order, divorce settlement, divorce decree or separation agreement, (viii)&nbsp;to us from one of our employees upon death, disability or termination of employment, in each case, of such employee, (ix)&nbsp;if the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party is not one of our officers or directors, in connection with a sale of such <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s shares of common stock acquired (A)&nbsp;from the underwriters
in this offering or (B)&nbsp;in open market transactions after the closing date of this offering or (x)&nbsp;to us in connection with the vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares
of common stock (including, in each case, by way of &#8220;net&#8221; or &#8220;cashless&#8221; exercise), including any transfer to us for the payment of tax withholdings or remittance payments due as a result of the vesting, settlement or exercise
of such restricted stock units, options, warrants or other rights, or in connection with the conversion of convertible securities, in all such cases pursuant to equity awards granted under a stock incentive plan or other equity award plan, or
pursuant to the terms of convertible securities, each as described in this prospectus, provided that any securities received upon such vesting, settlement, exercise or conversion shall be subject to the terms of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; provided that (A)&nbsp;in the case of clauses (i), (ii), (iii), (iv), (v) and (vi)&nbsp;above, such transfer or distribution shall not involve a disposition for value, (B)&nbsp;in the case
of clauses (i), (ii), (iii), (iv), (v), (vi) and (vii)&nbsp;above, it shall be a condition to the transfer or distribution that the donee, devisee, transferee or distributee, as the case may be, shall sign and deliver a lock up agreement containing
the same restrictions set forth above, (C)&nbsp;in the case of clauses (ii), (iii), (iv), (v) and (vi)&nbsp;above, no filing by any party (including, without limitation, any donor, donee, devisee, transferor, transferee, distributor or distributee)
under the Exchange Act or other public filing, report or announcement reporting a reduction in beneficial ownership of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall be required or shall be voluntarily made in connection with such
transfer or distribution, and (D)&nbsp;in the case of clauses (i), (vii), (viii), (ix) and (x)&nbsp;above, no filing under the Exchange Act or other public filing, report or announcement shall be voluntarily made, and if any such filing, report or
announcement shall be legally required during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, such filing, report or announcement shall clearly indicate in the footnotes thereto (A)&nbsp;the circumstances of such transfer or distribution
and (B)&nbsp;in the case of a transfer or distribution pursuant to clauses (i)&nbsp;or (vii) above, that the donee, devisee, transferee or distributee has agreed to be bound by a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement containing
the same restrictions set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the <FONT STYLE="white-space:nowrap">lock-up</FONT> party may (a)&nbsp;enter into a
written plan meeting the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act relating to the transfer, sale or other disposition of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities, if then permitted by us, provided that none of the securities subject to such plan may be transferred, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sold or otherwise disposed of until after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period and no public announcement, report or filing under the Exchange Act, or any
other public filing, report or announcement, shall be voluntarily made regarding the establishment of such plan during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, and if any such filing, report or announcement shall be legally
required during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, such filing, report or announcement shall clearly indicate in the footnotes thereto that none of the securities subject to such plan may be transferred, sold or otherwise
disposed of pursuant to such plan until after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, (b)&nbsp;(i) transfer its <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities pursuant to a bona fide third-party
tender offer, merger, consolidation or other similar transaction that is approved by our board of directors and made to all holders of our capital stock involving a change of control of us, in one transaction or a series of related transactions, to
a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold at least a majority of our outstanding voting securities (or the voting securities of the surviving
entity) and (ii)&nbsp;enter into any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of common stock or other such securities in
connection with a transaction described in clause (i); provided that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall remain subject to the provisions of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, (c)&nbsp;transfer the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities to us pursuant to an agreement under which we have the option to repurchase shares or a right of first refusal with respect to transfer of such shares, provided that no filing under the Exchange
Act or other public filing, report or announcement shall be voluntarily made, and if any such filing, report or announcement shall be legally required during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, such filing, report or
announcement shall clearly indicate in the footnotes thereto the circumstances of such transfer or distribution, or (d)&nbsp;convert outstanding shares of our convertible preferred stock into shares of common stock, provided that any such shares
received upon such conversion shall remain subject to the provisions of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions on transfers or other dispositions by us described above do not apply to us with respect to (i)&nbsp;the sale of shares of
common stock pursuant to this offering, (ii)&nbsp;the issuance of shares of common stock or any securities (or any securities (including without limitation options, restricted stock or restricted stock units) convertible into, or exercisable for,
shares of common stock pursuant to any employee stock option plan, incentive plan, stock plan, dividend reinvestment plan or otherwise in equity compensation arrangements in place as of the date of the underwriting agreement and described in this
prospectus, (iii)&nbsp;the grant of awards pursuant to employee equity-based compensation plans, incentive plans, stock plans, or other arrangements in place as of the date of the underwriting agreement and described in this prospectus,
(iv)&nbsp;the filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> in connection with the registration of shares of common stock issuable under any employee equity-based compensation plan, incentive plan, stock
plan, dividend reinvestment plan adopted and approved by the our board of directors prior to the date of the underwriting agreement and described in this prospectus, (v)&nbsp;the issuance of up to 5% of the outstanding shares of our common stock in
connection with the acquisition of the assets of, or a majority or controlling portion of the equity of, or a joint venture with another entity in connection with its acquisition us of such entity and (vi)&nbsp;the offer and sale of shares of our
common stock pursuant to the concurrent private placement (if consummated); provided that each recipient of any shares of common stock issued or sold pursuant to (ii)-(iii) and (v)&nbsp;above enter into a
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters with the same restrictions set forth above. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to
the offering, there has been no public market for the shares of our common stock. The initial public offering price has been negotiated among us and the representatives. Among the factors to be considered in determining the initial public offering
price of the shares, in addition to prevailing market conditions, will be our historical performance, estimates of the business potential and earnings prospects of us, an assessment of our management and the consideration of the above factors in
relation to market valuation of companies in related businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our common stock on the Nasdaq Global Market
under the symbol &#8220;SPTX.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell shares of our common
stock in the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are
required to purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#8220;covered short position&#8221; is a short position that is not greater than the amount of
additional shares for which the underwriters&#8217; option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open
market.&#8195;In determining the source of shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may
purchase additional shares pursuant to the option described above. &#8220;Naked&#8221; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised.
The underwriters must cover any such naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common
stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the
completion of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the
underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may
have the effect of preventing or retarding a decline in the market price of our common stock, and together with the imposition of the penalty bid, may stabilize, maintain, or otherwise affect the market price of our common stock. As a result, the
price of the common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected
on the Nasdaq Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that our share of the total expenses of the offering, excluding the estimated underwriting discounts and commissions, will be
approximately $3.1&nbsp;million. We have agreed to reimburse the underwriters for certain of their expenses in an amount up to $40,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
sales and trading, commercial, and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage, and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT>
activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to us and to persons and entities with relationships with us, for which they received or
will receive customary fees and expenses.</P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Concurrent Private Placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing stockholders, including affiliates of the underwriters, may purchase up to an aggregate of $20.0&nbsp;million in shares
of our common stock in a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended, on the same pricing, terms and conditions of this offering. The private placement, if consummated, would close
concurrently with, and be contingent and conditioned upon the consummation of, this offering, as well as other customary closing conditions. However, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this offering is not contingent on the consummation of the concurrent private placement. Because we have not entered into a binding agreement with such existing stockholders, we could determine
to sell fewer or no shares to these existing stockholders, and any of such existing stockholders could determine to purchase more, fewer or no shares in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of their various business activities, the underwriters, and their respective affiliates, officers, directors, and
employees may purchase, sell, or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps, and other financial instruments for their own account and for the accounts of their
customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of ours (directly, as collateral securing other obligations or otherwise) and/or persons and entities with relationships with us.
For example, affiliates of Goldman Sachs &amp; Co. LLC, including certain investment funds managed by Goldman Sachs &amp; Co. LLC, own an aggregate of 2,431,579 shares of our Series&nbsp;B preferred stock, which will automatically convert into an
aggregate of 774,212&nbsp;shares of our common stock in connection with this offering. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color, or trading ideas and/or publish or
express independent research views in respect of such assets, securities, or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities, and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Directed Share Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the underwriters have reserved up to 5% of the common stock offered by this prospectus for sale at the initial public offering
price for sale at the initial public offering price to our directors, officers, certain employees and certain other persons associated with us. The sales will be made by Goldman Sachs &amp; Co. LLC through a directed share program. We do not know if
these persons will choose to purchase all or any portion of these reserved shares, but any purchases they do make will reduce the number of shares of common stock available to the general public. Any reserved shares not so purchased will be offered
by the underwriters to the general public on the same terms as the other shares of common stock. Except for reserved shares purchased by our executive officers and directors, these reserved shares will not be subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> restrictions described elsewhere in this prospectus. We have agreed to indemnify Goldman Sachs &amp; Co. LLC against certain liabilities and expenses, including liabilities under the Securities Act of 1933,
as amended, or the Securities Act, in connection with the sales of the directed shares. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in the European Economic Area </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the EEA, or, each, a Relevant Member State, an offer to the public of any shares may not be made in that
Relevant Member State, except that an offer to the public in that Relevant Member State of any shares may be made at any time under the following exemptions under the EU Prospectus Regulation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a &#8220;qualified investor&#8221; as defined under the EU Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than &#8220;qualified investors&#8221; as defined under the
EU Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the EU Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall result in a requirement for the Company or any of the underwriters to publish a prospectus pursuant to Article 3
of the Prospectus Regulation or a supplemental prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, warranted and agreed to
and with each of the underwriters and the Company that it is a qualified investor within the meaning of Article 2 of the EU Prospectus Regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in
Article 1(4) of the EU Prospectus Regulation, each financial intermediary will also be deemed to have represented, warranted, and agreed that the shares acquired by it in the offer have not been acquired on a
<FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public, other than their
offer or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, warranties, and
agreements. Notwithstanding the above, a person who is not a &#8220;qualified investor&#8221; and who has notified the underwriters of such fact in writing may, with the prior consent of the Notwithstanding the above, a person who is not a
&#8220;qualified investor&#8221; and who has notified the underwriters of such fact in writing may, with the prior consent of the underwriters, be permitted to acquire shares in the offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any shares in any Relevant Member State
means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#8220;EU
Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in the United Kingdom </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An offer to the public of any shares may not be made in the UK, except that an offer to the public in the UK of any shares may be made at any
time under the following exemptions under the UK Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a &#8220;qualified investor&#8221; as defined under the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than &#8220;qualified investors&#8221; as defined under the
UK Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within section 86 of the Financial Services and Markets Act 2000, as
amended, or the FSMA, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall result in a requirement for the Company or any
Bookrunner to publish a prospectus pursuant to section 85 of the FSMA or a supplemental prospectus pursuant to Article 23 of the UK Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed
to have represented, warranted and agreed to and with each of the underwriters and the Company that it is a qualified investor within the meaning of Article 2 of the UK Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article 1(4) of the UK Prospectus Regulation, each
financial intermediary will also be deemed to have represented, warranted, and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they
been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public, other than their offer or resale in the UK to qualified investors as so defined or in circumstances in which
the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, the underwriters and their
affiliates will rely upon the truth and accuracy of the foregoing representations, warranties, and agreements. Notwithstanding the above, a person who is not a &#8220;qualified investor&#8221; and who has notified the underwriters of such fact in
writing may, with the prior consent of underwriters, be permitted to acquire shares in the offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the
expression an &#8220;offer to the public&#8221; in relation to any shares in the UK means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to
decide to purchase or subscribe for any shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Prospectus is only being distributed to and is only directed at: (A)&nbsp;persons who
are outside the UK; or (B)&nbsp;qualified investors who are also (i)&nbsp;investment professionals falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005, or the Order, or (ii)&nbsp;high net worth companies, and other persons to
whom it may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of the Order, or, all such persons falling within (1)-(3) together being referred to as, relevant persons. The shares are only available to, and any invitation, offer,
or agreement to subscribe, purchase, or otherwise acquire the shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this Prospectus or any of its contents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Canada </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT
STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption form, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if this offering memorandum (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed
by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory of these rights or consult with a
legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Hong Kong </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an
offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong), or the Companies (Winding Up and Miscellaneous Provisions) Ordinance, or which do not constitute an
invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the Securities and Futures Ordinance, or (ii)&nbsp;to &#8220;professional investors&#8221; as defined in the Securities and
Futures Ordinance and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no
advertisement, invitation, or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are
likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only
to &#8220;professional investors&#8221; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Singapore </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as defined under Section&nbsp;4A of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities and Futures Act, Chapter 289 of Singapore, or the SFA, under Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to
Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of,
any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or
purchased under Section&nbsp;275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital
of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the
shares under Section&nbsp;275 of the SFA except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (2) where such transfer arises from an offer in that
corporation&#8217;s securities pursuant to Section&nbsp;275(1A) of the SFA, (3)&nbsp;where no consideration is or will be given for the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in Section&nbsp;276(7) of the
SFA, or (6)&nbsp;as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore, or Regulation 32. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a trust (where the trustee is not
an accredited investor (as defined in Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries&#8217; rights and interest (howsoever described) in that
trust shall not be transferable for 6 months after that trust has acquired the shares under Section&nbsp;275 of the SFA except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in
Section&nbsp;275(2) of the SFA), (2) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction
(whether such amount is to be paid for in cash or by exchange of securities or other assets), (3) where no consideration is or will be given for the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in
Section&nbsp;276(7) of the SFA, or (6)&nbsp;as specified in Regulation&nbsp;32. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Japan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as
amended), or the FIEA. The shares may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of
Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any
relevant laws and regulations of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in the Dubai International Financial Centre </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority, or the DFSA.
This prospectus is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any
documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares of common stock to which this prospectus
relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares of common stock offered should conduct their own due diligence on the shares of common stock. If you do not understand the contents of this
prospectus you should consult an authorized financial advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Australia </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement, or other disclosure document has been lodged with the Australian Securities
and Investments Commission, or ASIC, in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or the Corporations Act, and does not
purport to include the information required for a prospectus, product disclosure statement, or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares of common stock may only be made to persons, the Exempt Investors, who are &#8220;sophisticated
investors&#8221; (within the meaning of section 708(8) of the Corporations Act), &#8220;professional investors&#8221; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in
section 708 of the Corporations Act so that it is lawful to offer the shares of common stock without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months
after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or
where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares of common stock must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account of the investment objectives, financial situation, or particular
needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Israel
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Israeli Securities Law, and has not
been filed with or approved by the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares of common stock is directed only at, (i)&nbsp;a limited number of persons
in accordance with the Israeli Securities Law and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks,
portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#8220;qualified individuals,&#8221; each as defined in the Addendum (as
it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the
Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notice to Prospective Investors in Brazil </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offer and sale of the shares have not been and will not be registered with the Brazilian securities commission (Comiss&atilde;o de Valores
Mobili&aacute;rios, or CVM) and, therefore, will not be carried out by any means that would constitute a public offering in Brazil under CVM Resolution No.&nbsp;160, dated 13&nbsp;July 2022, as amended, or CVM Resolution 160, or unauthorized
distribution under Brazilian laws and regulations. The shares may only be offered to Brazilian professional investors (as defined by applicable CVM regulation), who may only acquire the shares through a
<FONT STYLE="white-space:nowrap">non-Brazilian</FONT> account, with settlement outside Brazil in <FONT STYLE="white-space:nowrap">non-Brazilian</FONT> currency. The trading of these shares on regulated securities markets in Brazil is prohibited.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of our common stock being offered in this prospectus will be passed upon for us by Goodwin Procter LLP. Certain
legal matters in connection with this offering will be passed upon for the underwriters by Latham&nbsp;&amp; Watkins LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements as of December&nbsp;31, 2025 and 2024 and for the years then ended included in this prospectus have been so included
in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_23"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File Number <FONT
STYLE="white-space:nowrap">333-294976)</FONT> under the Securities Act with respect to the shares of common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the
information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer
you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a
contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is
qualified in all respects by the filed exhibit. The SEC also maintains an internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is
<I>www.sec.gov/edgar.</I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not file periodic reports with the SEC. On the completion of this offering, we will be
subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements, and other information with the SEC. These reports, proxy statements and other information will be available for review at the website
of the SEC referred to above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at <I>www.seaporttx.com</I>. Information contained in, or accessible through,
our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only as an inactive textual reference. Upon completion of this offering, you may access, free of charge, our annual reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports filed or furnished pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc73463_24"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin73463_1">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin73463_2">Consolidated Balance Sheets as of December&nbsp;31, 2025 and
2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin73463_3">Consolidated Statements of Operations and Comprehensive Loss for the years ended
 December&nbsp;31, 2025 and 2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin73463_4">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217;
 Deficit for the years ended December&nbsp;31, 2025 and 2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin73463_5">Consolidated Statements of Cash Flows for the years ended December&nbsp;
31, 2025 and 2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin73463_6">Notes to consolidated financial statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin73463_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the<B> </B>Board of Directors and Stockholders of Seaport Therapeutics, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the accompanying consolidated balance sheets of Seaport Therapeutics, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, of
convertible preferred stock and stockholders&#8217; deficit and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting
principles generally accepted in the United States of America. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the
Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;27, 2026, except for the effects of the reverse stock split discussed in Note 18 to the consolidated financial statements, as to which the date
is April 27, 2026 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#8217;s auditor since 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin73463_2"></A>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share and per share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets&#8212;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">315,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, convertible preferred stock and stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, par value $0.0001;
40,000,000 shares authorized, issued, and outstanding; liquidation preference of $4,000 as of December&nbsp;31, 2025 and 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, par value $0.0001;
26,342,102 shares authorized, issued and outstanding; liquidation preference of $100,100 as of December&nbsp;31, 2025 and 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, par value $0.0001; 47,578,938 shares authorized; 47,578,934
shares issued and outstanding; liquidation preference of $226,000 as of December&nbsp;31, 2025 and 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.0001; 159,070,000 shares authorized; 2,595,342 and 2,594,960 shares
issued and outstanding as of December&nbsp;31, 2025 and 2024, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities, convertible preferred stock and stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">315,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin73463_3"></A>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share and per share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP> (including
stock-based compensation expense of $2.3&nbsp;million and $0.7&nbsp;million for 2025 and 2024, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP> (including
stock-based compensation expense of $4.6&nbsp;million and $15.2&nbsp;million for 2025 and 2024, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss), net of tax:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,373,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">942,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related-party amounts of $0.3&nbsp;million and $14.2&nbsp;million for research and development
expenses for the years ended December&nbsp;31, 2025 and 2024, respectively. See Note 17&#8212;Related Parties. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related-party amounts of $0.1&nbsp;million and $5.8&nbsp;million for general and administrative
expenses for the years ended December&nbsp;31, 2025 and 2024, respectively. See Note 17&#8212;Related Parties. </P></TD></TR></TABLE> <P STYLE="margin-top:184pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The
accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin73463_4"></A><A NAME="fin73463_4"></A>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT><BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-2</FONT></B><br><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B><br><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net Parent<BR>Investment</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#8217;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss attributable to Seaport</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net transfers from PureTech Health plc prior to formation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense allocated from PureTech Health plc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock to PureTech Health plc upon formation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible
preferred stock to PureTech Health plc upon Asset Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Reclassification of net investments from PureTech Health plc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, net of
issuance costs of $343</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,342,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B convertible preferred stock, net of issuance costs of $429</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,578,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,990,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,342,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,578,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">225,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,594,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized gain on investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cumulative translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2025</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,342,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,578,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">225,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,595,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(114,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(92,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin73463_5"></A>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net amortization of premiums and discounts on investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,430</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(396,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from maturities of investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(184,245</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net transfers from PureTech Health plc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible
preferred stock <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of issuance costs associated with issuance of Series
<FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series B convertible preferred stock <SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of issuance costs associated with issuance of Series B convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rates on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(263,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> operating,
financing, and investing information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets obtained in exchange for lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets recorded in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes proceeds from certain related parties of $32.0&nbsp;million. See Note 17&#8212;Related Parties.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes proceeds from certain related parties of $16.7&nbsp;million. See Note 17&#8212;Related Parties.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin73463_6"></A>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. NATURE OF BUSINESS AND BASIS OF PRESENTATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Background </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport
Therapeutics, Inc., and its consolidated subsidiaries, Seaport or the Company, is a clinical-stage therapeutics company focused on inventing and developing medicines for patients with depression, anxiety, and other debilitating neuropsychiatric
disorders using the Company&#8217;s proprietary Glyph Platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements include the historical financial
position, results of operations, and comprehensive loss, convertible preferred stock and stockholders&#8217; deficit, and cash flows of the Glyph platform business, or the Seaport Business, which was a business of PureTech Health plc and its
consolidated subsidiaries, or PureTech, a public company incorporated, domiciled and registered in the United Kingdom. The Seaport Business was historically managed as part of PureTech prior to the completion of the
<FONT STYLE="white-space:nowrap">spin-off</FONT> of the Seaport Business from PureTech in April 2024, pursuant to the Asset Transfer Agreement (as defined below). The Company, which holds the assets, liabilities, and operations associated with the
Seaport Business, was incorporated under the laws of the State of Delaware as SP Therapeutics, Inc. on April&nbsp;1, 2024, and changed its name to Seaport Therapeutics, Inc. on April&nbsp;2, 2024. Its wholly owned subsidiary, SPTX, Inc., or SPTX,
was a previously created entity in February 2024 under the laws of the State of Delaware under the name Seaport Therapeutics, Inc. and changed its name to SPTX, Inc. in April 2024. In April 2024, the Company entered into a share exchange agreement
with SPTX, which resulted in SPTX becoming the Company&#8217;s wholly owned subsidiary. See Note 10&#8212;Common Stock, for further disclosure regarding the share exchange with SPTX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited
to, completion of preclinical studies and clinical trials, obtaining regulatory approvals for product candidates, dependence on key personnel, protection of intellectual property, compliance with government regulations, and ability to secure capital
necessary to fund operations. Product candidates currently under development by the Company will require significant additional research and development efforts, including preclinical and clinical development, and regulatory approval prior to
commercialization. There can be no assurance that the Company&#8217;s research and development efforts will be successfully completed, that any product candidates developed will obtain necessary government regulatory approval, or that any products,
if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnology companies. Even if the Company&#8217;s product development efforts
are successful, it is uncertain when, if ever, the Company will realize significant product revenue from product sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Asset
Transfer and Series A Financing </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was incorporated in April 2024 by PureTech LYT Inc., or PureTech LYT, a wholly
owned subsidiary of PureTech, as the sole stockholder, and the Company issued 318 shares of its common stock to PureTech LYT. On April&nbsp;8, 2024, or the Asset Transfer Date, the Company entered into an asset transfer agreement, as amended in
December 2025, or the Asset Transfer Agreement with PureTech Health LLC, or PureTech Health, and PureTech LYT, pursuant to which PureTech Health and PureTech LYT, agreed to contribute, convey, assign, transfer, and deliver to the Company all of its
right, title, and interest in, to and under the assets related to its Glyph technology and products, or the Asset Transfer. As consideration, the Company issued to PureTech LYT 40,000,000 shares of its Series
<FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 302,161 shares of its common stock on the Asset Transfer Date, and also agreed to contingent payments to PureTech upon successful development and commercialization of
products developed using the Glyph platform, each of which is referred to as a Seaport Glyph Product, including; milestone payments of up to an aggregate of $10.0&nbsp;million for the first product covered by assets transferred through the Asset
Transfer Agreement, or the Seaport Glyph Product, of $2.0&nbsp;million for the first patient dosed in the first phase 3 clinical trial, $4.0&nbsp;million for the first commercial sale </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the United States, $2.0&nbsp;million for the first commercial sale in a major European market, and $2.0&nbsp;million for the first commercial sale in Japan, and for each subsequent Seaport
Glyph Product, the Company has agreed to make milestone payments of $1.0&nbsp;million for the first patient dosed in the first phase 3 clinical trial, $2.0&nbsp;million for the first commercial sale in the United States, $1.0&nbsp;million for the
first commercial sale in a major European market, and $1.0&nbsp;million for the first commercial sale in Japan. In addition, the Company is obligated to pay royalties between 3% and 5% on the annual net sales of each Seaport Glyph Product and a
percentage of net income generated by the Company from third parties on any products licensed under the Glyph intellectual property which was transferred as part of the Asset Transfer Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the Asset Transfer and related <FONT STYLE="white-space:nowrap">spin-off</FONT> transaction represented the
transfer of a business between entities under common control. As a result, the net liabilities were transferred from PureTech to the Company at PureTech&#8217;s carrying amounts on the Asset Transfer Date, and the Company ascribed a nil value to the
Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and common stock issued to PureTech Health and PureTech LYT. The consolidated financial statements for the period prior to the Asset Transfer Date, were prepared on a <FONT
STYLE="white-space:nowrap">&#8220;carve-out&#8221;</FONT> basis from the consolidated financial statements of PureTech to represent Seaport Business&#8217; financial position, results of operations, changes in net parent investment and cash flows as
if the Seaport Business existed on a standalone basis. Effective April&nbsp;8, 2024, the Company&#8217;s financial statements are presented on a consolidated basis, as PureTech Health and PureTech LYT completed the transfer of the Seaport Business
on such date. The audited financial statements for the year presented, including the historical results of the Company prior to April&nbsp;8, 2024, are referred to as the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently, upon entry into the Asset Transfer Agreement, the Company entered into a stock purchase agreement with PureTech LYT and other
third-party investors, pursuant to which the Company issued and sold shares of its Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, or the Series A Financing, and together with the Asset Transfer, the Transaction.
Subsequent to the Transaction, PureTech LYT remained the controlling investor of the Company, until the completion of the Company&#8217;s Series B convertible preferred stock financing, or the Series B Financing (as further discussed herein), in
October 2024. The Series B Financing resulted in a decrease to PureTech LYT&#8217;s fully diluted ownership, resulting in PureTech LYT no longer maintaining a controlling interest in the Company. See Note 9&#8212;Convertible Preferred Stock, for
further disclosure regarding issuances of the Company&#8217;s convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United
States of America, or GAAP. These consolidated financial statements include the accounts of Seaport Therapeutics, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the period prior to the Transaction, the accompanying consolidated financial statements of the Company have been prepared on a standalone
basis and are derived from PureTech&#8217;s consolidated financial statements and accounting records. The consolidated financial statements reflect PureTech&#8217;s historical accounting policies, adjusting for differences between International
Financial Reporting Standards and GAAP as appropriate. These consolidated financial statements do not purport to reflect what the Company&#8217;s results of operations, financial position, or cash flows would have been had the Company operated as a
standalone company during the period prior to the Transaction, nor are they indicative of the Company&#8217;s future results of operations, financial position, or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the Company&#8217;s operations were not historically conducted by a single legal entity, net parent investment is shown in lieu of
stockholders&#8217; equity in the historical consolidated financial statements for the period prior to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Transaction. Net parent investment represents the cumulative investment by PureTech in the Seaport Business through the Transaction date, inclusive of operating results. All transactions
between the Seaport Business and PureTech were effectively settled in the consolidated financial statements at the time the Transaction was recorded. The effects of the settlement of such transactions between the Seaport Business and PureTech are
reflected in the consolidated statements of cash flows as &#8220;Net transfers from PureTech Health plc&#8221; within financing activities and in the statement of convertible preferred stock and stockholders&#8217; deficit as &#8220;Net parent
investment&#8221; for the year ended December&nbsp;31, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was dependent upon PureTech for all of its working capital and
financing requirements through the date of the Transaction. PureTech used a centralized approach for cash management and the financing of its operations. There were no cash amounts specifically attributable to the Seaport Business prior to the
Transaction; therefore, cash and cash equivalents were excluded in the consolidated financial statements prior to the Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements of the Company include, for the period prior to the Transaction, the assets, liabilities, and expenses of PureTech that Seaport management determined were specifically identifiable to the Seaport Business and its
related programs, as well as indirect costs that are not specifically identifiable to the Seaport Business or its related programs but are deemed necessary to operate as a standalone entity. The assets and liabilities in the consolidated financial
statements for the period prior to the Transaction were recorded based on their legal title or related to the exclusive use of the Seaport Business. Shared assets were not included on the consolidated balance sheet, but costs reflecting the use of
such assets by the Seaport Business were reflected in the consolidated statements of operations and comprehensive loss for the year ended December&nbsp;31, 2024. Indirect costs are the costs of support functions that are provided on a centralized
basis by PureTech prior to the Transaction, which include, but are not limited to, facilities, information technology, insurance, quality, compliance, finance, human resources, legal, corporate strategy, corporate governance, and other general and
administrative type functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Company also include, for the period prior to the
Transaction, indirect costs that have been allocated to the Seaport Business for the purposes of preparing the consolidated financial statements based on proportional cost allocation methods using headcount, proportional time spent, and other
organizational activities, as applicable, which were considered to be reasonable reflections of the utilization of services provided to or benefit received by the Seaport Business for the period prior to the Transaction. Seaport management considers
that such allocations were made on a reasonable basis; however, these allocations may not necessarily be indicative of the costs that would have been incurred if the Seaport Business had operated on a standalone basis for the full year ended
December&nbsp;31, 2024 and, therefore, may not be indicative of the Company&#8217;s results of operations, financial position, and cash flows had the Company operated as a standalone entity prior to the Transaction. See Note 17&#8212;Related
Parties, for additional information regarding related-party transactions with PureTech. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, PureTech continued
to provide various research and development and corporate services under the transition services agreement, or the TSA, which was initially set to terminate one year following the date of the Asset Transfer Agreement. In 2025, the TSA was amended to
extend through July 2026 to provide <FONT STYLE="white-space:nowrap">ad-hoc</FONT> support; however, the total value of the incremental services are not material. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the
Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements were available to be issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred losses and negative cash flows from operations since inception,
including net losses of $74.9&nbsp;million and $46.9&nbsp;million for the years ended December&nbsp;31, 2025 and 2024, respectively, and cash used in operations of $77.9&nbsp;million and $29.6&nbsp;million for the years ended December&nbsp;31, 2025
and 2024, respectively. The Company expects to continue to generate operating losses and negative cash flows for the foreseeable future as the Company continues to develop its product candidates. The Company&#8217;s future operations will be
dependent on its ability to raise additional capital to finance such operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements
have been prepared assuming it will continue as a going concern, which presumes it will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of
business. The Company believes its cash and cash equivalents and investments of $233.7&nbsp;million as of December&nbsp;31, 2025 will be sufficient to fund its expected operating expenses and capital expenditure requirements for at least 12 months
from the date these consolidated financial statements were available to be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time that the Company can generate
significant product revenue, if ever, the Company expects to fund its operations through equity offerings or debt financings, credit or loan facilities, collaborations, <FONT STYLE="white-space:nowrap">out-license</FONT> arrangements, other capital
resources, or a combination of one or more of these funding sources. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. The Company&#8217;s failure to raise or secure capital as and when
needed could have a negative impact on its financial condition and its ability to pursue its business strategies. If adequate funds are not available to the Company, the Company may be required to delay, reduce, or eliminate clinical programs,
obtain funds through arrangements with collaborators on terms unfavorable to the Company, or pursue merger or acquisition strategies. There can be no assurances the Company will be successful in obtaining sufficient capital on acceptable terms to
fund continuing operations, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting year
presented. Management of the Company evaluates its estimates which include, but are not limited to, accrued research and development expenses and stock-based compensation expense for periods after the Transaction. For the period before the
Transaction, Management included allocations of direct expenses and indirect expenses, such as personnel-related expenses, including stock-based compensation, facility, information technology, or IT, and other general overhead expenses from
PureTech. The Company based its estimates on the historical experience of PureTech and on various other assumptions that are believed to be reasonable. Actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of the Company&#8217;s foreign subsidiary are measured using the local currency as the functional currency. Assets and
liabilities are translated from their functional currency to their U.S. dollar equivalents at balance sheet date exchange rates and revenue and expenses are translated from functional currency to U.S. dollar equivalents at average exchange rates in
effect during the year. Any gain or loss from these translations are included in accumulated other comprehensive loss. Realized foreign currency transaction gains and losses are included in other expense, net in the consolidated statements of
operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash, Cash Equivalents, and Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments that are readily convertible into cash with original maturities of three months or less at
the date of purchase to be cash equivalents. The Company invests excess cash primarily in overnight cash sweeps and money market funds which are highly liquid and have high credit ratings. Such investments are subject to minimal credit and market
risks. The Company classifies all cash of which use is limited by contractual provisions as restricted cash. Restricted cash is recorded on the consolidated balance sheet within other <FONT STYLE="white-space:nowrap">non-current</FONT> assets and
includes amounts held as a security deposit for a letter of credit in connection with leased facilities and its corporate card program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s cash, cash equivalents, and restricted cash (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash within other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents, and restricted cash per the consolidated statements of cash
flows</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Short-term investments consist of investments in United States treasuries with original maturities greater than ninety days and less than one
year from the balance sheet date. Long-term investments consist of investments in United States treasuries with maturities of greater than one year from the balance sheet date and are not expected to be used to fund current operations. The Company
classifies all of its investments as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities. Accordingly, these investments are recorded at fair value. Realized gains and losses, amortization
and accretion of discounts and premiums are included in other income, net. Unrealized gains and losses on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities are included in other
comprehensive income as a component of stockholders&#8217; equity until realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses its
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities under the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt security impairment model
in ASC Topic 326, <I>Financial Instruments&#8212;Credit Losses</I>, as of each reporting date in order to determine if a portion of any decline in fair value below carrying value recognized on its <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities is the result of a credit loss. For any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities that may be in an
unrealized net loss position, the Company does not intend to sell, and it is not more likely than not that the Company will be required to sell, such securities before recovery of their amortized cost bases. The Company records credit losses in the
consolidated statements of operations and comprehensive loss as a component of other income, net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit
losses on its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued
interest receivable related to the Company&#8217;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities is presented within prepaid and other current assets on the Company&#8217;s consolidated
balance sheet. The Company has elected the practical expedient available to exclude accrued interest receivable from both the fair value and the amortized cost basis of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has
determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued
interest receivable associated with its investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash, cash equivalents and
investments. The Company invests its excess cash, in line with its investment policy. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are
subject to minimal credit risk. At times, the Company&#8217;s cash and cash equivalents may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation limits. The Company&#8217;s cash equivalents and investments are
comprised of money market funds and investments that are invested in U.S. Treasury obligations. The Company has no significant <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet risk such as foreign exchange contracts, option contracts or
other foreign hedging arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with <FONT
STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering,
either as a reduction of the carrying value of the convertible preferred stock or in stockholders&#8217; equity (deficit) as a reduction of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital generated as a result of the offering.
Should the <FONT STYLE="white-space:nowrap">in-process</FONT> equity financing be abandoned or delayed the deferred offering costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations and
comprehensive loss. The Company recorded deferred offering costs of $1.2&nbsp;million within other <FONT STYLE="white-space:nowrap">non-current</FONT> assets as of December&nbsp;31, 2025. There were no deferred offering costs as of December&nbsp;31,
2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounting Standards Codification, or ASC, Topic 820, Fair Value Measurement, or ASC 820, identifies fair value as the exchange price, or exit
price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, or in the absence of a principal market, the most advantageous market for the investment or
liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2 inputs are inputs other than quoted prices included within Level&nbsp;1 that are observable for the
asset or liability, either directly or indirectly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the
assumptions market participants would use in pricing the asset or liability. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the valuation is based
on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments
categorized in Level&nbsp;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, less accumulated depreciation, and consists of lab equipment, furniture and fixtures, and leasehold
improvements. Depreciation of property and equipment are calculated using </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the straight-line method over the estimated useful lives of the assets. Significant replacements and improvements are capitalized, while maintenance and repairs, which do not improve or extend
the life of the respective assets, are charged to expense as incurred. The estimated useful lives of the Company&#8217;s respective assets are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Estimated Useful Life</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">The&nbsp;lesser&nbsp;of&nbsp;5&nbsp;years&nbsp;or&nbsp;the&nbsp;remaining&nbsp;term&nbsp;of&nbsp;the&nbsp;lease</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon retirement or disposal of property and equipment, the cost, and related accumulated depreciation are
removed from the consolidated balance sheet and any gain or loss is reflected in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry
or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the recoverability of the asset group to be held and used is
measured by a comparison of the carrying amount of an asset group to future undiscounted cash flows expected to be generated by the asset group. If the carrying amounts of the asset group is less than its future undiscounted cash flows, an
impairment loss is then measured by comparing the fair value of the asset group to its respective carrying amount. There have been no impairments of long-lived assets recorded for the years ended December&nbsp;31, 2025 or 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company accounts for leases in accordance with ASC 842, Leases. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the relevant facts and circumstances present in the arrangement.
Leases with a term greater than one year are recognized on the consolidated balance sheet as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and short-term and long-term lease liabilities, as
applicable. The Company typically only includes an initial lease term in its assessment of a lease arrangement, and options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company
will renew. The Company has elected not to recognize leases with an original term of one year or less on the consolidated balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leases contain both lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components. <FONT STYLE="white-space:nowrap">Non-lease</FONT>
components may include common area maintenance, utilities, and other operating costs. The Company combines the lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components in its lease arrangements as a single lease component. Variable
costs are not included in the measurement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities and are expensed when incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating lease liabilities and their corresponding
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets are initially recorded at the lease commencement date based on the present value of lease payments measured over the expected remaining lease term.
Certain adjustments to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets may be required for items such as prepaid lease payments or any incentives received. The Company measures the net present
value of lease payments using a discount rate based on the interest rate implicit in the lease or an incremental borrowing rate if the rate implicit in the lease is not readily determinable. The interest rate implicit in the lease contracts is
typically not readily determinable, and as a result, the Company estimates an incremental borrowing rate, which reflects the fixed rate at which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. To estimate the incremental borrowing
rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have any outstanding third-party debt or a rating agency-based credit rating. Operating lease costs are
expensed using the straight-line method over the lease term and are classified within research and development or general and administrative expense based on the use of the underlying facility or using a reasonable allocation method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assumptions that the Company made at the commencement date are <FONT STYLE="white-space:nowrap">re-evaluated</FONT> upon occurrence of certain
events, including a lease modification. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has classified its convertible preferred stock as temporary equity on the Company&#8217;s consolidated balance sheets due to the
terms that allow for redemption of the shares in cash upon certain deemed liquidation events that are not solely within the control of the Company. The Company initially recorded its Series <FONT STYLE="white-space:nowrap">A-2</FONT> and Series B
convertible preferred stock at fair value, net of issuance costs. The occurrence of such deemed liquidation event is not currently probable and thus the carrying values of the convertible preferred stock are not being adjusted to their redemption
values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development, or R&amp;D, costs are expensed as incurred. Internal costs include personnel related expenses, stock-based
compensation, facility and IT costs, and depreciation. External costs include fees for goods and services to conduct clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> activities, such as costs paid to contract research organizations,
consulting fees, laboratory services and supplies, and costs incurred in connection with license agreements. Prior to the Transaction, these expenses included allocations from PureTech. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to estimate its accrued R&amp;D costs as of the end of the reporting period. In accruing R&amp;D costs, the Company
estimates the period over which services will be performed or goods will be provided and the level of effort to be performed in each period. The financial terms of the R&amp;D contracts vary and may result in payments that do not match the periods
over which the goods or services are provided. The Company accrues costs under its contracts based on analyzing the work performed and amounts paid. In circumstances where amounts have been paid in excess of costs incurred, the Company records the
excess as prepaid expense and recognizes research and development expense as the goods are received or the related services are rendered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses are primarily comprised of employee-related expenses, including stock-based compensation and occupancy
costs, depreciation, and third-party expenses related to finance, legal and other general and administrative functions. Prior to the Transaction, these expenses included allocations from PureTech. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses costs associated with intellectual property-related matters as incurred and classifies such costs as general and
administrative expenses within the consolidated statements of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Asset Acquisitions and Acquired <FONT STYLE="white-space:nowrap">In-Process</FONT>
Research and Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for acquisitions of assets or a group of assets that do not meet the
definition of a business as asset acquisitions based on the cost to acquire the asset or group of assets, which include certain transaction costs. In an asset acquisition, the cost to acquire is allocated to the identifiable assets acquired and
liabilities assumed based on their relative fair values as of the acquisition date. No goodwill is recorded in an asset acquisition. Assets that are acquired in an asset acquisition for use in research and development activities that have an
alternative future use are capitalized as <FONT STYLE="white-space:nowrap">in-process</FONT> research and development, or IPR&amp;D. Acquired IPR&amp;D that has no alternative future use as of the acquisition date is recognized as research and
development expense as of the acquisition date. The Company will recognize additional research and development expenses in the future or capitalize such amounts for completed technology if and when the Company becomes obligated to make contingent
milestone payments under the terms of the agreements by which it acquired the IPR&amp;D assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contingent consideration in asset
acquisitions is measured and recognized when payment becomes probable and reasonably estimable. Subsequent changes in the accrued amount of contingent consideration are measured and recognized at the end of each reporting period and upon settlement
as an adjustment to the cost basis of the acquired asset or group of assets, or, if related to IPR&amp;D with no alternative future use, charged to expense. The Company did not recognize any IPR&amp;D expense during the years ended December&nbsp;31,
2025 and 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees of the Company participate in the Company&#8217;s stock-based compensation plans and prior to the Transaction, participated in
PureTech&#8217;s stock-based compensation plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense allocated to the Company for the period prior to the
Transaction relates to equity awards issued by PureTech, including stock options, service-based restricted stock unit awards and performance-based restricted stock unit awards with both market and performance conditions. Stock-based compensation
expense recorded during the period prior to the Transaction was recognized through allocations, based on the proportion of time the employee spent on the Seaport Business during the year presented and PureTech&#8217;s estimate of fair value.
Stock-based compensation expense associated with service-based awards granted by PureTech was recognized over the requisite service period of the awards, which is generally the vesting period, on a straight-line basis. Service-based awards granted
to employees under the PureTech plans generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed during the applicable vesting period.
Performance-based restricted stock unit awards granted under the PureTech plans to its executives included both performance and market conditions, and did not have a material impact on the consolidated financial statements for the years ended
December&nbsp;31, 2025 and 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense of the Company for periods subsequent to the Transaction relates to
equity awards issued by the Company to its employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> under its 2024 Equity Incentive Plan, or the 2024 Plan, including stock options and restricted stock awards with both service and
performance-based vesting conditions. Stock-based compensation expense is measured at estimated fair value on the grant date and is recognized as compensation expense over the requisite service period, which is the vesting period during which an
employee provides service in exchange for the award. Compensation expense for awards to <FONT STYLE="white-space:nowrap">non-employees</FONT> is recognized in the same manner as if the Company had paid cash in exchange for the goods or services,
which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. Stock-based compensation expense for service-only based awards is recognized on a straight-line basis. Stock-based compensation expense for awards
with both performance and service-based vesting conditions is recognized over the requisite service period using an accelerated attribution method, commencing once the performance conditions are considered probable of being achieved, using
management&#8217;s best estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each stock option grant is estimated on the date of grant using the
Black-Scholes option pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. The fair value of
each restricted stock award granted is measured on the date of grant at the estimated fair value of the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there has
not historically been a public market for the Company&#8217;s common stock, the estimated fair value of common stock was determined by the Company&#8217;s Board of Directors as of the date of each option grant, with inputs from management,
considering third-party valuations of its common stock as well as the Company&#8217;s Board of Directors&#8217; assessment of additional objective and subjective factors that it believed were relevant. These third-party valuations were performed in
accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, <I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies. The expected
term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant for time periods
approximately equal to the expected term of the award. There is no expected dividend yield since the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company classifies stock-based compensation expense in the consolidated statements of operations and comprehensive loss in the same manner
in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. See Note 11&#8212;Stock-Based Compensation, for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Australia Research and Development Tax Credit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is eligible to obtain certain research and development tax credits, through its wholly owned Australian subsidiary, as part of a
program administered by the Australian Tax Office. The Company recognizes the research and development incentive as income within other income (expense), net within the consolidated statements of operations and comprehensive loss as it incurs costs
eligible for reimbursement under the Australia R&amp;D credit program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when the applicable conditions under the program have
been met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Transaction, the Company was included in PureTech&#8217;s income tax returns, and all income taxes were paid by PureTech. Income
tax expense and other income tax related information contained in these consolidated financial statements prior to the Transaction are presented on a separate return approach as if the Company filed its own tax return for those periods. Under this
approach, the provision for income taxes represents income tax paid or payable (or received or receivable) for the current year plus the change in deferred taxes during the year calculated as if the Company were a standalone taxpayer filing
hypothetical income tax returns. Current income tax liabilities were assumed to be immediately settled with PureTech and were relieved through the &#8220;Net parent investment&#8221; account and were reflected as &#8220;Net transfers from PureTech
Health plc&#8221; within financing activities in the consolidated statements of cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes income taxes under the
asset and liability method. Deferred income taxes are recognized for differences between the financial reporting and tax basis of assets and liabilities at enacted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statutory tax rates in effect for the years in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates are recognized in income in the period that
includes the enactment date. In evaluating the Company&#8217;s ability to recover its deferred tax assets, the Company considers all available positive and negative evidence including its past operating results, the existence of cumulative losses in
the most recent fiscal years, changes in the business in which the Company operates and its forecast of future taxable income. In determining future taxable income, the Company is responsible for assumptions utilized, including the amount of <FONT
STYLE="white-space:nowrap">pre-tax</FONT> operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future
taxable income and are consistent with the plans and estimates that the Company is using to manage the underlying business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
accounts for uncertain tax positions using a <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but
not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax
position. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense. For the years ended December&nbsp;31, 2025 and 2024, the Company had no tax reserves accrued for uncertain tax
positions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized
gains on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities and foreign currency translation adjustments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies the <FONT STYLE="white-space:nowrap">two-class</FONT> method when computing net loss per share attributable to common
stockholders as the Company has issued shares that meet the definition of participating securities. The <FONT STYLE="white-space:nowrap">two-class</FONT> method determines net loss per share for each class of common and participating securities
according to dividends declared or accumulated and participation rights in undistributed earnings. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income (loss) available to common stockholders for the period to be allocated
between common and participating securities based upon their respective rights to share in the undistributed earnings as if all income (loss) for the period had been distributed. The Company considers its convertible preferred stock to be
participating securities as, in the event a dividend is paid on common stock, the holders of convertible preferred stock would be entitled to receive dividends on a basis consistent with the common stockholders. There is no allocation required under
the <FONT STYLE="white-space:nowrap">two-class</FONT> method during periods of loss since the participating securities do not have a contractual obligation to share in the losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing the net loss in each period by the weighted average number of shares of common stock
outstanding during such period, excluding potentially dilutive common shares. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional shares of common
stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. The shares of common stock and convertible preferred stock distributed to PureTech upon the
formation of the Company and on the effective date of the Asset Transfer were considered as outstanding in the calculation of basic and diluted earnings per share for the period prior to the formation of the Company and the Asset Transfer, as the
formation and Asset Transfer were deemed to be common control transactions. Additionally, the SPTX March 2024 Shares were considered outstanding in the calculation of basic and diluted earnings per share as of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their date of issuance and the SPTX February 2024 Shares were considered outstanding in the calculation of diluted earnings per share as of their date of issuance (See Note 10&#8212;Common Stock,
for definitions and further disclosure regarding these SPTX shares). The Company had no additional shares of common stock outstanding or any potentially dilutive equity instruments other than described above prior to its formation and the Asset
Transfer Date. See Note 16&#8212;Net Loss per Share for definitions and further disclosure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the
chief operating decision-maker, or CODM, in deciding how to allocate resources and assess performance. The Company has one operating and reportable segment, which is the business focused on advancing the development of neuropsychiatric medicines in
areas of high unmet patient needs using the Company&#8217;s proprietary Glyph<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Platform. The Company&#8217;s CODM, its chief executive officer, manages the Company&#8217;s operations on a
consolidated basis for the purpose of allocating resources. All of the Company&#8217;s long-lived assets are held in the United States. See Note 15&#8212;Segments, for further disclosure regarding the Company&#8217;s segment information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2023-09,</FONT> <I>Income Taxes (Topic 740): Improvements to
Income Tax Disclosures</I>, or ASU <FONT STYLE="white-space:nowrap">2023-09.</FONT> Additionally, the amendments in the ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> update require entities to disclose certain information about income taxes
paid, income tax disaggregation, disclosures around unrecognized tax benefits, and the removal of disclosures related to temporary differences surrounding deferred tax liabilities to enhance the transparency and decision usefulness of income tax
disclosures. For public entities, the amendments in this update are effective for fiscal years beginning after December&nbsp;15, 2024 and for entities other than public entities, the amendments in this update are effective for fiscal years beginning
after December&nbsp;15, 2025. Early adoption is permitted for any annual periods for which financial statements have not been issued or made available for issuance. The Company elected to early adopt the standard in 2025 on a retrospective basis.
See Note <FONT STYLE="white-space:nowrap">12-</FONT> Income Taxes, for further disclosure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Standards
Updates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB, or other standard-setting bodies that are adopted
by Seaport as of the specified effective date. The Company qualifies as an &#8216;&#8216;emerging growth company&#8217;&#8217; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8216;&#8216;opt out&#8217;&#8217;
of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and <FONT STYLE="white-space:nowrap">non-public</FONT>
companies, the Company can adopt the new or revised standard at the time <FONT STYLE="white-space:nowrap">non-public</FONT> companies adopt the new or revised standard and can do so until such time that the Company either (i)&nbsp;irrevocably elects
to &#8216;&#8216;opt out&#8217;&#8217; of such extended transition period or (ii)&nbsp;no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is
permitted for <FONT STYLE="white-space:nowrap">non-public</FONT> companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial
position or results of operations upon adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <FONT STYLE="white-space:nowrap">2024-03,</FONT>
<I>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic <FONT STYLE="white-space:nowrap">220-40):</FONT> Disaggregation of Income Statement Expenses</I>, or ASU
<FONT STYLE="white-space:nowrap">2024-03,</FONT> which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, and amortization) included in certain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expense captions presented on the statement of operations. The guidance in ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> is effective for fiscal years beginning after December&nbsp;15,
2026. Early adoption is permitted. The amendments may be applied either (1)&nbsp;prospectively to financial statements issued for periods after the effective date of ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> or (2)&nbsp;retrospectively to
all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> may have on its consolidated financial statements and disclosures for
fiscal years beginning after December&nbsp;15, 2026. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. PREPAID EXPENSES AND OTHER CURRENT ASSETS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Australia research and development tax credit receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid employee compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;7,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;1,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. FAIR VALUE MEASUREMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth by level, within the fair value hierarchy, the financial assets, and liabilities carried at fair value on a
recurring basis (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted prices in<BR>active&nbsp;markets&nbsp;for<BR>identical assets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant other<BR>observable&nbsp;inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>unobservable<BR>inputs&nbsp;(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasuries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">233,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">187,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted prices in<BR>active&nbsp;markets&nbsp;for<BR>identical assets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant other<BR>observable&nbsp;inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>unobservable<BR>inputs&nbsp;(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025 and 2024, the Company&#8217;s cash equivalents consisted of money market funds
which are classified as Level&nbsp;1 financial assets, as these assets are valued using quoted market prices in active markets without any valuation adjustment. As of December&nbsp;31, 2025, the Company&#8217;s investments consisted of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States treasuries, which are classified as Level&nbsp;2 financial assets. The Company estimates the fair value of the investments by taking into consideration valuations obtained from
third-party pricing sources. As of December&nbsp;31, 2025 and 2024, the Company had no financial liabilities that required fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2025 and 2024, there were no transfers or reclassifications between fair value measurement levels of
assets. The carrying amounts reflected in the consolidated balance sheets for prepaid expenses and other current assets, accounts payable, related party payable and accrued expenses and other current liabilities approximate fair value due to their
short-term nature. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. INVESTMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s investments held as of December&nbsp;31, 2025. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized<BR>Holding<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized<BR>Holding<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasuries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">169,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">169,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasuries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">187,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">187,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, the Company&#8217;s investments were in net unrealized gain position of
$0.3&nbsp;million. These amounts are included in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. As of December&nbsp;31, 2025, there were no investments in an unrealized loss position. The
Company determined that there was no material credit risk associated with its investments as of December&nbsp;31, 2025. As a result, the Company did not record any charges for credit-related impairments for its investments during the year ended
December&nbsp;31, 2025. As of December&nbsp;31, 2025, the Company&#8217;s investments had remaining maturities of two years or less. The Company did not have any investments as of December&nbsp;31, 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. PROPERTY AND EQUIPMENT, NET </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property
and equipment, net consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(989</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense was $0.2&nbsp;million and $0.3&nbsp;million for the years ended December&nbsp;31, 2025
and 2024, respectively. The depreciation expense recorded for the year ended December&nbsp;31, 2024 consisted of $0.2&nbsp;million of depreciation expense on the Company&#8217;s assets included on the consolidated balance sheet as of
December&nbsp;31, 2024 and $0.1&nbsp;million of allocated depreciation expense from PureTech associated with shared assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued personnel and bonus expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional and legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. MONASH LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, PureTech Health exclusively assigned to the Company, and the Company assumed all rights and obligations under a license
agreement entered into in August 2017 between PureTech Health and Monash University, or the Original License Agreement. In March 2025, the Company entered into an amended and restated license agreement with Monash University, which amended and
restated the Original License Agreement, or the Monash License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Monash License Agreement, Monash University
grants the Company (i)&nbsp;a worldwide, exclusive, sublicensable license under certain Monash University intellectual property rights, including patent rights related to the Glyph platform, or the Licensed Patents,
<FONT STYLE="white-space:nowrap">know-how,</FONT> and intellectual property stemming from joint research and development activities, for the purpose of developing and commercializing products in all fields with one exception, (ii)&nbsp;a worldwide, <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable license under certain background technology and certain other intellectual property strictly to the extent necessary to exercise the license described in subclause (i)&nbsp;above, and
(iii)&nbsp;a first right and an exclusive option to obtain an exclusive license to any invention generated by Monash University&nbsp;outside of the Licensed Patents and pertaining to certain prodrug technology. Additionally, the Company and Monash
University agreed to collaborate in conducting research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Monash License Agreement, the Company has
agreed to use reasonable commercial endeavors to (i)&nbsp;develop at least one Licensed Product, (ii)&nbsp;seek regulatory approval for at least one Licensed Product, and (iii)&nbsp;after receipt of such regulatory approval in the United States or
Europe, promote, and develop the sale of at least one Licensed Product in such territory. Monash University agrees to provide reasonable technical assistance and advice based on Monash University&#8217;s
<FONT STYLE="white-space:nowrap">know-how</FONT> relating to the technology licensed under the Monash License Agreement. The Company granted Monash University a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, royalty-free license
under the Licensed Patents, related <FONT STYLE="white-space:nowrap">know-how,</FONT> and intellectual property stemming from joint research and development activities solely for academic, teaching, and
<FONT STYLE="white-space:nowrap">non-commercial</FONT> collaborative research uses, which includes the right to sublicense for <FONT STYLE="white-space:nowrap">non-commercial</FONT> collaborative research to other academic institutions or <FONT
STYLE="white-space:nowrap">non-commercial</FONT> research entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the licenses granted by Monash University, the
Company is required to pay Monash University: (i)&nbsp;between 3% and 5% on net sales per calendar year (subject to certain reductions); (ii) a <FONT STYLE="white-space:nowrap">low-double</FONT> digit percentage of any net income received under a
sublicense (subject to a license payment stacking reduction) with the percentage varying based on the development stage of the Licensed Products at the time the sublicense is granted during the term of the Monash License Agreement; (iii)&nbsp;an
agreed upon research funding amount to progress mutually agreed research and development or commercialization activities; (iv)&nbsp;a <FONT STYLE="white-space:nowrap">mid-five-figure</FONT> annual maintenance fee during the term of the agreement
commencing on the third anniversary of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
execution date of the Original License Agreement until the first commercial sale of a Licensed Product creditable against net income sharing, royalties, and milestone payments; (v)&nbsp;milestone
payments in the event of successful development milestones of up to $1.075&nbsp;million per Licensed Product for the first three Licensed Products; and (vi)&nbsp;milestone payments in the event of successful commercial milestones of up to
$7.25&nbsp;million per Licensed Product for the first three Licensed Products. The Company is also obligated to (a)&nbsp;pay all costs incurred for the prosecution and maintenance of the Licensed Patents and patent filings stemming from
collaboration activities and (b)&nbsp;reimburse Monash University for all patent prosecution costs of the Licensed Patents prior to the execution date of the Original License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Monash License Agreement commenced on the execution date of the Original License Agreement and will expire seven years after the last of
the Licensed Patents expires, unless terminated earlier. Either party may terminate for due cause, including for material breach and bankruptcy. Monash University may terminate if the Company fails to meet its diligence requirements. Either party
may terminate the Monash License Agreement if the Company determines that the activities are no longer commercially viable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Monash
License Agreement was determined to represent an asset acquisition, as the acquired licenses and intellectual property did not meet the definition of a business. All upfront consideration paid in exchange for the Monash License Agreement was
expensed as research and development upon execution of the agreement, as the Licensed Patents and intellectual property was determined to represent <FONT STYLE="white-space:nowrap">in-process</FONT> research and development with no alternative
future use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the formation of the Company, PureTech paid $0.2&nbsp;million in development milestones under the Monash License
Agreement. During the year ended December&nbsp;31, 2025 the Company paid $0.1&nbsp;million in development milestones under the agreement. No milestones were paid by the Company under the Monash License Agreement during the year ended
December&nbsp;31, 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. CONVERTIBLE PREFERRED STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has issued Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, or the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> convertible preferred stock, or the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, and Series B convertible preferred
stock, or the Series B Preferred Stock, and collectively with the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, the Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, the Company issued to PureTech LYT, a wholly owned subsidiary of PureTech, 40,000,000 shares of its Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, as part of the consideration for the assets contributed to the Company as part of the Asset Transfer Agreement. No value was assigned to the Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Preferred Stock as it represented consideration paid as part of a common control transaction. See Note 1&#8212;Nature of Business and Basis of Presentation, for further disclosure of the Asset Transfer Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently, upon the issuance of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock to PureTech LYT, the Company entered
into a Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock Purchase Agreement, or the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Financing, with PureTech LYT and other <FONT STYLE="white-space:nowrap">third-party</FONT>
investors pursuant to which the Company issued and sold 26,342,102 shares of its Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock at a price of $3.80 per share for gross aggregate proceeds of $100.1&nbsp;million. See
Note&nbsp;17&#8212;Related Parties, for further disclosure of the issuances of the Company&#8217;s Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock to related parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Series B Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, the Company entered into a stock purchase agreement with new and existing investors, or the Series B Financing, pursuant to
which the Company issued and sold an aggregate amount of 47,578,934 shares of its Series B Preferred Stock at a purchase price of $4.75 per share, for gross aggregate proceeds of $226.0&nbsp;million. See Note 17&#8212;Related Parties, for further
disclosure around the issuances of the Company&#8217;s Series B Preferred Stock to related parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of the Preferred Stock,
the Company assessed the embedded conversion and liquidation features of the securities and determined that such features did not require the Company to separately account for these features. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025 and 2024, Preferred Stock consisted of the following (in thousands, except share and per share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock Issued<BR>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conversion<BR>Price per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock<BR>Issuable<BR>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,736,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,342,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,342,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,387,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,578,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,578,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,149,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,921,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,921,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">325,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">330,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,272,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, the holders of the Preferred Stock have the following rights and
preferences: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock are entitled to vote, together with the holders of common stock, as a single class, on all matters submitted
to the shareholders for a vote and are entitled to the number of votes equal to the number of shares of common stock into which the Preferred Stock would convert on the record date for determination of shareholders entitled to vote. The holders of
the Preferred Stock generally vote together as a single class with holders of common stock except that, (i)&nbsp;the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, exclusively and voting together as a separate class
on an as converted basis, shall be entitled to elect two (2)&nbsp;directors of the Company, each, a Series <FONT STYLE="white-space:nowrap">A-1</FONT> Director, (ii)&nbsp;the holders of record of the shares of Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, exclusively and voting together as a separate class on an as converted basis, shall be entitled to elect two (2)&nbsp;directors of the Company, each, a Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Director, (iii)&nbsp;the holders of record of the shares of Series B Preferred Stock, exclusively and voting together as a separate class on an as converted basis, shall be entitled to elect one
(1)&nbsp;director of the Company, or the Series B Director and, together with the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Directors and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Directors, each, a Preferred Director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a majority vote of the holders of the Company&#8217;s Preferred Stock is required to, among others, liquidate or dissolve the
Company, amend the certificate of incorporation or bylaws, reclassify common stock or establish another class of capital stock, create shares that would rank senior to or authorize additional shares of Preferred Stock, declare a dividend or make a
distribution, or change the authorized number of directors constituting the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock are entitled to participate in any dividends payable to common stockholders on an as converted basis and
have priority over the payment of dividends to holders of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of a dividend on common stock or any class of stock that is convertible into
common stock, the dividend per share of Preferred Stock would equal the product of (A)&nbsp;the dividend payable on each share of such class or series as if all shares of such class or series had been converted into common stock and (B)&nbsp;the
number of shares of common stock issuable upon conversion of such share of Preferred Stock. In the case of a dividend on any class or series that is not convertible into common stock, the dividend per share of Preferred Stock would be determined by
(A)&nbsp;dividing the amount of dividend payable on each share of such class or series of capital stock by the original issue price of such class or series and (B)&nbsp;multiplying such fraction by the original issue price of the applicable class or
series of Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding share of Preferred Stock is convertible, at any time, at its holder&#8217;s discretion, and without the payment of additional
consideration, into such whole number of fully paid, <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock, at the applicable conversion ratio then in effect. The conversion price for each share of Preferred Stock shall
initially be equal to the original issuance price for such series of Preferred Stock and is subject to standard anti-dilutive adjustments for share splits and similar transactions. In the event certain conditions are not met prior to March&nbsp;31,
2026, the conversion price of the Series B Preferred Stock will be reduced to $11.94. During the year ended December&nbsp;31, 2025, the Company satisfied the applicable condition, thereby eliminating the conversion price reduction contingency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding share of Preferred Stock shall automatically be converted into fully-paid,
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock upon the earliest to occur of (i)&nbsp;the consummation of a qualified initial public offering at a public offering price of at least $17.91 per share, in a firm
commitment resulting in at least $100.0&nbsp;million of gross proceeds or (ii)&nbsp;the date specified by vote or written consent of the holders of at least a majority of the outstanding shares of the Preferred Stock, voting together as a single
class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, and the holders of a majority of the outstanding shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock and Series B Preferred Stock, which majority must
include at least one new investor from the Series B Financing that holds at least 2,100,000 shares of Series B Preferred Stock, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, or the Requisite
Holders, and the holders of at least 65% of the then-outstanding shares of Series B Preferred Stock, or the Series B Majority. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There
shall be no adjustment in the conversion price of the Preferred Stock as a result of the issuance or deemed issuance of additional shares of the Company&#8217;s common stock if the Company receives written notice from the holders of at least a
majority of the then outstanding shares of Preferred Stock, voting together as a single class, and, solely in the respect of an adjustment in the conversion price of the Series B Preferred Stock, the Series B Majority, agreeing that no such
adjustment shall be made as the result of the issuance or deemed issuance of additional shares of the Company&#8217;s common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Preferred Stock then outstanding shall be entitled,
on a pari passu basis among the series of Preferred Stock, to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Preferred Stock are
entitled to an amount per share equal to the greater of (i)&nbsp;the original issue price for such series, plus any dividends declared but unpaid thereon, or (ii)&nbsp;the amount that would have been payable had all shares of each series of
Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. After the payment in full of the Preferred Stock preference amount, the remaining assets of the Company
available for distribution to stockholders shall be distributed among the holders of common stock on a pro rata basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the following events shall be considered a &#8220;Deemed Liquidation Event,&#8221;
unless the Requisite Holders, elect otherwise; a merger, consolidation, statutory conversion, transfer, domestication, continuance involving the Company or a subsidiary, or a sale, lease, or transfer of substantially all of the assets of the
Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Preferred Stock does not have any redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation
Event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. COMMON STOCK </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The voting,
dividend, and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers, and preferences of the holders of the Preferred Stock set forth above. Each share of common stock entitles the
holder to one vote, together with the holders of the Preferred Stock, on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s board of
directors, subject to the preferential dividend rights of Preferred Stock. As of December&nbsp;31, 2025, no dividends have been declared or paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, the Company had authorized 159,070,000 shares of common stock, of which 2,595,342 were issued and outstanding,
including 154,778 unvested shares of restricted common stock that are subject to service-based vesting as of December&nbsp;31, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the Transaction, the Company issued 796,000 shares of restricted common stock in exchange for shares of restricted common
stock of SPTX. Such shares were originally issued upon the formation of SPTX in February 2024, or the SPTX February 2024 Shares. SPTX subsequently became a subsidiary of the Company upon the formation date. See Note 11&#8212;Stock-Based Compensation
for further disclosure of restricted common stock issued by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the Transaction, the Company issued 302,480
shares of common stock to a board member in exchange for shares of common stock of SPTX issued in March 2024, or the SPTX March 2024 Shares, and together with the SPTX February 2024 Shares, or the Exchange Shares. SPTX had no other material activity
beyond its previously issued shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the SPTX March 2024 Shares, the Company recognized $0.9&nbsp;million of
stock-based compensation expense in its consolidated statements of operations and comprehensive loss for the year ended December&nbsp;31, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had no shares of common stock outstanding or any potentially dilutive equity instruments for any period prior to its formation and
the Asset Transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. STOCK-BASED COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>PureTech Stock-based Compensation Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PureTech has stock-based compensation plans which provide for granting equity awards, including
<FONT STYLE="white-space:nowrap">non-qualified</FONT> and incentive stock options, restricted stock, restricted stock units, cash-based awards, and performance shares to employees, officers, and directors of, and consultants to, PureTech. All
stock-based compensation plans were managed on a consolidated basis by PureTech. Stock-based compensation expense was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
allocated to the Company based on the proportion of time each employee or <FONT STYLE="white-space:nowrap">non-employee</FONT> spent on the Seaport Business in the period. Accordingly, the
amounts presented are not necessarily indicative of future stock-based compensation of Seaport and do not necessarily reflect the amount that Seaport would have issued as an independent company for the year presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under PureTech&#8217;s stock-based compensation plan, the Company&#8217;s employees transferred pursuant to the Asset Transfer&nbsp;were
granted 22,500 stock options during the year ended December&nbsp;31, 2024. During the year ended December&nbsp;31, 2025, there were no stock options granted to the Company&#8217;s employees under PureTech&#8217;s stock-based compensation plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PureTech utilized the Black-Scholes option-pricing model for estimating the fair value of the stock options issued under PureTech&#8217;s
stock-based compensation plans on each grant date. The following table presents the assumptions used by PureTech in the Black-Scholes option-pricing model during the year ended December&nbsp;31, 2024: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.93</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value of options granted by PureTech during the year ended
December&nbsp;31, 2024 was $1.02. The aggregate intrinsic value is calculated as the difference between the exercise price and the market price of PureTech&#8217;s common stock at December&nbsp;31, 2024. As of December&nbsp;31, 2024, all outstanding
stock options issued by PureTech to the Company&#8217;s employees were fully vested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport employees continued to vest in their
PureTech equity awards until the completion of the Company&#8217;s Series B Financing (as discussed in Note 9) in October 2024 at which time PureTech no longer maintained a controlling interest in the Company. Accordingly, Seaport employees
forfeited their unvested awards in October 2024 as the employees were no longer deemed to be continuing service providers under PureTech&#8217;s plan, except for restricted stock units granted to an employee of Seaport for services performed to
PureTech. As of December&nbsp;31, 2024, Seaport employees held 873,617 of outstanding vested options that Seaport employees had 90 days to exercise from October 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2024 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2024 Equity Incentive Plan, or the 2024 Plan, was approved by the Company&#8217;s subsidiary&#8217;s Board and Stockholders and became
effective for the Company in April 2024 and was subsequently amended in April 2024 and October 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2024 Plan, the Company can
issue incentive stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards to employees, directors, and consultants of the Company. The 2024 Plan is administered by the Company&#8217;s Board of
Directors, or by a committee at the discretion of the Board of Directors. The exercise prices, vesting, and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that exercise prices
of each stock option shall not be less than 100% of the fair market value of the Company&#8217;s common stock and that each stock option term cannot exceed 10 years. The Company&#8217;s Board of Directors determines the fair market value of the
Company&#8217;s common stock, taking into consideration its most recently available valuation of common stock performed by third parties as well as additional factors which may have changed since the date of the most recent contemporaneous valuation
through the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of 3,184,003 shares of common stock were initially reserved for issuance under
the 2024 Plan, and it was subsequently amended to allow for the issuance of up to 12,292,486 shares of common stock. As of December&nbsp;31, 2025, there were 1,503,698 awards available for future grants under the 2024 Plan. Shares of common stock
underlying any awards that are forfeited, canceled, or reacquired by the Company prior to vesting will again be available for the grant of awards under the 2024 Plan. Through the completion of an Initial Public Offering, the Company will continue to
grant additional equity awards to certain individuals to maintain in total a 12.5% ownership on a fully diluted basis as specified by underlying agreements.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vesting periods for stock options issued under the 2024 Plan generally vest over four years with a
<FONT STYLE="white-space:nowrap">one-year</FONT> cliff and equal monthly installments thereafter and may be subject to accelerated vesting. Performance-based options vest in three annual installments that are contingent upon the achievement of the
Company&#8217;s annual goals. For restricted stock awards, the vesting periods can vary and may contain accelerated vesting that would result in unvested shares becoming fully vested upon the occurrence of certain events. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2024 Plan Stock Option Activity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the Company&#8217;s stock option award activity under the 2024 Plan during the year ended December&nbsp;31, 2025:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Stock<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term&nbsp;(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,812,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">903,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,877</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,569,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,569,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,007,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above excludes the 228,770 performance-based options which have an exercise price of $7.39
per share, that were approved to be issued by the Company&#8217;s Board of Directors in December 2024, but have not yet been deemed granted from an accounting perspective as of December&nbsp;31, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company utilized the Black-Scholes option-pricing model for estimating the fair value of the stock options issued under the 2024 Plan on
each grant date. The following table presents the ranges of assumptions used by the Company in the Black-Scholes option-pricing model during the years ended: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2025</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2024</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5.19&nbsp;-&nbsp;6.08</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5.19&nbsp;-&nbsp;6.08</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">3.73%&nbsp;-&nbsp;4.39%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">3.70%&nbsp;-&nbsp;4.39%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">89.40%&nbsp;-&nbsp;91.67%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">87.10%&nbsp;-&nbsp;92.33%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00%</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value of options granted during the years ended
December&nbsp;31, 2025 and 2024 was $5.72 and $3.21 per share, respectively. The aggregate intrinsic value is calculated as the difference between the exercise price and the fair value of the Company&#8217;s common stock as of each period end or
exercise date. The aggregate intrinsic value of options exercised during the year ended December&nbsp;31, 2025 was not material. There were no stock options exercised during the year ended December&nbsp;31, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, there was $14.0&nbsp;million in unrecognized stock-based compensation expense associated with issued and
outstanding service-based stock options, which is expected to be recognized over a weighted-average period of 1.3 years and is partially subject to future accelerated vesting upon the close of an initial public offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2024 Plan Restricted Stock Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has granted restricted stock awards to certain members of the Company&#8217;s Board of Directors and Chief Executive Officer. Of
the total 1,990,001 restricted stock awards granted: (i) 796,000 have service-based vesting in equal monthly installments over a three-year period, of which 50% of the unvested amount was subject to accelerated vesting upon the close of the Series B
Financing and 50% of any unvested amounts is subject to future acceleration upon the close of an initial public offering; and (ii) 1,194,001 have performance based vesting which vested in full upon the close of the Series B Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the Company&#8217;s restricted stock award activity under the 2024 Plan during the year ended December&nbsp;31,
2025: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total fair value of restricted stock awards granted during the year ended December&nbsp;31, 2024 was
$6.1&nbsp;million. No restricted stock awards were granted during the year ended December&nbsp;31, 2025. The total fair value of the restricted stock awards that vested during the year ended December&nbsp;31, 2025 and 2024 was $0.4&nbsp;million and
$5.2&nbsp;million, respectively, and the total stock-based compensation associated with the restricted stock awards during the years ended December&nbsp;31, 2025 and 2024 was $0.4&nbsp;million and $5.2&nbsp;million, respectively. As of
December&nbsp;31, 2025, there was $0.5&nbsp;million in unrecognized stock-based compensation expense associated with issued and outstanding restricted stock awards, which is expected to be recognized over a weighted-average period of 0.6 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents stock-based compensation expense recorded in the Company&#8217;s consolidated statements of operations and
comprehensive loss (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;6,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;14,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense for the year ended December&nbsp;31, 2024 of
$14.5&nbsp;million included $14.4&nbsp;million of stock-based compensation expense for Seaport employees, of which $9.6&nbsp;million was due to accelerated vesting of certain awards upon the close of the Series B Financing, and $0.1&nbsp;million of
stock-based compensation expense associated with awards issued to Seaport employees prior to the Asset Transfer under PureTech&#8217;s stock-based compensation plans. Seaport employees continued to vest in their PureTech equity awards until October
2024, at which time PureTech no longer maintained a controlling interest and the Seaport employees ceased to vest in their PureTech awards. No related tax benefits from stock-based compensation expense were recognized for the years ended 2025 or
2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2024, the Company allocated stock-based compensation of $1.3&nbsp;million, associated with
PureTech employee&#8217;s equity awards who spent a proportion of time providing services to the Company through the Asset Transfer, which is excluded from the table above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. INCOME TAXES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the
Transaction, income taxes and related income tax accounts have been calculated using the separate return method as if the Company filed income tax returns on a standalone basis. Prior to the Transaction, the Company&#8217;s operations were
calculated on a <FONT STYLE="white-space:nowrap">carve-out</FONT> basis and included certain hypothetical tax attributes. Following the Transaction, these hypothetical tax attributes are not available for future utilization by the Company and were
removed from the tax provision. Furthermore, the Company operated as part of PureTech until the completion of the Asset Transfer on April&nbsp;8, 2024, and therefore the Company will be included in PureTech&#8217;s U.S. Federal consolidated income
tax return until that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the components of loss before income taxes (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(76,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before the provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;(74,108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the provision for income taxes are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8194;&#8195;773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8195;&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the federal statutory income tax rate to the effective tax rate, in
accordance with the guidance in ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> which the Company has elected to retrospectively adopt, is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Federal statutory tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,845</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State and local income tax, net of federal income tax effect<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of cross border transactions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nontaxable or nondeductible item</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effective Tax Rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The state that contributes to the majority (greater than 50%) of the tax effect in this category is
Massachusetts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effective income tax rate differs from the U.S. federal statutory rate of&nbsp;21.0% primarily as a
result of the valuation allowance maintained against the Company&#8217;s U.S. net deferred tax assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts of cash taxes paid,
net of refunds, by Seaport are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US State and local:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Massachusetts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Australia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities reflect the net tax effects of temporary differences
between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other temporary differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,506</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right of use lease asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s change in its valuation allowance account with respect to deferred tax assets is as
follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning Balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reductions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The valuation allowance increased during the year ended December&nbsp;31, 2025 primarily as a result of the
increase to the Company&#8217;s taxable loss. The valuation allowance decreased during the year ended December&nbsp;31, 2024 primarily as a result of the hypothetical tax attributes which are not available for future utilization by the Company as a
result of the Transaction, partially offset by U.S. operating losses incurred, research credits generated, and capitalized research and other expenses generated after the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the need for a valuation allowance, the Company considers the cumulative income or loss position. The Company has assessed, on
a jurisdictional basis, the available means of recovering deferred tax assets, including the ability to carryback net operating losses, or NOLs, the existence of reversing taxable temporary differences, the availability of tax planning strategies,
and forecasted future taxable income. At December&nbsp;31, 2025, the Company maintained a full valuation allowance against its net deferred tax assets, as it has concluded that it is more likely than not that the deferred assets will not be
utilized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025 and 2024, the Company had U.S. federal NOLs of
$53.4&nbsp;million and $7.2&nbsp;million, respectively. The U.S. federal NOLs do not expire. As of December&nbsp;31, 2025 and 2024, the Company had U.S. federal tax credit carryforwards of $2.9&nbsp;million and $0.7&nbsp;million, respectively, that
begin to expire in 2044. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025 and 2024, the Company had $53.7&nbsp;million and $6.9&nbsp;million, of state NOLs,
respectively. These NOLs were generated in Massachusetts and that begin to expire in 2044. As of December&nbsp;31, 2025 and 2024, the Company had U.S. state tax credit carryforwards of $1.0&nbsp;million and $0.3&nbsp;million, respectively, that
begin to expire in 2039. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 382 and 383 of the U.S. Internal Revenue Code, if a corporation undergoes an ownership change,
the corporation&#8217;s ability to use its <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change NOLs and other <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change tax attributes, such as research tax credits, to offset its
post-change income and taxes may be limited. In general, an ownership change will occur if there is a cumulative change in the Company&#8217;s ownership by 5% shareholders that exceeds 50 percentage points over a rolling three-year period. Similar
rules may apply under U.S. state tax laws. Under the Tax Cuts and Jobs Act of 2017, the use of federal NOLs arising in taxable years beginning after December&nbsp;31, 2017 is limited to 80% of current year taxable income and NOLs arising in taxable
years ending after December&nbsp;31, 2017 may not be carried back (though any such NOLs may be carried forward indefinitely). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
may have experienced an ownership change in the current period and may experience ownership changes in the future as a result of future transactions in its share capital, some of which may be outside of the control of the Company. As a result, if
the Company earns net taxable income, its ability to use its <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change NOLs, or other <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change tax attributes, to offset U.S. federal and state
taxable income and taxes may be subject to significant limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undistributed earnings of Seaport&#8217;s foreign subsidiary are
indefinitely invested outside the U.S. The majority of Seaport&#8217;s cash flow is generated from domestic operations, and the Company is not dependent on foreign cash or earnings to meet funding requirements, nor does the Company intend to
repatriate these undistributed foreign earnings to fund U.S. operations. As a result, the Company has not provided U.S. deferred taxes on these undistributed earnings because it intends that it will remain indefinitely reinvested outside of the U.S.
and, therefore unavailable for use in funding U.S. operations. The Company estimates the income taxes that would be payable on the repatriation of the unremitted earnings would not be material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the United States and Australia. At December&nbsp;31, 2025, the Company is subject to examination by
taxing authorities in the United States and Australia for the years ended December&nbsp;31, 2025 and 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended
December&nbsp;31, 2025, and 2024, the Company had&nbsp;no&nbsp;tax reserves accrued for uncertain tax positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 4, 2025, the One
Big Beautiful Bill Act H.R. 1 was signed into law in the U.S. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The bill did not have a material impact on the Company&#8217;s
consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. LEASES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, the Company entered into an operating lease for office space in Boston, Massachusetts, which commenced in December 2024 and
has an initial lease term that continues through October&nbsp;20, 2030, with no options to extend. In conjunction with entering into the lease, the Company paid a security deposit of $0.2&nbsp;million in the form of a letter of credit, which is
recorded as restricted cash within other <FONT STYLE="white-space:nowrap">non-current</FONT> assets on the Company&#8217;s consolidated balance sheets as of December&nbsp;31, 2025 and 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2024, the Company entered into a laboratory license agreement with a third party
for lab space located in Boston, Massachusetts. The license commenced in January 2025 and is for an initial term of 24 months from the commencement date, with no renewal option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to entering into the lease and laboratory license agreement, the Company did not have any leases as it shared office and lab space with
PureTech and made payments to PureTech under the TSA. See Note 17&#8212;Related Parties for further disclosure of transactions with PureTech. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table contains a summary of the components of lease costs recognized pertaining to the Company&#8217;s operating leases (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;1,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table contains a summary of other supplemental lease information pertaining to the
Company&#8217;s operating lease for the year ended December&nbsp;31, 2025 and 2024: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Lease Information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liability&#8212;operating leases (in
thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;1,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term&#8212;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average discount rate&#8212;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.53</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;6.61</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below reconciles future minimum payments under
<FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating leases as of December&nbsp;31, 2025 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating<BR>Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2030</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Legal Matters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company, from time to time, may be involved with lawsuits arising in the ordinary course of business. The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition,
results of operations, or cash flows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contracts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in the normal course of business with various third parties for preclinical research studies, clinical
trials, testing, manufacturing, and other services. These contracts generally provide for termination upon notice and are cancellable without significant penalty or payment, and do not contain any minimum purchase commitments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License and Other Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is obligated to make fixed and contingent payments under the Asset Transfer Agreement and Monash License Agreement. See Note
1&#8212;Nature of Business and Basis of Presentation, for further disclosure of the Asset Transfer Agreement and see Note 8&#8212;Monash License Agreement, for further disclosure of the Monash license agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Guarantees and Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners
and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into
indemnification agreements with all&nbsp;board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential
amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not
aware of any claims under indemnification arrangements that could have a material effect on its financial position, results of operations, or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated
financial statements as of December&nbsp;31, 2025 and 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a defined-contribution savings plan under Section&nbsp;401(k) of the IRC (the &#8220;401(k) Plan&#8221;). The 401(k) Plan
covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. The Company will make a contribution of 3% of each employee&#8217;s annual
compensation up to annual safe harbor limits. The Company has expensed $0.4&nbsp;million and $0.1&nbsp;million in 401(k) contributions for the years ended December&nbsp;31, 2025 and 2024, respectively. The Company participated in the PureTech <FONT
STYLE="white-space:nowrap">defined-contribution</FONT> plan through July 2025. Beginning in August 2025, the Company implemented its own <FONT STYLE="white-space:nowrap">defined-contribution</FONT> plan for eligible employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note
13&#8212;Leases, for information related to the Company&#8217;s lease obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. SEGMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has one operating and reportable segment focused on inventing and developing novel medicines for patients with depression, anxiety,
and other debilitating neuropsychiatric disorders using the Company&#8217;s proprietary Glyph<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CODM manages the Company&#8217;s operations on a consolidated basis, and assesses
performance based on consolidated net loss that is reported on the consolidated statements of operations and comprehensive loss. The CODM makes decisions about allocating resources and assessing performance for the entire company. The measure of
segment assets is reported on the consolidated balance sheet as total consolidated assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents certain
significant segment expenses that are regularly provided to the CODM (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GlyphAllo direct research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GlyphAgo direct research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Glyph2BLSD direct research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical and early discovery assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related (including stock-based compensation expense of $2.3&nbsp;million and
$0.7&nbsp;million for 2025 and 2024, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other indirect research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related (including stock-based compensation expense of $4.6&nbsp;million and
$15.2&nbsp;million for 2025 and 2024, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative
expenses<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other segment items<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other general and administrative expenses include professional fees, facilities, depreciation, IT, and other
expenses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other segment items include interest income, net, research and development tax credit, income tax provision,
and other (expense), net. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. NET LOSS PER SHARE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the Company&#8217;s formation on April&nbsp;1, 2024, the Company issued 318 shares of its common stock to PureTech and on April&nbsp;8,
2024, the effective date of the Asset Transfer, an additional 302,161 shares of its common stock were issued to PureTech. The aggregate 302,479 shares were considered outstanding for the full year and the Exchange Shares were considered outstanding
based on their issuance or vesting dates, as applicable, in the calculation of basic and diluted earnings per share for the year ended December&nbsp;31, 2024, as the formation, Asset Transfer and Exchange Shares were deemed to be common control
transactions. There were no shares of the Company outstanding prior to the Company&#8217;s formation and the Asset Transfer Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, basic net loss per share is calculated by dividing the net loss
attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. The net loss available to common stockholders was not allocated to
the Preferred Stock as the holders did not have a contractual obligation to share in losses. Diluted net loss per share is the same as basic net loss per share for the years presented since the effects of any potentially dilutive securities, would
be antidilutive given the net loss of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share is calculated as follows (in thousands except share and
per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,373,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">942,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For accounting purposes, the computation of basic and diluted weighted-average common shares outstanding
for the years ended December&nbsp;31, 2025 and 2024, excludes all shares of unvested restricted common stock as such shares are not considered outstanding. See Note 11&#8212;Stock-Based Compensation, for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share attributable
to common stockholders, as their effect is antidilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock
<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,569,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,812,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (as converted to common
stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,736,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,736,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock (as converted to common
stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,387,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,387,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,149,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,149,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,996,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,372,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The table above excludes the performance-based options, as they were not yet been deemed granted from an
accounting perspective. See Note 11&#8212;Stock-Based Compensation, for more information. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. RELATED PARTIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During&nbsp;the year ended December&nbsp;31, 2024, there was $5.5&nbsp;million of corporate expense allocations from PureTech Health plc prior
to the Transaction and $14.2&nbsp;million of expenses incurred pursuant to the TSA after the Asset Transfer Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the
Transaction, the Company historically operated as part of PureTech and not as a separate entity. Accordingly, for the period prior to the Transaction, certain corporate expenses represent shared costs of PureTech that were allocated to the Company
based on a systematic and rational methodology and are reflected as expenses in these consolidated financial statements. These amounts include, but are not limited to, items such as payroll, general management and executive oversight, costs to
support Seaport&#8217;s information technology infrastructure, facilities, compliance, human resources, legal, and finance functions, risk management, and stock-based compensation, all of which supported the operations of PureTech as a whole.
Corporate expense and shared cost allocations are generally allocated to the Company based on proportional cost allocation methods using headcount or proportional time worked supporting the Seaport Business and other organizational activities, as
applicable, which were considered to be reasonable reflections of the utilization of services provided or benefit received by the Company during the periods presented prior to the Transaction. Total corporate expense allocations were
$1.7&nbsp;million in research and development and $3.8&nbsp;million in general and administrative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expenses during the year ended December&nbsp;31, 2024. Net transfers from PureTech Health plc within financing activities in the consolidated statements of cash flows and the consolidated
statements of convertible preferred stock and stockholders&#8217; deficit consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate cost allocations from PureTech</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General finance activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net transfers from PureTech</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As disclosed in Note 1&#8212;Nature of Business and Basis of Presentation, the Company entered into the Asset
Transfer Agreement with PureTech and issued 40,000,000 shares of its Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock to PureTech LYT. In connection with entering into the Asset Transfer Agreement, the Company entered into the TSA
with PureTech, under which the Company made an <FONT STYLE="white-space:nowrap">up-front</FONT> payment of $0.5&nbsp;million to reimburse PureTech for work performed by certain third-parties prior to the closing of the Asset Transfer Agreement to
advance the Company&#8217;s programs and activities. During the year ended December&nbsp;31, 2025, the Company incurred $0.4&nbsp;million of expenses from PureTech under the TSA of which $0.3&nbsp;million related to research and development and
$0.1&nbsp;million related to general and administrative expenses. During the year ended December&nbsp;31, 2024, the Company incurred $14.2&nbsp;million of expenses from PureTech under the TSA of which $12.4&nbsp;million related to research and
development and $1.8&nbsp;million related to general and administrative expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, as part of its Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Financing, the Company issued and sold 8,421,052 shares of its Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock to PureTech LYT, at a purchase price of $3.80 per share for gross aggregate
proceeds of $32.0&nbsp;million. Subsequent to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing, PureTech LYT remained the controlling investor of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, as part of its Series B Financing, the Company issued and sold an aggregate 3,031,578 and 494,734 shares of its Series B
Preferred Stock to PureTech LYT and to certain of the Company&#8217;s management and board of directors, respectively, at a purchase price of $4.75 per share, for gross aggregate proceeds of $14.4&nbsp;million and $2.3&nbsp;million, respectively.
Subsequent to the Series B Financing, PureTech LYT was no longer a controlling investor of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2024 the Company paid $0.2&nbsp;million, to Third Rock Ventures for professional fees. Such amounts were included in general and administrative expenses. During the year ended December&nbsp;31, 2025, amounts paid to Third Rock
Ventures were not material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through February&nbsp;27, 2026, the date these consolidated financial statements were available to
be issued, and, only with respect to the reverse stock split, through April&nbsp;27, 2026, the date the consolidated financial statements were available to be reissued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January and February 2026, the Company granted 962,655 stock options, under the 2024 Plan, at an exercise price of $10.31 to the
Company&#8217;s board of directors and employees, which vest over a one year and four-year period, respectively. The aggregate grant date fair value of these stock options granted by the Company was determined to be approximately $7.6&nbsp;million.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;24, 2026, the Company effected a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-for-3.1407</FONT></FONT> reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios of each series of the Company&#8217;s preferred stock (see
Note&nbsp;9). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and
adjustment of the preferred stock conversion ratios. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Events Subsequent to Original Issuance of Financial Statements (Unaudited) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the reissuance of the financial statements, the Company has evaluated subsequent events through April 27, 2026, the date the
financial statements were available to be reissued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2026 Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;7, 2026, the Company&#8217;s board of directors adopted, and its stockholders approved on April&nbsp;23, 2026, the
Company&#8217;s 2026 Stock Option and Incentive Plan (the &#8220;2026 Plan&#8221;). The Company expects to grant stock options and other equity awards under the 2026 Plan. The Company initially reserved 6,020,000 shares of its common stock for the
issuance of awards under the 2026 Plan. The 2026 Plan provides that the number of shares reserved and available for issuance under the 2026 Plan will automatically increase on January&nbsp;1, 2027 and each January thereafter during the term of the
2026 Plan, by 5% of the outstanding number of shares of its common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, if any, on the immediately preceding December&nbsp;31 or such lesser number of shares as determined by the
Company&#8217;s compensation committee. The number of shares reserved for issuance under the 2026 Plan will be subject to adjustment in the event of a stock split, stock dividend, or other change in the Company&#8217;s capitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock underlying any awards under the 2026 Plan and the 2024 Plan that are forfeited, cancelled, held back upon exercise
or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire, or are otherwise terminated (other than by exercise) will be added back to the
shares of common stock available for issuance under the 2026 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2026 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;7, 2026, the Company&#8217;s board of directors adopted, and its stockholders approved on April&nbsp;23, 2026, the 2026 Employee
Stock Purchase Plan (the &#8220;ESPP&#8221;). A total of 510,000 shares of common stock were initially reserved for issuance under the ESPP. The ESPP provides that the number of shares reserved and available for issuance will automatically increase
on January&nbsp;1, 2027 and each January&nbsp;1 thereafter through January&nbsp;1, 2036, by the least of (i)&nbsp;1% of the outstanding number of shares of common stock and pre-funded warrants, if any, on the immediately preceding December&nbsp;31,
(ii)&nbsp;1,500,000 shares of common stock, or (iii)&nbsp;such lesser number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock
split, stock dividend or other change in the Company&#8217;s capitalization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended Certificate of Incorporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;7, 2026, the Company&#8217;s board of directors adopted, and its stockholders approved on April&nbsp;23, 2026, the amended and
stated certificate of incorporation, which, among other things, increased the number of shares of common stock authorized for issuance from 159,070,000 to 700,000,000 shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>  <P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>11,800,000 Shares
</B></P>  <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g73463g00a03.jpg" ALT="LOGO" STYLE="width:2.98667in;height:1.12833in;">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>J.P.&nbsp;Morgan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Leerink&nbsp;Partners </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Citigroup </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Stifel
</B></P> <P STYLE="margin-top:48pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Through and including &#8195;&#8195;&#8195;&#8195;, 2026 (the 25th day after the date of this prospectus), all dealers effecting
transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#8217;s obligation to deliver a prospectus when acting as an underwriter
and with respect to an unsold allotment or subscription. </B></P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all references to &#8220;Seaport,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221;
&#8220;us&#8221;, or similar terms refer to Seaport Therapeutics, Inc. and its wholly owned, consolidated subsidiaries, or either or both of them as the context may require. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all expenses to be paid by us, other than underwriting discounts and commissions, in connection with this
offering. All amounts shown are estimates except for the Securities and Exchange Commission, or SEC, registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq Global Market, or Nasdaq, listing fee. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and mailing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">325,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Custodian transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;3,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against
liabilities arising out of actions, suits, and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may
cover expenses (including attorneys&#8217; fees) judgments, fines, and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit, or proceeding. Section&nbsp;145 permits
corporations to pay expenses (including attorneys&#8217; fees) incurred by directors and officers in advance of the final disposition of such action, suit, or proceeding. In addition, Section&nbsp;145 provides that a corporation has the power to
purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the
corporation would have the power to indemnify the director or officer against such liability under Section&nbsp;145. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will adopt
provisions in our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and the amended and restated bylaws, which will become effective upon the effectiveness of the
registration statement of which this prospectus forms a part, that will limit or eliminate the personal liability of our directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended.
Consequently, our directors and officers will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as directors or officers, except for liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our directors, any unlawful payments related to dividends or unlawful stock purchases, redemptions or other
distributions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which they derived an improper personal benefit; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our officers, any derivative action by or in the right of the corporation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations of liability do not alter director and officer liability under the federal securities laws and do not affect the
availability of equitable remedies such as an injunction or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our amended and restated bylaws will provide that:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to
the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will advance reasonable expenses, including attorneys&#8217; fees, to our directors and, in the discretion of
our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and intend to enter into such agreements with our executive
officers. These agreements provide that we will indemnify each of our directors, our executive officers, and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#8217; fees (but
excluding judgments, fines, and settlement amounts), to each indemnified director, executive officer, or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any
action or proceeding arising out of that person&#8217;s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification,
advancement of expenses, or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#8217;s or officer&#8217;s services as a director
referenced herein. Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide
indemnification for the expenses or liabilities incurred by those directors are secondary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain general liability insurance
which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended, or Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement filed as Exhibit 1.1 to this registration statement provides for indemnification of us and our directors and
officers by the underwriters against certain liabilities under the Securities Act and the Securities Exchange Act of 1934. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;15. Recent Sales
of Unregistered Securities. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding securities we have issued within the past three years that were
not registered under the Securities Act.<B><I>&nbsp;</I></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Preferred Stock Issuances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, we issued an aggregate of 40,000,000 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock in
connection with entry into an asset transfer agreement, dated as of April&nbsp;8, 2024, or the Asset Transfer Agreement, with PureTech LYT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also issued and sold to accredited investors an aggregate of 26,342,102 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT>
convertible preferred stock at a price per share of $3.80, for an aggregate purchase price of $100.1&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October and November 2024, we issued and sold to accredited investors an aggregate of
47,578,934&nbsp;shares of Series B convertible preferred stock at a price per share of $4.75, for an aggregate purchase price of approximately $226.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Common Stock Issuances </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
April 2024, we issued an aggregate of 318 shares of common stock to PureTech LYT in connection with our formation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, we
issued an aggregate of 302,161 shares of common stock to PureTech LYT in connection with the Asset Transfer Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since April 2024,
we have sold or issued by exchange to our founders an aggregate of 2,292,481 shares of restricted common stock under our 2024 Plan or pursuant to agreement, at a purchase price of $0.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(c) Grants and exercises of stock options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since April 2024, we have granted certain employees, consultants, and directors options to purchase an aggregate of 9,916,296 shares of our
common stock under our 2024 Plan and 2026 Plan, at exercise prices ranging from $3.05 to $10.31 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since April 2024, 216,457
stock options have been exercised under our 2024 Plan and 2026 Plan at a weighted average purchase price of $3.73 per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of
the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise specified above, the Registrant believes these transactions were exempt from registration under the Securities Act
in reliance on Section&nbsp;4(a)(2) of the Securities Act (and Regulation D or Regulation S promulgated thereunder) or Rule 701 promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering
or under benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view
to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships with the Registrant, to
information about the Registrant. The sales of these securities were made without any general solicitation or advertising. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;16. Exhibits and
Financial Statement Schedules. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d73463dex11.htm">Form of Underwriting Agreement.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0002042347/000119312526151211/d73463dex31.htm">Amended and Restated Certificate of Incorporation, as amended, as currently in effect.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d73463dex32.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation, as amended. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d73463dex33.htm">Form of Amended and Restated Certificate of Incorporation, to be in effect immediately prior to the completion of this offering.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0002042347/000119312526151211/d73463dex34.htm">Bylaws, as currently in effect.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d73463dex35.htm">Form of Amended and Restated Bylaws, to be in effect as of the effectiveness of the registration statement of which this prospectus forms a
part.</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0002042347/000119312526151211/d73463dex41.htm">Specimen Common Stock Certificate.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.2+&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, by and between the Registrant and certain of its stockholders, dated as of October&nbsp;18,
 2024. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d73463dex51.htm">Opinion of Goodwin Procter LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex101.htm">2024 Equity Incentive Plan, as amended, and form of award agreements thereunder. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d73463dex102.htm">2026 Equity Incentive Plan and form of award agreements thereunder. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d73463dex103.htm">2026 Employee Stock Purchase Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex104.htm">Form of Officer Indemnification Agreement, by and between the Registrant and executive officers. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex105.htm">Form of Director Indemnification Agreement, by and between the Registrant and its directors. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex106.htm">Senior Executive Cash Incentive Bonus Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d73463dex107.htm">Executive Severance Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d73463dex108.htm"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex109.htm">Compensation Recovery Policy.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex1010.htm">Offer Letter, by and between the Registrant and Daphne Zohar, dated as of April 8, 2024. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex1011.htm">Offer Letter, by and between the Registrant and Michael Chen, dated as of April 29, 2024.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex1012.htm">Offer Letter, by and between the Registrant and Anthony Loebel, dated as of June 11, 2024. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14&#134;+*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex1014.htm">Asset Transfer Agreement, by and between the Registrant, PureTech Health LLC and PureTech LYT, Inc., dated April&nbsp;
8, 2024, as amended by that certain amendment, dated December 16, 2025.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15&#134;+*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/2042347/000119312526151211/d73463dex1015.htm">Amended and Restated License Agreement between Monash University, ABN 12 377 614 012, a body politic and corporate constituted in accordance
 with the Monash University Act 2009 of Wellington Road, Clayton, Victoria, Australia 3800 and the Registrant, dated March&nbsp;12, 2025.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0002042347/000119312526151211/d73463dex211.htm">Subsidiaries of Registrant. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d73463dex231.htm">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d73463dex51.htm">Consent of Goodwin Procter LLP (included in Exhibit 5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (included on signature page). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d73463dexfilingfees.htm">Filing Fee Table. </A></TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates a management contract or any compensatory plan, contract or arrangement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain portions of this document that constitute confidential information have been redacted pursuant to Item
601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601(a)(5) and (6)&nbsp;of
Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> The registrant will furnish copies of any of the exhibits and schedules to the Securities and Exchange Commission upon request. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Financial Statement Schedules. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the
financial statements or the notes thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;17. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful
defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registrant hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of determining any liability under the Securities Act of 1933, as amended, the information omitted
from a form of prospectus filed as part of this registration statement in reliance upon Rule&nbsp;430A and contained in the form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act of 1933,
as amended, shall be deemed to be part of this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of determining any liability under the Securities Act of 1933, as amended, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Amendment No 1. to the
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Massachusetts, on the
27<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of April, 2026. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SEAPORT THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daphne Zohar</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Daphne Zohar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:&#8194; Chief Executive Officer and Director</TD></TR>
</TABLE></DIV>  <P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No 1. to the
Registration Statement and Power of Attorney has been signed by the following person in the capacities and on the date indicated. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daphne Zohar</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Daphne Zohar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(<I>Principal Executive Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">April 27, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lauren White</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lauren A. White</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer (<I>Principal Financial Officer and Principal Accounting Officer</I>)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 27, 2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven M. Paul, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director and Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 27, 2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Hombach</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 27, 2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Elenko, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 27, 2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 27, 2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 27, 2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Pitts, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 27, 2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandra E. Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 27, 2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denice Torres, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 27, 2026</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wheadon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 27, 2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lyne, LLB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 27, 2026</P></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daphne Zohar</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Daphne Zohar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attorney-in-Fact</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d73463dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock
</B></P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I><U>Underwriting Agreement </U></I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>April&nbsp;&#8195;, 2026 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman
Sachs&nbsp;&amp; Co.&nbsp;LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As representatives (the
&#8220;Representatives&#8221;) of the several Underwriters </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">named in Schedule&nbsp;I hereto, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co.&nbsp;LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York <FONT STYLE="white-space:nowrap">10282-2198</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">270 Park Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Avenue of the Americas, 5th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport
Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), proposes, subject to the terms and conditions stated in this agreement (this &#8220;Agreement&#8221;), to issue and sell to the Underwriters named in Schedule&nbsp;I hereto (the
&#8220;Underwriters&#8221; or &#8220;you&#8221;) an aggregate of [___] shares (the &#8220;Firm Shares&#8221;) and, at the election of the Underwriters, up to [___] additional shares (the &#8220;Optional Shares&#8221;) of common stock, par value
$0.0001 per share (&#8220;Stock&#8221;), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section&nbsp;2 hereof being collectively called the &#8220;Shares&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC (the &#8220;Directed Share Underwriter&#8221;) has agreed to reserve up to [____] Shares to be purchased
under this Agreement for the sale at the direction of the Company to certain parties related to the Company (collectively, &#8220;Participants&#8221; and such program under which such Shares are sold to Participants, the &#8220;Directed Share
Program&#8221;). The Shares to be sold by the Directed Share Underwriter pursuant to the Directed Share Program are hereinafter called the &#8220;Directed Shares.&#8221; Any Directed Shares not confirmed for purchase by the deadline established
therefor by the Directed Share Underwriter in consultation with the Company will be offered to the public by the Underwriters as set forth in the Prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The Company represents and warrants to, and agrees with, each of the Underwriters that:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) A registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-294976)</FONT> (the &#8220;Initial Registration Statement&#8221;) in respect of the Shares has been filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;); the Initial
Registration Statement and any <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment thereto, each in the form heretofore delivered to you, have been declared effective by the Commission in such form; other than a registration statement,
if any, increasing the size of the offering (a &#8220;Rule 462(b) Registration Statement&#8221;), filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#8220;Act&#8221;), which became effective upon filing, no other
document with respect to the Initial Registration Statement has been filed with the Commission; and no stop order suspending the effectiveness of the Initial Registration Statement, any <FONT STYLE="white-space:nowrap">post-effective</FONT>
amendment thereto or the Rule 462(b) Registration Statement, if any, has been issued and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Act has been initiated or, to the Company&#8217;s knowledge, threatened by the Commission
(any preliminary prospectus included in the Initial Registration Statement or filed with the Commission pursuant to Rule 424(a) of the rules and regulations of the Commission under the Act is hereinafter called a &#8220;Preliminary
Prospectus&#8221;; the various parts of the Initial Registration Statement and the Rule 462(b) Registration Statement, if any, including all exhibits thereto and including the information contained in the form of final prospectus filed with the
Commission pursuant to Rule 424(b) under the Act in accordance with Section&nbsp;5(a) hereof and deemed by virtue of Rule 430A under the Act to be part of the Initial Registration Statement at the time it was declared effective, each as amended at
the time such part of the Initial Registration Statement became effective or such part of the Rule 462(b) Registration Statement, if any, became or hereafter becomes effective, are hereinafter collectively called the &#8220;Registration
Statement&#8221;; the Preliminary Prospectus relating to the Shares that was included in the Registration Statement immediately prior to the Applicable Time (as defined in Section&nbsp;1(c) hereof) is hereinafter called the &#8220;Pricing
Prospectus&#8221;;<B> </B>and such final prospectus, in the form first filed pursuant to Rule 424(b) under the Act, is hereinafter called the &#8220;Prospectus&#8221;; any oral or written communication with potential investors undertaken in reliance
on Section&nbsp;5(d) of the Act or Rule 163B under the Act is hereinafter called a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;Testing-the-Waters</FONT></FONT> Communication&#8221;; and any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Act is hereinafter called a &#8220;Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#8221;;<B> </B>and any &#8220;issuer free writing prospectus&#8221; as defined in Rule 433 under the Act relating to the Shares is hereinafter
called an &#8220;Issuer Free Writing Prospectus&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) (A) No order preventing or suspending the use of any Preliminary Prospectus
or any Issuer Free Writing Prospectus has been issued by the Commission, and (B)&nbsp;each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Act and the rules and regulations of the
Commission thereunder, and did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading; <I>provided</I>, <I>however</I>, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information (as defined in Section&nbsp;9(b) of
this Agreement); </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For the purposes of this Agreement, the &#8220;Applicable Time&#8221;<B> </B>is [____]
[a.][p.]m., New York City time on the date of this Agreement. The Pricing Prospectus, as supplemented by the information listed on Schedule&nbsp;II(c) hereto, taken together (collectively, the &#8220;Pricing Disclosure Package&#8221;), as of the
Applicable Time, did not, and as of each<B> </B>Time of Delivery (as defined in Section&nbsp;4(a) of this Agreement) will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Free Writing Prospectus and each Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication does not conflict with the information contained in the Registration Statement, the Pricing Prospectus or the Prospectus and each Issuer
Free Writing Prospectus and each Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, as supplemented by and taken together with the Pricing Disclosure Package, as of the
Applicable Time, did not, and as of each<B> </B>Time of Delivery will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; <I>provided</I>, <I>however</I>, that this representation and warranty shall not apply to statements or omissions made in reliance upon and in conformity with the Underwriter Information; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Registration Statement conforms, and the Prospectus and any further amendments or supplements to the Registration Statement and the
Prospectus will conform, in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder and do not and will not, as of the applicable effective date as to each part of the Registration Statement,
as of the applicable filing date as to the Prospectus and any amendment or supplement thereto, and as of each Time of Delivery, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading; <I>provided</I>, <I>however</I>, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Neither the Company nor any of its subsidiaries has, since the date of the latest audited financial statements included in the
Pricing Prospectus, (i)&nbsp;sustained any material loss or material interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order
or decree or (ii)&nbsp;entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent,
that is material to the Company and its subsidiaries taken as a whole, in each case otherwise than as set forth or contemplated in the Pricing Prospectus; and, since the respective dates as of which information is given in the Registration Statement
and the Pricing Prospectus, there has not been (x)&nbsp;any change in the capital stock (other than as a result of (i)&nbsp;the exercise, if any, of Stock Options (as defined below) or the award, if any, of Stock Options or restricted stock in the
ordinary course of business pursuant to the Company&#8217;s equity plans that are described in the Pricing Prospectus and the Prospectus or (ii)&nbsp;the issuance, if any, of stock upon conversion of Company securities as described in the Pricing
Prospectus and the Prospectus) or <FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company or any of its subsidiaries or (y)&nbsp;any Material Adverse Effect (as defined below); as used in this Agreement, &#8220;Material Adverse
Effect&#8221; shall mean any material adverse change or effect, or any development involving a prospective material adverse change or effect, in or affecting (i)&nbsp;the business, properties, general affairs, management, financial position,
stockholders&#8217; equity or results of operations of the Company and its subsidiaries, taken as a whole, except as set forth or contemplated in the Pricing Prospectus, or (ii)&nbsp;the ability of the Company to perform its obligations under this
Agreement, including the issuance and sale of the Shares, or to consummate the transactions contemplated in the Pricing Prospectus and the Prospectus; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company and its subsidiaries have good and marketable title in fee simple to all
real property and good and marketable title to all personal property owned by them, in each case free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases
with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Each of the Company and each of its subsidiaries has been (i)&nbsp;duly organized and is validly existing and in good standing under the
laws of its jurisdiction of organization, with power and authority (corporate and other) to own its properties and conduct its business as described in the Pricing Prospectus, and (ii)&nbsp;duly qualified as a foreign corporation for the transaction
of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, except, in the case of this clause (ii), where the failure to be so
qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, and each subsidiary of the Company has been listed in Exhibit 21.1 to the Registration Statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Company has an authorized capitalization as set forth in the Pricing Prospectus and all of the issued shares of capital stock of the
Company have been duly and validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and conform, in all material respects, to the description of the Stock contained in the Pricing Disclosure Package
and Prospectus; and all of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and (except, in the case of
any foreign subsidiary, for directors&#8217; qualifying shares) are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Shares to be issued and sold by the Company to the Underwriters hereunder [and in connection with the concurrent private placement
described in the Pricing Disclosure Package and the Prospectus] have been duly and validly authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued and fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and will conform to the description of the Stock contained in the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that
have not been duly waived or satisfied; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) The issue and sale of the Shares and the compliance by the Company with this Agreement and
the consummation of the transactions contemplated in this Agreement and the Pricing Prospectus will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, (A)&nbsp;any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company
or any of its subsidiaries is subject, (B)&nbsp;the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or other applicable organizational document) of the Company or any of its subsidiaries, or (C)&nbsp;any statute or
any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties, except, in the case of clauses (A)&nbsp;and (C) for such defaults,
breaches, or violations that would not, individually or in the aggregate, have a Material Adverse Effect; and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is
required for the issue and sale of the Shares or the consummation by the Company of the transactions contemplated by this Agreement, except such as have been obtained under the Act, the approval by the Financial Industry Regulatory Authority
(&#8220;FINRA&#8221;) of the underwriting terms and arrangements and such consents, approvals, authorizations, registrations or qualifications as may be required under state securities or Blue Sky laws in connection with the purchase and
distribution of the Shares by the Underwriters; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its
certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or other applicable organizational document), (ii) in violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body
having jurisdiction over the Company or any of its subsidiaries or any of their properties, or (iii)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition contained in any indenture, mortgage, deed of
trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound, except, in the case of the foregoing clauses (ii)&nbsp;and (iii), for such defaults as would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) The statements set forth in the Pricing Prospectus and
Prospectus under the caption &#8220;Description of Capital Stock&#8221;, insofar as they purport to constitute a summary of the terms of the Stock, under the caption &#8220;Material U.S. Federal Income Tax Consequences for <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders&#8221;, and under the caption &#8220;Underwriting&#8221;, insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate, complete and fair in all
material respects; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Other than as set forth in the Pricing Prospectus, there are no legal, governmental or regulatory investigations,
actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#8220;Actions&#8221;) pending to which the Company or any of its subsidiaries or, to the Company&#8217;s knowledge, any officer or director of the Company, is a party or of
which any property of the Company or any of its subsidiaries or, to the Company&#8217;s knowledge, any officer or director of the Company, is the subject which, if determined adversely to the Company or any of its subsidiaries (or such officer or
director), would individually or in the aggregate have a Material Adverse Effect; and, to the Company&#8217;s knowledge, no such proceedings are threatened or contemplated by governmental authorities or others; there are no current or pending
Actions that are required under the Act to be described in the Registration Statement or the Pricing Prospectus that are not so described therein; and there are no statutes, regulations or contracts or other documents that are required under the Act
to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement and the Pricing
Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds
thereof, will not be an &#8220;investment company&#8221;, as such term is defined in the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) At the time of filing the Initial Registration Statement and any <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment thereto,
at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Act) of the Shares, and at the date hereof, the Company was not and is not an &#8220;ineligible
issuer,&#8221; as defined under Rule 405 under the Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) PricewaterhouseCoopers LLP (&#8220;PwC&#8221;), who have certified certain
financial statements of the Company and its subsidiaries, are independent public accountants as required by the Act and the rules and regulations of the Commission thereunder; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) The Company maintains a system of internal control over financial reporting (as such
term is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> under the Exchange Act) that (i)&nbsp;complies with the applicable requirements of the Exchange Act, (ii)&nbsp;has been designed by the Company&#8217;s principal executive
officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles (&#8220;GAAP&#8221;) and (iii)&nbsp;is sufficient to provide reasonable assurance that (A)&nbsp;transactions are executed in accordance with management&#8217;s general or specific authorization, (B)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets, (C)&nbsp;access to assets is permitted only in accordance with management&#8217;s general or specific
authorization and (D)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences (it being understood that this subsection shall not
require the Company to comply with Section&nbsp;404 of the Sarbanes Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith, as of an earlier date than it would otherwise be required to so comply under
applicable law); and the Company&#8217;s internal control over financial reporting is effective and the Company is not aware of any material weaknesses in its internal control over financial reporting<B>;</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) Since the date of the latest audited financial statements included in the Pricing Prospectus, there has been no change in the
Company&#8217;s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company&#8217;s internal control over financial reporting; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) The Company maintains disclosure controls and procedures (as such term is defined in Rule
<FONT STYLE="white-space:nowrap">13a-15(e)</FONT> under the Exchange Act) that comply with the applicable requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that material information relating to
the Company and its subsidiaries is made known to the Company&#8217;s principal executive officer and principal financial officer by others within those entities; and such disclosure controls and procedures are effective; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) This Agreement has been duly authorized, executed and delivered by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) Neither the Company nor any of its subsidiaries, nor any director or officer, or to the knowledge of the Company, employee of the Company
or any of its subsidiaries nor, any agent, affiliate, employee, representative or other person associated with or acting on behalf of the Company or any of its subsidiaries or affiliates has (i)&nbsp;made, offered, promised or authorized any
unlawful contribution, gift, entertainment or other unlawful expense (or taken any act in furtherance thereof); (ii) made, offered, promised or authorized any direct or indirect unlawful payment; or (iii)&nbsp;violated or is in violation of any
provision of the Foreign Corrupt Practices Act of 1977, as amended, or the rules and regulations thereunder, the Bribery Act 2010 of the United Kingdom or any other applicable <FONT STYLE="white-space:nowrap">anti-corruption,</FONT> <FONT
STYLE="white-space:nowrap">anti-bribery</FONT> or related law, statute or regulation (collectively, <FONT STYLE="white-space:nowrap">&#8220;Anti-Corruption</FONT> Laws&#8221;); the Company and each of its subsidiaries have conducted their businesses
in compliance with <FONT STYLE="white-space:nowrap">Anti-Corruption</FONT> Laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with
the representations and warranties contained herein; neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment
or giving of money, or anything else of value, to any person in violation of <FONT STYLE="white-space:nowrap">Anti-Corruption</FONT> Laws; no action, suit, proceeding or investigation by or before any court or governmental agency, authority or
regulatory body or any arbitrator involving the Company or any of its subsidiaries, directors or officers with respect to the Anti-Corruption Laws is pending or threatened; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) The operations of the Company and its subsidiaries are and have been conducted at all
times in compliance with the requirements of applicable <FONT STYLE="white-space:nowrap">anti-money</FONT> laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and
regulations promulgated thereunder, and the <FONT STYLE="white-space:nowrap">anti-money</FONT> laundering laws of the various jurisdictions in which the Company and its subsidiaries conduct business, the rules and regulations thereunder and any
related or similar rules, regulation or guidelines issued, administered or enforced by any governmental agency (collectively, the &#8220;Money Laundering Laws&#8221;) and no action, suit or proceeding or investigation by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) Neither the Company nor any of its subsidiaries, nor any director or officer, or to the knowledge of the Company, employee of the Company
or any of its subsidiaries nor, any agent, affiliate, employee, representative or other person associated with or acting on behalf of the Company or any of its subsidiaries is (i)&nbsp;currently the subject or the target of any sanctions
administered or enforced by the U.S. Government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#8220;OFAC&#8221;), or the U.S. Department of State and including, without limitation, the
designation as a &#8220;specially designated national&#8221; or &#8220;blocked person,&#8221; the European Union, His Majesty&#8217;s Treasury, the United Nations Security Council, or other relevant sanctions authority (collectively,
&#8220;Sanctions&#8221;), (ii) located, organized, or resident in a country or territory that is the subject or target of Sanctions (a &#8220;Sanctioned Jurisdiction&#8221;), and the Company will not directly or indirectly use the proceeds of the
offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person, or in
any country or territory, that, at the time of such funding or facilitation, is the subject or the target of Sanctions or (ii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the
transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions; neither the Company nor any of its subsidiaries is engaged in, or has, at any time in the past ten years, knowingly engaged in, any dealings or transactions with or
involving any individual or entity that was or is, as applicable, at the time of such dealing or transaction, the subject or target of Sanctions or with any Sanctioned Jurisdiction; the Company and its subsidiaries have instituted, and maintain,
policies and procedures designed to promote and achieve continued compliance with Sanctions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) Neither the Company nor any of its
subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder&#8217;s fee or like
payment in connection with the offering and sale of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y) Neither the Company nor any of its subsidiaries is a &#8220;covered
foreign person&#8221; as that term is used in the Outbound Investment Rules. Neither the Company nor any of its subsidiaries currently engages, or has any present intention to engage in the future, directly or indirectly, in (i)&nbsp;a
&#8220;covered activity&#8221; or a &#8220;covered transaction&#8221;, as each such term is defined in the Outbound Investment Rules, (ii)&nbsp;any activity or transaction that would constitute a &#8220;covered activity&#8221; or a &#8220;covered
transaction&#8221;, as each such term is defined in the Outbound Investment Rules, if the Company were a U.S. Person or (iii)&nbsp;any other activity that would cause the Underwriters to be in violation of the Outbound Investment Rules or cause the
Underwriters to be legally prohibited by the Outbound Investment Rules from performing under this Agreement. For the purpose of this Agreement, &#8220;Outbound Investment Rules&#8221; means the regulations administered and enforced, together with
any related public guidance issued, by the United States Treasury Department under U.S. Executive Order 14105 of August&nbsp;9, 2023, or any similar law or regulation as of the date of this Agreement, and as codified at 31 C.F.R. &#167;850.202 et
seq. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(z) (i) The Company and its subsidiaries (x)&nbsp;are in compliance with all, and have not
violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable requirements relating to pollution or the protection of
human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#8220;Environmental Laws&#8221;); (y) have received and are in compliance with all, and have not violated
any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z)&nbsp;have not received notice of any actual or potential liability or obligation
under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no
knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case
of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;except as disclosed in the Registration Statement, the Pricing
Prospectus and the Prospectus, (x)&nbsp;there is no proceeding that is pending, or that is known to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other
than such proceeding regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company and its subsidiaries are not aware of any facts or issues regarding compliance with Environmental Laws, or
liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be expected to have a material effect on the capital expenditures, earnings or
competitive position of the Company and its subsidiaries, and (z)&nbsp;none of the Company or its subsidiaries anticipates material capital expenditures relating to any Environmental Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(aa) (i) Each employee benefit plan, within the meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as
amended (&#8220;ERISA&#8221;), for which the Company or any member of its &#8220;Controlled Group&#8221; (defined as any entity, whether or not incorporated, that is under common control with the Company within the meaning of
Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;)) would have any
liability (each, a &#8220;Plan&#8221;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii)&nbsp;no prohibited
transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii)&nbsp;for each Plan that
is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of
Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#8220;at risk status&#8221; (within the meaning of Section&nbsp;303(i) of ERISA) and no Plan that is a
&#8220;multiemployer plan&#8221; within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#8220;endangered status&#8221; or &#8220;critical status&#8221; (within the meaning of Sections 304 and 305 of ERISA)&nbsp;(v) the fair market value of
the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#8220;reportable event&#8221; (within the meaning of Section&nbsp;4043(c) of ERISA and
the regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii)&nbsp;each Plan that is </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification;
(viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee
Corporation, in the ordinary course and without default) in respect of a Plan (including a &#8220;multiemployer plan&#8221; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and (ix)&nbsp;none of the following events has occurred or is
reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group
affiliates compared to the amount of such contributions made in the Company&#8217;s and its Controlled Group affiliates&#8217; most recently completed fiscal year; or (B)&nbsp;a material increase in the Company and its subsidiaries&#8217;
&#8220;accumulated post-retirement benefit obligations&#8221; (within the meaning of Accounting Standards Codification Topic <FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such obligations in the Company and its
subsidiaries&#8217; most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(bb) The financial statements included in the Registration Statement, the Pricing Prospectus and the Prospectus, together with the related
schedules and notes, present fairly the financial position of the Company and its subsidiaries at the dates indicated and the statement of operations, stockholders&#8217; equity and cash flows of the Company and its subsidiaries for the periods
specified; said financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) applied on a consistent basis throughout the periods involved. The supporting schedules, if any, present
fairly in accordance with GAAP the information required to be stated therein. The selected financial data and the summary financial information included in the Registration Statement, the Pricing Prospectus and the Prospectus present fairly the
information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required
to be included in the Registration Statement, the Pricing Prospectus or the Prospectus under the Act or the rules and regulations promulgated thereunder. All disclosures contained in the Registration Statement, the Pricing Prospectus and the
Prospectus regarding <FONT STYLE="white-space:nowrap">&#8220;non-GAAP</FONT> financial measures&#8221; (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> of the Act, to the extent applicable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(cc) The Company and each of its subsidiaries own or
otherwise possess, to the Company&#8217;s knowledge, valid and enforceable rights to use all patents, patent applications, trademarks, service marks, trade names, domain names, copyrights and registrations and applications thereof, licenses, <FONT
STYLE="white-space:nowrap">know-how,</FONT> software, systems and technology (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures and other intellectual property) and
similar rights, including registrations and applications for registration therefor (collectively, &#8220;Intellectual Property&#8221;) used in or reasonably necessary for the conduct of their respective businesses as now conducted or proposed to be
conducted in the Registration Statement, the Pricing Prospectus and the Prospectus (&#8220;Company Intellectual Property&#8221;), provided that nothing in this sentence shall be construed as a representation or warranty regarding the <FONT
STYLE="white-space:nowrap">non-infringement</FONT> or <FONT STYLE="white-space:nowrap">non-misappropriation</FONT> of any Intellectual Property owned by any third party. The Company and/or each of its subsidiaries is the sole owner of the
Intellectual Property owned by it, other than any <FONT STYLE="white-space:nowrap">co-owner</FONT> of any patent or patent application constituting such Intellectual Property who is listed on the records of the U.S. Patent and Trademark Office (the
&#8220;USPTO&#8221;) (or foreign equivalent); (ii) to the Company&#8217;s knowledge, the Company and/or each of its subsidiaries do not, through the conduct of their </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respective businesses as now conducted or proposed to be conducted, infringe, violate or conflict with any Intellectual Property of any third party, or will not, upon commercialization of the
Company&#8217;s product candidates as described in the Registration Statement, the Pricing Prospectus and the Prospectus, infringe any valid and enforceable Intellectual Property of any third party; (iii)&nbsp;the Company and/or each of its
subsidiaries have not received any written notice of any claim of infringement, violation or conflict with any Intellectual Property of third parties; (iv)&nbsp;to the Company&#8217;s knowledge, the Company Intellectual Property has not been or is
not being infringed, misappropriated or otherwise violated by any third party; (v)&nbsp;the Company Intellectual Property is subsisting, and, to the Company&#8217;s knowledge is valid and enforceable, and there is no pending or, to the
Company&#8217;s knowledge threatened action, suit, proceeding or claim by any third party challenging the Company&#8217;s or its subsidiaries&#8217; rights in or to any of the Company Intellectual Property, and the Company is unaware of any facts
which would form a reasonable basis for any such claim; (vi)&nbsp;there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by any third party challenging the validity, enforceability or scope of any
Company Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (vii)&nbsp;none of the Intellectual Property used or held for use by the Company or its subsidiaries in their businesses
has been obtained or is being used or held for use by the Company or its subsidiary in violation of any contractual obligation binding on the Company or its subsidiaries or in violation of any rights of any third party; (viii)&nbsp;neither the
Company nor its subsidiaries are obligated to pay a material royalty, grant a license or option, or provide other material consideration to any third party in connection with the Company Intellectual Property; (ix)&nbsp;the Company and its
subsidiaries have taken reasonable steps in accordance with normal industry practice to maintain the confidentiality of all Company Intellectual Property, the value of which to the Company or any subsidiary is contingent upon maintaining the
confidentiality thereof; (x)&nbsp;all employees or contractors engaged in the development of Intellectual Property on behalf of the Company or its subsidiaries have executed an invention assignment agreement whereby such employees or contractors
presently assign all of their right, title and interest in and to such Intellectual Property to the Company or its applicable subsidiaries, and, to the Company&#8217;s knowledge, no such agreement has been breached or violated; (xi)&nbsp;to the
Company&#8217;s knowledge, no employee of the Company or its subsidiary is in or has been in violation of any term of any employment contract, patent disclosure agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&#8217;s employment with the Company; and
(xii)&nbsp;no government funding, facilities or resources of a university, college, other educational institution or research center was used in the development of any Intellectual Property that are owned or purported to be owned by or, to the
knowledge of the Company, exclusively licensed to the Company or its subsidiaries that would confer any governmental agency or body, university, college, other educational institution or research center any claim or right of ownership to any such
Company Intellectual Property. The product candidates described in the Registration Statement, the Pricing Prospectus and the Prospectus as under development by the Company and its subsidiaries upon commercialization of such product candidates will
fall within the scope of the claims of one or more patents or patent applications owned or purported to be owned by, or exclusively licensed to, the Company or its subsidiaries;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(dd) All patents and patent applications within the Company Intellectual Property that are owned or purported to be owned by or exclusively
licensed to the Company and its subsidiary have been duly and properly filed and maintained. The Company is unaware of any facts that would preclude the issuance of a valid and enforceable patent from any pending patent applications included in the
Company Intellectual Property that are owned or purported to be owned by or exclusively licensed to the Company or its subsidiary. To the Company&#8217; s knowledge, the parties prosecuting such patent applications have complied with their duty of
candor and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosure to the USPTO in connection with such applications and all such requirements in the relevant foreign patent authorities having similar requirements. There is no pending or, to the
Company&#8217;s knowledge, threatened derivation or interference proceeding pursuant to 35 U.S.C. &#167;135, in each case, in which a third party patent or patent application contains claims that are derived from or interfere with the claims of any
patents or patent applications within the Company Intellectual Property that are owned or purported to be owned by or exclusively licensed to the Company or its subsidiaries, and the Company is unaware of any facts which would form a reasonable
basis for any such proceeding; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ee) The Company and its subsidiaries&#8217; information technology assets and equipment, computers,
systems, networks, hardware, software, websites, applications, and databases (collectively, &#8220;IT Systems&#8221;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of
the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants that would individually, or in aggregate, reasonably be expected to have a
Material Adverse Effect; the Company and its subsidiaries have, and have required all third parties that process Personal Data (as defined herein) on behalf of the Company or any of its subsidiaries (&#8220;Data Partners&#8221;) to have, implemented
and maintained reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all
personal, personally identifiable, sensitive, confidential or regulated data (&#8220;Personal Data&#8221;)) used in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of, or disclosures, or
accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same; the Company and its subsidiaries,
and to the Company&#8217;s knowledge their Data Partners, are presently and have been in compliance in all material respects with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or
governmental or regulatory authority, policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access,
misappropriation or modification; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ff) No <FONT STYLE="white-space:nowrap">forward-looking</FONT> statement (within the meaning of
Section&nbsp;27A of the Act and Section&nbsp;21E of the Exchange Act) included in any of the Registration Statement, the Pricing Prospectus or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in
good faith; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(gg) Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and <FONT
STYLE="white-space:nowrap">market-related</FONT> data included in each of the Registration Statement, the Pricing Prospectus and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(hh) There is and has been no failure on the part of the Company or any of the Company&#8217;s directors or officers, in their capacities as
such, to comply with any provision of the <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act of 2002, as amended and the rules and regulations promulgated in connection therewith (the
<FONT STYLE="white-space:nowrap">&#8220;Sarbanes-Oxley</FONT> Act&#8221;), including Section&nbsp;402 related to loans and Sections&nbsp;302 and 906 related to certifications; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Neither the Company nor any of its affiliates has taken or will take, directly or indirectly, any action designed to or that could
reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company or any of its subsidiaries in connection with the offering of the Shares; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(jj) The Company and each of its subsidiaries have such permits, licenses, approvals,
consents, franchises, certificates of need and other approvals or authorizations of governmental or regulatory authorities (&#8220;Permits&#8221;) as are necessary under applicable law to own their respective properties and conduct their respective
businesses in the manner described in the Registration Statement, the Pricing Prospectus and the Prospectus, except for any of the foregoing that would not, individually or in the aggregate, have a Material Adverse Effect. Neither the Company nor
any of its subsidiaries has received notice of any proceedings related to the revocation or modification of any such Permits that, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material
Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(kk) Each of the Company and its subsidiaries (i)&nbsp;has operated and currently operates its business in compliance
with all applicable Health Care Laws (as defined below) and any other applicable requirements of the Food and Drug Administration (&#8220;FDA&#8221;), the Department of Health and Human Services (&#8220;HHS&#8221;) and any comparable state, local or
foreign governmental authority to which its business and operations are subject (collectively, &#8220;Regulatory Authorities&#8221;), and has not engaged in activities which are, as applicable, causes for false claims liability, civil penalties, or
mandatory or permissive exclusion from any &#8220;federal health care program&#8221; as defined in 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(f),</FONT> except where the failure to so comply, whether individually or in the aggregate,
would not reasonably be expected to have a Material Adverse Effect; (ii)&nbsp;has not received any FDA Form 483, written notice of adverse finding, warning letter, untitled letter or other written correspondence or notice from any court or
arbitrator or Regulatory Authority alleging or asserting material <FONT STYLE="white-space:nowrap">non-compliance</FONT> with (A)&nbsp;any applicable Health Care Laws or (B)&nbsp;any licenses, certificates, approvals, clearances, exemptions,
registrations, authorizations, certificates, permits and supplements or amendments thereto required pursuant to any such applicable Health Care Laws (&#8220;Regulatory Authorizations&#8221;); (iii) possesses such valid and current Regulatory
Authorizations required to conduct its business as currently conducted, and is not in violation of any term of any such Regulatory Authorizations, except where failure to possess, or comply with the terms of, such Regulatory Authorizations would
not, whether individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (iv)&nbsp;has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other
action from any Regulatory Authority or any other third party alleging that any product, operation, or activity is in material violation of any Health Care Laws or Regulatory Authorizations and has no knowledge that any Regulatory Authority or any
third party has threatened any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v)&nbsp;has not received written notice that any Regulatory Authority has taken, is taking or intends to take action to limit, suspend,
adversely modify, revoke or terminate any Regulatory Authorizations and has no knowledge that any applicable Regulatory Authority is threatening such action, except for such limitations, suspensions, adverse modifications, revocations or
terminations as would not, whether individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (vi)&nbsp;has no knowledge of any event that has occurred which allows, or after notice or lapse of time would allow,
revocation or termination thereof or results in any other material impairment of the rights of the holder of any Regulatory Authorization, except for such revocations, terminations or material impairments as would not, whether individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect; (vii)&nbsp;has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required
by any applicable Health Care Laws or Regulatory Authorizations and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
materially corrected or supplemented by a subsequent submission) except where the failure to file, obtain, maintain, submit or correct the same would not, whether individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect; (viii)&nbsp;is not a party to nor has any ongoing reporting, disclosure and compliance obligations pursuant to any corporate integrity agreements, deferred or <FONT
STYLE="white-space:nowrap">non-prosecution</FONT> agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any applicable Regulatory Authority; and (viii)&nbsp;along with its
employees, officers and directors, and, to the knowledge of the Company, agents, has not been excluded, suspended, debarred or otherwise determined to be ineligible from participation in any government health care program or human clinical research
or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, exclusion, or ineligibility. The term &#8220;Health
Care Laws&#8221; means all applicable laws governing the research, investigation, development, testing, manufacturing, production, packaging, labeling, distribution, storage, shipping, transport, marketing, advertising, promotion, sale, export,
import, use, handling, control, safety or efficacy of pharmaceutical products, including, as applicable, the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et seq. and any other law pertaining to or governing a government
healthcare program; all health care anti-kickback, self-referral, false claim, fraud and abuse laws, including the Federal Anti-Kickback Statute, 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b),</FONT> the civil False Claims Act, 31
U.S.C. &#167;&#167; 3729 et seq., the Anti-Inducement Law, 42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;1320a-7a(a)(5),</FONT> the criminal false statements law, 42 U.S.C. <FONT STYLE="white-space:nowrap">1320a-7b(a),</FONT> any criminal laws
relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286, 287, 1035, 1347 and 1349 and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C.
&#167;&#167; 1320d et seq., (&#8220;HIPAA&#8221;), the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1320a-7a</FONT> and <FONT STYLE="white-space:nowrap">1320a-7b;</FONT> the Physician Payments Sunshine Act,
42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h;</FONT> the Exclusion Laws, 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7;</FONT> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, 42
U.S.C. &#167;&#167; 17921 et seq.; the amendments, statutes, regulations, rules, ordinances and governmental orders related to such laws; and any comparable foreign, federal, state and local laws and regulations; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ll) All <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical studies, tests and trials conducted by, for or on behalf of the
Company or its subsidiaries, or in which the Company or its subsidiaries have participated with respect to their product candidates that are described in the Registration Statement, the Pricing Prospectus and the Prospectus, or the results of which
are referred to in the Registration Statement, the Pricing Prospectus and the Prospectus, as applicable, were, and if still pending are, being conducted in all material respects in accordance with all applicable Health Care Laws, Regulatory
Authorizations and any applicable rules and regulations to which such studies, tests or trials are subject. The descriptions of the results from such studies, tests and trials contained in the Registration Statement, the Pricing Prospectus and the
Prospectus are accurate in all material respects, and the Company has no knowledge of any other studies, tests or trials not described in the Registration Statement, the Pricing Prospectus and the Prospectus, the results of which are inconsistent
with or call into question the results described or referred to in the Registration Statement, the Pricing Prospectus and the Prospectus. Neither the Company nor its subsidiaries has received any written notices, correspondence or other
communications from any Regulatory Authority, institutional review board or other entity having authority over the conduct of such studies, tests, or trials requiring or threatening the termination, material modification, clinical hold or suspension
of any such studies, tests or trials currently being conducted or proposed to be conducted by or on behalf of the Company or its subsidiaries, other than ordinary course communications with respect to modifications in connection with the design and
implementation of such studies, tests or trials, and, to the knowledge of the Company, there are no reasonable grounds for the same; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(mm) The Company and its subsidiaries, taken as a whole, are insured against such losses and
risks and in such amounts as are prudent and customary in the businesses in which they are engaged and as required by law; and neither the Company nor any of its subsidiaries has (A)&nbsp;received notice from any insurer or agent of such insurer
that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (B)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(nn) The
Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof (except as currently being contested in good faith and for which reserves required by
GAAP have been created in the financial statements of the Company or applicable subsidiary), and (ii)&nbsp;there is no tax deficiency that has been, or would reasonably be expected to be, asserted against the Company or any of its subsidiaries or
any of their respective properties or assets; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(oo) The Registration Statement, the Pricing Disclosure Package and the Prospectus, any
Preliminary Prospectus, any Issuer Free Writing Prospectuses and any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication comply in all material respects, and any further amendments
or supplements thereto will comply in all material respects, with any applicable laws or regulations of foreign jurisdictions in which the Pricing Disclosure Package, the Prospectus, any Preliminary Prospectus, any Issuer Free Writing Prospectus and
any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, as amended or supplemented, if applicable, are distributed in connection with the Directed Share Program; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(pp) No authorization, approval, consent, license, order, registration or qualification of or with any government, governmental
instrumentality or court, other than such as have been obtained, is necessary under the securities laws and regulations of foreign jurisdictions in which the Directed Shares are offered outside the United States; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(qq) The Company has specifically directed in writing the allocation of Shares to each Participant in the Directed Share Program, and neither
the Directed Share Underwriter nor any other Underwriter has had any involvement or influence, directly or indirectly, in such allocation decision;<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(rr) The Company has not offered, or caused the Directed Share Underwriter or its affiliates to offer, Shares to any person pursuant to the
Directed Share Program (i)&nbsp;for any consideration other than the cash payment of the initial public offering price per share set forth in Schedule&nbsp;II hereof or (ii)&nbsp;with the specific intent to unlawfully influence (x)&nbsp;a customer
or supplier of the Company to alter the customer or supplier&#8217;s terms, level or type of business with the Company or (y)&nbsp;a trade journalist or publication to write or publish favorable information about the Company or its products; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ss) No labor disturbance by or dispute with employees of the Company exists or, to the knowledge of the Company, is contemplated or
threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its principal suppliers, contractors or customers, except in each case as would not have a Material Adverse Effect.
The Company has not received any notice of cancellation or termination with respect to any collective bargaining agreement to which it is a party; and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(tt) From the time of initial confidential submission of a registration statement relating
to the Shares with the Commission through the date hereof, the Company has been and is an &#8220;emerging growth company&#8221; as defined in Section&nbsp;2(a)(19) of the Act (an &#8220;Emerging Growth Company&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Subject to the terms and conditions herein set forth, (a)&nbsp;the Company agrees to issue and sell to each of the Underwriters, and each
of the Underwriters agrees, severally and not jointly, to purchase from the Company, at a purchase price per share of $[______], the number of Firm Shares set forth opposite the name of such Underwriter in Schedule&nbsp;I hereto and (b)&nbsp;in the
event and to the extent that the Underwriters shall exercise the election to purchase Optional Shares as provided below, the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not
jointly, to purchase from the Company, at the purchase price per share set forth in clause (a)&nbsp;of this Section&nbsp;2 (provided that the purchase price per Optional Share shall be reduced by an amount per share equal to any dividends or
distributions declared by the Company and payable on the Firm Shares but not payable on the Optional Shares), that portion of the number of Optional Shares as to which such election shall have been exercised (to be adjusted by you so as to eliminate
fractional shares) determined by multiplying such number of Optional Shares by a fraction, the numerator of which is the maximum number of Optional Shares which such Underwriter is entitled to purchase as set forth opposite the name of such
Underwriter in Schedule&nbsp;I hereto and the denominator of which is the maximum number of Optional Shares that all of the Underwriters are entitled to purchase hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby grants to the Underwriters the right to purchase at their election up to [______] Optional Shares, at the purchase price
per share set forth in the paragraph above, for the sole purpose of covering over-allotments, if any, provided that the purchase price per Optional Share shall be reduced by an amount per share equal to any dividends or distributions declared by the
Company and payable on the Firm Shares but not payable on the Optional Shares. Any such election to purchase Optional Shares may be exercised only by written notice from you to the Company, given within a period of 30 calendar days after the date of
this Agreement, setting forth the aggregate number of Optional Shares to be purchased and the date on which such Optional Shares are to be delivered, as determined by you but in no event earlier than the First Time of Delivery (as defined in
Section&nbsp;4 hereof) or, unless you and the Company otherwise agree in writing, earlier than one or later than ten business days after the date of such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Upon the authorization by you of the release of the Shares, the several Underwriters propose to offer the Shares for sale upon the terms
and conditions set forth in the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. (a) The Shares to be purchased by each Underwriter
hereunder, in definitive or <FONT STYLE="white-space:nowrap">book-entry</FONT> form, and in such authorized denominations and registered in such names as the Representatives may request upon at least
<FONT STYLE="white-space:nowrap">twenty-four</FONT> hours&#8217; prior notice to the Company shall be delivered by or on behalf of the Company to the Representatives, through the facilities of the Depository Trust Company (&#8220;DTC&#8221;), for
the account of such Underwriter, against payment by or on behalf of such Underwriter of the purchase price therefor by wire transfer of Federal <FONT STYLE="white-space:nowrap">(same-day)</FONT> funds to the account specified by the Company to the
Representatives at least <FONT STYLE="white-space:nowrap">twenty-four</FONT> hours in advance. The Company will cause the certificates, if any, representing the Shares to be made available for checking and packaging at least <FONT
STYLE="white-space:nowrap">twenty-four</FONT> hours prior to the Time of Delivery (as defined below) with respect thereto at the office of DTC or its designated custodian (the &#8220;Designated Office&#8221;). The time and date of such delivery and
payment shall be, with respect to the Firm Shares, 9:30 a.m., New York City time, on [_______], 2026 or such other time and date as the Representatives and the Company may agree upon in writing, and, with
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect to the Optional Shares, 9:30 a.m., New York City time, on the date specified by the Representatives in the written notice given by the Representatives of the Underwriters&#8217; election
to purchase such Optional Shares, or such other time and date as the Representatives and the Company may agree upon in writing. Such time and date for delivery of the Firm Shares is herein called the &#8220;First Time of Delivery&#8221;, such time
and date for delivery of the Optional Shares, if not the First Time of Delivery, is herein called the &#8220;Second Time of Delivery&#8221;, and each such time and date for delivery is herein called a &#8220;Time of Delivery.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The documents to be delivered at each<B> </B>Time of Delivery by or on behalf of the parties hereto pursuant to Section&nbsp;8 hereof,
including the cross receipt for the Shares and any additional documents requested by the Underwriters pursuant to Section&nbsp;8(l) hereof, will be delivered at the offices of Latham&nbsp;&amp; Watkins LLP, 1271 Avenue of the Americas, New York, New
York 10020 (the &#8220;Closing Location&#8221;), and the Shares will be delivered at the Designated Office, all at such Time of Delivery. A meeting will be held at the Closing Location at 5:00 p.m., New York City time, on the New York Business Day
next preceding such Time of Delivery, at which meeting the final drafts of the documents to be delivered pursuant to the preceding sentence will be available for review by the parties hereto. For the purposes of this Section&nbsp;4, &#8220;New York
Business Day&#8221; shall mean each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in New York City are generally authorized or obligated by law or executive order to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The Company agrees with each of the Underwriters: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To prepare the Prospectus in a form approved by you and to file such Prospectus pursuant to Rule 424(b) under the Act prior to the earlier
of (i)&nbsp;the First Time of Delivery and (ii)&nbsp;the Commission&#8217;s close of business on the second business day following the execution and delivery of this Agreement, or, if applicable, such earlier time as may be required by Rule
430A(a)(3) under the Act; to make no further amendment or any supplement to the Registration Statement or the Prospectus prior to the last Time of Delivery which shall be disapproved by you promptly after reasonable notice thereof; to advise you,
promptly after it receives notice thereof, of the time when any amendment to the Registration Statement has been filed or becomes effective or any amendment or supplement to the Prospectus has been filed and to furnish you with copies thereof; to
file promptly all material required to be filed by the Company with the Commission pursuant to Rule 433(d) under the Act; to advise you, promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order
preventing or suspending the use of any Preliminary Prospectus or other prospectus in respect of the Shares, of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any
proceeding for any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement or the Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order
preventing or suspending the use of any Preliminary Prospectus or other prospectus relating to the Shares or suspending any such qualification, to promptly use its best efforts to obtain the withdrawal of such order; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Promptly from time to time to take such action as you may reasonably request to qualify the Shares for offering and sale under the
applicable securities laws of such jurisdictions as you may request and to comply with such laws so as to permit the continuance of sales and dealings therein in such jurisdictions for as long as may be necessary to complete the distribution of the
Shares, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation (where not otherwise required) or to file a general consent to service of process in any jurisdiction (where not otherwise required);
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Prior to 10:00 a.m., New York City time, on the New York Business Day next succeeding
the date of this Agreement and from time to time, to furnish the Underwriters with written and electronic copies of the Prospectus in New York City in such quantities as you may reasonably request, and, if the delivery of a prospectus (or in lieu
thereof, the notice referred to in Rule 173(a) under the Act) is required at any time prior to the expiration of nine months after the time of issue of the Prospectus in connection with the offering or sale of the Shares and if at such time any
event shall have occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made when such Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is delivered, not misleading, or, if for any other reason it shall be necessary during such same period to
amend or supplement the Prospectus, to notify you and upon your request to prepare and furnish without charge to each Underwriter and to any dealer in securities as many written and electronic copies as you may from time to time reasonably request
of an amended Prospectus or a supplement to the Prospectus which will correct such statement or omission or effect such compliance; and in case any Underwriter is required to deliver a prospectus (or in lieu thereof, the notice referred to in Rule
173(a) under the Act) in connection with sales of any of the Shares at any time nine months or more after the time of issue of the Prospectus, upon your request but at the expense of such Underwriter, to prepare and deliver to such Underwriter as
many written and electronic copies as you may request of an amended or supplemented Prospectus complying with Section&nbsp;10(a)(3) of the Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To make generally available to its securityholders as soon as practicable (which may be satisfied by filing with the Commission&#8217;s
Electronic, Data Gathering, Analysis and Retrieval System (&#8220;EDGAR&#8221;)), but in any event not later than sixteen months after the effective date of the Registration Statement (as defined in Rule 158(c) under the Act), an earnings statement
of the Company and its subsidiaries (which need not be audited) complying with Section&nbsp;11(a) of the Act and the rules and regulations of the Commission thereunder (including, at the option of the Company, Rule 158); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) (i) During the period beginning from the date hereof and continuing to and including the date 180 days after the date of the Prospectus
(the <FONT STYLE="white-space:nowrap">&#8220;Lock-Up</FONT> Period&#8221;), not to (i)&nbsp;offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, or file
with or confidentially submit to the Commission a registration statement under the Act relating to, any securities of the Company that are substantially similar to the Shares, including but not limited to any options or warrants to purchase shares
of Stock or any securities that are convertible into or exchangeable for, or that represent the right to receive, Stock or any such substantially similar securities, or publicly disclose the intention to make any offer, sale, pledge, disposition or
filing or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in clause (i)&nbsp;or
(ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise (other than the Shares to be sold hereunder or pursuant to employee stock option plans that are described in the Registration Statement, Pricing
Prospectus and the Prospectus and existing on, or upon the conversion or exchange of convertible or exchangeable securities outstanding as of, the date of this Agreement), without the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC and
J.P. Morgan Securities LLC; provided, however, that the restrictions in the foregoing sentence shall not apply to (a)&nbsp;the Shares to be sold hereunder; (b)&nbsp;shares of Stock or any securities convertible into, or exercisable for, shares of
Stock issued by the Company upon exercise or settlement of options, warrants or restricted stock units outstanding as of the date hereof and described in the Pricing Disclosure Package; (c)&nbsp;the grant of any shares of Stock or any securities
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convertible into, or exercisable for, shares of Stock (including without limitation options, warrants, restricted stock or restricted stock units) pursuant to employee equity-based compensation
plans, incentive plans, stock plans, dividend reinvestment plans or other arrangements in effect as of the date hereof and described in the Pricing Disclosure Package; (d)&nbsp;the filing of a registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> in connection with the registration of securities issuable under any employee equity-based compensation plan, incentive plan, stock plan, or dividend reinvestment plan adopted and approved by the Company&#8217;s
board of directors prior to the date hereof and described in the Pricing Disclosure Package; [or] (e)&nbsp;shares of Stock or other securities issued in connection with any bona fide merger, joint venture, strategic alliance, commercial or other
collaborative transaction, or the acquisition or license by the Company of the business, property, technology or other assets of another individual or entity that is an unaffiliated third party of the Company, or the assumption of an employee
benefit plan in connection with such a merger or acquisition [or (f)&nbsp;the offering and sale of common stock pursuant to the concurrent private placement described in each of the Registration Statement, the Pricing Disclosure Package and the
Prospectus,] provided that (i)&nbsp;the aggregate number of shares issued pursuant to this clause (e) (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> or <FONT STYLE="white-space:nowrap">as-exercised</FONT> basis, as the case may be)
shall not exceed 5% of the total number of outstanding shares of Stock immediately following the issuance and sale of the Shares hereunder and (ii)&nbsp;the recipient of any such shares of Stock or securities issued pursuant to this clauses (b),
(c), (e) and (f)&nbsp;during such period shall execute and deliver to the Representatives prior to such issuance or sale (as the case may be) an agreement substantially in the form of Annex II hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If Goldman Sachs&nbsp;&amp; Co. LLC and J.P. Morgan Securities LLC agree to release or waive the restrictions set forth in a <FONT
STYLE="white-space:nowrap">lock-up</FONT> letter described in Section&nbsp;8(j) hereof for an officer or director of the Company and provide the Company with notice of the impending release or waiver at least three business days before the effective
date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of Annex I hereto through a major news service at least two business days before the effective date of the
release or waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) During a period of three years from the effective date of the Registration Statement, so long as the Company is
subject to the reporting requirements of either Section&nbsp;13 or Section&nbsp;15(d of the Exchange Act, to furnish to its stockholders as soon as practicable after the end of each fiscal year an annual report (including a balance sheet and
statements of income, stockholders&#8217; equity and cash flows of the Company and its consolidated subsidiaries certified by independent public accountants) and, as soon as practicable after the end of each of the first three quarters of each
fiscal year (beginning with the fiscal quarter ending after the effective date of the Registration Statement), to make available to its stockholders consolidated summary financial information of the Company and its subsidiaries for such quarter in
reasonable detail; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) During a period of three years from the effective date of the Registration Statement, so long as the Company is
subject to the reporting requirements of either Section&nbsp;13 or Section&nbsp;15(d of the Exchange Act, to furnish to you copies of all reports or other communications (financial or other) furnished to stockholders, and to deliver to you
(i)&nbsp;as soon as they are available, copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange on which any class of securities of the Company is listed; and (ii)&nbsp;such
additional information concerning the business and financial condition of the Company as you may from time to time reasonably request (such financial statements to be on a consolidated basis to the extent the accounts of the Company and its
subsidiaries are consolidated in reports furnished to its stockholders generally or to the Commission),<I> provided</I> the Company will be deemed to have furnished such reports and financial statements to you to the extent they are filed on the
Commission&#8217;s Electronic Data Gathering, Analysis and Retrieval system (&#8220;EDGAR&#8221;); </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) To use the net proceeds received by it from the sale of the Shares pursuant to this
Agreement in the manner specified in the Pricing Prospectus under the caption &#8220;Use of Proceeds&#8221;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) To use its best efforts
to list for quotation the Shares on the Nasdaq Stock Market Inc.&#8217;s National Market (&#8220;NASDAQ&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) To file with the
Commission such information on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">10-K</FONT> as may be required by Rule 463 under the Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) If the Company elects to rely upon Rule 462(b), the Company shall file a Rule 462(b) Registration Statement with the Commission in
compliance with Rule 462(b) by 10:00 P.M., Washington, D.C. time, on the date of this Agreement, and the Company shall at the time of filing either pay to the Commission the filing fee for the Rule 462(b) Registration Statement or give irrevocable
instructions for the payment of such fee pursuant to Rule 111(b) under the Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Upon reasonable request of any Underwriter, to
furnish, or cause to be furnished, to such Underwriter an electronic version of the Company&#8217;s trademarks, servicemarks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating the <FONT
STYLE="white-space:nowrap">on-line</FONT> offering of the Shares (the &#8220;License&#8221;); provided, however, that the License shall be used solely for the purpose described above, is granted without any fee and may not be assigned or
transferred; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) To comply with all applicable securities and other laws, rules and regulations in each jurisdiction in which the
Directed Shares are offered in connection with the Directed Share Program; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) To promptly notify you if the Company ceases to be an
Emerging Growth Company at any time prior to the later of (i)&nbsp;completion of the distribution of the Shares within the meaning of the Act and (ii)&nbsp;the last Time of Delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. (a) The Company represents and agrees that, without the prior consent of the Representatives, it has not made and will not make any offer
relating to the Shares that would constitute a &#8220;free writing prospectus&#8221; as defined in Rule 405 under the Act; each Underwriter represents and agrees that, without the prior consent of the Company and the Representatives, it has not made
and will not make any offer relating to the Shares that would constitute a free writing prospectus required to be filed with the Commission; any such free writing prospectus the use of which has been consented to by the Company and the
Representatives is listed on Schedule&nbsp;II(a) or Schedule&nbsp;II(c) hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company has complied and will comply with the
requirements of Rule 433 under the Act applicable to any Issuer Free Writing Prospectus, including timely filing with the Commission or retention where required and legending; and the Company represents that it has satisfied and agrees that it will
satisfy the conditions under Rule 433 under the Act to avoid a requirement to file with the Commission any electronic road show; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company agrees that if at any time following issuance of an Issuer Free Writing
Prospectus or Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication any event occurred or occurs as a result of which such Issuer Free Writing Prospectus or Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication would conflict with the information in the Registration Statement, the Pricing Prospectus or the Prospectus or would include an untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, the Company will give prompt notice thereof to the Representatives
and, if requested by the Representatives, will prepare and furnish without charge to each Underwriter an Issuer Free Writing Prospectus, Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication or other document which will correct such conflict, statement or omission; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company represents and agrees that
(i)&nbsp;it has not engaged in, or authorized any other person to engage in, any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications, other than <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the prior consent of the Representatives with entities that the Company reasonably believes are qualified institutional buyers as defined in Rule 144A under the Act or
institutions that are accredited investors as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Act; and (ii)&nbsp;it has not distributed, or authorized any other person to distribute, any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications, other than those distributed with the prior consent of the Representatives that are listed on Schedule&nbsp;II(d) hereto; and the
Company reconfirms that the Underwriters have been authorized to act on its behalf in engaging in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Each Underwriter represents and agrees that any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications undertaken by it were with entities that such Underwriter reasonably believes are qualified institutional buyers as defined in Rule
144A under the Act or institutions that are accredited investors as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. The Company covenants and agrees with the several Underwriters that the Company will pay or cause to be paid the following: (i)&nbsp;the
fees, disbursements and expenses of the Company&#8217;s counsel and accountants in connection with the registration of the Shares under the Act and all other expenses in connection with the preparation, printing, reproduction and filing of the
Registration Statement, any Preliminary Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any Issuer Free Writing Prospectus and the Prospectus and amendments
and supplements thereto and the mailing and delivering of copies thereof to the Underwriters and dealers; (ii)&nbsp;the cost of printing or producing any Agreement among Underwriters, this Agreement, the Blue Sky Memorandum, closing documents
(including any compilations thereof) and any other documents in connection with the offering, purchase, sale and delivery of the Shares; (iii)&nbsp;all expenses in connection with the qualification of the Shares for offering and sale under state
securities laws as provided in Section&nbsp;5(b) hereof, including the reasonable and documented fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky survey (iv)&nbsp;all
fees and expenses in connection with listing the Shares on NASDAQ; (v)&nbsp;the filing fees incident to, and the reasonable and documented fees and disbursements of counsel for the Underwriters in connection with, any required filing with, review
and clearance by FINRA of the terms of the sale of the Shares, provided, however, that the reasonable and documented fees and disbursements of counsel for the Underwriters related to clauses (iii)&nbsp;and (v) shall not exceed $40,000 in the
aggregate; (vi)&nbsp;the cost of preparing stock certificates; (vii)&nbsp;the cost and charges of any transfer agent or registrar; (viii)&nbsp;all expenses incurred by the Company in connection with any &#8220;road show&#8221; presentation to
potential investors; and (ix)&nbsp;all other costs and expenses incident to the performance of its obligations hereunder which are not otherwise specifically provided for in this Section. In addition, the Company shall pay or cause to be paid all
fees and disbursements of counsel for the Underwriters in connection with the Directed Share Program and stamp duties, similar taxes or other taxes, if any, incurred by the Underwriters in connection with the Directed Share Program. It is
understood, however, that, except as provided in this Section, and Sections&nbsp;9 and 12 hereof, the Underwriters will pay all of their own costs and expenses, including the fees of their counsel, stock transfer taxes on resale of any of the Shares
by them, and any advertising expenses connected with any offers they may make. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. The obligations of the Underwriters hereunder, as to the Shares to be delivered at each
Time of Delivery, shall be subject, in their discretion, to the condition that all representations and warranties and other statements of the Company herein are, at and as of the Applicable Time and such Time of Delivery, true and correct, the
condition that the Company shall have performed all of its obligations hereunder theretofore to be performed, and the following additional conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Prospectus shall have been filed with the Commission pursuant to Rule 424(b) under the Act within the applicable time period
prescribed for such filing by the rules and regulations under the Act and in accordance with Section&nbsp;5(a) hereof; all material required to be filed by the Company pursuant to Rule 433(d) under the Act shall have been filed with the Commission
within the applicable time period prescribed for such filing by Rule 433; if the Company has elected to rely upon Rule 462(b) under the Act, the Rule 462(b) Registration Statement shall have become effective by 10:00 P.M., Washington, D.C. time, on
the date of this Agreement; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Act shall have been initiated or
threatened by the Commission; no stop order suspending or preventing the use of the Pricing Prospectus, Prospectus or any Issuer Free Writing Prospectus shall have been initiated or threatened by the Commission; and all requests for additional
information on the part of the Commission shall have been complied with to your reasonable satisfaction; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Latham&nbsp;&amp; Watkins
LLP, counsel for the Underwriters, shall have furnished to you such written opinion or opinions, and negative assurance letter, each dated such Time of Delivery, in form and substance satisfactory to you, and such counsel shall have received such
papers and information as they may reasonably request to enable them to pass upon such matters; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Goodwin Procter LLP, counsel for the
Company, shall have furnished to you their written opinion or opinions, and negative assurance letter, each dated such Time of Delivery, in form and substance satisfactory to you; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Womble Bond Dickinson (US) LLP, intellectual property counsel for the Company, shall have furnished to you their written opinion, dated
such Time of Delivery, in form and substance satisfactory to you; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) On the date of the Prospectus, on the effective date of any <FONT
STYLE="white-space:nowrap">post-effective</FONT> amendment to the Registration Statement filed subsequent to the date of this Agreement and also at each Time of Delivery, PwC shall have furnished to you a letter or letters, dated the respective
dates of delivery thereof, in form and substance satisfactory to you; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) (i) Neither the Company nor any of its subsidiaries shall have
sustained since the date of the latest audited financial statements included in the Pricing Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor
dispute or court or governmental action, order or decree, otherwise than as set forth or contemplated in the Pricing Prospectus, and (ii)&nbsp;since the respective dates as of which information is given in the Pricing Prospectus there shall not have
been any change in the capital stock (other than as a result of the exercise of stock options or the award of stock options or restricted stock in the ordinary course of business pursuant to the Company&#8217;s equity plans that are described in the
Pricing Prospectus) or <FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company or any of its subsidiaries or any change or effect, or any development involving a prospective change </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or effect, in or affecting (x)&nbsp;the business, properties, general affairs, management, financial position, stockholders&#8217; equity or results of operations of the Company and its
subsidiaries, taken as a whole, except as set forth or contemplated in the Pricing Prospectus, or (y)&nbsp;the ability of the Company to perform its obligations under this Agreement, including the issuance and sale of the Shares, or to consummate
the transactions contemplated in the Pricing Prospectus and the Prospectus, the effect of which, in any such case described in clause (i)&nbsp;or (ii), is in your judgment so material and adverse as to make it impracticable or inadvisable to proceed
with the public offering or the delivery of the Shares being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Prospectus and the Prospectus; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) On or after the Applicable Time (i)&nbsp;no downgrading shall have occurred in the rating accorded the Company&#8217;s debt securities or
preferred stock by any &#8220;nationally recognized statistical rating organization&#8221;, as that term is defined by the Commission for purposes of Rule 436(g)(2) under the Act, and (ii)&nbsp;no such organization shall have publicly announced that
it has under surveillance or review, with possible negative implications, its rating of any of the Company&#8217;s debt securities or preferred stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) On or after the Applicable Time there shall not have occurred any of the following: (i)&nbsp;a suspension or material limitation in
trading in securities generally on the New York Stock Exchange or on NASDAQ; (ii)&nbsp;a suspension or material limitation in trading in the Company&#8217;s securities on NASDAQ; (iii)&nbsp;a general moratorium on commercial banking activities
declared by either Federal or New York State authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States; (iv)&nbsp;the outbreak or escalation of hostilities involving the United
States or the declaration by the United States of a national emergency or war or (v)&nbsp;the occurrence of any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere, if the effect of
any such event specified in clause (iv)&nbsp;or (v) in your judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such Time of Delivery on the terms and in the manner
contemplated in the Pricing Prospectus and the Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Shares to be sold at such Time of Delivery shall have been duly listed
for quotation on NASDAQ; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) The Company shall have obtained and delivered to the Underwriters executed copies of an agreement from each
officer, director, and other stockholders of the Company representing all outstanding securities of the Company, substantially to the effect set forth in Annex II hereto in form and substance satisfactory to you; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) The Company shall have complied with the provisions of Section&nbsp;5(c) hereof with respect to the furnishing of prospectuses on the New
York Business Day next succeeding the date of this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) The Company shall have furnished or caused to be furnished to you
at such Time of Delivery certificates of officers of the Company satisfactory to you as to the accuracy of the representations and warranties of the Company herein at and as of such Time of Delivery, as to the performance by the Company of all of
its obligations hereunder to be performed at or prior to such Time of Delivery, as to the matters set forth in subsections (a)&nbsp;and (e) of this Section&nbsp;and as to such other matters as you may reasonably request. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) The Company shall have obtained all consents, approvals, authorizations, orders and
registrations or qualifications as required by FINRA and under applicable state securities laws required for the purchase and distribution of the Shares by the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. (a) The Company will indemnify and hold harmless each Underwriter against any losses, claims, damages or liabilities, joint or several, to
which such Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a
material fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, any &#8220;roadshow&#8221; as defined in Rule
433(h) under the Act (a &#8220;roadshow&#8221;), any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) under the Act or any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse each Underwriter for any legal or other expenses reasonably incurred by such Underwriter in connection with investigating or defending any such action or claim as such
expenses are incurred; <I>provided</I>, <I>however</I>, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any untrue statement or alleged untrue
statement or omission or alleged omission made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus or any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, in reliance upon and in conformity with the Underwriter Information (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Underwriter, severally and not jointly, will indemnify and hold harmless the Company against any losses, claims, damages or
liabilities to which the Company may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of
a material fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow or any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, any
Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow or any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, in reliance upon and in conformity with the Underwriter Information; and will reimburse the Company for any legal or other expenses
reasonably incurred by the Company in connection with investigating or defending any such action or claim as such expenses are incurred. As used in this Agreement with respect to an Underwriter and an applicable document, &#8220;Underwriter
Information&#8221; shall mean the written information furnished to the Company by such Underwriter through the Representatives expressly for use therein; it being understood and agreed upon that the only such information furnished by any Underwriter
consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the [__] paragraph under the caption &#8220;Underwriting&#8221;, and the information contained in
the [__] paragraph under the caption &#8220;Underwriting&#8221;. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under subsection (a)&nbsp;or (b) above of
notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof;
<I>provided</I> that the failure to notify the indemnifying party shall not relieve it from any liability that it may have under the preceding paragraphs of this Section&nbsp;9 except to the extent that it has been materially prejudiced (through the
forfeiture of substantive rights or defenses) by such failure; and <I>provided further</I> that the failure to notify the indemnifying party shall not relieve it from any liability that it may have to an indemnified party otherwise than under the
preceding paragraphs of this Section&nbsp;9. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate
therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the
indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party
under such subsection for any reasonable and documented legal expenses of other counsel or any other reasonable and documented expenses, in each case subsequently incurred by such indemnified party, in connection with the defense thereof other than
reasonable costs of investigation; provided, however, that in any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party
unless (i)&nbsp;the indemnifying party and the indemnified person shall have mutually agreed to the contrary; (ii)&nbsp;the indemnifying party has failed within a reasonable time to retain counsel reasonably satisfactory to the indemnified party;
(iii)&nbsp;the indemnified party shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the indemnifying party; or (iv)&nbsp;the named parties in any such
proceeding (including the impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. No
indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which
indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i)&nbsp;includes an unconditional release of the
indemnified party from all liability arising out of such action or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. Further, the indemnifying
party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason
of such settlement. Notwithstanding the foregoing, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by this Section&nbsp;9(c), the
indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid
request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If the indemnification provided for in this Section&nbsp;9 is unavailable to or insufficient to hold harmless an indemnified party under
subsection (a)&nbsp;or (b) above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a
result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering
of the Shares. If, however, the allocation </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such
proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or omissions which resulted in such losses,
claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be in the same
proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover
page of the Prospectus. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information
supplied by the Company on the one hand or the Underwriters on the other and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Underwriters
agree that it would not be just and equitable if contribution pursuant to this subsection (d)&nbsp;were determined by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of
allocation which does not take account of the equitable considerations referred to above in this subsection (d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect
thereof) referred to above in this subsection (d)&nbsp;shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the
provisions of this subsection (d), no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the
amount of any damages which such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section&nbsp;11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#8217; obligations in this subsection (d)&nbsp;to contribute are several in proportion to
their respective underwriting obligations and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The obligations of the Company under this Section&nbsp;9 shall be in
addition to any liability which the Company may otherwise have and shall extend, upon the same terms and conditions, to each employee, officer and director of each Underwriter and each person, if any, who controls any Underwriter within the meaning
of the Act and each <FONT STYLE="white-space:nowrap">broker-dealer</FONT> or other affiliate of any Underwriter; and the obligations of the Underwriters under this Section&nbsp;9 shall be in addition to any liability which the respective
Underwriters may otherwise have and shall extend, upon the same terms and conditions, to each officer and director of the Company (including any person who, with his or her consent, is named in the Registration Statement as about to become a
director of the Company) and to each person, if any, who controls the Company within the meaning of the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) (i) The Company will
indemnify and hold harmless the Directed Share Underwriter against any losses, claims, damages and liabilities to which the Directed Share Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims damages or
liabilities (or actions in respect thereof)&nbsp;(x) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in any material prepared by or with the consent of the Company for distribution to
Participants in connection with the Directed Share Program or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
misleading, (y)&nbsp;arise out of or are based upon the failure of any Participant to pay for and accept delivery of Directed Shares that the Participant agreed to purchase, or (z)&nbsp;are
related to, arise out of or are in connection with the Directed Share Program, and will reimburse the Directed Share Underwriter for any legal or other expenses reasonably incurred by the Directed Share Underwriter in connection with investigating
or defending any such action or claim as such expenses are incurred; provided, however, that with respect to clauses (y)&nbsp;and (z) above, the Company shall not be liable in any such case to the extent that any such loss, claim, damage or
liability is finally judicially determined to have resulted from the bad faith or gross negligence of the Directed Share Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Promptly after receipt by the Directed Share Underwriter of notice of the commencement of any action, the Directed Share Underwriter
shall, if a claim in respect thereof is to be made against the Company, notify the Company in writing of the commencement thereof; provided that the failure to notify the Company shall not relieve the Company from any liability that it may have
under the preceding paragraph of this Section&nbsp;9(f) except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided further that the failure to notify the
Company shall not relieve it from any liability that it may have to the Directed Share Underwriter otherwise than under the preceding paragraph of this Section&nbsp;9(f). In case any such action shall be brought against the Directed Share
Underwriter and it shall notify the Company of the commencement thereof, the Company shall be entitled to participate therein and, to the extent that it shall wish, to assume the defense thereof, with counsel satisfactory to the Directed Share
Underwriter (who shall not, except with the consent of the Directed Share Underwriter, be counsel to the Company), and, after notice from the Company to the Directed Share Underwriter of its election so to assume the defense thereof, the Company
shall not be liable to the Directed Share Underwriter under this subsection for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by the Directed Share Underwriter, in connection with the defense thereof
other than reasonable costs of investigation. The Company shall not, without the written consent of the Directed Share Underwriter, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or
threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the Directed Share Underwriter is an actual or potential party to such action or claim) unless such settlement, compromise or
judgment (x)&nbsp;includes an unconditional release of the Directed Share Underwriter from all liability arising out of such action or claim and (y)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act,
by or on behalf of the Directed Share Underwriter. Further, the Company shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Company agrees to indemnify the Directed
Share Underwriter from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing, if at any time the Directed Share Underwriter shall have requested the Company to reimburse the Directed Share Underwriter for fees
and expenses of counsel as contemplated by this Section&nbsp;9(f)(ii), the Company agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days
after receipt by the Company of the aforesaid request and (ii)&nbsp;the Company shall not have reimbursed the Directed Share Underwriter in accordance with such request prior to the date of such settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) If the indemnification provided for in this Section&nbsp;9(f) is unavailable to or insufficient to hold harmless the Directed Share
Underwriter under Section&nbsp;9(f)(i) above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then the Company shall contribute to the amount paid or payable by the Directed Share
Underwriter as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Directed Share Underwriter on the other from the offering of the Directed Shares. If,
however, the allocation provided by the immediately preceding sentence is not permitted by applicable law, then the Company shall contribute to such amount paid or payable by the Directed Share Underwriter in such proportion as is appropriate to
reflect not only such relative benefits but also the relative fault of the Company on the one hand and the Directed Share Underwriter on the other in connection with any statements or omissions which resulted in such losses, claims, damages or
liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Directed Share Underwriter on the other shall be deemed to be in the same
proportion as the total net proceeds from the offering of the Directed Shares (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Directed Share Underwriter for the Directed
Shares. If the loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement of a material fact or arise out of or are based upon the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, the relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission
or alleged omission to state a material fact relates to information supplied by the Company on the one hand or the Directed Share Underwriter on the other and the parties&#8217; relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission. The Company and the Directed Share Underwriter agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;9(f)(iii) were determined by pro rata allocation or by any
other method of allocation which does not take account of the equitable considerations referred to above in this Section&nbsp;9(f)(iii). The amount paid or payable by the Directed Share Underwriter as a result of the losses, claims, damages or
liabilities (or actions in respect thereof) referred to above in this Section&nbsp;9(f)(iii) shall be deemed to include any legal or other expenses reasonably incurred by the Directed Share Underwriter in connection with investigating or defending
any such action or claim. Notwithstanding the provisions of this Section&nbsp;9(f)(iii), the Directed Share Underwriter shall not be required to contribute any amount in excess of the amount by which the total price at which the Directed Shares sold
by it and distributed to the Participants exceeds the amount of any damages which the Directed Share Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person
guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) The obligations of the Company under this Section&nbsp;9(f) shall be in addition to any liability which the Company may otherwise have
and shall extend, upon the same terms and conditions, to each employee, officer and director of the Directed Share Underwriter and each person, if any, who controls the Directed Share Underwriter within the meaning of the Act and each <FONT
STYLE="white-space:nowrap">broker-dealer</FONT> or other affiliate of the Directed Share Underwriter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. (a) If any Underwriter shall
default in its obligation to purchase the Shares which it has agreed to purchase hereunder at a Time of Delivery, you may in your discretion arrange for you or another party or other parties to purchase such Shares on the terms contained herein. If
within <FONT STYLE="white-space:nowrap">thirty-six</FONT> hours after such default by any Underwriter, you do not arrange for the purchase of such Shares, then the Company shall be entitled to a further period of
<FONT STYLE="white-space:nowrap">thirty-six</FONT> hours within which to procure another party or other parties satisfactory to you to purchase such Shares on such terms. In the event that, within the respective prescribed periods, you notify the
Company that you have so arranged for the purchase of such Shares, or the Company notifies you that it has so arranged for the purchase of such Shares, you or the Company shall have the right to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
postpone such Time of Delivery for a period of not more than seven days, in order to effect whatever changes may thereby be made necessary in the Registration Statement or the Prospectus, or in
any other documents or arrangements, and the Company agrees to file promptly any amendments or supplements to the Registration Statement or the Prospectus which in your opinion may thereby be made necessary. The term &#8220;Underwriter&#8221; as
used in this Agreement shall include any person substituted under this Section&nbsp;with like effect as if such person had originally been a party to this Agreement with respect to such Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by you and the
Company as provided in subsection (a)&nbsp;above, the aggregate number of such Shares which remains unpurchased does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of all the Shares to be purchased at such
Time of Delivery, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the number of shares which such Underwriter agreed to purchase hereunder at such Time of Delivery
and, in addition, to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase its pro rata share (based on the number of Shares which such Underwriter agreed to purchase hereunder) of the Shares of such defaulting
Underwriter or Underwriters for which such arrangements have not been made; but nothing herein shall relieve a defaulting Underwriter from liability for its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by you and the
Company as provided in subsection (a)&nbsp;above, the aggregate number of such Shares which remains unpurchased exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of all the Shares to be purchased at such Time of
Delivery, or if the Company shall not exercise the right described in subsection (b)&nbsp;above to require <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase Shares of a defaulting Underwriter or Underwriters, then this
Agreement (or, with respect to the Second Time of Delivery, the obligations of the Underwriters to purchase and of the Company to sell the Optional Shares) shall thereupon terminate, without liability on the part of any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company, except for the expenses to be borne by the Company and the Underwriters as provided in Section&nbsp;7 hereof and the indemnity and contribution agreements in Section&nbsp;9
hereof; but nothing herein shall relieve a defaulting Underwriter from liability for its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. The respective indemnities, rights
of contribution, agreements, representations, warranties and other statements of the Company and the several Underwriters, as set forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall remain in full
force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf of any Underwriter or any director, officer, employee, affiliate or controlling person of any Underwriter, or the Company, or any
officer or director or controlling person of the Company, and shall survive delivery of and payment for the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. If this Agreement
shall be terminated pursuant to Section&nbsp;10 hereof, the Company shall not then be under any liability to any Underwriter except as provided in Sections&nbsp;7 and 9 hereof; but, if for any other reason, any Shares are not delivered by or on
behalf of the Company as provided herein or the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company will reimburse the Underwriters through you for all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses approved in writing by you, including fees and disbursements of counsel, reasonably incurred by the Underwriters in making preparations for the purchase, sale and delivery of the Shares
not so delivered, but the Company shall then be under no further liability to any Underwriter except as provided in Sections&nbsp;7 and 9 hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. In all dealings hereunder, the Representatives shall act on behalf of each of the
Underwriters, and the parties hereto shall be entitled to act and rely upon any statement, request, notice or agreement on behalf of any Underwriter made or given by you jointly or by Goldman Sachs&nbsp;&amp; Co.&nbsp;LLC on behalf of you as the
Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All statements, requests, notices and agreements hereunder shall be in writing, and if to the Underwriters shall be
delivered or sent by <FONT STYLE="white-space:nowrap">e-mail,</FONT> mail, telex or facsimile transmission to you as the representatives in care of Goldman Sachs&nbsp;&amp; Co.&nbsp;LLC, 200 West Street, New York, New York <FONT
STYLE="white-space:nowrap">10282-2198,</FONT> Attention: Registration Department; J.P. Morgan Securities LLC, 270 Park Avenue, New York, New York 10017, Attention: Equity Syndicate Desk; and Leerink Partners LLC, 1301 Avenue of the Americas, 5th
Floor, New York, New York 10019, Attention: Stuart R. Nayman, and if to the Company shall be delivered or sent by mail, telex or facsimile transmission to the address of the Company set forth in the Registration Statement, Attention: Secretary;
provided, however, that any notice to an Underwriter pursuant to Section&nbsp;9(c) hereof shall be delivered or sent by <FONT STYLE="white-space:nowrap">e-mail,</FONT> mail, telex or facsimile transmission to such Underwriter at its address set
forth in its Underwriters&#8217; Questionnaire, or telex constituting such Questionnaire, which address will be supplied to the Company by you upon request. Any such statements, requests, notices or agreements shall take effect upon receipt thereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed
into law October&nbsp;26, 2001)), the underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients,
as well as other information that will allow the underwriters to properly identify their respective clients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. This Agreement shall be
binding upon, and inure solely to the benefit of, the Underwriters, the Company and, to the extent provided in Sections&nbsp;9 and 11 hereof, the officers and directors of the Company and each person who controls the Company or any Underwriter, or
any director, officer, employee, or affiliate of any Underwriter, and their respective heirs, executors, administrators, successors and assigns, and no other person shall acquire or have any right under or by virtue of this Agreement. No purchaser
of any of the Shares from any Underwriter shall be deemed a successor or assign by reason merely of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. Time shall be of
the essence of this Agreement. As used herein, the term &#8220;business day&#8221; shall mean any day when the Commission&#8217;s office in Washington, D.C. is open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. The Company acknowledges and agrees that (i)&nbsp;the purchase and sale of the Shares pursuant to this Agreement is an <FONT
STYLE="white-space:nowrap">arm&#8217;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other, (ii)&nbsp;in connection therewith and with the process leading to such transaction each
Underwriter is acting solely as a principal and not the agent or fiduciary of the Company, (iii)&nbsp;no Underwriter has assumed an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the
process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) or any other obligation to the Company except the obligations expressly set forth in this Agreement, (iv)&nbsp;the
Company has consulted its own legal and financial advisors to the extent it deemed appropriate, and (v)&nbsp;none of the activities of the Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment
advice, or solicitation of any action by the Underwriters with respect to any entity or natural person. The Company agrees that it will not claim that the Underwriters, or any of them, has rendered advisory services of any nature or respect, or owes
a fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. This Agreement supersedes all prior agreements and understandings (whether written or
oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <B>This Agreement and any
transaction contemplated by this Agreement and any claim, controversy or dispute arising under or related thereto shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflict of
laws that would result in the application of any other law than the laws of the State of New York. The Company agrees that any suit or proceeding arising in respect of this Agreement or any transaction contemplated by this Agreement will be tried
exclusively in the U.S. District Court for the Southern District of New York or, if that court does not have subject matter jurisdiction, in any state court located in The City and County of New York and the Company agrees to submit to the
jurisdiction of, and to venue in, such courts</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. The Company and each of the Underwriters hereby irrevocably waives, to the fullest
extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. This Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of which shall be deemed to be
an original, but all such counterparts shall together constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform
Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be
valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. Notwithstanding anything herein to the contrary, the Company is authorized to disclose to any
persons the U.S. federal and state income tax treatment and tax structure of the potential transaction and all materials of any kind (including tax opinions and other tax analyses) provided to the Company relating to that treatment and structure,
without the Underwriters imposing any limitation of any kind. However, any information relating to the tax treatment and tax structure shall remain confidential (and the foregoing sentence shall not apply) to the extent necessary to enable any
person to comply with securities laws. For this purpose, &#8220;tax structure&#8221; is limited to any facts that may be relevant to that treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. Recognition of the U.S. Special Resolution Regimes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the
transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any
such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of
such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights
could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As used in this section: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;BHC Act Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with,
12 U.S.C. &#167;&nbsp;1841(k). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Covered Entity&#8221; means any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;&nbsp;252.82(b); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;&nbsp;47.3(b); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;&nbsp;382.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Default Right&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R.
&#167;&#167;&nbsp;252.81, 47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;U.S. Special Resolution Regime&#8221; means each of (i)&nbsp;the Federal
Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the <FONT STYLE="white-space:nowrap">Dodd-Frank</FONT> Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please sign and return to us one
for the Company and each of the Representatives plus one for each counsel counterparts hereof, and upon the acceptance hereof by you, on behalf of each of the Underwriters, this letter and such acceptance hereof shall constitute a binding agreement
between each of the Underwriters and the Company. It is understood that your acceptance of this letter on behalf of each of the Underwriters is pursuant to the authority set forth in a form of Agreement among Underwriters, the form of which shall be
submitted to the Company for examination upon request, but without warranty on your part as to the authority of the signers thereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Seaport Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Daphne Zohar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Founder and Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted as of the date hereof:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Goldman Sachs&nbsp;&amp; Co.&nbsp;LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>J.P. Morgan Securities LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Leerink Partners LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">On behalf of each of the<BR>Underwriters</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Number&nbsp;of<BR>Firm&nbsp;Shares<BR>to be<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Optional&nbsp;Shares<BR>to be<BR>Purchased&nbsp;if<BR>Maximum<BR>Option<BR>Exercised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co.&nbsp;LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B>(a)<B><I> Issuer Free Writing Prospectuses not included in the Pricing Disclosure Package: </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Electronic roadshow dated April 2026 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B>(b)<B><I> Additional Documents Incorporated by Reference: </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[None] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Information other than the Pricing
Prospectus that comprise the Pricing Disclosure Package: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price per share for the Shares is $[_____] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The number of Firm Shares purchased by the Underwriters is [______] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The number of Optional Shares to be sold by the Company is up to [_______] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The number of shares to be sold by the Company pursuant to the concurrent private placement (described in the Pricing Disclosure Package) is
[_____] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communications: </P></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Seaport Therapeutics, Inc. &#8211; J.P. Morgan Healthcare Conference 2026 Presentation, dated
January&nbsp;2026 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Seaport Therapeutics, Inc. &#8211; Corporate Presentation, dated March 2026 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Seaport Therapeutics, Inc. &#8211; GlyphAgo Phase 1 Topline Data Review, dated April 2026 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ANNEX I </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF PRESS RELEASE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Seaport
Therapeutics, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[Date] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seaport Therapeutics,
Inc. (&#8220;Company&#8221;) announced today that Goldman Sachs&nbsp;&amp; Co.&nbsp;LLC and J.P. Morgan Securities LLC, the representatives of the underwriters in the Company&#8217;s recent public sale of shares of common stock, are [waiving]
[releasing] a <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction with respect to shares of the Company&#8217;s common stock held by [certain officers or directors] [an officer or director] of the Company. The [waiver] [release] will take
effect on, 20, and the shares may be sold on or after such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This press release is not an offer for sale of the securities in the United States or
in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ANNEX II </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seaport Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several
Underwriters </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">named in Schedule I to the Underwriting Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10282-2198 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">270 Park Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Avenue of the Americas, 12th
Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Seaport Therapeutics, Inc. - <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that you, as representatives (the &#8220;Representatives&#8221;), propose to enter into an underwriting agreement
(the &#8220;Underwriting Agreement&#8221;) on behalf of the several Underwriters named in Schedule I to such agreement (collectively, the &#8220;Underwriters&#8221;), with Seaport Therapeutics, Inc., a Delaware corporation (the
&#8220;Company&#8221;), providing for a public offering (the &#8220;Public Offering&#8221;) of shares (the &#8220;Shares&#8221;) of the common stock, par value $0.0001 per share, of the Company (the &#8220;Common Stock&#8221;) pursuant to a
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#8220;Registration Statement&#8221;) to be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the agreement by the Underwriters to offer and sell the Shares, and of other good and valuable consideration the receipt
and sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period beginning from the date of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and continuing to and including the date 180 days after the
date of the final prospectus relating to the Public Offering (the &#8220;Prospectus&#8221;) (such period, the <FONT STYLE="white-space:nowrap">&#8220;Lock-Up</FONT> Period&#8221;), the undersigned shall not, and shall not cause or direct any of its
affiliates to, (i)&nbsp;offer, sell, contract to sell, pledge, grant any option, right or warrant to purchase, purchase any option or contract to sell, lend or otherwise transfer or dispose of any shares of Common Stock, or any options or warrants
to purchase any shares of Common Stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock (such shares of Common Stock, options, rights, warrants or other securities, collectively, <FONT
STYLE="white-space:nowrap">&#8220;Lock-Up</FONT> Securities&#8221;), including without limitation any such <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities now owned or hereafter acquired by the undersigned, (ii)&nbsp;engage in any hedging
or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transaction or instrument, however described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition (whether by
the undersigned or someone other than the undersigned), or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such
transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of Common Stock or other securities, in cash or otherwise (any such sale, loan, pledge or other disposition, or transfer of economic consequences, a
&#8220;Transfer&#8221;), (iii) make any demand for or exercise any right with respect to the registration of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities or (iv)&nbsp;otherwise publicly announce any intention to engage in or cause
any action, activity, transaction or arrangement described in clause (i), (ii) or (iii)&nbsp;above. The undersigned represents and warrants that the undersigned is not, and has not caused or directed any of its affiliates to be or become, currently
a party to any agreement or arrangement that provides for, is designed to or reasonably could be expected to lead to or result in any Transfer during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the undersigned may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfer the undersigned&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities (i)&nbsp;as one or
more <I>bona fide</I> gifts or charitable contributions, or for <I>bona fide</I> estate planning purposes, (ii)&nbsp;upon death by will, testamentary document or intestate succession, (iii)&nbsp;if the undersigned is a natural person, to any member
of the undersigned&#8217;s immediate family (for purposes of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, current or former marriage, domestic partnership or
adoption, not more remote than first cousin) or to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned or, if the undersigned is a trust, to a trustor or beneficiary of the trust or the estate
of a beneficiary of such trust, (iv)&nbsp;to a corporation, partnership, limited liability company or other entity of which the undersigned and the immediate family of the undersigned are the legal and beneficial owner of all of the outstanding
equity securities or similar interests, (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (a)(i) through (iv)&nbsp;above, (vi) if the undersigned is a corporation,
partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is a controlled subsidiary or an affiliate (as defined in Rule 405
under the Securities Act of 1933, as amended) of the undersigned, or to any investment fund or other entity which fund or entity is controlled or managed by the undersigned or affiliates of the undersigned (including, for the avoidance of doubt,
where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B)&nbsp;as part of a disposition, transfer or distribution by the undersigned to its
stockholders, partners, members or other equityholders or to the estate of any such stockholders, partners, members or other equityholders, (vii)&nbsp;by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce
decree or separation agreement, (viii)&nbsp;to the Company from an employee of the Company upon death, disability or termination of employment, in each case, of such employee, (ix)&nbsp;if the undersigned is not an officer or director of the
Company, in connection with a sale of the undersigned&#8217;s shares of Common Stock acquired (A)&nbsp;from the Underwriters in the Public Offering or (B)&nbsp;in open market transactions after the closing date of the Public Offering (the
&#8220;Closing Date&#8221;), (x) to the Company in connection with the vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of
&#8220;net&#8221; or &#8220;cashless&#8221; exercise) that are scheduled to expire or automatically vest during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, including any transfer to the Company for the payment of tax withholdings or
remittance payments due as a result of the vesting, </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
settlement or exercise of such restricted stock units, options, warrants or other rights, or in connection with the conversion of convertible securities, in all such cases pursuant to equity
awards granted under a stock incentive plan or other equity award plan, or pursuant to the terms of convertible securities, each as described in the Registration Statement, the preliminary prospectus relating to the Shares included in the
Registration Statement immediately prior to the time the Underwriting Agreement is executed and the Prospectus, provided that any securities received upon such vesting, settlement, exercise or conversion shall be subject to the terms of this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, or (xi)&nbsp;with the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC and J.P. Morgan Securities LLC (the <FONT STYLE="white-space:nowrap">&#8220;Lock-Up</FONT> Release Parties&#8221;)
on behalf of the Underwriters; provided, that, in the case of clause (xi), the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Release Parties shall provide immediate notice to the Company of any request for or intention to grant such consent and
shall obtain the explicit, written consent of the Company prior to granting any such consent or other release or waiver from any of the terms of this agreement; provided, further, that (A)&nbsp;in the case of clauses (a)(i), (ii), (iii), (iv), (v)
and (vi)&nbsp;above, such transfer or distribution shall not involve a disposition for value, (B)&nbsp;in the case of clauses (a)(i), (ii), (iii), (iv), (v), (vi) and (vii)&nbsp;above, it shall be a condition to the transfer or distribution that the
donee, devisee, transferee or distributee, as the case may be, shall sign and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in the form of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, (C)&nbsp;in the case of
clauses (a)(ii), (iii), (iv), (v) and (vi)&nbsp;above, no filing by any party (including, without limitation, any donor, donee, devisee, transferor, transferee, distributor or distributee) under the Securities Exchange Act of 1934, as amended (the
&#8220;Exchange Act&#8221;), or other public filing, report or announcement reporting a reduction in beneficial ownership of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall be required or shall be voluntarily made in connection with
such transfer or distribution, and (D)&nbsp;in the case of clauses (a)(i), (vii), (viii), (ix) and (x)&nbsp;above, no filing under the Exchange Act or other public filing, report or announcement shall be voluntarily made, and if any such filing,
report or announcement shall be legally required during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, such filing, report or announcement shall clearly indicate in the footnotes thereto (A)&nbsp;the circumstances of such transfer or
distribution and (B)&nbsp;in the case of a transfer or distribution pursuant to clauses (a)(i) or (vii)&nbsp;above, that the donee, devisee, transferee or distributee has agreed to be bound by a <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement in the form of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enter into a written plan meeting the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under
the Exchange Act relating to the transfer, sale or other disposition of the undersigned&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, if then permitted by the Company, provided that none of the securities subject to such plan
may be transferred, sold or otherwise disposed of until after the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and no public announcement, report or filing under the Exchange Act, or any other public filing, report or
announcement, shall be voluntarily made regarding the establishment of such plan during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and if any such filing, report or announcement shall be legally required during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, such filing, report or announcement shall clearly indicate in the footnotes thereto that none of the securities subject to such plan may be transferred, sold or otherwise disposed of pursuant to such
plan until after the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(i) transfer the undersigned&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities pursuant to a
bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the Board of Directors of the Company and made to all holders of the Company&#8217;s capital stock involving a Change of Control of the
Company (for purposes hereof, &#8220;Change of Control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold at least a majority of the outstanding voting securities of
the Company (or the surviving entity)) and (ii)&nbsp;enter into any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Common
Stock or such other securities in connection with a transaction described in clause (i)&nbsp;above; provided that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the undersigned&#8217;s <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall remain subject to the provisions of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfer the undersigned&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities to the Company
pursuant to an agreement under which the Company has the option to repurchase shares or a right of first refusal with respect to transfer of such shares, provided that no filing under the Exchange Act or other public filing, report or announcement
shall be voluntarily made, and if any such filing, report or announcement shall be legally required during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, such filing, report or announcement shall clearly indicate in the footnotes
thereto the circumstances of such transfer or distribution; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">convert outstanding preferred stock of the Company into shares of Common Stock, provided that any such shares
received upon such conversion shall remain subject to the provisions of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally
applicable to any issuer-directed or other Shares the undersigned may purchase in the Public Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is not a
natural person, the undersigned represents and warrants that no single natural person, entity or &#8220;group&#8221; (within the meaning of Section&nbsp;13(d)(3) of the Exchange Act), other than a natural person, entity or &#8220;group&#8221; (as
described above) that has executed a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement in substantially the same form as this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, beneficially owns, directly or indirectly, 50% or more
of the common equity interests, or 50% or more of the voting power, in the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that, during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Release Parties release or waive, pursuant to clause (a)(xi), in full or in part, any prohibition set forth in this
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement in respect of securities held by any Significant Holder (as defined below) (a &#8220;Triggering Release&#8221;), the same percentage of securities of the undersigned subject to this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement as the percentage of securities being released in the Triggering Release represents with respect to the securities held directly or indirectly by such Significant Holder (calculated as a percentage
of the total outstanding securities subject to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement held directly or indirectly by such Significant Holder) at the time of the request of the Triggering Release shall be automatically and
concurrently released from this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement upon the same terms and conditions. For the purposes of the foregoing, a &#8220;Significant Holder&#8221; shall mean any person or entity that beneficially
owns 1% or more of the total outstanding shares of Common Stock at the time of such Triggering Release. Notwithstanding the foregoing, the provisions of this paragraph will not apply (i)&nbsp;if the Triggering Release is effected with respect to up
to an aggregate of less than 1% of the outstanding shares of Common Stock at the time of such Triggering Release; (ii)&nbsp;if the Triggering Release is effected solely to permit a transfer not involving a disposition for value and the transferee
agrees in writing to be bound by the same terms described in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement to the extent and for the duration that such terms remain in effect at the time of transfer, (iii)&nbsp;if the Triggering
Release is effected for the purpose of allowing the Triggering Shareholder to sell the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities as </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
part of an underwritten public offering, whether or not such offering is wholly or partially a secondary offering of the Company&#8217;s securities; or (iv)&nbsp;if the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Release Parties, in their sole judgment, determine that a Triggering Shareholder that is a natural person should be granted an early release or waiver due to circumstances of an emergency or hardship. For
the avoidance of doubt, except as described in clause (a)(xi), none of the permitted Transfers listed above will be a Triggering Release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, (i)&nbsp;each of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Release
Parties agrees that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock, each of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Release Parties will notify the Company of the impending release or waiver, and (ii)&nbsp;the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service (or such other
method approved by the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Release Parties that satisfies the requirements of FINRA Rule 5131(d)(2)) at least two business days before the effective date of the release or waiver. Any release or waiver
granted by the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Release Parties hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this paragraph
will not apply if (i)&nbsp;the release or waiver is effected solely to permit a transfer not for consideration or that is to an immediate family member as defined in FINRA Rule 5130(i)(5) and (ii)&nbsp;the transferee has agreed in writing to be
bound by the same terms described in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned now has, and through the Closing Date will have, good and marketable title to the undersigned&#8217;s <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities, free and clear of all liens, encumbrances and claims, other than under applicable securities laws. The undersigned also agrees and consents to the entry of stop transfer instructions with the
Company&#8217;s transfer agent and registrar against the transfer of the undersigned&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that none of the Underwriters has made any recommendation or provided any investment or other advice
to the undersigned with respect to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement or the subject matter hereof, and the undersigned has consulted its own legal, accounting, financial, regulatory, tax and other advisors with respect
to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and the subject matter hereof to the extent the undersigned has deemed appropriate. The undersigned further acknowledges and agrees that, although the Underwriters may have provided
or hereafter provide to the undersigned in connection with the Public Offering a Form CRS and/or certain other disclosures as contemplated by Regulation Best Interest, the Underwriters have not made and are not making a recommendation to the
undersigned to enter into this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement or to transfer, sell or dispose of, or to refrain from transferring, selling or disposing of, any shares of Common Stock, and nothing set forth in such
disclosures or herein is intended to suggest that any Underwriter is making such a recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall automatically terminate and the undersigned shall be released from all of his, her or its obligations hereunder upon the earlier of (i)&nbsp;the date on which the Registration Statement
filed with the SEC with respect to the Public Offering is withdrawn, (ii)&nbsp;the date on which for any reason the Underwriting Agreement is terminated (other than the provisions thereof that survive termination) prior to payment for and delivery
of the Shares to be sold thereunder (other than pursuant to the Underwriters&#8217; option thereunder to purchase additional Shares), (iii) the date on which the Company notifies the Representatives, in writing and prior to the execution of the
Underwriting Agreement, that it does not intend to proceed with the Public Offering and (iv)&nbsp;June&nbsp;30, 2026, in the event that the Underwriting Agreement has not been executed by such date (provided, however, that the Company may, by
written notice to the undersigned prior to such date, extend such date by a period of up to an additional 90 days). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, Goldman Sachs&nbsp;&amp; Co. LLC and its
affiliates, other than the undersigned, may engage in brokerage, investment advisory, financial advisory, anti-raid advisory, merger advisory, financing, asset management, trading, market making, arbitrage, principal investing and other similar
activities conducted in the ordinary course of their affiliates&#8217; business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the Company and the
Underwriters are relying upon this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement in proceeding toward consummation of the Public Offering. The undersigned further understands that this <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement is irrevocable and shall be binding upon the undersigned&#8217;s heirs, legal representatives, successors and assigns. The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to principles of conflict
of laws that would result in the application of any law other than the laws of the State of New York. This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method, and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and
effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of Page Intentionally Left Blank</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IF AN INDIVIDUAL:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">IF AN ENTITY:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(duly authorized signature)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>&#8195;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>(please print complete name of entity)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(please print full name)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(duly authorized signature)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(please print full name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(please print full title)</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>d73463dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND
RESTATED CERTIFICATE OF INCORPORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport Therapeutics, Inc. (the &#8220;<U>Corporation</U>&#8221;), a corporation organized and existing under and by virtue of the General
Corporation Law of the State of Delaware (the &#8220;<U>General Corporation Law</U>&#8221;), </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> That the name of the Corporation is Seaport Therapeutics, Inc., and that this corporation was originally incorporated pursuant to the
General Corporation Law on April&nbsp;1, 2024 under the name SP Therapeutics, Inc. (the &#8220;<U>Original Certificate</U>&#8221;). The Original Certificate was amended by that certain Amended and Restated Certificate of Incorporation dated
April&nbsp;8, 2024. The Corporation&#8217;s Amended and Restated Certificate of Incorporation was amended and restated by that certain Amended and Restated Certificate of Incorporation dated as of October&nbsp;17, 2024 (the &#8220;<U>Amended and
Restated Certificate of Incorporation</U>&#8221;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> That the Board of Directors of the Corporation duly adopted resolutions
proposing to amend the Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the
Corporation to solicit the consent of the stockholders therefor, which resolutions setting forth the proposed amendments are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the following is hereby inserted into Article FOURTH immediately before the first sentence therein: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Effective upon the filing of this Certificate of Amendment of the Amended and Restated Certificate of Incorporation with
the Secretary of State of the State of Delaware (the &#8220;<U>Effective Time</U>&#8221;), every 3.1407 shares of Common Stock then issued and outstanding or held in the treasury of the Corporation immediately prior to the Effective Time shall
automatically be combined into one (1)&nbsp;share of Common Stock, without any further action by the holders of such shares (the &#8220;<U>Reverse Stock Split</U>&#8221;). The Reverse Stock Split will be effected on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">certificate-by-certificate</FONT></FONT> basis, and any fractional shares resulting from such combination shall be rounded down to the nearest whole share on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">certificate-by-certificate</FONT></FONT> basis. No fractional shares shall be issued in connection with the Reverse Stock Split. In lieu of any fractional shares to which a holder would
otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Corporation&#8217;s Board of Directors. The Reverse Stock Split shall
occur automatically without any further action by the holders of the shares of Common Stock and Preferred Stock affected thereby. All rights, preferences and privileges of the Common Stock and the Preferred Stock shall be appropriately adjusted to
reflect the Reverse Stock Split in accordance with this Amended and Restated Certificate of Incorporation.&#8221; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> That the foregoing amendment was approved by the holders of the requisite number
of shares of the Corporation in accordance with Section&nbsp;228 of the General Corporation Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> That said amendment has been
duly adopted in accordance with Section&nbsp;242 of the General Corporation Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> All other provisions of the Amended and
Restated Certificate of Incorporation shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Follow] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Certificate of Amendment has been executed by a duly
authorized officer of the Corporation on this 24<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day of April, 2026. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daphne Zohar</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Daphne Zohar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> C<SMALL>ERTIFICATE</SMALL>
<SMALL>OF</SMALL> A<SMALL>MENDMENT</SMALL> </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>4
<FILENAME>d73463dex33.htm
<DESCRIPTION>EX-3.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAPORT THERAPEUTICS,
INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seaport Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the
&#8220;Corporation&#8221;), hereby certifies as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The name of the Corporation is Seaport Therapeutics, Inc. The date of the
filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was April&nbsp;1, 2024 (the &#8220;Original Certificate&#8221;). The name under which the Corporation filed the Original Certificate was SP
Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The Original Certificate was amended by that certain Amended and Restated Certificate of Incorporation dated
April&nbsp;8, 2024 and by that certain Amended and Restated Certificate of Incorporation dated October&nbsp;17, 2024, as amended by a Certificate of Amendment dated April&nbsp;24, 2026 (the &#8220;Amended and Restated Certificate of
Incorporation&#8221;). This Amended and Restated Certificate of Incorporation (the &#8220;Certificate&#8221;) amends, restates and integrates the provisions of the Amended and Restated Certificate of Incorporation, and was duly adopted in accordance
with the provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The
text of the Amended and Restated Certificate is hereby amended, restated and integrated in its entirety to provide as follows. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the Corporation is Seaport Therapeutics, Inc. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the
Corporation&#8217;s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the
Corporation is to engage in any lawful act or activity for which corporations may be organized under the DGCL. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CAPITAL STOCK </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total
number of shares of capital stock which the Corporation shall have authority to issue is Seven Hundred and Ten Million (710,000,000), of which (i)&nbsp;Seven Hundred Million (700,000,000) shares shall be a class designated as common stock, par value
$0.0001 per share (the &#8220;Common Stock&#8221;), which class of Common Stock shall be subdivided into two series consisting of (a)&nbsp;Five Hundred Million (500,000,000) shares designated as voting Common Stock (the &#8220;Voting Common
Stock&#8221;) and (b)&nbsp;Two Hundred Million (200,000,000) shares designated as <FONT STYLE="white-space:nowrap">non-voting</FONT> Common Stock (the <FONT STYLE="white-space:nowrap">&#8220;Non-Voting</FONT> Common Stock&#8221;) and (ii)&nbsp;Ten
Million (10,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share (the &#8220;Preferred Stock&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in any certificate of designation of any series of Preferred Stock, the number of authorized shares of the class
of Common Stock or Preferred Stock may be increased or decreased (but not below the number of shares of such class then outstanding) by the requisite vote of the holders of the outstanding shares of capital stock of the Corporation entitled to vote
thereon irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL, and no vote of the holders of any of the Common Stock or the Preferred Stock voting separately as a class shall be required therefor. For the avoidance of doubt, the
elimination and reduction of the stockholder voting requirements otherwise applicable under Section&nbsp;242(b) of the DGCL, as permitted by Section&nbsp;242(d) of the DGCL, shall apply to any amendments to the Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The powers, preferences and rights of, and the qualifications, limitations and restrictions upon, each class or series of stock shall be
determined in accordance with, or as set forth below in, this Article&nbsp;IV. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A. <U>COMMON STOCK</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to all the rights, powers and preferences of the Preferred Stock and except as provided by law or in this Certificate (including any
certificate of designation of any series of Preferred Stock): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. the holders of the Voting Common Stock shall have the exclusive right to
vote for the election of directors of the Corporation (the &#8220;Directors&#8221;) and on all other matters requiring stockholder action, each outstanding share of Voting Common Stock entitling the holder thereof to one vote on each matter properly
submitted to the stockholders of the Corporation for their vote; <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Voting Common Stock, as such, shall not be entitled to vote on any amendment to this Certificate
(including any amendment to a certificate of designation of any series of Preferred Stock) that alters or changes the number of shares, powers, preferences, rights or other terms of one or more outstanding series of Preferred Stock if the holders of
such affected series of Preferred Stock are entitled to vote, either separately or together with the holders of one or more other such series, on such amendment pursuant to this Certificate (including any certificate of designation of any series of
Preferred Stock) or pursuant to the DGCL; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock shall be <FONT
STYLE="white-space:nowrap">non-voting</FONT> shares, and the holders thereof shall have no right to vote for the election of Directors or on any other matters requiring stockholder action, except as required by law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. shares of Voting Common Stock and <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock shall be treated equally, identically and
ratably, on a per share basis, with respect to any dividends or other distributions of cash, property or shares of capital stock of the Corporation (each, a &#8220;Distribution&#8221;), as may be declared and paid or set apart for payment upon the
shares of Common Stock out of any assets or funds of the Corporation legally available therefor, when, as and if declared by the Board of Directors of the Corporation (the &#8220;Board&#8221;) or any authorized committee thereof; in the event that
such Distribution is paid in the form of shares of Common Stock (or rights to acquire, or securities convertible or exchangeable for shares of Common Stock), holders of Voting Common Stock shall be entitled to receive only shares of Voting Common
Stock (or rights to acquire, or securities convertible into or exchangeable for, such shares, as the case may be) and holders of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock shall be entitled to receive only shares of <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock (or rights to acquire, or securities convertible into or exchangeable for, such shares, as the case may be); notwithstanding the foregoing, the Board may treat the holders of Voting Common
Stock or <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock differently with respect to Distributions (including by only paying a Distribution on one such class or paying a different or disparate Distribution to each such class
including with respect to the amount of such Distribution payable per share, the form in which such Distribution is payable, the timing of the payment, or otherwise) if such disparate treatment is approved by (i)&nbsp;a majority of the disinterested
directors, as such term is defined in Section&nbsp;144(e)(4) of the DGCL, then in office, or (ii)&nbsp;any committee of the Board expressly delegated the authority to oversee the treatment of such distributions); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. upon the voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the assets of the Corporation available for
distribution to stockholders shall be distributed pro rata to the holders of the Voting Common Stock and <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock, treated equally and identically; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. in connection with any merger or consolidation of the Corporation with or into any other entity or any conversion, domestication, transfer
or continuance of the Corporation, shares of Voting Common Stock and shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock shall be treated equally, identically and ratably, on a per share basis, with respect to any consideration
into which such shares are converted or any other consideration paid or otherwise distributed to stockholders of the Corporation in the merger, consolidation, conversion, domestication, transfer or continuance (any such consideration, &#8220;Change
of Control Consideration&#8221;), unless (i)&nbsp;such consideration consists, in whole or in part, of shares of capital stock of, or other equity interests in, the Corporation or any other corporation, partnership, limited liability company or
other entity, and the powers, designations, preferences and relative, optional or other special rights and qualifications, limitations and restrictions of such shares of capital stock or other equity interests received in respect of the shares of
Voting Common Stock and <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock differ solely to the extent that the powers, designations, preferences and relative, optional or other special rights and qualifications, limitations and
restrictions of the Voting Common Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock differ as described in this <U>Article IV</U>, then the powers, designations, preferences and relative, optional or other
special rights and qualifications, limitations and restrictions of such shares of capital stock or other equity interests received in respect of the shares of Voting Common Stock and <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock
may differ to the extent that the powers, designations, preferences and relative, optional or other special rights and qualifications, limitations and restrictions of the Voting Common Stock and the <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Common Stock differ as provided herein (including, without limitation, with respect to the voting rights and conversion provisions hereof), provided,&nbsp;however, that, if the holders of any series of Common Stock are granted the right to elect to
receive one of two or more alternative forms of consideration, the foregoing provisions shall be deemed satisfied if holders of the other series of Common Stock are granted corresponding election rights, or (ii)&nbsp;different treatment of the
shares of each such series in connection with such merger, consolidation, conversion, domestication, transfer or continuance is approved by the affirmative vote of the holders of a majority of the outstanding shares of Voting Common Stock; provided
further, for the avoidance of doubt, Change of Control Consideration shall not be deemed to include any consideration or other distribution paid to or received by a person who is a holder of Voting Common Stock and/or
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock, as applicable, pursuant to (x)&nbsp;any employment, consulting, severance or other compensatory arrangement (including, without limitation, any equity-based or cash compensatory award
or payment) whether or not entered into in connection with such merger, consolidation, conversion, domestication, transfer or continuance or (y)&nbsp;a negotiated agreement between a holder of Voting Common Stock and/or <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock, as applicable, with any counterparty (or affiliate thereof) to a merger or consolidation wherein such holder is contributing, selling, transferring, exchanging or otherwise disposing of
shares of the Corporation&#8217;s capital stock to such counterparty (or affiliate thereof) as part of a &#8220;rollover&#8221; or similar transaction that is approved by (i)&nbsp;a majority of the disinterested directors, as such term is defined in
Section&nbsp;144(e)(4) of the DGCL, then in office, or (ii)&nbsp;any committee of the Board expressly delegated the authority to negotiate (or oversee the negotiation of) and to reject&nbsp;such merger or consolidation, and that is in connection
with such merger or consolidation or any such conversion, domestication, transfer or continuance; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Shares of Voting Common Stock or
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock may not be subdivided, combined or reclassified unless the shares of such other series are concurrently therewith proportionately subdivided, combined or reclassified in a manner that
maintains the same proportionate equity ownership among the holders of the outstanding Voting Common Stock and <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock on the record date for such subdivision, combination or
reclassification;&nbsp;provided, however, that shares of one such series may be treated differently if such treatment is approved by the affirmative vote of the holders of a majority of the outstanding shares of Voting Common Stock. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B. <U>CONVERSION OF <FONT STYLE="white-space:nowrap">NON-VOTING</FONT> COMMON STOCK</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Each holder of shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock shall have the right to convert each share of <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock held by such holder into one share of Voting Common Stock at such holder&#8217;s election, which shall be made upon written notice to the Corporation delivered, provided that, the shares of <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock may only be converted into shares of Voting Common Stock during such time or times as immediately prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to or as a result of such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended, and the
rules and regulations promulgated thereunder (collectively, the &#8220;Exchange Act&#8221;)), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section&nbsp;13(d) of the Exchange Act,
in excess of the Beneficial Ownership Limitation. The &#8220;Beneficial Ownership Limitation&#8221; means initially 9.99% of any class of securities of the Corporation registered under the Exchange Act, which percentage may be increased or decreased
by a holder of outstanding shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock to such other percentage not in excess of 19.99% at the time of purchase of shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common
Stock without advance notice to the Corporation or, after the time of purchase, as such holder may designate in writing upon 61 days&#8217; notice to the Corporation, provided, however, that, in each case, such increase or decrease shall only be
applicable to such holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Before any holder of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock shall be entitled to
convert any shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock into shares of Voting Common Stock pursuant to Subsection 1 of Part B of Article IV, such holder shall surrender the certificate or certificates therefor (if any),
duly endorsed, at the principal corporate office of the Corporation or of any transfer agent of the Corporation, and shall provide written notice to the Corporation and any such transfer agent, of such conversion election and shall state therein the
number of shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock elected to be converted, the name or names (i)&nbsp;in which the certificate or certificates representing the shares of Voting Common Stock into which the shares of <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock are so converted are to be issued (if such shares of Voting Common Stock will be certificated) or (ii)&nbsp;in which such shares of Voting Common Stock are to be registered in book-entry form
(if such shares of Voting Common Stock are uncertificated). If the shares of Voting Common Stock into which the shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock are to be converted are to be issued in a name or names other
than the name of the holder of the shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock being converted, such notice shall be accompanied by a written instrument or instruments of transfer, in form satisfactory to the
Corporation, duly executed by the holder. The Corporation shall, as soon as practicable thereafter, issue and deliver to such holder, or to the nominee or nominees of such holder, (i)&nbsp;a certificate or certificates representing the number of
shares of Voting Common Stock to which such holder shall be entitled upon such conversion (if such shares of Voting Common Stock are certificated) or shall register such shares of Voting Common Stock in book-entry form (if such shares of Voting
Common Stock are uncertificated) and (ii)&nbsp;if applicable, a certificate or certificates representing the number of shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock for the number of shares (including any fractional
share) of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock represented by the certificate or certificates delivered to the Corporation for conversion but otherwise not elected to be converted pursuant to the written election (if such
shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock are certificated), or shall register such shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock in book-entry form (if such shares of <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock are uncertificated). Such conversion shall be deemed to be effective immediately prior to the close of business (i)&nbsp;with respect to certificated shares, on the date of such surrender of
the certificate or certificates representing the shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock to be converted or (ii)&nbsp;with respect to shares that are uncertificated, immediately prior to the close of business on the
date that the holder delivers notice of such conversion election as required by this Subsection 2(a) of Part B of Article IV to the Corporation and the Corporation&#8217;s transfer agent, and, in each case, the shares of Voting Common Stock issuable
upon such conversion shall be deemed to be outstanding as of such time, and the person or persons entitled to receive the shares of Voting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock issuable upon such conversion shall be deemed to be the record holder or holders of such shares of Voting Common Stock as of such time. Notwithstanding anything herein to the
contrary, shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock represented by a lost, stolen or destroyed stock certificate may be converted pursuant to Subsection 1 of Part B of Article IV if the holder thereof notifies the
Corporation or its transfer agent that such certificate has been lost, stolen or destroyed and provides an affidavit of that fact acceptable to the Corporation and executes an agreement acceptable to the Corporation to indemnify the Corporation from
any loss incurred by it in connection with such certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> conversion ratio for the conversion of the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock into Voting Common Stock shall in all events be
equitably adjusted in the event of any reclassification of the Voting Common Stock or <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock (including any split or combination thereof), any Distribution on the Voting Common Stock or <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock, or in the event of any merger or consolidation of the Corporation, any recapitalization or reorganization of the Corporation, or any other similar event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The Corporation shall at all times reserve and keep available out of its authorized but unissued shares of Voting Common Stock, solely for
the purpose of effecting the conversion of the shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock, such number of its shares of Voting Common Stock as shall from time to time be sufficient to effect the conversion of all
outstanding shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. If any shares of
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock shall be converted pursuant to this Article IV.B., the shares so converted shall be retired and restored to the status of authorized but unissued shares of <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C. <U>PREFERRED STOCK</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors or any authorized committee thereof is expressly authorized to provide by resolution or resolutions for, out of the
unissued shares of Preferred Stock, the issuance of the shares of Preferred Stock in one or more series of such stock, and by filing a certificate of designation pursuant to applicable law of the State of Delaware, to establish or change from time
to time the number of shares of each such series, and to fix the designations, powers, including voting powers, full or limited, or no voting powers, preferences and the relative, participating, optional or other special rights of the shares of each
series and any qualifications, limitations and restrictions thereof, all to the fullest extent now or hereafter permitted by the DGCL. The powers, preferences and relative, participating, optional and other special rights of each such series of
Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding. Without limiting the generality of the foregoing, the resolution or resolutions
providing for the issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE V </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>STOCKHOLDER ACTION </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Action without Meeting</U>. Any action required or permitted to be taken by the stockholders of the Corporation at any annual or special meeting of stockholders of the Corporation must be effected at a duly called annual or special meeting of
stockholders and may not be taken or effected by a consent of stockholders in lieu thereof; <I>provided, however</I>, that any action required or permitted to be taken, to the extent expressly permitted by the certificate of designation relating to
one or more series of Preferred Stock, by the holders of such series of Preferred Stock, voting separately as a series or separately as a class with one or more other such series, may be taken by consent in lieu of a meeting, without prior notice
and without a vote, if a consent or consents, setting forth the action so taken, shall be signed by the holders of outstanding shares of the relevant series of Preferred Stock having not less than the minimum number of votes that would be necessary
to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation in accordance with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Special Meetings</U>. Except as otherwise required by statute and subject to the rights, if any, of the holders of shares of any series
of Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the Board of Directors and may not be called by any other person or persons. Only those matters set forth in the notice of the special meeting may be
considered or acted upon at a special meeting of stockholders of the Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VI </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>DIRECTORS </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>General</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors except as otherwise provided herein or required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Number of Directors; Term of Office</U>. Except as otherwise provided for or fixed pursuant to the provisions of Article IV (including
any certificate of designation with respect to any series of Preferred Stock) and this Article VI relating to the rights of the holders of any series of Preferred Stock to elect additional Directors, the number of directors of the Corporation (the
&#8220;Directors&#8221;) shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors. The Directors, other than those who may be elected by the holders of any series of Preferred Stock, shall be
classified, with respect to the term for which they severally hold office, into three classes. The term of office of the initial Class&nbsp;I Directors shall expire at the first annual meeting of stockholders following the closing of the
Corporation&#8217;s sale of a class of its capital stock to the public pursuant to a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act (the &#8220;IPO Time&#8221;). The term of office of the initial
Class&nbsp;II Directors shall expire at the second annual meeting of stockholders following the IPO Time. The term of office of the initial Class&nbsp;III Directors shall expire at the third annual meeting of stockholders following the IPO Time. The
Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification of the Board of Directors becomes effective. At each annual meeting of stockholders, Directors elected to
succeed those Directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting of stockholders after their election. Notwithstanding the foregoing, the Directors elected to each class shall hold office until their successors are duly elected and qualified or until
their earlier resignation, death, disqualification or removal. No decrease in the number of Directors shall shorten the term of any incumbent Director. There shall be no cumulative voting in the election of Directors. Election of Directors need not
be by written ballot unless the Bylaws of the Corporation so provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, whenever, pursuant to the provisions
of Article&nbsp;IV of this Certificate, the holders of any one or more series of Preferred Stock shall have the right, voting separately as a series or together with holders of other such series, to elect additional Directors, the election, term of
office, filling of vacancies and other features of such directorships shall be governed by the terms of this Certificate, including any certificate of designation applicable to such series of Preferred Stock. During any period when the holders of
any series of Preferred Stock, voting separately as a series or together with one or more series, have the right to elect additional Directors, then upon commencement and for the duration of the period during which such right continues: (i)&nbsp;the
then otherwise total authorized number of Directors shall automatically be increased by such specified number of Directors, and the holders of such Preferred Stock shall be entitled to elect the additional Directors so provided for or fixed pursuant
to said provisions, and (ii)&nbsp;each such additional Director shall serve until such Director&#8217;s successor shall have been duly elected and qualified, or until such Director&#8217;s right to hold such office terminates pursuant to said
provisions, whichever occurs earlier, subject to such Director&#8217;s earlier death, resignation, retirement, disqualification or removal. Notwithstanding any other provision of this Certificate of Incorporation, except as otherwise provided by the
Board in the resolution or resolutions establishing such series, whenever the holders of any series of Preferred Stock having such right to elect additional Directors are divested of such right pursuant to the provisions of such stock, the terms of
office of all such additional Directors elected by the holders of such stock, or elected to fill any vacancies resulting from the death, resignation, disqualification or removal of such additional Directors, shall forthwith terminate (in which case
each such Director shall thereupon cease to be qualified as, and shall cease to be, a Director) and the total authorized number of Directors shall automatically be reduced accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Vacancies and Newly Created Directorships</U>. Subject to the rights, if any, of the holders of any series of Preferred Stock to elect
Directors and to fill vacancies in the Board of Directors and newly created directorships relating thereto, any and all vacancies and newly created directorships in the Board of Directors, however occurring, including, without limitation, by reason
of an increase in the size of the Board of Directors, or the death, resignation, disqualification or removal of a Director, shall be filled solely and exclusively by the affirmative vote of a majority of the remaining Directors then in office, even
if less than a quorum of the Board of Directors, or by a sole remaining Director, and not by the stockholders. Any Director appointed in accordance with the preceding sentence shall hold office for the remainder of the full term of the class of
Directors in which the new directorship was created or the vacancy occurred and until such Director&#8217;s successor shall have been duly elected and qualified or until such Director&#8217;s earlier resignation, disqualification, death or removal.
Subject to the rights, if any, of the holders of any series of Preferred Stock to elect Directors, when the number of Directors is increased or decreased, the Board of Directors shall, subject to Article VI.3 hereof, determine the class or classes
to which the increased or decreased number of Directors shall be apportioned. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Removal</U>. Subject to the rights, if any, of any series of Preferred Stock to elect
Directors and to remove any Director whom the holders of any such series have the right to elect, any Director may be removed from office (i)&nbsp;only for cause and (ii)&nbsp;only by the affirmative vote of the holders of not less than <FONT
STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the voting power of the outstanding shares of capital stock entitled to vote thereon. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VII </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>LIMITATION OF
LIABILITY </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the fullest extent permitted by the DGCL, as the same exists or may hereafter be amended from time to time, a Director
or officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of such Director&#8217;s fiduciary duty as a Director or officer of the Corporation. If the DGCL is amended after the
effective date of this Certificate to authorize corporate action further eliminating or limiting the personal liability of Directors or officers of the Corporation, then the liability of a Director or officer of the Corporation shall be eliminated
or limited to the fullest extent permitted by the DGCL, as so amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of this Article&nbsp;VII
shall not adversely affect any right or protection of any Director or officer of the Corporation existing at the time of such amendment, repeal or modification with respect to any acts or omissions by such Director or officer occurring before such
amendment, repeal or modification. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VIII </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AMENDMENT OF BYLAWS </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Amendment by Directors</U>. Except as otherwise provided by law, the Board of Directors shall have the power to alter, amend or repeal the Bylaws of the Corporation or to adopt new bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Amendment by Stockholders</U>. Except as otherwise provided therein, the Bylaws of the Corporation may be amended or repealed by the
stockholders by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the voting power of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as
a single class; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal, such amendment or repeal by the stockholders shall only require the affirmative vote of the holders of a majority of the
voting power of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IX </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AMENDMENT OF CERTIFICATE OF INCORPORATION </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation reserves the right to amend or repeal this Certificate in the manner now or hereafter prescribed by statute and this
Certificate, and all rights conferred upon stockholders herein are granted subject to this reservation. For the avoidance of doubt, the provisions of Sections 242(d)(1) and (d)(2) of the DGCL shall apply to the Corporation.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[End of Text] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AMENDED AND RESTATED CERTIFICATE OF INCORPORATION is executed as of this&#8195;&#8195;
, 2026. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SEAPORT THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Daphne Zohar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>5
<FILENAME>d73463dex35.htm
<DESCRIPTION>EX-3.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(the &#8220;Corporation&#8221;) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE I </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Stockholders
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Annual Meeting</U>. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an
&#8220;Annual Meeting&#8221;) shall be held at the hour, date and place within or without the United States that is fixed by or in the manner determined by the Board of Directors and stated in the notice of the meeting, which time, date and place
may subsequently be changed at any time, before or after the notice for such meeting has been sent to the stockholders, by vote of the Board of Directors. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders
shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section&nbsp;211(a)(2) of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;). In the absence of any such
designation or determination, stockholders&#8217; meetings shall be held at the Corporation&#8217;s principal executive office. If no Annual Meeting has been held for a period of thirteen (13)&nbsp;months after the Corporation&#8217;s last Annual
Meeting, a special meeting in lieu thereof may be held, and such special meeting shall have, for the purposes of these Bylaws or otherwise, all the force and effect of an Annual Meeting. Any and all references hereafter in these Bylaws to an Annual
Meeting or Annual Meetings also shall be deemed to refer to any special meeting(s) in lieu thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. Notice of Stockholder
Business and Nominations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Annual Meetings of Stockholders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Nominations of persons for election to the Board of Directors of the Corporation (the &#8220;Board of Directors&#8221;) and
the proposal of other business to be considered by the stockholders may be brought before an Annual Meeting (i)&nbsp;by or at the direction of the Board of Directors or (ii)&nbsp;by any stockholder of the Corporation who was a stockholder of record
at the time of giving of notice of the Annual Meeting provided for in this Bylaw, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in this Bylaw as to
such nomination or business. For the avoidance of doubt, the foregoing clause (ii)&nbsp;shall be the exclusive means for a stockholder to bring nominations or business properly before an Annual Meeting (other than matters properly brought under Rule
<FONT STYLE="white-space:nowrap">14a-8</FONT> (or any successor rule) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), and such stockholder must comply with the notice and other procedures set forth in Article
I, Section&nbsp;2(a)(2), (3) and (4)&nbsp;of this Bylaw to bring such nominations or business properly before an Annual Meeting. In addition to the other requirements set forth in this Bylaw, for any proposal of business to be considered at an
Annual Meeting, it must be a proper subject for action by stockholders of the Corporation under Delaware law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) For nominations or other business to be properly brought before an
Annual Meeting by a stockholder pursuant to clause (ii)&nbsp;of Article I, Section&nbsp;2(a)(1) of this Bylaw, the stockholder must (i)&nbsp;have given Timely Notice (as defined below) thereof in writing to the Secretary of the Corporation,
(ii)&nbsp;have provided any updates or supplements to such notice at the times and in the forms required by this Bylaw and (iii)&nbsp;together with the beneficial owner(s), if any, on whose behalf the nomination or business proposal is made, have
acted in accordance with the representations set forth in the Solicitation Statement (as defined below) required by this Bylaw. To be timely, a stockholder&#8217;s written notice must be received by the Secretary at the principal executive offices
of the Corporation not later than 5:00 p.m. Eastern time on the ninetieth (90th) day nor earlier than 5:00 p.m. Eastern time on the one hundred twentieth (120th) day prior to the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the
preceding year&#8217;s Annual Meeting; provided, however, that in the event the Annual Meeting is first convened more than thirty (30)&nbsp;days before or more than sixty (60)&nbsp;days after such anniversary date, or if no Annual Meeting was held
in the preceding year, notice by the stockholder to be timely must be received by the Secretary of the Corporation not later than 5:00 p.m. Eastern time on the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or
the tenth (10th) day following the day on which public announcement of the date of such meeting is first made (such notice within such time periods shall be referred to as &#8220;Timely Notice&#8221;). Notwithstanding anything to the contrary
provided herein, for the first Annual Meeting following the initial public offering of common stock of the Corporation, a stockholder&#8217;s notice shall be timely if received by the Secretary at the principal executive offices of the Corporation
not later than 5:00 p.m. Eastern time on the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the tenth (10th) day following the day on which public announcement of the date of such Annual Meeting is first made
or sent by the Corporation. Such stockholder&#8217;s Timely Notice shall set forth or include: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) as to each person whom
the stockholder proposes to nominate for election or reelection as a director, (i)&nbsp;the name, age, business address and residence address of the nominee, (ii)&nbsp;the principal occupation or employment of the nominee, (iii)&nbsp;the class and
number of shares of capital stock of the Corporation that are held of record or are beneficially owned by the nominee or its Affiliates or Associates (each as defined below) and any Synthetic Equity Interest (as defined below) held or beneficially
owned by the nominee or its Affiliates or Associates, (iv)&nbsp;a description of all agreements, arrangements or understandings between or among the stockholder and each nominee and any other person or persons (naming such person or persons)
pursuant to which the nominations are to be made by the stockholder or concerning the nominee&#8217;s potential service on the Board of Directors, (v)&nbsp;a questionnaire with respect to the background and qualifications of the nominee completed by
the nominee in the form provided by the Corporation (which questionnaire shall be provided by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Secretary upon written request of any stockholder of record identified by name within five (5)&nbsp;business days of such written request), (vi) a representation and agreement in the form
provided by the Corporation (which form shall be provided by the Secretary upon written request of any stockholder of record identified by name within five (5)&nbsp;business days of such written request) that: (a)&nbsp;such proposed nominee is not
and will not become party to any agreement, arrangement or understanding with any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a &#8220;Voting
Commitment&#8221;) that has not been disclosed to the Corporation in the questionnaire described in clause (v)&nbsp;herein; (b) such proposed nominee is not and will not become a party to any agreement, arrangement or understanding with any person
or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed to the Corporation in the questionnaire
described in clause (v)&nbsp;herein; (c) such proposed nominee would, if elected as a director, comply with all applicable rules and regulations of the exchanges upon which shares of the Corporation&#8217;s capital stock trade, each of the
Corporation&#8217;s corporate governance, ethics, conflict of interest, confidentiality, stock ownership and trading policies and guidelines applicable generally to the Corporation&#8217;s directors and, if elected as a director of the Corporation,
such person currently would be in compliance with any such policies and guidelines that have been publicly disclosed; (d)&nbsp;such proposed nominee intends to serve as a director for the full term for which he or she is to stand for election; and
(e)&nbsp;such proposed nominee will promptly provide to the Corporation such other information as it may reasonably request to determine the eligibility of such proposed nominee to serve on any committee or
<FONT STYLE="white-space:nowrap">sub-committee</FONT> of the Board of Directors under any applicable stock exchange listing requirements or applicable law, or that the Board of Directors reasonably determines could be material to a reasonable
stockholder&#8217;s understanding of the background, qualifications, experience, independence, or lack thereof, of such proposed nominee; and (vii)&nbsp;any other information relating to such proposed nominee that is required to be disclosed in
solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act (including, without limitation, such person&#8217;s written consent to being named in
the proxy statement as a nominee and to serving as a director if elected); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) as to any other business that the
stockholder proposes to bring before the meeting: a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting, the text, if any, of any resolutions or Bylaw amendment proposed
for adoption, and any material interest in such business of each Proposing Person (as defined below); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) (i) the name and address of the stockholder giving the notice, as they
appear on the Corporation&#8217;s books, and the names and addresses of the other Proposing Persons (if any) and (ii)&nbsp;as to each Proposing Person, the following information: (a)&nbsp;the class or series and number of all shares of capital stock
of the Corporation that are, directly or indirectly, owned beneficially or of record by such Proposing Person or any of its Affiliates or Associates, including any shares of any class or series of capital stock of the Corporation as to which such
Proposing Person or any of its Affiliates or Associates has a right to acquire beneficial ownership at any time in the future (whether or not such right is exercisable immediately or only after the passage of time or upon the satisfaction of any
conditions or both) pursuant to any agreement, arrangement or understanding (whether or not in writing), (b) all Synthetic Equity Interests (as defined below) in which such Proposing Person or any of its Affiliates or Associates, directly or
indirectly, holds an interest including a description of the material terms of each such Synthetic Equity Interest, including, without limitation, identification of the counterparty to each such Synthetic Equity Interest and disclosure, for each
such Synthetic Equity Interest, as to (1)&nbsp;whether or not such Synthetic Equity Interest conveys any voting rights, directly or indirectly, in such shares to such Proposing Person or any of its Affiliates or Associates and (2)&nbsp;whether or
not such Synthetic Equity Interest is required to be, or is capable of being, settled through delivery of such shares, (c)&nbsp;any proxy (other than a revocable proxy given in response to a public proxy solicitation made pursuant to, and in
accordance with, the Exchange Act), agreement, arrangement, understanding or relationship pursuant to which such Proposing Person or any of its Affiliates or Associates has or shares a right to, directly or indirectly, vote any shares of any class
or series of capital stock of the Corporation, (d)&nbsp;any rights to dividends or other distributions on the shares of any class or series of capital stock of the Corporation, directly or indirectly, owned beneficially by such Proposing Person or
any of its Affiliates or Associates that are separated or separable from the underlying shares of the Corporation, (e)&nbsp;if such Proposing Person is not a natural person, the identity of the natural person or persons responsible for making voting
and investment decisions (including director nominations and any other business that the stockholder proposes to bring before a meeting) on behalf of the Proposing Person (irrespective of whether such person or persons have &#8220;beneficial
ownership&#8221; for purposes of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act of any securities owned of record or beneficially by the Proposing Person) (such person or persons, the &#8220;Responsible Person&#8221;), (f)
any pending or threatened litigation in which such Proposing Person or any of its Affiliates or Associates or any Responsible Person is a party involving the Corporation or any of its officers or directors, or any Affiliate of the Corporation, and
(g)&nbsp;any other information relating to such Proposing Person or any of its Affiliates or Associates that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies or
consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to Section&nbsp;14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (a)&nbsp;through (g) are referred
to, collectively, as &#8220;Material Ownership Interests&#8221;); provided, however, that the Material Ownership Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer,
commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder of record directed to prepare and submit the notice required by these Bylaws on behalf of a beneficial owner; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) (i) a description of all agreements, arrangements or understandings to
which any Proposing Person or any of its Affiliates or Associates is a party (whether the counterparty or counterparties are a Proposing Person or any Affiliate or Associate thereof, on the one hand, or one or more other third parties, on the other
hand, (including any proposed nominee(s)) (a) pertaining to the nomination(s) or other business proposed to be brought before the meeting of stockholders or (b)&nbsp;entered into for the purpose of acquiring, holding, disposing or voting of any
shares of any class or series of capital stock of the Corporation (which description shall identify the name of each other person who is party to such an agreement, arrangement or understanding) and (ii)&nbsp;identification of the names and
addresses of other stockholders (including beneficial owners) known by any of the Proposing Persons to be providing financial support or meaningful assistance in furtherance of the nomination(s) or other business proposed to be brought before the
meeting of stockholders and, to the extent known, the class and number of all shares of the Corporation&#8217;s capital stock owned beneficially or of record by such other stockholder(s) or other beneficial owner(s); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) a statement (i)&nbsp;that the stockholder is a holder of record of capital stock of the Corporation entitled to vote at
such meeting, a representation that such stockholder intends to appear in person or by proxy at the meeting to propose such business or nominees and an acknowledgement that, if such stockholder (or a qualified representative of such stockholder)
does not appear to present such business or proposed nominees, as applicable, at such meeting, the Corporation need not present such business or proposed nominees for a vote at such meeting, notwithstanding that proxies in respect of such vote may
have been received by the Corporation, (ii)&nbsp;whether or not the stockholder giving the notice and/or the other Proposing Person(s), if any, (a)&nbsp;will deliver a proxy statement and form of proxy to holders of, in the case of a business
proposal, at least the percentage of voting power of all of the shares of capital stock of the Corporation required under applicable law to approve the proposal or, in the case of a nomination or nominations, at least 67&nbsp;percent of the voting
power of all of the shares of capital stock of the Corporation entitled to vote on the election of directors or (b)&nbsp;otherwise solicit proxies or votes from stockholders in support of such proposal or nomination, as applicable,
(iii)&nbsp;providing a representation as to whether or not such Proposing Person intends to solicit proxies in support of director nominees other than the Corporation&#8217;s director nominees in accordance with Rule
<FONT STYLE="white-space:nowrap">14a-19</FONT> promulgated under the Exchange Act and (iv)&nbsp;that the stockholder will provide any other information relating to such item of business that would be required to be disclosed in a proxy statement or
other filing required to be made in connection with solicitations of proxies in support of the business proposed to be brought before the meeting pursuant to Section&nbsp;14(a) of the Exchange Act (such statement, the &#8220;Solicitation
Statement&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Article I, the term &#8220;Proposing Person&#8221; shall mean the
following persons: (i)&nbsp;the stockholder of record providing the notice of nominations or business proposed to be brought before a stockholders&#8217; meeting and (ii)&nbsp;the beneficial owner(s), if different, on whose behalf the nominations or
business proposed to be brought before a stockholders&#8217; meeting is made. For purposes of this Section&nbsp;2, each of the terms &#8220;Affiliates&#8221; and &#8220;Associates&#8221; shall have the meaning attributed to such term in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act. For purposes of this Section&nbsp;2, the term &#8220;Synthetic Equity Interest&#8221; shall mean any transaction, agreement or arrangement (or series of transactions, agreements or
arrangements), including, without limitation, any derivative, swap, hedge, repurchase or <FONT STYLE="white-space:nowrap">so-called</FONT> &#8220;stock borrowing&#8221; or securities lending agreement or arrangement, the purpose or effect of which
is to, directly or indirectly: (a)&nbsp;give a person or entity economic benefit and/or risk similar to ownership of shares of any class or series of capital stock of the Corporation, in whole or in part, including due to the fact that such
transaction, agreement or arrangement provides, directly or indirectly, the opportunity to profit, or share in any profit, or avoid a loss from any increase or decrease in the value of any shares of any class or series of capital stock of the
Corporation, (b)&nbsp;mitigate loss to, reduce the economic risk of, or manage the risk of share price changes for, any person or entity with respect to any shares of any class or series of capital stock of the Corporation, or (c)&nbsp;increase or
decrease the voting power of any person or entity with respect to any shares of any class or series of capital stock of the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) A stockholder providing Timely Notice of nominations or business proposed to be brought before an Annual Meeting shall
further update and supplement such notice, if necessary, so that the information (including, without limitation, the Material Ownership Interests information) provided or required to be provided in such notice pursuant to this Bylaw shall be true
and correct as of the record date for the meeting and as of the date that is ten (10)&nbsp;business days prior to such Annual Meeting, and such update and supplement shall be received by the Secretary at the principal executive offices of the
Corporation not later than 5:00 p.m. Eastern time on the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) business day after the record date for the Annual Meeting (in the case of the update and supplement required to be made as of
the record date), and not later than 5:00 p.m. Eastern time on the eighth (8<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) business day prior to the date of the Annual Meeting (in the case of the update and supplement required to be made
as of ten (10)&nbsp;business days prior to the meeting). For the avoidance of doubt, the obligation to update as set forth in this Section&nbsp;2(a)(3) shall not limit the Corporation&#8217;s rights with respect to any deficiencies in any notice
provided by a stockholder, extend any applicable deadlines hereunder, or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or nomination or to submit any new proposal, including
by changing or adding nominees, matters, business and/or resolutions proposed to be brought before a meeting of the stockholders. Notwithstanding the foregoing, if a Proposing Person no longer plans to solicit proxies in accordance with its
representation pursuant to Article I, Section&nbsp;2(a)(2)(E), such Proposing Person shall inform the Corporation of this change by delivering a written notice to the Secretary at the principal executive offices of the Corporation no later than two
(2)&nbsp;business days after making the determination not to proceed with a solicitation of proxies. A Proposing Person shall also update its notice so that the information required by Article I, Section&nbsp;2(a)(2)(C) is current through the date
of the meeting or any adjournment, postponement or rescheduling thereof, and such update shall be delivered in writing to the secretary at the principal executive offices of the Corporation no later than two (2)&nbsp;business days after the
occurrence of any material change to the information previously disclosed pursuant to Article I, Section&nbsp;2(a)(2)(C). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) Notwithstanding anything in the second sentence of Article I,
Section&nbsp;2(a)(2) of this Bylaw to the contrary, in the event that the number of directors to be elected to the Board of Directors is increased and there is no public announcement naming all of the nominees for director or specifying the size of
the increased Board of Directors made by the Corporation at least ten (10)&nbsp;days before the last day a stockholder may deliver a notice of nomination in accordance with the second sentence of Article I, Section&nbsp;2(a)(2), a
stockholder&#8217;s notice required by this Bylaw shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be received by the Secretary of the Corporation not later than 5:00 p.m.
Eastern time on the tenth (10th) day following the day on which such public announcement is first made by the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>General</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Only such persons who are nominated in accordance with the provisions of this Bylaw shall be eligible
for election and to serve as directors, and only such business shall be conducted at an Annual Meeting as shall have been brought before the meeting in accordance with the provisions of this Bylaw or in accordance with Rule <FONT
STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act. The Board of Directors or a designated committee thereof shall have the power to determine whether a nomination or any business proposed to be brought before the meeting was made in
accordance with the provisions of this Bylaw. If neither the Board of Directors nor such designated committee makes a determination as to whether any stockholder proposal or nomination was made in accordance with the provisions of this Bylaw, the
chair of the meeting (as defined in Section&nbsp;9 of this Article I) shall have the power and duty to determine whether the stockholder proposal or nomination was made in accordance with the provisions of this Bylaw. If the Board of Directors or a
designated committee thereof or the chair of the meeting, as applicable, determines that any stockholder proposal or nomination was not made in accordance with the provisions of this Bylaw, such proposal or nomination shall be disregarded and shall
not be presented for action at the Annual Meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) Except as otherwise required by law, nothing in this Article I,
Section&nbsp;2 shall obligate the Corporation or the Board of Directors to include in any proxy statement or other stockholder communication distributed on behalf of the Corporation or the Board of Directors information with respect to any nominee
for director or any other matter of business submitted by a stockholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) Notwithstanding the foregoing provisions of this Article I,
Section&nbsp;2, if the nominating or proposing stockholder (or a qualified representative of the stockholder) does not appear at the Annual Meeting to present a nomination or any business, such nomination or business shall be disregarded,
notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Article I, Section&nbsp;2, to be considered a qualified representative of the proposing stockholder, a person must be authorized by
a written instrument executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders, and such person must produce such written instrument or electronic
transmission, or a reliable reproduction of the written instrument or electronic transmission, to the chair of the meeting at the meeting of stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) For purposes of this Bylaw, &#8220;public announcement&#8221; shall mean disclosure in a press release reported by the Dow
Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section&nbsp;13, 14 or 15(d) of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) Notwithstanding the foregoing provisions of this Bylaw, a stockholder shall also comply with all applicable requirements of
the Exchange Act and the rules and regulations thereunder, including, but not limited to, Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> of the Exchange Act, with respect to the matters set forth in this Bylaw. If a stockholder fails to comply
with any applicable requirements of the Exchange Act, including, but not limited to, Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> promulgated thereunder, such stockholder&#8217;s proposed nomination or proposed business shall be deemed to
have not been made in compliance with this Bylaw and shall be disregarded. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(6) Further notwithstanding the foregoing
provisions of this Bylaw, unless otherwise required by law, (i)&nbsp;no Proposing Person shall solicit proxies in support of director nominees other than the Corporation&#8217;s nominees unless such Proposing Person has complied with Rule <FONT
STYLE="white-space:nowrap">14a-19</FONT> promulgated under the Exchange Act in connection with the solicitation of such proxies, including the provision to the Corporation of notices required thereunder with timely notice and (ii)&nbsp;if any
Proposing Person (A)&nbsp;provides notice pursuant to Rule <FONT STYLE="white-space:nowrap">14a-19(b)</FONT> promulgated under the Exchange Act, (B)&nbsp;subsequently fails to comply with the requirements of Rule
<FONT STYLE="white-space:nowrap">14a-19(a)(2)</FONT> or Rule <FONT STYLE="white-space:nowrap">14a-19(a)(3)</FONT> promulgated under the Exchange Act, including the provision to the Corporation of notices required thereunder with timely notice and
(C)&nbsp;no other Proposing Person has provided notice pursuant to, and in compliance with, Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> under the Exchange Act that it intends to solicit proxies in support of the election of such proposed
nominee in accordance with Rule <FONT STYLE="white-space:nowrap">14a-19(b)</FONT> under the Exchange Act, then such proposed nominee shall be disqualified from nomination, the Corporation shall disregard the nomination of such proposed nominee and
no vote on the election of such proposed nominee shall occur. Upon request by the Corporation, if any Proposing Person provides notice pursuant to Rule <FONT STYLE="white-space:nowrap">14a-19(b)</FONT> promulgated under the Exchange Act, such
Proposing Person shall deliver to the Corporation, no later than five (5)&nbsp;business days prior to the applicable meeting date, reasonable evidence that it has met the requirements of Rule <FONT STYLE="white-space:nowrap">14a-19(a)(3)</FONT>
promulgated under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(7) The number of nominees a stockholder may nominate for election at the
Annual Meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the Annual Meeting on behalf of such beneficial owner) shall not exceed the number
of directors to be elected at such Annual Meeting. A stockholder may not designate any substitute nominees unless the stockholder provides timely notice of such substitute nominee(s) in accordance with these
<FONT STYLE="white-space:nowrap">By-laws</FONT> (and such notice contains all of the information, representations, questionnaires and certifications with respect to such substitute nominee(s) that are required by the
<FONT STYLE="white-space:nowrap">By-laws</FONT> with respect to nominees for director). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Special Meetings</U>. Except as
otherwise required by statute and subject to the rights, if any, of the holders of any series of Preferred Stock, special meetings of the stockholders of the Corporation may be called only by or at the direction of the Board of Directors. The Board
of Directors may postpone or reschedule any previously scheduled special meeting of stockholders. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the
Corporation. Nominations of persons for election to the Board of Directors and stockholder proposals of other business shall not be brought before a special meeting of stockholders to be considered by the stockholders unless such special meeting is
held in lieu of an annual meeting of stockholders in accordance with Article I, Section&nbsp;1 of these Bylaws, in which case such special meeting in lieu thereof shall be deemed an Annual Meeting for purposes of these Bylaws and the provisions of
Article I, Section&nbsp;2 of these Bylaws shall govern such special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. Notice of Meetings; Adjournments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A notice of each Annual Meeting stating the hour, date and place, if any, of such Annual Meeting, the means of remote communication, if
any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for
determining stockholders entitled to notice of the meeting, shall be given not less than ten (10)&nbsp;days nor more than sixty (60)&nbsp;days before the Annual Meeting, to each stockholder entitled to vote thereat by delivering such notice to such
stockholder or by mailing it, postage prepaid, addressed to such stockholder at the address of such stockholder as it appears on the Corporation&#8217;s stock transfer books. Without limiting the manner by which notice may otherwise be given to
stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section&nbsp;232 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notice of all special meetings of stockholders shall be given in the same manner as provided for Annual Meetings, except that the notice
of all special meetings shall also state the purpose or purposes for which the meeting has been called. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notice of an Annual Meeting
or special meeting of stockholders need not be given to a stockholder if a waiver of notice is executed, or waiver of notice by electronic transmission is provided, before or after such meeting by such stockholder or if such stockholder attends such
meeting, unless such attendance is for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting was not lawfully called or convened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Board of Directors may postpone and reschedule or cancel any previously scheduled
Annual Meeting or special meeting of stockholders and any record date with respect thereto, regardless of whether any notice or public disclosure with respect to any such meeting has been sent or made pursuant to Section&nbsp;2 of this
Article&nbsp;I or otherwise. In no event shall the public announcement of an adjournment, postponement or rescheduling of any previously scheduled meeting of stockholders commence a new time period for the giving of a stockholder&#8217;s notice
under this Article I. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) When any meeting is convened, the chair of the meeting or the stockholders present or represented by proxy at
such meeting may adjourn the meeting from time to time for any reason, regardless of whether a quorum is present, to reconvene at any other time and at any place at which a meeting of stockholders may be held under these Bylaws. When any Annual
Meeting or special meeting of stockholders is adjourned to another hour, date or place (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), notice need not be given of the
adjourned meeting if the time, place, if any, thereof and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are (i)&nbsp;announced at the
meeting at which the adjournment is taken, (ii)&nbsp;displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or
(iii)&nbsp;set forth in the notice of meeting given in accordance with this Section&nbsp;4; provided, however, that if the adjournment is for more than thirty (30)&nbsp;days from the meeting date, or if after the adjournment a new record date is
fixed for the adjourned meeting, notice of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting shall be given to each
stockholder of record entitled to vote thereat and each stockholder who, by law or under the Certificate of Incorporation of the Corporation (as the same may hereafter be amended and/or restated, the &#8220;Certificate&#8221;) or these Bylaws, is
entitled to such notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Quorum</U>. Except as otherwise provided by law, the certificate of incorporation or these Bylaws,
at each meeting of stockholders, the presence in person or by remote communication, if applicable, or represented by proxy, of the holders of a majority in voting power of the outstanding shares of stock entitled to vote at the meeting shall be
necessary and sufficient to constitute a quorum. If less than a quorum is present at a meeting, the chair of the meeting or the holders of voting stock, by the affirmative vote of a majority of the voting power present in person or by proxy and
entitled to vote thereon, may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice, except as otherwise provided in Section&nbsp;4 of this Article&nbsp;I. At such adjourned meeting at which a quorum
is present, any business may be transacted which might have been transacted at the meeting as originally noticed. The stockholders present at a duly constituted meeting may continue to transact business until adjournment, notwithstanding the
withdrawal of enough stockholders to leave less than a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. Voting and Proxies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The stockholders entitled to vote at any meeting of stockholders shall be determined in
accordance with the provisions of Article IV, Section&nbsp;4<B> </B>of these Bylaws, subject to Section&nbsp;217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section&nbsp;218 (relating to voting trusts and other
voting agreements) of the DGCL. Stockholders shall have one vote for each share of stock entitled to vote owned by them of record according to the stock ledger of the Corporation as of the record date, unless otherwise provided by law or by the
Certificate. Stockholders may vote either (i)&nbsp;in person, (ii)&nbsp;by written proxy or (iii)&nbsp;by a transmission permitted by Section&nbsp;212(c) of the DGCL. Any copy, facsimile telecommunication or other reliable reproduction of the
writing or transmission permitted by Section&nbsp;212(c) of the DGCL may be substituted for or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that
such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission. Proxies shall be filed in accordance with the procedures established for the meeting of stockholders. A
proxy with respect to stock held in the name of two or more persons shall be valid if executed by or on behalf of any one of them unless at or prior to the exercise of the proxy the Corporation receives a specific written notice to the contrary from
any one of them. In the event the Corporation receives proxies for disqualified or withdrawn nominees for the Board of Directors, such votes for such disqualified or withdrawn nominees in the proxies will be treated as abstentions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which
shall be reserved for the exclusive use by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Action at Meeting</U>. When a quorum is present at any
meeting of stockholders, any matter before any such meeting (other than an election of a director or directors) shall be decided by a majority of the votes properly cast for and against such matter, except where a larger vote is required by law, by
the Certificate or by these Bylaws. Any election of directors by stockholders shall be determined by a plurality of the votes properly cast on the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Stockholder Lists</U>. The Corporation shall prepare, no later than the tenth
(10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day before each Annual Meeting or special meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the
address of each stockholder and the number of shares registered in the name of each stockholder; provided, however, that if the record date for determining the stockholders entitled to vote is less than ten (10)&nbsp;days before the meeting date,
the list shall reflect the stockholders entitled to vote as of the tenth (10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day before the meeting date. Such list shall be open to the examination of any stockholder for any purpose germane
to the meeting for a period of ten (10)&nbsp;days ending on the day before the meeting date in the manner provided by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Conduct of Meeting</U>. The Board of Directors may adopt by resolution such
rules, regulations and procedures for the conduct of any meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with rules, regulations and procedures adopted by the Board of Directors, the chair of the meeting shall
have the right to prescribe such rules, regulations and procedures and to do all such acts, as, in the judgment of such chair, are necessary, appropriate or convenient for the proper conduct of the meeting. Such rules, regulations or procedures,
whether adopted by the Board of Directors or the chair of the meeting, may include, without limitation, the following: (a)&nbsp;the establishment of an agenda for the meeting; (b)&nbsp;rules and procedures for maintaining order at the meeting and
the safety of those present at the meeting; (c)&nbsp;limitations on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies, or such other persons as the chair of the
meeting shall determine; (d)&nbsp;restrictions on entry to the meeting after the time fixed for the commencement thereof; (e)&nbsp;the determination of the circumstances in which any person may make a statement or ask questions and limitations on
the time allotted to questions or comments; (f)&nbsp;the determination of when the polls shall open and close for any given matter to be voted on at the meeting; (g)&nbsp;the exclusion or removal of any stockholders or any other individual who
refuses to comply with meeting rules, regulations, or procedures; (h)&nbsp;restrictions on the use of audio and video recording devices, cell phones and other electronic devices; (i)&nbsp;rules, regulations and procedures for compliance with any
federal, state or local laws or regulations (including those concerning safety, health or security); (j) procedures (if any) requiring attendees to provide the Corporation advance notice of their intent to attend the meeting; and (k)&nbsp;rules,
regulations or procedures regarding the participation by means of remote communication of stockholders and proxy holders not physically present at a meeting, whether such meeting is to be held at a designated place or solely by means of remote
communication. The chair of the meeting shall be: (i)&nbsp;such person as the Board of Directors shall have designated to preside over all meetings of the stockholders; (ii)&nbsp;if the Board of Directors has not so designated such a chair of the
meeting or if the chair of the meeting is unable to so preside or is absent, then the Chairperson of the Board, if one is elected; (iii)&nbsp;if the Board of Directors has not so designated a chair of the meeting and there is no Chairperson of the
Board, or if the chair of the meeting or the Chairperson of the Board is unable to so preside or is absent, then the Chief Executive Officer, if one is elected; or (iv)&nbsp;in the absence or inability to serve of any of the aforementioned persons,
the President of the Corporation. Unless and to the extent determined by the Board of Directors or the chair of the meeting, the chair of the meeting shall not be obligated to adopt or follow any technical, formal or parliamentary rules or
principles of procedure. In the absence of the Secretary of the Corporation, the secretary of the meeting shall be such person as the chair of the meeting appoints. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Inspectors of Elections</U>. The Corporation shall, in advance of any meeting of stockholders, appoint one or three inspectors
to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders,
the chair of the meeting officer shall appoint one or more inspectors to act at the meeting. Any inspector may, but need not, be an officer, employee or agent of the Corporation. Each inspector, before entering upon the discharge of his or her
duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspectors shall perform such duties as are required by the DGCL, including the counting
of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors. The chair of the meeting may review all determinations made by the inspectors, and
in so doing the chair of the meeting shall be entitled to exercise his or her sole judgment and discretion and he or she shall not be bound by any determinations made by the inspectors. All determinations by the inspectors and, if applicable, the
chair of the meeting, shall be subject to further review by any court of competent jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE II </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Directors </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.
<U>Powers</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors, except as otherwise provided by the Certificate or required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Number and Terms</U>. The number of directors of the Corporation shall be fixed solely and exclusively by resolution duly
adopted from time to time by the Board of Directors, provided the Board of Directors shall consist of at least one (1)&nbsp;member. The directors shall hold office in the manner provided in the Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Qualification</U>. No director need be a stockholder of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Vacancies</U>. Vacancies in the Board of Directors shall be filled in the manner provided in the Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Removal</U>. Directors may be removed from office only in the manner provided in the Certificate or by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Resignation</U>. A director may resign at any time by electronic transmission or by giving written notice to the Chairperson of
the Board, if one is elected, the President or the Secretary. A resignation shall be effective upon receipt, unless the resignation otherwise provides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Regular Meetings</U>. Regular meetings of the Board of Directors may be held at such hour, date and place (if any) as the Board
of Directors may from time to time determine and publicize by means of reasonable notice given to any director who is not present when such determination is made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Special Meetings</U>. Special meetings of the Board of Directors may be called, orally or in writing, by or at the request of a
majority of the directors, the Chairperson of the Board, if one is elected, or the President. The person calling any such special meeting of the Board of Directors may fix the hour, date and place (if any) thereof. Notice thereof shall be given to
each director as provided in Section&nbsp;9 of this Article II. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Notice of Meetings</U>. Notice of the hour, date and place
(if any) of all special meetings of the Board of Directors shall be given to each director by the Secretary or an Assistant Secretary, or in case of the death, absence, incapacity or refusal of such persons, by the Chairperson of the Board, if one
is elected, the President or such other officer designated by the Chairperson of the Board, if one is elected, or any one of the directors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
calling the meeting. Notice of any special meeting of the Board of Directors shall be given to each director in person, by telephone, or by facsimile, electronic mail or other form of electronic
communication, sent to his or her business or home address, at least twenty-four (24)&nbsp;hours in advance of the meeting, or by written notice mailed to his or her business or home address, at least forty-eight (48)&nbsp;hours in advance of the
meeting provided, however, that if the person or persons calling the meeting determine that it is otherwise necessary or advisable to hold the meeting sooner, then such person or persons may prescribe a shorter time period for notice to be given
personally or by telephone, facsimile, electronic mail or other similar means of communication. Such notice shall be deemed to be delivered when hand-delivered to such address; read to such director by telephone; deposited in the mail so addressed,
with postage thereon prepaid, if mailed; or dispatched or transmitted if sent by facsimile transmission or by electronic mail or other form of electronic communication. A written waiver of notice signed or electronically transmitted before or after
a meeting by a director and filed with the records of the meeting shall be deemed to be equivalent to notice of the meeting. The attendance of a director at a meeting shall constitute a waiver of notice of such meeting, except where a director
attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because such meeting is not lawfully called or convened. Except as otherwise required by law, by the Certificate or by these
Bylaws, neither the business to be transacted at, nor the purpose of, any meeting of the Board of Directors need be specified in the notice or waiver of notice of such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Quorum</U>. At any meeting of the Board of Directors, a majority of the total number of directors shall constitute a quorum for
the transaction of business, but if less than a quorum is present at a meeting, a majority of the directors present may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice. Any business that might
have been transacted at the meeting as originally noticed may be transacted at such adjourned meeting at which a quorum is present. For purposes of this Article II, the total number of directors includes any unfilled vacancies on the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Action at Meeting</U>. At any meeting of the Board of Directors at which a quorum is present, the affirmative
vote of a majority of the directors present shall constitute action by the Board of Directors, unless otherwise required by law, by the Certificate or by these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>Action by Consent</U>. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken
without a meeting if all members of the Board of Directors consent thereto in writing or by electronic transmission. After such action is taken, the writing or writings or electronic transmission or transmissions shall be filed with the records of
the meetings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. Such consent shall be treated as a resolution of
the Board of Directors for all purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>Manner of Participation</U>. Directors may participate in meetings of the
Board of Directors by means of video conference, conference telephone or other communications equipment by means of which all directors participating in the meeting can hear each other, and participation in a meeting in accordance herewith shall
constitute presence in person at such meeting for purposes of these Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>Presiding Director</U>. The Board of Directors
shall designate a representative to preside over all meetings of the Board of Directors, provided that if the Board of Directors does not so designate such a presiding director or such designated presiding director is unable to so preside or is
absent, then the Chairperson of the Board, if one is elected, shall preside over all meetings of the Board of Directors. If both the designated presiding director, if one is so designated, and the Chairperson of the Board, if one is elected, are
unable to preside or are absent, the Board of Directors shall designate an alternate representative to preside over a meeting of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>Committees</U>. The Board of Directors may designate one or more committees, including, without limitation, a Compensation
Committee, a Nominating&nbsp;&amp; Corporate Governance Committee and an Audit Committee, and may delegate thereto some or all of its powers to such committee(s) except those which by law, by the Certificate or by these Bylaws may not be delegated.
Except as the Board of Directors may otherwise determine, any such committee may make rules for the conduct of its business, but unless otherwise provided by the Board of Directors or in such rules, its business shall be conducted so far as possible
in the same manner as is provided by these Bylaws for the Board of Directors. All members of such committees shall hold such offices at the pleasure of the Board of Directors. The Board of Directors may abolish any such committee at any time. Any
committee to which the Board of Directors delegates any of its powers or duties shall keep records of its meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16.
<U>Compensation of Directors</U>. Directors shall receive such compensation for their services as shall be determined by the Board of Directors, or a designated committee thereof, provided that directors who are serving the Corporation as employees
shall not receive any salary or other compensation for their services as directors of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 17. <U>Emergency <FONT
STYLE="white-space:nowrap">By-laws</FONT></U>. In the event of any emergency, disaster, catastrophe or other similar emergency condition of a type described in Section&nbsp;110(a) of the DGCL (an &#8220;Emergency&#8221;), notwithstanding any
different or conflicting provisions in the DGCL, the Certificate or these <FONT STYLE="white-space:nowrap">By-laws,</FONT> during such Emergency: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A meeting of the Board of Directors or a committee thereof may be called by any director, the Chairperson of the Board, the Chief
Executive Officer, the President or the Secretary by such means as, in the judgment of the person calling the meeting, may be feasible at the time, and notice of any such meeting of the Board of Directors or any committee may be given, in the
judgment of the person calling the meeting, only to such directors as it may be feasible to reach at the time and by such means as may be feasible at the time. Such notice shall be given at such time in advance of the meeting as, in the judgment of
the person calling the meeting, circumstances permit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The director or directors in attendance at a meeting called in accordance with
Section&nbsp;17(a) of this Article II shall constitute a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) No officer, director or employee acting in accordance with this
Section&nbsp;17 shall be liable except for willful misconduct. No amendment, repeal or change to this Section&nbsp;17 shall modify the prior sentence with regard to actions taken prior to the time of such amendment, repeal or change. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE III </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Officers
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Enumeration</U>. The officers of the Corporation shall consist of a President, a Treasurer, a Secretary and such other
officers, including, without limitation, a Chairperson of the Board, a Chief Executive Officer and one or more Vice Presidents (including Executive Vice Presidents or Senior Vice Presidents), Assistant Vice Presidents, Assistant Treasurers and
Assistant Secretaries, as the Board of Directors may determine. Any number of offices may be held by the same person. The salaries and other compensation of the officers of the Corporation will be fixed by or in the manner designated by the Board of
Directors or a committee thereof to which the Board of Directors has delegated such responsibility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Election</U>. The Board
of Directors shall elect the President, the Treasurer and the Secretary. Other officers may be elected by the Board of Directors or by such officers delegated such authority by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Qualification</U>. No officer need be a stockholder or a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Tenure</U>. Except as otherwise provided by the Certificate or by these Bylaws, each of the officers of the Corporation shall
hold office until his or her successor is elected and qualified or until his or her earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.
<U>Resignation and Removal</U>. Any officer may resign by delivering his or her written or electronically transmitted resignation to the Corporation addressed to the President or the Secretary, and such resignation shall be effective upon receipt,
unless the resignation otherwise provides. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party. Except as otherwise provided by law or by resolution of the Board of
Directors, the Board of Directors may remove any officer. Except as the Board of Directors may otherwise determine, no officer who resigns or is removed shall have any right to any compensation as an officer for any period following his or her
resignation or removal, or any right to damages on account of such removal, whether his or her compensation be by the month or by the year or otherwise, unless such compensation is expressly provided in a duly authorized written agreement with the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Absence or Disability</U>. In the event of the absence or disability of any officer, the Board of Directors
may designate another officer to act temporarily in place of such absent or disabled officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Vacancies</U>. Any vacancy in any office may be filled for the unexpired
portion of the term by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>President</U>. The President shall, subject to the direction of the Board of
Directors, have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9.
<U>Chairperson of the Board</U>. The Chairperson of the Board, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Chief Executive Officer</U>. The Chief Executive Officer, if one is elected, shall have such powers and shall perform such
duties as the Board of Directors may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Vice Presidents and Assistant Vice Presidents</U>. Any
Vice President (including any Executive Vice President or Senior Vice President) and any Assistant Vice President shall have such powers and shall perform such duties as the Board of Directors or the Chief Executive Officer may from time to time
designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>Treasurer and Assistant Treasurers</U>. The Treasurer shall, subject to the direction of the Board of Directors
and except as the Board of Directors or the Chief Executive Officer may otherwise provide, have general charge of the financial affairs of the Corporation and shall cause to be kept accurate books of account. The Treasurer shall have custody of all
funds, securities and valuable documents of the Corporation. He or she shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. Any Assistant Treasurer shall have such
powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13.
<U>Secretary and Assistant Secretaries</U>. The Secretary shall record all the proceedings of the meetings of the stockholders and the Board of Directors (including committees of the Board of Directors) in books kept for that purpose. In his or her
absence from any such meeting, a temporary secretary chosen at the meeting shall record the proceedings thereof. The Secretary shall have charge of the stock ledger (which may, however, be kept by any transfer or other agent of the Corporation). The
Secretary shall have custody of the seal of the Corporation, and the Secretary or an Assistant Secretary shall have authority to affix it to any instrument requiring it, and, when so affixed, the seal may be attested by his or her signature or that
of an Assistant Secretary. The Secretary shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. In the absence of the Secretary, any Assistant Secretary may perform
his or her duties and responsibilities. Any Assistant Secretary shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>Other Powers and Duties</U>. Subject to these Bylaws and to such limitations
as the Board of Directors may from time to time prescribe, the officers of the Corporation shall each have such powers and duties as generally pertain to their respective offices, as well as such powers and duties as from time to time may be
conferred by the Board of Directors or the Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>Representation of Shares of Other Corporations</U>.
The Chairperson of the Board, the President, any Vice President, the Treasurer, the Secretary or Assistant Secretary of this Corporation, or any other person authorized by the Board of Directors or the President or a Vice President, is authorized to
vote, represent and exercise on behalf of this Corporation all rights incident to any and all securities of any other entity or entities standing in the name of this Corporation. The authority granted herein may be exercised either by such person
directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16. <U>Bonded Officers</U>. The Board of Directors may require any officer to give the Corporation a bond in such sum and with such
surety or sureties as shall be satisfactory to the Board of Directors upon such terms and conditions as the Board of Directors may specify, including, without limitation, a bond for the faithful performance of his or her duties and for the
restoration to the Corporation of all property in his or her possession or under his or her control belonging to the Corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE IV </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Capital
Stock </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Certificates of Stock</U>. Each stockholder shall be entitled to a certificate of the capital stock of the
Corporation in such form as may from time to time be prescribed by the Board of Directors. Such certificate shall be signed by any two authorized officers of the Corporation. The Corporation seal and the signatures by the Corporation&#8217;s
officers, the transfer agent or the registrar may be facsimiles. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed on such certificate shall have ceased to be such officer, transfer agent or
registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the time of its issue. Every certificate for shares of stock which are subject to
any restriction on transfer and every certificate issued when the Corporation is authorized to issue more than one class or series of stock shall contain such legend with respect thereto as is required by law. Notwithstanding anything to the
contrary provided in these Bylaws, the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares (except that the foregoing shall not apply to shares
represented by a certificate until such certificate is surrendered to the Corporation), and by the approval and adoption of these Bylaws, the Board of Directors has determined that all classes or series of the Corporation&#8217;s stock may be
uncertificated, whether upon original issuance, <FONT STYLE="white-space:nowrap">re-issuance</FONT> or subsequent transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Transfers</U>. Subject to any restrictions on transfer and unless otherwise
provided by the Board of Directors, shares of stock that are represented by a certificate may be transferred on the books of the Corporation by the surrender to the Corporation or its transfer agent of the certificate therefor properly endorsed or
accompanied by a written assignment or power of attorney properly executed, with transfer stamps (if necessary) affixed, and with such proof of the authenticity of signature as the Corporation or its transfer agent may reasonably require. Shares of
stock that are not represented by a certificate may be transferred on the books of the Corporation by submitting to the Corporation or its transfer agent such evidence of transfer and following such other procedures as the Corporation or its
transfer agent may require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Stock Transfer Agreements</U>. The Corporation shall have power to enter into and perform any
agreement with any number of stockholders of any one or more classes of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the
DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Record Holders</U>. Except as may otherwise be required by law, by the Certificate or by these Bylaws, the
Corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect thereto, regardless of any transfer, pledge or
other disposition of such stock, until the shares have been transferred on the books of the Corporation in accordance with the requirements of these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Record Date</U>. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of
stockholders or any adjournment thereof or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose
of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date: (a)&nbsp;in the case
of determination of stockholders entitled to vote at any meeting of stockholders, shall, unless otherwise required by law, not be more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting and (b)&nbsp;in the case of
any other action, shall not be more than sixty (60)&nbsp;days prior to such other action. If no record date is fixed: (i)&nbsp;the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at
5:00 p.m. Eastern time on the day next preceding the day on which notice is given, or, if notice is waived, at 5:00 p.m. Eastern time on the day next preceding the day on which the meeting is held; and (ii)&nbsp;the record date for determining
stockholders for any other purpose shall be 5:00 p.m. Eastern time on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Replacement of Certificates</U>. In case of the alleged loss, destruction or mutilation of a certificate of stock of the
Corporation, a duplicate certificate may be issued in place thereof, upon such terms as the Board of Directors may prescribe. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE V </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Indemnification </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
1. <U>Definitions</U>. For purposes of this Article V: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#8220;Corporate Status&#8221; describes the status of a person who is serving
or has served (i)&nbsp;as a Director of the Corporation, (ii)&nbsp;as an Officer of the Corporation, (iii)&nbsp;as a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee of the Corporation or (iv)&nbsp;as a director, partner, trustee,
officer, employee or agent of any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan, foundation, association, organization or other legal entity which such person is or was serving at the request
of the Corporation. For purposes of this Section&nbsp;1(a), a Director, Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee of the Corporation who is serving or has served as a director, partner, trustee, officer, employee or
agent of a Subsidiary shall be deemed to be serving at the request of the Corporation. Notwithstanding the foregoing, &#8220;Corporate Status&#8221; shall not include the status of a person who is serving or has served as a director, officer,
employee or agent of a constituent corporation absorbed in a merger or consolidation transaction with the Corporation with respect to such person&#8217;s activities prior to said transaction, unless specifically authorized by the Board of Directors
or the stockholders of the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#8220;Director&#8221; means any person who serves or has served the Corporation as a
director on the Board of Directors of the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#8220;Disinterested Director&#8221; means, with respect to each Proceeding in
respect of which indemnification is sought hereunder, a Director of the Corporation who is not and was not a party to such Proceeding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#8220;Expenses&#8221; means all attorneys&#8217; fees, retainers, court costs, transcript costs, fees of expert witnesses, private
investigators and professional advisors (including, without limitation, accountants and investment bankers), travel expenses, duplicating costs, printing and binding costs, costs of preparation of demonstrative evidence and other courtroom
presentation aids and devices, costs incurred in connection with document review, organization, imaging and computerization, telephone charges, postage, delivery service fees, and all other disbursements, costs or expenses of the type customarily
incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settling or otherwise participating in, a Proceeding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#8220;Liabilities&#8221; means judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <FONT STYLE="white-space:nowrap">&#8220;Non-Officer</FONT> Employee&#8221; means any person who serves or has served as an employee
or agent of the Corporation, but who is not or was not a Director or Officer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#8220;Officer&#8221; means any person who serves or
has served the Corporation as an officer of the Corporation appointed by the Board of Directors of the Corporation; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#8220;Proceeding&#8221; means any threatened, pending or completed action, suit,
arbitration, alternate dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or investigative; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#8220;Subsidiary&#8221; means any corporation, partnership, limited liability company, joint venture, trust or other entity of which the
Corporation owns (either directly or through or together with another Subsidiary of the Corporation) either (i)&nbsp;a general partner, managing member or other similar interest or (ii)&nbsp;(A) fifty percent (50%) or more of the voting power of the
voting capital equity interests of such corporation, partnership, limited liability company, joint venture or other entity, or (B)&nbsp;fifty percent (50%) or more of the outstanding voting capital stock or other voting equity interests of such
corporation, partnership, limited liability company, joint venture or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. Indemnification of Directors and Officers.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the operation of Section&nbsp;4 of this Article V, each Director and Officer shall be indemnified and held harmless by the
Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification
rights than such law permitted the Corporation to provide prior to such amendment), and to the extent authorized in this Section&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) <U>Actions, Suits and Proceedings Other than By or In the Right of the Corporation</U>. Each Director and Officer shall be
indemnified and held harmless by the Corporation against any and all Expenses and Liabilities that are incurred or paid by such Director or Officer or on such Director&#8217;s or Officer&#8217;s behalf in connection with any Proceeding or any claim,
issue or matter therein (other than an action by or in the right of the Corporation), which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director&#8217;s or Officer&#8217;s Corporate
Status, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable
cause to believe his or her conduct was unlawful. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) <U>Actions, Suits and Proceedings By or In the Right of the
Corporation</U>. Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses that are incurred by such Director or Officer or on such Director&#8217;s or Officer&#8217;s behalf in connection with
any Proceeding or any claim, issue or matter therein by or in the right of the Corporation, which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director&#8217;s or Officer&#8217;s Corporate
Status, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation; provided, however, that no indemnification shall be made under
this Section&nbsp;2(a)(2) in respect of any claim, issue or matter as to which such Director or Officer shall have been finally adjudged by a court of competent jurisdiction to be liable to the Corporation, unless, and only to the extent that, the
Court of Chancery of the State of Delaware or another court in which such Proceeding was brought shall determine upon application that, despite adjudication of liability, but in view of all the circumstances of the case, such Director or Officer is
fairly and reasonably entitled to indemnification for such Expenses that such court deems proper.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) <U>Survival of Rights</U>. The rights of indemnification provided by
this Section&nbsp;2 shall continue as to a Director or Officer after he or she has ceased to be a Director or Officer and shall inure to the benefit of his or her heirs, executors, administrators and personal representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) <U>Actions by Directors or Officers</U>. Notwithstanding the foregoing, the Corporation shall indemnify any Director or
Officer seeking indemnification in connection with a Proceeding initiated by such Director or Officer only if such Proceeding (including any parts of such Proceeding not initiated by such Director or Officer) was authorized in advance by the Board
of Directors, unless such Proceeding was brought to enforce such Officer&#8217;s or Director&#8217;s rights to indemnification or, in the case of Directors, advancement of Expenses under these Bylaws in accordance with the provisions set forth
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Indemnification of <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employees</U>. Subject to the operation of
Section&nbsp;4 of this Article V, each <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee may, in the discretion of the Board of Directors, be indemnified by the Corporation to the fullest extent authorized by the DGCL, as the same exists
or may hereafter be amended, against any or all Expenses and Liabilities that are incurred by such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee or on such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee&#8217;s behalf in
connection with any threatened, pending or completed Proceeding, or any claim, issue or matter therein, which such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee is, or is threatened to be made, a party to or participant in by reason
of such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee&#8217;s Corporate Status, if such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee acted in good faith and in a manner such
<FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was
unlawful. The rights of indemnification provided by this Section&nbsp;3 shall exist as to a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee after he or she has ceased to be a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee
and shall inure to the benefit of his or her heirs, personal representatives, executors and administrators. Notwithstanding the foregoing, the Corporation may indemnify any <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee seeking
indemnification in connection with a Proceeding initiated by such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee only if such Proceeding was authorized in advance by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Determination</U>. Unless ordered by a court, no indemnification shall be provided pursuant to this Article V to a Director, to
an Officer or to a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee unless a determination shall have been made that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best
interests of the Corporation and, with respect to any criminal Proceeding, such person had no reasonable cause to believe his or her conduct was unlawful. Such determination shall be made by (a)&nbsp;a majority vote of the Disinterested Directors,
even though less than a quorum of the Board of Directors, (b)&nbsp;a committee comprised of Disinterested Directors, such committee having been designated by a majority vote of the Disinterested Directors (even though less than a quorum), (c) if
there are no such Disinterested Directors, or if a majority of Disinterested Directors so directs, by independent legal counsel in a written opinion or (d)&nbsp;by the stockholders of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. Advancement of Expenses to Directors Prior to Final Disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall advance all Expenses incurred by or on behalf of any Director in connection with any Proceeding in which such
Director is involved by reason of such Director&#8217;s Corporate Status within thirty (30)&nbsp;days after the receipt by the Corporation of a written statement from such Director requesting such advance or advances from time to time, whether prior
to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Director and shall be preceded or accompanied by an undertaking by or on behalf of such Director to repay any
Expenses so advanced if it shall ultimately be determined that such Director is not entitled to be indemnified against such Expenses. Notwithstanding the foregoing, the Corporation shall advance all Expenses incurred by or on behalf of any Director
seeking advancement of expenses hereunder in connection with a Proceeding initiated by such Director only if such Proceeding (including any parts of such Proceeding not initiated by such Director) was (i)&nbsp;authorized by the Board of Directors or
(ii)&nbsp;brought to enforce such Director&#8217;s rights to indemnification or advancement of Expenses under these Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If a
claim for advancement of Expenses hereunder by a Director is not paid in full by the Corporation within thirty (30)&nbsp;days after receipt by the Corporation of documentation of Expenses and the required undertaking, such Director may at any time
thereafter bring suit against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, such Director shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation
(including its Board of Directors or any committee thereof, independent legal counsel or stockholders) to make a determination concerning the permissibility of such advancement of Expenses under this Article V shall not be a defense to an action
brought by a Director for recovery of the unpaid amount of an advancement claim and shall not create a presumption that such advancement is not permissible. The burden of proving that a Director is not entitled to an advancement of expenses shall be
on the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an
undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Director has not met any applicable standard for indemnification set forth in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. Advancement of Expenses to Officers and <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employees Prior to Final Disposition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Corporation may, at the discretion of the Board of Directors, advance any or all Expenses incurred by or on behalf of any Officer
or any <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee in connection with any Proceeding in which such person is involved by reason of his or her Corporate Status as an Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT>
Employee upon the receipt by the Corporation of a statement or statements from such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee requesting such advance or advances from time to time, whether prior to or after final
disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee and shall be preceded or accompanied by an undertaking by or
on behalf of such person to repay any Expenses so advanced if it shall ultimately be determined that such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee is not entitled to be indemnified against such Expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In any suit brought by the Corporation to recover an advancement of expenses pursuant to
the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee has not met any applicable standard for
indemnification set forth in the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. Contractual Nature of Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The provisions of this Article&nbsp;V shall be deemed to be a contract between the Corporation and each Director and Officer entitled to
the benefits hereof at any time while this Article&nbsp;V is in effect, in consideration of such person&#8217;s past or current and any future performance of services for the Corporation. Neither amendment, repeal or modification of any provision of
this Article&nbsp;V nor the adoption of any provision of the Certificate inconsistent with this Article&nbsp;V shall eliminate or reduce any right conferred by this Article&nbsp;V in respect of any act or omission occurring, or any cause of action
or claim that accrues or arises or any state of facts existing, at the time of or before such amendment, repeal, modification or adoption of an inconsistent provision (even in the case of a proceeding based on such a state of facts that is commenced
after such time), and all rights to indemnification and advancement of Expenses granted herein or arising out of any act or omission shall vest at the time of the act or omission in question, regardless of when or if any proceeding with respect to
such act or omission is commenced. The rights to indemnification and to advancement of expenses provided by, or granted pursuant to, this Article&nbsp;V shall continue notwithstanding that the person has ceased to be a director or officer of the
Corporation and shall inure to the benefit of the estate, heirs, executors, administrators, legatees and distributees of such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
If a claim for indemnification hereunder by a Director or Officer is not paid in full by the Corporation within sixty (60)&nbsp;days after receipt by the Corporation of a written claim for indemnification, such Director or Officer may at any time
thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, such Director or Officer shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the
Corporation (including its Board of Directors or any committee thereof, independent legal counsel or stockholders) to make a determination concerning the permissibility of such indemnification under this Article V shall not be a defense to an action
brought by a Director or Officer for recovery of the unpaid amount of an indemnification claim and shall not create a presumption that such indemnification is not permissible. The burden of proving that a Director or Officer is not entitled to
indemnification shall be on the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In any suit brought by a Director or Officer to enforce a right to indemnification
hereunder, it shall be a defense that such Director or Officer has not met any applicable standard for indemnification set forth in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U><FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights</U>. The rights to indemnification and to advancement of
Expenses set forth in this Article V shall not be exclusive of any other right that any Director, Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee may have or hereafter acquire under any statute, provision of the Certificate
or these Bylaws, agreement, vote of stockholders or Disinterested Directors or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Insurance</U>. The Corporation may maintain insurance, at its expense, to
protect itself and any Director, Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee against any liability of any character asserted against or incurred by the Corporation or any such Director, Officer or <FONT
STYLE="white-space:nowrap">Non-Officer</FONT> Employee, or arising out of any such person&#8217;s Corporate Status, whether or not the Corporation would have the power to indemnify such person against such liability under the DGCL or the provisions
of this Article&nbsp;V. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Other Indemnification</U>. The Corporation&#8217;s obligation, if any, to indemnify or provide
advancement of Expenses to any person under this Article V as a result of such person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust,
employee benefit plan or other enterprise shall be reduced by any amount such person may collect as indemnification or advancement of Expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or enterprise (the
&#8220;Primary Indemnitor&#8221;). Any indemnification or advancement of Expenses under this Article V owed by the Corporation as a result of a person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or
agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall only be in excess of, and shall be secondary to, the indemnification or advancement of Expenses available from the applicable Primary
Indemnitor(s) and any applicable insurance policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Savings Clause</U>. If this Article V or any portion hereof shall be
invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each indemnitee as to any expenses (including, without limitation, attorneys&#8217; fees), liabilities, losses, judgments, fines
(including, without limitation, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974, as amended) and amounts paid in settlement in connection with any action, suit, proceeding or investigation, whether civil,
criminal or administrative, including, without limitation, an action by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article V that shall not have been invalidated and to the fullest extent
permitted by applicable law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE VI </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Miscellaneous Provisions </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Fiscal Year</U>. The fiscal year of the Corporation shall be determined by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Seal</U>. The Board of Directors shall have power to adopt and alter the seal of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Execution of Instruments</U>. All deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by
the Corporation in the ordinary course of its business without director action may be executed on behalf of the Corporation by the Chairperson of the Board, if one is elected, the President or the Treasurer or any other officer, employee or agent of
the Corporation as the Board of Directors or an executive committee of the Board of Directors may authorize or determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Voting of Securities</U>. Unless the Board of Directors otherwise provides,
the Chairperson of the Board, if one is elected, the President or the Treasurer may waive notice of, and act on behalf of the Corporation, or appoint another person or persons to act as proxy or attorney in fact for the Corporation with or without
discretionary power and/or power of substitution, at any meeting of stockholders or stockholders of any other corporation or organization, any of whose securities are held by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Resident Agent</U>. The Board of Directors may appoint a resident agent upon whom legal process may be served in any action or
proceeding against the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Corporate Records</U>. The original or attested copies of the Certificate, Bylaws and
records of all meetings of the incorporators, stockholders and the Board of Directors and the stock transfer books, which shall contain the names of all stockholders, their record addresses and the amount of stock held by each, may be kept outside
the State of Delaware and shall be kept at the principal office of the Corporation, at an office of its counsel, at an office of its transfer agent or in such manner as may be permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Certificate</U>. All references in these Bylaws to the Certificate shall be deemed to refer to the Certificate, as amended
and/or restated and in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Exclusive Jurisdiction of Delaware Courts or the United States Federal
District Courts</U>. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought
on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of, or a claim based on, a breach of a fiduciary duty owed by any current or former director, officer or other employee or stockholder of the Corporation to the Corporation or the
Corporation&#8217;s stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the DGCL or the Certificate or these Bylaws (including the interpretation, validity or enforceability thereof) or as to which the DGCL
confers jurisdiction on the Court of Chancery of the State of Delaware or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine; provided, however, that this sentence will not apply to any causes of action arising under
the Securities Act of 1933, as amended, or the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts
of the United States of America shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Exchange Act, or the respective rules and regulations promulgated
thereunder. To the fullest extent permitted by law, any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this
Section&nbsp;8. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. Amendment of Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Amendment by Directors</U>. Except as otherwise required by law, these Bylaws may be amended or repealed by the Board of Directors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Amendment by Stockholders</U>. Except as otherwise provided herein, the Bylaws of the Corporation may be amended or repealed at
any annual meeting of stockholders, or at any special meeting of stockholders called for such purpose, by the affirmative vote of the holders of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the voting power of the
outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal at such meeting of
stockholders, such amendment or repeal shall only require the affirmative vote of the majority of outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Notices</U>. If mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed to
the stockholder at such stockholder&#8217;s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given to stockholders, any notice to stockholders may be given by electronic
transmission in the manner provided in Section&nbsp;232 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Waivers</U>. A written waiver of any notice, signed
by a stockholder or director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person.
Neither the business to be transacted at, nor the purpose of, any meeting need be specified in such a waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adopted April&nbsp;7, 2026, effective upon
the effectiveness of the <FONT STYLE="white-space:nowrap">S-1</FONT> registration statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>d73463dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g73463dsp69.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter <SMALL>LLP</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">620 Eighth
Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">New York, NY 10018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 617 570 1000</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">April 27, 2026 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seaport Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">101 Seaport Blvd </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seaport Boston, MA 02210 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Securities Registered under Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT></U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to you in connection with your filing of a Registration Statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-294976)</FONT> (as amended or supplemented, the &#8220;Registration Statement&#8221;) pursuant to the Securities Act of 1933, as amended (the
&#8220;Securities Act&#8221;), relating to the registration of the offering by Seaport Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), of up to 13,570,000 shares (the &#8220;Shares&#8221;) of the Company&#8217;s voting Common
Stock, $0.0001 par value per share, including Shares purchasable by the underwriters upon their exercise of an over-allotment option granted to the underwriters by the Company. The Shares are being sold to the several underwriters named in, and
pursuant to, an underwriting agreement among the Company and such underwriters (the &#8220;Underwriting Agreement&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have reviewed such
documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinions
set forth below, on certificates of officers of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinion set forth below is limited to the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered and paid for in accordance with the terms of the
Underwriting Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter and the
opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 <I>Business Lawyer</I> 815 (Summer 2019). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
hereby consent to the inclusion of this opinion as Exhibit&nbsp;5.1 to the Registration Statement and to the references to our firm under the caption &#8220;Legal Matters&#8221; in the Registration Statement. In giving our consent, we do not admit
that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seaport Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 27, 2026 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Goodwin Procter LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GOODWIN PROCTER <SMALL>LLP</SMALL></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>7
<FILENAME>d73463dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2026 STOCK OPTION AND INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>GENERAL PURPOSE OF THE PLAN; DEFINITIONS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the plan is the Seaport Therapeutics, Inc. 2026 Stock Option and Incentive Plan (the &#8220;Plan&#8221;). The purpose of the Plan
is to encourage and enable the officers, employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors and Consultants of Seaport Therapeutics, Inc. (the &#8220;Company&#8221;) and its Affiliates upon whose judgment, initiative and
efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company&#8217;s welfare will assure a closer
identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#8217;s behalf and strengthening their desire to remain with the Company or one of its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms shall be defined as set forth below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Act&#8221;</I> means the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Administrator&#8221;</I> means either the Board or the compensation committee of the Board or a similar committee performing the
functions of the compensation committee and which is comprised of not less than two <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors who are independent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<I>Affiliate</I>&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as
such terms are defined in Rule 405 of the Act. The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Award&#8221;</I> or <I>&#8220;Awards,&#8221;</I> except where referring to a particular category of grant under the Plan, shall
include Incentive Stock Options, <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent
Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Award Agreement&#8221;</I> means a written or electronic document setting forth the terms and provisions applicable to
an Award granted under the Plan. Each Award Agreement is subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Board&#8221;</I>
means the Board of Directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Cash-Based Award&#8221;</I> means an Award entitling the recipient to receive a
cash-denominated payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Code&#8221;</I> means the U.S. Internal Revenue Code of 1986, as amended, and any successor Code, and
related rules, regulations and interpretations. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Consultant&#8221;</I> means a consultant or adviser who provides <I>bona fide</I>
services to the Company or an Affiliate as an independent contractor and who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Dividend Equivalent Right&#8221;</I> means an Award entitling the grantee to receive credits based on ordinary cash dividends that
would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Effective Date&#8221;</I> means the date on which the Plan becomes effective as set forth in Section&nbsp;19. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Exchange Act&#8221;</I> means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Fair Market Value&#8221;</I> of the Stock on any given date means the fair market value of the Stock determined in good faith by the
Administrator; provided, however, that if the Stock is listed on the National Association of Securities Dealers Automated Quotation System (&#8220;Nasdaq&#8221;), Nasdaq Global Market, The New York Stock Exchange or another national securities
exchange or traded on any established market, the determination shall be made by reference to the closing price. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which
there is a closing price; provided further, however, that if the date for which Fair Market Value is determined is the Registration Date, the Fair Market Value shall be the &#8220;Price to the Public&#8221; (or equivalent) set forth on the cover
page for the final prospectus relating to the Company&#8217;s initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Incentive Stock Option&#8221;</I> means
any Stock Option designated and qualified as an &#8220;incentive stock option&#8221; as defined in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">&#8220;Non-Employee</FONT> Director&#8221;</I> means a member of the Board who is not also an employee of the Company or any Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">&#8220;Non-Qualified</FONT> Stock Option&#8221;</I> means any Stock Option that is not an Incentive Stock
Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Option&#8221;</I> or <I>&#8220;Stock Option&#8221;</I> means any option to purchase shares of Stock granted pursuant to
Section&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Outstanding Shares&#8221;</I> means, as of a specified date, the sum of (a)&nbsp;the number of shares of Stock
issued and outstanding and (b)&nbsp;the number of shares of Stock issuable pursuant to the exercise of any outstanding, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to acquire Stock for a nominal exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Registration Date&#8221; </I>means the date upon which the registration statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> that is filed by the Company with respect to its initial public offering is declared effective by the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Restricted Shares&#8221;</I> means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of
forfeiture or the Company&#8217;s right of repurchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Restricted Stock Award&#8221;</I> means an Award of Restricted Shares subject to
such restrictions and conditions as the Administrator may determine at the time of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Restricted Stock Units&#8221;</I>
means an Award of stock units subject to such restrictions and conditions as the Administrator may determine at the time of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Sale Event&#8221;</I> shall mean (i)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis
to an unrelated person or entity, (ii)&nbsp;a merger, reorganization or consolidation pursuant to which the holders of the Company&#8217;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of
the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii)&nbsp;the sale of all of the Stock of the
Company to an unrelated person, entity or group thereof acting in concert, or (iv)&nbsp;any other transaction in which the owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of
the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<I>Sale Price</I>&#8221; means the value as determined by the Administrator of the consideration payable, or otherwise to be received
by stockholders, per share of Stock pursuant to a Sale Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Section</I><I></I><I>&nbsp;409A&#8221;</I> means
Section&nbsp;409A of the Code and the regulations and other guidance promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Service Relationship&#8221;
</I>means any relationship as an employee, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or Consultant of the Company or any Affiliate. Unless as otherwise set forth in the Award Agreement, a Service Relationship shall be deemed to
continue without interruption in the event a grantee&#8217;s status changes from full-time employee to part-time employee or a grantee&#8217;s status changes from employee to Consultant or <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director or vice versa, provided that there is no interruption or other termination of Service Relationship in connection with the grantee&#8217;s change in capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Stock&#8221;</I> means the Common Stock, par value $0.0001 per share, of the Company, subject to adjustments pursuant to
Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Stock Appreciation Right&#8221;</I> means an Award entitling the recipient to receive shares of Stock (or cash,
to the extent explicitly provided for in the applicable Award Agreement) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the
number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Subsidiary&#8221;</I>
means any corporation or other entity (other than the Company) in which the Company has at least a 50&nbsp;percent interest, either directly or indirectly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Ten Percent Owner&#8221;</I> means an employee who owns or is deemed to own (by reason of the attribution rules of
Section&nbsp;424(d) of the Code) more than 10&nbsp;percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;Unrestricted Stock Award&#8221;</I> means an Award of shares of Stock free of any restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Administration of Plan</U>. The Plan shall be administered by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Powers of Administrator</U>. The Administrator shall have the power and authority to grant Awards consistent with the terms of the
Plan, including the power and authority: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) to select the individuals to whom Awards may from time to time be granted; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) to determine the time or times of grant, and the extent, if any, of Incentive Stock Options,
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights, or any combination of the
foregoing, granted to any one or more grantees; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) to determine the number of shares of Stock to be covered by any Award; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan,
of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Agreements; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) to accelerate at any time the exercisability or vesting of all or any portion of any Award; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) subject to the provisions of Section&nbsp;5(c) or 6(d), to extend at any time the period in which Stock Options or Stock Appreciation
Rights, respectively, may be exercised; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) at any time to adopt, alter and repeal such rules, guidelines and practices for
administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for
the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Delegation of Authority to Grant Awards</U>. Subject to applicable law, the Administrator, in its discretion, may delegate to a
committee consisting of one or more officers of the Company including the Chief Executive Officer of the Company all or part of the Administrator&#8217;s authority and duties with respect to the granting of Awards to individuals who are (i)&nbsp;not
subject to the reporting and other provisions of Section&nbsp;16 of the Exchange Act and (ii)&nbsp;not members of the delegated committee. Any such delegation by the Administrator shall include a limitation as to the amount of Stock underlying
Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time but such
action shall not invalidate any prior actions of the Administrator&#8217;s delegate or delegates that were consistent with the terms of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Award Agreement</U>. Awards under the Plan shall be evidenced by Award Agreements
that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event the Service Relationship terminates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Indemnification</U>. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any
act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and
reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys&#8217; fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company&#8217;s
articles or bylaws or any directors&#8217; and officers&#8217; liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Award Recipients</U>. Notwithstanding any provision of the Plan to the contrary, in
order to comply with the laws in other countries in which the Company and its Affiliates operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to:
(i)&nbsp;determine which Affiliates shall be covered by the Plan; (ii)&nbsp;determine which individuals outside the United States are eligible to participate in the Plan; (iii)&nbsp;modify the terms and conditions of any Award granted to individuals
outside the United States to comply with applicable laws; (iv)&nbsp;establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such
subplans and/or modifications shall be incorporated into and made part of this Plan); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section&nbsp;3(a) hereof; and (v)&nbsp;take any
action, before or after<B> </B>an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the
Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Issuable</U>. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 6,020,000 shares
(the &#8220;Initial Limit&#8221;), plus on January&nbsp;1, 2027 and on each January&nbsp;1 thereafter, the number of shares of Stock reserved and available for issuance under the Plan shall be automatically cumulatively increased by (i)
5&nbsp;percent of the Outstanding Shares on the immediately preceding December&nbsp;31, or (ii)&nbsp;such lesser number of shares as approved by the Administrator, in all cases subject to adjustment as provided in this Section&nbsp;3(c) (the
&#8220;Annual Increase&#8221;). Subject to such overall limitation, the maximum aggregate number of shares of Stock that may be issued in the form of Incentive Stock Options shall not exceed the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Initial Limit cumulatively increased on January&nbsp;1, 2027 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or 6,020,000 of Stock, subject in all cases
to adjustment as provided in Section&nbsp;3(c). For purposes of this limitation, the shares of Stock underlying any Awards under the Plan and the shares of Common Stock of the Company underlying the Company&#8217;s 2019 Stock Option and Grant Plan,
as amended from time to time, that are forfeited, canceled, held back or tendered upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the
issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan and, to the extent permitted under Section&nbsp;422 of the Code and the regulations promulgated
thereunder, the shares of Stock that may be issued as Incentive Stock Options. In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan.
Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of Award.&nbsp;The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of
Stock reacquired by the Company. Awards that may be settled solely in cash shall not be counted against the share reserve, nor shall they reduce the shares of Stock authorized for grant to a grantee in any calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Maximum Awards to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</U>. Notwithstanding anything to the contrary in this
Plan, the value of all Awards awarded under this Plan and all other cash compensation paid by the Company to any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for services as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director in any calendar year shall not exceed: (i) $1,000,000 in the first calendar year an individual becomes a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director and (ii) $750,000 in any other calendar year. For the purpose of this
limitation, the value of any Award shall be its grant date fair value, as determined in accordance with ASC Topic 718 or successor provision but excluding the impact of estimated forfeitures related to service-based vesting provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Changes in Stock</U>. Subject to Section&nbsp;3(d) hereof, if, as a result of any reorganization, recapitalization, reclassification,
stock dividend, extraordinary cash dividend, stock split, reverse stock split or other similar change in the Company&#8217;s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of
shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other <FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such shares of Stock or
other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor
entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i)&nbsp;the maximum number of shares reserved for issuance under the Plan, including the maximum number of shares that may be
issued in the form of Incentive Stock Options, (ii)&nbsp;the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii)&nbsp;the repurchase price, if any, per share subject to each outstanding
Restricted Stock Award, and (iv)&nbsp;the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by
the number of shares subject to Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of
shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the
Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Mergers and Other Transactions</U>. In the case of and subject to the consummation of
a Sale Event, the parties thereto may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate
adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree. To the extent that the parties to such Sale Event do not provide for the assumption, continuation or substitution of
Awards, upon the effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate. In such case, except as may be otherwise provided in the relevant Award Agreement, all Options and Stock Appreciation Rights
with time-based vesting conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become fully vested and exercisable as of the effective time of the Sale Event, all other
Awards with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating to the attainment of performance goals may
become vested and nonforfeitable in connection with a Sale Event in the Administrator&#8217;s discretion or to the extent specified in the relevant Award Agreement. In the event of such termination, (i)&nbsp;the Company shall have the option (in its
sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A)&nbsp;the Sale Price
multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B)&nbsp;the aggregate exercise price of all such outstanding
Options and Stock Appreciation Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or greater than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no
consideration); or (ii)&nbsp;each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the
extent then exercisable) held by such grantee. The Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied
by the number of vested shares of Stock under such Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>ELIGIBILITY</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grantees under the Plan will be such employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors or Consultants of the Company
and its Affiliates as are selected from time to time by the Administrator in its sole discretion; provided that Awards may not be granted to employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors or Consultants who are providing
services only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule 405 of the Act, unless (i)&nbsp;the stock underlying the Awards is treated as &#8220;service recipient stock&#8221; under Section&nbsp;409A or (ii)&nbsp;the
Company has determined that such Awards are exempt from or otherwise comply with Section&nbsp;409A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>STOCK OPTIONS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Award of Stock Options</U>. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be
in such form as the Administrator may from time to time approve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock Options granted under the Plan may be either Incentive Stock
Options or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a &#8220;subsidiary corporation&#8221; within the meaning of
Section&nbsp;424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock Options granted pursuant to this Section&nbsp;5 shall be subject to the following terms and conditions and shall contain such additional
terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so determines, Stock Options may be granted in lieu of cash compensation at the optionee&#8217;s election, subject to
such terms and conditions as the Administrator may establish. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price</U>. The exercise price per share for the Stock
covered by a Stock Option granted pursuant to this Section&nbsp;5 shall be determined by the Administrator at the time of grant but shall not be less than 100&nbsp;percent of the Fair Market Value on the date of grant. In the case of an Incentive
Stock Option that is granted to a Ten Percent Owner, the exercise price of such Incentive Stock Option shall be not less than 110&nbsp;percent of the Fair Market Value on the date of grant. Notwithstanding the foregoing, Stock Options may be granted
with an exercise price per share that is less than 100&nbsp;percent of the Fair Market Value on the date of grant (i)&nbsp;pursuant to a transaction described in, and in a manner consistent with, Section&nbsp;424(a) of the Code, (ii)&nbsp;to
individuals who are not subject to U.S. income tax on the date of grant or (iii)&nbsp;if the Stock Option is otherwise exempt from or compliant with Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Option Term</U>. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than
ten years after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercisability; Rights of a Stockholder</U>. Stock Options shall become exercisable at such time or times, whether or not in
installments, as shall be determined by the Administrator at or after the date of grant. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder
only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Method of Exercise</U>.
Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods
except to the extent otherwise provided in the Award Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In cash, by certified or bank check or other instrument acceptable to
the Administrator; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Through the delivery (or attestation to the ownership following such procedures as the
Company may prescribe) of shares of Stock that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to
promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with
such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) With respect to Stock Options that are not Incentive Stock Options, by a &#8220;net exercise&#8221; arrangement pursuant to which the
Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares
of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase
price for such shares and the fulfillment of any other requirements contained in the Award Agreement or applicable provisions of laws (including the satisfaction of any taxes that the Company or an Affiliate is obligated to withhold with respect to
the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be
net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive
voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Annual
Limit on Incentive Stock Options</U>. To the extent required for &#8220;incentive stock option&#8221; treatment under Section&nbsp;422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with
respect to which Incentive Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To
the extent that any Stock Option exceeds this limit, it shall constitute a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 6.
<U>STOCK APPRECIATION RIGHTS</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Award of Stock Appreciation Rights</U>. The Administrator may grant Stock Appreciation Rights
under the Plan. A Stock Appreciation Right is an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Agreement) having a value equal to the excess of the Fair Market Value
of a share of Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price of Stock Appreciation Rights</U>. The exercise price of a Stock
Appreciation Right shall not be less than 100&nbsp;percent of the Fair Market Value of the Stock on the date of grant. Notwithstanding the foregoing, Stock Appreciation Rights may be granted with an exercise price per share that is less than
100&nbsp;percent of the Fair Market Value on the date of grant (i)&nbsp;pursuant to a transaction described in, and in a manner consistent with, Section&nbsp;424(a) of the Code, (ii)&nbsp;to individuals who are not subject to U.S. income tax on the
date of grant or (iii)&nbsp;if the Stock Appreciation Right is otherwise exempt from or compliant with Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Grant
and Exercise of Stock Appreciation Rights</U>. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section&nbsp;5 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Terms and Conditions of Stock Appreciation Rights</U>. Stock Appreciation Rights shall be subject to such terms and conditions as shall
be determined on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ
among individual Awards and grantees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>RESTRICTED STOCK AWARDS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Nature of Restricted Stock Awards</U>. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is
any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of <FONT
STYLE="white-space:nowrap">pre-established</FONT> performance goals and objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Rights as a Stockholder</U>. Upon the grant of
the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that if the lapse of restrictions with
respect to the Restricted Stock Award is tied to the attainment of vesting conditions, any dividends paid by the Company shall accrue and shall not be paid to the grantee until and to the extent the vesting conditions are met with respect to the
Restricted Stock Award. Unless the Administrator shall otherwise determine, (i)&nbsp;uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to
forfeiture until such Restricted Shares are vested as provided in Section&nbsp;7(d) below, and (ii)&nbsp;certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as provided in
Section&nbsp;7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Restrictions</U>. Restricted Shares may not be sold, assigned, transferred, pledged
or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Stock Award Agreement. Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section&nbsp;16 below, in
writing after the Award is issued, if a grantee&#8217;s employment (or other Service Relationship) with the Company and its Affiliates terminates for any reason, any Restricted Shares that have not vested at the time of termination shall
automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such
grantee&#8217;s legal representative simultaneously with such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder.
Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Vesting of Restricted Shares</U>. The Administrator at the time of grant shall specify the date or dates and/or the attainment of <FONT
STYLE="white-space:nowrap">pre-established</FONT> performance goals, objectives and other conditions on which the <FONT STYLE="white-space:nowrap">non-transferability</FONT> of the Restricted Shares and the Company&#8217;s right of repurchase or
forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall
no longer be Restricted Shares and shall be deemed &#8220;vested.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>RESTRICTED STOCK UNITS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Nature of Restricted Stock Units</U>. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an
Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Agreement) upon the satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on continuing
employment (or other Service Relationship) and/or achievement of <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals and objectives. The terms and conditions of each such Award shall be determined by the Administrator, and such
terms and conditions may differ among individual Awards and grantees. Restricted Stock Units with deferred settlement dates are subject to Section&nbsp;409A and shall contain such additional terms and conditions as the Administrator shall determine
in its sole discretion in order to comply with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Election to Receive Restricted Stock Units
in Lieu of Compensation</U>. The Administrator may, in its sole discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of an award of Restricted Stock Units. Any such election
shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with Section&nbsp;409A and such other rules and procedures established by the Administrator. Any such future cash
compensation that the grantee elects to defer shall be converted to a fixed number of Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if such payment had not
been deferred as provided herein. The Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems
appropriate. Any Restricted Stock Units that are elected to be received in lieu of cash compensation shall be fully vested, unless otherwise provided in the Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Rights as a Stockholder</U>. A grantee shall have the rights as a stockholder only as
to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his or her Restricted Stock Units,
subject to the provisions of Section&nbsp;11 and such terms and conditions as the Administrator may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination</U>.
Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section&nbsp;16 below, in writing after the Award is issued, a grantee&#8217;s right in all Restricted Stock Units that have not vested shall
automatically terminate upon the grantee&#8217;s termination of employment (or cessation of Service Relationship) with the Company and its Affiliates for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>UNRESTRICTED STOCK AWARDS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Grant or Sale of Unrestricted Stock</U>. The Administrator may grant (or sell at par value or such higher purchase price determined by the
Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect
of past services or other valid consideration, or in lieu of cash compensation due to such grantee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>CASH-BASED AWARDS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Grant of Cash-Based Awards</U>. The Administrator may grant Cash-Based Awards under the Plan. A Cash-Based Award is an Award that entitles
the grantee to a payment in cash upon the attainment of specified performance goals, including continued employment (or other Service Relationship). The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash
to which the Cash-Based Award pertains, the conditions upon which the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated payment
amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be made in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>DIVIDEND EQUIVALENT RIGHTS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Dividend Equivalent Rights</U>. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is
an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee.
A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Agreement.
Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at
Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof,
in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of
restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination</U>. Except as may otherwise be provided by the Administrator either in
the Award Agreement or, subject to Section&nbsp;16 below, in writing after the Award is issued, a grantee&#8217;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&#8217;s termination of employment (or cessation
of Service Relationship) with the Company and its Affiliates for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>TRANSFERABILITY OF AWARDS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferability</U>. Except as provided in Section&nbsp;12(b) below or otherwise determined by the Administrator, during a
grantee&#8217;s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee&#8217;s legal representative or guardian in the event of the grantee&#8217;s incapacity. No Awards shall be sold, assigned, transferred or
otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind,
and any purported transfer in violation hereof shall be null and void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Administrator Action</U>. Notwithstanding
Section&nbsp;12(a), the Administrator, in its discretion, may provide either in the Award Agreement regarding a given Award or by subsequent written approval that the grantee (who is an employee or
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director) may transfer his or her <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or
to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award Agreement. In no event may an
Award be transferred by a grantee for value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Family Member</U>. For purposes of Section&nbsp;12(b), &#8220;family member&#8221;
shall mean a grantee&#8217;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including adoptive relationships, any person sharing the grantee&#8217;s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than
50&nbsp;percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50&nbsp;percent of the voting interests.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Designation of Beneficiary</U>. To the extent permitted by the Company and valid under applicable law, each grantee to whom an
Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee&#8217;s death. Any such designation shall be on a form provided for that
purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the
grantee&#8217;s estate or legal heirs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>TAX WITHHOLDING</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Payment by Grantee</U>. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts
received thereunder first becomes includable in the gross income of the grantee for tax purposes, pay to the Company or any applicable Affiliate, or make arrangements satisfactory to the Administrator regarding payment of, any U.S. and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> federal, state, or local taxes of any kind required by law to be withheld by the Company or any applicable Affiliate with respect to such income. The Company and its Affiliates shall, to the extent
permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee or to satisfy any applicable withholding obligations by any other method of withholding that the Company and its Affiliates deem
appropriate. The Company&#8217;s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Payment in Stock</U>. The Administrator may cause any tax withholding obligation of the Company or any applicable Affiliate to be
satisfied, in whole or in part, by the Company withholding from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding
amount due; provided, however, that the amount withheld does not exceed the maximum statutory rate or such lesser amount as is necessary to avoid liability accounting treatment. For purposes of share withholding, the Fair Market Value of withheld
shares shall be determined in the same manner as the value of Stock includible in income of the grantees. The Administrator may also require any tax withholding obligation of the Company or any applicable Affiliate to be satisfied, in whole or in
part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company or any applicable Affiliate in an amount that would satisfy the withholding
amount due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>SECTION</U><U></U><U>&nbsp;409A AWARDS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards are intended to be exempt from Section&nbsp;409A to the greatest extent possible and to otherwise comply with Section&nbsp;409A. The
Plan and all Awards shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Section&nbsp;409A (a &#8220;409A Award&#8221;),
the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section&nbsp;409A. In this regard, if any amount under a 409A Award is payable upon a &#8220;separation
from service&#8221; (within the meaning of Section&nbsp;409A) to a grantee who is then considered a &#8220;specified employee&#8221; (within the meaning of Section&nbsp;409A), then no such payment shall be made prior to the date that is the earlier
of (i)&nbsp;six months and one day after the grantee&#8217;s separation from service, or (ii)&nbsp;the grantee&#8217;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or
additional tax imposed pursuant to Section&nbsp;409A. Further, the settlement of any 409A Award may not be accelerated except to the extent permitted by Section&nbsp;409A. The Company makes no representation that any or all of the payments or
benefits described in the Plan will be exempt from or comply with Section&nbsp;409A of the Code and makes no undertaking to preclude Section&nbsp;409A of the Code from applying to any such payment. The grantee shall be solely responsible for the
payment of any taxes and penalties incurred under Section&nbsp;409A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination of Service Relationship</U>. If the grantee&#8217;s Service Relationship is with an Affiliate and such Affiliate ceases to
be an Affiliate, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) For
purposes of the Plan, the following events shall not be deemed a termination of a Service Relationship: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) a transfer to the Service
Relationship of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) an approved
leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee&#8217;s right to <FONT STYLE="white-space:nowrap">re-employment</FONT> is guaranteed either by a statute or by contract or under the
policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 16. <U>AMENDMENTS AND
TERMINATION</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any
outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights under any outstanding Award without the holder&#8217;s consent. The Administrator is
specifically authorized to exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights, or effect the repricing of such Awards through cancellation and
<FONT STYLE="white-space:nowrap">re-grants</FONT> or cancellation of Stock Options or Stock Appreciation Rights in exchange for cash or other Awards. To the extent required under the rules of any securities exchange or market system on which the
Stock is listed, or to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section&nbsp;422 of the Code, Plan amendments shall be subject to approval
by Company stockholders. Nothing in this Section&nbsp;16 shall limit the Administrator&#8217;s authority to take any action permitted pursuant to Section&nbsp;3(c) or 3(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 17. <U>STATUS OF PLAN</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect
to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator
shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company&#8217;s obligations to deliver Stock or make
payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 18. <U>GENERAL PROVISIONS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Distribution</U>. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the
Company in writing that such person is acquiring the shares without a view to distribution thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Issuance of Stock</U>. To the
extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the
grantee, at the grantee&#8217;s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail
(with proof of receipt) or by United States mail, addressed to the grantee, at the grantee&#8217;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic &#8220;book
entry&#8221; records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of any Award,
unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of
governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the
Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock
certificate or notations on any book entry to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and
representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or
other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Stockholder Rights</U>. Until Stock is deemed delivered in accordance with Section&nbsp;18(b), no right to vote or receive dividends or
any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Incentive Arrangements; No Rights to Continued Service Relationship</U>. Nothing contained in this Plan shall prevent the Board
from adopting other or additional incentive arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any
grantee any right to continued employment or other Service Relationship with the Company or any Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Trading Policy
Restrictions</U>. Option exercises and other Awards under the Plan shall be subject to the Company&#8217;s insider trading policies and procedures, as in effect from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Clawback Policy</U>. Awards under the Plan shall be subject to the Company&#8217;s
clawback policy, as in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Fractional Shares</U>. No fractional Shares shall be issued or delivered pursuant
to the Plan or any Award, and the Administrator shall determine whether cash, other securities or other property shall be paid or transferred in lieu of any fractional Shares, or whether such fractional Shares or nay rights thereto shall be
cancelled, terminated or otherwise eliminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 19. <U>EFFECTIVE DATE OF PLAN</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan shall become effective upon the date immediately preceding the Registration Date subject to prior stockholder approval in accordance
with applicable state law, the Company&#8217;s bylaws and articles of incorporation, and applicable stock exchange rules. No grants of Awards may be made hereunder after the tenth anniversary of the Effective Date and no grants of Incentive Stock
Options may be made hereunder after the tenth anniversary of the date the Plan is approved by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 20. <U>GOVERNING LAW</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the General Corporation Law of
the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the State of Delaware, applied without regard to conflict of law principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE APPROVED BY BOARD OF DIRECTORS: April&nbsp;7, 2026 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE
APPROVED BY STOCKHOLDERS: April&nbsp;23, 2026 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-QUALIFIED</FONT> STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR COMPANY EMPLOYEES AND CONSULTANTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2026 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>[FMV on Grant Date]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Seaport Therapeutics, Inc. 2026 Stock Option and Incentive Plan as amended through the date
hereof (the &#8220;Plan&#8221;), Seaport Therapeutics, Inc. (the &#8220;Company&#8221;) hereby grants to the Optionee named above an option (the &#8220;Stock Option&#8221;) to purchase on or prior to the Expiration Date specified above all or part
of the number of shares of Common Stock, par value $0.0001 per share (the &#8220;Stock&#8221;) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the
Plan. This Stock Option is not intended to be an &#8220;incentive stock option&#8221; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except
as set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable as follows: ________________________, so
long as Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock
Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the
following methods: (i)&nbsp;in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the
open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee
delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that
in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as
a condition of such payment procedure; (iv)&nbsp;by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market
Value that does not exceed the aggregate exercise price; or (v)&nbsp;a combination of (i), (ii), (iii) and (iv)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#8217;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have
transferred the shares to the Optionee, and the Optionee&#8217;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect
to such shares of Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be
exercisable after the Expiration Date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Optionee&#8217;s Service Relationship
with the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination Due to Death</U>. If the Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates by reason of the
Optionee&#8217;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#8217;s legal representative or legatee for a period of twelve
(12)&nbsp;months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Due to Disability</U>. If the Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates by reason
of the Optionee&#8217;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination of employment, may thereafter be exercised by the Optionee
for a period of twelve (12)&nbsp;months from the date the Optionee&#8217;s Service Relationship is terminated by reason of the Optionee&#8217;s disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not
exercisable on the date of the termination of the Optionee&#8217;s Service Relationship by reason of disability shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause</U>. If the Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates for Cause, any
portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, &#8220;Cause&#8221; shall mean, unless otherwise provided in an employment or other service agreement
between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i)&nbsp;any material breach by the Optionee of any agreement between the Optionee and the Company; (ii)&nbsp;the
conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii)&nbsp;any material misconduct or willful and deliberate <FONT STYLE="white-space:nowrap">non-performance</FONT> (other
than by reason of disability) by the Optionee of the Optionee&#8217;s duties to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Termination</U>. If the
Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee&#8217;s death, the Optionee&#8217;s disability or Cause, and unless otherwise determined by the Administrator, any portion of
this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three (3)&nbsp;months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock
Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Administrator&#8217;s determination of the reason for termination of the Optionee&#8217;s Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all
the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified
herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is <FONT
STYLE="white-space:nowrap">non-assignable</FONT> and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#8217;s
lifetime, only by the Optionee, and thereafter, only by the Optionee&#8217;s legal representative or legatee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Tax Withholding</U>.
The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal,
state and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i)&nbsp;withholding from shares of
Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; or (ii)&nbsp;causing its transfer agent to sell from the number of shares of Stock to be issued to the
Optionee, the number of shares of Stock necessary to satisfy the Federal, state and local taxes required by law to be withheld from the Optionee on account of such transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or
this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee&#8217;s
Service Relationship with the Company or a Subsidiary at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Integration</U>. This Agreement constitutes the entire agreement
between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may process any and all personal or professional data, including but not limited to, Social Security or other identification number,
home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#8220;Relevant Information&#8221;). By entering into this Agreement, the Optionee
(i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes
the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have
access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. [<U>Clawback Acknowledgement</U>. The Optionee acknowledges that the Optionee may become subject to the Seaport Therapeutics, Inc.
Compensation Recovery Policy adopted pursuant to Rule <FONT STYLE="white-space:nowrap">10D-1</FONT> promulgated under the Exchange Act and NASDAQ Rule 5608, or any successor rule (the &#8220;Clawback Policy&#8221;). The Optionee understands that if
the Optionee is or becomes subject to the Clawback Policy, the Company and/or the Board shall be entitled to recover all Erroneously Awarded Compensation (as defined in the Clawback Policy) from the Optionee pursuant to such means as the Company
and/or the Board may elect. The Optionee agrees that the Optionee shall take all required action to enable such recovery. The Optionee understands that such recovery may be sought and occur after the Optionee&#8217;s employment or service with the
Company terminates. The Optionee further agrees that the Optionee is not entitled to indemnification for any Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation
recovered pursuant to the Clawback Policy and, to the extent any agreement or organizational document purports to provide otherwise, the Optionee hereby irrevocably agrees to forego such indemnification. The Optionee acknowledges and agrees that the
Optionee has received and has had an opportunity to review the Clawback Policy. Any action by the Company to recover Erroneously Awarded Compensation under the Clawback Policy from the Optionee shall not, whether alone or in combination with any
other action, event or condition, be deemed (i)&nbsp;an event giving rise to a right to resign for Good Reason (as defined in the Seaport Therapeutics, Inc. Executive Severance Plan) or serve as a basis for a claim of constructive termination under
any benefits or compensation arrangement applicable to the Optionee, or (ii)&nbsp;to constitute a breach of a contract or other arrangement to which the Optionee is a party. This Section&nbsp;11 is a material term of this Agreement.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Seaport Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionee&#8217;s Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionee&#8217;s name and address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR COMPANY EMPLOYEES AND CONSULTANTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2026 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Grantee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Restricted Stock Units:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Seaport Therapeutics, Inc. 2026 Stock Option and Incentive Plan as amended through the date
hereof (the &#8220;Plan&#8221;), Seaport Therapeutics, Inc. (the &#8220;Company&#8221;) hereby grants an award of the number of Restricted Stock Units listed above (an &#8220;Award&#8221;) to the Grantee named above. Each Restricted Stock Unit shall
relate to one share of Common Stock, par value $0.0001 per share (the &#8220;Stock&#8221;) of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Restrictions on Transfer
of Award</U>. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise
encumbered or disposed of until (i)&nbsp;the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii)&nbsp;shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting of Restricted Stock Units</U>. The restrictions and conditions of Paragraph&nbsp;1 of this Agreement shall lapse as
follows:<U></U> <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> (each such date, a &#8220;Vesting Date&#8221;), so long as the Grantee continues to have a Service Relationship with the Company or a Subsidiary on such Vesting Dates. If a series of
Vesting Dates is specified, then the restrictions and conditions in Paragraph&nbsp;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Grantee&#8217;s Service Relationship with the Company or a Subsidiary terminates for any
reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be
forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Issuance of Shares of Stock</U>. As soon as practicable following each Vesting Date (but in no event later than two and <FONT
STYLE="white-space:nowrap">one-half</FONT> months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have
vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this
Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the
Plan, unless a different meaning is specified herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Tax Withholding</U>. The Grantee shall, not later than the date as of which
the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state and local taxes required by law to be withheld on account
of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i)&nbsp;withholding from shares of Stock to be issued to the Grantee a number of shares of Stock
with an aggregate Fair Market Value that would satisfy the withholding amount due; or (ii)&nbsp;causing its transfer agent to sell from the number of shares of Stock to be issued to the Grantee, the number of shares of Stock necessary to satisfy the
Federal, state and local taxes required by law to be withheld from the Grantee on account of such transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Section 409A of the
Code.</U> This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section&nbsp;409A of the Code as &#8220;short-term deferrals&#8221; as described in
Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any Subsidiary is
obligated by or as a result of the Plan or this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any
Subsidiary to terminate the Grantee&#8217;s Service Relationship with the Company or a Subsidiary at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Integration</U>.
This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may process any and all personal or professional data, including but not limited to, Social Security or other identification number,
home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#8220;Relevant Information&#8221;). By entering into this Agreement, the Grantee
(i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes
the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have
access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. [<U>Clawback Acknowledgement</U>. The Grantee acknowledges that the Grantee may become subject to the Seaport Therapeutics, Inc.
Compensation Recovery Policy adopted pursuant to Rule <FONT STYLE="white-space:nowrap">10D-1</FONT> promulgated under the Exchange Act and Nasdaq Rule 5608, or any successor rule (the &#8220;Clawback Policy&#8221;). The Grantee understands that if
the Grantee is or becomes subject to the Clawback Policy, the Company and/or the Board shall be entitled to recover all Erroneously Awarded Compensation (as defined in the Clawback Policy) from the Grantee pursuant to such means as the Company
and/or the Board may elect. The Grantee agrees that the Grantee shall take all required action to enable such recovery. The Grantee understands that such recovery may be sought and occur after the Grantee&#8217;s employment or service with the
Company terminates. The Grantee further agrees that the Grantee is not entitled to indemnification for any Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation recovered
pursuant to the Clawback Policy and, to the extent any agreement or organizational document purports to provide otherwise, the Grantee hereby irrevocably agrees to forego such indemnification. The Grantee acknowledges and agrees that the Grantee has
received and has had an opportunity to review the Clawback Policy. Any action by the Company to recover Erroneously Awarded Compensation under the Clawback Policy from the Grantee shall not, whether alone or in combination with any other action,
event or condition, be deemed (i)&nbsp;an event giving rise to a right to resign for Good Reason (as defined in the Seaport Therapeutics, Inc. Executive Severance Plan) or serve as a basis for a claim of constructive termination under any benefits
or compensation arrangement applicable to the Grantee, or (ii)&nbsp;to constitute a breach of a contract or other arrangement to which the Grantee is a party. This Section&nbsp;12 is a material term of this Agreement.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Seaport Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grantee&#8217;s Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grantee&#8217;s name and address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCENTIVE STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2026 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>[FMV on Grant Date (110% of FMV if a 10% owner)]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>[up to 10 years (5 if a 10% owner)]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Seaport Therapeutics, Inc. 2026 Stock Option and Incentive Plan as amended through the date
hereof (the &#8220;Plan&#8221;), Seaport Therapeutics, Inc. (the &#8220;Company&#8221;) hereby grants to the Optionee named above an option (the &#8220;Stock Option&#8221;) to purchase on or prior to the Expiration Date specified above all or part
of the number of shares of Common Stock, par value $0.0001 per share (the &#8220;Stock&#8221;), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become
exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable as follows:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>, so long as the Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration
Date, subject to the provisions hereof and of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the
following methods: (i)&nbsp;in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the
open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; or (iii)&nbsp;by the Optionee
delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that
in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as
a condition of such payment procedure; or (iv)&nbsp;a combination of (i), (ii) and (iii)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#8217;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the shares of Stock attested to. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of
Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have
transferred the shares to the Optionee, and the Optionee&#8217;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect
to such shares of Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be
exercisable after the Expiration Date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Optionee&#8217;s Service Relationship
with the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination Due to Death</U>. If the Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates by reason of the
Optionee&#8217;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#8217;s legal representative or legatee for a period of twelve (12) months
from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Due to Disability</U>. If the Optionee&#8217;s Service Relationship with
the Company or a Subsidiary terminates by reason of the Optionee&#8217;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such disability, may
thereafter be exercised by the Optionee for a period of twelve (12)&nbsp;months from the date the Optionee&#8217;s Service Relationship is terminated by reason of the Optionee&#8217;s disability or until the Expiration Date, if earlier. Any portion
of this Stock Option that is not exercisable on the date of the termination of the Optionee&#8217;s Service Relationship by reason of the Optionee&#8217;s disability shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause</U>. If the Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates for Cause, any
portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, &#8220;Cause&#8221; shall mean, unless otherwise provided in an employment or service agreement between the
Company and the Optionee, a determination by the Administrator<B> </B>that the Optionee shall be dismissed as a result of (i)&nbsp;any material breach by the Optionee of any agreement between the Optionee and the Company; (ii)&nbsp;the conviction
of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii)&nbsp;any material misconduct or willful and deliberate <FONT STYLE="white-space:nowrap">non-performance</FONT> (other than by
reason of disability) by the Optionee of the Optionee&#8217;s duties to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Termination</U>. If the
Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee&#8217;s death, the Optionee&#8217;s disability, or Cause, and unless otherwise determined by the Administrator, any portion of
this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three (3)&nbsp;months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock
Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Administrator&#8217;s determination of the reason for termination of the Optionee&#8217;s Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all
the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is <FONT STYLE="white-space:nowrap">non-assignable</FONT>
and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#8217;s lifetime, only by the Optionee, and thereafter, only
by the Optionee&#8217;s legal representative or legatee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Status of the Stock Option</U>. This Stock Option is intended to qualify as an
&#8220;incentive stock option&#8221; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), but the Company does not represent or warrant that this Stock Option qualifies as such. The Optionee should
consult with his or her own tax advisors regarding the tax effects of this Stock Option and the requirements necessary to obtain favorable income tax treatment under Section&nbsp;422 of the Code, including, but not limited to, holding period
requirements and that <B><I>this Stock Option must be exercised within three (3)</I></B><B><I></I></B><B><I>&nbsp;months after termination of employment as an employee (or twelve (12)</I></B><B><I></I></B><B><I>&nbsp;months in the case of death or
disability) to qualify as an &#8220;incentive stock option&#8221;</I></B>. To the extent any portion of this Stock Option does not so qualify as an &#8220;incentive stock option,&#8221; such portion shall be deemed to be a <FONT
STYLE="white-space:nowrap">non-qualified</FONT> stock option. If the Optionee intends to dispose or does dispose (whether by sale, gift, transfer or otherwise) of any Option Shares within the <FONT STYLE="white-space:nowrap">one-year</FONT> period
beginning on the date after the transfer of such shares to him or her, or within the <FONT STYLE="white-space:nowrap">two-year</FONT> period beginning on the day after the grant of this Stock Option, he or she will so notify the Company within 30
days after such disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Tax Withholding</U>. The Optionee shall, not later than the date as of which the exercise of this
Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state and local taxes required by law to be withheld on account of such
taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i)&nbsp;withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an
aggregate Fair Market Value that would satisfy the withholding amount due; or (ii)&nbsp;causing its transfer agent to sell from the number of shares of Stock to be issued to the Optionee, the number of shares of Stock necessary to satisfy the
Federal, state and local taxes required by law to be withheld from the Optionee on account of such transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>No Obligation to
Continue Service Relationship</U>. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in a Service Relationship with the Company or any Subsidiary and neither the Plan nor
this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee&#8217;s Service Relationship with the Company or a Subsidiary at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes
all prior agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Data Privacy Consent</U>. In order to
administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may process any and all personal or
professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this
Agreement (the &#8220;Relevant Information&#8221;). By entering into this Agreement, the Optionee (i)&nbsp;authorizes the Company to collect, process, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes
the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have
access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or
delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. [<U>Clawback Acknowledgement</U>. The Optionee acknowledges that the Optionee may become subject to the Seaport Therapeutics, Inc.
Compensation Recovery Policy adopted pursuant to Rule <FONT STYLE="white-space:nowrap">10D-1</FONT> promulgated under the Exchange Act and Nasdaq Rule 5608, or any successor rule (the &#8220;Clawback Policy&#8221;). The Optionee understands that if
the Optionee is or becomes subject to the Clawback Policy, the Company and/or the Board shall be entitled to recover all Erroneously Awarded Compensation (as defined in the Clawback Policy) from the Optionee pursuant to such means as the Company
and/or the Board may elect. The Optionee agrees that the Optionee shall take all required action to enable such recovery. The Optionee understands that such recovery may be sought and occur after the Optionee&#8217;s employment or service with the
Company terminates. The Optionee further agrees that the Optionee is not entitled to indemnification for any Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation
recovered pursuant to the Clawback Policy and, to the extent any agreement or organizational document purports to provide otherwise, the Optionee hereby irrevocably agrees to forego such indemnification. The Optionee acknowledges and agrees that the
Optionee has received and has had an opportunity to review the Clawback Policy. Any action by the Company to recover Erroneously Awarded Compensation under the Clawback Policy from the Optionee shall not, whether alone or in combination with any
other action, event or condition, be deemed (i)&nbsp;an event giving rise to a right to resign for Good Reason (as defined in the Seaport Therapeutics, Inc. Executive Severance Plan) or serve as a basis for a claim of constructive termination under
any benefits or compensation arrangement applicable to the Optionee, or (ii)&nbsp;to constitute a breach of a contract or other arrangement to which the Optionee is a party. This Section&nbsp;12 is a material term of this Agreement.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Seaport Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionee&#8217;s Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionee&#8217;s name and address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-QUALIFIED</FONT> STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR COMPANY <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTORS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2026 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>[FMV on Grant Date]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>[No more than 10 years]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Seaport Therapeutics, Inc. 2026 Stock Option and Incentive Plan as amended through the date
hereof (the &#8220;Plan&#8221;), Seaport Therapeutics, Inc. (the &#8220;Company&#8221;) hereby grants to the Optionee named above, who is a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director of the Company but is not an employee of the
Company, an option (the &#8220;Stock Option&#8221;) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the &#8220;Stock&#8221;), of the Company specified
above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an &#8220;incentive stock option&#8221; under Section&nbsp;422 of the Internal
Revenue Code of 1986, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion
shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable as
follows: ________________________, so long as the Optionee remains in service as a member of the Board on such dates: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
foregoing, in the event of a Sale Event, 100% of the then-outstanding and unvested Option Shares shall immediately be deemed vested and exercisable on the date of such Sale Event; provided, that the Optionee remains in service as a member of the
Board until the date of such Sale Event. Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the
following methods: (i)&nbsp;in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the
open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee
delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that
in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as
a condition of such payment procedure; (iv)&nbsp;by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market
Value that does not exceed the aggregate exercise price; or (v)&nbsp;a combination of (i), (ii), (iii) and (iv)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#8217;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have
transferred the shares to the Optionee, and the Optionee&#8217;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect
to such shares of Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be
exercisable after the Expiration Date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination as <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</U>. If
the Optionee ceases to be a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director of the Company, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination Due to Death</U>. If the Optionee&#8217;s service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
terminates by reason of the Optionee&#8217;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#8217;s legal representative or legatee for a
period of twelve (12)&nbsp;months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Due to Disability</U>. If the Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates by reason
of the Optionee&#8217;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination, may thereafter be exercised by the Optionee for a period
of twelve (12)&nbsp;months from the date the Optionee&#8217;s Service Relationship is terminated by reason of the Optionee&#8217;s disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the
date of the termination of the Optionee&#8217;s Service Relationship by reason of disability shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause</U>. If the Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates for Cause, any
portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, &#8220;Cause&#8221; shall mean, unless otherwise provided in an employment or other service agreement
between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i)&nbsp;any material breach by the Optionee of any agreement between the Optionee and the Company; (ii)&nbsp;the
conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii)&nbsp;any material misconduct or willful and deliberate <FONT STYLE="white-space:nowrap">non-performance</FONT> (other
than by reason of disability) by the Optionee of the Optionee&#8217;s duties to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Termination</U>. If the
Optionee ceases to be a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for any reason other than the Optionee&#8217;s death, the Optionee&#8217;s disability or Cause, and unless otherwise determined by the Administrator, any portion
of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date the Optionee ceased to be a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, for a period of twelve (12)&nbsp;months from the date
the Optionee ceased to be a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date the Optionee ceases to be a <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director shall terminate immediately and be of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.
<U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b)
of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is <FONT
STYLE="white-space:nowrap">non-assignable</FONT> and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#8217;s
lifetime, only by the Optionee, and thereafter, only by the Optionee&#8217;s legal representative or legatee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Obligation to
Continue Service Relationship</U>. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this
Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee&#8217;s Service Relationship with the Company or a Subsidiary at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes
all prior agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Data Privacy Consent</U>. In order to
administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may process any and all personal or
professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this
Agreement (the &#8220;Relevant Information&#8221;). By entering into this Agreement, the Optionee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any
privacy rights the Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information
to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Seaport Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionee&#8217;s Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionee&#8217;s name and address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTORS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2026 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Grantee:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No. of Restricted Stock Units:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Seaport Therapeutics, Inc. 2026 Stock Option and Incentive Plan as amended through the date
hereof (the &#8220;Plan&#8221;), Seaport Therapeutics, Inc. (the &#8220;Company&#8221;) hereby grants an award of the number of Restricted Stock Units listed above (an &#8220;Award&#8221;) to the Grantee named above. Each Restricted Stock Unit shall
relate to one share of Common Stock, par value $0.0001 per share (the &#8220;Stock&#8221;) of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Restrictions on Transfer
of Award</U>. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise
encumbered or disposed of until (i)&nbsp;the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii)&nbsp;shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting of Restricted Stock Units</U>. The restrictions and conditions of Paragraph&nbsp;1 of this Agreement shall lapse as
follows:<U></U> <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> (each such date, a &#8220;Vesting Date&#8221;), so long as the Grantee remains in service as a member of the Board on such Vesting Dates. If a series of Vesting Dates is specified,
then the restrictions and conditions in Paragraph&nbsp;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event of a Sale Event, 100% of the then-outstanding and unvested Restricted Stock Units shall
immediately be deemed vested on the date of such Sale Event; provided, that the Grantee remains in service as a member of the Board until the date of such Sale Event. The Administrator may at any time accelerate the vesting schedule specified in
this Paragraph 2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</U>. If the
Grantee&#8217;s service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted
Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns or personal representatives will thereafter have any further
rights or interests in such unvested Restricted Stock Units. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Issuance of Shares of Stock</U>. As soon as practicable following each Vesting Date
(but in no event later than two and <FONT STYLE="white-space:nowrap">one-half</FONT> months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate
number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Section 409A of the Code.</U> This Agreement shall be interpreted in such a manner that all provisions relating to the settlement
of the Award are exempt from the requirements of Section&nbsp;409A of the Code as &#8220;short-term deferrals&#8221; as described in Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or
this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee&#8217;s
Service Relationship with the Company or a Subsidiary at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Integration</U>. This Agreement constitutes the entire agreement
between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may process any and all personal or professional data, including but not limited to, Social Security or other identification number,
home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#8220;Relevant Information&#8221;). By entering into this Agreement, the Grantee
(i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes
the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have
access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Seaport Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grantee&#8217;s Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grantee&#8217;s name and address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>8
<FILENAME>d73463dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2026 EMPLOYEE STOCK PURCHASE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Seaport Therapeutics, Inc. 2026 Employee Stock Purchase Plan (the &#8220;Plan&#8221;) is to provide eligible employees of
Seaport Therapeutics, Inc. (the &#8220;Company&#8221;) and each Designated Company (as defined in Section&nbsp;11) with opportunities to purchase shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common
Stock&#8221;). 510,000 shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January&nbsp;1, 2027 and each January&nbsp;1 thereafter until the Plan terminates pursuant to Section&nbsp;20, the number of
shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) 1,500,000 shares of Common Stock, (ii) 1% of the number of Outstanding Shares on the immediately preceding
December&nbsp;31, and (iii)&nbsp;such lesser number of shares of Common Stock as determined by the Administrator (as defined in Section&nbsp;1). The Plan includes two components: a Code Section&nbsp;423 Component (the &#8220;423 Component&#8221;)
and a <FONT STYLE="white-space:nowrap">non-Code</FONT> Section&nbsp;423 Component (the <FONT STYLE="white-space:nowrap">&#8220;Non-423</FONT> Component&#8221;). It is intended for the 423 Component to constitute an &#8220;employee stock purchase
plan&#8221; within the meaning of Section&nbsp;423(b) of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and the 423 Component shall be interpreted in accordance with that intent. Under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, which does not qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&nbsp;423(b) of the Code, options will be granted pursuant to rules, procedures or <FONT
STYLE="white-space:nowrap">sub-plans</FONT> adopted by the Administrator designed to comply with applicable laws or achieve tax and other objectives. Except as otherwise provided herein or by the Administrator, the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component will operate and be administered in the same manner as the 423 Component. Unless otherwise defined herein, capitalized terms in this Plan shall have the meaning ascribed to them in
Section&nbsp;11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Administration</U>. The Plan will be administered by the person or persons (the &#8220;Administrator&#8221;)
appointed by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) for such purpose. The Administrator has authority at any time to: (i)&nbsp;adopt, alter and repeal such rules, guidelines and practices for the administration of the Plan
and for its own acts and proceedings as it shall deem advisable; (ii)&nbsp;interpret the terms and provisions of the Plan, including to accommodate the specific requirements of applicable laws, regulations and procedures in jurisdictions outside of
the United States; (iii)&nbsp;make all determinations it deems advisable for the administration of the Plan; (iv)&nbsp;decide all disputes arising in connection with the Plan; and (v)&nbsp;otherwise supervise the administration of the Plan. All
interpretations and decisions of the Administrator shall be binding on all persons, including the Company and the Participants. No member of the Board or individual exercising administrative authority with respect to the Plan shall be liable for any
action or determination made in good faith with respect to the Plan or any option granted hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Offerings</U>. The Company
will make one or more offerings to eligible employees to purchase Common Stock under the Plan (&#8220;Offerings&#8221;) consisting of one or more Purchase Periods. Each Offering will begin and end on the dates to be determined by the Administrator,
provided that no Offering shall exceed 27 months in duration. Unless the Administrator, in its sole discretion, chooses otherwise prior to an Offering Date (as defined below), and to the extent an Offering has more than one Purchase Period and to
the extent permitted by applicable law, if the Fair Market Value of the Common Stock on any Exercise Date in an Offering is lower than the Fair Market Value of the Common Stock on the Offering Date, then all participants in such Offering
automatically will be withdrawn from such Offering immediately after the exercise of their option on such Exercise Date and automatically <FONT STYLE="white-space:nowrap">re-enrolled</FONT> in the immediately following Offering as of the first day
thereof and the preceding Offering will terminate. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Eligibility</U>. All individuals classified as employees on the payroll records of the
Company and each Designated Company are eligible to participate in any one or more of the Offerings under the Plan, provided that, the Administrator may determine, in advance of any Offering, that employees are eligible only if, as of the first day
of the applicable Offering (the &#8220;Offering Date&#8221;) (a) they are customarily employed by the Company or a Designated Company for more than 20 hours a week (or such lesser number of hours per week consistent with Section&nbsp;423 of the
Code), (b) they are customarily employed by the Company or a Designated Company for more than five months per calendar year, (c)&nbsp;they have completed such minimum period of service prior to the Offering Date (provided such service requirement
does not exceed two years of employment), and/or (d)&nbsp;they satisfy such other criteria as the Administrator may determine consistent with Section&nbsp;423 of the Code. Notwithstanding any other provision herein, individuals who are not
contemporaneously classified as employees of the Company or a Designated Company for purposes of the Company&#8217;s or applicable Designated Company&#8217;s payroll system are not considered to be eligible employees of the Company or any Designated
Company and shall not be eligible to participate in the Plan. In the event any such individuals are reclassified as employees of the Company or a Designated Company for any purpose, including, without limitation, common law or statutory employees,
by any action of any third party, including, without limitation, any government agency, or as a result of any private lawsuit, action or administrative proceeding, such individuals shall, notwithstanding such reclassification, remain ineligible for
participation. Notwithstanding the foregoing, the exclusive means for individuals who are not contemporaneously classified as employees of the Company or a Designated Company on the Company&#8217;s or Designated Company&#8217;s payroll system to
become eligible to participate in this Plan is through an amendment or subplan to this Plan, duly executed by the Company, which specifically renders such individuals eligible to participate herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Participation</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
An eligible employee who is not a Participant in any prior Offering may participate in a subsequent Offering by submitting an enrollment form to the Company or an agent designated by the Company (in the manner described in Section&nbsp;4(b) at least
15 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
<U>Enrollment</U>. The enrollment form (which may be in an electronic format or such other method as determined by the Company in accordance with the Company&#8217;s practices) will (a)&nbsp;state a whole percentage or amount to be deducted from an
eligible employee&#8217;s Compensation (as defined in Section&nbsp;11) per pay period, (b)&nbsp;authorize the purchase of Common Stock in each Offering in accordance with the terms of the Plan and (c)&nbsp;specify the exact name or names in which
shares of Common Stock purchased for such individual are to be issued pursuant to Section&nbsp;10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to participate. Unless a Participant files
a new enrollment form or withdraws from the Plan, such Participant&#8217;s deductions or contributions and purchases will continue at the same percentage or amount of Compensation for future Offerings, provided he or she remains eligible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing, participation in the Plan will neither be permitted nor
be denied contrary to the requirements of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Employee Contributions</U>. Unless otherwise specified by the Administrator in
advance of an Offering, each eligible employee may authorize payroll deductions or contributions at a minimum of 1&nbsp;percent (1%) up to a maximum of 15&nbsp;percent (15%) of such employee&#8217;s Compensation for each pay period. The Company will
maintain book accounts showing the amount of payroll deductions or contributions made by each Participant for each Purchase Period within an Offering. No interest will accrue or be paid on payroll deductions or contributions, except as may be
required by applicable law. If payroll deductions or contributions for purposes of the Plan are prohibited or otherwise problematic under applicable law (as determined by the Administrator in its discretion), the Administrator may require
Participants to contribute to the Plan by such other means as determined by the Administrator. Any reference to &#8220;payroll deductions&#8221; or contributions in this Section&nbsp;5 (or in any other section of the Plan) will similarly cover
contributions by other means made pursuant to this Section&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Deduction Changes</U>. Except as may be determined by the
Administrator in advance of an Offering, a Participant may not increase or decrease his or her payroll deduction or contributions during any Offering, but may increase or decrease his or her payroll deduction or contributions with respect to the
next Offering (subject to the limitations of Section&nbsp;5) by filing a new enrollment form at least fifteen (15)&nbsp;business days before the next Offering Date (or by such other deadline as shall be established by the Administrator for the
Offering). The Administrator may, in advance of any Offering, establish rules permitting a Participant to increase, decrease or terminate his or her payroll deduction or contributions during an Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Withdrawal</U>. A Participant may withdraw from participation in the Plan by delivering a written notice of withdrawal to the Company or
an agent designated by the Company (in accordance with such procedures as may be established by the Administrator). The Participant&#8217;s withdrawal will be effective as of the next business day (or such other date established by the
Administrator). Following a Participant&#8217;s withdrawal, the Company will promptly refund such individual&#8217;s entire account balance under the Plan to him or her (after payment for any Common Stock purchased before the effective date of
withdrawal). Partial withdrawals are not permitted. Such an employee may not begin participation again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Grant of Options</U>. On each Offering Date, the Company will grant to each eligible employee who is then a Participant in the Plan an
option (&#8220;Option&#8221;) to purchase, on the last day of a Purchase Period (an &#8220;Exercise Date&#8221;) and at the Option Price (as defined herein) hereinafter provided for, the lower of (a)&nbsp;a number of shares of Common Stock
determined by dividing such Participant&#8217;s accumulated payroll deductions or contributions on such Exercise Date by the Option Price, or (b)&nbsp;a number of shares of Common Stock determined by dividing $25,000 by the Fair Market Value of the
Common Stock on the Offering Date for such Offering (or such other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maximum number of shares as shall have been established by the Administrator in advance of the Offering); provided, however, that such Option shall be subject to the limitations set forth below.
Each Participant&#8217;s Option shall be exercisable only to the extent of such Participant&#8217;s accumulated payroll deductions or contributions on the Exercise Date. The purchase price for each share purchased under each Option (the
&#8220;Option Price&#8221;) will be 85&nbsp;percent (85%) of the Fair Market Value (as defined in Section&nbsp;11) of the Common Stock on the Offering Date or the Exercise Date, whichever is less. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, no Participant may be granted an Option hereunder if such Participant, immediately after the Option was
granted, would be treated as owning stock possessing 5&nbsp;percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in Section&nbsp;11). For purposes of the
preceding sentence, the attribution rules of Section&nbsp;424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock which the Participant has a contractual right to purchase shall be treated as stock owned by
the Participant. In addition, no Participant may be granted an Option which permits his or her rights to purchase stock under the Plan, and any other employee stock purchase plan of the Company and its Parents and Subsidiaries, to accrue at a rate
which exceeds $25,000 of the Fair Market Value of the Common Stock (determined on the option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to
comply with Section&nbsp;423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Exercise of Option and Purchase of Shares</U>. Each employee who continues to be a Participant in the Plan on an Exercise Date shall be
deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his or her accumulated payroll deductions on such date will purchase at
the Option Price, subject to any other limitations contained in the Plan. Unless otherwise determined by the Administrator in advance of an Offering, any amount remaining in a Participant&#8217;s account after the purchase of shares on an Exercise
Date of an Offering solely by reason of the inability to purchase a fractional share will be carried forward to the next Purchase Period; provided, that if such Exercise Date is the final Exercise Date of an Offering, such amount will be carried
forward to the next Offering and any other balance remaining in a Participant&#8217;s account at the end of an Offering will be refunded to the Participant promptly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Issuance of Certificates</U>. Certificates or book-entries at the Company&#8217;s transfer agent representing shares of Common Stock
purchased under the Plan may be issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship or in the name of a broker authorized by the employee to be his, her or
their nominee for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Definitions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;Affiliate&#8221; means any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by
or is under the common control with, the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;Compensation&#8221; means the amount of base pay, prior to salary reduction
pursuant to Sections&nbsp;125, 132(f) or 401(k) of the Code, but excluding overtime, commissions, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains related to
Company stock options or other share-based awards and similar items. The Administrator shall have the discretion to (i)&nbsp;determine the application of this definition to Participants outside the United States and (ii)&nbsp;on a uniform and
nondiscriminatory basis, establish a different definition of Compensation in advance of any Offering (and, with respect to the 423 Component, subject to compliance of such definition with Section&nbsp;423 of the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;Designated Company&#8221; means any present or future Subsidiary or Affiliate that has been designated by the Administrator to
participate in the Plan. The Administrator may so designate any Subsidiary or Affiliate, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the stockholders, and may further designate
such companies or Participants as participating in the 423 Component or the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The Administrator may also determine which Affiliates or eligible employees may be excluded from participation in
the Plan, to the extent consistent with Section&nbsp;423 of the Code or as implemented under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, and determine which Designated Company or Companies will participate in separate Offering (to
the extent that the Company makes separate Offerings). For purposes of the 423 Component, only the Company and its Subsidiaries may be Designated Companies; provided; however, that at any given time, a Subsidiary that is a Designated Company under
the 423 Component will not be a Designated Company under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term
&#8220;Fair Market Value of the Common Stock&#8221; on any given date means the fair market value of the Common Stock determined in good faith by the Administrator; provided, however, that if the Common Stock is admitted to quotation on the National
Association of Securities Dealers Automated Quotation System (&#8220;Nasdaq&#8221;), Nasdaq Global Market, The New York Stock Exchange or another national securities exchange or traded on any established market, the determination shall be made by
reference to the closing price on such date. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;Initial Public Offering&#8221; means the first underwritten, firm commitment public offering pursuant to an effective
registration statement under the U.S. Securities Act of 1933, as amended, covering the offer and sale by the Company of its Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;New Exercise Date&#8221; means a new Exercise Date if the Administrator shortens any Offering then in progress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term <I>&#8220;</I>Outstanding Shares<I>&#8221;</I><I> </I>means, as of a specified date, the sum of (a)&nbsp;the number of shares of
Stock issued and outstanding and (b)&nbsp;the number of shares of Stock issuable pursuant to the exercise of any outstanding, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to acquire Stock for a nominal exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;Parent&#8221; means a &#8220;parent corporation&#8221; with respect to the Company, as defined in Section&nbsp;424(e) of the
Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;Participant&#8221; means an individual who is eligible as determined in
Section&nbsp;3 and who has complied with the provisions of Section&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;Purchase Period&#8221; means a period of time
specified within an Offering, as may be specified by the Administrator in accordance with Section&nbsp;2, generally beginning on the Offering Date or the next day following an Exercise Date within an Offering, and ending on an Exercise Date. An
Offering may consist of one or more Purchase Periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;Registration Date&#8221; means the date on which the registration
statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> is filed by the Company with respect to its Initial Public Offering is declared effective by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;Sale Event&#8221; means (i)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis to
an unrelated person or entity, (ii)&nbsp;a merger, reorganization, statutory share exchange, consolidation, or similar transaction pursuant to which the holders of the Company&#8217;s outstanding voting power and outstanding stock immediately prior
to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction,
(iii)&nbsp;the sale of all of the Common Stock to an unrelated person, entity or group thereof acting in concert, (iv)&nbsp;any other transaction in which the owners of the Company&#8217;s outstanding voting power immediately prior to such
transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company, or
(v)&nbsp;the approval by the stockholders of the Company of a complete liquidation or dissolution of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term
&#8220;Subsidiary&#8221; means a &#8220;subsidiary corporation&#8221; with respect to the Company, as defined in Section&nbsp;424(f) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Rights on Termination of Employment</U>. If a Participant&#8217;s employment terminates for any reason before the Exercise Date for any
Offering, no payroll deduction or contributions will be taken from any pay due and owing to the Participant and the balance in the Participant&#8217;s account will be paid to such Participant or, in the case of such Participant&#8217;s death, if
permitted by the Administrator and valid under applicable law, to his or her designated beneficiary or to the legal representative of his or her estate as if such Participant had withdrawn from the Plan under Section&nbsp;7. An employee will be
deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a Designated Company, ceases to be a Subsidiary or Affiliate, or if the employee is transferred to any corporation other than the Company
or a Designated Company. Unless otherwise determined by the Administrator, a Participant whose employment transfers between, or whose employment terminates with an immediate rehire (with no break in service) by, Designated Companies or a Designated
Company, then the Company will be treated as having terminated Participant&#8217;s employment for purpose of participating in the Plan or an Offering; provided, however, that if a Participant transfers from an Offering under the 423 Component to an
Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, the exercise of the Participant&#8217;s Option will be qualified under the 423 Component only to the extent that such exercise complies with Section&nbsp;423 of the Code.
If a Participant transfers from an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to an Offering under the 423 Component, the exercise of the Participant&#8217;s Option will remain <FONT STYLE="white-space:nowrap">non-qualified</FONT> under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component. Further, an employee will not be deemed to have terminated employment for purposes of this Section&nbsp;12 if the employee is on an approved leave of absence for military service or sickness
or for any other purpose approved by the Company, if the employee&#8217;s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise
provides in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Special Rules and <FONT STYLE="white-space:nowrap">Sub-Plans</FONT></U>. Notwithstanding anything herein to
the contrary, the Administrator may adopt special rules or <FONT STYLE="white-space:nowrap">sub-plans</FONT> applicable to the employees of a particular Designated Company, whenever the Administrator determines that such rules are necessary or
appropriate for the implementation of the Plan in a jurisdiction where such Designated Company has employees, regarding, without limitation, eligibility to participate in the Plan, handling and making of payroll deductions or contributions by other
means, establishment of bank or trust accounts to hold payroll deductions or contributions, payment of interest, conversion of local currency, obligation to pay payroll tax, withholding procedures and handling of share issuances, any of which may
vary according to applicable requirements; provided that if such special rules or <FONT STYLE="white-space:nowrap">sub-plans</FONT> are inconsistent with the requirements of Section&nbsp;423(b) of the Code, the employees subject to such special
rules or <FONT STYLE="white-space:nowrap">sub-plans</FONT> will participate in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Optionees Not Stockholders</U>. Neither the granting of an Option to a Participant nor the deductions or contributions from his or her
pay shall result in such Participant becoming a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued to him or her. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Rights Not Transferable</U>. Rights under the Plan are not transferable by a Participant other than by will or the laws of descent and
distribution, and are exercisable during the Participant&#8217;s lifetime only by the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Application of Funds</U>. All
funds received or held by the Company under the Plan may be combined with other corporate funds and may be used for any corporate purpose, unless otherwise required under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Adjustment in Case of Changes Affecting Common Stock</U>. In the event of a subdivision of outstanding shares of Common Stock, the
payment of a dividend in Common Stock or any other change affecting the Common Stock, the number of shares approved for the Plan and the share limitation set forth in Section&nbsp;8 shall be equitably or proportionately adjusted to give proper
effect to such event. In the case of and subject to the consummation of a Sale Event, the Administrator, in its discretion, on such terms and conditions as it deems appropriate, is hereby authorized to take any one or more of the following actions
whenever the Administrator determines that such action is appropriate in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any right under the Plan or
to facilitate such transactions or events: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To provide for either (i)&nbsp;termination of any outstanding Option in exchange for an
amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such Option had such Option been currently exercisable or (ii)&nbsp;the replacement of such outstanding Option with other options or property selected by
the Administrator in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To provide that the outstanding Options under the Plan shall be assumed by the successor or
survivor corporation, or a parent or subsidiary thereof, or shall be substituted for similar options covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and
kind of shares and prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To make adjustments in the number and type of shares of Common Stock (or other securities or property)
subject to outstanding Options under the Plan and/or in the terms and conditions of outstanding Options and Options that may be granted in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To provide that the Offering with respect to which an Option relates will be shortened by setting a New Exercise Date on which such
Offering will end. The New Exercise Date will occur before the date of the Sale Event. The Administrator will notify each Participant in writing or electronically prior to the New Exercise Date, that the Exercise Date for the Participant&#8217;s
Option has been changed to the New Exercise Date and that the Participant&#8217;s Option will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering as provided in
Section&nbsp;7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To provide that all outstanding Options shall terminate without being exercised and all amounts in the
accounts of Participants shall be promptly refunded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Amendment of the Plan</U>. The Board may at any time and from time to time
amend the Plan in any respect, except that without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any other change that would require
stockholder approval in order for the Section&nbsp;423 Component of the Plan, as amended, to qualify as an &#8220;employee stock purchase plan&#8221; under Section&nbsp;423(b) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Insufficient Shares</U>. If the total number of shares of Common Stock that would otherwise be purchased on any Exercise Date plus the
number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares issuable under the Plan, the shares then available shall be apportioned among Participants in proportion to the amount of payroll deductions or
contributions accumulated on behalf of each Participant that would otherwise be used to purchase Common Stock on such Exercise Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.
<U>Termination of the Plan</U>. The Plan may be terminated at any time by the Board. Upon termination of the Plan, all amounts in the accounts of Participants shall be promptly refunded. Unless terminated earlier, the Plan shall expire on the <FONT
STYLE="white-space:nowrap">ten-year</FONT> anniversary of the Registration Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Governmental Regulations</U>. The Company&#8217;s obligation to sell and deliver
Common Stock under the Plan is subject to applicable laws and the completion of any registration or qualification of the Common Stock under any U.S. or <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> local, state or federal securities or exchange
control law, or under rulings or regulations of the SEC or of any other governmental regulatory body, and to obtaining any approval or other clearance from any U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> local, state or federal
governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. The Company is under no obligation to register or qualify the Common Stock with the SEC or any other U.S.
or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of such stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Governing Law</U>. This Plan and all Options and actions taken thereunder shall be governed by, and construed in accordance with, the
General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed and construed in accordance with the internal laws of the State of Delaware, applied without regard to conflict of
law principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Issuance of Shares</U>. Shares may be issued upon exercise of an Option from authorized but unissued Common Stock,
from shares held in the treasury of the Company or from any other proper source. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <U>Tax Withholding</U>. Participation in the Plan is
subject to any applicable U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> federal, state or local tax withholding requirements on income the Participant realizes in connection with the Plan. Each Participant agrees, by entering the Plan,
that the Company or any Subsidiary or Affiliate may withhold from a Participant&#8217;s wages, salary or other compensation at any time the amount necessary for the Company or any Subsidiary or Affiliate to meet applicable withholding obligations,
including any withholding required to make available to the Company or any Subsidiary or Affiliate any tax deductions or benefits attributable to the sale or disposition of Common Stock by such Participant. In addition, the Company or any Subsidiary
or Affiliate may withhold from the proceeds of the sale of Common Stock or use any other method of withholding that the Company or any Subsidiary or Affiliate deems appropriate to the extent permitted by U.S. Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.423-2(f)</FONT> with respect to the 423 Component. The Company will not be required to issue any Common Stock under the Plan until such obligations are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. <U>Notification Upon Sale of Shares Under the 423 Component</U>. Each Participant agrees, by entering the 423 Component of the Plan, to
give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased or within one year after the date
such shares were purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. <U>Effective Date and Approval of Shareholders</U>. The Plan shall take effect on the date immediately
preceding the Registration Date, subject to approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present or by written consent of the stockholders (the &#8220;Effective Date&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27. <U>Equal Rights and Privileges</U>. Notwithstanding any provision of the Plan to the contrary and in accordance with Section&nbsp;423 of
the Code for the 423 Component of the Plan, all eligible employees who are granted Options under the Plan shall have the same rights and privileges. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28. <U>No Right to Continued Service</U>. Neither the Plan nor any compensation paid
hereunder will confer on any Participant the right to continue as an employee or in any other capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29. <U>Entire Plan</U>. This Plan
constitutes the entire plan with respect to the subject matter hereof and supersedes all prior plans with respect to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE
APPROVED BY BOARD OF DIRECTORS: April&nbsp;7, 2026 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE APPROVED BY STOCKHOLDERS: April&nbsp;23, 2026 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>9
<FILENAME>d73463dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE SEVERANCE PLAN AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY PLAN DESCRIPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.
Introduction and Purpose </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document serves as the Plan document and Summary Plan Description (&#8220;<B><I>SPD</I></B>&#8221;) for
the severance pay and benefits provided under the Seaport Therapeutics, Inc. Executive Severance Plan (the &#8220;<B><I>Plan</I></B>&#8221;). Seaport Therapeutics, Inc., a Delaware corporation (including its successors, the
&#8220;<B><I>Company</I></B>&#8221;), considers it essential to foster the continuous employment of key management personnel. The Company acknowledges the possibility of an involuntary termination of employment exists and that such possibility, and
the uncertainty and questions that it may raise among management, may result in the departure or distraction of management personnel to the detriment of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, the Board has adopted this Plan to reinforce and encourage the continued attention and dedication of the Covered Executives to
their assigned duties without distraction. This Plan contains information that will help Covered Executives understand the severance pay and benefits being offered hereunder. The Company encourages all Covered Executives to read the Plan carefully.
Note that capitalized words and phrases used throughout this document are generally defined in Section&nbsp;4. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Establishment of Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of the effectiveness of the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the
&#8220;<B><I>Effective Date</I></B>&#8221;), the Board hereby establishes an unfunded severance benefits plan that is intended to be a welfare benefit plan within the meaning of Section&nbsp;3(1) of the Employee Retirement Income Security Act of
1974, as amended (&#8220;<B><I>ERISA</I></B>&#8221;). This Plan, along with the Participant Agreement, supersedes any and all severance plans, policies and provisions and all change in control plans, policies and provisions applying to a Covered
Executive that may have been in effect before the Effective Date, including by superseding all severance pay, benefits and equity acceleration provision in any Covered Employee&#8217;s offer letter, employment agreement or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Eligibility </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Covered Executives
who have executed and submitted to the Company a Participation Agreement, and satisfied such other requirements as may be determined by the Plan Administrator, are eligible to participate in the Plan. The Plan Administrator may determine at any time
that another employee should be designated as a Covered Employee and shall be eligible to participate in the Plan upon the Plan Administrator taking action by resolution to update the <U>Exhibit A</U> hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Definitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Plan, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#8220;<B><I>Accelerated Vesting Date</I></B>&#8221; means the later of the (i)&nbsp;Covered Executive&#8217;s Date of Termination or
(ii)&nbsp;effective date of the Covered Executive&#8217;s Separation Agreement and Release (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
&#8220;<B><I>Accounting Firm</I></B>&#8221;<I> </I>means a nationally recognized accounting firm selected by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
&#8220;<B><I>Adverse Benefit Determination</I></B>&#8221; means any of the following: a denial, reduction or termination of, or a failure to provide or make payment (in whole or in part) for, a benefit, including any such denial, reduction,
termination or failure to provide or make payment that is based on a determination of a Covered Executive&#8217;s or beneficiary&#8217;s eligibility to participate in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#8220;<B><I>Affiliate</I></B>&#8221;<I> </I>means any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are
defined in Rule 405 of the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#8220;<B><I>Base Salary</I></B>&#8221; means the of higher of the
Covered Executive&#8217;s annual base salary in effect immediately prior to (i)&nbsp;the Covered Executive&#8217;s Date of Termination or (ii)&nbsp;a Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#8220;<B><I>Board</I></B>&#8221; means the Board of Directors of the Plan Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#8220;<B><I>Cause</I></B>&#8221; means the good faith determination of the Board that any one or more of the following events has
occurred to the Covered Executive: (i)&nbsp;conviction of any felony, (ii)&nbsp;deliberate neglect of, willful misconduct in connection with the performance of, or refusal to perform duties reasonably assigned to the Covered Executive pursuant to
the terms hereof, if, within thirty (30)&nbsp;days after being notified in writing by the Chief Executive Officer or the Board of the conduct constituting Cause under this clause, the Covered Executive fails to cure such conduct (if such conduct is
curable), (iii) breach of any of the provisions of this Agreement or other written agreement with the Company if within thirty (30)&nbsp;days after being notified in writing by the Chief Executive Officer or the Board of the breach and such breach
is not cured (if such breach is curable) or (iv)&nbsp;any fraudulent or grossly negligent conduct, any action in bad faith, or willful misconduct, excluding conduct subject to clause (ii), that is otherwise materially detrimental to the reputation,
goodwill or best interests of the Company </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#8220;<B><I>Change in Control</I></B>&#8221; means a Sale Event, as defined in the
Company&#8217;s 2026 Stock Option and Incentive Plan, as amended from time to time, so long as such Change in Control also constitutes a &#8220;change in control event&#8221; within the meaning of section 409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#8220;<B><I>Change in Control Period</I></B>&#8221; means the period beginning three months prior to a Change in Control and ending on
the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#8220;<B><I>Code</I></B>&#8221; means the
Internal Revenue Code of 1986, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) &#8220;<B><I>Continuing Obligations</I></B>&#8221; means the Covered Executive&#8217;s
obligations to the Company pursuant to any agreement relating to confidentiality, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> of customers and employees, assignment of inventions and other restrictive covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#8220;<B><I>Covered Executives</I></B>&#8221; means the Tier 1 Executive and those other employees designated by the Plan Administrator
in its sole discretion as the Tier 2 Executives, in each case, who meet the eligibility requirements set forth in Section&nbsp;3 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) &#8220;<B><I>Date of Termination</I></B>&#8221; means the date that a Covered Executive&#8217;s employment with the Company and its
Affiliates ends, which date shall be specified in the Notice of Termination. Notwithstanding the foregoing, a Covered Executive&#8217;s employment will not be deemed to have been terminated solely as a result of the Covered Executive becoming an
employee of any direct or indirect successor to the business or assets of the Company or any Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)
&#8220;<B><I>Disability</I></B>&#8221; means the Covered Executive is disabled and unable to perform or expected to be unable to perform the essential functions of the Covered Executive&#8217;s then existing position or positions with or without
reasonable accommodation for a period of 180 days (which need not be consecutive) in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) &#8220;<B><I>Good Reason</I></B>&#8221; shall mean one of the following conditions after Good Reason Process (as defined below): (i) a
breach of this Agreement by the Company in any material respect, (ii)&nbsp;a material adverse change in the Covered Executive&#8217;s duties, authority, or responsibilities, (iii)&nbsp;a material reduction in the Covered Executive&#8217;s base
salary or material reduction in bonus opportunity, (iv)&nbsp;a change in the Covered Executive&#8217;s reporting relationship resulting in the Covered Executive no longer reporting directly to the Company&#8217;s Chief Executive Officer or the
Board, as applicable, except with respect to a change in reporting relationship in connection with a Change in Control, or (v)&nbsp;a relocation of the Covered Executive&#8217;s principal place of employment that increases the Covered
Executive&#8217;s <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than thirty-five (35)&nbsp;miles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) &#8220;<B><I>Good
Reason Process</I></B>&#8221; means that: (a)&nbsp;the Covered Employee has reasonably determined in good faith that a &#8220;Good Reason&#8221; condition has occurred, (b)&nbsp;within ninety (90)&nbsp;days of becoming aware of the first occurrence
of such condition, the Covered Executive has notified the Company in writing of the first occurrence of the Good Reason condition and the Covered Executive&#8217;s right to terminate the Covered Executive&#8217;s employment for Good Reason if such
condition is not cured, (c)&nbsp;the Covered Executive has cooperated in good faith with the Company&#8217;s efforts, for a period of thirty (30)&nbsp;days following such notice (the &#8220;Cure Period&#8221;), to remedy the condition (to the extent
capable of being cured or remedied), (d) notwithstanding such efforts, the Good Reason condition continues to exist, and (e)&nbsp;the Covered Executive terminates the Covered Executive&#8217;s employment within sixty (60)&nbsp;days after the end of
the Cure Period (or, if no Cure Period applies, the date on which the Covered Executive gave notice to the Company of the occurrence of such Good Reason) by providing written notice to the Company of the termination of the Covered Executive&#8217;s
employment during such sixty (60)&nbsp;day period, which termination shall be effective upon the date specified in the Covered Executive&#8217;s notice of termination. If the Company cures the Good Reason condition during the Cure Period (if
applicable), Good Reason shall be deemed not to have occurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) &#8220;<B><I>Notice</I></B>&#8221; or &#8220;<B><I>Notification</I></B>&#8221; means the
delivery or furnishing of information to an individual in a manner that is reasonably calculated to ensure actual receipt by the individual. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) &#8220;<B><I>Notice</I></B> <B><I>of Termination</I></B>&#8221; means a written Notice that indicates the specific termination provision
in this Plan relied upon for the termination of a Covered Executive&#8217;s employment and the Date of Termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)
&#8220;<B><I>Participation Agreement</I></B>&#8221;<I> </I>shall mean an agreement between a Covered Executive and the Company that acknowledges and agrees to the Covered Executive&#8217;s participation in the Plan and to any related terms set forth
in therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) &#8220;<B><I>Plan</I></B> <B><I>Administrator</I></B>&#8221; means the Board or a committee thereof designated by the
Board to administer the Plan; <I>provided</I>, <I>however</I>, that the Plan Administrator may in its sole discretion appoint a new Plan Administrator to administer the Plan at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) &#8220;<B><I>Plan Sponsor</I></B>&#8221; means the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) &#8220;<B><I>Qualified Termination</I></B>&#8221; means (i)&nbsp;a termination of the Covered Executive&#8217;s employment by the Company
other than for Cause, death or Disability or (ii)&nbsp;the Covered Executive&#8217;s resignation from the Company for Good Reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)
&#8220;<B><I>Separation Obligations</I></B>&#8221; means: (i)&nbsp;execution of a separation agreement and release in a form and manner satisfactory to and provided by the Company that contains, among other provisions, a confirmation of the Covered
Employee&#8217;s resignation from all officer and director positions with the Company and any Affiliate as of the Date of Termination, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of
property and <FONT STYLE="white-space:nowrap">non-disparagement</FONT> provisions, a reaffirmation of the Covered Executive&#8217;s Continuing Obligations and provides that if the Covered Executive breaches any of the Continuing Obligations, all
severance payments and benefits shall immediately cease (the &#8220;<B><I>Separation Agreement and Release</I></B>&#8221;) and (ii)&nbsp;the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or
such shorter period set forth in the Separation Agreement and Release). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) &#8220;<B><I>Target Bonus</I></B>&#8221; means the higher of
the Covered Executive&#8217;s target annual cash incentive compensation or target sales incentive plan commission, as applicable, in effect immediately prior to (i)&nbsp;the Covered Executive&#8217;s Date of Termination or (ii)&nbsp;the Change in
Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) &#8220;<B><I>Tier 1 Executive</I></B>&#8221; means the Company&#8217;s Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) &#8220;<B><I>Tier 2 Executives</I></B>&#8221; means the individuals holding the titles designated as such by the Plan Administrator and
whose titles are listed in <U>Exhibit A</U>, attached hereto, as such exhibit may be amended by the Plan Administrator from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) &#8220;<B><I>Time-Based</I></B> <B><I>Equity Awards</I></B>&#8221; means all outstanding stock options, restricted stock units,
restricted stock awards and other stock-based awards with respect to the Company&#8217;s common stock that are subject solely to time-based vesting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Covered Executive&#8217;s employment with the Company is terminated for any reason, the Covered Executive shall be deemed to have
resigned from any officer or director positions that the Covered Executive holds with the Company or any Affiliate as of the Date of Termination. the Company shall pay or provide to the Covered Executive (or to the Covered Executive&#8217;s<B>
</B>authorized representative or estate)&nbsp;(i) any base salary earned but unpaid through the Date of Termination; (ii)&nbsp;unpaid expense reimbursements (subject to, and in accordance with, the Company&#8217;s expense reimbursement policy then
in effect); and (iii)&nbsp;any vested benefits the Covered Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such
employee benefit plans (collectively, the &#8220;<B><I>Accrued Obligations</I></B>&#8221;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Qualified Termination not in Connection with a Change
in Control </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Covered Executive experiences a Qualified Termination outside of the Change in Control Period, then, in addition to
the Accrued Obligations, and subject to the Covered Executive&#8217;s fulfillment of the Separation Obligations: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Company shall pay
to the Covered Executive an amount equal to the sum of (i)&nbsp;0.75 times the Covered Executive&#8217;s Base Salary (or, in the case of the Tier 1 Executive one times the Covered Executive&#8217;s Base Salary), and (ii)&nbsp;a <FONT
STYLE="white-space:nowrap">pro-rated</FONT> portion of the Covered Executive&#8217;s Target Bonus (with such <FONT STYLE="white-space:nowrap">pro-ration</FONT> determined based on the actual number of days the Covered Executive was employed by the
Company or any Affiliate in the calendar year in which the Date of Termination occurs); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) subject to the Covered Executive&#8217;s
proper election to receive COBRA benefits, the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the employer portion of the monthly COBRA premium until the earliest of (i)&nbsp;the nine-month
anniversary (or, in the case of the Tier 1 Executive the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary) of the Date of Termination; (ii)&nbsp;the date that the Covered Executive becomes eligible for group medical plan benefits under
another employer&#8217;s group medical plan; or (iii)&nbsp;the cessation of the Covered Executive&#8217;s health continuation rights under COBRA; <I>provided</I>, <I>however</I>, that if the Company determines that such payments may violate
applicable law, the Company shall instead make such payments directly to the Covered Executive in the form of payroll. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts
payable under Section&nbsp;6(a) and 6(b), as applicable, will be paid out in substantially equal installments in accordance with the Company&#8217;s payroll practice over nine months (or, in the case of the Tier 1 Executive or a Tier 2 Executive
with an existing employment agreement as of the Effective Date that provides for 12 months of severance pay, 12 months), commencing within 60 days after the Date of Termination; <I>provided</I>, <I>however</I>, that if the <FONT
STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as <FONT STYLE="white-space:nowrap">&#8220;non-qualified</FONT> deferred compensation&#8221;
within the meaning of Section&nbsp;409A of the Code, shall begin to be paid in the second calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period; <I>provided</I>, <I>further</I>, that the initial payment shall
include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to the day immediately following the Date of Termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Change in Control </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a Change in Control the Tier 1 Executive shall be entitled to Tier 1 Executive Change in Control Accelerated Vesting. Further, if any
Covered Executive experiences a Qualified Termination within the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the Covered Executive&#8217;s fulfillment of the Separation Obligations: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Company shall pay to the Covered Executive an amount equal to the sum of (i)&nbsp;the Covered Executive&#8217;s Base Salary (or, in the
case of the Tier 1 Executive, 1.5 times the Tier&nbsp;1 Executive&#8217;s Base Salary) and (ii)&nbsp;the Covered Executive&#8217;s Target Bonus (or, in the case of the Tier 1 Executive, 1.5 times the Tier 1 Executive&#8217;s Target Bonus); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) subject to the Covered Executive&#8217;s proper election to receive COBRA benefits, the Company shall pay to the group health plan
provider or the COBRA provider a monthly payment equal to the monthly COBRA premium until the earliest of (i)&nbsp;the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary (or, in the case of the Tier 1 Executive, the <FONT
STYLE="white-space:nowrap">18-months</FONT> anniversary) of the Date of Termination; (ii)&nbsp;the date that the Covered Executive becomes eligible for group medical plan benefits under another employer&#8217;s group medical plan; or (iii)&nbsp;the
cessation of the Covered Executive&#8217;s health continuation rights under COBRA; <I>provided</I>, <I>however</I>, that if the Company determines that such payments may violate applicable law, the Company shall instead make such payments directly
to the Covered Executive in the form of payroll; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) notwithstanding anything to the contrary in any applicable Time-Based Equity
Award agreement or in any applicable Company equity incentive plan, all Time-Based Equity Awards shall immediately accelerate and become fully vested and exercisable or nonforfeitable as of the Accelerated Vesting Date, provided that in order to
effectuate the accelerated vesting contemplated by this subsection, the unvested portion of the Covered Executive&#8217;s Time-Based Equity Awards that would otherwise terminate or be forfeited on the Date of Termination will be delayed until the
earlier of (i)&nbsp;the effective date of the Separation Agreement and Release or the date of the Change in Control, as applicable (at which time acceleration will occur), or (ii)&nbsp;the date that the Separation Agreement and Release can no longer
become fully effective (at which time the unvested portion of the Covered Executive&#8217;s Time-Based Equity Awards will terminate or be forfeited). Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards will occur
during the period between the Date of Termination and the Accelerated Vesting Date. For the avoidance of doubt, upon a Qualifying Termination prior to the consummation of a Change in Control (1)&nbsp;all then unvested Time-Based Equity Awards held
by the Covered Executive as of the Date of Termination will remain outstanding for a period of three months thereafter (unless such Time-Based Equity Awards are forfeited prior to such date pursuant to clause (ii)&nbsp;of the preceding sentence) and
remain eligible to become vested upon the consummation of such Change in Control and, to the extent such Time-Based Equity Awards do not become vested in accordance with the terms set forth in this Section&nbsp;7(c) on or prior to the date that is
three months following the Date of Termination, all then-unvested Time-Based Equity Awards held by such Covered Executive will automatically and without further action be canceled and forfeited on the three-month anniversary of the Date of
Termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts payable under Section&nbsp;7(a) shall be paid out in a lump sum within 60 days
after the Date of Termination and the amounts payable under Section&nbsp;7(b) will be paid out in substantially equal installments in accordance with the Company&#8217;s payroll practice over 12 months (or, in the case of the Tier 1 Executive, 18
months), commencing within 60 days after the Date of Termination; <I>provided</I>, <I>however</I>, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments, to
the extent they qualify as <FONT STYLE="white-space:nowrap">&#8220;non-qualified</FONT> deferred compensation&#8221; within the meaning of Section&nbsp;409A of the Code, shall begin to be paid in the second calendar year by the last day of such <FONT
STYLE="white-space:nowrap">60-day</FONT> period; <I>provided</I>, <I>further</I>, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to the day immediately following the
Date of Termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, (i)&nbsp;in no event will the Covered Executive be entitled to severance payments and
benefits under both Section&nbsp;6 and Section&nbsp;7 of this Plan and (ii)&nbsp;if a Covered Executive has begun receiving severance pay and benefits under Section&nbsp;6 prior to the date that the Covered Executive becomes eligible to receive
severance pay and benefits under this Section&nbsp;7, the severance pay and benefits previously provided to the Covered Executive under Section&nbsp;6 shall reduce the severance pay and benefits to be provided under this Section&nbsp;7. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Section&nbsp;409A </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) This Plan is
intended to be administered in accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Plan is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that
all payments hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this Plan is intended to constitute a separate payment for purposes of Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> This Plan may be amended as may be necessary to fully comply with Section&nbsp;409A of the Code and all related rules and regulations in order to preserve the payments and benefits
provided hereunder without additional cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) To the extent that any payment or benefit described in this Plan constitutes <FONT
STYLE="white-space:nowrap">&#8220;non-qualified</FONT> deferred compensation&#8221; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Covered Executive&#8217;s termination of employment, then
such payments or benefits shall be payable only upon the Covered Executive&#8217;s &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions
set forth in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Anything in this Plan to the
contrary notwithstanding, if at the time of the Covered Executive&#8217;s separation from service within the meaning of Section&nbsp;409A of the Code, the Company determines that the Covered Executive is a &#8220;specified employee&#8221; within the
meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Covered Executive becomes entitled to under this Plan on account of the Covered Executive&#8217;s separation from service would be considered
deferred compensation otherwise subject to the 20% additional tax imposed pursuant to Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit
shall not be provided until the date that is the earlier of (A)&nbsp;six months and one day after the Covered Executive&#8217;s separation from service, or (B)&nbsp;the Covered Executive&#8217;s death. If any such delayed cash payment is otherwise
payable on an installment basis, the first payment shall include a catch- up payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision
(without interest), and the balance of the installments shall be payable in accordance with their original schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company makes no representation or warranty and shall have no liability to any
Covered Executive or any other person if any provisions of this Plan are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Additional Limitation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Anything in this Plan to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the
Company to or for the benefit of the Covered Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Plan or otherwise, calculated in a manner consistent with Section&nbsp;280G of the Code and the applicable
regulations thereunder (the &#8220;<B><I>Aggregate Payments</I></B>&#8221;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the
Aggregate Payments shall be $1.00 less than the amount at which the Covered Executive becomes subject to the excise tax imposed by Section&nbsp;4999 of the Code; provided that such reduction will only occur if it would result in the Covered
Executive receiving a higher After Tax Amount (as defined below) than the Covered Executive would receive if the Aggregate Payments were not subject to such reduction. Notwithstanding the foregoing, if, immediately before the change in ownership or
control, no stock of the Company is readily tradeable on an established securities market or otherwise (determined in accordance with Q&amp;A 6 of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.280G-1),</FONT> the Company shall
use reasonable efforts to satisfy the shareholder approval requirements set forth in Q&amp;A 7 of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.280G-1</FONT> with respect to the amount of any such potential reduction, and if
such requirements are satisfied then no such reduction will apply. In the event of a reduction, the Aggregate Payments will be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that
are to be paid the furthest in time from consummation of the transaction that is subject to Section&nbsp;280G of the Code: (i)&nbsp;cash payments not subject to Section&nbsp;409A of the Code; (ii)&nbsp;cash payments subject to Section&nbsp;409A of
the Code; (iii)&nbsp;equity-based payments and acceleration; and <FONT STYLE="white-space:nowrap">(iv)&nbsp;non-cash</FONT> forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not
subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c)&nbsp;shall be reduced before any amounts that are subject to calculation under Treas. Reg. <FONT
STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) For purposes of this
Section, the &#8220;<B><I>After Tax Amount</I></B>&#8221; means the amount of the Aggregate Payments less all federal, state and local income, excise, employment and social security taxes imposed on the Covered Executive as a result of the Covered
Executive&#8217;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Covered Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to
individuals for the calendar year in which the determination is to be made, and state and local income taxes and social security taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum
reduction in federal income taxes (if any) that could be obtained from deduction of such state and local taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The determination as to whether a reduction in the Aggregate Payments shall be made
pursuant to Section&nbsp;9(a) shall be made by the Accounting Firm selected by the Company prior to the closing of the Change in Control, which shall provide detailed supporting calculations both to the Company and the Covered Executive within 15
business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Covered Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Covered
Executive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Withholding; Tax Effect </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All payments made under this Plan shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing
in this Plan shall be construed to require the Company to make any payments to compensate the Covered Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Death </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Covered Executive dies
after the Date of Termination, but before all payments or benefits to which such Covered Executive is entitled pursuant to the Plan have been paid or provided, any remaining payments and benefits will be made to any beneficiary designated by the
Covered Executive prior to the Covered Executive&#8217;s death (or the Covered Executive&#8217;s estate, if the Covered Executive fails to make such designation). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Plan Administration </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Plan
Administrator</I>. The Plan Administrator and Plan Sponsor shall serve as the &#8220;named fiduciaries&#8221; of the Plan under ERISA. The Plan Administrator shall be the &#8220;administrator&#8221; within the meaning of Section&nbsp;3(16) of ERISA
and shall have all the responsibilities and duties contained therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Decisions, Powers and Duties</I>. The general administration
of the Plan and the responsibility for carrying out its provisions shall be vested in the Plan Administrator. The Plan Administrator shall have the maximum discretionary authority permitted by law to discharge such duties and responsibilities, which
also include, but are not limited to, interpretation and construction of the Plan, the determination of all questions of fact, including, without limitation, eligibility, participation and benefits, the resolution of any ambiguities and all other
related or incidental matters, and such duties and powers of the Plan administration that are not assumed from time to time by any other appropriate entity, individual or institution. The Plan Administrator may adopt rules and regulations of uniform
applicability in its interpretation and implementation of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan Administrator shall discharge its duties and
responsibilities and exercise its powers and authority in its sole discretion and in accordance with the terms of the controlling legal documents and applicable law, and its actions and decisions that are not arbitrary and capricious shall be
binding on any Covered Executive, and the Covered Executive&#8217;s spouse or other dependent or beneficiary and any other interested parties whether or not in being or under a disability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Reports</I>. The Plan Administrator shall be responsible for the preparation and
delivery of all reports, notices, plan summaries and plan descriptions required to be filed with any governmental office or to be given to any employee, former employee or beneficiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Company to Furnish Information</I>. Upon request of the Plan Administrator, the Company shall furnish such information in its
possession and aid the Plan Administrator in the performance of its duties hereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Claims Procedure and Payment of Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Application for Benefits</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>General</U>. All applications for benefits under the Plan shall be submitted to the Plan Administrator at such location as designated by
the Plan Administrator from time to time. Applications for benefits must be in writing on forms acceptable to the Plan Administrator and must be signed by the Covered Executive. The Plan Administrator reserves the right to require the Covered
Executive to furnish such other information and documents as the Plan Administrator determines are necessary or appropriate. Each application shall be acted upon and approved or disapproved by the Plan Administrator within 90 days following its
receipt by the Plan Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>Notification</U>. The Plan Administrator shall provide a claimant with written or electronic
Notification of any Adverse Benefit Determination. Any electronic Notification shall comply with the standards imposed by 29 C.F.R. <FONT STYLE="white-space:nowrap">2520.104b-l(c)(l)(i),</FONT> (iii) and (iv). The Notification shall set forth, in a
manner calculated to be understood by the claimant: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the specific reason or reasons for the Adverse Benefit Determination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reference to the specific Plan provisions on which the Adverse Benefit Determination is based;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a description of any additional material or information necessary for the claimant to perfect the claim and an
explanation of why such material or information is necessary; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a description of the Plan&#8217;s review procedures and the time limits applicable to such procedures,
including a statement of the claimant&#8217;s right to bring a civil action under Section&nbsp;502(a) of ERISA following an Adverse Benefit Determination on review. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Review of Benefit Denials</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Appeal</U>. A claimant shall have a reasonable opportunity to appeal an Adverse Benefit Determination to the Board and under which there
will be a full and fair review of the claim and the Adverse Benefit Determination. The Board shall be identified in the Notification described in Section&nbsp;13(a)(ii) and may be the Plan Administrator. Such full and fair review shall: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide claimants at least 60 days following receipt of a Notification of an Adverse Benefit Determination
within which to appeal the Adverse Benefit Determination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide claimants the opportunity to submit written comments, documents, records and other information relating
to the claim for benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide that a claimant shall be provided, upon request and free of charge, reasonable access to, and copies
of, all documents, records and other information relevant to the claimant&#8217;s claim for benefits; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide for a review of the initial Adverse Benefit Determination that takes into account all comments,
documents, records and other information submitted by the claimant relating to the claim, without regard to whether such information was submitted or considered in the initial Adverse Benefit Determination. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>Timing of Benefit Determination on Review</U>. The Board shall notify the Covered Executive, in accordance with
Section&nbsp;13(b)(iv), of the Plan Administrator&#8217;s benefit determination on review within a reasonable period of time. Such Notification shall be provided not later than 60 days after receipt by the Plan Administrator of the Covered
Executive&#8217;s request for review of the Adverse Benefit Determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <U>Furnishing Documents</U>. In the case of an Adverse
Benefit Determination on review, the Board shall provide such access to, and copies of, documents, records and other information described in Section&nbsp;13(b)(iv) as is appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) <U>Content of Notification on Review</U>. The Board shall provide a claimant with written or electronic Notification of a Plan
Administrator&#8217;s benefit determination following an appeal described in Section&nbsp;13(b)(i). Any electronic Notification shall comply with the standards imposed by 29 C.F.R. <FONT STYLE="white-space:nowrap">2520.104b-l(c)(l)(i),</FONT> (iii)
and (iv). In the case of an Adverse Benefit Determination on review, the Notification shall set forth, in a manner calculated to be understood by the claimant: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the specific reason or reasons for the Adverse Benefit Determination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reference to the specific Plan provisions on which the Adverse Benefit Determination is based;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a statement that the claimant is entitled to receive, upon request and free of charge, reasonable access to,
and copies of, all documents, records and other information relevant to the claimant&#8217;s claim for benefits; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a statement of the claimant&#8217;s right to bring an action under Section&nbsp;502(a) of ERISA.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Calculating Time Periods</I>. The period of time within which a benefit determination (including an Adverse
Benefit Determination on review) is required to be made shall begin at the time a claim (or appeal) is filed in accordance with the reasonable procedures of the Plan, without regard to whether all the information necessary to make a benefit
determination accompanies the filing. In the event that a period of time is extended due to a claimant&#8217;s failure to submit information necessary to decide a claim, the period for making the benefit determination shall be tolled from the date
on which the Notification of the extension is sent to the claimant until the date on which the claimant responds to the request for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Extension of Notice Period</I>. The 90 day and 60 day periods applicable to the Notice furnished by the Plan Administrator in Sections
13(a) and 13(b) above may be extended at the discretion of the Plan Administrator for a second 90 or 60 day period, as the case may be, provided that written Notice of the extension is furnished to the claimant prior to the termination of the
initial period, indicating the special circumstances requiring such extension of time and the date by which a final decision is expected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Facility of Payment</I>. Whenever and as often as any person entitled to payments hereunder shall be determined to be a minor or under
other legal disability or otherwise incapacitated in any way so as to be unable to manage the person&#8217;s financial affairs, the Company, in its discretion, may direct that all or any portion of the benefit payments be made: (i)&nbsp;to such
person; (ii)&nbsp;to such person&#8217;s legal guardian or conservator; or (iii)&nbsp;to such person&#8217;s spouse. The decision of the Plan Administrator shall, in each case, be final and binding upon all persons. Any payment made pursuant to the
authority herein conferred shall operate as a complete discharge of the obligations of the Company under the Plan in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<I>Responsibility for Payment</I>. The Company shall be liable for the payment of benefits in accordance with the terms of the Plan. The benefits under the Plan shall be payable solely by the Company and each Covered Executive who shall claim the
right to any payment under the Plan shall be entitled to look only to the Company for such payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Limitation on Benefits</I>.
The Company shall have no obligation to set aside, earmark or entrust any fund, policy or money with which to pay its obligations under this Plan. The Covered Executive, or any successor in interest, shall be and remain simply a general, unsecured
creditor of the Company with respect to the benefits under this Plan in the same manner as any other creditor who has a general claim for an unpaid liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent
permitted by law, all employees, officers, directors, agents and representatives of the Company shall be indemnified by the Company and held harmless against any claims and the expenses of defending against such claims, resulting from any action or
conduct relating to the administration of the Plan, whether as a member of the Plan Administrator or otherwise, except to the extent that such claims arise from gross negligence, willful neglect or willful misconduct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Plan; At Will Employment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan is not a contract between the Company and any employee, nor is it a condition of employment or services of any employee. Nothing
contained in the Plan gives, or is intended to give, any employee the right to be retained in the service of the Company, or to interfere with the right of the Company to discharge or terminate the employment or services of any employee at any time
and for any reason. No employee shall have the right or claim to benefits beyond those expressly provided in this Plan, if any. All rights and claims are limited as set forth in the Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Severability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any portion or
provision of this Plan (including, without limitation, any portion or provision of any Section of this Plan) is to any extent declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Plan, or the application
of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Plan shall be valid and enforceable to the fullest extent
permitted by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Waiver </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No
waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Plan, or the waiver by any party of any breach of this
Plan, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Successors and
Assigns </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No right or interest of any Covered Executive in the Plan shall be assignable or transferable in whole or in part either
directly or by operation of law or otherwise, including, but not limited to, execution, levy, garnishment, attachment, pledge or bankruptcy. The Plan Sponsor may assign or otherwise transfer this Plan without any Covered Executive&#8217;s consent to
any affiliate or to any person or entity with whom the Plan Sponsor shall hereafter effect a reorganization or consolidation, into which the Plan Sponsor merges or to whom it transfers all or substantially all of its properties or assets;
<I>provided</I> that if the Covered Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the Covered Executive shall not be entitled to any payments or
benefits pursuant to Sections 6 or 7 of this Plan solely as a result of such transaction. This Plan shall inure to the benefit of and be binding upon the Covered Executive and the Plan Sponsor, and each of the Covered Executive&#8217;s and the Plan
Sponsor&#8217;s respective successors, executors, administrators, heirs and permitted assigns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. <FONT STYLE="white-space:nowrap">Non-Duplication</FONT> of Benefits and Effect on Other Plans20.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision in the Plan to the contrary, the benefits provided hereunder and, if applicable, pursuant to the
Participant Agreement, are in lieu of any other severance payments and/or benefits provided by the Company, including any such payments and/or benefits pursuant to an employment agreement or offer letter between the Company and any Covered
Executive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. Amendment or Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan Sponsor may amend or terminate this Plan at any time or from time to time, but no such action shall adversely affect the rights of any
Covered Executive who has signed a Participation Agreement without such Covered Executive&#8217;s written consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. Governing Law and Limitation on
Actions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan and the rights of all persons hereunder shall be construed in accordance with and under applicable provisions of
ERISA, and the regulations thereunder, and the Plan and the rights of all persons under the Plan shall be construed in accordance with and under applicable provisions the laws of the Commonwealth of Massachussetts (without regard to conflict of laws
provisions), to the extent not preempted by federal law. No action (whether at law, in equity or otherwise) shall be brought by or on behalf of any person for or with respect to benefits due under this Plan unless the person bringing such action has
timely exhausted the Plan&#8217;s claim review procedure. Any action (whether at law, in equity or otherwise) must be filed and litigated in the U.S. District Court for the District of Massachusetts, and must be commenced within one year. This <FONT
STYLE="white-space:nowrap">one-year</FONT> period shall be computed from the earlier of (a)&nbsp;the date a final determination denying such benefit, in whole or in part, is issued under the Plan&#8217;s claim review procedure and (b)&nbsp;the date
such person&#8217;s cause of action first accrued. If a person does not bring such an action within such <FONT STYLE="white-space:nowrap">one-year</FONT> period, the person will be barred from bringing such action. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. ERISA Required Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Official Plan
Name</I>: The official name of the Plan is the Seaport Therapeutics, Inc. Executive Severance Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Administrator</I>: The Plan Administrator is
the Board (or its designee) of the Plan Sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Sponsor</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COMPANY NAME </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ADDRESS </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(617) <FONT STYLE="white-space:nowrap">807-4062</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Number</I>: Documents and reports for the Plan are filed with the U.S. Department of Labor under
Seaport Therapeutics, Inc. Employer Identification Number (EIN) and the Plan Number (PN). The EIN for Seaport Therapeutics, Inc. is <FONT STYLE="white-space:nowrap">99-2235719,</FONT> and the PN is 503. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Plan Year</I>: The Plan year is January&nbsp;1 through December 31. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Agent for Service of Legal Process</I>: Seaport Therapeutics, Inc. is the Plan&#8217;s agent for service of legal process and may be served at the address
indicated in the section entitled &#8220;Plan Administrator and Sponsor&#8221; above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Funding</I>: All severance pay and benefits are paid from the
Company&#8217;s general assets and, thus the Plan is considered unfunded for tax purposes under Title I of ERISA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ERISA Rights</I>: The Plan is
subject to ERISA. As a Covered Executive, you are entitled to certain rights and protections under ERISA. Under ERISA, you are entitled to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Examine, without charge at the Plan Administrator&#8217;s office, all official Plan documents (including
insurance contracts) and copies of all documents filed with the U.S. Department of Labor, such as detailed Summary Annual Reports. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtain copies of all official Plan documents and other Plan information upon written request to the Plan
Administrator. The Plan Administrator may charge a reasonable fee for the copies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Receive a summary of the Plan&#8217;s annual financial report. The Plan Administrator is required to furnish each
participant with a copy of this Summary Annual Report. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You also have the right to expect &#8220;fiduciaries,&#8221; the people who are
responsible for the management of the Plan, to act prudently and to act in the interest of you and other Plan participants and beneficiaries. Another one of your ERISA-guaranteed rights means that no one &#8211; including the Company or any other
person &#8211; may fire you or otherwise discriminate against you in any way to prevent you from obtaining a Plan benefit or exercising your rights under ERISA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ERISA also guarantees your rights to written notice if any part of a claim is denied or ignored, in whole or in part. Because your rights under ERISA are
protected by law, you also can file suit if a right is denied. For example, if you request certain Plan-related materials from the Plan Administrator and do not receive them within 30 days, you may file suit in a federal court. In such a case, the
court may require the Plan Administrator to provide the materials and pay a fine of up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator. You may file
suit in a federal court if you have a claim for benefits under the Plan that is denied or ignored, in whole or in part. You also can seek assistance from the U.S. Department of Labor or file suit in a federal court if a Plan fiduciary has misused
Plan funds or if you are discriminated against for asserting your rights. The court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose
because, for example, the court finds your claim frivolous, you may be ordered to pay all these costs and fees on your own, including any court costs and attorney fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any questions about the Plan, you should contact the Plan Administrator. If you have any
questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of
Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Ave. N.W., Washington, D.C. 20210. You may also obtain certain
publications about your rights and responsibilities under ERISA by calling the Employee Benefits Security Administration&#8217;s publications hotline at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-444-3272.</FONT></FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Tier 2 Executives </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>Title</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Medical Officer&nbsp;&amp; President, Clinical Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">General Counsel</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>10
<FILENAME>d73463dex108.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAPORT THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NON-EMPLOYEE DIRECTOR COMPENSATION POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of this <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy (the &#8220;Policy&#8221;) of Seaport Therapeutics, Inc.
(the &#8220;Company&#8221;) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (&#8220;Outside
Directors&#8221;). This Policy will become effective as of the effective time of the registration statement for the Company&#8217;s initial public offering of its equity securities (the &#8220;Effective Date&#8221;). Unless otherwise determined by
the Board of Directors, Outside Directors who are employees of, or otherwise affiliated with, an institutional investor in the Company shall not be eligible to receive compensation under this Policy. In furtherance of the purpose stated above, all
Outside Directors shall be paid compensation for services provided to the Company as Outside Directors as set forth below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Cash Retainers
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Annual Retainer for Board Membership</U>: $40,000 for general availability and participation in meetings and conference calls of our Board of
Directors, to be paid quarterly in arrears, <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the number of actual days served by the director during such calendar quarter. No additional compensation will be paid for attending individual
meetings of the Board of Directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Additional Annual Retainer for <FONT STYLE="white-space:nowrap">Non-Executive</FONT>
Chairperson</U>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Additional Annual Retainers for Committee Membership</U>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee member:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee member:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee member:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Science and Technology Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Science and Technology Committee member:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Equity Retainers </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All grants of equity retainer awards to Outside Directors pursuant to this Policy will be made in accordance with the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Initial Award</U>: Upon his or her initial election to the Board of Directors, each Outside Director will receive an initial,
<FONT STYLE="white-space:nowrap">one-time</FONT> stock option award (the &#8220;Initial Award&#8221;) to purchase 49,033 shares, which shall vest in equal monthly installments over three years from the date of grant, provided, however, that all
vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as on the Board of Directors of the Company, unless the Board of Directors determines that the circumstances warrant continuation of vesting. The
Initial Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value (as defined in the Company&#8217;s 2026 Stock Option and Incentive Plan) of the Company&#8217;s common stock on the
date of grant. This Initial Award applies only to Outside Directors who are first elected to the Board of Directors subsequent to the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Annual Award</U>: On each date of each Annual Meeting of Stockholders of the Company following the Effective Date (the &#8220;Annual Meeting&#8221;), each
continuing Outside Director, other than a director receiving an Initial Award, will receive an annual stock option award (the &#8220;Annual Award&#8221;) to purchase 24,516 shares, which shall vest in full upon the earlier of (i)&nbsp;the first
anniversary of the date of grant or (ii)&nbsp;the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve on the Board of Directors of the
Company, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Such Annual Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value of
the Company&#8217;s common stock on the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Expenses </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will reimburse all reasonable out-of-pocket expenses incurred by Outside Directors in attending meetings of the Board of Directors or any committee
thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Maximum Annual Compensation </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
aggregate amount of compensation, including both equity compensation and cash compensation, paid by the Company to any Outside Director in a calendar year for services as an Outside Director shall not exceed $750,000 (or such other limit as may be
set forth in Section&nbsp;3(b) of the Company&#8217;s 2026 Stock Option and Incentive Plan, as amended from time to time, or any similar provision of a successor plan); provided, however, that in the first calendar year in which an individual
becomes an Outside Director, the aggregate amount of all equity compensation awarded and all other cash compensation paid by the Company to such Outside </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Director for services as an Outside Director shall not exceed $1,000,000 (or such other limit as may be set forth in Section&nbsp;3(b) of the Company&#8217;s 2026 Stock Option and Incentive Plan,
as amended from time to time, or any similar provision of a successor plan). For this purpose, the &#8220;amount&#8221; of equity compensation paid in a calendar year shall be determined based on the grant date fair value thereof, as determined in
accordance with FASB ASC Topic 718 or its successor provision, but excluding the impact of estimated forfeitures related to service-based vesting conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adopted April&nbsp;7, 2026, subject to effectiveness of the Company&#8217;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>d73463dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of Seaport Therapeutics, Inc. of our report
dated February&nbsp;27, 2026, except for the effects of the reverse stock split discussed in Note 18 to the consolidated financial statements, as to which the date is April&nbsp;27, 2026, relating to the financial statements of Seaport Therapeutics,
Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading &#8220;Experts&#8221; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;27, 2026 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>12
<FILENAME>d73463dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:ffd="http://xbrl.sec.gov/ffd/2026">
<head>
<title>EX-FILING FEES</title>
</head>
  <body>
  <div style="display: none"> <ix:header> <ix:hidden> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-342">S-1</ix:nonNumeric> <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-343">S-1/A</ix:nonNumeric> <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-344">EX-FILING FEES</ix:nonNumeric> <ix:nonNumeric name="ffd:RegnFileNb" contextRef="rc" id="ixv-345">333-294976</ix:nonNumeric> <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-346">0002042347</ix:nonNumeric> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-347">Seaport Therapeutics, Inc.</ix:nonNumeric> <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric> <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric> <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd" xlink:type="simple"/> </ix:references> <ix:resources> <xbrli:context id="rc"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0002042347</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-04-23</xbrli:startDate> <xbrli:endDate>2026-04-23</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_1"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0002042347</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>1</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-04-23</xbrli:startDate> <xbrli:endDate>2026-04-23</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_2"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0002042347</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>2</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-04-23</xbrli:startDate> <xbrli:endDate>2026-04-23</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:unit id="USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit> <xbrli:unit id="pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit> <xbrli:unit id="Shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit> </ix:resources> </ix:header> </div> <div>
<table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
<tr>
<td colspan="4" style="padding-bottom: .5em"> <p> <b>Calculation of Filing Fee Tables</b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-384">S-1</ix:nonNumeric> </b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-385">Seaport Therapeutics, Inc.</ix:nonNumeric> </b> </p> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 1: Newly Registered and Carry Forward Securities</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
<tr style="background-color:#9ADAF6">
<th style="width: 12%;">
 </th>
<th style="width: 2%;">
 </th>
<th style="width: 12%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 14%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title </b> </p> </th>
<th style="width: 2%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Calculation or Carry Forward Rule</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount Registered</b> </p> </th>
<th style="width: 15%;"> <p style="margin: 0pt; text-align: center;"> <b>Proposed Maximum Offering Price Per Unit</b> </p> </th>
<th style="width: 10%;"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Rate</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Registration Fee</b> </p> </th>
<th style="width: 1%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Form Type</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward File Number</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Initial Effective Date</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b> </p> </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Newly Registered Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_1" format="ixt:booleanfalse" id="ixv-386">Fees to be Paid</ix:nonNumeric> </td>
<td style="text-align: center;"> 1 </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-387">Equity</ix:nonNumeric> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-388">Common Stock, $0.0001 par value per share</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457aFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-389">457(a)</ix:nonNumeric> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="Shares" decimals="0" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-390">8,014,444</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-391">18.00</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-392">144,259,992.00</ix:nonFraction> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="7" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-393">0.0001381</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-394">19,922.30</ix:nonFraction> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_2" format="ixt:booleantrue" id="ixv-395">Fees Previously Paid</ix:nonNumeric> </td>
<td style="text-align: center;"> 2 </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_2" id="ixv-396">Equity</ix:nonNumeric> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_2" id="ixv-397">Common Stock, $0.0001 par value per share</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457aFlg" contextRef="offrl_2" format="ixt:booleantrue" id="ixv-398">457(a)</ix:nonNumeric> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="Shares" decimals="0" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-399">5,555,556</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-400">18.00</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-401">100,000,008.00</ix:nonFraction> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-402">13,810.00</ix:nonFraction> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Carry Forward Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Carry Forward Securities </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p> </td>
<td>
 </td>
<td style="vertical-align: top; width: 16%;"> <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-403">244,260,000.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td style="vertical-align: top; border-bottom: 1px black; width: 16%;"> <p id="TotalFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-404">33,732.30</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fees Previously Paid: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-405">13,810.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fee Offsets: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-406">0.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Net Fee Due: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="NetFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-407">19,922.30</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr> </table> </div> <div>
<table style="width: 100%; text-indent: 0px;"> <tbody>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td> <p style="margin:0pt;text-align:left; margin-bottom: 5px;"> <b>Offering Note</b> </p> </td>
<td/> </tr> </tbody> </table> </div> <div style="padding-bottom: 20px;">
<table style="width: 100%; text-indent: 0px;">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td style="width:10pt;"> <p style="margin:0pt;text-align:left;"> <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup> </p> </td>
<td colspan="7" style="white-space: pre-line;"> <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_1" id="ixv-408">(1) (a) Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(a) under the Securities Act of 1933, as amended. (b) Includes 1,770,000 shares that the underwriters have the option to purchase. (2) The Registrant previously paid a registration fee of $13,810.00 in connection with initial filing of the Registration Statement on Form S-1 on April 10, 2026. The fee was estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. This Maximum Aggregate Offering Price was originally registered under 457(o) and is now converted to 457(a). (b) See note 1(b) above.</ix:nonNumeric> </td> </tr>
<tr>
<td colspan="7"> <hr style="width:100%;text-align:left;margin-left:0"/> </td> </tr>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td style="width:10pt;"> <p style="margin:0pt;text-align:left;"> <sup style="vertical-align:top;line-height:120%;font-size:10px">2</sup> </p> </td>
<td colspan="7" style="white-space: pre-line;"> <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_2" id="ixv-409">(1) (a) Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(a) under the Securities Act of 1933, as amended. (b) Includes 1,770,000 shares that the underwriters have the option to purchase. (2) The Registrant previously paid a registration fee of $13,810.00 in connection with initial filing of the Registration Statement on Form S-1 on April 10, 2026. The fee was estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. This Maximum Aggregate Offering Price was originally registered under 457(o) and is now converted to 457(a). (b) See note 1(b) above.</ix:nonNumeric> </td> </tr>
<tr>
<td colspan="7"> <hr style="width:100%;text-align:left;margin-left:0"/> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 2: Fee Offset Claims and Sources</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 10%; text-align: left;">
 </th>
<th style="width: 8%; text-align: left;">
 </th>
<th style="width: 16%;"> Registrant or Filer Name </th>
<th style="width: 6%;"> Form or Filing Type </th>
<th style="width: 7%;"> File Number </th>
<th style="width: 6%;"> Initial Filing Date </th>
<th style="width: 6%;"> Filing Date </th>
<th style="width: 6%;"> Fee Offset Claimed </th>
<th style="width: 6%;"> Security Type Associated with Fee Offset Claimed </th>
<th style="width: 8%;"> Security Title Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Unsold Securities Associated with Fee Offset Claimed </th>
<th style="width: 9%;"> Unsold Aggregate Offering Amount Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Fee Paid with Fee Offset Source </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rules 457(b) and 0-11(a)(2)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> </td>
<td style="text-align: left;"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> </td>
<td style="text-align: left;"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rule 457(p)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> </td>
<td style="text-align: left;"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> </td>
<td style="text-align: left;"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 3: Combined Prospectuses</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 4%">
 </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 25%"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title</b> </p> </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Securities Previously Registered</b> </p> </th>
<th style="width: 18%"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price of Securities Previously Registered</b> </p> </th>
<th style="width: 6%"> <p style="margin: 0pt; text-align: center;"> <b>Form Type</b> </p> </th>
<th style="width: 10%"> <p style="margin: 0pt; text-align: center;"> <b>File Number</b> </p> </th>
<th style="width: 8%"> <p style="margin: 0pt; text-align: center;"> <b>Initial Effective Date</b> </p> </th> </tr>
<tr style="background-color:#E7E7E2;">
<td style="text-align: center;"> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td> </tr> </table> </div> </body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g73463dsp69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463dsp69.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ] /D# 1$  A$! Q$!_\0
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M &(_VNK_ /:7L==M]=T^TT[5]-E!6&T)PR$9!))Z_3B@#1_;-_:FU+]G#2=
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ML4T@/./^"8,9/[4WBUP0R_V3=#(/4_:(^??\*=@/U<VGUI@?%?\ P40D,?\
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> !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g73463g00a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g00a03.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[12:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %'T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                         /_A0$IH='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB
M5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z
M>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#8N
M,"UC,# R(#<Y+C$V-#0X."P@,C R,"\P-R\Q,"TR,CHP-CHU,R @(" @(" @
M(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q
M.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @
M(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T
M;W-H;W O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T
M179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @
M(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN
M9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,C4M,3$M,3E4,#$Z,C(Z,C<K,#4Z,S \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R-2TQ,2TQ.50P,3HR.3HP
M."LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A
M=&%$871E/C(P,C4M,3$M,3E4,#$Z,CDZ,#@K,#4Z,S \+WAM<#I-971A9&%T
M841A=&4^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R
M;6%T/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H
M;W Z0V]L;W)-;V1E/@H@(" @(" @(" \<&AO=&]S:&]P.DE#0U!R;V9I;&4^
M<U)'0B!)14,V,3DV-BTR+C$\+W!H;W1O<VAO<#I)0T-0<F]F:6QE/@H@(" @
M(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.F)B93!F-&,V+6(W,6(M
M,F0T,"UB.#1C+3)D8C%D9&$W-#AE8CPO>&UP34TZ26YS=&%N8V5)1#X*(" @
M(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P
M.C5F8F1F8V4X+34P9C$M,64T,RTY,#DQ+3)C-F5D-V,T,S8V-#PO>&UP34TZ
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)
M1#YX;7 N9&ED.F$X,S<R,V(V+6,P8F8M.# T8RUA,C5B+34S8F(Q8CEB,&8U
M9CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F-R96%T960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IA
M.#,W,C-B-BUC,&)F+3@P-&,M83(U8BTU,V)B,6(Y8C!F-68\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C4M
M,3$M,3E4,#$Z,C(Z,C<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R
M,BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&EM86=E+W!N9R!T;R!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IF9# T.68X
M.2UE-F0R+60Y-# M.#,X-RUC.&4X83-D.#DS-S$\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C4M,3$M,3E4
M,#$Z,C@Z-3(K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXP("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.3!F,V$U,CDM.#$P92UB,C1A
M+6)D9F0M.&8W,V4X-3DT8S<S/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(U+3$Q+3$Y5# Q.C(Y.C X*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV
M97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z8F)E,&8T8S8M8C<Q8BTR9#0P+6(X-&,M,F1B,61D83<T.&5B/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(U+3$Q+3$Y5# Q.C(Y.C X*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @,C(N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HY,&8S834R.2TX,3!E
M+6(R-&$M8F1F9"TX9C<S93@U.31C-S,\+W-T4F5F.FEN<W1A;F-E240^"B @
M(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z83@S-S(S8C8M
M8S!B9BTX,#1C+6$R-6(M-3-B8C%B.6(P9C5F/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD
M:60Z83@S-S(S8C8M8S!B9BTX,#1C+6$R-6(M-3-B8C%B.6(P9C5F/"]S=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E
M9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^
M"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H\/WAP86-K970@96YD/2)W(C\^_]L 0P &! 4&!00&!@4&!P<&" H0"@H)
M"0H4#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH
M_]L 0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@!4@.  P$B  (1 0,1 ?_$
M !P  0 #  ,! 0             %!@<" P0!"/_$ $H0  $# @(#"0L*!P "
M @,    ! @,$!081$B$Q!Q-!451Q<I&Q%!46%R(T-E-A<Y(C,C,U0H&AP='A
M)%)B@I.BLE6#)4,F\/'_Q  : 0$  P$! 0              ! 4& P$"_\0
M-1$!  $# 00'" (# 0$! 0    $" P01!1(A,15!87&!H;$3%#,T45*1P2+1
M,E/A\/$C0O_:  P# 0 "$0,1 #\ _5(
M
M
M
M
M
M
M
M
M                           /CWMC8KGN1K4UJJKDB$!<<7VBA<YCJE)7
MIP1>4B_>A]T6J[DZ41JY7;UNU&MRJ(6 &?56Z/'DJ4U"[/C>_P#+(CI-T2X*
MOR=/3HGMS4ET[.OSU:(%6V,6GE5KX-2!ET>Z)<$5-.G@5/9FA)4NZ-"JHE31
M.3^IK\_PR%6SK\=6KVC;&+5PWM/!?P0=MQ5::]4;'5-C?_++Y/:3;51R(K51
M47A0B5VZK<Z51HGV[U%V-;<Q+Z #X=
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MR]5BNBW3>GE/+P;9A^XLNEIIZIBZW-R<G$Y-I(F:;EUW2*IEMTJ^3+Y<>?\
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MQ#*%VJ:ON6_44WOE[$+_ &E\">^&5V-\U'=*X@ SC8               -B
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MW3Z,60V+<Z]&8NFXQTV+<Y]&8NFXN]J?!\6:V)\SX3^EF !GFN
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MJK1S+FW^A>(KE%4RT=3'40/5DD;M)JH:&[;HS+/#P9*Q=N;.R)BKJYQ]8_\
M<GZ"!$87O45[MK9FJB3-U2,XE_0ES-5T315--7.&SMW*;M,5T3K$@ /E]@
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M]NG2?$ !'2P
M
M
M
M
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MX*7D\7PCN"EY/%\(%8BQFY\C6]Q99JB?/_8N"+FB*>=*&E1<TIXD7HGH
M5N^XF[UUZTW<V^9-1=+2RVED,^Q6U'8J8CD145&9H![O#9>1?[_L/#9>1?[E
MG;;:/13^&BV?RGWO;1<EB^$"$H<84<SD;4,?"J\.U$+)%(R6-'Q.1[%V*BZE
M(*\X9HJJG>ZGB;#,B+HJS4B\Z$+@6NFBK9:"95T%S5$7@5 +R     'QSD:U
M7.7)$3-54^D%C"X)16I[&KE+-Y#>;A CDQBU;AO"4Z;SIZ&GI:\L]I;D5%1%
M1<T7A,T?8E;AQMP3/?=+25/Z=A<,(7#N^TL1ZYRP^0[\OP FP     A,1WWO
M.Z%-XWW?$5?G999$V4K=%^DH^9W:@'+PV7D7^X\-EX:+_<GK5;Z1]NIW.IHE
M56)FJM/4MLHE3):6++H@1-NQ90U3T9-I0.7A=\WK+ U4<U%:J*B[%0J^(<+T
M\M,^:A8D4S$ST4V..C 5S?*DE#,Y7*Q-)F? G"@%P   Z*^H[EHYI]'2WMNE
MEQG>>"_?4]7[M0*VF-E791?[_L/#5W(?]SKP!!%,RLWV-C\M'+23/C+=W!2\
MGB^$"J^&KN0_[G93XQ=-/'&M%EI.1,]/]BS=P4O)XOA/K:&E:J*V"-%3AT0/
M0     KS,1Z=\[WI3ZM/0T]+\BPF?4_IO_[U-!   "OKB+*^=[^Y]6GHZ>E^
M18#/G>FZ>]_(T$   .$S][AD?EGHM5V7,4_PV7D7^_[%S5$5%14S1=IY.]M%
MR6+X0*MX;+R+_<)C=5V42?'^Q-7Z@I8[-6.93QM<D:JBHW806 J6">.JWZ)C
M\E3+23,#L\-EY%_O^Q8;#<^^M&L^];WD[++/,[^]M'R:+X3O@AC@9HPL:QO$
MU,@.P  "+Q!=>]-*R;>M\TG:.6>1*%7W0/JJ'WGY 35EK^^5OCJM#>]+/R<\
MSW$'@KT>I^=W:3@   #C+(R*-SY'(UC=:JJZD.2JB(JKL0S^_P!RGO5R;0T2
MNWE':*(B_.7C4"8N.,*:%RLHXUG<BY:2KDTCO#"M5V:4C-'BS)VS8;HZ"-%E
M8V:?A<Y-2<R$RD4:-R1C<N+("JT.,XGOT:RG6+@TFKF6BEJ8:J%LM/(V1B\*
M*1=VP[17!BJD:13<#V)V\9Y,*V2JM=14.GF^274UC5U.]H%D    CL0U3J.T
M5$T:^6B9-YUU >.\8FI+>]T3,YIT^RU=2+Q*I"KC*J5<VT3$;TE.&"K3#6K+
M65;4DT79-:NO7QJ7=L4;6Z+6-1O%D!5:+&<+WZ-93NBX,VKF6>EJ8:N))::1
MLC%X6J1]RL%!7,=I0M9(OVV:E/N'K.VT4SV;YOCWKFKLLM0$J
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M;R]G4I,X;LD]KFE?/4)*CVY(B9Z@)X    !GU/Z;_P#O4T$SZG]-_P#WJ:"
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M<KJ2J1438CM2@7<&=;[?+$J.DWU8L]>?E-+=AV]QW>%WD[W.SYS,_P 4 EP
M                   'QWS5YC/<,^E3^D_M-"=\U>8S[#*+X5/U?:?V@:$
M    $9B?ZBK.@29&8F^HJSH 0NYYYG4]-.PMI4MSU,J2IS_G3L+: *YCWZE;
M[U.Q2QE<QXF=E;EZU.Q0.W!/U%'TE)X@<$ZK%'TE)X   /+=?JRJ]V[L*EN=
M^<UG0;VEMNOU;5>[=V&=X<O"V>6=RPK)OB(FW+(#3@4[PU3D2_&/#5.1+\8%
MQ!3VXTTG(G<2Z_ZRWM7-J+QH!]   S_%/I7'_8: 4#%*?_E;/[ +\WYJ<QY+
MM017&BDIY436GDN_E7C/6WYJ<Q] SNRUL^';O)25>>\.7)R<7$Y#0V.:]B.8
MJ*U4S14X2!Q994N5(LL+4[IC3-/ZDXB,P7>'-5+=6*J*FJ-7?\@7(   #QW>
ML2AMT]0NM6MU)QJ!3L75,ETO45OIU148NBG27:<V83NC&HUE9&UJ;$21WZ'/
M!%$ZIK9[C4(KE1<FJO"Y=JEW H_@M=N6L_R._0X283NCV*U]7&Y.)9'?H7L
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MR+)'"QKU^TB:SN       /DC&R,5CVHYJZE1>$^@#K@@B@14AC:Q%VHU,CL
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M3QQK_2W(](
M
M
M
M
M
M
M
M
M
1                   '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g73463g00n44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g00n44.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1I^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &F$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M#CDOG^D9]P67])+\P73=*>U>S_J</T @YO;^F1D52(;_ &:>CR?91DDM\[2
M?@74;3<J.[T$59;:AE132#+7M^8]Q\A6KJ*P6[4%!)27.F9*UPPU^!O8>]I[
M"N/]&%54Z2Z1:W3-5*74TSW1C/(O RQP[LM_D@[JBB=4:@H=-VJ2ON3RV-IV
MM:T9<]W8T!<XAZ2]3W)CJJSZ2EEH03A^'OW#S@8^#*#KJ*E:$Z0:+5$\E%+
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MDW[N6-I7._\ 1]?*S2MR=('>#MJ26?L#=CY%H2:3K[I$RANO2%3U-M)&8FR
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M=HC!ZOJPUN<\LG)5Z1 5!CZ/7R=()U-77)M0!)UC*;J,;<-VM&[<>7/DK\B
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M\C^M>,GS K#JGHHIZ2F?<-)5%325]..L9$)"=^.QKLY!^%7+HP_!_8OU9O\
M-6=!1>B75TFIK))'7D&Y4;@R4\M[3R=CX0?*/*KTN+=$6(>DS4\,'"GQ+P'+
MA+P^<KM* B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@Q551#24\D]3*R*&,;G
MO><!H[R5R*Z7FX])5RDM5CD-%IR-P%35/\5TOD'\F^DKI6K+!!J6R2VRKEEB
MAD<UQ=%C=P.>T%45O0O9VC#;G<@/(YG]*"]:<M%KT];(Z&V"..-H\9Q<-SS^
M4X]I41TEZIK=*6>GKZ"CBJXWS".3>2 T$$@\/*,>E5W_ ,&+1[J7/]IG]*OT
M=DHS8([/51^%4;86PD2C.X <SY4&6RW2EN]LIZVBF9+#*P.!:>1[0>XA<EZ1
M9X[UTK::H;:YLLU)+'UQ9QVXD#B#Y@WY5,3=#]$R9YMEZN-% \Y,379]&>'R
MY5FT9H6TZ5+YJ1LD];(,.J9CEV.X=P06I<L_TA?:M;_UP?0<NIJO:UTI2ZMM
M\-'6SSPLBEZT&+&2<$=H/>@F+7][:3]"SYERO27X==1_H7?-&NM4\0@@CB:2
M6L:&@GR#"KMMT?1T&KZ[4,51.ZJJVEKXW8V#.WEPS^*.U!AZ5OP?7O\ 0CZ0
M5<T97BV="9JW4HJVQPS$PGD\;W#!\G?Y%?=16F&^V6KME3(^.&H;M<Z/&X<0
M>&?,J7JYLN@.C%]-9'R2EC^J;+* 2P/<27$8QVX]*"D:+HH665LU%KVGL[JG
M+IJ,$ 1DGD-SL@^5=+Z.[#9+-#4R6FXLN=74'=/5&5KW.\G#D,\5"Z,Z/-+U
MNF:&KJ*=M?/41"62;K'#+B.( !&,'AA5?5MDHM(:ZT_ZU)9(*JHE EIVR%V&
M[@..>.""1@]R#N:XUTP4E18=86C5=)$YT37,;,1V.:3@'SMR/0NRK!7T=/7T
MDM+6PQST\HVOC>,AP0:MBO5!?;='6VVH9-"\=AXM/<1V'R*&Z0M64>FK%4/?
M,PUTC"RGA!RYSCPSCN'/*K=9T/6SPATMIN=?;@[FQCMP^'@?E5"@M=LT9K>6
M'6U)45U+G=2U)!+7\?9.;^-Y1G@>PY0= Z"K%/;=/5%QK&.9-<'A[ X8/5C.
M#Z22?-A0>DY&1].=]=(]K&XFXN..UJZ3I;55FU&)666<R>#AN]IC<S:#RYCR
M*LWWHHM5XO%7<9J^NCFJ7F1S6%N 3W<$%YJKG04L+I:FMIHHFC)<^4 #Y5Q7
M6=R_\2=96ZS6/=+;J9Q,DX! /'QG\>P#@.\E6:'H8L37@SUMQF:/Q2]H^9JO
M6GM/6O3U*:>T4D<#3[)PXN?[YQXE!)Q1MBB9'&,,8 UH[@%Z1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 5$O&N9;/T@4]DN-/!!;9VAS*MS
MB#Q!QGL]D,*]J"U;I2UZII&PW2$E[,]7,PX>SS'N\B"8FJ88*=\\TK&0L;N<
M]SL #ORN0=#Y]4ND'5%WI6_ZB\O#78P#NDR/D;GTJ1;T.TQQ'-?[E)2 _:>&
M,=W=\BZ#I^R4%@MK*&UP"&!O$]I<>\GM*#DU1*W273C)4UKA%17%I(D=P: \
M#_G:NFZUO=-9-,U]9-,UIZIS8@#Q>\C#0/2OFL-)VS5=$V"Y1N#X\F*:,X?&
M3W'N\A5.H^ARVMJ8WW"Z5U;3QGQ878:,=V>[S809.@.V24FE:BME:6FMGW-S
MVM;P!^'*Z8L=+3Q4M/'!31MBAC:&,8P8#0.0 61!Q_HX_"]JOSR?Q K;TP_@
M\NWF9],+<L6C:.SZFN-[@J*A]17;M['XVMR[/# RI/4]EAU#9*FV54DD<,^
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M=E/31C#6-^?RGRK;1$!$1!"W#2EAN,SI:VT44LKN;S$-Q](4S&QL;&L8 &M
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MIV"1HD86.P>\'B"N.V@55 W1-R;<[C-5WJU5$E<Z:I<]LKO!Q(TAI.&D.Y8
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M'-/X"R+)ZYN/&!SP66NK;C#?JS0K:NI%177-E53S]8=[*!P,LF'<QAT;X_\
MUA!?K+K*S7F[.MM!.]]6T3$M,9 ^Q2=6_B>YRL*I>L+';K5IJ\UULE@LU<Z"
M8"O.[$1E?O<21Q +N.1RYJ#Z,IGT.J*NTU=/64M3)1-J!&VY>'4LC0[!D:7>
M.QQR.!X$>9!T""\T<U]JK/'(XUU-"RHD9M. QY(:<\N;2I!<\HJREH^F;4)J
MZF& .M-( 97AN?'EY94=KJL@O&J10TGA-P%/0"H>QMT\"I8FN>X"4O;XSW>*
M1PR!CRH.J(OS[;]2WB@TC8[DZOJ*B2]6V>UPN=(7CPMLQ; X'O+2[CS.T*S]
M&E;<KAJ*DLU;65,SM,03P5CW./V>9TA9$7]_V)N[_P!007K46K[98+C34%8R
MMEJZB-TT<5+2OF<6-(!)V@XXD+)IO55KU#/54]!).RKI=IFIZF!\,K [D2UP
M!P>]5'6,%UJ.EBR,L5=3455ZDU),E13F9I;UD?#:'-\G'*K4%QEMIUO7:ON-
M5%JJEIF4KG4+&Q@4Q=]C?!G/LB[BYQ\4]V$'<$7 )ZNOLUVN]'!UUM;+IVKJ
M74_JLZL?O;C9*2?8.XGD>*L5)355@NNDJBW5MPJJNZ6VI?5-J*E\K:B1L D8
M=I. =WY..!P@ZZBX50RTS+;H&ZPZ@KI+W=+G3BMB-:YPG)W&1CH\X:&NX8 &
M.2C[9<+[4VV"_OGCI[L^Y=6^IFO#P >NVFG-*&X V\,<^3LH.RZ]?4,TE<_!
MH&2Y@>'[I-FUNTY(X'/F4[!]IC]Z%!:]G?!I*Y[*>6?? ]IZO;X@+3XQR1P'
MDXJ=@^TL]Z$'M$1 15O56L[3IO$=;*Z2I(R((AN?CO/8/2JNWI:I@=TUDKF0
M?G,@_5\ZIOQ&*DZM/5OP^R^+ST\3'CF8_#\-]W3$41IO4=MU%2F>UU DV^SC
M<,/8?*/Y\E+JVMHM&X[,>3'?%::7C4QY2(B+J B(@(B("(JIKK54^FC0"GML
ME;X2\M<6D@-QCAP!XG/#S*-[Q2O-;LNP8+\1DC%CC<RM:+S$_K(F/+2W< =I
MYCR%>E)2(BUW5](VL%(ZJ@%4>(A,@WG_ -.<IO3L5F>S81$1P1$0$1$!%KRU
M])#5,IIJJGCJ'^PB=( ]WF&<E;";=FLQW@1$1P1$0$6I>*QUOM=55L@?.Z&,
MO$3.;L=@41H74,NI+.ZLJ*)U(]LA9M))#L=H)4)O$6Y/-=7A\EL4YHCW8G2Q
M(M>"OI)ZB2G@JJ>2>/V<;) 7-[.(!R%H:JO]/INTNKZN*66(/:S;%C.3YR%V
M;1$<TST1IAO>\8ZQUGM"71:MJK67*V4E;"US8ZF)LK6NY@.&1GX5M+L3N-PA
M:LUF:SW@1$77!$1 1$0$1$!$1 1>*B0Q022!CGEC2[:WF[ Y!5G0>J9]30UC
MZBW249@D#0220[/9Q',=OG4)O$6BL]Y74X>]\=LM8]VNM_7LM*(BFI$1$!$1
M 1$0$1$!$6&NJ6T=%/4R N9"QTA#>9 &4[.Q$S.H9D4%H_4M-JBW2UE%#-%'
M'*8B)<9R #V$]ZCZ35L\^N9[";7*R&,'%0<]@SG&.1Y!5^+343OOV:?L6;FO
M2:]:1N?@MJ(BL91$52T_JV>ZZLN-HDM<L$5,';9G9XX('$8X9SD*%KQ68B?-
M=BX>^6MK4CI6-RMJ(BFI$1$!$4%K#4U+I>@BJZV&:5DDG5 1 9S@GM([E&UH
MI'-;LLQ8KYKQCQQN93J+#1U#:JDAJ& ADK \ \P",K,I(3$Q.I$1$<$1$!$1
M 1$0$1$!$1 4#:9&#55^C+V]81 0W/$C8>.%/*OVF"(ZMOLYBC,S1 T2%HW
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M4$;(XVC#6,:  /( O:"LUFF9:[55LN%54T_J7:P7T=$RGP6RENS<Y^>( )P
M!S\BQ.T-:ZK4]VN]WI:.X^&=08HZBF:_J#&TMX$YYY![.2M:((R\:?L]Z;$V
M[VNAKA%]K\(@;)L\V1P6S%;Z*&>*:&DIXYHHNHC>V,!S(\YV ]C> X<EM(@A
MX=+V&"XLKX;+;8ZUA+FSLIF!X))).<9R23Q\JVQ:;<U[7"@I0YLYJ01$W(E(
M(,G+V1!(SSXK=1!ITMJM](^)]+0TL+X6.CC='$UI8UQRYHP. )XD=ZTYM+6&
M:X2UTUEMLE;+@R3NIF%[B"""3C)X@? %,(@AYM+V&:X-KY;+;7UK7]:)W4S"
M_?\ E;L9SP'%;<MIMTKIG2T%*]TTC)I"Z)I+WLQL<>'$C P>S 6ZB#6DM]')
M/--)20/FFC$,CW1@N>SCXI/:.)X>5:%!I>PV^FJ:>ALMNIX*ENV>..F8ULH[
MG #B/(5,(@P"BI14QU IH?"(HS$R38-S6'&6@\P. X>1:\=EM<6SJ[=1MZMD
MD;-L+1M:\Y>T<.3CQ([>U;Z((>W:6L-LDCDMUEMU+)&[>Q\5,QI:[!&00.'
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M6Q.<.T@- \^T9]*O=RT=8+G4FHK+9 ^8G+GM!:7'RXQE2]!14UOIFT]%!'!
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M_-+?K[_\/,K"@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M1$!:E;;:*NDB?6TD$[XCF-TC XM/DSY@MM%R8B>Z5;36=UG4B(BZB(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M$0$1$!$1 1$0$1$!$1 1$00=M]MU[_04O_54XH.V^VZ^?H*7_JJ<0$1$!$1
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MT%\)=0 \^M9P_;67IY^]MG_3N^9>96E8X2;1'6?Y?7WXC)?VU7%:VZQ/2/\
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MGO6]=3$STCM'R^#TN0Z[_"]8?-#]-RZ\N0Z[_"]8?-#]-RHXO[D?.'H>P_\
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M*Y(UJ-=MH8LM,V7AK<TWM%M<TQK<>F_.8:FE=!NU!:[?<]17"H>.I8*:"%P
MCC  ;Q(/8!R75VC:T <@,*#T'[3++^JQ_,IU:\&.M*1,>;Q/:/%9<^:U;STK
M,Q$>4=1$17O/$1$!$1 1$0$1$!$1 1$0$1$!$1 1%BJZF&DII:BID;%!$TN>
M]W)H':@RJ$M'MFO_ /['T"MG3MYIK_:V5]$V5L#WO8T2L+'>*XM.0>(XCM6K
M:/;-?_\ =_H%!.(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M"O:F^_FEOU]_^'F5A5>U-]_-+?K[_P##S*PH"(B B(@(B("(B B(@(B("(B
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M/".K&V,F5X+PWD<-:< ^3*GM-5E?3ZEN=@NE8ZX"&GBJX*B2-K'ECRYI:X-
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M?,!ATFP-W'OP.2S("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MH#1?W%<O[SJ_XSE/J T7]Q7+^\ZS^,Y!/HB("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B(*KKRIN4=ANT<%NBFI33/!F-2&N VG)V[>S
MSJSP?:8_>A06O8YY-)7/P>HZG; ]S_$#M[=IRWCRSWJ=@^TQ^]"#VB(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@I^L.C^@U3>J*YUEPNE/44;-L#::9K6,.2=X:6GQN.,^0*'O]D;I>"D
MN-1J75=6SPRG@ZHUK"UQ?(UHW#9Q;QXCN6;I#U!66J]0P4NL-/V1CH \T]QA
MWR..YPW@[AXO#'H*KD'JMK26DH7:\TO<8(JJ&J?!1P8E=U4@?P\<GL[D'941
M$!$1 5<M5,':ROE1ULP+6P,ZL/.P^)S+>_RJQJN6JE8[6=\J2^;>UL# T2N#
M,%G,MS@GRXR@L:(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
MKVIOOYI;]??_ (>96%5[4WW\TM^OO_P\RL* B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@KEBIA3:MU !+-)OCIG_ &5Y=MSUO 9Y
M#R*QJN6*E92ZMU (WS/ZR.FD/6RN?@GK> R3@>0<%8T!$1 1$0$1$!$1 1$0
M$1$!$1!@KZ85E#44QEEA$T;HS)"[:]N1C+3V'RJAV?HJHK-3N@M6HM24D3WF
M1S8JM@W./,GQ.)\I5WO,SJ>TULT=3#2OCA>X3S#+(R ?&<.X<RN1,UC='N#6
M])FB\G@/]6Q_U$%[T&YD%PU!:VU]VKI*"HCC?+<)VRDET8=XF ,#![>U6Y4S
MHVM%72>J]UK[O07:6[3,GZ^A9MBPU@9PXG/+O5S0$1$!0>N6[])W-N7#=%C+
M3@CB.14XH/7+0_2=S82X!T6"6G!YCD>Q!+4< IJ6.$22R!@QOE>7./G)YK,L
M-'3MI:6."-TCVL& Z60O<?.XDD^E9D!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 4!HO[BN7]YU?\ &<I]0&B_N*Y?WG5_QG()]$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!7]>TPJ=)7/,LT?5P/?
M]B>6[L-/ ]X\BG8/M,?O0H+7M*RJTE<][YF]7 ^0=7*YF2&G@<$9'D/!3L'V
MF/WH0>T1>99&11/DD<&L8"YSCR ',H=WI%S1FL-1:EKJF/1]! **!VTU-3^-
M_P#>[BMFSZSNE%J""RZOH8J::? AJ(CXCB>7?YLCM6>.)I,_#U\GIV]D\16)
M[<T1N:[CFB/E_P ET)%3^DW4M9IBU4M30,A>^6;JW=:TD8P3V$=RA3JC5E]B
M$^F+3&RB P)JC ,I[2T$CAGSKMN(K6TTZS*.'V9FRXHS;B*SOK,ZCHZ4BH_1
MWK&JOM566V\4S:>Y4HRX-! < <'(/(@X^%9-15NM(;M,RR6ZCFH!CJWR$!QX
M<?QAVKL9ZS3GC<PC/L[+3-."\Q68Z]9B(^DKHBX_>-<ZQM%=!15M#;VU<^.K
MB8-[CDX' .[58]4ZMN>GM0V>*KBI_4RK:T2.VG<QW)PSG'#(*A'%4G<]>G[K
MK>Q^(B:Q$Q/-$S&IWO7=?43(QG/!4?1VJKAJ'4EWB9' +31DM8\-.]QSAO'/
M: 2KK9(K,5GO+%BX:^6E\E>U>_UZ0O"+DEAZ1[Y=X9J2BMD=5=7/^Q]6TMCC
M9CBYV3W^4+-+K74VF[G2LU;0TXHJAV.LA'%H[2""<X[BJ(XO',<W77KIZ$^P
M^)K:<<ZYO3<;GY0ZJBYQ-J;5E\+Y]*VF..W D1SU. Z4=X!(X?"I#HZUE/?Y
MJNWW:G;3W.EXN#1@. .#P[""IUXBEK17U[?%1D]EY\>*<LZGE[Q$Q,Q\X7=%
M4-<ZQ]0)::@M]-X9=JK[7".303@$X[^P>1059?=>6:E=<;G;:&>C;XTD<1\9
MC?0?EXI;B*UF8ZSKO\##[,S9:5ON(YNVYB)GY.F(HO35ZIM06>"X4>0R08<P
M\V.',%2BNK,6C<,.3';'::7C4PK>M=3C3M/2-AI_"JVKE$<,&[;N[S\WPJPP
MEYA89FM;(6C<&G(![<+F-,_UP],DI>=U-:8SL',!PP/I./P+J*IPWF\VGRWJ
M/HV\;@IP],>/7O3'-,_/M'TC]53Z0=8-TG3TCFT[:F:H<0(R_;AH'$\O*%)Z
M0OC-16&GN+&",R9:^,'.QP."/Y^E<_VLU=TMR->.LM]K86$'B"6Y'RN/R+-T
M5S.LFJ+YIJH<0&R&6 'MQ];2T^A44SVG+N?NS.H^</1S>S\->#U$?XM8BT_*
M9GIKX1J70M17(VBQUMP;&)33QE^PG&['E4?H743M3V/P]].*<]:Z/8';N6..
M?2OO2#[2KS^KN4#T(^TL_K,GS-5TWMX\4\M,5.'QS[/OFF/>BT1OX:7Y<XNN
MOKS1W*JIH=,5,T<4CF-D ?AX!QGV*Z.BLR5M:/=MIEX7-BQ3,Y<?/]9C]')H
M>E:XS5,E/#IQ\E1'G?&U[BYN.!R-N0K#I;5]WO5;/3S6"6CV0.D8^4N#7.&,
M-R6]N57-!_A=U)[Z?^(%UM9N'\2\<UK^?I#UO:<\+P]O"QX8W-8G>YZ;^JN:
M)U.S4E%4.?!X+64TABF@+LEI[#\_P%6-<O+O6YTPM9'XE)=XP7CLW'/'S[F_
M_)=05^"\VB8MWB=//]H8*8KUOBC5;Q%H^'K'TD1:%]NM-9+545]:XB&%N<#F
MX]@'E*H-#J'6]_@-?9K;14]"2>K$Y\:0>0D\?/P7;YJTGE[S\%?#\#DSTG)$
MQ6L=-S.HWZ.FJI7[5S[7K"UV04C9&UFS,I?@MW.(Y8X\EAT3K*6\5]3:;Q2>
M!7>FXN8,X>!SQW=BKFNOPM:9_P#:_B.567/O'%J3YPV\'[/Y>)MAXBO:LS^6
MXF)AU9%H7Z[4UDM51<*UQ$,(S@<W'D /*2J#0Z@UQ?X/#[-;J*GH228Q.?&D
M'G)^7@K;YJTGE[S\&/A^!R9Z3DB8K6.FYG4;]'345,T3K*6\5]5:;O2>!7>G
M!+F#.'@<R,\N8^=8M#:KK[I?KK:+S'#'5TA\3JVENX X/,GR'TKD9Z6UKS2O
M[.SX^?FC[D1,]?*?./6%X10NLKSZ@:<K+@ TRQMQ&UW(O)P/E45:=3U$&A/5
M^_LC:YS3(V.$8R"<-'$\S_-2G+6MN6?3:K'P>7)CC+6.DSRQZS*WHN8V^^Z[
MOU)X?:J"@IJ-V71-E/C/'DR>/GX*9T'K&>]UM9:[O2MI+K2YW-:>#\'!X=F.
M'?S4*\16TQ'6-]NG=HR^R\V*EK[B>7O$3$S'S6&[W^V6BIIH+C5-AEJ3B)I:
M3NX@=@\H4F\D,<6#+@. [RN#=(E3J*6^VHWFDIH9F2'P01G@_P 8<^)\G<NH
M:3J]4S5%3ZY**EIX&QYC,1R2[/(^,>Q0Q<3SWM34_A^J_BO948.'IFB\3,Q.
M^L>NO=]?B\Z$NNH;E)<!J*W-I&Q/ A(:6YYY'$\0.'%6Q4CHTU57:E?=17L@
M8*5[&LZII&<[N>2>X+%JO6U7!>VV+3-&VMNG_F.=[&/AG'UG. NTS5KBBTSO
M]4.(X'-EXNV*M(K,=9B)Z1&HZ[E?$7+ZO5.L=-AE5J.V4T]O+@U[X" 69\H)
MQZ0N@TMSAKK*VXT+P^&2$RL)\W(JRF:MYF.TQZLW$<!EP1%YF)K/2)B=QOT;
MZ+DU@Z1KY>*62EH;7'5W9S_%V-+8HX\>R<2>>?*%E]>NIM/WBD@U;0P"DJ78
M$D0QM&<$@@D''<JHXO',;ZZ]=-<^Q.)K::3KFCRW&Y^4.J(H36&H8--622OF
M893D,CC!QO<>0SW<%4*6Z=(-PI&7"EH;=%3O D9"_P!DYIXCF>[S*R^:M9Y=
M3,_!EP<!DS8_%W%:[UN9UN?@Z4BJ6@=7>N2*I@JZ;P6Y4AQ-%V=V1GB./#"M
MJG2\9*\U>S/Q'#Y.'R3BR1J816J+U#I^R5-QJ!N$0\1F<;W'D%DT[75%QLU+
M6UE.VEEG;OZH.W;0>63WX5 Z39#>-7Z?TZ">H=()IFCMR2/D:'?"N@WNW"Z6
M>IH!*Z 3,V"1G-G<0JJWM:]M=HZ?5LR\/CQ</BY^EK]9GTKVCI^,M]%S-OKV
MTEP(;J"VL[L]:T?/\ZG]/:_LMX>())30UF<&"J\0Y[@>1^==KGK,\MND_%'+
M[-RUKXF*8O7UKU_&.\?6%JFE9#$^69[61L!<YSC@ #F2N?5_2K;8ZE\5MH:N
MX-:<&2,;6GS9X_(K7JZTRW[3]3;J:J%,9]H,FW=XH.2.8YX7S25@I].66&BB
M$;I&C,LP;M,CN\ID\6UN6G2/5WAIX3'BG)GB;6WJ*[UT]9G]D9I37MJU#4^"
M1B6EK<9$,PP78YX/:K:N0ZS$%=THV-EBZM]8QS'5#X<$##L^-CM#>?H5KU_J
M*ZZ9FHJR""&>TN<&5 +3O8<\\YQQ'+AS'E5>//,1;Q.O+/>&GB?9U;WQ1P\:
MG)&^69[?7X^2YHH6\:CHK?IE]Z$C9*8Q!\6#]L)'BCTK3Z/[G=[U9O5"\1P1
M-F.8&1M(.W\HY)YJ_P 2O-%([O.^R9/"G-/2(G77U](^7FLR(BL9A$1 1$0$
M1$!$1 1$0$1$%<U'==*4-<R/455:(:LQAS6UA8'[,G!&[CC(/RJC:RN.D[FZ
MS0:5DMM3?_5*G=2FWAI?&!(TR.<6\F;-V<KJ%?2V]XZ^X04KMN&]9,QIQD\!
MD^4_*O/56VUL,PCI*-KB&;PUK,DG &?*4&\B(@(B("KMJAD.LKY,*F41-; T
MP -V..SV1.-V?3A6)5VU23#65\C$&8"V F;>.!V<MO/TH+$B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B(*]J;[^:6_7W_P"'F5A5>U-]_-+?
MK[_\/,K"@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB(*Y8H9(=6Z@$M3+4;HZ9S3(&C8#UOBC:!P'ER?*K&JY8Y)I-6Z@\(@ZDMCI
MFM\<.W-^RX=PY9[E8T!$1 1$0$1$!$1 1$0$1$!$1!AK9*>*CGDK71MI6,+I
M728VAN..<]F%3/7%T=8^^&FOVHE>'L;(QS)&AS'#!:1D$*.9;+0^62-E%0.D
MCQO:(F9;GED8X(*AT4&DEK-4U-B9LT]-7-=1;&[8W.$8$KHQ^27=W#.5T%8*
M>:F<^2GII(BZ##7QL(^QY' $#EP6= 1$0%!ZX:7:3N;0XM)BP'#F.(X\5.*#
MUP2-)W,L;N<(LAN<9.1P02U'$^"ECCEGDJ'M&#+(&ASO*=H ^ +,L5(^62FC
M?40]3*1ET>X.VGNR.:RH"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B H#1?W%<O[SK/XSE/J T7]Q7+^\ZO^,Y!/HB("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B(*_KV&2;25TZJIEI]D#W.ZL-.\!I\4[
M@>!\F#Y5.P?:8_>A0>O9)H])73J(.NW4[VN\<-VMVG+N//S*<@^TQ^]"#VJW
MTCS/@T1=WQG#C#MSY"0#\A5D6C?;>RZV>LH)#AM1$Z//<2.!^%0R1-J3$+^%
MO7'FI>W:)B?S<LZ/KKJ2WZ7IHK1IQM92N<]PGZ\-WG<<\/)C'H7G65-JW4[J
M%TFFS2RTKRYLC)VN/''#GY%GT/JAFC8I[!JF.:EZF1SH9>K+FD$\>79GB".]
M9K_JVLU5>J"V:+GJF,:[=/4L:6#'ESV =Z\V)K.**VM.^VNF_P!'UDQFKQEL
MU,-8CK///-K4[Z[WKK'DS].F[ULVW?P=X0,^?85T6TM:RU4;6@-:(6  # 'B
MKGG3L"--VX$Y(J>??XA71+7][:3]"SYEKQ_Y]_E#Q.*_]NP?._[.8:9 ;TUW
MD-X L?\ ,U=%U+>:>PV>HKZL^+&/%;GB]W8T>=<ZTW^&R\^\?\S5!Z_U%3WG
M6C**ZOFALUOE+'MC;ESW ^,<>7&/(%GKF\+':?.;3IZ67@9XWBL<3]V,=9GU
MUKM'QE9.C.RU-YND^K;ZW=-,X^"L/)HY;@.X<AZ5-=+MG%STC-,QN9Z(B=F.
M[DX?!Q]"U8.E'3,$,<,(JV1QM#6M$/  < .:NU+-!=+9',P%U-4Q!P#AS:X=
MH\Q5V.F.^.<=9WOO_+#Q6;BL'%4XK+2:Q$QRQY:CR_!3*75(_P#"DW5SP:AE
M,8#G\[[ ?+@K-T26KU-T9%+(W$U873NSW'@WY #Z5R]U#717IVBN/@S[B),_
M[..?FV\?0OT%#"RGI&00M#8XV!C6CL & %'AIG+;FM_3&OKYK_:E*<)B\+'/
M3);F_P#K_3'YRY?T"-'@5Y=@;NN8,]N,%;'3PUIT_;W$<14X!\[2L/0)][[S
M^F9\Q6QT[^UV@_6?^4JN/^R^G[M-O_?OK'_^70+0 VU40:  (68 ]Z%S+2OB
M=-%\:W@"V3(';[$KIUJ^]='^A9]$+F.F/PU7KWLG_*K\_?'\WG>S_N\5_LG]
M81MSK+BWIAK)[=0"X55.W$<)>&<-@&<GNRK3/?M8SP20RZ08Z.1I:X&I;Q!X
M=ZCM=4E7IO6M)JNCIWSTC@&5+6#);PVG/G&,>4*4K^E*PLMCY*&2:>L<W$<'
M5.!W=F3R^ JBNJ3>+WY>LSY?P]#+%N(IAO@P1DCEB-^]TF.\3J8UZG0_9[K9
M;57T]WIGTX=,)(VN<#G+<'D3W!7Y4_HPCO1L3ZG4%1/)-4/W1,F/C,9CY,\?
MD5P6SAXB,41'YO#]IWM?B\EK3$SOR[?1RKH?'7:FU14OXR&7&?.]Q_DK]JVZ
MMLFG:^O+@'QQGJ\]KSP;\I"H71R/4OI%U+:Y.!D)E;Y0'9'R/3IGKI:VKM.G
M:3C+42"1X'E.UH/RE9L>3P^'F?/K'UV];B>&CBO:=:S]V8K/_P!8K&T!T::Q
ML^G**M=<A525U5+N>Z.,.&T<N.1VDE:VHM76Z77-OU!9A.TLVBH;(P-W <.P
M\<M./0NS6[3MLHZ"FIO :5_4QMCWNB:2[ QD\% ](VFJ2LTC7>!T<$=1"WKF
M&.,-)V\2. [LJ%N'RUQ<NXZ=>R[%[3X/)QDWFD[O[LSOIJ>G;79(Z]>V30UV
M>PAS'4Q<".T%0G0C[2S^LR?,U1%EO'JIT.7*)[BZ>C@= _// XM/P''H4-T=
MZ_MVF]/FAK*>JDEZYTF8P",''>?(I3GIXM<DSJ)A"OL_-]BS<-2N[5O^W=VY
M%SAO2[920/ Z[C_LM^M=&:=S0X<B,K9CRTR?<G;P>)X+/PNO&K-=]G)=!_A=
MU)[Z?^(%UM<DT'^%S4?OI_X@76U3P?W)^<M_MO\ SZ_[:_HY5TM'JM7Z6F9]
ML$@'P/;]:ZJN5ZX'JITJZ>H(_&ZAK9']N/&+CGT-"ZHNX.N3)/Q_9'VATX;A
MJ3WY9GZ3/1S/IXF>S3M!$TG9)4Y=Y<-./G6:W7W5]-;Z:"GTDPPQQM8P^$MX
M@#@>:F^DRP2:ATQ+!2MW54+A-$W\H@$%OI!*@=*](]LI;3#1:@,U%7TK!$\.
MA<=V.&> )!\ZIO[N:9M;EB8CT_=MX>?%X"E<6*,DUF=QUW&^TZB8^30H+?J2
MNZ1J"^5ED-!& &3%LK7 C:1D\<\B!Z%ZUU^%O3/_ +7\1RVM/7RZZLUT*NVR
M55/IZF;AP=P;*0#V=Y)] "U.E5L]KUE8K\:=\M'!M#RP<BUY.#W9!X*NT1X4
MVKN8YM[_ ':L<WGC*XLD1%O#F(B-].DZB=S/5M]/$SVZ?M\32=DE3EP[\-./
MG6:W7W5]-;Z:"GTDPPQQ-8P^$MXM P.U9]5Q0Z_T*ZILPD=)%)UD+7MVN<YO
M M]()6KI;I'ME-:8:/4#IJ*OI6")[70N.[;PSP!(/#D5.TQXTVFVHF(U/3]V
M?%6T\%7%7#%[4M/-$[W&_/43'R:%OMVI*[I&H;Y660T$7!DQ;*UP(VD9/'/<
M/0O>L?\ \F^E"T7IOBTU:!',>S/L3GT%I]"V-/7NZZKUUX7;9*J#3U,,.#N#
M9"!W=Y)^ *;Z6;2+GH^ID8W,]&1/&>W ]E\F?@7(I%L5K4W.IWU\])SFMCXS
M'BSQ$1->28C?2)WJ)W,]8Z('I@G?<KE8].4SO'J9A)(!V G:T_2/H5LU=#8J
M32PAOS3ZF0!C6L:7 DM&&@8.<JA=%G7ZEU;47RX#=X%3QPL)Y;]NW(^!Q]*F
M^F^WU57IRFGIF.DCIIMTK6C. 01N]'\UV+;QWSQ&]]OE"%\,4XGA_9\VY>7K
M,Q_JGKW_  B'VSZNN$]OACTSI.KDH(FAD3Y90P%HX<SS^$J#T9-55'2_72U]
M(*.I?"XO@#P[:=K>T<U8J#I+T]':*9L/7FJ;&U@HXX7;MP&-H.,?*JUH>HK:
MOI:JZBY4W@M3+ YYA_(!#< ^7&%"UHFU-7WUCTTOQXK4Q\1-L/)[L]9F=SU^
M,]?G$-SIC]LVF/?GZ;5U:3[4_P Q7,>FNCJ0;-=:>!TL='(>LVC..((SY/%/
M%6G3&L[9J9T\-O;.V:*+K'MD9C Y<\J_':*YKUGO.M?@\[B<5\O 8,E(W%>:
M)^'7S5#H+.'ZB/\ ^=C_ .=8NAP"KU1J*NF&:C.,GF-SR3\P67H*^V:A_2Q_
M\ZU1)+T>:\K:FKAE?9;ADB5C<[<G=\(.1CN*SX_=ICO/:)G]WJ\5'B<1Q>"G
MW[177QU$3,0Z/K*G95:4NT4H!::9YX]X!(^4*G=#\\DN@:Z-Y);#)*UF>P%H
M./A)6#6?2!0W2T2VK38GK:VL;U66Q.&T'GP(!)PK+HRQ/T_HCP2< 5+XWRS
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MY!%AHXGP4L<4D\D[VC!ED #G>4X 'R+,@(B("(B B(@(B("(B B(@(B("(B
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MM\_>$GUJQ(@KOK4@]U;Y^\)/K3UJ0>ZM\_>$GUJ=JZF&CIWSU4K8H6#+GN.
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MCJ8:VEBJ*9XDAD;N:X=H69:'CS$Q.I$1$<$1$!$1 1$0$1$!$1!!VWVW7O\
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M1?WKQ7TZO5X6?L_"WS^=O=C]UM1$5[RA$1 1$0$1$!$1 1$0$1$!$1 1$0'
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MC;"R.FZUU$[:[89&.D& UN?9.=LR <=@?HA%Q[HRZ1JS4&H:RDK(IHFMJ,;
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M[#K*+5-DI7UD3^%3 S)=RP> XX(^ A>;KTBU-VH)*"P66O\ #YVF/<]G"//
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M+B]S87N=&7<(W@XVD;N!:3GCGR$+TBK>AM3-U+;C5!ACW8DC88W@]61XI+B
M"3Q.&Y R K(@(B("(B B(@(B("(B#F.E_L?2C<F-X!SIOG!73ES'2_V7I1N;
MQQ#73?. NG*G!VGYO4]J_P"93_; B(KGEB(B B(@(B("(B"N6.F;3:MU &R2
MOZR.F>>L>78SUO 9Y#R*QJN6*JCJM6Z@,0D CCIHW;XW,XCK<XW 9'E'!6-
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%!ZX;OTG<VDD!T6,@X(XCDIQ0>N
M'!FD[F]V<-BR<#)YCL'-!+T< IJ:.%KY'A@QND>7./G)XE95AHZAE531SQ!X
M8\9&]CF.]+7 $>E9D!$1 1$0$1$!$1 1$0$1$!$1!Q?_ $M&AW18W+FMQ71'
MCV\'\ OQ_9:3P^Z4M*9&Q]:\,WO#MH\^T$X\P7[ _P!+5KG=%C2T$AM?$3CL
M&'+\CZ4ABJ-26V&H+Q%)4,8[9[+B<8'E07ZHI[;!:J&TQUCXI9!(3)3%LC1(
MW+'-+VL#L'V6.(#<$9)X=<U)#J"'25-2VAU-7DMBCZE\QDA=&V1NU_5F-H9E
M^W&3N.2#D<1Q;6]CJ-/UM6RGI^JH!UKXY2_K.J)<?$$@'/D#V9R.87Z&Z$]0
M35VB*FKO=-/4L ;,8Q1.<Z7:6YE,A.)'9&0T<0&X X()#HKT'2TKWWF2&E$L
MTY?(PLZQSB&@'<',;U<C9 X^*,<<<L8ZA<JV&W4,U95%X@A;N>6,+B!VG X\
M.:A-,:OH-0U$T- >M,;Y 9(CNC#6NPTEW87#B&\\+:UA315%@JC--' (F]8)
MI9'L9&1^,[802 ,G&<(.<=(C?7Y0U%'9:NKZR)LLA$+FO#1&XM:YF&DATA)
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M;JBEJGQL+,R,#,5(8' ]6"_:W.<NVEWL3CO =H1$0$1$!$1!":V:':4N@/9
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M=@^TQ^]"#VB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MH:=@F=(^7K",N#GXW8)Y X' =R#3TG8(=/6TTL0A+MQW2QQ",R >Q+@.!=C
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MB("(B B(@(B("(B J[:JJ-NLKY2G?UKFP/'B.VX##^-C /DSE6)0EH]LU_\
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MIF[6U3140.:X$.:_ #G,X'&.(!4#I6Q5NJ;F9JZ>2:GC($U6^-C))0/8M):
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M'I2AM-W9+*VV6J:&GK7#A40F6,QDG\H ;3YLKKB B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M&5$9,9>,$$<L^D*HZ0U!'8V3VV[-?#M>2';<[3V@A=#BBCAC;'"QL<;>36C
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M8 MVFIX::,1T\3(F#\5C0 NUSXL>YQQ.YZ=7+<-GRS6,UHU$[Z1UEE1$6-Z
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MTK'8I-0W*S45;)<+?$^HA;*6"B<0W(SC/6*SD9&#R7R-C8V-9&UK6-& UHP
M$$/X+?O=6@^(N_S4\%OWNK0?$7?YJF400W@M^]U:#XB[_-3P6_>ZM!\1=_FJ
M91!"/IM0!CBVYV\NQP'@+N)_XJQT4&I9*2%]5<+=#4.8#)&VC<X-=CB,]9Q4
M^B"&\%OWNK0?$7?YJ>"W[W5H/B+O\U3*(*^Z#4HK6,%?;C3&-Q=)X&[(=D8&
M.L[03Q\BS^"W[W5H/B+O\U3*((22FU (WEESM[G@':WP)PR>[[:O%)3ZD?2P
MOJ;A;HIW,!D8*-S@UV.(SUG'BIY$$#5T^I&4LSZ:X6Z6=K"8XS1N:'.QP&>L
MX9*]LIM0%C2^YV]KB.(\!<<'_BJ;1!7S!J7PUK!7VXTQC+C+X&[(?D8;CK.[
M)SY$KH-31TSG4E?;II@6X8ZC<T$9&>/6=@R58$004]-J)L,CH;E;WR!I+6FB
M<,GL&>M7F.#4IHVO?<+<VH,8)C%&X@.QRSUG?VJ?1!4KE-J:@TY/<)JRW>$P
MTYE=!X([&X#);NZSOX94DRFO[F-)NEO!(S]PN_S5,R,;(QS)&M>QPP6N&00O
M2"&\%OWNK0?$7?YJ>"W[W5H/B+O\U3*((*PU-Q-WNE#<ZBGJ/!V0R1OA@,7!
M^_((+G9]CS4ZJSIV*FBU9J(4C]X<RG<_[*7X>3+D<2<>;L5F0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$04&_TM=%TE:7J:BY224LLU0R*D8W9'&! XY/:YV>WL
M'8H.YT;;K9]<WZIDE;=+=43LH9A(X&F$# 6[0#@9(R>_/%=&N5GBK[O:+@^5
M[9+<^1[&@##]["PY]!4'=M$-KJFY-BNM52VVYO#ZZBC8TMF. '8<1EFX  XY
M^1!@@L=WN=SH]0>JE'XU/$Z"GJ*)T@ILM&\L(D W.R?&QG'#DK%JJMJ;=I^M
MJJ'J_"8V9CZP9:#D#)&1GGWJ3C8V.-K& -8T  #L 4)KH-=I&Z"0X88L..<8
M&1GCV(/3*34 8-UVM[CW^ .&?_YJ]>"W[W5H/B+O\U2-NC@BHH64C]\#6X8[
MK"_(]\22?A6P@AO!;][JT'Q%W^:G@M^]U:#XB[_-4RB"&\%OWNK0?$7?YJUZ
MV#4T=.74E?;IIMS0&.HW-&,C)SUG8,E6%$$-X+?O=6@^(N_S4\%OWNK0?$7?
MYJF400W@M^]U:#XB[_-6""#4SJBI;-7VYD37 1/%&XEXVC)(ZSAQR/0K B"&
M\%OWNK0?$7?YJUZV'4T<&ZDKK=-+O8-IHW-&TN <<]9V#)]"L*((;P6_>ZM!
M\1=_FK!50:E9U/@]?;I-T@:_-&X;6=KOMG'S*P(@AO!;][JT'Q%W^:M>G@U,
M^:I;/7VZ.-CP(G"C<=[=H))'6<..1Z%8405Z>#4S:BF;#7VY\3W$3/-&X%@V
MD@@=9QXX'I7VL@U+'$#2U]NEDWL!::-S<-+@''/6=@R<=N%8$05^L@U+'"#2
MU]NEDWM!::-S?%+@''/6=@R?0M:Z2ZAHZBW1LN%OD\*J.H)-$X;1L<[/VSC[
M'Y5:5Y<QCRTN:UQ:<M)&<'ED?"4$1X+?O=6@^(N_S4\%OWNK0?$7?YJF400W
M@M^]U:#XB[_-3P6_>ZM!\1=_FJ91!#>"W[W5H/B+O\U8*B#4K)*<05]ND8Z3
M$KC1N&QNT\1]DX\0!CRJP(@AO!;][JT'Q%W^:G@M^]U:#XB[_-4RB"&\%OWN
MK0?$7?YJCK'/J"Y05,CKC;X^IJIJ< 43CD1O+<_;.W"M2@-%_<5R_O.K_C.0
M9O!;][JT'Q%W^:L%1!J5LU.(:^W21N>1*XT;AL;M)R!UG'B ,>56!$$-X+?O
M=6@^(N_S5@E@U*VJ@9'7VYT#@[K)#1N!81C&!UG'/%6!$$-X+?O=6@^(N_S5
M@HX-2R1.-57VZ)XD> T4;G9:'$-/VSM&#CLRK B"OF#4OA@8+A;O!NK),G@;
MLAV1@8ZSNR<I/!J5L].V&OMSXG.(E<:-PV#:2"!UG'C@>E6!$%>J(-3,GIFP
MU]NDC>\B5QHW#8W:2"!UG'C@>E:U1-J&*^T5O%PM[FU$,LID\"=ENPL &.LX
MYW_(K4O)C89&O+&E[00'8X@'F,^@((CP6_>ZM!\1=_FIX+?O=6@^(N_S5,H@
MAO!;][JT'Q%W^:G@M^]U:#XB[_-4RB"&\%OWNK0?$7?YJUWP:F%;"QE?;G4S
MF.+Y? W M<"-HQUG'.7? K"B"&\%OWNK0?$7?YJ>"W[W5H/B+O\ -4RB"%-+
M?\'%TMY/9_J+O\U8:*#4LE)"^KK[=#4.8#)&VC<X-=VC/6<58$00W@M^]U:#
MXB[_ #5@=!J45L;&U]N-,8W%\O@;LM<"W:,=9QR"[CY/*K B"&\%OWNK0?$7
M?YJP-@U*:U[#7VX4PC!;+X&[)=DY&.L[L<?*K B"$?3:@#'%MSMY<!P'@+AD
M_P#%6.C@U+)20OJKA;H:AS 9(Q1N<&NQQ&>LX\5/H@KT,&IG550R6OMS(&[>
MJD%&XE^1XV1UG#!7TP:F\-:P5]N-,8RYTO@;LA^1AN.L[LG/D5@1!7W0:E%:
MQ@K[<:8QN+I? W9#LC QUG:,\?(M:"74,E\JZ W"WAD$$4H?X$[+B\O&,=9V
M;/E5I7D,8)'/#6A[@ 78XD#D,^DH(CP6_>ZM!\1=_FIX+?O=6@^(N_S5,H@J
M]]=J&W6BKK67.WN--&Z79X"X;L#.,]9P5FC=NC:X\R 57ND&*FETE<?"G[-L
M+W1_92S+MIP.!&?,K!!]IC]Z$'M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MLK<#LSQ':%T5 1$0$1$!$1 1$0$1$!0&B_N*Y?WG6?QG*?4!HO[BN7]YU?\
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M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$%>U-]_-+?K[_\
M#S*PJO:F^_FEOU]_^'F5A0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$%?L\,4.KK\(8V1AT-,YVUH&2>MR3Y58%!VWVW7S]!2_\
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M0P,8Z7@R5G 9)X>0A26@XVQZ9I2P %^YQ\IR5(7*T4-RDADK8.L?%[ [B,?
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MB B(@(B("(B B(@(B("(B B(@(B("^/8UXP]H<.XC*^H@\1PQ1G,<;&G_9:
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M6LF8 71DC@X \,A4EFB]2,<'#I NY(.<.I8"/HJ[UL4D]'/%#.ZGE>PM;,T
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MXTM'&"W(YGL^4D^A;/236SP4E)30O=''.XB1PX9 QP^55UK:ML>&O?O/S_\
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MN%ON=-#)4QN\3K&Y.!D'&?0H\+RQCR3._+MWTGQL6G+BB-:Z]^VV76DMDJJ
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MFGJUSW %\9C:.\NX?S3-?)&>L1/H[P^/%/#7FT1Y[1&F[M(S1$M4\[I*5KV
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MHR&N$0PW=AV?Y+TJ3$WR=9F=3OT>3>MJX\4ZB(W&O7_GJZ,B(O)>X(B("(B
MB(@CM1/J8[)624%734=2QF]D]2,Q,P<^-Y" 1GLRN=6+I#N6JKI;[71,IK.]
MQZR:JJ#O;5M:[#A29 #P<>R., C@NFW*@I;G124E? RHII,;XGC+78((R/.
MM6\VRTU=)3QW6"F,$$L;H.LPT1R C9M/8<XQA!)HB("(B H"TPQG5E^E,;#*
M! T/VC<!L/#*GU7+5).-97R-L#33EL!=+OXAVS@-N./GR@L:(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@KVIOOYI;]??_AYE857M3??S2WZ
M^_\ P\RL* B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B H#1?W%<O[SJ_XSE/J
MT7]Q7+^\ZO\ C.03Z(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B"&UG[4[Q^JR?1*EH/M,?O0H+7L\D&DKGU=-+4;X'L/5EHV M/C'
M)' >3BIV#[3'[T(/:(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B#G.H[!;]1=(\U/+5WB@K8;5$]T]%6=2
MU\9ED :0!G(.3G/:E'T3V:F%)&V\7Z2FI9F31TTE=NBW,<'-\7&.86S?-$4^
MH.D*:OO%))+;FVR*")[)W1_91+(7##7 \G#GP6Y2]&NF*6IAJ(:*H$L3Q(PF
MLF."#D<"[B@N*(B B(@*$M'MFO\ _P"Q] J;4':/;-?_ /=_H%!.(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B"O:F^_FEOU]_\ AYE857M3
M??S2WZ^__#S*PH"(B B(@(B("(B B\ND8SV;VM\YPO'A$/YZ/]H+NI<W$,J+
MXU[7^P<UWF.5]7'1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!!VWVW7O]!2_
M]53B@[;[;KW^@I?^JIQ 1$0$1$!$1 1$0$1$!$1 1$00NMG0,T?>W5D;Y*84
M4QD8QVUSF[#D \<'':J/:NC&TU]OM=>+YJ6-S8&R0 W')A#FC(:<<.'#@KWK
M&CGN&D[S1T;.LJ:BDEBC;D#<XL( R?*JK9NBW3K;11-KJ"H%4(&"4"MFX/VC
M/)^.?<@G]':4HM+MKO JNNJY*R1LLTM9-UKR0W:...X*Q*(TWIRVZ<@FAM$,
MD4<K@]X?,^3) QS<3A2Z B(@*$UK[5KC^C'SA3:A-:^U:X_HQ\X038Y!$'((
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("@-%_<5R_O.K_C.4
M^H#1?W%<O[SJ_P",Y!/HB("(B B(@(B("(L9FB;[*5@\[@FMN3,1W9$6,5$)
MY2QG_P!060$$9!!"[HB8GL(B+CHB(@(B("(B B(@(B("(B B(@(B("(B"&UG
M[4[Q^J2?1*EH/M,?O0HG6?M3O'ZI)]$J6@^TQ^]"#VM2\3/I[3630NVR1PN<
MTXS@@%;:T-0?>*X?H'_1*GCC=H5Y9U2TQZ(S0MQJKG:9)JV7K)!*6@X X8'<
MK$JCT9?>&7],?F"Q7Z[5UPOHLMFEZ@M^VS \1PR?-A:<F#GSVK7I$?DQX>)\
M/AJ6OUF?QF5S146NLEZL]*^MH[Q-4.B&]\;LX(',X).5)-N<M\T?/4TLCX*M
MC3NZMQ!#F\3C'81\ZA/#QJ+5MN-ZWZ+*\7.YK>LQ:(WKU6A%7]"W%]QL3'3R
M.DGB<6/<XY)[1GT%575-[KVW^I=0U$[:6D+&O:QY#<YXY\YX+M.%M?)./?9S
M)QU,>*N;6]NE(M7PV/U,\-R!%U76Y\F,JLZ'K*J6@N%TN55*^+<=K7N)#0.)
MP/3CT*NN&9K-O1=;B*UO6GKN?HN"*AV\7;5DL]1X=)0T#7;6,CSD_*/A7I]3
M<]*W.FCK:Q];;ISMW/YM^'EA6_9.O)%HYO1G^W=.>:SR>O\ ;OI>D53Z1:VI
MH[;2/I)Y87.FP3&XM)&T\."PV^WWVZ5-/7UM:ZD@#FO93@GBT'D1PYCO4:\/
MND9+6B(3OQ6LLXJUF9C2Y(BJ&L;Q6-N%-:+2XMJ9L%SV\QGD!W<LY56+%.6W
M+"[/FKAISV6]5/1%VK;E5W%E;-UC8B P;0,<3W>9:XL-\MD9JZ6[R5,S/&=
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M=[\W(XRGAVO:-<O28^*RHJ8=,7AL)G;?:@UN,[<G;GNSG^2W]%WN:YT\]/7
M"LIG;7G&-PY9QW\%R^"(K-Z6W$=RG$S-XIDK-9GLLB(BSM8BIW2+755$RWFD
MJ)82YS]PC>6[L8YX7EUEOMWB\)K+HZC<X993QYPT=F<$<?A6JO#Q-(R6M$1+
M%;BYC);%2DS,:7-%3M"72LEJJVVW&0RRT_$.<<G@<$9[5ZU7>JQUTALUG=LJ
M9,;Y!S;GL\G#CE<^RV\3P_S^'J['&T\'Q=?#7GOT6]%2*C3EZHJ=]52WN>:H
M8-Q8<X=CCCB2IO2%Z-ZMI?* VIB.R0#D>X^E<O@B*\]+;A+'Q,VOX>2O+,]O
MBG%5+#=JVJU=<Z*>;=30M<6,V@8PX <?2K6J-I?V^WGWK_IM7>'K$TON/)'B
MK6K?'$3WE-:CMETK:VCDMM;X/%&?';DCMY\.?F*GQRX\2J7KNNJZ6ZVME-4S
M0L>?&:QY =XPYK[J*LJ[1JN@G-3-ZGU! =&7G8#R/#EV@JR,-LE*1N.TZ53Q
M%,5[SJ>\1/U7-%CGF9!3R32'#&-+B?(%4=$UE551W*ZU]3,ZG!(9&YQ+6@>,
M<#R< L],4VI-_1JR9XI>N/UW]-+DBH=!ZK:LEGJ!6R4-O:_:QL?-WDX'S<4F
MJ;GI2Y4K:NL?6VZ8[29.;>_S85WV3KR<T<WHS_;NGB36>3U_MWTOB*I=(M;4
M4=MI'T=1+"YTN"Z-Q;D8/<L-NH;[=YJ:OK*YU)3AS7LIVY\9H.>(!',=ZC7A
M]XXR6M$0G;B]99Q5K,S&ES1%5=6WBKCK::TVD@5D^"Y_Y(_^@E58L<Y;<L+\
MV:N&G-9:D5+J-.7BDIWU5+>ZB6J8-Q8[.'>3F5,:/O+KS;"^8 5,3MDF.T]A
MPK+X(BO/2VXA5CXF;7\/)7EF>WQ3B+FNGZR^W.>LHZ2KD#2_+ZB5Q=U3<G@W
MRG^2RWJFN^F'05K+K+5,<_#VO)P3SP02<@\5;]CU;DFT;41[0W3Q(I/+YS_S
MNZ*BCJR.6ZV=O@=4^E?,UKVRLSD#GY%5KM:;E:Z"6JJ=2U6Q@X ;LN/8!XRI
MQ8:WZ3;4^FI7YN(MCCFK3<:WO<?NO2*D:0@NM=9JZ>IKJG[.S;3ETAW C/C#
MNXX6YT?W2>LI*FEK9'R5-._BYY)<0>_/<<J63AII%IB=\O='%QD7FD377-O2
MUHJEKZY5,#:*BH)I(JF>3.8W$''(#X3\BT=:5==:Y+/%35=07!F'XD(,I!'/
MOS_-=Q\+.3EZ_>W^3F7C:X^?IOEU^:]HJ7+8+]<8S4U5V=3SN&YL$>0UO<,@
MJ/L=UOUU@?;()-LT;CUM6_V3&\L>?.>*['"Q:)FMXG7?X(SQLUM%;4F-]OC_
M  Z(BYU>Z2[Z9ZFO9=9JIKGX>U^<9Y\02<@\5<Y[M%!8O5-X\3JA)M[R1P'P
MJ&3A^6(FD[B5F+BHM-JWCEFO7Z))%1+70WC4L!KJNYRTD#R>KBBR!COYK-;Z
M^XV+4$-KNE2:JFJ,"*5W,$G ^7AA3GA>]8M$VCR0KQO:UJ3%9[3_ &758:RH
MCI*66HF.(XVESCYEF52Z2:LPV6.G8>-1( 1W@<?GPJ<./Q<D4]6CB,O@XK9/
M1N:-K*ZY4U175TGV*60B"/: &M!^$]WH4[4S,IZ>2:4[8XVESCY M>S4PH[5
M24[1CJXF@^?''Y5 ](M>::S-I8_MM4_9@<]HXG^0]*LY8S9N6L:B9_)5SSP_
M#\UYW,1^?_E":?U5<9;U3^J$O^I5#W-:"T  ]G''8<!=%5!U+9#1:0H'L&)Z
M,ASR.?C'C\N%;[#7"XVBEJAC+V#<.YW(_*K>*BEJQDQQJ.L*.!MDI:<.6=SJ
M)_'O^$J_=+Q70:VI*"*;%*_9N9M''.<\>:MZH-[_  CT'_M_S5^5?$5B*TU'
MDLX2]K7RQ,]K(G4;+H^DC%E>UD^_QB['L<'O]"I]XK=56BG;/6U488YVP;0P
M\<$]WD71E3^D_P"\E/\ K ^BY3X/)$WC'-8F)^'5#C\4QCMEK:8F/2>C3IFZ
MQJ*>.:*IB+)&AS<[.1]"D+W<+G9F6FKJ)0^ AL=6P-&-V.)!QY_@4_8OO-0_
MH&?1"U]4THJ]/U\9&2(B\<.UO$?,GC1;)%;5C6]=C[/:F&;5O.];ZS]4I&]L
MD;7L(+7 $$=H7U5[0=8:O3D >XN?"3$23W'A\A"L*RY*>'>:SY-N')&7'%X\
MX$1%!8(B(-&^5-726JHJ+=2>&543=S(-VTR8/$ ]^,X\JJE)KF;4-7!2Z1MT
MM26O:*VIJVF**D&1N8>UTH&1M' 'F5GZ0[19C0U%\O+KH12PAG5T=7)&7^-X
MH#6N +BYV,^9<WM0L]'>6.@TIJBDF]488)YI[IAC)G%I;UF)#G@6\QQR @[T
MB(@(B("J#:JZ0:KO@MMMAJXR("YSZGJL'8>&-IRK>H2T>V:__P"[_0*#%ZHZ
MB]P*7]X#^A/5'47N!2_O ?T*P(@K_JCJ+W I?W@/Z$]4=1>X%+^\!_0K B"O
M^J.HO<"E_> _H3U1U%[@4O[P']"L"(*_ZHZB]P*7]X#^A/5'47N!2_O ?T*P
M(@K_ *HZB]P*7]X#^A/5'47N!2_O ?T*P(@K_JCJ+W I?W@/Z$]4=1>X%+^\
M!_0K B"O^J.HO<"E_> _H3U1U%[@4O[P']"L"(*_ZHZB]P*7]X#^A/5'47N!
M2_O ?T*P(@K_ *HZB]P*7]X#^A/5'47N!2_O ?T*P(@K_JCJ+W I?W@/Z$]4
M=1>X%+^\!_0K B"O^J.HO<"E_> _H3U1U%[@4O[P']"L"(*_ZHZB]P*7]X#^
MA/5'47N!2_O ?T*P(@K_ *HZB]P*7]X#^A/5'47N!2_O ?T*P(@K_JCJ+W I
M?W@/Z$]4=1>X%+^\!_0K B"@ZBK[\;QILR62F:X5KRP"N!W'J)>'L.'#*GO5
M'47N!2_O ?T+YJ;[^:6_7W_X>96%!7_5'47N!2_O ?T)ZHZB]P*7]X#^A6!$
M%?\ 5'47N!2_O ?T)ZHZB]P*7]X#^A6!574.LJ2WET-$!550X</8-/E/;Z%9
MCQ7RSRTC:K-FIAKS7G3/)==011N?)8Z1C&C)<ZX@ ?\ P4')T@S13F.6UP%H
MYOBJ]X^@,K6@L]^U,YL]RF=!3$Y ?PX>1GUJTVK2=JMX:[J/")1^/-QX^;DM
M7A8,/^9/-/I'\L49N)XC_)KRQZS_  K9U/J"Z<+71=6T\G,CW?*>"PU%GU=5
M,)DFD)(]B:@-'R+I+0&@!H  [ BY]LBO^72(_-W[!-_\W),_E#D1TCJ=[CUE
M)3.\OAF?^5??6;J''W%3Y_6A_2NN(N?;\_K^4)1[,X;_ $_G+D;-)ZI9("RF
MIV#O%9Q'_P 5*PVS6%&S=%-(['XO7!_R%='1/MV2?O1$_.'/^F88^Y,U^4N>
M-U=>K:X-NU!N'++F&,GT\EFI=>U-54&**UTS>/BF6MV9_P#AA7N1C9&%DC6N
M:>!#AD%5V[:-ME<USH6&EF/)T?+TM7?$X?)TO7EGUC^'/!XK#UQWYH])_E[;
M<M0N +;#2D'B"+@/Z%]]4=1>X%+^\!_0JL^GU!I0E\+_  BB:>./&9CRCFU6
MC3VJZ*[;8GGP>K/_ );SP=[T]JADX6U8YZ3S5^"S#QM;V\/)'+;TG]GWU1U%
M[@4O[P']">J.HO<"E_> _H5@196U7_5'47N!2_O ?T)ZHZB]P*7]X#^A6!$%
M?]4=1>X%+^\!_0GJCJ+W I?W@/Z%8$05_P!4=1>X%+^\!_0GJCJ+W I?W@/Z
M%8$05_U1U%[@4O[P']">J.HO<"E_> _H5@1!7_5'47N!2_O ?T)ZHZB]P*7]
MX#^A6!$%?]4=1>X%+^\!_0GJCJ+W I?W@/Z%8$05_P!4=1>X%+^\!_0GJCJ+
MW I?W@/Z%8$05?3,U9/J:^NN-)'2R]32@,9-UH(^R<<X"M"@[;[;KY^@I?\
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M B"O^J.HO<"E_> _H3U1U%[@4O[P']"L"(*_ZHZB]P*7]X#^A/5'47N!2_O
M?T*P(@K_ *HZB]P*7]X#^A/5'47N!2_O ?T*P(@K_JCJ+W I?W@/Z$]4=1>X
M%+^\!_0K B"O^J.HO<"E_> _H4'I&OO[:.X=58Z9X-QJB2:X#!ZYV1[!7Q0&
MB_N*Y?WG5_QG(/GJCJ+W I?W@/Z$]4=1>X%+^\!_0K B"O\ JCJ+W I?W@/Z
M$]4=1>X%+^\!_0K L554PTD#IJF5L43>)<XX"[$;Z0Y,Q$;E">J.HO<"E_>
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M>88/4C4?NZS_ (0^I-+6.2VW:KJ9J^&IEE:0]K.!SG.2%KMU)>V0F&2Q2FJ
MQN .W/?C_NMK1EDJ:%]57W+ K*DY+ <[1G)SY257>;UQVYYB-^FNOX+,<8[Y
M:^'$SKUF>GXK0BH=NK+Q#KDTM;+(Z.1SCU><MV<<$#LY!7Q9<V&<4Q$SO<;;
M^'SQGB9B-:G751NE#V%L]^__ )5=XOM3/>A5+I"MU77MMXHJ=\VQSB[:.7)6
MV(8C:#S "MRS$X,<?/\ 51@K,<3EF8Z>[^BB:3]O-W_]SZ87RV_A,JNM]EXV
MW/O1CY%NZ;MM93ZON=3/3O9!)OV/(X.RX%9-4V2L]5(+Q9FAU5'C?'^5CM^#
M@5IF]9R37?>NF*N*\8HOK[MMZ^"VJA=&WWQNVS[7D8^$K/57Z^UU,ZEI;--!
M.\%ID.<-\HSA36D;)ZBVTQRN#JB5V^0CEY %3R^!AO6\];::>?[3GI:D=*[W
M.M=_).*C:8]OMY]Z_P"FU7E4:MH+O9]3U-RMM)X7#4 Y:#WX)![>84.%U,7K
MOK,+.,W$TOK<1/73'TB??FS^?_F"F=?T!K+!)(QN9*<]:,=W;\GS*-U?05]Q
MK;//#22.V@&0-X[#D'!5TEC;+$^-XRQX+2.\%66R>'7%,=XW^JJF'Q;YJS'2
MVOT46\7WKM!TQ:[,]1B!V.?#V7S?*I5U ;?H*:G Q(*9SG^^/$JMVK3=P%]@
MIZF"3U/@G=('GV)'_? 7298VRQ/CD&6/:6N'>"I9[TQ<M:3N-[_A#A:9,W-?
M)&IURQ^\N>Z1M]WJ;.V2W75M-#O<#'U><'S_  +<N^F[K6P,9<KW Z-KLMWL
MV\<+Q1PWC2E3/%3T;J^W2.W-V<V_!R.%YKH;MJRJ@CGHGT-!$[<XOYGX>9QY
M%=-K3DYXF(KZ]-_SMGK2D8HQVK:;]M;G7\:9>DAG5V.WLW!VUX&1V^*K?:_O
M;2?HF?,%7-?VVIK+71PT%.^8QR>Q;QP-N%9;>QT=!3,>"'-C:"#V'"QY+1."
MD;\Y;\-9CB;SKIJ&=<ZO$-7-TA=72U IIW-'5R$9P-A[/A7155]766JJ:FFN
M=JQX;3X\7.-P!R/2N<'DBEYB?.)AWC\4Y,<36-ZF)Z//J/J/'&^L_P"$/J67
M1ME-I?6$UL-3UI!(C[",\UHR:CODD#H(['*RJ/B[SG:#W_\ TJ1T78Y+/12N
MJB/"IR'/ .=H'(*[)-ZXK1>8C?E&NOX*<,8[YJSCB9UOK,ST_%#]&?W3=O?M
M^=RW>DS[PQ?IF_,5XT#;JRAGN1K*=\(D<TLW#V7$K;U_15-=9XXJ.%\T@E#B
MUO/&"I6M7[9%M].GZ(5I;[!-==>OZI:PG%CH">74,^B%3ZV1^K]0MI('$6RE
M.7N'XWE]/(*7O45R9H^EIJ"&0U+F,BD:T>,UNWC\H ]*A[!/>K-0^#T]@>XD
M[GO)XN*YAIJ+9*S'-Y=8Z?$XC)S33#>)Y=1,])Z_#^5]AB9#$R*)H;&P!K6C
ML 5(V^H?2 "!LIJX8'=D_P#Z0^53MAN=TK*I\=QMAI(@W(>3S.>2C^D:EW6J
M&M8X,FI906GR'_O@JO!$TR3CO_5T7\3:,F&,M/Z9WZ=N_P"34@__  ST@R2>
MRIZ!N!W9'#YR?@6/I&^^UG\Y^D%)]'=&Z&S/JY>,M7(9"3VCD/YGTK7US;:R
MMN5L?24\DK(R=Y:/8^,%?2]8XF*[Z5C7Y,N3':W"3?76T[_/^%Q'(*D: ^_-
M]_2#Z3E=QR52T7;ZNCNEXDJH'Q,E>"PN'LO&=R^%9<,Q&+)'R_5MSUF<^*8C
MU_1[Z2O:Z/TS?YK2OP<>CJDV\MD6[S?_ '"E->4=176,14<+YI.M:=K>>.*V
MZ.V^$Z6AH*QKF%U.&/!YM.%;CR5IBI,^5E&7%;)FR1'G72O6"VWR:S4DE'>&
M10.9XD?5@[1W+[6Z;N-164LMRO,#WQ.!9N;M/,'@O%LGO>F8W44MN?6TH<3&
M^(D\_A7J*AN>I+W35ERI31T5,06L=S=@YQW^E7S:T6F^XBOKTW_+/%:6I7'R
MVFW3I,SK^-+RJ/TE<9[0#[$R.S\+5>%4>DFE,MGAJ6 [J>4$D=@/#Y\+'P<Q
M&:NV_P!H5F>'MK_G5;APY+F6HZR>XZOS14SZL41 $;03G:>)X=F5?&5CYM/M
MJZ5AEE?3A[&MXDNQR^%0>@+1444=757")T=5,[&'\]O,GTE3X>8PQ?);O'32
MOBXGB)IBKVGK,_HT:V]7^LI)J>:P/,<K2P^(_M7KHUK'Q^&6NIW,EB=O:QW
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M=X_59/HE2T'VF/WH45K/VIWC]4D^B5*P?:8_>A![1$0$1$!$1 1$0$1$!$1
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M8SP+&W83-LY9VG.?3A7E0XF*UY8K&HUOX_5/@K7OSS>=S$Z^'3T$1%E;A$1
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MMO%>]CQW^&OP>=P7N9<N/X[_ !>D1%B>B(B("(B B(@(B("(B B(@(B("(B
MA.!E%IWFI%'::NH/_EQ.(\^."[6.:8B$;6BL3:?)2-"?ZUJNYU7XN'G]I_#Y
MET-4?HNIBVDKJEP^V/:P'S<3\ZO"U<=.\TQ'EJ&+V;68X>)GSW(B(LC>(B("
M(B B(@(B(*Y8Z9E-JW4 C=*[K(Z:0]9(Y^">MY9)P/(."L:@[;[;KW^@I?\
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M65\J-\VYK8&;!(X,/B'B6YP3Y4%B1:4MVH(KO!:Y:N%EQGC=-%3N=A[V X)
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M2GZ_)_AIE8T$5J2RQ7J@,+\-E;XT<F/8GZE4M+7N:R5CK/><LC:[#'N_$/\
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M0$1>(YHY'R,CD:Y\9P\ Y+3C.#W<$'M$1 1>)I8X6!TKVL:2&Y<<#). /22
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M_(_6IVFU?9IP,U75'ND80JK\)FIWJOQ\=P^3M:/KT3Z+0%YM[XW.BK:=^!G
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M9+$R2)S7QO <US3D$'D0@](O,LC(HGR2N:R-@+G.<<  <R5Z:0YH+2"#Q!"
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M3UL6_P#.7#X]-_4IM$$!-I*US,#)O#7M#@X!U;,1D'(/LNP@%9/6Q;_SE?\
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M4]4^GZJ4@OPT Y=CD3GEV('K8M_YRX?'IOZD];%O_.5_QZ;^I3:((3UL6_\
M.7#X]-_4L<^DK7/&8Y_#9(R0=KJV8C(.1^-W@*?1!">MBW_G*_X]-_4GK8M_
MYRX?'IOZE-H@A/6Q;_SE?\>F_J6./25KCDED9X:U\I!>X5LV7$# SXW< I]$
M$)ZV+?\ G*_X]-_4L<^D;741]7/X;(S(=M=6S$9!R#[+L(!4^B"$];%O_.7#
MX]-_4L<NDK7+LZWPU^QP>W=6S'#AR(\;FI]$$)ZV+?\ G+A\>F_J6./25KB?
M*^/PUKY7;GD5LP+C@#)\;N "GT00$FDK7))%))X:Y\1)8XULQ+21@D>-W$A)
MM)6N=@9-X:]H<' .K9B,@Y!]EV$ J?1! 3:2M<S V;PY[0X.PZMF/$'(/LNP
MC*2Z1M<SHG2^&O=$[>PNK9CM=@C(\;G@GX5/H@A/6Q;_ ,Y7_'IOZD];%O\
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MV+?^<K_CTW]2>MBW_G+A\>F_J4VB"#]:]OQC?7_'IOZEX@TE:Z>%D,'AT<3
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01 1$0$1$!$1 1$0$1$'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g73463g01f03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g01f03.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1W&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ':D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" /2!VP# 2(
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M"LJX82?P7.&?FZJQ37^U5,@C@N%.YYZ#GQGYU&K)H>*2,5-^DEGJI/:='SD
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MJ+G4Y,]6XX)Z\H/7XG/S!:/2_AIOE_\ ^?U_M#'ZW\;&/#/GS;]/[RF30&@
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M\S_),[%;VVNTTU&W<QL]H^+CN3\^5SFTUMPAU9=9[?1BLJ"Z1I:X_);S]?H
M^*ZJN;W(R:4UF:\L<ZBJB2>7P/RA[P=U3P[]<WB>\S'\U_M"GIQBF)U6L_+Y
M-O\ 9O5'_8+/ZW_%/LWJC_L%G];_ (J54-93UU.V>DF9+$[O:?K\%[654%'
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M (_[H[K^68:OMK88Q,^-D;HXST<[G.WQP%M_LWJC_L%G];_BK'$BW39I;O2
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M(BQ/1<[T< S7UX8T8:'3 #_Q%F<5I'"VT,8/LNE+B/,#;ZRL/2/WP;Q^5/\
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MTU61W#V0?>=RIJBU3S<\QKJ_9CCV;QHG?3_6=?R6Z:"*F@9#3L;'$P8:UHV
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MIJO !>!D.QXCQ\U)45F/+;%;JI.I59L-,U>C)&X0NAT3*RM@GKKO/.(7![
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MIWZ>X*]=;?3W6W5%#6L+Z:=O)(T.(R/>-T&)I+;2MFQ_L4/Z@43U-]][2?\
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MGVM%#^89^J%3>;527FUS6^X1F2EF #VAQ;G!!&XWZ@+*@B;##'%&,,8T-:/
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MKC<Z6W2M9!6D>U("79!/?C 7O![^+;Y^E)_V*9VJVT=IHV4EMIHJ:G9T9&W
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M$!$1 1$0$1$!$1 1$0%9I*6GHXC'20101DEQ;$P-&3U.!WJ\B B(@(B("(B
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M 1$0%3)&R5CF2,:]CA@M<,@A5(@Q:*W45"7&BHZ:F+_E=C$UF??@+*1$!$1
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MP$2BJT&JKE7KB %1SYRI1!X5YPJ"Y4<VRISE=B$9EZ3X*A>Y7BG$(;%X%ZO
MCBKN7B][EXNP"\RF5YE=<,JDN57<J'#9=AQ2YRMN<55RG"\Y5*!:+BJ22K_(
M%YV:.PL9*IYG;K([)>=D$%CG*J:XY5T0A>MB3;HPD+"KCS'!6R;&K<E.'%9<
MT=4:>KP;16W9IZ=O(XE7GN#RKU3$V/..JQ&'?*Q133V;9.J5;G!@W6.Z8C.%
MD,B,SL!9;;>"Q(K-O#EKUIYEJ1+D[E94#@<87DUN<S):E-&YA&0H333M;Q;P
MW-*0UN5K-0W 1P.;E9?-RL^"A>J:S,A:#G!W6C!&W*4W;<M-5S-ED<<XRL:,
MGGQE8LDO5412X<3E;8\-$0V3'>(51 (&^%B1U.V" 5<[0$;KG4LTV5.][8B.
M;+<J=:6DYX!A<[IG]6-=\KQ4JTQ<&T[2UYZ+):\=7=W/CM?'J$[<!RJQ)410
MM)<1LM)7W^)K"&'=1BNO+I"?:^E57S5JR8.!DR>4FN%Z#FEL> %H*BM+\G*T
M[J_F[U:-4"L=\_4]?#PHQQVAL'SYRKU%EQR5J(Y@YRW%$]H'54Q.UN2G3#:L
M=@85;=PL42#&Q5QD@PK=L,U4U4(<TGO6I< UQ&%M99FAIW6HF<"X[J%FC#OQ
M+T;KUT8*H856'**[O"AL."5>8WE0.51!(R$A&9F?+)<.:';P6-&W"RJ;>/!5
M#V<IV4]*HG6X9=(<%;RC> %'J=V%LZ:0K1BMIDSTVWC7]2.A5;,..ZQ(7>RK
MS7$%>ACR=GA9^+$SMD]F,;+$J80X$862Q^0O'8*OK9YF3'T=D5N=O#LD!1NJ
MIG0N. NBS0AP.RTESMX<TD!7>6?7U<7U=ICMNTKK<S[9UDA'X7F//R4)HJJ>
M@JXZFDD=%/$[+7-Z@KNE93.B>2 H#K#37:=I7V]OM]986CKXN'[EHQY/]-F+
M/Q]>_1/M":NAU%2\DG+%<(A]LC'1P_&;Y?4I95T]/<:*6DK(Q+!(,.:?^>J^
M8K973VROAK*1Y9/$[F:?'R/DOH+1VHZ;4=M%1![$[,-FASNQW[CW%+TUWA+#
MFZXZ;-IIJ>>W2?8>X2.EY!FDG=UEC'X)_E-Z>8W4C#LK25$ J8V@GE>QP?&\
M=6N'?^SW$K8,D\5GM5JQSJ.EF8V5LM)1D@*NLP2H>%\=U$;1GHLJ%O*=L[JE
MC-UE1-W!PJ[63K5[V>1T5/9[K-;&7#HO'1$=57U)]+':,!7J(_;\>2M2;!>V
M]V:G'D4GQ*6VS1$5*8B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B H9
MQ"XEZ:T)"/LY6YK'MYHZ. <\KQXX[AYD@+9\0-1,TGHR[WR1H?ZG 7L:>CGD
M\K1\7$!?+G K0AXJ:HNVI=92RU=)#*'2-+B/6)G;\I(Z- [AX@=$$\=Z4EC%
M06C3UR,&=G]JSF(_)_XKIO#_ (JZ6UR[L;17&.O R:.I'9RG\D9P[X$K>1:-
MTS%1^JQZ>M I^7E[/U./!'GMNH5:.!VEK3KZ/4U R:)L)$D-"UV(HY1^&#UQ
MTPWH#Y;(.FUM73T-)+55L\<%-$TODED<&M:!U))Z+BNI?23TE;*I\%KIJZ[<
MAQVL31'&3Y%VY]^%!?2FU;<+QJ^DT+:7N[&,Q&:-IQVL\@!8T^0:YI^/DNQ<
M..#^F=(6F&.:W4MQNA:#/5U,0D)=W\@<,-'ACXH(GIWTE]*W"J;#=:*OM0<0
M!*\"5@]_+N/F7:[9<*2ZT$-;;:F*JI)F\T<T3@YKAY$*$Z^X3:6U?:YH9;92
MT5<6GL:REB$;V/QL3C',/(_0N >C_JB[:'XG2:+N\SW4,]0^D="3EL4X)P]O
M@"1CSSE!]#<5>(]!PYM]#5W.BJJME7*Z)K:?ERT@9R>8A;G0NK;9K33M/>+-
M(702[/C=CGB>.K' ="/W+BWIG?<QIW^>2?J+CW"76MVX6:CHYZ^";["72)DL
MT)Z21'I*S^4-_F(0?<%TK&6^VU=;(USF4T+YG-;U(:TD@?,N>\*^+]JXBW2M
MH;9;JZEDI81.YU1R8(Y@W P3ONI7?:^ENF@KG76^=E125%NEDBE8<A[3&X@A
M?-/H9_=E?OY@/[QJ#L%BXVV>Y:^_@E4VNX6^X^L/I>>HY.3M&Y&-G9WQM[PN
MK+Y-]*O3<VG=;6K6%I!B];<TO>P?(J8L%KO>1C^J5])Z!U'#JS1UJO=/CEJX
M0Y[0<\KQ[+V_!P(^"#+U1?*33>GKA>+BXBEHXC*_'4XZ >9. /,J)\*>)]'Q
M'^R#K9:ZZD@H^4/EJ.3E<YV?9&"=\#*YAZ7VK'1T-LTC1.)FJW"JJ6MZE@)$
M;?BX$_T0NK<%M&C1&@:"VR >O2#UBK=C_6NZC^B,-^"#G]Q])C3U#<*JDDLE
MV<^GE=$YS3'@EI(R/:\EC_\ X4>F_P#L*[_/'_[ES#@C!;:CCK<X[U%1RTA-
M9[-6UKF<W/ML[;*^I?L-H;_L[37]A!^Y!I^%'%2V<1Y;BRV4%92&B#'/]8Y?
M:YLXQRD^"P.('&JR:'U;'8KM0USWNCCE=41!I8QKB1D@G.V/!3ZQVVRT;'S6
M*BMU.V3V7OHXF,#L=Q+1OA?(OI5025/&%D$(YI9:.G8P9QDDN 0?9%'505M)
M#54DK)J>9@?'(PY:YI&005'>)&LJ30FF9+W<*:>I@9*R(QP8YLN. =R OGKT
M=.)=1I>\.T/JXOIZ?MC%3NGV---G!C=X-)Z>!/@5TSTKOO15/\[@_6*"16?B
MA;;IPSK=:Q4-8RAI1(70.Y>T/(<'&^._Q7/?_P */3?_ &%=_GC_ /<MYZ+M
M-!6<&8*>L@BGIY*J</BE8'-<.;H0=BIW>](:;99J]S-/6=KA3R$$440(/*?Y
M*#E'_P"%'IO_ +"N_P \?_N4GX<\<K-KK4\-DH+7<*:>2-\@DG+.4!HR>CB5
MQ3T2;7;[IK>]17.AI:R)EO+FLJ(6R!I[5@R X'!7UC;].V6VU(J+=9[=25 !
M E@I61N /49 R@@%)QIM%3Q'=HUMMKQ6MJG4G;GD[/F!._7.-O!=37QK9/\
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M&>S=Y.;GW[K[KX9ZVM^O-+T]VMS@V3Y%33YRZ"7&[3Y=X/>$$6=QJM#>)/\
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M.*^T0+8^T.&S1[DQD]QSN#[_ !R.1:6XS:PX:TL.G]8V"2HAIF]G#V^896M
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M+7O%BZV2:M?1,=+4S=JR,//LO.V"1XKL'_X+-#_^-57_ /:-_P#<N-:2UL=
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MH^4!\FKI\[$>#V_7Y%=+]#'[EM1?SUGZBZGQ9T%1\0=*RVVI(BK(SVM)4?\
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MJ(#%*,M.#MU!!R"/,'=>RK6:#O+-1:6M]Q!;VDD8$H!Z2#9P^?ZUNI>4$-)
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MNL*M >PY"N,!7DK"6E0U"42A]>T,D)"X=Q#MOV/U%-)&W$-5]N;X9)]H?/\
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M?#!VW:QG!=RD'L\Y'ROD_'O6SX44M?1\.=/0WB:::O%(QTKYG%S\N]H D[[
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MPLBA8UD;&AK6M&  -@ @J1$0<DU=H#4]'KZ?6'#VYT%/75D+8:RCKV$Q2XP
M<C)[AX;CKNIEH&FU;#1U<FN*^W5-5+('0Q4,1:R!N,%O,=W9.^XV\3W2E$'-
M^%.B;II74^N[A<WTKH+W<C5THA>7.#.>5WM @8.'CIGO72$1!SOA-HRYZ4NF
ML*BYOIG1W:XFKI^Q>7$,)=\K(&#N/%7.(_#=FJ:^CO5GN<UCU-1#E@N$#<\S
M?Q'MR,CK\YZC9= 1!Q\4'&ML8I!=M*N9CE]=,3^U]_+CES\%-.'>EZ_35OJ_
MLS?JN]W*MF[>>:;9C78 Q&W\$8 ^;N4L1 7+^/>A+MKRS6>ELCZ1DM)6BHD]
M8>6 MY2-L [[KJ"("^>/22T\+KKC2%-9JE]/>KR'VZH$7X5-D9<_'X(R[WC/
M@NEZ]TYK"OO%/<]&ZJ9;'1P]B^BJ8!)!)[1//WX=OCH>G=NL+07#FMMNJ*G5
M6L;P+WJ.6/L8GMCY(J9G>&-\_AU/B2@GEDMM/9K116VA8&4U)"V&-H_%:,+G
MG&;0EVUC>-'U5I?2-CM-8Z>H[>0M):71GV< Y/L'P74$0%S?B%HFZ:@XAZ*O
ME"^E;1V>9[ZD2/(>02TCE !ST\0ND(@+E^JM"7:Z<;=-:MIGT@M=NI.QF:]Y
M$A=F4^R,8(]L=_BNH(@Y;Z37WG+U^7#_ 'C5'=*:%U=IRP6ZOX;WVECI*VEB
MJ)K5=&.?"V5S 7.8X;MSX;>_PZ)Q;TI4ZTT+7V.AJ(:>HJ'1ELDV>4<KP[?
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MOD#7//@T$Y)]RR'N:QI<]P:T;DDX 0>HM7#J&RSU7JT-XMTE3G'9,J6%^?#
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MXA1SLM7I77 5AY!=;*V.F)V#W#LSC_\ 5.7;R0 23@#O0<%T5_I5ZQ_1X_\
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M<LAC;@ETCBW9H:T$H)%:'774O &$4DCGWBMLACC>7;OD,9:#GQ/CXE0G@EQ
MT;I32E)IZ]?_  ]?*;+:QE93F,RR<QRXOQOW=>F,= IMP[OE%IO@78KO=7N9
M14EN9)(6MYCCP [RL^+4O#W65$)9:^P7&$CY-7V?,WWM?N"@WED_@U=JO[-6
M/[$5E46&/UVD[-[^4D9:7MWQL-LKA]ZJ:?0_'^ZZBUY03RVBNA:VW7 0F:.
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M=+&V&&,$D,8T8 R=^BRD01ZW:)TY;[;<+?36BF]2KYC454$H,K)9#C+B'$^
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M8>T>;3AP^(6^0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$18UT>Z*VU<D;BU[(7N:1W$ H,E%R[T;[]=-1\-8Z^^5LM;6&JE8993EW
M*",!=10$1$!$1 1$0$1$!$1 16:QQ91SN:<.;&X@^!P5R?T8=17?4V@ZRLO]
M?-753*]\39)3DAH8P@?.3\Z#KR(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B((9K@_](0?FOVE1T%2#7/\8P?F
MOVE1YJV8_AAAR_%+)B"OM&RQXRK[3LIJI5X7B]:=UZ4<4]%[W;+PD!6G2XV"
MY,Z2I2;2N2.RTA8$DI!(5]SBY6W1<PR.JAU-5<<5A:!)536KT-QU507";/ %
M[C=5-"]PNJYLIPO0JL+Q=1V\"JP@"]1S;S"]15!I/1/!$3:=1#P!5-83W+W+
M&?+(5N6M9'LU9[\BM7J<?V5ER=[=F7'2YW<<!6ZB:FI]G.W6NFK7.8[#_I6C
MJ722O)<XK'DYDZ[/;XOL?%'Q)!)>H@\-8W;Q5B>Y\_R7+1-;CJJ'OP>JR3R+
M3Y>M3AXZ_##=QU9).7+-IZT @'YU%FR'.Q6QBJBV'/*T@=ZY7*[DX\);'4#D
M!:5K:^L<)CS%H"P**Z^SR%H"PKJ\O?SYV*G;)V[,V+C:OJS:&L!;D$'W+',\
MY=S1YQY+1B1S>CBJV5,C>CRJ?5:XXVO#;R71X8Z.9CNF,J,7B&*=DH<>9C@0
M6NZ$+:"M<YO+( X>:Q*IL<K21[*[&1R<$16>SY<U5:'V2]U%(<F('FB<?PFG
MI^[X*K1E1ZKJNTS$X#:EF?B<+KG$'2K;S0N?!@5D(+HC^-_)7#QVE-4C(+)8
MG]#U!!7HX[^I5\IR<$\;+N/'R?9-$7]F"XX"V<$WLX!48TY6BYVJDK(SEL\3
M9!\0M["US?E$#XKSHF8E]/,1:L2S.W+3U63!6X_"6KD<%2TY[U?7-,*YQ1:.
MZ4T=Q+3GFZ+>4E^C(Q*,>:Y\R8L/59<4Y</E*^N?;'FX-+>72H+A3S#V9!\5
M>S&\;.:?<5S42O9NUQ^"S+?53N<YK9'9[MTG+6>TPP7]FZC=;)Z(@.A22$21
M.8[H0HE!=*B/,4KSG/>K[]0N@(;D.7*32L[AGMPLGB.Z[462=CB8L/;Y+$DH
MIH\\['#X+.I=3Q/.)6X\UN:>MIJEF6O:<]Q6VG*VQY>#:GQ1I":B%PSW+#+2
M"N@34%-.#[#<GO"T]5I[))A?\"%JIR*SY99X\QX1IKY&]'%7A-D$2-!"S9[1
M40CY!(\E@OA>TX<TCX*>L>2':6RXIW69424E+49#F@96LJ=/-<"82"%L^7"-
M>]O0K-DX.._AZ6#VSGQ>>Z+55DFCS["UDM&]F<M*Z"V?;#P'!69HZ6;/.P#*
MPY/9LQ\+VN/_ .H*3\?9SPP$=RH,1"G4MGIG_(*P)["X?(P0L-^)>GF'KXO:
M>')XE$BQ>"-2":T2LZL*Q'4#VDY:51.*T>8;*\BL^):L,W5;6K.-(X?@JD4Y
M'<N124O5B6.QN"K[ KC:<JZR YZ*45E7:\/86K94D?,0K%/"?!;2&,11Y<%K
MPXIM.GG\K/7'69EY6R!D0C'58D YG*W/(7O))7D4G9Y/>OI,=.BFGPF7).3)
M-Y9DTG(>4+'+LE63(7.))W*]#EVL:<M;<+["LB*0A8;"LAA4U#.AER5L(W#&
MRU4(W68Q_*%7:$H797!Q*L.=C.,+WM!GQ5!:7'8=5V$=,*X'#"5"K\[%'5N\
M(GGZ"IS70YC(<H/JA@CM=<0?]4[ZEWZ(VG59<D7T3IPB&Q6]A/2G9^J%\[%?
M0$+^QH*9GXL31]"NOW>?P_,M/J;4OJ&I[;3,?B$',_AAVPS[NJZ7HQP== ?^
M[=^Q<2U!04\NJ[?'+SO];DS*2[&Q. !X8"[/H*#U:MBB[1TG)"6A[NIZ=5GS
M?!+3Q;6G+:+?5/D1%Y3UQ$1 1$0$1#T..J#F5QMG##1MYK*Z]&S072LE=/(^
MN>)9<N/X+79+6^X+F_&^\<-[II26X:7N5JAU-0R1S4DM"WLY7$.&1D 9VWWZ
M869Z/=ET]J0:@K=84M'<=8NN,K:J&O:)'L:,$<L;N[/-OCNQW+-](J'0]@T+
M7T%%9[)#?JH-$#*2DB;-& X%SR6C+0 #O\$'9='W"2ZZ3LUPJ/\ +55'#-)^
M4Y@)^DKYXX#Z)HM4:IU77W]OKEMMUUE]7H9#F)T[G'F>YO?AK6@9VW7>^&OW
MO=-?HZG_ +MJYGZ,/37?Z;D_:@Z)J?A]IG4-EGMU79J!C7L+62Q0-8^(XV<T
M@9!"AOHQ7.LJM!U=MKY3,ZSU\E#'(>^-N"!\,GX8775Q;T7OXFU;^G)OJ"#3
M6^T-XO<7=05%_D?)IO3,XHX*#)Y)I/:!+OBTD_T1T78JK1.F*JW.H)M/VLTA
M;R]F*5C0!Y8&WP7(-+7FGX7\8M46?4;_ %6UZBJ!7T5;)M%S$N)#G'INXM\B
M!XKN=5=*"DM[J^IK::*A:WF-0^5HCQX\V<(/G;16F9=(^DO36<54U1;H;=*Z
M@[9W,Z.%P)Y,^ =S!?2J^;])ZICU?Z3E/<Z*.06S['RPTDKVEO;L8""\9[B[
MFQ[E]((,*[T%)74CQ6TM/4!C7%O:QA_+MW9&RXKZ*-IMU;PODEK*"DJ)?LA*
M.>6%KSCE9MDA=SJ 74\K1U+2!\RXIZ)=3!#P]K[=)-&VNI+C+V\)=AS!RMP2
M.N-COY%!T'BM&R+A5JN.)C61LM-0UK6C  $3L !<W]&_05LGT3;]1WVFAN5Q
MJ6%E.:EHD;30,<6M:P$8&X)SUW71N*<T51PIU7+3R,EB=:JDM>QP<#]K=T(6
ML]'O[SFF/S#_ .]>@E.I]/6J^Z<GM%VB M;FM#V,?V0:UI! R,8&WS*"PW_A
M!88G6Z&ITQ"QHY7,9&R0'WN .3[RL3TI:FMI^&(%(^:.EFKH8JYT0W$!#L_^
M8,^I273>BN'K;#3RVJR6"KMXC!;4O@CFYACJ7N!)/O*#E>C;GIVW^D-2P\/Z
MVG?9+S1/];IZ7(B9*T.<"&]!\D'RR?%23TM_O5QX_P"T8?U7J,4E;INJ])G3
MT6D*6AAHJ:FFAEDHH6QQ22ACR['* '8! RI1Z6_WK(_TC#^J]!*.'G#6S6*T
MQU%RI(;G?:MHFK:ZL8V61\CAEP!(V:#T 4#](735!I6EM.M],TT%LN]OKHVO
M-.P,;,UV=G ;'ICW$A=XH_\ -(?R&_4N2>E7]ZB3^?4_UE!N./7V4K>#UX=8
MF3&HEBC>]D62_L>8&0#'\G.?+*T_"JY\+Y]*6ZCM;[$R80L;-#6-C9.Z3'M<
MW/NXYSN,CPV70[AJ"U:<T]15E]KH:*D<(H1),<-YG  #_GH,DK1W#06@=6PN
MK9+/:*QD@+C4TW*TN\^>,C/OR@W%@TCIRSW.HNUBM=%2557&&22TS0T/:#G8
M#;KX=<!<.XM6*IU+Z1%GLU-5RTD59;!'521'#NPR\O:#Y@8^*V'#^"#2W'A^
MFM%W.>LTW+0NFK*8S=M'2O /* [)P<\H\?:P<K!XJZF;I'TCK'=YXY)*.*W!
MM5V;>8MB<9 YV/+(/P0=LM&A=+VFVLH*&PVUM,UO*0ZG:\N_*)!)/F5R+5-K
MI^$'$_3][T\32Z?OU0**XT0)$49)&'M'EDNQW8(&Q7<[7>+==;>VOMM=355&
MYO,)HI YN/?W+A_$>YTW$WB=I?2NG96UE!::KUZYU4/MQLY2/8STS@$>]P\"
M@W7'NY7"YW?3.@[15/I'7^5WKD[/E"G;\H#W^U[\8Z%3O3O#_2U@M<=#;['0
M=DUH:Y\L#7OD\W.(R2N?\>J:KL6IM(:]I8)*BDLTYBKV1C+FPO(]H#XN'O(7
M5=/Z@M6H;9'<+-7T]72O:'<\;P>7R<.X^10<4XGV:FX4ZLL>MM+,%#0556VC
MNE##M#(QV3SA@V!P#\0".];3TN"#PIC(.0;C#@C\EZU_&JZ4_$+45@T%IJ9E
M;**QM7<)X3SQT\; 007#;."3\PZE;'TMP!PIC & +C#L/R7H))PLX>VBT:;H
MJVXT=/<+[6Q-J*NMJ6-ED<]P!(!(V:.@ \%IO2BH*3_!/>*SU6G];[6G';]F
M.?\ RK1\K&>FRZ?IS[GK7_-8OU N>^DU3R5'!N]B)I<6.AD=CN:)6DE!*]$V
M:ULTO8:AEMHFSBB@>)! T.#N1N^<9SYJ3J-:$NM!/H.PU<593NIC1P,[3M!R
M\W(!RY\<[8\5)4$8XH_>YU-^CY_U"N2>CCP\M]RTE;]2:GA9=*ES3%015(YX
MZ:%KB/9:=LEW,<_\5UOBC][G4WZ/G_4*YCZ,.N[=/HNCTW<JAE)=*/F[".<A
MGK$+G$AS,_*P<@@>"">:[X7Z:U;99J.:VTM)5<I["KIXFQR1.[CD#<9ZA:;T
M=]25][T=5VZ]R&6Z6.L?;Y9'.)=(UOR7$^/5O]%2_7.LK-HRS3W"]5<4?(PF
M*#G':3.QLUC>I)4(]&RS5]%I"X7F[Q&&LOU<^O[-PP6L/R?/?<CR(0<_T=H^
MFU=QZUU'><SV:BK/6)*,GV)YN8B/G'>T O./<N_7-UNTAIBYU]'0T]-3T=,^
M<Q4\38P[D:2!L/+"Y9P:^_5Q2_G+/UG+K6J[4+YIFZVHNY/7*62 .\"YI /S
MX0<CX(:,IM3V]VO-:11W>]79[I(14LYXZ>(.(:&-.W=\!C'?F>ZTX::9U39Y
MZ.HM5)3SN;]IJJ>%L<D+NX@@>/=T*AGH^:KIJ.P#1.H)&6_45FD?3FGG<&&5
MG,2',S\KKW>1[UTC6>K[-H^SSW"]UL4+8V%S(B\=I*[&S6-ZDE!S[@?K"K_@
M)?Z344SJBNTK--33R$DNDCC!+<D]3[+A\ M1P2TG!K:&?B#K:*.Z7&XS/%)%
M4-YXJ:)CBT!K3MU!QX8\22LW@7I:LK=":HN-YB-+/JV>:H#""',C>' $^\N<
M1Y$*WZ/FIJ>Q6J;06II8[=?;1/(R.*=P8)XW.+@6$XSNX_#!03O67#/2^JK3
M)1UEKIJ:3'VJJI8FQRPGN+2!]!V6KXM7Z?A[PEGEMU1--6Q1QT--/4.YG\SO
M9YW'O( )]X4KU;JNS:2M<M??J^&FB8TN#"X<\GDQO5Q]RA_&>S/U]PAJ38VO
MGE<R*OI6.86F0-]KEY3ODM+L#QP@T?#*U\-M-6"F=77O35=>ZB-LM;5U=;!+
M(Z4C+@"YVP!)'UK0<7OX'VFECUCH&]6&DU+;9&/,5!5Q?XW&7 .8Z-A]K8YZ
M= 5M^&%AX6:UL-+)!8+4RZLC#*NB?D2Q2 8=[.<D9S@K;Z@TCPCT_4TE-=K5
M9:>IJIFP10G)>YSC@>R#D#S.R#2^D/65%[X8Z=N4$52;%455/4W)D&2X4[FY
MWQW GY\*6:3N'"^Z6R&FL3M-N@+0&T[F1LDQCO8\!V?,A26Z7C36DJ2V6NYU
M=%;:6<>K4L,[@UA#6_)WV Q@;^('>M'>.&7#Z_4SZJHL5K[)S>8U%+B$8\>9
MA \\H-_8=+6?35-<#IBVTU"^L/:O$(PUSPW#=N@'D-MRN%<":[1UM=>*;71H
MJ?6;JZ0U+KNT!Q&=N5[]NN>_/T+=\#:[[$:UUO9K?=Y;AHVUL;-#432=HR!W
MX30_PP'>7LY71&T^@^(U*VI$-EO8(!Y^5CI6CP/X3?<4&52Z2T=<+G1WR@M=
MIEJZ9_:0U5*UNQQC.6;'XY4K7S;Q$T_:>'.L=+3\.:N6CO-7<&03VJ&H=(R6
M(]7.82<#H-]M\[87TD@T>LZ"DK--W-]72T\[XZ28L=+&'%OL'ID;+F7HQ6BV
MU?"2WS5=OHYY3/."^6!KG'[8>\A=9U#"^HL%SAB&9)*65C1XDL("Y7Z*U=2G
MA1#3>L1"HI*F83QEP#H\OR.8=VQ09GI$ZHN.G-(T%NTZ]U/<[O4MHX9(MC&S
M'M%N.A^2-O%;W0/"_3FD[-!3_8ZEK;@6@U-;41-DDE>?E')!P,]!_P#G49])
M"RUUXT?:K[IUIJJFS5;:UK8?;YXB-RW&<X(:?=E3O0.MK/K6R4]=:*N)\CF
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M%ZMJ>)MXO]5;])TM!8[73/Y/LE6.$KJC;.6,P<#<#IX[]RU_HI_>L+>YMPG
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M"=1UZ\L&-Q:[8K)F=SQ;HVGP07-..]7WQ1EH$0=GS78R=G+6C;683"S_ %;
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M!E-%5 EG:MY7 AQ:01X@@CJ5N4!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MTW"=T-!=*&IF;UCAJ&/</@"H9K#A=9=5:ADNNJKC<*NB:UHAM[JCLZ>$@8)
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MV;>G@/$_M0= K[G06XQ"X5M+2F4\L?;RM9SGP&3N5EKD/#?0]UO%Z9K?B/\
M;;T_VJ"W._R5O8>F&GH_ZNIWZ=>0%BW"Y4-MC$EQK::DC)P'3RMC!^)*C?%?
M5PT1H:XWIK&R5$8$=.QW1TKCAN?(=3Y!031/!ZBO5OAOW$EU1?+_ %S!-(R>
M9PCIP[<1M#2.F?=X(.PT-=27" 34%5!50GH^&0/;\X*Q+]>J"S4;Y:^NI*1[
MF/,0J)FQ\Y:.@R1GN^=<:XB<.6\/[=-K'AI--:JJW 2U5$)'.AJ80?:!#CU
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MYQ<?%43;;Q\O(GY=EID);AN<^:OM9A5 +T!(KMBF\R\Y5Z O<*H!65QPAMX
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M-S] 7<?C;!RIZLD5AURPTWJ=HHX<8+(FY]^-_I6^I)L#<K & W"UEUN\=M=
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MYYVAW0#H.Y56OICRY==H**!\AQ",$]Y[AXJ14UK;)R&8ES&@8'B550T08QH
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M$0%HM<ZB9I32=SODM.ZI911]H86NY2_<#&>[JMZH#Q\^]!JC^;#]=J"1:'U
MS56E+9?(J=U,RMB[41.=S%FY&,]_1;Q<)X=\3[)ICAGI:UMAKKM>31AWJ%M@
M,TK07'=V-A[NJD-EXW6.IO$%LO\ ;+QIRIG/+";I3&)CSG&,]WO.WF@ZJB*
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MURBO-P?M!24),AD<>@+ALT9^/@"@V'%RBIK;P7U'14,+(*6GMKHXHV# :T#
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M>4@GW94QB8&,:UH  6:T[G3Y[G9HCW8\RN!>@( J@%?6CQ]O0%Z%Z$6BL:1
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MCHK(53;<*BPO.1LJH8P'95YD>QPLF&!H)YE;6JBV34/8&%WN6;%'D>2IC&P
M&RS:5FQSWJ^M6+)=2R'RRLZF:0,JB*,<VZS(8]ME?2K)DNNPMR=@LAD3M\ J
MNFC\1L%=K:ME'$2<9 RK8^S#:\S.H6JB>&AIS+,=P,KGU_O$EPF(:<1#H O;
M[=Y*Z5S0[V,_.M,MF'%KWI8\N3S6% 7J(M3(]!PJ24[E:<3E=1EZ7;JII!5
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M:J#':PLD:Y\>>G,T'(^*R4!$1 18T=PHY:Z6BCJZ=];$T/D@;(TR,:>A+<Y
M62@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M/^*@+&OFE#6!TDCS@ ;EQ*\ <]^!ESG'WDE=7X<:292O96UK ZJ(RQI&T?\
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M,G);W^84(B.Y7@^UK[M%7Z!_Z6P]/&MD^LKL>RJRJ =U5E>/#Z65;3A9%,2
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MD;CU6+]0*QK#3M#JS3==9+JUQI*MG*XL.'-(.0X>8(!^"YS8.&FL[4^BHO\
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M8]V5V^PVNFLEFH;90L#*:DA;#&/)HPN#>COI2@JM;ZHU;0,?]AX:J6EM(=T
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MW;X#054Z C\+99 ;CO.W<J7Y*KR5B8=ZY8XB9OD9'O53(V[@#JJ\+T$,!)V
M[U1%#JEZ6>SMU7C=C@]5Y%,R0.=&[+1W]RP:JX"E/-,<G?V6[^Y75Q]4^[",
MS$?%+9$ M(*U=TKXK7%D\G:'?=:&XWJKJ-H&F(=Y!ZJ/UOK$I+I7/>?%QRMV
M/B7GSV46Y5*^)VV-XU1)4M,=,"!^,[]@49ED?(\O>XN=XE>O8X$Y!5O"WX\-
M<<=H8[YK9/,O"4**DE6H;#NO$7F5QP*\7N$#5UQX!NKC6K(IJ&28^RTX6P?;
MNS9S'JFD.N/#6,8JL*[(.3*M%X'5<E..[T!>EP 6ON-UI:"$R54[(VCQ.Y]P
M[U ;[KJ>8OBM;1%'T[5PRX^X=R1$V\.7R5Q_$G=WO=':X>TJYVL)Z-ZN=[@N
M=W[6M76E\5 #30';F_#/[E%JB>6HE=)42/DD/5SCDK:6/3E?=W P1%D&<&5^
MP'N\?@K(I%>\L=^1?)[M6I]J1_X3WN/O)*EVGM&3U1;-<\P0[$1CY3O?X*7Z
M>TQ0VD!P;VU3_P!:\;CW#N6_9%RY7)O]$\?&^=F#14$%)"V&"-K(P,  +);"
M&JZ0 O6X(]RAMKB/E#)H3RN\UYJ"^PVF@,LK979&PC83\YZ#XK6U%PBHF/FG
MD#(V#<E0FKKZW5=>(6<T-M8[?'>//Q/DH1WE#-EZ(Z:^9;>P7RKOMTF>6B*C
MB;GD&Y)/3)^=29H6IL-MBML<S(>DC^;X=P6V&RNA7CBT5][R]*\1>*2;TE4K
MUQ5.5UU6SKGPW5HG*J:[ ?[E;78<>L&7CWJ4</W$ZD=OMV3OV*,P_+SX;J2\
M/,?PA_\ "=^Q59_P[?DLQ?'#IJ(B\1ZHB(@(B("(B B(@(B("(B B(@*'ZET
M)37W7&GM2S5DT4]FYNSA:T%LG-XGJ%,$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MKYC_ "EXO*K_ #R;\I <97R>?\27Z_Q(UAK'V>JMAP%:RJ@Y4M$PO-.2K@D
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M=CN(&5<9RN;GE(!WW5L]-.RB<]M;8$=,#@!N5DMI, <K@%54SQ0MYYI&QC&
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M.9T#FU+ UV1@Y&"01@CO4IF>V.)\C_DM:7'W!1WA_JBS:MT^+EIMKFT':NB
M=%V7M#&?9^*#'I-<T-3Q'K-&,IJH7"EI!5NF(;V1:>78;YS[8[E+%Q"R?Z6=
M_P#T(W_T5UK4FH;3IJWFNOUP@H:4''/*[&3X =2?((-JBY1_^$!H+U@1FOK.
MSSCM_4Y.3W],_0NE66[4%[ML-PM%7%5T4PS'+$[+3_SX((_J77=!8-86'3M5
M354E7>.;L9(PWD9R]>;)!^8%2U<-XNG''CAF3T^W*4ZAXVZ(LEPDHI;G)53Q
M.Y9/4X72M8? N&WS$H.DJ.Z_U=0Z)TS47NYQ5$U/"YK.2G:'.)<<#J0![R5;
MT9KO3FLHGNT]<XJF2,9DA(+)6#S8[!QOUZ++UM?K7IG3-;=K\TNMM/R=L!'V
MA/,]K1[/?NX(,O3MV@OUBH+M1ME93UL+9XVRMY7 .&<$>*T?#[7-#K>*ZOMU
M-50"W53J23MPT<SAWC!.RD-HK:>Y6FBKJ+/JM5 R>++>4\CF@MV[MB%QOT7/
M\SUI^FI$$\N'$2U4/$6AT;+3UKKE5Q=HV5L>8F[$@$YSW'?&%,U&*S5=DIM>
M4.G)VN^SE33F:%PAR.S&21S]WR3LN7>DEQ)H*"P773-!5W"FO[3"]LD+7,:
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MK3TZSV[*880WN69"S"M1C=9487$H[KS&@!5\V%2,XZ+27:^T]%(8&<]15?\
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M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!"];G%R@_-?M*C;RI'KG^,J?\
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MXK?P .A.?!:&5O+5OQXIA^;S^3K7ZMG;WX?N5Y>ZH04V5A1R%KQA86HY7N@
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M+WDY7E=4<[SNL,/7*1J'M8<$4JRR[98<[]U47[+&E*ZT4JI<<JE,KT+L+O
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MK@RGN%+)VE,]VVQW);U\3COVW76+=1T]NH*:BHHFQ4M/&V**-HV:UHP /@%
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M74[WO,L=.3#2TT8)#72/>XX)QG&=UVZZ_P 65GYE_P"J5QOT1Z*"#AM554;
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M[3_%.XT6I*33O$>P_8&XUAY:6IBD[2FG=G  =DX.?,^>%U=C6L8UC&AK6C
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M,[,;8 5DY*U\RNG+OQ#6&-P;T*V5NM?/&))WE@/0 ;K)I_5R\<Y"S'RL ^4
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MY'G?'<W?P#O'?MJB7%31[-<:*KK-SLBJ7XEI97YQ',W=I.-\=0?(E!!-4_\
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MHVWV7ID#1@+&?,2J.=>F\33)8\\V<J9\+#G5G_@/_8H('X*G'"AV=5C^;O\
MV*GD?A6_)9A^.'941%X#UA$1 1$0%CU-=24I JJF"$GIVCPWZUH]4W*M]<I;
M-9G-9<*II>Z5PR(8QU=[^X+&_@C9J"D=45U/]D*DEO:3U1+W.)<!W[#JM%<5
M=1-Y\^(CRRWSVF9KCCQYF?"50313L#X)&2,/X3' A5J'W'2_V*#[AI4NI*J,
M<SJ8.)BF ZM+>XJ06"YQWBTT];""T2-]IIZM<-B/@5&^.(KUTG<)X\MIMT9(
MU/\ 26P6%5W>VT<QAJ[A1P2@9+)9FM</@2LU?.UZTO9]6^E!=;=J*B%91MM#
M)A&9'L]L", Y:0>\_.J5[N[+]:)'AL=UH'./0"H82?I6R!! (.0>A"YG)P)X
M=.86MT\(R?PFU<^1\[U"W05_!?7]@HJ.XU5;HN_3^JBFJ7\[J24D %KCT'M
M^8!SD@%!] (B@U[XM:&LE:ZDN.HZ1E0P\KF1-?-RGP)8" @G*+5Z=U!:=1T/
MKEBN--7TV<%\+^;!\".H/D5M"0T$D@ ;DE 6AUQJNVZ,L$EXO1F%'&]L9[%G
M.[+C@;96ANO%_0=KK'TM9J6D$['<KA$U\H!][&D?2H7Z1M]M>H."-76V2OIZ
MZE-7 .T@>' 'FZ'P/D4';8)6SP1RLSR2-#AGP(RJUA6V1L5EI9)#AC*=KG'P
M :L;2VH[5JFU-N5@JQ5T+GNC$H8YGM-V(PX _0@VR*B:5D,,DLIY8V-+G'P
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MU;Z*U4$PYHHFMW+BWH3@M^.<]V.K:AX?Z7OUJDM]?9*'L7-+6NBA:Q\9\6N
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M=;:Y\;>8P@\W*2/Z6?Z)\D'3K-H32]GMS*&@L-N9 UH:>:G:]S_-SB,D^97
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M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MR17.VQLK8HZW'^9U/]D[]R\%'79_S.I_LG?N4HC2,WVR63;+TS8*L-I:T?\
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M?YM.7ZT55@U)$PO]4J#S-D:.I8[O\?=T)718(8Z>&.&"-D<4;0UC&##6@;
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;$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g73463g01f04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g01f04.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1/^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $^$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M3F/^"+@XC7;N!U02"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M<;M2-\43@X@!K]<W3L>P4@@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M&3P[%.23GZ<P&]??T^Q>K/#G\H?:WQ)$^[>HLC@A>)*K^0N_FXQHGT5QX;X
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MZ'6_+J=?>NI+F'LQR_"6/=%C<9>DM9:XXF6>2%X=*_1)ZD=!T*Z>@(B("(B
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M0.GGECCA:-F1[@&@>I)22>&*!T\DL;(6MYC(YP#0/7?;2#(BQNGA;7,[I8Q
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M@C[%K?)M']2K?LF_DL\T\,,#IYI8XX6CF,CG - ]=I)/#'7,\DL;8 WG,CG
M-#?7?;2!!!% SD@B9$W>],:&C^Q8YJ569Y?-6@D>>[GQ@E>WV(65C8?-&VN&
M\_BEP#>7UWVU\5]=/"VN9W2QB -Y_$+AR\NM[WVU\4&.*C4BD#XJL#'CLYL8
M!'WK86,3PFOXXEC,'+S^)S#EY=;WOMKXHR>&2N)V2QN@+><2!P+2WUWVT@R(
ML<,\,T#9X98Y(7#F$C7 M(]=KY#8@GKB>":.2 C8D8X%I'KL=$&5%CKSQ6(6
MS5Y8Y8G#;7L<'-/V$)6L0V8&S5IHYH7=GQN#FG[P@R(L=:Q#:B$M::.:(D@/
MC<' Z.CU'Q7RM8ALQ^)6FCF9LMYHW!PV.XV$&5%BK6(;4?B5IHYH]D<T;@X;
M'<;"^U[$-ECG5YHY6M<6DQN#@".XZ>:#(BQU[$-@/->:.4,<6.+'!W*X=P==
MC\%\@L0SF0031RF-Q8_D<'<KAY'78_!!E18H;$,[I6PS1R.B=R2!C@2QWH==
MBOL-B&=TK89HY'1.Y) QP)8[T.NQ09$6.*Q#-)*R&:.1\1Y9&M<"6'T(\E\B
ML0RRRQ131OEB($C&N!+-]MCR0:EC&NFS=/("];C;7C?&:K)-0R\VOG/;YD:Z
M>FRI!14M=MGB&O9ARDC33C>R:C&\%KR_7*YX[@C73[5(LL0OL20,FC=/& 7Q
MAP+F@]B1W&U(R(L;+$+YY(&31NFC +XPX%S0>VQW&U\;8A=8?7;-&9V .=&'
M#F:#V)'?2@946(6(39-<31FP&\YBYAS!OKKOI??>(?>?=_&C]XY/$\+F'-R[
MUS:[ZWYH,B+'X\7O'@>+'X_+S^'S#FY=ZWKOK?FOAL0BR*YFC%@MYQ%S#F+?
M77?7Q0946)UB%MAM=TT8G<TN;&7#F('<@=]+Z^Q"R>.!\T;9I 2R,N <X#N0
M.Y09$6.2Q#'/%#)-&V:7?AQN< Y^NIT//2^/L0QSQPOFC;-+ODC+@'/UWT//
M2#*HK&\/X['9:]DJD+F7+IW.\O)#ON/0?<I"6Q#%+%%+-&R678C8YP!?KOH>
M:^RV(89(HY9HV/E/+&US@"\^@'F@R*)J\/8ZKG[.9AA<,A8;R22<Y((Z>78=
M@I*:Q# Z)LTT<;I7<D8>X O=Z#?<KY/8A@,8GFCC,C@QG.X#F<>P&^Y^""/X
MBX?Q_$-:&#*PNEBBD$K UY;IVM;Z?:O-;AS&UL]-F8X7'(RL\-TCI'.TWH-
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MHGR.E<R*-C07N.R[H>Y3'<98'&LF90Q<U=LTKII!%&QO.]W=QZ]SZKG*)H[
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M!JR8ZG)DHLA)5A=>B88HYRT<[6'NT'T*38ZG-D*]Z:M"^Y7:YD4SF@OC#OI
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MG_#T^?K*?:GQ=?EZ0(B+L>>(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MU6MLC4U<K!B>%LQ-%/CA=@GC;)$UYZQ]2".OV*4RC\%C\'2R3L) ]MKETP
MMVW??[E2N*,T[.9/WDQ^%&UH8QN]D $GK\>JLG%O^(>"_J_]@K2K"J_\>?,W
MG;KG<RHQZ?\ S=E$9L:XU1O5#+V:]O(2S4ZPK0.URQ#^CT6_PYDL=2CE9?Q;
M;SWN'(3K;?AV7WA^[AJM>5N7Q\EJ0NVQS3K0UV[A9XL;9R5Z;)<.T7,JPR-+
M(W$;! !\SUZ_WKKKFFTX=43$1WWMUO=PX=-6=&+1,35/=$7GE:RR<2QX?'X
M238J"O>LL(BB !<P^I/EI1V)QV*Q/#468R]<VY9SJ.(GH.^O[ 3M6"%]V_PY
MD7<4U8H6,83&2 #V[ZV='>M**M59<]P#CFX\"6>L0'1M/7H"W\>H*\[#KF*<
MR9_Y:YOJ\I>MB41-?:4TWG-O$6UWOMF&GF\5C<EPV<UAH#6=&=2Q;Z=]'I]X
M/V+.S'XGAO!U+>5IF[<L@$,<>C>F]>G3I]ZS,@?@/9[:AOZCL6G.Y8R>OSM#
M7X#:R<54YN(N'\7<Q;#.6#3F-/4; W^!&E>*YF8HFK]&=,7ORULYPHB)Q*:8
M[3-B;6[[ZYM\D9Q)BJ#L/5SV&A\.$N'B0N&QWUV^T:]%@XWQM2.IC<GCH6PP
M6HQS,:- '6Q_>?P4KFF'#>SZ#'6R&VYB/F;V1\[F/X=%J\0?-]GF&$GTRX$;
M]-._W*^%75>F;WC.F/G#/&PZ+5Q:TYL3/A/T4=$1>H\45_\ 9-_ALG_JQ_WN
M5 5_]DW^&R?^K'_>Y<>7_#U>7J[_ &7\51Y^DLGM:_R7_6_\"YXNA^UK_)?]
M;_P+GB>S_AZ?/UE/M3XNOR]($1;;L?:;CF7S$?='/,8D!!^=Z:[A=<S$;7!%
M,SLAJ(BW+^.M4&P.MPF(3L\2/9&RW[/+[TF8B;$4S,3,1L::(I##XT9)]AIL
MP5_"B,FY3H.UY!*JHIB\IIIFN<VG:CT1%*HB(@(INMPME[-:*Q#5:8I6AS"9
MF#8/P)6ODL'DL;&)+E5[(STYP0YOXC86<8V',YL51?YM9P,6FG.FF;?)&(B+
M1D(B("(B B(@(BW</1&1R$=8SQ5P_?\ .2'0&@HJF*8O*::9JF*8VRTD7N9G
MAS21AS7\KBWF;V.CW"\*4;!$1 1;N*QEO*SOAH1"61K.<@N#=#8&^I^(4B_A
M+-,87>Y\VO)DK''\ =K.K%HIFU541+6G Q:XSJ:9F/D@46S6JNEO1U9'"![G
MAA,O0,Z^:^Y*J*5^>L)F3"-W+XC.SE?.B]E,R;9W<U41%*HB(@(BD,ABY:-*
MC9D>QS+;"]@;O8 ]?Q435$3$3WK13,Q,QW(]$12J(BV<;2ER%Z&I7 \25W*-
M]A\2HF8B+RFF)JFT;6LBD68BU-/=CIM%AM0$R/8=#0\QOJ5')%43L35153M@
M1;?R=:&-^4#"14+_  Q(2.KOL[K>I<,Y6[4CLUZS70R#;7&5C=_<2JSBT4Q>
M9A:G!Q*IM33,]^SN0R*5R/#^3Q\/C6JCFQ#N]K@\#[2"=+!BL7<RLSXJ$0E>
MQO.X%X;H;UYD)&)1-.=$Q8G!Q(JS)IF^ZS113TG"6:8PN]SY@.NF2L<?P!VH
M[&8]][)1TN=L$KW%H\0$:=Z%1&+15$S$WLF<#$IF*:J9B9WZFDBR6(7UYY(9
M1RR1N+'#T(.EC6D:V4Q;5(B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#Z#H['0KI7 G%9M<F.R
M3_Y\#44I_I_ _'^]<T7UI+2"TD$=00L,HR>G'HS:G3DN55Y-7GT^<;WZ#14G
M@?BP76LH9)X%D#4<A_\ J? _'^]79?-8V#5@U9M3[')\HHRBC/HD1$63<1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$007%F:L8>&A[E6BL6+EIE
M5C9)"QH+MZ)(!]/1:DV3XIK-,DN!I6(V]7,K727Z^ <P _BL?'_^'X9_^[P?
M[U;$$=@,Q5SF/%ND7AO,6/9(WE?&\=VN'D0MAF0I26379;KNG'0QB5I=^&]J
MEXRQ2BR/'-Z9SOD;F8V1["=%XCU)RD>?4#IYJ&SU2&3A2W)3X(?2BC@=-#;\
M2".2+E&P_7-S;&M^J"^9[B.CA;-""U+'XEJ=L.O$:#&"">=P)^C\W6_BI2&U
M7FK^/#/%)!U_G&/!;T[]>RHO%%:O>AX+M6ZT$L]B[7;*]T8)>#$\D'X;\E-<
M6,Q%'#5JMK&>]0R6&LKT8& "67J0-=!KH2=]$$]4O5+G-[I:@GY?I>%(':^W
M16:1[(HW22N:R-@+G.<=  =R2N99)DE/,X"W#PQ\B2>^LA,[)8M/8X$%C@P[
M/W^BZ;+&R6)\<K&OC>"US7#8<#W!""EX?/WLWF9W5<KBZ]*&V:[*I ?+.UO=
MP/,._76@K>+M4^'JS ?$<6,_G!\YP[@>I^"IOLYQM$.S4PIUQ+#E)VQO\,;8
M 1T!UT6/V;X>FZC;R<T#+%T7; CDD',8@)'::S?;KL]/,H+K:NU:A8+5F" O
M^B)) WF^S:S/D8R)TCWM;&T<Q>3H >N_14?@;%4<YB),OF:L%Z_<EE\5T[ _
MPP'D"-H/T0 .RTX6"AC^/,/5>YV.J57/@:3L1%\+BZ,? $#IY;07R3(THY(V
M27*S7R %C72M!<#V(&^J]6KU2H6BW:@@+OH^+(&[^S955X:X2PUGA&@VY1@L
M2V:L;Y9Y&!TA<Y@Z\QZC6^GIH+1]G&!Q^2X4KWLO6CR-RP7M?-::)'<K'N8U
MH)[ !H0= :0YH+2"#U!'FH'C#.6,)6HFI6CL3V[3*S6R2%C07;T20#Z+0]F[
M? H9BBQSC7HY.>M ''?)&.4AOW;*UO:C(^*M@9(XGS/9E(7"-A +S\[H-]$&
MY:S'$M"%]BW@JDU:,%T@J7"Z0-'<@.:-]/+:]Y?B$^Y\-V\4]KJ^2OPPN+F]
M3&]KR?L/S0L=W,9ZY6DKT.&K$,TK2T2VYXFQQ[Z;(:XD_8%!\3X!E'AG@_".
MF?RMRD$3Y&'E))9(7$>FR2@O\5ZI-8=!#:@DG;]*-L@+A]HWM99IHX(W23R,
MCC;W<]P 'WE4?CW 8O&<*6+^+HUZ=RCR2P30,#'-(<!W'<$$CKZK>XKLXZ9V
M)AN8E^7ORATM>HW7+T YG'F/+H;'?UZ(+15LP6X_$JSQ31[US1O#AO[0L5C(
MTJTHBL7*T4I_H22M:?P)5$P[7TO:#0;'@SA&6ZLPEB;)&YLW+RD.TPD C?GZ
MKY6PS\1[ZS,\,#,B:>25U^+DE?('.) <QQ#AH:'380=$DD9'&9)'M;&T;+G'
M0 ^U8JMRM;:XU+,,X;T)B>':_!<WS%R#*9#ANCB<<_(8-U1UF.FR1L39"T\H
M:[G(!#>OS?5;HH9)F9QEO$\*.Q+XYVML2,L0!CX#T<'-:[KKN.GD@O60L.J4
M9[#();#HVEPBB&W//H%6;F>XAQ].2_>P$ I1-\25L5OGF8P=2=<H!('76_)6
MY4_B.]-Q!8L\.84CD<WP\A<[M@8>A8WU>1L:\O-!MYC/21V>&78][#5R=@-<
M7-V2PQEPUZ'LIV"]4GF?#!:@DE9])C) 7#[0"J1Q_C*SG<(8SG?#4]]$'S'<
MIY1&1K?Q'3[UN<7<,X6IPU;M4ZD&/LTHG35[%=@C?&YH)'4>IZ?':"YHM+!V
M);>%H6++>6>:O')(W6M.+02/Q1!NKGOM:_R5_6_\"Z$N>^UK_)7];_P+L]G_
M !%/GZ2\_P!J_"5^7K#GJ(B^E?')&CF\E1B\.I=FCC\FAVP/L!6"YD+=V0/M
MV99G-[%[B=?9Z+<CX?R#HV.=''%S_1;-,R-SOL:X@K7CQ=IU]]-\?A3L:YY:
M_IT:TN/]@643A7FJ+7;S&-:*9O;S;=?)LR&0A=Q'/8GK1M(')K8VI/B#/TWX
M.'$89LXJL.WOE[N&]Z_%5-%$X%$U1.[N[DTY573353OVSW_*ZU\$9RGAXKXN
M&0&9K0SD;OMO\U#S9[*35C7EOV'0D:+2_N/B5&+8-208]EP\OA.E,0Z]>8 $
M_P!X3L<.*YKG;)[QBSAQAQ.JF^SQWLE#)7*#)FT[#X6S !X;_2 W^97G'W[6
M.F=+2F=#(YO(7-\QL'7]@6JBTFBF;WC:QC$JBUIV;&]+E;TM$4Y++S5!WX?E
MO>_[UJ0ROAE9+"\LD80YK@>H*V+>.M5*]:>Q$616&\T;M]Q_N7GW.3Y/]\^;
MX/B^#WZ\VM_AI1&9$:MDK5=I,_JO>/1M_+^4][]Z]]D]XY/#\3IOEWO2PU<M
M>J^\>[V7Q^\'<NOZ??O^)6&_4DI63!-R\X =\T['4 C^]:ZB**)C5$63.)B1
M.N9O'BV:%^U0E,E*Q)"\]"6.UO[?5>\AD[N1+3=M2S<O8.=T'W+316S*;YUM
M:F?5FYM]0B(K*B]1O,;VO8=.:00?BO*(+1Q;FJF8CH6J[I([\;.24:U\>A^W
M?XJ-9Q'F&1>&W(V.76NKMG\>ZB465.!133%-KQ&]O7E.)77-=[3.[4VJV0MU
MKGO<-B1MGK_.;VX[[]2L-B>2S/)-.\OE>>9SCW)6-%IFQ$WLRSJIBTSJ%N6<
ME<LTX:L]A[Z\.O#8>S=#0_L6FB33$[415,7B)VBVZ&1N4'$TK4L.^X8X@'[0
MO$]22&K6L/Y?#L!Q9H]?FG1VM=1JJBVV$Q-5$WC5+?OYC(9!@9<N33,'7E<[
MI^"QX_(W,>YSJ5F6$N[\CM _:%J(F93;-MJ3VE<U9UYOO;5^_;R$@DNV))G#
MH.=V]?9Z+WC\K>QP<*5J6%KNI:UW0_<M)$S*;9MM1VE<59U]>]M6+<]^T)+]
MB21Q(!>\EQ ^'Y*:XOS5;(QT:F.#Q4JQ\HYAK9UKM]@_M5;15G"IFJ*MVQ:,
M:J*:J>+:(B+1D*_^R;_#9/\ U8_[W*@*_P#LF_PV3_U8_P"]RX\O^'J\O5W^
MR_BJ//TED]K7^2_ZW_@7/%T/VM?Y+_K?^!<\3V?\/3Y^LI]J?%5^7I K]A+-
M6+@NK7R#0:MNR^%[O-FP2'?<0%05,V,E!)PK5QS0_P!XCL.E<=?-T0?/[UIE
M&'VD4QX_=CDF+&%-57ASUQJ;M' FCE;;\J/^98_3Y'>4O^:!_K+=XUL#(3X*
M=T+G">$.,3.A.W?1"@LAGKE[%U:$SAX4'F.[]=M_8%NSYV%LV!FKL<]]",->
MUPT"0?)93AXDU175KF+^GUEO&+A115AT3:)M/CM^D+'2P@L3,@L\-0UJS_FF
M3WH&1@]>_4J PN*@;F<S4LL;,VM7F+"[U:1HK89E.'XLRS*-;D))S,)#&_EY
M6$G9.^YUY!9\)SSYC/9 0RQU9:DSFOD86C3B"%C':4TU7O&KQVW\9ET6PJZJ
M<VTS$SNV6\(A'8^K1QN"BRF1K&Y+8D+(82_E: .[CI>W08_-XB]9I4Q1MTFB
M1S6.+F2,\^_8A:V+RM-^).+S,4KZ[7F2*6(CGC)[C1[A>[.5Q]+%V*.$CG)L
MZ$T\^@XM']$ +:::\[OO?RM_ISTU8>9&N,VVSOO;GM\K-NQ\E8W!XN>3'-LW
M+$+B>9Y:T:)^<==S^2J9[J4R]^&WC\7#$'\]:$QOV.F^8GHHI;X-$TQ,SMF9
M]7-E%<551%-K1$>D76?BMQ&)X>T2/^:>7W)P+;F?EFXZ4F:E::YDD3CMO8G?
MP*RSW\%D,;C8;TEZ.:K"(CX3&D'\2L,>8QF(AF&#@G?;E:6>\V" 6 ]^4#S7
M/$3.%.'FS?7Z[77>FG&C&SXMJ^>R+Q;HW,%PZR2M<N"H<@8YS##!XH8TZ[N<
M2>W;HO>:P'/AK-Q^,;C+%?1Y63"1DK?/H"=$*(PN8KQ4)\=E(I9:<K_$:^)V
MGQO]1ZK'E)<.VGX6-]]EG<X$RSN  'IH=TS,7M-<]_3G;HC/P>QU1&S?&WE?
MJE[8Q.+P^)L28UMFW8@V0YQ:SXN.NY6ID*M#)8"7*8^M[G+6D:R:$.+FN!Z
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MZUX,K1I.?/CJ,D=P@AKY)>=L1(T2T:'7[25HNN X>.ER';)W3<^^^VM&M?\
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M/ANH'<OC.D9S>@,G=>&WL:+WNOR7"ZES>'S[=XNMZYN;??SUK2T79-[:^-;
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M9BXORUV2/5:>O R-^Q\XMYMC7?S"D,W3=D,-?I,<&NLUY(0X]@7-(W_:@B.
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MXG$BO0L17!'(^T\OF8UNF=1KE ]   I5%><:J:<UG3DU%-6?MG\_-;'+!'+
MZ"1C71.;REA[$>B\V*E>S7\">&.2'I\QPV%F19Q,QL;33$[8:U*A4HM<*=>.
M$..W<@UM83AL<;)L>Y0>,3S<W(-[]5OHISZKWNKV=%HBT6AX@ACKPLBA8&1L
M'*UH[ +7N8VE<E9):JQ2R,Z-<YNR%MHHBJ8F\2F:*9C-F-34NXRE><TVZL4Q
M:- N;L@+8ABC@B;%"QL<;1IK6C0"]HDU3,6F=1%%,3G1&MKW:-6\QK+D$<S6
MG8#QO17JI4KTX?"JPQPQ[WRL&@LR)G3:U]1F4WSK:V%E6".U)99$QL\@#7R
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M.[D*='D]]MUZ_/OE\:0,YM=];/7N%K?+^'^ML?\ O+/S7*_^49VX?_\ R/\
MVUQA6R7V;3CX48DU6O\ =7*?:-6#B3AQ3>S]=_+^'^ML?^\L_-/E_#_6V/\
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M6?FGR_A_K;'_ +RS\U^1$30]/'T-+5<+]=_+^'^ML?\ O+/S3Y?P_P!;8_\
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M(K]ZSGZ=7$U[+X&3NT7/#20'$;TW>M@$[5L]GV7X>S7#<'!T3;E2S9A/C21
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MPR-+?IES 7$_;LJ,]DM&O%P34D;$TR3.D,CW#9=RR.:-GX!H"MU*M'3IP58
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M7D^1'(>@\NJYLBY_<L"TTYNWQET>^8T3$WV>$.AYWC[#9/'78(^#,=6LV&.
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MQK#/,QH=(&\Y^:S8(!)\_+2W;?REPMD,=*[*6,CB[5AM6:.WRNDC<_HUS7
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M3KOL3KU6[QGDZV5]EF2LTV\K/":QT)&G1.#V@L(\B#T02'\LN:(VJ^$RL^-
MYO>F1-T6_P"<&D\Q'QTI*WQ+C:^$@RC)73UK!#:XA:7/F<>S6M[[Z'I\"M.K
MQC@&8=MF3(5X&QL ? ]P;)&0/H<G??EK2I(IVJ?#F"R5B:SCJHR$]A[HXPYU
M6.7FY'%I!  \^G3F07BKQ1_SR"#*8N]C/>'<D,M@-+'.\FDM)T3Y;[K8S/$4
M./NLHUZUF_D7,\3W:LT$M;O7,XD@-'VE56_7H9,5J-CC>>Y[Q*PQQ1"%SG.:
M>8$<K=C1'=;]2Y7P/'6;.8E97;DFPR5;$IY6/#&D.9S'H"#UU\4$I6XEDL,M
M1MP^0;D*X:YU1X:USFDZ#FNWRD=_-:/LXSV2S.#HOR-&P2^(N==<Z,,D/,1T
M:#O^SR4]C<YC<G<GKXZU'9DA:'2.B^<T;[#F'3?PVJS[,;]/^1N-Q9MP,R+6
M21.KF0"1K@YQ(Y>_0=4$E-Q8'V+#,7BK^3AKO,<L]<-Y X=VMYB.8CX*0CXA
MQKL$_+FP&4F \[G@AS2#HM+>_-OIKOM4#A)ON.)^3[_%D^)N4G.9-5D$+ WJ
M3S-+F[<T]]]>ZVKF*B;PBZ]C+=C,5CDX\C/S, ,K6N ?RM  (Z;[==()NUQ:
M[Y.FFMX3*5*+V. LRQMTT$="YH)<T?$A;7LS_P 1,+_W'^\KYE>+,'+@YY(+
M]:VZ:)S(Z\3PZ25Q! :&]]_<OOLR_P 0\+Y?S'^\H-G)X.WDL@^2;,W:](-
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MX^D(*TMS1<_DT"[F!V[7<]%.(@U#C:3IFSR4ZS[#0/YUT32[\=;6TYH<TM<
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M9/3X!5:O;S.1XOS-&"['6Q]"2$[\$/>[FC:XL!/0#>R2=GJ-:4UQ1_BUE_\
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M=2QM&:*?)6;<)KMC<'.9RN!+^G8 ;Z_%!*Y'BRC1RLV-,-RQ>C:QXAKQ<[I
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M-I\P1ZKQ<IR:<&;QL?;>S?:5.64VJU5QMCZPWT1%RO4$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 (!!!&P?)1 X8P0L>\##X
M_P ??-S^[LWOUWI;&3DR#+% 8]E5T+IM63,XAPCU_0UW/VK>+FC>W :[]>R#
MQ8KPV('P6(HY87C3F/:"TCX@K4QN&QF,>]^-Q]6JY_1QAB:PG[=!;S7->-L<
M'#U!VOJ#"RK RU+99#&VQ*T-?(&CF<!V!/GI?37A-IMDQ,-AK#&).7YP:2"6
M[]-@'[E$TLO--Q7E,9(V)M>K!#*QX!#B7\V]G>M=/1337->-L<'#U!V@Q2U8
M)K$$\L,;YH"3$]S07,)&CH^6QT4$SAT2\39F[D(JMBA=@@C;$\<QVSFWL$:\
M^BL0()(!!([_  3F'-R[&^^D&IC<50Q;',QM*M5:[JX0QAF_MTLT-6"":>6&
M&..6=P=*]K0"\@:!)\^G19#(P#9>T#>M[7TO:&\Q< WU)Z((VU@,1;M^]6L7
M2FL[WXKX&N=O[2%(20QR0NADC8Z)S>4L(VTCTUZ+TUP<-M((]0OAD8UW*7M#
MO0E!HU<)BZE2>K5QU2&M.")8HXFM;("-:< .O<K:?5@?5]V?#&ZOR\GA%H+>
M7TUVTLQ(:-N( ^*\\[.?EYF\WIOJ@T<;A<9C)'R8['U*KWC3G0Q-83^ 6TVI
M79;DM-@C%F1H8^4-',YH[ GT69$&&6K!+9@L2PQOG@YO"D<T%S.8:.CY;"S+
MRV1CB0U[21Y K[S '6QO6]((VUP_A[=OWJUBZ4UC>_%? USOQ(6[:JP6ZSZ]
MJ&.:N\:=&]H+2/0A96/:_?(YKM>AVCGM8-O<&CXG2#Z    - = %A=4KNMLM
M.@C-EC2QLI:.9K3W /IT68$$;!V/4*#X/S,F8X>@OW1#%+(^1I#-AOS7N:.Y
M/D$$LVI7;;?:;!&++V"-TH:.8M'4 GT2M5@J^+[M#'%XLAEDY&@<SSW<?4GU
M7R_,ZO0L3QZ+HXG/;OL2 2H*AE<MDN#,?DJ$5+Y0LQQR.9*7-B )'-KKOMVZ
MH)&YP]A[MCQ[F*HSS]_$D@:YWXD+<L4JUFH:MBO%+6(#3$]@+-#L-=EFY@-!
MQ <1VVC'M?OD<UVO0[0:^/H5,=7$%"M#6A!WR1,#6[^P+97QSFM&W$ >I*^!
M[2 0YI!Z#KW0>D1$!<L]N7^1/Z__ -M=37+/;E_D3^O_ /;73D?^:GS]'F>V
M/@Z_+UARQ=4@:^;V-%N+WSC?C!G<CG/-O[O[%RM3_"G%5_AR5_NI;)7D.Y()
M/HN/K\"O6Q\.:XC-VQ-WR60X]&#75&)LJB8O'=?O?.",+'GLZVE+-) TQN=S
MQ]^@5]]GU1M"IQ=48XO;!(Z(./<@!PVH3]) @$C\=@:-6R\:,HZD_@!O\5%X
M#C2;%Q982U6V9<BXO>_GY.4D'?31]5CB4XN)$ZK;-7F[LFQ<DR:JF8JO.N\V
MGOBT0L'"3AQ-P#D,'(0;5,>)!L]2.I;_ &['WA?.(9/Y/<'X7!,'):MN;-9'
M8@;!(/WZ'_E67V;\.7,;/5SS[U2.A)"[Q6E_4 ]@?+R![]%4N*\N,UQ?+:8\
MN@$K8XO]0'0_'O\ >JTTQ7BS%/[8U^?YK:8F).%DM-5<6KF,W_\ 7;?EJ=%]
MI?$^1X?=0CQHC9XS2Y\KF<V]:^:-_:HOCH1Y7A+"9NS"R&^]\;7$#6P=]/LZ
M;"F/:#Q,W!V*,,^-K7X)8R_EF_HN!UL;!_N7-N*N+;G$-F!TT;(*T!W' P]
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MZB(/B^HB B(@(B("(@0$1$!$1 1$0$1$!$1 5J]EW^/.-_K?_2>JJK5[+O\
M'G&_UO\ Z3UEC?XZOE+JR'XG#_\ :/5:?;E_D7^N_P"!<L74_;CVPO\ 7?\
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M.MC?5>V31O<6LD8YP[@.!(466B8G7#VBCH,@^3/V\>6-#(8(Y0_S)<7#7_\
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MXVC%4JAPACV&AQV>I)_WK6;A*(Q1QSH>>J7%W*XG8)<7;![@[*CMHFJ9G?\
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MS_G-8X@L(:0#H$'0Z[7CA2WQAQ52N66YBMBZ]>[8KPN;3;,^<,E<T%VR &@
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M+RU+ADMDTWY48Z0S,&]\[(BSYKO3^<[H,.5Q>8G]L$?NO$$M;GQ4CV:J1/\
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MW/9!VT/:7<H<WF]-]5'W\U2HY7'8^Q(6V;QD$(UT^8WF.SY=%SWCS@_#\/\
M >0S>+K>#G<;![W'D@X^\/D9HGG?W<':T0>G7LMSCGAS"Y/VA<'R9'$4+3[1
MLMG=-7:\RAL.VAVQU /;?9!T@$$ @[!0$'L0?+HL=6O#5K15ZT3(8(F!D<;&
MAK6- T  .P 5,]D8Y<%EVNZ.;FLAL>F[#S_<04%N@J5(+-FW!%$R>R6^-(T
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M7PMC1+03H$@ZWW4S=JPW:<]6U&)*\['1R,/9S2-$?@5F1!!5.%,36X4?PY'
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;(B("(B B(@(B("(B B(@(B("(B B(@(B(/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g73463g01f05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g01f05.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1[F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'LD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^% 6&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M W<"G0$!$0#_Q  =  $  P$! 0$! 0          !@<(!00! P()_\0 91
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MU15$E)&.T=$UW)T)?L07%Q!V'K4"UHP6UX'<Z"@H;\Z\5TT9DJG$-!BZ@-!
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MQ5D5RI&04U#%%.7RAG8N8P-<';]VQ![_ &K/6@_-D7$76WJV1[6^(U52]PZ
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M?#%:HKS'4W;(JVY4$;MQ2.A#"6CN:7AQZ>P!6QG6#4.5X4[&>U=;Z':,,,#
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M\Z@/!S?+><2NEE,\;+DRM=4]FX@.DC<QH#AZ=BTA07B-KX,IUKL=NL3VU-1
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MT4O1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$47OV
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M,!<)33W6XT,?5\4G^6,Y1]+FC;T;*]-&=4X-1*>LIYK=-;KO0-;Y5 [JSKN
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M#9=IY!RLY1RENP=MX<SNNRUFB+)&H&2##^*&:]9#325%#"V(1!HWY8S$T![
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M<.7F^O9:)TS$M9II86W)ID?+0L;*'_S@6[;'YES_ 'G]/_T4MO\ 4/WI[S^
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MM_\ :8'5W*6]=NF[NOAW>E6?PK6FJI]1KZ;W5OAN]#":>2BJ.9TIW/5P<>A
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M<!ONJ\MFL-QM^I5US2*W4;JZOIO)S Y[NS9^+YP\3^+W>M6CPUV"^Y#G=UU
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MCZPU%?IOQ QY:VD,]%5\DL8=T$@#&MD8'>!Z;_.%8<W$WA[;<98:*[OJ^7I
M86M'-Z.;F[O7LH1PW07#,-7;]FM1!V-.TRN=R@\G:2GHP'QV'?\ ,M6(B(B(
MB(B+('&;\/K/\E#[61:FPGX&V'XA!]FU=E$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$5)ZHZ#PYWE]1?7WZ:B=-'&SL6P!X'*T#O)]2B?X*M/^E51^
MJM^]/P5:;]*JC]5;]ZL/1K1^+36Y7*KBN\E>:R)L7*^$,Y=COOT*M517*M0L
M5Q2O919%>J>@JGQB5L<@<26[D;] ?05$,GU'TERBV/M]^OELK*1W7DD9)NT^
MD'EW!]858QXWH VM[8Y&Y\6^_8&HEY/9OR[_ %J[--\IP*IC98<%KZ%S8&<X
MIJ9CALWQ)W'4^L]5.T1$1$1$1%D#C-^'UG^2A]K(M383\#;#\0I_LVKLHB(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(JBU<T:H=0<BI[K5WJ6A?%
M3B 1L8T@@.)WZ^U0C\%^T_I34?V3/O3\%^T_I34?V3/O4UTET8H< R.6ZTMZ
MFKI'PF'LWL:  3W]%;Z(B(B(B(BR!QF_#VS_ "4/M9%J;"?@;8?B%/\ 9M79
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1%1NOFLM5AMPAQ_%X(Y[Y*
MT.DD>WG$(=^* S^<X]_W[J&:,Z@9O7:AW2CRZMK2ZFM<U0:*:'L^5XY2T\@
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M0W.ZT=+*_HUDLH:3\RZ5/-%4PLFIY&2Q/&[7L<""/40O[>YK&ESW!K1U))V
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M5&H^045R@N\5"VGI/)BQ\1=OY[G;_P!Y6-18S2_P(IL:NK65E(VB913 C82
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792(B(B(B(B(B(B(B(B(B(B(B(B(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g73463g01f06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g01f06.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1W<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ';\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" -< I,# 2(  A$! Q$!_\0
M'  !  (# 0$!              $'!08(! (#_\0 71   0,# @($!PL)! <&
M! 0'  $" P0%!@<1$B$($S%!%"(V46%QLQ<8,E9U@9&4H;+1%18U4E5S=)*3
M(T*QTC,W4V)RE<$D)52"H^$X0^+Q@\+#\#1C96:BT^/_Q  7 0$! 0$
M             04$_\0 (1$!  $#! ,! 0            (!! 4#,3)1$Q12
M$A'_V@ , P$  A$#$0 _ .J0                "F^DKG57C&/4UKM,SH*Z
MY\:.F8NSXHF[<2IYE7?;?U@;W?=0L2L,[H+KD%!!.U=G1]9QN:OI1NZI\Y[L
M?RRP9$G_ ''=Z*M=MNK(I45Z)Z6]J?045ICH-17;'Z2\Y75U+YZZ-)VT\3N'
M@:[FU7.[5<J*BKZ^\PN::.Y%B.4T-;IZM=5,>O'&]GBOIWIVHYW8K53S]O-
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MG8FRJB<D7?S%S:*6?*+;C3ILUN-74W"I<CF05$G&M.Q$Y(J_K+SWY^8"PP
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M         H?%M-<BM^M\^35,-.EJ?43R(])45VSFJB>+MZ2^
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M3"KI3._T<-:JL_\ ,U%7_ "\
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M6VWTU%1QI'34\;8HV)_=:U-D0#T
M
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MVSFJBIZ^98VD]NRRT6BJM^:5D==+3R(VEJ6.XE?'MWJJ(JKZ^?K W@
M
M                                        #D;4_$<SQ*BRR-K&2XC<
MJE*JHF8K%W57IP[[^.BHNR<CKDT[5K+VX3A=3=O!F54W&R&&)_P7/<O+B]"(
MBK\P%)V&NUO99+>VU4;5MZ4\:4Z]73<X^%.'M=OV;=I:^CU1GL\=U]T2%(G(
ML?@FS8DW3QN/X"K_ +O:5E39CK=64\=128_"E/*U'QIX$B>*O-.2O1>SSEG:
M/73.;E'=5U H&4;HW1^"\,*1\2+Q<78Y=_[H%B@
M
M                         :!KQ0MN&F-VA_)L]RE18W10TZ+UB/XT1'-V
M1>:;JO9V;F_E2?G+J7^3LID_-VG\)I9&):V<'^G:LNRJOC_J<^X#1K/JUJ10
M6RFI*C"9ZV2%B,6=]/,QS]DVW5$;MN6EI'F60Y:RZ+DF/NLRTRQI"BLD;UO%
MQ;_#1.S9.SSE?_GIK7\3J3^G_P#]"P])KUFEW9<USJSQ6QT2Q^#)&W;C1>+B
M_O.[-D^D#?P
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MJ*BQ,5/@;;JG;Y@-Q
M                                                     .?.D5I[
M<YKK!F.,,D?40-:M3'#_ *1CF+NV5J=^W?ZD.@RGM0-<*7#\HJK-+99ZI\"-
M596S(U%W3?LV KNQ](Z]T=(RGN]II:N>-J-=,CG1N<J=[F]RF&R_5_*=0:=<
M?M5OCIXJO9CX:1'22RIV\*N7L3S_ .)L%SUJQ&ZSK-<< IZF9>:R2K&YR_/P
M[F3QK7?$K4JLI<1=;(W+LYU*V/L].R(JE%DZ(8(_!<26"MX%NE8])ZI6KNC5
MVV1F_?P\_G52PC$XMD5LRBS0W2R5+:BDE3M3DK5[VN3M1R=Z*98@'->J6F^?
M7K.[K<+&R1;=,]JQ;5S8^7"B?!XN7,Z4 '#,F.YFW*GXW#)5U-YC3BD@IZSK
M.K3E\)R.V3M3O[S,WC3;4JTV^2MJJ>M?!&G$_J:U)'(GGX4=N97&LNETOUAR
MB3(:*:9M7-(R5R?#1KI.-DC=_A(J?3R\Q9UWZ16*PT$KK33W"KK-O[.*2!8F
MJOI<O<4>7HIT]Q6QWFOKJKPFGJ98TA<M1UBM5J.XD5-]VKS3DI>ASOT2*>O?
M^<UQD8YEOJ)(T;RV8Z5%<KN'U(Y$^=#H@@
M
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MK7*KFNX5\R\**="@
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M\
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M<U7/>Y&_,BI])T28#!L;M&+X[3V_'FIX%_I.MXD<LJJB>.KD[579.9GP
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MK:Q)J:))7]?%P)PJNW+F;R<L]$-=\LO:KVK0,7_U$.I@
M
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MQG3!9[Y#9%\G5'LW <Z]$'RJO?R>SVB'4YRQT0?*J]_)[/:(=3@
M
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ML]HAU.<L=$'RJO?R>SVB'4X
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M_B=A@"K]"--YL#L]7+=)(WW:O5JRMC7=L3&IR8B]Z[JNZEH
M   P6>^0V1?)U1[-QG3!9[Y#9%\G5'LW <Z]$'RJO?R>SVB'4YRQT0?*J]_)
M[/:(=3@
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MLBJUR=RINAGCG'HEO5EVRZ"DD?);FK$Z-SN_QGHU?6K4.C@
M 8+/?(;(ODZH]FXSI@L]\ALB^3JCV;@.=>B#Y57OY/9[1#J<Y8Z(/E5>_D]G
MM$.IP
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M8+/?(;(ODZH]FX#G7H@^55[^3V>T0ZG.6.B#Y57OY/9[1#J<
M
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MO=*&G6GXI_'9::DM2E?U4 !PNL
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M+Y.J/9N,Z8+/?(;(ODZH]FX#G7H@^55[^3V>T0ZG.6.B#Y57OY/9[1#J<
M        !0N1^4%S_B9/O*7T4+D?E!<_XF3[RFCCN4G%>\:,>""369H 0!(
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M?.]&/?NK6M5R[>+V\@,MT0?*J]_)[/:(=3G+/1$7?+;XJ=] U?\ U$.I@
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M *25746J:&TV1E'62-X4J)9^-(U7O1NR;K\Y1L_19RNNNMGN=AN<CY7VM6+
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M5'LW <Z]$'RJO?R>SVB'4YRQT0?*J]_)[/:(=3@           *&R/R@N?\
M$R?>4ODH7(_*&Y_Q,GWE-''<I.*]XT8X DUF< @D( $ 2020%"00!( " ! 4
M)( $@ ($$@*]-K_25)^^9_BAT"<_6O\ 25)^^9]Y#H$RLCO%H6.T@ &:[@
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MCH$Y^M?Z2I/WS/O'0)E9'>+1L=I  ,UW
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MQG3!9[Y#9%\G5'LW <Z]$'RJO?R>SVB'4YRQT0?*J]_)[/:(=3@
M  *&R/RAN?\ $R?>4ODH;(_*"Y_Q,GWE-''<I.*]XT8X @UF<$D$@0"0!!(
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M" "0/3:_TE2?OF?>.@3GZU_I*D_?,^\= F5D=XM"QVD  S7<
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M%>FU_I*D_?,^\= G/UK_ $E2?OF?>.@3*R.\6A8[2  9KN
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MCH$Y^M?Z2I/WS/O'0)E9'>+1L=I  ,UW
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M7>WJU.!R*B\]N7)5Y@;-T0?*J]_)[/:(=3G+/1$1$RV^(G8E WVB'4P
M      "A<C\H+G_$R?>4OHH7(_*"Y_Q,GWE-''<I.*]XT8\@ UF:D$ *$@
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MJ3]\S[QT"<_6O])4G[YGWCH$RLCO%HV.T@ &:[@
M            I'4G7.7#LMJ[*RQ1U:0(U>M=5<"KNF_9PJ!J%KBO>GO2%J8X
MZ%9J2_52Q,E>U>%T4LB/5S53^\U=]T]!X+EE%RT<U1R:.&WLJ*&XNZZ)DJJQ
M'([QD>U4\RJY%3T&3EZ2CI7,=+BE,]T;N)BNJ]^%?.GB<E/#>M?:"^1L9><&
MMM<QB[M2HJ$?P^K=A1G>BZMQNN4YAD53#U=/7.:YSF-VC=*Y[GJUOJW^U#HH
MJG0K4.'-([C14=BIK/36YL?!'!(CFKQ;]R-3;X):Q   ')6(X6W.]:\HH\MJ
M)XW4TTT\D2.X7RHDG"QJ+W-1JIV=VQ;UZT)PBHMLD=/2RV^5K5VJ8YEW:OG=
MOR5"E]0[?GD^I=WNEOM]X22"JD92U=-3N:Y8D=XJ<34\9-D3;?<\5WJM6;O0
MNH[A'DDM,].%\:0/:CT\R[)S L'HBOK&NR>FXG/ML;XU:[^YUN[D54];415^
M8Z+.,,>DU0QVW-H;)07JBI$57=7%1*B*J]Z^+S4Z%T(K<HKL;K7YFE:E:E1M
M'X5'P.X-D[$V3EN!90             8+/?(;(ODZH]FXSI@L]\ALB^3JCV;
M@.=>B#Y57OY/9[1#J<Y8Z(/E5>_D]GM$.IP           %"Y'Y07/\ B9/O
M*7T4+D?E!<_XF3[RFCCN4G%>\:,> #69P  @  H" !)!("(!) 4!) $@ (@
MD* $!'JM?Z2I/WS/O'0)S]:_TE2?OF?>.@3*R.\6C8[2  9KN
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M 2""0H 0!ZK7^DJ3]\S[QT"<_6O])4G[YGWCH$RLCO%H6.T@ &:[@
M                           <A:ISYF[5:Z7&V4%RCDHYW14M71T;FN=&
MFVR*]J>.G=SW/'=LQU7NM ZCJVWML#F\+NIH'1.<GI<C=SLG9/,-D\R <58E
M?=1L2M[Z+'[774L#W]8__NI7.>[SJY6[J=#:#7[*;]9;E+F3)V5,<[6P];3=
M0O#P\^6R;\RS]D\R#L  '-NJ.3:F4.=72GQUUR2UL>U(>JI&O;MPIOLJM7?F
M!E]9-%JV]WV7(L0FBCKYG(^>F>[J^)Z)\-CD['<N?IY[E=MTRU2OJI0W%U=X
M-NG%X=7JL7;V[;KO]!]_GCK%^O>/J+/\H_/'6+]:[_46?Y2CHC2? Z; <:_)
M\<J5%7,_KJFHX=N-^R)LG^ZFW+YS="I.C_>,ONT%[7-5JU?$^)*?PB!(N2H[
MBVV1-^XML@             !@L]\ALB^3JCV;C.F"SWR&R+Y.J/9N YUZ(/E
M5>_D]GM$.ISECH@^55[^3V>T0ZG            4+D?E#<_XF3[RE]%"Y'Y0
M7/\ B9/O*:..Y2<5[QHQY )-9FH)()"H!( @D  ""0!!("()()      !!)
M5ZK7^DJ3]\S[QT"<_6O])4G[YGWCH$RLCO%H6.T@ &:[@
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MYGWD.@3GZU_I*D_?,^\= F5D=XM"QVD  S7<
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M+D?E!<_XF3[RFCCN4G%>\:,<"0:S-""0!!) "I!!($$@! @D!4$@ 02 $ 0
MJ0" /5:_TE2?OF?>.@3GZU_I*D_?,^\= F5D=XM"QVD  S7<
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M3@           *%R/R@N?\3)]Y2^BA<C\H+G_$R?>4T<=RDXKWC1CR 2:S.
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M4-S_ (F3[RE]%#9'Y07/^)D^\IHX[E)Q7O&C&D@&LSD D@"002! )(")()(
M D@*D@ "2"0! )( D@$A'IM?Z2I/WS/O'0)S]:_TE2?OF?>.@3*R.\6C8[2
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M_P")D^\I?10N1^4%S_B9/O*:..Y2<5[QHQY !K,X) " () @$@*@D@D($$D
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MD?E#<_XF3[RFCCN4G%>\:,>02#69J"00!(()  @D    () $$@" 2 H""0@
M KTVO])4G[YGWCH$Y^M?Z2I/WS/O'0)E9'>+0L=I  ,UW
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M]%"Y'Y0W/^)D^\IHX[E)Q7O&C'$@&LS0  0 2   $$@@*D$$A @D!0  ""0
M ( ]5K_25)^^9]XZ!.?K7^DJ3]\S[R'0)E9'>+0L=I  ,UW
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M") ("A( $$@@ "0$0"0%>FU_I*D_?,^\= G/UK_25)^^9]XZ!,K([Q:%CM(
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M !(()" ()"H)! 1ZK7^DJ3]\S[QT"<_6O])4G[YGWCH$RLCO%HV.T@ &:[@
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M'LW&=,%GOD-D7R=4>S<!SKT0?*J]_)[/:(=3G+'1!\JKW\GL]HAU.
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M<9TP6>^0V1?)U1[-P'.O1!\JKW\GL]HAU.<L=$'RJO?R>SVB'4X
M  "A<C\H+G_$R?>4OHH7(_*"Y_Q,GWE-''<I.*]XT8\$$FLSD$D$A$$D$A0$
M "0   ( $D$@"  )!  D @(]5K_25)^^9]XZ!.?K7^DJ3]\S[QT"961WBT;'
M:0 #-=P                                  .2,U9DFD>J=ROMMC5:&
MOEDD9,]BNBE8]W&Z-R]RH[Y^6Y^UZZ1E^N5NDI+=045#/*W@ZYDBRNY_JM5.
MWZ2V=7]7+1A\ZV=*)EUN:M1TL#]NKB14W3C5>]47?9#4M.M2J:Y6C)[S68S9
M*1;13MJ(_!HN%SU55397+OM\WG US":2]Z;:/Y+DL\#J>NNCX(*6&=J\36*O
M#UCFKWKQKLGH-]Z+>-U]HQBXW2Y0R0.NDK'Q,D:K7*QN^SE1>Y5<JIZ#?-/,
MTM&H-A6MH8U1T3T9/33M171/VW3T*GF4V].2<@ !S;JCJEG-ASJZVVS(SP"!
MZ)%O1=9RX47X7>!I]JPVXZI:L95!<+BM'-2SRNEDDC5[D:DBL8QK=TV39$-[
M][/3_&:;ZJG^8J%<PR]F6RY+2LEI+O,W@FDIZ-6ME3E\)NRHO8GT&T)K3J3M
M_P#+_P"7%%^:1Z;1Z>17-D=R?7>&NC<JNB1G!PHJ>==^TL$J3H_YGD>7P7MV
M4</%3/B2':GZGDY';^OL0ML@        UK4#,[7@]B6YW=SW-<[JX88]E?*_
MMX4W]6ZKW%(P])J1:Y$FQIB4G%SX*O>3;U<.VY@>E?=I*G.J.VM>O54=&UW#
MW=8]RKO]"-+8R_!;3#H756]E%#'+16U*ELJ-3C25C$>KN+MW547?U@;_ (=D
MMNRVP4UWM$JOIIDYM<FSHW)R5KD[E13-'-/1"NTOAV06ISMX7115;$7^ZJ*K
M7;>O=/H+^R#)[)CJPI?+G34*S;]7US^'BV[=@,P8+/?(;(ODZH]FXQGNG85\
M9K9_5,/F>HN(5>(7RFILBMTL\U#/'&QLNZN<L;D1$]:J!4'1!\JKW\GL]HAU
M.<B=&+(+3CN1W::^7"GH8I*)L;'3.X4<[C1=D.B_=.PKXS6S^J!N -/]T["O
MC-;/ZH]T["OC-;/ZH&X T_W3L*^,UL_JCW3L*^,UL_J@;@#3_=.PKXS6S^J/
M=.PKXS6S^J!N -/]T["OC-;/ZH]T["OC-;/ZH&X%"Y'Y07/^)D^\I97NG85\
M9K9_5*;ON5V&:]W"6*[4CXWSO<UR/Y*BJNRFACY4C*7]JX[R-:QI_'J!A_SG
MLO[3I?YQ^<UD_:=+_.:GEAW1G_B73+DF'_.>R?M.E_G'YS67]J4O\X\L.Z'X
METS ,/\ G-9/VG2_SC\YK+^TZ7^<>6'=#\2Z9<DP_P"<]D_:E+_./SGLO[4I
M?YQY8=T/Q+IEP8C\Y[)^U*7^<?G-9?VG2_SCRP[H>.73,$&(_.:R?M.E_G'Y
MSV3]ITO\X\L.Z'XETS!!B/SGLG[4I?YQ^<]E_:=+_./+#NA^)=,P##?G/9/V
MI2_SD_G/9/VI2_SCRP[H>.73+DF'_.:R?M.E_G'YSV3]ITO\X\L.Z'CETRX,
M1^<UE_:=+_./SFLO[3I?YQY8=T/Q+IL-K_25)^^9]XZ!.9+=E-CCKZ9[[K2-
M:V5JJJO[$W+K]T["OC-;/ZIF9"5)5C_*N^RC6E*_UN -/]TW"OC-;/ZH]T["
MOC-;/ZIG.UN -/\ =.PKXS6S^J/=.PKXS6S^J!N -/\ =.PKXS6S^J/=.PKX
MS6S^J!N -/\ =-PKXS6S^J/=-PKXS6S^J!N -/\ =.PKXS6S^J%U.PI$55R:
MV;)__- W 'Q!+'/!'-"]'Q2-1[')V.14W13[                      .4
ML,_(CND!DGY]^#[^$3^#I6;=7UO6)P;[\O@=FYGM+YL=3+-1XK_-;FV69Z(K
M9WM2)[$<J[)W+W=A^NH%@PS4[-ZNALET?;\J@>Z&?BIU?%4JSEW+W;;<7V&
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MC1GKX>?_ $ OT        \;+5;V5'7LH*1L^_%UB0M1V_GWVW/8
M                        !4O2>C?)IC(V-CWN\+A79K55>U?,6T%1%394
M14](%.]%6*2+3.=LL;XW?E&9=GM5%VV9YRX@B(B;(B(GH
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MN/Y;8H+VF9MJD?,^):?KZI)N2([BVV<NW:A;A
M
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M[9>FSNM-=3UC().JD= ]'HUWFW3O R
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MJWU-1U*ME<K41.%5WY>H"Q :EI9E,^8X927FKIXZ>:9SVK'&JJB<+E3O-M
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M>&VK";&VV65DG5[\<DDCN)\C_P!9>[YDY&Q@
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M/9T5*VHJ=.JB"=RNCI:U\<._<U6M=M]*J!<H
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M.SL>DLS-Y)Y439))'=J^KN^8V:**.%O#%&QC?,U-D/L
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MO4W\_.GGBJ8634\K)8GINU['(YKD\Z*A^A
M                  *FZ;+V  ?+8V,^ QK?4FQ]  %3?M")MV
M                                                8V^V*UWZD6EO
M-!3UD"_W96;[>I>U"G,OZ.EEK4DFQBLFMLR]D$R];#]OC)]*EZ@"F>C]@F0X
M-<,@I;\UBTLJ1+3R0S<<;]E=OLG:B]G:B%S
M
2                     ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g73463g01f07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g01f07.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1;T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %M<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" )?!VP# 2(
M A$! Q$!_\0 '0 !  ,  P$! 0            4&!P(#! $("?_$ %T0  $#
M @($!0\'"P$%!@8!!0 ! @,$!081!Q(A,1,705'1%!46(E-456%Q@9&2DZ&Q
M"#(V4G.4P2,S-#4W0G)TLM+ALR1B=<+P)28X0X*B&"=68X/QA41%1F6C_\0
M&@$!  (# 0                ,$ 0(%!O_$ #@1 0 ! @,#"@8# 0 " @,
M   ! @,$$5(3%"$%$A4Q47&!D;'P,C,T0:'A(F'1P2-"-?$D4W+_V@ , P$
M A$#$0 _ /U2 JF13:></LKJREAL]_J7TLSH9'4]*CVZS55%W.\0&N@R)-/6
M'VN3JJSXBI(N66:AR:GER52^X3QE8,64SIL/W2GK-1$5\;'9/9_$U=J>@"P
M)M          !2NXOQI8<(TS9;_<8:57IG'$JYR2?PM3:H%B!D::?,,(]%FH
M;W!2JN254E&J1KX\\\_<:3A^^VW$-MCK[+6PUE(_8DD;LTSYEYE\2@28(/%F
M*[-A.W=6W^OAHX5549KKVSUYFM3:J^0S[C]PQK:RT%[2DSRZJ6C_ "?ESSS]
MP&N@A<+8HL^*K<E;8*^&LAW.U%[9B\SF[VKY2:0 #A-*R&)\DSVLC8FLYSER
M1$YU7D/E-/%4PMEIY8Y8G?-?&Y'-7R*@'8
M
M
M
M
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MR*YJ+E[P/<
M
M
M
M                                                    "[C\VZ$\
M<X=PG<<:P7^YQ4<L]UD?&UZ+VR(]_2?I)4(B3#%AD>Y\EDM;WN57.<ZDC555
M=ZJN0%.J]-N Z>%TG7MDN29ZL4;GN7S(A1;Q<+UIRJZ>V6>BK+1@V&5)*NMJ
MF*UU7DNQK$_#-?'D;9%AFQ0R(^&RVR-Z;G-I8T5//D2K6-8U&M1$:B9(B;,@
M*MC##\E3H\N5BL&K32.HUIZ9&[$;LR1#+=$.E'"N&<(4N'[\DECNEO18ZB*:
M!6\(_/:[-$WKX]NPWS(\%=9K97R-DKK=1U,C=SIH&O5/.J ?FO3GCUF-;5;6
MV"AJ76&EN$:ON,S%8V27)41C$7:NQ555\1^GXOS3?(AYZBV4$],RGGHJ:6"-
M45D;XFN:U4Y414R0J6,M)%LP?>8J*\T-S;321<(VLAIEDBSS5-7--N>SFY4
MR+29=KEHMQ[>YK1#(^BQ+3:T+&)VK*I51%<OCV>\V?13A:/">"J"@U?]J>Q)
MZI_*^5R(KE7QF>6Q]5I5TE6^[I0U4&#[,BO@=4Q\&M3-SZJ\FTW)-P!-@R
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MJ<C43)/<?8((J>)L<$;(HV[FL:C43S(=@
M
M
M
M
M                       * .$D4<C5;(QKVKR.3-#(L6:3L2T>D6JPKAG#
M4%UG@@;/K.J.#56JFW>F1Q[-M*3-K]'D"M3>C:Y%7S(!L#&-8U&L:C6IL1$3
M+(Y(F1E=BTQT"WB.S8OMM9AV[2+DUE2W\D[FR>B_%$-3:N:9@?0 @ !0@  )
MM0    *3I ON+[364K,)X9BO,#XU=+(^H2+4=GN\>P@M&>D:]8DQC=\/8AL<
M-JJ[?"V1Z,FX1<U7=NRW :F @                  *9IB73/AK#U_JK/61
MW&2LIERD2&GUT].8&E@R)=/^$FIG)3WAC>5SJ-<D]Y<<':0\,XP566*YQS3-
M3-T+D5DB?^E=H%L 0        * !2L<:3L,X,J&4MYK7=6O:CFTT,:R29<BY
M)N\YX,+:8L(XBN3+?3UDU+72+JLAJX5C5R\R*NQ5\68&B )N
M 5#2#I!L^!(J22]I4JE4]61I!'KKGDJ\_B*EQ^X5V_[)>ON:](&N SC#NFG!
M=\K&TD5Q?2U+ER;'5Q.BS7FS79[S16N1R(K5145,T5 .0"        \MUKHK
M9;*NNJ=;@*6)\TFJF:ZK455R3R(93#\H/",T:/AI[P]B[E;29I\0-@!D?'[A
M7EI+S]T7I+KH_P ;6O'5FEN=CX?J:.98'<,S4761$5>7=VR 6<
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M@<)0QNDEI[NQC=ZK2;/B!KX/':+A%=;71U]+K=3U4+)X]9,EU7(BIFGD4]@
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M*BLH5DRU7U5,YK%SY<TSR3R@:L#JI*B*KIXYZ>1LD,C4>Q[5S1R+N5#M
M   !4](>/;1@.CHZF^=4K'52K%&D$>NNLB9\X%L!D?'[A7O2\_=%Z22L.FS!
M5XJV4K;B^CJ7JC6LK(G19JJY99KL]X&E ^,<CVHYJHK5VHJ<I]
M*5W&N,+5@ZW1U=XE>G"R)%#%$W6DE<J[FMY=Z 6('323]44L4RQ21:[4=J2)
MDYOB5"#QCC.QX/HVU.(*^.E8_/4;DKGO_A:FU0+$#)Z33Y@J:H9'-/74D;_F
MS3TKFL7SIF:A0UD%?2155'*R:GE:CXY&+FCFKN5 /0 @
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MR)XDS(KY2?[&[_Y(?]9@%MT>?0/#G_#J?_3:6 K^CSZ!X<_X=3_Z;2P
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M=%<,G_D\]NJN_P!Z;S:L,W>"_P!@MUUI?S-93LG:B[TUFHN2^3,"3
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MJ4]+&C$5=[EWJY?*JJI,@      PWY4?S,#_ /&6?@;D89\J/YF!_P#C+/P
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M"M-ACY1=+;K?+).Z"UK-632+FZ25VUSEYLU7,#](IR@(
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M;L$TD+GPW/JQZ)LCIFZ[E]!<>Q/#_@:W^P;T'=38<LU*_7I[50QO^LV!J+\
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MFKMSVH!#://H'AS_ (=3_P"FTL!PABC@B9%"Q&1L1&M:U,D1$W(AS
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MHDS5&;=J;]WB0T.ALEKH'ZU#;Z2G=]:.)K5]*(2&0!-P
M                                  #(  FP
M              #C+$R:-S)6->QVQ6N3-%.0 ZJ>GAIV:E/%'$SF8U&I[CM
M                           !DAT0T=-#*LD-/#'([>YK$15\YW@!D@
M                        9(=#**E9,LS*>%LR[WHQ$=Z3O #(
M                    !T5%'35*IU1!%+ENUV([+TG<C4:B(U$1$Y$/H
M                        #B]C7M5KD147>B\IUT]+3TR*E-!%$CM_!L1N
M?H.X ,@                            '0M%3+/PRT\*S=TU$UO3O._(
M                           "H=$5'30R.DBIX62.WO:Q$5?.=X 9
M                         .B*BIHI5EBIX62KO>UB(J^<[T3(
M                                                       \UQJ7
M4M(^9D:R.;N:G*?;?.ZII(Y7QK&YR9JU>0XW*2:&D>^FC225$V-7E.5NDEEH
MXWU#$9*J=LWF ]
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M)S@>*T5TE='(Z6!85:[51%Y3WD?9YZF>*1U9"D3D=DU$Y4)
M               "[B.M=PDK)YXY*=T21KDBK^]M)%=Q&VJIJYJBH;50)&QB
M]HJ?O;0)(                          #C([58YR)FJ)GD<CC(JI&Y6IF
MJ)L \-GKY*^.1TD#H=5V2(O*2!&V2IJJB.5:N%(E1V341-Z$D
M                !5(U;C+UVZDZG=P>6?"\A(J1JU-9UW6'@$ZER_.9 2:
M(
M \UQ=4-I'K1M1TW[J*?;>L[J2-:MJ-F5.V1.<^7%E0^D>VC>C)OW54^V]L[*
M2-M4Y'3(G;*G*H'H
M                      $;?64<E(B7!RLAUMBIS[3VTB1I31I"N<>KVJ^(
M\5\?1QTB.N#%?%K)DB)GMVGMI%C=31K"F4:M[5/$!V@
M         >2XNJ&TCUHVHLZ?-13UGEN+)WTDC:1Z,F7+550/M Z=U'&M6U$G
MR[9$YSTGFM[)V4D;:IR/G1.V5.<](                           =-4L
MK::1:=,Y43M47G.BTOJWTN=>U&S9[DYCOJVRNIY$@=JR*G:KS*>>TQU<=+JU
M[T?-GO3F ]P                          '&362-^I\[)<O*<CC+K+$]&
M+D[)<O*!XK0^M?'(MP:UK];M43F/>>"T15D44B5\B/>KLVJG,>\
M                  "D;:WU[JBH2M8UL:+^35.4DE(VUQ5T=14+6RM?&Y?R
M:)R 20                          '&3-&+J[\MAR.,F>HNKORV >"S/K
MGME6X,1BZW:Y<Q(D=9HZZ-LO7"1KW*O:Y<B$B
M   .N>5L,;I)'(UC4S55Y$!U.PC%DN'7;41C>HLOG<I]MEZH;GK=15#9'-7)
M6[47WGQ8J_KMPB2IU'E\SE-JJ9IG*J,FM%=-<<ZF<X2: (#5L
M                                               #RW*&2HI'QPR+
M$]=SN8Y6Z%\%'''+)PCVIM=SG"Z0=44<D2R\%K?O\QRML/4]''$DO"ZJ9:_.
M!Z0                                  /-<:^EMM'+5W"HBIJ6),WRR
MN1K6[<MJJ>DSKY0O['\1_9,_U&@3;M(>$6M5RXDM62<U2U?Q.E-)N"__ *EM
MOM3\M:'-#;=(>'ZFY.N[J+@9UAU$BUL]F>>\OO\ \+;/_J5WW=.DS&7W:SG]
MF[T>,\/5D#9J6[4TT+MSV*JHIW]E-F\(P^_H*+@_1!38?L,-ODNDT[HU<JO1
MB-SS<J[O.3?%U2=^S^JA=IHPDQ'.JG/W_3G5W<=%4Q31&7V]YI_LILWA&'W]
M [*;-X1A]_00'%U2=^S^J@XNJ3OV?U4-MG@]<^_!KM>4-%/G^T_V4V;PC#[^
M@=E-F\(P^_H(#BZI._9_50<75)W[/ZJ#9X/7/OP-KRAHI\_VG^RFS>$8??T#
MLILWA&'W]! <75)W[/ZJ#BZI._9_50;/!ZY]^!M>4-%/G^T_V4V;PC#[^@=E
M-F\(P^_H(#BZI._9_50<75)W[/ZJ#9X/7/OP-KRAHI\_VG^RFS>$8??T#LIL
MWA&'W]! <75)W[/ZJ#BZI._9_50;/!ZY]^!M>4-%/G^T_P!E-F\(P^_H'939
MO",/OZ" XNJ3OV?U4'%U2=^S^J@V>#US[\#:\H:*?/\ :?[*;-X1A]_0.RFS
M>$8??T$!Q=4G?L_JH.+JD[]G]5!L\'KGWX&UY0T4^?[3_939O",/OZ!V4V;P
MC#[^@@.+JD[]G]5!Q=4G?L_JH-G@]<^_ VO*&BGS_:?[*;-X1A]_0.RFS>$8
M??T$!Q=4G?L_JH.+JD[]G]5!L\'KGWX&UY0T4^?[2EQQ39. 3.>*IV_,1/?N
M/1!BFR\"S*NA9L^;DNSW%5NV"*6@IDE9/4S*KM75:U#TTVCZDF@9(M7.U7)G
MEJIL&SP>N??@;7E#_P#73Y_M9.RFS>$8??T#LILWA&'W]! <75)W[/ZJ#BZI
M._9_50;/!ZY]^!M>4-%/G^T_V4V;PC#[^@=E-F\(P^_H(#BZI._9_50<75)W
M[/ZJ#9X/7/OP-KRAHI\_VG^RFS>$8??T#LILWA&'W]! <75)W[/ZJ#BZI._9
M_50;/!ZY]^!M>4-%/G^T_P!E-F\(P^_H'939O",/OZ" XNJ3OV?U4'%U2=^S
M^J@V>#US[\#:\H:*?/\ :?[*;-X1A]_0.RFS>$8??T$!Q=4G?L_JH.+JD[]G
M]5!L\'KGWX&UY0T4^?[3_939O",/OZ!V4V;PC#[^@@.+JD[]G]5!Q=4G?L_J
MH-G@]<^_ VO*&BGS_:?[*;-X1A]_0.RFS>$8??T$!Q=4G?L_JH.+JD[]G]5!
ML\'KGWX&UY0T4^?[3_939O",/OZ!V4V;PC#[^@@.+JD[]G]5!Q=4G?L_JH-G
M@]<^_ VO*&BGS_:?[*;-X1A]_0.RFS>$8??T$!Q=4G?L_JH.+JD[]G]5!L\'
MKGWX&UY0T4^?[3_939O",/OZ!V4V;PC#[^@@.+JD[]G]5!Q=4G?L_JH-G@]<
M^_ VO*&BGS_:?[*;-X1A]_0>6XXAM512210W6*.1V63DSV$5Q=4G?L_JH=<N
MCRC;&J]7RM\;D3(;/!ZY]^!M>4-%/G^TU;\16FGHXXIKI%(]J9*Y<]IZ>RFS
M>$8??T%=BT>4CF(O5\KO&U$R4Y<75)W[/ZJ#9X/7/OP-KRAHI\_VL'939O",
M/OZ!V4V;PC#[^@@.+JD[]G]5!Q=4G?L_JH-G@]<^_ VO*&BGS_:?[*;-X1A]
M_0.RFS>$8??T$!Q=4G?L_JH.+JD[]G]5!L\'KGWX&UY0T4^?[3_939O",/OZ
M!V4V;PC#[^@@.+JD[]G]5!Q=4G?L_JH-G@]<^_ VO*&BGS_:?[*;-X1A]_0.
MRFS>$8??T$!Q=4G?L_JH.+JD[]G]5!L\'KGWX&UY0T4^?[3_ &4V;PC#[^@=
ME-F\(P^_H(#BZI._9_50<75)W[/ZJ#9X/7/OP-KRAHI\_P!I_LILWA&'W] [
M*;-X1A]_00'%U2=^S^J@XNJ3OV?U4&SP>N??@;7E#13Y_M/]E-F\(P^_H'93
M9O",/OZ" XNJ3OV?U4'%U2=^S^J@V>#US[\#:\H:*?/]I_LILWA&'W] [*;-
MX1A]_00'%U2=^S^J@XNJ3OV?U4&SP>N??@;7E#13Y_M/]E-F\(P^_H'939O"
M,/OZ" XNJ3OV?U4'%U2=^S^J@V>#US[\#:\H:*?/]I_LILWA&'W] [*+-X1A
M]_00'%U2=^S^J@XNJ3OV?U4&SP>N??@;7E#13Y_M,U6)+1+321QW.)CG)DCM
MNPZ+3?[724G!U%VBF?K9ZRYD4_1W1M8J]73)XU:F1QAT>T;V9]7RO\;43(;/
M!ZY]^!M>4-%/G^UD[*;-X1A]_0.RFS>$8??T$!Q=4G?L_JH.+JD[]G]5!L\'
MKGWX&UY0T4^?[3_939O",/OZ!V4V;PC#[^@@.+JD[]G]5!Q=4G?L_JH-G@]<
M^_ VO*&BGS_:?[*;-X1A]_0.RFS>$8??T$!Q=4G?L_JH.+JD[]G]5!L\'KGW
MX&UY0T4^?[3_ &4V;PC#[^@=E-F\(P^_H(#BZI._9_50<75)W[/ZJ#9X/7/O
MP-KRAHI\_P!I_LILWA&'W] [*;-X1A]_00'%U2=^S^J@XNJ3OV?U4&SP>N??
M@;7E#13Y_M/]E-F\(P^_H'939O",/OZ" XNJ3OV?U4'%U2=^S^J@V>#US[\#
M:\H:*?/]I_LILWA&'W] [*;-X1A]_00'%U2=^S^J@XNJ3OV?U4&SP>N??@;7
ME#13Y_M/]E-F\(P^_H'939O",/OZ" XNJ3OV?U4'%U2=^S^J@V>#US[\#:\H
M:*?/]I_LILWA&'W] [*;-X1A]_00'%U2=^S^J@XNJ3OV?U4&SP>N??@;7E#1
M3Y_M/]E-F\(P^_H'939O",/OZ" XNJ3OV?U4'%U2=^S^J@V>#US[\#:\H:*?
M/]I_LILWA&'W]!QDQ/9G1O:ERA15141=NP@N+JD[]G]5#XNCJC1%_P!MG3_T
MH-G@]<^_ VO*&BGS_:0M%]ME)%(VHO$4SG.S15SV)S$AV4V;PC#[^@K<&CVC
M>BKUPD?MRS:B';Q=4G?L_JH-G@]<^_ VO*&BGS_:?[*;-X1A]_0.RFS>$8??
MT$!Q=4G?L_JH.+JD[]G]5!L\'KGWX&UY0T4^?[3_ &4V;PC#[^@=E-F\(P^_
MH(#BZI._9_50<75)W[/ZJ#9X/7/OP-KRAHI\_P!I_LILWA&'W] [*;-X1A]_
M00'%U2=^S^J@XNJ3OV?U4&SP>N??@;7E#13Y_M/]E-F\(P^_H'939O",/OZ"
M XNJ3OV?U4'%U2=^S^J@V>#US[\#:\H:*?/]I_LILWA&'W] [*;-X1A]_00'
M%U2=^S^J@XNJ3OV?U4&SP>N??@;7E#13Y_M/]E-F\(P^_H'939O",/OZ" XN
MJ3OV?U4'%U2=^S^J@V>#US[\#:\H:*?/]I_LILWA&'W] [*;-X1A]_00'%U2
M=^S^J@XNJ3OV?U4&SP>N??@;7E#13Y_M/]E-F\(P^_H'939O",/OZ" XNJ3O
MV?U4'%U2=^S^J@V>#US[\#:\H:*?/]I_LILWA&'W] [*;-X1A]_00'%U2=^S
M^J@XNJ3OV?U4&SP>N??@;7E#13Y_M/\ 939O",/OZ!V4V;PC#[^@@.+JD[]G
M]5!Q=4G?L_JH-G@]<^_ VO*&BGS_ &G^RFS>$8??T$;:[Y;:6>H?/>8I6R+V
MJ+GVNT\/%U2=^S^A#J@T>T;W/3KB]V7(U$S3RC9X/7/OP-KRAHI\_P!K+V4V
M;PC#[^@=E-F\(P^_H(#BZI._9_50<75)W[/ZJ#9X/7/OP-KRAHI\_P!I_LIL
MWA&'W] [*;-X1A]_00'%U2=^S^J@XNJ3OV?U4&SP>N??@;7E#13Y_M/]E-F\
M(P^_H'939O",/OZ" XNJ3OV?U4'%U2=^S^J@V>#US[\#:\H:*?/]I_LILWA&
M'W] [*;-X1A]_00'%U2=^S^J@XNJ3OV?U4&SP>N??@;7E#13Y_M/]E-F\(P^
M_H'939O",/OZ" XNJ3OV?U4'%U2=^S^J@V>#US[\#:\H:*?/]I_LILWA&'W]
M [*;-X1A]_00'%U2=^S^J@XNJ3OV?U4&SP>N??@;7E#13Y_M/]E-F\(P^_H'
M939O",/OZ" XNJ3OV?U4'%U2=^S^J@V>#US[\#:\H:*?/]I_LILWA&'W] [*
M;-X1A]_00'%U2=^S^J@XNJ3OV?U4&SP>N??@;7E#13Y_M/\ 939O",/OZ!V4
MV;PC#[^@@.+JD[]G]5!Q=4G?L_JH-G@]<^_ VO*&BGS_ &G^RFS>$8??T#LI
MLWA&'W]! <75)W[/ZJ#BZI._9_50;/!ZY]^!M>4-%/G^T_V4V;PC#[^@^.Q1
M9E:J=<8=WC('BZI._9_50^+HZH\OTV?U4&SP>N??@;7E#13Y_M[K/?+=2<+U
M3>(IM9<TSSV$EV4V;PC#[^@K4&CVD?K?]HO?E]5$V'=Q=4G?L_JH-G@]<^_
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M_P!E-F\(P^_H'939O",/OZ" XNJ3OV?U4'%U2=^S^J@V>#US[\#:\H:*?/\
M:?[*;-X1A]_0.RFS>$8??T$!Q=4G?L_JH.+JD[]G]5!L\'KGWX&UY0T4^?[3
M_939O",/OZ#JJ<16*H@DAEKX58]JM<FW<OF(7BZI._9_50XNT>434575TR(F
M]51!%O"1_P"\^_!B;N/F,IMT^?[56[45';YNJ+'=62(FU&HJM>WS\I(V#%TS
M;C$ZZS/6)$R5S<_>A%7ZBM%"YT5%5354Z;U3+43S\ISP_AFLNTB9JE/#OUW[
MU3Q)RG3KHLUVL[T\.V>$N+:N8BW?RP\<>R.,-=HZV"LA26EF9+$O[S5S/0U<
MR)P]8Z6S4RQTVLYR_.>Y=Y+HF6X\]7%,53S)X/66IKFB)N1E( #5(
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MOZ9.D,-KA;\AD5#C M/<ZOU&_P!PXP+3W.K]1O\ <-SOZ9.D,-KA;\AD5#C
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M" C2@
M   \=V?3LHI'5C=:!$[9,LSE:WP/H8G4C=6%4[5/$?+K/'3T4DLT7"L;O;SG
MVV31ST44D,?!,<F:-RRR ]0                                  &=_
M*%_8_B/[)G^HTT0SOY0O['\1_9,_U&@?GG0=]&ZO^87X(:,9QH/^C=7_ #"_
M!#1SU&#^13W/$\H?4U]X "RJ
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M'2)',U6Y.1[EWN1.53-S.'Q%-^GG4F)PM>%KYE<QGEGP $!,K9@ #(
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M\RGOAKMCEH)'S]01JQR+V^:;U)8B;)6T]5)4,IZ;@58O;+DB:Q+'D7O0
M                      "(6:WI>^#6->K<OG9$NI$+74R7M:;J7\OE^=R0
M"70!
M    'FN,[J:D?*R-97(GS4Y3[;YG5%)'*^-8G.3-6KR'&Y2S0TCWTT7"RIN;
MEGF<K=)++21OJ(^#E5.V;S >@                                  #
M._E"_L?Q']DS_4::(9W\H7]C^(_LF?ZC0/SQH/\ HW5_S"_!#1S.-!_T;J_Y
MA?@AHYZC!_(I[GBN4/J:^\ !94P
M    .^@IUJZVGIV[%ED:STJ=![;+4)27:CG<O:QS-<ODS0Q5GS9R9IRYT9]3
M5[[61X;P\KJ9B9L1(XFY9IK+S^]3)JRY5E9,LM34R22*N>:KN\G,:GCJADN.
M'9$ID5[XW-E:C=NLB<WF4R')4S1=BH<WDRFF:)J_]LW8Y9JKIN11_P"N7#L3
M=/BJZP4$E*VI5S';$<[:YJ>)3UZ.]N)H5SSS8[:6G1W24\V'%?-3Q/?PKDUG
M,15Y.<KV#$1,:R(B9(CI,D3DVF:KE%5-VBFG++\M+=FY378N5U9Q,\/Z2>DY
MS&UUM=*Q)(T1=9JKEFF9VW["]LDPZ^LM%/J/1B2M5'*N;=ZIM/-I63\O0_PN
M^)(:.+BE9:IZ"=4<Z'8U%7>Q>0KQ-=&&HNT3U=?FM3%NYC+MFY$?RZI[)R9Y
M:J.2X7"&EB3-\CLO,7#&]HM%FM<;:>F1*R78UVNJY9;UWDIA/#;K=?:ZHF;^
M3C56PJJ;\]N:? I^-[IURO<RM7.*'\DSQY+M4M1=F_?B*)_C$9RJ38C"X6J;
ME/\ .J<HS^V2X6O"-KK;!32+"K*F6)%61'+FB\^6X^PVO"4,J43WT[ZCYJZ\
MBJY5\NY%).A65N#(EI\^%ZF[7+?N,>57:RJN>MGMSWYE?#T7,1->=<Q$2M8J
MY:PE-$TVHF9CL7;&&$(J"E=76Q7<"W\Y&JYZJ<Z$CHH_0J[[1/@3EOUG8.CZ
MMSUNI>VU_)L_ @]%/Z'7\W")\".J[77AJZ:YSYL]?BEHL46\9;KMQE%43.7@
M]EVM&'J:XS5=YF8LM0[61LK\D3R(ATW7!UKKJ!T]G1L<RMUHW,?FQY3L;R/D
MQ-7:[E5&NU6YKN3(N^C)RNP^Y'*JHV5R)GR&URBY9LTWHKG/AP^S6S79Q-^O
M#U6XRX\?NRV1CHY',>F3FKDIHVC*VM@H)[E,B(LJZK%7D8F]?3\"FUU(^LQ/
M/2PIVTE2K4RY.VWFLSVQ'6-UNI).IFNCX-'HW/53E_$GQ]^-G31GESNON5N2
ML-.UJN99\WJ_N4=AF_,O53<Z=^JJ1R+P:9;X]W_7E,UQ+;'6F\5%+EVF>M&O
M.U=Q?\/X.?9KDRKBN:O1$5'LX++63FW^0Z=)EL2HMD=PC;^4@5&N5.5BK^"_
M$@P]ZW;Q'-MS_&KU]^JQBL/>O83G7HRKISGP\/?!Y-$NZZ>6/_F('''TRJ?X
MH_Z4)[1+NNGEC_YB!QQ],JK^*/\ I0GM_6U]W^*UW_XVW_\ U_J]Z0OHK5>5
MG]2% PEAN6^3O?(Y8J2->W>F]R\R%^TA?16J\K/ZD.&CK4[%X=3+6UWZV7/G
MT9%6Q>JLX29IZYE>Q&'IQ&.BFOJBG/\ ,O+/:,*6V1*:LX!LSDW2R*KO\'@Q
M!@JF=1+56)5S1NOP>OK->F6?:KSE&N?#+<:KJI7<-PCM;6WYYJ:CH\65<,Q<
M.KE:CW:F?U>C>37J;F%HB[%<SVY]2OAJ[.-N56*K<1'VF.N&2^4'JNB,2Z5B
M1;(^%<C?)FIY3K1.<9N#,93,  ,@
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M4C%J:WKNL/4W^RY?G<E DT 0
M                       !Y;EU0E(_J)&K/^[K99>\Y6]9UI(^K,DGR[;+
MG.-RCGDI'MI9.#F7YKN8Y6YDT=)&VJ?KS(G;.YP/0
M               !G?RA?V/XC^R9_J--$,[^4+^Q_$?V3/\ 4:!^>-!_T;J_
MYA?@AHYG&@_Z-U?\POP0T<]1@_D4]SQ7*'U-?>  LJ8
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ML1G4.6_9GTDFI&<!7==^%2=.H\OS>8$F@"
M                                  /+<H9:BD?'!+P4B[G[=GH.5OBD
M@I(XYI5ED:F2O5<\SA=(&U-%)$^7@FN_?YCE;(6T]%'$R7A6M3)'\X'I
M                               SOY0O['\1_9,_U&FB&=_*%_8_B/[)
MG^HT#\\:#_HW5_S"_!#1S.-!_P!&ZO\ F%^"&CGJ,'\BGN>*Y0^IK[P %E3
M                                              !C(  9
M                                                        "U:.
M$5U]>UJY*L+D1>;854M6CAJ.OLC57)%A<F?-L*^+^37W+6!^IH[X3&.J6>EP
M^QM34+.YU1FBJJ[$RW;3/30,;TD='AYC(JCAT=4ZRKS;-QGY!R;\CQE:Y8^I
MGN@ !?<L                  8R!D #(  9
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M%UZZJZJ7A,D_(Y@2R;@$
M                    >2Z1034<C*IZ,B7>Y5RR/MLCABHHV4S]>)$[5V>>
M9QNJ4ZT4G5JJD'[V6?X'*V) E%$E(N<&7:^0#U
M             9W\H7]C^(_LF?ZC31#._E"_L?Q']DS_ %&@?GC0?]&ZO^87
MX(:.9QH/^C=7_,+\$-'/48/Y%/<\5RA]37W@ +*F
M
M                                   6K1PB+?9$<N35A=FOBR*J6K1Q
MJ]?)-?YO NS\F17Q?R:^Y:P/U-'?"6QO!2T^'FMHIN%8M3FY4<BY+EXC/R_X
MU2B3#S>MRJL?5/;9Y_.R\90"#DWY'C*URQ]3/=  "^Y8
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MNZ]YJY>KLMVW+H ET 0
M                  !X[M)!%12.JF:\*;VY;SE:WPR443J9FI"J=JWF0^72
M>.FHI)9H^$8W>W+/,Y6R9E1112Q,X-CDS1N660'I
M               SOY0O['\1_9,_U&FB&=_*%_8_B/[)G^HT#\\:#_HW5_S"
M_!#1S.-!_P!&ZO\ F%^"&CGJ,'\BGN>*Y0^IK[P %E3
M
M                                      +5HX5$OLBN3-J0NS3Q9%5+
M5HX<C;[(YR9HD+E5/,5\7\FON6L#]31WPE<:S4DV'6K0Q+&Q*G)R999KEO*
M:!C>LAK,/,=!#P2-J=54R1,]F\S\@Y-^1XRM<L?4SW0  ON6
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M;- +V#XG+F?0"D0M10]?."X%>K,OGY$LI%+70)>NI>I_RV7YS)/B!+( @
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ML*0IU)E\_("30!
M              'FN/5'4K^I,N&_=SW'VW\/U)'U5EPV7;9<YQN3)Y*1[:1Z
M,F7<Y3E;F3,I(VU+D?,B9.<G*H'H
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M9O=EZ"IX0^DUM^U+5I7C7*WR<G;M^!5<(?2:W?:E/"_1^$_]7\;_ /(>,?\
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MF6X    !&KU?UU_<ZBR\Y(J1O 5W7?A>&;U'E\SE DT 0
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ME/?#7J&BEAN,\SZKA&/W1Y_-)1"*H*&*&Y3SLJ%>]^]F>XE4/(O>@
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M)>:2\4_"T<FU/G,78K5\9*-W'(JIFF>;5'%WZ*Z:Z8JIG.  &&P
M                         /)=8X):*1E5(L<2[W9Y9'VV1PQ443*9^O$B
M=J[G.-VZGZBDZMSX#][(Y6O@.H8NI,^ R[7/F ]0
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M2,FR_J-!A>V2-'L<CFKM14Y3SM_#UV*N;7#UN&Q5O$T\ZB?!S !"L@
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MI_,I-F2HN2GZ4^37I:E95PX5Q'42S)._5HJB1V>HN7S%7F7D _48"
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M,VGHI)9(N%8W>SG Y6V2&6BB?3-U(53M6Y99'J/);)FU%#%+''P37)L9S'K
M                          #HK'1QTLKIFZT:)FY-^:'FLLU-/2:U''P<
M6LO:Y9;3TULC8J65[V:[6IFK><\UEJ8ZJCX2*#@&ZRIJY 2
M              '&56MB>KTS:B*JIXCD<951L3W*F:(BKES@1]DGI)XI5HHN
M#8C\G)EEFI)$;9*N.KBE=%3K C7Y*F66?C)(
M   "[B+M%11S5-2VDBU)&KVZZN6>TE%W$7:*R*IJ:ED5-P+F+DYV7SMH$H
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M[H_H _6X/R1Q]Z0_ :?='] X^](?@-/NC^@#];@_)''WI#\!I]T?T#C[TA^
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MY\L_.?S[/V;\D61[]%DK7YY,N,K6^358OQ50-L 3<
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M<D\8'AL]5-512.J*98%:[)$R5,TYR0(^SSU<\<BUL21N1V34RWH2
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M=S'?5LD?32-A=JR*F37<RG1:8:F"EU*V9)I<U76SY /:
M          !QEUN#?J?/R7+RG(XRHY8WHQ<G*BHB\R@>*T=7<%)UQU=?6[7+
M+=YCWG@M$%7!'(E=.DSU=FU455R3F/>                           !=
MQ&VOKAP]1U?J\'G^3RRW$DNXCK735L%14.K*A)8WK^31%5=4"1
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M075K8*I4@K$Y%^:_R=!;&[CS]VU5:JYM<<7J[%^B_3S[<YP  C2@
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MAY=N7^^XV,"*PS8+;AJSP6RS4S*>CA3)K4WJO*JKRJO.2H
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M*IA6GJ9H'+FZ-ZL7S+D2X7$57>=37&54(<;A*;'-KMSG35U.H %M1
M    1=5<V[%3E0OF%,:NB1*6\2*K$R1DV6[Q.Z2A@BO6*+U/-KA/A\3<PU7.
MMR_0$,C)8T?&]KV.3-'-7-%.Q#&\,8HJK+(C'*Z:C7?$J[O&U35;5<Z:Z4K9
MZ.5'M7>F>UJ\RGGL3A*\//'C':]7@L?;Q491PJ['O ;N!47P
M                !X[PN5IK51<E2!ZY\W:J?FS0/HUM6.,#==[W<+PE7U5)
M#^0J]5NJU&Y;,EYU/TG>?U17?8/_ *5/S)H#TD2X7P(MO9A2_P!U3JN23JBA
MIUDCVHW9GS[/>!H]3H'LT<:OM-]Q#15C4SCF2L1R-7D54U?Q0X:&\2XBI\9W
M[ >+ZI+A6VJ)L\%:B;9(UU?G+R['M7;MWH>>Y:<:V"CDDIM'N*%D:BJG#TSH
MV)Y51%V'G^3ZM-?K_B#&5PNE)/B.Y(C)K?%FCJ*-%3)JH[;^ZW;NV;\\P-Q5
MR-155<DYU(U,0V?JCJ?KO;^'SRX/JEFMGY,\R"TA8)9C6.AIZN\7"BM\+U=4
M4U*_5;5)R-<OB5/'R^5(.IT,:/I;:M(VSPQ.U=5)V3OX5%Y\U=O]P&FM7--^
M9U5%1#31.DJ)8XHV[WR.1J)YU,<^3_7UUNNN*<&5]=+71V:H1:2:5VLY(G;=
M55]'I4@+[!18ST]W&QXWKWQ6>WP,?04#YECCJ'JC55>3-=J[MNP#=Z*]VJND
MX.BN=#42?5AJ&/7T(I[\S,KKH4P-<*34H[9UNF1.TJ:*9S7M\>U51?.AZ-*^
M)9< :/HFVSA)J^34H*-TKU<[75,D>Y5WJF6?C O%?=K?;U1+A7TM*J[DFF:S
M/TJAZ*:HAJHDEIIHYHG;GQN1R+YT,FPCH<P]'0-JL9N7$%\G37GJ*N9RHU5_
M=1,]R>,@<78=31+<J3%&#*J>.R+.R.Y6M95=$K'.1J.;GNRS MWRDOV0WK_\
M?]2%JP'&R;1]9(I41T<EOB:]%Y45B(I4?E%2LGT,W6:)<V2-B>U>=%<BH6_
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MT>K0O5\.LNU5SVF73:4ZR6)T<MJI7,<F2IPCCA1Z3:FDBX.FM%+''GGEPKE
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MY.$K:F2=R;M9=B>1.0\Q+A<--G.JJ<ZIZT.,Q<8CFTT1E33U  +2D
M      ![;3<ZJU523T4FH[E:OS7>)4/$#$TQ5&4]3--4TSSJ9RELF&<34M[C
MU6KP54U,W1.^*<Z%@;N/S]%(^&1)(GJQ[=K7-7)44T7"6-&SZE)=G(R78UL^
M?:N\O,IP\5R=-&==KC'8])@.5HN?^._PGM^TKX#XQ4<U%145%W*A].6[@
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MQ%ZD3;JIS(8& !]^!\  ^[#YR<@
M             +QHC5J8CG5Z9M2!RJGBR4HY>-$+D;B29SMJ) Y5]X$[I*GI
M*C"C'4,/!,2K1')EEFN2[3*C6=*-93UF%HW4K-1K:I&JFKEMR4R8
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M7\%[N_UBG06_1A^OY/LE*AT%OT8?K^3[)2]B_DU=SFX#ZBCO2NE?\U;O*_\
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M1HS^B--_$_\ J4M)5M&?T1IOXG_U*6D
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M45CFQN=D_9JL555$7S 8 #LG5KJB9S/F*]RM\F:Y'6
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M\1+HB'T'!KKJKGG53G+U%NW3;IYM$90  U;@
M                             9/\J']D-Q^VB_J-8,G^5#^R&X_;1?U
M81HS^B--_$_^I2TE6T9_1&F_B?\ U*6D
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MMP38#E.X
M       9/\J']D-Q^VB_J-8,G^5#^R&X_;1?U 81HS^B--_$_P#J4M)5M&?T
M1IOXG_U*6D
M
M        %XT0HY<23HQ<G+ [)?'M*.7C1$U78CG:BY*L#D1?2!8-)\-7#A:-
M*Z5)'K5(K51=R9*9.:OI.I):3"L;9Y^&5U4BHN>>29+L,H
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M%CAQJ[3) FP J+X
M                &3_*A_9#<?MHOZC6#)_E0_LAN/VT7]0&$:,_HC3?Q/\
MZE+25;1G]$:;^)_]2EI
M
M                 !>-$2([$<[57)%@<F?-O*.7C1$B+B.='+DU8'9KXLE
MGM)E(RDPJQL=0LZ.JT579[MB[#*35=)<-+!A5C:*19&+5HKE5=RY*94
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M4\RW&4";  1I@
M                 R?Y4/[(;C]M%_4:P9/\J']D-Q^VB_J PC1G]$:;^)_]
M2EI*MHS^B--_$_\ J4M(
M
M                  +QHBU>R.?7^;P#L_)DI1R\:(U:F(YU>F;4@=FGBR4"
M=TEI1)A1G6Y<X^JTUL^?)3*C5=)4U)-A1BT,2QL2K1'(J99KDIE0
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M$>7^NFBI8*2G;#31MCC;L1&ID=X!QYF9XR]%$1$90  PR
M                                                    9/\ *A_9
M#<?MHOZC6#)_E0_LAN/VT7]0&$:,_HC3?Q/_ *E+25;1G]$:;^)_]2EI
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MSXU$5#[N&X%!U
M                          R?Y4/[(;C]M%_4:P9/\J']D-Q^VB_J PC1
MG]$:;^)_]2EI*MHS^B--_$_^I2T@
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M(W(J(S55%UDY<T384C#D5-!I=K(Z%&I U'IDW<BZNU$\^8''3?\ I-L_@?\
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MY<DY2TPQLCC1D;4:UJ9(B)L1#GD@)*[M=R(BJ>I#:L6[4S-$<9XR  C3
M
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M5+P62?D@)1 $
M                                                  RCY4'[(;E]
MM%_4:N91\J#]D-R^VB_J J'R<\'6J^:-:6KKVS++PTK<V2*B9(]34.+3#_U*
MCVRE3^2G^RBE^WE_K<;$!2>+3#_U*CVRCBTP_P#4J/;*78 4GBTP_P#4J/;*
M.+3#_P!2H]LI=@!2>+3#_P!2H]LHXM,/_4J/;*78 4GBTP_]2H]LHXM,/_4J
M/;*78 4GBTP_]2H]LHXM,/\ U*CVREV %)XM,/\ U*CVRCBTP_\ 4J/;*78
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M 4GBTP_]2H]LHXM,/_4J/;*78 4GBTP_]2H]LHXM,/\ U*CVREV %)XM,/\
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M]!. "#[$K#X)H_9-Z!V)6'P31^R;T$X (/L2L/@FC]DWH'8E8?!-'[)O03@
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M*JN8[QM=R*7C#=\LM_KVU<$SHJY4VP2+DOFYP+B@"
M
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M &0=;](G=:K[PSI'6_2)W6J^\,Z37P!D'6_2)W6J^\,Z1UOTB=UJOO#.DU\
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M3-[4\;N4LB
M
M
M
M
M
,            ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g73463g01f08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g01f08.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1NB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &X4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M "81 0 " @(" @(" P$        ! @,1!"$2,1-!(C(4T4)A<?'_V@ , P$
M A$#$0 _ +4@
M
M
M                                   :SJ#EU%AV/5%QK9&(]B?FXU7F
M]? #9@1!HOJS/G]SKJ::D9 V!$5JM[T4E\ "$LVU^MN,Y#46M;?)4+#MN]KN
M6Y@OI.VWNM$OO@6*!J>F>9PYQCK;M3T[H&*Y6\#EW[#3M3-;[/B%<^WT\?EM
M<U/.1B\FKZP)=!7?&.DE1U5='3WJWK3MD<C4D:J[)[2?[974]RH8:NCE;+!*
MU'-<U=T4#T@
M
M
M
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M%3=%W0
M
M
M
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M4141JJF_CLH$F0RLFB9)&Y',<FZ*G><S5],II9\-H'SN<Y^RINOAN;0
M
M
M
M
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MM]##2P)LR-NR'I.NFGCJ:>.:%R.C>B.14.P
M                                 JHB*JJB(G>IYXZVEDD6..HB<]/U
M4<FX'H .N>>*!O%/(R-OBY=@.P'7!/%.SBAD9(WQ:NYV
M
M
M                                              &H:KI='X76LL/6
M>7O\UG!V\T4K%<]';Q1X5=<ERRJ?Y7$S=D+U5SM]^U54N81]KW^BJ^_PT^($
M'=#W[07;_H;_ -RS>66*#)+'4VRK<YL,[>%RM*R=#S[077_H;_W+9 1IIII)
M:<&N5164CNNDD;PM5Z*JM_$BWI=7FV2-H+9"V)]P;NYSV[*K$W[%-ZUPU>IL
M.I9+;:G)+>'M3;ENV-%\2$-*].+QJ3D"WN^.?Y!UJ22R/799._9 ).T<6JL&
MA%PK)D?&LC9%8B\N2[\R*>CE0Q7?5-CZMB2(U'R>=SYEH-1K5%1Z95MOH6<,
M,,'"UJ=R(BE:>BRY&:F\+EV58G@2GTMK=#)BM)5=6U)8W*B.1.?<=71%N3Y\
M=KJ-[E5L+DX4\.9D>EC(C<'A:O:KUV_L8#H>0/2W7254\U51-_Y@33F&=6+$
M.J^7:OJ.L^KRWW-9^?'!O2O_ -J?[G+5W2V'4)U*Z6M?3+!X=_;ZO61M]%^E
M],R_@G^P$C_/C@WI7_[?_DJ_K-D-NR341:^T3==3.X41VVQ+*=%^E],R_@G^
MQ"6H6(LPO,TM3)UG1BHO$H%YL(^R-H^[,^!FS"81]D;1]V9\#-@
M !C\@=(VRUJP;]9U3N';V$8Z>(Q+'(K=N-97<?M)=<U'-5KDW14V4B*[VZMP
MJ[SU-/3OJ;).[B<V/F]CE[0-G,3EK8W8_5I+MMPKMOX['FCS"R.AXW5B,=MO
MU;D7B]AX&^79Q61TEO@DI[4QR.FFD3;C1/V0-\TQ=*_#*!9U57[+V^&YM)T4
M-+%14D5/ WACC;PHAW@
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MQ0UU*L#G.3S7\E5-_86NQNLDN%BH:N9/SDT+7N]JH!D@
M:/EN6U,%R2T6&)L];VR/5?-C3_<P/D&2++URY'.CM]^JV\WV 2L#1<4RVJ?=
M%M%^B2*IV_,RHOFR)_N;T
M
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M&;%,(IXZQBLJYT1\C53FAL-DT^Q>R5"3VZSTL4J+NCN'=47^9M2(B(B(FR(
M   I1TB_TK/_ -)=<I1TB_TK/_T@6\PC[(VC[LSX&;,)A'V1M'W9GP,V
M        ^/:U[5:]J.:O:BINA] &)=C=F?(LCK71J]5WW6%N_P #)P0QP1I'
M#&V-B=C6ILB',
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MUB=6SZJ;=Y9W"/LG:ON[/@A6;I9?;NU_PV?$LSA'V3M7W=GP0#-@
M    !\?OP.V[=N1] $28NC77[(I'KO4+4>=OW&R)WG@RO'JZV7B6]6*/K6R_
M^8@\?68U,E?U6ZVRKZ[]CJU Z<U7@J;%)'RF\L:B*GANA+K=^%-^TC?&+!7W
MB[Q7:^1=33Q>=!3KX^*DD@
M
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MSX&;
M                              *E]++[=VO^&SXJ69PG[*6K[NSX(5FZ
M67V[M?\ #9\2S.$?9.U?=V?! ,V                =?41<7%U3.+QX4.P
M$Y=@
M
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M9&T?=F? S8
M                                   !4OI9?;NU_P -GQ+,X1]D[5]W
M9\$*S=++[=VO^&SXJ69PC[*6K[NSX(!FP
M
M
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M5-_Q)=^0[5Z,HOZ#?]CT4E!24:N6DI8(%=V]6Q&[_@!Z0
M
M         %2^EE]N[7_#9\5+,X1]E+5]W9\$*S=++[=VO^&SXJ69PC[*6K[N
MSX(!FP
M
M                                                7L4J_JCH?DF2
M9C77.AEIDIYG;M1[N:%H !3+Z.&7?YM'[P^CAEW^;1^\6:U(U"M6"V_KK@]'
M3N_PX4[7?_FQ#$W2BV>J16%CF]RK(J :9]''+O\ .H_>)+T*TDOV%9*^NNLD
M#H58J;,7<P?THW^@(_ZJF]:2ZSNSV^.M[K6REV;Q<2/50)D            )
MS[     (N_8
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MX1]D[5]W9\$ S8
M
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M._:JOZ2GWZ1.&_M57])0)E!#7TB<-_:JOZ2FX:?:DV3.9*B.S.E5T*;NXV[
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MN[/@A6;I9?;NU_PV?%2S.$_92U?=V?! ,V
M
M
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M9 -STRAE@PVA9.BH_95V7PW-H.$$3((611-1K&)LB(<P
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MV?! ,V
M
M                                                /CUX6.5.Y-R
M:[I"P6;)J^W7>@?U-/*L:/C;S79?:3^:ID&G^.7U)%KK; KW\W/:Q$<O\P-+
MH=5L RB1KJWA;)V;U##<;;28?<V\5 R@F1?V2.+[T<,=J6.6V5%132+XJBHA
MHMVT%RRR-5^/7::?;FC6.5O_ ' LHF*V-4W2VTZIZD/5;[);K?(LE%1Q0O7O
M:A5&&LU<PB-734]1+$G[:J__ +DB:0:O7W(\BALU]MCHGR;_ )W@5NWX@3V
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MA'V3M7W=GP0#-@
M
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MS]_^4"WF$?9&T?=F? S9A,(^R-H^[,^!FP
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M^)9G"/LI:ON[/@@&;
M
M  /'5W.BI%5M150L<GZJO1%_ #V \U+<*2KY4U3%(O@UZ*IZ0
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M4JG*B+NBH7]_)NR^BJ+^BTIQT@:6GI-4714D$<$:(W9K$V0"X6$?9&T?=F?
MS9A,(^R-H^[,^!FP
M                  :[J!;*^\8G7T5HE2*NE9M$]5VV4V( 55G36'$$3BF=
M60L[&LV<9"@Z0%_M<C(\FL3V,3ZSVL7<LTJ(O::GDU;B,+E9?'6]7=Z2(U5
MTFR=(/$KB]D<JU%/(O)>-FR(2)9\OL5XX$M]R@F>[L:CN9$F18]I->W*Z2L@
MIW^,*HTPN(:>XI1YA1U6,Y(KW1NWZA7)YR 63 3L0    ,7=<AM-JF;%<:^"
MGD=V->[95.K+<@I,;L=3<:Z1K&1,54W[UV["B.?Y779;E<ERJ7/;"Z1$B;NN
MR-W _02&5DT39(G(YCDW1R=Z'ANM[MMIV^4:V&GW[.-VQB+17);=/::M54_,
MT:/Y^I"J%AH;GK)J)6QU=;+'3-<Y^R.79K=U[ +CVJ]VVZHJVZLAJ-NW@7<R
M!2B[0771S4B&"BK)):7B;]9R\+FKMOR+F6FM9<;;35<2[ME8C@/6  *E]++[
M=VO^&SXJ69PG[*6K[NSX(5FZ67V[M?\ #9\2S.$_92U?=V?! ,V
M       #7\HRJCL+6QR;RU<GU(6]JFL?EM?E=Q_(3^K\-^8$C@UW%\KH[[QP
MI^9K8_\ $@=VH;$
M                                      &JZB9$['[,UU.F]94NZJ!%
M[.(C&&Q,J7^5WA\E57/YN>KE1$]1MNM5-(ZGLU6UJK%357%(J?JIXF+CD;*Q
M)(U1S')NBIX&_B4K,3;[8N3:T3$1Z8:2TK;)%KK!(^FJX_.V5VZ/3P)8P:_-
MR&P0UFRI)S9(B_M)R4CVJF9!3RR2JC6-:NZJ;'HO2RPXN^65BL2:9[FHOAOR
M4<RE8B+1[=XMK3N);^ # V
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M1V[-7S=STV;,+I9KC'190C'T\J\,=4SL_F!)P/C'(]B.8N[53=%3O/H
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MWAZU-EVW+T83]D[5]W9\"LW2Q^W=L_AL^)9G"/LG:ON[/@@&;
M  #XY>%JKX)N?0O--@(DM#?E/*;U7UFTKXI>KB1W/@0V5%7;D:[=H)<2R6MJ
M9F.?:JY_&LC4WX'&0;?+:M,LZ5*=5V[[?]@,5DG_ (7>;/<J-.KGEJ&PR</+
MB:JDN-7=J+XD2T,4F87^C\GC<EKHY$E65R;<;D);3L
M
M     #S7*A@N-%+2U<:20R)LJ*1E68!=K:YR6:L26!5W;&_]4E8$Z9+4G=91
MM2MO:+;;I_<*^6-]^JMH6JBK SFCB3:2FBI*:."G8C(HTX6M3N0[0<O>UYW:
M2M(K&H  12
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M*Q5$;9(U[6N3=#!KAMEZWC\E3V=WX&P@#II:6&DB2*FB9&Q.YJ;'<
M
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M['K &D/TRL#I5?P3HBKOPI)R-FLUDH+/#U=! R-.]VW-?YF1
M                                   .,L;)6*R5J/8O:BINBG( 0SDV
MEE1?=2F72OZAUBC9LV%/-5#8<"T\LV'7FMKK?6>;.J\,2R<FFZY!%-/9:V*E
M54G?$Y&*B]^Q16K3,9<DGM5%5UM56(]45D+U7;GV 7T\JI_\^+WT/J5,"KLD
MT:K_ -2%&[GC&IMLHW557!=&PM3B<Y'JNR&.QJGSK($D=99KA4NB^LUDB[I_
M<"_7;V JAHWJ3DEFS*''<J?*YDKME2=5XVJ6N:J.:CD[%3= /H
M  "I?2R^W=K_ (;/BI9G"?LI:ON[/@A6;I9?;NU_PV?%2S.$?92U?=V?! ,V
M
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M0B(B;(FR%6?D?+&HC4+,.'X^Y]@ ,R\
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M;
M      PN:S3T^*W26CXNO9 Y6</;OL5FZ,F26JCR&XMO\L;+C.Y5;-.J?%2V
M,L;)8W1R-1S')LJ+WH5IU*Z/53572:X8K.QK9%5[HI';*BJO<!/%WR;'Z>V5
M$E9<:)\"1JKF]8U>)-NS8J]I)?E76NOFL:N9:YW.<K&_51G+GL8V#0C-JN=(
M9E8UF^W$YZ[$YZ7:.Q89:ZJ5\C9KQ/"L:OW\UN_@!#&;72CR#7>CELNSFME:
MUSFIVJF^Y<.E14IH47M1B;_@0=I=HC)C^42WR^U$<U0DCGQ,C7DF_B3JG(
M            J7TLOMW:_P"&SXJ69PC[)VK[NSX(5FZ67V[M?\-GQ4LSA'V4
MM7W=GP S8
M                                             (HZ0^3W/%\5BJK/
M+U4SI.%51-^6Q6GYZ<T](+[H%W<@B=/9:V.-5XW1.VV[^1#&(+M:.H<W@ECD
M<CV+VIS4@GYZ<T5%1;@NR_\ *81-0+^E?/6-JG-EF^OLG)5-''S1BF=J<V*<
MD:A:O8U"]I7.RNCJ+/3NJ$IV*M2UG<A!":DY(NZ>5N]TY6;4G)+1)42T=4J2
MU"[R.5NZJ7Y.7&OP]J<?&F)_)92EN]'/$CW2I"O>V5>%4_D>6H=49!4):+1"
M^3K%VEFV\Q&=_,K?6Y]=Z^99JQL4DJ\U<K5YF0MVK&46V'JJ"=L$?@UA"W,F
M8U$)5XM8G<RLQ/I[<\=C;^3<B5--MYU-(NVR^I3ICL&67!Z0/HXK>Q?K3(_B
M5/Y%=_GJS1/_ *BJ?Z0FM>9KR2XJO^DIKR,E8U$K9PTF=S"=[EC+\%NL<B+)
M/0U2?GI]E_Q/7X&4CJ(9&<<<L;F^**5NK-7<KKJ=\%95I+"Y-G-<WDIK+LHO
M"<7554D<:_J,["[#RO"-6[59./Y3NO2T59UE\N%/:K6BS.<]'3/;S:C._F3?
M;Z9M'10T[%\V-J-0H/9=2<ALD*MML[8N+ZRHWFID_GJS3T@[W2C-EG+.UV+'
M&.-+V@HE\]6:>D5]TLCT=,INF48U-4WB9996N5$54V[RI8EP
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M/LC:/NS/@9L
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MX 9L
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M)QGTILT6TM CFRMYHC]E1QN]B=%):*1T'#U:L3;8]R&NN"E8UIFMFO,[V\6
MX;B&04DL55:FQ5].[@D9RY^OL-L^:/$/1C?[?[&!T_1S]0)WT_\ Y=L"MDV[
M.,EP\S+2*7FL/0QVFU8F6@_-'B'HQO\ ;_8?-'B'HQO]O]C?@5IM!^:/$/1C
M?[?[&S8WCEMQRE6GM,"0Q+W(9@
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MEN$=TMD%9"OF2-W_ )GM
M     :_GU1<J3%*^>R1K)7QLXHVIWJ@&1O\ '--9:V.E7:=T3D8OKV*97+23
M/*FYRU;J=72JY51_'S)0Q_I#/H)5HLQMCZ:HC\URM1=R2K-K!A]SA1Z76*!5
M_5D78"M":8:D(FWY[;^*;EI)@6<6K,Z2JO"R^2,^MO)N3T[4?$6MXOEVCV_Z
MC6K_ *XX?:47@K4JG>$7,"4@5WH-:KWEN1TU%C%I<M"YZ))+LNZ(6%@5RPQJ
M_P"NK4W]H',*FZ*GB#XYR-:KG+LB)NH&@5NG&,T5YGR::F5U5%O,Y57=.7,K
MMK?F]%J#=J2TV2F1CHI>'K7)MOW%FORXQJZ7.2Q)7Q2U$F\3XM_Y;$-](O ;
M#8,9CNMIC;1UB2\E;R5P&_VRURX9HI/2R2))*V!RJYJ[\W)_\$+]%&CBK<ZN
M554,1[F,5S>+N554W'2Z\7#)]$[U35RND=3L=P2+VJB=QJ?1'G;%FETIWJB/
M6/DB^U0/-TIJ**@SVEK8&(R23A<JIZBS&'W='8#0W*J551M.CW+["MO2OJ&5
M&;45*Q461J-W3VEC\#MB)I];J"J:O"ZG1KD7U@1_/TB,8AJ)8G1S[QN5JJC?
M X?2,Q?_ "ZCW3,3:$8A-/)*^G?Q2.5R\D[5.'S"8?\ N[_P0"O&M^<V_.,J
MH*RUM<D<;6L7B39>TN+A'V3M7W=GP0J'KYAULP[+K?2V=BLB>UKE1?'<MYA'
MV3M7W=GP0#-@
M                                                 #Q7JF6KM57
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MF7CFD\5-D *)F9G<KHC70 #@
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M)VK[NSX(!FP
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MP1+"]>[B)</+RUBEYK#T,=IM6)D !6F
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MEB'EU900353)EX9'-W5"P;6HUJ-:FR(FR(!]             5+Z67V[M?\
M#9\5+,X3]E+5]W9\$*S=++[=VO\ AL^*EF<(^R=J^[L^" 9L
M
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M28];FTE$B[=KWKVO7Q4RX!4L
M                  B#I/5E12Z>RMIG.:V1>%ZIX<B7S 9SC%+EF.U5KJ]D
M25JHUVWU5\0(,T@TCQ+)<#IZNK?U]=.S=[D5-XU-)OECR'1'+&7"VOEFM+E[
M57S51>Y4_D25I)I7D.%YH]\]?)+:&M7A:URHU>?+D2[F5-8;E;9+?D4E*D,R
M;(DSD1?Y;@5-U6S.WYOEF-7"WKYR*ULK/V7<2%P<:_\ 0*#^"WX%7+_H+=;=
MD5+78U(RNMRS)(B-_5;N6GL4+Z>ST<,J<,C(FM<G@NP'N       !QD>V-CG
MO<C6M3=57L1"",BZ0E%0Y2ZU6ZE;4Q-EZI9MUYKOL>GI&ZC_ "#:UL-GDWNE
M6B(Y6+S8U2J,%%54.1T;*]CF3NF:YR.[>:@?HI:JORZVTU5MP]=&C]O#<CG4
MS62QX54K1.5:JOVW6-G-&^TVRBK$H,"BJE7;JJ+B1?7P\BFN$4#L_P!5D;<W
M+*R65SW[\]T3N FO'>DI:ZNO9!=*)U/&]R-21NZHGK4GFUU]-=*&&LH96RT\
MK>)KV]BH5MZ2NGMFLV.TMQLU(RFDBW:[@3;=.1LG1/O\UPQ:HM\\BO\ )53A
MW7?9-P)X!PEFBB_Q9&,_ZG(AU^6TO[S!_40#O*4=(O\ 2L__ $ET/+:7]YA_
MJ(4MZ0\C)-57NC>U[?-YM7= +?81]D;1]V9\#-F$PC[(VC[LSX&;
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MW+<SL*W:G6*LII&QOW[]E+O6[_T^F_AM^ 'H             5+Z67V[M?\
M#9\2S.$_92U?=V?!"LW2R^W=K_AL^)9G"?LI:ON[/@@&;
M
MQ==D%KH)>KJZZ&)_@Y34]3<BJ*5T%HMK^&JJD7B<G:UO>:;36.ECB1*GBJ9.
MU7R^<NYHP\><D;]0HR9XQ])JHJVFK8NMI)F2Q^+5/002YM3CM0VZ6J>1C8O\
M2%R[L5O?R)GL5QBNUII:Z!?,GC1Z$,N&<4ZE/'DC)&X>\ %2P
M        Z:REAK*=\%3&V2)Z;.:[O0[@!H%5IE;^N<ZW5,]'&J[JQB[H9K&\
M,M5BE6HIX>LJU[9GKNILH)3>TQJ9<BL1V  BZ
M                                  '">:."%\LSVLC8F[G.79$0#F5A
MZ7+Y&W*T<#GM3E]55]9)V0ZX8?9YY*?RY)YV+LK6(JIN:9<=;,$O<\:W:@9.
MC%Y.D8J[?V ES3)57"+2J[[]2WM]ALYHN#:CXGD/5T5CK8FO:B(V'ZNWJ-Z
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M_6=NQ^C&Q2CI&*JZK/W\&@6\PC[(VC[LSX&;,)A'V1M'W9GP,V
M 'DNU+Y9;:FG_P R-6_V(HP:;R9M5::KS*J"151J_L]RDQ&H9?A<%ZG;74DK
MJ2Y1IYLC>QWM \Z(I@,UKV4MG?!OO/4+U;&)VKOR.?Y/9DQ>I2KIWHO+K>'L
M,SC.")35Z7.^5"UM<GU4V\QOL0#.8+;)+3C%'23?XC6\2^K==S/
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MU3::*KX)7=B2-5J?BIE\9UMHW#< ?&N1S4<U45J]BH?3CH
M    -*O>FF/76^0W>2C9'71O23K&I]94.O5+/:7 ;52U%73K/',](N%#>'O:
MQ-WN1J>*KL15KMALV>6:BI+;6TT<D,W&O&].P#[!I_C.:)09)!2)25#E23S&
M]O?_ -R4H8TBA9&WL8U&I_(P>"VI]EQFCH)I&220MV5S%W0SX    :?FVHM@
MP]NUUJ=IE152-O-5-1LVOV*7&L2![Y8-UV1STY 2\#IHJJ&MIHZBED;)"]-V
MN;WFAYOJWCF)5*TU9.Z6I:JHZ.--U0"0@1_@VK&.9=4)34,[HZE>R.3EN2
M  %2^EE]N[7_  V?%2S.$_92U?=V?!"LW2R^W=K_ (;/B69PG[*6K[NSX(!F
MP
M              !$>I4+Z/,[?6RI_P .]JMXO!3BBHO8NY)6162DOMO?2UC-
MVJGFN[VKXD>/P._43ECH*Z%].G)O&FZHAMX_(K2OC9DSX)M/E5ALDE;'9ZEK
ME3B>WA:GBJ]Q)NG=)+18?;8JA%;(D2*K5[C7+#I[)Y?'67^H2I?&N[(V\FDB
MM:C6HUJ;(B;(A7R,T9)B*^H68,4XX[?0 9EX
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M>K5O;L3O:[?36NABI**)L4$3>%K6ILAZ@    I1TB_TK/_TEURE'2+_2L_\
MT@6\PC[(VC[LSX&;,)A'V1M'W9GP,V             PF2Y/;\?B1:V15E=]
M6-O-5 S8(U74FL5ROCL50L/[6_-4-EQC,;=?7K Q70U;4\Z&3DH&R@
M         $&5+5HL_N\52G"^H>LD:KWIS)S(]U:M%!+;4NDD[:6NIT_-2?M>
MKUEN#)\=_*5>6GG73"'&1[8XW/>J(U$YJII5MRNYK#_Q%JEDVY->WDCO68++
MLFNM1"L#Z9]%3+]97)S=ZCUO*(C;SHI,SILV"P-?57&M:QO#)(J-7;M-M<U'
M(J.1'(O:BIN8C$YJ2>R4RT*IP<*<2=^YF-CL(S[:'EE))9+G#<+/#$G6KP21
MJFS5]9VTV)7!\[JUMUEHYIF^<R'DW93LS!S;Q<:6S4[U557BE<W]5/:?8JFO
MQFKA@KY/*;?(J,;)WL]I&:Q;J8Z3BTQ'7MXX[?58FO6R,2X4SG;R2/3=Z>LV
MA]%;KW0-EBC9PO3S9&)LJ+_(R$Z1S4CT>YJQ/8O:O+;8U[!42*GJZ.-R.BAD
M7AY[]I*(UU]([WW]MYTFOE4M15V"YRNFGID1\3W+S6/N^!)9#NF<3JS42Y5\
M'G4T4"1*[_FW7D3$>1FK%;S$/2Q3,TB9  5+              .JJF2GII9G
M=D;5<O\ ([3A41-G@DB?]5[5:O\ ,"J[[GF>K.372"R5:TMMHY5C7A=MLF^W
MCZCWMT*RU//_ "BJ./\ B_\ R<+M@V;Z=Y)6W#"4?5T=7(LCHHT7ESWYG#YP
M]6T=P?(4O%V?X8'11W?,M+,MMU#?JI:NWU3D1.)V^^_+Q+24DR5-+#,WLD8C
MD_FA6:P8-FN?Y51W7-4?2TM*Y')&].W8LU31-@IXX6?58U&I_(#L.,F_5NX/
MK;<CD *RWC1[(LEU)DN%^3BM3YN+D[?S=^S8\_2+T\QO&,5IJNU1)3576(U$
M3;=W(L#F^66[$+--7W.5K4:U58S?97KX(5-N%7D>M^9)'3QRQVQC]T1=U9&W
MQ7U@2UH7>ZRFT7KZNJ>[_AT?U3W+OW$3Z)X_3ZAZB7&:_HM1&W>547GNJJOB
M6'R/&8,9TAKK3;D\V*'=51-MU[U(6Z(CD3++LU?K=7_W4#7M9;#%I]J333V%
M74T#G,<U$7;;LW["WV-7-MPQRBN#W(ULD2.55["K_2W5%RJ@:W;BV3X$_8-1
MS56EE#2-=P2R4O"CE[E V%V361KE:ZZ4:*B[*BR)R/GY46/TK1_U4*VUO1ZR
MJ>MJ)FWZ)&R2.<GUNQ5.GZ.N6>GXOQ=_N!XNE'<*2X9O;'T-3%.Q(V(JQNW1
M%W+181]E+5]W9\$*0:CX1<<(R"CH[K6MJY'\+D<W?LW]9=_"/LG:ON[/@@&;
M
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M&@AJZ9W%%*WB:I')BMCG5G:9(O&X>H %:8
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MSC!K-EMNGAN5*QTSF*C)D1.)JE4-,TFP[6E;93R.6-)5@=S[4W0"[("<TW
MZZB5(8))7=C&JY3L/CFHYJM<FZ+R5 *+:V99<LKRZI1[)EHJ61611\/+;<V'
M!M9)L.LL5!;,<:BM3SY%1=W+ZRU[\6LCWN<^V4JN<NZJL:<SY^2=B]%4G]-
M--T]RBIU+PJXK6TB4KY&NB1J^SDI7/'J^YZ-:A5LE;0R24[G.9OMR<W=>:*7
M/M]OI+?&L=%3QP,7GPL;LAT7:QVV[(B7*B@J=NSK&(H%-[S5736/4B":AHWQ
MTO$W;=.36HJ;\RYUHHF6ZV4U)$FS(6(Q#IM-CMMH14MM%!3(O;U;$0R(   5
M+Z67V[M?\-GQ4LSA'V3M7W=GP0K-TLOMW:_X;/BI9G"/LI:ON[/@@&;
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MHC7/:G$WP4YEPVQ3V8\L9(Z9< %*T
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M+V  R-(
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M)'502=4_9=^/_F)%(*Z+EBJ;-;+M',]'QMG5F[>Q5Y$ZF.8U.I:(G?8 #CH
M       8+.4J5Q.YI0HY:GJ7<'#V[F="HBILO- *)30:B];)PQ7/;B7Q.*0Z
MC)SZNY_W+V=5'_EL]U!U,?\ EL]U **I==1K6BU#TN+&Q^<JN:JHFQ-6@&L%
M9D5<MDR-S5JD;O'-WNY]A/%=14<]'-'500NA<Q4>CFIMML4OQV.*AU\6*V;-
MIVU2M:C%Y;<@+M@-[$W              !4OI9?;NU_PV?$LSA'V4M7W=GP0
MK-TLOMW:_P"&SXJ69PG[*6K[NSX(!FP
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MU/;N'+;)O<-I !F7@
M                            !P66-%V5[45.Y5.3OJK["E^JMQS6+.KH
MRWSW-M*DJ]6D6_#L!<[KHO\ ,9[R'SKXO\QGO(4%^5=0/WF\?_<$NFH'9Y5>
M/_N N+JSDULL^'7'RJJB222)S&,XN:JJ*5EZ,5/)4ZF1U#&KP,1SE]1J2X[F
M^33,944UQJEWY+(BJB%H]!-,%PFW/J[ALMQG3FFWU4 ET           :KD.
M?XW8)5BN5TIXY4[6<:;GGL>I>+7JH2"BNM.Z5R[(U7IS W('QJHYJ*U45%[%
M0PN2959\<BX[O70T^_8CG)NH&;!I5GU0Q2[524])=H%E<NS45R<S=&N1[4<U
M45J\T5.\#Z  !2CI%_I6D_TEURE'2+_2L_\ T@6\PC[(VC[LSX&;,)A'V1M'
MW9GP,V         -)U:J)&8TM/$Y6K.]K%5/#=#=C6M0K/)><<GAIO\ S#-G
ML]:HN^W]@-=H6TUHLL2;MB@CC157^7-37(\BO%WG=\@V]'42+MU[UV4PMVO+
M[S%;K*[C@JFR(E3$[DNR<ME)(I*>*CIV00,1C&)LB(FP$69?:,K\LAN5%&V.
M6+_$E9V\/?R[S8\#MU!4M^49)W5=Q[)%D_47V=QNO:BHO-/!2,LM?7X_DJ+C
M=,LLU>G#U3$Y(OCL!F72-GU(B="J*D,"I(Y.Y?69S3.):O++U<X>=,J)$CO%
M44U?%<-R:NAD\K1:)\[MYY7IYZIZB9,=LM+8K;'1T;$1$3SG=[U\5 R8
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M\2S.$_9.U?=V?! ,V                   !C[S>**STRS5\[8F]R+VJOJ
MR -"74FFXUX;96NC_;1O)3:+#?[?>X>.AF1ST3SF+]9OM RH
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MDX?#\H^W>/E\^I;L #(T@
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MG+_QW%BC&  I6@
M                         /COJK["A6N*URZ@77RE*CJNM7@XT7AV]1?8
MU[)L-L62QJV\6^*=5_65-E I5I>F%OJ43,$D1$7ZR+R+'7F/"$TSN:XW\G_^
M77A5.'C[/Q-:S+HUT<[))<:JUBF7LCE7S2$\HTWR[%%E;44TKX$WXGPJKF[
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MNDL%X61:9?-5)FKQ)S3O4M>J(J*BHBHO<IBY<?M4E>RM=04_E3.R5&(B@90
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M$VF;&G$G@I3S(B)B8]K>+,S$[9\ &)J
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MQ0L3N8U$/249<LY9W*W'CC'&H  5+
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MG]Q])R/T8G]P++@KWC72)CO%[HZ#Y/1G7R(S?GRW4L'&[C8UWBFX'T
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MZ*Y?-3^1NZ<D .3,VG<NQ$1U  #CH
M
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M#M\ULCOULDNU^;6.^O(KW^:WU ;K1464Y)1)+75D=%32)_A(GG;>T\R8A?\
M':2H?CUPB<YZ+UC7INYW\S:'YIC<<:K\K4O"U.SB-4EU8MM1520VM\*]6NRO
MF79%]@$@Z-NH?D.1(TVN7&OE2.7SN(D$J54YHD.9,K**X,HI%;N](U_-O=X*
M3EANJ5@NUI22ON5+354:\$C7.VW7Q0"0P:U^7F+^G*+WQ^7F+^G*+WP-E!K<
M><XS)(UC+W1N>Y=D1']JFQ12-EC:^-R.8Y-T5.] .0
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MO);6U4<YJ\G/]1,%-"RG@CAB39C&HU$]2&/+%(G5):<<VF-W=@ *E@
M
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M&LF90W=56I:J*NZGZ)%*.D7^E=_^D"WF$?9&T?=F? S9A,(^R-H^[,^!FP
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MU8[Q/T$QEKFX_;T>BHY(6[HOL.]+90HJ*E) BI_R(>M$1$1$39$
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M>[BIJ.)')V*J;JAEQFSSEZ^C%AC'W]@ *%P
M
M                                     .BOI8ZZBFIIM^KE:K7;>!H6
M(:1X_BU[6Z6[KO*%55\Y4V)$  TG/--+#F:<5S@5DW^;&B(XW8 0]CV@&+6F
MO95.6>H<QR.:V145"7::"*F@9# QK(F)LUK4V1$.P    *4=(O\ 2M)_I+KE
M*.D7^E:3_2!;S"/LC:/NS/@9LPF$?9&T?=F? S8      .FKJH*2)9*F5D3$
M[W+L*RH924DU1*NS(VJY5]A"WRE%F-UFK+K<F06^.160TBR;;[+MO_,"2VYQ
MCZU'4I<&=9OMMLIC=2XDN>*OJK>]DRP.23=KDVVWYF!K[=9**URU4T$7D\;=
MU>W;=?YFHXS9+K=$J96UTU'9IU\RGW54>T#TY!515MMM5ZMSHY'P.:DR-5-T
M:G;\#>;=74]?1LJ*>5KF.3?M[/:1]D&)T&.VF26DK)(GO54:S?='KX;'EQ#"
M[R^F6>LN<U+'+SZAN^VWB!(]VH:2XT$L-6K%BV^MNGF^O<C6DK;G0U]7366X
M1NMU.F_63+OOZD,CDF%7E]KF9;+W,F[><?/SCAI]9\:CI$9D-QX*R%=I()7<
M/-%[?6!D,'L=WS5\E3D$SF6R-VT:1^;UA--!1PT-+'3TL:,B8FR(B&LU&8XY
M:+8BTE5!(UO)L%.J*Y?Y&E735NY17.&DM]BZY9OJHKEXFIXJG<!,0(K3)<PE
M3KO((8]N:1(XS&-9V^>N9;L@I/(:QZ^8[?S'?S WP!.:;IV
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M?.)BGIND]X#:P:I\XF*>FZ3WQ\XF*>FZ3W@-K!JGSB8IZ;I/>'SB8IZ;I/>
MVL&J?.)BGIND]\?.)BGIND]\#:P:I\XF*>FZ3WQ\XF*>FZ3W@-K!JGSB8IZ;
MI/>'SB8IZ;I/> VL&J?.)BGIND]\?.)BGIND]\#:P:I\XF*>FZ3WA\XF*>FZ
M3W@-K!JGSB8IZ;I/?'SB8IZ;I/> VL&J?.)BGIND]\?.)BGIND]\#:P:I\XF
M*>FZ3WA\XF*>FZ3WP-K!JGSB8IZ;I/>'SB8IZ;I/? VL&J?.)BGIND]X?.)B
MGIND]\#:P:I\XF*>FZ3WA\XF*>FZ3W@-K!JGSB8IZ;I/>'SB8IZ;I/> VL&J
M?.)BGIND]X?.)BGIND]X#:P:I\XF*>FZ3WQ\XF*>FZ3W@-K!JGSB8IZ;I/?'
MSB8IZ;I/> VL&J?.)BGIND]X?.)BGIND]\#:P:I\XF*>FZ3WA\XF*>FZ3W@-
MK!JGSB8IZ;I/>'SB8IZ;I/> VL&J?.)BGIND]X?.)BGIND]\#:P:I\XF*>FZ
M3WA\XF*>FZ3W@-K!JGSB8IZ;I/>'SB8IZ;I/> VL&J?.)BGIND]\?.)BGIND
M]X#:P:I\XF*>FZ3WA\XF*>G*3WP-K!JGSB8IZ;I/>'SB8IZ;I/> VL&J?.)B
MGIND]X?.)BGIND]X#:P:I\XF*>FZ3WA\XF*>FZ3W@-K!JGSB8IZ;I/?'SB8I
MZ;I/? VL&J?.)BGIND]X?.)BGIND]X#:P:I\XF*>FZ3WQ\XF*>FZ3W@-K!JG
MSB8IZ;I/>'SB8IZ;I/? VL&J?.)BG=>Z15_ZS9J2HBJZ:.HIWI)#(G$UR=BH
M!V@                                                       '%
M[VL3=[FM3Q5=CY42M@@DED79D;5<J^I$W*;:E:@9!GN8OLN/S/92\?5Q,B<K
M>)4[U4"Y$<\,B[1RQO7P:Y%.PHY>K=G6E=?25M=4S,;(J.1>M5[5V[EYEL-)
MLQ;FF)4MP=LE1PHV5J>(&Y@  4HZ1?Z5I/\ 277*4=(K]*S_ /2!;S"/LC:/
MNS/@9LPF$?9&T?=F? S8    #RW57I;:I8?\3JW</MV C'*[O69==*JR6R1T
M%K@7JZJ5.2N7?FB'51X39Z6E;"D2O5$Y/<O,^8 B?)M4YW_F%E7KO'B-G BW
M+K%76=]''35;Y;54SHV:*1=U3M["3:2.."EACA1$C:Q$;[#%9G2Q56-UJ3OZ
MM&-XD?\ LKXFMX9FD+;?%2WW_A71HC63/Y-D;W+N!Z\H8E7EUMI)^<#421$7
MLXDV-T[.2)LG<:!G=SMD]/3UUNN5/)64[^)&1NW5Z>!FL>S"UW6CC?-4,I*G
M;9T4R\*[_P P-E12/[I:*";4%BSTS)>M;LY%-FN636FA@<Y:V*67;S8HW;N<
MOL,1B5)5UUTJ+Y<6+'UJ;0QKW)W*!UY/A-N=2NJ[9&VEJJ?SF*U>6Z>)U:7T
MSZBCJKG<>&2X+(L:R>KU&[3QI-!)&_DUR;*I&F*WZEM]/>[1),C96O>Z-Z]B
MKMV(!L-VR&OK+E):\;:U:B-?ST[T\QGJ,9=<'N5TC;)5W-WEC5XFN:NR-7U&
M8TWIF1XXRI39T\[G*]_>O,VCUH!BL7S"X6JNI[/E:-57[1PU4:>:O<B*28G-
M/41;FE+%48_52RMW?3M66->]%0W;!JN2NQ&TU,R[R2P-<Y0,X
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MEG !6+Z,4BISO;?<4^?1ADV_]:;[BEG@!6-.C%)M_P"MM]U1]&*7TVGNJ6<
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M<3W5+. "L:=&.5%_]<;[JEB<7M?R+C]OMJOZSR6%L7%X[&3
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M\;HXIVHY&N7=4(V^CWA/[K-_54D^PVFFLEK@M]"U6T\*<+45=^0&0
M            ZIZ:&H;PSQ,D3_F3<[0!UP4\4#>&&-D;?!J;'8
M             "I]MP[(&:[17)]LG2A2=7K-MYNW,M@?.%N^_"F_CL ;]5/8
M?0                         !5C63#[_<]6J2NH+;--2),U5D:G)$1Q:<
M^*U%7=43<#RVACHK93,>FSFQHBHIZP                         !7GI1
M8S>+]);%L]!+5=6_SN!.SD6&/BM1>U$4#5-*Z*HM^$6ZFK(G13QMV<QW:AM@
M1-NP                         "(NDM9;C>\'\GM-*^IG25KN!B;KLBDN
MA41>U$4"*^CE9Z^RX+Y-=:9]-/QHO _MVV)4"(B=G(
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M]%?]&3/X[B8B(NB_3S4VFS&5$3XG]>Y>%Z;*2Z
M                                         >:Y5L%NH9ZNJ=P00M5S
MU\$-&T_U5L68UL]'23-CJ8WJUK'<N)/4!(0                        .
M,DC(F*^1S6L3FJN79$,?'?;5)-U3+A3.D_921 ,D B[ING-
M              541%55V1#&R7ZU1R]4^X4R2?LK(@&2!QCD9*Q'QN:]J]BH
MNZ*<@                         !CZJ]6VEDZNIKJ>-_9LYZ;@9 '535$
M-5&DE/*R5B]CF+NAV@
M
M  >-]KH7S=<^EB=+OOQ*WGN>Q$1$V3D@                       .BKHJ
M:L:C:J%DJ)V(Y-SO '534\--'U=/&V-G[+4V0[0
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MR(J<T4IID;Z7+==:5^.,XHVU**][4Y+YW:7'IV+'!&QR[JUJ(H'8
M              &EW?4K'[5D\=BJZGAK'+LO+DU?6!JW2 U&DPZT,HK8J?*5
M5LC51=E8GB0_:](,URFT?+59=I63SMZUC'N7==^9F>EI9JGY3MU_A\^D1K6<
M3>:(OB27HYJE9;_C5+35-0REK:6-L;V/5$1=D[4 @O!\XR333,6VK(9)WTG'
MU;V3*NVV_:FY<>CJ&5=+%40KO'(U'M7U*5'Z2%SMN3YM04=AX:BL148]\?/=
M2U&(TDE#C=OIIUWDCA:COP RP
M
M       1YJ=J+:L<M-7#%<8FW/A_-M39W,"0FN:[?A5%V\%/I3+2_6RZ67))
M/ERH?56^JE\_?]7UH6_LEUI+U;8:ZWRME@E:CFJB@>X
M  1QJ1JY8L*XH)W.J:Y/_9C_ .Y'=NZ3EOFK&LJ[1-%"J[*]'(NW]P+%@PN*
M9-;,HMK:VT5#98EVW3O;[4,T
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M[=A8#1;"UPK#:>AF55JG_G)=^Y5Y['NP[3K',257VF@C;*NWYQZ;N3^9MX
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M-A<]>:;=J+^ &YZ7Z*6G$)V5]9(ZMN*(B\4B(J,7U$N
M
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MK9%76V=LT$B;HJ&1*D]%K)[A0Y7+C\\CWTCT<O J[HUR>!;8
M  &L:E7S\GL,N=>Q=I61+P>TUK5S5:CP!8(74SJFJEV7A1=D1%WY_P!CLK;E
M;=4=-:Y+7(Q\LT"_FD7=S7;;[; 5XT4P^+4O+ZZOR"5TD4:]8YF^_%NO83!J
M%H)8+A9Y78_ M'6QMW8C=MG>TK_I[E=PTLS6=E5!)U2/ZJ:)WF[HB]I9F77;
M#DLKJQE<CI^'E!^MOX 5\T0R"XX9J,RTU+G-BEFZF:-57;P+L,<CFHY.Q4W*
M7:86RKSS5I;O#3NCHV5'6O=MR:FZJG,NBQO"QK4[DV ^@
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M!>-/LG7',G5Z4?%P;2;JK5W[4 MZ#KIIXZF".:!R/C>G$UR=Z'8
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M>8MMEY1_R<YWG-?NK5:O>@%SP>*RW.FO%LIZ^BD22"9B/:J>M#V@
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M_&ZVR2?K;JU[-^T"Z8,-B&0T>3V&FN=!(CXIFHO+N7P,R
M
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M*!U8;B-IQ&VMH[/3-B9LG$[O<OBIL
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M7@1Z[;+OW;EH2(LJTRJ+AJ?19%;'LIV-V=.O>Y4)=0
M
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M4Z57O7CC9(B\2KOVKN6;:U&M1K4V1$V0#IH:2"AI8Z>EC;'#&B-:UJ;;(=X
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MWUG[;*H';BN%V;&)9Y+32MCDF7=SMDW-D   'DNERI+72NJ:^HC@A;VN>[9
M/6#P6F\V^[0)+;JR&=B_L/13WKV*!"VL.K\N-W2.QX_ VJNDBHU47N52$,UT
M\SB61^45=&YLK]I'=6[SFGHUABK,2UE^6*N%TD"SI,Q53DJ>&Y:'%\XQ_)K
MVJ964R1N9^<BD>G+Q38"%-+-2+=F5H=B.=<"2JWJHI7IVKV?CR.F]]&ZH\N=
M+8;DYM,]=V^<B;(1GEUA?>L[O]3AK5?!1R.FWA[ME7LV)QZ-^IE1?(EQZ].<
MM;3-\Q[UYN1%[ ,UI=HE;<3JFW"X2.K:]%W17[*C5)A3DFP
M
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M;?4*YTUO7@57+NNRJH$S@
M$?:C:JV+"%ZFMD=-6*FZ11\]O:;CD-:MOLE;5-3=T43G)[=BI6C-EI=0M1:Z
MLR219U8]RI$Y?K?B!(]DZ2=EJZU(J^CFIXG.1J/1-R<++=:2\V^*MM\S9:>5
M-VN12(M6=%['<\?J*JS4R4=;3QJ]J1[(CMD[S2NBC?JRGNUPQ^J>YT4:+PM5
M?JJB@6;JX&55++!(B*R1JM5%(3Q/0F@M^9UEWN7#/3];UD$6_8N^_,G$ <8H
MV11MCC:C6-39$3N.0                (EU%UGM^'Y+3VJ2%TF^RROV7S4
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M#N
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MA.&VK$*:HCM,/ M0]7R.W^LN^YL@
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MJL1.:^LUS6;3)N?0T?52,AGA>G$]>6[3<\-QVGQ>Q4]LI%<Z.).UR[[J!FP
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M3R;+*[?DJ^H#=@
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M$<:+X_4YIJ@^^04ZP4$%0LRN1-D3O1 +F
M          !U5=1'24TE1.[ABC;Q.7P0[3KJ8(ZFGDAF:CHWIPN1>] *\WCI
M)4U%E$U)3T#9K;&_@6;FCN2[*NQ*&(:J8MD\;?([BR.94YQR^:N_AS*FZB8O
M!BFJ,E-<8E6VU$_$B[;(C7+W>S<V_,M$W6RT)D.+W=JT' DK=UV<GL7<"S.?
MX[#E^(5UJ<_S:AF[7)XIV%0\<OV1Z,95/3U5,[R9S]GQO^K(U%[4/-A>L668
MY*F]3+7T[%V5DRJJ(GM)KQG4C#]3I8+;D5FC2O<B-:Z1-^:^ &C:AZR3Z@VR
M#'[+;51U1(WK.2JNW9R_$P&KNGK<!AM%SH*AT=1(QKW1[\VN]1(VIZ4>FU3&
MS$L5:^L=LJ5G5;HGJ3E[# 8EAV5ZIY%!=LP2:"VPJFT<B+LY$[D0"P6E5RJK
MK@MJJJY%29T#=U7OY=IMIYK;106ZA@I*5B,AA8C&M1-MD0](
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M<MCII:"DI)'OIJ:*)[UW<YC$15/2     P.:Y10XE8I[G<7HD<:*K6[[*Y?
M@*EZ2\GRS_Q5J5MM<[9%1?.V\0-?Z1MUGN>J5)9:V9T=MCZM%1%V1=U7=5)Q
M;I/B5PQ*&AAHV=6^%."9NW%NJ=N^Q'NM&'T^H]DARO#Y&5%3&Q$DCCYN=_\
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M7:HV*U>L3S4]FYKEEH$L.N<5)C4[I*=*K94B7DB;]B@75!QBWZMO%];9-SD
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M';?C&HUNCQB9OE#G,XXH?U')MX 72!C\>=.^RT3JQ%2H6)O'OXF0
M
M                   5=D53PWJZTEFMTU=<)6Q4\2;N<Y=C6L%U$L>:)4,M
MD[4EC7AZMSDW7UH!77I!Y57Y/G+,:H9G-HXI$9LU=MU7DNYOMLZ-UC=8F-JJ
MRH6N>Q'=8FVR*OJ(EUVL];BVILES;')U,DJ2LDVY*O;MN6'TXU@QZ_V2!:ZM
MAHZQC4:^.5Z)OMW@5>RC'[WI-FD#F2/8C'\<,J+RD:B]^Q<_3?(DRG#;==MD
M1TT?G;>*=I6SI-YA:\JN5LM=B>RJEB<O%+%SW5>6Q/VB-FGL6F]IHJMJMF1G
M&J+W;@;T             &I7C4+';1?8;16U[&5DJ[(WN1?6IMCDW:J;]J%5
M.D'I7<:2Y39)9Y)JECW*^1J;JYG?N!:&ON-+04#ZVJF9'3,;Q*]5Y;$:V77/
M$KC>)*!U6L*H_@9(YJ\+OYD4:/ZI4]UH/R3S=W'3R;M9-*[L\$4RF9]'*&I8
MZMQ*O1$<BO2-R;HO?R5 -UU_Q2FS;"77&TNCJ*FEWD;)&J+NU$YH:%T3LQ6"
M>HQFNDX>)5?"CEY\7>A'D-9G^FT[H:J*M6A1>!8I458GH:A:\GEMV9Q7VEC2
M"5)>-6-Y(F_:!>;47![;FUDEH[A&B2\*]5*B<V*4XO%HO^D69I*L7FLD_-RO
M;NV1J+N7<Q*]09!C]%<J5Z/9-&BJJ+OSVYGASO#;7F=G?0W2%B[_ %)>'=S%
M]0&*TEU"HL]LGE$")'61>;-$B<FKZC>C4].L$M>#6GR.V,17N55DF5-G/]IM
M@     !Y[A21UU%-33(BQRM5JHJ%'+S3U.FFJV[-T@94<2;]CV;EZRO?2MP]
M*ZT07VDBWGIT5)%:WNW[5 [-7:S Z["8+M<((%KZF+BB;"FSN)4[]BN.*8/?
MLK=/+8*)\D4:JO%OMM_,R6E^+U6?9'3VR>M<V"+9RH]V_+?L1"\6)8U;L7M,
M5!:X&1,:GG*UNRN7Q4"G&#W/4/&L@AME!'5]:Z1&+%,BN:O\RUU]M%]R#!F4
MGEBV^Z21_G',\53L-K=0TKJALZTT*S-['\";I_,] %4[)T;[K5757WZOX:?B
MW5R.1SGEDL2QJW8M:(K?:H4CB8B(J][E\5,T
M                 (+Z4V'K>,9BO%*Q/**#=SU3M5I 5DR#*\SMEMPRW3/6
MFBY<*<MTW[_Q+S7>ACN5LJJ.=J.CGC<Q=_6A3C%*"ZX#K<^AMU.^7:7JUY;[
MQJJ+N!8# =&[#8L;6BN=+'65,R;S2.^"&5Q/2G&,8NTMPMU"B3N7=JO7?@]A
MOC%W8B[;;IOL?0.FII*>I1$J(8Y43L1[478[(HV1,1D;6L:G8C4V0Y
M              !UU,$53 ^&H8V2)Z;.:Y-T5#L $59-H9B5YG?.RD6GF>NZ
MJQR[?@>C$]%<3Q^I94LH^OJ6+NUSW*J?@2: .,<;8F-9&U&L:FR(G<AR
M :UGV86_#+')<+BY=DY-:G:Y3,7JL?;[74U4<2ROB8KD8G>4[RC4.7/,IH+;
MDL?DM!%5><G--F^L!J3JZS/Y[?0STCJ:@9.G6;K]9N_M)NNVE6+9C@]*EFAB
MBE2)%BF:O?MWGAU"T5LF08Q%48U&V&KCAXHE9MM)R[R)M+M0[OIG?GV/(HWI
M0H[@5K]U5G/M0#P8KD>0Z-Y8Z@N:2+;U?^<BVW:]/%-_86@91V+*,:;?Z*TP
M3S2P];&US-E<[;?93OR+$\?U!MM)55L*2,5$?'(B<]O VBV4%/;*&&DHXTC@
MB:C6M3N0"IEU;J5D5YJ;51P/H*%[N!(F-X6(WL[2=-'=,J3!;:KY.&:YR\Y)
MN]-^XDA&M1=T1-_'8^@        #XYJ.:K7(BHO:BGT 1SEVCN*Y)*^>>A2*
MI=^O&JI_8Q./Z"8E:ZIL\U,ZH>QR.:CG+LA+@ Z**D@HJ9D%)$V*%B;-:U-D
M0[P    &(RJ_T>-62IN=Q?PP0M5R^*^HRE0]8H)'M:KE:U51$[RG&KFIMRR*
M]36&ZTODEO94HQ4YHO#Q<U4#LU6UP7,+1):::B?!3+)OUF_UFDO8K@6'YCII
M2T]'3Q<:Q(BRM7SFO/E9I)BV58%2-LK&,FZI'1SLVW<[;O(/Q7(,@T;RU:*Y
M1O\ (5=Y[';[.3Q0#A/%DFB>9\4;GK0NDWY<VR,1>SV[%G\4KK%J)CD=Y^3(
MI9'-YI(Q-^).[<]3Z.Q:FXG335,*2TLS4>U53FU38,=LE%C]KBH+;$D<$:;(
MB=X%8\Q346MR*6VV6B6WT3O,9'"WA;MZUV)1T8TGBQ-BW.\*E1>)MG.<J[\*
MDO;)OOLFX           #2LRTSQK+%62YT#?*-EVD8O"O\S3[;T>L3IJKK:B
M.29B+NC%<J$R@#P66ST-EHFTELIV00-_5:A[P    'GN%9#044U54O1D,35<
MY5\$/0O)%4J[K_JC>*6Y5F/MI.IHG)P]8Y%17<@..I'2!BKJ6X6BUT3G0R(K
M.O7;_<SV@F.XID^#5%/44T4M;)_C*Y?.153M0]FF>GN(Y5IM'&R-DE5(B\<R
M?6:XA^Z6S(M&,O;44_&M"LFZ._5>U%[]@/5J%A-[THR5+O89'I0\>['LW79.
MW92?-*\OM>I]CWN5 R2L@\V3K&(J>TRN&9#:-4,059X6O1[>&:-6]B]G+<S^
M'XC:L3HG4UHA2-KG<3E[U @O5?\ +.@O;:#$+:VAH556H^!G-_M4RVD6D%5%
M<TR/,W^4W!_G-C<JKLOB3\J(O:B* ")LFR=B
M
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M6V6*OK417+!"Z1$3U(!Y+_E5EL"?^*W""!?V7/3?\#G8\FL]\C1ULN%//O\
MJM>F_P"!4G"[#4:PYS=EN]QDB;'N]K=]N6^VR(=.:X/E&D]U;<;552/HFJBM
ME8JK^* 74-&U0T[MN<6E\4\;(ZQJ*L<R-YHNQKVB6J]/FE"E'7N2*ZQ(C51>
M7'["6@*38_><BT9RY:2N;,ZA5WG-7=&O3Q0M#$VP:I8BR26)DT$K$YJB*K%4
M]>H&!6C-:!(+G"G6-5.&1.U#)XAC=#B]GBMUMCX(F)M[0.O#<5MN)VMM#:H6
MQQIVJB;*IG@
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M]'1M7N38"90
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M,0#U@
M                                  #X]J/8YKDW14V5"E&O>.5&&ZA_
M*-"WJX9E2:)R)R1>9=@BKI$8@W)<)GFB8GE=)L]KD;NNW@!7'$K%DFL&20R5
MTKWTD*HV67?DQ/46ZQG!;)8L?AM4-%%)"QJ(Y9&HJN7OW*W=%/)*BW9)469\
M3WPU"IV)]1?66Z U3'L Q^P76:X6VB9'4R=J[)R]AM8
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M&BI8Z>F8V.*-J-:U$[$0[@
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M13.5WU7.V1$ L,G+L!C\?HZB@M%/35M2ZIJ&-1'RN[7*9
M     ,7E25"XU=/(W<%1Y,]8W)W+PJ0UT:<XJ;HEQL-ZG?+<J=ZO17]JIN3P
M]J.8YKDW:J;*A4/5RV7/3/5#\I+4US:.JDX]T^KZV\@)@RS2=UYU2H,F\H1:
M9B(DL3NW=.S8\>N.C]-E5"^Y6:-D-VA8J[)RZW;N]I(.GN96[,[%#76^5JOV
MVEC[VN[S: *@:.ZIW# [N['LJ25:%KNK1')SB7?X%M[?605])%4TKTDAD3B:
MY.]#0-0-([%F5TIJ^J:L$\;MY%C3;K$\%-\M%NI[5;X:*B9P01)LU /6
M
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M)/Q2PTN-6.GME CNHA;LG$NYDZ:-T-/'&]ZR.8U&J]>UWK.P
M
M         8_(+9%>+-64%0U'1SQJSFF_:AD !3+';S<=&M2:JCK6R+;9'\+D
MYM:J*N^Y;VQ7BCO=NBK;?.R6&1-T5J[[&G:M::T&=VI6N:V.X1\XYNS^2E<[
M)>,RT9O"TM;%)-;.+=S43B:J+RY*![NE!8*V/.Z>JI8I'K5_45C5[3>]"-&V
M6]D5]R:/K:QZ<4<,C?J^M=S<<5U"PW/$I9JGJF5L&W"R?9%1WJ)1B<Q\;71*
MBL5.2IV <FHC41&HB(G<@
M              :_F^*6_+[)+;KG$US7)NQZINK'>*&P "F%;8\PT8R7RFW]
M?46[BWXF-7@>GK0GC3G6NPY1"R"NE9;[AR:L<KMMU)0K:.GKH'0U<+)HG)LK
M7INA%.4:#8Q=I5GH&/M\ZKOQ1*O:!+-/40U#$?3RQRL\6.14.PU?3W$VXA9&
MV]*N2J5%_P 21=U-H
M
M                   '172N@HIY8V\3V,<Y$\=D [S4-6;3/>L"N]'2JJ2N
MA54V[]BO=KUYO-NS^H2]JKK9UBL6%$3S/66AL=WH<@M4=902MFIIF[]OBG8H
M%/NCWF4&%YA/0W9K8X:A>J<]W)6NWV++ZC:?V;/[(Y',A2I<W>&J8B*OXD*=
M(?2.:GJYLCQZ'>)[E=-$S?=J^*&.T1ULFL*LLV3R224:+PQRJG-GJ4#07,O^
MDF;MW66-8I-^6[6S-12Z>GV4TV7XQ276E5J+(U.L8B[\+N]"&.DO<\7OF%15
M=-4P3W%%3J58N[D15,AT16U+</K%DXO)UD\S?VJ!/0
M
M         !XKI:J&ZP+#<*:*>->Y[=SV@")+IH/C%5<&UE*M12RH_BVC=LG:
M2?:*".V6Z"CA<][(F\*.>NZJ>P
M
M
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M1CN:-7FJ%E<8L-%CEGI[;;8T9!"W9/%?6IE0
M
M
M
M
M           $>:WX<F6X;511,1:J!JOB7OW3GL5^T&U%FPF^26&^N>VC<_J]
ME3_#=N7$5$5%1>Q2O6O6C3KP^2^8Y&OENZNEB;RXO6@%@::>*J@9- ]KXGIN
MUR+R4["G&EVK]WP.I2SY)#(^B8[9R2(O''["U&*Y?9<HI&3V>MCFW1%5F^SD
M_D!@<WTMQ_+KE3UUP@1L\3D<JMY<?M-UMU#3VZCCI:.)L4$:;-:WL0]
M
M
M
M
M                                   5-TY@ :+G6EV.9?$]:VCCAJ7?
M^_&Q$<0S4Z"9/C]:^IQ&_NC:B[HU%5KOB6@ &K:<T%[MV.PPY+5^4UR(G$[?
DF;2                                         !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g73463g01k38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g01k38.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1H 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &>,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_P  +" 37!V0! 1$
M_\0 '0 !  (# 0$! 0            <(! 4& P$""?_$ %L0  $# P("!04*
M"@<%!0<$ P ! @,$!08'$1(A"!,Q05$8(F%QX10R-U9T@9&3E+(5(S5"<G.A
ML<'1%A<S-E)BDCA35%6")#1#PM(E)BA78Z+Q)T9D@_"$L__:  @! 0  /P"U
M(
M
M
M
M
M
M
M
M                                             /S+(R*-TDCD:QJ;
MJJ]B$!Y#K1>KO?I[3I[:%KEB<K%J%3=N_P Y@ID>M]O1]57V>":F;YRL8QFZ
M)\R[G:Z5:OTV75K[5=:;\&WB/EU+U7SE[]CIM7;]78U@%UNMJ>QE93L18W/;
MQ(F[D3L/SH_?Z_)L!METNSV/K)VN5[F-X479RIV?,=F     0]8L[OE9K9<,
M;GFA6U0LW8Q(T1R<M^TF$ Q;A<*.W0];7U,-/%OMQ2N1J?M/>"6.>)LL+VR1
MN3=KFKNBH?L
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MJT6VO;/<*;G+&UJ^;\_8=&
M
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MY)^\C#HKV69MFN5_K4WGKYE5KE[5:G(G<
M
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M$[=F_P#X+.8/98\?Q>@MT+=FQ1\_6O/^)O0
M
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M\J)W=JHG[RXB)LB(G8
M
M     5QL%%5MZ3%7.ZEG2!6KM*L:\/O?'L+'         $2:C:SX]8J6YVR&
M:9]Z8UT;(>J<GG<T[3 Z-&,5%!9*N^W.)S*ZYN63=Z;+PJNY-0
M
M                                     V3??9-P         :.X8ACU
MPN"5]=9J&HK$7=)I(D5WTFZC8V-C61M1K&ILB(FR(?H
M
M
M
M
M
M
M
M
M
M
M                                  &BR/+K'CDU/%>KC#225"\,;7KS
M<INXGMEC;(Q=V.1%1?%!(]L;%?(Y&L3FJJNR(<I5:CXE2UR4<]\HVU"KLC./
MO.FHJRGKJ=L]),R:)W8YB[H>X
M
M                   !K,DO='CUGJ+E<I6Q4\+=U55[5[D*4Y]?;KEN9460
M5\3X[?/.D=&UR;>8B\MB[]H_)='^I9^X@_7[++A7WFAP;'I%945KVI42-[6M
M7N^A386GH\XO':$BN*U%17N;SJ%>J*UVW<ARF'UEPTBU+;C%PJGU-BKTXH9)
M/S%+*-5'-14[%3<^@
M
M          'Q[FL8KGJB-1-U5>XKIGURK-5=0&8C9Y599*)W%5S,YHY4[C3]
M(NU4MDK\.MU!&V.GI^%C6IZRS-I_)5)^I;^XK5C[OPKTIZ]TZ\20M=PHO=LQ
M"T!7'I;0I35.,5\7FS]>YO$G;LB(3_8)EJ++13.]\^)JK]!G@P;I>+;:4C6Z
M5]+1I)NC.OE:SBV\-UYFO_IEC7_/[7]J9_,?TRQK_G]K^U,_F;UCFO:CF*CF
MJFZ*G8J'T
M
MB_I$7RYV7 )_P+'*ZHJ')$JQM5RHU>WL(*TNU-GP.TR4\.&UE563.XIJEW$C
MGK_I--JWJ759G<[54U-BFMSJ1R*C'JOXSGZ4+$Z.:EU69JZCJ+%/;FT\:-1[
MU79VR>E"-*9/Z/=*6H?4>9#5)PL<[ENKFH6@*V]*B=;G?\9LE-YU0DBR*U.:
M[*GL+#6:G]RVNE@_P1M;^PS 1AK;I:[4F.U-9<DH?<3GKSCX^+B1/2G@17Y+
M$OQD;]F]I$FKFGRZ=Y%26MU<E<LT+9^L1G!MYVVVV_H+XV+\B6_Y/']U#-
M
M                                                 /R]C7IL]K7)
MZ4W/Q[F@_P!S'_I0KETH:-[\DQI::F>YJ/3?JXU5.WOV+"V>)D=MI.%C6KU3
M-]DV[B+=>=/*S(Z>FO>.;-OMO<CXT3DKT3GMZSD*#7'(K50-MMZQ:OENZ-X&
MO8WS55.6ZF9I7AN09-F\F:YS L2L3AI8']J?-X%@DY  %/NE_P#"+;/D3?OJ
M6TL?Y$M_R>/[J&:
M
M       ?B2&.1462-CU3LXFHNQ^^SL!YNIX7.XG11J[Q5J'HB(B;(FR   I]
MTO\ X1K7\B;]]2VEC_(MO^3Q_=0S0
M
M                         "G_ $O_ (1;7\B;]]2V=C_(EO\ D\?W4,T
M
M                                                        I_TO
M_A%M?R)OWU+9V/\ (EO^3Q_=0S0
M
M                       "G_2_^$6U_(F_?4MG8OR);_D\?W4,T
M
M                                                  I_TO\ X1;9
M\B;]]2V=C_(EO^3Q_=0S0
M
M                 "G_ $O_ (1;7\B;]]2V=C_(MO\ D\?W4,T
M
M                                            ;[#=/$   I_TO_A%
MM?R)OWU+9V/\B6_Y/']U#-                                 *A:OZ
MLYG8M2+Y;;7=^HHJ>5&QQ]4U>%.%%[50X[^N_/\ _GJ_4,_D;[ ]<<S3+;9'
M<Z]M?233-A?"^-K$7B7;?=$WY%SVKNU%\4W/H
M                                                    -=D5UBLE
MDK+C/SCIXW2*F^V^R=A7.P5&::T7&NJJ6\OLMBB>K(^J;NO\-SVR?$L\TPMR
MWBRY1/=J2#SIF3LYHWU*JDSZ59@W-<2I;HK$CG5.&5B+OLXA_72"Z7_5.S6&
MVW:IMZ31KNZ*141/6B*?K^H+)]_[]5_^IW_J.LTRTJO>)Y&VX7'**JXP(W98
M9%7;]JDQ  %/NE_\(ML^1-^^I;2Q_D6W_)X_NH9H
M            !0C7SX7<D_7M^ZAP!M\/_O99?ED7WD/Z.Q_V;?4A^@
M
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M%47<NM@VL=HO?5TUSX:"K79J(Y=VN7U]Q*%//#4QI)3RLE8OYS'(J'H
M
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MGF/7T;=A+$4C98V21N1S'(CFJG>BGZ
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MA?*B/J(^;.'<M320MIJ6&!GO(F(Q/4B;'J
M                                                #F,GP/',F7>\
MVV*=W^+=6K^PUEATFPVQ5'76ZSQLDWWW<]SN?SJ=RQC8V(UC4:U.2(G<>-=1
MT]=3/@JXFRPO396N3=%.&GT>PF:M;5R66-9FKNBH]R)]&YVEKME':J5M/00,
MAB3L:U#,  *?]+_X1;9\B;]]2V=C_(MO^3Q_=0S0
M         JHB*JKLB$?YGJM8,<C>QDRUE6FZ)'#S1%_S+W$#9KJK?<F1\*.;
M1T3N2PQ\]_G[3FL<QF[Y-4\%LII)U5=G2+[UOK4LGH]I[5X9!/+75B/GJ-N.
M%G-B?.26     1CJGJ:F&W*AIJ:!M3(YV\['+MLSQ0Z/"\\LN61)^#YE94;<
MX).3D.K
M                         !3[I?\ PBVSY$W[ZEM+'^1+?\GC^ZAF@
M                         X[43/:'"Z9BU<4DL\K5=$UJ<EY[<U*[9CJM
M?\B62)DZT=&Y>4<2[*GSG-8]C=VR2N2*WTTLSWKSE<B\/SJ3CA.AM'2\%1D<
MRU$G;U#.2(OK[R8K5:Z*U4S8+?314\:)MLQJ)OZ_$S      0KJ_I767^MGO
M-KJ5DJN'^P?X)X*0"YESQZX\TJ**KC=R7FQ>1,& :W3TR1TF4-6:/L2H8FSD
M]:$]VBZT5WHV5-OJ(YHG(B[M<B[>LS0
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M+FOFO7QW[$)3C>R1B/C<US%YHK5W13]
M                                                I_TO_A%M?R)O
MWU+9V/\ (EO^3Q_=0S0                          :R_7VW6*C?4W.JC
M@C:F^SEYK\Q N=ZW5%7(D&.L?!3L>BOE5?.>B+W$XX3>X\@QJBN$;D<Z2-JO
M3?=6NVYHIO          %1%394W0C;/]*+3DK7U%&QE'7[+Y[$V:Y?25SR["
MKUBU4Z.X4LBQHOF3,3=KBSVCENJ[?@]"E=/),^5J2-XUW5K5[$.W
M
M        !3_I?_"+:_D3?OJ6SL?Y%M_R>/[J&:
M   #RJJF&DA=-4RLBC:FZN<NR(1!GNME!;'24F/,2MJ.:+-_X;?:0!?+W=,E
MN/75\\U3.]VS6[JNV_<AW^":,W>]/CJ+RBV^A79VSO[1R>A"QN+X]0XU:V4-
MLCX(DYJO>Y?%3;@          \:ND@K(5BJ8F2QKVHY-S]PQ,AB9'$U&L:FR
M(G<A^P<-%JCCBW^IM-14K3S0NX..3WKU]"H=M!-'/&V2&1KV.3=%:NZ*?L
M
M            %/\ I?\ PBVOY$W[ZEL['^1;?\GC^ZAF@
M         '!9UJ?9<7CDB25*JN3=$AC7?A7TE=<YU$O.72;54GN>D1=VP1=B
M?/VJ?G"].[YE3VNI*=8:7?SIY4V14]'B6*P/2ZS8LR.9S/==>WMFD[/H[#OT
M1$39.2             'A7).M',E(K4G5J\"N[-RG>;X7?[%<JJ>Y4DCHWR.
MDZ^-%5O-=^T^X;J'?,7>QM)4++2HNZPR<T7Y^TG?#=9K'>49#<W?@^IVYK(O
MF;^A23J6HAJH6RTTK)8G<T<U=T4]0
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M;]A.^":SVJ^.CI;M'[@K5\7;QK_U+V$K,>V1C7L<CFN3=%1=T5#Z
M                                                          #R
MJZF*DI9:BH>C(8FJ]SE[D0@"]:P9-D5_JK9IS:FU;*=5:M0J;M=Z>9A2:IZB
M89)#)G5B:ZD>NRR1ILB>G=-R>\6OU'DEDIKG;I$?!,W=-N[T&GU+SF@P:P25
MU8J23KYL,"+YTCE["&8M1-5KHS\*6O'VMM:><K',YJWY^9(VD>J<.9NGH+C!
M[@O-/[^G=VN3Q3<DX  I_P!+_P"$6U_(F_?4MG8OR);_ )/']U#-
M              !\<Y&M5SE1&IVJIPN:ZG6/&8WL]T,JJQ.R&-=]_G0_&D^>
M?TUI*Z2:-L$L,B-;&B\^'8[X                 'C5TL%9 Z"JA9-"[M8]
M-T4C',]&++>6/FM7_L^KVY<*>9]!&&/:47BESFEI;G3*Z@8[CZW;=LC4_<6@
MAB9#"R*).%C$1K4\$0_8
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MRUBQV\Y'5K':Z.>JE7FYVW+U[J6+T<TUJ\1E?77*JXJB5NW4L7S6[IW^DE8
M                 #9-]^\ B75#5.3$\BI:&C8R9C?.J&[;KMMV(O<ITF':
MF8]DZ-C@JDIJM4YP3+LOT]AVK7(YJ*U45%[%0^@
M                                           ^*J-[51/6<GJ;;+]=
M\7FIL3KDHKBYR*V;BVV3?GS*T:A:=ZEQV]*O(J]]XI8/.<QDBNV1.WD3WH1D
M5FO6$P0V2!*9:5.KE@VV5KN\B?#=XNE+=$F79RM?MO\ H(6A*Z=+US5@QAB+
MY_NA^R?,A/&,-<W'Z!K_ 'R0MW^@V8(FUZU+NNGD5H=:+?!6+6.>C^M1WF\*
M)MMMZR(O*8RK_D%#]$A&&I^=7#/K]2W*ZT<5)-#$V%&1(NRIQ;[\_67XL7Y$
MM_R>/[J&:                     <MG^:46&6YE5712R]8O"QK$[5*XYKJ
MM?,D=)%%(M%1KRZN)R^<GI.6Q_&[OD55U5LI)IW*OG/V79/2JDW8/H9%32,J
M<DJ$F>U=T@C3=J^O<F:UVRBM5*VGM]-'!"U-D:Q-C,
M  !"6I.CE1>:^JNEKKW25,JJY8INQ/0A!=\Q^[X[5<%RI)J9Z+YKMEV7THIU
MV#ZLWK'.&&I=[NI.SAE<N[4]!/6':G6#)6,8RI2FJW<NIF79=SN&N1R(K514
M7O0^@
M        C?7UMX9@-358]*Z.KIW(]RM[>#O,+0K4"AR+$:6"LK6?A6!O!,QZ
M[.54[SJ<\R^R6#'ZN:Y5D*(Z-R-CWYO79>2(1!T2J*I=!>KCPJRCFJ%X/!?2
M8.KM)+@FL-NS+@5U!5/:V9R?F=R_N+"6K(+9=+4VXTE9$^E5J.5Z.Y-Y=Y77
M.:J/536.VVFSOZ^W6].*65O8B]Y9R"-(861M[&M1$/V#QJ*6"I1J5$,<J-[.
M-N^QX_@J@_X.#_0A4?I<010:A6ML$;(V^XF\FIM^>I;>Q?D2W_)X_NH9H
M                 !R6I^+)E>+3T3$1:EF\D&_9Q[*B;_21SA>A,$"15&35
M"32IS=3Q>\^GM)GM=LH[72LIZ"!D,3$V1&IW&8
M8-XM%#>*1]-<:=DT3DV5%[?I(7S30F*97U&,5"1.5=_<\J^;])"=_P ?NV-5
M:Q7.GEIGM7D_L1WJ4[##-7+YCR1PU#FUM$SEU;^2HGK++89D<.462*XT\$T+
M'_FRIMS]'H-X
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MB;20HO*1?.<Y/X$VZ:Y$W)<5I:OC1TS6HR547\_9-SJ0
M        # N]HH+O3N@N5)#4,5-O/:BJGJ7N(=RS0FDFGZ^PU"PL5R<4#^?+
M?GS)@QRUQV:R45OA1$93Q-C3T[(;$
M                                      I]TO\ X1;7\B;]]2VEC_(M
MO^3Q_=0S0                 #G\FS"R8W LETKHHU[F-7B=OZD('S76VZ7
M%TE/88VT=-V=8OG.<GBG@1;_ .TK]7;_ /::ZID7;?F]=U)8PC0^NKECJ,D>
MZEA[5@;LKG)Z]^1/>,8[;\:MR45JAZJ'?==UW55\5-N
M          8URK(J"WU-7.O#%#&Y[E]"(JE8+/K%?+7?:J221*RWOF<J1O[>
M'?ELO<3]AN=V7*J9CJ&JC94*GG0/=LY%\$W[3J@
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M;$
M        I_TO_A%M?R)OWU+9V+\B6_Y/']U#-                [#QIZN"
MI?*R"9DCHG<+T:N_"O@I[ XS4#3^WYG-0R5LKX5IG;JK$3=Z>"FYQK&+5CM(
MD%LI(XTV3B<C4W<OB;H                              T&5XG:LFHGP
M7*G8YRIYLB-3B:OBA7?.M'+Q8NMJ;6BU]"W=?-]^B>E#AL<R&Z8S<&U%OGEA
M>U?.8JJB.]"H6#T^UGM]Y=%17QJ45:[DC_S'+^_<EQCD>U'-7=JINBGT
M
M I_TO_A%M?R)OWU+9V+\B6_Y/']U#-               -1DF16W':%U5=*A
ML343DWO=Z$(!S[6NNN3I*3'$6DI5Y+,Y//=_(RNC=?ZUU_N-!.Z6:&H;UKGN
M55\_?8L6                                #XY$<BHY$5%[44CO/=*;
M+DS'ST\;:*X;<I(TV1?0J=A&.&:3W*WZ@4\5UC1U' BS-F;S:[;L0LFU$:B(
MB;(G<                                #Y(]L;'/>J(UJ;JJ]R'*/U&
MQ%CG-=?Z)'-794XEY?L/G]9&'_&"A_U+_(]:74#%*J=D-/?:.25Z[-:CEW5?
MH.H1=TW3L  !KKQ?+;9DB6Z5L5*DKN!G6+MQ+X(;!CD>Q'-7=JINB^)] !KK
MI?+9:JBG@N-;%3RU#N&)KUV5Z^"&Q:J.:BHNZ+S0
M    I]TO_A%M?R)OWU+:6/\ (MO^3Q_=0S0             #SJ)HJ>%TL\C
M(XVINYSUV1/G(<U"UJI+=UM%CK/=-4F[5F7WK?2GB0)>;U=LEK^.NGFJYWKY
ML:;JF_H0D?3O1FMO+(ZV_.=1TCDW;'MY[D]/@6!QK&+5CE(VGM=*R)$397[>
M<[UJ;H                                   AO475N;%\O904E-'54L
M;4ZW=VR[]Z'8X9J-8LHB1*>H;!4]BQ2JC55?1SYG9IS3=
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M-:[BW[>?["0@"!.D2F^:81\K9]XG6B_[I#^@G[CV
M   !3_I?_"+:_D3?OJ6SL?Y$M_R>/[J&:          <EGN6LQRF8R%&R5<G
M8Q5[$\3&P#-&W]'T]9P1UC.:)V<2>@[8  Y?4/+X<.LONZ>%TSG.X&,3O78J
M]F>HE]RJ5R5-2^&D7DV")>%NWI\3]8/IY><IJ6=3 ^"C5?.G>W9$3Y^TL?@V
MFECQ5C9(H4J:W9-YI4W5%]'@=P
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MIH(J:%L5/&R.-J;-:U-D1#T
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M(C6>E=SVZ);E7 )T7?9*A^R>!RV T\4_25R)TT;7K')(YNZ;[+Q(3CJ?&R3
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M3&VKM#:1[5[)(43^!M@ "GW2_P#A%MGR)OWU+:6+\B6_Y/']U#-
M!^99&1L5TKVL9WJY=D(;U-QJ"*H6Y6J2%T3_ .U8U[?-7Q-'BV(RWN"6:2IA
MIXT3:-72)YRGE>L/O-F>YSX721-Y]=%[T_5KU-KL?5$K)TJHT3;JY'<T3T&E
MS36N[7>%U-9XTH(O]\U5ZPF/1K)WY-B44E2_BJ8%ZIZJO-VR)S4[P
M                                 P;M:*&[TSJ>XTL4\3DV5'IN0UDV
MA,,EPCJ;%5)'&LC7/@E39J-WYHA-=NHXJ"A@I*=.&*%B,:GH0R ?&N:Y-VJB
MIV<E/%U93,<K75,+7)R5%>B*A\]W4G_%0?6)_,]V/;(Q',<CFKV*B[HI]
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M"2HAO$53*UN[88D57.7P.%T1MU=EF?7?.*^F?!2R.X:5'IS5N_\ (U>I*_\
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M6H@BE5.2*]J+L>7X*H/^"I_JT'X*H/\ @J?ZM#+8QL;$8QJ-:U-D1$V1#Z
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MV?.=4Q[7M1S'(YJ]BHNZ'T
M A_I6+MI+4;_ /%1?N<4I!*?1SQ>W99F]107=LCH&TKI$1CN%=]T+.4^C.)P
M-<B4TSM_\4FYNZ'3S&*16JRTT[^%-OQC4<;!F(X^S;ALU"FWA$ANHHV0QMCB
M:C&-39&HFR(A^CX]C7L<QZ(YKDV5%[T,."TT$&W4T<#-EW\UB)S,W9
M                                       1YKG^%WX/4T]BML=PJ)E1
MBQ/;Q;)XIZ4(2Q;)-7\=M,5NI+$Z:GBY,ZYFZM3P0V_]8.LOQ;A^J)0T<O\
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M:F/FJIUV6>;F]K?\*+X'>
M         &JR>_6_&[-47.[3-BI84W55[U[D3TD)5727LC9G-IK+<)(T79'\
M*<_2>7E,VO\ Y%7_ .@D?2C4FFU BK7TM#/2)3*W=)4VWWW_ )$@
M%/\ I?\ PBVOY$W[ZEL['^1;?\GC^ZAF@               *FZ;*::]XU;+
MPU?==,Q9.'A:]&INA&U^TNJX%DDM4R31IS1C_?KZCCV/O6-5O-*BDF3N7?L.
MYQ_5)6(D5XIU<B)LDD?-?6I(EER"V7B-'4-5&]VV[F;\V^LVH
M
M                (<Z3]#4UF%4[H^):2.H8M0UO>WB0[/ ;#C[,0M?X.H*5
M],L+5:YT:.5?6JG0?@2U?\NH_J6_R,BDHJ6C1R4E/#"CNWJV(W?Z#(
M  *?=+_X1;7\B;]]2VEC_(MO^3Q_=0S0                #$N-MI+C3OAK
M8&2QO39=TY_21_?M+:65'26>987=T3N;?I(^NN/7C'JARR1O:C5_M8E\TWMA
MU+NE"U&5R-K(^2;N\U6I\Q)%@S>T7=B(V;J9>2<$G+=?0=.U4<B*B[HH
M
M                      .!ULRBDQC!ZR6KI6U;ITZED+NQRKR_80/A=DU=
M_ [*C&WLIK;4*LD4,LG-B+W(BIR0WWX)UV_XNE_UI_(E#1VDSBEAKOZ>312/
M56]3P+OX[]WJ)(        *?]+_X1;7\B;]]2V=B_(EO^3Q_=0S0
M         #\3PQ3QJR:-LC%[6N3=#C[_ *>6FYN?) U:6=WYS.SZ"-;]@EWL
MZOFB8L\+5\U\>_%]!X67,KU99.KZY\C$7SHIN:^KGV$CX]J5;Z]6QU\:TLSE
MV3GNWZ3N:>HAJ6<=/+'*SQ8Y%0]
M                                                    "+>D-8EN
MV%I41OB;+12MG1)'(U'(B[JG/T(;O3[-;'=<4H)FW"DA>V-&/C=(C5:Y.[93
MH_Z16;_FM#]>W^9ET5PHZY'+154%0C>WJGH[;Z#)        *?\ 2_\ A%M?
MR)OWU+9V/\BV_P"3Q_=0S0                   :&]XE:+PQ?=-(QLBKOU
MD:(URKZ5(VR'3*NI4=):W)4L55_%[[*B?.<K1W"]8Y4;125%.K%_LW;\"KZN
MP[S'=4=^&*]1<U7G,Q-D1/42+:[S;[I"V6BJHY&N[$WV7Z#8
M
M           'XJ)HZ>%\TSD9&Q.)SE[$0_%+505<22TLT<L:\T<QR*AS&I>%
MP9S8%M=5.^&-7([B9V\B)DZ,MI1.5TJ4^=?YGWR9K3_S6J^E?YDAZ6Z=46G5
M/7=36NE94<*N=*NR-VW\?6=W1U=/6Q++2RLECWVXFKNFY[@       I_TO\
MX1;7\B;]]2V=C_(MO^3Q_=0S0                    85RM5#<H^"MIHI4
M[N)O81YD.ES)%62SSI&J\W,D[/4A'];:KUCM0CY(IZ=Z+YLC._Z#I<=U*KZ)
M617)JU,#>2K^>258,PM%ZX64]2UDZ_\ A/793H6JCDW:J*GB@
M
M          !X5U+%74<U+4-XH9F*QZ>**0=7Z;9;A59)7:>W=T](JJ]]!4KR
M7T)L>46MF1V)JMS/$*B!6\NLIFKLOIYJ>J=)C'-O.LUX1WAU2?S/%^OEPN[7
M-Q+$ZRJE[&]<U=M_F4^Q8GJ+J"]KLLN#;+:).;Z2F]\J>"HI-&,6*DQRSP6Z
M@XNIB39%<O-?2;4  U5[R.T6-G'=;A3TR?YWHBF#8LXQN^R=7:KQ2U#_  :\
MZ/M[#X][8V*][D:U.:JJ[(ARU5J'BE+6I23WRC94*NR,5YTE'5P5L#9J29DT
M3NQS%W0]@ "GW2_^$6U_(F_?4MI8_P B6_Y/']U#-
M  !^)HF31N9*Q'M5-E14.(O^FUKN"NDHU=22[*J(SWJKZ2.+[@UYL^\BQ=?$
MB;K)#OYOK/M@S>\6-4C5W7PM39(IMT1"1[!J1:K@UK*U5I)MO.5WO=_0IVL$
M\51&U\,C7M<FZ*U=ST
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M (A95JHYJ*G8O,  I_TO_A%M?R)OWU+9V/\ (EO^3Q_=0S0
M         %1')LJ(J>"G.9!AUJO7$^>'@G5-DD9RV^8C>_Z97&C<^2VO2J@3
MGLOO_H.;HKM>L:JU:U\M/*G:R1.[YR0+!JE%(J1WBG6/DB))'SW7Q4D&UW:A
MND?%0544Z(FZHQVZIZS.
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M]/LRZ1MJ6?XV[-5/YDD6'*[5>8^*GJ&L=V<$BHB[F^
M
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MU$2+YS9>;OI[B2\>U!M5T1C*AZ4M0Y=D8Y=T^D["*1DK>*)[7M\6KNA^@
M
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M0+"C$X:6"1.?T>!8-.2;(  4_P"E_P#"+:_D3?OJ6SL?Y$M_R>/[J&:
M                     %1%[3F+]A%GN[7*ZG;!,O/K(DV55])&M]TVNU!Q
M/HN&KBYJB,[43T[FCM5^O./3HV&:>-K%YPO5>!?F)$QW4^EG:V*\1NAD[Y4]
MX=];KE1W&!LU'41RL=V*BF6
M                                        1]K@R[3814T]CM"W6>54
M:L"-W7;Q^8@_#[QJ_C%M]PTV+5T].U?Q;96+YB>"<S??T[UC^)<_^A?YDFZ0
M7S+[S#7.S.S/MCF*WJD<U4XNW?\ @2,  ?'-:]JM>U'-7M14W/#W#2?\+!]6
M@]PTG_"P?5H>L4,4**D,3(T7MX6HA^SR=30.=Q.AB5WBK$W/5$1$V1-D]
M*?\ 2_\ A%M?R)OWU+9V/\B6_P"3Q_=0S0
M :N\6&W7>/@K::-ZHG)VR;H1Q?\ 2V5B.EM%0CT[5CD[?4AQ$L%ZQJJ:LC*B
MDE[6KSV4[+']4*B!L<5U@ZUC>2R,7SE)&LF3VJ\(QM'5QK,Y-^J5?.0W0
M
M            !^9'MCC<^1R-8U-U5>Q$.,KM4<0HJE\$UYI^L8NSD1=]E,=^
MKF&HQRI>(55$WV\37:.ZFSZ@55W9)014T-&]&Q21N5>-%5>:[^HDX
M I_TO_A%MGR)OWU+9V+\B6_Y/']U#-                            !X
M5='3UD3HZF)LC7)PKNG<<#?M+Z"I5\MKE=3/5.4?:U5]:D>7G%;S89%?)$JM
M;SZV%>2&QQ_46[6Q$CJ.&K@:FR-?R5OSDD8_G]INK4;+(M-,B><DG)-_0IUS
M'MD:CF.1S53=%0^@
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M6[;^:Y%/<
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MY9'HOXQ6_F'34-7#74L=13/1\4B;M<A[@
M                                           '+U&>X[3Y.W'Y;@UM
MV=MM#PKW^DS\KR>U8K;5K[[5-IJ5%X>-45>9Q3-;=/6.5S+U"UR]JI$J;_L-
M->-1=(KS4-GND]!53,YH^2!55/V'?8+EV.9-2R1XM4QS04R(US6,5J-WWV_<
MIU(       !3[I?_  BVSY$W[ZEM+'^1;?\ )X_NH9H
M              !BU]OI*^+JZRGCF9X/3<X#(M,*>H1TEIE2&55W5K_>[>@C
MF[62[8W.V2H9)!SV9*U>2^HT\LKYI'23/5[W<U<O:IV."YL['F/@JV2STB\V
MM:OO5]!W$>J-H<B*Z&=JKW+MR,V+46Q/=LZ=6)XJADQY[CKT55N#&^M%,N/+
M;'(C>"X1+OV&;%>[=*[A960JOZ1DLK*9Z;LJ(E3]-#T2:)>R1B_]2'Z1S5['
M(OJ4^@
M            ''7#'L/;E"7FN@HVWEFWXY[]G)\VYD9-%BN36]:&^24572JJ
M+U;Y$VW^DY+^K32S_EML^M]H_JTTL_Y;;/K?:=;@^.8O8&5#<4IZ:%LBIUO4
MNXM]M]M_VG4@       %/^E_\(MK^1-^^I;.Q_D6W_)X_NH9H
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M751+MV^<AD-J(7)NV6-4_20_22,7L>WZ3ZCD7L5#Z
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MVWX(W;J;T  I]TO_ (1;9\B;]]2VEC_(MO\ D\?W4,T
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M>Q#"I;K0U=0^"FJHI)F>^8U>:&:
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M_?>LL%C>1T=ZML50R5C)%39T:N3=%-VU4<F[514]
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MS#-+?78_5>Z::.E;$YW"K=G<:KMS+HV/\BV_Y/']U#-
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MO:'+[)6JB05S%W_Q<C;Q5M+*F\53"_U/13(145-T7=/0
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MC^ZAF@
M  QZ^CAKZ26FJF(^*1-E13C;!IU06NZK62/69&.WB8O-$]9W6Q^)(HY&JV1C
M7-\%0UU3CUHJE5:BW4TBKWJPT=;IY8JE%1L#H=_]VNQHJW2FF5%]Q5;FKW=8
MJJ<]5:77F!%6.>GF]#-T-4_$\FMSGK%25#43\]CN2GFR]9-;7HUU57-1/S7;
MJAM*;4B_4W*7JI&]_6-7<WU!JPQJ)[MHI'>/5[&^HM2[)4)^-62G_3]AO*/*
M[+6;>Y[A$[?YC:Q54$K46.:-R+X.0]D5%3ES
M                  (?Z2;>+'+9U^Z4?NR/KE[MN)-C;:GI3MT>JDH^'W/[
MF3@X>S;8W>E*HW3RT*]41J0)NJD>:(R1U.I><U%OV_![IF(U6]BKL[?;Y]R<
M@  :[(_R#</U#_W*0'T1T5'9%NBI^/7M3;O0L:5VUCP*^6?-8\YQ"%U1,UR.
MG@C3SN7;V=VR'NWI$I%2MIJG':]MV5NR,X?-5QK-.\1R+/-0?Z89;2OHJ6#^
MQAD3WWALB]Q95J;(B)V)R  *?]+_ .$6U_(F_?4MG8_R+;_D\?W4,T
M                                                       \WP1/
M14?$QR>EJ&KJ\9M%7OU]%$[?_*:&NTWL]0U4B1\"_P"1$-#6:3L1%]QUSE7N
MZQ#1U6F5ZI]UBDAD3NX%7<U4F-Y+;GJK*6JV3\YJ\@S(\DMKVI+45+6I^:[?
M93<4>IUVITVD@BE]+U4WU'JO!R]V4;T\>KYF[HM2+)4IY[WP?K$-Y29/9JO9
M*>XP/5>[<VD4\4K4='(QS5[T4]
M     #19MC5)EF.5=HK]TBF;R<G:UR=B_25QRFPZEXM8*S'(6I=K$Y%;"K$1
M7M:?JP/U6OV/TV/T5&VUT36=4Z25-E5I/&EV$4V#X['0Q/6:J?YT\R_GNW5?
MXG8@  .1'(J.3=%[4/&FI*>EXO<T,<7%S7@;MN>P5$5-EYH8KK;1.>CW4L*O
M3OX$W,EK4:U$:B(B=R'T  I_TO\ X1;7\B;]]2V=C_(MO^3Q_=0S0
M                                                        %3=-
ME/&2E@D39\+')Z4--7XA9:Y7+44355>W950T=9IA99D_[.LE/ZO._>:.LTFX
M=UI+BY_@CV(AHZG36^TW.)87M_ROYFJ?9LBMDRJV"IW;^<WFAD1YADMMV1]0
M]K4[GL3F;:BU4ND*;34L-0OI7A-[1:KTKMO=M&^/ESZM=S>T&HECK$14EDBY
M[;2-V-Y39!:JE42&NA<J]W$;*.1DC>)CD<GBBGZ
M              !7?5G6Z[8CFM19Z*CADBC1NSG+SYFLI=9L\JX.NI,=Z^/;
M?BC:KD_8AC.UQSQKE1<4JMT_^@[^1^':ZYTU/.Q:I3UPN_D2OHGG-[S*&X.O
MEM?0K K>!',5O%OOOV^HE         I_TO\ X1;7\B;]]2V=C_(EO^3Q_=0S
M0
M       %1%394W0Q)K90S_VU) _])B*:BLPNQU?%UE$UN_\ @\TT=9I?:)$_
M[,Z6'UKN:&LTGE8CEIZ])/!',V-'4:>WZC57P-8K4[V.5%-<Z+);8]=O=Z</
M+S>)4,N'-\DH5\^9R)X2,-Q0ZJU\342II8YU\478WM#JI1R;>ZJ1T7Z*[F_H
M,\L=8B<-0YB]FST1/XF\@N]OGVZJM@<O@CTW,UCVO;NQR.3Q13Z
M                       #B,YTOQG,G.ENM%PU2IM[HA7A>OK7;F1/<M)\
MWPV5:O ;Y-40L][1R/W^E%Y*+1K5D>-U#:#4+'I&RHNSJB*/9$3QY<E)<Q74
M3$\HA:ZVW*F<]>2QR)P.1?#93L8TCX>*-&[+WM[S]        %/NE_\ "+:_
MD3?OJ6TL?Y%M_P GC^ZAF@
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MY$W[ZEL['^1;?\GC^ZAF@
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ML?Y$M_R>/[J&:
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M  C6OY$W[ZEM+'^1;?\ )X_NH9H
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MVEB_(EO^3Q_=0S0
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MUISGV19#9[CDMUHI9*"1'1<$;(UVWW7L7F6&I&.931-D7=Z-1%7TGJ
M    %Y)S.5S#.;#C=LJ9ZVY4Z2,:J)&QZ.=Q=R;(1GT:LGN&3UN1U=?65$\3
MIU=$R1ZJC$Y<D3N)V(SUJU%7#+7%2VQ$FOE8J,IXMM^WEN1O287JS>*9MWGR
M!])4;<;*5)%1%WY[;)R.GTBU'NSL@GQ/.6I#=X^<+U3;K$\";0 "G_2_^$6U
M_(F_?4MG8OR);_D\?W4,T
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M?S*B]+F:*;4.UNAE9(WW$WFQR+^>O@6WL?Y$M_R>/[J&:
M               JHG:IREWS:BMF96[')J>=U56MXF2-1.!O;V_0=7NGCS
M                   !P>6:@_T:RFCMM=:JM:"H;SK6)NQB[]_><]964F/Y
MME&45=<KZ&9C5C8U5<J^;OV'7:<YA-F%'4U3[54T$+'\,2S?^(GBAKLIU%_H
MWE]/:[A:*O\ !TR-3W>U-V-5?';F<[:*>EQ3,<CR>LKEEI)HE<R-JJY>;MT1
M$.QTWS&HS"CJJJ6T55NBCDX8^OV\]/%#L3'DKJ2)ZLDJH&.3M1ST13\_A*A_
MXRG^L3^9[13Q3)O#(QZ?Y7(IZ                          'QS6O39S4
M<G@J;AK4:FS41$\$/I\<UKDV<B*G@J&IRNCJJO&[A36J9]-5OB7JI(^2H[T$
M&Z3:I_@+W58M2JJIBKH7[-J*MJO1>:\M]CH=3M6,9FQ2OMF/U:7*Y5D:PQ0T
M\;N2KWJNQM^CSBE9C&$M;<X^JJZEZRN9WHBKR)15$5-EYGX2*-%W2-B+X['[
M/RK&JY%5K55.Q50_1^6L:U55K6HJ]JHG:?IR(Y-G(BIX*?&M1J;-1$3P0^JB
M.39414])^6QL:N[6-1?0A^CXC&M55:UJ*O:J)VGU41R;*B*GI/RV-C/>-:WU
M)L%8Q7<2M:KO';F?7-1R;.1%3P4^,8QGO&M;ZDV",:URN1K45>U40*QJN1RM
M:JIW['Z/B,:CN)&MXO';F?3\.BC<N[F-5?2A^T1$39$1$]            -=
MD?Y!N'ZA_P"Y2 ^B-VY%^O7]Z%C5[%*NXJGN#I3W*.?S5>UW#OW[L0M$5RZ7
M4S9%QBD9SF]T.=PIX;(3YCD3H+%0QO\ ?-B:B_0;$%+M6-/=0ZO-J^>:FK;J
MV1RNBGIU56I&JKPM]:(<A_5KGO\ R"[?M_F<]D%BO%@KH::_T=125+T1[63]
MJMW[3^BEC_(MO^3Q_=0S0                             </JCCUZOE%
M128]>%MM32R=8N[MFR)X*IRU3?>JO]K_  M2,FO<#%8D\7G1;\]O.-U@>/Y(
MW**Z^7Z],G@J&[14<#^*.--]R1R$=6=7KQB^906#'+5!<:E[$<YCE7BW5-T1
M$0TBZJ:J;_W!_8X]J/76^6>KA9G>+S6V"5W"V1B+_$G:R72EO5KI[A;Y4EII
MV\3'(9H/"LK*>B@?/5S1PQ,3=SGNV1$(HR+72PTMU@M=B1]SJY7HSCB3=C=U
M[R4OPA##:VUM;(R"+JT>]SEV1O(BN[=(+$*"N6GB6IJVH[A66%N[3O<-S6R9
M?2==9:QDRI[Z/?SF^M#HP8%\O%!8Z"2MNM3'34S.U[UV0BJHZ0V(Q7#W,UM7
M)'O_ &[6>82=C.16O);<RMLU7'4P.[VKS1?!3;$?9OJWC&(U"TU;5+45;>;H
M8/.<GK/#"]9,6RFJ;2P5#Z2J=[V*H3A5WJ)(1=TW3L!Q^5Y_:\;R"UV>K9-)
M55[N%G5[*C?2IV#5W:B^(         ([S/(;\F44ECLMB;413-WEK)V_BXT]
M9SEKM#8\FOK;-4Q5%^ID:YU/*OXM55-]O4=GIGD5TOM#4MO=E?:ZFG?P*G#L
MQ_I;Z#5YCDF0?TMAL%DQ]*B*1J*^MJ&_BV(O;S\3GK=:H8,BN_\ 1^ICK+W3
M1J]]/,OF.7?FAVFF6272_P!%5)>[)):JFGDX%:K=FO\ 2AV4\C8H7R/79K4W
M52H6/X8_5G47)9I[C4T=/33</%&N^_-43]QV_DQT7QFN'T>TYB_VS)M$KY;*
MRGNLU?9)94C5CW+S]"H6FM5:RXVZGJXO>2L1R&4 "(]7M3ZC'Z^#'\8I4KK[
M5<D8G/@W]7><4ZFUDMT*WJ2:.HCVZQ:+C551.W;8D_2/4>GSBVR,GC]RW:F7
M@J*=>U%]'T$A @_4C5&Z5&2IBF!4J5=R[)ID[(CG*FHU<PR%;Q<G1W2D3SI(
M&N558A,VF>;46<8['<*/S)D\V:)>UCD[3K'N:QJN>Y&M3O5=B&.D%J3%C]CC
MH+%<FMN\\J-WA=NK&^))& 5<]=B=OJ*N599WQ[N>O:JF^ED;%$^214:QB*Y5
M7N1"O%ZU(RS-\HJ[)I_3MBIJ9ZQOJW*J;+X[^'(QZY-7,$I7W6X54-YI8UXI
M(VO5VR$O:6YY1YW8?=M,WJYXU1LT2_FNV.S                  !I;[BME
MOK=KK;J>H]+F)O\ 28=AP3&[%(DEKM--"].Q48BJATR)LFR
M           UN2?D&X?J'_N4@3HC=N1?KU_>A8TKMKU8*W&LPM^>VF)TD<+V
M^ZVM[=NSZ-D._LVM6'5]F;6RW-E/(C-WPR<G[[<T1.\BJ@EDUFU<AN%-"]F/
MVQNW$]/?+_,L\QJ,8UJ=B)LA] !3_I?_  BVOY$W[ZEL[%^1+?\ )X_NH9H
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M&^U+6N;2/F\U%[RQH
M/*KIXZJFE@F15CD:K7(G@IS6$8%8\+]U?@*&6/W2[BDZR17;J=4>-92P5M-)
M3U<+)H)$V<QZ;HJ>HCJNT/P:LKDJY+4K9$7?AC?PM^@[FPV*VV"B2EM%'%2P
MIW1M1-_6;(  I_TO_A%M?R)OWU+9V/\ (MO^3Q_=0S0
M            #QDI*>2H9/)!$Z=G)LBM17)ZE/8U>45R6S'KA6*NW4PN?OZD
M*=:6Z@7#$;M>;E1X[479U;,KDE9Q;-YKRY)Z22?*&R%>28)5[^M_\C6UE+G>
MLU9307.E=:+$QZ/>QS51?W<RPEALD.+8I%;;6WS:6+9O+M7Q*>W.^W#*LZDH
M\_O-=;Z+K5C1C6JUJMXMMMMT3YRS^FN$879Z&*;&X:6K<G/W0JI([?U]Q((*
MTY%M7=)BD94)Q-A1O!OZT++$'=+")G]"()]OQL<[.%?G)+TTF?48)9))-U>M
M*S?Z#I)%VC<J=R*5KTR=[KZ1N32S<WHU=M_F++%;NE$QL658I4,3:7KV\T_2
M-STF:B1=-K6Q57AGD8C_ -A*.F,#*?!+/'$FS4A_BIM,FB9-8*^.1-V.B5%0
M@_HG3/ZG)*?_ ,*.K7A3PYN+!E7]65_^(>Q?H,_>I9Z+^S9ZD/T
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M)E%3=5C3CZB9SE1VW/O53M>C9F5/<;=/CTE#'15U"FSD8FW'MRW7TDW@
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M5R]R;(0KT9Z&KO.>7S)NI?#1R[HFZ;(JJN_(L^
M                           4^Z7_ ,(MK^1-^^I;2Q_D6W_)X_NH9H
M                            !"'20QN_Y5^![?9;?-4TJ2<<SVJFS>[F
M2WB]O_!>/6^B5O"L,+6*GI1#:  '/Y5AUCRBE?#>+?!.JILCW-\YOI12&)=&
MK_B%^AN&#7:5M%UB++3*Y45R;\T).U%P6GSO$8Z"X;,K(VH^.14]Z_8B"@I=
M8L.IDM%OITN=*Q>".951>%O=VG2:9:57=<H_I5G52VIN/;'$J[\'K]1)NI<-
MTJ,,N,=@ZW\(JS\5U2[.W]!R?1_HLJH\>K&9G[K]UK-NSW2_B7AV0R=9M-FY
MS;X9J&5M-=Z9=X9EY<O#<C2"76BU4K;-%2)4Q-3@2KW151.SM.VT=TLGQRMF
MOV2SMK+[4*KE=V\&_I)8KJ6*MHYJ:H8CX96*QS5[T5-BN=7IUFVGE]JJ[3Z5
M*FWSKQ>Y-^_THIYOPG434RNIDS9R6ZV0NXG4^_OOF3O+$V.UT]FM5-;Z)B,@
M@8C&HB>!G%?M1\-O]RUMM%WH;;+-;8FM1\[539NRJ6 C39C47MV0^@
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ML]JH;-1,I+931TU.Q-D9&FR&:
M              4_Z7_PBVOY$W[ZEL['^1;?\GC^ZAF@
M
M PKU<H;3::NX5".=#31K(]&<UV3P-=A64T676-ETMK)60.>YB)*FR[HNRF^,
M.\7&&U6RIKJA'+# Q7N1O-=D-;AF44>662.YV]DL<#^Q)41%0WQA7FY0VFU5
M5?4(YT-.Q7N1G-51/ P<-R2DRNPP7:WLE93R[[)*FSD-V
M                    4_Z7_P (MK^1-^^I;.Q_D6W_ ">/[J&:
M
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MT
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M ,(ML^1-^^I;.Q?D2W_)X_NH9H
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MOG3<X;HHU+YM.7,?NJ1U#FM]6R$TE5[>O_Q0U?Z:EJ
M0GK-J9D>,9306;%Z&&LGJ&*Y6.;NY5]!RW]9.L/Q1;]6AU^E^9ZA7G)&TN58
M^VAMZM55EX-N9,P !3_I?_"-:_D3?OJ6SL?Y%M_R>/[J&:
M
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MK'61RN9[^/L<WUH=*  4^Z7_ ,(MK^1-^^I;2Q_D6W_)X_NH9H
M
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M'#2TS49#$U&-:G<B'N5RH<3OS.D/57=UKJ$MCGJJ5&WF+\Y8T
M      $$ZA:-W#,M2$NU3/#%:%5O&UKUXW(B)NFQ)5-IUBM/;4H666D6'AX5
M56(KE^?M*_Y%0?U0:OT,UED=':*U//AWY>HM3"])86/3L<U%/V"GFIFMF<46
M8U]+3.6S0P/6-E.Z/=7(BJB/\[Q.6_KVS[_GB?5-.2RW+;QF%R@KK_5^ZJF-
MJ1-?PHW9N^^W(_H98OR);_D\?W4,T
M
M                     #N*ZW'/[[BVN*V[(*QWX!E7@B14V;YR)LN_K+!,
MK:9]-[H;41+!MQ<?$FVWK*NZIUT>H6LEJM%I7KZ>F3SI&<TWY[\T+34T:14\
M<:=C6HAZ U5RQRRW.I]T7*TT-5/LC>LF@:]VWANJ&+_0S&?B_:OLC/Y%4NE;
M;:&UY];(;914U)$M&URL@C1B*O&O/9.\M_8_R+;_ )/']U#-
M
M                                         ./U#T]LN<T"0W:%4G9_
M9SQ\GM^?P(JDT$O;9&P4^95K+;V+ N_9X=I)&FNE]DP5DDE"U\]=+[^HF7=W
MS>!WH !3[I?_  BVOY$W[ZEM+'^1;?\ )X_NH9H
M
M                                   !3_I?_"+:_D3?OJ6SL7Y$M_R>
M/[J&:
M
M  4_Z7_PBVOY$W[ZEL['^1;?\GC^ZAF@
M
M                            %/\ I?\ PBVOY$W[ZEL['^1;?\GC^ZAF
M@
M                                                         %/N
ME_\ "+:_D3?OJ6TL7Y%M_P GC^ZAF@
M
M                          %/NE_\(MK^1-^^I;2Q?D2W_)X_NH9H
M
M                                                    !3[I?_"+
M:_D3?OJ6TL?Y%M_R>/[J&:
M
M               8=VN=':*"6MN-0RGIHDW<]Z[(A%=7T@\/@KDIV>[)F*NR
MS1Q[L3Y]R1<4RFT950>Z[+61U$2+LY&KS:O@J&[  *?]+_X1;9\B;]]2V=C_
M ");_D\?W4,T
M
M     KEK?=:S+]1+;@E#.Z.DXVNJD:NW$G;^Y26;1IEBMNLZ6]EHII(U9PN>
M]B*Y>7;N0M5P.T=U=I66Z1[<?N:>=$J[HBEFXWI)&U[>QR(J'Z !3[I?_"+:
M_D3?OJ6TL?Y$M_R>/[J&:
M
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M.0?*6?=+&                      %->D5\/\ 3_\ ^G_ N4G8
M              8]Q_)]5^J=^Y2H/1:^&2O^3S_?0N,
M       5 Z7R.746V;-<O_8F]B*OYZELK'^1;?\ )X_NH9H
M        !3;2!KO*6E56N1/=-7S5%\'%R0                     ""NEW
M;JRMP.@EHZ:6>*EJ^MG<QN_5LX53B7T;F'T/;=64N+7:JJ:66*GJIVN@D>W9
M)$1-E5"P(                     !3;I$M<NO].J-<J?\ 8^:(OH+D@
M                  &/<?R?5?JG?N4J%T6VN362OW:Y$]SS\U14_/0N*
M                     8=9:Z"MD;)645-/(U-D=+$CE1/6J&8U$:U$:B(B
M<D1                       84-JM\%4M3#0TT=0JJO6MB:CN?;SVW,T
M                    \ZB"*HA=%41LEB>FSF/3=%3TH?*:GAI86PTT4<,3
M?>L8U&HGS(>H                     !AU-JM]54)45-#32SIMM(^)KG<N
MSFJ&8                      %1%147FBF'26JWT<RS4E%30RKR5\<36JO
MSHAF
M
M
M
M
M
M
M
M                           %?<QUZN]ES"XV.W8W%7+2OX4<V1W$J>.R
M&N\H#+?B*[_4\SK3TC.JK(8<IQ^:VMD7;B9NNWTD]6FXTMVM\-;0RI+3RM1S
M7(98   !&N(:D5%^U"N^-R6^*&*A1529'JJN\Y4[/F,G4#/:W&,CM%MI;6E7
M%6KL^57*G5G?Q.XXVN5-E5$78_0                !QVJN65F&8K-=Z&AC
MK71.1'1O<K>2]_(]M,LO9FN+4]V;$V%[^3XVKNC5.K5=D55[$(-O&NWX/U,_
MHRVVQ/I&U#8'5*O7=-U3GL3A&])(VO;V.1%0T^9WUF-XU7W61B/]S1J]&*NR
M.7N0YC1S/*W/K))<JRVQT4:.5K$8]7<7/TD@@ #N(RL6I=1<]5;GB+[?$R&D
M8KTJ$>JN=S1.SYR30#XYR-:KG*B-1-U5>XCG+-9L0QJ=\-76OJ)6<G-IF\>R
M_2;#"]4<8RYR1VNMX9U[(IDX7+\QVX             !$.H.K=9B&>4-CGM,
M,E%5.:UM2LBH[GV\B6X9$EB9(WWKD14-/FE_CQG&JZ[2L1[:9G%PJNVZ^!P&
MBNKCM0ZNNI:F@BHIX$XF-8]7<3?'F2T19K)JI)@-=:J.CM\==45JJG"]ZMX>
M>W<219ZF:LM=+45,20S2QM>^-%W1JJG898 !I<SO3\>QFOND<+9GTT:O1CEV
M1QHM),UFSK&_PG44;*1_&K>!CE<G([< \JNIAI*>2>ID;%#&F[GN79$0BR[:
M^X5;;BE(^HJ9G*NW60Q\3$^?<[O%,LL^4T?NBS5;)VI[YOYS?6AO0
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M('<MVKV+X*;,'%7S4JPV?+:/'*A\S[C4JB-2-G$UJKV<2[\CM47=$4
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M"E;(K6-9W<C%U*PRMTP9#DV&U]7'14[V^Z*9\BN;PJO/EX$C9=?(<CT7K;I
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MFN7?EZ^Q3YJHU&:^XRUJ;-:YB(B=W8639[QOJ/H
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M9TH^'K*OT5^^I[Z_?")B7Z:_N4W72:^#)GZ3?W'<:3?!_9OU#?W$6=*?_O\
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MU!U-BAM\]K7'[2KMYEFW;(Y.]-B9\4L=/CEAI+71\2Q0,X=U7=57O4VP
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M$3T'T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M    ^.<UJ;N5$3TJ?&2,D]X]KO4NY^@
M
M                           11K=JY2X!1)34;6U-XF14CB7L;Z5(1MEE
MU?U"5UP2NJ;=22^<QKY%8Q47P0RJS336"P0K4T=[FJE9YW5P3JJK])TFE.NE
M?37A,;U IUIJMKDC29VZ*CM]O.W+*M>V2)'L5%:Y-T5.]"MN!YU?Z_7FNLE5
M72/MS'2-;$J\N2;EE       "O6ON:7S'L]L%%:JV2&GG<WK&-79'<T)^M[W
M244#WKNY6(JJ>X!\>]L;'/>NS6INJKW&IMF2VBZ5DE)05\,]1'[Z-CMU0VX
M         -;DEWAL-BK;G5?V5-$Z14\=D["L=IU/U*SZZ3S8I;8TH(7[;INB
M;;]_/MV+)X[5U<.+TM3D/#!5-CWGW7DU3(LM_M=Z23\%5L53U:[.ZM=]C9@
M   B75#7&P835/H&-?<+DWMBA7DQ?2I%K>E'<4J=WX^GN;?N1V^Q+^ENL=AS
MV1:6G5U)<43?W/*O-WJ)-  "JB(JJNR(0GJ5T@;'BMQEMMMA?<JZ/D]8U\QJ
M^'I."H>E'6-J46XX^J4V_-8T5%V^<GG3G4*R9Y;5J;--^,8B=9 ]?/9ZSL
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MP?%9[M4HU[FJC(XU7W[EWY?L,72+-7YWBK;O)3I3N61S.!%\-OYG;
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M7/-5E=,VKQJZ0/3=KZ:1O_VJ54Z*50^AU"NU Q5ZM5X53U;EP#SJ7]73RO\
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M17-1?H:I%FMN;7[,76*2^8VZS11S[Q.<]55ZKMXH7&PK^ZEK^3L_<0#TS/\
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MHV<2*L<STV3NYDSE>>F+6MAQ6AIN+9TSUY>I4.UZ-E*^FTJM7'_XB*].1*)
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M'J;0YU[@QG$Y%JXY94ZR1B<G+OR1"P^E.,)B6$V^UJFTK&;R+XN.N
M     (KIL4N%RUGJ<AN$/5T%+3]33*OYR\2+N2H   >-:Y[:.=T+>*1&.X6^
M*[<B-=$\5N%F??;K>XNJKKG5=;P>#=B4
M                                     "/=;;-<LBQ5EHM4*R+4S-;*
M[_"SO4[+'[>VU6:DHF)LD,;6?0AL                    :;+<:MV56>6V
M7B-TE+(FSD:[A7Z3\89BUMQ"RQ6JRQOCI(U56H]W$O-=UYF\           !
MRFH>"6C/+6RAOC)'1,=Q-5CME13F\'T0Q'$;DVX4=*^>K9[Q\SMT;\Q)X
M                    #E1J*KE1$3FJJ:^W7JV7.::&W7"DJI85VD9#,UZL
M7THB\C8                               &OJ+U;*>X14%1<*2*ME]Y
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MG-S/ [[2;+HLRPZDN35;UVW!*U%[')R.R
M            !7_5/2O)ZC,G91BM^932\:/ZJ>96HBIW)W;&JJ\F<_,K/7W&
MU\654U/)#LQS>KE=MLC^+?AVWY]IE89IOF-\SN#*,KOD:11NXFT]/-NJ)W)R
MW0L-/#UM+)#Q.3B8K>)%YIR*UP:?YQI[E<]WLUZIZRW.D61]+-.B.>W?FFSE
M1-SQLUXF6ORJ/!J-(+Q<WQI)+.Y&-I^2[[*NV_->X[70W3&^8K<ZN[Y'>?=M
M34)[R.17-15[=R:BM/3+O*QVRSVJ)Z\4DBO>U.]-MB5-";&RT:8V:"2)$D=&
MKW<2;]KE4[_J8O\ =L_TH1CT@\:M=VTZN<]730I44T?612\*(YJIW;D>=#"O
MGEL-TI)'JL,;T<U%[$4LH   54Z2^75N193283997(WK49.C%VXG+MM^\E+3
M_1#$[%9(&7*U07"M>Q%E?4M1^SMN>W(X/I Z,VVELBW_  ^D2BJZ5462*#DU
M4\40ZWHPYW-E6)/H;C+QU]O7JU5R\W-Y<R: 0STG<XEQ?#VT-NE5E?<56-JM
M[4;WG(]'[1BU5-A9?LMI$KJJJ\Z.*;SFHWQ5-NT[K4+1#%+[8YV6NUT]NKF,
M58I*=J,15VY;[)S(JZ-6:5^/954X3?)7=7UBMB21?>.3N3UEKRO>INNUTQR\
M5EJMEBJ))HMT;.L:N;OS[BLU[R:]97G,%QR%S_=3WMV:YBM1J;\D1.Y#^AU@
M_(E#^I9^XSRFFOM[K\VU7I\5IYG>XXIVQ-8WDG/;=5+$X=I'B6/6F*F2STM3
M/PHDDT[$>YR[<^>Q'VOVC5BFQ6IN^.T$5#<*;9ZMA3A:]-^?(_71$RFLNF,U
MEIKY7S+0OVC<[GLWP^DL" #\RLZR-[-U3B14W0K3+ISFV#9C47VPWR"IH'2+
M(ZFGGV<]J]J*CMDW/&TWR5+[DLF'T74WZX-:U[IG-8R!5[5W79%^93KM#],,
M@QR^U=]R>]I6U%0WE'%*KDW5=UW[B4,\Q]V3XO6VIE2^F?.B<,K';*BHNY N
M-V+,--8*ZAO5937G':EKFRQLF17L1>6Z(J[_ #(AB6_\/7["(<;P!8[?1/>]
M9:N>1&.=NY>2(JH[]A,6BV"5F#8ZM+<KBZNJI5XGN1RJU.:KRW]9O-2,9DRW
M$JVTP53Z269/-E:Y4V5/'T$%8_9LJTZM]=:\GJH+SCM2U6N;%,CGQKXHBKOM
MZ$0Q*2GR/)L(M^.X'+%;+6WBZZHFE1CI=W+V)OQ=_@3=H[AE3A.)LMU?7.K:
MESN-\G$JM3U;G<E.=;JEV6:ZVVUP*LD<3F1[)W*BKO\ N+=6VAAI:"G@;$SA
MC8C4Y)X&3U,7^[9_I0K)TOL:ME);*2]TM/'#7]8C'*Q$17=O-27]"JZ>OTUM
M$M2Y7/2)&[KX)R._-1D.2V?'J5T]YN$%+&W_ !NY_1VE?-0.DFDCW4.!4CZF
M;=6I4OCXD7U-[3C[-ICJ1J=4MK\JK)J2AE<CMIWJB*W_ "M3?8L#@6C6)X@V
M*6GH4JJUJ)^/J-GJB^*<N1)*(B(B(FR(>=1,R""26141C&JY54IE=6U^MNL,
MM&DLGX(I7[;(NR-C1R(OS\RR=MT@P>BMS*3^CU%-PMX5EEC1SW>G<KMK5@4V
ME.2T638F^6"A=*B\+7?V:\N2^A2T&FV4Q9?B5%=8E3CD:B2(GYKN]#IS\R/2
M.-SW+LUJ;JI3',:VX:Q:P_@6FGD_!4,O C479&M:OG+^\L?9]'<(MUNCI5L%
M'4*UJ-66=B.>[T[D!:[Z=?U;7:ARG#EEI:9)//:UW]F[?]Q8O2/+VYIA='=%
M5.O5.&9J=SD4P-<<U3"<)J:N-_#5SHL4&W:CMEYD(]'S2BFR^.7+,P8^K;/(
MY8XY';H]=^:KXH31DVC.%WBT3TL-DI*.9S5ZN:G8C'-=MRY[$ :.WJYZ7ZJ3
M8M=97_@^HE6+A>O+MV1R?07&8Y'L:YJ[HY-T(6U?UEK,(OJVNCLE15O6/C;,
MUBJU"J.HN;Y!FE_BJ\@22-J.VBBX%8UJ>A"^&EWP?V#Y'%]U#J  5/U&JGYY
MK[;[&QZR4-%*F[4[$5.W]Q:EL38*+JHT1K&,V1/F*'Y/C#LIU:RFDBXEG9(Z
M2-$7M5":>B'DBK;KIC59)^.I)=XF+V[<^+]I8XYS42_18WAMUN<S^!(H7(U?
M\R\D_:4/_ \ETQ>[Y5<4<Y\E1U;'+WN7F6_Z,_P56S_J_>I*AXNJZ=CN%T\2
M.\%>AZM<U[=VJCD\44^@\Y:B&%=I98V+_F<B'[8]KVHYCD<U>]%W/H/.6HAB
M7:66-B^#G(A^V.:]J.8Y'-7O1=SZ  0%TN\:_"&%Q7>&/BFH7HFZ>"KL;7HL
M9%^%\ CI)';RT?XO;T<R:%79-U*?:SH[/]<J:PPJZ2"FVB<C5[$[54\]%II=
M/-:ZO'*F18X)9%C5'=B^:O#^]"XI#_2EOWX'TQJ8(Y.&:M<D34[UV7=3FNB-
MCJT.&U]UECX9*MRHQ?0B?S.)TU_VE+K^D_\ >A;:2HAB=M+-&Q?!SD0_<<C)
M&\4;FN3Q1=S]&+#;Z.&H6>&FA9,O:]K415^<CGI&SRTVF==)3ROBD14V<U=E
M-)T3JJ>JTX5]3,^5_7N3B>[=>TFL'BM53H_@6>)'>'$FY[(NZ;IV ^.<C6JK
ME1$3O4\F55.]W"R>)SO!'(I[   '#:U2R0Z<7F2%[F/;"JHYJ[*A'O1%JZBK
MPZJ?53R3.2=R;O=NO<3V?E[VQMXGN1K?%5V/Q'4P2KM'-&]?!KD4]0><D\,2
M[2RL8O\ F<B'V*6.5-XGM>GBU=S]D"]+BKJ*3$*5U+/)"[C[6.V7M0[S0N:2
M;3.S232.?(Z)-W.7=5.LR2W1W6Q5U#,U',FB<U47U%;>C!<YL?S>]XG6.5J*
MJR,8O<J?_DM(                                       "OVH^GF<9
MEGZL=='4V-*]%1(Y%3S>]-O$P;C)8[?J=:<$CI6+;6T[XYE5.;GN;[[UF1C&
MEV98;J)3R62ZNFQQ7*KHY)%V1O@J%@:E)5I)$A5$FX%X57LWV*ZX]I)D]ZRV
MINNH%S?+;XI5>VG1ZJCT3FB;>!A8A%;=4KCF%DD8E,Z%[%H96<EBX.)$_<AV
M6AF(9OBMXKZ?(Z_W7:D3:)72*Y?0J$UE+ND=<HKYK)2T#YD93TZ,B>Y5Y-7?
MF6=L^;8K0VNDIFWJC1(HFM]^G@>E9J7B%'"Z6HOM(UB<U7BW( UXUEI<NMS<
M8PQLE4E2]$DG:B^=SY(A*71KP:JP[#.*YLZNMJUZQS%3FU/!3UU;UCIM.[Q3
MT%1;*BL6:))$='V)S5/X'">5-;_B_6CRIK?\7ZT>5-;_ (OUH\J:W_%^M)1T
MBU*@U$HZJHIZ&:D2!W"J2=YW\SN"%[O!JJ4NTQ_]X>D5-53)Q[3R/Y\]N'L+
MJ(8-]IFU=GK8)$16OB<G/U*5(Z,U0ZT:MW6W-7S'HZ-4]/&A<4%/NDQ6.NFK
M=GMCMUCA<Q-O6XMCC],VCLU)3L:C6QQHB(;#N*4:G1_@#I&0U$'+K*R*7ERY
M<2%TZ9_64T3_ /$Q'?2A]=#$Y=W1L5?%6H4PZ3#6MULI4:U&IU,7)$V[U+AV
M#\B4/ZEG[C/7LV.#72O'%RE,@ZA?PBDG6<>R=IFY5J1BN*W#W#?KM%25*L1Z
M,<BKNB^HA?6S7BQU^-5%FQ61U;4U6S5E1-FM3<WO1.PZOL.-U=SND+H)*]R.
MC8[MX?$GH 'YF1ZQ/2/9'[+P[^)7"UZ39;D&;U5RSJZ/=:8I5>E.V151Z)V)
MMX&)B[;7J-DN68W+$VGBB1&4;V)SC5BJB*GT'5Z(X7G&(Y'74]]N/NNR\.T7
M'(KN_DJ)ZB3M0J>\U6*5L.-2-BN;D1(W.7;;GS(1Q73BNQ6PW;+\_JWU]RIH
MG2PQ/=Q(Q4[%7T[F%8\135'3B&ZVB;W#D5/(_@E8O#Q><J[+])+.B5IRJSXV
MZES&I2HG8[:-RN5SMMU[5-WJ=27RNP^MI\6E2*YO1$8]5VV3OV4A2P8'68%B
M=TR[.*I]PN\3/Q+)'<21[JB;^LP[7A,FIFG%NOE@J5H,AI^-KGL7A23FJHB_
ML)FT9MN26K$(Z7+YTGKF.5&N5RN7AW[U.SN-2VCH*BI>NS8HU>J^I"E.E5PH
M;AKK4WB\5D<%-#/+(CY%Y+NKMOWEM4U Q9.7X:H_]9KKQJSA=IA=)57RFW1.
M36+Q*OT%8-2\MN.M&:4EJQRDE_!\;D:S=%YIOS<I;3%;;%AV$4U-,OF4--Q2
MJG^5-U*^YSTB[A=JJ2SX-;'K,]>K25_OU7_+LIHL>T3S;/ZMESS2X34T+^>T
MSE63;T(6)P'2S&\,IV)04<<U4B<ZB5B*]3NT1$39$V0 XO6.Y.M6G=WJF+LY
ML>R?.I"?0THVR)?K@YOXQTB-XO7S4M 19TEK<VX:4W+=$XHE;(B^I3BNAG<'
MSXE<Z1RJJ15'$GSM:6(.=U#K5MV$WJJ;[Z*E>Y%^92N'1!HFU.2WFXO;N]-U
M1WK4MB1QTA;<VXZ57F-VV[&H]%5/!2,>A=7N=9+Q0JJJV.9')]!J^F9<'/K;
M+;$5>%6K(J>G=4)\TFHFV_3RQP,;PI[F8Y4]*HBJ=:5!Z5M(EOU.LMRB\UTC
M&=G+FCE+2X95K6XM;*AW:^!BK]!MGQ1O7=\;'+XJB*5,Z8S&LR*R(QK6IP=R
M;=ZECM+O@_L'R.+[J'4 &/<)DIZ"IF7LCC<[Z$*H='1BW?6B_7&1.)6/D>BK
MSVW<I;2?^QD_14J!@DS8^DQ>&.3='RO;^P\KKUFF/2&;(UJLH:V9-NY%:YR(
MJ_M+B02MFA9+&N['M1R+XHI77I=9(OX,M^,4CMYJN5%E:B\T3DJ&AU4QI,5T
M M-"YJ-F=-UDO+\Y=_X$K]&?X*;9_P!7[U.7Z1&J-?8JVGQC&N5SJT1'2HNR
MQ[KRV])S]IT)RNYT#*V[Y=5QUTK>/A:]51%7Q-!09-F>C^=4UKR2MDN5KG>C
M$<]ZJG"J]J>DMC%4MJK:E3"OFR1\;5]:%.F:HY-9-4[U!%55=QW>Z*GHW.56
M([NY&_K=*=5<L<MUKKY'2OF\]M.^9R<"+W;&FP_-,RTMSNGL>6RS5-'(]&*D
MCU5-E[VEOY)TFM;YX7<G1*]J_-R*96+5'*[=J!>:6"JK+G/*YT%+3/<JM1RK
MR78Z6MTDU5R9772NOT<$DWGI ^9R*Q%[C78%G>7:9YU%CF7R35%+)(UB]:]5
MV1>Q6^CF7 AD;-$R1B[M<FZ+Z#]@ Y_/[0V^8?=:!S4<LL#N%%3OVY%7NBA=
MGV7/KC8:IW#UB+&C5_Q(I:O*[G'9\<N%?,Y&LAA<[=?45GZ,EO?D>HM]R:J3
MB1CG-:J\^:KR_8AB=*"UOQW4VSY'3-5K)U8^1R=RM5$+28I<X[SCU!7Q.W;/
M"U_TH5@Z6EX6\9A9<<IUXEB>CG(GB[D6.P&R,Q_"J&W,;MU4*[\N]>?\2FUQ
MRBMQ76F]U=KITJ*V21T,3%_Q.VV_:2)!I#J3E<+KK>,B6EFG3K&0.D=YF_/9
M? YRRY-FND&>T]LR:JEK*"1R-5'/56.1>]I<6"J95VYM3 N[)(^-J_,5JTDR
MF^W#7F]6ZMNM5/0QK*C('OW8W9Z;;(8'2-Q#-F.N]XDOF^.N>BLI.L7DGJ[#
ME=$<)SZ]62"NQJ_^XK6R?SX>M5N^R\^2%HM1IZVUZ9W"6*H?'6PTW]JQ>?$B
M=I6'374+.K]:ZG';)/55UUJG\ZN9ZKU#/%%[C;731;5*G@DN/](&U%0Q./@9
M.[C7U'5='+4R\37RIQ'+72/K(47JY9557(J?FJ6%OMUI;+:JFX5ST93T[%>Y
M5\$*O.R;-M:<BJ*3&*A]IL43N%9FN5N[4\?2;*[:%YA:J-U;8,MJIJV)./@>
M]4XMNY#>:#:K7&NO$F)9DQ8[M%ND<KUYO7P7?O/+I55V0V!MJO-DNE72TJ.Z
MJ6.%RHBKW*I+>EM^3(\'M=PZSK)'Q(V1V_/B3M-!T@,LDQ33ZMGI)EBKI=F0
MN:NRHJKVH:WHVQ7R;#$N60W&IK)*M4?'USMU:TEP%9ND+AV<SU%YO%+?>KQW
MJT7W)UJIR1.?+UD:Z*89G=_M3JG%+][@HF3;/CZU6[JFV_)"W.09%#A&$K<;
M[-QOIH41RHO.1_H*\VJ;/-;[E/54E=)9;!&[A3JW*B._FIF9!HSG.-4CKCC6
M4555+"G&Z)SU17;<^1WF@>JS\MADLU^8D-[I%X';_P#B;;^/?R.BUSSYV!8B
MM53,;)7U+EBIVN[-^]2&<2TQSC/J!E\ON455)#5)UD4;'JJHB^@Q,FQ_4'1Y
M\5ZIKW+<[0QZ))&YZJB)_F0L#I;F\&>XA'<J9$CJ.'@E8B^]<5<U\Q#-K/'/
M6Y%?/=EMFG<L,/6J[@17<DV7L[4.LT3P;4*6GLEU@R'AL.Z/]R]<OO?#8M8B
M>;LO@5)NKOZ.=*&&2->%E3,QJ[>"HA;9CN)B.3L5-SZ
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M('E,6#XO7WZMG_J(5O>5PWS6>VY'8K;6TD*S,=(V=J(NZ>I2T6K>/)EVFE3
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MA<&OKJ6WTSZBNJ(Z>!G-TDCN%$^<Q;/?K5>N/\$W&EK.#;BZF1';;^.QL@
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M#WMCC<]ZHUC4W55[D-);\OQ^X5WN*AN]'/5[JG5,E17;IZ#>@
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M*Q&0Q-1K6H90
M           5$5-E3= B(B;(FR
M              $.:MZ)09]?&7-;I-2RHS@5B=BFWTFT@L^GJ230N6LKY.2S
MR-YM]"$F
M
M
M
M
M
M
M
G                                                '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g73463g01n38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g01n38.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1?L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %\\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"C_P  1" ,<!U,# 2(  A$! Q$!_\0 '0 !  (" P$!
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MRR4W>V[_ $.K!5:U:'$K1RWV7.WB$1%SG8$1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!K
M[Y:*:\T?<U:USHLAV XCB/(4L=HIK+1=RT32V+>WL%Q/' '7Y%L$5^)/+DOI
MT,^#3S\7*LVU^81$5#0CUYTC;+O<'5E9&\S.:&DA[AP'D*P/<\L?]R_UCOK4
MP1=$<56BK1F[')/ X:<G*5--OP(_;-'V6WR-DBHHWR-Y.DR_'IRI     , (
MBRG4G4=YNYO2HTZ*RTXI+P"(BH:!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M 1$0!$1 $1$ 1$0!$1 :*ZZ3M%UK75=;3&2=P#2[I'#@/$"L,:"T^#_8B?\
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M*KK2_AT"(BH:!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MWC)1$61T!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M(B (@1 %W4G]H9Y5TKNI/[2SRJ'L6CN;A$18'6$1$ 1$0!$1 $1$ 1$0!$1
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M!$1 %I-7?>MG[9OS%;M:35WWK9^V;\Q5*G<9TX3^='S-YVKXB*YS!$1 $1$
M3J1"@-W![RS]4+FN$'O+/U0N:YSL6P1$0D(B( B(@"(B (B( B(@"(B (B(
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M$1 $1$ 1$0!$1 $1$ 49U)^$FGOVDG^E291G4GX2:>_:2?Z5G5[OP^IU8/\
MF^DO_P"629$1:'*:'6MWI['8YJ^KST<6. &22> 'I5)6+:8X:IGJJNC#:>L<
MUAW>)9@  _(K&VVU=#[5S;ZIQ-34O;T3&]N>9\7!4;:-,NJ+JVGJZ^FIX&$;
M\P+CU9[WO>:XZ]6HII0Y?4^E[)P^ 6&J5,8TG)/=V]U6U7K\]#TM#(V:%DL9
MRQ[0YI[01D+FH+3T.J;-31>Q%9376WM8.C9.2UY;CA@X/4N^+7<-&]L.HJ&I
MMTYX%VZ'QY\1!S\B[E62[^GYU/GGV=.>N':FO!Z_#?Y$S185MNM#<X!+05,<
MT9&01P^=9JU33U1P2A*#RR5F$"(I*FIU;^#%U^+/^B5F6G[UTO[)OS+#U;^#
M%U^+/^B5F6G[UTG[)OS+)?S'Y?<ZG_\ &7^I_1&4B!%J<H3J1.I %TUE5!14
M[YZN5L4+/">02!Z%W!8MTSW#)NT;*PX]X>T$.\QX)=+5EHK,[&![:K"!GV5@
MQ^J_^52FR5$-5;HYJ:021/XM<,X/I534[)!K"LE]JU([-*QO<_11X;Q/''+B
MK4TYGV)BWJ6.D/\ <L  ;YAP5)U*<E:%_7_8ZWAIT7>=OBG]S9HB+(!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!2^J=7ZK=K6[TEB
MJ[?!!:V BDJ.#JC())!(QU8YKHT]=;S9-:4,5?JFFN1K6;]72EQW(1Q[YI(Q
MR'R*R-5:&T[J::.HO-OAEFC&!+N@.QV$XR0M -D&AGD[MLB+B,9#AG'H41T)
M=F3>OO%!06B6YU52QE#&W?=+S&,XZO&H"S;=I!U2(NDKVLWMWIC3'<\N<YQY
MEM-<:4HI-G[[-12Q4,-.&F#I>,8(D#@'#'$$CLZU7DTNM)[2ZT24NE64IBZ$
MU0/>[F,9#=SL3FQR+TMU;3W&A@K**42TTS0^-XY.!60HWLWL\=AT5:[=%4-J
M6Q,<3*WP7.<]SG8\0)('D4D5GN56P5-_99_BAJ?C4?S.5R*F?LL7L=LBJ@US
M2>ZH^ /B<H)1,]C?XN+'\6C^BU3-0S8W^+BQ_%H_HA3- $1$ 1$0!$1 $1$
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M+/*H>Q:.YN41%@=81$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MDGS2*W"A4?O=&=M#$3I)J-O5)_5&@%DN>C7ONEGD-=1O._<:3=.7<>+V =G
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ME&KNT[]X;?\ L&?,%27V6_WITS\</THU=NG?O#;_ -@SY@@-@B(@"(B (B(
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M]Z=,_'#]*-7=IW[PV_\ 8,^8*DOLN/O3IGXX?I1J[=._>&W_ +!GS! ;!$1
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MY_\ LH;]:[Q:].MME;%4NCK,N#,\,NC^I>@-._>&W_L&?,$!L$1$ 1$0!$1
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M.&^$YH\K@%U/J::/WRI@8/'(%$QH1DA)K+[=ZCQ&=X'TUW,V?V#G4,JJ@_\
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M0>DJ\/\ 0,</2I?3P14\8C@C9&P<FM& %HL15_Z:4/F_B]/D:Y,'2T>:H_\
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MK7O_ ,OY/^*/\BM=$!4_N@ZZ_P#EO4_\6?\ TT]T'7/_ ,MZK_BS_P"FK81
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M/S)W4_ +W'GD#ER'!3569 5*_92#.F+3PS_M?U*Z)9&0Q/EE>UD;&ESG..
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M==1#'44\L$S=Z*1I8]O:",$+S!]D'LUTSI&S4UTL=')!5U5<S?<97.'&1N<
M^4KU&J.^RR_ VU_'H_IL4 MO2,;&:8M!8UK2:.') Y]X%MEJ]*?@O9_B</T
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M"/05"!L@T0.5CB]8_P"M18FY']#ZOBTS04%GOVI*6^U%34]!2.I6C>:PXP'
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MGJ:*MELYHY)IC"P.;))WVZUPR. +02>/ \E)M@%TBN.SVCCBIJB#N4F$]*T
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M47./HZM\1WVXQR<0#YP ?.D=8W_.?Z"6CM^<B2HB( B(@"(B (B( B(@"(B
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M 0>0R"<]A47U2)2T;+T')%TT+M^B@=G>S&TYSG/!=RLU8JM4$1%!(1$0!$1
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M:C)&,"1KN''L!40T2_[?O<M*UWZ_:QD737]ZN=]N%MT;;(IQ;!OU,\[^]D
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MN^H2L$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!:R^WV@LD EN$VX'<&M R2MFJOVB03TNJ:*YU=,ZIMK.&X.(
M' 9&#Y%U82C&M4RR?[^!P]H8F>&H\2"UNEY>+\C?,VCV%S@"ZI8#^4Z+A\ZE
MM)415=/'/3OWXI '-=VA0RCU'I.]1"FEAAC+@.\E@ QY.:WM[97PV6./3;8&
MR##6[_!H9@\N'D5ZU&*:BHN+\=C+#8F<HRFYJ<4OZ5K]6;M%6=UI]5VJD?7"
M[Q3]%WSXPX\O(I)1ZKC=HT7NICP0PY8.MP&<*L\)))2@U)-VTZEZ?:$')PJ1
M<6E?7IZ$H15M;AJW45*ZX0UL='"_WJ,$C(\RV]IO-WMEBN-1J2G:.XP3'(T\
M9>'UJ9X-QT4DWTYD4NT8SLW"2BU=-K2R^GJ3)%6MN.K-24S[A!61T4#\]#&"
M1D>/"W^F:C43J"M@ND$8J801!,3PD..&5%3"9$_>5UNKDT>T%5:M"23V=M_T
M\+DK15\^WZOJ0^::ZT]-+QQ"QYPL[06HJNO-;0W8 U='G>>W\H X*2PC4'.,
MD[;V$.T%*I&G.#CFVO\ FA,U'-7ZE.G^Y<4YFZ=V[P/)1=EWOVJ[M4QV29M'
M04[BWI"2"<'Q=JTFKFWFFGHJ2^/9,ULF]#.WCO>(KIP^!7$4:C7BN9QXKM5N
MBYT8NU[*5M-RP-;76[6VC@DLU*)W/=A^<<%(:-\LE-&ZH8&2D=\T'."H3M2N
MM;:K;1R6^H?"YSL.+21E9NK-326.RTKH&B6MJ#N1AW;V_*%C[/*I2IJ*5VWY
M^IT/&0I5JKG)VBD[<M>G.[)<BKAUNUM'1BM[OC=,WOS3[QXXXX[%-M/3UU3:
MXI+K3BGJSG>8#E8U</PXYE)/R.C#XMUI97"4=+ZK\^!\O]YI;'0]UUW2=%O!
MO>#)R5'O=(L?96>J_JN.UL%VEB!S,K /2%J=/ZOT_06:DI:V%SJF)FZ\B .R
M<]JZZ&%A.@JF5R=[:?['!B<=4ABG1SQA%).[7/XHE^G=3T%_DF90"<&(9=TC
M-WT<5O%%HZ^FOFG*ZHT[O4TK6G=>&!AR/)Y%U;.;[+=+5+!7R%U=2.+)2>OB
M?Z+GJ8?W93BK).S3W1V4<6LT*4W=R3::V=N6Y+D4$H;O6776MP;%4.CM=N!W
MFM)[]PP#_%8++M?M4U]3[$5,5%;H'EH>YQ#G<2.KR*RP4N;2T3?A?9>91]IT
M_P"F+;;:27.V[\BR45>6J^W:R7^GM5_FBJ8:GWJ9AR<^-6&L*U"5%J^J>S.G
M#8J.)3LFFG9I[HT=GU1;[M<:BAI^F;40G#FR- [>7'Q+>*L-:1G3FM+?>8<B
MGG.)L<!SX_(5+M77R.V::FK&NRZ6/$>.LD8_BMZN&3<'2VE]>9RT,<TJL<1H
MZ>_ENF=]KU+0W.[5%OI!*Z6 9>XM ;Z<K=*!Z*@9IK1L]SKAF:4NF?CB>/ #
MY L&@DU1J* W"&X04-.\GHHPX@D XXX\ZM/"1<I9':*TN^;*4L?-4X<2+<Y*
M]ER7C<LI1S3VI?9:\W"@[G,?<I(WL^%@@?Q6NT;J&MFNL]DO88:Z$;S9&'(>
MW@?XK7:!(;K#4)/(%Y_YFHL+DC44]TDUZDO'<65)TG9-M->2V+%15O)?;UJ>
M]U5#8)&4M)3.(?,XX)XXZO.N+KS?M)W.!E]E;5T%0[=$@)):?/Y5'L$^[=9M
M[<R?\6I=_*\E[9K:?K:_,LI%"M::EJZ:LI+58V-?75/Y3N31PQ\ZU]11ZTM;
M8ZF*K97'.'0[Q_BJPP;E%2E)*^UR]3M&,9RC"#EEW:6WZ^AO-;7:\6PT8LU&
MVH$C\/)(X<L!;2X7NFM-O@J+L_H-\#. 3@]GRJ*[0[O<J&*T.IY74LDTF[(Q
MI/:%J]IE/6M@IJJIJ>DHGM:&P\>#N''Y0NBCAHU%3C*RO?;=G)B,;*C*M.#;
M<4M'LKKX^99]/,RH@CFB.8W@.:>T+L4'LEKOD=BJWRW,OZ2FS3!I.6$#(_@%
MD[.+Y-=+=/3U[R^LI9"R0GKX\URU,-:,I1=TF=U+&J4H4YQ:<E=>GY<EZ*#4
M-TK[SKR>"EG?';:'A(T' ><?65.3P!6=6BZ32>[5S;#XB-=2E%:)M>=B-WC4
MW<FH*2T4E.:BIF&\[C@-"S;_ *CMUB8TW"8M<[P6-;EQ4.TBT5^T2\5DC<]"
M'QM)ZN^ 6%JQK[/KCV4N=*ZKH',PP8#@/,5WK"4W45+FHW?5OH>3+M"M&C*N
MMG*RZ12TNR21;1K"]X:^2HB!_*?%@?.MU?=0T-EHXJJK,AAE(#3&W/SD+14U
MZTGJ!HIW1T^\>3980#\RP]L+,V&E9'@?=0!C@J1P].5:%-Q<;[W_ -C2>,K4
M\-4KQG&=EI9?75F;[I%C[*SU7]5G4NL[94VRIKX65)@ISA^8P#Y0,K06O6FF
MZ>@AAJ('&5C<.(IP>*E=GJ;=?K-++0PAE-.'1N!C#2>&#P\ZBM1A25W3:5][
M_L7PV)J5W:-:,G;9+]S*L=VI;U;V5E"YQA<2.^&""%V7:XT]JH):RK<1#&,G
M R57^SV:2Q:CK]/U1.Z7&6(D]9 _@%V[2JE]TNUOT[3')D<V27R9/U93V->T
M<-/W=[^!"[2E[&ZK7OKW;?YMK&VK-;Q0T]MK8J61UNK9.C$CAAS3DCEGM"ET
M3VR1L>PY:X!P/B*AVN+5'#H-U/$,"DC:68[01Q6VT+4FKTG;97N+G="&DGQ<
M/X+*M3INBJE-6U:_0VP]:JL0Z%5W]U/[/YF]1$7&>D$1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MLNB=_J0+:=1NM]PH-04W"2%S628X9 )(SY<X7W9S!)>+U7ZCJN)>>BCZ\8:
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M=;<]A6K**ZR]T5MJ>:)]1C'2ALPW78[=W" N'2-9-<-*V6MJR'5%310S2$#
M+G,!/RE;&*>&5[V12QO<PX<&N!+3XU1FM]22T&B-"63NR6@HZ^BIG5-3"S?D
M$;8<[H'C(;Q4?N]9HBU40K]&U5XI+]2@&"0Q.<)#G!WP1QR,\L(#TNH_K*\.
MH-*7:MML\3JFEB)&#O;KL]8"K[55VNNKIM'Z?BG-NI[S1-KKBY@W90-QIZ-N
M<XXOZP>2Z-H.S"VV/1UQK],35%%7T]/C+Y-]DHR,[P(^;" LS0EPJ+MHVRU]
M:X.J:FDCED(& 7%H)6EVM:OJ=&Z?IJVAIF5%145<5*QKW8 +W;H)]*S]EYSL
M[TV0,?[!#P_\ 4*^R7+6:.M4CSB..[4KWGGAHD!* V+KUM%HHA555CM]73M&
M\Z&FE)D<.>&\^/F6VM>MH=1;/+M?K3')3STL%0##..^BE8PNPX?NGJYK5>['
MI6&D&Y+632-9PCCIG%SCCD M+HJTW&GV>:WN]VIGT4MU955$=*\%KF1] U@W
M@>()+"?(0@)ULLO%9?\ 0=JN=R<U]7.V0O<T8!Q(YH^0!26*I@ED?'%-&^1G
MA-:X$CRA5%I.&V3[!+4V^7*2W4 ;(Z26.1K''$[SN@N!XGEA034-;H2W6CN[
M2$]UI[Y2N8^GE>P[LAWQD/R,8(SRP@/3JZXZB&21\<<L;I&>$UK@2WRA5-K.
M^W.]4NB;!357<4VH88Y:N>,#(9T>\YK<\LGRK:'9#9:3N>HLM3745RIR',J1
M*'%YZ]\$8.?%A 622 "2< =:X0315$?202,D9RWF.!"HS:A?Z>JUU#IS4U=5
M4]BHX&SR"DCR^HE(;@./' PYZC];J#3FF+I17/9X^Z"I?*(JFB? YT<L7,XX
M9!R!U]: MBKU'<8]L]%I]LC/8R6VNJ',W>^WP3QSGQ*=0SQ3%W0RLDW#AVZX
M'!["J3UQ:9[_ +=K5015;Z2GFM+NZG1COWQY=EK2>6>/'"SM;;/:+2=AJ=2:
M3J*FAN=KB-1WTF^R9K.+@\$=8&.!" N)=<,\,^]T,L<FZ<.W7 X/853>HKS5
MZZONE--P5<E%;KE0BOK71X#Y&9=W@)SC/1NZNM9&LMGM%I*PU.H](S55'=+5
M%W2-Z0.9,UG?.:\$<<M!' CF@+@4*VI:CK;):Z&FLI8;K<*J.GAR-[<&2YSM
MWF>]:Y2#2ET]FM.6ZXXP:B%KW#Q]?RY4"U5*'[>M&TSQEK:2>4#Q]',$!D[2
M-HIV?U5@BN%.:NGJW"*HF9P+3NN[['9EH]*L2DJ(JNEAJ*:1LD,K!(Q[3D.:
M1D$%5-M7BCJ-I^A*>>-LD$TLS'L=R<#!.NO2E15;,]7-TQ=I<Z7N#GOME9+W
MK89#EW0.<>'(/QGCWJ F6@=63:EN6I::>G;"VU5SJ5A!SO@%PR?W5,%4^Q@#
MV:VB!YPWV7DR?%O2*+5%LV7]T2])J"X!^\=X"J9S]" NC5<E[BM@=IJ&FFKM
M\=[4.PW=XY_@H]LWU5=;Y<;Y;+]204]=;)6QN,#MYKLY^I=6R:FTQ3PW'VIW
M"HK&N+.FZ:5K]T]]C& ,=:P=FOXR-H'QF/\ U(#&MVK]9ZBJKA+IJVVYUNII
MS U\\A#G$ $_2"WQJ-8G1MZFN$=%27:&-TE+T&9&NW6[V"/'@CSJ*Z;TKM!T
MI1U-)9ZNSS4[YW5#1-$[)) &"=\?FA2G9SK"LU!4W6SWZ@%'>[8X-J&,ST;P
MX AS#V<<>8H#<Z!OCM0Z4H+A+NMJ'L+9F@^"]KBT^3B,J0*L=AN60ZIBSED=
MVD#1V @'^*LY $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1=51.V!
MH+@3DXX(M2&[:L[46'[(1_FN]">R$?YKO0K965SQZF8BP^[X_P UWH3N^/\
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MJ(CVM#BT'_E5D+"LEKI;+::2VT#"REIHQ'&"<G [3VK-0!$1 $1$ 1$0!$1
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MD!NX/>6?JA<UP@]Y9^J%S7.=BV"(B$A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M'B4<[$\BRMG[[1J6B@U##:XJ.XL+H'AF6[A'$C .#S"FDLC(F%\KVL8.;G'
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0(@"+ZOB (B( B91 $1$ 1$0!$1  B(@"=2(@"(B (B^@90'Q$1 $1$ "(B
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M +G' XG"U7MNL75<Z<GLW^(5E"4M4A<WJ+C#(R:)DD;@YCP'-(ZP5R50$1$
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MT+-W3V+X6D<U7%1I*\V:G=76^[RSRQ-+WQ.! < .(Y^5<]E,TLU?<G32R/)
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MOL=LO$YJ*23DYY)('4X?4L_:W(^*GMQ;*^,;S\EIQV*?89<6-.^DMF4_Q2/
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M( N$W@>=<UPF\#SH#'1$4D!$1 $3J0( %6>O:F6]ZEI[-1#?,!ZCP+RW/'R
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MU'33O8RP==XFC&JU:X77401U-/)!.W>B>-US>T+'NUTH[32FHKYA%&.763Y
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"\_:[NU;H/5EQ;8KU;&,N9#YH:F%TCX#RWB0PY'B)/+DO0*I"\0UNE=4W
MN>MTLR^Q71V:2H#8Y#O8/>N#G#='$<0.M5Y_GP)6Q86RVR0V+2%/3P5;*PRN
M=,^:,]XYQP#N\!@<!U*M=8WG0D>M:ZWW/2-TK+M@/>Z,'$@QP+>_ /+Y%8NR
M6Q5^G]'0TEU:(ZETCI3$'!PB!QAN1PZL^=1C7>I[=+K&&BLUBJ;OJ.W;K^DB
M/1LBSQW7.+FY[<<1Q5Y=\B/=9T;.JK2TFJJ9EGTA=;96$.W:FH:=QO>NS^4>
MK(\ZN!071&OV7NY/L]VH)[7>F@NZ"1HW7CB>]<"0> *G2,A<PBZG5,+:AL!E
M8)G#(9GB?,N4\T<$3I9GMCC:,N<XX 4$G-4W]EG^*&I^-1_,Y6_2U,-7"V:F
ME9+$X9#F.R"J@^RS_%#4_&H_F<@1,=C?XN+'\6C^B%,U"MC+V/V<63<>UV*:
M,'=.<'="FJ (B( B(@,>X5L%OIG5%6\LB;@$AI=S..0!*KVSZCMC-HM^J'5#
MQ%)#"&GH7\3NMZL94SU5?+=I^Q5=SN[VMHZ=H<_AO$Y(  '7Q(7G?3.W2R/U
MY65=;:98:"X%D,<O1M.[C !(WN&<957FY$-2Y'IV*1LL3)&'+' $'&."Y+KI
M9HJBFBFIW!T,C0YCAR((X+L5B0B(@"(B @.TZENGM?K)!7M%*9H-V+<;P^ZL
MQQW<\_&I-IF"OAHHS7UC:ACHF;@# W=X#L 6MVG?@=4_MJ?_ ,YBD-L^]M)^
MR9\RBQ%C)1$4DA$1 %J]0,J9*5@HYQ!+O>&6AW#R$%;1:G4E*:ND9&V:2$[V
M=YG-2BLDFK-V()8*>Z>V?40;<6-<)F;YZ)O?</U5,U![%:'/U-J!HKZH&*9F
M2".^X=:G Y+2"?,QJ1C'NRN$1?<$ DX '63A7,SXBUETU!:+5$Z2X7*GB:.>
M"7GT-RHO5;4[$'NCME-<KD\< 8*<AI\[L*+DY63L<>2JW:QKZQT,9LCY)IJV
M.=LDHB9D,P#P)[>/R+8MO^O+NW>LVGZ:AIY.+)ZJ5N\&GD2W>/'S*B->Z=OU
MKU'72WNF,D]1*9'5$6"R0DYR,<N?+ 4-EX1ZGJ;3NH+?J>W"XV>4RP..' M(
M<P\\$'RK9JB=D^DM:T-FJ*JUUT%J;4O:X0U(#M\ 'CC==CGXE-L;3J(G+K1<
MF'EC=9C_ )6HGH0XZD_15^=1:]I@>[-)TT@'Y450SC_SKC'M,Z %MSTW=HI6
M\'"&-K@/^=3<KE982!06':KIMQ J&7*ESURTQP/1E;.DV@:5JI R&\1[QY!\
M4C?G;A+C*S>UERI:!\?=<CF;QX88YWS J):'O- SV9C=,[>EN#W,'1/XCCXN
M"R=6Z[LFGK8VOG(KHW.#6"##B'=602#A0'9SM-MLMUJ+?56Y\<M=4NEB>UK<
M GC@Y=PZU5J5]#:'#R^\G?S_ &/0\'O+/U0N:XQ MB8#S "Y+(T6P1$0D+C(
M'&-P8=UQ!P>PKDB K#:%2W1ESTUTUP:_>N#0S[FWO3O-_P JL2VQ5<,3A75
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M'2;K<?26M.A4J*\%<JY);LLU%@66\4-ZHFU5MJ&30NZVGEY5GK-IIV98(B*
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M]"U>@OQMZZ\D'^I1NS1W?9YM/IO9ZNAJZ+4^6R31LZ,,G8>&02>?2'KZE(M
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MT76RMCZ.X-(#V8WN^;R5B6NM?70O>^EGIBUV-V9N"?&L<R9SYTS,1$4@(B(
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M8NLL%6J9G=3=O*^WD;:Q7Z_7JZP2PT(@M#G8)=Q);U'.%BUVL+G<+K+1::I
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MMIVV"UUKZR&H:?NDF7.< ?._Y%N-:6?4^IK)<*6MMEOF$-;O4K=XM<Z$;V'
MYX/QCJ/,\%7^E?FFG[DK=_G4Q--[3X+)'>:#7%RIQ-::GN45>0SNC!<,[I/
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M/9!$19FP7;!S*ZEVP>$4!W(B*"0B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MH\.3N[WTV7@O (B+F.X(B( NV#PBNI=L',H#N1$4$A$1 $1$ 1$0!$1 $1$
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M"(B (B( N$W@>=<UPF\#SH#'1$4D!$1 $1$ 1$0!$1 ?5\1$ 1$0!$1 $1$
M1 B (B( B(@'4B(@"(B (B( $1$ 1$0!$1 $1$ "$ C! ([",HB QXJ"BBDZ
M2*BIF2?G-B:#\RR$12VWN0HJ.R"(B@D(B( B(@"(B (B( B(@"(B !$1 $1
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M  A4^I_J@+>15!]L3L__ $^I]3_5/MB=G_Z?4^I_J@+?15!]L3L__3ZGU/\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M!L@+\8(ZU>(T5IH@'V#M_J0HAM.ET4W5%CK-2R5#KG;9!-!W-WPC[[(Z0 '
MSQXX5E4-3#64<-33/#X96A['#K!3?4&E]I6FO@.W^I">TK37P';_ %(4@1 1
M_P!I6FO@.W^I">TK37P';_4A2!$!'_:5IKX#M_J0GM*TU\!V_P!2%($0$?\
M:5IKX#M_J0GM*TU\!V_U(4@1 1_VE::^ [?ZD)[2M-? =O\ 4A2!$!'_ &E:
M:^ [?ZD)[2M-? =O]2%($0$?]I6FO@.W^I"HG:1:+91[>-)4=-;Z6*E<'%T3
M8P&N][YA>EE5&LJO03]HUMJ;S43>SE [<8Z(YB:XXX//(<AUCK3P)+6C8V-C
M6,:&M:, #J"^KXUP>T.:0YIX@@Y!7U" B(@"(B (B( N$W@>=<UPF\#SH#'[
M41 I("(G4@"(B (B( B(@"(B (B! $1$ 1$0!$"( B(@"(B (@1 $"(@"(B
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M.A/:$!U(%V]">T)T)[0H!U+M@YE.A/:%RC86DY*$G8B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
7B (B( B(@"(B (B( B(@"(B (B(#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g73463g01n39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g01n39.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1=\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %U\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\
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MX6*"(T(D0_%R_]H # ,!  (1 Q$ /P#]4HB("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@P[N7POMW<OA6&,B(BJ"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(@
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$"($!$\$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!!WH@[T'HB(L68B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M##NY?"^W=R^%88R(B*H(B("!$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 "(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B!$!$1!A9'>B#O0>B(BQ9B(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B@.K]1ZAAU[B=-Z=^*XS;I2VGS78GOVY';;#E<
M%KYO,Z]TS0FRN1IX/,8^LTR6(:(D@F:P?*<WG+@=AUV06,BYM#.8^[A:.59:
MB92N,8^*21P:'<X\T=?'U+:BO5);<M2*S ^U$ Z2%KP7L![B1WA!L(M"[F<9
M1L,KW<C3KSOVY8Y9FM<=^[8$[K?!! (((/4$("+PO"R:4XH.B;;+#V1F!+ [
M;IS $$CV*M-4YO7^GABS-8TS-Y?>BHMY:LXY"_?SC_&=PV06DBB5*SJ;%,MW
M]5W,([%UH'RO\BKRLD'*-]]W/(VV!\%Q,%G-=:HQT68Q-/!XS&V1VE6&]VLL
MSX_Q7.+" W?O\=D%D(HE3U)D\;I3*9;6F,BQK\?SN<*\W:MF8T;AS?$;]VQZ
MKD8K)\0LY0CR=2G@,;5G:)8*EOM9)BP]1S.:0&DCU'9!8B*)5[.LK^GHGBGB
ML3F6S.9+'8<ZQ$Y@[G-+"TC?IWJ*NU#K\:[;ICMM,]NZB;W;^33<O+S\O+MV
MG>@M=%R--LSK*\WW23XV:?F_BS1B>QH;MX\SCUW770$1$!$1 1$08=W+X7V[
MN7P%88R(B*H(B("(B B(@(B("(B B\C/"'%IEC#M]MN8+U0$1$!$1 1?/.WG
M+>8<P&^V_5?2 B(@(B\K5B&I6EL696101-+WR/.S6M'4DGT(/5%K8V_4R=&&
M[CK$5FI,WFCFB<'->/2"%LH"+PO6Z]"G-;NSQP5H6E\DLCN5K&CO))[DHVZ]
M^G#;HSQV*TS0^.6-P<U[3W$$=Z#W1$0$1$!$6CE\MC\-4\JR]VO2K%X9VD[P
MQO,3L!N?%!O(@.XW'4(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B @1$!$0("(M(96@<L<6+</QB(NW-;F':=GOMS;>C?Q0;J(B B(@(B(
M"(B B(@(B("#O1!WH/1$18LQ$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!4'$
M#.0:?XU:<O6:UVS&,389V=.!TTFY>.O*.NW3O6_G->SZAQ%S$Z8TUJ";(W87
MP,DMTG5H8>8$<[WOZ #??Q)[E(<CINY8XH8C44;X11J8^:K(TN/.7O<"-AMM
MM]*EZ"E>)^ FP/!73V#CL\MFM;I0=NP=TG-U</I.ZFTN#Q.@-)9K)8*A$R[!
M3EFDL/'-+.YK2[>1YZNW/7J5[<3]-W-48"K2Q[X6RQ7Z]EQE<0.5C]SW ]=E
M*K5>*U6FKV&!\,K#&]I\6D;$(/S[I:334F AFSN@-3YS)W8VS6[]C$/F=,]P
MW):X]S?1ML-ME+^%V6O8K$ZG9)A=0LPF.E9)BZUJF\6#$YOG1,:>KN5P.W7N
M(6Y2P6O-+5X\7IJ[ALIAXARUSE.TCFKLWZ,)8"'@#N/0J9Z6J9BICG?=%DHK
M]Z1YD)AA$4<0.WF-'>0/2>I0<W2^LQG\BZH-/ZAQW*PO[;(470QG;;IS'QZ]
MRY/%_P"3I'^OZO\ WE8"BVO<!;SS<"*3H6^0Y2&[+VCB-V,WW V!Z]4$AR%.
M#(4+-.VSGKV(W12-WVW:X;$>XJNL3IS7&CZ[*.G\EC<SA:_FUZN0:Z&:*/P;
MVK00[;NZA6)DJ\EO'V:\%F2K++&YC)XP"Z,D=' 'IN%!'1<3Z.]>O/IG*Q@;
M,MV&RUY#ZW,;N-_84&[@\S3X@XC/X+,XRQ0MU_\ H>0I2/W+0\'9S7CH00"0
M1Z%R\9A^(&E8&5<=?Q>H<7 .2"&X#7L-C \UO. 0X^&Y73T]HS)4<9G9KF=?
M]T>:<V2>_7A ;"6C9C8V'<<K1N.O4[K3<SBC5YJ\,FEK[1T9;E[:%Q'I=&-Q
MO["@D&A]51ZHIW"^G-C\A1L.JW*<Q#G0R#KMS#HX$$$$*,/_ -H>+_X>/^,I
M+H33,NG:=U^0N^7Y;(V#;NV SD:Z0@#9K?!H#0![%JNTU=/%=FI>>#R 8HTN
M7F/:<_:<V^VVVVWK03!$1 1$0$1$!$1!AW<OA?;NY?"L,9$1%4$1$!$1 1$0
M$"(@(B(*'X[Z"TWBL+\?T,8R++3Y6!TE@2/)<7R;NZ$[=?8KX'<JN^$9]X%?
M^LZG^(K1"'<(B("\[$T=>O+/.]L<4;2][W'8- &Y)7HJOX]YV:IIZII_'PSS
MW<]*:Q9787RM@'65S6^)V('TH0@3;UVOD(.,'-,*-K(&K+ [\7&G:)KMO \S
M>;Z5^C&.:]K7,(<UP!!'<0JLEU/BI-*NT]]QNK!C#5\C$?Q=W,Y>7YW?ZUM\
M!-06<MH\XS*QRPY7"R"E/',WE?R ?Q;G#P);^PJ*-XP8.6.9E.AE[U^.S+6\
MAJ5NVF/9G8O(:2&M)/0DC?KZ%UM&\0\7J7*3XKR7(8K,1,[0T<E 892SYP'<
M0HS\'BA7@QFJ;L;-K%G-V6R/](:?-']Y]ZW.)S&P<0^&]R)H99.0EKF0#SC&
MZ,[M/J5$>X@<2LIC.)>G:%/#ZB;2BFL,L015=_C'9GFF+KYX:>OAT4_9J"IG
M]#9:_F<%DZ=!D,K;%+(0=G+)&UN[MF[]Q'=U4:XC?AEX8?I+W^$%->('WC:A
M_4)_\-R#RT):PXT)BK>&@&/PODHEBCE(;V4?4^<=SZR3NHM_#%BY^>;%8#4N
M3QK"0Z_4Q[G0].\@D@D?0H7J>:2+X,VF8^=S*ECR*&VYIVVA+_.W]70*^Z5>
M"I4AKU(VQUXF!D;&#8-:!L $$4R6H].:BX<9/+O;\9X'R:1UB$#9Y#1NYA:=
MBUPV[CLOJ'4&'T[PPKYVE2FAPE:A'8BK1@<[8R 0WJ=M^OI3B;6@K<,M5-KP
MQPM=1G>X1M#07%IW)V\3Z5#]3?[,)_J*#]QB#M6^+&+[=T6%Q&=SIBV$[\92
M,S(7$;\KG;[;CQ W4CT7K+$:OJ3RXF6035W<EFK/&8YH'>A[3W=Q]2SP]HT,
M?HG"08EK6TQ4C<PM'RMV@EQ]9)W44R,;:?'O$/Q[ V6]B9O+N4?*:Q[>1Q]>
M^XW0;N:XH8ZCE[>,QN(SN;MU']G8&-I.E;&[Q!=T&X]2Z>D-=XO5-;(''Q7(
MKM#_ %BA9A,=AAVW'F'OW[AZU'CKO4.7O7VZ%TI%D<=5L.KOO6;C:[99&]'<
MC=MR >F_BH_I&WG+/'YTNH\36Q5R3!D&*O8$PD:)1LXNV'7P^A0T:V+XK93^
M$?.METWJRQ0;5A['&LI;R5W==WN;OT#O J;\1,CI^QH?'Y#5V$M6*,]BN6TY
M6<LL4KSLWF&XV(WZC?T]ZT-,?A\UG_5E/_-8^$1]X5;^M:G^(@G6I,[C=,X6
M?)YFRVK2@ YG$;DGN#6@=23X *#_ ,,>+B:VQD,!J:ABW;$9"QCG"';TDC<[
M?0M?B,&W.+W#S'9$<V,<;5AL;OD/L,9NS<>D=X]JM&>&.>"2&=C7PR-+7L<-
MP0>A!"HYF1U!1IZ8LY^.06\?#6=:#ZY#NT8!OYIWV/10^?BWBGLB.'Q&=S;G
M1,EE&-J=L(>9H/*]P/+S $;@$[**:3Y8^!NNJM1[I,74FR,%%Q._\2-]MCZ-
MR59'"O'UL9P[T]7I1B.(THI"!XN<T.<3ZR24'OHG6.)UC1FL8F25LM=_96*T
M[#'+ _T/:>[]GN6=+:LIZCR&:IU*]N&3%635F,\?*USO2T[]0HMA(HZO'S43
M:[!&VSAZ\TP;^.\/+0X^O964 !OL!U[T1\696UZ\LSP2V-A>0._8#=5S'QAP
MMFC3EQ6-S.4N68C,:-&KVTL+ XM!DV.S=RT[#??93_+_ ,TW?T#_ -TJN/@V
MT,?5X7TK% -,]J:9]I^_4R"1S=CZ-FAO_HH)'H[7^)U->GQT<=W'9>!O/)C\
MA 89@WYP![Q["O+5'$;"Z9U <3E199/Y(+;71Q\X?N_D#&M!YB\GP 7!XS,;
M5S^@\E2'+EQF(ZT;F_*?"\$2-/I&RU\G1@M_"4Q,L[ YU7"/FCW\'<Y;O[G%
M%3;"ZMJWM.6LWD*=_"TJQ=VGQG#V+N0 'GV]!WZ*+#C%C',\JCT_J>3#[<WQ
MDW&N[#E^=OW[?0M#X1LEPX;35:I7;9BL9B%DL#Y.S9-T):QSO $K?&?XF!G(
M-#8D- VY1E1MMZ/DH:)O)G\?]S,V>JS"WCHZSK0? 0>=C6EW3U[#N*A8XOX:
MS6JNP^+S68M30,L25<?5[9]=KANT2$'E!]6Y7(TOA,W@N&.NZ^<Q\..CF;;L
MU:T,XE;&Q\1):"/ ']J[OP?J-"EPGP+\:UO_ $B(S3O'>^4N(=O[-MOH0=K1
MNNL1JJ:S4JBS3R=;K/0NQ&&>,>!+3WCUA:>J.(^-P>8DQ%?'Y?,92-H?)6QM
M1TQC!&XYCT Z==MUQN)$3:G$SA]?H, R<]N6K*6][ZY82X.'H'>MG*:ZR]O4
M.3Q>A]-LR\F/>([MN>TVO$R3K_%C<$N('N0T=;1FO\9J?(V<:RKD,9E:[!(^
MED8##+R'\8 ]X^U8U3Q#PFE\_'BLRZ:%[ZAN"4,YFD!W*& #SBXGN !5?27]
M2V^,^AY-3X.IB9#%<CC->T)S,WD!(=T&VQV]Y77U'CJ]_P"$=IEUI@D\EP\M
MB,'N#P]P!^C??VJ&B=:;U3!F<-:R=BAD,/5KN<'')P]@2P#<OV)^3Z_45%'<
M8,7)S3X[ ZER.,:3OD*N/<Z#8=[@202/7LL?"*DL-X9V(ZS.=DUNO%.TOY Z
M,R#<%W@"=@3ZUY4LUQ(JTX:]70N(97C8&1M;E0 &@; #S5318.GLUC]0XF#)
MX:TRU2G&[)&@CU$$'J"/$'JMC)WJV,Q]F]?F$-2O&999""0UH&Y/3JH#PHQ>
MH\?E]2SY[$UL54R$[+4->"R)FMD+=I-MN[<@'Z5,=5YNCIS3M_+Y7?R*K'SR
M -YBX;[  >))('THB$.XPT'1NLU=-:JLXQHYC>CQKNRY1WNW)WV^A3O3N;H:
MBPU7*XB<6*5EG/&\#;U$$>!!Z$*!5]6<0K]>.UCM"4XZ4S ^)MG)M;)R$=.8
M!O3IX)\'PS#2N9CLUHZLK,U<:ZO&[F9"><;L:?$ [A%T6'F,G3PV+M9')SMK
MTJS#)+*[N:T?^NY5ZWC#1?'Y5%IC5<F+V#A?;C7&(M^<.N^RE?$33(UAHW)8
M,V#7=:8WDEVW#7-<'-W'B-P-U#H=2:^TQ0:W4&DJF4HU(]I+>)M@.Y&MZN[)
MX!/0=P(1(2K/ZYQ>&TWC,Y*RQ+1R$T,,):SE<.U^2YP=ML/2N!-Q=QCWR/Q.
M"U'E\?&XM=?I8]SX.G?LX[;CUA1KCIE\7JCA'A,E7E=\4WLE6<7D<K@PEP=N
M/ CK[E=%.O#5J0UZK&QUXF!D;&C8!H&P 17.TMJ/%ZIQ,>2PEIMBLX\IZ;.C
M<.]KFGJUP]!48S/%#&4LK9QV*Q>;SUFJ_L['Q73,S(G>+2[H-QX@*+Q<^)XA
M<4(\ "T.Q,5Q[&=S;18_8CT$CJN7PDRFN:/#[#QX#2&,M4'1&1ME^3#'S.<X
MESG#;O)W4-%L:,UCBM6U9Y,8^9D]=W)8JV(S'- [T.:?V]RYFJ.(V*P>6=B:
M]3)9G+,:'RT\77,[X@>XOVZ-W]!ZJ-:>QVLKO%.AJ',:?I8FJ*<E2VZO=$QF
M;\IA(V'4.']ZBO"C)ZTKTLY9PFE\?D9+.4L.M6I\@(I#(';<I;MT &VWM0T6
MOH[7F*U/;GH1Q7<?EH&A\N/R$!AF:WYVQZ$>PK[UGKK$:4FK5;@M6\G:W,%"
ME"9IY .\AH[AZRH-=JZ_S>KM-92YI7'8UV-M;R68<@V1SH'#ED81L-QL=_:%
MT.&#&7N)/$+(9!@=E:]QE6,OZF.L&GD ] .WT[*FCL:>XFXO*9B#%9''9?!9
M&Q_J\.5JF'M_4T]03ZE%-1:@QVF>/-G(9>?LH&X!K&AK2Y\CS-T:UHZEQ] 5
MP3UH+#XGSPQROA=SQE[02QW=N-^X^M55/0KV_A+0SV&![ZF"[6+?\5QD+=_<
MXH0Z=7BYC!D*U?,874&$@LO$<5O)4C%"XGNW=OTW]:L<$$ @@@^A0KC7!%8X
M4ZG9.P/:VD^0 ^#F]0?H("[.@Y'S:)P$DCBY[J$!<X]Y/9M1'=1$0$1$!$1
M1$0$1$!!WH@[T'HB(L68B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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ME>>]_9O! <?$A!J2P0T^.<+<>T1NR&%D??;'TYN20"-Y]?5PW7-T]C=;</\
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M7U/6&G+.;R]6YAJ=?F<\7V!CPP?C;-)Z'?H._P!2#O+#WM8QSWN#6M&Y).P
M4!=Q0I156W[> U%6PSO.&1EICL@WP<0'%X;X[EJXO'[.O;HEM.IC\A;I9"2O
MSVZO(8C&Z5N\>Y<';N'0;#;KWH+(BSN)F@EGBRE%\,1#7R-G:6L)Z $[]%T5
M16O*N.CX79>7'Z3M:=D$M.)WE$4;'3-$K=MN1[M]O7UZJV]6:FQNEL<RWE9'
M@2R"&&*)A?)-(>YC&CO)0=I%"Z?$*J<E4IYC#9K".MO$=>6_7:V.1Y[F\S'.
M )V[G;+KZMU7B]+5H)<K+)VEF3LJ]>&,R2SO^:QH[S_<@[J*%5.(=/XSIT<S
MB,S@Y+C^RK29"!K8Y7GN8',<X!Q]!V45M\0LU!Q;=C68#/2X]F.<_P A9'!S
MR/$NPF:3)\C;IW@]>Y!;Z*+:BUM1P%/%OOT\@;V2\VMCH81)8<[8$MV!V!&X
MW.^WK3 ZQ&3RS,;:P.<Q5F1CI&>6UVAC@-M_/8YS=^OB4$I1>5JQ%4K36+,C
M8X(F%\CW=S6@;DE02'B?6M5#>H:;U+<Q/4B_#4;V;FC?=S07AY'3OY4%@(JF
MXHZ_R6+.EW8/'9?R>[>K.=.R&,-L1OW)A >X.#R-N\#VJ;Q:IY=,Y'-9'#Y3
M&QT6/D?7M-C[5[6MYB6AKR/>0@D2*'Z6X@8_5%BNS"4<G9K/:#)<$($$#BT.
MY'.+NKAOL>7FV*QD]?TZ^8MXO%8K+YNY3V%EN.A:YL)(WY7.>YK=]O $E!,4
M4>TUJ_%:@HW;%9\U=U$\MN"U&8I*YVW\]I[N@/7NZ+@P<3JUNNZYC-.:DOXL
M;[7H*C>R<!ON6@O#B.G>&H)^BBV:UUBL3A\5?DCNSG*;"E5@KET\Q+>;8,.V
MW3OWVV7SA-9C(9>#&W,!G<58G:YT1NUV\CN4;GSV.< ?:@E:(H+_  E4;5NS
M%@<-F\Y!6D,4UK'UVNB:\=[0YSF\Q'_#N@FC;5=UM]5L\1LL:'NB#QSAIZ D
M=^WK7LJCT/G:&HN-N:OXJ4R0'"0L<'-+7,>)3S-<T]01Z%8&!U-3S69SF-JQ
M3LGQ$S()W2 !KG.;S MV)W&WIV0=Q>-BI6L/C?8KPROC.['/8'%I](W[ES,G
MJ&KC]18;#31S.LY7MNQ<T#D;V;.=W,=]^[NV!7(U)Q"Q&GM1,PMZ.X^])6%B
M%D$7:&;=_(&, .Y=ON=MMM@>J"56;5>JUCK4\4+7N#&F1X;S./<!OWGU+V4!
MUME<'9T]@;FK,%>[.QDH8Z]69K1+#.7.#'. ?MMTW[ST/<NSK#6N(TC9QL6;
M?)$R]VO9RM;S-:8VAQ!Z[[G<   [DH)*B@<G$RE3L5AFL'GL12LR".*]<K-;
M#S'HT.+7$MW_ .(!2?4NH<9IO#R9/,6FUZ;-AS;%Q<3W!H'4D^@(.JB@D?$J
MJR&.UD\!J'&8Q^VUZU4;V0W[BX-<YS1ZR %(-&:EIZMP$.7QK)F597R,:)@
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M6^74.6S\.&DPF'?5AH8VI+'V;S$PO<Y[F?B[N=T!Z^/B@LQ$1 1$0$1$!$1
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M%\3PX II)$Q/1OHB**(B("(B B(@(B("(B##NY?"^W=R^%88R(B*H(B("(B
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M-^BAJX/ **.+A+@.R8UG.R5[MAMS.,K^I]:TL\ /A :6( !.*L@GT]2IOI'
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M1$!$1 1$0$1$ (B("(B B(!OW("+/*4V*&C"(B B(@(@W6>4H,(L\I6$!$1
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MI?[W,]^A=^XY>'P?_P %V+_IS?XCEYNT?/9]'\/^C3TG^5B(B+G>@(B("(B
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M(;*QQ[@X$^]6>_4&*_A0AR(O1>0MI]F9M_-YN4]%O?P!:D_.&+_[3_\ E3^
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M;UNC(VW:959V3G$ASM]B=QW=%^C.&VD(-&:;CQ\4G;3O<99YMMN=YV[AX
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M2#OCDJ/YA[@O)W$&YF0ZOH_3]^W,X;-LVH^Q@9ZR3W^Q6"8HR=RQI/I(7V
M-@-@IOXXZ5_<TMWRK6GB3I&*UJW6$L^8S!V:Y\$?,VJP^#!X >)Z*>8S(5LK
M0ANT)FS5IF\S'M[B%N2,;)&YDC0YCAL6D;@A5E@6/T3Q ?@6G; Y8.GI _\
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MW/$QWI *\?)6(K%H^\>SWL5YFTUG[3[_ /\ 'TB(M+>(B("(B B(@(B("(B
MB(@(B("J[07X8-?>R#]BM%5=H+\,&OO9!^Q91WL+=8:MSY#OTKOVE::W+GR'
M?I7?M*TU[,='QV3JE6E_O<SWZ%W[CEX?!_\ P78O^G-_B.7MI?[W,]^A=^XY
M>/P?_P %V+_IS?XCEYFT?/9])\/^C3TG^5B(B+G>@(B("(B B(@(B("(B##N
MY?"^W=R^%88R(B*H(B("(B B(@(B("(B B(@(B("(B B(@(B! 1$0$1$!$1
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M6#<(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M]HT8Q\NO@L%%YUYH[%>*:%P='(T/:X>((W"]%QMHB(@(B("(B B(@(B("(B
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MG =P&_<>]=>7/6:S%9UF7E;+L.2N6+WC2(:W"T]OQ*XAV8SS0^4Q1AP[B1S
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MY.2<-_Z18,C"#ONW99UBN[:9Z]S5>;1>L1T[W61$6#:(B("(B B(@(B("(B
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MW;^"V5FN[;7KW-5XMOUF.G/5O(B+6VB(B B(@(B("(B B(@(B(,.[E\+[?\
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M#>)EN2,SY,LL"%[F,E\SJ"-^HW\#NM/C7DL[1U5H6'34I;<M69X0QSR(G$L
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M5:GS<#Y*S#7KXZQV 8S8 %[MBY[G;!Q)/CLM3%R:QM:VR/#M^>F;CZ,8M/S
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M,KM<V#/8QC7.+R!*.I/4E>O\(>D?]X<=]:%C7%DTYU_8FU>Z4I11;^$+2/\
MO#COK0G\(>D?]X<=]:%EPK^63>CQ2E%'\=K33>2NQ4Z&:I6+4IV9%'("YQVW
MZ#Z%(%A-9KU@B8GH(B**J7.Q9'AWKW(:DH8ZUDM.YP,.3CK,YI*DK.@E#1U+
M2"=__P R[[>+NAG0=HW4-8NVW[(-=VGLY-M]_H4[6NVC4;-VK:L E^>(QS>]
M!5O$#/9G4G!_*7\9BLQBWNF8TQ%O+9?5$C>=[ .HW;OT/ANH\UO!M^*:W'4*
MN4R;H^6*HQLDEJ63;H"#UWW[R>BOM>$=.M',Z6.O"R5W>]K ''VE!57 UACX
M$M8YG9N8+S2S??EVEDZ+5TY_LNN_J6;]URN.*&**+LXHV,CZ^:UH Z]_18;7
MA;!V#8HQ#MR]F&CEV]&W<@C?"O\ !OIG^KX?W HOI_\ VAM5_P!3U?WE9\;&
MQL:R-K6L:-@UHV "^6PQ-F=,V-@E<.5SPT<Q'H)05O\ "+_!5D?UBK_CL5C5
M?]5A_H#]B^IH8YXS'-&R1AZEKV@CW%??=W((1QDPMK+Z(LRXLEN4QKV9"HYO
M?VD1YMA[1N/I7&X166:NS.=UR^!S66RVA1YP?-@C'G;;_.>3O[%:! ((/4%?
M$,,<$;8X(V1QM[FL: !] 0?GR[6OU]56^&<<$GQ;?RT>2C<&^:*!)DE;Z@)&
M@?\ S*:\?19;I_# >6-P0R,0RHI<P?Y-UW^3UY?3]"LXQ1F42EC>U Y0_;J!
MZ-U]D C8C<(/SKK*/A/+I3*,TICJ.3S#JLAACIA[Y&$-.\CB>C0T=23Z/2I+
MFO\ 9:__ ++%_P!U6[%1J1!XBJP,#QL[EC YO;Z5Z&O"8.P,49AVY>S+1R[>
MC;N05OQ%QEO+\!K5/'0NGLOQL+F1L&Y=RAKB /$[ KKZ'U_IK.Q8W&XO*139
M%U8$U@UP>SE:.8.&W0CUJ:- :T-:  !L /!><56"&1\D4$3)'_*<U@!=[2@K
M+@=_KFOO_B"?]@6UP+_F747]?7?WU8L4,4)>8HV,YSS.Y6@<Q])])2**.$.$
M4;&!Q+B&M W)[S[4%<\5/OQX<_UN?\)R\-90Y+27$&'6&-QEC*8VY5%')0U6
M%TL(:[F9*UHZN'4@A6;)%'(YCI(V.<P[M+F@EI](]"C6L3JV&S2LZ49C;5>,
M/%FE;<8W2[D<I8\ [$;'H?2@CF7XFP9+&S5='XW)9/*RL,;6NJR0QUR1MSRO
M< &@=_T+'P;FN;P=P0>#OO,?;_'/7SF,CQ#SV-L8RAI>K@Y;+3$^]9R#)FQ-
M/0EK6#<G;?93?2&!K:8TUCL-1ZP4XA&''O<?%Q]9.Y^E!UT1$!$7$R^K<!A[
MGDN5R].I9Y0[LY9 ';'N/]RL5FW*(29TZNVBB_\ "#I+_>''?7!9_A TG_O#
MC?K@L^%?RRF]'BDZ*,?=_I/_ 'AQOUX6?N^TI_O#C?KPG"OY9-Z/%)D4:^[W
M2G^\.,^O:L_=YI7_ 'AQG]H;]J<*_EDWJ^*2*.Z,^1EOUZ3_ "6!KK2Q_P#R
M@QG]H;]JPW6VE6[\N?Q8W.YVL-&_]ZSK6\5FN[/-KM$3>+:]-4D11X:WTN?_
M ,H,9_:6_:L_=MIC\_XS^TM^U:^'?PEMWH\4@1< :TTS^?\ &?VEGVK/W9Z:
M_/\ C/[2S[4X=_"3>CQ=Y%P1K'39_P#Q]C/[2S[5G[L-.?G[%_VIGVIP[>!O
M1XNZBX@U=IT__CW%_P!J9]JZM.U7NUF6*<\4\#^K9(G!S7>'0A2:S'6")B7L
MB(L5$1$!$1!$N)_WKN_3,_S51*WN)_WKN_3,_P U4*]_X;]'\OF?BWU_Q B(
MO0>8(L+**(B("(B((@1 1$0$1$47M5JV+3G-K02S%HW(C87;>Y>*[>E=02:?
ML6)8X&S&5@:0YVVVQW6%YM%9FD:RSQQ2;1%YTAI?%&2_-]SZEWV)\49+\WW/
MJ7?8K6T9J634!M]K79#V/+MRN)WWW^Q<G4&NI\7F;5)E*.1L+@ XO(WZ ^CU
MKAC:L\WG'%(UC[O2G8]GKCC+-YTG[*SEC?$]S)6.8]IV+7#8CVA?*E6)Q$FL
MLID;8F95=S!Y;R\W?O[/0MO^#ZZR*U+/:B9'$'%GF[EX'CMX;KIG:<=9W;SI
M+CC9,MXWJ1K7Q8TOHIF9PXNRW'1%Y<&-:T';8[=?I4/M0.K6IH'D%\3RPD=V
MX.RFFB<3E+V&GDH9=].$R%CHPW?<[#J.O3O41HT+.0OBI3C=+.YQ&P_O)] 6
M.*\[]]ZVL1^S/-CCAX]VFDS^[513V'AM:=&#-D(6/\6M87 ?3T4<U'IN]@7L
M-H-DA>=FRQ]Q/H/H*SIM6+);=K;FUY-CS8Z[UZ\G%12O36C9,YC/+&7&PCG<
MSD,>_=Z]TR6B;>-PD^0MV(@Z( F%H)/4@=_TIVG%O;F]SZ$;)FFF_N\M-447
MU%&^5X9$QSWGN:T;D_0OE6QPWQU:MI]N0;$'VIN?F<.IV#B.4>Y3:<\8*;TQ
MJNR;-.T7W(G17/Q#EA'VGQ;;Y/3V3EH3120R%DT;XWCO:X;$?05/9.(]EEDA
MV.8U@/5CGD.']W>N)K3446??3=# Z(1,/.';$\Q/I\1T6.+)GFT1>FD>K/-B
MV>M9G'?68[M$:12?3VC,AF*S;)>RM6=\ET@)+O6!Z%TKO#F[% Y]6W#.\?B%
MI9O["LK;7AK;=FW-A78L]J[T5Y(,B])J\L%A\$L;FS,=R.81U!]"E^+X>Y"U
M V6W-'4YAN&$%SA[?0L\F:F.-;SHUXL&3+.[2-4,4NT?I!F>Q\UJ:V^$-D[-
MK6-![AON=_:F<T)?QM1]F&5EJ*,;O#&D. ].WBO706,R=ZG;?C<JZDP/#7-#
M>;F.W?ZEHRYZVQ3?'?3[NG!LUJ9HIEI,_9%LK3=C\C9J/<'NA>6<P\=O%:JZ
M];"V\CG;&/@D;+88]_-)([;FV/4^E2>/AK8+ 9,C$U_B&QDCW[K9;:<>*(B]
MN;539,N:9G'7D@"[^&TKD<O1\KIB(Q%Q;YS]CN%YZDTW=P+X_*N22&0[-ECW
MV)]!]!5A\,?O5'Z5ZU[3M.YBXF.=6W9-DXF:<66)CDJ(C8E%EWRC[5V]%8Z'
M)ZAKU[0!A +W-/XVW@NJ]XI6;3W./'2<EHI'>Y]/%7[C>:I2L3-/XS(R1[UB
MWC;U,$VZ=B%H[R^,@>]6GJ_4LFG3!!5H\S'-W#SYK&^'*-O%<!_$/RC'68;%
M$-E?&YK'-(<W<CIN"N+'M.?)$7K3E/W>ADV79\<S2V2=Z/L@+6EWR02?4%@M
M+3LX$'UJS.%^&,<!RKI6N;.UT?9\O=L[OW^A?6L](/O6[N5;;;&UL7-V79[G
MS6^G?U+*=NI&6<<^_P!_!A'P_).&,L=?#[>*L44GTKI)^?IRV&6VP".3DY2S
MFWZ ^GUK8LZ$N5,5:NVK,3.Q:YXC:"2X#T^C^];IVG%6VY-N;179,UJ[\5Y(
M@B[^F]*W\XPRP\D-8';M9.XGQV'BNY9X;W&0N=7O0RR#N8YA;O\ 3U4OM6*E
MMVUN:TV/-DKOUKR01%LRT+45\TGPO%H/[/L]NI/@IC4X<79(@ZS=AA>?Q&M+
M]OIZ++)GQXXB;SU88MFRY9F*5UT05%)]2:.M8.H;3[,$T (;TW:[<^I>F T1
M?RM1EI\L=:!XW87@ESAZ=E.TXMS?WN3+LF;?X>[S11%.KG#FW% Y\%Z"0M&Y
M#VEG3V]5!2-B1^Q98LU,O.DZL,NSY,.D9(T;%:C:M-+JU:>9H.Q,<9< ?H7M
M\49+\WW/J7?8NMI;5<NGZLT$55DPD?SDN?MMT _R5FZ2S#\YBO*Y(6Q.[1S.
M5IW[ES;1M.7#K.[^GU=FR[)AVC2N_.]X:*;^*,E^;[GU#OL6D1L2"-B%85GB
M+8BGFB^+XB&N+=^T/@=O0HSI_3M[4,TKZP;'"UWGRO\ D@GKL/25MIFO%9MF
MC=CU:,F#'-HK@F;3Z.&BGLW#:TV(F'(0OD\&N86@_3U4,NXZU2O.IV8'-L@@
M!FV_-OW;>G=9X]HQY?DG5AEV;+A^>NC513>APZO3P-?:M0UW.&_(&EY'M[EI
MZAT3:P]&2X;4$L$>W-WM=U.W0>/O6-=KPS;=BW-E.Q9ZUWYKR15K'.ZM:X^P
M+"NK1>".$QLD3YFS&9XDW#=MN@Z*!ZSTL_$L=>-ILHGL$!@9MMON>_=:L6VT
MR9)I[?=NR_#\F/%&3W^R(HIMEM!R4<$^Z+C7SQ,[1\?+LW;QV*A*Z<6:F6-:
M3JY<V"^&8B\::B(BV-(B(@(B(HB(@PLHB(($1%$1$!;N#_GFA^GC_>"TENX/
M^>:'Z=G[P6-_EEEC^:%^HB+Y)]L(B("(HEF.(>G<1DIZ%ZU.RS >5[6UI' '
M;?O#=CWK*M+6Y5C5)F(ZI:B@_P#"II3\ML?V.7_E3^%32GY;8_L<O_*L^!D\
MLIOU\4X10?\ A4TI^6V/['+_ ,J?PJ:4_+;']CE_Y4X&3RR;]?%.$4'_ (5-
M*?EMC^QR_P#*G\*FE/RVQ_8Y?^5.!D\LF_7Q3A%!_P"%32GY;8_L<O\ RK'\
M*NE/RVQ_8Y?^5.!D\LF_7Q3E%!_X5-*?EMC^QR_\J?PJ:4_+;']CE_Y4X&3R
MR;]?%.$4'_A4TI^6V/['+_RJ0Z:U%C=25);.(E?+%$_LW%\3H]G; ]S@/2%C
M;%>L:S"Q:)Z.NB(L%$1$!4<-*8G57'O64.:AGE9!2IOC$5F2'8E@!W+'#?Z5
M>*^&PQ-F?*V-@E> '/#1S. [MR@I/7O#3&:6=C]4Z>Q#\DS%R<]S&VIGV6S0
MGY3VB1QV>WY0V]'<I3Q-QT6O^&';:>$61'-%>JQ ^;8Y' F,^C<;C;TJQCU&
MQ7Q!#%!&(X(V1QCN:QH 'T!!1.-=P:DI1G+XK'XG(; 34;D<D<L;_%O*>_KX
MA2?%:3TUJ/AUJ"OI7"OQ$.6C? UTD3HC*6[]G)L[KR[]0K+FIUII6RS5X9)&
M_)>Y@)'L*]T%6Z.XG8C&X"KCM:3' YJC&VO-!=:6=H6#;G8=MG-.V_1;>0R$
M7%31&J<;BJEN&I)&8:EVPPLCM.VW#F;]>4.&Q*L&Q5KV>7RB"*7E.[>=@=M[
M-UZM:&M#6@ #H $%7:-XH8>CI^IC]:V1@L[2C%>S6N-+.9S1MSL.VSFG;<;>
ME>&E'3ZXXJ'5T%:Q7P&+I.I4I9XRPVY'NW<]H/7D \?6/6K3L5*]DM-BO#*6
M]W.P.V]Z]@ !L!L$%/\ %/*?P=:SIZRBKNDHY&L_'WV,'?(T%T+CZ^]OL4GX
M7Z<L4M!\F<#OC;+]I;R#B.5W:2[DM]7*"!MZE-9X(;#.2Q%'*S??E>T.&_TK
MT0?G'2.$T)IJG)A.)6$J8_*TWN8R[98\17(]_-D:\';?;O"G.@J'#N]J@2Z/
MP4;Y*4?;-R<,+Q"UQ/+R->>A=L3W*T;%>&PSDL11RL[^5[0X?WKZBC9%&&1,
M:Q@Z!K1L!]""L=$_ASXC?H:'^"%+>(>G6ZIT=D\3ORS2Q\T$G<62M/,QP/AL
MX!2!L,3)7RLC8V1^W,\- +MN[<^*ANH\OK6KD+=;"Z9J7:[P!5N&^U@82.^1
MA&_0^C=!!^&V2L\0M4XRUEH)6MTI4[&9L@V#L@X\KG>OE:S_ .Y7:HOPWTN[
M2NFVU;,K9\E8E?;O6!O_ !L[SNX]?#N ]04H0$1$!$1 1:&=R]/!XV2]DI'1
MUHR YS6%YZG8= "5%OX5-*?EMC^QR_\ *LZX[VC6L:I-HCJG"*#_ ,*FE/RV
MQ_8Y?^5/X5-*?EMC^QR_\JRX&3RRF_7Q3A%!_P"%32GY;8_L<O\ RI_"II3\
MML?V.7_E3@9/+)OU\4X10?\ A4TI^6V/['+_ ,J?PJ:4_+;']CE_Y4X&3RR;
M]?%.$4'_ (5-*?EMC^QR_P#*G\*FE/RVQ_8Y?^5.!D\LF_7Q3A%!_P"%32GY
M;8_L<O\ RI_"II3\ML?V.7_E3@9/+)OU\4X10;^%72GY;8_L<O\ RJ:5+$=N
MK#8@),4S&R,)!&[2-QT/<L;8[5^:-%B8GH]41%@HB(@(B("(B B(@(B("(B"
M/WM54Z>LL?IN2O<=<NP/L,E9%O$UK>\.=OT/T>CTA2!1+(:DLU^)N)T\R"N:
MMJA-:=*0>T:YKF@ '?;;KZ%'=8\1<KA.(\.F,9AV9.2S0$]:)A+7NEYB/.>3
MRM8&@DG;P06>OF21D4;GR.:QC1N7..P"JW.ZMUYI&J,QJ?#X2U@HW-\J^+))
M.WK,)VYCS]';$C?8)QWM9BYPPOVL _&/PTU%TEI]CM.U+#REIBY>F_4_*]2"
MTV.:]@<QP<TC<$'<$+*K_A2=7G#8CX\^(?B?XOB[#R,3=O\ (;R\W,>7N[]O
M%8M9;B'D,G<BPF!P^.HP2.CCGRT[WNGV.W,UL?<#W]4%@K@8[55.]K++:;BA
ML-N8V&*>61P'9N$@W :=]]_3N N-H/5^3RF;RNG]3XR+'9O'M9+_ !#R^*Q$
M[<"1A/7;<;;'T^U<72G^T!KG^KZ7[J"TD4"9K:WG]6QXC1D%:W0JO/QGE)0Y
MT,6V_P#%1[$<TA].^P]:]M7ZPR-74%;3NE,9%E,U)%V\YEEY(:D>^P=(1UZG
MN Z]$$W15G8UCJO2EFK)KS&8MV'GD;$_(XI\G+6>X[#M&OZ\N^PW'<K,0$1$
M!$1 7Q/#%8C,<\3)6'KRO:'#W%?:(-/XIQWY!4^I;]BQ\4X[\@J?4M^Q;J*[
MT^*:-/XIQWY!4^I;]B?%.._(*GU+?L6XB;T^)I#3^*<=^05/J6_8GQ3COR"I
M]2W[%N(F]/B:0TOBG'?D%3ZEOV+/Q5COR"I]2W[%N(F]/B:0U8L=2AD;)#3K
M1R-[G-B:"/IV6TB*:ZJ(B("(B B(@(B("*M-;\1+^GM=U]/T<6W)2W*(EJP1
M[MDDG,A;L7;\K6!H))(\.]?.3S_$?!4W93)8'!Y"A&.>:KCII!9C9MN3N[S7
M$>KO06:BBF4UYB*6A6ZIAD=:HRQM=7CBZOF>X[-C:/G$]-O#KZ%P&9CB=-3&
M2CT_@(X"T2#'26)/*B/1S_(#MO#9!92**X+5\><T7:S=2N^O9KQRB:I8^7!-
M&#S1O[NXCW%17AYKG5>N:&,OXW$XROC?-%VU8=(WM'_]8V!@)/3J-W$@E!-*
M6JJ=O660TU'!<%RE798DE=%M$YKCT#7;]3]&WN*D"B&*U+9M\3,YI]\%=M6E
M2@L,E:T]HXO+@0X[[;#;IT7)R^MLWDM4V\!H3%5;DE#9MW(77N;6A>?^K'+U
M<X#OV/1!8J*MZNM-18+/X_&:]Q-&"M?D[&OE<=(XU^U._+&]KO.:3W D]ZZ>
MOM:S8&]C\-@\:[+ZAR&Y@JM?RMC8.^21WXK4$RL2B""25P);&TN('?L!NN)H
M;4]36.F:F;QT,\-:SS<K)P \<KBT[[$CP]*AF7U#KW!8V:WJ7"8BYBC&[RA^
M(DD[6LTCJXM?OS@>/*O3X-OX'L'_ /5_Q7(+-1$0$1$!$1 1$0%KST*EB3GL
M58)7[;<SXPX^\A;")KH-+XIQWYOJ?4M^Q/BC&_F^G]0W[%NHKO3XII#1^)\9
M^;J?U#?L3XFQGYMI?4-^Q;R)O3XFD-#XEQ?YMI?4-^Q8^),5^;*/U#/L701-
MZ?$TAS_B3%?FRC_9V?8L?$>)_-='^SL^Q=%%=Z?$TAS?B'$?FJA_9V?8GQ!A
M_P U4/[.S[%TD3>MXFD.9]SV&_--#^SL^Q8^YW"_FFA_9V?8NHB;]O$TARON
M;PGYHH?V=OV+'W-8/\SX_P#L[?L761-^WB;L.1]S&"_,^/\ [.W[%TJE:"G7
M9!5ACAA9T;'&T-:/8 O5%)M,]9(B($1%%$1$!$1!$N)_WKN_3,_S51*W>)_W
MKN_3,_S51+W_ (;]'\OF?BWU_P 0(B>"]!Y@B(@(B("(B B(@(B("($0$1$%
MB<(?E9/V1_\ >48UU]]N2_IM_="[G##(T\>[(^76H:_/R<O:/#=^_N4>UC/%
M:U-D)JTC)8GO!:]AW!\T=RX,=9[7>=.6G^'IY;1.Q4C7GK_E*^$/\ID_8S_-
M<W7&I,@_-6JE>P^&M"[L^1G3F/COZ5L<,,C3Q[\@;UJ&N'AG+VCPW?O49U/-
M'8U!D)8)&R1/F<6N:=P1OWA2F*+;5>UH[H_I;Y9KL=*UGOG^UB<*_O;L?K#O
MW6K3X55H]\G:(WF[3LP?0.__ ->Q?/#C+8^C@9HKEVO!(9W.#9'AI(Y6]5&-
M):B.!RDSWM,E68[2-:>[KT<%IMBO><T5CKHZ*YL>.,%K3TU_"59F+'6LG++8
MU8^&5CR!&UP:(R/#;U+;SN7P]G2]FF_*UK4XA(:[?SG.'<=AXK%TZ.S4@M69
MZS93U<3(8G'VCHHQK>73QK5H,(QAGC)!?%\GE]9/RCZUABIQ+5K,6UC[1R9Y
M;\*M[5FLQ/WF9E+N%_WKC],__)5WG-19'*3SB:R\5WD@0MZ-Y=^@V\?!37AY
MF,=2TZ(K=ZO!+VKSR/D .RK)WRC[5T;-C_\ GR6M'?R<FU99C9\5:SW<_P!F
M%)]*ZOLX.(UG1-L5-]PPGE+2?05&%/-*6-,3X..CE1$RP'%SGS#EW)]#AW=-
MET[3N[GZJ[T.78XMQ/T6W9^[MQZETUG',@N0<KY"&CMXAW^CF'<N/JS2%.A8
MH3TN=M>:PR&2,NW W/>#[UTH<%I"I*VR;<+FL\X-?9#F^[Q7%U]JBODF0T\8
MYSHHG]HZ4#;=P[MO8O/PQ/$B,&L5[]>CT\\QPIG:-V;=VG5)^(=^QBL!$W'N
M[$/>(BY@V+6['H/1W**<-\K>^/HZ;IY)*\S7%S'GFV(&^XW_ /75=W$ZKQ.:
MQ0IZ@[..78!_:#S'D?C ^!7O4N:3T[')/1FADF(V_BW]H\^H'P6-=<>*V&U)
MFT_9G;3+FKGKDB*QW:_MHSEL;6DXA8R5S1S.A=(X>ES>XGW_ -RY7%'+78+D
M%&"5\5=T?:.+"07'<C;?T*-9#4MJUJ1F69YAB<.RCWZ!@_%/MZ[^U3A^9TUJ
M6E&,J^*&5HWY97<CF'U.\5GPKX;4O>-Z(C3T:XS4SUR8\=MV9G7PU0:MJO+U
M\:^E':)8X]'N&[VCT GP4RX2=<;?)[^V'[J\\KD=+XK"34Z$5:XY_41CS]W>
MDN]7M6OPSRM"A0NMNVX*[GRAS6R/#=QMX;K+//$P6FM-.<?ECL\<+:*1?)%M
M(GOZ.-CL=>R&M;OQ9*()8IY'F8]S!S$=WC[%W[>(J8Z\UU[5D\5QOG>>X=/H
MW[ER=-:@JXK5>3DG>#4M2/':-Z@><2#[%V<O5TC;OOR=C(M<X^<^&.7<2'V=
MZN6UXO$3KIIW1JF"N.<<VB8FVO?.FGW=77T;)]'32%PEY Q[7^D[@;_WKSX8
M_>J/TKUK:NS>+N:2L0U+E<R/8SEA:\<PZCIMZEX\/<QCJ6FQ#;NUX9>U>>1[
MP#L5S;E^RS72?F=?$IVR+:Q\JLG?*/M7OCKL^.NQ6ZK^2:,[@^'L/J6N?E%=
M;2MBA4S4$^58YU=F_0-Y@#X$CQ"]J_*L\M?L^?QQK>(UT^Z;4.(5&Q%V>6IO
M8?$L >P_0>O[5O.P.G=34Y+&.#8WDD=I$"TM=ZVK5DQ.C<DXRQ68(2>I$<_9
M_P#VGN6Q\<Z>TMC9(L7(R:0^=V<;^<O=ZW>"\:T5C_CQ:+>'<]ZDVF/_ ,FU
M;5\>]Q>&<<M;460J2/<>Q8YG+OTW#MMP%RN(LTK=56V-ED#.1GFAQ ^2/!>.
ME-0?%VHY+ML;QV2X2D>',=]_H*F6:^Y/+.?<L7:_E!BY0X2$'NZ$M\2%TWF<
M6T<2U=8F.[Q<E-W-LO#I:(F)UYSW/GA-_,MO]8_[H4/U1J/(WLG;A-E[*S7N
MB$3.C>7<CKZ5).&N5Q^/Q5J.Y=KPO,^X$CPW<;#KU4 R3VR9&V]C@YKI7D$=
MQ!<>JRPX]=HR6M'HQVC+,;+CK6?5<SX8,?I2*%MT48&Q-;Y1MW;^/M._]ZCN
M$=B<5>%ANJS,T[\\<CP6O]J\=)ZOHOQ;,9G-@&,[,2/&['M\ ?1T6Y%5T34D
M-D35'D=0PRF0#V-W*Y-RV/>I>)Y^$1.KNXE,L4OCFO*.^9C1S=5YG%MU/A\G
M3FCLB(GMNR.YV!Z?3U/N7:RSL7JED/DV==7+?^K8_EW/K!V.Z@!FPYU4)FQR
M-Q(E#BTC?I[/1OX>A362IHBZ1-VU6(GKLV4Q_P#VK=EQQCBFF]K$==-?=SX<
MMLLWUFNDSTUT_,.)JW3V9HXKFFR#K]"-W.=]]V'N!Z[].OI4AQN>Q>7T]%0D
MR!H6>S;&[9W(X$>@^CHM'5^IL8S OQ6)<V;G:(MV[EK&CU^*QC&Z-O8JM%9,
M,4T<8:]TA,3R?$DCH5)WKXHG+6>4\M(_>895W:9K5PVC28YZS^T22Z4R<5&9
MV%SCK,3V%IB<[HX'O .Y&ZKE[7,>YKP0YIV(/@5;$&8TUIK'RMQD[)2?.[.-
MY>7GV^"JNW.ZS:FG> '2O+R!ZSNNG8[9+;V]'+NG327'MU,=8KN3S[XB=8AY
M*W.%WWL?_6?_ )*HU9W#O+XZCI[L;EVO!+VSCRR2 ';IU3XA6;8=(CO7X7:*
MY];3IR5Q?_UZS^E=^TJXL-%#2T57Y; J,-</=/L/,+AN7?WJG+C@ZY8<T@M,
MCB"/$;J<Z+U=5@QXQF9V$+1RLD(Y@6G\5P4VW':^.N[&NB_#\M,>2T7G36.K
M:Q8Q6.OMM1ZM=([?SVR.#@\>@]5X:US.,?EL/D*,\-E]>0]J(SN>4$$?YK?;
M2T1%,;';5';=>3MBYH]C=U"\E/AI-3MEJQ2,QG:-+V@=_7KL/ >I:<-8R9-Z
M=[E'?$1^&_/><6+<B:\YCI,S^>:?92UB=45(609MU1S?.+&OY2=_!P/L4=U-
MIK,4\0\LR+[]!A[1S"3NT#QZ[[@>U=:2OHC( 2F2K"3UV$AB_NZ)GM38C&8%
M^-PSVSN<PQ-#"2U@.^Y)/?WK5BF])BN*)Z])C^VW+6EZVOFF.G6)GG^'KPID
M?)AK9D>]Y$^PYB3^*%7.9ED?DKC7RR.8)G[!SB0/.*E'#G457%=O3ON$44K@
M]LI[@=MMC_<O?5U73+J-JUC[<)O/>) V.3FYCOU&WAONNBDSBVBV]6?U::.;
M)$9MEINVC6NNO-&[>I<K;Q0Q\]@NK;!I\W9S@.X$^*XRL[4&7T_-H]\-=U=S
MS&!%"T /8[PZ>&RK%=.S7BU9TKN\W)M=)I:(F^]R$1%TN01$" @1$41$1!$1
M%$1$!$1$%NX/^>:'Z>/]X+26Y@_YYH?IV?O!8W^66>/YH7\B(ODGVPB(@+Y,
M;"=RUI/L7TB#Y[-GS&^Y.S9\QON7TB#Y[-GS&^Y.S9\QON7TB#Y[-GS&^Y.S
M9\QON7TB#Y[-GS&^Y.S9\QON7TB#Y[-GS&^Y.S9\QON7TB#Y[-GS&^Y9:T-^
M2 /8%E$!$1 1$0$1$!$4+XKZQDT1I^IE&1POB==A@F[1KG<L;B>8@ CSMAT0
M31%6M;.<2,M4^,\7@L%2I/!?#4R$TALRL[P26^:PD>![EWM":SCU)0NB_5.*
MRV.D,5^E,\$P$#?FW\6D=04$L15AC=8:QU>)[FB\1BJV%9(YD-S+ODWM@';F
M8QG4-]!*[NBM6WLGE;N"U+C!B\]48)>1C^>*S$3MVD1]&_0CO""9+@ZLU14T
MS\6>6P6YCD+;*<?D\?/RN=W%W4;!05O$3461UMJ+2^ P]*U>Q\X$<TSG1Q10
M\H//*=SS$N) #=E)-6:BRFG\?I;RF&A+>R&1KTK7*UQC;SAW,Z/<[CJ.F^Z"
M:(H?Q!UI]S Q]+'T'Y3.Y)YCIT8W<O-MWO<?Q6CIN5P<AJ#B1@J3LGE<!@\C
M1C;SS5L;-(+$3>\GS]VNV] 06<BB>6U[AJ&A6ZJ9*;-"6-KH&1=7S/=T;&!\
M[?IMX=5'Z^:XGVZ+<G!I[ 0UW@/9CI[$@M%OH+_D [>!'1!*\/JRGE=69S3\
M$-AEO$"(S2/#>1_:-YAR['?V[@*0JE>#&7.=XJ:_R#ZD]*61E1LE:<;/B>UA
M:YI]A!Z^*NI 1$0$1$!$1 (!&Q (]:^>S9\QON7TB#Y[-GS&^Y.S9\QON7TB
M#Y[-GS&^Y.S9\QON7TB#Y[-GS&^Y.S9\QON7TB#Y[-GS&^Y.S9\QON7TB#Y[
M-GS&^Y.S9\QON7TB#Y[-GS&^Y?0Z=R(@(B("(B B(@(B("(B B(@(B(*VS7X
M>M.?U/9_Q&K5>QKOA(L<YH+FZ?.Q([OXU3NSIVC8U34U!)VOE]6N^M'L[S.1
MQ!.XV[^B^/N9H?=?]TO\=\9>2>1_+\SL^;F[MN_?Q0<SB]^##5'ZA+^Z5$M2
M@GX,T@ )_P#P%$?_ +&JS,_B:V=PMW%WN?R6W$Z&3D.SN4C8[%?%/"TJNGH<
M*(^UQ\=<5>24\W-&&\NQ]/1!IZ"<UVA]/%K@X''P;$'??^+"K;2MK6G$:&_E
MZ&JHL!0CMRUH*4--DTC0P[;R.=XGT*7Z5X88'3&7BOXN3)@PAP@KRW7OAA#A
ML>5AZ>_=:^8X2:;R.5L9")V3QUBR[GG&/N/@;*[Q+FCI[D$4X?P7:G'+*U<I
MJ(9^W#AVM?,(FQF(]KOV9#>F_CZ>JY>;Q&?S_''6&*P.09C*UFE4%^V.LK8N
M7Y,?K=N1OX;*U].:$P>G,G'>Q$$D$S*GDFW/N'-Y^<N=OU<XGQ)6[1TS0I:J
MR>H8>V^,,A%'#-S/W9RL&S=AMT05[PDLNT/E'<.LXV%D[>>QB[<;0UER$G<@
M]W\8.N_I^CKQ+>%S8XWZH@I:I.GY<I7K6:Q\F9+Y4QC2PM!<>A:? =_-NK:U
M;I7':HAJ-R';1STYVV*]FN_DEB>/%KMCT/B/%8U9I##:KI0ULY5-CL#S0S!Y
M9+&[YS7-V(*"O=3:!U+>P\]'/\2SY!;V@>V:C"P/+CL&@[CJ3W;=5;5"!U6C
M7@?(97Q1M89"-BX@;;_2H1A>$VF\;D(;LSLEDYX'B2'XQN/G;&X=Q#3TW]JG
MR B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B"HM0YBAB/A$X49(LC\K
MP[J\,K^@;(920-_#?8CZ5:&9R=+$8JSD,G/'#3@C+Y'O( V _O\ 8JXS^(HY
MWC6['9:LRS3FT\0^-_=_+]X]!]86Y4X,:5BL1/M?&F0AB(='5NWGRPL([MFG
M_-!5IQ.2H\ M+79)WXZ*OF&9!THB[0UH'R.Y7\I\!S@[>M615TEK2U6CL5N)
MTLL$C0]DC,="6N!\0=U9D]6"Q4?5GACDK/88W1.:"TMVVVV]"KR3@QI?MB:\
MF8J57'=U.OD)&0'TCEWZ#V%!C2^G)<#I#5D\VH&9U^1[>P^PR-K )!&6.'FD
MC?=O7UKH\#HV1\*-,B-H:#3:X@>D]25(\?I[&8W3OQ'CJS:N-[)T0CCZ;!V^
MYW])W/5>FF\+5T]@J6)Q_:>25(Q%'VCN9VP])00;3OX>=6_U54_>>O+@O9AH
MWM7:?N2,;F:^7GLR1NZ.DBD(<R0#Q&VP4WJ:<HU=47\_%VOE]V".O+N[=G*P
MDC8;=#U*YNL- 8'5=B*UDH)HK\3>6.Y4F=#,T>CF;WCVH(UQ_GBMZ:Q^ K/8
M[,9/(UF5(@=WMY9 YTFW?L #N?6OB>:+!\>:\V6E9''EL.VK3E?T:98Y-W,W
M])!!4CTCPZP&E\@_(4XK-K)/;R^67IW3RM;Z YW=]"[&JM-8G5.+./SE1MFO
MOS-W):YCO!S7#J#[$'SK3+T<'I?)7\K(QE6.!^X>?ED@@-'I)[ME#?@W?@?P
M?3;K+T_^JY;N&X2Z;QMZ*W([)Y&6 \T R%Q\[(CZ6M/3?V[J3:0TY1TI@*^'
MQ7:^1P%Q9VK^9WG.+CN?:4'91$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$01/B?][#OTS/\U4*MWB?]Z[OTS/\U42]_P"&_1_+YGXM
M]?\  B(O0>8(B(HB(B"(B B(@(B(HB!$01$" B(BB(B((B("(B*(B("(B((B
M(,+*(BB(B B(B"(B B(BB(B((B("(B B(BB(B B(B"(B*(B("(B((B("(B B
M(@(B(HB(B"(B B!$!$1 1$0$1$41$1!$1 6[A/YYH?IV?O!:2W<'_/-#].S]
MX+&_RRSQ_-"_41%\D^V$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 55_"
M,MPT-'8NY:C,E>OEZLLC -]VM<2?[@K45<\<6AV%T\UP!!SM,$$;@CG*">XZ
M]5R&.@NTIHY:LT8D9(QP+2TC?O5.X^M)J;7?%"Y@BU].;&MQC)F?)ELMC(.Q
M'0[;@;J2W^#FE[=N:6,Y2G!.XOEJ5+SXH'D]^[!T /H&RFNGL)CM/8J'&X:K
M'5I0CS8V?WDGO)]904MPKPFILWHK'287B'-5A@C$#Z8Q\1=6>WH8SN=^FWCW
M]ZEVFM&Y6KKJOE,QK49BY2K/B-8UHXWB.0COY3OMNWIN/!=/47"[3N;R<N1Y
M;V.OS$&6?'6G5S)_2 Z'V[;KK:.T5A=(LG^)Z\@GL;=O9GE=+++MW<SG=4$5
MX81,'$3B1*&#M#D(FEVW4@1-(']Y6QQE_P#R+_\ B*K^QZEN%TY1P^5S&0I]
MKY1E)A/8YW;CF#0T<HVZ#8+.HM/4L_\ %WE_:_\ 0+;+L/9NY?XQF^V_I'4]
M$$%U5:APG&_3>0RKFQT;V.EQ]>9_1K)^<.V)\.8; *Q,UDZ>'Q-K(9*>.&I!
M&7R/>X ; >M>6HL%C=18N7'9FI':J2=['^!\"#W@^L*%4^#>EH;4,MEV4R$,
M+P^.K=O/EA:1W>8>A^E!6>/HVL-P8T?ELA"^.A3ST>4FBY"3%6<]W*=O0.8'
MZ5^C*MRO:I1VZT\<E61@D9*UP+2TC???T+-BK7LU)*MB&.2M(PQOB<T%I:1M
MMMZ%78X+:5;*\1OR\=)Q)=19D)&USOX<@/=ZMT'$X296EF>,'$B[BWLDJN=6
M8V1G5KRUI:7 ^()!._BKE4=T]HW#Z>S.0R6)@=!+=CAADC:?XMK8F\K0UNW3
MHI$@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+6ER%.
M*_#2EM0,N3M<^*!T@#WM'>0WO("V567#^4Z@XG:USDWG1X^2/#T]_P 1K 72
M[>UQ'N06:B@^8XH:<P^5S&/R,MB*SC7PQO:(N<S/E;S-;&T$EQV[^G1>&%XK
MX+(96OCKM7+X:S9=R5_C6DZNV5WH#CTW]J">]FSM>TY&]IMR\VW7;T;KZ7!U
MAJK'Z3J4[.5[7LK5IE1AC .SG[[$[D;#IWK2TOKO%ZGRT]/#P9":")A>+YK.
M;6EV(!#)#T<>OAZ"@E:* 9KBM@<?DYZ%*ME<S8KNY9_BJFZPV%WH<X=-_4I%
MI#5>)U90?:PU@R=D[LYH9&EDL+_FO8>H*#NINB@VH^%6D]19B?*9:C/+<GVY
MWMM2L!V&PZ!P Z!!.=QZ47YUX3<,-+Y^758RM.Q,*.8FJ5]K<K>6-NVPZ.Z^
MTJ5:OH?$U[1_#_3E^Q@L3D'SOFLLE<92UOG&)CW'<.<2>N_H07 BK4\&=-5^
M:;#SY?%Y'O;=KWY>T#O2=R0>_J/%>W$_+Y31W#.+R6^Z7).=!1.1F:-V%YY7
M3.'=Z3]*"Q$58UN#.F9X8K&2L97(Y,M#G9%^0E$CW?.&SMAZEV&\/*ES3+\'
MJ7(Y'.5!9[>)]J9S96 #9K2]I!=MUZGOW03;<>E>5JS#5KRV+,T<,$32]\CW
M!K6M'>23W!?GCB#PQTOB-=Z"QM"G8CJ96U/%;8;4KN=K6M(&Y=N.\]RM;37"
M[2FG+TEO%8^1DTD+H']K8DE:YCN\%KB1UV03*O/%9@CGKR,EAD:'LD8X.:X'
MN(([PO15IP'FEK8++Z<LN<Z3 9&6DPN[S%OS1_W';Z%9: B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B((EQ/^]=WZ9G^:J)6]Q/^]AWZ9G^:
MJ$+W_AOT?R^:^+?7_$"(B]!Y8B(@(B("(B*(B("(B B+"#*(B((B(HB(B"(B
M*(B(@B(@(B("(B L+*("!$0$1$!$1 1$11%A90$1$!$1$$1$41 B B(B"(B
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MC9(W%KV$.:X=X(\5KQ4O%9FWS2VY<E)M$4^6/]G_  EF5S%+%9*Q3IX'']G
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MC_K7?:GW#8'\D?\ 6N^U29$[3F\T^YV3!Y(]D9^X; _DC_K7?:GW#8'\D?\
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MW3@LP[]E/&V1FXV.SAN-_>@]46EF\G5PN(N9/(/[.I4B=-*X#?9H&_3UJ):
MXIZ;UUD;%'!R6A9AC[4LL1<G,W?8[=3OMN$$Z1% M>\5M.:'RL6.SANBQ+$)
MF]C#SCE)([]QZ"@GJ*GA\(K0Q.Q=E #X^2_^93K1FO-.:QC><!DXK$K.KH';
MLE:/3RGKMZQT02<(H+K#BEI_2&H(,1GA>KS3AKHYA"'1.:3MS<P/<#OOT4Y8
MYKVAS'!S7#<.!W!'I"#**.:[UIA]$8AF0STTC(7R"*-D3>9[W'KT&_@!U70T
MUF8-082KE:<5B*M:9SQ"=@:\M\#MN=@4'31%R=5:@H:7P%O,9=[F4JK07E@W
M<=R  !XDDA!UD4.X>\1L!KTW1@)+'/4Y3*R>/D.SM]B.IW'0J8H"*$ZBXFZ?
MP&L*FF<@;GQG:,38^SBYF;R'9NYW]/J4@U9GZ6E]/W,SE.U\BJAKI.R;S.ZN
M#1L/:0@ZR*/Z'U=BM:8093!RO?7[1T3FR-Y7L</ C<[>!^E2! 11K7NML-H;
M%Q7\]+*V*:3LHV1,YWN.VYV&XZ#Q^A='2^<J:DP-/+XWM/([;.>/M&\KMMR.
MH^A!U$1$!$1$$1$41$1!$1 1$0$1$41$1!$1 1$11$0(@B(BB(B B(@(B("(
MB B(@(B! 1$0$1$!$1$$1$41$0 B(B"(B B(@(H-K_BCI[0F1K4LZ;G;6(NV
M9V$/..7<CKU'B%%A\(K0V_RLH/\ ^E'_ #(+B1171?$#36L@\8#)QS3L&[H'
M@LE ]/*>I'K&ZW=:ZJQVCL&_+9CMO)&/;&>Q9S.W/=TW"*[J*G?](K0WIRG]
ME'_,NYI?C1HG45V.G6R;JMF0[,9<C,0<?1S?)W^E!8R+&XY=P=QMON%"-&<3
M]/ZOS]O#X@W/+*S'/D[:'E;LUP:=CN?$H)PBB'$+B'A-!,I.SWE6ULN$781<
M_P G;??J-N\*38N]7R>.K7Z,HEJV8VRQ/'XS2-P4&RB*$:RXGZ=TCGJF'RTM
MAU^R&N:R"/GY0YVPYNHVW03=$!!&X[BN%K756,T;@I,MFY)&56/;'M&WF<YS
MCL ![S]"#NH%%>'^O,+KNC:M8"29S:T@CE9,SD<"1N#MN>AZ^Y2I 15EJGC;
MI/3.>N8?)G(>657!LG9U^9NY /0\WH*YL/PB-"OD#72Y*,'O<ZKT'N=N@M]%
MQM*ZHPNJJ'EF R,%R$='<AV<P^AS3U'TJ..XJZ;BUN=*7'6ZF5[;L!V\7+&7
M$;MV=N>CNFQ]803Q$4-U]Q(P&AK%*#-R6'6+@)BBKQ=H[8$#<C<;;D[#Z4$R
M1>5.8V*L4QBEA,C0[LY1L]N_@0"=BN?JK/4],:?N9G)]IY'4:'2=DWF=L7!H
MV'M(0=5%3O\ I%:'].4_LH_YD_TBM#^G*?V4?\R"X@BXV7U'1Q6E)=0V^U^+
MXZ[;+N5F[^0[;=-^_J%SN'^O<'KNG:L8":1WDSPR6*9G(]NXW!VW/0]>OJ*"
M5(G@5!=$<4M/:SSEG$X8W/*Z\;I7]M#R-V:X-.QW/B0@G2*'\0N(F#T$*)S_
M )4!<Y^R["+G^3MOOU&WR@H;_I%:&].4_LH_YD%Q(J^TIQAT9J6['3HY3L+<
MG1D5N,Q<Q] )\W?U;JP0@(JUU;QITII74%O#94Y#RRL6B3LH YO5H<-CS>@A
M<F+X1&AGR!KI,FP'\9U7H/<Y!<"+B:3U7A-643;T_D8;D;=@\-.SXSZ'-/4+
MM.<UC2Y[@UH&Y).P 0915;J3COHC"6GUA=L9&5AV=Y%%SM!_I$@'Z-U\Z=X\
MZ)S5R.JZW9Q\LAY6FY%R,W];@2!].R"U$6&/:]@?&YKF.&X<T[@A0C6G$_3^
MC\[4Q&8-SRNRUKX^QAYF[.<6C<[CQ""<(N=J#,U<#@;N7O\ :>25(C-)V;=W
M<H] 7&T#KW!:ZI6+&!L/<8'\DD4S>21OH/+N>A]/J*"5(G<"5"=%<3<!K'.7
M<3A_*_*ZC'/D[:+D;L'!IV.Y\2@FR*JLWQXT=ALO=QMPY+RFI*Z&3DK@CF:=
MCL>9:7^D5H?TY3^RC_F07$BK#37'#2.HL[2Q&..0\KMR=G'VE<-;OZSS>I6>
M@(B("(B B(B"(B B(BB(@0$1$!$1 1$1!$1%$1$!$1 1$0$1$01$0$1$!$1%
M$1$01$0$1$!$1%$1$01$0$1$41$0$1$! B("(B @1$01$11$1 0(B B(@(B(
M@$1$!$1 1$11$1 1$0 B(B"(B B($!96$0$1$41$0$1$01$13THB("(B B(B
M'@B(BB_/OPQ/O9T_^N/_ '"OT$OS[\,3[V=/_KC_ -Q!-N'&A=*W= Z?L6]/
M8R:>6C$^21]=I<XEO4D^E5%\)7A[A-(U,7G=-1.H2S6.Q?#&\\FX;S!S?$'I
MZ5MZ2XC<4:.F,74Q6A?*J$-9D<$_D-AW:, Z.W#MCOZEJ6]'<3.+><K2:OA?
MA\7"=VMEC[-D0/?R1_*+CZ3[T%L9+,3Y_P"#M;RES8V;.&<^4[;;NY=B?IVW
M5:?!3TUA,[@]029K%4KSXK$36.L1!Y:"T[@;JY>(N/KXK@_G:%)G)6JXMT,;
M?0UK=@OS+P2U;K33>.RD6C=,_',$TK'3O\FEE[-P! 'F$;;CTH+VXI\)-)7=
M(Y2U3Q<&.O5:\D\4U4<@W:TG9P[B#LH_\$/-VKVELQB[,CI(:$['0;]>5KP=
MV[^C=N_TE5MQ#XG:_P _,W3&9JQ:>\LY(Y(.R=7+VN.PYG2$D-/CU 7Z(X-<
M/V</M+NHOG;9O69.VLRM&S>;;8-;X[#_ #*"B:W^UP?ZR=_@E6-\+;\&]3^L
M(_W'JN:W^UP?ZR=_@E6-\+;\&]3^L(_W'H*[^#-K2?36?CTQF@8<?E@V:JZ3
MIRR$>;MZG@;>W;UK]3Y2_6Q>-M7KT@BJUHW2RO/XK0-ROS1J+09SW 73&HL2
MQXS6)IA^\0V?)"'$D;CQ;\H?2N'J3B;E^(^E=-:.Q<<XRUIXAR#@>DY;L&_0
M>KG>Q! N*&H[^M=1W-23PR1X^64UJN_R6-:.C?;L03ZW+]SZ9^]O$?J</[@7
MYH^$5I:IH[AWHK"T@UP@EG[64-V,LA:PN>?:?[M@OTEA;,%+2&/M6Y6Q5X:$
M4DDCCL&M$8))^A!3/PJ]33LQV*TCC"76LF\23L9WE@< QO\ \SOW57.8P-_@
M?KO3&7C+Y*TT#/*#ON'.VVGC'=Z=Q]"X\/$#&W>,TNK]2PV[5&&9SZM> -<0
M&](QYQ V'?[5*^,G%_2VO](.QL.,RD-^*5LU::5D?*UPZ$'9Y.Q!/]R#]65;
M$5JM%8KO$D,K ]CQW.:1N"ORS\)N-DO%W3L<K0]CX(&N:1T(,KMP587P6]7G
M.Z)?A[<W/>Q+N1O,[=SH3\D^P=6^Y5O\*>66#BE@Y:T?:SLJQ.C9L3S.$KMA
ML/24'Z&GX<Z-E:]C],XKE/S:[6GWA?FCBKAJW"?BSAKVDR^"-S&6A"YQ<&^<
M6N9Z2T@=WK*F.2XM\6*=&Q9M:$95AC87/G?0L 1CYQW=MT]:CG"?365XN:R.
MJM59*&Q6H3,[6'<<[MNK&!@Z-9O[^OCN@N+CSH5NN=$^45&'XVQ[#9K;#J\$
M;NC^D ;>L!<+X,NOV9K3#]/Y27ER.(CW:]_3GK@]#[6]Q]6RNX=.Y?D'X2&G
M)-&:Y^.,'.ZG7S44A<R!W)RN(Y96]/Q7;[_24'6=+-QSXQQ1ECQI7$[[\N^Q
MB![S_P 4A ]@]B_4L$3((610L:R-C0UK6C8- [@%!."6C*NC=#4X8BV2Y=8V
MU9F V+G.&X;[&@[#Z3XJ?("_./PG<[;SF?PN@<+M)-/(R6=H[S(X[1M/J )<
M?:%^@LSDJV'Q-S(WI!'5JQ.ED<3MT W7XMT'Q"Q]#BC<UCJRO<N3/,DD,< :
M[D>[H/E$=&M) ^A!*Z]*;@?QFQS#,YV#OQ,C?(X[\T;M@\GNZM>-_9MZ5^LP
M00"""#U!'BOQ_P <>*.FN(>$I14<?DJV2IS%\4LS(^4L<-G-)#B?!I^A7C\'
M75OW3\.JD=B7GR&-_P"B3\QW<0/D.^ENP]H*"J.-'^TGIS])1_Q%<7PA?P.Z
ME_1Q?XS%3O&C_:3TY^DH_P"(KB^$+^!W4OZ.+_&8@_-O 76TVA-3UW93M(\!
MEAV4KS\EI!V$@_HGH?5NOVHY[&QF1SVB,#F+B>@'IW7YAT5H)NNO@Z115FM&
M6IW+$]1VVY<=QO'['?MV4==Q=RMSA.W1PCM2:BDE%'M0#SN@^;Z>;\3V(.)Q
MRUE9UWJBW:J-+L%BG^2UW-^3YQ/GGUN+3]#0OT+P_P M:P7P=*&4QU86K=3'
M22QQ$$AQ#G=^W@._Z%6'%'0\.AN F+J.C;\96+\4UV3;JZ0QO\W?T-'3WGQ5
MU<" #PBTT"-P:Q'_ -[D$:^#OQ%SNNX<PW/PPN\D<PQV(8^1IYN;=AZ[;C8;
M*XEK8^G3IPEF.KUZ\)<26P1M8TN\3L/%;* B(@(B("(B B(B"(B B($!$1 1
M$0$1$41$1!$1%$1$!$1 1$1!$1%$1$!$1 "(B B(@(B(@B(@(B! 1$11$\$1
M!$1%?ECX6#6OXAZ::X!S35:"#XCM7*_'<.M'2PEC],XK9S=CM7:#[PJ ^%L]
M\>O=//B;SR-I@M;MON>U=L%('<4.+QCV;P]Y3MT<,?9/_>00CC3@:O"OB1AL
MEI OJA[!:;"7%P8X.((&_7E(\/:K@^$G.;/!ITY&QEEKOV]&_50/3/#+6FOM
M:5]0<2@ZO4@<TF&4!KI&M.XC:QOR6[]^^W?XE6%\* !O":RUH  LP@ > W*#
MD_!XT?IW+\*\9<RF#Q]NT^68.EF@:YQ D<!N3ZER_A$<,--8W0]K4&&HLQUV
MH^/=L!(9(USPT@M[M_.WW'H4/X5:[XB8/15.AIC1PRF+C?(8[7DD\G,2\EPY
MFN Z'<+E9[5&MN*^J:VD,K)6Q!?,0ZFYI@8U[03YW-NYQ'78>GP07U\'//VL
M_P +:CK[C)-3D?4$A[WM: 6[^D@$#Z%4?P9/POZB_03_ .,U?HK0>EZVC=(T
ML)3=VC:[#SRD;&1YZN<?I_NV7YU^#)^&#4/Z"?\ QFH.W\,C_5M+_P!*?]C%
MZ?!=UO+7?/HK.R&*:/\ C<>).AV/G.C_ +^8>TKX^&3_ *MI?^G/^QBT^+VC
MK532VD]>Z;88K]"E6-MT+>NP8WDE/IV[CZMO0@_0FKM0TM+:=O9C)R!E:LSF
MV\7N[FM'K)V"_"UO)Y//ZVIY[+AQER-ULC7'Y) D V;ZAW?0K-U5K#)\;\SI
MO3&'A?5K\K9KVWR1)MY[S_PM&^WK/L7M\(/%4\'KS1&-QD+8*E:O%'&QHVZ"
M8]3ZSWDH/U:SY#?8%^9OA!9.WK?B3A]!8CSV02M,W+U_C7C<D^IK.OJZJ_\
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M=W$#Q"M-$$2X48FYA>'>#QN5@["Y7KADL1(=RG<]-QN"N7HKA1@M)ZNRF?H
MOFM$]A$]HY:H))<&>WN]0Z*P404O\)K1N>U?B\#%IS'NNR5II72ALC&<H+6@
M?*(]!76XLXW4MWA15P.F\9+9OVH(:]D-D8WLF-:.<$N<-]R .GK5I(@JW@SP
MQHZ:T37AS^+I3Y>PXSV.VB9*8R>@8"=^X#P\25.?N5T_^8L5_9(_L791$?G/
M2_#O4^@^-;\C@\6ZUIF>5S'OBDC;RPR==N4N!\P[>WE6WQTT%J34G$O!Y/"X
MQ]JC7CA;+*)&-Y2V4D]"0>Y?H%$5B9C)62,D:U\;P6N:X;AP/>"OSIB.'VJN
M&W%9V1TCCI<EIFP?XZ*.9C7")QZL(>X;N:=B#X[#TE?HQ$&&G=H.Q&XWV/>%
M1GPFM$:AU>_ G3F.==%82B7ED8SEWY=OE$>@J]$0:."@DK83'03MY98JT;'M
MW[G!H!"WD1!4_P (G%ZGU#I>OA-*XR:VVQ*)+<C96, 8WJUOG.&^YZ_0NOPS
MX;XG3>C,=C\EC*%K(!G:6998&2$R.ZD;D=P[A[%8(1!Q)=(Z=EB?&_!8OE>T
MM.U5@Z'Z%2G"C0FJN'O%3(-AQDUC2]MSH/*62Q[!F^\;RTNW\WN/3?J>]?H9
M$'Y_XGZ#U)F>..$SN-QCY\37?4,M@2L :&/W=T)WZ#U*S.,V&OZ@X:9S%XBN
M;-ZPR,11!P;S$2L<>I('<"IHB(KGX/\ I[*:8X<P8W.U'5+K;,KS$7-=LTD;
M'=I(7U6X2X"OQ)=K")I$QWD%3E'9B8]\H]?>=O3U5B(BJL^$9IC,:KT16HZ?
MI&Y;;=9*8P]K=FAKP3NX@>(6SIK3>>K<"H=/PDX[/BA)"W=X\QY<[IS D#<'
MO'=NK*1!2WP;='ZKTG4S#-3M=7K3O88*SY1(0X;\S^A( .X]OT*Z41 1$1!$
M1%$1$01$11$1 65A$01$0$1$41 B B(B"(B*(BRB,(B(HB(B"(B B(BB(B(!
M$1%$1$01$0$1$!$1 1$0$1$41$1'Y_\ A"Z#U)JG6N"O8'&.MU:T#62R"1C>
M4]H3MLX@]RO]O1H]@64"**NN/FGLIJ;AY8QN#JFW==/&\1AS6[@$[G=Q 5BH
M$17_  'P.2TUPUQ^,S=4U;T4DSGQ%S7;!TCB.K21W%1'C[PQR6>O4M3Z.:1G
MZSF-D8QX8Z0 ^:\.) #F_P!X]G6[D14?T/=S%_3%5^I<=)0R[6=G8C<YC@]P
M'RVEKB-C^W=4WP(T#J737$G-9/-XMU6C/#*V.4RL<'$R CHUQ/<%^A$04A\)
MK1>H-7P8!NG,<ZZ:SIC+RR,9R[\NWRB/05:N"Q8.C,?B\K7:X>01UK$+]B/Y
M,-<T^'I7:1$0/AIPOPN@)\C/BW2SSVW["2;;FCBWW$8/H])\>GH4 X]Z&U'J
M77VG<C@\8^W3JQL$TC9&-Y2)2X]'$'N5]HBJ5^$=@-6:KQ^)PVF<7)9I-<9[
M4HE8P<W<QOG.!Z><3[0IOHKA[A,!I7&8RSB\;:LUX0V:9]=KS)(>KCN1N1N3
MMZME,T""/9'16F[]"S4EPF.;'/&Z-SHZS&N:"-MP0.A50\!M(:NT#K'+T<AB
MY'X"X2UMILL9:',)Y'\O-S;$$CN\0K_1!^>WZ!U*?A'C4HQ;_B3RL2>4]JS;
ME[+EWY>;F[_4KTU!AZ>?PMS%9./M:=N,QR-[CMX$>L'8CV+H(@H'@[I/6?#G
M6N1QDF-DO:6MR["U'-'LPCY,O*7 ]W1PVW]NROY$1% <4]!ZDS7&[!YW&8Q\
M^*KNJ&6<2, ;R2;NZ$[]!ZE?Z(BBAW&+#WL]PUSN,Q,!L7K$;&Q1!P;S$2-)
MZD@=P*F*(C\J:%PW&;1.*EQ^!P43*TDIF<)3 \\Q '>7^@!2/XYX^_F:I_V*
M_P#SK]$+**K_ %?CL]G^#%VC9JA^HK=!K9(&%K=YMP2!UY1X^.RX/P:])YK2
M6ELI5U%1=3L36Q(QCGM=S-Y -_-)\5;J((?Q1T)1U]IN3'7-HK4>\E2QMUBD
MV_=/<0JB^#KPYU1H_75^WG\8:U1U-\+)A*QS7NYV$; '?J 3U"_1J(*.^$WH
MK4&L(]/#3F.==-4S]MRR,9R\W)M\HCT%1[%V^.^,QE2A4PM85ZL+((PYL!(:
MT #<\_7H OTD$0?F2[P[XK\0YH8M:Y.*AC&/YG1.D:0/6(X^A/7Q/TJ^M":1
MQFB]/PXG$1[1L\Z25P\^9_B]WK_8%(40?GG-Z U-8^$7!J2'%O=A&W8)39[5
MFP:UC03MS<W>#X+]#(B HEQ,T+CM>Z>=C<B3'-&3)6L-&[H7[=_K!\1XJ6H@
M_,6)P'&3AM$ZC@F0Y;%,.[&-+9F#<_BM<0]OL'19RN"XQ\28?B_.LAQ.*+@9
M&.+8F.]H:2YVWH*_3B((?PNT%C] :=;CZ1$UF0\]FT6[.F=_D!W ?:JLX]:!
MU+J7B)A<E@\6^U2KPQ-DE$K&\I$A)Z.<#W+]!H@BW$S&7,OPZSV-QT)GNV:;
MHHH@X#F<?#<]%#_@W:5S.DM(7Z>H:3J=F2X96,+VNW;RM&_FD^(5LH@A_%+0
MM+7NF)L=:#([;-WU+)'6&3_E/<1]BJCX.G#K4VC=:96QG\=Y/5?5=#'.)6.;
M([G:>@!WZ@$]0%^AT0%^=M-</M3U/A$6-1V,4]F%==LRBSVK""US7AIVYM^I
M(\%^B40>=ELCZTK(7B.5S"&/VWY7;="J!X&:"USIOB%D<AJ1[Q0DCD;+(ZR)
M!:>2.5P&^_?UW.R_02("(B B(B"(B B(@(B(HB(@(B("(LHC"(@11$1$96$1
M 1$11$1 1$0$1$!$1 1$0$1$01$0$1$41$0 @65@(@B($!$1%$1$!$1$$1$!
M$"!%$1$!$1$$1$!$1 1$0$1$!$1%$1$01$0$1$41$0$1$01 B B(BB!$1!$1
M%$1$01$11$641A$1%$1$!$1$$1$!$1 1$11 B("(B((B(HB(@(B("(B((B(H
MB(B"(@11$1$$1$!$1 1$11$1$$1$41$0 B(B"(B LK"("(B*(B(@B(BB(B((
MB("(B B(@(B("(B*(B(@B(@(B("(B*(B("!$1!$1 1$0$1$41$0$1$01$0$1
M$41$1!$1%$1$01$0$1$40(B B(B"(B*(B(@B(BB(B((B(HB!$01 @0$1/!%$
M65A$$1$!$1%$1$01$0$1$41$1!$1 "RL(@(B(HB(B"(B*(B>"((B(HB(@(B(
M@B(@(B("(B B(@>E$1%$1$01$11$1 1$0$1$01$11$1 1$0$1$01$0$1$41$
M1!$1 1$11$1 0(@0$1$01$0$1$41$0$1$01$11$"("(B B(B"(B B(BB(B B
M(@(@1 0(B B(@(B(@LK"("(B*(B(@B(@(B(HB(B"(B**$WL!K::]/)3UK7KU
MGR$QQ'$L>6-WZ#FYNNWI4V66_*'M04OPYM:]UC@[&0.L*U3LK<M7D^*HW[\A
MVYM]QW^A6SA(+U7%00Y:\V_=8#VEEL(B#^IV\T$@=-A]"KOX.GWD7_ZVM?O!
M9XG36M0ZVT]H>O:GITKD;[V0E@D+'R0LW C!'4 D'=!/JVH,/:NFG6RM&6W_
M .Y9.US_ ' [KIJ$7>%6C+.+?2BP-.F2W9EFM&&3QGP<)/E;@^DK4X+YF_>P
MV5Q.7L.M7<%>?CS9=\J9C?DN=Z]NGT(+"7/R6;Q6,D;'DLE3J/=\EL\S6$_0
M2N/Q.U%)I30>8S,# Z>O#M$#W<[B&M)]A<%P-'<+\!#A:]C45"'-YJU$V2W<
MR [=[GN&Y YMP .X;(+%CD9+$)(GM?&X;M<T[@^PJM^#.:<=%Y&YG,B2&96U
M'VUN;Y+0_8-YG'N'H4FTAI"CI.3)C$2V64K;VR,I/DYH:Q ._9@_)!)W(]05
M6\$M$8S-X_+Y/4$0R<3<I9CK4[/GP0[/\YP8>A<3WD^ ""[,;D:63K]OC;=>
MW#OMSP2![=_:%L2RLAC=),]L<;1N7..P'TJH=5X"AH?7VC<OIB!F-BR%[XNN
MU*PY(IVO:=G%HZ;@J5\2JVD7Q4+6N;4;*E=SNRKS3N;',\[=\8/\81MT&QVW
M027&YS%921\>-R5.W(SY38)FO+?: 5M7;5>C5DLW9XJ]>,;OEE<&M:/63W+\
M[<2,GPY9IJ:_HPPXK4-+EFISTJ<E=Q<#\EQ#0""/2K(XT3NM<$,W8>-G2THI
M"/67,*">29*C%/6ADN5VS6?Y!AD =+TW\T;]>G7HLY')4L;!VV1N5ZL7SYI
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MM,W6M\.]1W<'DHIG0TIBV:K,"6.##U#FGH5L: ND\.L%>R-DD_%T4LT\S_\
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MAQN-C[&M5EF<V.8[ =8V_P H1R^@]Y]*"8XS.8K*2/CQN2IVWL^4V"9KR/:
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ML^_;U]^ZDFHW09S1N0^+\XRA!/ X-R<$@(A /5P=OMX;=X57PZ0TX>/]G&G
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M$4K;:MS*4H++NZ*6=K7'Z"=U461=F- \%ZS8GEFJ<Y:8VQ9DZ/CGL.)<X_\
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MNB"K]?:;&"X!Y+ XV.2PZM19$T1M+G2.YFEQ '7J=RIUI%CH]*85DC2U[:,
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M>I!,$5=MS.1/'AV'\KF^+/B46/)M_,[3M-N;;T[*P(9XIVET$L<K0>4EC@X
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M)Q7?O8&3TK&X^<*?82EH_P"$R=_T[*4:,R^8R=>U%J'"OQ=^K+V3RV020S=
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MB*(B("(B B(@(B("(B B(@+*PB B(B"(G@BB(B((B(HB(@+*PB(R%A$11$1
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MWL%D:KK.,\I<7R5G,.SXN8]2W8[A:4&,EXH:MS_QU:LMTIB;1HP4(93&+$S
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MC 0(B*>E9"(B,)XHB!XH$1%/%/!$0%E$0%CP*(B!0(B*RB(B,! B( [T\$1
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CG@LA$1& LA$0$1$&$"(BP>E/!$0@"#N1$#Q3P1$!9"(@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g73463g02n39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g02n39.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1\>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'P$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                              #_X4!*:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E
M:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E
M.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W
M.2XQ-C0T.#@L(#(P,C O,#<O,3 M,C(Z,#8Z-3,@(" @(" @("(^"B @(#QR
M9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R
M,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN
M<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C
M(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7 Z
M0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]X
M;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(U
M+3$Q+3$W5#$W.C$S.C,R*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @
M(" @/'AM<#I-;V1I9GE$871E/C(P,C4M,3$M,3A4,38Z,# Z,3 K,#4Z,S \
M+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR
M,#(U+3$Q+3$X5#$V.C P.C$P*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@
M(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @
M(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R
M36]D93X*(" @(" @(" @/'!H;W1O<VAO<#I)0T-0<F]F:6QE/G-21T(@245#
M-C$Y-C8M,BXQ/"]P:&]T;W-H;W Z24-#4')O9FEL93X*(" @(" @(" @/'AM
M<$U-.DEN<W1A;F-E240^>&UP+FEI9#HR,&0S9F%B,2TU.#,Q+61E-&8M.&-D
M,2UE-S4U965F.3@W9C,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX
M;7!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#IB-30R.6$Q
M9BUA,C(Y+68X-#@M83%B-2TY-&4Y964Y86)B,#@\+WAM<$U-.D1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I
M9#IF9F9A86)F-2TX-F5C+34Y-&$M.#@S-"TT,C Q-F$P,V(X.#<\+WAM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYC<F5A=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z9F9F86%B9C4M
M.#9E8RTU.31A+3@X,S0M-#(P,39A,#-B.#@W/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(U+3$Q+3$W5#$W
M.C$S.C,R*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC
M;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G!A<F%M971E<G,^9G)O;2!I;6%G92]P;F<@=&\@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-C5D8C8R,3DM-F-F8BUA
M.31E+3@S,3<M-30Q93 S864X,V4W/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(U+3$Q+3$X5#$V.C P.C Q
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD\
M+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.C0Q96,W,#@P+64P,C4M,3DT9"TY-C1F+34U
M-3$Y-65E-S=D-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R-2TQ,2TQ.%0Q-CHP,#HQ,"LP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T
M97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I
M;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C(P9#-F
M86(Q+34X,S$M9&4T9BTX8V0Q+64W-35E968Y.#=F,SPO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-2TQ,2TQ
M.%0Q-CHP,#HQ,"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C @
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D
M1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS
M=%)E9CII;G-T86YC94E$/GAM<"YI:60Z-#%E8S<P.# M93 R-2TQ.31D+3DV
M-&8M-34U,3DU964W-V0W/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @
M(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.F9F9F%A8F8U+3@V96,M-3DT
M82TX.#,T+30R,#$V83 S8C@X-SPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.F9F9F%A
M8F8U+3@V96,M-3DT82TX.#,T+30R,#$V83 S8C@X-SPO<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C
M:V5T(&5N9#TB=R(_/O_; $, !@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7
M%!@8%Q06%AH=)1\:&R,<%A8@+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'
M"@@*$PH*$R@:%AHH*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*/_  !$(! L%2 ,!(@ "$0$#$0'_Q  <  $  P$!
M 0$!            !0<(!@0# @'_Q !A$  ! P," @4$#0@%"04%!@<  0(#
M! 41!@<2(0@3,4%1%")A<18R-E-4<X&1DJ&BL<$5(S="4G)TT1<U8K+2&"0S
M0U6"DY3A-%9UE;,XI,+B\"5$15=C@_$H1F2$TZ/_Q  : 0$! 0 # 0
M        ! 4! @,&_\0 .!$!  (! @,#"0<$ P$!      $" P01!1(A$S%Q
M%3(T05%2D:'!%")"8;'1X2-R@? D,T,U\?_:  P# 0 "$0,1 #\ U2
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MFQNJEL]NIJ+RI_63=1&C$>[Q7 $F
M
M
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MM2UD+I'+$UB*C>Y.P":
M
M
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MFO8G$[A3*JJ8Y^!\DV6TQ1:LMU_L4+[;4TLR2NBC571/3&,<*]GR 6<
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M0N        Y^@]U==\6GX'0'/T/NKKOBT_ #H
M
M
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M85.L1<KDW                          ("A]U==\6GX$^0%#[JZ[XM/P
MGP
M
M
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M GP
M
M
M        !GSI@W.>'35EML,KXX:FI5TJ(O)Z-3DB_*N2$W0TE:=(V/;VEL]-
M&QSZV)\T_"G',Y415<Y?P[BTM_M SZ[T<V&VI'^5*.7KX$>N$>F%1S,^E.ST
MF8-2[C7RLH-/VK4= OE5BG:YKWM6-[VMY(UR>/+&0+;Z7ENIH[=IB\1-;'<6
M3.AZQO)SFX1R?,J?6I?&C*J6MTI::FH7,TM,QSUQVK@RE22ZHW[UM;UJJ=M/
M8K>_SN%JI'#&JHKDXOUGJB(AL&E@CI::*"%O#%&U&-3P1.2 ?0'BOEP;:;/6
MW"1CI&4L+I5:WM5&IG!6NDM^M&7][(9JF:UU3E1O!6-1K<_OHJI\^ *PZ0,\
MNE][K#J2KA?-0=7$Y.'E[151R(OCW_*:)MFK]/7.W)745ZM\E*J<W^4-1&\L
MX7*\E/#K/2EAW%TXVDN'!54JKUE/40296-^%3B:Y/N["AZSHO5R5+TH=1TWD
MJ^UZV%R.^7"X C]?WVEUYT@-.0Z;7RJ&CGBB6I@3*/X7\3G(O[*)W^LUF5OM
M+M)9]OHG5$3G5MXE9P2U;TPB)WHQOZJ?660
M("A]U==\6GX$^0%#[JZ[XM/P GP                        #RW2OI[7;
MYZVM?U=- WC>[&<(!Z@<*FZ^D%3/Y37'Q+OY#^E?2'^TU_X3OY =T"'TSJ2U
MZEI9:BS5'7Q1/ZMR\*MPORDP
M
M                                                           $
M?J"]6[3]JFN5YJXZ2BA]O*_L3/8GI5? HV]](/1%35JCK'-<&,Y-EF@9E?4B
MY7!\^F+65+-.V.BC<]E+-5.=)A51'*C>2+\^3K]#[*:,M^F:*.X6JGNE4]C9
M9*F=%57.5$[,+R;X(!RE+TDM,4T38:6R5<,:=C(VM:B?(A>MDN$=VM%'<(6N
M;'4Q-E:UW:B*AR7]$6@O^Z]O^BO\SLZ&D@H:.&EI(TCIX6HQC$[&HG8@'UDC
M9+&Z.1K7L<F'-<F45/ K#5NQ>B]1.?*E%);:EW/K*)W F?W<*WZBT0!F"MVC
MW!T'4]?M[>YJRD[5@61&+G/8K%7A<?NBW[U=IBJ92:_TVG+*+*QBPO7Y.;5^
M0OV^:STY8JWR2\WJAHJKA1_532HUV%[%P0=QUUMY<X'07&]V*JA<F%9,]CT7
MY% \.E-Z]%:B='%'=$HJIZHU(:MBQJJKW(O8OSED,<U[4<Q4<U4RBIV*AGC4
MVA=G]2R/=:;_ &ZTU2KGBHZAO#]!5QV^&"P]E='UVC[174E3>TO%'+,CZ69K
MU5$9CL3FJ)S\% L4                        @*'W5UWQ:?@3Y 4/NKKO
MBT_ "?                        /#?;9%>+156^H>]D50S@<YGMD3T'N
M%):OVHM-BTO<;E35UPDFI85>QLCF\*JGCAIS^U>A:#6%)<):^IJH74TC6-2%
MR)E%3//**7)NE^CZ^_PR_>AQ'1S_ *MO7Q[/[H'>Z(TE1Z0H)Z2AGJ)V32=8
MJS*BJBXQRPB'1@
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M@                        .?H?=77?%I^!T! 4/NKKOBT_ "?
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MJ2.@H*>DA5RQ0,2-JN7*X1,<ST
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MK4MKJ;/-'-5<N;\BY3Y@+)Z7NKG0T-!I6F<BK4JE548PJHUJKPI\J\_D+)V
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M5%7GSPGUF;=O[]N)<]Q**RU%_N$553U#73TU54<"N:U<O;A>U<9Y&T0
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M_CV?W3M]TOT?7W^&7[T.(Z.?]6WKX]G]T"X
M !2?2/\ ;6/US?<A:&AO<A9_X9GW%7](_P!M8_7-]R%H:&]R%G_AF?<!.
M
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M]?'L_NG;[I?H^OO\,OWH<1T<_P"K;U\>S^Z!<
M    I/I']MC]<WW(6AH;W(6?^&9]Q5_2/]M8_7-]R%H:&]R%G_AF?<!.
M
M
M    K_>S0*[@:/6@II(XKA3R)/3/DSP\2(J*U<>*+C)E74]_UQ34]FLVI;?4
M.6RS(^F6:G7B5&\D;Q)R<U,&I-\-PI=O-.T5;201U%54U38FQR9X5:B*KN:=
MG)#[:UUW^0=K$U546]K:J2"-\5++SP^3&$7'=SR!06F+#K+>G6-%<]4,=%9*
M%Z<2OCZIB,RBJR-N/.5>65^LUW#&R&)D<34:QB(UJ)W(AE;3N^^LZ&]VJ;5=
MO@98;@]$8Y*98L1JJ)Q,=WXSZ35,4C98VR1KECD147Q0#]% ;P77<;1NL)KW
MIQLM7I^9C>*!&=<QKD[<M[6^M"_P!FZQ])ZF9$V+4-@J&5#4Q(^F>F%=^Z[F
MGSD\G29TAC_L%X_X3/\ &6A?M#Z:OS^.[66BJ).WC=$B.^=.9SS]F-"/E9)^
M0H4X?U4<J(OK0"M[STH;:V)S;-8:N27/)U3(UK?F3*GQVZU-N1N-K2WW">-]
M%I>GFZV2-K>JB<B)V9QEZ_4779] Z5L\B26ZPT$4B=CNI15^LZ9C6L:C6-1K
M4Y(B)A$ _H     >6[4$-TME7053>*"IB=$]/0Y%3\3U #-6U.IUVBU#<-#:
MTXZ>BEG6>BK53\WA>657P=A.?<N44O:NUIINBH):RHOMM2"-G&Y6U#'+CT(B
MY4^^I],VC4] M'?*"&KA[N-OG-]2]J' 4FP.@Z:N\I2@J9%XN+JY*A59ZL>
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MK'ZYON0M#0WN0L_\-']Q5_2/]M8_7-]R%H:&]R%G_AH_N G
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M!J*S3_Z&ZT+_ %3M_F>V.MI9$_-U,#OW9$4QHC6^"I]1_8W]6[,<CF+XHY4
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M5]=1*D4CU[7ICDX[P
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MJG3^[FU&F.NCL%)Y$UZ^>ZGHU3C^7MP!R6\-2S4'2(TQ;+?(R22DEABDX>?
M[CXE1?4AJ0HRW;G;67'6E)<J6B7\O3R)"RJ\E5'*YWFIE?EQDO,
M                0%![JZ[XM/P)\@*#W5UWQ:?@!/@
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M([T>DT&UR.:CFJBM7FBIW@?T
M                         /Q40QU$$D,[&OBD:K7-<F45%[4/V *2U;LU
M,D[Y],5#%C<N?)JA<</J=X>LYJEVDU5+,C)8:2%F<*]TR+A/%$3M-) #B-O=
MO:'2:+4ND=57-[>%TSDPC4\&IW';@         4MTH-)WS5FGK-3Z=MTM=-#
M5.?(V-6IPMX%3/-4[R2Z-FF[OI?0L]%?Z&2BJEJWR)'(J*JM5&\^2KX%K@
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MZUK%9[]-F@7E#4O556)?V7?V?N+Y8YKV-<Q4<UR914[%0#^@
M
M                                               %8])']$=Y]3/[
MZ%G'';N:9K=7:%N%FMDD,=5/P\+IE5&\G(O-4 YOHV5$#-HK.UTT;7(Z5,*Y
M$7VZE8[<RQLZ45[<^1C6JM1A5<B(O(B(.COKN"-&0W:WQL3GPMJ'HG]T_#>C
MCK=LZSMN=M29?UTG?Q?/P@=STP)8Y=*6+JI&/Q6NSPN1?U2Y-OO<18_X2/[C
M,DW1UUS.C6U%UMTK47*(^H>J?W34^E;?+:M.6V@J7-=-30,B>K.Q51,<@)0
M <GJ?0&D]05S[EJ"T4M34HQ&NFE54PU/'GV(5W66[8RBK?)*G\@-G1<*B2.<
MGTD7'UD'TG]67*HNUKT/897LFK.%]1U:X5_$JHQBKX=Z_(?FT=&"A2UM2[7R
M=;@J95U.Q$C;Z$1>:_4!9=@VXV[J%IKE9+1;)TC>DD4]._C1')S1<HI89DC;
MR>\[.[P1Z6N$RU%KN4K(E1B^:]'+ADJ(O8J+VIZ_0:W
M        $!0^ZNN^+3\"?.?H?=77?%I^ '0                      !_'
MN1C'.<N&M3*J!3'2&O2+';[+$_FKO*)D1>Y.345/E4XO:"S?EC6]&LC.*GI,
MU#\IE,I[5/G(S<"[_ES5]RK455B63JXO0UO)/YEN[ V;R33E1<Y6XEK)51B_
MV&\OOR!U.Z7Z/K[_  R_>AQ'1S_JV]?'L_NG;[I?H^OO\,OWH<1T<_ZMO?Q[
M/[H%P                          "D^D?[:Q__O?<A:&AO<A9_P"&9]Q5
M_2/]M8_7-]R%H:&]R%G_ (9GW 3ASNMM)T.J[6ZFJT2.=O.&=J>=&[^7H.B
M&0M1V*NT_<Y*"YPJR1O-KL>;(W]I"P=I]QGVJ2*S7V5TE"]4;!4/=S@_LK_9
M^XMO6VE*'5=J=2UC4;,WG#.GMHW?R]!F/4EBKM.W26@N4?#(WVKT]K(W]IH&
MO(WMD8U\;D<QR91R+E%0_I0.U.X[[0^.T7Z5S[<N&P3+S6%<]CO[/W%^L<U[
M4<Q4<U4RBHN45 /Z
M
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M93T'?                         " H/=77?%I^!/D!0^ZNN^+3\ )\
M                  .4W/O2631EPG1V)I6+#%^\[D=641T@[RE1=;?:(GY;
M3M6:5$7]9>2)\R 5524TM7504L#>*6>1L;4\55<&O[+;X[7:J6AA3#((VL3T
MX3M,_;&V9+GK!:J5F8*"/K.:917JN&_+VJ:. Y;=+]'U]_AE^]#B.CG_ %;>
M_CV?W3M]TOT?7W^&7[T.(Z.?]6WKX]G]T"X
M !2?2/\ ;6/US?<A:&AO<A9_X9GW%7](_P!M8_7+]R%H:&]R%G_AF?<!.
M<_K72M#JJU.I*UO#*U%6&9OMHW>/J]!T  R)J:P5VG+K+;[E'PO;S8]/:R-_
M:0[S:G<9;-)%:;Y)FVN7$=0[*K"O@O\ 9^XN#6>E:#55J=25S$;(WG#.B>=&
M[Q3^1F/4^GZ[3ETDH+G&J.3FR3'FRM\4 US&]LD;7QN1S')EKD7**GB?HS_M
M3N*^S21VF]RNDMSW(V*9[O\ 0>A?[/W%_12,EC;)$]KXW)EKFKE%3Q10/T
M
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M<Y<(@%!;U[9:WU7K1UQTY70PT'4,C:Q]6Z-4<F<\D0X/^@W<_P#VI3?^8/\
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MW1Z8MD%5>:2.:*G8U['.YM5$[% [X'SIYXZF".:!Z212-1S')V*B]BGT
M0.L=+T&J;4ZDKV8>G.*9OMHG>*?R)X 9&U5IVNTU='T%R8F>:QR(GFRM\4.V
MVIW%DL;H[5>I'26M?-A?VK N>Q?[/W%SZOTS0ZHM+Z*O9A<9BE;[:-WBAF35
MFFZ_3-U?17&/EG,4J>UE;XI_(#6L;VR1M?&Y',<F4<BY14/T9ZVIW$?89([5
M>)..U.7S)G95T"KW?N_<:"AE9/$R6%Z/C>B.:Y%RBIX@?L
M
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MQ4LBUM5U,G7M5<-]&%0LJED66FBD=CB>Q'+CTH!]      @*'W5UWQ:?@3Y
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MQR)E8%5>W]TT-#+'/$R6%[7QO3B:YJY14 _8
M
M                           /+<Y**"DEJ;DL#*:!JO?),B<+$3M557L*
M(U)TAM(4%6L-GL[KFQJX=+U;8FKS[LIE3[=+N^5-%I&VVJE>^-*^I_/*U<(Y
MC45>%?EPOR'1[=;+Z3L^FZ3\IVNFNE?-$V2::I9QX54RJ-1>2(@'UVXW5T=K
M>J;0TT,='<W)EM-41-3C\4:[L5?06DU$:B(U$1$[$0R=TA-#T>WM\L6I](M\
M@;)4<X8U\V.5F'-5OH5,Y3T>DU#IRO6Z6&WUSL<51 R1<>*IS D0 !E?>ZEC
MN?2)L-%=%3R%S*=J(Y4PK>)55/E7*'6:K?#2]*;2R/X8HW4"1QIPX155)$1$
M.GW<VM@UOJ"RW.EN<5MN%$]$D>K.)[V(O$W'/M1<XSXGRWQVMJM;PVZX6:M2
MFOEO;P,D=EO6-SGVR<T5%RJ>M0*_W2K(=*=(?3M;8U2"HK%B2NCC7"2(Y_"J
M.3TI_,TT9RVLV,O-)K"#4.MZ]M1+22)+%%UBRNE>G8KG+W)VX-&@      SH
MV9-$]**JDK%X*&_1(C)')A.-Z)A,_O)CY319P6[VW5-N#9(H.O\ ([E2OZRE
MJD;GA7P7OPO(#O2!U[?(=.:-O%UJ'-1M-3/<U'?K/PJ-;\JJB%/T6I]W-(4C
M;9<-*KJ18EX8ZV)SE5S4Y)Q</:OI7F?&JTEK[=BXTKM:M33VG:>1)%H(U57R
M^*+Z>[*]F5Y 3'11LLE%H*HNL[4:ZYU+I&)C"\#5X4^O)=AYK904UKMU/0T,
M38:6GC2..-J81K43"(4_M-_22FX-Z35[JA;)YZQ]<U.!5XO,ZKT8[0.=W0VZ
MW$U+N-^7*)+;-14,B+;XZB5%:UJ<_.8J*F<]OR$IU&_?PNQ?1C_PE[@#'N]<
M6Y3(+)[-Y[:]BU7^:^3HQ,2>G"=A;>CH=XVWJTK?:FT.LB/9Y0D21\:Q8[L)
MG/J'22T_=[]3::;9;;4URP5O'*D#.+@;XJ7#1-5E' UR*CDC:BHO<N /L
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MBLO5(WRM_#Q8SVY+#T1H?5]LU5;ZRYSRNHXI,R(M8YZ*F/#/,"[@
M
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MY'JC6M;4-555>Q$YDX9OL?1L6T7NWW!VI&O2FJ(Y>#R;'%PN1<>V[\&D
M                     ! 4/NKKOBT_ GR H?=77?%I^ $^
M      (W4MR99[!<+A(O*GA<]/2N.2?/@R'4U$M5-+43*KIYG*]R]ZN52].D
M%>5I[/16F)V'5;U?*G]AO_4K#;6R_EW6-#3.:JPQ.Z^7]UJY^_ &A=NK&FG]
M(T%%PHDO!UDOI>[FIT@3EV
M            16IK!0ZCM4M!<HN.)_-KDY.8O<J+XDJ ,G:TTM7:4NBTE<G'
M"]56"=J>;(W\%]!/[8;@3Z7J6T5P<^:RR+C@3FL#E7VR>CQ0O[4MBHM0VJ:@
MN,?%&].3D]LQ>Y47Q,QZVTI7:4NKJ:K8KZ9ZKY/4=TB?@OH U92U$553QST\
MC9(9$XFO:N45#Z&;-L-?S:6J6T=>Y9++*[+^2JZ%5_6;Z/%#1M'4PUE+%4TL
MK98)6HYCVKE'(H'V     9W;^GN/^/3^X:(,[I^GN/\ CT_N&B
M
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MDM(                         0%#[JZ[XM/P)\@*'W5UWQ:?@!/@
M           $!KR\)8=)W&OSA\<?#'Z7+R3[P,][I7I;UK.N>UW%#3N6"/GR
MPU>?UY+$Z/EDZJ@K;S(WG.O4Q93]5J\U3UK]Q2#&RU,S6)E\TST1/%7.7^:F
MMM'VAMBTU;[<U$18(D1V.]R\U7Y\@3
M                        1FH['0Z@MDE#<H6R1.3S55.;%[E3P4DP!E#6
MVDZ[2=U6FJT=)3/YPU"-PUZ>'K]!-[9:_GTO5-I*Y7S6B5R(Y%7G!_:;Z/%#
M0.HK'0Z@M<M!<X4E@?S\%:O<J+W*9DUQI.MTG=/)ZM.LII558)T['IX+X*!J
MBBJX*ZEBJ:.9DU/*U',D8N4<A]C-.V>OI]*U*4M:Y\MG>O.-.:Q*J^V;Z/%#
M2%'505M+%4TLK)8)&HYCVKE%0#[  #.[?T]1_P >G]PT09W;^GN/^/3^X:(
M
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M15^P=D6ATY47*5N)*YZ*Q53]1O9]>2T
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M-$@
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MJ@KBGW9M,NZ,NC'P313M_--G>F&OF3GP(GACL7O+'
M      $!0>ZNN^+3\"?("A]U==\6GX 3X               .2W2OGY!T;6U
M#'8FE3J(OWG93[LF8J"CDKZRGHX$5TL[TC:B=N5+2Z05[\IN]'9HG9;2MZZ5
M$_:<G)/F(O8RRK<=8)7/;FGH&*_T*]>2?S O^R4$=KM%'0Q(B,IXFQICT)S4
M]H
M  #P7RT45\MLM#<H4FIY.U.Q47N5%[E/> ,KZ]T=6Z1N2QS?G:&956GG3L5/
MV7>#B)I+]=:2W.H*6X5$-&Y>)8F.PF2W.D57R1T5HM[<=7-(^5_^ZB8^\I$#
MZ13RQ5#9XY7MG:O$V1'+Q(OCDM/;G=*MIZ^&WZCF=4TLSDC94.1.*)5Y)Q+W
MH50?Q>Q0-HHJ*B*BY1>\'*;5W"2YZ"M%1.N9$BZM5\>%5;]R'5@
M
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MNLY9]./J-1&<]C]KKY5:J76^O5>ZM5>NIXY7?G'2+^N].["=B?R-&
M                  #GZ'W5UWQ:?@= 0%#[JZ[XM/P GP             ^
M55.RFI9IY51L<3%>Y5[D1,GU.#WGO?Y)T940QNQ/6_F&8\%]LOS?>!GW4UT=
M>M07"Y29S42JY$5<X;V(GJPA?NR%E6U:-9/*W$];(LSLISX>QIGZP6U]VO%%
M;X4RL\C6?)W_ %&O:2!E+2Q01)B.-B,:GH1 /J
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M$T
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M9PU%0BSRY3"Y=S1%]28.Q
M                            #.[?T]1_QZ?W#0E3!%4P203L;)%(U6N:
MY,HJ*9[;^GN/^/3^X:( SSN;MM-899+C9&/FM3E5SXTYN@_FW[CBM,7^NTY=
M65]LD1)$Y.8[VDC?!4-=/8U[',>U'-<F%14RBH49NGMFZBZZ\:=B5]-VS4;&
MY5GBYOH] %GZ&UA;]66[K:1W!5QHB3TZ]K%_%/2=*8]LMUK++<8JZVS/AJ(U
MSR7DY/!R=Z&D=O-=46K*)&JK*>YQI^=IU=]IOB@'8@
M
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MGN=XE;R9BGB5?'M=^ %V1L;&QK&)AK4PB>"']
M                                             #.[?T]1_P >G]PT
M09W;^GN/^/3^X:(   "G=TMLDF;-=]-Q-9*B+)/2I_K/%6>GT%,4%74V^MCJ
MJ*62GJH79:].3FJG<O\ (V25=NAMJR\];=;&Q&7/MDBRB-F_D[[P)+;/<*GU
M/"VCKN&"[L3SF]C943]9O\COS&J>44-9_K::K@?^Z]CD+[VOW*CO;8[9?'QP
MW-,-BD[&S_R<!9X
M                                             H/I=V6:LTG;+I3H
MK_(JG\ZS^PY%\[YT3YRRMOM;V'4&D[?64EQI(\0LCDB?*UCHGHU$5JHJG.[Z
M;<77<&EMT-IN--1I3N<LB3*[#T5,?JHI3[>C#J5N>&^VI/5UG^$#4OY:M?\
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M#/6V%F2]ZUM]/(Q'4\;NOE1>SA;SQ\YJ=$PF$
M                                               ,[M_3U'_X@G]P
MT09W;^GJ/^/3^X:(      *^W,V\I]2PNK;>C(+LQO)V,),G@[T^DSQ54U5;
M:Y\%3'+35<#L*UWFN:J=Z?S-D'&;BZ$H]5T2R,1L-TB:O4SIRS_9=XH!R6UN
MYS:E(;1J25&3HB-BK'NY2+W-=X+Z2X$7*93L,=WBV5=GN,U!<8EBJ8EPYO<O
MI1>]"T]K=S74RQ6C4DKG1*O#!5N_4\&O]'I O$'\8Y'M1S%1S53**G8J']
M
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MV^)$1(8T1V.]W?\ 62H
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MZ -)@\]OK::X4D=513QST\B9:]BY13T
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MY.:?]2YP                        ! 4/NKKOBT_ GR H?=77?%I^ $^
M        ?QSD:U7.5$:B955 I7I#WA7.MMFB?RYU$R)\S4^]3D=F[,EXUM Z
M5O%!1-\H=ZT7#?K(37%V6]ZKN=;G,;I59'^XWDA<^PME2BTS)<I&XEKGY15_
M8:N$^<"S0
M                                 $9J*QT.H+9+0W.%)8GIR7O8O<J+
MW*9IUYHVNTE<%9.BRT,CEZBH1.2^A?!35)Y+K;:6ZT$M'7PMFIY4PYKD^M/2
M!FK;O7-9I*K2-5=-:GNS+3IW+^TWP4TE9+K1WJVPUUNF;+3RIE%3M3T*G<IG
M'<7057I.I=/ CY[0]?,G7FK%7]5W\R.T-JZNTE<^OI%XZ654\HIW=CT\4\%]
M(&K016F;_0:BMD=;;9D>Q4\YJ\G,7P5"5
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M^!9.#M<J2X3*>HT\9.V=H[ONAN_+K*[,5*"WR]:F55&M=SZN-GCCM7_J:Q
M                       '/T'NKKOBT_ Z Y^A]U==\6GX =         <
MCNM>?R+HFOFC<C9YD2"+GA<NY?=DZXH7I WE:B^4=HB=F*FCZZ1$_;=V?5]X
M%8VVDDK[A2T<65EJ)6QIXY5>W\37EFH([7:J6A@1$C@C2-,>@H'8JR)<M6OK
MI&HL-N9QIG]MW)/Q-%
M                                               ?&MI*>NI9*:LA
M9-!(F'QO3**AGC<S;FHTY*^OM;9*BU/55<B-RZGY]B^+?2:-/Q-$R:)\4S$?
M&]%:YKDRBIX 9*TKJ2X:9N;*VV2JB<DEA5?,E;X*GXFF=&ZJH-56QM50O1LJ
M<I8'+Y\:^GT>DJ'=';66TOFNU@B62WJO%+3MRKH?%4\6_<5YI^]U]AN+*ZTS
M]5.WQYM>G@J=Z ; !RF@-:T6KK?Q1?F:Z)$2>G=VHOBWQ0ZL
M
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M!H+92R?DG1T4\C<35R]>[U?J_4=\?*C@92TL-/$B-CB8C&HB8Y(F#Z@
M       /-<ZMM!0353VJ]L3>)6IVJ<Q$VG:'%K16)M/=#T@XU->TOP*?Z2#V
M>TOP*?Z2%/V+/[J+REIO?_5V0(K3UZCO5/++%$^)(W<*HY47)*D]Z32>6W>K
MQY*Y*Q>D[Q( #J[@
M                         J(J*BIE%*4W3VS<WKKOIN%7?K3TC/K<Q/P+
MK &.;5<:JU7"&MH)715,+LM<GW*GX&C=M]?TFJJ=M-4*R"\1MS)#V(]/VF^/
MJ[CG]T=LV7!LUVT_$V.L1%=+3L;A)O2G@[[RCH9:F@K&R0OEIJN!_)4RU['(
M!LH%<[8[C0:AC9;[JZ."[-3#<KA)T\4]/H+&
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MBRO#RY9YFLBLMH-W;7N$V6E6):&[PMXW4SG<2/;WN8O?CP[2S0
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M7DI_3X4$'DM%! KN)8V(W.,9P?<S9VWZ-FLS,1,]X #AR
M                            5MN;MM!J!)+E:&L@N_:_*X;.B)V+Z?26
M2 ,:S15%#6.CE;)3U4#^:>U<QR=Y>6UFY;;GU5IU!*C:_DV&H7DDWH7P=]Y/
M;E: IM54RU5+B"[Q-Q'+V->G[+OYF<[E;ZNU5TE)7POIZJ)<.:O<OBB_B!L8
M%*[6[G</4V?4LJ(U$1E/5NSE5[FO_F74BHJ(J+E%[P
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MU5_F:K                         $!0^ZNN^+3\"?("A]U==\6GX 3X
M   5COS>_(--16Z)V):]W"Y$7GP)S7Y%["SC,^\=[6[ZTJ8F.58*'_-V^&?U
ML?*!!Z(LSK]JB@H&IECI$?)Z&-YJ:S:U&M1K41&HF$1.XI7H]655EN%ZD;YN
M/)XE].<N_ NL                "(U=[FZ_XO\ $@-LO]!7_O-^Y2?U=[FZ
M_P"+_$@-LO\ 05_[[?N4OQ^B7\?V96;T_'X3]7;  @:H
M       #@]SO;T'^_P#@=9IW^I*+XIIR>YWMZ#_?_ ZS3O\ 4E%\4TOS>BT_
MRRM/Z=E\(^B0 ! U0
M     Y/7^B:'5MO5KT2"OC1>IJ6MYHO@OBAU@ Q]?;-76*Y2T%T@=%/&N,X\
MUZ=SFKWH6/M=N8^V.BM6H97/HE7$=4]V5B\$=_9^XMK66D[?JJW+3U[,2MRL
M4S>3HW>/J]!F?5>FZ_3%T=071B95.*.5OM)&^*?R UM#(R:)LD+VOC<F6N:N
M45/%%/T9TVPW$FTY*RWW5\DUI<J(U>U8/5_9]!H:DJ8:RFBJ*61LL$C4<Q[5
MRBH!]0
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MY2?U=[FZ_P"+_%" VQ_[/7_OM^Y2_'Z)?Q_9E9O3\?A/U=L "!J@
M               .#W.]O0?[_P"!UFG?ZCHOBFG)[G>WH/\ ?_ ZS3O]247Q
M32_+Z+3_ "RM/Z=E\(^B0 ! U0
M                "(U3IZ@U+:I*&Y1\3'<VO;R<Q?%%)< 92UOI&X:3N'55
MC>.DD5>HJ$['IX+X+Z"2VXUY5Z3JD@E5T]ID=Y\*\UCY^V;_ "-&7RT45[ML
MU#<8&302MPJ.3FU?%/!3-FO]#UNDJQ5P^HMCW?FJGA[/[+O!?O TO:;E27:A
MBK+?.V>GD3+7M^X]9EC06M:_2-=Q1<51;WK^=I5=A%_M-\%-*:=OE#?[;'6V
MV9LD;D3*(O-B^"IW*!)@
M                       %8])']$=Y_P!S^^A9QX[Q04-QMTU-=88IZ-R9
MD9*F6X3GS RGM9OU1:+T716.HLE1524[GKUL<S6HY%<J]BIZ3D]-;H4UFW<K
MM8+;9I:>I63_ #;K$1S>-/'L-86W1FAKG2,J;=:;354[TRV2)C7-7Y4(W5UG
MVXTC;5KM06ZU4D&<-XH45SU\&M1,JOJ SIO3N_1[BV>WT5-::BB?35"RJ^25
M'HY%3&.2&L=O?<18_P"$C^XX/1E3M/K&I=36*EM<M4B9ZB2F6-ZIXHCD3/R%
ML4T$5-!'!3L;'%&B-:UJ81$\ /H 9LU%H?<6HWQ9=*5]1^2'5T<S*AE1B)D*
M*F6JW/@B\L<P+*WHVMI=Q;=3+'4-HKK2K^:J%;Q(K5[6.1.>.]/ YS9S8UNB
MK\Z]WJX1W"X1HK:=(FJC(\IA7+GFJX^8B-[M&;BWW6SJO24D[;7Y.QC497-B
M3B3/%YJN0X#^C+>7WVK_ /-&?XP+CN6T]PN6\]+K"ONT51;J=[9(J96*V2/A
M3S6)A,*G%SSVEOF3M.;<;N4VH+9-<)*I:..IC?,BW-JIP(Y,\N+GRR:Q
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M65:J[SW<3:9J_JI_:^[L3TVX      " H?=77?%I^!/D!0>ZNN^+3\ )\
M#GMP+VVP:3N%<JXD1BQQ_ONY)_,#/.YM[_+NLJZH8[,,2]1%ZF]_RJ67T?+,
ML%LK[M*U.*I>D4:_V&]OUE&0Q2U$K(8DXIY7HUJ>+E4UWI:ULLVGK?;XTQU$
M+6+Z5QS^L"4                  $1J[W-U_P 7^) ;9?Z"O_?;]RD_J[W-
MU_Q?XD!ME_H*_P#?;]RE^/T2_C^S*S>GX_"?J[8 $#5
M       <'N=[>@_W_P #K-._U'1?%-.3W.]O0?[_ .!UFG?ZDHOBFE^7T6G^
M65I_3LOA'T2  (&J                     !%2:AM4;W,?6Q(YJX5/22JI
ME%0XVHT+#-42RK7R)QN5V.K3EGY3WP5Q6W[6=DNIOGK$=A6)\4Y[([3\.B/I
M37VVU,[(8*N-\CUPUJ=Y6:6IJZB2V=:[A67J^LQS]>#L[5HR*WW""J;6R/6)
MW$C58B9*\VFT^*.MIWF-X0Z?6:O-;I2-HG:?]W=6 #-;
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MG_V;<?HM_F!:P(/1VI*?5%H_*%)#-#'QJSAE1$7EZB<
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M;@^WWJG>CL1R.2.1/%%+<,#6:?L+[1W2^LX=JYU.+>W?'>  D7@
M           "LF_I ;_%(6:5DW](#?XI"S2_7?@\&5PO_P!/[I  0-4
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MDV;T?8K_ *5EJ[O;XZFH;4OC1[G.3S41,)R7TG7;X^X"J^-C^\\'1\]Q,_\
M&2?<T#O;'9J"QT7DEJIVT]/Q<7 U57G\I(
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MGUGEV(LWY0U;+7RLS!0Q9:JI_K'<D^K(%_6JBCMUNIJ.!,1P1MC;\B8/4
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M3S26^ES4[ZKL>NT^3S;Q^GZID'SBGBF3,4K'IXM<BGT)YC95$Q/<  .0
M      5DW](#?XHLTK)OZ0&_Q19I?KOP>#*X7_Z?W2  @:H
M                  "K]TMMH[TV2ZV1B1W-J9DB3"-G_D[TE".;4458J+UE
M/5P/_=<QR&RRO]RMNZ;4T#JRW]72W9B9X^'E-_9=_,#P;8;E17ID5LOCV173
MVL<F,-F3\'%GF-JRDJK=624]9%+3542X5KLM<U?%/YES[6;F).V.T:DF1LR8
M;#5O=A'^AZ^/I Z3?'W 57QL?WG@Z/GN)G_C)/N:>'>35MDKM-5-JHJ^*HK5
MD:O#$O$G)>?/L/SL'>;;3:<EMU16P15SJI[VPO>C7.143"IGM MT
M                                             "JB(JJN$0'SJHNN
MI9HD7"O8K<^&4P!SVL;O1)I6\]3<:9)4I)<<,S<HO"OI*DZ)EZ1^DKS^5;DU
M9$K$X?*)N>.!.S*]AR>H>CA645!<;D[4,3FPQOGX.H7GA%7':<7M#M#4;B6>
MMKJ>[,HDIIDA5CHU=Q<LY[0+CZ6-TDBTE8IK76N:UU8YJOIY>2^;V912W]!/
M=)HNROD<Y[W4L:JYRY55P9JWIT;)H3:73UFFK&UCTN4DO6(WA3FWLP:3V^]Q
M%C_A(_N Z   5_O%N32;=V*.H?%Y5<*ERLIJ='8YHG-SO[*<C/C-T=W[RBW6
MV0U24*<T;36]'1+ZLM55^<G=\H677I!Z?MUV>B6[@@1K7*B)A7*J_.O(U)&Q
MD3&LC:UC&IA&M3"(GJ I+8O>>;6%QDL.IH8Z>\M15B>QO"V7'MFJWN<GAZR[
MS*N\E#26CI#Z:J;2U&U=3/3S3QQICS^LQGEXHAJH
M     0%#[JZ[XM/P)\@*'W5UWQ:?@!/F==YY6P;H,F>F61PP/5/0BJI96M]S
M[9IVHDHJ5JUUQC7#XVKAL:_VG>/H*(UAJ&HU1?'W.KABAE=&V+@BSC"9QV]_
M,#R:@N#[M>[A<)%RM1,YZ9_9[D^;!H;9:S?DO15/-(W$]8JSO7T*OF_5]YGO
M3U#^4[];J'B1J5$[&*JKC"9YFO*:%E-3Q00IPQQM1C4\$0#Z
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M88/Q!+'/"R6%Z/C>G$UR=BH?LQNY]%$[]8  '(
M         #C-Q-!T>K*19&<,%T8F(JCN7^R[Q0S5<J*:W7"JH:M&I44\BQ2(
MU<IE/!39"YPN.TQM7O?)<:R21561T\BN5?'B4#X)R[ G)R.3DY.Q4[4  OO9
M/6E1>(I;/=95EJX&HZ&1W:]G9A?2A:IE3;2N9;M=VBHGF;! DBMD>Y<(B*U4
MY_*:HAECGB;)"]LD;DRCFKE%^4#]@
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ME2FM&;P373=B[Z5O5$M!&DBPT+7-\_C;G*/7/ZR<T_ZER@
M          "M=P+^[3L=ZJ878JI8DA@7.,/7'/UIVEE%*[XTTDT$TL:*K()F
MO?Z$QC(%,JKG.<Z1SGO<N7.<N5<O>J@ #^L<Z-[7QN5LC51S7(N%14[T-2;7
MWZ34.CZ.JJ'<54S,,RYRJN;W_*F#+1H;8&GDBT7)*]%1DU2]S/2G),_4!90
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M>+]EWFK\Q@Z_!:,DWK'27U/"M56V&,=K=828 ,]K@
M            !F7=K2\VG]33U#(U_)]<]98WHWS6N5>;331X[M;*.[4,E'<:
M=E13R)AS'I_]8 QV.6"U]S=MK=IVS3W:V5$S8V/:WR=_G)S7')>T_>SFA;/J
M"TONUWCDJ'QU#HFPJ[$:HF.:HG;V@55+2U$5.R::FF93R)YLCHU1KO4O825A
MU->;%*C[5<9XF)VQ*Y71K_NKR-7S6ZCGHDHYJ6%]*C>%(G,16HGA@KW4NS]E
MKT?+9W/MM0O/#55T:_[J]@$+IO>EJ\$-_H5:O8L\"Y3UJTM"QZCM%[B1]LKZ
M>=>]C7IQ)ZT[3.FI-NM0V%'/FIFU=.G^MILN3Y4[4.3IYI:6H26GDD@J&=CF
M*K7(!LT&<--;L7^UJV.X.;<Z9.6)$1LB)^\G;\I:^FMS]/WMS8G3/HJE?]74
M(C4^1W8!W /XQS7M1S'(YJ]BHN44_H
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MG"O-527"93U&GS)NT5+=]TMXI-8W2%[+?02]<W.58Q4SU<357MQVK_U-9
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M4G]7>YNO^+_$@-L?^SU_[[?N4OQ^B7\?V96;T_'X3]7;  @:H
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MQNF-R-/7U&L2K;1U*_ZFI5&+GT+V*=BUS7-16JBHO8J*!_0
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MJ875D34>^%')QM:O8JIX'J \%BL]OL-MAM]HI(J2DB3#8XTPGK]*^D]X
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M-:2TT-SIJ=7K(K$@1?.7M7GZ@-+ Y/;.:]S:;1^I6SMKNL7E,Q&NX>6.2'6
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M_'-:[VS47UH?T ?GJV?L-^8=6S]AOS'Z W<;0)R[  '(
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M3DJ*GH!"Z2MU3;+8L%8K5DXU7S7<28)H@O6*VF(G=JXKS>D6M&T^P !T>@
M        /XYK7-5KD1S5[45,G':FVXT_?6O>ZD;1U+N?7TR(Q<^E.Q3L@!GC
M4FT-ZMB.DM<C;G GZK4X)$^3L4KRLHZFAF6*MIYJ>5OZLC5:J&RB.O5CMMZ@
M6&Z44-2S^VWFGJ7M0#-&F]>:@L#FI35SZBG;_J*A5>W'H[T+6TSO):ZY6Q7J
MG?;I5_7SQQK\O:AX=3;+T\O%+IRL\E=V]34*KV>I%[4*LU#I*]Z?>YMSH7M8
MG^MC\]B_*GX@:IM]QH[C"DU!50U$:_K1/1WW'J,=VJZ5UJG2>V5<U-(G/,;L
M?5V%DZ9WEN-)PQ:@IFUL2<NMA1&/]:IV*!?8.:TUKBPZA:GD%:ULOO,WF/3Y
M%.E                           #.W3'I95L5@K$YP1U3F.3P56JJ?<I^
M-_JYD^A-#:BM[6SVZGFAD56KV>:BHGU*A>FK--VO55FDME\IVU%&]R/5JKA4
M5.Q47N.,U%==MIK-["JZY6IM*Y&P,I(I$58U1?-QC.'(H%-])#<'3^K;%IRB
MT[6)6U#9.ODX&JG59:B(U<I[;*]GH-+Z.;4,TK:6UV?*4IHTDSVYX4*WTQL+
MH[3]\IKBZ2HJY(WH^GAJ7MX4<G-%QA.)4+@   #..[6C[!JO>9E-?M3-H'2T
M\4<5'%&Y\KW>O'"U%YEP:*VYTSHV-$LMN8V9.VHE\^5?]Y>SY"A>E'=*"V;@
M6>X6V9\>H*!L;Y&<&&O9E7-7B3Y45/!3J[;TF].RT,3[A:J^"JQ^<9&K7M1?
M0N4Y 7Z4U4;9WFLWZCU;734S[/$SBBX.3VJUO"UBM]:JN3YVKI$Z8N5SI*&G
MH;EUU3*V%BN:W"*Y<)GGZ2Z0        /'>:UENM-96R+AD$3I%7&>Q,]A1?
M13H%N":GU97+UMPKJM8N->Y/;NQZU<GS%SZUC?-I*\1QIE[J61$3_=4JSHEU
M#)=N:J)OMX:Y[7?*C5 NPIGI3V&*NV\=>(V8K[7,R2.5JX5&N=AR9^5%^0N8
MK;I%U#:?9_4'%P_G&1QIE<<UD:!TNVMV??-!6"Y2OZR6>CC<]WBY$PY?G13I
M#A=BF.CVDTPCTPODB+\BJJG= 5[T@OT.ZF^)9_ZC#[;$_HETS_"I]ZGQZ0?Z
M'=3?$L_]1I]MB/T2Z9_A4^]0.\     " H?=77?%I^!/D!0^ZNN^+3\ )\'&
MWG6;[?<ZBD;1L>D3L<2R8S]1X_9]+\ C_P"(O\BNNAS6C>(^<(+<3TU9FLVZ
MQ^4N^!PM-KN2:IBB6AC1'O1N>M[,KZCNCRRX+X=N>.][X-5BU&\XYWV #XUE
M5#1T[YZF1K(V)E553RB)F=H>\S$1O+]SS1T\+I9GM9&U,JY>Q"LM5:D?=9'0
M4RJRB:O9V*_TKZ#XZEU#->)E8Q71T;5\UF?;>E3S6"RU%XJD9"BMA;[>7')O
M_4V=-I:X*]KE[_T?-ZW77U5NPP=WZ_P^5FM51=JM(*9O),<;^YB>):EEM-/:
M:1(:=,K^L]>URGTM-MI[92-@I6(B)[9V.;E\5/81:O5SGGECS6GH.'UTT<UN
MM@ $32
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M=.R"G8C(F)A$0^QG:K56SS^38T.AKI:^VT^L !(O
M                                                  _G W]E/F/Z
M /SP-_93YC^HQJ+R:B?(?T#=QL  .0                        C+C8;;
M<,K4TK%>OZ[?-=\Z$F#M6]J3O6=G2^.N2-KQO#A+CH1R*KK=4(J?L2_S.7N-
MGKK>JI4T[T3]I$RGSEQA4145%1%1>Y2[%Q')3I;JS,W!\-^M/NRH^":2"1'P
M2.C>G>U<*=#;M8W*E5&U#FU,?]M,.^<[:YZ9MEPRZ2#JY%_7B\U3EKEH:IBR
MZWSI,W]F3S7?/V%D:K3Y^F2-O']V=.AUFEG?%.\?E^R<MVL[=5*C9^.GD7]M
M,M^=#HX)HIV(^&1DC%[VKDIJNMU90N5M73R1^E4Y?.?*DJIZ1_'2S21.3O8[
M!TOP['>-\<_5Z8N,9<<\N:N_RE=I^)I8X8W23/:QC4RKG+A$*[MVMZZ##:R.
M.H9^TB<+OY$9J._37FHYYCIF>TCS]:DU.'9)OM;N]JS)QC#&/FIUGV)_6.HJ
M"NMLE'2N?))Q(O$C<-Y'XT-?:&WT+Z6KD6.1TJN1RIYN%1._Y#BNX&G]CQ]E
MV7J8OE'+VW;]-^Y>,;VR,1\;D<Q>:*BY13]%6Z1OTEKJV02NXJ.5R(Y%_47Q
M0M)%14147*+WF)J=/;!;:>Y]+H]9754YHZ3'?  "=8
M      _$T4<T;HY6->QR85KDRBG!:DVIT]=>.6DA=;ZIWZ\"^:OK;V%@ #->
MI-K-069KY861U],WGQ09XD3TM7\#A'-?!/A[7PSL7L5%:YJ_>;/(74.EK/J"
M%8[I112KW2(G"]/4Y.8&?]-[FZBLJLCDJO+J5O\ JZA,KCT.[2U=-[MV*Z*R
M&MZVWU#L)B5,L5?0Y#EM2;+21(Z33E:LGA!4JGU._F5C?-/76QR*R[4,U/\
MVG)EJ_*G(#7%//#4PMEIY62Q.3*.8Y%1?E0^AD&Q7ZYV*;KK36RP+WM1<L7U
MM["R[/O761TLC+M;8IIT:O!)"O"CE[N)/Y 7=4U$--"Z2HECBC3M<]R-3YU,
M]:5GA=O9-,V5BPOK)E:_B3A5%SC"G&ZBU!<]15KJFZU+I'*OFQHJHQB>"(1?
MJY>KD!M &==L-PZRR5T%ONT[I[3(O#Q2*KG0JO8J+X>@T2UR.:CFJBM5,HJ=
MX']        /S+(R*-7RO:QB=KG+A$^4_1RFZ6FJK5NB;C9K?4LIJFH:G!(_
M/#E%SA<<\+@"=FKK9/$^*:JHY(GHK7,=(U4<B]RIDIZ_[%;?W.L6HI*S\G(Y
M55T5/4-X.?@BYP9BUKI;46C+HZAOT4T+L^;*URNCD3Q:[O+$TELI6:MMZ5M@
MUI:ZJ+"<34ZQ'QKCL<W&44#06WFW^C-"JZ:U24TU<Y,+55$K'2(G@WP3U%BL
M<U[4<QR.:O-%1<HIE1O1HU.BIG4MO^:7^1IK35N?:;!;[?)(DKZ:%L3GIV.5
M$[0)(  9=WS_ /L/?[3EYK(7NH96P>>O)N6N5J\_1R4F-W[M'I#?O2NIK@U5
MM3Z3JW2M:J\*9>BX\53B13H=T]?Z+M^N:>QZZLCZEE&UE53U:-ZQL;G)WM14
M7N])V=RMVCMT].PQ2OIKE1(J/C=#)A\:^C'-OI0#/>N-74VX&^6E9-*=;*RF
MFAC;,B*WB7K.)RX[D1._UFNCAM"[5Z5T56OK+)0O\L<G"D\\BR.:G>C<\D.Y
M                         '/T2HFJJ]55$1(T557Y#H"N=85TM)=*R*!W
M"L[4:]4[>'"<CUPXIRWBD>MXZC/7!CG);U):^:TBI97P6^)M0]O)9%7S?D\3
MB;E<9[A7>5U'#UW)/-3"<NP\2>@'T.'38\/FQU?(:G6Y=1/WYZ>QV]OUVYL:
MMKJ7B<B>:Z->U?2BG+WFZU%VJW35#E1,^9&B\F)Z#P$UI"WT]SO"05:KU;6J
M]&IRXU3N.L8<6GWRQ#O]HSZOEPVL].E=-R761)ZE'1T35Y\L*_T)Z"S*>&.G
MA9% QK(VIA&M3"(?J.-L4;61M1K&IA$3L0_1B:C4VSVWGN]CZ;1Z.FEKM'6?
M7( "98
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MI7TS>)5[\<C*]NH:BYUT%#1,5]1.Y&,1/$US8+<RTV6BH(_:T\+8_F3F![P
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M
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MZ7A8]Z=CE;V*J<@.+W/UUH71^X;I+YIV:OOJ4\:^5-8UZ-;^JB<2\E^0\O\
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MQP  \5(
M
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M.5?V<>*FJP                        !S]#[JZ[XM/P.@("A]U==\6GX
M3V4\4*TUMSU8F/V8SWW[3-VK+O55%.YG4R.RW,N/J(Y=&WE5RY(57Q64UM)3
M%BGGF\=886NR9\]>SC%/2>_P_P +-:Y.%.:']*XI-)WF*KAD>Z/A:]'+^>7L
MR6.09\5,>W+;F:>ESY,T3STY=@ '@J
M
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MG"JKS5J_R*W.QVS1?RA6*GM>J3/SDFNI%L,S/J:/"\EJ:FL1ZUA  ^=?7@
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M)                         $!0>ZNN^+3\"?("A]U==\6GX 3X
M
M
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M=\6GX$^0%#[JZ[XM/P GP
M
M
M           7L4K2T^[U_P#$/^]3T72'4RW&I6F2MZGC7@X7\L>CF14=FO\
M'4^4,I*EL^>+K$5,Y\<Y-?38:XZVWO'WH?/ZS47RWIMCG[L[]RV 5Y:H=3)<
M*=:E*WJ>-./B?RQ\Y89GY\/93$<T3X-?3:B<\3,UFNWM  >"D
M  "'U=IV@U5I^LL]UB22FJ6<*KWL7N<G@J+S)@ 99?T7[E^45C9J.F_)O&JH
MY8G=8C>[+>S/RFB]%Z9H-(Z=I;/:F<-/ G-R]KW+VN7TJI-@"FK/M-<TWDGU
MA?[I#74[7.FIF(Q<M=S1K<+V(U.:*G>7*               49TDM07":>Q:
M(L<CXZF^2I',]JXS&KD;P_*JY7T(6;H+15HT78J>W6NFB1S&_G:A6)UDSN]S
ME[?D[BH-6,2HZ56G&3.5S(J='L15Y(J->IH4#C]R=!6K6^GJFAK*>%E8K/\
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MTT'E])\)A^F@'I!YO+Z3X3#]-!Y?2?"8?IH!Z0$YIE.P
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M;[Q]I3^^QVV^\?:4E@!$>QVV^\?:4_J:=MJ*BI!V?VE)8 &HC6HB=B<@
M
M
M
M
M                         %3[H;LNL%[BTSI6WNN^IYN'$:)F.+/<["Y5
M<=W=WJ<[)4;[Q1/KEBLCXT3C\D1&*['[*=^?E OH%8;5;KT^KZZ:QW>AEM>I
M*9JK-32)AK\+SX<\_#DOUEG@
M             "J-RMX:?3=Z]CUAME1>-1+A.I8U49'GLRO:O:G)/G M<%"1
M2[\7&)*F)++0L?E4@D:SB:F>_*+]YZM+[NWNT:II]-;FVIM!65"MC@K(4Q&]
MV<97GC"KWIV> %X@%3;F[LOLE]CTOI*WON^IY<+U:)F.)%15YX7*KCGCL3O4
M"V04+Y3OO!"E?)%998FMZQU(C6<2IX>.?E.LVHW7I]8UDUFNE%+:]1TK56:F
MD3#787FK<\_D4"S@
M      !3.NMP;]<]?TFC-NY(6UT3N*X5DL221PMY<N>>S//TX0N.!KV01ME?
MUDB-1'/QCB7'-<=P'[!Y[E6T]MM]16ULK8J:GC621[NQK43*J42NY^M]>7*>
M+:^T116N%_#Y?7L1$<ORKA/5S4"_@9_K=;;J:"8ROUO:J*ZV='?G9*+".C3U
MM3"?*A<NC=3VW5UAI[O9Y5?32IS:[DYCN]KD[E FP
M                             <GN/KVT:!LS:^\+(]TKE9!!$B*^5V,X
M3/=V<_2591ZGWCU@QU=IRUV^S6YR9B2L:G&],]OG(OW(!?X*3LMUWCM-[M]/
MJ*W6RYT-5.V.26#"=2U5YJJMQCY44NP "E=<;NW&;4LNE]M[;^5;Q%E)JAR9
MBC5.W'/GCO5>7K(ZHN.^-EA?<J^FL]PI8DXWTL+6\?#WXQA<_*H%]@X':G<R
MW:_I)V10R45VI$3RJCE[6+E4RU>],I\AWP
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M&K[1>;4=\[57Y4R:/1<IE.PS_P!+IR+:]*1(U5D=7N5JHGH3E]:%^P?Z"/\
M=3[@/V                                          !X;[;8;Q9JVW
MU+4=%4PNB<B^E%0]P SUT;;[[&;E=]O;_(D-Q@JG24K7<D>BIYR(OBN$<B>E
M30I7VYFU-CUY+%653YZ&[0M1L5;3*B.1$7*(Y/UOO3Q.)7:37<BK1S;AUJVQ
M6]6J(KN-68QCM[0(O?BYKKW6UDV_L3^N=#4)-7*U?-;Z%7Q:W/RJ:&I*>.EI
M8:>!.&*)B1L3P1$PAQFVFV=CT#!*MM26IKYTQ/65"HLC^><)X)Z$.X
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M/0@':4T$=-3100-X8HF(QC?!$3"(?0
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M)QJBRSRJCI)5_M+CZNQ#J
M                                              '\XDXL93/@!_0
M
M    JHB9541/2
M
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M9Y1HW.>SS<8)OH>^X2Z_QW_P-.;]F.HTZ2S[)^6Z[\D^7]6E)UB]7P\.<8\
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M[5:U5YKE780X_0B__P U%QY]MPJOO<:ZX6^"?,!_0
M
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M455:E99WUM1*VHZZ-45KE7A7"+GGGP-'@
M
M
M                             #X5T3IJ*>)F.)[%:F?'!]P!1NPVUU^T
M/JJ\7"\NI%@JHE8SJ9%<N>//@G<7D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
L                                                      !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g73463g04c52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g04c52.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1N.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &W$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*/_  !$( Z$&CP,!(@ "$0$#$0'_Q  <  $  @,! 0$
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M[J4"=D#LH4CHF4$=U*)XH"#DH4A PF$0('1.R(@^H?ZP+U+S1?3:O2HN"(B
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MHL%Z-70TM$ZBX0CX1<X.W]_KD]MT*J.VXWFBVA3:9KK)1U)AJ7TV]1N?ORN
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MVH+C&'OBI:9T9B=O<XVNR=YP&"/'P5VVN;28M!62WU+:/TFLN#BR".1VZU@
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MG= [*%/L4()1%""4"!,=0@#DA3"((4A/%/$H'9$0("@(B I0=40$1/:@A2%
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M*ATZZ6IJ+E7W6Z2,X1K:V3?>QGV6@\FCD/;A!^;]-_[5,_\ G%5^4BS;6O\
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M*U['$=#]$$'KW5[INKD&)$\40.Y1%"">B)CJ@01R4H@Z\T =$PH'DI0$ZJ$
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M]971,#Y7N;@%K"<@8)QS'8KZV6W?7L&O+GI_5-+75EGAXO N<]-N;V'>J=\
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MF$#Q4CHB!  4!2B $Z*$03XJ%(4!!]P_U@7J7EA_K O4HN"(B B(@(B("(B
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M6-C:UCXW&3(RT8+QNC/M![JB\HH4A 3JH4H"A/%2@)CDH"=D$A/8H4H"=T1
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M]R5T% @I.O-F.FM;RQSWFED;61C=%33OW)"WP/(@CVA>_1NAK'I&/_W12O\
M2"SANJ9Y#)*YN<XR>@\A@*S]T04FY[+-'72[272OM!GN$CQ(Z=]7/O;PZ'._
MRQ@+ZONS#2-_K!5WFU.K:EL8C$DM7,2&CH/IJZ*$'FME!3VN@@H:-KF4T#0R
M-KI'/+1X9<23[RO4G90@!2@1 3LH]JE 4*4]J @[HH!02410@GNH4CS1 '1
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M4>*GL@C'9%*('O105/LZH 10B"44*4!$3W("A3XIXH">*@*4#S[(H"()">U
MHR@E$1!"GV*%.4 >:8Z\T]Z! 6:FZN6%9:8<W(,7CT1"G) **%/O01V4IV1
M3HB("'VH/:@[H("D=T">/- 10.ARI0$4*>2 B(@)_)$00BE$!.Z!0@E/%.BA
M!/Y(B("A2.2A!*=T"! [)TSW4*4#Q11U3\D$CNG;DB>Q!"*0B!XI[E'=2$!.
MJ*$$CX!0I1!"E%'=!*!/'"("*%(0%"E/:@(B("#H@Y)[T!0BG\T =T'DB('Y
MH/)$\4#V\E"D=U"!E2@*A!*! B %"GWJ$$]D3VE1[4$@(G9$!/>B(")V4("(
M%* HZ*?8B!GFBCQ4]$'U#_6!>I>:'^L"]*BX(O#<_P#=^]>+GV7><+E<[RC=
MHM(/:F<>*OYIW;M%I,GN43\_Z=V[1:3*#..J?F=V[1:11GEU3\SNWB+2#/B@
MRGYG=NT6D!3GS3\SNW:+1]N:GLGYG=NT6DYH$_/^G=NT6D!0%/S.[=HM)S_]
M$"?F=V[1:3*C*?G_ $[MXBT@Z(#YI^9W;M%I,^:9Y)^9W;M%I.>43\SNW:+2
M!1D^*?F=V\1:3/F@/FGYG=M:GHU8$MG^]]W\U[5QN38ZS_7CRH"]J(1X^J@+
MVHA'CPGBO8B#QY0=U[$0>-%[$17BPI7L1$CQA1XKVH@\:>*]B**\84>Q>U$'
MC1>Q%1X\<^2+V(B1XT"]B**\?BA7L14>)2.Z]B*#QA%[$1'BQR4KV(BO'V0=
MU[$51XO%3V7L1!XT7L10CQ*<+V(@\?9/%>Q$'C0KV(JKQIA>Q$'C'=/%>Q$2
M/&GBO8B$>-%[$4(\:A>U$5XPG9>Q%4>/LB]B(1XT7L117C4>2]J*CQ*5[$4'
MC[*,+VH@\8[J O:BH\:%>Q$'B"G/5>Q$1XPG9>Q%!XP@7L14>-%[$17C'1!W
M7L1!XTPO8B)'C3Q7L1!XAT6:G(!=D@+.M9?/H0^TJ*SIV*]@Z!$'B1>U%1XT
M \%[$0>-%[$0>,(%[$4'B3"]J*H\8Z(%[$4'B3LO:B*\:+V(J/&%"]J(/&B]
MB*)'C4=,KVH@\:!>Q$'C1>Q%2/&B]B(KQIT7L1$CQ*>J]B(/%V4]U[$4'C4+
MVHBO&@7L15(\>$7L117C1>Q$'C1>Q%4>+JB]J(/&B]B(/&$'=>Q%%>)2O8BH
M\13/5>U%!XT]J]B*H\7=3XKV(@\:+V(BO&.Z=E[$1'C"+V(H/&H7M1%>+Q4K
MV(@\2GNO8B)'C 0+V(J/&H7M10CQ*5[$17C\D"]B(/$I"]B*H\93LO8B*\2E
M>Q$1Y8OI@GE[5ZNO1>6Y_49?9_-+7SH8O9_-16.Y_P"[]Z\*]USZQ^]>+LMN
M'C+EZA$]ZE=(!0B=D#QPI3RP@[H"%1URB">R810@E0$'12@)XH5 [H'M1$02
MH124!.V5"()10I""$SXHI0,J%*=D$!2.Z@!$$J%("@<D!%*(/;;/][[OYKW+
MQ6S_ 'GN_FO:L>?K3CX(B+ET(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B M9?/H0_O%;-:N^?1A_>
M*#:#H$0= B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B#RW3ZA-[/YI:_J,7L_FES^HR^P?FEJ
M^HQ>S^:#'<^L?O7A"]URZQ^]>(>"VX>,^7J G=/%!W73D[]4\5*A!*#DH"#V
MH Z(G9.F4$H,J%*"$"*0@=#R4#JIPH03WYJ!U1/<@*0@[J/) "E0$P@#'-$"
ME!'BI4>PJ>W) \5 12.J" I'=!U*CL@E0GL4^*!V*)T3R0>VU_[WW?S7N7AM
MG^]]W\U[ECS]:\?!$1<J(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B M7?/H0_O%;1:N^_0A_>*#:-
MZ!$;T"("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B(/+<_J,OL'YI:_J,7L_FES^HR^S^:6OZC%
M[/YH,=SZQ^]>'HO=<_\ =^]>);</&?+T4*0H73D4H@0$3LH_)4 .J=5(4>*@
M>*94J$$H@1 \5"E0@D^2CL@\%(" H4J/% [H$4A [($4!!/3DH ZJ5" #U12
MB"$[*>>%"">W+JH3*8QT0,(I"A![K9_O?=_->Y>*V?[WW?S7M6/+UKQ\$1%R
MHB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("U=]^A#^\5M%K+Y]"']XH-FWH$1O0(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@\MSY4,OL_FEK^HQ>S^:7/ZC+[/YI:OJ,7O\ S08[G_N_>O">97NN
M?^[]Z\(6W#QGR]!R4^*>]1[UTY,(I'+P4()PH3HF>:"5'BGBI_)!6M?:LIM(
MV-U=4,,LSW<.&$'&^[&?<!W5-T3%J77-)^F+Q?*FWVYSRV"EH/FG. /,EXYX
M[=^_OHOR@ZR2?6\5.]Q,5/3,#&]@7$DGW\O@%WS2M-%2::MD$ Q$RFCP/^Z"
MI[JJKJR@U)I^QU-9IR]SU+*>,O?!7,;,[= YEKR,Y\CD+QZ^O=XL^SBV7BV7
M*6"JX< DS&R02;S1DG>:3E=*(#FEI (/(@]"N;;=860;-W0PM#(XYH6,:.@
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ME]+41PN>R5C6N((!/1P([+D6J+W?:'1-HU90ZAK'RU4C6R4TC&"+)WOHM R
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MV$IMGFEJ-D-;-40F&:2.![XCU8XN:2WW'DKB+5I>2JKM$6YYJ7BLFHFGCO\
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MS2L?&)GAF^.9Y9Z\B%.QT@[1MH1:00:Y^,?\5ZZ!>]%Z=OEP977:TT]35L
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MR'[S6D ^\(*3LGM9J-?ZSU)&#Z%45#J>FD'T9AOY<YOB,M;S\RIM#FGY1-[
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MJC4Z?</]&%*<C=_1G7_\V57_ ).Y'^C*GP>E1-_$KE#I>TPV4VB*GE9;3RX
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MLNF-=5C]:5>D]34]-#=8QO0RTF]PIF[N]T<20<<U3[975]%MOUA^B* UU=)
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M*ZS27B*X0OAW:F!],V-K&DC+HRWGR^\2F(NNSNOJ;IHBRUM?*9JJ>F:^20@
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MK0W>FJ:J",S26YU(T0O &2UCAZ^>N,NYK:[/-64^LM-Q7.G9PGAQBFBZ[D@
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M(/=:_P#>^[^:]R\-L_WON_FO<L>7K7CX(B+E1$1 1$0$1$!$1 1$0$1$!$1
M1$0<HF_VC(?\J_\ YEY]MW]K=!_YBS^-JL;MGA.K?Z2#4-S_ $F&E@=NQ%H9
M@C=W=W&.:R:OV?,U1<Z.MK;U<(GT;@^G9"V-HC<"#GZ.2<CNJCR[?OU67?\
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M#0 <>>#\ K32Z L=+$^")M9Z"XDFB-5(:?GVX><8\E:V,;&QK&-#6-& T#
M\$5H=?T<UPT3?:2F:732T<K6-'4G=/)<_P!C]\TK>-,4]'<*6V072B8(IFU,
M; YX'(.!(Y_GR77U2;WLNTG>+B:VKMC6SN=O.X+C&UQ\2!R.>Z#<:8K;153U
M[+!34[::!S6/J*=C6QR/QDM!'7 QSZ<USW9F1_IGUZ.^1_$NHTUII*.T"V4$
M?H=(UA8QM.=PL![@CH?-5JU[-K':[G/<;?)<H*Z<N,LS:Q^])DY.]SYY/-$:
M'Y1WZOH_\=%^3EN-;T,]QV05E+2-+YGV^,M:.KMT-=CX!;75FB[5JH-;>75D
ML+2'"%E0YD8(&,[HY96RL=FALU.V"FJ*R6%K QC9YS(&-'( 90<ZV4WS2%YT
MG115=-::>XT<+8:AD\4;22T8WP2.>0,KW:N%%?MGFJZ?2E)#P6QA@EI6AHG>
MTASF@ <\# SWR1VY[*[;*](W.X&LGM;62D[SFPO,;''S:.2N%OHJ:W4<5)0P
M1T]-$W=9'&,-:$%#V/ZQM5ST30025D$-900MAJ(Y'!F[N\@>?8@95FCO-/>K
M/=Y:$B2EA;)"V8'(D(9S+?($XSY%:6Z;*])7*Z.KZBV 3.=O.;&\L8X^;1R5
MRHZ2GHJ2*EI(8X::)H8R-C<-:/ !%<S^3O40Q[-J</E8TFLD8 3SWB1@>U=2
M57T[H+3NGKK/<;50-BJI<^L7%PCSUW ?H]>RM":8(B* B(@(B("(B B(@(B(
M"(B B(@(B("(B#RW/ZC+[!^:6KZC'[_S2Y_49?8/S2U_48O9_-!CN?6/WKQ+
MVW/K'[UX>RVX>,^7HG<H$YKIR(.2*0@#HB*.W) '1%(Y90((0<E(Z*$$A%'B
MG0("D*.RGN@C*!,=5(0%&<'FG92@=L*%/BH"!W4IV*@( \@IZ)[%';F@>Y2G
M5.B % Z(I[\\("?DBA 0*4'7D@]ML_WN/+^:]R\-K_WON_FO<L>7K7CX(B+E
M1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 57UOH6SZR]#-X;4!]*7&-T,FX<
M'&0>1Y<@K0B#P6*T4-BM<%OM<#8*6$8:UO?S)[D^*]Z(@(B("(B B(@I]=H&
MBK=34U_GNEU-SIN4,@DCPP<^0;N8QZQY>:MT;2R-K7/<\@8+G8R?,X "^D0$
M1$!$1!3-4;-K!J:_PW>[,J7U$;6L+&RX8\-)(!&//L0K?3014U/'!3QMCAC:
M&L8T8#0.@ 61$!:C5%ABU%:YK?5U=7!23-W964[FM+QG."2TGX86W1!H](Z;
MI]+VQEOH*NLEHX\\..H<UVYDY."&@]2MXB("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+5WSZ$/[Q6T6LOGT(?
MWB@V8Z!$;T"("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("\UQHHZ^E=!+)/&QQYF"9T3O_$T@KTH@J^F]"6/3=4ZHLT55
M3O>=Y[15RN;(>?TFEV#U[JT(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@\MS^H3>S^:6OZC%[/YI<_
MJ,OL'YI:_J,7L_F@QW/K'[UXE[;EUC]Z\*VX>,^7H.0*E0I73E"! I01RP@4
MJ.R"0F4"@! "(B"?-/%% 0/=S09Z!2@Z%!"(.Z=BJ)4(A4#HG=.OFGB@# RI
MSR4*4$$=4"?!$$CHB*!W02H4J /! 0=TPIZ=T$)V0(@]UL_WON_FO<O%;/\
M>>[^:]JQY>M./@B(N70B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("U=]^A#^\5M%J[Y]"'VE!M&]
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MPWUKG@B(HHB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MC=:<E7?:+M$N6C;C34\ENI*EE1%Q&N$K@1CD0>7BI?\ %=)IC(ZGB=.T-F+
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M?D@TFA1_\;M<?\*+\F+'K7]?>BO\-)^4BW5DT'=+7K"NU"W4<<E17$"IA-
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M_5M//.'$'F/' &4'3+5+336ZG?0-:RD+!P@UNZW<[8'88Z*G[;OU:7G]QO\
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M-TIZ*9M1%"RE; '2M^BYY!.<9/(8"\6T?0=3K62C:^]>A4M(_B1Q,I=]V_\
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M<3S(YC&?#HK9IW2D6F[)/26>I=Z?,=^2NJVF9\C^F\X9&>7( $ ?'(4;8/\
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M+8H@UE1IZSU%+34T]JH9*>F.]!$Z!I;$?%HQR7JK[?1W&D=2U]+!4TSNL4K
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MR]=\4D8=\<+;M:&-#6@-:!@ # "J--#I33\+BZ*RVYA)R=VG8,GX+=    #
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MH(KQ32&%[*ASHXGN'<$ GW>/=5/3FMM<:MTC55VGZ&C],BJ7!SG@!I9AN(V
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MM%:GM5-?JZENEGN3C&V>.$120.! )(!((]8*0=21%6]4:B_1]PM]GH3$Z[7
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M@W=_KYY7FT]H"XV72%UL,5XIY(:W>(D=2D%F\T-=^WSY *05?Y-7T;[[8O\
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M\RNA;1=G]1K!U"P7.&CI:)KA$ST<O/K8SD[P^R.R]=7H9MST-%I^[U4<TD
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M(B B(@(B("(B B(@(B("UE\^A#^\5LUK+Y]"']XH-F.@1&] B B(@(B("(B
MB(@I.VC]6M[_ .$/S"T;J>6O^3_#1T7K54MI:8XVGUG[H!<![A^*Z/=[;2W>
MVU-!<(A-2U##'(P\L@^?9:?2&C;5I6G?%;6SOWN0?42F0M;]EN>31Y <^ZJ-
M-L.N,%?LVM+8)&NDIFN@E:.K'!QY'W$'WK0V2@=6;?KS7TI(IZ*E:R<CH9'-
MP&GSQS]RML>@;12W"HK+3+7VI]2<S,H:DQQR'Q+>8!]F%O+'9:&R4SX;?$6"
M1YDD>]Y>^1YZN<XY+C[4&Q7*=0Z%H=67&MO^DKI/:;W#/+2S/C):UTD;BUV]
MCF,X!SW&.2ZLJI2:&H:&Y5U=;J^ZT<U;,^><0U/J/>]Q).Z00.O+'-,5SZDN
MFHM1[-M:V*[LW[O:@(C+'UF&=X^TX:?:"%:]C.JK==]$6^G;/'%5T$3:>>%S
ML%NZ,!W/L1S5OL=CH;+32Q4,1!F>99I)'%[Y7GJYSCS)51N6R+2E==):[T:I
MIGRDNDCIIS&QQ/7EV]@PB+;;KO374UPHG<6*F=PC,T@L>[&2&D>'0^:YW\FC
M]7L_^/D_A8NB4UDI:*R1VJU%]NI8V;C/1@T.:._,@\SX]>^5JM&:)M^D&2Q6
M:IKA3RNWWP2R->PNP!GZ.0>0Z%%4G;*1'KG0<DA#8Q5.RX\@.;%G^4C4PMT)
M'3NE8)Y*N-S69YD#.3A7K5^E;5JRWLI+Q"Y[8W\2.2-VZ^-WBTK43[-=/U-D
M-KJFU<\1D;(Z66H+Y7;O1I>>8;Y# 1%;V\X.R2+!Y<2G_)=+L\L;K?2,:]I>
M*>-VZ#SP1R/X%:ZXZ1LU?IM]BGI +<X#U&N.6D='!W7(P.:Q6;1]OLMFFM]L
MFK(>* UU3Q=^;='0!S@<#P '+L@IGR;_ .Q=?_F$G\+5\;%O[3ZW_P =_P"J
MMVEM#46EZ6II[+7W*&&H.\]CI&/ =TWAO,.#_P#?91IG0M!IROJZNV5UR;+5
MG>G$DK7MD/B06]?,(*9;_P#:/N/^ '\#5];0?UX:&_X;_P W*W4V@:"GU0_4
M++A=#=7\GRNE80X8QN[N[C&.V%-ZT%;[QJ*FO=777,7"E(,#XYFM$6#G &[C
M'MSGNE$[2]8PZ/L#IVXEN4_S=)3XR9'^/L'5:C91H]^F;;4WB^R&2^7!O&JI
M)<$Q#J6Y_/V>2VE^V?VR^7NFNU?5W%U;3M:V)S9FAK".X;NX!/7EW7HK-'LK
M*66FJ;[?7PRMW7M]* WAX<FH.:ZPK[5;=LM#<=0TT-38KG;V,BEFC#V,/9Q!
M'+'_ %*_U])HNW4L54VV6B9\CVLIXX88W/F>?HM:/$K::@TA9;_9X;;=:-LT
M$#0V)W1\8&!ZKAS'0+5:3V9Z;TQ7"LH*:66J;_5R5$G$X?[HZ ^?5!=%Q7:Q
M-1VC:GIR[7ZD9461].ZGDXC ]K22[F0?#>!]R[4M9J.PVW4=M?07BE944[N>
M#R+3XM/4'S"F*KE;3:$I+2;C)0V5]-N@L,<$;C(3T:T8YD] %7-O9']&+"1'
MPAZ=%B,@#<\N7@M_IK95I?3]Q974E+--/&[>B](E+Q&?$#IGS*V6L-%4&K'0
M_I:KK^%"[?CBAE#&M=X_1R3[2JC6;8OU57C_ (#/XFJM7O\ V;?_ -!A_P"8
MU7R^:1I[Y8VVBY7&Y24> '@2,:Z0#IO$-R?Y]\KR3:!H9M,MT_+<;H;2T!HA
MXK,X!R 7;F\1GME![MG7]@]/_P"!A_A"YSL<?)9]HVM[+="65U1.*F/?/]8T
M.>=[/?(D:?>5U'3-BAT];([?1U-5-21 -B9.YKN&/ $ ''MRO'J+1MHOM;#7
M5,<U/<8>4=922F*5H\-X=??E!2]OM$ZZTVFK;2@.KZBXM$31UQNG)]@R%Y?E
M$-W;7III).*]HR>_)=$MNF*"BN(N$CZJMN#6&-M163&5S&GJ&@\F].P"\.LM
M#V[5TE.;O4U_#ISO110RAC6.\?HY)Y=RE'GVO_JQO_\ AA_$%BTS^IZG_P J
M=_ 5M[]I:"^V1MJN-PN#Z7&)-U[&NE'+ <0WGC'EYY7Q2:2IZ73+K##<+B*#
M<X3<R,WVLYY:';N<'/?GX8053Y.GZN(O\3+_ "6NV/?K'V@?\>/^)ZO.D]'4
M>E;?+16>MKXZ60E^Y(]C]QQQZPRWKRZ=/)>?3^@K?8;S572WUUS%55.WJ@OF
M:YLW//K M\STQCL@JUW_ -HZR?Y0[\YEHK546.U[7=46S5])22?I"9DU)/4Q
MM<QO(G=R>F00/:U=&FT'0S:ICU$^X73]+1C=9+Q68:W!&Z&[F,8)Y8[K/K#0
MMBU<R+]-4I?-$,,GC=N2 >&1U'D>248A3Z3MEVM\=%;;:;C/)B 4T+"]H YO
MR.@ [^Q4NL_VE:'_ "X_P/5XT?H2Q:2=))::=_I$C=QT\S]]^[]D$]!RZ!>>
M30% _5 U$;A=!=P,"82LP&XQN[NYNXQVP@K.V+^VVSG_ #1O\<:\ORBOJ^ES
MX5__ /*KIJ/0M!J&[4=QN-=<_2*-_$IN%,UC879!RT!OB!S.3R7MU3I.VZHL
M\=OO8EG;&X/;,"&2!P[@@ #/LP@WK7M<YP:X$MY$ ]%5]IVJ9-(:2J+I3P-G
MJ ]D4;'_ $=YQZG'8#*W-@LU)8J!M)0-DW,[SGRO+WO/BYQYDJ-162@U#:)[
M;=H>-238WFY(((.001T(*BN4[3;3##LMJKE=KE)<+I4,B>V267# 7.;RC9T
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MFM;I'1E%I2AGH[/65[*:4EVY(]KPUY&-YN6\CR'EY(*9LQ_6OM!_XS/S*4Q
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M3A^^QDI)W6!W<\L^0*[&FF"(BBB(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("U=]^A#^\5M%K+Y]"''VB@V;>@1&] B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#RW
M3ZA+[!^:6OZC%[/YI<_J,OL'YI:_J,7L_F@FX?5_>%K!W6SN'U?WA:U;</&?
M+T4(,J5TY0G3/12F$!0%/FH0!WRGBI"@('93[E&0%3;EM(T]0S5+.-4U,=,X
M-GFIH'21Q$G #GCD@N7+W*>BTD&J;1-I\WN*KXEM RZ6.)[RWQRT D8[Y"U]
M-M#TO545;5P75CH*1K73.,3VXR2  "T9)(Z!*18[C60V^AJ:RI<6P4\;I'D#
M. !DJOZ+UK:M8"K_ $5Z0UU,1OMF8&G!S@C!/+D5BHM=:=NUAJ[@V:9UOB>8
M9]ZF>_=RTG+@T'#<=SR7ETE?=%06^XS:;EIH::F EJG,A>S&<@$[P&>AY!%7
M?.%"XA0;4J:Y[18ZBMD=162FADCB&XYY>XX]9P:"<GV<EUQ]^MD=B%YEJV1V
MPL$@G>"WU3TY$9]V,IFI&T4*J6S7]CKZZEI ^JIY*P9IG5-.^)LX^X3R*]^H
M]66;3;XFWJL=2\4$L)@D<'8Z\VM(0;P=57M9ZOMND:.&HNO'=QG[D;(6!SB>
M_4@?BO%==HNFK;;J.MFKS)%5M+H6Q1N+W-!(SND @9'?"PZLU#HV:WTD>IGM
M?1U+1- 9:65S7>8<&XSXC.?%%6>QW.FO-IIKC0EQIZAF^S>&#CIS"]RU-IN-
MI_H[#76^6&*SMBWHY,&-C6#//!Q@<E7ZO:9IZEB9.\U[J*1Q:RK;1R<%Q[X<
M0,^Y$790,KSVVNIKG10UE!,R>FF&\R1O0A>A "=TZ*0$$)V1!R0$4J$!%*(-
MK1?5F+,L-%]68LRPWUKG@B(HHB(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B A (((!![%$08C30&,1F&,Q@YW=T8S[%#:2F;G=IX1D8.&#FLR(,+*2G
M8X.93PM<.A# "%]MAC;(7MC8'GJX-&3[U]H@^61LC+C&QK2XY.Z,9*@Q1F02
M&-AD'(.QS'O7VB L<E/#*<R11O/BYH*R(@^!#$(C&(V",_L[HQ\%\,I*9C@Y
ME/"UPZ$, (69$& T5*22::$D_P#Y,+*^-CV;KV-<WP(R%](@^8XV1-W8F-8W
MP:,!?1 (((R"B(     P H:T-&&@ >2E$!8I::"5V]+#&]W3+F@E940?$44<
M+=V*-C!X-&$EABEQQ8V/Q]IH*^T00&M#=T !O3 ')8O1*?>!]'AR.^X%F1 6
M-D$3'.<R)C7.ZD- )61$'P(HQ&8Q&S</[..7P7PRDIV.#F4\+7#H0P A9D0?
M#XHY'-=)&QQ;T+AG'L4200RG,D4;S]YH*R(@^8XV1-W8F-8WP:,!?2(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("U=]^A#[2MHM7??H0_O%!
MM&] B#H$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%5M-Z5FL^J;[=Y+M4U4=R
M>'-IG_1BYY\>>.@Z8"L\K7/B<UDCHW$8#V@$CSY@A<HV5U=PFVBZXHZZY558
MRE>V*)TKOH@/>!R'('&.@5'647&H/T])MGN-FBO]08&T8?Q96@F-K@TD-8,-
MWNP<1RZX*^'QUVAMK-DH:>[7"OMUW9N2,K9N(0\N(R,  =!^*1*[0BHNKZ"^
MW75ENIG/?2Z2BB=+5SPU B>]XSAKCG(;R'3SYJJV"]16[;#1633]XEN%DK:9
MYEC?.9FQRM:]WJO/[C>63](I%=D1<>U[/?Z3:IIJBH+Q*^*KWWLAEPV*-V'#
M)#<;P YX/4A:K7]@U/H=D>JJ#4U=<C#*WTJ&8$,P3C.Z#@-)P,>?5(E=V1<9
MVRWNY3;-;1?[5<ZJB96<'B01$-!#V%WTL;V00.Z]NN-&:DJ:"KOT&IJR.Z4[
M'3QT<'JP-: 3PQSYGS/P2#K*+E.FM4W'5FR.MN0KI**Z4<<D<DL(:=]S6@AQ
M!'+.>V.ZT^CM/:@UGL]M52-35=OFBE+HRPE_$PXY<\Y!)SC S@ 'KGDBNW(N
M<5UXJ-1:^.E*.LFIJ"@@XE;-$[$LS^@9G]D=R1^"T^O8:_9N^CU!8Z^LGM9F
M;%6T-5,Z5I!_::2<CH1[<)!U]%QW:O<[G'>=$5=IN=0*6Y5<1%*7!D9]9A;D
MM&2#O8.<KS[0=+:EL-NGU70ZIKJFX4I$T]/C=A+<C.ZW.  /'.0$B.U(N1ZL
MU+77S8H-26^OGM]28F\6. MP7B3<>,XWAW(P1V7WI[2M]OULTI>W:FK*5T,<
M4CZ5N7,?&,=\C+G ').>OES15NJ])S3[0:/4C;M4LAIX'0FB'T'D@C/7ISSC
M'4!6M<BFK+E3_* MUMENE544+Z1\PA>0UH)8_EAH /3N%9-4VZ]7;5])!4R2
M4FDX('2S305 B=)+V:XYWL#RQ[41>57=8ZG@T['0,<6.JZZI9!#$3S.3ZSO8
M!^87.M+WMM!M?;9+%=YKA8JBF+RR2<S-9(,YW7'KT\>Z\FVZRT@UMI2?YWBU
MM262NXAS@%N W[/4]$A7<D7.]97:+1-):+-;GU3'7:H='Z0XOJ)(6#=WWM',
MN< 1@<^?95+6,[+92P7/1%?J2:\02M+H)Z:J='.TGUMX/8!\,)!W%%KM-U\M
MTL-!75-,^EGJ(6R/@>"#&XCF#E5#;A/7T6@JVNMMQJ*.2$L!$.!OAS@TY.,C
MKV(45T!%QV/1FH-3:2H+BW5%;2UC:9KJ6GA)$> T?3.<N<3S)Z<^BV.RG5UY
MU!HR[P2QMGO]KWH&E[@.*[!W-[P.00?''96(ZBBXM>;<^TZ&FN&I;[6TFKI(
MW3L8*W)$G,AC8VG!'+'0^U6O0UTN6I-D]%<9ZZ6GN#X9=ZHB:TN)8][02"".
M>Z"4BK\J_JC4D%DK+-1Y8ZLN57'3QQG[)(WW>X?B0N2;/+-?]<Z >7:EK:%[
M*EY9(UQ>979Y[YR#@=  ?'KVR;0],T]+K[0L51/45%362MCJJ@R.#I"TL&1S
M]7J>GBD2NNZSLDFHM.5EKAK9:%\[<":/J/:,C(\E[;+1.MMII**2HDJ701-C
M,TGTGX'4JA;5:.HT]LYK'V.YUM(("#CB;Y?DX.7.];OV*]M?JEVF-DU)>9&F
MIJ6TL+8VO=].1V ,GWY/L07U0]N^QS<D9&,@X(]BYW5Z/N%QTH^L?=KC)J22
M#C1R1U)BC;(1D,#1ZH;T'/XK=:6AU'7:-AAU#,ZVWH L=+!N/=@=''J,GOC\
M%%9-GNF)M)V::AJ+I/<G25#YQ)*,;H=CU1S/AD^9*LZY;L'JZ^];/JV2LN-2
MZKDK96BH)#WM]5G3>!'X*N;.**_ZNH]1T-7J*L@IXK@YDM0PYF>1R#6GHQO<
MX5B.ZHN*Z-N=YT7M*&C[S<);E;ZQN]2SSGU@<$CF2? @CQ5CK+9=+AJZ\5>K
MJE]OTQ3,#*(QU@A8_F,N<0<Y]N.J0='1<FV0WN:HU7J>R07.>X6BE#)**:=V
M\]K3VR1S',<SX>:\D!OTFVBY6>*^5#H!1AW$E:"8VN#2=UHPW>YX!(Y>!2%=
MD6AU5J6FL#[5#*0ZIN-;%20Q]SO/:USO<'?DN</@KM"[4[#2T]XN%PM]Y#HY
M(ZV7B%KL]1@ #J/Q7GVT6*C_ *=Z)G^>XMPN+8IG<1V=T/B #?L_2/1(.VHN
M9[1:UFBK':::GDK(K34UP;6U E<^5D9Z@..3S\O#DO?:K72U=QLEVTI=YZFV
M,D<:F(59D8X%A )!.00<<OP2*OJ(B@(B("(B B(@(B("(B B(@(B("(B B(@
M\MS^HR^S^:6OZC%[/YI=/J$OL'YI:OJ$7L_F@FX?5S[0M:>JV5P^K^\+6+;A
MXSY>@[J<(BZ<H12,*$!2@4<LH)">*@*4%2VJW">V:$NL](XME='P@\=6AW(G
MX%4_8I;*&];,KA;ZMA='454C)L'#OHMP0?@NE:CM$-]L=;;*D[L=3&6;PZM/
M9P]AP5R+0UCUKH6\5-/3VEMRMTY&]NSM8TD=' D^J?<I]7'0Z33%!I715VH+
M7QC$Z":1SIG[SBXL/D!V'9<C^3_:*2Z7JZOKX63QPPM 8\9&7$C./9GXKLM3
M'>YM,7(54$4MQJHW,BIHG@-A#FX +CC.#DD_!4/9!I+46D;O5NN=N8::K8UA
M?'4,/#P2<D9Y]>R"Y733]KT]H>_4]FI&4L4E-+(]K23EVX1GF3X+FWR;?Z_4
M6?[N'\WKKFLHJRITW74MMI#55%3$Z%K>(U@;O C>)/@N?[&])7_25QKQ=:!@
MIZQC!Q&3L=N%N\>8SDYRGT^*?L=_6U6^RH_B6Y^4C<)^-9K>UV*?=?.X?:=G
M=&?8,_$J+3I/5.FMI%7=*"TMKJ::2;<?QFL;NO)()[C'+LK5M5T17:LL=!+3
MNB-WI&^LW.&R9 W@">G,9&5/B_7@UCI'5.KK?;6#^C])'2D20/@GFSC'(#,?
M(=%Y]NT=1#L_L\5;(V2J9-&V5[>CG!A!(]ZV.C:C7-/9X++5V:.%\31"RX2R
MM(C8!@$L!.\1RPL^UO3EZU%8[?;;73BI?$\22U$DC&;Q#<=,]3G/@JCR[,M'
M6:Z[.J+]+T4=6:DF4N<YP<,.( #@01CGT\5J_E%PQTVG;%!"P,BCF<UK6CD
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M:MJI1#3"-Q+Y!N[H.\!G/3J%O]L-Q@J]&S6:WR1U5RNSF04T,1WR[UP2[ [
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M#!!Y'LL6LMH=%I>]6ZW5=#5O=62!G'(W8V@G!.3UQG. $%V142V[0GUEZN-
M[3EWB%+!Z0QY8"96Y&,#/+.\#U\<X7GL&T^#4%JFJK+9+A5U#93&VE86[VZ
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M:YK=,"CJF5-- )S.YHX;@<=/_$/Q069$1 1%7M;:LI-(VE]?74U9/&WM!%O
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MN]CEG'Q7MNVF7Q:'DTYIOT:EADIW4I=.'.PQS2USN75W/J4&EV!,#=F=NPT
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M3.I'.,CHVL ^ER ;T'Q6[O\ L[N3]3T6H--WH6^XQ4[*:7B1[['M:W=Z8YY
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M21QF&*<MD&&G/5O<\U\[.=+7W1^G9+2:BV53&ETD+\2-.^XCD[RZ]/)!H]C
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M95BVF7^Z1;/!=;&^&&*>%CI9"X\1C7[H 9RQGUCDDC&.7E3/E%_U6GO^&_\
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M5UGJ+A;*6K8R&1T1BG#6O<X ' PXCOW*Q:9UI27Z_P!TL\=#74E;;@#,*AK
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MT% S:51U[FBPTU6Z/F<#<!E:<?\ =#4%X_TD4+[1/=Z>TW>>T0N(=6,B9N$
MX+@"\.+?/"M5CNM)>[337*W2<2EJ&;['8P<>8\5S&:2MJMFE8-.TL-KTQ'12
M<(U ,D\[,'F!G#0?$Y/DMYL#_579O;/_ ,YZ#0?)Y^EJ_P#S(_\ 4KM)K6D?
M=ZZVVN@K[I44./2#2M86QDY]7+G#GR/(*D_)Y^EK#_,C_P!2VVGIH9+S?X-
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M:S>M/7&V"3A&K@?"'_9R,945SJT2MBV?W&WZ-HGRV"*FJ!^D:^3^M]4[Q8P
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M(SX'\P%:] 7.>\Z+LUPK/K,],UTAQC>=T)QYXS[T5O9'LCC<^1S6,:,N<XX
M'B2JY_3K38K(Z9]UCC?*[=C?(Q[(WG[LA :?<55]M]SJ*>FL%L@>UD-RK1'/
MO$@.:T@[IQSP2>>%ZM;:6U!JS3K[351V.",EKHY&.D)C(Z$#'N1%KU1?*:QV
MN2HJ'R-<YCN$60OERX-)&=T' \SR7--@^H:";3,U-<7RR7"OKY'2 TTDC7EP
M:/6?NEOQ*OUNH*ZUZ!=0W6J;5U=/1OC?,T'#L-..ODJE\F[]7/\ ^F2_DU/@
MKNKKM9;?K+2%LL\<E/::2KDGGA92RM!DY\P"W+L<^F>JZI'#8+_)2WUU.R26
MA+N%4SQ/A=%@<SAX!Q[>2HVTK];>A/WG_P UL-MURJZ6@L-!2R-9'<;C'!.'
M'#7LSS:['/=/+..R"RG76FQ61TS[K%&^1VZQ\C'LB>?NR$;A]Q5BDD9'&Z21
M[6QM&2YQP /'*Y_K32]_U3IN2SU$=B@C.Z8Y&&0F(M/(M&/#E[U6M??I&QZ-
MTGIB[U_&-75LIJRI9R:^$'Z))Y]"WX(.AR:YTW'51P27:!AD=N,E<UPB<? 2
MXW#\5K=JFLV:3TU/+3MEDKYXW-IW,C+FL)Y![G8(&"<X/5;35^DZ'4FE9+%+
M_JU,0SA.B:,Q%I&,#V#'L)5.VQV\6G8V;>V:2<4K8(1+)])P;RR?@F"U[.[[
M37;35LCBFJ):J&B@X[I89&Y=N#)WG !W//,$JT+2Z'_L7I__ "^G_P"6U;I1
M1$1 1$0$1$!$1 1$0$1$!$1 1$0%K+Y]"']XK9K5WWZ$/[Q0;0= B-Z!$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0<K@TWK72=UN<VEY[?=*"OJ75)@K<L>QSB2?6
MSSZ]<]NBW]);M47YK8]4NMU%;O\ >T='O/=/TY.>3R;X@=5=45H    # '9$
M10$1$%'VMVJ\:@TQ4V6S4#)C4[A,\D[6-9A^<8/,GD/BMOH."XT6FJ*AN]&V
MEJ*6)L1W91(U^.X(Z>]6%$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$'EN?U&7V?S2U_48O9_-+G]1E]G\TM7U"+V?S03</J_O"UBV=P^K^\+6>U;
M?^?C/EZ=D"=%/+GA=.10.:E0@>U2!R1 @@*5 ZH@+#6TT-=1STM2P/@F88WM
M/=I&"%FPB#E&G]G6HM,7>L_H[>Z2"V53@'<6,OE:T$XP",;PR>>5CTQLJN5G
MU0Z\"]QL>V5[V!D>^YS7$\G%W<@\^2ZVG)2+7/=IVSANKIX*VAJ8Z2XQ-W"]
M[26R-&<9QS!!/7FO5IK3NJ6"FAU-?8*FBI]TMBI6EKI"TY;OOP"0,#V]U>%*
ML12Y[)J6CU)<[C9*^WFCK'-<:.J:[&\&!I=O 9!R.@[+#H;14^GI;O<:B>F?
M>+BYSB8V'@Q9)=@#ERR?+HKT42#D]EV876UZM.H&7NEDJG3/FD8:4AKM\DN'
MTN755;6MVU39MIURJ;/O5<IC#6-CB$P9%V!:,[IR/)?H#NJ:=$RTE[N%TL-Z
MJ+=/7.WYV&%LS'.R3G#NG7Q4G_%KE\6U'6MLE9/>K:32;P#A)2.AR.X#O%7W
M7VC*K:!!:ZF&X145(R+BLC="7/R\ G)#L=,+;5.D*RZL;!J*_5%PHL@NIHZ=
MD#),'EO%O,CWA6YC6L8UK &M:,  8 3,_P"CFUVV?W:YZ*H-.2WBD$%*YI$H
MIG;S@T8:/I=LE6#9QIFLTI9GVVJK8:N$/+XG,B+",]0>9SV_%6KDBL1*CNG7
M.4[('O12$'1!"!3U4>*"?-0/%2H'- 3\TYJ4&UHOJS%F6&C^K,698;ZUSP1$
M441$0$1$!$1 1$0$1$!$1 1$0$1$'*'T]V=MG9?S8[@+4RD-+QMT$YP[UMW.
M<<U\[6[==KMJ33,]JL];5PVVJ;43/8UH& YIP,D9. NLHK4CGFV"*X7[0<]M
MM-JK:BJK#&X-W0WAAKPX[V3U]7IYK0ZUT_?KWH?2SK;;YVUMH=$Z:@G(:9"Q
MH'+G@\Q\"NPHE5QK:;0ZPUEI:D=%8&4A@JF2^ANF#YGD C>SR:&C/3JNK6*6
MMGMD,ESI64E2X9,#7[_#'@7="?9R7O50U_6:NHG6]^CZ"DKF%Y%2R9V"!RQU
M(Y=>G-!2YM'@[<G>BR8MLD++I5TX/JF0/(;O#I]+UA[UV-5S1MFJZ%E9<+TZ
M%]YN+Q)4&('=C &&QMSSPWG\58T,:K5EOGNNF+K;Z23AU%33211N)P XM(&3
MX+FFD*;6$.@WZ6?IZ.CDBIY8?39IVEC@[>Z,',NY^.,]5V!%!S#8Y2W[3>CY
M:*]6>2%E,][HVQN#Y9B2.C0< =>9/@OC8?1733]FN%!>K16TLCZE]0QY:'-<
MT@<N1//DNI(K1R?2%'=:3:SJ&\U=EKX;=<8VQPRN:TX(W1S .0#@J=8TEVJ=
MJVGKS1V2OJ+?;F.CFD:UHR27<V@G)'-=70]$J1QK:)4U$&VO1M11TCZJ9M*]
MP@!#7.&),@9P,XSU[JR:TI;KK:@AL4%MJ:"W5$C'UU55;K2UC2'!C6@DDD@<
M^BTVHJ._5VU>PW^#3M>;;;HGQ/)DAWW9#QD#?Z>L%U>!YDA8]T;XRYH)8_&\
MWR."1GWH*%M?ME76:%=9;%;9ZJ5^XR-D( ;&QOB2?(<E[[)-64FSFFIY;57>
MG04;:8TVX-XO#,<CG&//*N***YOL3H[C8='.MMYME725,,LDN'-#@]IQT(/7
MR6JT[!>:?:S=KY56"X0VRLBX39"UKG#&,$M!SSPNNHK4CY+6S1%KV L>W!:\
M=0>Q"Y%LJTHZVZXU"1,9K7;:E[:)H.6LDD:"_P!X;NM]ZL6KZW7D6IH:?3%O
MH);3)$&F>=P^;><Y<[F#RY<@"K+I*R-L-G;2F4SU#WNGJ)C_ +R5QRYWES0;
MA5;:E^KV_?X5RM*J>TV.OK-)7&W6NV5%=4U<)C9PW,:UIR/I%SA^&5,56=D%
MXK:39I:XQ9:VH+(Y. Z$M+91ON/4GU>?+FMWL]TO-8S=KU=FAUYNLKIYF1^M
MPFDY$8\2.ZG9%37*UZ-H;1=[944531L<TN>YCF/R]QY%KB>_<*[*HY1L^H[M
M1;2=47*OLM=34-U>#!*\-(&Z[EO '(R#E8--T.JM)ZQU.8+ ;G37:JX\-5Z0
MUC6#><1O$\\ .Z>2Z\B4<DT'9=5V?:1J*IKK= ^EN3VO?6!^[&,$GU&]3U(Y
MXZ+R7?36J=&ZYK+[HRD;<+=<W\2JHP0"#DDCGYDD$=,D+LR)2*=I0ZFN]P9<
MM2TL5KIH&D4]%')O.<X\B^0].0Z#S5*O^FM6Z2UO6W_1,#*ZBN)WZBBR  [O
MD$COS!'/F0NS(E6*5I3^E5YN$-QU-3QVFEIP>%0PORZ1Y!&](<] #R'O6A?9
M;YIK:C=-1TUK?=K;<XA&YM,]HEAP&_LN(!YM\>ZZFB4<[N=CN6M]16JJNU"^
MVV.UR\=M-4.!EJ9,<B0TD- ([GGDK%M!TE<SJNUZNTQ%'-<:/U:BF<_=](9S
M'(GEG!(^'@NDHE'/=6LO&MK!^A:>T5EJ;4N;Z54599B-@.2&AKB7$_!7FUT,
M%LMU+0T;-RFIHFQ1MZX:T8'Y+THH*;M5T<[6.FQ2TLK(;A!()J:5Y( /<9'3
M(_DJCIZ[;464D5IJ;'3&<#ABY5$@PT=-YP!]8CKTYKL"*TBNUM/-:-'RT<4=
M9<ZKT=[!N^L^1[@>9). "3[ JIL-H;EI_2QM5ZM=92U/I+Y&N<T%A:0.>0>7
M0KIJ*#D>OJ>]7#:-IRY6ZPU\]#:W_.RX:-[)Y[H)R<!6;:7I9VN=*""D<^DK
MX)1/3.F:6$/&1@]P"._L*NR)1Q_3MUVHPT<5HJ;'3.F8.&+C42#  Y!S@#ZQ
M \N:WVN]G\E_T-3VN*L?)=*-_'BJ9G',DG,NR>P))]G+P70D5I')-/7?:8*"
M&TU-A@;5,'"-RJ)1N #]H@'F?S5@VBZ6K;ILUFLUN>ZJK(V,<'2N]:9S3DDD
M_M$Y/O5[1**GLWDO)T_14UYM?Z-;1TT=,UCY ]\A:T#>Y<@.73JK8B* B(@(
MB("(B B(@(B("(B B(@(B("UE\^A#^\5LUK+Y]"']XH-F.@1!T"("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B\DERHHZYE$^K@;5O!<V
M$O&^0!DG'D$'K7@O-YMUEI75-UK8*6$?M2.QGV#J5AMVHK-<JN2EM]THZFIC
M.'Q13-<X>X%<]^4;04CM!RUKJ:$UC)XF-GW!OAN3RWNN.9Y*X.JQ2,FB9)&X
M.8]H<TCN#T7TO#9WM98Z%SW!K13QDDG 'JA>2CU58:VK;2TEXH9JAW2-DS23
M[.:@W*(M1+J:R15XHI+M1-JR=T1&9N]GPQE!MT3( SD8ZY6FAU389JX445XH
M7U9.!$)F[Q/LR@]=WN]OLU*:BZ5D%+"/VI7@9]@[^Y>R-[9(VOC.\QP#@?$%
M<L^490TLFA'UCZ:)U7'/&UDQ8-]H];EGKCR5X;J"T6NDMU/<KG24L\L+.''+
M*&N=R'0%!O44,<'M#F$.:1D$="%JKGJ2RVN<0W*ZT=-*?V)90T^"#;(L=//%
M4PMEIY&2Q.&6O8<@^]9$!%X;K=[?:8FR7.MIZ1CN0,SPW/Q7W;;G0W2E])MU
M7!54_P#>1/#A\0@RUE5!14[YZN9D,+/I/>< +5VG5=CNU:^CM]R@EJV=8>;7
M_ X)7-M=:OMU5M)TA2-N5))::>1]14G?!8V0!P;O'MC^:LNHYM'\>GU:^IHG
M7*"*7T.H$^Z)7-:1N\CAV,@>658BQWG5ECLTO#N=S@@>" 0<G=)Z;V <>];6
MCJH*RFCJ*29DT$@WF/8[((]JY3L;N5ENNB?T==ZREJ;C<YI75,$L@,DQ<3U'
M7HKW01:?T/98J&.>"WT+"7,;--W)R>;CGJ45847FMUPI+E3"HM]3#4P$X$D3
MPX9]H6.Z7:WVJ(27.MIZ5AZ&5X;GXJ#VHO'072AN%&ZKH:R"HIFYS+&\.:,=
M>85"M^T^TUNNZNA_2$$%II:3E-*=P33%XS@GJ /YH.DHOF-[9(VOC<',< YI
M'0@KZ0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!Y;G]1E]
M@_-+7]1C]_YI=/J,OL'YI:_J,7L_F@FX?5_>%K%L[ASIS[0M8.BUX>,^7IV*
M>Y @*[<G=$3N@#NBGLHZH'12H!0(&>N$[(.0/@G) 0(B"<(%"()ZH.I494]T
M$! I4()11^2G"" G-3W4?D@#\$4]N2?D@A3V4(@=$"D=/:H03XJ /!.83S03
MW0'X(@0;6B^K,698:+ZLQ9EAOK7/!$111$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%K+Y]"']XK9
MK5WWZ$/[Q0;0= B#H$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 7$KSI^AGV]T]&QKX(*J@<^=L+BTR>J<C(YC(Y'"[:N.ZCK)*'Y0%LF
MCI9JK_4"US(1EP:0[+@.^.N%<36HVT:.H=)4%NU)I2']&U-).UC^"X@'/T3C
MQR/?GFK!MTJC6[((JIS2'324\A!&,$\U[]H%+6Z[90V&W4=;2V]TS9ZVLJJ=
MT36L:>36AP!<X\^73HL.W>EJ*K0K+/:;=7UE098BQE-2OE#6-SU+1@)@W>L+
M*;_LYBH3=A:H701.EJ",C< !(/,<C[5SS:W66^79] ZP6>3T2CEAX5T$386
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M&QCHX*&1Y,CR2,R2# QTP![53^'=].;8[M<FV&X7&CNE.R.*6D9EK#EOTW'
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M0(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M=.>JV&P!ACJ-9,<]TA;<BTO?C+L;W,X[KXV8?K@U]^^/XT'7QTY]5RKY1_\
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MIYV"$@MF;*3*?+)SR\L8\%>/:I2#2V[3-KH=/NLL5.7V]S"Q[)'EQ>#UR?\
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M$ ]\K"-GE92ZZK[Y:;[-14EQ'^MP,C:7OYY(:XCU?;C(Y\UT1$I$-:&M#1T
MP%1-J.CKKK.EIJ*FN5)14<$K:@;T+GO,@#@.><8PX]E?$4%1U98;WJ'2$UG?
M6V^":I;PYYFPO(W<@^J-[D>7?*\=HTM?K;H3^CD=PMSRV)U.RH,#^4;@[.1O
M=>85Z1!2-G^E[UI+3OZ)%=;ZJ./>="\PO:0YQSZWK<QU7DT5HR^:<U!=+@^Y
M6^HBN4O$GB%.]I:<_LG>_-="1*.;R:'OSMHK-6?I2W"9K."*?T=^[N;I;C.]
MG//.5EU1HN]WG6MKO\-SH(1;#_J\+H'NW@3SWCO=?8NAHK13-HFBWZRLM'$^
ML%)<J20313,;E@?RSZIYXY<N:QW'25YJK5;VC44IN]-5MJW5;X@6DACV[@8,
M -]97=%!3+CI2X:B?;VZIK*.:FHYA/PJ2%T?%>.F\7./+R"N:(@JFT31%OUM
M:HZ:N<^*> EU/.SJQQZY'<' R/)5S3^S>[POA@U#JJLN5JA(+:(9:U^#D!YR
M21GLNG(E%/VC::N>J;'):*"MHZ.BE#>(Z2%SW^J<@#!  Y!>O1]IO-DL4-MK
M*NAJA30<.&1D3FDD=-X9Z>Q65$'-[9HK45#KRXZH_2MLEJ*V+@R0&F>&!H#0
M,'>SD;C?Q7MVFZ/NNL[;2T$5PHZ2GBD;,\F%SW.> 1RY\AS5[16BN5FFQ?=)
MFS:G,%27-#3)3M+,$#DX9)PY4JQ[+[[;&BWMUE6LL+2<4T#-U^"<XWN>._1=
M812BE:ZT#3:BL%NH+?4&VRVU[7T<C!O"/ P ?+H?'DM-J39M=-16"*"[ZFGJ
MKI%*V2.=T3611@9SAC<9)Y<SD\ETY$HK=7I.GNNDS9+_ %$UQWV^O4/PU^_V
M<T 8;CL,?%4VQ[,;[;FBW/UC6?H $@4L3=QY8?V=[MGOCS75D2C!04D%!1PT
ME)&(X(6!C&#L N??H*W77;0^YP1N$UJI&^D/QZKIG AH]H8?R6XVAZ0JM51T
M!H+W56F:ED+]^$G#@?($<_-;G2UAI]/6QM+!)+/*X[\U1,XNDF?W<XE4;=$1
M0%J[[]"']XK:+5WWZ$/M*#:-Z!$'0(@(B("(B B(@(B(.9Z^T'?M67:VUOZ7
MH*+]'/,E,(Z=Y<';P())=U]4+>.HM=%I O-@:2,9%!)D?_\ 17!$HJ>BM-7"
MU/NM3J"YMNM?7N;OR"/<:&-! 8&] .96MM6B+AI>X5C](7."GM]6_BR459"9
M6,=XL(<".PYY5^1!7;%IH6VMN-UFF%7?*T 25+V[K6@ !K&M'1HQ[?-5RR:+
MOUNU[<-327.VRR5[!%-"*=X 8-T#=.]UPP=<KHJ(.=WW1E^N>N;;J,7.VQNM
MP+((#3O(+3O9WCO=<.[+7ZWM=7J77=MIK%>G4%ZME&Z6:6,!\<0>=W&[UWCD
M]?V5U1474^S\7"_.OMBNU39;R]H9)-"-]DH'+UF'D>@^"N(T0TMM,I,R0ZVH
MY@PD[L]. UP\_5*W5ST[3[2M!VUU[:*>M?&)F2P=(Y,$$C/5I\/8ONWZ-O<Q
M#-3:MK+E2YR:>&%M.U_DXM]8CR!"O$4;(8F1Q,:R-@#6M:,!H'0 (.7V+9G=
MX@RDO^K*VOL\9!;1LRP/P>0<<DX\@MOM/T;<M8VV"V4M=1T5#%(V7UH7.>7-
M! '(@ <_!7M$JQX+'%7P6]D5VEIIJEGJ[].PL:0!RY$GGU7O1%!0+SH&KFUW
M_22RWN2W2SL$54P1->7-  ]3(P#@#KGFO'J?0%XN^I[-=J:ZT=/^B2/1VOA>
M]S\.SZYWN9/DNEHK2/'-1BOM3Z2ZLBF$T?#G:P$-=D<\9YX7+:+9)=;)72#2
M^K*RW6V5V\^'=WG?'IGSPNO(H*E7Z&H:K0]5ILSU'#J/6DJ7NWI7R;P=ON)Z
MG('NY+00[.;O4Z6GLE[U1/54K8.!2QQQ-C8P 8:7X]9^,#D3A=,1**IHO2<U
MCTM^A[E<Y;@#$81EH:R-F"-UH]_4Y*U.B-#7;2U-+2LOWI5#$XOHZ5\(:QKC
MWD(]9WL! 7042CGVA-&WO3%ZO%;+<K?4Q76H-341B![2UQ+CZAWOO=\K!'HF
M_LVA/U7^D[9QW1<$P>COW=S&.N]G/)=(16CGVN=&WO4M\L]?#<K?2MM4QFIV
MF![BXDM)WO6Z>J.F%Z=>[/Z?6=OI7U\PIKS3-Q'54X( YY(P>WORKPBE(YSI
MG9]=8*BG=JG4M5>*:E>'PTI!;'O#H79R78[+)M"T3=]5W>UU,%RHJ6GMLPFA
M8Z!SG.<"#ZQWARY=ET)%:11MH&EKYJ[3HM+J^W4L<A:Z=[8'N+BTYPWUN0Z+
MT7'2$][T(=/7JJAWVQL8R>F86C+!ZI(<3X<U<44%7T+IVX6&W10W:\27*6&)
ML$0#!'''&,8 :.IY#F22K.YH<TM< 6D8(/<*40<QH]FURT]>:FHT7J$VR@JG
M[\M'-")F@Y/T<^ Z=_:O19]F]50ZXJ]12ZCK9)IFL:<,9OR -:'!Y+<8);RW
M0,!=&16D<^U+H*OJ-7?TBTS>C:*^6,15&81*V0#R/L'P7Q<-FTE9JBTWIU^K
M&U=%'AT^ZTRROR>?,;H&#C ;C"Z(B4CG.IM$7V[ZMM-[AN]%$^U@B!KX'.+Q
MGF7X(&3Y *U:FL U+I6IM%TD#'5$8#Y(1@->""" <\LCNMXB@YG2;.;O+IBH
ML=YU3455"(3#30Q1-C:P8PW?(&\X#D<9PM]H/24^G=+FT7"Z2W!A88F^J&-C
M8<\FCK^T>9)[>"MR*T<_V?Z"N&E'OIW7Z6IM,4CI::D$89AQ[O=U/L&!E8K=
MHS4%+KZJU0^Z6V2:IB$,D'H[PT,  &#O9R-T+HJ)13-6Z'9=[W27ZU5K[;?:
M4;K)VMWF2-^R]O<=>F.166;2]9>ZBBDU95TM7!1R<6.EI871QR/QR<_+B3CJ
M!T\<JW(H*#M(T;=]734+:>XT5)2T<PGC:^!SWN<,?2.\.7L7HUMIJ^:HTN;,
M^OMU.)@T3R-@><[KLC=&]RZ#KE79$&DT9;*ZS6"FMUQGIJAU,P1QR0,<S+1X
M@D\UL;M0Q7.V5=#4;PBJ(G1.+3@@$8R%ZD0479UHJX:5I_1*R^25M! YQI:9
ML0C:S>/,N/5QYGEG'/IT7Q#H6JLFHJR[:1N4=&*UV]4T=5$987'KO-P00<^?
M<J^HE(KMFTV8+Y-?+K4-K+M)$(6O:S<C@C'5K&Y/7D222?8K$B(.>ZTT7>M0
MZGM-UAN=!3QVN7B4\3H'.+N8/K'>\NRG:3HR\:TME'0NN-#21Q.$LA;"YQ<_
MR];D/Q7045I%3OMEOMVTC/9WUEM9/4PNIYIA"\C<(QEHWNO58M&V"^Z;TM':
M!76VH=3-W::4P/&,N).^-[GU[85Q10<]V=:+NNCHKE%47&CK*6LD=42;L+F/
M#R,<CG&%4]A5/=G6_4$UIK:>,&XO:Z&IB+V9P/6!!!![>')=BNT59/02Q6V>
M&GJ'C DFB,C6CV!PY^]4[9KHBYZ,=51OO%-6T=5*9Y6>B%C]\C&6NWR!V[%6
MHV^GM+"VW2X7JMG;67RM&Z^<LW61L'1C&]F\AXD^*KU#HK4-+KZJU3^E;8^>
MIC$,D!IG[H8-WD#O9SAHYKHZ**T^K-.4&J;++;+LQSH'D.#F'#F.'1P\QE:&
MV:;U+0VD6<:AIW6]D?!CG-*?261XP!O;V[D#OA79$&MTY9*'3UH@MMKBX5-"
M.0)R23S))[DE:;6FB:#5-QLM;5X$MNJ!*>61+'U+#Y9#3\?%6M$!<JO6R>>/
M44]XT??)K)/49,K&MWFY)YXQCD? Y75405S1^EQ8633U==47*ZU  GK*AV7.
M Z- [-'@K&B("(B B(@(B("(B#RW3ZA+[!^:6KZA%[/YI<_J,OL'YI:_J,7L
M_F@FX?5_>%K%L[A]7/M"UJUX>,^7J.V$4XYIA=N10 B()4>84H.Z".2D810@
M=\*5K[]455):*NJH>"9H(W2ALP):[ )QR.1TZ\_8J3LKV@5>LZRX0U=%!3"F
MC:]IB<3G)(YY2CHN41!T5$CNBCN@4!$'DGCX()480+S4MPIJFJJJ:GE;)-2N
M:V4#]@D9 SXH/4,>*+G5\U/JFEVAT5KH[3OVB21C72[A=O,)&\[>Z-QSY>2Z
M*$P1V4J/@B >ZE0@Z()491$#L@3Q4CH@* B=D!2%!1!MJ+ZLQ9EAHOJS%F6&
M^M<\$1%%$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1>*\W6DLU!)6W"1
MT=/&,N<UCGX]S02O!H[4]#JRTNN-K;,*83.A!E:&EQ;CF!D\N??F@WB(H<0U
MI<>@&2@E%5[3KJS7;5$UAM[JB6LAC,DCC$6,;@CEZV#GF.@PK0@(B("(B B\
M-[NU)9;=+77&1\=/&,N<V-SSTST:">R\.CM34.K+2ZY6L3"F$KH@96AI<6]P
M,GES0;Q$5=9J^VNUH[3 %1^D6P<?>,?S9'AG/7'/ICS06)%5+UKZRVF_45FG
M=425]5,V%K(XCAI)QDN.!C/AE;#66IJ+2=CENER9/) QS6;L# YQ).!U('Q*
M#=HL%!515U#3U=.289XVR,)&#@C(Y+.@(B("(B B+YD>R.-SY'-8QH+G.<<
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MNB*K:4UW9=4W:OH+1)-(^D8R0R.CW62-=W:>O+(Z@>65:4!$1 1$0$1$!$1
M1$0$1$!$7BO-TI+/;Y:ZX2.CIHAE[FL<\CW-!*#VHM#HS55!JZV2U]I;.*:.
M9T.96AI<1CF!D\N??!6^0$1Q#02>@YJK6C75GN^J);#;W5$M7%$97O,18QH&
M.7K8.>8[806E$1 1$0$1:Z_7FBL5MEKKD][*>,$N+(W//P:"@V*+3:2U%1ZI
ML[;G;6S"F>]S&\5H:3@XSC)Y+<H"*NT>K[;5ZSK=,0BH_2-)")Y'%F(\'=Y
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MG=,RJ+@,]P-P94:EVG55BUB+%/9XI-Z2-K9FU1YM?C!QN=>?14.J_P!H-O\
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M#VHB#JJ-M1_5F+,L-']68LR\^^M<\$1%%$1$!$1 1$0$1$!$1 1$0$1$!$1
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M?%/74]SB87OCJ(@T 8SU!/94NRPQP_*)O)B8&\2WA[L=W'<R?P7Q1_[25?\
MX%O_ "VJHNMUUU;;5J:BL=?35\5762MBIWF$<.0D@ AV>F2LUZUS8+/=(+;5
MUP].FD;$(6-+B">Y/0#WJB;7/UF[/O\ &,_YK5BV[015.L- 0S,WHY*J5KQX
MC>AY)!>[!KZP7V\UMLM]4]T]*PR/<]FZQS0<%S2>H6&7:'9VTLU9##<*BV0O
M+)*Z&F+H!@X)WL\P#W 6UO%FLHH;A/64U/3,EIG0U%2QH8\18YC> R  /P5!
MHGG_ $<5M#I&CX>FX*:815U:\N?/S<7%C .F]GF<=>0[(.ASW"ENFEZBNM\[
M9Z6>F>^.1O1PW2N0[(-9V;2>S*)UVG?Q7U4I9!$W?D<,M&<>"M&R,G_0Y%DY
MQ!-U]Z\'R<[=1R: ,\M+!)-)4R,<]S XEHQRR>WD@O\ I75=GU1;WU=GJVRQ
MQ\I&N&ZZ,_>'9>"UZKTU=-6.H;;)#4W40$NGCB!PP'Z)?U[].BH=@ML>GOE!
M55%:&"*BK:!TTL+.369Y].WK ?\ B7OI6M;\HFLW6@9MK2<#J<!(//MB_6#H
M/_%M_C"O6N-3:<L= ^/4LL$D;P#Z*^,2F09Y>H>O,=U1ML7ZP=!_XMO\86U^
M4.UIV95A(!+9X<$CIZX0;W6VJ7V+1TETMM!4U1=3\2+AL]2(%N0Y_@!R5?V?
MZP-+H"WU%=:[Q-PX'2RU$=,',?EQ)(.]SZK::P_4U7_Y0/\ EA>G9" =F=@!
M (--S'_>*?!ZM%:TMVL(IY;/#6>CPG==+-&&-WN7JCF3GGE9#JRE&JOZ/^A7
M UVYQ-X0CA\/.-_>STRJ#HW<T'M0NFG)#P;3=AZ91%W(!_=H_P#F'_="MV@V
M?I2XWC4LN]FLF--39Z"GB.Z"/WB"Y!<EJ[S?J&TR00U+Y'U<^>#30L,DLN.N
MZT>'CT6T7)MGU>^[;8=935V'34;6TU."/ZN,.(P/;R)45<[5K:TU]W_14OI-
M!<SS;35T1B>\>+>Q5=VXWJ6CT5=**&DK29H@UU2V+,0:3@@NSR/N6K^492BG
ML%JOM(>%<J&M8V*5HY@.!/OYM'XK:[9)9)]DE5+41F.62.)SV$_1)(R%<1M=
M U\-TTQ;[?46BM9 *1@<ZJIP(9!@<AS.?@K7-+3T%(Z29\5/31-YN)#6L'\@
MM9HG^R-G_P +'_"%NE%4O_2;I@P7*>.N=)#0%HD>R,D/)S@,[D\BMK:]76>X
MZ99?H*DMMSN6](TAV]G=W<=SGE@+G>RFWTD^T/7;YJ>.0MJ-P!S<@!Q=O<NG
M/^97IU^746O=$62UNIZ"B+Y9F,X68FR8=@E@(!YD]^I51;':_M%/<J:BN<5?
M;'U)Q ^MIS$R7V$^[KCJM[>;Q26ED/I)>Z6=_#AAB;O22NQG#1WY E4_6>A;
MKJZV1T5VOE((HY!*U\-!NN:1GH2\^*\FOM-ZA;1Z<NFF:GTVZV5FYN2$?ZPT
MM#2[F<$G'CW*"VT&JJ.KO$-K?3UU+7RQNE;#4P[AW6XR<Y(/4="5XSM"TU^E
MYK<VY1NEAB=-*]H^;C:WKEWC[,JLZ+UY0ZBU1345_MDMIU+2,>R-C_HO#@-Y
MH./(''EU6NK:"EK/E%,CJH(Y8_T:)"QS<@N'0D=T@MFGMJ&F;[=A;:6JEAJG
M'$8J(^&)#]TJTWBZT5GI/2;C.V&(N#&\B2]QZ-:!S)/@%R7Y1UEIH=/V^]T<
M3(*ZEJ6QA\;0UQ:02.?D6\O:EYN,]?MGTG07'(IX:1E0V(\V\9P=ZWMY)!?#
MKRU07"GI+I#7VM]0=V!]=3F)DI\ [IGIUQU"]NJ=7673%-Q;Q6LB);O-C'K/
M>/(+2[:;9#<=G%X,K 9*:+TB)_=KFD'E[1D>]434=747+Y,\%5<,OJ=V(;S^
M9PVHW0?_  @?%(+[>-IVG+5' ^>:HE$K&2.X$1?P@X C?QR:<'HK32W6AJK0
MVZ0U,;J!T7&XV<-# ,DGV*K1VZC9L@?3LIHFPOL^^YH;])W!SO'Q.>>57MEU
ML??]A#+8)C$^JAJ8&R#]DF1X&?+Q\D%MK-=6ZCH'U]327..VAH>VK-,>$\'H
M0<YP>6"0!S"L-QKJ:VT4M773-AIXAESW=O\ U/DN*1ZQNFFK:S3.TJQO-L='
MZ(*Z'#FO8!@'P/(9\?+*WVU"ZR5.IM!4U!61-HZVI=.V5S=^,N ;N$C(R/6\
M4A5GGV@V>CKJ:FND5PMK:D[L,]93&..0^1/NZXZJWCF,CHJ#K'1-VU;:/T==
MKW1\#?$@=%0%KP1X$O/BK?8*-]NLE!1R53JM]/ R(SNZR8 &\?:HKWHB("(B
M B(@(B("(B B(@(B("(B B(@+5WWZ$/[Q6T6KOO]7#^\@V@Z!$'0(@(B("(B
M B(@(B("(B M!==54=!//#%2U]PE@_KFT-.9>%RSAQZ X[=5L;]424ECN-3#
M_6PTTDC/:&DC\ES38V+U<=%1U=%=Z2,S3R/F$U(97F0NYESM\9/3LJ+]8-46
MS4%HEN-FF=5Q19#XV-^<:X#.Z6GNN70:CDEVY3U4EKNSVQ6SAQTW S*S)!+M
MW/(<SS5RT)H632U^NEP-V](_2'K24[(>&P.SG> R5H+?_M&7'_*Q_P!*(]FU
MRZQT^BKG54]GK(JZJHPPU9I6@Q,<\-+)'YR.6>7/J%L-G=VI:G1%KHJ^VU<-
M'%;F<2:K@#:=[0T \R>8/7F.BS;;/U77_P#X;/\ F-6UV<_V#T__ (&+^$)\
M&#2>HM-W:[W*DTZ(73TS8Q42PPAC7  M:-X=< $>79;&\:CM]KJF4<CI)[A(
MS?91TS#),YOVMT=!YG 7/=F#0W:UM"#0 .*P\AW+G$K+LFJV7'7>NJFL?OW"
M.KX$8><ED+7.  \L@(+KI[5UKOE?4T%.Z:"XTW.6DJ8^'*T>.Z>H4735]NH;
ML;7$RJK[DUG$?3447$?&WQ=T ^*'2=K;K/\ I/\ /-N;HN!_6>HX8QT\<#Q5
M8I76Z@U[>OZ)4DMQO]5NFXOEF+8*49Y G'4]=T9/+LBK9IC55JU)Z2VVS/\
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M7K6U5UW%JF%5;[DX9CIJZ$Q/D'/FWL>A5'T56/N>W/53ZX[TE'%Z/3 _L,!
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M=#J6VRVC4E'OL@8_.Z\O&'@<N6=T<O)(+*=H^F/TI4T+;DQ\E/"Z>61H^;8
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M]XH-FWH$1O0(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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2"(B B(@(B("(B B(@(B(/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g73463g13a34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g13a34.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1:(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %FL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M9 ,!(@ "$0$#$0'_Q  =  $  @,! 0$!             08$!0<# @@)_\0
M8A   00! @,$ PL(!@8%"@ /  $" P0%!A$'$B$3,4%1%&%Q"!8B,E)3@9&2
ML=$5-D)R<W2ALB,S-3=BP30X=;/A\"1#5)/"%Q@E)T1%8X*B\295*$=69&6#
MA(64TG:CT__$ !H! 0 # 0$!               ! @,$!0;_Q  Q$0$  @(
M! 0#" ,! 0$      0(#$002%"$3,4%246%Q(H&1H;'!T>$R,_ %\2/_V@ ,
M P$  A$#$0 _ /U2
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     '/L[J'*
MP9ZU4J2_!;(C(V(Q%5=T3H=!.79B5D&N)9I5VCCLL<Y?)$1IV\#6+6MN-]GG
M?^C>U*5Y9UW9OY3U5_V>Q_W!DXS(:EDR-9EF&=('2(CU6'9$;X]3?>^S#_\
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MM-9I':&'&8LG#UBT9)G<_%FKD]5[+_06/^X-WJ7*7J&GZ,\;^SLO<U).9O\
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M$<;GQ.YF*Y.K5]1D'+FR4R:FM=2[.'Q9,6XO;FCT  8.D
M
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M(B>/12B:#QUVIFGR6JD\+.Q<G,]BHF^Z=#/AYB,.2);<569XC%,0Z <PU?\
MG7)^LS_(Z><ZU1C+T^I9)H:<\D2JSX;6*J>'B. F(R3N?1'_ *=9MBC4>O\
M*QZWKOGTV]8TW6)6R*GJ3O\ O-7PWO1I#8I.<B2\_:-15[TV1%V^HNC6HL2-
M<FZ*W944H><TE:JV_2L)NK47F2-KN5[%_P /J&"]+XYPWG7PDXG'?'ECB,<;
M])A?B%<B.1JJFZ]R>9SIF:U/"U8703N=W;NKJJ_6>N*P^=R&2CN7IIZW9KND
MCU^%MY-;X(1/!\L3-[1$+1Q_/,5QTF9;G5,&>EO1+AY'M@2/X2->C?A;KYFO
MQM35+<A6=;EE6NDB+(BRHOP=^I> 9UXF:UY>6/P:VX.+7Y^:?Q#F&L/SN=^M
M%_D=/.=ZJQMZ?4[IH*<\D7-%\-K%5.FV_4TX"8C)._@Q_P#2K-L41$>O\NB%
M=USD5I898XUVEL+V:>:)XK_SYEB.>ZGJ9+,Z@1C*EAM5BI$QZL5&HGZ3O^?(
MSX2D6R;MY1W:\;DM3%,4CO/9J-/9Y,(LRLKQR22;(KG.VV3R/74&I$S5>..6
MO'&^-W,U[7[JGFATRO2KP01Q,ACY6-1J?!3P/IU6!S5:Z&-45-E^"AT3QF+G
MY^3O]7+' 9O#\/Q.WPTJW#O)K-3DH2NW?!\*/?Q8OA]"_>:WB5_:%3]DOWGE
M4QV0PFIN>M4L2U6R<O.QBJBQK^'^1G:_H6[EZLZK5FF:D:HJL8J[+N:UBE>)
MB]9[3#&TWMPDX[1.ZSIKZ%K5#:4"4XY5KHQ$C5(V*G+X&NDFR&9R45/(VU;)
MS\B)*FR-=[$\3I6 C?%A:4<K',D;$U'-<FRHNQ7-<X%]E6WJ$+GS[HV1D:=7
M>3O:A&+B:3DFLQ$?"5LW"7C#%HM,^6XVW^)P\.-Q3J42JY'HO.]>]RJFRJ4'
M2DZ8G4J1V?@HJNKN5?!=^B_6G\2\:5M7)\:C,E!-%8B^"JR-5.=/!37ZJTLF
M2>ZU25L=K;X35Z-D_!?68XLD5O?'EG_+U;9L4WI3+@C_ !]%I*OQ$54P<>RJ
MG],WN]BE?@N:GQ2=DL-E[4Z(CX^T3Z%0\[,6H\]RQSP2]EONB.;V;$7SZEL7
M"^'>+S:-1\U<W&>+CG'%)YI^2UZ#55T]%NJK\-W?[2F,J1WM7RUI^;LY+#T=
MRKLO>IT'3>-?BL5%6E>CWHJJY6]VZJ4*W1RU?/6;52E9YDF<YCTC547JO4O@
MO$Y,DUGS\E.)I-<.*+1O7FM/O)Q7RK/_ 'G_  -EA<#3P\DKZG:\TB(CN=V_
M<5'\I:K_ .SV?^X,G%Y#4K\C6;:@G2!TB(]5AV1&^/4I?%FFLQ;)$Q]5\>;!
M6T37',3]%Z.7:G_.^7]K'_D=1.<ZBQEZ;5,DT-.=\*RQKSM8JILFV_4IP$Q%
MYW\&G_IUFV.NH]?Y=&*GQ(_L>O\ MT^Y2V%9U]5L6\7 RK!),])D548W=439
M3'A9B,M9ET\9$S@M$)X>_F\G[5Y4\G^?+OWMGWH7'0U::K@TCLQ212=JY>5Z
M;+L5K(8R\_6*SLISNA]*8[M$8O+MNG7<[,5HC/DG?Q>?FI:>'Q1KUA9-7X%,
MK5[:!J)<B3X*_+3Y*E#BRDT6%M8J=KN17HK-^]BH[JG\#KI3-;:=?8=Z?CXN
M:;NEC8G5W^)/-3/@^(CMCR>7HUX[A;=\N+S]?G#VX;?V39_;+]R%8AD7":M<
MZ=%1L<R\R_X7>/\ $MN@*EBIC+#+4$D+UFW1'MV54V3J9.J=/,S$;9(G-BML
M39KU3HY/)2T9J5SWBWE92>'O?AJ6I_E7NWK'->QKF*CFN3=%1>BH:;62JFF[
MJHJI\%.[]9"G5UU+@T[&.&=8F]S4;VC/HV[CZM2ZES4:P/KS)"[HK4CY&K[5
M4K3A.6\7YHU'S6R<=SXYI-)YICX-SPT55QUW=57^G3O_ %4+@:+1^&FP]"6.
MR]CI97\ZHWN;T1-M_'N-Z<W$VBV6TU\G9P=+4PUK:.ZNZ^_-N;]HS^9#&X;_
M -BS_O#OY6F=K6O-9P$L=:)\LBO8J-8FZ_&*;C%U%C8'0TZ=ED;G<ZIV*KU_
MY0ZL-/$X>:1,1.W'GOX7%1DF)F->GWNGFCUM^;-WV-_F0K'Y2U7_ -GL?]P;
MJ\W(7M$RMLPRNNOVWCY-G+\-/#V&=>'G%>MIF/.&MN*C/2]8K,=I\X8_#/\
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M4:GJ3O.CU(>PK10[\W(U&[^>Q3B>6N*F/>YA?@^:^;)EU,1.O-Z@ X'I@
M
M
M
M
M
M
M
M                                            &/;O5:;>:W9A@3SD
M>C?O R 8].[5NLYJEB*=OG&]'?<9
M
M
M
M
M                                         %7XDZJCT=I.YEGM1\D:
M<L3%_2>O<ARC2O#+(\0:#,_K[+WN:XG:14Z\G(V-B]QO_=1PRR</(7QHJQQ7
M8WR;>#>O>=*TG9KV]-8R>F]KX'UV<KF]W<!Q?4_#+(\/:+\_H/,7]J7]++2G
MDYVR,3JIUKAUJB+5^DZ67B1&NE;RR-3N:].]#,UE/#6TGF);+FMB;5DYE<O3
MXJG-O<MP31\/)9)&N;%+<D?$BI^B!V$
M
M
M
M
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MO78C&IY[>*FP
M
M
M
M
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M4]*8EM:LG:69/AV;+NKYG^*JOB6,
M
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M%14Z*BDA(
M
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MT!$;48QK6_%:FR$@
M                                           *NR;KW %79-U[C$EM
M[+M'U]:GE8G6151N_)]YX%HAG-O@^GO<_JYRJ?(!90"!$W  D@  "4 @D@D"
M !]X0!/4!W!( @0 20-P" =P10 'M $@@($ "#P"0D@ /,  2U5:NZ*J+ZC(
MBMN1=I$W3S,8$$3,-LQR/;NU=T)-9#*L3MV]WBGF;&-Z2,1S5Z%9C36MMOH
M$+
M
M                                               #YD<UC'/=W-3<
MK6F-7Q:AR-RO5QUZ&&NY6^D3,1K'JB[=.NY9S59'-8_%WZ=&PY66+CN6)K6*
MJ*OK5.X#:@(    \K<"6:LL"N5J2-5O,WO3<H&/X704\I#=3.9*18I>T[-SO
M@KU[E]1T1>Y2EXO3.H*V?],M:HN6*7.KO17(WEVWZ)W 71.B;    >=B>*M$
MZ6Q(R*)J;JYZ[(GT@>@*OA->Z<S.1EHT,G$^PQ539WP4=M\E5[RT
M
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MOQ7?>8X((G3;@^('<\357OV/LHW
M
M
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M^LL]HY65->4G6:V^S<I2;NQ4\WM_1 ZB#"Q&4I9BE';QEF*S7>FZ/C=NAF@
M
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M\VA\\R)KGO=5>B-:FZJ>FB&N9I/%M>US')"FZ*FRH!O !L2  0   )("#S
M #/HKO"J>2F08N/^(_VF44EK7R  0L
M
M
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MMW3Q12Y'+>"W]IZK_?G?>H'4@
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M39$V3R0 )/O   )W D"        9N/\ B/\ :91BX_XC_:912?-K7R  0L
M
M
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M<7/^@W=>B&"K>,7*N[\1MLO>W_B8WN6.V_)^JO2MO2?RBO:[=W-UW_B!W(
M#EG!7^TM5_OSOO4ZF<LX*_VGJO\ ?G?>H'4P   -#J[)Y?&T&RX+$KD["NV6
M/G1FR>?4#? H6 U-J^YE88,GI-U*HY?AS]NUW+]&Y?47?N
M                                                     #RM?U#S
M6FRM_P!0XUI:K*_F>8 +*@0(  \P " DCP >95>*?]WV;_8I_,A:BJ\5/[OL
MWO\ ,I_,@(;C3/YO8[]BW[C9&MTS^;V.V[NQ:;, " !) 0      !   )\"
M '@ !) 0( )W"?Q $> 0     )\R$[@,VA\1_M,HQ<?\1_M,HI/FUKY  (6
M
M
M                                       >%ZI#>IS5;4;9()F*Q[')
MNBHO13F.C[%G06J7Z6RLKG82VJR8NS(OP6+XP[KW;>!U4KFO=+P:KP$M&5RQ
MV&KVM>9.^.1/BJ!8P47ACJ6U?K6,)GF]EG\8J13-7_KFIW2)ZE+TB[IN
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M[6Q"K6^S=4+D5?2&ML9JJ:>+&QVV.A1%=VT7(A:
M                                               \K7]0XUILK?\
M4.-<6JROYH"=P!94 ">L"2 $  ! !2]4:\T=227'YG)5I4=\&2%O](B]>Y=C
M5\<M26L%I=E3&.5M[(R)78Y.BM1?%#UT-PPP.'Q,#[M1E_(2L1\\T_PMW*FZ
M[;D"PZ6U;IW.QMAP61KR*Q-FPHJ-<B>II8CC?%?0%+%8U=2Z58M#)T7)(Y(E
MV;(U.]-D.BZ"SR:ETGCLFJ;231IVB)X.\0-^@)()0>  "0  $'L \P"!   \
M  )("=  !) $H0   0D"    ">(&;0^(_P!IE&+C_B/]IE%):U\@ $+
M
M
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M'Q'^TRBDM:^0 "%@
M
M                                                          #%
MR="MDZ,U.]$V:M,U6/8Y.BHIE #28'2>#P,?)BL;7KIYHW=?K4W:(B)LG1
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MK5Y)IW(R*-JN<Y?!$.?2:LS.J^>OHBHD51%5CLE;39G_ ,B)U+5K;\T\IO\
M,.^XP.%7]W> _=D[O:I \-+Z!Q^)L?E#(/?E,P[X3[5CJJ+X\J>1<4[M@$)$
MD      3O'< !) $D(    #P)\"!X "4(  ! @   /N!)  ( !) \    &;0
M^(_VF48N/^(_VF44EK7R  0L
M
M
M              "K)JG!Y74]S2<K5FNQQ<\L4D>[%;_F9":,TS$J/;@<:U6?
M"14KMZ;?0<:;G\9ISW1>9MYJVRI7=51J/?W*NQTJ3BSHIT;VIGJNZHOB!MM*
MZSQ&H\AD*&*=(LN/=V<J.9RHB^HLQP/W.5F&YJW6-FL])();',QR=RIT.^
M !SKAU^?>M_WB+^4Z*<ZX=?GUK?]XB_E.B@  O<H%1Q.H].ZWMY;#-A;<7'R
M<EB*Q%NWF1=NF_>9J:7TWC56[%A,?"^!.=)(Z[4<W;Q3H</X3ZKPNE^(&NUS
MM^*GVUMW9\_Z6SUW.F97BMHR;&6HX\[65[HW(B;]Z[ 671FKL9J^C/:P[Y'1
M0RK"[G;RKS)WE@.+^Y:<C](Y1[5W:Z_(Y%\T7N.T #YE_JG_ *JGT?,O]4_]
M50.?\$OS=RG^U+/\YT(YYP1_-W*?[4L_SG0P        !J-8_FGF?W.7^13;
MFHUC^:>9_<Y?Y% T?!K^[7!?L$^\LF;_ -!7]9"M\&_[ML%^P0LF;_T%?UD)
MKYD*^/  W7                >M;^N:9I@UOZY#.+5<?$?Y(*EF=%Z<R^0<
ML\$<5U6\RI"[D<J>>R%N*A'O_P"4U_7IZ%_F68/7!:3TYA;Z-J00NO(G.G:*
MCGHGFFY:2G__ )TD_P!GK_,7$    0    "%6XD_FR[]O']Y:2K<2?S97]O'
M]X%CH_Z'!^S;]Q['A2_T.#]FW[CW $  2   " #QM00V*\D5F-DD+TV<UZ;H
MJ%+3AYI:\]\]6->17*CDAD^#OXIT+M8_T>7]5?N*GPO_ +!M_OLOWH!M]-8K
M#XRN]F$BKM:U5:]\>RKNG>BJ;DI_#3_0<I^_S?S%P F/XR'J>4?QD/4ROYM<
M?D>  *-$D GV :/6WYIY3]@[[C X5?W=X']V3[U,_6_YIY3]B[[C X5?W=X'
M]V3[U M2 $@1X   "4( D@$@1YCS  >!*#OZ$ 2A'F  0  /$DA @0!"2 D_
MB20  ]@  (20$"  )$  0S<?\1_M,HQ<?\1_M,HI+:OD  A8
M
M
M                                      'YY_(&,U'[HK,T\U49:KMJ
MHY&/[D7;O.DOX2:*;&]4P5?HB^*GWC=!K3XFWM6>E\R68>R[';N]9>7MYF.;
MYIL!P3W.5:&EJW6-:JSD@BL<K&^2=#OA0^'V@5TGG,WD%MI/^49>TY=OBE\
M  #G7#K\^];_ +Q%_*=%.=<.OSZUO^\1?RG10 7N4!>X#\V\*-*875/$#7:9
MVC';[&X[L^??X.[UW.F93A1HR#&6I&8.!'-C<J+NO1=C+X?:!72>H=0Y-;?;
MIE9EE1FWQ.JK_F72]!Z52G@WY>T8K=_+<#CON6FHS2658WHUM^1J)Y(AVDI?
M"W1*Z(Q-RFMI+"SV'3\R)W;^!= !\R_U3_U5/H^9?ZI_ZJ@<_P""7YNY3_:E
MG^<Z$<\X(_F[E/\ :EG^<Z&         -1K'\T\S^YR_R*;<U&L?S3S/[G+_
M "*!H^#?]VV"_8(63-_Z"OZR%;X-?W:X+]@A9,W_ *"OZR$U\R%? 0&ZX
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MQUET,=JPC)43]).I Z1[ &]6I[$!(  #-Q_Q'^TRC%Q_Q'^TRBDM:^0 "%@
M
M
M                                                         <OT
M5D:F.XD:MIWYFUK%J6-\+95Y>T1&[?!5>\Z@5S5VC</JB%$R5?:PS^KM1?!E
MC7S:[P*;)9U?P_:WMVOU%I^/HLO5;,+?-?E= .J@T>EM58C4]1)\3;9(Y$^'
M"Y=I&?K-[T-X     A[D8U7.5$:G557HB 28F4O5<?1EGO6(Z\+6KN^1R-3^
M)2-1\2(8[WY)TG57-Y=5VY8NL,?ZSTZ(:VSH>]F:EC+Z^OOM210ND9CH7<M:
M/9%7JGZ2^L">!.:QMC$Y*I#=A=97(3RI'S(CE:YW143Q.IGYGX(Z6Q>KL/EY
M(W2X_)5+;G5[=1W(]B*JJB>M.[H=%?JC4VB)F1:NJKD\/NC6Y*HQ5>W]=B?>
M!U,&NPF:Q^<HLMXFW#9@=XL<B[>I?)38@    /B>:*O$Z6>1D434W<]Z[(B>
MM5 ^RN<0,E3Q^D<JMVQ'#VE:1C$<Y$5SE:J(B)XE6R_$:UE,@_%:!H?E6TU>
M62V[=*\7KYNYWL/?$<-VV\A'EM9WI<QD47G;#(O_ $>%?\+/4 X(YW&6M"XJ
MC!=A6Y7BY)87.1'M=Y;%VS?^@K^LARWB7P>AR4LF9T?*_$YQJ;[0.Y&2_5W+
MZSEF)XKZQTU>=@M50+9[)>O;M5).GBCO%":^:8?H4%+TSQ'P6:1K%L)5L+WL
MEZ)O[2Y1O;(U'1O:YB]RM7=%-UGT   !XVK,-.!TUJ:.&%J;J][MD ]C6YG-
MT,/$C\A8;&JKT8G5R_05J74^2SEE]72M15A1>5]Z=NS&^MJ>)G8;1U2M96[E
M)9,GD%[Y+"\S6_JIX ;S%92EE:Z2T+#)FKX(O5/:G@9J%3R.BZ;K*V\//-BK
M:]=ZZ\K'+_B;XF([4&<P$B,U#1])IHNR6ZK55=O-6H!=QX&!B<O1RT"2X^S'
M,FVZM:Y.9OM3P,]  /A[VQHJR.:QOFY=B8Y&2HJQO:]/-J[@>]?^N3Z3-,*M
M_7--9G]4T<2[T=BK:ONZ,KP_"=OZ]NXM7R<?$?Y-\Y[6,5SW(UJ=ZJNR(<XM
M9F:77LDV JKD%]'[%9&KM&UV_BOB;1N'S.I&H_4,SJ--5W2G6=LKD_Q.\?86
MG&8VIBZK:U""."%/!B;;^M2S!0*>9FAX@QSZ@JNQ[EJ]@CUZQN=S>"^!TECF
MO:CF.1S5ZHY%W13&R6.J9.JZO?@CFB=X.3?;UH51V&S.FT=)IZ=]^GONM.R[
M=6I_A=X>P"[ K^G]4T<LO82*M2^WHZM/\%V_JW[RP    '@1W;[E9S>K:]6?
MT/%1+DL@J[)%#U:W]94[@+'/-%7A=+/(R.-O57/79$*'J/,/U36DQVGZ<ME&
M/1[[#O@Q_!7N3?O,V'3=_-O;8U59=RIU2C [:-/UO,MM6K#4@;#5B9#"Q-FL
M8FR(!7<%JJK-*W'9"*3'WF-1O9S]$=MY.[E+.G7N-=FL+0S-?LLA V3;XK^Y
MS%\T7P*TZ#/Z79O2<[+XQO58Y5_IHT]2^(%W!J,#J&AFH_\ HLR-G3X\$GP9
M&KZV]YMP'M(0E  ((>]L;'/D<UC&][G+LB%2R&K9+-MU'3%7T^RG1TW_ %3/
M_F[E L67O5L?0FFN3,BCY5ZN7;?IW)YG.]$Y/-08NQ^3<0Z6JEF29TDB\JR-
M7Y*>99*6DO2;+;NH[+LA:1>9(E_J8U]32UL8UC4:Q$:U.B(G1$ HW"R_%+4R
M$,N\%QUN21:\G1Z(J_Q+UXFAS^F*F5E;:C>^GD&?$LP+RN^GS0U5;460PEME
M/5$']"Y>6._$GP'>7-Y 75GQCU,>O+',ULD+V21N3='-7=%,C?9O,[9$\U,K
M^;7'Y!/<?+%1R;M5'-\TZD^PHT!OLBJO<G>J^!7]5:NQ6FXE].FY[3D_HZL/
MPY7+X?!3J5:.KJK6L?-DI%P.$DZI#"O]/*WUN\.@&3K?5]&Q!:P.'9)D\I88
MK.SK]6,W\7.[D,;A_JBIAL?1TSGXY,9DJC$C19OZN7UH[N+CIK3>*T[4['$5
M&0JOQY=OAO\ 6Y?$],_@,9GZBU\M4CL-VV:YR?"9ZT7P4@;-JHY$<W96KU14
M7HJ$G-WXO4^BF.DP<[LWAV=5J65WFC;_ (7>/L+'I/6F)U&U8Z\JP7F?UE2P
MG)(U?4B]5)%E0(/H $D> )ZKW=X$''N,S4M:]T11L)O5?,KG(O<Y44NVHM=8
MO$6XZ$*NOY*1Z,2O63G5O7O=MW&GXM:6N:EPE*_B/@9G'N2>!%\?%6D$.AHU
M&M1K4V:U-D1/!#G_ !UJ0V.&N3DG1%DKHDL2KX.W\"O83C54JU4K:MQURADH
M4Y'HD2JCU3INAI\]J#*\5[M?"8''SUL"DJ/LVY6JWG:B]R;@TZMPWGELZ$P<
MUC?M75FJ[<L96LUD/>?IVJM*A-<K5]HG,B3=S6)^ELG>9VG-1XS4=-)\59;*
MOZ42KM(Q?)S>]"1MP!Y^( (20Y4:Q7*J(B=55>B(@$[G%.)#4N<:]+UK:;UH
MV(]B+W<VY=[^OJ:YF'%8*!^5MJ]&RNAZQQ-\55R=-_4:/C/I:_D6X_4.!:K\
MMBGH]L2?]8U%W7VD$.GO[U,.>C3L6X;-B"%]F'I%(Y/A-]AR[&\<<0E1&YVE
M<IY%J;21=DOQO'^)A8'*YSB/KFI?@AMXO3N.151=U8LZ[]R^8-.S331P0/FG
M>V.)B;N>Y=D1#YJV8K55EF!Z/@>WG:].Y4\RA<6<%?R^&NO=DY*V*@@YNPA^
M"Z5W^)?(V6F'R1\**;X&N=*F-7D:WO5W(NP&1/Q TS!/)#+E84D8[E<F_<I2
M/='S1V>'M.>!R/CDLQN8Y/%%[BKX&>+!X"*QG-!-LP<ZR6KDL>\C57O7;;?9
M"P<>K-2]POQ5C%HBTI)HG1(Q.B-\$V"83B<OQ59B:3:N%QCJZ0L2-RNZJW9-
ME7Z"M:SNZPMZDTPFL*%2I&EE%B6!=]UZ]YWO3B__ (/8S?O]%C_E0YIQOW7/
MZ07953TM.[Z00Z;ELO0PU-MC*6HJ\6R(BO=MOT\"<1EZ&8J^D8RU%9B\58[?
M;VE=U?I;&Y.Y#F<K%+?;1A_HZ*]8W+Y\OBO4IO!^2O)K/.3PTW81DD;4;BW)
MR[]?CHB^80ZS>OUJ$+9;DK8HW/1C5<O>Y>Y#(:J.1%3N7JAQSBUALCS8[*Y/
M).DB;DX8Z]2-.5C6JJ]7>:G8H>D,?ZJ$C/Q_Q'^TRC%Q_P 1_M,HI/FUKY
M(6
M
M
M "HBHJ*G10 */J?AW0R,RWL)*["Y=.J6JB<G,O\ C1-N;Z334-:9O2<R4=?T
MGNK[[1Y6LSFC<GF_;XIU$\K->&U"Z&Q$R6)R;.8]NZ+] 'EC,C3R=1EG'VH;
M-=Z;M?$Y'(OU&4<SR7#V[A+LF4T!?6C.J\\E"556";QV_P /T'E-:UYJIJ4(
MJD6G86]+-M5YWN\TC1?#U@6C5FNL/IS^AEE=;R+D_HZ59.TE<OA\%.I5(,+J
MS7$OI&HK,F$PCNK<?7<J2R-_QN3JGL+5H[0N)TPQ7P1NLWGKS26["\TCE]J]
MWL0M0&JT]I[%Z?J)7Q%*&LS;X2L:B.=ZU7Q4P.)%Q*&ALU,Y=MJSVHOK5%0L
MAS3W1-ST/A9DU1=G2*R-/I4#F/N0KNU_/5'NZO:Q[4]?7<_2\L;)8W1RL:]C
MDV<UR;HJ'Y!]RW=]'XC>CJNR3UWIMYJA^P .=Y_ARL5EV2T5>?A,@GPEBB_J
M)5_Q,[NOF>.%XAV<79;C-?4'XNVB\C;B)O6E]?/W(J^1THQ,IC:>5IR5<A7C
ML0/145CV[@>]:>&S"V6O*R6)R;M>QVZ*GM/151$W5>ARY^C,YHVRZYH6YV]%
M5YI,5;>JMV\>1W5=_4?-BKK37.T5E?>UA_BRM8O-/+YIZD]8&]U5Q$QN)F=1
MQ;'Y?,+\%M2HG:*UW^-4^*AHZ.C]0ZLF2YKR\Z"DOPF8FJ]48GZ[D[_8732N
MDL1IBJD.+JM:_;X<S_A2/7S5R]3? 8>(Q='$4VU<74AJUV]S(F(U/X&8  *5
MQ*T7B-3XY77J[&W&;-CLM;\-N_K\4+J8&;_T!?UD)KYD/QOJW1V3TU>6*Q Z
M2%SMHIV(JH[R]BG<>'])VE]&)8S=MZ.<WM9.U<JI&G@B;EQL5H;+$99B9(U%
MW1')OLOF<^XWS/9INC5C<K66+3(W[>+=EZ&Z[%]^FI-03R.TIB?^@M7E;8FZ
M(_UGI3UWF<->BK:PQ3J\$CD:EJ/JQ%.@X:G#0Q56M58C(F1MV1/8:W75&'(Z
M3RD-EJ*U(7/:J^"HBKT R\Q=M18A;.'@;=F?MV;>;9%1?'<KU'2EK)2I<U;:
M=:D7JVHQ=HF>I4[E'!Z[+=T-4?,JJZ-SHT5?)"Z=P'G7ABKP-B@C9%$U-FL8
MFR)]!Z  "'-1S%:Y$5JILJ+W*2 *OE=&T;+W3XQS\9=[TEKKRHJ^M$[S)R&1
M=IG2TMO*V/29J[%^'MMVB^"&_*!QPCEDT1)V2*J-E:YVWD!I<#I?,:PC3,:@
MRMFO7G^'%5B<J(C5[MSZSVDLMI2N[+::REJ5(/A259'*Y'-\=CHFF)(Y-.XU
MT2HK%KLV5.[N0R,M+'%B[CYE1&)$[??V*!JM,Y1NKM-0V*TSZ[YF\LCF+U8[
M;JB&ZP>GL?AV\U>%'6%^-8D^%(Y?6Y>I0^ +7)INR]=TB?;D5B+Y;(=4+U<?
M$?Y  )8"! 0!J,YI['9A.:U"C;"?%GC^#(WV.3J5_P!(U!I9^UMC\OB47;M6
M)O-&GK3Q+P0J=/X :_#9FAEX>TH6&2?*9OLYOM3P/#.:BQV&;M:FY["_%KQ?
M"D=[&F#FM(U;MA+="5^.O)_UT*=%]K>X]]/Z6HXCFE7FM77+N^Q-\)RKZO(#
M3-JY_5$G/=>_$XI>J0,7^ED3UKWM+/A\-0Q$/9T*S(M_C/1/A.]J]ZFQ   @
M"0GJ() T&;TO1R3UGC:M2\G5MF#X+M_7MWFHBS&8TY(D.H8'W:/<V] W=4_6
M:G=[2['RYK7M5KD1S5[T7JB@8V.R%3(UTGHV(YXE\6.WV]IJ<UJJECWK6K(Z
M]D%Z-KUTYU1?\6W<AB9/1=>:RZQC+<V-?)TE2'XKT\>G@;?!X*CA8$92A1'K
M\:5W5[E\U4"OP8++9Z1)]2V%@J][:,#MD_\ F5._V%LH4:V/KI!2@C@B3]%C
M=C() (  !XVJ\-JN^"S$R6)Z;.8]-T4]@!7WIC=%X*]<YGLI1(LJM<Y51/4G
MD<OP6(U5Q163,Y'+V</AGN5*T$#E17-\^GWEPX[-D7AMD^SWV3EY_9N;_AD^
M)^@L$M=6]EZ,U$Y3*_FVQ^3F^;T)JG1E5^8TQJ.Y>2LG:2U;#U5'-3JO0O\
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M[3*,7'_$?[3**2UKY  (6
M
M
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M,]?\2]YO"$       ,3+4(,ICK%*VWF@F8K7&6 .4U:VL=%<U3&UF9C$HO\
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MH?$?[3*,6A\1_M,HI/FUKY  (6
M
M
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ML^?=]E#; <TFVI_(S?GW?90?D5GS[OLH;8#FDVU/Y%9\^[[*#\BM^?=]E#;
M<TFVI_(K?GW?90?D5OS[OLH;8#FDVU;<-&B_"E>J>I$0S:U2&NG]$S9?->JG
MN")F90  @>$E2%Z[\NR^H\_0(O-_UF6"W//Q4Y*_!B>@1?*?]8] B^4_ZS+
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M"P
M
M
M           *B*BHJ;HIXUJE>JCDK010HY=W)&U&[KY]#V $2,;(QS)&HYCD
MV5JINBH?%:O#5B2*M$R*-.YK&HU$^A#T
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M  /  (21X > 2 'W#'VDB-3N\?8"&?5;RPM]?4]0B;)L@,V\=@
M
M
M
M
M              ^98TD8K5/H :M[%8Y6N[T/@VDL39&[+W^"FOEA?'OS)NGF
MA>)VRFNGGW@("53P  !  @ > )0(0  D )\0(  0D@D@):O4>!H:BQ$V.RT*
M35I/#Q:O@J+YG-(^$V8QO-!I_5UZM15?ZI[MU1/).AU\$"@:(X88[3F0=E+=
MB?)Y=>OI%A>;D7_"7] "00D@D(0 $"0E"  \    " $ /J-CGKLQ-P(1%5=N
M]?(V%:'LF=?C+WBO72+JO5WGY'L4F6E:Z[R  A<
M
M
M
M
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M0W_*:$IN\7I]1F@;DY(8[*D;?C*KCW:B-39J(B$@C:8B(  $@
M
M
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MM:YC)1>Z:J4XLA;947(TVK"V9R,V5K-TY=]NH'ZE
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M^G#(CT3V[=P&:
M
M
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ML+^V-._N\O\ ,@'Z*TG^:V&_<H?Y$-J:K2?YK8;]RA_D0VH
M    _)7N@_[\L;^K4_WBGZU/R1[HA[(N-U"21R-8R.JYSG+LB(CUW50/UN0[
MXJ^PK7O_ -(__I-A_P#^K9^)G8C4^#S4TD&'R]&],QG.YE>=KU1O=NJ(O=U
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MB=_E])8?<<_V;J/]I!_*XRO=8:;=Z%B=54$<RW3D2O*]B;*C5W<QV_J<G_U
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M7R _0%.Q';J0685WBF8V1B^:*FZ'J>5.M%3J05J[>2"%C8XV^3439$^I#U
M
M
M
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MKU53=@#G5OA'@[6OV:ODMY%,BVPVPD39&=ES-3HFW+OM])T4
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M8H/3Z,=1JHB5Y6[R*J[JYZN:JJIU5M>-*J5W-1\2,[-4<F_,FVW4]0!R?47
M/1>9MOLQ0W,;(]>9R4Y4:Q5_5<BHGT&XT-PBTIHZVVYCJDMB^SXMFV_M'L_5
M39$3Z$.@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*L;/EO7HU/KV./>YNRFHM039G4.I,W<GQU;>-D4DJ]FCU^$Y=O)J;;>T#]
M_,NH^.6J-0:@EQO#S&\T+%<V-Z0K-+,B+MS[=S4_$QO_ "G\6-.31R9_!OFK
MJY$Y9J2L1=U[N=O<H'ZC!S3C3K#,Z3X=5LQC6Q5<E)-"R1DC4E:SF1>9O7OV
M7IN:O06>U!K_ (.92W/>=!FE69L$]1O9JCF=6[;>OH!U\'Y[]S/Q R^8RV4T
M_J.Y-;L-9Z1!+.[=[514:]GLZHOUGZ$
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M5711SM<YNW?NB+OT,FAD:6125:%RO:2)W)(L,B/Y7>2[+T4#*
M
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MD>R)CGR.:QC4W5SEV1$ ^@:NMJ+"VK/H];+X^6QOMV;+#%=OY;(IM
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M9["-_-'$K>:665W3N3=$1$^]3HO%+3\FE_<X5,3.N\]=8.UZ[HCU=NY$^E5
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M4_BJ'ZY/R-BT;FO=12OAV=&W*2/1R=VT;5Z_6A^N0
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M'MCA[B,C3M7XKKK4Z3(Z-BMY=F[;=3A' W_6$G_7O?YGZ[
M
M                  <G]T[D)Z/"VS'6D5GI5B."14\6*JJJ?3LAU@K'$K2D
M>L]&Y##2/2.65J.AD5-T9(WJU?\ +V*!R_W)N#IP:4O9GD8^_9L+$K]NK&-[
MFIY==U.MZVS>+T_INW?SS%DQK41DK$CY^9'=-N7Q/RMPWU[F.$&:O834&,E?
M2=+O-77X+V/3ISQJO1R+M[%\RT<7^->G]5Z*LX;$U;W;V5:JOF8C&LV7?S7?
MZ .Q8'5F#U9H#,3Z::]E&K7EK(QT79HU4BWV1/+94.%>Y-K17<_J2K8;S0SX
MYL;V^;5=LI</<Y5YH>#VIWS0R1LEDG=&YS51'IV#4W3S3=%*M[D#\Z\[^XL_
MG U>@9).%O'67%77*VK-(M-SE[G1R*BQN\/%$_B6[W66I)))<3I:GN]TNUJ5
MK5ZN555K&[>W=3W]UII='4\9JBJBMF@>E6=6IU5J[JQV_J5%3Z4*CP8H7N)'
M%CWPYU$DCQ[8YGJU-FJ]C4;&W_Z=_H WG%#-W>&?#?3NC,-(ZKD;=?MKUB/H
MY$7XS6KX*KE5-_)/68FFO<[7LQIV/(Y/.I5R-AB2QPI%VC4W3=.=RKOO["S>
MZHT5>RM2CJ/%Q26%HL=#9BC;NYL:KNCT3Q1%[_5])JM)^Z,JX_2\%3,8FQ-D
MJT21(^%S4CEV39%7==V^OO M'"[#:FX7Z1SUS5=ZO+B:L;YH:C7J]S7-\4<O
M1J.V3IZSA&/FAXAZCNY+7>K8L1$Y>9.T:Z1W7N9&WN1J=W4[KP_U1F>,&C=2
M8S,XN*I4FB=#%=B548KE3=&[+ONJ=%544X)IU]#0^IKF-X@Z5CR3&NY'LDW9
M)&J?I1KNB.:O?Z_,#)LVXN&^I:>2T)JR',0K\=&-<Q51-MV2,7HJ+X*AUGW2
M^4CS?##2V4B:K8[DC)VM7O1'1[[?Q*EC]3\-,KJ;&X[&\.E?6L2=G([=SI45
M>B*UC7+T3QZET]U-2K8WA]IZE0A;!4KV4CBB;W,:C%1$ H?"WA1G]9T,;G+.
M4CKXZK(U*L<W,]7-8[?9$3HU.A]>Z1;R\8J+5[TK54_^MQW7W/G]T^$_5=_,
MIPSW2O\ ?+2_=ZO\[@+G[J#6]_$TL;IW%SR5O2X>WLRQNY7*SJB,1?)51=S0
M::]SO<R>F*V4GSRU,G8A;/%"V+=K=TW:CG;[[^>QM/=4Z1OW(L7J.E#)-6KU
M_1[/(BJL:;JJ/7U=53<^-,^Z,J4-)UJ>0Q%B7*5H$A:^-Z=G(K6[-5=UW3?9
M-^\"A\'JUVGQTH5LHYSKT-F6.9SEW57(UR*NY9O=&ZTN9;6_O4J9%*6*JJR.
MPYSU:QTCNJN>J=>5J*G3VE:X09"SE>.M#(7V=G:M6)9I&<JILKFJO<O4V_NB
M])V\#Q"?J1E%+F)O.9,_M&*Z))$39T;]O!>5%\.\"NYK1VD*&%=<PG$.K;RT
M+>T2!8'QH]R=51CDZHOEN=R]S/KN]JG 7<9F)'3W<8K.6P[JZ2)V_+S>:HK5
M3?QZ')GZXX7_ ))YF\/&?E+D^(LJ]ES_ *W-OM]!WC@;6T_8TNS-X#3OY#FN
MHC)V<KDYU;XM5R]6[JNR@=(
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MUE8K5?*]4<Y4W\D^\_31#6HU-FHB)ZD)
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MQ-FL8U&M:GDB(>@ T6-TAI[&91<EC\-1K7U5RK8BA1K_ (7QNOK-Z
M                                 0Q[7[\CFNV79=EWV4D
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MQC4V1K4V1$)          $-<CDW:J*GFBD@
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MEH?3KTL3]GN@1-^S14\TW_@!TR+4V"EN^AQ9K&OM[[=BVTQ7[_J[[E$TVO\
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M^".9R$U7.:=S-A]NY@+CJB67KNZ6/]!5]>R =,
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M[=YTO2"Q2X*O9AQ"X=;#>T=4<QK',5?E(GCL;%E&JR=9F58&S+WR)&B.^LR
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MD[FKNBOW^%LOMW.LGQ##%"CDAC9&CE5RHQJ)NJ]ZKZS[
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ME:2TW;=4RV9@CM-79T,>\CF^U&[[&XTWJ;#:EJNL8+(U[L;5V=V3MU;[4[T
MVX-/EM28O$Y;&8V_9[*YD7*RLSE5>=4[^J=WTF+@]:Z?SV:M8K#Y.&Y=K,5\
MK8MU:U$7E7X7<O4"Q Q,OD:V)QEG(7Y.SJUV+)(_95V:GCLAQW"<<L([5F>;
ME,NQ,&WL_P GJVL[F7X/P]]DW[_,#MH-,NIL4FEO?$MG_P!$=AZ3VW*O]7MO
MOMWFNN<0=,4[..K3Y:%+602-:\";J]R/^*JM3JB+ZP-_/DZ,&0@HSW*\=V=%
M=% Z1$>]$[U1.]3+*%J'$Z3L\4]/V\G)+[YF0/=2B15Y'M;S+S*FVVZ;NVZE
MUR%VKCJ4UN_8BKU86\TDLKD:UJ>M5 R 42EQ<T/<O^B1:@K)(KN5KGHYC'+Z
MG*FQ9J.H<;>S=W$U;*27J;&23,1%V:UZ;M7?N7= ,IN2I.R;L<EN!;[8^U6O
MSIVB,[N;E[]O699RBG_K*W_]@M_WC2_Z;U+BM1MNKB+*3.IS+7G:K5:Z-Z>"
MHH&X!Y7+,5.I/9LO2."%CI)'KW-:B;JOU(8>'S=#+X2'+TIT7'RL[5LST5B<
MORNO<@&Q!09^,&A8;WHK]05U>B[*]K7.8B_K(FQ=Z-NO?IPVJ4\=BM*U'QRQ
MN1S7)YHJ >X*?J3B7I+3EQU3*YJNRTU=G11[R.9[4;OM])O-.Z@Q.HZ/IF#O
MP7:Z+RJZ)V_*ODJ=Z+[0-H%5$155=D3Q-/>U+BJ&<AQ%RVV*]- ^RUKD5$[-
MOQG*[N1$V7O,33VKM/ZN7)5<+?COLJHC+"QHO*B.YD39?'N7N W&,R='*122
MXVY7MQQO6-[H)$>C7)WHNWB991>$&*TMC,'?31<DTM22[)V[YG*KNU39%;U1
M.B)ML;;5FN=.:4<QF>RD%:9Z<S8NKGJGGRIU WMZY6H5);5Z>.O6B3F?+*Y&
MM:GFJKW'I#*R:)DL+VOC>B.:YJ[HJ+XH<KXAZQP&J^$NJ78#)P7%CIJKXVKL
M]B;^+5ZH=!TA^:V(_=(OY4 VP*7G^*.C\#?=2R.;KMM,7E?'&BR*Q?\ %RHN
MQ9<)F,=G:#+N'N0W*K^Z2)VZ>SU*!G@&FOZGQ-#/5\-<MMBOSP/LL8Y%1.S;
MOS.5W<B)LO>!N05_3&L<#JBS=@P.0CNNI\O;.C1>5-]]ME[E[E[C&U5Q!TQI
M:=*^;RT$%G9%[!N[Y$1?%6MW5/I M(-+I?5.%U34?9P&0AN1,7E?R+U8ODJ+
MU0:GU3A-+UFSY[)5Z3'[\B2.^$_]5J=5 W0*=IOB9I'45MM3%YJ!]IZ[-AD1
M8W.]B.1-S=X;4.-S-W)5*%CM+..F6"S&K5:YCO8O>GK[@-L#SL31UZ\LTSD;
M%&U7N<O@B)NJE;77FGVZ5;J-UQS<.Z3LVSK$Y.9>;EZ)MOMNG>!: 4_4O$O2
M>F[3:V6R\45E6H]8F-<]S45-TYD:B[?2;S3NH,5J.BES"7X+M=>BNB=ORKY*
MG>B^T#: XYKKC%C,3J_$8^CE&,K0VI(LLUU=SE8U$Z;+MY^1T+1^LL)K"&Q+
MI^VMEE=R,D58W,V54W\4 V]')4K\EF.E;@L/K2=E,V-Z.6-_R7;=R^HRCC7#
M/-XW3UWB-?S-R&G49G)$625VR*NW<GFOJ0NFF^)ND=1W_0L5F8'VU79L4B+&
MY_ZO,B;_ $ 7$ I6<XIZ-PN0=2OYRNEECN1[(T63D7_$K45$ NH,'"Y?'YS'
MLO8BY#<J/Z-EB=S)OY>I?4:G5>N-.Z4<UF>RD%69[>=L*[ND<G=NC4Z[ 60Q
M$R=%<FN.2Y76^C.U6MVB=HC?E<O?L:/2VOM,ZHF['"9BM8L;<W8[JV3;]5=E
M-97Q6E6<7[-Z*27WV/QZ+)%NO)V.Z-Y]MMM^B)W_ $ 7H&@U3K' :58QV>RE
M>FYZ;L8]=WN3U-3JI@Z9XCZ4U+9;6Q&9KRVG?%@?O&]WL1VVX%M
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M2X')U[B-3=[&.V>SVM7J@&\!K,YGL?@UHIDY^Q]-L-JP?!5>:1R*J)T[NY3
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MDL([HF^V_=]!U72FI<7JO%?E'!V?2*G:.BY^16_"3;=-E]J ;@
M#FGN@<_=PFAV08R9]>UE+<=%)V=\;7[\RHO@NR;;^LZ65+BEI'WZ:.M8N*5(
M+B.;/5F7N9*Q=VJOJ7JGT@>VDM#8'36#@QU/&U7\L:-EEDB:Y\R^*N54W7==
M_K*'D,16T%Q@P-K3\?HN/U$LE6Y3CZ1)(B<S7M:G1%_XF9@^)E_%XZ*AK#2^
M?BR]9$BD?4INGBG5.G.UR>>Q\Z8IYS6_$"MJK/8J;$87&1/CQM.RO],^1W19
M7M_1Z>'W@8^>I5?_ #B]-Q>C0=F[%3JYG9ILJ_"ZJAUVO7AKL5E>*.)BKORL
M:C4W^@YEFZ5I_NA-.6V5IW5&8N=CYDC56-<O-LBN[D4ZB!4^+/\ =KJ7]QD^
MXJG C1>-J:'Q67OUXKV5NP-D6Q8:DCHV;;,C8J_%:C=NB>:EKXL_W:ZE_<9/
MN.:\*]7Y31VBL11U#ALGD,=)6;8I7\=7=.B1N3?LWM3JCFKNGCX ;3C5IREI
M^"CKC P18_+8NU$Z5T#>1+$3GHUS7HG?W_>6;B-D-&4Z6*RFM8()W,7>G"^)
M9G/>Y.J-8F^_T]"HY^WF^*V2Q^)HX3(8K2L-AEB];R$:POL(U=TC8SOV7_G;
M8V/%&A?Q&MM+ZLJXNSF,;CF/K3TZ[>=\/-W2L;XJFWJ[D K>N-=Z+S^ELC1E
MTGF4<ZN](9EQ*-[)VV[7(Y%W;LJ(NYT?@[=GR'"S 6+<BR3+4:U7JNZKLFR;
M_0A7-1:^NZEPEW%:3TUF76[4+XWV,A4=7@@8K5YG*J]7+MW-3O4L'!>K/3X6
M8.O:AEAG975'1R,5KD7=>]%ZH!S_ -SKI*A=J97.Y2%ER9M^>O59,U'L@:CM
MW*U%[G*J]_J/OCUG:,>J].:8S<EJ#3+XUMW8ZD:JZ9&JO)'LW]'=O5"T^Y[I
MV:6B[T=VM-7D7*V7HR5BL56JJ;+LO@9'%33.6LY'#:JTHV.7.89SE]&>NR6H
M7)\*/?P7OV]H%8EXD\,)<3^3'X>=:/9]DD/Y)=LC=MNG3^/>>ON=\VV:;46"
MH/M2X*C,DN-?98YKVQ/5=V+OY*;IG%R%*VUG26J8L@C=EJICW.^'\E']RIOX
MEOT3DLQEL+Z9J#$MQ-F21RQUNTYW-B_15_D[S0#E7"71^.RVN-:YK+0,NK6R
M\T-:&9.>.)R[*YZ-7IS+T3?U%AX[Z9QLF@[^7JTX*V5Q:-MUK4+$9(QS%WVY
MD3?;U&5P;J6:MO6RVJ\T*2YR:2/M&*WG:J-V5-^]/6;?C%7FM<,M1P58I)IG
MU'HV.-JN<Y?)$3O ^,W*W+\);EZY#$^>7"R3;JU%Y7+ J[IOW&KX!TJK^$VF
M9GUH'3=BY>=8T5V_:.Z[F^QF,EO\+Z^+<BPSV,2E9>=-E8YT7+U3U;G.N%NL
MK6D])4-,9K2VH?RK1<M=$KTUD9*BO5>=']$VZK]0';SD'$"LW6G%K#Z-R3I$
MPE6FN4L0M79+#T=RM:Y?)#KZ+NB+Y^9S/BC@LU5U!B=9Z2K)=R6/:M>S2WV6
MS7<NZHB^:+W>WU 7*WI3 6L6['3X7'NI.:K>R2NU&HGJV3HOK0Y3P,P_Y XE
MZ^Q;9I9H:OH\<+I7<SDC^%R-5?4FR?06-_%E)::MHZ0U/+E5:B-J/HN8B/7P
M<_N1-_$T7 [&YVGK_6]G4E=\=RWV$SW(QR1\SN958QR]'<NZ)T\@//5>FZNI
M_=#5*F2YI*,6(;/+!O\ !FY9%V:Y/%NZHNWJ.GZEI5:.B\U#1K05HDI3;,AC
M1C4^ O@A5$IV?_."6WZ/-Z+^0NS[;D7DYNU^+S=V_J.@Y.HR_C;5.551EB)T
M3E3R<BI_F!4^"O\ =7IG]RC^XT'&K\X>'G^W(_Y5-/H/5.1X>XCWL:IT]FYF
MT'NCJWJ55T\<\6Z\J].[H:W5U_4.K]9:,RK,#D<?@*F58R-EF-4FD<O597,3
M?D8B)LBKY@63CE9M9+)Z4T?!8DK5<Y;5ER2->5SHF]58B^OK_ O^+TI@<9C&
M8^GB*+*C6HQ8U@:O,FVWPMTZK[30\5]&6-5XNE8Q%EM3/8N=+5&=W=SIWM7U
M+LG4T=?B5J6K"VIE^'V;?EFIRJM1$?!([S1_@BK[0-#2TM6TIQ^P];%/>S%V
M:5BQ%45^[:[U5.=&)^BU=D7;SW.YG -/QZBEX]X?(:L[*&]<QTTD=&)W,E.%
M%V:Q5\57JJKYG?P.-\1HG:RXN8'1EU[VX."L[(VXF.V](<B_!:[S;T3ZU.E6
M=*8"SBUQTV%Q[J*MY>Q]':C43NZ;)T7UIU*9Q3TWEV:@P^M-)P)9RV+1T=BG
MORK:KKU5J+\I.NWM]1#^+;'55;7TAJF3);;)4=0<U.;R5_<B>O\ @!@<3F.X
M<\(TQ6EIK,:SSLI0RS2J]\*2*NZM=X;)W>1<=$Z$P>FL!7HU\?6DD[-.WGEB
M:]\SE3X2N<J;KNNYJ<SIW+Z_X6R8_4]>OC<W.U)HVQ.5R02-=NQ5]?@NV_>I
MJ-/<2,EA,9%C-9Z9SS,K41(734ZCK$5CE3;G:Y/,##U!BZ>@.*^G,G@(_1*N
MH)74;M.)-HG.VW:]K4Z(NY@\5\#%J;CEH_%6WR-IS4976&QNY5DC:KG*Q5\G
M;(B^I3<8&KF]>Z_HZCS6(GQ&G\0U_H%:UTFGE=T[1S?#I_SWF5J2E:DX_P"D
MK;*T[JL>-L-?,V-58U5YMD5W<B@7'):.P%_ 38>3$TF4I(EB1C(&MY.FR*W9
M.BIYG(_<XZ7KWZN0R^;5V2FQ]A^,H):VD;7A8J+\%%[E55[SOARWW/%*U1TI
MEX[M:>N]V7L/:V:-6*K5Y=E1%\ -3[H+#T\-0PVK,5"RGF*&0AC;- U&*]CE
M7=KMN]/Q4L_')ZR<(L[(B;*ZNUWUJAK_ '1M*U>X?1PT:T]F7\H5W<D,:O=L
MBKNNR>!G<;4_]3N::[=%]%:B_6@'OPQT/B\)IVI9L5HKF7MQ-FM7;#4DED>Y
M$54YE[D3N1$\BH<6,57T-J73VL].Q1T97W64;T,+>2.Q&]5^,U.BKW]?9Y&5
MI/6^6TEA:F'U?@LK;6O"Q*^2QM=UB*S'LG+OMU:[;HJ+Y'A;@S'%;5F)?/B;
MV(T?BIDM.].C[.6Y*B]$1G@WU^T"=35%UYQMBT[E7.7 82JV\ZJB[-L2N5-N
M=/%$W^_S.E972&G\IB7XRYAZ+J;F\B,;"UO)ZVJB?!7UH4CB/@,UA]9T-=Z3
MJK>GAA]&R-!J[/L0^;?-R>7J3UGK<XL/DJ.CPND-2VLJY-F5IJ3HF(Y?E/7H
MB)Z@,;@?//CTU5I.:S-:AP5UT-625=W)"Y-VM5?49GN?OS,N_P"U+?\ O5,_
MA%I3(:?PM^UJ%[),[E[+KESD7=&*[N8B^.R%/TOD\IPOR^<Q&8P.5O82S=DN
M4;M"!9T:CUW5CD3N_P#N!M/=-?W<Q?[1K_>ION-G]T.I=O\ L2_>AS#C/G,Y
MKG3\$>%TYEZV'JVXI));-=S)+#]]D:R--UY4W555?4=4XQUY[7"G44%6&2:=
M]-6MCC:KG.7=.B(G50,#@YH[$8O1&)MNHPSY&[6CFL69V))(Y7-1>7F7]%.Y
M$[NAI<[AJFE^-6ELA@H(J3<Q%-5N0PM1K)$:B.1W*G3?NZ^HZ#H&*2'1&!BF
M8Z.1E&%KF/396JC$Z*G@5C7]2Q-Q(T#-#7FDAAFL+)(QBJUF[$VYE\/I T/$
MVK)K'BI@-&7)9&8)M9V1MQQNY5G5%5&M7S3=$^M3I,VE,!+BEQC\-06BK.3L
M4@:B(FVW3IT7U]Y2N*VF\VW/8?6>D(FV<MBD6.6FY=O28%WW:B^?5?\ (^EX
MLI)35E;2.IG996[)4=1<UJ2>2R=VV_CY 5G@_@DTUQGUGB66)9X*U.!('2NY
MG-B7E5C57QY45$^@[F<0X.XS4-3BQJVYJB![;ENI#*][6N[)KG<KNS:Y>B\J
M*C>GDIV\           !4.+_ $X7ZH_V?-_*I;RJ<6();/#;4L-:*26:2A*U
MD<;5<YR\J]$1.\#2\&='XS$Z-Q=^2M'9RUV".Q/;F:CY%56HJ-1R]S6ILB(G
MD4#7^I=/S\8[%?6Z7+&*PD,?HM**!TL4DSTYE>]J=^R*B)OY'9]!120Z)P,4
MS'1R,I0M<QZ;*U48G14\"DZTQV=TOKKWY:;QSLK2LUVULGCX5VE?RJO+(SS5
M$Z 5O5>ON&>HL'8Q]K'6V\\:MBE9BW-?"[;X+FJB;HJ*:]O$#-1>YW6ZDLS,
MJVU^266G(J/5N^R2>"H[EVZ^9>;/%E)J[H\-I/4UG)N3EB@EHNB8CO#G>O1$
MW[UZF[U;IJUKGAS)B\S'%0REB%LBI&]7L@G3JFR^*;] /O0>@,'I3 P4Z]*"
M>PYJ.L69HT?),]?C*KE3?;?P/7'Z1PFELIF-08FL^M+9K_T]>%W+"[E^%S(Q
M.G-T[_6OFI3M-\1,OI_&Q8K76F\W^4ZJ)%Z51JNL0V&IT1Z.;XKXEFT3J+.Z
MGRF1EO:?DQ>G>S1E9;J<MB9^_559X-5/^5 I7 W"U=6MR&O-11MOY:]:EBA2
M=J/96B8[9K6-7?9>G_/4WO&;1.-O:5NYG'0,H9W%1K;JW*S4C>BL3FY55.].
MAHL!^6>$N9R6.FQ%[+:/N3NM5+%")99:KG=[',3KM_\ ?Q4^]8ZCSG$;'KIK
M2."RE&I>V9=R>1@6NR*+?X36HO5RJ@&/KK4F0U#H'0-!)G5GZIFA@NRQ+RKV
M:M17M1?#FW.J8?2. P^,90H8BC'6:U&JWL6KS^MRJG5?:5O6O#QF4T-C,3AY
MDK9'"=G+C9W)T22--D1WJ=X_\#4U.)&J*,"5,[P_S,F38G+ST=I()53Q1WZ*
M+](%=MZ7J:9]T+I1N(3L,=<BLSI4:OP(I.1R.5C?T479.AF^Z*QWY7SW#W'+
M))&RUDGQ/=&[E<C51B.V7PZ;FCJ+J*YQ_P!)9+54,5*>U6G6OCXW\_HT*,?L
MCE\7*NZJ77B]2M6M:\.):U:>:.#)N=*^.-7)&FS>KE3N3V@7>EI+3]+%-QM?
M#8]M)&\O9+7:J.]:[IU7UJ4/@Y033VKM<:<IN5,74MQV*\2KOV7:,W5J>KN.
MKG/-%5;$7%37D\M>5D$RU>SD<Q4:_:/KRKW*!K<3_K(9S_8<?\[#QX@TZR<9
M>'C4KPHV3TM7IR)L[X"=_F9N+IV6^Z$S-MU:9*CL+&QLRL7D5W.WHCN[?U'E
MQ@KW\=J;2&JZ.-M9.#$S2LLUZK.:1&2-VYT3QVV Z;#6@K,<VO#%$U>JI&U&
M[_4<OX,6?0](ZJM(WF6'*WI-O/9RK_D7#2.KX=4.M)5Q>7IQ0M3^EO55A1ZK
MOT;OU7;_ #*YP5Q\T6G]007ZLL39LO;7DE8K>=CG=_7O14 T7 W3M;4-*SKG
M4<;,AFLI/)R.G1'MKQ-=LUK$7N[C8\;]'8YVE;>I,9$S'9[#,],KVZS4C<O)
MU5KMN]-C4Z:ES7"7(7\/>Q-_*Z3FF?8HVZ$2S/K\W58WL3KM_P ^).LLYG.)
ME+WLZ7P>3Q^,N*U+^3R,*P(R/?=6M:O557_@!D\4\I-GO<[+DW?!L7*U25=D
MVV>Z1F^WEU+EH30^%T]IZM!%1@GLRQH^S:GC1\L[U3=5<Y>J]? TG%_"K6X.
M6<1B:\LR5VU88HXF*YRM;*Q.Y/4FYT.BBI2KHJ*BI&U%1?8!R2GCX-+>Z"KU
M,)$RIC\SC'36*T2<L?:,5=G(U.B+T^\[$<QSM.T_C]IRVRM,ZK'BYV/F1BJQ
MKE5=D5W<BG3@.3<=ZM?TC1#^PBYY-15D>[D3=R;.Z+YEAXL91=(\.\WE,/7A
MANMB2.-[(T39SG(W?IY;JOM-7QMIV;<FB?1*TT_9:@KR2=DQ7<C4YMW+MW)Z
MRYZRP%?5&E\EA;:JV*Y"L?.B;JQW>UWT*B*!7.%^AL/@=+T9%IPV<E;A;/;M
MSL22661Z(YV[EZ[;KW%3XEXNCH/5NG-6Z?A;1EMW8\=>KP,Y8YXW[]5:FR<R
M;=YD:3UOE](8N/ ZTT[F)+&/:D$-ZA6=8BLL;T:[=.J+LG_V(2/,<3M88FU<
MPUS$:4P\OI3$NMY);DZ=&_ \&I]/\0-?Q\QJYG7G#_&I++"RW8DADDB=RN1B
M\O-LO@O+NGTG8,+A,9@ZD=;$T*U2&-J,1(HT:NR>:]Z]WB<ZXGT;5CBCPZGK
MU9Y8(+,BRR,C5S8TV3JY4[OI.K ?,C&2,<R1K7L<FRM<FZ*<IT+1JOXO:^C?
M5@=&WT;E:L:*B? \$V.L''+F1MZ#XKY_)7L-D[N'S,,3X[-&!9EC>Q.56N1/
M^>X"W<8F,BX4ZF9$QK&-HR(C6ILB=/(P>#FC\9B-'8RZ^M'8RMR!EBQ;F:CY
M5<Y$5$1R]S439$1.G0:XR,NI^#N?LU,;D()+%25L=:Q K9G;;HGP._KWH6C0
MT;X=&X2.9CHY&4XFN:Y-E1>5.BH!0M7?ZPFB/W"S]SC!URSWZ<:<3H_(OD_(
M="HN2L5D79MF1%3E1WFB;IT]IMM54K4G'G1MJ.M.^K%1L-DF;&JL8JH[9%=W
M(>_$S2>6DSN,UAH_LW9[&M6.2K([E;<@7JL>_@OE_P $ N%G2V!LXU<?-AL>
MZDK>7L?1VHU$]6R=/H.7<(L&FG.+&L\5%9FL5Z\%=(%F=S.9$J*K6;^/*B[)
MZD-NG$O4=B/T:IP[SC<JOP4;.J-@:OFLGD:3@Q1R]/BCK--1666LK)#7EL/C
M3X#'.17<C?4U%1$]@&WI?ZRM_P#V"W_>-/FY$W1/&J"\Q>SQ&JHNPFW7X+;C
M.K5]2N3ZU53*J4K2>Z(O7%K3)47"-C2?LUY%=VC>G-W;^HW7&'34FIM#W(*;
ME9D:JI<J/3HK98]U39?#?JGT@:/CA?L7JV*T7BW*E[4,Z0RN3_JZR+O([ZO\
MS4<5:RS930_#JB^2MA[J_P#2EC=RN?!$B)V>_DO7?Z#[X)V+.N,U<UQEJZQR
M101XVHQW7E5K465Z>UZK]Q8N+VE,AF(<3G--HQ=08.?TFO&Y=DG9^E&J^O9/
M^5 M-72F JXQN.APV/2DC4;V2UV*B^WIU7UE-U54J\*^%>H9M+MECY5=-"R5
MZO;"^14;\%/!$WW1#Y@XMM2HC;ND-4Q9-&_"JLH.>BN\D?W;;^)M*%3+:[T!
ME:6L<8S%.R/:,A@:[G?%$O6-S_\ $B]?H\ .:</=;\.M-8"&*6K?M9.=B27;
M<V.?(^:5>KE5RIU3?<^,;JO3+.*V$R&A:]JI^4G+3R==:CX8GM7JR1$VV1R*
MFWTEITSK?+Z.QT6!UEIW,S34&)!%D,?7=8BLL;T:[IU1=D3I]Q9]):SRFI\^
M]E;35^A@HXE5US(-6&223ILC(_+OW4"C\4,!%J7CCI7&6Y)&TI*$CK+&.Y>U
MC:Y55BKY*J(B^H['2QM+&4U@QU.O5A:WE1D,:,39.[N.?9ZG:?Q[TW;96F=5
MCQD[7S(Q58U55=D5W<BG3)/ZMWL4#CW ^]^2^&&I[Z-YEJY&],C?/E:B[?P/
M3@3IRIE=/)K+/1QY+.YF1\[I[#$>L34<K6L9OORHFW@9G ?%RMT/FJ>3JS0M
MGREI'1S1JQ7,=RIOLO@O7J:;2-[,<)W6M.YG#Y/*Z?;*Z7'Y"A"LW(QR[]F]
MJ=45.H&1[H+1&,ET9D<]C(&4,K3A572UFI'V\2KL]DB)\9-C,XE:BMZ;X(U;
M..D6&S/!!6;*U%WC1[=E<FWCMW%;XKZAU!KS2>0H:;P&4I8B*+M[=J[7=')8
MVZMBBC[UW7;=?5]?0\WI1-6<+(,).Y:UA]2)8GN146*5K45JJG?W@<\T7KCA
MGI?!18^K2OROY=YYYL:Y\D[U3X3G*J==S#TCJC!U^,E!VAHK<&*S3'19"I)6
M?%$V5-U9(U%Z(OA]9<,%Q&RN H1XO6^FLVF3JHD2VJ-5UB&RB=$>BIW*OE_]
MBR:*U9E]39>TYVG+6+P,<7]%8O?T<TTF_A'X-VWZ^H"Z'"^*F"BU)QTTIBK3
MY&TIJ$BV6QNY5DC:YSE8J^2[(B^H[H<MU%2M/]T!I>VRM.ZK'C9FOF2-58U5
M5VR*[N10+9J5:VDM#YFYA:5:JM*E)+&R&)&MW:U53HAQ7AEK70> Q'IF6BR%
M_4-_^FO7)J#IG.>O56M<J?%3U=Y^A,UCHLMA[V.L_P!3;A? _P!CD5%^\Y-I
M/46<X<T6Z;U9@LID*=/=E+*8V%9VR1;_  6N:G5JHG_/B!3M0ZVTTS6V S^A
M:URMD?265KT*4G0QV8'+LO-TVYDW[_9Y%BUK&_3?&1^IM382WF=/2TVPUI88
M.W2E(BINJL\.Y>OK+MI_7.4U)J.M7Q.F,A7PK45;5_),6NJ+LNR1L7J[KL1G
M]?9+3VH;-7*:3RT^)3;T>_CX_2.;SYFIU3Q_ #PP6H^'.L,K3;27'296!_:P
M1S5^QF:Y$[T1R(J]_<:K5DJZ*XOXC.I\#$Z@:W'77;_!;,B_T;U\$[T3<T.L
MYV\1\AAZFE],9*E=ANQV9LO<I+6[&-J]41R_"55\CJ/$G3#-6:*R&)<J)8='
MSUY%_0F;U8[?PZ_P50-'QLR\L&GJFGZ#U3)ZBL-QT7*FZM8Y=I'_ $-7^)7^
M/6*APG ]N,H)RQ5'UX8_H7;<UO!3\I:WU-[Z-10.1,+49C*J2+OO.B;2R)Z^
MG\?46KW1-.S>X:68:5>:S,MB%4CA8KW;([R0#>: T5A\!INI"VE#/;FB;):L
MSL226>1R;N5SEZKU\"DT<7#I+W0M>MA&-JX_.8V2:Q5C3ECYV*NSD:G1%W3^
M*G7L<BMQ]9'(J*D345%\.ASG/T[+^/NE[3*TSJL>+G:^9&*K&JJNV17=R*!C
M\4JE9.(7#W_H\/\ 279N?X"?"^ G?YG4:]6"LBI7@BB1W?V;$;O]1S;C15R5
M>YI;46,QT^29A[KGV*U=O-(L;V[*YJ>.VW\2R:/UI!JBS/%5Q.9IQQ,1RS7J
MBPM557XJ;]ZH!S+A9I+'YKB/KC*Y>%MR.EE9&5J\OPHV2*N[I.5>BNV1$12R
M\>]+XRSP\R62@J05\EC6MLU[,,:,D:YJ]W,B;[=5Z'MP>IV:N<UZZS6FA;-F
M9'QK(Q6H]NW>W?O3UH;SC#7FM<,M1058I)IGU51D<;5<YR[IT1$[P*CQ)UCD
M<=P,QN6KRK#D,G5JQOG8G6-96(KG-V\>J[&DTEKSAGIO!0XZKC[LFS$2::3%
MN<^=VW5SE5.JKU+I+I'WU<$\1@K"NJV_R956)[VJBPS,C;RJJ=Z;*FR^/>:W
M"<2<CA:+,;K+3&>9DZK4A=8IU76(;*M3;G:Y//O JV@M0X%G&")-#QVZ^)S%
M=Z7:DE9\,3)F]6O8B]$W3=-D]9[K=KZ&XF:HR&ML)<NP9&=):6595](9%#ML
MD?FW;NZ'1M%:KS&I\K;DDTY:Q6"CC1(9[W]'/-)O\WX-V_BGU:JWQ)NX?+7Z
M6HM(YN**.9S:UFE MF.:+]%R\O<J^74#,TGE= :GSD60T\[&2YFLQW*K(NRG
M8UW1V[51%7_+<TU;_63M_P"P&_[U#0^COUOQ+TWE--Z9N86GBY76+F2M5O17
M3HO_ %:)WNW]?FI9:].TGNA[5Q:TR5%P;8TGY%Y%=VB?!YN[?U 5S4<T.DN+
MV5SNK,%<R>+N5XFTKT5?TAM1&ILYJM_1Z[KNG^9;M.YSAWJ[,TYL6N,ES-9>
MVA:Z'L9V+LJ=RHBKMY=3ZS/$*[@,_=IYC2>9=CVO3T6]1B])9*W;JKD3JU=]
M^G4H^H/_ %A:NTV[3&EK^-?1O,N6LO<J>BJD;5ZL1>]RJ!WD          "K
M\3\[/IO06:RM-$])KP*L2JFZ(Y>B+]&Y:#6:GPU?4.G[^)N?U%R%T3E1.K=^
MY?H790*7P?T/C<3I.ED+D$=[,Y*)MRW<LM221SY$1RHBKU1$W+#5T-@J>K6Z
MCH5?0\AV3H7I77LXY47Q>Q.BKZSG^CM4YOA_C&Z;UE@LM<91_HJF2QU=;$<T
M*?%YMNJ*B="TZ5U?G=3:G5*VG+6/TU'$O/:R+5BFDD_1Y&>7M_X 4G*Z9IZF
M]TA<@RL?;4:V+AL/KN7X$KD79J.3Q1%7?8Z;JG1>!SNGK6-M8NFD3X7,C<R%
MK71+MT5JHG147;N*OBZ=IONA,U;=6F2H_"Q,;.K%Y%=SIT1W=OZCIDO6)^WR
M5 Y5PNJ/UAP*BQ66<DG:02T>95W5$8JM:N_FFR?4;'@9G[&2TM-B,LJIF,%,
MM"RUV_,J-^(Y=_-/N4^N 56Q3X;U(;E>:O,EB=5CE8K'(BR+MT4I7&-N2T3K
M!^>TY"^1VI*BXN2.-=N6U_U<FWBNV_U*!9=&)'K'BCG-4.1'T<.JXF@O@YR=
M99$]JKLGJ//1_P#?_K3]PK_>7;AYIN+2>C\;B(]EDAC19GIWR2KU>Y?:NY4=
M)TK4?'35]J2M.RM+1@:R9T:HQZHO5$=W*!HM&4J_$/BCJC,:AC2W5P4Z4*%*
M9O-$SOW>K5W17+M_'U(= UMH' ZJPD]*Y0KQ2\B]A9AC1DD+D[E:Y$\%\.XI
MF3Q^8X=<0,EJ+#XRSE].9KE=>JU$YIJ\R?\ 6-;^DB]?K]F_OG^(^5S>/DQN
MB-,9Q^4M(L+;-VJM>*MNFW.KG=ZION!.B,U<S7 K(/R;UDN5:=FI)(O57]FU
MS4<J^*JB'A[GK1V+KZ"QV8MUH[F3O1\SI[#4D6.-%5&L9O\ %:B>"%BQVE5T
MOP@M8.%5L68\?,DCF(JK+*YBJY43O7=5,G@O7FJ<,-/06H9()F5D1T<C5:YJ
M[KWHO5 .:\:=)0,U_IC\C2.Q?Y>E_)]_T3^C[:+=%7?;INJ;I]1V&#2&GX,+
M^28\122AV78K$L+5W;MMU7;=5]?>4SBM3M6==</9:]::6*'(JZ5[(U<D:;=[
ME3N3VG4 .0>Y[67'RZRTZDKI*&(R:LJHY556,=NO+U\/@_Q4V>B_[Z^('[*E
M_ND,7@S2M5=7\1I+56>&.?)L=$Z2-6I(FS^K57O3V&PTA4L1<8M=V):\S*\T
M=-(Y7,5&OVB1%Y5[EV K&DL76X@\5-3Y;4;/2Z^ M>@T:<J;Q,5-]WJU>BJ=
M&U7H33^I\>E3(X^)G(Y'1S5VI'+&J+O\%R)NA1,K0SO#SB!DM18;%SYC3>95
M'WZU5-YJ\J?]8UOBG_/3H;'(<3LCDX65=&Z4S5C*2N1J.R%1U>"%/%7N7_(#
M6^Z9A='P]Q4%9[T>F2KQQO5V[D79R(NZ^/K.AZ8TMB=+8J*#'TXDDA9O)85B
M++,[;J]SN]7+U^LI'N@:5^_HO"LAJR3VFY2L^5E=CI.7;?F7HF^R>9U=4W39
M>X#BG!_#5]:9?-ZVU+&R]<=<DITX9D1\=:)BI\5J[[+O_P ]2T<6]"XC-:6O
M78J\=++8^%UJK=KM2.2-[$5R)NG54Z%;QT.8X4ZHRJ18JYEM'92=;4:T8^TE
MIRK\9%8G>U?/U)ZT/O5VK\YKG%RZ>T5I_+5EOM[&QDLA ZM'7C7H[;?JJ[?\
MJ!Z9S.3ZB]S3;REI>:U/BMY7;;<STV15^E4-[PBT7B<1H_'69*<5G)7(&36;
M4[$DD>KD1=N9?T4Z(B=W0\]<Z=_(_ W)8'&1R6%K8U((TC8JND5$1-T1-^J]
MY;]&1OBTGAXY6.9(VK&CFN3947E3HJ <RSF-KZ7X[Z7L8.&.G#F()8+D$+48
MR3E151W*G3?NZ^H\>*].?&<3\%J?+X:UF]-5ZSHG101]MZ-*N^SUC\?;^!N]
M?4[4W%W05B&M-)7A6?M)&,56LW:NW,O<GTFWU9K;)Z:S_8V-+9.]A'1HJ7J#
M>V<U_7='1]Z)Z]P-5CM5<--96JE1?R>ZZV5'P06ZO8R(]J[IR\R)X^"+U.G)
MW=.XX'Q)R$?$K'0X?36D\HW+2SL<F1NT%KMK-15W?VB]?H.ZX^%]:C7@ED66
M2.-K'/7O<J)LJ@<L]TC7A]YV.E[&/M79BHU7\J<RIN[HJELUO>9I;0N5S..J
M5V7*U57,<V-$ZKT3?;U]2O\ NA:5J]HW'1TJTUB1N6JO5L3%>J-15W79/ O>
M9Q,&;T[:Q=U/Z"U L+^G=NG?]'>!1>"^B\?1TE3S&1ACOYS*L2Y:N66I(]7/
M3?E153HFQIN,^!HZ5EQFNL!$F/R=.[#'82NU&-LQ/=RN:]J;;KU/G1NH\UPY
MQ_O9U=A,K>K4=V4<ECJZSLEAW^"CD3JBH,Q)F^*N<Q=&'#7L3I*C:9;M6+\?
M9R6U8N[6-8O7;?\ 'P0#)]T+ _*X/2%>":2NZWFH&)(Q=G,1T;T54]>RG1]-
M::Q&F\?#3P]"O6CB:C>9C$1[O-7.[U5?-2G<9:5BRNBTIUI9FPYV![TB8KN1
MB-?U7;N3NZG20!R/1G^L-KK]QK?<TZX<KTA2M1<>M:VY:L[*LM*NV.9T:HQZ
MHC=T1W<H'GAGLT7QFOX=$[/%ZF8M^OOW-LIT>U/:B;GKQ=M/U!J#3V@Z3U_]
M(S);R"M7XM6->947RYE3^">9F\<]/S932"Y7%_ S&$>E^K(WH[X'5S=_6B?P
M-;P1@L:@M9?7F5K]E9R[TCJ,=U6*LWN1%\E7[D Q>/\ BFY!-$8N&22O'-E&
MP<\3N5S6<BHNR^'3=#HN/TAI^AB$QE;#T4I<G(Z-8&KSIMWNW3JOK4JO%JI9
MLYW0CJU>:9L.71\BQL5R,;R.ZKMW)ZSHX'Y]X4:(I3\1-2T\@Y]S$:>M*S&T
M9G*^*%9%557E7HJHB(A;./\ IS'OX>W,I6K0U<EBU;9JV86(Q\:H[N14Z[=>
MXR.%U.S7X@<0Y;%::**:]&Z)[V*ULB<J]6JO?]!M^-E:>WPOU!!5ADGF?!LV
M.-JN<Y>9.Y$Z@>ER[+DN#MF]95%GLX)\SU3NYG0*J_>5+@!HC&0:'Q6:R->.
M_E+<#7-FL-2188TZ-8S?XJ(GD6=L;X>"#HIF.CD9I]6N8]-E:J5UW14\%.><
M(]5YC1VB,/5SV%R.1P\]=)Z=[&PK.L;7=>SD8G5%3S W7'?3]/"X6+66!@BH
M9S%3,D[:!J,[9BKLYC]OC)[3S]T+9?D^$-"U$O9R6K%61J_)5W5/O/+55[+<
M6)*NG\7A,GC-.]JV;(7\A"L*R,:O]6QJ]5W\S;\?<9-)P[ITL74FF[&[61L<
M,:O5&M7;N3P0"W:6T5A<#A(:,6/K2O5B)8FFB:^2P]4^$Y[E3=RJN_?YE!TO
MCHM*>Z R>*P[&U\5E<6EU]9G1C96OVW:U.B>/UG9#F,U.RONAZUQ*TWHB8-T
M:S\B\G-VGQ>;NW]0'IK_ #6@]/:HANZ@HLNZB? UL4455;$R1HJ[*C>Y.N_7
MHIS3BQK;3.9P#+&+T]E\?FZEB&:K>EQJ0=FY'IT5Z+W*F_3SV+GFIKFB>+N4
MU!<PF0RN(RU6)C+5*'MGU',3E5G*G79=M^GF:KBMJC+ZUT9>HZ<TWE8J#49+
M:M7JSHG.1'IM'$SJKG*NRJO<B(H'0^(K&6^%N5GL1QR2_DYST<YJ*J*K>JIY
M&/P6I55X8Z8F6M!VWHC5[3LTYM]UZ[FYSN*FS&@+>,A^!8LT.R;S=-G*SHB_
M2<YX9ZXL:>TMBM-9?2NHFY:DJ5'-AI.?&Y.;9'H_NVV7?Z -CQ0_O8X:?O4W
M\AY\4:[M6\1M.:+MO>S#.@?DK;&.Y5GY%Y6L5?DF9Q)I69^*/#N>"M-+#!9F
M661D:JV-%9TYE3HGTF3Q7T_F'Y##:KTG VQFL0YS7UE7;TFN[XS-_-%3=/:H
M%M72F 7&?DY<+CO0N7E['T=G+M]7?ZS[TIIZEI?"PXK%]MZ)$JJQ)9%>K45=
M]D5?!/!"D-XML6IM[T-5?E/E_P!$] =\?;NY^[;?Q_@7/1MS,7\!7M:CHQ4,
MA+NYU>-_-V;57X**ORMN\#,SL,4^(N)-$R1&PO<B/:B[+RKUZG+/<QTJL_"^
M)\]:"1Z79]G/C15^,==MP^D59H57E21CF;^6Z;'"N&&H+7#?!W=,YS3>>FMU
M[DLD$E.HLS+#'+NBHY.B ;KW2M9US!:8JLD?&Z?-P1(]B[.;S(Y-T]:;G1]-
M:8Q&FZ$-7$4:\"1M1JR-8G.]?-SN]57S4HO&R"UDL=HN2I2M/5,W5FDC;$KG
M1-V555R)OMMXG4P.2YG5'#S2NJ<FR+%OR.>FE66YZ%26S(QRIU1SEZ-];47Z
M"AZCU5@[_$G162TQA\EB,BN0;!9DGI>C-GB>J(K5V7X2]5^LLND<G9X99K4F
M.S^!RUR.Y>?=@R5&JLZ3,?W-=MU14,'7F5SFL-4:+N5M/9"G@JF7CY7V87-F
MD7=%616;? 8B>*@67W2\,EC1&-@@D6*67*UV,D:NRM5>9$5"[:8T7@L#A(L?
M4QM5S.3^E?+&U[YG*G5SU5/A*OK*QQZIV;FG,*RG7FL/;F*SW-B8KU1J*NZK
MMX>LZ5'\1OL0#CFAZ4>F./.I,'BFI#BKM!N0]';T9')S-1>5/!/A+T]AJ)YH
M=$<6-29C6N#N7J.1Y%HY-E=;+(&)WLVZ\OAW>1:J=*TGNBKUQ:TZ5%PB1I.L
M:\BNYV=.;NW]1E7>(]_#9>]3U#I#-1U62*E:W2B]*9*SP5>7XJ^KKW@96E<Q
MH#56:@OX)V-ES-9BJS:+LIV(J;+NU41?P*1Q)P+=2\>=.8R>:2.G+CY'6FQN
MY5EB:JJL:^IRHB+ZB+4+]><1=-9'36F[N(KXR?TBYD[=5:KI6HO]6B=[M_7Y
MGSQ0;F&\=-/VM.HR2_3QTEE*[E5/2&-5>>+?P5S55$]>P'77Z4T^_%KCG87'
M+15O+V/H[>7;ZN_UG.N%S?>;J[6.D8I))<311N0IL<Y7.B8]NZL15\-T-C)Q
M;8E7ECTAJEV2VZ5%HN1.;RY^[;U_P/?A1IS+QV,UJ;5T3(LUFI$5:R+S)7@:
MFS(U]>P&AX(:?HZDIV==9Z%E_,92=[F+8:CVUHT=\%K$7?;;S-EQNTE172MC
M4.*@BQ^=Q'_2X+==B1O7E[VN5.]%3S\C4Z>L9KA3DLAB;F%OY32DT[YZ-O'Q
MK,^NCE5>S>SOV3_G<G6&;S'$VHS36F<+E<?CK+FK?R60@6!K(D7JQC5ZN5?\
M@,3C5EILYP!Q>45$99MOJ3*B)LB/5.NWJW.G:*TCB].X:K#7J0NM\B.GM/8B
MRS2*F[GN=WJJJJ_64GCM@WP\):F*P]2:=M:Q6CCBAC5[D8WIOLAUB#I#&B_)
M0#DUJE5_\XNC%Z+!V2X*1>3LTVW[1.NVQUB""&NSDKQ1Q,WWY6-1J;_0<JX@
M+>TQQ3P^KV8J[DL4ZB^A82E&LDD+E=S([E3O3_B7K1^IH]3U;-B#'9*E#%(C
M&K>KK"LO1%W:B]=O#Z -^                  *]Q"QUG+:(SF/H1]I:LU7
MQQ,WVW<J=$W'#O'6<1H;!8^_'V=NM4CBE9OOLY$V5-RP@
M            -'K2GG+V#?%I?(PX_*->U[)9H^=CD1=U8J>"+YE19G^)-5B0
M6=)8RW8VV](KWN6)5\]G)NATH <XT%I'.MU9>U=K6S6DR\\/HM>K5W6*K#OO
MLBKWK_Q.C@            *CQ9P]W/</\QC,7$DMRQ$C8V*Y&[KS(O>I;@!B
M8B%]?%4X94VDCA8UR>2HB(IE@
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MW)MWG00
M
M
M
M
M                                            !I,UJ6GB+:5[,<[G
MJQ'[L:BIMU]?J,#W\XSYJW]A/Q-J\/EM&XKV<]N*PTF:VM&UJ!5??SC/FK?V
M$_$>_G&?-6_L)^);I<WME7K<'OA:@57W\XSYFW]A/Q'OYQGS-O["?B.ES>V3
MK<'OA:@57W\XSYJU]A/Q'OYQGS5O["?B.ES>V4]9@]\+4"J^_G&?-6_L)^(]
M_.,^:M_83\1TN;VRCK<'OA:@57W\XSYFW]A/Q'OYQGS-O["?B.ES>V3K<'OA
M:@57W\XSYJW]A/Q'OYQGS5O["?B.ES>V4]9@]\+4"J^_G&?-6_L)^(]_.,^:
MM_83\1TN;VRCK<'OA:@57W\XSYJW]A/Q'OYQGS5O["?B.ES>V3K<'OA:@57W
M\XSYJW]A/Q'OYQGS5O["?B.ES>V4]9@]\+4"J^_G&?,V_L)^(]_.,^9M_83\
M1TN;VR=9@]\+4"J^_G&?,V_L)^(]_.,^9M_83\1TN;VRCK<'OA:@57W\XSYF
MW]A/Q'OYQGS-O["?B.ES>V4]9@]\+4"J^_G&?-6_L)^(]_.,^9M_83\1TN;V
MR=9@]\+4"J^_G&?,V_L)^(]_.,^9M_83\1TN;VRCK<'OA:@57W\XSYJW]A/Q
M'OYQGS5O["?B.ES>V4]9@]\+4"J^_G&?,V_L)^(]_.,^:M_83\1TN;VR=9@]
M\+4"J^_G&?-6_L)^(]_.,^9M_83\1TN;VR=9@]\+4"J^_G&?-6_L)^(]_.,^
M:M_83\1TN;VR=9@]\+4"J^_G&?,V_L)^(]_.,^:M_83\1TN;VR=9@]\+4"J^
M_G&?-6_L)^(]_.,^:M_83\1TN;VRCK<'OA:@57W\XSYJW]A/Q'OYQGS-O["?
MB.ES>V3K<'OA:@57W\XSYFW]A/Q'OYQGS5O["?B.ES>V3K<'OA:@57W\XSYJ
MW]A/Q'OYQGS5O["?B.ES>V4]9@]\+4"J^_G&?,V_L)^(]_.,^9M_83\1TN;V
MRCK<'OA:@57W\XSYFW]A/Q'OYQGS-O["?B.ES>V4]9@]\+4"J^_G&?-6_L)^
M(]_.,^9M_83\1TN;VRCK<'OA:@57W\XSYFW]A/Q'OYQGS5O["?B.ES>V3K<'
MOA:@57W\XSYFW]A/Q'OYQGS-O["?B.ES>V4]9@]\+4"J^_G&?,V_L)^(]_.,
M^:M_83\1TN;VR=9@]\+4"J^_G&?-6_L)^(]_.,^:M_83\1TN;VR=9@]\+4"J
M^_G&?,V_L)^(]_.,^:M_83\1TN;VR=9@]\+4"J^_G&?-6_L)^(]_.,^9M_83
M\1TN;VR=9@]\+4"J^_G&?-6_L)^(]_.,^9M_83\1TN;VR=9@]\+4"J^_G&?,
MV_L)^(]_.,^:M_83\1TN;VRCK<'OA:@57W\XSYJW]A/Q'OYQGS5O["?B.ES>
MV4]9@]\+4"J^_G&?-6_L)^(]_.,^9M_83\1TN;VRCK<'OA:@57W\XSYJW]A/
MQ'OYQGS5O["?B.ES>V4]9@]\+4"J^_G&?-6_L)^(]_.,^9M_83\1TN;VR=9@
M]\+4"J^_G&?-6_L)^(]_.,^:M_83\1TN;VRCK<'OA:@57W\XSYFW]A/Q'OYQ
MGS5O["?B.ES>V3K<'OA:@57W\XSYFW]A/Q'OYQGS5O["?B.ES>V4]9@]\+4"
MJ^_G&?-6_L)^(]_.,^:M_83\1TN;VR=9@]\+4"J^_G&?-6_L)^(]_.,^:M_8
M3\1TN;VR=9@]\+4"J^_G&?-6_L)^(]_.,^:M_83\1TN;VRCK<'OA:@57W\XS
MYFW]A/Q'OYQGS5O["?B.ES>V4]9@]\+4"J^_G&?-6_L)^(]_.,^9M_83\1TN
M;VR=9@]\+4"J^_G&?-6_L)^(]_.,^:M_83\1TN;VR=9@]\+4"J^_G&?,V_L)
M^(]_.,^:M_83\1TN;VRCK<'OA:@57W\XSYJW]A/Q'OYQGS-O["?B.ES>V4]9
M@]\+4"J^_G&?-6_L)^(]_.,^:M_83\1TN;VRCK<'OA:@57W\XSYJW]A/Q'OY
MQGS-O["?B.ES>V4]9@]\+4"J^_G&?-6_L)^(]_.,^9M_83\1TN;VR=9@]\+4
M"J^_G&?,V_L)^(]_.,^:M_83\1TN;VRCK<'OA:@57W\XSYJW]A/Q'OYQGS5O
M["?B.ES>V3K<'OA:@57W\XSYJW]A/Q'OYQGS5O["?B.ES>V3K<'OA:@57W\X
MSYJW]A/Q'OYQGS5O["?B.ES>V4]9@]\+4"J^_G&?,V_L)^(]_.,^:M_83\1T
MN;VRCK<'OA:@57W\XSYFW]A/Q'OYQGS-O["?B.ES>V4]9@]\+4"J^_G&?-6_
ML)^(]_.,^:M_83\1TN;VR=9@]\+4"J^_G&?-6_L)^(]_.,^9M_83\1TN;VRC
MK<'OA:@57W\XSYFW]A/Q'OYQGS-O["?B.ES>V3K<'OA:@57W\XSYFW]A/Q'O
MYQGS5O["?B.ES>V4]9@]\+4"J^_G&?-6_L)^(]_.,^:M_83\1TN;VRCK<'OA
M:@57W\XSYFW]A/Q'OYQGS-O["?B.ES>V3K<'OA:@57W\XSYFW]A/Q'OYQGS5
MO["?B.ES>V4]9@]\+4"J^_G&?-6_L)^(]_.,^:M_83\1TN;VRCK<'OA:@57W
M\XSYFW]A/Q'OYQGS-O["?B.ES>V3K<'OA:@57W\XSYFW]A/Q'OYQGS-O["?B
M.ES>V4]9@]\+4"J^_G&?-6_L)^(]_.,^:M_83\1TN;VR=9@]\+4"J^_G&?-6
M_L)^(]_.,^:M_83\1TN;VRCK<'OA:@57W\XSYJW]A/Q'OYQGS-O["?B.ES>V
M3K<'OA:@57W\XSYJW]A/Q'OYQGS5O["?B.ES>V3K<'OA:@57W\XSYFW]A/Q'
MOYQGS-O["?B.ES>V4]9@]\+4"J^_G&?-6_L)^(]_.,^:M_83\1TN;VR=9@]\
M+4"J^_G&?-6_L)^(]_.,^9M_83\1TN;VR=9@]\+4"J^_G&?-6_L)^(]_.,^:
MM_83\1TN;VRCK<'OA:@57W\XSYJW]A/Q'OYQGS-O["?B.ES>V3K<'OA:@57W
M\XSYFW]A/Q'OYQGS-O["?B.ES>U/68/?"U JOOYQGS5O["?B/?SC/F;?V$_$
M=+F]LHZW![X6H%5]_.,^:M_83\1[^<9\S;^PGXCI<WME/68/?"U JOOYQGS-
MO["?B/?SC/FK?V$_$=+F]LHZW![X6H%5]_.,^:M_83\1[^<9\S;^PGXCI<WM
ME/68/?"U JOOYQGS5O["?B/?SC/FK?V$_$=+F]LG68/?"U JOOYQGS5O["?B
M/?SC/F;?V$_$=+F]LG68/?"U JOOYQGS5O["?B/?SC/FK?V$_$=+F]LG68/?
M"U JOOYQGS5O["?B/?SC/F;?V$_$=+F]LG68/?"U JOOYQGS5O["?B/?SC/F
M;?V$_$=+F]LHZW![X6H%5]_.,^9M_83\1[^<9\S;^PGXCI<WME/68/?"U JO
MOYQGS5O["?B/?SC/FK?V$_$=+F]LG68/?"U JOOYQGS5O["?B/?SC/FK?V$_
M$=+F]LHZW![X6H%5]_.,^9M_83\1[^<9\S;^PGXCI<WMDZW![X6H%5]_.,^:
MM_83\1[^<9\S;^PGXCI<WME/68/?"U JOOYQGS-O["?B/?SC/FK?V$_$=+F]
MLHZW![X6H%5]_.,^9M_83\1[^<9\S;^PGXCI<WME/68/?"U JOOYQGS-O["?
MB/?SC/FK?V$_$=+F]LHZW![X6H%5]_.,^:M_83\1[^<9\S;^PGXCI<WMDZW!
M[X6H%5]_.,^:M_83\1[^<9\U;^PGXCI<WME/68/?"U JOOYQGS-O["?B/?SC
M/FK?V$_$=+F]LG68/?"U JOOYQGS5O["?B/?SC/FK?V$_$=+F]LHZW![X6H%
M5]_.,^9M_83\1[^<9\U;^PGXCI<WMDZW![X6H%5]_.,^9M_83\1[^<9\S;^P
MGXCI<WMDZW![X6H%5]_.,^:M_83\1[^<9\U;^PGXCI<WMDZW![X6H%5]_.,^
M:M_83\1[^<9\U;^PGXCI<WME/68/?"U JOOYQGS5O["?B/?SC/F;?V$_$=+F
M]LG68/?"U JOOYQGS-O["?B/?SC/F;?V$_$=+F]LG68/?"U JOOYQGS5O["?
MB/?SC/FK?V$_$=+F]LHZW![X6H%5]_.,^:M_83\1[^<9\S;^PGXCI<WME/68
M/?"U JOOYQGS-O["?B/?SC/F;?V$_$=+F]LHZW![X6H%5]_.,^9M_83\1[^<
M9\U;^PGXCI<WME/68/?"U JOOYQGS5O["?B/?SC/FK?V$_$=+F]LG68/?"U
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M]@W[W%8+/Q$_MZ/]@W[W%8/:X7_57Z/GN+_WW^J"2 ;N9)   $D $!)  $D
M "0(!( $ D"   !) $@@ 2020 )!  D$  20@$D$H0 )!   D 020!)!("4$
MD (2020 )  @$D(    $D 2020!)!*$ "2  "$D 2020!)!( $  "00  ) @
MDCP $D  "2  !)" "2$) @D@ 20  '@   0D" 20!(  @ D" 20!) ) $  "
M00!) ) @D@ $ ) A"4() @D$     ) @ D "$ $D$D "2  !)  $D  "0! )
M @D@D" GB20!)!)    "00 !( A  !) )    020 )(   D @ 0" 20
MD" 20      20"0! ) @ D 0 !(()   " 20 !)  (20!)!(0  0 )(  E 0
M!) ) @$D 2 @ @ D""2"0( ) @  "00 !( @ D" 2 ()!" 20 !*=P( $D$@
M ""0! ) A"2"0() "4?2!T 0M'$3^WH_V#?O<5@L_$7^WH_V#?O4JYAPO^JO
MT=/&?[[_ %  ;N9((    "00!)   D@ 202 !!( @ D 02 (   D@ 21X  2
M0"0(!( (0"0!  $D   "0()()  @       D@D" 20!)   D@ 2/,$  @
M 2" @ D@ 20$) @D  020  )    0"0()()  $ 2 0!)!)   D 020@$@@ 2
M""0( ) @$D  2 (   ! !((  D   $ @D@D 0 !)   ! !(! $D$H0!(() $
M$D  "0    @ 2""0(!( @  /,$H (!)    2""0("  "2"0()  $$CP @D@
M"2"0 ( $A""0(!) $@@(  ) $   "0 () @ D" "0(!( @D@D $! $@$ "2
M )  $$D 2""0(   D " 2A $D$D "0  () $$D  2 ()( $D D 0       "
M0 !!) $H02 ()() @E/$@ 2 0 )() @D "  !:.(O]O1_L&_>XJY:.(G]O1_
ML&_>XK!APO\ IK]'3Q?^^_U02 ;N9!)  D$  $) $$D$@0 -P!)   ^XHGRJ
MJ11O>J)NJ-15V3S/@   !)  D@]'Q21M:Z2-[$<F[5<U41R>H^ G2 20$!)
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M)5V1ZM7E5?:$Q#X!!(0$$@  0!)"$@" "0 (    "2    $D D" 2 ()()
M(&HKE1&HJJJ[(B>($$GU)&^)ZLE8YCT[VN394#HI&,:]\;VL=\5RM5$7V*-I
MU+X!(" 'TV*18W2-C>L;5V<Y$Z(OK4^ E)  0 D@   !)  D$ "0  ! 0
M /MD4CVO<R-[FLZN5$54;[?(^0E )("$@  02 ()( $@@]'0R-B;*Z-Z1.79
M'JU=E]BA+S!("$ ]&12/C=(R-[F-^,Y&JJ)[5/,)T$D ("0U%<Y&M15<O1$3
MQ/J6*2)ZLE8Z-_R7)LOU!.GP20 @)! $D'VD4G8]KV;^RWVY^5>7?RW/@)
M$)(!($$D$@"/,$@0202 !  $D "2"4 $ ^F-<YR-8U7.7N1$W53[F@F@5$GA
MDCW[N=JMW^L;3J?-YD ! "2  )( $@@"0"  0$@0"0! )  @$@" 2!"$^!
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MUCK1.^+NGBJ?6?"ZNRCI-W.@='W+$L?P53R-/$M:9BD;TS\*E8B;VU,_+?\
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M=%0M.H&^FZ:Q-RONYD#5BD1.O(NR=_U?<5<V&'R]G%2/6!6OBDZ/B>F[7?\
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M.NU:M2>LZ%&/=)%SK&Y.]%7P--[YIO\ L.-Z_P#ZO_Q,3#YJUBT>R+DDKO\
MCPR)NU?P-@W4-*)SI:N#J1V.]'JNZ(OGML5C#R=N3?\ WJM.?G^USZ^6OT8&
M;RMK(=C%<@BA6!%Y6LC5BHB[>"^PU9D7KD]^T^Q:?SRN[UVV3;R0QSJI7EK$
M:TX\EN:TS,[ 20642""4  ! ()0@ "2    %HXB?V]'^P;][BKEHXB_V]'^P
M;]ZE7,.%_P!-?HZ>,_WW^H #=S!)    "2 2 (     "0! )( ! 2! )( D
M 0"0! 0   2!!)  D$$@0"2 )(  $@ 0  !G7LG/=J4Z\S8TCJMY8U:B[JG1
M.OU&"")K$SN?1:+3$3$>H "50D$ $ )\ ()! $D$@)0"2 @  $@@D" "0!!)
M     20 !) $@@ 2     @D@ 2""0(  $^! )\P!   D$ "2!Y@"2  !)
MD""2 !*$$D  "0(!( A   !) $@$   !) ) @D@D  0 !)   D" 2@ @ D"
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M"  0  0$D  "0(!( $  2A" D""2  )(  ! !)     20"0(!(0" 20!)!(
M @  20 \P"0! )  $  "0(\"2"0()(  $@ 0  !( @> ) ( 0 !( @!  )
M@$@""2"0!" D 0    $D$D  "0!!( @E  ()  $       $D#S)3N @$@" "
M0! 'F!)    E !"  2  ( ) @D ""0 ! ) @  "00!(() @(  )  @D@  20
M 0D@ "2"0(!( @D$ 2""0!   D@  20 )(  D@D""2"0()() $!"0(!)
M$!( @!"0 0 " "0()( $D$D  2$ @ D" 20 )( $D   20 )("       $D
M2""0 (0 202 !!) $A" !) 0  20!*  "S\1/[>C_8-^]Q5RT<1?[>C_ &#?
MO<5<PX7_ $U^CIXS_??Z@ -W,D@$@0"0$H )" @D@  2!!)!( $$@ 0  )
M$( )(   D 02" )!  $D "2  !(( D$  $  $D  "2 " D " @ D$$@02"
M  D @ 202! )( GV @ "2 !(  @D$ 2020 )( $D D""2"?,"   "  "2 !)
M!) $D$D 2 0    $D    )! $D$@" 2$ @$D 2"$)    " !(!  D@  20!)
M!)"    0  20"0!!( @D "   )(  D@D 0"0()(  $@""2 !)   E" !)!(
M$ D"  !(( $D$@""2"4 @$D "2 !(!   D 02  () @$@""2 !((  $@""0
M()(0 "00 )0#P  $ 2" !(()  @D""2"0()  !"$"   !* $ 20"0()( $@$
J(!*$ D""0  (     2  () @D@ 20$  D " 20   $D$@ 020   '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g73463g14k41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g14k41.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1B44&AO=&]S:&]P(#,N,  X0DE-! 0
M    &'<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJS!$111$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MB6-KP/3<;KYW_!'T]BKFF<ME+=&O8N>U^ U\S _E8&-.PW[=25]'- :T!H
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M;9IV+DS(?'&_N-,0YNW?IOT72=4XG_(3PHR;=/Y"Q:OY.RR(6)6@&)Q:07-
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M6 TGBY75F9&-EB=[7$%_.XL8S?T!!)]>GHO:?\&/'?R?9[%G;@SH:'&:1K?
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MJQV*D)QF1/M]0$<O*X'WF[?)W_=75;MW!Z8QM:*Y)1QE"1[:\,98&,<X]F@
M?^/-<PXA:=JZ'U7A-9X2$5:8N-AR,,?U6A_0O \@1N"!TWV0=E'=5*EI:X!S
M"'-<-P1Y@JH* @[H@14HB(@I4*501$0 I0(@*0H"D("!$02%4WZP^:H"J;]8
M?-!S;A/^6M0_VA_&Y=)"YMPHZ9K4'S'\;ETE<]+RL8=%2*%*Z-BE0JD$(B(*
M@B#L@0%+5"EOF@E$1$2%*@*51SSC7!SZ=I3#_P E:V/VM/\ P7,=)R^#J?$2
M#RM1_M< NO<7(O$T18=MN8YHG_\ >V_Q7%L4_P +*4I/T)V.^YP7@U^6INY9
M^9].CZRUA_5[C\3^];-OY_:M8\S\U[XZL[B1M2;\25>*TQG^AQ_;^]7: B(@
ME$1112%"D( 1 B"0B!$! B!!*(B(\#'-[7SA_P") ^K\5<*W,+C;$OB'DVVY
M%<>J B(J*D1$! B#L@E$1!+?-2% \U/S0 I:HV4A!*(B@(B(L$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$06UN.=[XC#)RM!]X>H5RK:W ^9\3F2E@8=R!YJY0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!XVXGR
MPED3^1V_=5UV.CA8Q[N9P&Q/JO.Y")H"POY.N^ZKK,\.!C.;FY1MOZH/1$1
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MXFZO8VW@H*F!Q$OO0.L.'B/8>Q/0D_<%[_A%L><#@II@YV/CR+?:@/0CIO\
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MF,.)]_%%.'FW]>0+*JEH:T!K  UH  'D!V52@($1%2B(B"E0I0$1%1(10%*
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M(@(BU&:7*:AS%ZK1R#\7CZ$@B?)"P.EFDVW/5W1K1OZ;E2W8;<BU7^2^2_\
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M1^AS2 O;\@[K]JW99PY[VI!$1;5Y2UH)F[30QR#T<T%6APF*)).,I$_J&_\
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M/ :>W.%Q%.J__6-9S/\ ^L=S^U!K'#'3%R+(Y'5VHV<F<RVY97\JD)ZAGS(
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M[A!S[AC^5\[\Q_&Y=!7/^&7Y7SOS'\;ET!8PZ,8=$A2H"+;:5+52I:@E$4H
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MB3:FKTS;T[:)?<J1_P Y6?\ ZZ+_ ! 7EU=+O&,L7&$63S>(DQ<D;VR"Q0L
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M6 .#>;H"-]]_@4G2G>.C;';?;HH"^<<[I+B[A\59S<VKYI9:S#/-7BOO+FM
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MF\=Y=Q$1:41$0$1$!$1!;WFQ/KD6'%L>XZA>E4,;7C$)WC ]T_!>=XPBN?:
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MHMX#</FN!&&DW!W'^=R__$D*U"JX/_"WLN80YIQS2".Q'A-6(X*X#%YCC#Q
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MDTTMYX]Q'H9G]?VK;J\,=:".&!@9%&T-:T=@!V"[Z.&6&\K>$L>B(B[-B(B
MB(@(B(/"Z^*. NG;S,W'3;=5UG,?7C=&.5A&X'H%1=F$$!>8_$ZCW576?XM>
M-X;R\PWY?1!Z(B("(B B(@(B("\+U9ERE8K2_P W-&Z-WR(V*]T0<SFQC<[A
M1I/-3>R9F@>:K*X;MF8.C7M]00=B.X*TUO"W4IM>$8Z;8]]O'\?=NWKMMO\
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MF(/1[7^0;TW'_@<QGFEL<"M)R6'E\GM--I<3OT;8+1U\^@ 6YYG_ )Y\!O\
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MOVGGB]GVY=_?W]%<JWM1SO?$8) UH/O#U"N$!$1 1$0$1$!$1 1$0$1$!$1
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M-<2WW=QOWVWZ*=COLV>#B%?L51DX=)Y-V!(YQ=YV!QB[^*(OK<NW7UV\EX\
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MFL#8RMN*26&$L!9'MS'F<&C;?YJ*S"* I02B>2(@I4*0BB(B"W\2+VT1F/\
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M&_3ZH\EN3=4,OZ3N9?"TK=F>#GC?3<UL<T,K?K->''8%O<^H[+$\(@!A\Z0
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M4I6>S10/YF[L.Y?N & =SOMV]5<:@REBAI_2=<99V$H6X8V6<BU@<8]HFEK
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M6 B(@(B("(B B(@(B(+>T+!?%[.X!N_O[^BN%;6X999(C%(&!I]X>JN4!$1
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M!C6L:&L:&M V  V "Q,> IQZIFSX\3VZ6HVD[WO=\,/+AT]=RLNAW$1$!$1
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M0B(B"!$"HE-D1!(Z(H52 B(@E% 4H'DI:H"D()"(@02%*I"J4!$1 1$11$1
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M+8B(@E2H'92@*5"D("(B"6]-U(4#NI0$'=$05(B(@%4J5([("E$5$A H:I"
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MBRV(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M8Z.!C)'<S@-B?5478O&@+#)X?4>\JZS/#@C8'<W*-N;U0>B(B B(@(B("(B
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M9C\E7/U3OW%8C07Y%D_7._<%N>6L7S-C1$6&Q$1 1$0$1$!$1 1$0$1$!$1
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MQ]2H'FB&ZH$]>I^]-SZG[U \U*B[@)]3]ZD$^I4(AND$^I4[G](_>J0I0E5
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M[Q]%<H"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M4*76K3AC=^ER[N^\]5?A7?"=M_[_ 'NFVK>MD_/^_@P[;V5>?Q>):UI_UM@
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MYQ$TN^9ZG]I5OJ4.GKUJ33_I4S6._L#=SOW?M5WE+\&*Q\MJR[:.,= .[CY
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M_P"LN4K[GT9CMIW+W?F_IC*W5F/I$(I39?1?)0JXHWS2,CB87R//*UK>Y*I
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M[%^G_H\\C-W1]=^A\NJRR(*)HHYHGQ3,;)&\;.:X;@CXA:[CM!Z5QN2^D*.
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M(^U>H0=UG+'BFS>&=PN\8'4W/]$2&-A<YKFNW'=NQ^LJJ=Z2+!QV[YWE+=P
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M/M,+PQUD&"5I[$;?6^87IQO'J<'OR_ON\>4^%I?$]N?W_P //'/DBQ>)L3
MLE\($#;\6[<#]JVZJTM82?,K7LS&QF (B(,<886D>@(ZK8X#O$TGS&Z969_7
M][_/[KIXW3ET]^V/[S]GJ%4%2I'8K+25(4*0BI"! B@D*0H"GS14A2% 4J*\
MO#<;'/S[-V^JO;R7AX;?:N?G][;;E7N.H68U52(.RE" 4A0.RD(J4"!2%%B0
MI4#N5(45(4A0I"BJE*CT4J**5"E!6$/8H.R++31=282?$V?IC !T;V=9HFC<
M$'N0/3U"V'3&<@S=(2,V9.P;2Q;]CZCX+,.&X(6D:EP-JA>&8P +9&G>6)@[
M^I \P?,+UX9S7Q^'J=>U_:O!GIY>&RNKI3?&]9^\;PBUG#ZQQER%OM,HJV-M
MG,D! !^!5Y?U/B*D9<^Y&\[=&Q^\3]RXW0U)>'AN[TSQ.E<>*93;YL/Q0D8,
M-7C/65TV[1\@=UM6-88\=58_ZS8F@_/9:1BZ]G5F=CREN(Q8VN?Q3'=>;8[@
M??U)^Q;^.@777^IACI=YSOW]G#PN^IJ9Z_:[2?=W$1%Y7N$1$!$1 1$0$1$!
M$1!;6X'ROB+)2P-.Y'JKE6EV!DTD)?+X9:=P/7LKM 1$0$1$!$1 6(U0Q_T7
M[1$"9*LC;  '<-/7]FZRZ$;@@]05K#+ALK&>''C<7G7E9-#')&X.8]H<TCL0
M?->BU^#Q< ]\1BDEQ1)>Q[!S.K[GJTCN6^8([+,T[4%N(2UIF2L/YS3NKEAM
MSG1-/4XN5Y5[HBQ][+4Z<HBEF#IW=HHP7O/V!9DN7*-993&;VLANL+9RDMN=
M]7"L;-*T[26'?S47PW_.=\!]JH-:]F"?;@:=#?\ T=AWDE']=P[#X#[UF8(8
MX(FQPL:R-HV:UHV 6]L<.O.N>^6ITY3\_P#3&U\+"9F6;[G7;;>TDHZ-_LM[
M#]ZRP[(BSEE<NKICACATBWR(+L?: [F)P'W%<*;VV7?2 00>Q7#\S4=0RMNJ
M\;>'(0/BTG<'[E]3Z+RF^6+XOTSA=L,OF\:M6>TZ05H7REC"]W*-]FCS7BM@
MTAJ$X6R8Y6A].4^_L/>:?4>OR6Q:ET[!F*XR>#+'RO&[FL(#9!ZCT<O9GXFZ
M>IPZDVEZ5\[#PDU=+CTKOE.L_ASP=ET326#@PU%V8RVS90SG:'#^:;MZ?I%6
MVBM.>#OE,LSPQ%N8XY!MMMW>?\%A]8:A=F+1B@<6T8C[@_UA_2/^"Y:N=\3E
M\+3Z=[^SOHZ>/A,/CZL^MVG[K34F<GS5PO>2VLPGPHOT1ZGXK$(B]VGACIXS
M''H^=J:F6IE<LKO:A=$X5@^R9$^1D8/^ZN=KK'#ZDZIIV-SQL^=QE/R/0?L"
M\?TCE)H[>KW_ $5A<O$2^DO\-E1$7P'Z@1$0$1$!$1!X7(?'@+.<LZ@[A5UH
M_"@8SFYN4;;^J\[S(Y*Y;,_D9N.J]*K6-KQMC=S,#=@?4(/1$1 1$0$1$!$1
M 1$0%9YK\C7_ .[R?PE7BL\W^1K_ /=Y/X2M8>:,:GDOR:%K3^C.G?U8_@"T
MP]UN>M#_ /PUIW]6/X M,7Z'P7V7WW]7Y7Q_VWW3](W;0?Y!SGZMW\!6ZZ;_
M */XW^[Q_P (6E:$_(.<_5N_@*W73?\ 1_&_W>/^$+Y?C?/E\Y^C[/T=Y,/E
M?U9%$1>!]06'U/@XLU1\)Q#)V=8I/T3_ ,"LPBUAG<+,L>K&>&.IC<<IRKA>
M0I6,?:?6N1&.5GD>Q^(/F%;=QU7;\IBJF4@,5V$2-\CV+?D5HV4T%:B<Y^-G
M9-'Y,E]UP^WL?V+[>A](89S;/E?R?G/$_1>IIW?3YS\VDHLW)I;-1D[T)#\0
MYI_Q4Q:5S4AZ4'MW\W.:/\5Z_CZ>V_%/Q>'_ (VMOMP7\*P:O<1C;.5N-K4V
M;O/5SCV:/4K;<3H"5SFOREAK&><4/4G_ &O+[%O./H5L?7$%.%L48\@._P _
M5>/7^D,,9MI\Z^AX;Z*U,[OJ\I^:WP.)@P]!M:N"X_6>\]WN]5DD1?$RRN5W
MO5^BPPF&,QQZ01$4:$1$!$1!;9/\G6OU;OW+%Z-_);_UI_<%D\I^3;7ZMW[E
MC-&G?%O_ %I_<%VQ^ROS<K]I&=1$7%U<TXY78Z6$INFUF_2\3I2)'0QF22=N
MWU6AHYMQZCUZKB&GM<V]/<0\!6T[K/*ZAQ%^Q'#9AR44@+>9X:0.<?'<%J[/
MQJX:7M:SXC)X2]!6RN+?S1,LMYHI.O,-^AV.X]""M3S'"[76H-3:;SF>R6&D
MEQ]ECWUJS#&R.-KP[W3M[SCL>^WDD*M]59C4FO\ C'=T7A\Y8P6*Q\9?*^L>
M620MVYCN-CW=L!OMLM>U=7U3HSBGHS"SZORF2QL]F%T9DF<UY:90US)-C[XZ
M>?KLL_QJQFG:_$2'(8W6#=+ZM\%KY2]CS'(WL"7-'NNV';KN-NGKSVE1L9_C
M-I5M;4TFJ[\<\<]NVV-S8H&L?S<K=^X &^_3J=DQ[&72NC:KSVI]=\8K6B,'
MF9L)BJ3"ZS-7Z2.#0.8AW?<EP &_Q5-#):EX8\5L-IS*9^UG<'EVCPS:/-)&
M22.YW.X(]=B"MFXB\*,E?U>S5^A<NS%9]HVD;*#X<O3;?< [;CH0005XZ'X5
M9YVM8]6\1,U#E,G79RUH(&GDC/D=]@!MN>@'<[[IB5IK8]4ZHX[ZMP&.U3D<
M9C6'FE\.4NY& -V;&"=F$D]QLL7A/Y=?Y3+O#B'65[V/G<]]UYYYFQ-;S>ZX
M^\">@Z%=<TCH'*XCC%J;5-F2J['9)O+"UCR9!]7N-MO+U5KB>'67J<=KFLI9
M:GT7-$]C6!Y\3<M '3;;]J3L>K4] 7]1:.XWR:+R6?N9K&3P>(QUIY>YN[0X
M'<[D$=1L#L5J.:XAR:MU?F&YO6.4TWAJDSHJE;&P2.>\ D<SG,'PW._KT78;
MG#_+3<=(-8LEJ_1C*XB+"\^)N&;=MMN_Q6"U'PEU)BM57\YPVS=:@+[_ !+%
M*VS=G.3N2WW2"-^NQ'3<J3W&$X,Z_P ED[^I-,9#*39JC#1EFHY":%T;W-:-
MB';C?LX=^O0JR_!ZE,'"G6LC<NW#.;<)%]P!$)Y&]=CW75] :5U/B\'EF:KS
MD&4OWFN\-L<0:R EI&P=L"1VZ; !:1I3@KDHN&>HM,YN[6AGOW!:@FKN+VM(
M VY@0/,*WN1RS46JSAJS<GICB?G<KEHY!SQ3UY6P2#S+>8<H'P*V#\((9'.<
M/=)ZJM9.407HX _'M&T8E,;G&0=>_<=O-;%?X3\0\EH5NF;N6P3*--K6UV01
M$.GY3TYW\HV '7L23W]5N>I^%UC47![#Z6L6XJ^4QT41CF&[H_%8TM(/GRD$
M]?+H?@E6,%F\3G-'\$,]8FU/D+]J:&&:O,7&-]=NS?=:0=UIVLM09F+\&S2.
M1BR^09D)K#A+9;9>)7CGD&SG[[GL.Y6]1:$X@9#AUGL!J7+XV[-8BBBH\I($
M08>O,[E'<;>1/16FHN$N?R/!;3VDH)J(R6/F=)*]TCO#(+GGH>7?\X>27O\
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M/HNT/AA=/XSH8G3>4A8"[[]MU7\^I5FG>MK%U9MMC'S+^# ".(6?W!_T1_\
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M?<CRZ+J@[(@\UUDVFSCEE<KO1/)/5!YJH%!YHB B! @($1 1$]4$J%*A")1
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M$<G- QYY2V/GW/7IU/S5%QIWBAQ"UF;5[2M33452&4QMH6K!]I?MU]1WW[[
M+/\ $KBAG]-W-.X*GC\=#GLI R26:Y,16@>3L6[]-]COUW^]<SU1H_5N;%FI
M/PMH09F9W3)TYO#8#OOS='\FZWC5^ UA5TSIK&V])X[5]>G2$=M\TF\K9?ZA
MW#M@ !N-]_-!OO#;):XN7+,>L:V&--L0=#;QTI<)'$_5VW/8;]?DM^7 > ^B
M=28C6F3S=W$#3F#G@\-F,%@R<S^FQY221ML3N=CUZ=%WX("(B B(@\;;)7PE
ML#^1^_=55VO9"QLKN9X'4^I5-R)TT)8R0QG?ZP55=AC@8QSN<M&Q=ZH/1$1
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M02B#LB B*45AL!_I%O\ \>9686'P'^D6_G_B5F5O4\S&GY0)YH%!7-L"E B
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M*OSW<!-$]_AROY_ <&<XZ^H^J?7==!X@<'L9JO/#.4\C=PF9Y0U]FF=O$VZ
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M,.V^]/5)'S-B-:9[5/#;B+#E9?I'&UH![/DS5$!E/,!L0/,@;^H6;T15K_\
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M4JD("I514)$0B(@I>T.:6N <UPV((W!5I1Q>/H/>^ACZ=5[_ *SH(&1EWS(
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MWW5S#-'/"R6"1DD3QS->P@M</4$=U9M4YQA\IBIK.I,'>B,8KTA.)6D]2'M
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M!WLT7-'LY]7>\01\._HM7_RH:TU)GLG7T92P<%2C,81'D)FMFE(.V^SGCOZ
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M("(B B(@(B("(B B(@M;L[89(0Z(2<QV!]%=*VMS2Q/B$47.''9Q]%<H"(B
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0(@(B("(B B(@(B("(B#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g73463g14k43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g14k43.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[28:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )?T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M              #_X4!*:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \
M/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z
M:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X
M.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ-C0T.#@L(#(P
M,C O,#<O,3 M,C(Z,#8Z-3,@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+R(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B"B @(" @(" @
M(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @
M("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^
M061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O
M;VP^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(V+3 R+3(U5#$S.C4T
M.C4S*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-;V1I
M9GE$871E/C(P,C8M,#(M,C54,30Z,S,Z,30K,#4Z,S \+WAM<#I-;V1I9GE$
M871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(V+3 R+3(U5#$T
M.C,S.C$T*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \9&,Z
M9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @(" @/'!H;W1O
M<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @
M(" @/'!H;W1O<VAO<#I)0T-0<F]F:6QE/G-21T(@245#-C$Y-C8M,BXQ/"]P
M:&]T;W-H;W Z24-#4')O9FEL93X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E
M240^>&UP+FEI9#HV,6(X.3$V."TQ-#$S+34T-#(M83 Q-"TR,V0R930S,&(X
M934\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N
M=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#HX,#AF8S@X8BTX-30T+3AC-#,M
M8C4X.2UB93DT,#@S9C<X-#(\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @
M(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HP-#@U,F4P-"TU
M9# V+6(X-&8M8F(U-RTY8C<Y,F8R,60Y-S0\+WAM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYC<F5A=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,#0X-3)E,#0M-60P-BUB.#1F+6)B
M-3<M.6(W.3)F,C%D.3<T/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(V+3 R+3(U5#$S.C4T.C4S*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E
M<G,^9G)O;2!I;6%G92]P;F<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z,&,T9F-D-F(M.3$X-2TU9C1D+3@T-30M-#(V
M8F$P8S0P,#5D/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(V+3 R+3(U5#$T.C,S.C T*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C5D.#5B,S=E+60P.#DM93 T8RTY8C=F+3@V-#5C860V83EB-#PO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C R-BTP,BTR-50Q-#HS,SHQ-"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO
M=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C8Q8C@Y,38X+3$T,3,M-30T
M,BUA,#$T+3(S9#)E-#,P8CAE-3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R-BTP,BTR-50Q-#HS,SHQ-"LP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-
M.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC
M94E$/GAM<"YI:60Z-60X-6(S-V4M9# X.2UE,#1C+3EB-V8M.#8T-6-A9#9A
M.6(T/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C
M=6UE;G1)1#YX;7 N9&ED.C T.#4R93 T+35D,#8M8C@T9BUB8C4W+3EB-SDR
M9C(Q9#DW-#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C T.#4R93 T+35D,#8M8C@T
M9BUB8C4W+3EB-SDR9C(Q9#DW-#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_
M/O_; $, !@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:
M&R,<%A8@+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:%AHH
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*/_  !$(!)D%4P,!(@ "$0$#$0'_Q  =  $  @(# 0$
M!P@%!@(#! $)_\0 8A   0,# 0,%!1 /!@4"!0('  $" P0%!A$'$B$($S%!
M410B87&!%A<8,C8W5%5S=)&2DZ&QLQ4C.$)25W)UE+*TP<+1TC,U5F)VTS13
M@J+A)$-CE:/P\26#PR8G1&2$1O_$ !H! 0 # 0$!               " P0!
M!0;_Q  W$0$  @(! P(#!@4#! ,!     0(#$002(3$302(R404487&!H2,S
MD;'A4L'1%35"\%-B\23_V@ , P$  A$#$0 _ +4@
M
M
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M".O/-J_Q?9K^A1_[@\\VK_%]FOZ%'_N 2*".O/-J_P 7V:_H4?\ N#SS:O\
M%]FOZ%'_ +@$B@CKSS:O\7V:_H4?^X//-J_Q?9K^A1_[@$B@CKSS:O\ %]FO
MZ%'_ +@\\VK_ !?9K^A1_P"X!(H(Z\\VK_%]FOZ%'_N#SS:O\7V:_H4?^X!(
MH(Z\\VK_ !?9K^A1_P"X//-J_P 7V:_H4?\ N 2*".O/-J_Q?9K^A1_[@\\V
MK_%]FOZ%'_N 2*".O/-J_P 7V:_H4?\ N#SS:O\ %]FOZ%'_ +@$B@CKSS:O
M\7V:_H4?^X//-J_Q?9K^A1_[@$B@CKSS:O\ %]FOZ%'_ +@\\VK_ !?9K^A1
M_P"X!(H(Z\\VK_%]FOZ%'_N#SS:O\7V:_H4?^X!(H(Z\\VK_ !?9K^A1_P"X
M//-J_P 7V:_H4?\ N 2*".O/-J_Q?9K^A1_[@\\VK_%]FOZ%'_N 2*#"X;D-
M/E6.4EYHX*BG@J%>B15#421JL>YBHY$54Z6KUF:
M
M
M               1U1_=!7+_ $W#^T/)%(ZH_N@KE_IN']H>!(H
M                                                           #
M1=B'K:VWW>K_ &J4WHT78AZVMM]WJ_VJ4WH
M
M
M          !'5']T%<O]-P_M#R12.J/[H*Y?Z;A_:'@2*
M                                                      T78AZV
MMM]WJ_VJ4WHT78AZVMM]WJ_VJ4WH
M
M
M   !'5']T%<O]-P_M#R12.J/[H*Y?Z;A_:'@2*
M   19RD<LFQ?9O4MHI'15MQ>E)%(U=%8BZJ]4_Z45/*!C<]V\VFQW62SXY13
M7Z[,=N.;!KS;7=FJ:JY?$GE-87;%M-IV]TUFSQR42<55M-.U=/'JOT&W\G7
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M1R+T*BG8           &B[$/6UMON]7^U2F]&B[$/6UMON]7^U2F]
M
M
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MHNQ#UM;;[O5_M4IO1HNQ#UM;;[O5_M4IO0
M  #1ML^7NPS!:ZX0*U*UZ<U3Z_AKU^1-5 ]69;1\9Q%5CO%RB94?\EG?/\J)
MT&O6#;EA=WK&TWV06FD<NC5F:J(J^,JWLWP^Y[4LPF94U4B(NLM55.[Y4_\
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M:GH
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M3PN3I\NIA\5V(X3CE>RLI[?)65$:ZL=6R<ZC5[4;HB:^0DL $X)P
M     :+L0];6V^[U?[5*;T:+L0];6V^[U?[5*;T
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MO1X"3.1[ZFKM[L@%A
M
M       CJC^Z"N7^FX?VAY(I'5']T%<O]-P_M#P)%  !R(Y%1R(J+P5%ZSQ_
M8JW^P*3Y%O\ (]@.Q,QX<F(GR\?V*M_L"D^1;_(?8JW^P*3Y%O\ (]@.]5OJ
M=,?1J.?X_3U>+U:45)"RHBTE;S<:-5=.E."=FI!1:-4U31>@AK/<&GMU1+76
MF%TM"Y=YT;$571=O#\$]/[/Y,1O'>?R8.9@F?CK#00 AZ[S0G79_8::FQ6C6
MLI())YD695DC1RHCN*)Q3LT-'P'!I[C/%776)8Z!O?-C?JCI5ZN'X),K6HUJ
M-:B(U$T1$ZCR?M#D1/\ #I/YO1X>&8^.SR?8JW^P*3Y%O\A]BK?[ I/D6_R/
M8#R^JWU>ATQ]'C^Q5O\ 8%)\BW^1[&HC6HC41$3@B)U ')F9\D1$>  ''0 Q
M^0W>EL-CKKK<'[E+1PNFD7KT1.A/"O0GC ZZC(;53WZGLLU=$VZU#%DCIN*O
M<U-=5X="<%Z3[=<@LUHF9#=;M044KV[S65%0R-53HU1%5.' B?D_VVIR"X7G
M:)?&*M==9'142._]JG:NFB? B?\ 3X31>4]117+:_A]#4[W,544,$FZNB[KI
MW(NB^)0+"^;;%O\ $EE_3H_ZC*V^Y4-QCW[?64U4S\*&5KT^92)/0X8/V7/]
M)_\ !HNT#8[<MG=,_*MG=XK&)0MYVHAD?W[6)Q5R*B:.;VM5.C7I M #1]C.
M;IGF$4UTD1C*Z-RT]6QJ:(DC=%U3P*BHOE-UFECAC629[(XV]+G+HB>4#F#%
MT.166OJ%@H+Q;JF=.F.&I8]R>1%U,H !Y+C<J&V0\[<JVFI(OPZB5L;?A54.
M%LO%MNK%=:[C1UK4X*M/.V1$^*J@>X \%SO-LM2)]E+E146]T=T3MCU^,J >
M\'GH*ZDN$"34%5!50KT20R(]J^5%/0  .$\T=/!)-,]K(HVJ][G+HC41-550
M,?69!9J*O;0UEVH(*UVF[!+4,;(NO1HU5UXF3*.912W+.)LUSZEDDYFWUT:0
M.:NFD6\J-T[%:U(U\JEO-F6319?A%JO$:ISDT2-F;JB[LK>#D^'Z0,W=[G1V
M>VSW"YSMIZ.!N]+*Y%5&)VKH<[97TMTH(*ZW3QU%).Q'QRQKJUS5ZT.5?205
M]%/25D39::=BQR1NZ'-5-%0A+8K<9L.SN^;-;E*Y\,3W55K>Y=?M:IO*W7Q*
MB^1P$Z                T78AZVMM]WJ_VJ4WHT78AZVMM]WJ_VJ4WH
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MK^%QQY'OJ:NWNR'+EA^I.T^^OX7''D>^IJ[>[(!80
M
M                              (ZH_N@KE_IN']H>2*1U1_=!7+_ $W#
M^T/ D4          8BMQJRUKE=4VRE>]>ER1HU5\J'VBQJRT3T?36RE8].AR
MQHY4\JF6!/U+ZUN4/3KO>@ $$P        A?E87I]MV:)0Q*J.N54R!RI^"W
M5ZI\+4)H*]\L5CO,YCDFG>-K7(J]G>+_ " E_9G;&V?9_CU"SHBHHM?&K4<O
MSJI!'**]?'!/'3?M*ECK ]LEBMSV.1S'4T:HJ="INH5QY17KXX)XZ;]I4"SA
MY;M315EJK::H8CX9H7QO:J:HK5:J*GP'J-<VB7^GQG"[Q=*F2-JPTS^::]VG
M.2*U=UJ>%5T @OD>U#XJ_++<U56"-T<C45>O5S?H1#PUC[MMNVKW2R)=JBBQ
M:V*[5D*KHYK7;NJIT*YRZ\5UT0V'D@V*6+';W?:AJM[OG2&+5/3-8FJN\6\Y
M4\BF/Y+DC;?GF<6FK7FJU9-Y(W<'*C)'H[AX-Y/A V+(.3GCSK4Y<9JZZW7:
M)N]%.Z97HYR=&\G#3QIT'IY-V=7._P!LNMAR)[IKK9G(SGGKJZ1FJIH[M5%:
MO'K14\LT.<C6JYRHC43557J*U<FU65FU+/+O"J)0ZOT=IHW1TJN3YFJ!@,'M
MUMVM;1L@ESV[U#)89G)26[G]Q-Q'.3=37J:B)P31>LW#,=A-19):2[;*ZZKH
M[E%(F]#)4Z-5.U'?2BZZF7R?91@NTZOK;O8;LV*NWMVHEH'MDC5^FNKF]J^!
M4UT(_P DP[:!L>H)+Y8\E=66:G<U98W.71-51J;T;E5%371-4X\0)KVG9G7X
M3LM==ZR&+[-NCC@1C%WF-G<G%=>M$T<OD(VV;;':;,;)!D^T*YUMSKKFQ*B.
M/GU:D;'<4U7KU1>A-$0\^VZ_SYIR>+#D#H$A?+6L?-&SBC51)6+IX-?I.K =
M@>/9-AMGO#;_ '5KJNF9)(R)S-UDBIWS4[WJ=J@'DVAXK5[$KG;,FPNYUBV>
M2H;%544DJN:O2NCM."M5$5./%%+,6:X17:T45PIM>9JX63LUZ='-14^DKYD&
MP3"+#!#)?<ON%%%,_FXW5$D;4<[371-6^ GC#[=36G%K506^I?54=/3L9#.]
M459&:<'<.'0!ER*N4KD[\<V95<=.JI4W.1*)BH[16HY%5R_%:J>4E4JSMEAK
M=I^VZFPVUSI!#;8E:Z9R*YC7;F^]ZHGC:WQ@2SL;PFEMNQZCM-=$U_V5IEGJ
MT5O2LK>A47K1NB>0CKDP7.HQW+,FP2Z/5)(972P-UX(]BJU^GC3=7R*9%FQ[
M:*QJ-9M-K$:B:(B/FT1/C$;9SC&0[)<XQS)[M>5O$T]1OOJ51VJ[FZCFN555
M5U:OS*!<HKCR@G+C&U_!\H@7=61R12[O!51CT1=5\+9%3R%A[?5PU]#3UE+(
MDE//&V6-Z=#FJFJ*5XY8#VO?A],Q%=.^>56M1-55.\3Z50"QS5U:BIU@ZJ1J
MLI86N],C&HOP':              :+L0];6V^[U?[5*;T:+L0];6V^[U?[5*
M;T                                           %?>6'ZD[3[[_A<<
M>1[ZFKM[LARY8?J2M/OK^%QQY'OJ:NWNR 6$
M
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ME4\"=@$L                T78AZVMM]WJ_VJ4WHT78AZVMM]WJ_P!JE-Z
M                                          "OO+#]2=I]]?PN./(]
M]35V]V0Y<L/U)VGWW_"XX\CWU-7;W9 +"
M
M                      !'5']T%<O]-P_M#R12.J/[H*Y?Z;A_:'@2*
M
M      T78AZVMM]WJ_VJ4WHT78AZVMM]WJ_VJ4WH                   /
M-<*^DMU*^IKZF&F@9Q=)*]&M3RJ0?G'*.LMJEDIL=I77.9.'/*[<C:OP<36]
MN&,YMF^T.>V6J&HDL].UFXJKNQ-U1-57MXGLQ/DR4C&-ER:ZRR2<%YJE1$;X
ME54U C3(-O>9W5[^YZMEO8O0E.WH3QJ:R[:CFKG[RY%7:_E)_(M_9]C>$VN-
MJ0V=DCD^_E<KE4V&/"<;CC1C;-1;J?\ PD IO9MMN;VU^\Z[/JV_@SHBH2AB
M?*;57LBR6TM1%X+/3/X)X=TF:X[+L.N"*E39*9=?P45OT&A9!R;L6KFN=:ZF
MLM\G'1&N1[=?#J@$HXEF-BRRD2>QW"&H3KC1R(]OC;TH; 4YN6Q[-\#O-/<+
M%(^LACD:[G:5=%1-?OF]9;NT/EDM5$^IUY]T+%?JFB[VZFOS@>L
M   !7WEA^I.T^^_X7''D>^IJ[>[(<N6'ZD[3[[_A<<>1[ZFKM[L@%A
M
M                                            CJC^Z"N7^FX?VAY(
MI'5']T%<O]-P_M#P)%
M                           :+L0];6V^[U?[5*;T:+L0];6V^[U?[5*;
MT                        !&'*#S"[87AM/<;%+''4OJFQ*Y[$>FZK7+T
M+XD-?Y-NT._YU)?&Y#/#*E*D2Q<W$C--[>UZ/$A\Y7?K<4GO]GZKC4>1A_;9
M1^3!_&!9X               %?N6'ZD[3[[_ (7'#D>^IJ[>[(<N6'ZD[3[Z
M_A<<>1[ZFKM[L@%A
M
M      CJC^Z"N7^FX?VAY(I'5']T%<O]-P_M#P)%
M       !51$5571$/.ROI'R;C*JG<_\ !21%7X-0/0
M                     #1=B'K:VWW>K_:I3>C1=B'K:VWW>K_:I3>@
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M:??7\+CCR/?4U=O=D L(
M
M         $=4?W05R_TW#^T/)%(ZH_N@KE_IN']H>!(H
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MCR/?4U=O=D.7+$]25I]]_P +CCR/?4U=O=D L(
M
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MO[SQHQNO[B?37-GN)46$XK1V6WJY[(45TDKNF21>+G+XUZNPV,
M -%V(>MK;?=ZO]JE-Z-%V(>MK;?=ZO\ :I3>@                   $?;=
M[%47_9K=:>D1731,6=K4Z7;J*NB$@F(RV]TN.X[<+K7<8*:)TBM_"T1>'E K
M1R1WV9MXNM/<&0?916MYGG4371%XHW7K+5)3P]44?Q4/SMR7(G7+*ZN]6V%+
M6Z617L93.W>;\2H>Z/:/ET;$:W(+AHG#C,J@?H)W/#_RF?%0Y,C8S7<8UNO8
MFA^??GE9A_B"O^54L!R3\FO.02Y$EZN-16)"D/-\ZY7;NN]KI\" 6&
M         !7WEA^I.T^^OX7''D>^IJ[>[(<N6'ZD[3[[_A<<>1[ZFKM[L@%A
M
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M^ [@                -%V(>MK;?=ZO]JE-Z-%V(>MK;?=ZO]JE-Z
M              1ERC**HK=EET2E156)$E>B?@IKJ2::UM(O$5BPJ[7"HI6U
M<,4#E?"[H>FBZH!6/DQ8)8\KK+E4WV)*E:5&[D#E[WCUJG66.39?A:)HF.T'
MR92RQ9O5XKE<UWQ-'4<4CE_]/(N\U6_@KIIJA*%/RG<B:Q$GM-L<[M:CT_B
ML)YU^&?X=H/DS,X[BUEQSG_L';J>BY[3G.:;IO:=&OPE9_1/7SVGM_\ W?U$
MK;"-J-?M%DN[:^BIZ;N)(U:L.O?;V]TZJO8!+8               *^\L/U)
MVGWU_"XX\CWU-7;W9#ERP_4G:??7\+CCR/?4U=O=D L(
M
M                                 $=4?W05R_TW#^T/)%(ZH_N@KE_I
MN']H>!(H       /'>;=!=K554%4BK#41K&[3I37K3PITE4<CLE7C]VGH*^-
M6R1KWKM.#V]3D\"ENC"Y1C%KR:C2GND&^K?22L71[/$O[N@V\/E^A,Q;Q*K+
MCZX[>53 2_==BE4DJK:KK"^/J;4M5JIY6HNOP"U;%*I946[76%L76VF:KE7R
MN1-/@/7^_8-;ZF7T;_1&>-V2LR"[0V^@8KI)%XNTX,;UN7P(6ML=NBM%HH[?
M3_V=-$V-%[=$XKY>GRGAQ;&+9C-&M/:X-U7>GE?QDD\:_NZ#-GD<SE^O.H\0
MU8L?1'?R  Q+0      -)VT9,_$]G%YN5-(UE9S:0TZN_P"8]=U%3PHBJOD
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M3KT7BB+X>Q>PW@KS45*X#RFF,BTBM62Q-YUB<&\X[5$73MWT_P"Y0+#
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MNR'+EA^I.T^^OX7''D>^IJ[>[(!80
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MG:???\+CCR/?4U=O=D L(
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M+55"MW>?W=R73LWVZ+\YC<?V2818:N.JM^/TW=$:ZL?.KIE:O:F^JZ+X3>@
MZ.@TG)=E6%Y'5.J;I8*5U2]V\^6'>A<]>URL5-5\9NP U;%-GN*XI)SMBLM+
M35'%$G5JOD1.S?=JOSFT@ #0\FV289DM[J;O>K2ZHKZG=YV3NF5N]NM1J<$<
MB)P:AO@ B_SAMGGM$[]+F_J-KQC!,8Q>3G;%9**DGTTYYL>LFG9OKJOSFR@
MO!-5*^X-3KM!V^WC+$^V6:Q?^EI7.35KY-%:BI_W.\K2<<CMLEXL5?;HJN2C
M?51.B[HC35T:*FBJGAT,?@6)V_"L:IK-:D<L46KGRO\ 32O7I<[PJ!L(
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M6'ZD[3[Z_A<<>1[ZFKM[LASY8?J3M/OK^%QPY'OJ:NWNR 6$
M                                     "IJBH!BI\BLT$SXIKI1LD8N
MCFNE:BHOPG#S46+VWH?EF_S(VOVP'&[S>:VY5-36MFJI5E>C9%T15(JVY[)+
M+@V*0W*U3U3IW3I&J2/U31=0+/>:BQ>V]#\LW^9Z[?=K?<7N;05M/4.;TI%(
MCM/@(,QWD]XS<;!;:R:JKN<J*:.5VDBZ:N:BK])(&SC999\#K:FJM4U3)).W
M==SKU5- )              "NU!]UI-[W=]4I8DKM0?=:3>]W?5*!8D
M                                (ZH_N@KE_IN']H>2*1U1_=!7+_3<
M/[0\"10
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M9#ERP_4G:???\+CCR/?4U=O=D L(
M                  !"'*W];NF]]M^A2;R$.5OZWE-[[;]"@2KA/J.L?O*'
M]1#-&%PGU'6/WE#^HAF@              5VH/NM)O>[OJE+$E=J#[K2;WN[
MZI0+$@                                    !'5']T%<O]-P_M#R12
M.J/[H*Y?Z;A_:'@2*
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MF(4<-3?Z+N>&5^XQV^CM5_\ M"P?(]]35V]V0"P@
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MU57MX'O@R_(8&HV*[5J(B:?VBJ7T\Q&+_P"'[9^CM_D??,1B_P#A^V?H[?Y
M4/\ -MDOMQ6?'4L+R2+Y<[Q+D:72LFJ4C2'<YQVN[KO:Z$U^8C%_\/VS]';_
M ",A:+':[/SGV*M]+1\YIO\ ,1HS>TZ-= ,B5EY0NS+*LKSA*^Q6WNFEYAK-
M_G6-XIX%4L-?,@M5B@YZ[5T%,S73OW)JJ^+I,C3S,J((YHG;T<C4>U>U%35
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M^V_0I-Y"'*V];RF]]M^A0)5PGU'6/WE#^HAFC"X3ZCK'[RA_40S0
M      *[4'W6DWO=WU2E@JVLIZ&!TU9-'#$WBKGKH5RHKC2,Y2<M\=4,2TK"
MYB5/WNO-Z?23KCO?O6-N3:(\RLH#II*J"L@;-2RLEB<FJ.8NJ'<0UIT
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M_P"%QQY'OJ:NWNR'+EA^I.T^^_X7''D>^IJ[>[(!80
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ME-UZ%+0;*'S/P:W+4:[VZJ)KV:\#R_M/%749(\M/'M.^EMP /&:@
M                        CJC^Z"N7^FX?VAY(I'5']T%<O]-P_M#P)%
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M=+707:E6FNM%35M.JZK%41-D;KXE136X-F.$0S\]'BMGW_\ -3-<GP*FAN
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M4=IKU]/3V*A?;9]D"9/B%MNW#?GB19-.I_7\X&P@
M     "OO+#]2=I]]?PN./(]]35V]V0Y<L/U)VGWU_"XX\CWU-7;W9 +"
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MVGWU_"XX\CWU-7;W9#ERP_4G:???\+CCR/?4U=O=D L(
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MDFP'10U<%=215-+(V2&1-YKF]"H=YAF-=EP
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M_P!+M>*\>/0;V         !HNQ#UM;;[O5_M4IO1HNQ#UM;;[O5_M4IO0
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M7WEA^I.T^^OX7''D>^IJ[>[(<N6'ZD[3[[_A<<>1[ZFKM[L@%A
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MY4;CYX_?_*GOC_)-8.BAJX*^DCJ:25LL,B(YKFKJBH=YAF-=I7
M                 $=4?W05R_TW#^T/)%(ZH_N@KE_IN']H>!(H
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M5Q=*SQ[J:ZJ3ULFV=46S_%Y;6R5M;/4O62JG='NI*NFB-W=5[U$X:>%>TWH
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M[[_A<<>1[ZFKM[L@%A
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MG:??7\+CCR/?4U=O=D L(
M         0W<?_YOVOP4[5YRAMJ:N1>CAT_.2=E=T99\>KZYZZ<U$N[^4O!/
MG-(V&VMS;/5WBI36HKI55%7IT1?YFSC_ ,/';+^D?JJO\5HJDU$T31"$.5OZ
MWE-[[;]"DWD(<K?UO*;WVWZ%,:U*N$^HZQ^\H?U$,T87"?4=8_>4/ZB&:
M           !7:@^ZTF][N^J4L25VH/NM)O>[OJE L2        >"^6BCO=N
MEHJ^)LD4B:<4XM7M3PGO!V)FL[@F-H2H*VY;+;ZE#<%?56"H=JR1/O/_ #X"
M9J&K@KJ2*II)&RP2)O-<WH5#S7VT4E[MDU#7QH^&1-/"B]J$16^MN6RZ_=P5
M_.5./SN[R73TNO6GA\!MF(Y4;CYX_?\ RI[XY_!-H.B@JX*^DBJ:21LL,C=Y
MKFKJBH=YAF-=I7
M                                                          -,
MS[9KCN;0*EVI=RI1-&U,.C9&^70KQF7)OOEO?)+CE2RXP?>QO7=D1/"O0I;H
M ?GQ<-G^8VMZMGL=S33AK%$YR?"AXTQG*GKNI9[RJ]G<\G\C]$SXC6IT(GP
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MOMOT*3>0ARMO6[IO?;?H4QK4JX3ZCK'[RA_40S1A<)]1UC]Y0_J(9H
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M+L7P&V8CE1N/GC]_\J8WCG\$V Z*&K@KJ6.II)6RP2)O->U>"H=YAF-=I7
M
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MVGWU_"XX\CWU-7;W9#ERP_4G:??7\+CCR/?4U=O=D L(
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M_P RQ7F#Q;VAM_R*$#T6/6AW*?FMCK;3+;^8<O<^YWFO-ZZZ 8U;]L/T7_\
M1;C\DO\ ,L?@$UJGQ.WR8]$^*V.C3F6/3143PG5Y@\6]H;?\BAGZ*DIZ&F93
MT<+(8&)HUC$T1$ [@          ,??+/17NWR4=QA;+"].OI1>U#( [$S6=P
M3&T)6^MN>RZ^)0W%7U-@J':QR)QW/#X_ 3-0U<%=21U-)*V6&1-YKFKP5#S7
MVST=[MTM%<(6R1/33BG%J]J$1V^LN>RV^)0W%SZFP5+M62)QW/Y+X#;,1RHW
M':\?O_E3WQ]O9-@.B@K(*^DBJ:21LL,B;S7-75%.\PS&NTK@
M
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M2=I]]_PN./(]]35V]V0"P@
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M_P#*GOCG\$V@Z*&K@KZ2*II)62PR-1S7-75%0[S#,:[2N
M
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M-7;W9#ERP_4G:??7\+CCR/?4U=O=D L(
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M_P#?_*F-XY_!-H.B@K(*^DCJ:21LL,B:M<U>D[S#,:[2N
M
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MF!,0(=]$/AG_ /G_ "*?S-JP':;8LXJZBGLO='.0MWG<ZS=X?"!O
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M,'LRVFVW: ^L;;:.KIEID17<^B)KKV&^'DH+90V_?[@HZ>FW_3<U&C=?@/6
M
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M74X^3)&ZU56S8Z3JTK(@QECOMOO4/.6^H;)HFJMZ')Y#)E5JS6=3"RMHM&X
M <=                   ,??K/27RV34-?&CX9$\K5[4,@#L3-9W!,;[(3H
M*RY[+KXM'7I)48]._P"URZ<&>%/#X"9:"L@KZ2*II)6RP2-WFO:NJ*AYK]9Z
M.^6V6BN$220O3RHO:A$=!6739=>^X[AOU&/5#_M<G3N>'P+X#;,1RHW':_\
M?_*F-XY_!-@.BAJX*ZECJ:25LL,B:M<U>"G>89C7:5P  (!Y77]P6+WXGT$Z
M6G^[*7W)OT$%\KK^X+%[\3Z"=+3_ '92^Y-^@#U
M
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M#<+C50M=O,;4O<Y$7P:ED.1[ZFKM[L@%A
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M!Y77]P6+WXGT$Z6G^[*7W)OT$%\KKU/V+WXGT$Z6G^[*7W)OT >H
M
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M+W5TM:B?>N/O(]]35V]V0Y<L/U)VGWW_  N./(]]35V]V0"P@
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M$;\+*@Q]@N]+?+7#74,B/AD3RHO6BF0/-F)K.I:(G8 #@
M
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M35V]V0Y<L/U)VGWU_"XX\CWU-7;W9 +"
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MY:].XZ]O!S)."*O@-P3CT&;)CMCG5H7TO6\;K( ""8
M/CW;K'.[$U*D976RW#([C4SN57OF<G'L1=$+<*B*BHO0I5?:)9)K'E-;#*Q4
MAE>LD3NIR+Q/4^RYCKM'NS<B)U#6@ >VRIGY/-PD5MSM[EUB:J2M3L5=$_<3
M,05L)NEJMU160UU0D%=4.1L:/X(K>'7VZDZHJ*FJ+JA\[SXUFF=-V"?@  8E
MH
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M+#]2=I]]?PN./(]]35V]V0"P@
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M.N'X_%CUJ2F8Y'RN7>D?ITJ9N=GK7'-/>5_$Q3:\6]H9P '@O7
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MWO><?P:]?W';<:+1UX9W'T]X<C)KM?LDP'&*1DL;7Q/:]CDU1S5U13D9%H
M
M          <9?[)_Y*G(*FJ*B] 'YP97QR6Z>^'_ *RG;8\EN-DXVY8XW_A[
MB*[X2]-1LRPZHGDFFL%&^215<YRMXJIP\ZS"O\/47Q0*>)M<S5$1$O50B)U(
M//<S7V[J?A+A^=9A7^'J+XH\ZS"O\/47Q0*=^>YFVG]]U/PEQ=CUSJ[QL^M5
M;<9G35,K-7O=TJ<?.LPK3U.T7Q3:[7;J2U4,5';X&04T::,C8G! /4  !K>T
M:P39/AUSM%-(V.6JB6-KG="*J&R "I7H9;[[9TOP#T,M]]LZ7X"2-KFW:AQ2
MIEM=AC977-G![U76.)>Q>U2$:GE 9Q-4<XVKIXDU](R+A](&S>AEOOMG2_ 2
MSL&V85^SR2[NN%5%/W8D:-W.K=WOYD<[/^4E5=VQTV8TT2T[M&]TP-T5GA5.
MLLS;:ZFN=#!64,S)J:9J/9(Q=45% ](               *^\L3U)6GWW_"X
MX\CWU-7;W9#ERP_4G:??7\+CCR/?4U=O=D L(
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M'+JNA[0
M                   !IVUW(7XSL_N]?"[<J$A<R%W8]470W$C/E%V^6X;+
M+JD":K G/._);KJ!4_9=@]?M&REU,DKFPHO.U50O%6HJ_2I9NAY/.%T]&D4\
M-142Z:+*^1477R<"&>2SF%OQW**R@N;VPLN+&LCE=P1KD7H7QEQ&31/8CF2,
M<U>.J.14 I_MPV*-PVW?9FPS2SVY';LL<G%T>O0OB-VY(645%7072PU<KGLI
MMV6G1RZZ(NNJ>+@ALG*:S*VVW!JFS)-'-7U^D:1M5%5C>E7*1[R.:&62^7RM
M1-(8HF,5>U5WOY 6K               !7WEB>I.T^^_X7''D>^IJ[>[(<N6
M'ZD[3[Z_A<<>1[ZFKM[L@%A                                   "K
MHBJO0@-?SR\)8\5KZS>TD2-6Q_E+T$J5F]HK'NY,ZC:.[<GFNVPS5/\ :4%M
M31J]6J)P^<F0CW8G9UH<6[NF;_ZFN<LBN7IW=>!(1HY=HF_1'BO9#%';<^X
M#*L   541-5Z".,NR*KO-?\ 8+&E5SU56SS-Z$3LU.699+4W.N^P&.*YU0Y=
MV69J\&IT*FILN'XU3X_0HUJ(^KD1%EETXN4V4I&"OJ7\^T?[RRVM.:>BGCWE
MV8GCE+CU D4+4=.[C+*O2Y3. &6]YO/5;RT5K%8U 0ARMO6[IO?;?H4F\A#E
M;>MY3>^V_0I%)*N$^HZQ^\H?U$,T87"?4=8_>4/ZB&:             8+-\
MD@Q/'*N\5<,L\-.FJLB35R@9TKM0?=:3>]W?5*>_T2UB]I+M\1O\R+Z;:C01
M;:Y,R6VURT+HG1I#NIO\6;O;I\X%R@0+Z):Q>TEV^(W^9,>)WR')+!276FBD
MBBJ&[R,D31R>,#+@            ,#DN+6Z_1+W1$C*A$[V9G!R*:7#67_!Y
MTCN"/KK2J\'IQ5J$I'">&.>)T<T;9(W)HK7)JBFC'R)K'1>-U_\ ?"B^&)GJ
MKVEC[%?:"]TJ34$S7]K%X.3R&3(\OV$5%%5.N6*SK33IQ6!%5&N\7\COQO.V
MOJ$MV01.I*YG>J]WI7*2MQXM'7AG<?3WARN::STY>T_LWP'QCD>U'-5%:O%%
M0^F5H          ! /*Z_N"Q>_$^@G2T_P!V4ON3?H(+Y77]P6+WXGT$Z6G^
M[*7W)OT >H       &)R''K;?Z1T%SIF2HJ<'Z:.;XE(MJ[%D^SZI?5V"9]?
M9T75T#N^5$\7\B: J(J*BIJBFC%R+8XZ9[Q])0M2+=_=I^&Y]:LD8D6_W-7-
M3OX)>"Z^#M-P-!S/9M0WEZUEJ<ENN2+O))$FZCE\.G1XS6[3F]ZPZK;;,SIY
M9H==(ZIO%=.WPH63@IFCJP3W^GO^B,7FO:_]4Q \=IN='=J-E5;YV30NZ'-4
MYW"OI;=3NGKIXX(F]+GKH9.F=ZUW6;CR@'9Q]TYE?O5_ZS"PY6S!+G1T?* R
M*\5-0R.VU,#F13N]*]RJWA\RECZ>>*IB;+!(V2-R:HYJZHI*V.]/FC1%HGP[
M  0=
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M#3_)H/L1;O85/\FA[@!X?L1;O8-/\FA[(HV11HR)K6,3H:U-$0Y
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M2(]B/17(NO6AM1\MDIT6FOT>E6=QL !!T
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ME&?7[+J^K@O6/R6N.)J.:]S7)O+V<23=UOX*? ?41$Z$1
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MIJ7K)O22Q(YRZ/7I4DVVX=CMLJV55OLM#35+/2R1Q(CD\H&>
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MH)2PMIZ:*%GI(V(Q/$B:&J8%L[Q_"87I9J-J3O\ 3SOXO=Y>HV\
M     K[RP_4G:??7\+CCR/?4U=O=D.7+#]2=I]]?PN./(]]35V]V0"P@
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MGN4W?/>[CN^!#;P#/DR6R6ZK+J4BD=-0 $$P
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M:+.*-L:KNSHL;T[=1S.-3)2;1'>#%DFLZ6: !\\W
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MR/?4U=O=D.7+$]2=I]]_PN./(]]35V]V0"P@
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MM"3<%Q-:%?LK=U66Z3=\N]QW/_)NP1=414Z >7ER6R6ZK-^/'&.O3  "M,
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M>X 'B-8
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M7
M     ".]HN%27*1;E:FHM3_[D>OI_"GA)$!;AS6PVZJJ\F.N2O396&KIIJ-Z
MLJXGPN1=-'IH92Q8U<KU.UE+3O;&J]](]-&HA[>5JJQ6.R/B7<>ZK1%<W@JD
MXV9C66NE1C4:G-M7@FG4>A;[3G7:O=CC@1OO/9B[1BEMHK-'02T[)VIQ>YR<
M7+UF(N6SBU3*Z2@=+1R]7-N71#=P8(Y&6L[BS7.#',:F$:?8C,[&G_Z?7,K8
M&]#'Z=!VT^T&JH'<WD%JFA<G!7L3@2,=-32P5+=VHACE;V/:BEOWBM_YE(G\
MNTJ_0M7^7;7[L/:<NLUT1.YZQC7+][)WJ_.9UCFO:CFJBHO6AJ=UP"RUVKHH
M5I9?PXET,$[$LELZ[]DO#I8TZ(Y%U5?AX#T\-_DMK\_^3KRT^:N_R24"-69K
M?+0Y([]:'N1O3)%QU_<;#:,[LEQ5&]T<Q*OWDJ:*0MQ<E8WK<?AW2KR,=NV]
M3^+:0<(9HYFHZ&1CV]K5U.9G7NBMK*:A@6:LGB@A3@KY'(U/A4QWFIL/MQ0?
M+M_F>;.\4H\RL$EIN,DL<#W(Y71KHNJ+J137[ ,.M\*RUESK(F)UN>=B)F=0
MY,Q'>4O>:FP^W%!\NW^8\U-A]N*#Y=O\RJ5@V<6:HVA7&BN594Q8XUB]S5.]
MQ>[5-$^DE2GY/.)54*24]QK9(W)JCFOU_>2MCO3YHTY6];?+.TWP2QSQ-EA>
MV2-R:M<U=45#F>"PVN&RVBEMU,YSH:=B,:KNE4/>02          !%NT7:_3
MX7?_ +%RV2NK7<VDG.P^EXZ\.CP$;Y]MO@R7$+G:(,<N44M7$L;7NXHGCX%D
M:B@I*B3?J*6"5_1O/8BJ=?V)MWL&E^2;_("LVRS;+%AV%4-DJ<>N,\M.K]9&
M<$75RKV>$DG"=ME-E.1TUICL%PI73:Z2R>E33R$H?8FW>P:7Y)O\CG#;J*&1
M)(:2"-Z=#FQHB@>H
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M
M    /,ZOHVJJ.JZ=%3@J+(G\STN35JIVD$7/DZ6^ON-55NOM>U9Y'2*U%3AJ
MNN@'BY6E3!/8+&D,\4BI5HJ[KT4G"U7"C2V4J+5T_P#9-_\ <3L\9"#^3-:G
MIW]]KG>/1?W').33;=/[_N'PH!/D%1!/KS$T<FG3N.1=/@.TCW95LRIMG[ZU
MU-<*FL6I1$5)5]+IV$A      '&2-DC5;(QKFKTHJ:FOW;#++<T59:1L;U^^
MB[U?F-B!.F2U)W6=(VI6W:T(XFP&Y6YZR6"\3,[(Y%5$^DZDR/*[$J-NML[L
MA;_[C$TX$F!414XIJ:(Y4V[9(BRG[O$?),PT6GVE6N2DE=+'+#4,:JI&]--Y
M>S4BB_WJKO==)45DCE15[V/7O6IXB4MK%LIDQ]]7%2QI,UZ:R-;Q1-2&T/3X
M-,4UG)2-,'*MDB>BTG4;%AN3U./W!B[[GTCU1)(U7@B=J&NGQ>**;+TB\36W
MAEK::SN%H89&S1,D8J*UR(J*AS(LLF=5MNM=-3U%EJI&QMT21$71R=IE8MIE
MOZ*FEJ85[%:IX%N'EB9U&WL5Y6.8[RWX&HT^T*P2HFM2Z->Q[=#)4^6V*=.\
MN=,GY3T0IG!DCS65L9L<^)AG >&&\6Z9-8JZF>G@D13UQS12)K'(QR>!VI7-
M9CS"<6B?$N8"*B]"@XZ   #&9%>J6QVY]55O3@G>,UXO7L0A^[[0KS73*M/(
ME+%U-9T^533@XE\_>OA1EY%,7:?*<P01:\_OE%,CI9TJ8^MDG'4EW%<AI<AM
MZ3TZHV5O"2+7BU3N?B9,,;GO#F'DTRSJ/+-  RM
M                                                         K[R
MP_4G:???\+CCR/?4U=O=D.?+#]2=I]]?PN.'(]]35V]V0"P@
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MO$?2%N/#6G?S/U  4+0
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M._4C2;P ?,O=
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MN3I1%XH!R /CG-:U5<J(B=:J!]!\:J.1%:J*B]:'T #BLC$>C%>W>7JUXG(
M O!.)\8]KTU8Y')VHNH'T XN>QBHCG-15Z-5Z0.0   XMD8]51CFN5.G1>@Y
M  ?'O:QNKW(U.U5T/J*BIJBZH  .*2,5^XCF[W9KQ Y !RHU%5RHB)UJ !\8
MYKV[S'(Y.U%U/H '%SV-<C7.:CEZ$5>DY  #BQ[7HJL<UVG8NH'( XO>QB)O
MN:W7AQ70#D   .+9&.<K6N:KDZ41>*'( #XYS6-57.1J)UJI]:J.35JHJ=J
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MH.+'M>FK'(Y/ NH'( XO>QFF^YK=>":KH!R   '%LC'.5&O:JITHB]!R
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MH[)[<VW]*9_,>:.R>W-M_2F?S R@.,;V2QMDB<U\;T1S7-75%1>A44Y
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MV+0?$'HE,L]BT'Q#E<?3:;;\IYN5.7%7%,1'2MED3*R2Q5S+8[=K71.2%?\
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MA8'Z+[/O4'C?YLIOJFF>,!L^]0>-?FRF^J:9\
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M;OE7$H@"+O.(P3VK=\JX><3@GM6[Y5Q*( B[SB,$]JW?*N'G$8)[5N^5<2B
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MC2A@'Z+[/O4'C?YLIOJFF>,!L^]0>-_FRF^J:9\
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M.NFNH$[TW_#Q_DI]!V'&-NY&UO3HFAR
M    IYRM_5]3^]T^@GOD]>M79_R#&[5-C%+G]\CN4]VFHW-C1FXR)')])O.
MXS'B.,4EGBJ'5+*=-$D<W15\@&P@                               $
M%<KOU"T'OK^%2=32=JV P[0;)!;JBMDHVQ2\XCV,1VO#30")N1K_ '3?_=F?
MJECR/=D6S.#9S2UT-/<)*WNIZ/57L1N[HFA(0
M      !'O*!]9W)O<&?6-*&%\^4#ZSN3>X,^L:4, _1?9]Z@\;_-E-]4TSQ@
M=GWJ#QO\V4WU33/
M  '"66.)NLLC&)VN70^QR,E;O1/:]O:U=4 Y
M         'QSFL:KG*C6ITJJZ ?0=451!*[2*:-Z]C7(IV@
M                    #X][8VJY[D:U.E571 /H.J&HAF54AFCD5.E&N13M
M                                  X2S1PIK+(QB=KG(A]CD9*W>B>U
M[>UJZH!R                                 .$LL<2:RR,8G:Y= .8.
M$4L<J:Q2,>B=;7(IS                              (]Y0/K.Y-[@SZ
MQI0POGR@?6=R;W!GUC2A@'Z+;/O4'C?YLIOJFF?,!L^]0>-_FRF^J:9\
M                                       !K&TG+:?"L2K;Q4-WW1(B
M11];WJNB)\YLY6WEBW-[:&RVUKE1CGNF<B+T]7[@(?FR/.MI.0RLH:JX5$[]
M7MIJ>5S61M\2+H<K5F6;;.,D2&NJJYDL3DYVDJI'.:YNO8J_.3)R.;=$VS7N
MX*Q%G=*V)':=#=%X&.Y9%NA8^Q7!C$2:3?C>[3I1.@"P.%9'2Y7C5%=Z)?M=
M1&CE:O2U>M%,X5_Y'UR=/BETH'O5W,5"/:B]2*B?R+
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M6^VV6:.LE@7??/'Q:G^5%ZR3>2S8JNT[/^Z*UKH^[)%DC8Y-.]ZE\H$R@
M                         (]Y0/K.Y-[@SZQI0POIR@?6=R;W!GUC2A8'
MZ+;/O4'C?YLIOJFF?,#L^]0>-_FRF^J:9X
M                 !53EC-=]G[*[CN=SJGEWE+5E=^6#9Y)K%:KI$U7-@E6
M.1?P47H^=0/=R/\ 3S%W/3I[I37X%,7RRM/L3CZ=?/2?0>'D@9'1T\-XLU5/
M'%/(YL\:/<B;R)P7Z3&\KO(J.X72TVJCGCEDI$=)+N.UT5W0@&5Y&C5W<A=I
MWND:?269(,Y)-FEH,'JZZ=BM6LGWH]4Z6(B<2<P
M         83,,GMF)V6:Y7>H9%"Q%W6JO%[OP43K4]UZNE+9K557"OD2*FIV
M*][E[$*);5<_N.?Y$Z6>3<H8WJRE@1=&M;KP5?"!W;1\XO.U#)X6,A>L6_S=
M)1Q(JZ:K\ZEHM@6SGS#8VLE<U%N]9H^9?^6G4TTS8A8,)PNBBN5TO5NJ+Y*U
M'*Y9$5(47J3P^$FBUY=8+I5MI;==:6HJ'<4C8_55 SH
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M7!:DJ(I*^6=LC8VN15:U-=5\!JO(WI)_LE?JK=<E/S<;->I5U4"TH
M                     "/>4#ZSN3>X,^L:4,+Z<H'UG<F]P9]8TH6!^B^S
M[U!XW^;:;ZIIGC [/O4'C?YMIOJFF>
M              8C+,?H<HL%7:+I&CZ:H;HO:B]**GB4RX ICDVPC,K!=GOL
M$;ZVG1WVJ:!^CT3PIU'=AVP/*[W=V2Y*Q:&C5V],^5^LCN/4A<@ >&QVNELM
MII;=;XTBI:=B1L:G4B'N                               (UV^X_?LG
MPM+5C;&NEEG:Z75V[JQ->!6SS@<Z]@P?*_\ @NZ *1^<%G?L*#Y;_P &][%-
MD>5XOGU%<[O2Q1TD37(YR2:KQ+0@
M 1[MVQFY99L_JK79HVR5;Y8W(USM$5$<BJ2$ *_\G'9MD6%9!<ZJ_4\44,U-
MS;%:_>57;R+^XL                                #5=I&%6_.<=EME
MQ3==KOPS(G&-_:AM0 I/==B&>6"XO^Q5,^I8BJC)J23153P]AE\(Y/\ DMXN
MK*C*?_14:.1TF^_>E?X-/WEP0!X[/;:6SVRGH+?$V&E@8C&,:G!$0]@
M                         !KV=XG;\RQZHM5T9JR1%W)$Z8W=3D*H7W85
MF^/7-TEC8ZKC:NL4U-)H_3PIU%T !2NU[$L]R*YL?>89*=JJB/GJY-7(G@[2
MUFSK#*#",<@M=O3><B:RS*G&1W6JFT
M C[E ^L[DWN#/K&E"R^?*!]9W)O<&?6-*& ?HOL^]0>-_FRF^J:9XP.S[U!X
MW^;*;ZIIG@                                              #5-I
M^5Q8;AM?=GJWG6-W(6JOIGKT)^\Q&Q#.4S?#8*FH>S[)0?:ZEJ+QU3[[3P@2
M$
M
M                                                        "/N4
M#ZSN3>X,^L:4++Y\H'UG<F]P9]8TH8!^B^S[U!XW^;:;ZIIGC [/O4'C?YLI
MOJFF>                                             %XIH!4+E59
MLMWR1F/4<N]1V]4=+NKP=(J?NU5#7>3EFB8IG44-5)NV^X(D$FJ\$<JINN7Q
M<26.45L\QJT857WN@MS8KG).USIM]RJJN5=>"KH8#DU[/\;RK&ZNKOEN;4U$
M4VZQZO<FB>10+2M5'-1S5U14U13Z<((FP0LBC31C&HUJ>!#F
M
M
M                                          1]R@?6=R;W!GUC2A9?
M3E ^L]DWN#/K&E"P/T7V?>H/&_S93?5-,\8'9]Z@\;_-E-]4TSP
M                                    !&'*-MM9==FM536ZG?43K*Q4
M8Q-5TU,%R6;-<;-BM=%=*26FD=/JC9$T54)L'1T
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MU [0
M                 !'W*!]9W)O<&?6-*%E].4#ZSN3>X,^L:4+ _1;9]Z@\
M;_-E-]4TSY@=GWJ#QO\ -E-]4TSP
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MT4J*D;T7@[=U735-0)G
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M+W;TB0(QWC:JI^XK+RK$:FU%^[TK2QZ_.3YR9M[SJ[=O=&KM/C*!*H
M
M        CWE ^L[DWN#/K&E#"^?*!]9W)O<&?6-*& ?HML^]0>-_FRF^J:9\
MP&S[U!XU^;*;ZIIGP                                     #"9=B]
MKRRU.H+S3\[%KO,<URM<QR="M5.**:'YSC96=RUN4WJHM>O_  CI51%3L5R+
MJJ$K@#6ZC#;7YC)<9H8^X[>^+FDYOBJ)V\>E3M9BM [#&8S5[U10)3)2NWET
M5S4337AUF? $54VQNG2C^QU;D5VJK.C5:RB=)NM:WLWD754\9DF;+:!F'6S'
M>[JA:6WU*5,3]U-Y='[R-7P$A@ B:)H:!E&S.CNM\?>;5<:RRW.9-V>:E7A,
MGA:O#7PF_@#0<)V86O%;A=JJ*IJ:QUSA2*I;4+O;_%=5U\.IB7[&Z6+GJ6V7
MZZT-FF<JR4$;]6*B]*(Y5U1%\!*@ TNX;-L?JL0@QV.G?3T=,Y)('Q/5'QR?
MAZZZZF+M>RN%ESHJN^WRXWEM$])*>&H=NL8Y.A51.G3PDD "/\DV8T=QODMY
ML]RK++<YTTGFI5U25/"U>!D\%P2VXBM5/3/GJKC5JBU%94/5SY-.CQ)X$-M
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M]H>UE6M:K^[JQ9)/ S7BOP%\Z*G924<%/&FC(F-C;XD30#N
M
M $>\H'UG<F]P9]8TH87SY0/K.Y-[@SZQI0P#]%MGWJ#QO\V4WU33/F!V?>H/
M&_S93?5-,\
M
M                        8S)K-39!8JVV5K4=#4QJQ=4UT54X+Y"J>R^V
MY!LUVMRTTMLKI;<^1:>26.%RM='KWKM=-.PM^-$[$ (        19RB[K<*3
M :B@LU'55-77JD*\Q&KE:SK7@2F%1%Z4 K[R7-G=19:6HR.\T[X:VH3FX(I6
M*US&]:\>TL$
M                           $>\H'UG<F]P9]8TH87SY0/K.Y-[@SZQI0
MP#]%]GWJ#QO\V4WU33/& V?>H/&_S93?5-,^
M
M
M
M                    !'O*!]9W)O<&?6-*&%\^4#ZSN3>X,^L:4, _1;9]
MZ@\;_-E-]4TSY@=GWJ#QO\V4WU33/
M
M
M
M              1]R@?6=R;W!GUC2A9?/E ^L[DWN#/K&E# /T7V?>H/&_S9
M3?5-,\8'9]Z@\;_-E-]4TSP
M
M
M
M       $>\H'UG<F]P9]8TH87SY0/K.Y-[@SZQI0P#]%]GWJ#QO\V4WU33/&
M V?>H/&_S93?5-,^
M           8G+,@H,6Q^MO-V>YM'2LWG[B(KG<=$:U%5-55=$0BZDY1^%5-
M5# D-XC65[6(^2G8C6ZKIJJ[_0!,X"*BHBHJ*B\45
M        (KV_;1KIL[M5IJK/2T50^KF?&]*IKW(B(W7ANN:!*@(4V!;6;UM$
MO-UI+Q1VZGCI*=LK%I6/:JJKM..\]W FL    !XKE=K=:TC6YU])1I)KN+43
M-CWM.G354U ]H/#;;Q;;HZ1+9<:.L6/17I3SMDW=>C715TZ#W  44S_:?FM5
MF5T<M]NEN2"I?$RDIJA\+(D:Y41JM14U7AQ52UVPS(+GDVS6U7*^:NK7;\:R
MJW194:Y41_E1 -]                   %;MJNWG(\1SRZ62WVZT2TM*YB,
M?/'(KUU8CN.CT3K["8]DN35>8[/K3?KE%!#5U:2[[($5&)NRO8FB*JKT-3K
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MGNT*/543@DK.]<GP;J^4G+DSY&R^[+:"!9$=56QRT<K575=$XL7Q;JHGD7L
MV_/,XL>#4%/69#4/BBJ).:C2.-7N<NBJO!.KAT^%#QX#M*QS.ZBL@QZIEDEI
M6M?(V6)8UT<JHBIKT]'SH5LY663I=\[@L]/(CZ>T1;KMU=4YU^BN^!$:GD4U
M7D_9-YF=I]IED?NTM8[N*?5>&DBHB*OB=NJ!>\B^KVZ8337F:UK5U<M9'.M-
MNQ4KGHYZ.W=&JG3QZS8MK60KB^SN^72.1K*AE.L<"JNGVQW>MT\**NOD*F\F
MS'?-'M3HIJAKI(+<BU\BKQ[YJIN:_P#4J+Y +GWJ^6NQT7==YKZ:@I_PZB1&
M>3CTJ1G<>4-@5',L<=76U>BZ;T%,N[\+E0\_*)V7UV>4]JJ["C%NE-)S+VR2
M(QBQ.XJY57\%4ZN*ZJ:3;^2TJTR+<<G1)U3BD%+JU%\:NU7X$ E3%]M6#Y%5
M,I::[=RU+UT9'61K%O+V(Y>]U\I(Z*BHBHNJ+UE!=K>S:X;.+M34U;415=+5
MM<^FJ(TW=_=5$<BM7H5-4[4XIQ+&\E'*ZN_X566ZY3OGGM4S8XWO75W,N;WJ
M*O7HK7)XM )8R/(K1C="ZLOMQIZ&G3[Z9^BN\")TJO@0C.KY1>"03.CCFN-0
MB+IOQ4O>K\944K;MZO\ 67[:A?%JWOYJCG=201*JZ,8Q=W@GA5%5?"I*&#\G
M6T7_ !B@N<^33/EJ86RN2D8QS(U<FN[JO%53HZ@)AQK;+@^03L@I+W'3U#UT
M;'5M6%57QNX?.2$5IM_)H=;\PM=0MWBKK'',DE1')'N2Z-XHWAJBHJHB+T<%
M++ "N?+._N+&??,WZK2QA7/EG?W%C/OF;]5H&G\DZ\VZQ7+**^\UL%'1QTD>
M]+,[=3TZ\$[5\"<27)^45@<52L39[A*U/_=92KN_.J+\Q4S L1NF;9##9K,U
MJS2)OR/>NC(F)TO=X$U\?'0G.X<ER=EL<Z@R1DM>UNJ,EIMV-RZ=&J*JIQZ]
M% G_ !#-,?R^F6;'KG!5[J:OC1=V1GY35XI\!L)^=%!67G!LLYV%TU#=K=.K
M7MU5JZM7BU>UJZ>)4+LU&T>D9L?7-XV-W5I.=;"YW#GM=SF]?R^ &P97F%@Q
M2FY_(+I34353O6/=J]_Y+$XKY$([3E%X&M0L?/7)&:Z<[W*N[].OS%7;=2Y!
MM6V@-B?.E1=;@]7/EDX,B8U-57P-:U.")X$Z2=?0MT/V/T\TM3W=N^F[G;S>
M]XM==/*!..)Y?8<MI%J,>N=/6M1.^8QVCV?E-7BGE0]&7>I2]>\IOU'%#ZN+
M(-EF?211S.IKI;Y4T>Q5W)F=*>-CDTX+])=B.^PY-LKFO-,B)'6VJ256HNNX
MY8UWF^1=4\@%$,,]5]B]_0?6-/T=/SBPSU7V+W_!]8TO7M=S!<'P2X7F)K)*
MMN[#3,?T.D<NB>/1-7:=C5 ]V79QCF(P[^076GI7+Z6+7>D=XF)JOETT-!;R
MC,$6?FUEN36Z_P!HM+WOTZ_,52M-OO\ M'S/F(G/KKO7R*^265>#4ZW.7J:B
M?N1.HG&3DM2_8U%CR9BW#=UW74JI$KNS7>UT\.GD G_$LRQ_+:99L>NE/6(U
M._8U='L\;5XI\!TYWFMHP>VPU]_=41TLLG--?%$LFCM%5$73HZ%*)?\ Z_L\
MS%4UFMUYMTO%$=T]?5P<UR>144MS>IX=KVP:IJJ:%$JIZ996Q)QYNHB77=3Q
MJFB>!P&SX#M*QO.JBK@QZIEDFI6(^1DL2QKNJNFJ:]/$W(HKR=<A;CNU6UOJ
M).:IJW>HI55=$[_TNO\ UHPMQM?R=,1V>WBZ-D1E5S2PTW'15E?P;IXN*^10
M-=N.WO!;?<:JBJ*ZKYZGE="]64SG-WFJJ+HO6FJ=)*4,C)HF2Q.1T;VHYKDZ
M%1>A3\S7*KG*YRJJJNJJO67EY..4-R79C;V2R(^MMO\ Z*=->.C?2+Y6;OP*
M!M&>9U8\&H::JR&HDBCJ)%CC2.-7N<J)JO!.KP^%#C@6=V7.J6JJ<>?4R04S
MTC>^6%8TWE371->GAI\*%7>5?D;;OM%9;:>7?I[53I"Y$=JB2N57/\NFXB_D
MEB=@>-.QC9A:*:9N[4U3.[)DTT5'2:*B+X4;NIY )"(DV]YSCE%B&1XW57-D
M=[FHE2.E6-ZJY7)JWBB;O'QDME=.49LGENL][S=+NR*.FI&N[D6G55=N)IZ?
M>X:^("ONRZY4EGVA8_<;E,D%%35D<DLBHJHQJ+Q71.)=[%]I6(Y3=$MU@O,=
M96JQ9$B;%(U=U.E=7-1"B.&V-<ERFUV5DZ4[JZ=L"2JW>1FJ].FJ:_"6OV1[
M#IL!RYMZDOT=<U('P\RVE6->^TXZ[R]G8!K7+1_X'$_=*GZ(S7>29>K;89<L
MKKS74]%2,AIT669Z-37>?P3M7P&Q<M'_ ('$_=*GZ(R MGV'W3.,BBLUG1J2
M.19)9)%T9$Q.ESOA1.''B!;&IY1.!PU2PMJ;A,Q':<['2KN>/BJ+IY#?\/S*
MP9A1NJ,>N4-6UGIV)JU\?Y35XH5PR;DRW&WV*:KL]ZCN%;"Q7K3.@YOG-$XH
MU=Y>/8B])#F 9%6XCF%NNE'(Z*2"9&RMZ$>Q5T<QR=BH!^B1@LJRZPXK2\_D
M%TIJ)B^E:]VKW_DM3BOD0Z\ZR6#%\+NE^?NR-I:=9(FJNB2/7@QOE<J)Y2CE
M)%D&U;:"R.29*B[7&155[UT9$Q$U7Q-:U.C]Z@6B]$7@?="Q\]<MS73G>Y5W
M?IU^8D/$LQL&6TJSX]=*>L:B:N8UVDC/RF+Q3RH0>WDMT/V/T=DM3W=N^F2G
M;S>]XM==/*01<::_[+,^DA9.ZFNEOE1S9(U7<F9THOA:Y-."^)0/T&!A,(O\
M.4XG:KU3HC6UD#9'-1==QWWS?(NJ>0S8                   1]R@?6=R;
MW!GUC2A9?3E ^L[DWN#/K&E"P/T7V?>H/&_S;3?5-,\8'9]Z@\;_ #93?5-,
M\                                                    @3E;9@R
MVXI3XU3/3NNYO229$7BV!BZ_]SD3R(I/,LC(HGR2N:R-B*YSG+HB(G2JGY_;
M7,J7,]H%UNL3G.I7R<U2HO5$U-UNB=6NFOC50,1A>2U>)9#37FW0TLU73[W-
MI4L5[&JJ::Z(J<>))TW*0S.>&2*6ELCXY&JQS5IGZ*B\%3TY->S38QBU/@]H
M\T-BIJN[2P-FJ9)MY7(]W?;O3U:HGD-F\Z# ?\+T'P._F!0CG7)-SL?VMV]O
M)N\-U=>HOWL@RWS;[/:"YR.3NW<6GJD3JE;P5?+P=Y2$^4SLMM5BQ^AOV+6V
M*BIZ=_,UK(M=-'*FX_CX>'_4A@^2?F:V?+9L=JY%2BNJ:PHO0V=J</%O-U3Q
MH@$-9)1SV_(;G1U;%9405,D4C5Z4<CE13]!, OE!D.(6NOM4L3X'T\:*R-R+
MS3D:FK%[%3HT(<V][$*G)+E+D6(M8MRFT[JHW/1J3*B:;[55=$=HB:IP1>GI
MZ:^4MLSK$J]\5'29%:JIR[J]SLEC5_5P5OID\* 6WY1M_M]GV77>EK98^ZKA
M'W/30*O?/<JIJJ)V-3CKX$*H;$/79Q;WZS]Y[*W!,VN]CN>4Y,RNBI**'G'5
M%T>[G9>*(C6H[OEU54X]!Y=AK%?M:Q=&IQ2L:OD1%4"8N6A!*OF5G1%YAO=#
M%7_,NXJ?,BGDY&=;21W/)*-[FMKIHHI(T5>+V-5V]IXE<GPDZ[5L)IL\P^JM
M$RLCJ47G:6=R:\U*FNB\.I4547P*4IN5JRS9AD['RLJK5<H%UBJ(^+'I_E=Z
M5S5ZT\BH!^@Q0;;M64M=M:R6>@5KH.Z$9JWH5S6-:]?C(ID[EMWS^OMZTC[R
MR%KF[KY(*>-DCD_*1.'_ $Z'1LIV4WS/+I%,^GEIK*V1%J*V5%;O-Z51FOIG
M+X.":\0+"X%!+3\EJ5LZ*CG6>M>U%_!<DJI\**B^4JMLS:U^T;%&/1'-==J1
M%1>A4YYI>?.Z2"@V79#1T<38::"T5$<4;>AK4A<B(GD*-;,/7)Q/\[4GUS /
MT/*0\J%J)MCNRHB(JPTZKX?M32[Q2+E1>O%=/<*?ZIH%A>2Y&UFQ^VJU-%?/
M.Y?"O.*G[CJY5#4=LAK55-5;4P*G@[_3]YZ.3!ZSMI]UG^M<=/*F]:"O]\P?
MK@0'R5O7=H_>L_ZIZ^5K#+'M3;)(B\W+01+&O@17(OSZGDY*WKNT?O6?]4L+
MM]V9KM QZ*2VMB;?:%5=3N>NZDC%]-&J^'1%15Z%[-5 K?LKP7-,MLD\^)9!
M%1TT$RLDIUKY85:Y41=[=:BIQ[? ;HNQ7:PJ*BY1$J+P5%NM1_21);[AENS/
M(9TIGUEEN;46*5KXTT>FNO%'(K7)UHO%.PV>X;>]H%92+3_9>*GU31TD%-&U
MZIX].'C30#:\9Y.^8VW([57SU-GYFEJXIG[E0]7;K7HJZ=YT\#;N6;ZG<;]]
M2_J(=O)3K<REHZR*\4]1+CC]98*JK>J/215U5&:\7-7555>A%3IU53JY9GJ=
MQOWU+^H@&L\C/U49%[S9^N;+RB-LEUQN^+C>*RLIJF*-KZNJ5B.<U7)JC&HO
M!."HJKIUH:UR,_51D7O-GZYXN51@USH\PJ,J@@?/:J]L:2RL37F9&L1FCNQ%
M1J*B]'4!X,0PW:MGMM;>:6^UD5)+KS<U5<9(^=T71=U&ZKIKKU(:QM:PO+,1
M=;4S"Z-KUJ$?S&E7)/N:::^G1-.E.@S.SG;MD&%X_'9F4=%<*.#7N?GM6NB1
M5UTU;TIJJKQX\>DU[:3DF59S#3Y)D46Y;DD6EI$9'N1-73><C->+NCBNJ]2
M2]R*_3YCXJ/_ /C'HY9Z+W%BZZ<.<GX^1IY^17Z?,?%1_P#\8WWE.896Y7@T
M,]H@?45]MGYY(6)JY\:HJ/1$ZU3O5\B@1UR+_P"\LK]QI_UI"TA^=^$YG?\
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M6!D;W)^5IJGDT)[Y+]5F,N,30Y13S_8EB-6W3U2Z2JG'5J(O%6="HJ^)-4Z
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MAR<$X\44F+9AMQRZZ[0K#0WVL946ZJF;2R114S&;SG]ZUZJB:\%5%X+IIKP
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M6[R025D,DKG+ ]7,T<]53151.I>PW@^1JY6-5Z(UZHFJ(NJ(I]
M         "/>4#ZSN3>X,^L:4,+Y\H'UG<F]P9]8TH8!^B^S[U!XW^;*;ZII
MGC [/O4'C?YLIOJFF>
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M+NFQ #XUJ-:C6HB-1-$1.A#PW>RVN\QQQWBVT5>R-5<QM5 V5&KVHCD70]X
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M*Q'-7QHIK_F Q#?W_,K8M[IU[@B_I-E '""&*")L4$;(HVIHUC&HU$\2(<P
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M^8TH>!^B^S[U!XW^;*;ZIIGC [/O4'C?YLIOJFF>
M                                   -4R/:-B6-W'N"]WZCI:Q$170J
MJN<W7HWMU%T\IL5MKJ6YT,%;;ZB*II)VH^.6)V\UR+UHH'I        !Y[C7
M4MMH9ZRX5$5-20-5\DLKD:UB)UJIK>.[1\1R*Y);[+?J2JK7(JMB;O-<[3BN
MFJ)KY -L              <)9HH=.=D8S7HWG(AR8]KVHYCD<U>M%U0#Z
M                        !B,FR:S8O1-J\@N-/04[G;K72NXN7L1$XKY
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MIIJ&"&5FJ+NO;&B*FJ<%XH98
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MWQQ2[['HG#?;V(O'AJH&P
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ML/8L:M5CKKK66RF6&HND_=-6Y9'.YR3CQT551.E>":(9@
M
M *P<HS9OEN5;0DN-@LTE91]QQ1<ZV6-J;R*[5-'.1>M"4>3KC=VQ;9VENO\
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M1MBC8G0UJ)HB? =YU
M
M            '!8HU556-BJO6J'-$1$T1$1.Q
M                                      'QS&N5%<U%5.A53H/H
M                                          !\W&[V]NIO=NG$^@
M
M
M
M
3                      #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g73463g32a32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g32a32.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1?R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %]4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0 " P$                #! $"!0;_Q  R$0$  @$"! ,&!@(# 0
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MS5VIJ&F,:EK(/ZO=R11M]](]>Q$*_@.("V,E#2S^,L8B6RNU59DZ2[]G9OU
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M]O\ T*AXUK2/BCF\10S*>:SQBG7F1.1[?3UVW+!-%Q$DKSKE,A2H4XXW/?/
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M7'/EJK)$@;NU7=4&/XI8/(ZP@T]22>6S*BJV1&^8J;=NX%]
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MGT%BTI@:^F\+#C:CG.BB5515]J[@=#AUI=NDM,PXU)%DD15DD=WN7MV+,
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MVIX\!I%:J/5+&1>E9J-3==G=%4T@K.>T=1SFH\;ELAO(M%%\%$OO=U5%W_T
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M?DRM:9J+'NJJB)WH6XC=.X:K@,7'CZ"/2O&J\J.<JJF_QDD
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M$^\O91..'P9YGY"?>!(<)?@RTM_+8/P(6LJG"7X,M+?RV#\"%K
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MW::AP8UA2CXK-H8G$35H;]9K)5E]]S(BJKE^,,/48 #(
M                             &/:S_36$XMPYRCA+&2INHI"JQ*B<KN9
M5-A &7^434/J9?\ K(/*)J'U,O\ UD-0 &7>434/J9?^LA]\HFH?4R_]9#4
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MU,O_ %D/GE%U#ZF7_K(:B ,O\HFH?4R_]9!Y1-0^IE_ZR&H #+_*)J'U,O\
MUD'E$U#ZF7_K(:@ ,O\ *)J'U,O_ %D/GE$U#ZF7_K(:B ,O\HFH?4R_]9!Y
M1-0^IE_ZR&H #+_*)J'U,O\ UD'E$U#ZF7_K(:@ ,O\ *)J'U,O_ %D/GE$U
M#ZF7_K(:B ,N\HFH?4R_]9#[Y1-0^IE_ZR&H #+_ "B:A]3+_P!9#YY1=0^I
ME_ZR&H@#+O*+J'U,O_60^^434/J9?^LAJ  R_P HFH?4R_\ 60>434/J9?\
MK(:@ ,N\HNH?4R_]9#[Y1-0^IE_ZR&H #+_*)J'U,O\ UD'E$U#ZF7_K(:@
M,O\ *)J'U,O_ %D'E$U#ZF7_ *R&H #+_*)J'U,O_60>434/J9?^LAJ  R_R
MB:A]3+_UD'E$U#ZF7_K(:@ ,O\HFH?4R_P#60^>434/J9?\ K(:B ,N\HFH?
M4R_]9#[Y1-0^IE_ZR&H #+O*)J'U,O\ UD/J<1-0[_W,O_60U  9)PJK9>WK
MS4.=R>*FQL%EB,C9*NZJNZ&M@
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MLPX>%$1U9'=)'^E6].G0T'@-JIS^+D=:''M@I3Q)#"V7J^&-$79-_CW ]?@
M
M
M
M
M                                           !1..'P9YGY"?>7LHG
M'#X,\S\A/O D.$OP9:6_EL'X$+653A+\&6EOY;!^!"U@
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MY.BM>G=N!LH.MC[U;(U66*4\<T+DZ.8NZ'9
M
M
M
M
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MA9*A5R=*6I?A9/7D39S'INBE"TMA,KA<U=T_>C\?TS88YT#Y5W\$FWO%]GH
MX),+:P:-U#H>=9L?(U)9<=S;LD;VKR=RENTCJJCJ6DDM9RQ6&]):\G1\:]RH
M5?2>2MX'6<^DYZ*QXKD66C.U/-V]+57XU)K5>CHL@KK^'?\ H_,L\YEB+IS+
MW.[T MH*+I?6-AEQ,/JR%*64;YK95Z1S^U%_Y%Z
M
M
M
M
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M:^U )T
M
M
M
M                                        "B<</@SS/R$^\O91..'P
M9YGY"?>!(<)?@RTM_+8/P(6LJG"7X,M+?RV#\"%K
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M@R$:;JQ/0CT TP'%5L16Z[)Z\C9(GINUS5W13E
M
M
M
M
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M+%;?E]+S+1RJ><K$_LYO8Y/;[ +L"G:3UFV_97%YR']'9IG1T+^C7^UJEQ
M
M
M
M
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M>WV%YT]G:&?I)9QL[96)T<G8K5[E0"3
M
M
M
M                                                       *)QP^
M#/,_(3[R]E$XX?!GF?D)]X$APE^#+2W\M@_ A:RJ<)?@RTM_+8/P(6L
M                 &7>Z)QU.?ASDK4U:.2Q$U.214ZMZ^@U$Q[W24>==HNV
MZA)7;BT:GC#7+YZ]?1T T+0*[Z/Q6_\ L&D^0.@MOU0Q7+V> :3P
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MZ$<OH4#10?B&6.:)LD+VOC<F[7-7=%0_8
M
M
M
M                                                    "B<</@SS
M/R&_>7LHG'#X,\S\A/O D.$OP9:6_EL'X$+653A+\&6EOY;!^!"U@
M          0VK-14M,8B3(9)SDB;T1&INKE]"(53&<1W0W:U35.+FQ,UQ_+5
M55YFO[MU]"@:("CZGUZF/S#L5AZ,F3OP-26S&Q=O!1]_QEATMGZNH\6EZDV5
MC.96.9(WE<UR=J 2YE'NC,UCJN@;^/LVFQW)VIX*-4ZNZFKF6^Z)QM*?AWD;
M<]6*2S$U/!R*WSF]?0H%ST$BIH_%(J;+X!I/D!H%=]'XI57?]@TGP
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MKK&\SHD7SD0[H
M
M
M
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M'Z&K[2^
M
M
M
M                "B<</@SS/R&_>7LHG'#X,\S\A/O D.$OP9:6_EL'X$+6
M53A+\&6EOY;!^!"U@                      R_P!T11JR\-\E8E@8^>-J
M<CU3JG4U R#W2-[)0Z'N5ZM)):<C4\+-O[SKW :!H%571^*W_P!@TGR!T%LF
MD,5MV> :3P                 J/$7%Y.?&-OZ91C<S6>CV;HF\C?2Q5_\
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MMOB.8H/##'K,R7/Y&ZEG)Y!J/5B/W;"ST-1"_
M
M
M
M                                              "B<</@SS/R$^\O
M91..'P9YGY"?>!(<)?@RTM_+8/P(6LJG"7X,M+?RV#\"%K
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M6D\%#=9%.C>9T4WF.;\>X%F!^8I&2L1\;FO:O5%:NZ*?H
M
M
M
M                                              43CA\&>9^0GWE[
M*)QP^#/,_(3[P)#A+\&6EOY;!^!"UE4X2_!EI;^6P?@0M8
M  $7J+!X_/4/%<M"DM9%1ZM5=DZ&79J!-><1L57Q43?T-A'^$GM-;LCGITY&
MKZ?07OB5BLWFM-34-.7&4[4R[.E=Z&^PJFG=,ZWPS:52O<QS*$2IX1&L\YZ>
ME5Z]H'5QW#7.0ZIU'F4S;8Y+C^:OR(CMNNZ-=NG86/A9JJWFX\EC,RUK<OC)
M5CFY$\US=U1KD^/8C+NF=;8_*Y"7 9J%]2TY7LCL)NL2KZ$Z]A/<-=(2:9HV
M9LA,EG+W9%EM3I^\N^^R>Q-P+@]51CE:FZHG1# .-.I-46M%YBK<TZZ"ES(W
MQA=_>[]IZ ,S]T+9ACX:92)\T;)7M3E:KME=U] %NT%LFD,5LNZ> :3Q :!_
MN?BO\AI/@                     %1XBZ:DS6*6SBU2'-5?VE:9$\[=.O+
M\2G;T3FILABH*^76.'-Q,3QFOOYS5[]NY2QF>:_Q'Z)S$.M*#)G6*;%2U#'_
M -[%MU54].R(H%TO4GS6X++)Y&-A156-O8\C=)ZKHZC9.VNJQ68)%CD@DZ/;
MLO;MW$E@LI6S6)JY&D[F@L1H]O>FZ=B^TJ6L-&69]04=0:;E;5R<+T2=O8V>
M/THOM O@..&1KTY>9JR-]\B+V*<@   1VHZD%W"7*]N98(7QJCI47;D]NYYH
MU]JI,1:TWCLU92\[&7?#168EW2:/KM\_H/2VHYZ=;"7)<DQ7U&QJLC43=53N
MV,<PO"RGK6&SEL_1\09(BMH5V=%C;Z'+[54"U\-)_P!)Y.?-Y3(QNR%QB>"H
MM?\ V$?H3;O-*,OX8TJV/RUC&9/&M@S=).5ME$Z3Q^AR+WFH    5$<BHY$5
M%]"E;S^B<%F^MRDQ'\W-SQ>8Y5]JH60 9K-HG/8)TDVDLRY6JO2M:ZL:WN1>
MI^J6OLEBWI7U9A;-=^_*V>%BN8[;TFD'Y?&R1-GM:Y.Y4W AL/JK#9=O_0[\
M*O[%C<Y&N1?B4FT5%3=%14]A4L_H#"9>3PZU_%K2=4EA\U47O(%F$UEIE$7#
MW69:HW=? 6%V>O\ \2J!I8,_I\0I**MAU7BK.-E7MD1O/&G_ ,2="W8C.XS+
MQ-DQUV&=')NB-=U^@"2
M
M
M
M              HG'#X,\S\A/O+V43CA\&>9^0GW@2'"7X,M+?RV#\"%K*IP
ME^#+2W\M@_ A:P                      91[HW#T[7#^_>F8Y;,#4\&Y'
M=$Z]QJYCWNDKN7BT7:KTZ#)<?(U/#3J[JSKW :'H)=]'XI5_V#2>('02(FD,
M4B+NG@&D\                      #\R,;)&YDC4<QR;.:J;HJ'Z &:Y6>
MYH;5%>Q&UJ:4L[MF1.B5WKV+MW&CPRLGB9+$Y'QO1'-<G8J*=3.8JKFL59Q]
M^-)*\[%8Y%]IGNE,Q+HK-4M&YQ[YF3(JT;?H<W?HQ?:!:-76K>GJ;\IBJ2V_
MVB.LQH[KR>E4^(E]/YJEGL9%>QDR2P2)VIVHO<I(/:CVJUR(K53947TH53 :
M5KZ7RV3R%.R]E"RBR/J_N1N[5<@%L!PT[,5RNR>N[FB>F[5[SF _,L3)6*R5
MC7L7M:Y-T4_341J(C41$3HB( !^/ Q^%\+X-GA-MN?;KM\9^P
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MHG8NQI7!%E]E".=M6LZ"VWPUBWS;ROD7T.[@-9
M
M
M
M           "B<</@SS/R&_>7LHG'#X,\S\A/O D.$OP9:6_EL'X$+653A+\
M&6EOY;!^!"U@                 <%ZY7H57V+DS(86)NY[UV1"$Q>M,%DK
MC:M:ZWPSO>M>BMYOBW L0.IE<E4Q-"6[D9V05HTW=(]=D0Y:-J&]4BLU9$D@
ME:CV.3L5% YC-_=!O:G"_+-5Z(JM39-^WJ:09'[I#!U[FA;N0DEF;+7:G*UK
MO-7KZ4 ON@?[GXK_ "&D^0.@EWTABE_\!I/
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MOYA'_P S3L7_ -F5/\EGW =D
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MMMB=KH)6R(GT*>*>'.F\OQVUSDK.I<Q89#7B\--*QO-R[NV;&QJKLU/?+_\
M#[26U3PWUCPEUS2NZ ;F<M6<Q)4DK4WR;(CNL4J,145%V3NW1?8![+(N]J'"
MX^SXM?R^/K6/]E-88QWT*NYD/NB>)62TQH##MQ:24,OG(]W*Y-I*S.1%>FR]
M6NW<C?9U]*&2\-^&V@L_I%F4UGKJI4S-SF>D/Z2@8Z%-]D\(CU5RN795]':@
M'LF"6.>)DL$C)(GINU['(J.3O14/#_NKE5.,>0V5?^K5_P !8>!&K[FBN*[M
M&-S$>5T[:M.JQ212))$KNO@Y(U151.;HBHB[=?9N5WW5_P ,>0_X:O\ @ ]I
M6\WB\;X&+(Y*E4D>B<K)YVL5WQ(JDBQS7L:]CD<UR;HJ+NBH>7\Q[G>]D=*W
M\]GM0V[>K)*[K;H^5'1K(C5=X/?M7_#NFR)Z$V.E[C[6U]<U;TG=L.FHO@=9
MJI(Y56)S53F:WV*B[[>SXP/55B>&M"Z6S+'#$WM?(Y&M3YU.CCL_A\G,Z''9
M6A;E;VL@L,>Y/F13Q]KO/YOC)Q>9I>G=?7P[;;J\$;>K&L9OS3.1%\Y=D5?H
M1#O<7N!R\.=-1:ET[FKD[ZLL;9^9J,<S==DD:YJ]/.VZ>WMZ >Q09)[FO7]S
M7.BYDS#TERF-E2"67L65BINQZIW]J+W[;FM@
M
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MY[NQ$D3=0.X!NBKLBH
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MM68HHG*G1RQM=S*GUT0]&G0P.'H8#$UL9AZL=6C7;R1Q1ILB)_S5>U5])WP
M
M                                                   !1..'P9YG
MY"?>7LHG'#X,\S\A/O D.$OP9:6_EL'X$+653A+\&6EOY;!^!"U@
M              R+W2&%2WH6[>\<L1K U/V37;-?U]*&NF2^Z/R<E?05ZHVE
M-*R5J;S-3S6=?2!?-!+OI#%+V?L&D\0.@DVTABNO_<-)X
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M7S4]@$V#@KVZ]E\C()HY'QKL]K5W5J^TYP
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M8ZE=9R6ZL,S=]]GL10(O&ZOP61;S5\E7_P#C>C?O)F*S!-_931O^2Y%*WF=
MZ=RS8TLX]C59U:L2JS[B!R7"RM(QGZ+REVB]J[JK'JN_=VJ!HZ+OV RS]5=<
MXU[?T5J"*:)%\YLZ=51.Q.P[RYK7&/G8EO#06ZS>LCX7>=M[ -%!GKN)D=6;
MER>$R=6%/?3.C16M^A3NX_B=IB[;CK,O*R1_9X1BM3Z0+J".IYS%W)UAJWZ\
MLJ)OR->BJ=]KV.54:YJJG<H'Z
M
M
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M(R18UW1>9 .8%8AUA2CU*_!WF25;/1(9).C)NGH4LX
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M?":]T_F))65;S4=%[Y)$5I/5,C3MM<ZM9BE:U=E5KDZ =H'QKFN]ZY%^)3Z
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M5$YNGI5'-^@]/<+LQ+GN'>G<G855GL4HW2KWO1-G+\ZHH%H
M
M                                            "B<</@SS/R&_>7LH
MG'#X,\S\A/O D.$OP9:6_EL'X$+653A+\&6EOY;!^!"U@
M 06LM,UM58E<?>EEC@5R.=X-=E7;T&6ZCJ5M3<2,/B=,5VQ0XEZ2W;</1$VZ
M<G3M7L-%XD+J+]7)8](,A7(R+RHZ7L:GI4HVCZ>L]/K#5K8/'LBED1UJ?G57
MR*O:[L N/%#"7\MI>W#@JU63)RM2-'S)V-].R_$=+@WD\?)IY</4K+4NXQ?
MVH%_Q]BN^)513HY.7B'BLG=9C8:62I2*KX%DW:YG^ZNQ)<+=*6\)'?RF;<U<
MUDW^$L(SWK4W54:GQ;@7IR[-5>W9-S#>-NLVY#0F:H_HF[%RN1GA7IYO;V]A
MN9G'N@4_^Y?ET3;=6I]X%IT$FVC\4G_@-)X@- ?W/Q7^0TGP
M                    ,9]T'FH(;>FL-81[66+;9G2M;OR(FZ%0XVYVOJ&#
M3%&?&7F5$N-:JJFSGHB=K>AH_%?5L&F\]A(+6!BRC;B\C'JSF<QV_8A2>+6L
M\=>O:/ECBGB=6OM<^)S-E;T7H!]X9ZGKT^,5_$,CD\7L5VQPR2IL[IUV4]!F
M&29YFI]9_J_%I]N.GLU_"I?Y.69G;L[?XT- X>Y:5E=VG\Q<CFS5!O+)LO5[
M.Q'?/L!<P ! :QTM2U1C/%;B*R5CD?#.SH^-R=BHHPB6,#B*]?.Y!MJ;F\&R
M5&JBN[MR?..>O%.C4FC:_E7=O,F^R]X'(G5 4/(:BRNELU*[/L;/@YW?LK$3
M>L/L=["[4K4%VK'8J2MEAD3F:]J[HJ <P                     <-Q94J
MRK78U\R-7D:[L5?0<P H>B]'6&6+F7U8Z*WE[:JBL1J+'"S?9&M^;8_&E=,Y
M?2^JK<5*5L^F[6\J,>OG0/5>QOL+^                            *F_
M:<4U:"9O++#&].YS44Y0! 971^#R;&MM4(EY5W16ILI6;_";$/>BXRU;QK?W
MVP/Z/7O7<T4 9K6T'GL*US-/:EE1DG5Z6VJ_Z-C]1NXA89R5TBI9ICNOAU=X
M-6^S95-( &<.X@Y3&3I4S6FK:VDZJZLO,S;X]CN0<4].JO@[DLU2RGOX9(UW
M:7O8B[>G<1;F=+9QU625R[N>Z--U X,9JO"9*%LM7(UU1W8CGHU?H)B*6.5B
M.B>U[5[%:N^Y3KG#/35FXZSXH^*1W^R?RI]!T6\-O%+#I<9G<C G8V-S^9K0
M-"!G#L9K_'J[Q3*5+L?[K98]E1/0<=?5.L\<R3]-:>9.B=6NJJJ] -+!G..X
MI5N61<UB[N-5/>^$9[Y"=P^OM.Y2NZ6')0QHU=E25>50+2#K4K]6[ DU2Q%-
M$O8YCMT.RB[ING5                    'YE=R1/=MS;(J[)Z3]'YF5Z1/
M6)$5Z(O*B]X'FO66NTT3J.3-X?%W*J2O<R>E+T9*N_OTZ=.\G.%VH(9\C!E;
M>*OY#)9*3K;5-V5T5>C4Z=$Z_P"AS<2-.6Z^C\MG-1O99RDT[6QL[8XH]UV1
M$[]BUZ8TUD\+DL9?P,[?T3=@B6Y5D7HQ>5.K.[T@:2@  QWW67P.W/\ BX/Q
M%5]REB*>>X1:AQ64A;-2MW7Q2L7THL;.J>U.U%[R_>Z-T_E-3<,K6-P-.2[>
M=8A>V)BHBJB.W5>JHA%>Y=TMFM)Z)R%/46/DHV9+SI61R*U55O(U-^BKZ44#
MS\JY?@%Q;?&JNM47-ZHB\J6ZKE7;XG(J?,J=Q(>Y2E;/QGEE9NC9*EAR;]NR
MJBGH?CSPUAX@Z5<E5K6YRDBR4Y.B<_?&J]SO]%V7O,?]S9PWU;I?B0W(Y_"6
M*5)*DL?A7N8J<R[;)T5>X"W\4]0<8:.N<E7T7C99\"Q(O%Y&U(Y$7>-JO\Y>
MJ^=S%4_6OW07\'G_ /(1'JD 85PASO%J_K.&#76.EKX589%>]U2.-.=$\WJG
M7M-U  \,7_\ VJ&__P 4Q?\ ^0T]B\1-02:5T1FLW#"V>6E7=(R-R[(KNQ-_
M9NJ'FNYPSU@_W0K<\S!6%Q'ZPQV_&>9G+X))T<K]M]]MDW[#U;D\?4RE":ED
MJT5JG.WEDAE:CFO3N5%[0/"?##B#BL%KF[JS6-*[F,M(YTD*L5J-9([WSUW7
MM1.B)Z/H.KQQU]3XAZPK9BA3GJ115&5ECF5%<JM>]V_3T><A[.\EVA?5+"?^
M49^1YZX]\'LM:UO7DT'I5K<2E.-'I3;'&SPO._FZ;IUVY?\ 0"X7=>5>*' C
M6=;&8^Q6?BZ4*/29R+S\OG[IM_EJ5WW$U^-EW56/5R>%EC@G:F_54:KVK^-#
MT)I72&$PF"=3H8>G12W QEQD,2,\*O+LO-MV]KOI/+F>X4:_X::SERO#Z*W;
MJ;N2O/61LDB1K_W<C%3KZ/1LNVX$M[M;(12YS3&/:]%EK5YYGM[DD<Q$_P#E
MJ;UP0HOQW"72M>1%1_B+)51>U.?S]O\ \(\WZ:X1:\XBZS9F.($=BI5<]CK,
MMM$9)(Q%3]G&Q/>].G8B)[?3[$KPQUX(X8&-CBC:C&,:FR-:B;(B ?L
M
M                S7+9#*:*U<ENY.^UIO(R;/5W;5?Z/F[$ TH&8W,Y=UMJ
MIF*TY9\%A:+DDMW8^OA'(O\ 9M--:G*U$3L3H!]
M           *)QP^#/,_(3[R]E$XX?!GF?D)]X$APE^#+2W\M@_ A:RJ<)?@
MRTM_+8/P(6L                      &/>Z3P#;NB[636[8B6LU-H6KYC^
MOI-A,D]T?FZM305ZA*DGAYVIR;)T[>\"^Z#7FTABE_\  :3Q Z"3;1^*1?\
M8-)X                                #)_=$<\6G\3:J1M==BOL\$J]
M^RD'K' ZOU'-IZRS#TF+1F98=T3S^GIZDMQPKYS(9K3E3%XZ6Y1CF2Q81J=-
MT541%4_:Z@XC-W;#I^ND:=&(LGH C^'<V7L\9,^_*486*R!K.9%ZQIOV(7K5
M.G((<F[56/@>_,5(51&-=LDK41>BI])0=+S:D9Q?9<MX>:I5NUT9:<B*K.=%
M5=]_H-O5-T5%[ (#1.I(=48*'(11OAD=YLD+TV<QR=J$^9OQ#QV0PF0Q^I,
M]T<-1^UVLWHR2->URIWHFZE^Q60K92A#<I2ME@E;S-<U=T [0  X;=6&Y7?!
M:C;+$]-G-<FZ*16)P[-/UFU,3&OBSI%>K7NWY-^[V$V /Q'-'(][(Y&.<SWR
M(NZI\9^RA:VP&3J6TSVE)7LNL5%L5M_,G8G;T[RTZ:RR9G$Q6W0R5Y%Z/BD3
M96N3M0"4
M            ': !P6*5:PW:>"*1/]YJ*5_*:#T[DG\]G&Q\VVV[%5OW%G &
M>V>%N.Y5CQM^]0KK_P!U%)T1>_J<*Z2U?3B2MBM2L;59T8LT?,_;VJ:0 ,WC
MR/$&L[Q=V-J64CZ>&[.?V]I\=Q'OTWK7R&F;WAX^DCHUW;\W0TD^*UJ]J(OS
M 4FGQ0TU95K'6I(I>QS'Q.3E7N5=BTULQC;*(L%^K)OZ&RM5?O.&73V(EY_"
M8VJJO]\O@TZD [AKIQK9/%JKZ\CNJ/B>J*B]Z 7-%1>Q47X@9UY.KM9JKC]3
M9-CTZHDDBN3?T>DZ_B7$+%UWO;?K9%6]4:K4:J^P#309A7UMJBA5YLUIN5SV
M^^\!NX[]7BGA_!(N2AM49-O.9+&J; : " K:QP%B%DK<K5:UR;IS/1":KV(;
M$+)8)621O3=KFKNBH!R@       SOCU\'=O_ #&?>7/37]WL9_PT?X4*;QZ^
M#NW_ )C/O4N6F_[O8S_AH_PH!(@
M
M          &8Z^S#]39&71^':CV*QSLA95-VPL1%79/][=/]33B*7%4J%;(3
M5*T<<L[7.E>B=7KMZ5 Q7@GFI-()+B,@Q%P=BV^.I<VZH_IYKU-_0RS@YC:F
M4TI?AOUXYXVY*1[6O3?9R;;*AJ341K41.Q.@'T
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MAADMZ%N7O&9HU@1/V;5\UW7TH!?= _W/Q7^0TGR!T&N^D,4O_@-)X
M                            &P  X[$,=B"2&9J/BD:K7-7L5%[4,ZCL
MMX=Y?%X6K4E?@[\KD\.N[O R.7HGL0TDX+M9ENK)!(G1[53?TI[0.=%1R(J+
MNB^D&;:'R-S3&5DTSJ:VCW2R.?CYWK_:M5=^7?O3<TD   !T[M!EED;4>^'D
M>C_V?3?XSN "KXG65*WG;.'L,?4N1+LQ)NB2IWHI:"NZSTG1U13C9918[,#O
M"03LZ.C=W[DAAFV*.+JP96TR:TB<JR=G.H$D
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M8U\,T<C7=45KD7<,N4
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MJC6U5<JN1%V1@$J#K5+]6W)+'6L1RR1+M(UKMU:OM.R
M
M       _,R.=$](W<KU14:O<I^@!BO$72K-/: R]R>5;>4MV6OELO[=MUV:G
M<B;EJP^CFI?P^=Q=A:OA*T:7($3=DZ<J=J''QZ^#NW_F,^]2YZ;_ +O8S_AH
M_P * =++Z/P66:K;N.A=OZ6IR+_H5:;AA%5G\9P>4MTYF+O$WG5S6_2:. ,P
MDQW$##ODL5LA#E4<G*D$B(WE]O1#]4]=Y_&[5]1:=LK.WSGRUDYF(WO[333X
MK4<BHJ(J+W@4[%<2=-Y";P3;O@7IVI,U6(B]VZEHIY&G<B22K:AE8O8K7HI&
M9?26$RU=8;N.@<U7<VZ-1%W*M=X6U$NI/B,C;Q[$;LD43U1B+W[ :,#,X<7K
M_#<RU\A5RD:+YK)/-7;XU.V[765QDS(<YIVTU-O.F@7G:GT(!H(*3CN)NG+=
MA8);$M25O:EF-6(GSJ6VE?J7H6RT[,4\;NQS'(J*!V0
M
M             *%+J^U4U+?PF?JI4AG1Z4+'[LW1>F_>7TS+C%:IY6HW3=-B
M39^=%?7<WMK;=5>J^CHBH!5>'&J+%*E/AL#72]EG9-ZV(_1#'TW<JF[IOLF_
M:8+[G;)4,/XYALG!X+-RSOWNN3I:VV['=_L-Z
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MW,J[JY>WIL64A-#Z@AU5I+%9RNWDCNP-E5G^!W8YOS*BI\Q-@
M   R/W1]+(RZ%NV*U](JD;4\) K=^?KWFN&1^Z0SU*GH2[CIUE\9L-3P?*Q5
M3M]*@7[0772&*_R&D\0.@DVTABD_\!I/
M               !FNJ*"Z&R5S5&"HNL-N.:V]79T1$W]^B=_4T#%WHLECZ]
MROOX*9B/;OV[*=B1C9&.8]$5KDV5%,_J.MZ)U!,W(WFR:>O2;PNEZ+!(O[OQ
M=@&A ^-<CVHYJHK53=%3TGT      SS5NG[^$RDNI])M62VJ?]*I;^;.WV=R
MEPTWEV9K$076Q/A<]-GQOZ*UWI0DSI7:#9UA<R1\*1/Y]H^G-[% [H*Y@M65
M,EDK..G8^G>A=LD4W19$[V]Y8P
M                                               !^95>D3UC1%>B
M+RHOI4#/>/7P=V_\QGWJ7/3?]WL9_P -'^%#(^(^J79G0V6QN3@2CEJ]A&K
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M,B :4"EXGB1@KSE9+)+4D;[Y)V*Q$^=2TT\G2N1,DJVX)6/]ZK'HNX';
M
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MT#_<_%?Y#2?('0:HND,5LFR> :3P
M           "%U?IRGJG"38S(H[P3U1R.;VM<G8J$T *%IC.SXC4C=(9*)ZM
MA@:M2XO_ 'S43KO[>POI ZQPDF8Q4C:4WBV1C3FKSHB;M<G9\QU]#YF>Y26C
MEY8OTU4\RPQJ[*O<[;V@68       %2UQHV'44E6[7G?4RU->:"=GW+WH35"
MU-6ITH<LYGCTB<KN3WJN3N),_$L;9$ZHG,GO55.Q0/V#/HM49/3>:DI:L;ST
M)Y%\6O1M\U$_PNV[/C+]#+'-$V2%[7QN3='-7=%0#]@
M                                                           !
M^9$<L;D8NSE1=E[E/T?)&\['-W5-TVW3T >8^*6G,]J[//PM/(PW<K&JO<Z)
MB-2)GH:YR>PL_"&OF&I!C:68@@DHR(V]4DB1)';+W]JIVFM:7TOC].MLK18J
MS6972RS/7=SE5=^WYSAM:0QDVIJ^>C8Z#(1)RN=&NR2)_O)Z0+$
M          5-TZ@ 163T[BLE&YERC!(CNBKR)N4K(\)<<^5)L5D+U![%YHV1
MR>8B_$:4 ,V;0U]AN:6O>J95FW*D,K>7;V[H<+^(.=Q+$@SFFK,EM.JK4:KF
M;?&:>?',:Y=W-1?C0"DX;B;I[(RM@=86O8V\]DJ;<B]RELHY.E?8KJ=J&9J=
M%5CD4C\II/"9."6*YCH'ME7=ZHG*JK\:%=?PNPT+V+B9K>.:GOF0RJJ.^/?<
M"^@S>7"ZWQ"RR8S,17H&?V5>9B;JG<JGXCUSG\0YK-2Z>F\[HCZOG(GQ]H&E
M@J>(X@X#)2>!2WX"=/?1S-5G+\ZEEKW*UEO-6L0RIWL>CON YP
M                                                           X
M,A_U"S_EN^XYRK5M64<GD,QAVH^&]48Y%9)TYTV7JWO @.!/]V\C_P ?+_R-
M(,:X:ZFI:;TQ-XYS236LH^**&/J]=]NNW<;(U=VHJIMOZ /H
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M!PUR\T-*NV541>=(T1=]^W<"Z:"16Z0Q2+_L&D\0&@>NC\5_D-)\
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M-;[Y43?O4^@
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M70>RZ0Q6R;)X!I/$!H)-M'XI%_V#2?
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M<?+MNO<!Z+3JG0'QB;-1.Y#Z
M
M               J(O:FX '0O8;'7D<ENE!+OV\S$*I=X7X&9'>)I9HJJ[_]
M&E5B;_,7H 9O/I_6N*<DN)S45V.--FUYV=7)[7*?J#5^IL3$YFH-.V)Y57=K
MJ35D3;V[(:, *?3XBX&:2.*S.^G,Y/.;89R(Q>Y57L+!C\UC,BCEHY"K81OO
MO!RH[8_&4P&+RE:6"[2ADCD]]YJ(J_/VE0R?"G"V$B3'26,<C.B^ >OG?'U
MT%KD<F[514[T/IE\>CM78>5S,'J#GH,3FCBG3=RKW*NQS1:MU9AZ_A-1:?=+
M'ORHZHO,OQ[ :4"CX[B9@[$R07/&*%CTLL1JFWSEHH9O&Y!G-3O5Y4[/->@$
M@ BHJ;HNZ          %1%147JB]%  K.IL;3QNC,\RC7CA;)6E>_D3;F<K5
MZJ5K@UCJF3X7XJ&]7CGC;L]&O3?94VV4N&M_[GYK_A)?PJ5K@1\&N+^3^0%_
M8U&,:UJ;-1-D0^@
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MDE5-^C4-2T9K:KDI8,5=K38_(I"U613[?M$V3JT"[
M
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M -%!\:J.:BM7=%ZHI]
M                          43CA\&>9^0GWE[*)QP^#/,_(3[P)#A+\&6
MEOY;!^!"UE4X2_!EI;^6P?@0M8 R75G /2.J-17LUDILLERX_P )(D4[&L1=
MD3HBL7N[S6CJY6=]7%W+$:(KXH7R-1>]&JJ?<!YLU%PJX+:=ONI9K5%RK<9[
MZ%;K'/;\:)&NWSG2IZ0X U[#)9-4SV6M7?P<MEW*[X^6-%_U*KH;AG0UIPOU
M7K;+9&U-F(%M3,BB>FR/8SGW?NBJJJJKTZ=#LV>#.)L<#*NM,1>LOR3*J6[$
M4CVK$]$7:1K=DW:J;+Z5[-@/76F[F,OX*C8P,D4F*=$B5G1)LSD3HFWLZ;$B
M4S@P_'2<+M-NPR2MHK43D;*Y'.:NZ\R*J=NSN9/F+F        !7M=5LW;P4
ME?3<T<%V14:LC_W6^G;VF79*.UH35N#Q.#R]N];O/Y[4%A>9$C1%57=.SL--
MX@ZI9I+3L^1=7DLRIYL<4:;JYQF>B,W@(<H_)9B>Q;U!DDY%>YG2!'?N-[@.
M33]+)<2LSF<A>R5BG1I670TF5G<N_*O:XM?";45W(.R^%S#O"7\7.K%D3]Z-
M55&K\>R%+T-J!>'N7U'B,_7FC@6=]FJ]&[I(U5Z=2S<$L=8E_3>H[L3X9<K8
M56,<FW[-JKRK\Z*!J"KLFZ]ADG'G4&)M<.<O6@R$#[";-\&UZ*N^_9L:VJ(J
M*B]BF,<<]&X.AH#,7JU%K;2[/Y]_3N!I&@=_U/Q6_P#L&D^0.@EWT?BE7_8-
M)X                                                    [4Z@ 9
MMG:M?AQ8NZBQM>>>M=F:ER%J[I&G7=[4-!QMR'(4(+=9W-#,Q'M7V*A^[5>*
MU7D@G8V2)Z<KFN3=%0SO!7[6BLQ=QV?E:S!2R(M"R[HC=^UBJ!I(/C'->QKF
M*BM<FZ*GI0^@        #*/=&6)(=(4FM:KX9+T;98T7;G;UZ*:N06M--U=5
M8"?&W-T1_G,>G:QZ=B@>;>(C,OC<?3=2Q;JNG9;$2K7<N_(_E_=^/JI9>(6I
M96:@T-8M8]^,ECL1IXRYW1T?+V*=;BOD=0XO16,Q&HL<^:2O=8D=N%/,D8FZ
M-1?;ML7?%Z1R6LL]7R6L*T3,/5@8E*IZ579/.<!JU.S#:@9+7E9*QR(J.8NZ
M*<QG$G#NUBI5FTGF;%-SI$5T4J\[$;OV(B]A=[5J>C7K(L,EF1RM8Y6)V=Z@
M2 (ZYF\;2NQU+ER*&Q)[QCW;*[XB08YKVHYCD<U?2B[@?0
M
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M[3]YZ-FB:F[J[UV3F3V;J!Z 8U&-1K4V:B;(A]/C'(]C7-7=%3=#Z
M
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M;1^*14V_8-)\
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MP
M
M         (/6K6MT=FD:B(GBDO8G^ZI6>!3&OX:8QKVHY.7L5-^XL^M_[GYK
M_A)?PJ5K@1\&N+^3^0&@(B(FR=$
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M5='XI5[? -)\@=![?JABMNSP#2>
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MYHGM>WO:NZ'[
M
M            5=D55[$ A-;_ -S\U_PDOX5*UP(^#;%_)_(F=39.ED='Y]*=
MF.5T5:5LC6NW5B\J]%3T%:X-9.GC.&6(?>L1PI)YC$>[97KTZ)W@:8#XQR/:
MCDWV5-^I]
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M?X5&]47?M T?02;:/Q2+_L&D^0&@EWT?BE7_ &#2?
M                                        #ANU8KM.:M8:CX9F*Q[5
M]**FRF;5KB\,KM#%6O"2Z>MR.;%9=U\ Y5\UB^ST&GD5J?"5=08:QC[L;7LD
M3S55-^5WH<GM0"5:J.:BM7=%ZHJ H^@<G=Q]2'":KGB9EF.5L*J[^V8B^:J>
MW8O                          XIJ\<T,L;FIRR-5KMNBJAR@#-K&ALSA
M9'2Z0S$D4:N61]:=>9KEW[-UW+/HN[G;-&9NIJ3*MJ)VR+&[=KT[T+$ .I3R
M->U7?.QW+&U=E5Z<NWTG:8YKVHYCD<U>J*B[HITLOC(,IB[%&;F9#,WE<L:[
M*GQ&??JOK'3TB.T[EV7:C/-CJVE7S6IV=5[5 T\$%IO,6KN%?:RU*2E/"JI(
MQ>N^WI3V$O5LQ6:[)HW?LWINBKT Y@
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MJBILV1F_OD]J;JH&BL7F:BIV*FY]/S$[GC:Y45NZ;[+Z#]
M                                                      *)QP^#
M/,_(3[R]E$XX?!GF?D)]X$APE^#+2W\M@_ A:RJ<)?@RTM_+8/P(6L >?].:
M(U%5]T[D]2V,7*S!R^%Y+:N:K5WB1$Z;[]O3L/0   $1J34V%TS36UG\G5H0
M[;HLTB(KOB3M7YD EP1VG,U2U%A:N6Q4JRT;35?$]6JWF3=4WV7KZ"1
M    'Y;%&UZO:QJ/7M<B=5/T .I9QM&S+X2S3KRR?XGQHY?I4[3&M8U&L1&M
M1-D1$V1#Z !DWNCK=^+0-^&O2\)5>U/"3;^\Z]QK)F/NA[E:+AMDX);$;)I&
MIRL5W5W7N N&@DVTABMO]@TGB T"FVC\5_D-)\
M                                        K.LM*5M0/HVU>^&_0D2:
M"5G;NG7E^)3@T%K&+4[;L$E:2I>HR>"EAD[?C^(MI0M:X#(U<Q5U%I=(VVXW
M(EN%4V2>/T_.!?01^$S%/,U5FHSLE1J\KT:N_*[THI(
M             !R(Y%1R(J+T5%(G4>$CS.+=32:2JJ*CF21+LK53XB6 &;15
M=::6:Y[+$>>HL3^S5.67YB[XG)/M8>&[?KNI/<F[XI%ZLZDD?B>&.>)8Y6HY
MB]J*!^FN1R(J*BHO5#Z5W5>"N9..!^*R4F/LP^]<U-VJG<J%7?G-9Z<5K,IC
M(LM75Z1LDK;M?M_B=V@:4#K,N1I6@ELJD+I439KE]*^@[(
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M.2<E:1&UO+>>\=.D]Y^B+41&/!&U>69[Q_>KM@ ]4Y@
M
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M/$#H-$32&*1%W_8-)X
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M>O(EJ+SF/?\ $G8!H /PZ:-LK(W/:DCTW:U5ZJ?L
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M:\NT^[]&FJIC\+FM'+?X[I@ 'K7*
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MBJW??N UG0/]S\5_D-)\@=!*JZ0Q2K_L&D\
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MGZRMXBZ<R#\'*U[865KMJ+WDC-M]^T#>@$[
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M(AM-HK&\R1&_9^P?B*:.5-XI&/3_ '7(I^Q$Q:-X)C;N  RP
M
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MU:#3;2&*1%W_ &#2>(#0/31^*_R&D^
M                                      RWBI>P^C,M6U5*RRF3<WP"
M,A:JI/W([Z#4C-/=!1L_4&2SRIX:M.R2-VV^SDW IG%_6V&U+P_P]BO<BCG?
M<C<^![MGQ[;[HJ>@OU7B5@HLCAL- Z:Q9MM9&Q\;-V;\O>9!QAPTE#$8C+OI
M5Y,1=6!TO(FSV/Y$W7;V]5+7I>QCLQQBH04UB=1Q^-9) QC=N1_3M].X&Z
M                                           !^&0Q1O<]D;&O=[Y4
M395/V (M,5XI'?DH2/;9L(JHKUW1KO04RKJ#5N 5$U+B_'ZRJJNLU$W5C?:U
M#1PJ(Y%14147T*!$:;U%0U#5?/CGO5&+RO9(WE<U?:A+HJ*FZ*BI[#@AIUX%
ME6"%D:R]7\B;;D7D:-VEA+,>GU8MU5YH_#N7EW FP9NWB#>PB,AU7A;4+D1&
MNL0-YV.=Z53;KL7K#96GF,?'=H2I) _][LV7THH'> 145-T7=
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M[??]$6KGQ<%,T]^R0 !ZES
M
M                 "B<</@SS/R&_>7LHG'#X,\S\A/O D.$OP9:6_EL'X$+
M653A+\&6EOY;!^!"U@#'.+7'C"Z'N6,31K293.1)L^-%Y(H7*G1'N[57KOLB
M?.AL9YNXD>YWRNK-<9?.U\[1KQ79?"-B?$]7-3E1.JI\0%2HZ*UWQLOQ9K6&
M4CQ.&5=X(Y%V1&_^%#OTW_Q.VW]IZ;T/@<3H[3-/!XJQS5:R*B.EE1SG*JJJ
MJOQJJGFS_P!%3->LF.^Q>?F3W*^8C8Y\FIL8UC4W5SH7HB(!ZW:YKVHYJHYJ
M]BHNY]*KPKP[,!P_PN*CO5[[:L*Q^,UUWCD\Y>K?N+4              #(O
M=(X&O=T+<R,DTS9J[4Y6M=YJ]?2AKID'ND<I>KZ*MTX<7)/4F:GA+*.Z1=?2
M@&@Z"7?2&*7_ ,!I/$#H)$32&*1%W3P#2>
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M":TQJFAJ"DRQ75T*O[(YO-<OS 3P
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M/''Y8  =M2
M
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MRUF9CE1_@G=G;V :=H'^YV*_R&D^0.@EWTABO\AI/
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M;P\R(FZ*!LX/C'(]C7-7=KDW0^@
M
M                                              *)QP^#/,_(3[R]
ME$XX?!GF?D)]X$APE^#+2W\M@_ A:RJ<)?@RTM_+8/P(6L <3[,#'*U\T37)
MVHKT14.4\R\3> FJ=4:[S.:QV6QT-2Y*DD<<DDB.:G*B=41NWH W'5.D](ZJ
M1/U@QN-NO:FR2/V1Z?$Y-E_U,3UI[FG"6GOL:0SR8]_:E:VY)8]^Y'HO,WY^
M8PK6NA,UI'6M+3.0OPR7+:1*R2&1RL1)'*U-]T1>U.XTG_T9=:?QS%?;2_\
MT@>F.%N'NX#0&%Q64E9-=JP^#DD9)SM<O,NRH[TIML6DK/#+ VM+Z$P^%R,L
M<UNG#X.22-55KEYE7=%7KZ2S         #KQ4:L-N2S%!&VQ(FSY$3JY/:=@
M =1V-INR#;SJT:W&MY4E5/.1/C.V  ,B]TAEY:NAKE-M*26.9J;S)V,Z^DUT
MSGW02;\+LOLF^S4^\"T:#3;2&*3??]@TGB T#_<_%?Y#2?
M                                                      0VH-,8
MG4,E9^8IQVO%W<T:/[$4F0!6UT-IE555PU3=?]TXWZ"TXMZC;CQD,4]-_/$Z
M--ME+0         !#Y[36*SBQNR-5DDL:HYDB='-V[E)@ 4?(4-48O/,MXJV
MVYBW\K'TY$\YB)TW:I(X_6^'M9.3'RS^+7&N1J1S>;S+[-^TLY$Y/3F)R<\<
M]RA!)/&[F;+R(CT7X^T"6!2;6"U'5U.V_C<PLN/D=^UJ3)T:W;]TY:&O*4VH
MG86Y5LU;>ZHUTC-F.^)0+B#\12QRHJQ/:]$795:NY^P
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MH
M
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MD_\  :3P
M                                  ."U3KVF*V>)C]T5-U3JF_0YP!G
MT.BKVG<BZYI:\]L#E5\M29=VO7V>T[>F-;37LK)B\SB[&/N-W5KGM\QS4]._
M878XYX(YXW,D:BHY%:OQ*!\KV(;+%?7FCE:B[*K'(Y-_F.4HU'1,FGK5VYIV
MW*WPC7.;5D=NSG7TC#:TMPR2P:KQDN+6-O-XPO6)R)TWW] %Y!UL??JY&NV>
MC8CGB<FZ.8[=%.R
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M(#BAG9)!'+[UKT141W1>IR@
M
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MHS,T='9B_9U-8L5N9'^+.1=MM^SM V+0']S\5_D-)\@=!KOI#%*B;?L&D\
M
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M,UB$R$"NV=;K+MMO_N@:,#JS7X(&5W3O\&LZHUB.[55?0=H
M
M                                             %$XX?!GF?D)]Y>R
MB<</@SS/R&_>!(<)?@RTM_+8/P(6LJG"7X,M+?RV#\"%K
M  '0K8BE6R4]^&!K;<Z<LDGI<AWP!5-7:"P>JK,5G*0/6Q&G*DD;U:JIW+L3
M> PU+ XR&AC(4BK1)LUJ?>I(  8_[I+4$=+1=O&/J6)'66IM,Q$Y&]?2; 9S
M[H)N_"_+JC454:G7;LZ@6C02<ND,4F^_[!I/$!H'^Y^*_P AI/@
M
M                           #\3PQSQ.BF8V2-R;.:Y-T4_8 J&:T17GQ
M?B^#L28F9LGA620]B+UZ;=W4ZMO460T=B*::AAER3W.Y'V*K>Q.]44O)^9&-
MD:K7M1S5[45-P(S3VH,=J"DEG&V$D9OLJ+T5%[MB5*;J'0E>ZY)\/;FQ-MJ=
M'UUV1?C0ZV3SV7TA2Q[,E5DRD"-VL6H47F;[=@+V",H9W'76U_!6HTDG8CV1
M.<B/5%]A)@
M       J(J;*B*GM  XYJ\4RL66-KU8O,W=.Q>\J&I],YRWEDR6%SKZTC$\R
MM(W]DJ^WTES %*Q>2U51R5>CF*$-N*3JZW779K/8J*6^>S# ^-DKT:Z1=FIW
MJ<Q^)(8Y',<]B.5B[M5?0!^]TWVW3?N!3M6:8R=[()DL)F)Z=IC=O!+UC?\
M&AT<-DM9T,C4I9NC6N0S.\ZU!NU&)OZ4Z@7\'$MF)+*0*]/"JG,C?8?66(7S
M/A9*QTK$W<Q'=4^- .0
M                              '5REV+'8ZS<L+M%!&Z1WQ(FYD-K(ZC
MUGI&]J&&^N(QC(GRU8HDWD?MV*[V&F:XIRW](9BK7;S2RUGM:G>NRF%Z'TW:
MO<++/@]2WHWTZ\C)Z2+LD:HB^:J=P$GHW.ZIP7#_ !^J)[JYBG+RK9KO39[$
M7]YJ^PW+$7XLGC*MZO\ V5B-)&_$IY3TYC[;."+;LVH+T<<LWBT-1GO7JO1$
MV/3>A:DM'1^'JV&\DT59C'M[E1 )P
M HG'#X,\S\A/O+V43CA\&>9^0GWH!(<)?@RTM_+8/P(6LJG"7X,M+?RV#\"%
MK                      !C_NDL)/;T7:R#,G/!%7:G-6:B<DG7TFP&6>Z
M*RE.OP\R-2>=K;$K4Y&+VKU NN@UWTABE3I^P:3Q Z"3;1^*1?\ 8-)X
M
M                                      'Q[&O8K7M1S5Z*B^D^@"J:
MKT-C<]&U[%?2O1IM%9@545GS=A V;.K-()$CHUS>+C1&*]$_:IWN4TD*B*FR
MIN@$92SM"S(R%+$;+*M1RPO=LYNY)E<SVC,1F;+;-B!8[;514FB=RN(NZ_5>
M,U$CZ[8[^'E5&I'V/C3OW NX(;'ZEQ=[(348K+&W(5Y71/\ -7YM^TF0
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MH!R
M       &<:MX:U[UR[?QF1L8OQB)R68X$W;+T7JJ&CG!D/\ J%G_ "W?<!A'
M GA]7?42W>R$URMC[4C(*KT\QKDV\[XS?C-^!/\ =O)?\?+_ ,C2
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MQRTU<CDB1%WY=^P#5= KOH_%*O\ L&D^0.@E1=(8K;_8-)X
M
M                                     K^<TCBLO9CLS0^"MQKS-FB\
MUV_M5.TA*F/U-I_+M>RY^E<7,]5D;(FSXD]G>7L 5S#ZRQ&4R,M".98KC'*W
MP,J<KG;>E/86,Z%K#T;-E++Z\?C2-5K9D3SF[E)@P>J]/7)9J&1;D<>KUE=!
M-UD[?>M4#10573>MJ&7F=4L,DH9%N_-6G39VR>GXBT12,E8CXGM>Q>QS5W10
M/T
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M3:6/INW;O/36F\E^F,#0R/+R>,PMEY>[= )$
M        HG'#X,\S\A/O+V43CA\&>9^0GW@2'"7X,M+?RV#\"%K*IPE^#+2W
M\M@_ A:P                !!8[3%&AJ*]F86KXW;9R2;]FV^Y.@#.,KPR1
M^3N6\)F+6,;<55GCC551RKVJG7H6G1FF:FEL0VE459'*Y7R2N]](Y>U5)X #
M*?=%YC'U>']^A9M,CMSM3P<2]KNIJQF'NAZ-6;AOD[$M>-\\;4Y'JG5O4"XZ
M"14T?BD5-OV#2>('02JNC\5O_L&D\
M
M                        '0N8BC;E?+-6C6=S/!K*B;.Y>[<J6*TYE=)V
M;DV-N2W\<K-XJ4B[N:N_8BE\ %9T[JV+(PS_ *1JSXV>OLDS;#>5J+V=%])8
MX9HYXT?"]KV+U16KNAULGC:N2I35;<2/AF39Z=BK\Y4L?I*[IB&_)I^[),BL
M3P%2=V[&JF_3?V@7D%.P6M6R4IG:AJ2XNQ7<C)?")YFZ]BHJ%MKSQ686RUY&
MR1N3='-7=% Y
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MUDVYC T,@U-O&(6R*G<JIU)(AM&8V3$:7QE&==Y8(&,?\:)U)D
M                    B]4XYV6TYDJ$;N5]B!\;5]JHI@>E-.Z=KZ*R6)S$
M<E74.-KR-?')*K>?9%V<B=BH>D"M:OTGAL]3G?DJ;7O1CEYV^:Y>GI5.T#S)
MI/$X>QPFK5J\4EO4-^UX*&".1=T;Z7*G<B'JO2>.?B=-8S'RKO)6@9&Y?:B&
M<>Y^T_C*6#NSP56>%BNR,C>[JK4Z=$-<
M     %$XX?!GF?D)]Y>RB<</@SS/R$^\"0X2_!EI;^6P?@0M95.$OP9:6_EL
M'X$+6                      #'?=)P9Q^C+4E&Q S&-:GC$;D\YW7T&Q&
M4>Z,S6.JZ OX^S:;'<G:G@HU1=W=0+SH/;]4,5R]G@&D\0.@D5-'XI%_V#2>
M
M
M ZF4QM3*4Y:MZ".:"1/.:Y-]RJ6-.Y/3^&6'2$Z*J2>$6.RO,G+Z6IW%V %&
MQNMY*=1K]84_T2]\G@XU<[F:[Y_07*E<KW8&S5)F31.[',7=#@R^)HY>MX#(
MUHYXD7=$>F^R]Z%9GT9-C<?X+2V0DHO219>1_G-<NW8O<@%T!2[FK9]-5J$>
MIJ[G22[I)8KIO&S;TKZ2TXO)4\K3CM4)V302)NUS5[0.V
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MCB$TAB<J^#PMQB*K'2><C%5.NW<:+K?^Y^:_X27\*E:X$?!MB_D_D!H
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M='XI57?]@TGB!T%M^J&*V[/ -)X
M
M                                 X[->&S"^*Q&V2-Z;.:Y-T5"EYO0
MSTFBM:9R$N+FA3=(6?V3U[E0O  HN6UA<TM%0ASU*6U)*B^%L56*K6KOW>@N
M%&_7NQ1O@E:OA&(]&[]=OB.>6*.5JME8U[5]#DW*IJ+1%?)6V7:%RQCKK/\
MO(7+LJ=W+V 6X%"RNJLS@,YX'(8J2;#;(UMR--UW[-U+;4S./M6?%H;4:V.7
MF\'OL[;X@)      (#7.HDTMIRSEG5GV6P;<T;.W;O)\B=6P16-,Y2.=B/8M
M:1=E^2H%6Q'%?3MS'P6+DSZ+YF(](YF[+LJ;[H1>J.,>-Q5=DN.HV;\;Y&Q-
MD:U48JK[2C:5U11I</*5W4&FENQ5G+ EET:+YJ=$3?YC\ZZS:VLQH6E7PSL?
MC;%R.18N1$:_=R;*!Z)IS+8J0S*U6+(Q'*U?1NG8<I\8B(U$1-D1.P^@
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MG6/9L4:=J+[5/1.&Q\6*Q56A73:&O&D;?B1 .X
M          43CA\&>9^0GWE[*)QP^#/,_(;]X$APE^#+2W\M@_ A:RJ<)?@R
MTM_+8/P(6L                 5W%:3I8W5.0SL+Y%M7&(QZ*O1$WWZ%B $
M7J'"5<YA[F.LM1L=EBL<YJ)OU/WI[$P8/#5,=5W\#7C2-JKVJB=Y(@ 97[HK
M*TJW#W(4YYVLL3-3D9Z5ZFJ&8^Z'IUI>&V3GDKQOF8U.5ZM15;U]"@6_02;:
M/Q6_^P:3Y :!ZZ/Q7^0TGP
M
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M-T.8(FR;)V
M                =/,X^+*XJU1L)O%8C6-WSH=P >?Z<M31FF<UI;4E!C/
M5Y/$[JQ[ME:J*B=?0I!8*[!F>&^&TK@**6,AD7<DUA(_-@8FRN55[]MS>^(%
M.M:T?F/&J\4W+5D5O.U%V7E7L*WP$JUXN'.-?%!&QZINKFM1%7L N^ QK,1A
M:6/B7=M>)L>_?LFVYWP                               <%NG7MLY+4
M,<K>Y[=SG '!5IUJJ*E:".)%_P #40YP
M     !1..'P9YGY#?O+V43CA\&>9^0GW@2'"7X,M+?RV#\"%K*IPE^#+2W\M
M@_ A:P                      8_[I*'-.T3;DHV(&8U&IX=CD7F=U]!L!
MF/NA[=:+AMDX)9F-F>U.5BKU=U N&@METABN7L\ TGB T"FVC\5_D-)\
M
M
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M,KV]K6.150[89
M                  #XYR-:KG+LU$W50(76_P#<_-?\)+^%2M<"/@UQ?R?R
M([6VNVY+!YFEIBE)DN6"1DLZ=(F>:N_4K_!O6[,+HK$UL]1FIU7KR,N;;Q[]
M-MU] &X@_,4C)8VR1N1S'(CFJGI0_0
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M5T?BM_\ 8-)\@=!HB:0Q7*NZ> :3P
M
M                                                "L\27Y%NC<BS
M"UW6+TK/!,8GIYNBEF 'G#5*:FQ'""+%W-/MKQ1>#YY/"(OG>GT]YW=8PZIR
MF&TY;CTRGA:#H)(YV/:JJQ$3?TE_X]+MP[M]=OVC/O+EIO\ N]C-_P#W:/\
M"@%<QVA,76O5LQCHY*-Y6\[VM>JM>Y4['(J^TX<7:UEC\LVKE*E>]2>Y7+;A
M=MR-V[-EV7<O0 IU#B'AK&5_1MCQBI=<_E9'+&OG^U%[BUU[5>SS^+S1R*Q>
M5W(Y%V4Z]K$4+5IEFQ4A?88FS9%8G,U/8I5X] Q4\\W(XK)6JC5<KY:Z*JLD
M5>_J!=@46/(ZNQN?2O=HPW\;-*O)8B=RK$U5Z(J;=21BU[@79UV'?;\%>:[E
MY'IMNOL M("*B]BH
M             !7N(,TU?1>8EK.<R9M=_*YJ=4Z%A..Q"RQ!)#*U'1R-5KD7
MTHH'G/0N4U)7X/R,I:>CDJ2U)%DL^$;N[=J[N7KON="ED-02\"Y*TN!CDQ[8
MN9+#I&IR[;*CMM^TOEK!:@T?C\OAL/37)X.[')X#S]GP.<BIR[==T["$T_IK
M5>9TOA]*7Z'Z.Q4;T?=L*_=ST;LJ-1-O2J :UPWEDFT/A7S.<YZUF;JY.O8A
M9#AHUHZ5.&M G+%"Q&,3N1$V0Y@
M                                  %$XX?!GF?D)]Y>RB<</@SS/R$^
M\"0X2_!EI;^6P?@0M95.$OP9:6_EL'X$+6                 *QB-(5\;J
M[)9YDSW2WH_!NC7L3KN6< 9Q)HC/XZ_DI-.Y]T5:\Y7NCG3F\&Y?\)/Z TE#
MI3%OA65;-V=ZRV+#D\Z1RKO]!:  ,T]T+8ACX9Y2)\S&2/:FS%=LKNO<:69%
M[I#3^.NZ&NY.S$YUNLU/!.1VR)U[@+]H%-M'XK_(:3Y Z"55TABE7_8-)X
M
M
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MKX2RVO)89SL9,O*O^H$\#XUR.:BM5%1>Q4/H
M
M                                       "B<</@SS/R$^\O91..'P9
MYGY"?>!(<)?@RTM_+8/P(6LJG"7X,M+?RV#\"%K
M !CGNE+F:BT;9AHTXI<:]J>'F55YF=?0;&9E[H:W7CX;9."2Q$R9[4Y6*Y$<
M[KZ$ M^@MOU0Q6R[IX!I/$!H'IH_%?Y#2?
M
M                                                      5;B:[*
M)HS(LP4"SWY6>"8Q$]"]%+2 ,>T<NNL'IJCCX,)58D4:([F<NZKMU4A>(T6N
M,JS&6Y,#"L]"TR:-\2JKD1%W7H;V .&D^22G ^9O+*YC5<G<NW4Y@
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M3=.P
M
M*)QP^#/,_(3[R]E$XX?!GF?D-^\"0X2_!EI;^6P?@0M95.$OP9:6_EL'X$+6
M                !\>]L;'/>Y&M;U5579$*_I_6.'S^6O8_%6FSSTEVEY>Q
M%)NY6BN59*]AO/%(G*YO>AD7#;'U,7Q;U)3Q\#8*T==-F-^4@%LS_$?%XK*)
M1ABGO2L=M.M9O,D/M<6C"9>EFJ+;>-G9-"J[;M7L5.U%]I4]6R8G1^-R$N,J
M1IF,GNV.)B<SYI'=B[=VYV>%&FY]-:59!=_Z[8D=9G3_  O>NZI\P%R,F]T;
M@\?;T'>R-B%76Z[4\&_F[.IK*[HB[=5,+XUYK44^ALU!<PW@::.1J2[_ +N_
M;V@:MH)=](8I5_V#2>('07]S\5M_L&D\
M
M
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M
M                                                 %$XX?!GF?D)
M]Y>RB<</@SS/R&_>!(<)?@RTM_+8/P(6LJG"7X,M+?RV#\"%K
M      %2PFD$QFM<KGTL*];L:,\'M[WKN6T 9!>T#J^;5]W.,SD#G.7:M')&
MCDA;[-_27S15'.T:<K-1WX[LZNW:YC4;LA8P ,R]T-:@BX:Y.&29C)7M3E:J
M]5ZFFF4>Z-PU&UH"_?L0<UJ!J>#?NO3KW 7C0*;:/Q7^0TGR T$N^C\4J_[!
MI/@
M
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M_P 2]A;([,$DKXF31ND9[YJ.3=/F Y0
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MM'XK_(:3Q :!_N?BO\AI/@
M
M
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MR*FZ*B[[@?H
M      '%:5$JS*J[(C%W^@QO@3'+&S6-MNR127)'1/W[>AK^4JNNXVU59(L;
MIHW1\Z?N[IMN9=CN#=+$85\,>;RF[4?(_E>B(YRHOL J^HKU_,\(,C+=E=/)
M#EV]57?E8UR&Y:;D9+@,?)&[F8Z!BHO>FQA/#?AG6U!I'+Q/R^09SVI(D:CT
MY=T[%5-O:;5HC"3:=TU3Q=BTZTZNQ&)(OI1.P$)T
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M](8I?_ :3Q Z#3;2&*3??]@TG@
M
M
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M'*B+LAZ+T1C:^(TIC*=1B,BC@:G3TKMV@A.
M       %$XX?!GF?D)]Y>RB<</@SS/R$^\"0X2_!EI;^6P?@0M95.$OP9:6_
MEL'X$+6                 *=@=(OQFNLOGEGYF78T8D?\ AZ[EQ %7XDZ9
M?JS3$F+BF\"YTL<G-\EVY/8FJM+&5:JKS+#$V/?OV38[0 &;^Z!1$X7Y;E1$
MW:GWFD&0>Z1P,5W1%O(OLSQOKM3:-KO-=U]* :!H'^Y^*_R&D^0.@EWTABE_
M\!I/
M
M
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M,_(3[R]E$XX?!GF?D-^\"0X2_!EI;^6P?@0M95.$OP9:6_EL'X$+6
M               #'_=)9J6IHJW09CK$T<[4WG:GF1]?2; 9S[H)5\EV7V7]
MU/O M&@TVTABNN_[!I/$!H'^Y^*_R&D^
M
M
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MU<GI-XTM!'6TYC886\L;(&-:GLV E
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MBO\ (:3Q Z"3;2&*_P AI/
M
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M\CX&K&U/"0<N_A.O>!>] _W/Q7^0TGR!T%UT?BMNG[!I/
M
M
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M.0ZN)I1X[&5:<*[QP1-C:O>B)L=H
M                                   !1..'P9YGY"?>7LHG'#X,\S\A
M/O D.$OP9:6_EL'X$+653A+\&6EOY;!^!"U@                      R#
MW26H:E'1%O&3,D=/9:G(J)T3KZ37S-O="11NX8Y5[HVN>UJ;*J;JG4"UZ#3E
MTABD7_8-)X@- ?W/Q7^0TGP
M
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M,?4BH48*E=%2*%B,8B]R'.
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M :MH-472&*Y4V3P#2>('02*W2&*1?]@TG@
M
M
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MP_\ ];^%'_7^Z8 !R'7
M
M              *)QP^#/,_(3[R]E$XX?!GF?D-^\"0X2_!EI;^6P?@0M95.
M$OP9:6_EL'X$+6                   &+\1'S29O(Q6=%SWY_!;5+D#=VN
M5>SF^(N'!W3EG3>C8(+[&QW)WNGD8W]U7==OF+QL@ &8<?:%2+AGEY(JD+9-
MD57(Q-^WM-/,@]TE0RLVBK=FIDFP4(VIX:NK=UDZ]X&@:!_N?BO\AI/D#H/;
M]4,5LFR> :3P
M
M                                                    !41R;*B*
MG<I^61L9[QC6_$FQ^@ /CFM<FSD14[E0^@#XUK6ILUJ(GL38^@
M
M                                                 HG'#X,\S\A/
MO+V43CA\&>9^0GW@2'"7X,M+?RV#\"%K*IPE^#+2W\M@_ A:P
M           8_P"Z2U'0HZ)MXJQX7QJTU/!\K=T[?2IL!FGNA8(G<,\I(^%C
MI&M3E<K=U3KZ% MN@T5ND,4B]O@&D\0&@?[GXK_(:3X
M
M
M
M
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M4CDV7P#2>
M
M
M
M   BM39ZEIW$RY#(R<D3.Q$[7+W)[3FP>5KYC'Q6ZCT<QZ(NR+V>Q0.^
M                                              !1..'P9YGY"?>7
MLHG'#X,\S\A/O D.$OP9:6_EL'X$+653A+\&6EOY=!^!"U@
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M34K%;W\B_F:@ ,M_5777K*SZB_F1+\7Q!9JIF*_3"K2?"LGC2,79')Z.TV@
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MIYM+=AJHB1-8O5-_C-D &6,TMKIS&N_61J;HBJBL7I_J??U5UUZRL^HOYFI
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MB*G,J+VEXLUX=.\<L3#BHFPP9&K)X:*-.5N[4Z+L@&P
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M#AF2N=?L6W8^H]R[[,Z;O7XD53Y[G*O5P^L]6XN*ZVR]CTWD5>LCM^J@>@@
M
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MZ=@'H\'QBHYC5:N[53=%/H
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M"U$="Q.B(KD]*]H&W=O8#\0L\%"R-%5>1J-W7T['[
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M^-@I>.0*V5C&(G:G8I1_<_Y)9,-E<.K?-QER2)CM^UO,NR?-L!JH
M                                       !5N)NF4U=HS(8?9O/,U.1
M7=B.1>BEI &0:@X1,R.C]*8B.1J+B9F22HJ='IMYR?22VM],9>#4&$U!I>)D
MUFE'XO-75>7PD?Q_,:2 ,MQ^DLKJ;5&1S6JJ[*L3J?B5>KS(_9-U7G^/=2&B
MP.M<9HV31]&HR6NBK#'D%D1-HE7KTW[E4VL 8Y=X>9?3E_3N6TLK)[&/KI7L
MUU\U)DVVYM_I)K1^GLS>UQ:U1J:!E:1L?@:E=KD=R-5-E7<TD
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M_P"J^L]09>1(UAN/WKM3M8FYIX
M                            !^9F))$]B]CFJA^@!DF#X5+1T_JW'/D8
MBY:5SHG(GO6]J?ZG[BX8SLX1U--).QF1K*V9LK4[9$7?_4U@ 9!?Q&L=4LPV
M*RU&*E0J21R69?"(Y9E9MZ-_3LIRPZ=U'H[5F7N:<J,R&,R2([P*O1BPN1-D
M^\UH 8I5X99;]6VW[$D;M2LNI?1KNJ*J;IR*N_<I*9_&:KUO!5Q.5QL6,H-E
M;+-/SH]51J[[(B>U#5P!^((TAA9&WL8U&I\Q^P
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M[!4,]!%#DXO#11O21&+V*J+TW).-C8V-8QJ-8U-D1.Q$ ^@
M
M
M
M "A\0=96=*9[ QOB:['7IEAE>O[J[=#IZLUU<IZWKX'$Q,>K*LEJRYWH1&[M
M T@&%TN(V<U-+2QF/LU\7=D:LJSS(G+*G:B-W+5FM6:BP.@<IE,K3ACO54VB
M5J[MDZ+YP&E PJSE>("YG"U(LM6:W*QI,W]FW]FG<;7BV68\? R_(V2TC=I'
M-39%4#M
M
M
M
M
M                *GQ0T]%J+2-RN^/FFB3PT3D3SFN;UZ?09EP@J9#*:<U)
MJ7.0\M^:M)59S)YR-8U>\WE4145%ZHIPQ5*\,+HHH(F1.WYF-:B(N_;N@'GW
M2ZZ,ETMA*6K_ /HV08U[H9EW:J)T]*'2LYC(9;AIK*IX62[B*;D92LNW5STV
M7=#?K>F<'<2)+>'Q\Z1=&))78[E^+=.AV*^%Q=>@ZC7QU2*F[M@9"U&+_P##
MML!F;V/_ %NX?KR.Y4J)NNW9T4ULX/$ZW/$_P$7/$FT;N1-V)[.XYP
M
M
M
M
M
M
M
=                                   #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g73463g48a48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73463g48a48.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1L"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &N4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!0,$ P$        !D0(#!!054E,1404T@:&Q$F%Q$S$R,P8AP='_V@ , P$
M A$#$0 _ /5(
M
M
M
M
M
M
M               !@T#G+75J*Y51')HBKQ&<:^W\OK^T@&P
M                   ,&SN<ZF<KG*J[2\:F<8%EY*[MJ!G@
M                   Z:U52DE5%T79XT.*!56CB5555V4WJ*[DDW9.+=R*'
MLH!D                                Z*Y52CF5%5%1J[T%O55HXE55
M5=E-ZBOY%-V5.+=R*'LH!D                                PKNY6T
MJ*U51=I.)3,;XJ=1A7CDB=I#-;XJ=0'(
M   ,&M<Y*ZD1'*B*JZHB\9G&!7<OH^TIG@
M
M                                             -?;^7UW:0V!K[?R
M^N[2 ;                                 P++R5W;4SS LO)7=M0,\
M                              '17<DF[)Q;N10]E#FNY)-V3BW<BA[*
M 9                                .BOY%-V5.+=R*'LH<U_(YNRIQ;
MN10]E ,@                               &#>.2)VD,UOBIU&%>.2)V
MD,UOBIU <@                               P*[E]'VE,\U]=R^C[2F
MP
M
M             :^W\OKNTAL# M_+Z[M(!G@
M      &!9>2N[:F>8%EY*[MJ!G@                               Z*
M[DDW9.+=R*'LH<UW))NR<6[D4/90#(
M !T5_(INRIQ;N10]E#FOY%-V5.+=R*'LH!D
M       P;QR1.TAFM\5.HPKQR1.TAFL\5.H#D
M        &!7<OH^TIGF!7<OH^TIG@
M          =-55T](U'551#"B\2R/1NOI/N":*>-)()&21KQ.8Y%1?.@'V
M                                 -%C'$]+A6UI75T4TL2O1FS$B*NJ
M]:H9.&+U!B&QTMTI(Y(X*A%5K9$1')HJIOTZ@-H           ,.\7&GM-LJ
M*ZL<K8(&*]ZIQZ$=P7C^U8LJIJ:@9/%-$FULS(B;2=*:*H$N
M                         #7V_E]=VD-@:^W\OKNT@&P
M                   ,"R\E=VU,\P++R5W;4#/
M          !T5W))NR<6[D4/90YKN23=DXMW(H>R@&0
M              #HK^13=E3BW<BA[*'-?R*;LJ<6[D4/90#(
M                   !@WGDB=I#-;XJ=1A7GDB=I#-;XJ=0'(
M                     ,"NY?1]I3/,"NY?1]I3/
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M[XM\Z:7U7ZCOBWSII?5?J0X#)W&R#4,5R35,>^+?.FE]5^H[XM\Z:7U7ZD.
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M35VRFB:Z$C(EA/\ <EC[/Y$M,M?1%F\M1'>6ZPUJ;5S8M3^\Q  #R>X
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M;_R.[PWS-GU^)5GC/D[?I\P@@ -2P@         "0 !
M
M
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MX39U<OG P,ML-+A?#,-'(J+4/7A9E3BVE)2
M                                                      "I<UOW
MA3];_P BVBI<UN7T_6_\CN\-\S9]?B59XSY.WZ?,(( #4L(
M
M
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MK@YRHNFK(G.3THAN+#C*Q7UZ1VZX1/E7BC<NRY>I% D
M                           $.S1Q5581L4%=0P03R23I$K9M=$145==W
M4!,0:3!=XFOV'*2XU,<<<LS=5;'KHGI-V             ^97*R)[DXVHJ@?
M0*WRMQ]7XNKZR"NI*6!L+=I%BVM5WZ<ZED     (7FGBVKPA:*6KH:>"=\LW
M!JDVNB)IKS*!- :C"=TEO.'Z.OG8R.6=B.<UFNB=6IMP         !!<S\67
M7"5/2UE#24M11O=L2+)M;35\R@3H&OP]=8;W9J6X4RHL<[$=HG,O.AL
M    !4N:W+Z?K?\ D6T5+FM^\*?K?^1W>&^9L^OQ*L\9\G;]/F$$ !J6$
M                                                       2  (
M                 $@ "
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MK<OI^M_Y%M%2YK<OI^M_Y'=X;YFSZ_$JSQGR=OT^800 &I80
M                $@ "
M                                          !(  @
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M5,CB..:2C0)/\!;]\T;ZQ!\!;]\T;ZQ!FKG?%3)8CCFDHP"3_ 6_?-&^L0?
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MNFTG,J=)9TC&R,<R1J.8Y-%14U14*QQ%D[:KA4OJ+94R6][UU5K6[34ZDW:
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M]+E73V%[         # M_+Z[M(9Y@6_E]=VD SP
M          # LO)7=M3/,"R\E=VU SP
M  =%=R2;LG%NY%#V4.:[DDW9.+=R*'LH!D
M      Z*_D<W94XMW(H>RAS7\BF[*G%NY%#V4 R
M           8-XY(G:0S6^*G485XY(G:0S6^*G4!R
M            #7UW+Z/M*; P*[E]'VE,\                        "A\
MP(7X+S+HK[ Q4I*EVV]>955?"3[]2\J&JBK:2*IIWH^&5J.:Y.=%/FLHJ6M8
MC*RFAJ&HNJ)*Q'(GI.V&*.")L<,;(XVIHC6)HB>8#[
M        &NQ'3UE79*R"V3-AK)&;,;W<2+_^"DZ'$N-<!O[EN]&^MI47=MKM
M>AR:E^GS+&R5BME8U[5XT<FJ 5 S.^B:Q$GM<[9.=$<FAJ[WFG>+_$^@PW;)
M(EF39X5-7/T7=NYDZRY'V*TO=J^V43EZ5@:OY&32T-)2<EI8(?HXT;[ *]RB
MP)+AV*6Y79$6YSIHC==>#;SIKTJ64
M                           *XSPQ"EJPPM!!(B5=:J1HU%W['/\ V+',
M6KMU%62-?5T=/.]NYKI(T<J>E (GE#A];#A&!)V;-54_M9.E->)";!$1$1$3
M1$Y@         ,"W\OKNTAGF!;^7UW:0#/
M      ,"R\E=VU,\P++R5W;4#/                               !T5
MW))NR<6[D4/90YKN23=DXMW(H>R@&0
M #HK^13=E3BW<BA[*'-?R*;LJ<6[D4/90#(
M      !@WCDB=I#-;XJ=1A7CDB=I#-;XJ=0'(
M        ,"NY?1]I3/-?7<OH^TIL
M
M                                        &!;^7UW:0SS7V_E]=VD
MV                                !@67DKNVIGF!9>2N[:@9X
M                         .BNY)-V3BW<BA[*'-=R2;LG%NY%#V4 R
M                             =%?R*;LJ<6[D4/90YK^13=E3BW<BA[*
M 9                                ,&\<D3M(9K?%3J,*\<D3M(9K?%
M3J Y                               !@5W+Z/M*9Y@5W+Z/M*9X
M
M
M       # M_+Z[M(9Y@6_E]=VD SP
M# LO)7=M3/,"R\E=VU SP                               =%=R2;LG
M%NY%#V4.:[DDW9.+=R*'LH!D                                Z*_D
M4W94XMW(H>RAS7\BF[*G%NY%#V4 R
M 8-XY(G:0S6^*G485XY(G:0S6^*G4!R
M  #7UW+Z/M*; U]=R^C[2FP
M
M                                   8%OY?7=I#/-?;^7UW:0#8
M                            &!9>2N[:F>8%EY*[MJ!G@
M                    Z*[DDW9.+=R*'LH<UW))NR<6[D4/90#(
M                       !T5_(INRIQ;N10]E#FOY%-V5.+=R*'LH!D
M                             P;SR1.TAFM\5.HPKSR1.TAFM\5.H#D
M                              &OKN7T?:4V!KZ[E]'VE-@
M
M
M   U]OY?7=I#8&OM_+Z[M(!L                                # LO
M)7=M3/,"R\E=VU SP                               =%=R2;LG%NY%
M#V4.:[DDW9.+=R*'LH!D                                Z*_D4W94
MXMW(H>RAS7\BF[*G%NY%#V4 R                                8-X
MY(G:0S6^*G485XY(G:0S6^*G4!R                               #
MKN7T?:4SS KN7T?:4SP
M
M                              &OM_+Z[M(; P+?R^N[2 9X
M                       !@67DKNVIGF!9>2N[:@9X
M               .BNY)-V3BW<BA[*'-=R2;LG%NY%#V4 R
M                   =%?R.;LJ<6[D4/90YK^1S=E3BW<BA[* 9
M                        ,&\<D3M(9K?%3J,*\<D3M(9K?%3J Y
M                         !KZ[E]'VE-@8%=R^C[2F>
M
M                                                          U]
MOY?7]I#8&OM_+Z[M(!L                                # LO)7=M3
M/,"R\E=VU SP                               =%=R2;LJ<6[D4/90Y
MKN23=DXMW(H>R@&0                               #HK^13=E3BW<B
MA[*'-?R*;LJ<6[D4/90#(                               !@WGDB=I
M#-;XJ=1A7CDB=I#-;XJ=0'(                               -?7<OH
M^TIL#7UW+Z/M*;                                           JZ)
MJO$?+)&/71CVN7R+J!]                                   #B1Z,8
MY[O%:FJD;PYC6S8AN-116R:1\\&NVCHU:G'IQJ!)0           (K<,?X>H
M+U[U5-;LU>TC%\%5:UW0J\2 2H!%U35.(
M         -?;^7UW:0V!K[?R^N[2 ;
M   P++R5W;4SS LO)7=M0,\                               '17<DF
M[)Q;N10]E#FNY)-V3BW<BA[* 9                                .B
MOY%-V5.+=R*'LH<U_(YNRIQ;N10]E ,@
M   &#>.2)VD,UOBIU&%>.2)VD,UOBIU <@
M     P*[E]'VE,\P*[E]'VE,\
M     "#9PXA]XL)S,B?LU57K#'HN]$YU3J*=R^O%;A;%MOFN;YDIJV--=MRJ
MBL?Q*FJ].AO<;328XS0IK32N5]%3.2-53>B)QN=[$)-G=A9C\,4E?0LV9+:B
M1Z-3_N_T70"V$75$5.)00_*G$*8@PE32/=K4TZ)!*G/JFY%\Z$P  $+QEF-9
ML,O6"1[JJL3CAAT56]:\P$T!2JYT5[W:T^'%?%S.X1WY--]AG-RV7*L;272G
M?;IG+HBO75NO1KQH!9@*^OF84ENQS;[#%0130U3HV]T<*J*B.735$TW^DL$
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M.61VOW-)#A/-FU7BK;1U\3[?4N79;PBZM5>C7F\X%D -5'(BM5%1=Z*@
M                  !K[?R^N[2&P-?;^7UW:0#8
M            &!9>2N[:F>8%EY*[MJ!G@
M    Z*[DDW9.+=R*'LH<UW))NR<6[D4/90#(
M       !T5_(INRIQ;N10]E#FOY%-V5.+=R*'LH!D
M             P;QR1.TAFM\5.HPKQR1.TAFM\5.H#D
M              &!7<OH^TIGFOKN7T?:4V
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M>&^9L^OQ*L\9\G;]/F$$ !J6$                          2  (
M                                                    ]%VC]V4O
MT3?8>=#T7:/W92_1-]A3>,?QL>K2?X[_ #O/1E  H6J        =%?R*;LJ<
M6[D4/90YK^13=E3BW<BA[* 9                                ,&\<
MD3M(9K?%3J,*\<D3M(9K?%3J Y                               !@5
MW+Z/M*9Y@5W+Z/M*9X
M   !@WRLDM]HJZN&%T\D,;GMC;QN5$XBLL*YPT<O_9L21.HYVKHLJ(JIYT1-
M4+;(UB+ ]AOSE?74+.&_J1^"[[@.R'&F'YHT?'=(-E>+75#1XIS0L5HI)%I*
MAM96:>!$Q%TU\JZ::&KER4P^]ZJVJKV)T->W^QL;/E+AJW3)(^*:K<W>B3.U
M37S: 0_)RQUEZQ)4XINK55FT[@U?_.Y>=.HO ^((8X(FQ0L;'&U-&M:FB(A]
M@
M                   J7-;E]/UO_(MHJ7-;E]/UO_([O#?,V?7XE6>,^3M^
MGS""  U+"               "0 !        )  $             )  $
M                       "0 !            >B[1^[*7Z)OL/.AZ+M'[L
MI?HF^PIO&/XV/5I/\=_G>?B&4 "A:H       !T5_(INRIQ;N10]E#FOY%-V
M5.+=R*'LH!D                                P;QR1.TAFM\5.HPKQ
MR1.TAFM\5.H#D                               &!7<OH^TIGF!7<OH
M^TIG@                         "NZW,29V.X\.VFWLJ_#1DDRR*FSSN]
M" 6( 8%SO-NM<>W<*R&!O^V[?Z ,\$5[X6%=O8]^J7:UTTU7^QOK;=*&YQ<)
M0544[/\ 8=J!F &#>;M0V6A6LNE2RFID<C5D?Q:KQ 9P(GWQ<)_YW2_?_8=\
M7"?^=TOW_P!@)8".6['&'+C6Q4E%=J>:HE71C&ZZJOH)&
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M6_\ ([O#?,V?7XE6>,^3M^GS""  U+"               "0 !        )
M $                                          "0 !
M>B[1^[*7Z)OL/.B'HNT?NRE^B;["F\8_C8]6D_QW^=Y^(90 *%J@       '
M17\BF[*G%NY%#V4.:_D4W94XMW(H>R@&0
M    #!O')$[2&:WQ4ZC"O')$[2&:WQ4Z@.0
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MJ6$               $@ "          !(  @
M           2  (  $@ "            ]%VC]V4OT3?8>=#T7:/W92_1-]A
M3>,?QL>K2?X[_.\_$,H %"U0       #HK^13=E3BW<BA[*'-?R*;LJ<6[D4
M/90#(                               !@WCDB=I#-;XJ=1A7CDB=I#-
M;XJ=0'(                               ,"NY?1]I3/,"NY?1]I3/
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M  HFI        =%?R.;LJ<6[D4/90YK^13=E3BW<BA[* 9
M                  ,&\<D3M(9K?%3J,*\<D3M(9K?%3J Y
M                   !KZ[E]'VE-@:^NY?1]I38
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M $@          Z*_D4W94XMW(H>RAS7\BF[*G%NY%#V4 R
M                  8-XY(G:0S6^*G485XY(G:0S6^*G4!R
M                   # KN7T?:4SS7UW+Z/M*;
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M+=;JBI<*ANC6+QQM7CU\JEG
M                     "N,\;_[V866A@>B55:Y(]$7>C.?=Y>(L<U-UPW9
M[M5QU5RM\%341HB,?(FJHB :#**P.L6#Z=L[-FIJ/VTFJ;TUXD)J<-:C6HUJ
M:(B:(AR         ,"W\OKNTAGFOM_+Z[M(!L
M         # LO)7=M3/,"R\E=VU SP
M =%=R2;LG%NY%#V4.:[DDW9.+=R*'LH!D
M     Z*_D4W94XMW(H>RAS7\BF[*G%NY%#V4 R
M          8-XY(G:0S6^*G485XY(G:0S6^*G4!R
M           #7UW+Z/M*; P*[E]'VE,\
M
M                                           !K[?R^N[2&P,"W\OK
MNT@&>                                8%EY*[MJ9Y@67DKNVH&>
M                            #HKN23=DXMW(H>RAS7<DF[)Q;N10]E ,
M@                               '17\BF[*G%NY%#V4.:_D4W94XMW(
MH>R@&0                               #!O')$[2&:WQ4ZC"O')$[2&
M:WQ4Z@.0                               8%=R^C[2F>:^NY?1]I38
M
M
M           ,"W\OKNTAGFOM_+Z[M(!L
M    # LO)7=M3/,"R\E=VU SP                               =%=R
M2;LG%NY%#V4.:[DDW9.+=R*'LH!D
MZ*_D4W94XMW(H>RAS7\BF[*G%NY%#V4 R
M     8-XY(G:0S6^*G485XY(G:0S6^*G4!R
M      #7UW+Z/M*; P*[E]'VE,\
M
M                                      !K[?R^N[2&P,"W\OKNT@&>
M                                8%EY*[MJ9Y@67DKNVH&>
M                       #HKN23=DXMW(H>RAS7<DF[)Q;N10]E ,@
M                           '17\BF[*G%NY%#V4.:_D4W94XMW(H>R@&
M0                               #!O')$[2&:WQ4ZC"O')$[2&:WQ4Z
M@.0                               8%=R^C[2F>8%=R^C[2F>
M
M
M      U]OY?7=I#8&OM_+Z[M(!L                                #
M LO)7=M3/,"R\E=VU SP                               =%=R2;LG%
MNY%#V4.:[DDW9.+=R*'LH!D                                Z*_D4
MW94XMW(H>RAS7\BF[*G%NY%#V4 R
M8-XY(G:0S6^*G485XY(G:0S6^*G4!R
M # KN7T?:4SS KN7T?:4SP
M
M                                 &!;^7UW:0SS7V_E]=VD V
M                          !@67DKNVIGF!9>2N[:@9X
M                  .BNY)-V3BW<BA[*'-=R2;LG%NY%#V4 R
M                      =%?R*;LJ<6[D4/90YK^13=E3BW<BA[* 9
M                           ,&\<D_P")#-9XJ=1A7CDB=I#-;XJ=0'(
M                              -?7<OH^TIL# KN7T?:4SP
M
M
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M[E]'VE-@8%=R^C[2F>
M
M                              U]OY?7=I#8&OM_+Z[M(!L
M                       # LO)7=M3/,"R\E=VU SP
M               =%=R2;LG%NY%#V4.:[DDW9.+=R*'LH!D
M                   Z*_D<W94XMW(H>RAS7\BF[*G%NY%#V4 R
M                        8-XY(G:0S6^*G485XY)_Q(9K?%3J Y
M                         !@5W+Z/M*9Y@5W+Z/M*9X
M
M                                                         #7V
M_E]=VD-@8%OY?7=I ,\                                P++R5W;4S
MS LO)7=M0,\                               '17<DF[)Q;N10]E#FN
MY)-V3BW<BA[* 9                                .BOY%-V5.+=R*'
MLH<U_(INRIQ;N10]E ,@                               &#>.2)VD,
MUOBIU&%>.2?\2&:WQ4Z@.0                               :^NY?1]
MI38&!7<OH^TIG@
M
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ML_C;3]A_L+=LO)7=M2HQ^'L7%Y]-C]NC1>%8J\Q5S-N\_?KT9X .%9@
M                       #HKN23=DXMW(H>RAS7<DF[)Q;N10]E ,@
M                           '17\BF[*G%NY%#V4.:_D4W94XMW(H>R@&
M0                               #!O')$[2&:WQ4ZC"O')$[2&:WQ4Z
M@.0                               8%=R^C[2F>8%=R^C[2F>
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MEEY*[MJ5'EE\;:?L/]A;EEY*[MJ9SQ;^Z/PV7@'EI_/_ "&> "K7@
M                      Z*[DDW9.+=R*'LH<UW))NR<6[D4/90#(
M                         !T5_(YNRIQ;N10]E#FOY%-V5.+=R*'LH!D
M                               P;QR1.TAFM\5.HPKSR1.TAFM\5.H#
MD                               &OKN7T?:4V!@5W+Z/M*9X
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M$3?M)T:: 7.""90XJ?B7#RMJW;592*D<CEXWIIN<3L  ==3(D-/+*O$QJN]
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MJ5'EE\;:?L/]A;EEY*[MJ9SQ;^Z/Q_ZV7@'EI_/_ "&> "K7@
M                  Z*[DDW9.+=R*'LH<UW))NR<6[D4/90#(
M                     !T5_(INRIQ;N10]E#FOY'-V5.+=R*+LH!D
M                           P;QR1.TAFM\5.HPKQR3_B0S6^*G4!R
M                            #7UW+Z/M*; U]=R^C[2FP
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M+'MN=Y=.)$+$S/=*S =X6#7A.!W:=:$,]SO'2>\=PD8C.[.%1'K_ #(FF[S
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M45% ["N\]H(Y<#2O>U%?'*Q6KSIO+$*4SXQ)'5=S6"@?PTJO1\R,WZ+KN3K
MEN1\CGX"IMI==F1[4ZC7>Z!^*5/].GL)9EY9G6+"5!1R)I,C$?(G^TO&1/W0
M/Q2I_IT]@$ARG^(=K['YE0YO5LL693)5BX;N?85D:ZZ.TWZ%O93_ !#M?8_,
MK_/2V36^^VS$-.S:C1R->NFY')Q:]8'RW-^^M:C4PXW1$T3<_P#L<]^&_?\
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M # OUJIKU:JFWUK=J&9NRO2GE0HY^%L:8'KI78?=+4T;UW)%J[:3_:;S'H
M42R]YF7-%IXZ":F5^[A%C5FGG4Z<29<W*BPK-5U"3W.^U$C=M(_VBL37F+\
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MA;MEY*[MJ9SQ;^Z/PV7@'EI_/_(9X *M>
M  #HKN23=DXMW(H>RAS7<DF[)Q;N10]E ,@
M      '17\BF[*G%NY%#V4.:_D4W94XMW(H>R@&0
M           #!O')$[2&:WQ4ZC"O')$[2&:WQ4Z@.0
M             8%=R^C[2F>:^NY?1]I38
M                                   &IQ18J;$5EJ+=6:HR5-ST356+
MS*AAX&PRN%;4Z@;7S5D.VKV+*U$5O%N33FW$B
M                                (GCW!R8O@IZ>:XSTM/$[:5D;45'+
MY=26 ##LUN@M-LIJ&D;LPP,1C4,P          5+FMR^GZW_ )%M%2YK?O"G
MZW_D=WAOF;/K\2K/&/)V_3YA!  :EA                             !
M*LLOC;3]A_L+<LO)7=M2HLLOC;3]A_L+=LO)7=M3.>+?W1^/_6R\ \M/Y_Y#
M/ !5KP                             =%=R2;LG%NY%#V4.:[DDW94XM
MW(H>R@&0                               #HK^13=E3BW<BA[*'-?R*
M;LJ<6[D4/90#(                               !@WCDB=I#-;XJ=1A
M7CDB=I#-;XJ=0'(                               ,"NY?1]I3/,"NY
M?1]I3/
M
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MT5W))NRIQ;N10]E#FNY)-V3BW<BA[* 9
M    .BOY%-V5.+=R*'LH<U_(INRIQ;N10]E ,@
M         &#>.2)VD,UOBIU&%>.2)VD,UOBIU <@
M           U]=R^C[2FP-?7<OH^TIL
M
M                                           &OM_+Z[M(; U]OY?7
M=I -@                                8%EY*[MJ9Y@67DKNVH&>
M                            #HKN23=DXMW(H>RAS7<DF[)Q;N10]E ,
M@                               '17\BF[*G%NY%#V4.:_D4W94XMW(
MH>R@&0                               #!O')$[2&:WQ4ZC"O')$[2&
M:WQ4Z@.0                               8%=R^C[2F>:^NY?1]I38
M
M
M           ,"W\OKNTAGF!;^7UW:0#/
M    ,"R\E=VU,\P++R5W;4#/                               !T5W)
M)NR<6[D4/90YKN23=DXMW(H>R@&0                               #
MHK^13=E3BW<BA[*'-?R*;LJ<6[D4/90#(
M    !@WCDB=I#-;XJ=1A7CDB=I#-;XJ=0'(
M      -?7<OH^TIL#7UW+Z/M*;
M
M                                      !@6_E]=VD,\U]OY?7]I -@
M                                8%EY*[MJ9Y@67DKNVH&>
M                       #HKN23=DXMW(H>RAS7<DF[)Q;N10]E ,@
M                           '17\BF[*G%NY%#V4.:_D4W94XMW(H>R@&
M0                               #!O/)$[2&:WQ4ZC"O')$[2&:WQ4Z
M@.0                               8%=R^C[2F>8%=R^C[2F>
M
M
M      U]OY?7=I#8&OM_+Z[M(!L                                #
M LO)7=M3/,"R\E=VU SP                               =%=R2;LG%
MNY%#V4.:[DDW9.+=R*'LH!D                                Z*_D4
MW94XMW(H>RAS7\BF[*G%NY%#V4 R
M8-XY(G:0S6^*G485XY(G:0S6^*G4!R
M # KN7T?:4SS7UW+Z/M*;
M
M                                 !U10,BEED9KM2+J[53M
M                          ZJ>!E.Q6QZZ*NN]3M
M                'S(Q)(W,=XKDT411MBC:QFNRU-$U/H
M                   ?,K$DC<QWBN311%&V*-K&>*U-$/H
M                    ==1 R=FQ)KIKKN4[$W)H
M             !U2P,DECD=KM,75-YV@
M
M
M
M
M
M
M
M
M
M
M
M                                                TU^Q/9[$G_Q2
MNAA>O$Q5U<OFXP-R"",S7PF^382OD1==-5A<B>G0E=GO-NO,'#6RLAJ6<^P[
M54ZT V      #4WW$5JL4>U=*V&!535&N7PEZDXR-)FQA-9-CN^37737@7:>
MG0"=@UEEOULO<7"6NMAJ$3C1CMZ=:&S  ^9)&11NDD<C6-35SE71$0AE;F?A
M:DG6)]P61R+HJQ1.>WTH@$U!J[#?[9?J=9K55QU#4\9&KO;UIS&T  ^99&0Q
M.DE<C6-35SEXD0T>&L5VO$;YVVF265(5T>]8G-;KY%7C WP           &)
M<[G16NG6>XU,5/$G\TCM ,L$%FS6PG%)L+7O<O2V%RIZ=#=V#&%COKD9;;A%
M)*O_ ':KLN]"@;\   #IK:F*CHYZFH56PPL61ZHFNB(FJ@=P($N;>$T546MF
MW?\ T'_V..^WA+Y[-ZA_]@)\"!,S:PFYS6I6S:JNB?L'_P!B=0R-FA9+&NK'
MM1R+Y% ^P:Z^7NWV.D[INE5'3Q<2;2[W+Y$YR-4F:&%:FH2%MP<Q573:DB<U
MOI5 )L#X@FCGA9+ ]LD3TVFN:NJ*A]@ :C$N([9AND94W:?@HWNV6HC5<KE\
MB(9]OJXZ^CBJH$>D4K4<W;:K5TZE R           !B7:XT]JMM175KE93P,
M5[W(BJJ(GD0AG?;PE\]F]0_^P$^!$\/9@X?O]R906RIDDJ7HJHUT3FIHGE5"
M6    !PYR,:KG*B-3>JKS$2NV8V&+9,Z*HN3'O;QI$U7Z>@"7 AMNS,PM7RI
M''<FQN5=$X9BL3TJ3"*1DT;9(GM>QR:HYJZHJ ?0!J[]B"V6&!);K5QT[5\5
M'+O=U(!M 0NAS/PM65#867!8W*NB.EC<QOI5-"912,EC:^-R/8Y-4<BZHJ ?
M0!I,38HM6&HHGW:H6/A5T8UK5<YWF0#=@ZJ2=M531SQH]&2)M(CVJU=.I3M
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M>K5KY':<[87*GL G8(K:,P,-765(J6YQ-D=XK9=6*O5J2I%141475%YP
M&NO5\MMEAX6Z5D-.U>+;=O7J0#8@@BYL83238[ND5==-4A=I["26+$EIOK-;
M770SJB:JQ'>$G6G&!MP  !%[]CW#MDJ74]=7MX=NYS(FJ]6]>G$=V'L:6*_R
M\%;:YCIN:)Z*QR]2*!(@  !'X\86B7$3K'#/)+<&[G,9&YR-ZUXD)
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M%@M[JVZ3I# BZ:Z:JJ^1$XP-D#"LUSI[O;HJVCX3@)4U8KV*Q53IT4S0
M
M                                             "&9H8O;A6QJL*HM
MPJ-60-7?HO.Y>HKS N751BEB7O%53.Z.==MC-KPGHN_5=4W(868JR8ES9IK0
MKM(62L@TYF]*E_4L#*:FB@B:C8XVHUJ)S(@$-ERNPO) Z/N)6ZIIMM5$<GW%
M8XGP_=<LKO#=+)4226YSOYE5=-_BO3=Z3T*:7&=KCO&&:^CE;M;<:JWR.3>B
M@?6$K]3XCL5/<:7<V1-'-7C:Y.-#<%(^YYN<D=7=+3*]58W21C?]K71WY%W
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MU8J>@ID35J:R/TWO=SJ0[*3#LSEGQ1>4VKE7JLC$7^1B_P#OT%F
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M?MV'L46>"U0)#'+'MN1.==O0]#47)(.PWV%'9^?'&Q?0?]9>-%R2#L-]@'<
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MYZ\8&^AB9!"R*)J-C8B-:U$W(A]@
M
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M4P\N;5'8+/68MQ*__ME4BRJY_&QB[T1/*IJ;?#+F5CM];.CO>"W.TC3B1_\
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M$39JJ6=NP]./15WI]Q.L+U;Z[#MNJI?\26!KG=>@&S
M
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M8WKLIKY0/O(JU2T&$G54Z.:ZLD61K53^7F4L<^88F0Q,CB:C(V)HUJ<2(?0
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M:HITI'4E3$FWL*_;VF\6NNB&MQSF-486Q3!1RV]7V]6HKY%U15UYV]1M<O\
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M81=/_P EM4\? T\4>NNPU&Z]2$8P9@>W88<^>)9*BNDW/J)5U5>KH)6
M         41GY\<;%]!_UEXT7)(.PWV$-QY@"/%=WH:Y]<^G6F9L(QK$7:\+
M4FT+.#B8S779:B:@0/'^9--A*YP4*T;ZJ9[4>_1^QL-7B7B74E$%ZCJ\-)=Z
M&-TS'P<*R-O&JZ:Z$:QWEQ18LN<-=)4RT\S6HQ^RFJ.:G$GD)?9K=!:;734%
M*FD,#$8W7C73G4"L\(YOTE7(ZFQ'$E#/M*B/356\?$O1H6)38@M-3$DD%PIW
ML7G1QI\39?V#$,CY:NE6.H=QRPKLJJ^7I(7/DC2.>O<]WJ(V="M10)UB+'%C
MLE')+/6QR2HG@Q,75SEZ"H\"4M9CC,22^5$2MHX'J]VN]$X]EOWDLMF2UJ@F
M:^X5M35M3?LZ[.I95HM=':*-E+;H&00-_E:G'Y5 S#3XMOU/ARQU%PJE31B:
M,;\IR\2&X(AC/!?PJN%$^NKY&T%.[:6E:U-'KY5 C.4UAJ;E75&+KZFW552J
ME.UW\K>E/86?6P-JJ.:![4<V1BMT4^Z>&.G@CAA:C8V-1K6IS(A]@5/DK6LM
M4MSPW7/2*L@F<]C7;MIN[B+$Q+>(+)9*NOGD:U(6*K45>-W,GI-'C# -OQ%5
M,K4DEH[@S1$GA715ZT-'394Q2U,;[Y>*RXPQKJD3UV4\X'SD3;98K+6W.=KF
M+73N>QJIQMUUU+..NEIXJ6GC@IV(R*-$:UJ<2(=@         *J(BJNY$!TU
ML'=-'/!M*SA&*S:3FU0"G,U,Q9)IY+#AQ^KW+L33M71=?DM_N;;+#"MHP[ V
MON573S765-55SD7@M=-R>7RFM=D="KW.]^IM577_  T'>/B_SRH^P@%K>_%N
M^>P?:/IEVH'O1K*N%7*NB(CN,J?O'Q?YY4?80RK7DU'07*FJTO,[UAD2395B
M;].8"Q<57VGP[9*BXU2*YD2;FIQN7F0C^7F/Z;&#JF)*5U)4P^%P:OV]6].N
MB$@Q/8J;$-EGMM8KDCD3<YJ[VKTFBR_P#1X0=42Q3R5-3-X*R.331O1H!V9G
MX7^%&&Y((D_[7 JRP^5R(N[SE>Y68]986OP_B55ITA>K8Y7ZZ,Z6J7B13%V
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MD(UA/+RWV.O6X5$\U?<>::9?%ZDZ2:@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$-73LGI98YH7IJU['(YKD\BH=I',OL/RX:PS!;ZF9)9D<Y[U3B:JKQ)Y"1@
M          !6^)\SG63%4EF2TI.C'L9PW=&SKM(B\6RO3TED
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MEQN-1$C&1NC8R)==O7G7H0M0
M
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MW,J*5'D-=9J;$%7:9'KP$\3I$8O$DC53?Z-?0@%[
M
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MVH/^LN(#SSGK\>4^JQ^UQZ H>14_T;?8>?L]?CQ__%C]KCT#0<BI_HV^P#N
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M %&%C9S_ ,/KAVXOQH!&/<[\AO?TD7L<6\5#[G?D-[^DB]CBW@//&>WQX_\
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M(L4NCK*Z26@AC=)(U6-1./1J:HGE^X"Y@
M
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M4M(U\;F4Z1+X*-TW)INYBT@ (-CS+FBQ34]VLG=1U^RC72(W::]$XM4_,G(
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MS088MO<EN:J[2[4DK]-MZ^5?R-V
M
M
M
M
M
M
M                                       51FYC*\X<OE)36JH9%%)3
M\(Y'1M=OVE3GZ@+7!J,'UT]RPQ;:RK<CYYX6O>Y$TU5?(;<
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M.V19-J-':Z*W3CZU)1ES=:J]8-MUPN#TDJIN$VW(U&HNDCFIN3R(@$D
M                   !1LN86(6X\=;$JH^XTN7<VSP+==CA=G373H+R
M"E<:9AXCM>,JBAHXXV4\,B,9"Z+:65.G7CW^0NB%ROB8YS=ERHBJG0!]
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M+E4QR4SV/<YJ1-:NJ-54WHA<X
M
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M5B4[V\"^5$?JK%T337GU3TDE*TQ[EO1W6KNM]DKZB.98EDX)K4V=6,T1-?\
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MB/1.E-44]#5W(JCZ-WL4#SODI_$"E^BE_"IZ./..2O\ $&F^CE_"IZ.
M
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MG^CE_"IZ-/.63/@YB4[5W+L3)_Z5/1H
M
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MWP/:UJ1-<W75/*JDV
M
M
M                                                 5UF-EY/BV]P
M5T-?%3-CIVP;#XU<JJCG+KQ_[1/+93+1V^FIG.1RQ1M8KD3371-#)    8=Z
MHUN-GKZ)KT8ZI@DA1RIJC5<U4U^\A>6^ )\(W*JJIJZ*I2:'@T:QBMT\)%UX
M_(6
A                                         /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Apr. 23, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0002042347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Seaport Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_RegnFileNb', window );">Registration File Number</a></td>
<td class="text">333-294976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_RegnFileNb">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_RegnFileNb</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Apr. 23, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457aFlg', window );">Rule 457(a)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">8,014,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">18.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 144,259,992.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 19,922.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">(1) (a) Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(a) under the Securities Act of 1933, as amended. (b) Includes 1,770,000 shares that the underwriters have the option to purchase. (2) The Registrant previously paid a registration fee of $13,810.00 in connection with initial filing of the Registration Statement on Form S-1 on April 10, 2026. The fee was estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. This Maximum Aggregate Offering Price was originally registered under 457(o) and is now converted to 457(a). (b) See note 1(b) above.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457aFlg', window );">Rule 457(a)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">5,555,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">18.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 100,000,008.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 13,810.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">(1) (a) Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(a) under the Securities Act of 1933, as amended. (b) Includes 1,770,000 shares that the underwriters have the option to purchase. (2) The Registrant previously paid a registration fee of $13,810.00 in connection with initial filing of the Registration Statement on Form S-1 on April 10, 2026. The fee was estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. This Maximum Aggregate Offering Price was originally registered under 457(o) and is now converted to 457(a). (b) See note 1(b) above.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457aFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457aFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Apr. 23, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 244,260,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">13,810.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">33,732.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 19,922.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="d73463dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d73463dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d73463dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="d73463dexfilingfees.htm">d73463dexfilingfees.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
    <BaseTaxonomy items="32">http://xbrl.sec.gov/ffd/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>41
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d73463dexfilingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "d73463dexfilingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 9,
    "http://xbrl.sec.gov/ffd/2026": 7,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2026": 32,
    "http://xbrl.sec.gov/dei/2026": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d73463dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d73463dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d73463dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d73463dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal8ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>42
<FILENAME>0001193125-26-178716-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-178716-xbrl.zip
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MFRP,"'UU"$/Q=A?*=BE^MO.561M*N)$HY$8$"D#,"4E%MV(67^AD.'SS@<Q
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M2@6>%^U,,D'P4[O=EM8;MH9#[2CA:J6!R(8U2$X"L2F3$Z%_C @=:13-\\Y
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>9F5E<RYH=&U02P4&      $  0!%    $0P

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>d73463dexfilingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002042347</identifier>
        </entity>
        <period>
            <startDate>2026-04-23</startDate>
            <endDate>2026-04-23</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002042347</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-23</startDate>
            <endDate>2026-04-23</endDate>
        </period>
    </context>
    <context id="offrl_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002042347</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-23</startDate>
            <endDate>2026-04-23</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-342">S-1</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-343">S-1/A</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-344">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:RegnFileNb contextRef="rc" id="ixv-345">333-294976</ffd:RegnFileNb>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-346">0002042347</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-347">Seaport Therapeutics, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="rc" id="ixv-384">S-1</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-385">Seaport Therapeutics, Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-386">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-387">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-388">Common Stock, $0.0001 par value per share</ffd:OfferingSctyTitl>
    <ffd:Rule457aFlg contextRef="offrl_1" id="ixv-389">true</ffd:Rule457aFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_1"
      decimals="0"
      id="ixv-390"
      unitRef="Shares">8014444</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_1"
      decimals="2"
      id="ixv-391"
      unitRef="USD">18.00</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="2"
      id="ixv-392"
      unitRef="USD">144259992.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="7"
      id="ixv-393"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="2"
      id="ixv-394"
      unitRef="USD">19922.30</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="offrl_2" id="ixv-395">true</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_2" id="ixv-396">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_2" id="ixv-397">Common Stock, $0.0001 par value per share</ffd:OfferingSctyTitl>
    <ffd:Rule457aFlg contextRef="offrl_2" id="ixv-398">true</ffd:Rule457aFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_2"
      decimals="0"
      id="ixv-399"
      unitRef="Shares">5555556</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_2"
      decimals="2"
      id="ixv-400"
      unitRef="USD">18.00</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_2"
      decimals="2"
      id="ixv-401"
      unitRef="USD">100000008.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeAmt
      contextRef="offrl_2"
      decimals="2"
      id="ixv-402"
      unitRef="USD">13810.00</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="2" id="ixv-403" unitRef="USD">244260000.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="2" id="ixv-404" unitRef="USD">33732.30</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="2" id="ixv-405" unitRef="USD">13810.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="2" id="ixv-406" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="2" id="ixv-407" unitRef="USD">19922.30</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-408">(1) (a) Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(a) under the Securities Act of 1933, as amended. (b) Includes 1,770,000 shares that the underwriters have the option to purchase. (2) The Registrant previously paid a registration fee of $13,810.00 in connection with initial filing of the Registration Statement on Form S-1 on April 10, 2026. The fee was estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. This Maximum Aggregate Offering Price was originally registered under 457(o) and is now converted to 457(a). (b) See note 1(b) above.</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="offrl_2" id="ixv-409">(1) (a) Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(a) under the Securities Act of 1933, as amended. (b) Includes 1,770,000 shares that the underwriters have the option to purchase. (2) The Registrant previously paid a registration fee of $13,810.00 in connection with initial filing of the Registration Statement on Form S-1 on April 10, 2026. The fee was estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. This Maximum Aggregate Offering Price was originally registered under 457(o) and is now converted to 457(a). (b) See note 1(b) above.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
